11058428
D008775_D013119 NONE High-dose\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 may\MD\15209706 do\VB\1640855 more\JJR\1740 harm\NN\14052046 for\IN\1740 <e2>spinal\JJ\1740 cord\NN\3670849 injury</e2>\NN\14052046 .\.\1740
D008775_D013119 NONE Because\IN\1740 of\IN\1740 the\DT\1740 National\NNP\7846 Acute\NNP\6822198 <e2>Spinal\NNP\14027674 Cord\NNP\3670849 Injury</e2>\NNP\14052046 Studies\NNPS\635850 (\-LRB-\1740 NASCIS\NN\1740 )\-RRB-\1740 ,\,\1740 high-dose\FW\1740 <e1>methylprednisolone</e1>\NN\1740 became\VBD\146138 the\DT\1740 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 the\DT\1740 acute\JJ\1740 spinal\JJ\1740 cord\NN\3670849 injury\NN\14052046 .\.\1740
D008775_D013119 NONE Because\IN\1740 of\IN\1740 the\DT\1740 National\NNP\7846 Acute\NNP\6822198 Spinal\NNP\14027674 Cord\NNP\3670849 Injury\NNP\14052046 Studies\NNPS\635850 (\-LRB-\1740 NASCIS\NN\1740 )\-RRB-\1740 ,\,\1740 high-dose\FW\1740 <e1>methylprednisolone</e1>\NN\1740 became\VBD\146138 the\DT\1740 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 the\DT\1740 acute\JJ\1740 <e2>spinal\JJ\1740 cord\NN\3670849 injury</e2>\NN\14052046 .\.\1740
D008775_D013119 NONE Further\RB\1740 ,\,\1740 steroid\NN\14727670 myopathy\NN\14204950 recovers\NNS\1740 naturally\RB\1740 and\CC\1740 the\DT\1740 neurological\JJ\1740 improvement\NN\7359599 shown\VBN\2137132 in\IN\13603305 the\DT\1740 NASCIS\NN\1740 may\MD\15209706 be\VB\836236 just\RB\1740 a\DT\13649268 recording\NN\6791372 of\IN\1740 this\DT\1740 natural\JJ\1740 motor\NN\3699975 recovery\NN\7357388 from\IN\1740 the\DT\1740 steroid\NN\14727670 myopathy\NN\14204950 ,\,\1740 instead\RB\1740 of\IN\1740 any\DT\1740 protection\NN\407535 that\WDT\1740 <e1>methylprednisolone</e1>\NN\1740 offers\VBZ\2327200 to\TO\1740 the\DT\1740 <e2>spinal\JJ\1740 cord\NN\3670849 injury</e2>\NN\14052046 .\.\1740
D000305_D009135 NONE In\IN\13603305 the\DT\1740 NASCIS\NN\1740 ,\,\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 mention\NN\6765044 regarding\VBG\689344 the\DT\1740 possibility\NN\5944958 of\IN\1740 acute\JJ\1740 <e1>corticosteroid</e1>\NN\14745635 <e2>myopathy</e2>\NN\14204950 that\IN\1740 high-dose\JJ\1740 methylprednisolone\NN\1740 may\MD\15209706 cause\VB\1617192 .\.\1740
D000305_D009135 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 discussion\NN\6252138 considering\VBG\689344 the\DT\1740 possibility\NN\5944958 that\IN\1740 the\DT\1740 methylprednisolone\NN\1740 recommended\VBN\875394 by\IN\1740 NASCIS\NN\1740 may\MD\15209706 cause\VB\1617192 acute\JJ\1740 <e1>corticosteroid</e1>\NN\14745635 <e2>myopathy</e2>\NN\14204950 .\.\1740
D008775_D009135 CID In\IN\13603305 the\DT\1740 NASCIS\NN\1740 ,\,\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 mention\NN\6765044 regarding\VBG\689344 the\DT\1740 possibility\NN\5944958 of\IN\1740 acute\JJ\1740 corticosteroid\NN\14745635 <e2>myopathy</e2>\NN\14204950 that\IN\1740 high-dose\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 may\MD\15209706 cause\VB\1617192 .\.\1740
D008775_D009135 CID Further\RB\1740 ,\,\1740 steroid\NN\14727670 <e2>myopathy</e2>\NN\14204950 recovers\NNS\1740 naturally\RB\1740 and\CC\1740 the\DT\1740 neurological\JJ\1740 improvement\NN\7359599 shown\VBN\2137132 in\IN\13603305 the\DT\1740 NASCIS\NN\1740 may\MD\15209706 be\VB\836236 just\RB\1740 a\DT\13649268 recording\NN\6791372 of\IN\1740 this\DT\1740 natural\JJ\1740 motor\NN\3699975 recovery\NN\7357388 from\IN\1740 the\DT\1740 steroid\NN\14727670 myopathy\NN\14204950 ,\,\1740 instead\RB\1740 of\IN\1740 any\DT\1740 protection\NN\407535 that\WDT\1740 <e1>methylprednisolone</e1>\NN\1740 offers\VBZ\2327200 to\TO\1740 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 injury\NN\14052046 .\.\1740
D008775_D009135 CID Further\RB\1740 ,\,\1740 steroid\NN\14727670 myopathy\NN\14204950 recovers\NNS\1740 naturally\RB\1740 and\CC\1740 the\DT\1740 neurological\JJ\1740 improvement\NN\7359599 shown\VBN\2137132 in\IN\13603305 the\DT\1740 NASCIS\NN\1740 may\MD\15209706 be\VB\836236 just\RB\1740 a\DT\13649268 recording\NN\6791372 of\IN\1740 this\DT\1740 natural\JJ\1740 motor\NN\3699975 recovery\NN\7357388 from\IN\1740 the\DT\1740 steroid\NN\14727670 <e2>myopathy</e2>\NN\14204950 ,\,\1740 instead\RB\1740 of\IN\1740 any\DT\1740 protection\NN\407535 that\WDT\1740 <e1>methylprednisolone</e1>\NN\1740 offers\VBZ\2327200 to\TO\1740 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 injury\NN\14052046 .\.\1740
D008775_D009135 CID To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 discussion\NN\6252138 considering\VBG\689344 the\DT\1740 possibility\NN\5944958 that\IN\1740 the\DT\1740 <e1>methylprednisolone</e1>\NN\1740 recommended\VBN\875394 by\IN\1740 NASCIS\NN\1740 may\MD\15209706 cause\VB\1617192 acute\JJ\1740 corticosteroid\NN\14745635 <e2>myopathy</e2>\NN\14204950 .\.\1740
D013256_D009135 NONE Further\RB\1740 ,\,\1740 <e1>steroid</e1>\NN\14727670 <e2>myopathy</e2>\NN\14204950 recovers\NNS\1740 naturally\RB\1740 and\CC\1740 the\DT\1740 neurological\JJ\1740 improvement\NN\7359599 shown\VBN\2137132 in\IN\13603305 the\DT\1740 NASCIS\NN\1740 may\MD\15209706 be\VB\836236 just\RB\1740 a\DT\13649268 recording\NN\6791372 of\IN\1740 this\DT\1740 natural\JJ\1740 motor\NN\3699975 recovery\NN\7357388 from\IN\1740 the\DT\1740 steroid\NN\14727670 myopathy\NN\14204950 ,\,\1740 instead\RB\1740 of\IN\1740 any\DT\1740 protection\NN\407535 that\WDT\1740 methylprednisolone\NN\1740 offers\VBZ\2327200 to\TO\1740 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 injury\NN\14052046 .\.\1740
D013256_D009135 NONE Further\RB\1740 ,\,\1740 <e1>steroid</e1>\NN\14727670 myopathy\NN\14204950 recovers\NNS\1740 naturally\RB\1740 and\CC\1740 the\DT\1740 neurological\JJ\1740 improvement\NN\7359599 shown\VBN\2137132 in\IN\13603305 the\DT\1740 NASCIS\NN\1740 may\MD\15209706 be\VB\836236 just\RB\1740 a\DT\13649268 recording\NN\6791372 of\IN\1740 this\DT\1740 natural\JJ\1740 motor\NN\3699975 recovery\NN\7357388 from\IN\1740 the\DT\1740 steroid\NN\14727670 <e2>myopathy</e2>\NN\14204950 ,\,\1740 instead\RB\1740 of\IN\1740 any\DT\1740 protection\NN\407535 that\WDT\1740 methylprednisolone\NN\1740 offers\VBZ\2327200 to\TO\1740 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 injury\NN\14052046 .\.\1740
D013256_D009135 NONE Further\RB\1740 ,\,\1740 steroid\NN\14727670 <e2>myopathy</e2>\NN\14204950 recovers\NNS\1740 naturally\RB\1740 and\CC\1740 the\DT\1740 neurological\JJ\1740 improvement\NN\7359599 shown\VBN\2137132 in\IN\13603305 the\DT\1740 NASCIS\NN\1740 may\MD\15209706 be\VB\836236 just\RB\1740 a\DT\13649268 recording\NN\6791372 of\IN\1740 this\DT\1740 natural\JJ\1740 motor\NN\3699975 recovery\NN\7357388 from\IN\1740 the\DT\1740 <e1>steroid</e1>\NN\14727670 myopathy\NN\14204950 ,\,\1740 instead\RB\1740 of\IN\1740 any\DT\1740 protection\NN\407535 that\WDT\1740 methylprednisolone\NN\1740 offers\VBZ\2327200 to\TO\1740 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 injury\NN\14052046 .\.\1740
D013256_D009135 NONE Further\RB\1740 ,\,\1740 steroid\NN\14727670 myopathy\NN\14204950 recovers\NNS\1740 naturally\RB\1740 and\CC\1740 the\DT\1740 neurological\JJ\1740 improvement\NN\7359599 shown\VBN\2137132 in\IN\13603305 the\DT\1740 NASCIS\NN\1740 may\MD\15209706 be\VB\836236 just\RB\1740 a\DT\13649268 recording\NN\6791372 of\IN\1740 this\DT\1740 natural\JJ\1740 motor\NN\3699975 recovery\NN\7357388 from\IN\1740 the\DT\1740 <e1>steroid</e1>\NN\14727670 <e2>myopathy</e2>\NN\14204950 ,\,\1740 instead\RB\1740 of\IN\1740 any\DT\1740 protection\NN\407535 that\WDT\1740 methylprednisolone\NN\1740 offers\VBZ\2327200 to\TO\1740 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 injury\NN\14052046 .\.\1740
D013256_D013119 NONE Further\RB\1740 ,\,\1740 <e1>steroid</e1>\NN\14727670 myopathy\NN\14204950 recovers\NNS\1740 naturally\RB\1740 and\CC\1740 the\DT\1740 neurological\JJ\1740 improvement\NN\7359599 shown\VBN\2137132 in\IN\13603305 the\DT\1740 NASCIS\NN\1740 may\MD\15209706 be\VB\836236 just\RB\1740 a\DT\13649268 recording\NN\6791372 of\IN\1740 this\DT\1740 natural\JJ\1740 motor\NN\3699975 recovery\NN\7357388 from\IN\1740 the\DT\1740 steroid\NN\14727670 myopathy\NN\14204950 ,\,\1740 instead\RB\1740 of\IN\1740 any\DT\1740 protection\NN\407535 that\WDT\1740 methylprednisolone\NN\1740 offers\VBZ\2327200 to\TO\1740 the\DT\1740 <e2>spinal\JJ\1740 cord\NN\3670849 injury</e2>\NN\14052046 .\.\1740
D013256_D013119 NONE Further\RB\1740 ,\,\1740 steroid\NN\14727670 myopathy\NN\14204950 recovers\NNS\1740 naturally\RB\1740 and\CC\1740 the\DT\1740 neurological\JJ\1740 improvement\NN\7359599 shown\VBN\2137132 in\IN\13603305 the\DT\1740 NASCIS\NN\1740 may\MD\15209706 be\VB\836236 just\RB\1740 a\DT\13649268 recording\NN\6791372 of\IN\1740 this\DT\1740 natural\JJ\1740 motor\NN\3699975 recovery\NN\7357388 from\IN\1740 the\DT\1740 <e1>steroid</e1>\NN\14727670 myopathy\NN\14204950 ,\,\1740 instead\RB\1740 of\IN\1740 any\DT\1740 protection\NN\407535 that\WDT\1740 methylprednisolone\NN\1740 offers\VBZ\2327200 to\TO\1740 the\DT\1740 <e2>spinal\JJ\1740 cord\NN\3670849 injury</e2>\NN\14052046 .\.\1740
7785794
D014700_D012770 NONE Refractory\JJ\1740 <e2>cardiogenic\JJ\1740 shock</e2>\NN\7510495 and\CC\1740 complete\VB\352826 heart\NN\5919034 block\NN\21939 after\IN\1740 <e1>verapamil</e1>\NN\2938514 SR\JJ\1740 and\CC\1740 metoprolol\NN\2832168 treatment\NN\654885 .\.\1740
D014700_D006327 CID Refractory\JJ\1740 cardiogenic\JJ\1740 shock\NN\7510495 and\CC\1740 complete\VB\352826 <e2>heart\NN\5919034 block</e2>\NN\21939 after\IN\1740 <e1>verapamil</e1>\NN\2938514 SR\JJ\1740 and\CC\1740 metoprolol\NN\2832168 treatment\NN\654885 .\.\1740
D014700_D006327 CID A\DT\13649268 seventy-eight-year-old\JJ\1740 woman\NN\9605289 presented\VBN\2137132 with\IN\1740 complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 and\CC\1740 refractory\JJ\1740 hypotension\NN\14057371 two\CD\13741022 days\NNS\15140892 after\IN\1740 a\DT\13649268 therapeutic\JJ\1740 dose\NN\3740161 of\IN\1740 sustained-release\NN\1740 <e1>verapamil</e1>\NNS\2938514 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 metoprolol\NN\2832168 .\.\1740
D008790_D012770 NONE Refractory\JJ\1740 <e2>cardiogenic\JJ\1740 shock</e2>\NN\7510495 and\CC\1740 complete\VB\352826 heart\NN\5919034 block\NN\21939 after\IN\1740 verapamil\NN\2938514 SR\JJ\1740 and\CC\1740 <e1>metoprolol</e1>\NN\2832168 treatment\NN\654885 .\.\1740
D008790_D006327 CID Refractory\JJ\1740 cardiogenic\JJ\1740 shock\NN\7510495 and\CC\1740 complete\VB\352826 <e2>heart\NN\5919034 block</e2>\NN\21939 after\IN\1740 verapamil\NN\2938514 SR\JJ\1740 and\CC\1740 <e1>metoprolol</e1>\NN\2832168 treatment\NN\654885 .\.\1740
D008790_D006327 CID A\DT\13649268 seventy-eight-year-old\JJ\1740 woman\NN\9605289 presented\VBN\2137132 with\IN\1740 complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 and\CC\1740 refractory\JJ\1740 hypotension\NN\14057371 two\CD\13741022 days\NNS\15140892 after\IN\1740 a\DT\13649268 therapeutic\JJ\1740 dose\NN\3740161 of\IN\1740 sustained-release\NN\1740 verapamil\NNS\2938514 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 <e1>metoprolol</e1>\NN\2832168 .\.\1740
D014700_D007022 CID A\DT\13649268 seventy-eight-year-old\JJ\1740 woman\NN\9605289 presented\VBN\2137132 with\IN\1740 complete\JJ\1740 heart\NN\5919034 block\NN\21939 and\CC\1740 refractory\JJ\1740 <e2>hypotension</e2>\NN\14057371 two\CD\13741022 days\NNS\15140892 after\IN\1740 a\DT\13649268 therapeutic\JJ\1740 dose\NN\3740161 of\IN\1740 sustained-release\NN\1740 <e1>verapamil</e1>\NNS\2938514 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 metoprolol\NN\2832168 .\.\1740
D008790_D007022 CID A\DT\13649268 seventy-eight-year-old\JJ\1740 woman\NN\9605289 presented\VBN\2137132 with\IN\1740 complete\JJ\1740 heart\NN\5919034 block\NN\21939 and\CC\1740 refractory\JJ\1740 <e2>hypotension</e2>\NN\14057371 two\CD\13741022 days\NNS\15140892 after\IN\1740 a\DT\13649268 therapeutic\JJ\1740 dose\NN\3740161 of\IN\1740 sustained-release\NN\1740 verapamil\NNS\2938514 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 <e1>metoprolol</e1>\NN\2832168 .\.\1740
D001285_D007022 NONE The\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 remain\VB\2604760 <e2>hypotensive</e2>\JJ\1740 with\IN\1740 complete\JJ\1740 heart\NN\5919034 block\NN\21939 ,\,\1740 even\RB\1740 with\IN\1740 multiple\JJ\1740 uses\NNS\407535 of\IN\1740 intravenous\JJ\1740 <e1>atropine</e1>\NN\14712692 as\RB\1740 well\RB\1740 as\IN\14622893 high\JJ\1740 doses\NNS\3740161 of\IN\1740 pressor\NN\9190918 agents\NNS\7347 such\JJ\1740 as\IN\14622893 dopamine\NN\14807737 and\CC\1740 dobutamine\NN\1740 .\.\1740
D001285_D006327 NONE The\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 remain\VB\2604760 hypotensive\JJ\1740 with\IN\1740 complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 ,\,\1740 even\RB\1740 with\IN\1740 multiple\JJ\1740 uses\NNS\407535 of\IN\1740 intravenous\JJ\1740 <e1>atropine</e1>\NN\14712692 as\RB\1740 well\RB\1740 as\IN\14622893 high\JJ\1740 doses\NNS\3740161 of\IN\1740 pressor\NN\9190918 agents\NNS\7347 such\JJ\1740 as\IN\14622893 dopamine\NN\14807737 and\CC\1740 dobutamine\NN\1740 .\.\1740
D004298_D007022 NONE The\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 remain\VB\2604760 <e2>hypotensive</e2>\JJ\1740 with\IN\1740 complete\JJ\1740 heart\NN\5919034 block\NN\21939 ,\,\1740 even\RB\1740 with\IN\1740 multiple\JJ\1740 uses\NNS\407535 of\IN\1740 intravenous\JJ\1740 atropine\NN\14712692 as\RB\1740 well\RB\1740 as\IN\14622893 high\JJ\1740 doses\NNS\3740161 of\IN\1740 pressor\NN\9190918 agents\NNS\7347 such\JJ\1740 as\IN\14622893 <e1>dopamine</e1>\NN\14807737 and\CC\1740 dobutamine\NN\1740 .\.\1740
D004298_D006327 NONE The\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 remain\VB\2604760 hypotensive\JJ\1740 with\IN\1740 complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 ,\,\1740 even\RB\1740 with\IN\1740 multiple\JJ\1740 uses\NNS\407535 of\IN\1740 intravenous\JJ\1740 atropine\NN\14712692 as\RB\1740 well\RB\1740 as\IN\14622893 high\JJ\1740 doses\NNS\3740161 of\IN\1740 pressor\NN\9190918 agents\NNS\7347 such\JJ\1740 as\IN\14622893 <e1>dopamine</e1>\NN\14807737 and\CC\1740 dobutamine\NN\1740 .\.\1740
D004280_D007022 NONE The\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 remain\VB\2604760 <e2>hypotensive</e2>\JJ\1740 with\IN\1740 complete\JJ\1740 heart\NN\5919034 block\NN\21939 ,\,\1740 even\RB\1740 with\IN\1740 multiple\JJ\1740 uses\NNS\407535 of\IN\1740 intravenous\JJ\1740 atropine\NN\14712692 as\RB\1740 well\RB\1740 as\IN\14622893 high\JJ\1740 doses\NNS\3740161 of\IN\1740 pressor\NN\9190918 agents\NNS\7347 such\JJ\1740 as\IN\14622893 dopamine\NN\14807737 and\CC\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
D004280_D006327 NONE The\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 remain\VB\2604760 hypotensive\JJ\1740 with\IN\1740 complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 ,\,\1740 even\RB\1740 with\IN\1740 multiple\JJ\1740 uses\NNS\407535 of\IN\1740 intravenous\JJ\1740 atropine\NN\14712692 as\RB\1740 well\RB\1740 as\IN\14622893 high\JJ\1740 doses\NNS\3740161 of\IN\1740 pressor\NN\9190918 agents\NNS\7347 such\JJ\1740 as\IN\14622893 dopamine\NN\14807737 and\CC\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
D002122_D007022 NONE However\RB\1740 ,\,\1740 shortly\RB\1740 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 intravenous\JJ\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 ,\,\1740 the\DT\1740 refractory\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 complete\VB\352826 heart\NN\5919034 block\NN\21939 resolved\VBN\352826 .\.\1740
D002122_D006327 NONE However\RB\1740 ,\,\1740 shortly\RB\1740 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 intravenous\JJ\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 ,\,\1740 the\DT\1740 refractory\JJ\1740 hypotension\NN\14057371 and\CC\1740 complete\VB\352826 <e2>heart\NN\5919034 block</e2>\NN\21939 resolved\VBN\352826 .\.\1740
3057041
C020976_D006255 NONE Multicenter\NN\1740 ,\,\1740 double-blind\NN\1740 ,\,\1740 multiple-dose\NN\1740 ,\,\1740 parallel-groups\JJ\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 trial\NN\786195 of\IN\1740 <e1>azelastine</e1>\NN\1740 ,\,\1740 chlorpheniramine\NN\1740 ,\,\1740 and\CC\1740 placebo\VB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>spring\NN\15236475 allergic\JJ\1740 rhinitis</e2>\NN\14336539 .\.\1740
C020976_D006255 NONE <e1>Azelastine</e1>\NN\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 antiallergic\JJ\1740 medication\NN\3247620 ,\,\1740 was\VBD\836236 compared\VBN\644583 with\IN\1740 chlorpheniramine\NN\1740 maleate\NN\2718811 and\CC\1740 placebo\NN\3740161 for\IN\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>spring\NN\15236475 allergic\JJ\1740 rhinitis</e2>\NN\14336539 in\IN\13603305 a\DT\13649268 multicenter\NN\1740 ,\,\1740 double-blind\NN\1740 ,\,\1740 multiple-dose\NN\1740 ,\,\1740 parallel-groups\NNS\1740 study\VBP\630380 .\.\1740
C020976_D006255 NONE <e1>Azelastine</e1>\NN\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 safe\JJ\1740 ,\,\1740 efficacious\JJ\1740 medication\NN\3247620 for\IN\1740 <e2>seasonal\JJ\1740 allergic\JJ\1740 rhinitis</e2>\NN\14336539 .\.\1740
D002744_D006255 NONE Multicenter\NN\1740 ,\,\1740 double-blind\NN\1740 ,\,\1740 multiple-dose\NN\1740 ,\,\1740 parallel-groups\JJ\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 trial\NN\786195 of\IN\1740 azelastine\NN\1740 ,\,\1740 <e1>chlorpheniramine</e1>\NN\1740 ,\,\1740 and\CC\1740 placebo\VB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>spring\NN\15236475 allergic\JJ\1740 rhinitis</e2>\NN\14336539 .\.\1740
D002744_D006255 NONE Azelastine\NN\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 antiallergic\JJ\1740 medication\NN\3247620 ,\,\1740 was\VBD\836236 compared\VBN\644583 with\IN\1740 <e1>chlorpheniramine\NN\1740 maleate</e1>\NN\2718811 and\CC\1740 placebo\NN\3740161 for\IN\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>spring\NN\15236475 allergic\JJ\1740 rhinitis</e2>\NN\14336539 in\IN\13603305 a\DT\13649268 multicenter\NN\1740 ,\,\1740 double-blind\NN\1740 ,\,\1740 multiple-dose\NN\1740 ,\,\1740 parallel-groups\NNS\1740 study\VBP\630380 .\.\1740
C020976_D006970 CID <e2>Drowsiness</e2>\NN\14015731 and\CC\1740 altered\JJ\1740 taste\NN\5712076 perception\NN\5926676 were\VBD\836236 increased\VBN\169651 significantly\RB\1740 over\IN\5867413 placebo\NN\3740161 only\RB\1740 in\IN\13603305 the\DT\1740 high-dose\JJ\1740 <e1>azelastine</e1>\NN\1740 group\NN\2137 .\.\1740
C020976_D013651 CID Drowsiness\NN\14015731 and\CC\1740 <e2>altered\JJ\1740 taste\NN\5712076 perception</e2>\NN\5926676 were\VBD\836236 increased\VBN\169651 significantly\RB\1740 over\IN\5867413 placebo\NN\3740161 only\RB\1740 in\IN\13603305 the\DT\1740 high-dose\JJ\1740 <e1>azelastine</e1>\NN\1740 group\NN\2137 .\.\1740
9214597
D004967_D010911 NONE Over\IN\5867413 expression\NN\4679549 of\IN\1740 vascular\JJ\1740 endothelial\JJ\1740 growth\NN\13526110 factor\NN\7326557 and\CC\1740 its\PRP$\6125041 receptor\NN\5225602 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>estrogen-induced</e1>\JJ\1740 rat\NN\2329401 <e2>pituitary\JJ\1740 tumors</e2>\NNS\14234074 may\MD\15209706 mediate\VB\761713 estrogen-initiated\JJ\1740 tumor\NN\14234074 angiogenesis\NN\13489037 .\.\1740
D004967_D010911 NONE Over\IN\5867413 expression\NN\4679549 of\IN\1740 vascular\JJ\1740 endothelial\JJ\1740 growth\NN\13526110 factor\NN\7326557 and\CC\1740 its\PRP$\6125041 receptor\NN\5225602 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 estrogen-induced\JJ\1740 rat\NN\2329401 <e2>pituitary\JJ\1740 tumors</e2>\NNS\14234074 may\MD\15209706 mediate\VB\761713 <e1>estrogen-initiated</e1>\JJ\1740 tumor\NN\14234074 angiogenesis\NN\13489037 .\.\1740
D004967_D009369 NONE Over\IN\5867413 expression\NN\4679549 of\IN\1740 vascular\JJ\1740 endothelial\JJ\1740 growth\NN\13526110 factor\NN\7326557 and\CC\1740 its\PRP$\6125041 receptor\NN\5225602 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>estrogen-induced</e1>\JJ\1740 rat\NN\2329401 pituitary\JJ\1740 tumors\NNS\14234074 may\MD\15209706 mediate\VB\761713 estrogen-initiated\JJ\1740 <e2>tumor</e2>\NN\14234074 angiogenesis\NN\13489037 .\.\1740
D004967_D009369 NONE Over\IN\5867413 expression\NN\4679549 of\IN\1740 vascular\JJ\1740 endothelial\JJ\1740 growth\NN\13526110 factor\NN\7326557 and\CC\1740 its\PRP$\6125041 receptor\NN\5225602 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 estrogen-induced\JJ\1740 rat\NN\2329401 pituitary\JJ\1740 tumors\NNS\14234074 may\MD\15209706 mediate\VB\761713 <e1>estrogen-initiated</e1>\JJ\1740 <e2>tumor</e2>\NN\14234074 angiogenesis\NN\13489037 .\.\1740
D004967_D009369 NONE <e1>Estrogens</e1>\NNS\14745635 ,\,\1740 which\WDT\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 several\JJ\1740 types\NNS\5839024 of\IN\1740 human\JJ\1740 and\CC\1740 animal\JJ\1740 <e2>cancers</e2>\NNS\14239425 ,\,\1740 can\MD\3094503 induce\VB\1627355 tumor\NN\14234074 angiogenesis\NN\13489037 in\IN\13603305 the\DT\1740 pituitary\NN\5329735 of\IN\1740 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
D004967_D009369 NONE <e1>Estrogens</e1>\NNS\14745635 ,\,\1740 which\WDT\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 several\JJ\1740 types\NNS\5839024 of\IN\1740 human\JJ\1740 and\CC\1740 animal\JJ\1740 cancers\NNS\14239425 ,\,\1740 can\MD\3094503 induce\VB\1627355 <e2>tumor</e2>\NN\14234074 angiogenesis\NN\13489037 in\IN\13603305 the\DT\1740 pituitary\NN\5329735 of\IN\1740 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
D004967_D009369 NONE The\DT\1740 mechanistic\JJ\1740 details\NNS\6634376 of\IN\1740 <e2>tumor</e2>\NN\14234074 angiogenesis\NN\13489037 induction\NN\7450842 ,\,\1740 during\IN\1740 <e1>estrogen</e1>\NN\14745635 carcinogenesis\NN\1740 ,\,\1740 are\VBP\836236 still\RB\1740 unknown\JJ\1740 .\.\1740
D004967_D009369 NONE To\TO\1740 elucidate\VB\939277 the\DT\1740 role\NN\719494 of\IN\1740 <e1>estrogen</e1>\NN\14745635 in\IN\13603305 the\DT\1740 regulation\NN\6652242 of\IN\1740 <e2>tumor</e2>\NN\14234074 angiogenesis\NN\13489037 in\IN\13603305 the\DT\1740 pituitary\NN\5329735 of\IN\1740 female\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 density\NN\4941325 of\IN\1740 blood\NN\5397468 vessels\NNS\5246511 was\VBD\836236 analysed\VBN\78760 using\VBG\1156834 factor\NN\7326557 VIII\NN\13741022 related\JJ\1740 antigen\NN\20090 (\-LRB-\1740 FVIIIRAg\NN\1740 )\-RRB-\1740 immunohistochemistry\NN\791527 and\CC\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 vascular\JJ\1740 endothelial\JJ\1740 growth\NN\13526110 factor/vascular\JJ\1740 permeability\NN\4940146 factor\NN\7326557 (\-LRB-\1740 VEGF/VPF\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 by\IN\1740 Western\NN\6615026 blot\NN\4692157 and\CC\1740 immunohistochemical\JJ\1740 analysis\NN\633864 .\.\1740
D004967_D009369 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 over\IN\5867413 expression\NN\4679549 of\IN\1740 VEGF\NN\1740 and\CC\1740 its\PRP$\6125041 receptor\NN\5225602 (\-LRB-\1740 VEGFR-2\NN\1740 )\-RRB-\1740 may\MD\15209706 play\VB\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 initial\JJ\1740 step\NN\168237 of\IN\1740 the\DT\1740 regulation\NN\6652242 of\IN\1740 <e1>estrogen</e1>\NN\14745635 induced\JJ\1740 <e2>tumor</e2>\NN\14234074 angiogenesis\NN\13489037 in\IN\13603305 the\DT\1740 rat\NN\2329401 pituitary\NN\5329735 .\.\1740
D004967_D063646 NONE The\DT\1740 mechanistic\JJ\1740 details\NNS\6634376 of\IN\1740 tumor\NN\14234074 angiogenesis\NN\13489037 induction\NN\7450842 ,\,\1740 during\IN\1740 <e1>estrogen</e1>\NN\14745635 <e2>carcinogenesis</e2>\NN\1740 ,\,\1740 are\VBP\836236 still\RB\1740 unknown\JJ\1740 .\.\1740
D004958_D009369 NONE The\DT\1740 high\JJ\1740 <e2>tumor</e2>\NN\14234074 angiogenic\JJ\1740 potential\NN\14481929 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 elevated\JJ\1740 VEGF/VPF\NN\1740 protein\NN\14944888 expression\NN\4679549 in\IN\13603305 the\DT\1740 <e1>E2</e1>\NN\1740 exposed\JJ\1740 pituitary\NN\5329735 of\IN\1740 ovariectomized\JJ\1740 (\-LRB-\1740 OVEX\JJ\1740 )\-RRB-\1740 rats\NNS\2329401 .\.\1740
15893386
D013390_D014313 CID <e1>Succinylcholine-induced</e1>\JJ\1740 <e2>masseter\NN\5602132 muscle\NN\5289601 rigidity</e2>\NN\5023233 during\IN\1740 bronchoscopic\JJ\1740 removal\NN\383606 of\IN\1740 a\DT\13649268 tracheal\NN\1740 foreign\JJ\1740 body\NN\19128 .\.\1740
D013390_D014313 CID Here\RB\1740 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 <e2>masseter\NN\5602132 muscle\NN\5289601 rigidity</e2>\NN\5023233 (\-LRB-\1740 jaw\NN\5269901 of\IN\1740 steel\NN\14586769 )\-RRB-\1740 after\IN\1740 <e1>succinylcholine</e1>\NN\3800001 (\-LRB-\1740 Sch\NN\1740 )\-RRB-\1740 administration\NN\1133281 during\IN\1740 general\JJ\1740 anesthetic\JJ\1740 management\NN\1123598 for\IN\1740 rigid\JJ\1740 bronchoscopic\JJ\1740 removal\NN\383606 of\IN\1740 a\DT\13649268 tracheal\NN\1740 foreign\JJ\1740 body\NN\19128 .\.\1740
D013390_D014313 CID Here\RB\1740 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 masseter\NN\5602132 muscle\NN\5289601 rigidity\NN\5023233 (\-LRB-\1740 <e2>jaw\NN\5269901 of\IN\1740 steel</e2>\NN\14586769 )\-RRB-\1740 after\IN\1740 <e1>succinylcholine</e1>\NN\3800001 (\-LRB-\1740 Sch\NN\1740 )\-RRB-\1740 administration\NN\1133281 during\IN\1740 general\JJ\1740 anesthetic\JJ\1740 management\NN\1123598 for\IN\1740 rigid\JJ\1740 bronchoscopic\JJ\1740 removal\NN\383606 of\IN\1740 a\DT\13649268 tracheal\NN\1740 foreign\JJ\1740 body\NN\19128 .\.\1740
D013390_D014313 CID Here\RB\1740 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 <e2>masseter\NN\5602132 muscle\NN\5289601 rigidity</e2>\NN\5023233 (\-LRB-\1740 jaw\NN\5269901 of\IN\1740 steel\NN\14586769 )\-RRB-\1740 after\IN\1740 succinylcholine\NN\3800001 (\-LRB-\1740 <e1>Sch</e1>\NN\1740 )\-RRB-\1740 administration\NN\1133281 during\IN\1740 general\JJ\1740 anesthetic\JJ\1740 management\NN\1123598 for\IN\1740 rigid\JJ\1740 bronchoscopic\JJ\1740 removal\NN\383606 of\IN\1740 a\DT\13649268 tracheal\NN\1740 foreign\JJ\1740 body\NN\19128 .\.\1740
D013390_D014313 CID Here\RB\1740 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 masseter\NN\5602132 muscle\NN\5289601 rigidity\NN\5023233 (\-LRB-\1740 <e2>jaw\NN\5269901 of\IN\1740 steel</e2>\NN\14586769 )\-RRB-\1740 after\IN\1740 succinylcholine\NN\3800001 (\-LRB-\1740 <e1>Sch</e1>\NN\1740 )\-RRB-\1740 administration\NN\1133281 during\IN\1740 general\JJ\1740 anesthetic\JJ\1740 management\NN\1123598 for\IN\1740 rigid\JJ\1740 bronchoscopic\JJ\1740 removal\NN\383606 of\IN\1740 a\DT\13649268 tracheal\NN\1740 foreign\JJ\1740 body\NN\19128 .\.\1740
D015742_D008305 NONE Anesthesia\NNP\14034177 was\VBD\836236 continued\VBN\2367363 uneventfully\RB\1740 with\IN\1740 <e1>propofol</e1>\NN\1740 infusion\NN\14589223 while\IN\15122231 all\DT\1740 facilities\NNS\21939 were\VBD\836236 available\JJ\1740 to\TO\1740 detect\VB\2163746 and\CC\1740 treat\JJ\1740 <e2>malignant\JJ\1740 hyperthermia</e2>\NN\14034177 .\.\1740
3461217
D008770_D011471 CID Production\NN\30358 of\IN\1740 autochthonous\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 in\IN\13603305 Lobund-Wistar\NN\1740 rats\NNS\2329401 by\IN\1740 treatments\NNS\654885 with\IN\1740 <e1>N-nitroso-N-methylurea</e1>\NN\1740 and\CC\1740 testosterone\NN\14747587 .\.\1740
D008770_D011471 CID More\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 Lobund-Wistar\NN\1740 (\-LRB-\1740 L-W\NN\1740 )\-RRB-\1740 strain\NN\7358060 rats\NNS\2329401 developed\VBD\1753788 large\JJ\1740 ,\,\1740 palpable\JJ\1740 <e2>prostate\NN\5329735 adenocarcinomas</e2>\NNS\14242337 (\-LRB-\1740 PAs\NNS\285557 )\-RRB-\1740 following\VBG\1835496 treatments\NNS\654885 with\IN\1740 <e1>N-nitroso-N-methylurea</e1>\NN\1740 (\-LRB-\1740 CAS\NN\14625458 :\:\1740 684\CD\1740 -\SYM\1740 93\CD\1740 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 and\CC\1740 testosterone\NN\14747587 propionate\NN\1740 [\-LRB-\1740 (\-LRB-\1740 TP\NN\1740 )\-RRB-\1740 CAS\NN\14625458 :\:\1740 57\CD\1740 -\SYM\1740 85\CD\1740 -\SYM\1740 2\CD\13741022 ]\-RRB-\1740 ,\,\1740 and\CC\1740 most\JJS\1740 of\IN\1740 the\DT\1740 tumor-bearing\JJ\1740 rats\NNS\2329401 manifested\VBD\1015244 metastatic\JJ\1740 lesions\NNS\14204950 .\.\1740
D008770_D011471 CID More\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 Lobund-Wistar\NN\1740 (\-LRB-\1740 L-W\NN\1740 )\-RRB-\1740 strain\NN\7358060 rats\NNS\2329401 developed\VBD\1753788 large\JJ\1740 ,\,\1740 palpable\JJ\1740 prostate\NN\5329735 adenocarcinomas\NNS\14242337 (\-LRB-\1740 <e2>PAs</e2>\NNS\285557 )\-RRB-\1740 following\VBG\1835496 treatments\NNS\654885 with\IN\1740 <e1>N-nitroso-N-methylurea</e1>\NN\1740 (\-LRB-\1740 CAS\NN\14625458 :\:\1740 684\CD\1740 -\SYM\1740 93\CD\1740 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 and\CC\1740 testosterone\NN\14747587 propionate\NN\1740 [\-LRB-\1740 (\-LRB-\1740 TP\NN\1740 )\-RRB-\1740 CAS\NN\14625458 :\:\1740 57\CD\1740 -\SYM\1740 85\CD\1740 -\SYM\1740 2\CD\13741022 ]\-RRB-\1740 ,\,\1740 and\CC\1740 most\JJS\1740 of\IN\1740 the\DT\1740 tumor-bearing\JJ\1740 rats\NNS\2329401 manifested\VBD\1015244 metastatic\JJ\1740 lesions\NNS\14204950 .\.\1740
D013739_D011471 NONE Production\NN\30358 of\IN\1740 autochthonous\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 in\IN\13603305 Lobund-Wistar\NN\1740 rats\NNS\2329401 by\IN\1740 treatments\NNS\654885 with\IN\1740 N-nitroso-N-methylurea\NN\1740 and\CC\1740 <e1>testosterone</e1>\NN\14747587 .\.\1740
D008770_D009369 NONE More\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 Lobund-Wistar\NN\1740 (\-LRB-\1740 L-W\NN\1740 )\-RRB-\1740 strain\NN\7358060 rats\NNS\2329401 developed\VBD\1753788 large\JJ\1740 ,\,\1740 palpable\JJ\1740 prostate\NN\5329735 adenocarcinomas\NNS\14242337 (\-LRB-\1740 PAs\NNS\285557 )\-RRB-\1740 following\VBG\1835496 treatments\NNS\654885 with\IN\1740 <e1>N-nitroso-N-methylurea</e1>\NN\1740 (\-LRB-\1740 CAS\NN\14625458 :\:\1740 684\CD\1740 -\SYM\1740 93\CD\1740 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 and\CC\1740 testosterone\NN\14747587 propionate\NN\1740 [\-LRB-\1740 (\-LRB-\1740 TP\NN\1740 )\-RRB-\1740 CAS\NN\14625458 :\:\1740 57\CD\1740 -\SYM\1740 85\CD\1740 -\SYM\1740 2\CD\13741022 ]\-RRB-\1740 ,\,\1740 and\CC\1740 most\JJS\1740 of\IN\1740 the\DT\1740 <e2>tumor-bearing</e2>\JJ\1740 rats\NNS\2329401 manifested\VBD\1015244 metastatic\JJ\1740 lesions\NNS\14204950 .\.\1740
D043343_D011471 CID More\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 Lobund-Wistar\NN\1740 (\-LRB-\1740 L-W\NN\1740 )\-RRB-\1740 strain\NN\7358060 rats\NNS\2329401 developed\VBD\1753788 large\JJ\1740 ,\,\1740 palpable\JJ\1740 <e2>prostate\NN\5329735 adenocarcinomas</e2>\NNS\14242337 (\-LRB-\1740 PAs\NNS\285557 )\-RRB-\1740 following\VBG\1835496 treatments\NNS\654885 with\IN\1740 N-nitroso-N-methylurea\NN\1740 (\-LRB-\1740 CAS\NN\14625458 :\:\1740 684\CD\1740 -\SYM\1740 93\CD\1740 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 and\CC\1740 <e1>testosterone\NN\14747587 propionate</e1>\NN\1740 [\-LRB-\1740 (\-LRB-\1740 TP\NN\1740 )\-RRB-\1740 CAS\NN\14625458 :\:\1740 57\CD\1740 -\SYM\1740 85\CD\1740 -\SYM\1740 2\CD\13741022 ]\-RRB-\1740 ,\,\1740 and\CC\1740 most\JJS\1740 of\IN\1740 the\DT\1740 tumor-bearing\JJ\1740 rats\NNS\2329401 manifested\VBD\1015244 metastatic\JJ\1740 lesions\NNS\14204950 .\.\1740
D043343_D011471 CID More\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 Lobund-Wistar\NN\1740 (\-LRB-\1740 L-W\NN\1740 )\-RRB-\1740 strain\NN\7358060 rats\NNS\2329401 developed\VBD\1753788 large\JJ\1740 ,\,\1740 palpable\JJ\1740 prostate\NN\5329735 adenocarcinomas\NNS\14242337 (\-LRB-\1740 <e2>PAs</e2>\NNS\285557 )\-RRB-\1740 following\VBG\1835496 treatments\NNS\654885 with\IN\1740 N-nitroso-N-methylurea\NN\1740 (\-LRB-\1740 CAS\NN\14625458 :\:\1740 684\CD\1740 -\SYM\1740 93\CD\1740 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 and\CC\1740 <e1>testosterone\NN\14747587 propionate</e1>\NN\1740 [\-LRB-\1740 (\-LRB-\1740 TP\NN\1740 )\-RRB-\1740 CAS\NN\14625458 :\:\1740 57\CD\1740 -\SYM\1740 85\CD\1740 -\SYM\1740 2\CD\13741022 ]\-RRB-\1740 ,\,\1740 and\CC\1740 most\JJS\1740 of\IN\1740 the\DT\1740 tumor-bearing\JJ\1740 rats\NNS\2329401 manifested\VBD\1015244 metastatic\JJ\1740 lesions\NNS\14204950 .\.\1740
D043343_D011471 CID More\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 Lobund-Wistar\NN\1740 (\-LRB-\1740 L-W\NN\1740 )\-RRB-\1740 strain\NN\7358060 rats\NNS\2329401 developed\VBD\1753788 large\JJ\1740 ,\,\1740 palpable\JJ\1740 <e2>prostate\NN\5329735 adenocarcinomas</e2>\NNS\14242337 (\-LRB-\1740 PAs\NNS\285557 )\-RRB-\1740 following\VBG\1835496 treatments\NNS\654885 with\IN\1740 N-nitroso-N-methylurea\NN\1740 (\-LRB-\1740 CAS\NN\14625458 :\:\1740 684\CD\1740 -\SYM\1740 93\CD\1740 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 and\CC\1740 testosterone\NN\14747587 propionate\NN\1740 [\-LRB-\1740 (\-LRB-\1740 <e1>TP</e1>\NN\1740 )\-RRB-\1740 CAS\NN\14625458 :\:\1740 57\CD\1740 -\SYM\1740 85\CD\1740 -\SYM\1740 2\CD\13741022 ]\-RRB-\1740 ,\,\1740 and\CC\1740 most\JJS\1740 of\IN\1740 the\DT\1740 tumor-bearing\JJ\1740 rats\NNS\2329401 manifested\VBD\1015244 metastatic\JJ\1740 lesions\NNS\14204950 .\.\1740
D043343_D011471 CID More\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 Lobund-Wistar\NN\1740 (\-LRB-\1740 L-W\NN\1740 )\-RRB-\1740 strain\NN\7358060 rats\NNS\2329401 developed\VBD\1753788 large\JJ\1740 ,\,\1740 palpable\JJ\1740 prostate\NN\5329735 adenocarcinomas\NNS\14242337 (\-LRB-\1740 <e2>PAs</e2>\NNS\285557 )\-RRB-\1740 following\VBG\1835496 treatments\NNS\654885 with\IN\1740 N-nitroso-N-methylurea\NN\1740 (\-LRB-\1740 CAS\NN\14625458 :\:\1740 684\CD\1740 -\SYM\1740 93\CD\1740 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 and\CC\1740 testosterone\NN\14747587 propionate\NN\1740 [\-LRB-\1740 (\-LRB-\1740 <e1>TP</e1>\NN\1740 )\-RRB-\1740 CAS\NN\14625458 :\:\1740 57\CD\1740 -\SYM\1740 85\CD\1740 -\SYM\1740 2\CD\13741022 ]\-RRB-\1740 ,\,\1740 and\CC\1740 most\JJS\1740 of\IN\1740 the\DT\1740 tumor-bearing\JJ\1740 rats\NNS\2329401 manifested\VBD\1015244 metastatic\JJ\1740 lesions\NNS\14204950 .\.\1740
D043343_D011471 CID Within\IN\1740 the\DT\1740 same\JJ\1740 timeframe\NN\1740 ,\,\1740 no\DT\7204911 L-W\JJ\1740 rat\NN\2329401 developed\VBD\1753788 a\DT\13649268 similar\JJ\1740 palpable\JJ\1740 <e2>PA</e2>\NN\10080869 when\WRB\1740 treated\VBN\2376958 only\RB\1740 with\IN\1740 <e1>TP</e1>\NN\1740 .\.\1740
D043343_D011471 CID In\IN\13603305 L-W\JJ\1740 rats\NNS\2329401 ,\,\1740 <e1>TP</e1>\NN\1740 acted\VBD\1619354 as\IN\14622893 a\DT\13649268 tumor\NN\14234074 enhancement\NN\248977 agent\NN\7347 ,\,\1740 with\IN\1740 primary\JJ\1740 emphasis\NN\14434681 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 .\.\1740
D043343_D009369 NONE More\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 Lobund-Wistar\NN\1740 (\-LRB-\1740 L-W\NN\1740 )\-RRB-\1740 strain\NN\7358060 rats\NNS\2329401 developed\VBD\1753788 large\JJ\1740 ,\,\1740 palpable\JJ\1740 prostate\NN\5329735 adenocarcinomas\NNS\14242337 (\-LRB-\1740 PAs\NNS\285557 )\-RRB-\1740 following\VBG\1835496 treatments\NNS\654885 with\IN\1740 N-nitroso-N-methylurea\NN\1740 (\-LRB-\1740 CAS\NN\14625458 :\:\1740 684\CD\1740 -\SYM\1740 93\CD\1740 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 and\CC\1740 <e1>testosterone\NN\14747587 propionate</e1>\NN\1740 [\-LRB-\1740 (\-LRB-\1740 TP\NN\1740 )\-RRB-\1740 CAS\NN\14625458 :\:\1740 57\CD\1740 -\SYM\1740 85\CD\1740 -\SYM\1740 2\CD\13741022 ]\-RRB-\1740 ,\,\1740 and\CC\1740 most\JJS\1740 of\IN\1740 the\DT\1740 <e2>tumor-bearing</e2>\JJ\1740 rats\NNS\2329401 manifested\VBD\1015244 metastatic\JJ\1740 lesions\NNS\14204950 .\.\1740
D043343_D009369 NONE More\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 Lobund-Wistar\NN\1740 (\-LRB-\1740 L-W\NN\1740 )\-RRB-\1740 strain\NN\7358060 rats\NNS\2329401 developed\VBD\1753788 large\JJ\1740 ,\,\1740 palpable\JJ\1740 prostate\NN\5329735 adenocarcinomas\NNS\14242337 (\-LRB-\1740 PAs\NNS\285557 )\-RRB-\1740 following\VBG\1835496 treatments\NNS\654885 with\IN\1740 N-nitroso-N-methylurea\NN\1740 (\-LRB-\1740 CAS\NN\14625458 :\:\1740 684\CD\1740 -\SYM\1740 93\CD\1740 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 and\CC\1740 testosterone\NN\14747587 propionate\NN\1740 [\-LRB-\1740 (\-LRB-\1740 <e1>TP</e1>\NN\1740 )\-RRB-\1740 CAS\NN\14625458 :\:\1740 57\CD\1740 -\SYM\1740 85\CD\1740 -\SYM\1740 2\CD\13741022 ]\-RRB-\1740 ,\,\1740 and\CC\1740 most\JJS\1740 of\IN\1740 the\DT\1740 <e2>tumor-bearing</e2>\JJ\1740 rats\NNS\2329401 manifested\VBD\1015244 metastatic\JJ\1740 lesions\NNS\14204950 .\.\1740
D043343_D009369 NONE In\IN\13603305 L-W\JJ\1740 rats\NNS\2329401 ,\,\1740 <e1>TP</e1>\NN\1740 acted\VBD\1619354 as\IN\14622893 a\DT\13649268 <e2>tumor</e2>\NN\14234074 enhancement\NN\248977 agent\NN\7347 ,\,\1740 with\IN\1740 primary\JJ\1740 emphasis\NN\14434681 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 prostate\NN\5329735 cancer\NN\14239425 .\.\1740
8251368
D009543_D013684 CID Photodistributed\JJ\1740 <e1>nifedipine-induced</e1>\JJ\1740 facial\JJ\1740 <e2>telangiectasia</e2>\NN\1740 .\.\1740
D009543_D013684 CID Five\CD\13741022 months\NNS\15113229 after\IN\1740 starting\VBG\2009433 <e1>nifedipine</e1>\NN\2938514 (\-LRB-\1740 Adalat\NN\1740 )\-RRB-\1740 ,\,\1740 two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 photodistributed\VBN\1740 facial\JJ\1740 <e2>telangiectasia</e2>\NN\1740 ,\,\1740 which\WDT\1740 became\VBD\146138 more\RBR\1740 noticeable\JJ\1740 with\IN\1740 time\NN\7308889 .\.\1740
D009543_D013684 CID Five\CD\13741022 months\NNS\15113229 after\IN\1740 starting\VBG\2009433 nifedipine\NN\2938514 (\-LRB-\1740 <e1>Adalat</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 photodistributed\VBN\1740 facial\JJ\1740 <e2>telangiectasia</e2>\NN\1740 ,\,\1740 which\WDT\1740 became\VBD\146138 more\RBR\1740 noticeable\JJ\1740 with\IN\1740 time\NN\7308889 .\.\1740
D017311_D013684 CID One\CD\13741022 commenced\VBD\348746 the\DT\1740 closely\RB\1740 related\JJ\1740 drug\NN\14778436 <e1>amlodipine</e1>\NN\1740 3\CD\13741022 years\NNS\15144371 later\RB\1740 ,\,\1740 with\IN\1740 recurrence\NN\7342049 of\IN\1740 <e2>telangiectasia</e2>\NN\1740 .\.\1740
17019386
D008353_D005910 NONE Passage\NN\199130 of\IN\1740 <e1>mannitol</e1>\NN\3214670 into\IN\1740 the\DT\1740 brain\NN\5462674 around\IN\1740 <e2>gliomas</e2>\NNS\14236743 :\:\1740 a\DT\13649268 potential\JJ\1740 cause\NN\7323922 of\IN\1740 rebound\NN\7309781 phenomenon\NN\29677 .\.\1740
D008353_D005910 NONE METHODS\NNS\5616786 :\:\1740 <e1>Mannitol</e1>\NNP\3214670 (\-LRB-\1740 18\CD\13745420 %\NN\1740 solution\NN\14586258 ;\:\1740 1\CD\13741022 g/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 bolus\NN\13899404 to\TO\1740 patients\NNS\9898892 (\-LRB-\1740 ten\CD\13745420 had\VBD\2108377 <e2>malignant\JJ\1740 glioma</e2>\NN\14236743 ,\,\1740 seven\CD\13741022 brain\NN\5462674 metastases\NNS\13533470 and\CC\1740 four\CD\13741022 meningioma\NN\14235200 )\-RRB-\1740 about\RB\1740 30\CD\13745420 minutes\NNS\6502378 before\IN\1740 craniotomy\NN\671351 .\.\1740
D008353_D005910 NONE <e1>Mannitol</e1>\JJ\1740 concentrations\NNS\4916342 were\VBD\836236 measured\VBN\697589 in\IN\13603305 plasma\NN\5398023 and\CC\1740 white\JJ\1740 matter\NN\5670710 by\IN\1740 a\DT\13649268 modified\VBN\109660 version\NN\7170753 of\IN\1740 the\DT\1740 enzyme\NN\14723628 assay\NN\5733583 of\IN\1740 Blonquist\NNP\1740 et\FW\1740 al.\FW\1740 RESULTS\NNS\34213 :\:\1740 In\IN\13603305 most\JJS\1740 <e2>glioma</e2>\NN\14236743 patients\NNS\9898892 ,\,\1740 mannitol\NN\3214670 concentrations\NNS\4916342 in\IN\13603305 white\JJ\1740 matter\NN\5670710 were\VBD\836236 2\CD\13741022 to\TO\1740 6\CD\13741022 times\NNS\15113229 higher\JJR\1740 than\IN\1740 in\IN\13603305 plasma\NN\5398023 (\-LRB-\1740 mean\JJ\1740 3.5\CD\1740 times\NNS\15113229 )\-RRB-\1740 .\.\1740
D008353_D005910 NONE Mannitol\JJ\1740 concentrations\NNS\4916342 were\VBD\836236 measured\VBN\697589 in\IN\13603305 plasma\NN\5398023 and\CC\1740 white\JJ\1740 matter\NN\5670710 by\IN\1740 a\DT\13649268 modified\VBN\109660 version\NN\7170753 of\IN\1740 the\DT\1740 enzyme\NN\14723628 assay\NN\5733583 of\IN\1740 Blonquist\NNP\1740 et\FW\1740 al.\FW\1740 RESULTS\NNS\34213 :\:\1740 In\IN\13603305 most\JJS\1740 <e2>glioma</e2>\NN\14236743 patients\NNS\9898892 ,\,\1740 <e1>mannitol</e1>\NN\3214670 concentrations\NNS\4916342 in\IN\13603305 white\JJ\1740 matter\NN\5670710 were\VBD\836236 2\CD\13741022 to\TO\1740 6\CD\13741022 times\NNS\15113229 higher\JJR\1740 than\IN\1740 in\IN\13603305 plasma\NN\5398023 (\-LRB-\1740 mean\JJ\1740 3.5\CD\1740 times\NNS\15113229 )\-RRB-\1740 .\.\1740
D008353_D005910 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 results\NNS\34213 of\IN\1740 our\PRP$\1740 study\NN\635850 show\VBP\2137132 that\IN\1740 even\RB\1740 after\IN\1740 a\DT\13649268 single\JJ\1740 bolus\NN\13899404 ,\,\1740 <e1>mannitol</e1>\NN\3214670 may\MD\15209706 leak\VB\933821 through\IN\1740 the\DT\1740 altered\JJ\1740 BBB\NN\1740 near\IN\1740 <e2>gliomas</e2>\NNS\14236743 ,\,\1740 reversing\VBG\109660 the\DT\1740 initial\JJ\1740 plasma-to-blood\JJ\1740 osmotic\JJ\1740 gradient\NN\13859043 ,\,\1740 aggravating\VBG\126264 peritumoral\JJ\1740 edema\NN\14315192 and\CC\1740 promoting\VBG\2556126 rebound\NN\7309781 of\IN\1740 ICP\NN\1740 .\.\1740
D008353_D001929 NONE AIM\NN\5980875 :\:\1740 Widespread\JJ\1740 use\NN\407535 of\IN\1740 <e1>mannitol</e1>\NN\3214670 to\TO\1740 reduce\VB\441445 <e2>brain\NN\5462674 edema</e2>\NN\14315192 and\CC\1740 lower\RBR\1740 elevated\JJ\1740 ICP\NN\1740 in\IN\13603305 brain\NN\5462674 tumor\NN\14234074 patients\NNS\9898892 continues\VBZ\2367363 to\TO\1740 be\VB\836236 afflicted\VBN\1790020 by\IN\1740 the\DT\1740 so-called\JJ\1740 rebound\NN\7309781 phenomenon\NN\29677 .\.\1740
D008353_D019586 CID AIM\NN\5980875 :\:\1740 Widespread\JJ\1740 use\NN\407535 of\IN\1740 <e1>mannitol</e1>\NN\3214670 to\TO\1740 reduce\VB\441445 brain\NN\5462674 edema\NN\14315192 and\CC\1740 lower\RBR\1740 <e2>elevated\JJ\1740 ICP</e2>\NN\1740 in\IN\13603305 brain\NN\5462674 tumor\NN\14234074 patients\NNS\9898892 continues\VBZ\2367363 to\TO\1740 be\VB\836236 afflicted\VBN\1790020 by\IN\1740 the\DT\1740 so-called\JJ\1740 rebound\NN\7309781 phenomenon\NN\29677 .\.\1740
D008353_D001932 NONE AIM\NN\5980875 :\:\1740 Widespread\JJ\1740 use\NN\407535 of\IN\1740 <e1>mannitol</e1>\NN\3214670 to\TO\1740 reduce\VB\441445 brain\NN\5462674 edema\NN\14315192 and\CC\1740 lower\RBR\1740 elevated\JJ\1740 ICP\NN\1740 in\IN\13603305 <e2>brain\NN\5462674 tumor</e2>\NN\14234074 patients\NNS\9898892 continues\VBZ\2367363 to\TO\1740 be\VB\836236 afflicted\VBN\1790020 by\IN\1740 the\DT\1740 so-called\JJ\1740 rebound\NN\7309781 phenomenon\NN\29677 .\.\1740
D008353_D001932 NONE As\IN\14622893 a\DT\13649268 contribution\NN\786195 to\IN\1740 this\DT\1740 issue\NN\5809192 we\PRP\1740 decided\VBD\352826 to\TO\1740 research\VB\789138 the\DT\1740 possible\JJ\1740 passage\NN\199130 of\IN\1740 <e1>mannitol</e1>\NN\3214670 into\IN\1740 the\DT\1740 brain\NN\5462674 after\IN\1740 administration\NN\1133281 to\TO\1740 21\CD\13745420 <e2>brain\NN\5462674 tumor</e2>\NN\14234074 patients\NNS\9898892 .\.\1740
D008353_D009362 NONE METHODS\NNS\5616786 :\:\1740 <e1>Mannitol</e1>\NNP\3214670 (\-LRB-\1740 18\CD\13745420 %\NN\1740 solution\NN\14586258 ;\:\1740 1\CD\13741022 g/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 bolus\NN\13899404 to\TO\1740 patients\NNS\9898892 (\-LRB-\1740 ten\CD\13745420 had\VBD\2108377 malignant\JJ\1740 glioma\NN\14236743 ,\,\1740 seven\CD\13741022 brain\NN\5462674 <e2>metastases</e2>\NNS\13533470 and\CC\1740 four\CD\13741022 meningioma\NN\14235200 )\-RRB-\1740 about\RB\1740 30\CD\13745420 minutes\NNS\6502378 before\IN\1740 craniotomy\NN\671351 .\.\1740
D008353_D009362 NONE In\IN\13603305 meningioma\NN\14235200 and\CC\1740 <e2>metastases</e2>\NNS\13533470 patients\NNS\9898892 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 <e1>mannitol</e1>\NN\3214670 were\VBD\836236 higher\JJR\1740 than\IN\1740 white\JJ\1740 matter\NN\5670710 concentrations\NNS\4916342 except\IN\1740 in\IN\13603305 three\CD\13741022 cases\NNS\7283608 with\IN\1740 infiltration\NN\975452 by\IN\1740 neoplastic\JJ\1740 cells\NNS\3080309 .\.\1740
D008353_D008579 NONE METHODS\NNS\5616786 :\:\1740 <e1>Mannitol</e1>\NNP\3214670 (\-LRB-\1740 18\CD\13745420 %\NN\1740 solution\NN\14586258 ;\:\1740 1\CD\13741022 g/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 bolus\NN\13899404 to\TO\1740 patients\NNS\9898892 (\-LRB-\1740 ten\CD\13745420 had\VBD\2108377 malignant\JJ\1740 glioma\NN\14236743 ,\,\1740 seven\CD\13741022 brain\NN\5462674 metastases\NNS\13533470 and\CC\1740 four\CD\13741022 <e2>meningioma</e2>\NN\14235200 )\-RRB-\1740 about\RB\1740 30\CD\13745420 minutes\NNS\6502378 before\IN\1740 craniotomy\NN\671351 .\.\1740
D008353_D008579 NONE In\IN\13603305 <e2>meningioma</e2>\NN\14235200 and\CC\1740 metastases\NNS\13533470 patients\NNS\9898892 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 <e1>mannitol</e1>\NN\3214670 were\VBD\836236 higher\JJR\1740 than\IN\1740 white\JJ\1740 matter\NN\5670710 concentrations\NNS\4916342 except\IN\1740 in\IN\13603305 three\CD\13741022 cases\NNS\7283608 with\IN\1740 infiltration\NN\975452 by\IN\1740 neoplastic\JJ\1740 cells\NNS\3080309 .\.\1740
D008353_D004487 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 results\NNS\34213 of\IN\1740 our\PRP$\1740 study\NN\635850 show\VBP\2137132 that\IN\1740 even\RB\1740 after\IN\1740 a\DT\13649268 single\JJ\1740 bolus\NN\13899404 ,\,\1740 <e1>mannitol</e1>\NN\3214670 may\MD\15209706 leak\VB\933821 through\IN\1740 the\DT\1740 altered\JJ\1740 BBB\NN\1740 near\IN\1740 gliomas\NNS\14236743 ,\,\1740 reversing\VBG\109660 the\DT\1740 initial\JJ\1740 plasma-to-blood\JJ\1740 osmotic\JJ\1740 gradient\NN\13859043 ,\,\1740 aggravating\VBG\126264 peritumoral\JJ\1740 <e2>edema</e2>\NN\14315192 and\CC\1740 promoting\VBG\2556126 rebound\NN\7309781 of\IN\1740 ICP\NN\1740 .\.\1740
9209318
D015215_D009190 CID Lifetime\NN\15113229 treatment\NN\654885 of\IN\1740 mice\NNS\2329401 with\IN\1740 <e1>azidothymidine</e1>\NN\1740 (\-LRB-\1740 AZT\NN\3834836 )\-RRB-\1740 produces\VBZ\1617192 <e2>myelodysplasia</e2>\NN\1740 .\.\1740
D015215_D009190 CID Lifetime\NN\15113229 treatment\NN\654885 of\IN\1740 mice\NNS\2329401 with\IN\1740 azidothymidine\NN\1740 (\-LRB-\1740 <e1>AZT</e1>\NN\3834836 )\-RRB-\1740 produces\VBZ\1617192 <e2>myelodysplasia</e2>\NN\1740 .\.\1740
D015215_D009190 CID Above\IN\6392001 mentioned\VBD\730052 <e1>AZT</e1>\NN\3834836 incorporation\NN\1237415 may\MD\15209706 have\VB\2108377 induced\VBN\1627355 an\DT\6697703 ineffective\JJ\1740 hemopoiesis\NN\13526110 in\IN\13603305 the\DT\1740 primitive\JJ\1740 hemopoietic\JJ\1740 progenitor\NN\9792555 cells\NNS\3080309 ,\,\1740 which\WDT\1740 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 seen\VBN\2106506 commonly\RB\1740 in\IN\13603305 the\DT\1740 <e2>myelodysplastic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D015215_D000748 CID <e1>AZT</e1>\NN\3834836 has\VBZ\2108377 induced\VBN\1627355 a\DT\13649268 <e2>macrocytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 AIDS\NN\13974317 patients\NNS\9898892 on\IN\1740 long\JJ\1740 term\NN\6286395 AZT\NN\3834836 therapy\NN\657604 .\.\1740
D015215_D000748 CID AZT\NN\3834836 has\VBZ\2108377 induced\VBN\1627355 a\DT\13649268 <e2>macrocytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 AIDS\NN\13974317 patients\NNS\9898892 on\IN\1740 long\JJ\1740 term\NN\6286395 <e1>AZT</e1>\NN\3834836 therapy\NN\657604 .\.\1740
D015215_D000163 NONE <e1>AZT</e1>\NN\3834836 has\VBZ\2108377 induced\VBN\1627355 a\DT\13649268 macrocytic\JJ\1740 anemia\NN\14189204 in\IN\13603305 <e2>AIDS</e2>\NN\13974317 patients\NNS\9898892 on\IN\1740 long\JJ\1740 term\NN\6286395 AZT\NN\3834836 therapy\NN\657604 .\.\1740
D015215_D000163 NONE AZT\NN\3834836 has\VBZ\2108377 induced\VBN\1627355 a\DT\13649268 macrocytic\JJ\1740 anemia\NN\14189204 in\IN\13603305 <e2>AIDS</e2>\NN\13974317 patients\NNS\9898892 on\IN\1740 long\JJ\1740 term\NN\6286395 <e1>AZT</e1>\NN\3834836 therapy\NN\657604 .\.\1740
8514073
D008874_D014652 CID <e2>Venous\JJ\1740 complications</e2>\NNS\1073995 of\IN\1740 <e1>midazolam</e1>\NN\2830852 versus\IN\1740 diazepam\NNS\2830852 .\.\1740
D008874_D014652 CID Although\IN\1740 some\DT\1740 studies\NNS\635850 have\VBP\2108377 suggested\VBN\1010118 fewer\JJR\1740 <e2>venous\JJ\1740 complications</e2>\NNS\1073995 are\VBP\836236 associated\VBN\628491 with\IN\1740 <e1>midazolam</e1>\NN\2830852 than\IN\1740 with\IN\1740 diazepam\NNS\2830852 for\IN\1740 endoscopic\JJ\1740 procedures\NNS\407535 ,\,\1740 this\DT\1740 variable\NN\2452 has\VBZ\2108377 not\RB\1740 been\VBN\836236 well\RB\1740 documented\VBN\1000214 .\.\1740
D008874_D014652 CID We\PRP\1740 prospectively\RB\1740 evaluated\VBD\670261 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 complications</e2>\NNS\1073995 after\IN\1740 intravenous\JJ\1740 injection\NN\320852 of\IN\1740 diazepam\NNS\2830852 or\CC\3541091 <e1>midazolam</e1>\NN\2830852 in\IN\13603305 122\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 colonoscopy\NN\642045 and\CC\1740 esophagogastroduodenoscopy\VB\1740 .\.\1740
D008874_D014652 CID Overall\RB\1740 ,\,\1740 <e2>venous\JJ\1740 complications</e2>\NNS\1073995 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 with\IN\1740 diazepam\NN\2830852 (\-LRB-\1740 22\CD\13745420 of\IN\1740 62\CD\1740 patients\NNS\9898892 )\-RRB-\1740 than\IN\1740 with\IN\1740 <e1>midazolam</e1>\NNS\2830852 (\-LRB-\1740 4\CD\13741022 of\IN\1740 60\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D003975_D014652 CID <e2>Venous\JJ\1740 complications</e2>\NNS\1073995 of\IN\1740 midazolam\NN\2830852 versus\IN\1740 <e1>diazepam</e1>\NNS\2830852 .\.\1740
D003975_D014652 CID Although\IN\1740 some\DT\1740 studies\NNS\635850 have\VBP\2108377 suggested\VBN\1010118 fewer\JJR\1740 <e2>venous\JJ\1740 complications</e2>\NNS\1073995 are\VBP\836236 associated\VBN\628491 with\IN\1740 midazolam\NN\2830852 than\IN\1740 with\IN\1740 <e1>diazepam</e1>\NNS\2830852 for\IN\1740 endoscopic\JJ\1740 procedures\NNS\407535 ,\,\1740 this\DT\1740 variable\NN\2452 has\VBZ\2108377 not\RB\1740 been\VBN\836236 well\RB\1740 documented\VBN\1000214 .\.\1740
D003975_D014652 CID We\PRP\1740 prospectively\RB\1740 evaluated\VBD\670261 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 complications</e2>\NNS\1073995 after\IN\1740 intravenous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>diazepam</e1>\NNS\2830852 or\CC\3541091 midazolam\NN\2830852 in\IN\13603305 122\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 colonoscopy\NN\642045 and\CC\1740 esophagogastroduodenoscopy\VB\1740 .\.\1740
D003975_D014652 CID Overall\RB\1740 ,\,\1740 <e2>venous\JJ\1740 complications</e2>\NNS\1073995 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 with\IN\1740 <e1>diazepam</e1>\NN\2830852 (\-LRB-\1740 22\CD\13745420 of\IN\1740 62\CD\1740 patients\NNS\9898892 )\-RRB-\1740 than\IN\1740 with\IN\1740 midazolam\NNS\2830852 (\-LRB-\1740 4\CD\13741022 of\IN\1740 60\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D003975_D010146 NONE <e2>Pain</e2>\NN\14299637 at\IN\14622893 the\DT\1740 injection\NN\320852 site\NN\8673395 occurred\VBD\2623529 in\IN\13603305 35\CD\1740 %\NN\1740 (\-LRB-\1740 22\CD\13745420 of\IN\1740 62\CD\1740 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 <e1>diazepam</e1>\NN\2830852 group\NN\2137 compared\VBN\644583 with\IN\1740 7\CD\13741022 %\NN\1740 (\-LRB-\1740 4\CD\13741022 of\IN\1740 60\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D008874_D010146 NONE <e2>Pain</e2>\NN\14299637 at\IN\14622893 the\DT\1740 injection\NN\320852 site\NN\8673395 occurred\VBD\2623529 in\IN\13603305 35\CD\1740 %\NN\1740 (\-LRB-\1740 22\CD\13745420 of\IN\1740 62\CD\1740 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 diazepam\NN\2830852 group\NN\2137 compared\VBN\644583 with\IN\1740 7\CD\13741022 %\NN\1740 (\-LRB-\1740 4\CD\13741022 of\IN\1740 60\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>midazolam</e1>\NN\2830852 group\NN\2137 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D000431_D010146 NONE Smoking\NN\831191 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drug\NN\14778436 use\NN\407535 ,\,\1740 intravenous\JJ\1740 catheter\NN\4493505 site\NN\8673395 ,\,\1740 dwell\NN\1740 time\NN\7308889 of\IN\1740 the\DT\1740 needle\NN\13156083 ,\,\1740 <e1>alcohol</e1>\NN\7881800 use\NN\407535 ,\,\1740 and\CC\1740 <e2>pain</e2>\VB\64643 during\IN\1740 the\DT\1740 injection\NN\320852 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 venous\JJ\1740 complications\NNS\1073995 .\.\1740
D000431_D014652 NONE Smoking\NN\831191 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drug\NN\14778436 use\NN\407535 ,\,\1740 intravenous\JJ\1740 catheter\NN\4493505 site\NN\8673395 ,\,\1740 dwell\NN\1740 time\NN\7308889 of\IN\1740 the\DT\1740 needle\NN\13156083 ,\,\1740 <e1>alcohol</e1>\NN\7881800 use\NN\407535 ,\,\1740 and\CC\1740 pain\VB\64643 during\IN\1740 the\DT\1740 injection\NN\320852 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 complications</e2>\NNS\1073995 .\.\1740
6892185
D002122_D015878 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 injected\VBN\81072 into\IN\1740 the\DT\1740 cerebral\JJ\1740 ventricles\NNS\5303402 of\IN\1740 group-housed\JJ\1740 unanaesthetized\JJ\1740 cats\NNS\2120997 upon\IN\1740 vocalization\NN\33020 (\-LRB-\1740 rage\NN\7516354 ,\,\1740 hissing\VBG\983824 and\CC\1740 snarling\VBG\941990 )\-RRB-\1740 ,\,\1740 fighting\VBG\1090335 (\-LRB-\1740 attack\NN\955060 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 ,\,\1740 defense\NN\952963 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 and\CC\1740 biting\VBG\1224001 )\-RRB-\1740 ,\,\1740 <e2>mydriasis</e2>\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 produced\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 eserine\NN\1740 injected\VBN\81072 similarly\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D002122_D015878 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 <e2>mydriasis</e2>\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 evoked\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 eserine\NN\1740 were\VBD\836236 not\RB\1740 significantly\RB\1740 changed\VBN\46534 by\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 .\.\1740
D002122_D015878 NONE It\PRP\6125041 is\VBZ\836236 apparent\JJ\1740 that\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 can\MD\3094503 "\``\1740 dissociate\VB\2431320 "\''\1740 vocalization\NN\33020 and\CC\1740 fighting\VBG\1090335 from\IN\1740 autonomic\JJ\1740 and\CC\1740 motor\NN\3699975 phenomena\NNS\29677 such\JJ\1740 as\IN\14622893 <e2>mydriasis</e2>\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 caused\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 eserine\JJ\1740 .\.\1740
D002122_D014202 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 injected\VBN\81072 into\IN\1740 the\DT\1740 cerebral\JJ\1740 ventricles\NNS\5303402 of\IN\1740 group-housed\JJ\1740 unanaesthetized\JJ\1740 cats\NNS\2120997 upon\IN\1740 vocalization\NN\33020 (\-LRB-\1740 rage\NN\7516354 ,\,\1740 hissing\VBG\983824 and\CC\1740 snarling\VBG\941990 )\-RRB-\1740 ,\,\1740 fighting\VBG\1090335 (\-LRB-\1740 attack\NN\955060 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 ,\,\1740 defense\NN\952963 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 and\CC\1740 biting\VBG\1224001 )\-RRB-\1740 ,\,\1740 mydriasis\NN\365995 ,\,\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 produced\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 eserine\NN\1740 injected\VBN\81072 similarly\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D002122_D014202 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 mydriasis\NN\365995 ,\,\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 evoked\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 eserine\NN\1740 were\VBD\836236 not\RB\1740 significantly\RB\1740 changed\VBN\46534 by\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 .\.\1740
D002122_D014202 NONE It\PRP\6125041 is\VBZ\836236 apparent\JJ\1740 that\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 can\MD\3094503 "\``\1740 dissociate\VB\2431320 "\''\1740 vocalization\NN\33020 and\CC\1740 fighting\VBG\1090335 from\IN\1740 autonomic\JJ\1740 and\CC\1740 motor\NN\3699975 phenomena\NNS\29677 such\JJ\1740 as\IN\14622893 mydriasis\NN\365995 ,\,\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 caused\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 eserine\JJ\1740 .\.\1740
D002122_D004830 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 injected\VBN\81072 into\IN\1740 the\DT\1740 cerebral\JJ\1740 ventricles\NNS\5303402 of\IN\1740 group-housed\JJ\1740 unanaesthetized\JJ\1740 cats\NNS\2120997 upon\IN\1740 vocalization\NN\33020 (\-LRB-\1740 rage\NN\7516354 ,\,\1740 hissing\VBG\983824 and\CC\1740 snarling\VBG\941990 )\-RRB-\1740 ,\,\1740 fighting\VBG\1090335 (\-LRB-\1740 attack\NN\955060 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 ,\,\1740 defense\NN\952963 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 and\CC\1740 biting\VBG\1224001 )\-RRB-\1740 ,\,\1740 mydriasis\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 <e2>clonic-tonic\JJ\1740 convulsions</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 eserine\NN\1740 injected\VBN\81072 similarly\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D002122_D004830 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 mydriasis\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 <e2>clonic-tonic\JJ\1740 convulsions</e2>\NNS\14081375 evoked\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 eserine\NN\1740 were\VBD\836236 not\RB\1740 significantly\RB\1740 changed\VBN\46534 by\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 .\.\1740
D002122_D004830 NONE It\PRP\6125041 is\VBZ\836236 apparent\JJ\1740 that\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 can\MD\3094503 "\``\1740 dissociate\VB\2431320 "\''\1740 vocalization\NN\33020 and\CC\1740 fighting\VBG\1090335 from\IN\1740 autonomic\JJ\1740 and\CC\1740 motor\NN\3699975 phenomena\NNS\29677 such\JJ\1740 as\IN\14622893 mydriasis\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 <e2>clonic-tonic\JJ\1740 convulsions</e2>\NNS\14081375 caused\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 eserine\JJ\1740 .\.\1740
D002217_D015878 CID The\DT\1740 effect\NN\34213 of\IN\1740 calcium\NN\14625458 chloride\NN\14818238 injected\VBN\81072 into\IN\1740 the\DT\1740 cerebral\JJ\1740 ventricles\NNS\5303402 of\IN\1740 group-housed\JJ\1740 unanaesthetized\JJ\1740 cats\NNS\2120997 upon\IN\1740 vocalization\NN\33020 (\-LRB-\1740 rage\NN\7516354 ,\,\1740 hissing\VBG\983824 and\CC\1740 snarling\VBG\941990 )\-RRB-\1740 ,\,\1740 fighting\VBG\1090335 (\-LRB-\1740 attack\NN\955060 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 ,\,\1740 defense\NN\952963 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 and\CC\1740 biting\VBG\1224001 )\-RRB-\1740 ,\,\1740 <e2>mydriasis</e2>\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>carbachol</e1>\NN\1740 and\CC\1740 eserine\NN\1740 injected\VBN\81072 similarly\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D002217_D015878 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 <e2>mydriasis</e2>\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 evoked\VBN\1617192 by\IN\1740 <e1>carbachol</e1>\NN\1740 and\CC\1740 eserine\NN\1740 were\VBD\836236 not\RB\1740 significantly\RB\1740 changed\VBN\46534 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 .\.\1740
D002217_D015878 CID It\PRP\6125041 is\VBZ\836236 apparent\JJ\1740 that\IN\1740 calcium\NN\14625458 chloride\NN\14818238 can\MD\3094503 "\``\1740 dissociate\VB\2431320 "\''\1740 vocalization\NN\33020 and\CC\1740 fighting\VBG\1090335 from\IN\1740 autonomic\JJ\1740 and\CC\1740 motor\NN\3699975 phenomena\NNS\29677 such\JJ\1740 as\IN\14622893 <e2>mydriasis</e2>\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 caused\VBN\1617192 by\IN\1740 <e1>carbachol</e1>\NN\1740 and\CC\1740 eserine\JJ\1740 .\.\1740
D002217_D014202 CID The\DT\1740 effect\NN\34213 of\IN\1740 calcium\NN\14625458 chloride\NN\14818238 injected\VBN\81072 into\IN\1740 the\DT\1740 cerebral\JJ\1740 ventricles\NNS\5303402 of\IN\1740 group-housed\JJ\1740 unanaesthetized\JJ\1740 cats\NNS\2120997 upon\IN\1740 vocalization\NN\33020 (\-LRB-\1740 rage\NN\7516354 ,\,\1740 hissing\VBG\983824 and\CC\1740 snarling\VBG\941990 )\-RRB-\1740 ,\,\1740 fighting\VBG\1090335 (\-LRB-\1740 attack\NN\955060 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 ,\,\1740 defense\NN\952963 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 and\CC\1740 biting\VBG\1224001 )\-RRB-\1740 ,\,\1740 mydriasis\NN\365995 ,\,\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>carbachol</e1>\NN\1740 and\CC\1740 eserine\NN\1740 injected\VBN\81072 similarly\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D002217_D014202 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 mydriasis\NN\365995 ,\,\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 evoked\VBN\1617192 by\IN\1740 <e1>carbachol</e1>\NN\1740 and\CC\1740 eserine\NN\1740 were\VBD\836236 not\RB\1740 significantly\RB\1740 changed\VBN\46534 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 .\.\1740
D002217_D014202 CID It\PRP\6125041 is\VBZ\836236 apparent\JJ\1740 that\IN\1740 calcium\NN\14625458 chloride\NN\14818238 can\MD\3094503 "\``\1740 dissociate\VB\2431320 "\''\1740 vocalization\NN\33020 and\CC\1740 fighting\VBG\1090335 from\IN\1740 autonomic\JJ\1740 and\CC\1740 motor\NN\3699975 phenomena\NNS\29677 such\JJ\1740 as\IN\14622893 mydriasis\NN\365995 ,\,\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 caused\VBN\1617192 by\IN\1740 <e1>carbachol</e1>\NN\1740 and\CC\1740 eserine\JJ\1740 .\.\1740
D002217_D004830 CID The\DT\1740 effect\NN\34213 of\IN\1740 calcium\NN\14625458 chloride\NN\14818238 injected\VBN\81072 into\IN\1740 the\DT\1740 cerebral\JJ\1740 ventricles\NNS\5303402 of\IN\1740 group-housed\JJ\1740 unanaesthetized\JJ\1740 cats\NNS\2120997 upon\IN\1740 vocalization\NN\33020 (\-LRB-\1740 rage\NN\7516354 ,\,\1740 hissing\VBG\983824 and\CC\1740 snarling\VBG\941990 )\-RRB-\1740 ,\,\1740 fighting\VBG\1090335 (\-LRB-\1740 attack\NN\955060 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 ,\,\1740 defense\NN\952963 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 and\CC\1740 biting\VBG\1224001 )\-RRB-\1740 ,\,\1740 mydriasis\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 <e2>clonic-tonic\JJ\1740 convulsions</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>carbachol</e1>\NN\1740 and\CC\1740 eserine\NN\1740 injected\VBN\81072 similarly\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D002217_D004830 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 mydriasis\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 <e2>clonic-tonic\JJ\1740 convulsions</e2>\NNS\14081375 evoked\VBN\1617192 by\IN\1740 <e1>carbachol</e1>\NN\1740 and\CC\1740 eserine\NN\1740 were\VBD\836236 not\RB\1740 significantly\RB\1740 changed\VBN\46534 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 .\.\1740
D002217_D004830 CID It\PRP\6125041 is\VBZ\836236 apparent\JJ\1740 that\IN\1740 calcium\NN\14625458 chloride\NN\14818238 can\MD\3094503 "\``\1740 dissociate\VB\2431320 "\''\1740 vocalization\NN\33020 and\CC\1740 fighting\VBG\1090335 from\IN\1740 autonomic\JJ\1740 and\CC\1740 motor\NN\3699975 phenomena\NNS\29677 such\JJ\1740 as\IN\14622893 mydriasis\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 <e2>clonic-tonic\JJ\1740 convulsions</e2>\NNS\14081375 caused\VBN\1617192 by\IN\1740 <e1>carbachol</e1>\NN\1740 and\CC\1740 eserine\JJ\1740 .\.\1740
D010830_D015878 CID The\DT\1740 effect\NN\34213 of\IN\1740 calcium\NN\14625458 chloride\NN\14818238 injected\VBN\81072 into\IN\1740 the\DT\1740 cerebral\JJ\1740 ventricles\NNS\5303402 of\IN\1740 group-housed\JJ\1740 unanaesthetized\JJ\1740 cats\NNS\2120997 upon\IN\1740 vocalization\NN\33020 (\-LRB-\1740 rage\NN\7516354 ,\,\1740 hissing\VBG\983824 and\CC\1740 snarling\VBG\941990 )\-RRB-\1740 ,\,\1740 fighting\VBG\1090335 (\-LRB-\1740 attack\NN\955060 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 ,\,\1740 defense\NN\952963 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 and\CC\1740 biting\VBG\1224001 )\-RRB-\1740 ,\,\1740 <e2>mydriasis</e2>\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 produced\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 <e1>eserine</e1>\NN\1740 injected\VBN\81072 similarly\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D010830_D015878 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 <e2>mydriasis</e2>\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 evoked\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 <e1>eserine</e1>\NN\1740 were\VBD\836236 not\RB\1740 significantly\RB\1740 changed\VBN\46534 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 .\.\1740
D010830_D015878 CID It\PRP\6125041 is\VBZ\836236 apparent\JJ\1740 that\IN\1740 calcium\NN\14625458 chloride\NN\14818238 can\MD\3094503 "\``\1740 dissociate\VB\2431320 "\''\1740 vocalization\NN\33020 and\CC\1740 fighting\VBG\1090335 from\IN\1740 autonomic\JJ\1740 and\CC\1740 motor\NN\3699975 phenomena\NNS\29677 such\JJ\1740 as\IN\14622893 <e2>mydriasis</e2>\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 caused\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 <e1>eserine</e1>\JJ\1740 .\.\1740
D010830_D014202 CID The\DT\1740 effect\NN\34213 of\IN\1740 calcium\NN\14625458 chloride\NN\14818238 injected\VBN\81072 into\IN\1740 the\DT\1740 cerebral\JJ\1740 ventricles\NNS\5303402 of\IN\1740 group-housed\JJ\1740 unanaesthetized\JJ\1740 cats\NNS\2120997 upon\IN\1740 vocalization\NN\33020 (\-LRB-\1740 rage\NN\7516354 ,\,\1740 hissing\VBG\983824 and\CC\1740 snarling\VBG\941990 )\-RRB-\1740 ,\,\1740 fighting\VBG\1090335 (\-LRB-\1740 attack\NN\955060 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 ,\,\1740 defense\NN\952963 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 and\CC\1740 biting\VBG\1224001 )\-RRB-\1740 ,\,\1740 mydriasis\NN\365995 ,\,\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 produced\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 <e1>eserine</e1>\NN\1740 injected\VBN\81072 similarly\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D010830_D014202 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 mydriasis\NN\365995 ,\,\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 evoked\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 <e1>eserine</e1>\NN\1740 were\VBD\836236 not\RB\1740 significantly\RB\1740 changed\VBN\46534 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 .\.\1740
D010830_D014202 CID It\PRP\6125041 is\VBZ\836236 apparent\JJ\1740 that\IN\1740 calcium\NN\14625458 chloride\NN\14818238 can\MD\3094503 "\``\1740 dissociate\VB\2431320 "\''\1740 vocalization\NN\33020 and\CC\1740 fighting\VBG\1090335 from\IN\1740 autonomic\JJ\1740 and\CC\1740 motor\NN\3699975 phenomena\NNS\29677 such\JJ\1740 as\IN\14622893 mydriasis\NN\365995 ,\,\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonic-tonic\JJ\1740 convulsions\NNS\14081375 caused\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 <e1>eserine</e1>\JJ\1740 .\.\1740
D010830_D004830 CID The\DT\1740 effect\NN\34213 of\IN\1740 calcium\NN\14625458 chloride\NN\14818238 injected\VBN\81072 into\IN\1740 the\DT\1740 cerebral\JJ\1740 ventricles\NNS\5303402 of\IN\1740 group-housed\JJ\1740 unanaesthetized\JJ\1740 cats\NNS\2120997 upon\IN\1740 vocalization\NN\33020 (\-LRB-\1740 rage\NN\7516354 ,\,\1740 hissing\VBG\983824 and\CC\1740 snarling\VBG\941990 )\-RRB-\1740 ,\,\1740 fighting\VBG\1090335 (\-LRB-\1740 attack\NN\955060 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 ,\,\1740 defense\NN\952963 with\IN\1740 paws\NNS\2153445 and\CC\1740 claws\NNS\5581514 and\CC\1740 biting\VBG\1224001 )\-RRB-\1740 ,\,\1740 mydriasis\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 <e2>clonic-tonic\JJ\1740 convulsions</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 <e1>eserine</e1>\NN\1740 injected\VBN\81072 similarly\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D010830_D004830 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 mydriasis\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 <e2>clonic-tonic\JJ\1740 convulsions</e2>\NNS\14081375 evoked\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 <e1>eserine</e1>\NN\1740 were\VBD\836236 not\RB\1740 significantly\RB\1740 changed\VBN\46534 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 .\.\1740
D010830_D004830 CID It\PRP\6125041 is\VBZ\836236 apparent\JJ\1740 that\IN\1740 calcium\NN\14625458 chloride\NN\14818238 can\MD\3094503 "\``\1740 dissociate\VB\2431320 "\''\1740 vocalization\NN\33020 and\CC\1740 fighting\VBG\1090335 from\IN\1740 autonomic\JJ\1740 and\CC\1740 motor\NN\3699975 phenomena\NNS\29677 such\JJ\1740 as\IN\14622893 mydriasis\NN\365995 ,\,\1740 tremor\NN\345926 and\CC\1740 <e2>clonic-tonic\JJ\1740 convulsions</e2>\NNS\14081375 caused\VBN\1617192 by\IN\1740 carbachol\NN\1740 and\CC\1740 <e1>eserine</e1>\JJ\1740 .\.\1740
11337188
D010068_D018366 CID <e2>Cutaneous\JJ\1740 leucocytoclastic\JJ\1740 vasculitis</e2>\NN\14336539 associated\VBN\628491 with\IN\1740 <e1>oxacillin</e1>\NN\3910417 .\.\1740
D010068_D018366 CID <e1>Oxacillin</e1>\NNP\3910417 should\MD\1740 be\VB\836236 included\VBN\690614 among\IN\1740 the\DT\1740 drugs\NNS\14778436 that\WDT\1740 can\MD\3094503 cause\VB\1617192 <e2>leucocytoclastic\JJ\1740 vasculitis</e2>\NN\14336539 .\.\1740
D010068_D013203 NONE A\DT\13649268 67-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>oxacillin</e1>\NN\3910417 for\IN\1740 one\CD\13741022 week\NN\15113229 because\IN\1740 of\IN\1740 <e2>Staphylococcus\FW\1350855 aureus\FW\1740 bacteremia</e2>\NN\14204950 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 failure\NN\66216 and\CC\1740 diffuse\JJ\1740 ,\,\1740 symmetric\JJ\1740 ,\,\1740 palpable\JJ\1740 purpuric\JJ\1740 lesions\NNS\14204950 on\IN\1740 his\PRP$\1740 feet\NNS\5563034 .\.\1740
D010068_D016470 NONE A\DT\13649268 67-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>oxacillin</e1>\NN\3910417 for\IN\1740 one\CD\13741022 week\NN\15113229 because\IN\1740 of\IN\1740 <e2>Staphylococcus\FW\1350855 aureus\FW\1740 bacteremia</e2>\NN\14204950 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 failure\NN\66216 and\CC\1740 diffuse\JJ\1740 ,\,\1740 symmetric\JJ\1740 ,\,\1740 palpable\JJ\1740 purpuric\JJ\1740 lesions\NNS\14204950 on\IN\1740 his\PRP$\1740 feet\NNS\5563034 .\.\1740
D010068_D051437 CID A\DT\13649268 67-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>oxacillin</e1>\NN\3910417 for\IN\1740 one\CD\13741022 week\NN\15113229 because\IN\1740 of\IN\1740 Staphylococcus\FW\1350855 aureus\FW\1740 bacteremia\NN\14204950 ,\,\1740 developed\VBD\1753788 <e2>renal\JJ\1740 failure</e2>\NN\66216 and\CC\1740 diffuse\JJ\1740 ,\,\1740 symmetric\JJ\1740 ,\,\1740 palpable\JJ\1740 purpuric\JJ\1740 lesions\NNS\14204950 on\IN\1740 his\PRP$\1740 feet\NNS\5563034 .\.\1740
D010068_D011693 NONE A\DT\13649268 67-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>oxacillin</e1>\NN\3910417 for\IN\1740 one\CD\13741022 week\NN\15113229 because\IN\1740 of\IN\1740 Staphylococcus\FW\1350855 aureus\FW\1740 bacteremia\NN\14204950 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 failure\NN\66216 and\CC\1740 diffuse\JJ\1740 ,\,\1740 symmetric\JJ\1740 ,\,\1740 palpable\JJ\1740 <e2>purpuric\JJ\1740 lesions</e2>\NNS\14204950 on\IN\1740 his\PRP$\1740 feet\NNS\5563034 .\.\1740
6111982
D011433_D001145 NONE Its\PRP$\6125041 antiarrhythmic\JJ\1740 effectiveness\NN\5190804 surpasses\VBZ\1101913 that\DT\1740 of\IN\1740 <e1>propranolol</e1>\NN\1740 and\CC\1740 pindolol\NN\2832168 inhibiting\VBG\2510337 the\DT\1740 ouabain\NN\1740 <e2>arrhythmia</e2>\NN\14103288 in\IN\13603305 dogs\NNS\2083346 and\CC\1740 cats\NNS\2120997 .\.\1740
D010869_D001145 NONE Its\PRP$\6125041 antiarrhythmic\JJ\1740 effectiveness\NN\5190804 surpasses\VBZ\1101913 that\DT\1740 of\IN\1740 propranolol\NN\1740 and\CC\1740 <e1>pindolol</e1>\NN\2832168 inhibiting\VBG\2510337 the\DT\1740 ouabain\NN\1740 <e2>arrhythmia</e2>\NN\14103288 in\IN\13603305 dogs\NNS\2083346 and\CC\1740 cats\NNS\2120997 .\.\1740
D010042_D001145 CID Its\PRP$\6125041 antiarrhythmic\JJ\1740 effectiveness\NN\5190804 surpasses\VBZ\1101913 that\DT\1740 of\IN\1740 propranolol\NN\1740 and\CC\1740 pindolol\NN\2832168 inhibiting\VBG\2510337 the\DT\1740 <e1>ouabain</e1>\NN\1740 <e2>arrhythmia</e2>\NN\14103288 in\IN\13603305 dogs\NNS\2083346 and\CC\1740 cats\NNS\2120997 .\.\1740
10533019
D004110_D013746 CID Rapid\JJ\1740 reversal\NN\199130 of\IN\1740 life-threatening\JJ\1740 <e1>diltiazem-induced</e1>\JJ\1740 <e2>tetany</e2>\NN\14304060 with\IN\1740 calcium\NN\14625458 chloride\NN\14818238 .\.\1740
D004110_D013746 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>tetany</e2>\NN\14304060 with\IN\1740 sudden\JJ\1740 respiratory\JJ\1740 arrest\NN\88481 after\IN\1740 the\DT\1740 infusion\NN\14589223 of\IN\1740 intravenous\JJ\1740 <e1>diltiazem</e1>\NN\2938514 .\.\1740
D004110_D013746 CID The\DT\1740 emergency\NN\7417644 physician\NN\10305802 should\MD\1740 be\VB\836236 aware\JJ\1740 that\IN\1740 life-threatening\JJ\1740 <e2>tetany</e2>\NN\14304060 may\MD\15209706 accompany\VB\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 intravenous\JJ\1740 <e1>diltiazem</e1>\NN\2938514 and\CC\1740 that\IN\1740 calcium\NN\14625458 chloride\NN\14818238 may\MD\15209706 be\VB\836236 a\DT\13649268 rapid\JJ\1740 and\CC\1740 effective\JJ\1740 remedy\NN\258854 .\.\1740
D002122_D013746 NONE Rapid\JJ\1740 reversal\NN\199130 of\IN\1740 life-threatening\JJ\1740 diltiazem-induced\JJ\1740 <e2>tetany</e2>\NN\14304060 with\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 .\.\1740
D002122_D013746 NONE The\DT\1740 administration\NN\1133281 of\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 rapidly\RB\1740 resolved\VBD\352826 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>tetany</e2>\NN\14304060 with\IN\1740 prompt\JJ\1740 recovery\NN\7357388 of\IN\1740 respiratory\JJ\1740 function\NN\13783581 ,\,\1740 averting\VBG\2452885 the\DT\1740 need\NN\13920835 for\IN\1740 more\RBR\1740 aggressive\JJ\1740 airway\NN\3253398 management\NN\1123598 and\CC\1740 ventilatory\JJ\1740 support\NN\407535 .\.\1740
D002122_D013746 NONE The\DT\1740 emergency\NN\7417644 physician\NN\10305802 should\MD\1740 be\VB\836236 aware\JJ\1740 that\IN\1740 life-threatening\JJ\1740 <e2>tetany</e2>\NN\14304060 may\MD\15209706 accompany\VB\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 intravenous\JJ\1740 diltiazem\NN\2938514 and\CC\1740 that\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 may\MD\15209706 be\VB\836236 a\DT\13649268 rapid\JJ\1740 and\CC\1740 effective\JJ\1740 remedy\NN\258854 .\.\1740
D004110_D012131 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 tetany\NN\14304060 with\IN\1740 sudden\JJ\1740 <e2>respiratory\JJ\1740 arrest</e2>\NN\88481 after\IN\1740 the\DT\1740 infusion\NN\14589223 of\IN\1740 intravenous\JJ\1740 <e1>diltiazem</e1>\NN\2938514 .\.\1740
14982270
D008713_D041781 CID <e1>Methimazole-induced</e1>\JJ\1740 <e2>cholestatic\NN\1740 jaundice</e2>\NN\14299637 .\.\1740
D008713_D007565 NONE A\DT\13649268 43-year-old\JJ\1740 woman\NN\9605289 had\VBD\2108377 severe\JJ\1740 <e2>jaundice</e2>\NN\14299637 and\CC\1740 itching\VBG\63291 1\CD\13741022 month\NN\15113229 after\IN\1740 receiving\VBG\2210855 <e1>methimazole</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 and\CC\1740 propranolol\NN\1740 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 hyperthyroidism\NN\14059928 .\.\1740
D008713_D011537 CID A\DT\13649268 43-year-old\JJ\1740 woman\NN\9605289 had\VBD\2108377 severe\JJ\1740 jaundice\NN\14299637 and\CC\1740 <e2>itching</e2>\VBG\63291 1\CD\13741022 month\NN\15113229 after\IN\1740 receiving\VBG\2210855 <e1>methimazole</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 and\CC\1740 propranolol\NN\1740 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 hyperthyroidism\NN\14059928 .\.\1740
D008713_D006980 NONE A\DT\13649268 43-year-old\JJ\1740 woman\NN\9605289 had\VBD\2108377 severe\JJ\1740 jaundice\NN\14299637 and\CC\1740 itching\VBG\63291 1\CD\13741022 month\NN\15113229 after\IN\1740 receiving\VBG\2210855 <e1>methimazole</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 and\CC\1740 propranolol\NN\1740 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 .\.\1740
D011433_D007565 NONE A\DT\13649268 43-year-old\JJ\1740 woman\NN\9605289 had\VBD\2108377 severe\JJ\1740 <e2>jaundice</e2>\NN\14299637 and\CC\1740 itching\VBG\63291 1\CD\13741022 month\NN\15113229 after\IN\1740 receiving\VBG\2210855 methimazole\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>propranolol</e1>\NN\1740 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 hyperthyroidism\NN\14059928 .\.\1740
D011433_D011537 NONE A\DT\13649268 43-year-old\JJ\1740 woman\NN\9605289 had\VBD\2108377 severe\JJ\1740 jaundice\NN\14299637 and\CC\1740 <e2>itching</e2>\VBG\63291 1\CD\13741022 month\NN\15113229 after\IN\1740 receiving\VBG\2210855 methimazole\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>propranolol</e1>\NN\1740 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 hyperthyroidism\NN\14059928 .\.\1740
D011433_D006980 NONE A\DT\13649268 43-year-old\JJ\1740 woman\NN\9605289 had\VBD\2108377 severe\JJ\1740 jaundice\NN\14299637 and\CC\1740 itching\VBG\63291 1\CD\13741022 month\NN\15113229 after\IN\1740 receiving\VBG\2210855 methimazole\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>propranolol</e1>\NN\1740 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 .\.\1740
D008713_D002779 NONE <e1>Methimazole-induced</e1>\JJ\1740 <e2>cholestasis</e2>\NN\14052403 was\VBD\836236 diagnosed\VBN\644583 ,\,\1740 and\CC\1740 propranolol\NN\1740 therapy\NN\657604 was\VBD\836236 resumed\VBN\2679899 .\.\1740
D011433_D002779 NONE Methimazole-induced\JJ\1740 <e2>cholestasis</e2>\NN\14052403 was\VBD\836236 diagnosed\VBN\644583 ,\,\1740 and\CC\1740 <e1>propranolol</e1>\NN\1740 therapy\NN\657604 was\VBD\836236 resumed\VBN\2679899 .\.\1740
8638876
D011374_D006261 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 <e2>headache</e2>\NN\5829480 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 left\VBD\120316 hemiparesis\NN\1740 and\CC\1740 seizure\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 <e1>progesterone</e1>\NN\14747338 and\CC\1740 estradiol\NN\14749794 .\.\1740
D011374_D009325 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 headache\NN\5829480 ,\,\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 left\VBD\120316 hemiparesis\NN\1740 and\CC\1740 seizure\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 <e1>progesterone</e1>\NN\14747338 and\CC\1740 estradiol\NN\14749794 .\.\1740
D011374_D014839 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 headache\NN\5829480 ,\,\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 ,\,\1740 left\VBD\120316 hemiparesis\NN\1740 and\CC\1740 seizure\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 <e1>progesterone</e1>\NN\14747338 and\CC\1740 estradiol\NN\14749794 .\.\1740
D011374_D010291 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 headache\NN\5829480 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 left\VBD\120316 <e2>hemiparesis</e2>\NN\1740 and\CC\1740 seizure\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 <e1>progesterone</e1>\NN\14747338 and\CC\1740 estradiol\NN\14749794 .\.\1740
D011374_D012640 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 headache\NN\5829480 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 left\VBD\120316 hemiparesis\NN\1740 and\CC\1740 <e2>seizure</e2>\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 <e1>progesterone</e1>\NN\14747338 and\CC\1740 estradiol\NN\14749794 .\.\1740
D004958_D006261 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 <e2>headache</e2>\NN\5829480 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 left\VBD\120316 hemiparesis\NN\1740 and\CC\1740 seizure\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 progesterone\NN\14747338 and\CC\1740 <e1>estradiol</e1>\NN\14749794 .\.\1740
D004958_D009325 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 headache\NN\5829480 ,\,\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 left\VBD\120316 hemiparesis\NN\1740 and\CC\1740 seizure\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 progesterone\NN\14747338 and\CC\1740 <e1>estradiol</e1>\NN\14749794 .\.\1740
D004958_D014839 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 headache\NN\5829480 ,\,\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 ,\,\1740 left\VBD\120316 hemiparesis\NN\1740 and\CC\1740 seizure\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 progesterone\NN\14747338 and\CC\1740 <e1>estradiol</e1>\NN\14749794 .\.\1740
D004958_D010291 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 headache\NN\5829480 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 left\VBD\120316 <e2>hemiparesis</e2>\NN\1740 and\CC\1740 seizure\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 progesterone\NN\14747338 and\CC\1740 <e1>estradiol</e1>\NN\14749794 .\.\1740
D004958_D012640 NONE A\DT\13649268 forty-six\NN\1740 year-old\NN\1740 premenopausal\JJ\1740 woman\NN\9605289 developed\VBD\1753788 headache\NN\5829480 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 left\VBD\120316 hemiparesis\NN\1740 and\CC\1740 <e2>seizure</e2>\VB\1740 two\CD\13741022 days\NNS\15140892 after\IN\1740 parenteral\JJ\1740 use\NN\407535 of\IN\1740 progesterone\NN\14747338 and\CC\1740 <e1>estradiol</e1>\NN\14749794 .\.\1740
D004958_D003920 NONE In\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 the\DT\1740 authors\NNS\9610660 postulate\VBP\756338 that\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>estradiol</e1>\NN\14749794 and\CC\1740 progesterone\NN\14747338 and\CC\1740 the\DT\1740 underlying\VBG\2604760 <e2>DM</e2>\NN\14117805 increased\VBD\169651 vascular\JJ\1740 thrombogenicity\NN\1740 ,\,\1740 which\WDT\1740 provided\VBD\2199590 a\DT\13649268 common\JJ\1740 denominator\NN\13733167 for\IN\1740 thrombosis\NN\14100769 of\IN\1740 both\CC\1740 the\DT\1740 ICA\NN\1740 and\CC\1740 the\DT\1740 venous\JJ\1740 sinus\NN\5248181 .\.\1740
D004958_D002341 CID In\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 the\DT\1740 authors\NNS\9610660 postulate\VBP\756338 that\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>estradiol</e1>\NN\14749794 and\CC\1740 progesterone\NN\14747338 and\CC\1740 the\DT\1740 underlying\VBG\2604760 DM\NN\14117805 increased\VBD\169651 vascular\JJ\1740 thrombogenicity\NN\1740 ,\,\1740 which\WDT\1740 provided\VBD\2199590 a\DT\13649268 common\JJ\1740 denominator\NN\13733167 for\IN\1740 <e2>thrombosis\NN\14100769 of\IN\1740 both\CC\1740 the\DT\1740 ICA\NN\1740 and\CC\1740 the\DT\1740 venous\JJ\1740 sinus</e2>\NN\5248181 .\.\1740
D004958_D012851 CID In\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 the\DT\1740 authors\NNS\9610660 postulate\VBP\756338 that\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>estradiol</e1>\NN\14749794 and\CC\1740 progesterone\NN\14747338 and\CC\1740 the\DT\1740 underlying\VBG\2604760 DM\NN\14117805 increased\VBD\169651 vascular\JJ\1740 thrombogenicity\NN\1740 ,\,\1740 which\WDT\1740 provided\VBD\2199590 a\DT\13649268 common\JJ\1740 denominator\NN\13733167 for\IN\1740 <e2>thrombosis\NN\14100769 of\IN\1740 both\CC\1740 the\DT\1740 ICA\NN\1740 and\CC\1740 the\DT\1740 venous\JJ\1740 sinus</e2>\NN\5248181 .\.\1740
D011374_D003920 NONE In\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 the\DT\1740 authors\NNS\9610660 postulate\VBP\756338 that\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 estradiol\NN\14749794 and\CC\1740 <e1>progesterone</e1>\NN\14747338 and\CC\1740 the\DT\1740 underlying\VBG\2604760 <e2>DM</e2>\NN\14117805 increased\VBD\169651 vascular\JJ\1740 thrombogenicity\NN\1740 ,\,\1740 which\WDT\1740 provided\VBD\2199590 a\DT\13649268 common\JJ\1740 denominator\NN\13733167 for\IN\1740 thrombosis\NN\14100769 of\IN\1740 both\CC\1740 the\DT\1740 ICA\NN\1740 and\CC\1740 the\DT\1740 venous\JJ\1740 sinus\NN\5248181 .\.\1740
D011374_D002341 CID In\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 the\DT\1740 authors\NNS\9610660 postulate\VBP\756338 that\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 estradiol\NN\14749794 and\CC\1740 <e1>progesterone</e1>\NN\14747338 and\CC\1740 the\DT\1740 underlying\VBG\2604760 DM\NN\14117805 increased\VBD\169651 vascular\JJ\1740 thrombogenicity\NN\1740 ,\,\1740 which\WDT\1740 provided\VBD\2199590 a\DT\13649268 common\JJ\1740 denominator\NN\13733167 for\IN\1740 <e2>thrombosis\NN\14100769 of\IN\1740 both\CC\1740 the\DT\1740 ICA\NN\1740 and\CC\1740 the\DT\1740 venous\JJ\1740 sinus</e2>\NN\5248181 .\.\1740
D011374_D012851 CID In\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 the\DT\1740 authors\NNS\9610660 postulate\VBP\756338 that\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 estradiol\NN\14749794 and\CC\1740 <e1>progesterone</e1>\NN\14747338 and\CC\1740 the\DT\1740 underlying\VBG\2604760 DM\NN\14117805 increased\VBD\169651 vascular\JJ\1740 thrombogenicity\NN\1740 ,\,\1740 which\WDT\1740 provided\VBD\2199590 a\DT\13649268 common\JJ\1740 denominator\NN\13733167 for\IN\1740 <e2>thrombosis\NN\14100769 of\IN\1740 both\CC\1740 the\DT\1740 ICA\NN\1740 and\CC\1740 the\DT\1740 venous\JJ\1740 sinus</e2>\NN\5248181 .\.\1740
6732043
D000728_D020181 CID Induction\NN\7450842 of\IN\1740 the\DT\1740 <e2>obstructive\JJ\1740 sleep\NN\14034177 apnea\NN\14299637 syndrome</e2>\NN\5870365 in\IN\13603305 a\DT\13649268 woman\NN\9605289 by\IN\1740 exogenous\JJ\1740 <e1>androgen</e1>\NN\14745635 administration\NN\1133281 .\.\1740
D000728_D020181 CID We\PRP\1740 documented\VBD\1000214 airway\NN\3253398 occlusion\NN\14081375 during\IN\1740 sleep\NN\14034177 and\CC\1740 an\DT\6697703 abnormally\RB\1740 high\JJ\1740 supraglottic\JJ\1740 resistance\NN\37396 while\IN\15122231 awake\JJ\1740 in\IN\13603305 a\DT\13649268 54-yr-old\JJ\1740 woman\NN\9605289 who\WP\8299493 had\VBD\2108377 developed\VBN\1753788 physical\JJ\1740 changes\NNS\7283608 and\CC\1740 the\DT\1740 <e2>syndrome\NN\5870365 of\IN\1740 obstructive\JJ\1740 sleep\NN\14034177 apnea</e2>\NN\14299637 while\IN\15122231 being\VBG\836236 administered\VBN\2436349 exogenous\JJ\1740 <e1>androgens</e1>\NNS\14745635 .\.\1740
D000728_D020181 CID A\DT\13649268 rechallenge\NN\1740 with\IN\1740 <e1>androgen</e1>\NN\14745635 produced\VBD\1617192 symptoms\NNS\5823932 of\IN\1740 <e2>obstructive\JJ\1740 sleep\NN\14034177 apnea</e2>\NN\14299637 that\WDT\1740 abated\VBN\441445 upon\IN\1740 withdrawal\NN\7206096 of\IN\1740 the\DT\1740 hormone\NN\5404728 .\.\1740
D000728_D020181 CID Development\NN\248977 of\IN\1740 the\DT\1740 <e2>obstructive\JJ\1740 sleep\NN\14034177 apnea\NN\14299637 syndrome</e2>\NN\5870365 must\MD\9367203 be\VB\836236 considered\VBN\689344 a\DT\13649268 possible\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 <e1>androgen</e1>\NN\14745635 therapy\NN\657604 .\.\1740
D000728_D012891 NONE Previous\JJ\1740 reports\NNS\6470073 have\VBP\2108377 favored\VBN\2397637 a\DT\13649268 role\NN\719494 of\IN\1740 <e1>androgens</e1>\NNS\14745635 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e2>sleep\NN\14034177 apnea</e2>\NN\14299637 .\.\1740
15814210
D003907_D009422 CID Minor\JJ\1740 <e2>neurological\JJ\1740 dysfunction</e2>\NN\14204950 ,\,\1740 cognitive\JJ\1740 development\NN\248977 ,\,\1740 and\CC\1740 somatic\JJ\1740 development\NN\248977 at\IN\14622893 the\DT\1740 age\NN\4916342 of\IN\1740 3\CD\13741022 to\TO\1740 7\CD\13741022 years\NNS\15144371 after\IN\1740 <e1>dexamethasone</e1>\NN\2721538 treatment\NN\654885 in\IN\13603305 very-low\JJ\1740 birth-weight\JJ\1740 infants\NNS\9918248 .\.\1740
D003907_D009422 CID The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 assess\VB\670261 minor\JJ\1740 <e2>neurological\JJ\1740 dysfunction</e2>\NN\14204950 ,\,\1740 cognitive\JJ\1740 development\NN\248977 ,\,\1740 and\CC\1740 somatic\JJ\1740 development\NN\248977 after\IN\1740 <e1>dexamethasone</e1>\NN\2721538 therapy\NN\657604 in\IN\13603305 very-low-birthweight\JJ\1740 infants\NNS\9918248 .\.\1740
D003907_D009422 CID After\IN\1740 <e1>dexamethasone</e1>\NN\2721538 treatment\NN\654885 ,\,\1740 children\NNS\9622049 showed\VBD\2137132 a\DT\13649268 higher\JJR\1740 rate\NN\13815152 of\IN\1740 minor\JJ\1740 <e2>neurological\JJ\1740 dysfunctions</e2>\NNS\14204950 .\.\1740
6153967
D004737_D012640 CID In\IN\13603305 one\CD\13741022 patient\NN\9898892 ,\,\1740 <e1>enflurane</e1>\NN\3299929 administered\VBN\2436349 during\IN\1740 a\DT\13649268 donor\NN\9608709 nephrectomy\NN\393369 resulted\VBD\2633881 in\IN\13603305 unexpected\JJ\1740 partial\JJ\1740 motor\NN\3699975 <e2>seizures</e2>\NNS\14081375 .\.\1740
D004737_D012640 CID Epileptic\JJ\1740 foci\NNS\5704266 delineated\VBD\2137132 and\CC\1740 activated\VBN\1641914 by\IN\1740 <e1>enflurane</e1>\NN\3299929 were\VBD\836236 surgically\RB\1740 ablated\VBN\469382 and\CC\1740 the\DT\1740 patients\NNS\9898892 are\VBP\836236 now\RB\1740 <e2>seizure-free</e2>\JJ\1740 .\.\1740
D004737_D004827 NONE <e2>Epileptic</e2>\JJ\1740 foci\NNS\5704266 delineated\VBD\2137132 and\CC\1740 activated\VBN\1641914 by\IN\1740 <e1>enflurane</e1>\NN\3299929 were\VBD\836236 surgically\RB\1740 ablated\VBN\469382 and\CC\1740 the\DT\1740 patients\NNS\9898892 are\VBP\836236 now\RB\1740 seizure-free\JJ\1740 .\.\1740
D004737_D004827 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 <e1>enflurane</e1>\NN\3299929 may\MD\15209706 prove\VB\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 safe\JJ\1740 fast\JJ\1740 acting\VBG\1619354 activator\NN\19613 of\IN\1740 <e2>epileptic</e2>\JJ\1740 foci\NNS\5704266 during\IN\1740 corticography\NN\1740 or\CC\3541091 depth\NN\5123416 electrode\VBP\1740 intraoperative\JJ\1740 recordings\NNS\6791372 .\.\1740
17574447
D010634_-1 NONE <e2>Hepatonecrosis</e2>\NN\1740 and\CC\1740 cholangitis\NN\14336539 related\JJ\1740 to\TO\1740 long-term\JJ\1740 <e1>phenobarbital</e1>\JJ\1740 therapy\NN\657604 :\:\1740 an\DT\6697703 autopsy\JJ\1740 report\NN\6470073 of\IN\1740 two\CD\13741022 patients\NNS\9898892 .\.\1740
D010634_D002761 CID Hepatonecrosis\NN\1740 and\CC\1740 <e2>cholangitis</e2>\NN\14336539 related\JJ\1740 to\TO\1740 long-term\JJ\1740 <e1>phenobarbital</e1>\JJ\1740 therapy\NN\657604 :\:\1740 an\DT\6697703 autopsy\JJ\1740 report\NN\6470073 of\IN\1740 two\CD\13741022 patients\NNS\9898892 .\.\1740
D010634_D008107 CID <e1>Phenobarbital</e1>\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 has\VBZ\2108377 a\DT\13649268 reputation\NN\14436875 for\IN\1740 safety\NN\13920835 ,\,\1740 and\CC\1740 it\PRP\6125041 is\VBZ\836236 commonly\RB\1740 believed\VBN\686447 that\IN\1740 PB-related\JJ\1740 increases\VBZ\169651 in\IN\13603305 serum\NN\5397468 aminotransferase\NN\15077571 levels\NNS\4916342 do\VBP\1640855 not\RB\1740 indicate\VB\952524 or\CC\3541091 predict\VB\916909 the\DT\1740 development\NN\248977 of\IN\1740 significant\JJ\1740 chronic\JJ\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 .\.\1740
D010634_D008107 CID Phenobarbital\JJ\1740 (\-LRB-\1740 <e1>PB</e1>\NN\14625458 )\-RRB-\1740 has\VBZ\2108377 a\DT\13649268 reputation\NN\14436875 for\IN\1740 safety\NN\13920835 ,\,\1740 and\CC\1740 it\PRP\6125041 is\VBZ\836236 commonly\RB\1740 believed\VBN\686447 that\IN\1740 PB-related\JJ\1740 increases\VBZ\169651 in\IN\13603305 serum\NN\5397468 aminotransferase\NN\15077571 levels\NNS\4916342 do\VBP\1640855 not\RB\1740 indicate\VB\952524 or\CC\3541091 predict\VB\916909 the\DT\1740 development\NN\248977 of\IN\1740 significant\JJ\1740 chronic\JJ\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 .\.\1740
D010634_D008107 CID Phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 has\VBZ\2108377 a\DT\13649268 reputation\NN\14436875 for\IN\1740 safety\NN\13920835 ,\,\1740 and\CC\1740 it\PRP\6125041 is\VBZ\836236 commonly\RB\1740 believed\VBN\686447 that\IN\1740 <e1>PB-related</e1>\JJ\1740 increases\VBZ\169651 in\IN\13603305 serum\NN\5397468 aminotransferase\NN\15077571 levels\NNS\4916342 do\VBP\1640855 not\RB\1740 indicate\VB\952524 or\CC\3541091 predict\VB\916909 the\DT\1740 development\NN\248977 of\IN\1740 significant\JJ\1740 chronic\JJ\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 .\.\1740
D010634_D008107 CID Our\PRP$\1740 findings\NNS\7951464 illustrate\VBP\955601 that\IN\1740 <e1>PB</e1>\NN\14625458 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 <e2>liver\NN\5298729 damage</e2>\NN\7296428 ,\,\1740 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\IN\1740 more\RBR\1740 serious\JJ\1740 and\CC\1740 deleterious\JJ\1740 consequences\NNS\34213 .\.\1740
D010634_D004827 NONE Here\RB\1740 we\PRP\1740 report\VBP\831651 of\IN\1740 two\CD\13741022 adult\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 long\JJ\1740 history\NN\15120823 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 treated\VBN\2376958 with\IN\1740 <e1>PB</e1>\NN\14625458 who\WP\8299493 died\VBD\146138 suddenly\RB\1740 :\:\1740 one\CD\13741022 as\IN\14622893 consequence\NN\34213 of\IN\1740 cardiac\JJ\1740 arrest\NN\88481 ,\,\1740 the\DT\1740 other\JJ\1740 of\IN\1740 acute\JJ\1740 bronchopneumonia\NN\14147627 .\.\1740
D010634_D006323 NONE Here\RB\1740 we\PRP\1740 report\VBP\831651 of\IN\1740 two\CD\13741022 adult\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 long\JJ\1740 history\NN\15120823 of\IN\1740 epilepsy\NN\14085708 treated\VBN\2376958 with\IN\1740 <e1>PB</e1>\NN\14625458 who\WP\8299493 died\VBD\146138 suddenly\RB\1740 :\:\1740 one\CD\13741022 as\IN\14622893 consequence\NN\34213 of\IN\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 ,\,\1740 the\DT\1740 other\JJ\1740 of\IN\1740 acute\JJ\1740 bronchopneumonia\NN\14147627 .\.\1740
D010634_D001996 NONE Here\RB\1740 we\PRP\1740 report\VBP\831651 of\IN\1740 two\CD\13741022 adult\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 long\JJ\1740 history\NN\15120823 of\IN\1740 epilepsy\NN\14085708 treated\VBN\2376958 with\IN\1740 <e1>PB</e1>\NN\14625458 who\WP\8299493 died\VBD\146138 suddenly\RB\1740 :\:\1740 one\CD\13741022 as\IN\14622893 consequence\NN\34213 of\IN\1740 cardiac\JJ\1740 arrest\NN\88481 ,\,\1740 the\DT\1740 other\JJ\1740 of\IN\1740 acute\JJ\1740 <e2>bronchopneumonia</e2>\NN\14147627 .\.\1740
D010634_D056487 NONE For\IN\1740 this\DT\1740 reason\NN\9178821 ,\,\1740 each\DT\1740 clinician\NN\10462860 should\MD\1740 recognize\VB\686447 this\DT\1740 entity\NN\1740 in\IN\13603305 the\DT\1740 differential\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e1>PB-related</e1>\JJ\1740 asymptomatic\JJ\1740 <e2>chronic\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 dysfunction</e2>\NN\14204950 .\.\1740
2220369
C015173_D020246 CID Central\JJ\1740 <e2>vein\NN\5417975 thrombosis</e2>\NN\14100769 and\CC\1740 topical\JJ\1740 <e1>dipivalyl\JJ\1740 epinephrine</e1>\NN\14807929 .\.\1740
C015173_D020246 CID A\DT\13649268 report\NN\6470073 is\VBZ\836236 given\VBN\2327200 on\IN\1740 an\DT\6697703 83-year-old\JJ\1740 female\NN\15388 who\WP\8299493 acquired\VBD\109660 central\JJ\1740 <e2>vein\NN\5417975 thrombosis</e2>\NN\14100769 in\IN\13603305 her\PRP$\1740 seeing\NN\5708432 eye\NN\5299178 one\CD\13741022 day\NN\15154774 after\IN\1740 having\VBG\2108377 started\VBN\2009433 topical\JJ\1740 medication\NN\3247620 with\IN\1740 <e1>dipivalyl\JJ\1740 epinephrine</e1>\NN\14807929 for\IN\1740 advanced\JJ\1740 glaucoma\NN\14252864 discovered\VBN\2163746 in\IN\13603305 the\DT\1740 other\JJ\1740 eye\NN\5299178 .\.\1740
C015173_D005901 NONE A\DT\13649268 report\NN\6470073 is\VBZ\836236 given\VBN\2327200 on\IN\1740 an\DT\6697703 83-year-old\JJ\1740 female\NN\15388 who\WP\8299493 acquired\VBD\109660 central\JJ\1740 vein\NN\5417975 thrombosis\NN\14100769 in\IN\13603305 her\PRP$\1740 seeing\NN\5708432 eye\NN\5299178 one\CD\13741022 day\NN\15154774 after\IN\1740 having\VBG\2108377 started\VBN\2009433 topical\JJ\1740 medication\NN\3247620 with\IN\1740 <e1>dipivalyl\JJ\1740 epinephrine</e1>\NN\14807929 for\IN\1740 advanced\JJ\1740 <e2>glaucoma</e2>\NN\14252864 discovered\VBN\2163746 in\IN\13603305 the\DT\1740 other\JJ\1740 eye\NN\5299178 .\.\1740
17366349
C092292_D009459 CID <e2>Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>ziprasidone</e1>\NN\1740 on\IN\1740 the\DT\1740 second\JJ\1740 day\NN\15154774 of\IN\1740 treatment\NN\654885 .\.\1740
C092292_D009459 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>ziprasidone</e1>\NN\1740 .\.\1740
C092292_D009459 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>NMS</e2>\NN\13649268 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>ziprasidone</e1>\NN\1740 .\.\1740
C092292_D009459 CID Although\IN\1740 conventional\JJ\1740 neuroleptics\NNS\4470232 are\VBP\836236 more\RBR\1740 frequently\RB\1740 associated\VBN\628491 with\IN\1740 <e2>NMS</e2>\NN\13649268 ,\,\1740 atypical\JJ\1740 antipsychotic\JJ\1740 drugs\NNS\14778436 like\IN\5839024 <e1>ziprasidone</e1>\NN\1740 may\MD\15209706 also\RB\1740 be\VB\836236 a\DT\13649268 cause\NN\7323922 .\.\1740
C092292_D009459 CID The\DT\1740 patient\NN\9898892 is\VBZ\836236 a\DT\13649268 24-year-old\JJ\1740 male\JJ\1740 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 schizophrenia\NN\14398067 who\WP\8299493 developed\VBD\1753788 signs\NNS\6643763 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 <e2>NMS</e2>\NN\13649268 after\IN\1740 2\CD\13741022 days\NNS\15140892 of\IN\1740 treatment\NN\654885 with\IN\1740 an\DT\6697703 80-mg/day\NN\1740 dose\NN\3740161 of\IN\1740 orally\RB\1740 administrated\VBN\2436349 <e1>ziprasidone</e1>\NN\1740 .\.\1740
C092292_D009459 CID <e2>NMS</e2>\NN\13649268 due\JJ\1740 to\TO\1740 <e1>ziprasidone</e1>\NN\1740 reported\VBN\831651 in\IN\13603305 the\DT\1740 literature\NN\6362953 .\.\1740
C092292_D012559 NONE The\DT\1740 patient\NN\9898892 is\VBZ\836236 a\DT\13649268 24-year-old\JJ\1740 male\JJ\1740 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 who\WP\8299493 developed\VBD\1753788 signs\NNS\6643763 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 NMS\NN\13649268 after\IN\1740 2\CD\13741022 days\NNS\15140892 of\IN\1740 treatment\NN\654885 with\IN\1740 an\DT\6697703 80-mg/day\NN\1740 dose\NN\3740161 of\IN\1740 orally\RB\1740 administrated\VBN\2436349 <e1>ziprasidone</e1>\NN\1740 .\.\1740
19370593
D004967_D054556 CID Long-term\JJ\1740 <e1>oestrogen-only</e1>\JJ\1740 HT\NN\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thrombo-embolism</e2>\NN\1740 ,\,\1740 stroke\NN\556313 and\CC\1740 gallbladder\NN\5512139 disease\NN\14061805 (\-LRB-\1740 after\IN\1740 one\CD\13741022 to\TO\1740 two\CD\13741022 years\NNS\15144371 ,\,\1740 three\CD\13741022 years\NNS\15144371 and\CC\1740 seven\CD\13741022 years\NNS\15144371 '\POS\1740 use\NN\407535 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D004967_D020521 CID Long-term\JJ\1740 <e1>oestrogen-only</e1>\JJ\1740 HT\NN\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 venous\JJ\1740 thrombo-embolism\NN\1740 ,\,\1740 <e2>stroke</e2>\NN\556313 and\CC\1740 gallbladder\NN\5512139 disease\NN\14061805 (\-LRB-\1740 after\IN\1740 one\CD\13741022 to\TO\1740 two\CD\13741022 years\NNS\15144371 ,\,\1740 three\CD\13741022 years\NNS\15144371 and\CC\1740 seven\CD\13741022 years\NNS\15144371 '\POS\1740 use\NN\407535 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D004967_D005705 CID Long-term\JJ\1740 <e1>oestrogen-only</e1>\JJ\1740 HT\NN\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 venous\JJ\1740 thrombo-embolism\NN\1740 ,\,\1740 stroke\NN\556313 and\CC\1740 <e2>gallbladder\NN\5512139 disease</e2>\NN\14061805 (\-LRB-\1740 after\IN\1740 one\CD\13741022 to\TO\1740 two\CD\13741022 years\NNS\15144371 ,\,\1740 three\CD\13741022 years\NNS\15144371 and\CC\1740 seven\CD\13741022 years\NNS\15144371 '\POS\1740 use\NN\407535 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D004967_D001943 NONE Long-term\JJ\1740 <e1>oestrogen-only</e1>\JJ\1740 HT\NN\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 venous\JJ\1740 thrombo-embolism\NN\1740 ,\,\1740 stroke\NN\556313 and\CC\1740 gallbladder\NN\5512139 disease\NN\14061805 (\-LRB-\1740 after\IN\1740 one\CD\13741022 to\TO\1740 two\CD\13741022 years\NNS\15144371 ,\,\1740 three\CD\13741022 years\NNS\15144371 and\CC\1740 seven\CD\13741022 years\NNS\15144371 '\POS\1740 use\NN\407535 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
2466960
D005472_D066126 NONE Although\IN\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 anecdotal\JJ\1740 reports\NNS\6470073 of\IN\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 associated\VBN\628491 with\IN\1740 <e1>fluorouracil</e1>\NN\2722166 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 therapy\NN\657604 ,\,\1740 this\DT\1740 phenomenon\NN\29677 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 in\IN\13603305 a\DT\13649268 systematic\JJ\1740 fashion\NN\4916342 .\.\1740
D005472_D066126 NONE Although\IN\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 anecdotal\JJ\1740 reports\NNS\6470073 of\IN\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 associated\VBN\628491 with\IN\1740 fluorouracil\NN\2722166 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 therapy\NN\657604 ,\,\1740 this\DT\1740 phenomenon\NN\29677 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 in\IN\13603305 a\DT\13649268 systematic\JJ\1740 fashion\NN\4916342 .\.\1740
D005472_D009369 NONE We\PRP\1740 prospectively\RB\1740 performed\VBD\2367363 continuous\JJ\1740 ambulatory\JJ\1740 ECG\NN\7000195 monitoring\NN\879759 on\IN\1740 25\CD\13745420 patients\NNS\9898892 undergoing\VBG\109660 <e1>5-FU</e1>\NN\1740 infusion\NN\14589223 for\IN\1740 treatment\NN\654885 of\IN\1740 solid\JJ\1740 <e2>tumors</e2>\NNS\14234074 in\IN\13603305 order\NN\7168131 to\TO\1740 assess\VB\670261 the\DT\1740 incidence\NN\13821570 of\IN\1740 ischemic\JJ\1740 ST\JJ\1740 changes\NNS\7283608 .\.\1740
D005472_D007511 CID We\PRP\1740 prospectively\RB\1740 performed\VBD\2367363 continuous\JJ\1740 ambulatory\JJ\1740 ECG\NN\7000195 monitoring\NN\879759 on\IN\1740 25\CD\13745420 patients\NNS\9898892 undergoing\VBG\109660 <e1>5-FU</e1>\NN\1740 infusion\NN\14589223 for\IN\1740 treatment\NN\654885 of\IN\1740 solid\JJ\1740 tumors\NNS\14234074 in\IN\13603305 order\NN\7168131 to\TO\1740 assess\VB\670261 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>ischemic</e2>\JJ\1740 ST\JJ\1740 changes\NNS\7283608 .\.\1740
D005472_D007511 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>ischemic</e2>\JJ\1740 episodes\NNS\7283608 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 was\VBD\836236 0.05\CD\1740 +/-\CC\1740 0.02\CD\1740 prior\JJ\1740 to\TO\1740 <e1>5-FU</e1>\NN\1740 infusion\NN\14589223 v\IN\13634784 0.13\CD\1740 +/-\CC\1740 0.03\CD\1740 during\IN\1740 5-FU\NN\1740 infusion\NN\14589223 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .001\CD\1740 )\-RRB-\1740 ;\:\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 ECG\NN\7000195 changes\NNS\7283608 was\VBD\836236 0.6\CD\1740 +/-\CC\1740 0.3\CD\1740 minutes\NNS\6502378 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 before\IN\1740 5-FU\NN\1740 v\IN\13634784 1.9\CD\1740 +/-\CC\1740 0.5\CD\1740 minutes\NNS\6502378 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 during\IN\1740 5-FU\NN\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 .\.\1740
D005472_D007511 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>ischemic</e2>\JJ\1740 episodes\NNS\7283608 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 was\VBD\836236 0.05\CD\1740 +/-\CC\1740 0.02\CD\1740 prior\JJ\1740 to\TO\1740 5-FU\NN\1740 infusion\NN\14589223 v\IN\13634784 0.13\CD\1740 +/-\CC\1740 0.03\CD\1740 during\IN\1740 <e1>5-FU</e1>\NN\1740 infusion\NN\14589223 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .001\CD\1740 )\-RRB-\1740 ;\:\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 ECG\NN\7000195 changes\NNS\7283608 was\VBD\836236 0.6\CD\1740 +/-\CC\1740 0.3\CD\1740 minutes\NNS\6502378 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 before\IN\1740 5-FU\NN\1740 v\IN\13634784 1.9\CD\1740 +/-\CC\1740 0.5\CD\1740 minutes\NNS\6502378 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 during\IN\1740 5-FU\NN\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 .\.\1740
D005472_D007511 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>ischemic</e2>\JJ\1740 episodes\NNS\7283608 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 was\VBD\836236 0.05\CD\1740 +/-\CC\1740 0.02\CD\1740 prior\JJ\1740 to\TO\1740 5-FU\NN\1740 infusion\NN\14589223 v\IN\13634784 0.13\CD\1740 +/-\CC\1740 0.03\CD\1740 during\IN\1740 5-FU\NN\1740 infusion\NN\14589223 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .001\CD\1740 )\-RRB-\1740 ;\:\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 ECG\NN\7000195 changes\NNS\7283608 was\VBD\836236 0.6\CD\1740 +/-\CC\1740 0.3\CD\1740 minutes\NNS\6502378 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 before\IN\1740 <e1>5-FU</e1>\NN\1740 v\IN\13634784 1.9\CD\1740 +/-\CC\1740 0.5\CD\1740 minutes\NNS\6502378 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 during\IN\1740 5-FU\NN\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 .\.\1740
D005472_D007511 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>ischemic</e2>\JJ\1740 episodes\NNS\7283608 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 was\VBD\836236 0.05\CD\1740 +/-\CC\1740 0.02\CD\1740 prior\JJ\1740 to\TO\1740 5-FU\NN\1740 infusion\NN\14589223 v\IN\13634784 0.13\CD\1740 +/-\CC\1740 0.03\CD\1740 during\IN\1740 5-FU\NN\1740 infusion\NN\14589223 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .001\CD\1740 )\-RRB-\1740 ;\:\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 ECG\NN\7000195 changes\NNS\7283608 was\VBD\836236 0.6\CD\1740 +/-\CC\1740 0.3\CD\1740 minutes\NNS\6502378 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 before\IN\1740 5-FU\NN\1740 v\IN\13634784 1.9\CD\1740 +/-\CC\1740 0.5\CD\1740 minutes\NNS\6502378 per\IN\1740 patient\NN\9898892 per\IN\1740 hour\NN\15154774 during\IN\1740 <e1>5-FU</e1>\NN\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 .\.\1740
D005472_D007511 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>5-FU</e1>\NN\1740 infusion\NN\14589223 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 silent\JJ\1740 ST\JJ\1740 segment\NN\3892891 deviation\NN\7337390 suggestive\JJ\1740 of\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 particularly\RB\1740 among\IN\1740 patients\NNS\9898892 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 .\.\1740
D005472_D000787 CID <e2>Anginal</e2>\JJ\1740 episodes\NNS\7283608 were\VBD\836236 rare\JJ\1740 :\:\1740 only\RB\1740 one\CD\13741022 patient\NN\9898892 had\VBD\2108377 angina\NN\14171682 (\-LRB-\1740 during\IN\1740 <e1>5-FU</e1>\NN\1740 infusion\NN\14589223 )\-RRB-\1740 .\.\1740
D005472_D000787 CID Anginal\JJ\1740 episodes\NNS\7283608 were\VBD\836236 rare\JJ\1740 :\:\1740 only\RB\1740 one\CD\13741022 patient\NN\9898892 had\VBD\2108377 <e2>angina</e2>\NN\14171682 (\-LRB-\1740 during\IN\1740 <e1>5-FU</e1>\NN\1740 infusion\NN\14589223 )\-RRB-\1740 .\.\1740
D005472_D003324 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>5-FU</e1>\NN\1740 infusion\NN\14589223 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 silent\JJ\1740 ST\JJ\1740 segment\NN\3892891 deviation\NN\7337390 suggestive\JJ\1740 of\IN\1740 ischemia\NN\14195315 ,\,\1740 particularly\RB\1740 among\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 .\.\1740
12448656
D013792_D002292 NONE A\DT\13649268 phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 in\IN\13603305 advanced\JJ\1740 metastatic\JJ\1740 <e2>renal\JJ\1740 cell\NN\3080309 carcinoma</e2>\NN\14239918 .\.\1740
D013792_D002292 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 toxicity\NN\13576101 and\CC\1740 activity\NN\30358 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 metastatic\JJ\1740 <e2>renal\JJ\1740 cell\NN\3080309 cancer</e2>\NN\14239425 and\CC\1740 to\TO\1740 measure\VB\697589 changes\NNS\7283608 of\IN\1740 one\CD\13741022 angiogenic\JJ\1740 factor\NN\7326557 ,\,\1740 vascular\JJ\1740 endothelial\JJ\1740 growth\NN\13526110 factor\NN\7326557 (VEGF)165\NN\1740 ,\,\1740 with\IN\1740 therapy\NN\657604 .\.\1740
D013792_D002292 NONE CONCLUSION\NN\5837957 :\:\1740 These\DT\1740 results\NNS\34213 are\VBP\836236 consistent\JJ\1740 with\IN\1740 a\DT\13649268 low\JJ\1740 level\NN\4916342 of\IN\1740 activity\NN\30358 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 in\IN\13603305 <e2>renal\JJ\1740 cell\NN\3080309 carcinoma</e2>\NN\14239918 .\.\1740
D013792_D002292 NONE The\DT\1740 dose-response\JJ\1740 relationship\NN\31921 ,\,\1740 if\IN\1740 any\DT\1740 ,\,\1740 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 for\IN\1740 <e2>renal\JJ\1740 cell\NN\3080309 carcinoma</e2>\NN\14239918 is\VBZ\836236 unclear\JJ\1740 .\.\1740
D013792_D064420 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 activity\NN\30358 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 metastatic\JJ\1740 renal\JJ\1740 cell\NN\3080309 cancer\NN\14239425 and\CC\1740 to\TO\1740 measure\VB\697589 changes\NNS\7283608 of\IN\1740 one\CD\13741022 angiogenic\JJ\1740 factor\NN\7326557 ,\,\1740 vascular\JJ\1740 endothelial\JJ\1740 growth\NN\13526110 factor\NN\7326557 (VEGF)165\NN\1740 ,\,\1740 with\IN\1740 therapy\NN\657604 .\.\1740
6942642
D049971_D007008 NONE <e1>Thiazide</e1>\NN\3214670 diuretics\NNS\3247620 ,\,\1740 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 cardiac\FW\1740 arrhythmias\NNS\14103288 .\.\1740
D049971_D007008 NONE <e2>Hypokalemia</e2>\NNP\14299637 is\VBZ\836236 a\DT\13649268 commonly\RB\1740 encountered\VBN\2604760 metabolic\JJ\1740 consequence\NN\34213 of\IN\1740 chronic\JJ\1740 <e1>thiazide</e1>\NN\3214670 therapy\NN\657604 .\.\1740
D049971_D007008 NONE In\IN\13603305 conclusion\NN\5837957 we\PRP\1740 found\VBD\2426171 that\IN\1740 <e1>thiazide</e1>\NN\3214670 diuretics\NNS\3247620 cause\VBP\1617192 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 depletion\NN\351638 of\IN\1740 body\NN\19128 potassium\NN\14625458 .\.\1740
D049971_D001145 NONE <e1>Thiazide</e1>\NN\3214670 diuretics\NNS\3247620 ,\,\1740 hypokalemia\NN\14299637 and\CC\1740 <e2>cardiac\FW\1740 arrhythmias</e2>\NNS\14103288 .\.\1740
D006852_C563897 NONE We\PRP\1740 treated\VBD\2376958 38\CD\1740 patients\NNS\9898892 (\-LRB-\1740 22\CD\13745420 low\JJ\1740 renin\NN\14999106 ,\,\1740 16\CD\13745420 normal\JJ\1740 renin\NN\14999106 )\-RRB-\1740 with\IN\1740 moderate\JJ\1740 <e2>diastolic\JJ\1740 hypertension</e2>\NN\14057371 with\IN\1740 <e1>hydrochlorothiazide</e1>\NN\4423288 (\-LRB-\1740 HCTC\NN\1740 )\-RRB-\1740 administered\VBN\2436349 on\IN\1740 a\DT\13649268 twice\JJ\1740 daily\JJ\1740 schedule\NN\5898568 .\.\1740
D006852_C563897 NONE We\PRP\1740 treated\VBD\2376958 38\CD\1740 patients\NNS\9898892 (\-LRB-\1740 22\CD\13745420 low\JJ\1740 renin\NN\14999106 ,\,\1740 16\CD\13745420 normal\JJ\1740 renin\NN\14999106 )\-RRB-\1740 with\IN\1740 moderate\JJ\1740 <e2>diastolic\JJ\1740 hypertension</e2>\NN\14057371 with\IN\1740 hydrochlorothiazide\NN\4423288 (\-LRB-\1740 <e1>HCTC</e1>\NN\1740 )\-RRB-\1740 administered\VBN\2436349 on\IN\1740 a\DT\13649268 twice\JJ\1740 daily\JJ\1740 schedule\NN\5898568 .\.\1740
D011188_D007008 NONE In\IN\13603305 conclusion\NN\5837957 we\PRP\1740 found\VBD\2426171 that\IN\1740 thiazide\NN\3214670 diuretics\NNS\3247620 cause\VBP\1617192 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 depletion\NN\351638 of\IN\1740 body\NN\19128 <e1>potassium</e1>\NN\14625458 .\.\1740
2598570
D013496_D021501 CID The\DT\1740 epidemiology\NN\6043075 of\IN\1740 the\DT\1740 acute\JJ\1740 <e2>flank\NN\8426461 pain</e2>\NN\14299637 syndrome\NN\5870365 from\IN\1740 <e1>suprofen</e1>\NN\1740 .\.\1740
D000431_D006255 NONE Case\NN\7283608 patients\NNS\9898892 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 men\NNS\8208016 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ,\,\1740 3.8\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.2\CD\1740 -\SYM\1740 12.1\CD\1740 )\-RRB-\1740 ,\,\1740 suffer\VBP\2110220 from\IN\1740 <e2>hay\NN\7800740 fever</e2>\NN\14299637 and\CC\1740 asthma\NN\14145095 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ,\,\1740 3.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.0\CD\1740 -\SYM\1740 11.9\CD\1740 )\-RRB-\1740 ;\:\1740 to\TO\1740 participate\VB\2367363 in\IN\13603305 regular\JJ\1740 exercise\NN\621627 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ,\,\1740 5.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.1\CD\1740 -\SYM\1740 30.7\CD\1740 )\-RRB-\1740 ,\,\1740 especially\RB\1740 in\IN\13603305 the\DT\1740 use\NN\407535 of\IN\1740 Nautilus\NN\4347754 equipment\NN\3575240 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.02\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 to\TO\1740 use\VB\1156834 <e1>alcohol</e1>\NN\7881800 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ,\,\1740 4.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.1\CD\1740 -\SYM\1740 17.5\CD\1740 )\-RRB-\1740 .\.\1740
D000431_D001249 NONE Case\NN\7283608 patients\NNS\9898892 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 men\NNS\8208016 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ,\,\1740 3.8\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.2\CD\1740 -\SYM\1740 12.1\CD\1740 )\-RRB-\1740 ,\,\1740 suffer\VBP\2110220 from\IN\1740 hay\NN\7800740 fever\NN\14299637 and\CC\1740 <e2>asthma</e2>\NN\14145095 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ,\,\1740 3.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.0\CD\1740 -\SYM\1740 11.9\CD\1740 )\-RRB-\1740 ;\:\1740 to\TO\1740 participate\VB\2367363 in\IN\13603305 regular\JJ\1740 exercise\NN\621627 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ,\,\1740 5.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.1\CD\1740 -\SYM\1740 30.7\CD\1740 )\-RRB-\1740 ,\,\1740 especially\RB\1740 in\IN\13603305 the\DT\1740 use\NN\407535 of\IN\1740 Nautilus\NN\4347754 equipment\NN\3575240 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.02\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 to\TO\1740 use\VB\1156834 <e1>alcohol</e1>\NN\7881800 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ,\,\1740 4.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.1\CD\1740 -\SYM\1740 17.5\CD\1740 )\-RRB-\1740 .\.\1740
D007052_D007674 NONE Possible\JJ\1740 risk\NN\14541044 factors\NNS\7326557 included\VBD\690614 young\JJ\1740 age\NN\4916342 ,\,\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 analgesic\NN\3740161 agents\NNS\7347 (\-LRB-\1740 especially\RB\1740 <e1>ibuprofen</e1>\JJ\1740 )\-RRB-\1740 ,\,\1740 preexisting\VBG\2603699 <e2>renal\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 kidney\NN\5333259 stones\NNS\19128 ,\,\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 gout\NN\14186541 ,\,\1740 a\DT\13649268 recent\JJ\1740 increase\NN\13576355 in\IN\13603305 activity\NN\30358 ,\,\1740 a\DT\13649268 recent\JJ\1740 increase\NN\13576355 in\IN\13603305 sun\NN\11473954 exposure\NN\5042871 ,\,\1740 and\CC\1740 residence\NN\8491027 in\IN\13603305 the\DT\1740 Sunbelt\NNP\1740 .\.\1740
D007052_D007669 NONE Possible\JJ\1740 risk\NN\14541044 factors\NNS\7326557 included\VBD\690614 young\JJ\1740 age\NN\4916342 ,\,\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 analgesic\NN\3740161 agents\NNS\7347 (\-LRB-\1740 especially\RB\1740 <e1>ibuprofen</e1>\JJ\1740 )\-RRB-\1740 ,\,\1740 preexisting\VBG\2603699 renal\JJ\1740 disease\NN\14061805 ,\,\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>kidney\NN\5333259 stones</e2>\NNS\19128 ,\,\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 gout\NN\14186541 ,\,\1740 a\DT\13649268 recent\JJ\1740 increase\NN\13576355 in\IN\13603305 activity\NN\30358 ,\,\1740 a\DT\13649268 recent\JJ\1740 increase\NN\13576355 in\IN\13603305 sun\NN\11473954 exposure\NN\5042871 ,\,\1740 and\CC\1740 residence\NN\8491027 in\IN\13603305 the\DT\1740 Sunbelt\NNP\1740 .\.\1740
D007052_D006073 NONE Possible\JJ\1740 risk\NN\14541044 factors\NNS\7326557 included\VBD\690614 young\JJ\1740 age\NN\4916342 ,\,\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 analgesic\NN\3740161 agents\NNS\7347 (\-LRB-\1740 especially\RB\1740 <e1>ibuprofen</e1>\JJ\1740 )\-RRB-\1740 ,\,\1740 preexisting\VBG\2603699 renal\JJ\1740 disease\NN\14061805 ,\,\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 kidney\NN\5333259 stones\NNS\19128 ,\,\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>gout</e2>\NN\14186541 ,\,\1740 a\DT\13649268 recent\JJ\1740 increase\NN\13576355 in\IN\13603305 activity\NN\30358 ,\,\1740 a\DT\13649268 recent\JJ\1740 increase\NN\13576355 in\IN\13603305 sun\NN\11473954 exposure\NN\5042871 ,\,\1740 and\CC\1740 residence\NN\8491027 in\IN\13603305 the\DT\1740 Sunbelt\NNP\1740 .\.\1740
458486
D063325_D004409 NONE <e1>Tiapride</e1>\NN\1740 in\IN\13603305 levodopa-induced\JJ\1740 <e2>involuntary\JJ\1740 movements</e2>\NNS\191142 .\.\1740
D063325_D004409 NONE <e1>Tiapride</e1>\NNP\1740 ,\,\1740 a\DT\13649268 substituted\VBN\126264 benzamide\NN\1740 derivative\JJ\1740 closely\RB\1740 related\JJ\1740 to\TO\1740 metoclopramide\NN\1740 ,\,\1740 reduced\VBN\441445 levodopa-induced\JJ\1740 peak\NN\13758296 dose\NN\3740161 <e2>involuntary\JJ\1740 movements</e2>\NNS\191142 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D007980_D004409 CID Tiapride\NN\1740 in\IN\13603305 <e1>levodopa-induced</e1>\JJ\1740 <e2>involuntary\JJ\1740 movements</e2>\NNS\191142 .\.\1740
D007980_D004409 CID Tiapride\NNP\1740 ,\,\1740 a\DT\13649268 substituted\VBN\126264 benzamide\NN\1740 derivative\JJ\1740 closely\RB\1740 related\JJ\1740 to\TO\1740 metoclopramide\NN\1740 ,\,\1740 reduced\VBN\441445 <e1>levodopa-induced</e1>\JJ\1740 peak\NN\13758296 dose\NN\3740161 <e2>involuntary\JJ\1740 movements</e2>\NNS\191142 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D007980_D004409 CID These\DT\1740 results\NNS\34213 fail\VBP\1798936 to\TO\1740 support\VB\2199590 the\DT\1740 notion\NN\5833840 that\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 are\VBP\836236 caused\VBN\1617192 by\IN\1740 overstimulation\NN\1740 of\IN\1740 a\DT\13649268 separate\JJ\1740 group\NN\2137 of\IN\1740 dopamine\NN\14807737 receptors\NNS\5225602 .\.\1740
D063325_D010300 NONE <e1>Tiapride</e1>\NNP\1740 ,\,\1740 a\DT\13649268 substituted\VBN\126264 benzamide\NN\1740 derivative\JJ\1740 closely\RB\1740 related\JJ\1740 to\TO\1740 metoclopramide\NN\1740 ,\,\1740 reduced\VBN\441445 levodopa-induced\JJ\1740 peak\NN\13758296 dose\NN\3740161 involuntary\JJ\1740 movements\NNS\191142 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
C037689_D004409 NONE Tiapride\NNP\1740 ,\,\1740 a\DT\13649268 substituted\VBN\126264 <e1>benzamide</e1>\NN\1740 derivative\JJ\1740 closely\RB\1740 related\JJ\1740 to\TO\1740 metoclopramide\NN\1740 ,\,\1740 reduced\VBN\441445 levodopa-induced\JJ\1740 peak\NN\13758296 dose\NN\3740161 <e2>involuntary\JJ\1740 movements</e2>\NNS\191142 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
C037689_D010300 NONE Tiapride\NNP\1740 ,\,\1740 a\DT\13649268 substituted\VBN\126264 <e1>benzamide</e1>\NN\1740 derivative\JJ\1740 closely\RB\1740 related\JJ\1740 to\TO\1740 metoclopramide\NN\1740 ,\,\1740 reduced\VBN\441445 levodopa-induced\JJ\1740 peak\NN\13758296 dose\NN\3740161 involuntary\JJ\1740 movements\NNS\191142 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D008787_D004409 NONE Tiapride\NNP\1740 ,\,\1740 a\DT\13649268 substituted\VBN\126264 benzamide\NN\1740 derivative\JJ\1740 closely\RB\1740 related\JJ\1740 to\TO\1740 <e1>metoclopramide</e1>\NN\1740 ,\,\1740 reduced\VBN\441445 levodopa-induced\JJ\1740 peak\NN\13758296 dose\NN\3740161 <e2>involuntary\JJ\1740 movements</e2>\NNS\191142 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D008787_D010300 NONE Tiapride\NNP\1740 ,\,\1740 a\DT\13649268 substituted\VBN\126264 benzamide\NN\1740 derivative\JJ\1740 closely\RB\1740 related\JJ\1740 to\TO\1740 <e1>metoclopramide</e1>\NN\1740 ,\,\1740 reduced\VBN\441445 levodopa-induced\JJ\1740 peak\NN\13758296 dose\NN\3740161 involuntary\JJ\1740 movements\NNS\191142 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D007980_D010300 NONE Tiapride\NNP\1740 ,\,\1740 a\DT\13649268 substituted\VBN\126264 benzamide\NN\1740 derivative\JJ\1740 closely\RB\1740 related\JJ\1740 to\TO\1740 metoclopramide\NN\1740 ,\,\1740 reduced\VBN\441445 <e1>levodopa-induced</e1>\JJ\1740 peak\NN\13758296 dose\NN\3740161 involuntary\JJ\1740 movements\NNS\191142 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D063325_D004421 NONE <e1>Tiapride</e1>\NNP\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 levodopa-induced\JJ\1740 early\JJ\1740 morning\NN\15113229 of\IN\1740 "\``\1740 off-period\JJ\1740 "\``\1740 segmental\JJ\1740 <e2>dystonia</e2>\NN\1740 .\.\1740
D007980_D004421 NONE Tiapride\NNP\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 early\JJ\1740 morning\NN\15113229 of\IN\1740 "\``\1740 off-period\JJ\1740 "\``\1740 segmental\JJ\1740 <e2>dystonia</e2>\NN\1740 .\.\1740
D004298_D004409 NONE These\DT\1740 results\NNS\34213 fail\VBP\1798936 to\TO\1740 support\VB\2199590 the\DT\1740 notion\NN\5833840 that\IN\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 are\VBP\836236 caused\VBN\1617192 by\IN\1740 overstimulation\NN\1740 of\IN\1740 a\DT\13649268 separate\JJ\1740 group\NN\2137 of\IN\1740 <e1>dopamine</e1>\NN\14807737 receptors\NNS\5225602 .\.\1740
17786501
D004221_D009901 NONE <e1>Disulfiram-induced</e1>\JJ\1740 transient\JJ\1740 <e2>optic\NN\5299178 and\CC\1740 peripheral\JJ\1740 neuropathy</e2>\NN\14204950 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D004221_D009901 NONE AIM\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>optic\JJ\1740 and\CC\1740 peripheral\JJ\1740 neuropathy</e2>\NN\14204950 after\IN\1740 chronic\JJ\1740 use\NN\407535 of\IN\1740 <e1>disulfiram</e1>\NN\3740161 for\IN\1740 alcohol\NN\7881800 dependence\NN\24720 management\NN\1123598 .\.\1740
D004221_D010523 NONE <e1>Disulfiram-induced</e1>\JJ\1740 transient\JJ\1740 <e2>optic\NN\5299178 and\CC\1740 peripheral\JJ\1740 neuropathy</e2>\NN\14204950 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D004221_D010523 NONE AIM\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>optic\JJ\1740 and\CC\1740 peripheral\JJ\1740 neuropathy</e2>\NN\14204950 after\IN\1740 chronic\JJ\1740 use\NN\407535 of\IN\1740 <e1>disulfiram</e1>\NN\3740161 for\IN\1740 alcohol\NN\7881800 dependence\NN\24720 management\NN\1123598 .\.\1740
D004221_D000437 NONE AIM\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 optic\JJ\1740 and\CC\1740 peripheral\JJ\1740 neuropathy\NN\14204950 after\IN\1740 chronic\JJ\1740 use\NN\407535 of\IN\1740 <e1>disulfiram</e1>\NN\3740161 for\IN\1740 <e2>alcohol\NN\7881800 dependence</e2>\NN\24720 management\NN\1123598 .\.\1740
D004221_D000437 NONE He\PRP\14622893 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>disulfiram</e1>\NN\3740161 for\IN\1740 <e2>alcohol\NN\7881800 dependence</e2>\NN\24720 for\IN\1740 the\DT\1740 preceding\VBG\2690708 3\CD\13741022 years\NNS\15144371 .\.\1740
3961813
D003345_D009422 NONE Dose-related\JJ\1740 beneficial\JJ\1740 and\CC\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 dietary\JJ\1740 <e1>corticosterone</e1>\NN\14752057 on\IN\1740 organophosphorus-induced\JJ\1740 delayed\VBN\439958 <e2>neuropathy</e2>\JJ\1740 in\IN\13603305 chickens\NNS\7644706 .\.\1740
D003345_D009422 NONE Although\IN\1740 low\JJ\1740 concentrations\NNS\4916342 (\-LRB-\1740 less\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 50\CD\13745420 ppm\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>corticosterone</e1>\NN\14752057 had\VBD\2108377 beneficial\JJ\1740 effects\NNS\13245626 on\IN\1740 TOTP-induced\JJ\1740 <e2>neuropathy</e2>\NN\14204950 ,\,\1740 greater\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 200\CD\1740 ppm\NN\1740 exacerbated\JJ\1740 clinical\JJ\1740 signs\NNS\6643763 in\IN\13603305 chickens\NNS\7644706 given\VBN\2327200 either\CC\1740 TOTP\NN\1740 or\CC\3541091 DFP\NN\1740 .\.\1740
D010755_D009422 NONE Dose-related\JJ\1740 beneficial\JJ\1740 and\CC\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 dietary\JJ\1740 corticosterone\NN\14752057 on\IN\1740 <e1>organophosphorus-induced</e1>\JJ\1740 delayed\VBN\439958 <e2>neuropathy</e2>\JJ\1740 in\IN\13603305 chickens\NNS\7644706 .\.\1740
C025541_D009422 CID Although\IN\1740 low\JJ\1740 concentrations\NNS\4916342 (\-LRB-\1740 less\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 50\CD\13745420 ppm\NN\1740 )\-RRB-\1740 of\IN\1740 corticosterone\NN\14752057 had\VBD\2108377 beneficial\JJ\1740 effects\NNS\13245626 on\IN\1740 <e1>TOTP-induced</e1>\JJ\1740 <e2>neuropathy</e2>\NN\14204950 ,\,\1740 greater\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 200\CD\1740 ppm\NN\1740 exacerbated\JJ\1740 clinical\JJ\1740 signs\NNS\6643763 in\IN\13603305 chickens\NNS\7644706 given\VBN\2327200 either\CC\1740 TOTP\NN\1740 or\CC\3541091 DFP\NN\1740 .\.\1740
C025541_D009422 CID Although\IN\1740 low\JJ\1740 concentrations\NNS\4916342 (\-LRB-\1740 less\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 50\CD\13745420 ppm\NN\1740 )\-RRB-\1740 of\IN\1740 corticosterone\NN\14752057 had\VBD\2108377 beneficial\JJ\1740 effects\NNS\13245626 on\IN\1740 TOTP-induced\JJ\1740 <e2>neuropathy</e2>\NN\14204950 ,\,\1740 greater\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 200\CD\1740 ppm\NN\1740 exacerbated\JJ\1740 clinical\JJ\1740 signs\NNS\6643763 in\IN\13603305 chickens\NNS\7644706 given\VBN\2327200 either\CC\1740 <e1>TOTP</e1>\NN\1740 or\CC\3541091 DFP\NN\1740 .\.\1740
D007531_D009422 CID Although\IN\1740 low\JJ\1740 concentrations\NNS\4916342 (\-LRB-\1740 less\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 50\CD\13745420 ppm\NN\1740 )\-RRB-\1740 of\IN\1740 corticosterone\NN\14752057 had\VBD\2108377 beneficial\JJ\1740 effects\NNS\13245626 on\IN\1740 TOTP-induced\JJ\1740 <e2>neuropathy</e2>\NN\14204950 ,\,\1740 greater\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 200\CD\1740 ppm\NN\1740 exacerbated\JJ\1740 clinical\JJ\1740 signs\NNS\6643763 in\IN\13603305 chickens\NNS\7644706 given\VBN\2327200 either\CC\1740 TOTP\NN\1740 or\CC\3541091 <e1>DFP</e1>\NN\1740 .\.\1740
C025541_D020258 NONE <e2>Neurotoxic</e2>\JJ\1740 esterase\NN\1740 activities\VBZ\1740 24\CD\13745420 hr\NN\15154774 after\IN\1740 <e1>TOTP</e1>\NN\1740 or\CC\3541091 DFP\NN\1740 were\VBD\836236 less\JJR\1740 than\IN\1740 20\CD\13745420 %\NN\1740 of\IN\1740 values\NNS\5941423 measured\VBN\697589 in\IN\13603305 chickens\NNS\7644706 not\RB\1740 given\VBN\2327200 organophosphorous\JJ\1740 compounds\NNS\5869584 .\.\1740
D007531_D020258 NONE <e2>Neurotoxic</e2>\JJ\1740 esterase\NN\1740 activities\VBZ\1740 24\CD\13745420 hr\NN\15154774 after\IN\1740 TOTP\NN\1740 or\CC\3541091 <e1>DFP</e1>\NN\1740 were\VBD\836236 less\JJR\1740 than\IN\1740 20\CD\13745420 %\NN\1740 of\IN\1740 values\NNS\5941423 measured\VBN\697589 in\IN\13603305 chickens\NNS\7644706 not\RB\1740 given\VBN\2327200 organophosphorous\JJ\1740 compounds\NNS\5869584 .\.\1740
D010755_D020258 NONE <e2>Neurotoxic</e2>\JJ\1740 esterase\NN\1740 activities\VBZ\1740 24\CD\13745420 hr\NN\15154774 after\IN\1740 TOTP\NN\1740 or\CC\3541091 DFP\NN\1740 were\VBD\836236 less\JJR\1740 than\IN\1740 20\CD\13745420 %\NN\1740 of\IN\1740 values\NNS\5941423 measured\VBN\697589 in\IN\13603305 chickens\NNS\7644706 not\RB\1740 given\VBN\2327200 <e1>organophosphorous</e1>\JJ\1740 compounds\NNS\5869584 .\.\1740
C025541_D009410 CID <e2>Degenerating\NN\1740 myelinated\VBD\1740 fibers</e2>\NNS\14580897 were\VBD\836236 also\RB\1740 evident\JJ\1740 in\IN\13603305 distal\JJ\1740 levels\NNS\4916342 of\IN\1740 the\DT\1740 peripheral\JJ\1740 nerves\NNS\14373582 of\IN\1740 chickens\NNS\7644706 given\VBN\2327200 <e1>TOTP</e1>\NN\1740 or\CC\3541091 DFP\NN\1740 .\.\1740
D007531_D009410 CID <e2>Degenerating\NN\1740 myelinated\VBD\1740 fibers</e2>\NNS\14580897 were\VBD\836236 also\RB\1740 evident\JJ\1740 in\IN\13603305 distal\JJ\1740 levels\NNS\4916342 of\IN\1740 the\DT\1740 peripheral\JJ\1740 nerves\NNS\14373582 of\IN\1740 chickens\NNS\7644706 given\VBN\2327200 TOTP\NN\1740 or\CC\3541091 <e1>DFP</e1>\NN\1740 .\.\1740
1504402
D007741_D004342 CID <e2>Hypersensitivity</e2>\NN\14531772 immune\JJ\1740 reaction\NN\13446390 as\IN\14622893 a\DT\13649268 mechanism\NN\13446390 for\IN\1740 <e1>dilevalol-associated</e1>\JJ\1740 hepatitis\NN\14127211 .\.\1740
D007741_D056486 CID Hypersensitivity\NN\14531772 immune\JJ\1740 reaction\NN\13446390 as\IN\14622893 a\DT\13649268 mechanism\NN\13446390 for\IN\1740 <e1>dilevalol-associated</e1>\JJ\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
D007741_D056486 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 lymphocyte\NN\5449959 reactivity\NN\5652926 to\TO\1740 <e1>dilevalol</e1>\NNS\1740 and\CC\1740 to\TO\1740 serum\NN\5397468 containing\VBG\2632940 putative\JJ\1740 ex\FW\10287213 vivo\FW\1740 dilevalol\JJ\1740 antigens\NNS\20090 or\CC\3541091 metabolites\NNS\20090 in\IN\13603305 a\DT\13649268 case\NN\7283608 of\IN\1740 dilevalol-induced\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 .\.\1740
D007741_D056486 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 lymphocyte\NN\5449959 reactivity\NN\5652926 to\TO\1740 dilevalol\NNS\1740 and\CC\1740 to\TO\1740 serum\NN\5397468 containing\VBG\2632940 putative\JJ\1740 ex\FW\10287213 vivo\FW\1740 <e1>dilevalol</e1>\JJ\1740 antigens\NNS\20090 or\CC\3541091 metabolites\NNS\20090 in\IN\13603305 a\DT\13649268 case\NN\7283608 of\IN\1740 dilevalol-induced\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 .\.\1740
D007741_D056486 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 lymphocyte\NN\5449959 reactivity\NN\5652926 to\TO\1740 dilevalol\NNS\1740 and\CC\1740 to\TO\1740 serum\NN\5397468 containing\VBG\2632940 putative\JJ\1740 ex\FW\10287213 vivo\FW\1740 dilevalol\JJ\1740 antigens\NNS\20090 or\CC\3541091 metabolites\NNS\20090 in\IN\13603305 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>dilevalol-induced</e1>\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 .\.\1740
D007741_D056486 CID PATIENT\NN\9898892 :\:\1740 A\DT\13649268 58-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 a\DT\13649268 clinical\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e1>dilevalol-induced</e1>\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 .\.\1740
D007741_D056486 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 methodology\NN\6166748 used\VBD\1156834 allowed\VBD\797697 the\DT\1740 detection\NN\5708432 of\IN\1740 lymphocyte\NN\5449959 sensitization\NN\14531772 to\TO\1740 sera\NN\5397468 containing\VBG\2632940 ex\FW\10287213 vivo-prepared\JJ\1740 <e1>dilevalol</e1>\JJ\1740 antigens\NNS\20090 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 involvement\NN\1080366 of\IN\1740 an\DT\6697703 immunologic\JJ\1740 mechanism\NN\13446390 in\IN\13603305 dilevalol-induced\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 .\.\1740
D007741_D056486 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 methodology\NN\6166748 used\VBD\1156834 allowed\VBD\797697 the\DT\1740 detection\NN\5708432 of\IN\1740 lymphocyte\NN\5449959 sensitization\NN\14531772 to\TO\1740 sera\NN\5397468 containing\VBG\2632940 ex\FW\10287213 vivo-prepared\JJ\1740 dilevalol\JJ\1740 antigens\NNS\20090 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 involvement\NN\1080366 of\IN\1740 an\DT\6697703 immunologic\JJ\1740 mechanism\NN\13446390 in\IN\13603305 <e1>dilevalol-induced</e1>\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 .\.\1740
12760988
D013390_D010149 CID <e2>Postoperative\JJ\1740 myalgia</e2>\NN\14322699 after\IN\1740 <e1>succinylcholine</e1>\NN\3800001 :\:\1740 no\DT\7204911 evidence\NN\5816287 for\IN\1740 an\DT\6697703 inflammatory\JJ\1740 origin\NN\8620061 .\.\1740
D013390_D010149 CID A\DT\13649268 common\JJ\1740 side\NN\8630039 effect\NN\34213 associated\VBN\628491 with\IN\1740 <e1>succinylcholine</e1>\NN\3800001 is\VBZ\836236 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 .\.\1740
D013390_D010149 CID IMPLICATIONS\NN\5774614 :\:\1740 Administration\NN\1133281 of\IN\1740 dexamethasone\NN\2721538 before\IN\1740 <e1>succinylcholine</e1>\NN\3800001 was\VBD\836236 not\RB\1740 effective\JJ\1740 in\IN\13603305 decreasing\VBG\169651 the\DT\1740 incidence\NN\13821570 or\CC\3541091 the\DT\1740 severity\NN\5036394 of\IN\1740 succinylcholine-induced\JJ\1740 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 .\.\1740
D013390_D010149 CID IMPLICATIONS\NN\5774614 :\:\1740 Administration\NN\1133281 of\IN\1740 dexamethasone\NN\2721538 before\IN\1740 succinylcholine\NN\3800001 was\VBD\836236 not\RB\1740 effective\JJ\1740 in\IN\13603305 decreasing\VBG\169651 the\DT\1740 incidence\NN\13821570 or\CC\3541091 the\DT\1740 severity\NN\5036394 of\IN\1740 <e1>succinylcholine-induced</e1>\JJ\1740 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 .\.\1740
D013390_D010149 CID Pretreatment\NN\1740 with\IN\1740 dexamethasone\NN\2721538 is\VBZ\836236 not\RB\1740 justified\VBN\1012073 to\TO\1740 prevent\VB\1740 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 after\IN\1740 <e1>succinylcholine</e1>\NN\3800001 .\.\1740
D013390_D063806 CID The\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e1>succinylcholine-associated</e1>\JJ\1740 <e2>myalgia</e2>\NN\14322699 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 64\CD\1740 patients\NNS\9898892 pretreated\VBN\1740 with\IN\1740 saline\NN\14849367 or\CC\3541091 dexamethasone\NN\2721538 before\IN\1740 succinylcholine\NN\3800001 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 for\IN\1740 each\DT\1740 )\-RRB-\1740 .\.\1740
D013390_D063806 CID The\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 succinylcholine-associated\JJ\1740 <e2>myalgia</e2>\NN\14322699 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 64\CD\1740 patients\NNS\9898892 pretreated\VBN\1740 with\IN\1740 saline\NN\14849367 or\CC\3541091 dexamethasone\NN\2721538 before\IN\1740 <e1>succinylcholine</e1>\NN\3800001 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 for\IN\1740 each\DT\1740 )\-RRB-\1740 .\.\1740
D013390_D063806 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 for\IN\1740 an\DT\6697703 inflammatory\JJ\1740 origin\NN\8620061 of\IN\1740 <e1>succinylcholine-associated</e1>\JJ\1740 <e2>myalgia</e2>\NN\14322699 .\.\1740
D003907_D063806 NONE The\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 succinylcholine-associated\JJ\1740 <e2>myalgia</e2>\NN\14322699 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 64\CD\1740 patients\NNS\9898892 pretreated\VBN\1740 with\IN\1740 saline\NN\14849367 or\CC\3541091 <e1>dexamethasone</e1>\NN\2721538 before\IN\1740 succinylcholine\NN\3800001 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 for\IN\1740 each\DT\1740 )\-RRB-\1740 .\.\1740
D003907_D063806 NONE Incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>myalgia</e2>\NN\14322699 did\VBD\1640855 not\RB\1740 differ\VB\1740 significantly\RB\1740 between\IN\1740 the\DT\1740 two\CD\13741022 groups\NNS\2137 :\:\1740 15\CD\13745420 patients\NNS\9898892 in\IN\13603305 the\DT\1740 <e1>dexamethasone</e1>\NN\2721538 group\NN\2137 complained\VBD\843959 of\IN\1740 myalgia\NN\14322699 compared\VBN\644583 with\IN\1740 18\CD\13745420 patients\NNS\9898892 in\IN\13603305 the\DT\1740 saline\NN\14849367 group\NN\2137 ,\,\1740 and\CC\1740 severe\JJ\1740 myalgia\NN\14322699 was\VBD\836236 reported\VBN\831651 by\IN\1740 five\CD\13741022 patients\NNS\9898892 and\CC\1740 three\CD\13741022 patients\NNS\9898892 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 not\RB\1740 significant\JJ\1740 )\-RRB-\1740 .\.\1740
D003907_D063806 NONE Incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 myalgia\NN\14322699 did\VBD\1640855 not\RB\1740 differ\VB\1740 significantly\RB\1740 between\IN\1740 the\DT\1740 two\CD\13741022 groups\NNS\2137 :\:\1740 15\CD\13745420 patients\NNS\9898892 in\IN\13603305 the\DT\1740 <e1>dexamethasone</e1>\NN\2721538 group\NN\2137 complained\VBD\843959 of\IN\1740 <e2>myalgia</e2>\NN\14322699 compared\VBN\644583 with\IN\1740 18\CD\13745420 patients\NNS\9898892 in\IN\13603305 the\DT\1740 saline\NN\14849367 group\NN\2137 ,\,\1740 and\CC\1740 severe\JJ\1740 myalgia\NN\14322699 was\VBD\836236 reported\VBN\831651 by\IN\1740 five\CD\13741022 patients\NNS\9898892 and\CC\1740 three\CD\13741022 patients\NNS\9898892 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 not\RB\1740 significant\JJ\1740 )\-RRB-\1740 .\.\1740
D003907_D063806 NONE Incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 myalgia\NN\14322699 did\VBD\1640855 not\RB\1740 differ\VB\1740 significantly\RB\1740 between\IN\1740 the\DT\1740 two\CD\13741022 groups\NNS\2137 :\:\1740 15\CD\13745420 patients\NNS\9898892 in\IN\13603305 the\DT\1740 <e1>dexamethasone</e1>\NN\2721538 group\NN\2137 complained\VBD\843959 of\IN\1740 myalgia\NN\14322699 compared\VBN\644583 with\IN\1740 18\CD\13745420 patients\NNS\9898892 in\IN\13603305 the\DT\1740 saline\NN\14849367 group\NN\2137 ,\,\1740 and\CC\1740 severe\JJ\1740 <e2>myalgia</e2>\NN\14322699 was\VBD\836236 reported\VBN\831651 by\IN\1740 five\CD\13741022 patients\NNS\9898892 and\CC\1740 three\CD\13741022 patients\NNS\9898892 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 not\RB\1740 significant\JJ\1740 )\-RRB-\1740 .\.\1740
D003907_D010149 NONE IMPLICATIONS\NN\5774614 :\:\1740 Administration\NN\1133281 of\IN\1740 <e1>dexamethasone</e1>\NN\2721538 before\IN\1740 succinylcholine\NN\3800001 was\VBD\836236 not\RB\1740 effective\JJ\1740 in\IN\13603305 decreasing\VBG\169651 the\DT\1740 incidence\NN\13821570 or\CC\3541091 the\DT\1740 severity\NN\5036394 of\IN\1740 succinylcholine-induced\JJ\1740 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 .\.\1740
D003907_D010149 NONE Pretreatment\NN\1740 with\IN\1740 <e1>dexamethasone</e1>\NN\2721538 is\VBZ\836236 not\RB\1740 justified\VBN\1012073 to\TO\1740 prevent\VB\1740 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 after\IN\1740 succinylcholine\NN\3800001 .\.\1740
11827497
D006493_D013921 CID Delayed-onset\JJ\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 .\.\1740
D006493_D013921 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 presents\VBZ\2137132 5\CD\13741022 to\TO\1740 12\CD\13745420 days\NNS\15140892 after\IN\1740 heparin\NN\2718259 exposure\NN\5042871 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 arterial\JJ\1740 or\CC\3541091 venous\JJ\1740 thromboemboli\NN\1740 .\.\1740
D006493_D013921 CID BACKGROUND\NN\4921011 :\:\1740 Heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 presents\VBZ\2137132 5\CD\13741022 to\TO\1740 12\CD\13745420 days\NNS\15140892 after\IN\1740 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 arterial\JJ\1740 or\CC\3541091 venous\JJ\1740 thromboemboli\NN\1740 .\.\1740
D006493_D013921 CID Delayed\VBN\439958 recognition\NN\13932421 and\CC\1740 treatment\NN\654885 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 contribute\VBP\126264 to\TO\1740 poor\JJ\1740 patient\NN\9898892 outcomes\NNS\7291312 .\.\1740
D006493_D013921 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 and\CC\1740 increase\VB\169651 awareness\NN\5804793 of\IN\1740 a\DT\13649268 clinical\JJ\1740 scenario\NN\7009946 in\IN\13603305 which\WDT\1740 the\DT\1740 onset\NN\7325190 or\CC\3541091 manifestations\NNS\7321772 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 are\VBP\836236 delayed\VBN\439958 .\.\1740
D006493_D013921 CID PATIENTS\NNS\9898892 :\:\1740 14\CD\13745420 patients\NNS\9898892 seen\VBN\2106506 over\IN\5867413 a\DT\13649268 3-year\JJ\1740 period\NN\13575869 in\IN\13603305 whom\WP\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 became\VBD\146138 apparent\JJ\1740 on\IN\1740 delayed\VBN\439958 presentation\NN\1027379 with\IN\1740 thromboembolic\JJ\1740 complications\NNS\1073995 .\.\1740
D006493_D013921 CID RESULTS\NNS\34213 :\:\1740 Patients\NNS\9898892 went\VBD\2367363 home\RB\1740 after\IN\1740 hospitalizations\NNS\15113229 that\WDT\1740 had\VBD\2108377 included\VBN\690614 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 --\:\1740 in\IN\13603305 most\JJS\1740 cases\NNS\7283608 ,\,\1740 with\IN\1740 no\DT\7204911 <e2>thrombocytopenia</e2>\NN\14189204 recognized\VBD\686447 --\:\1740 only\RB\1740 to\TO\1740 return\VB\1835496 to\IN\1740 the\DT\1740 hospital\NN\3739518 (\-LRB-\1740 median\JJ\1740 ,\,\1740 day\NN\15154774 14\CD\13745420 )\-RRB-\1740 with\IN\1740 thromboembolic\NN\1740 complications\NNS\1073995 .\.\1740
D006493_D013921 CID CONCLUSIONS\NNS\5837957 :\:\1740 Delayed-onset\JJ\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 is\VBZ\836236 increasingly\RB\1740 being\VBG\836236 recognized\VBN\686447 .\.\1740
D006493_D013921 CID To\TO\1740 avoid\VB\2452885 disastrous\JJ\1740 outcomes\NNS\7291312 ,\,\1740 physicians\NNS\10305802 must\MD\9367203 consider\VB\689344 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 whenever\WRB\1740 a\DT\13649268 recently\RB\1740 hospitalized\VBN\2348568 patient\NN\9898892 returns\NNS\6479665 with\IN\1740 thromboembolism\NN\14100769 ;\:\1740 therapy\NN\657604 with\IN\1740 alternative\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 not\RB\1740 heparin\NN\2718259 ,\,\1740 should\MD\1740 be\VB\836236 initiated\VBN\1617192 .\.\1740
D006493_D013921 CID To\TO\1740 avoid\VB\2452885 disastrous\JJ\1740 outcomes\NNS\7291312 ,\,\1740 physicians\NNS\10305802 must\MD\9367203 consider\VB\689344 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 whenever\WRB\1740 a\DT\13649268 recently\RB\1740 hospitalized\VBN\2348568 patient\NN\9898892 returns\NNS\6479665 with\IN\1740 thromboembolism\NN\14100769 ;\:\1740 therapy\NN\657604 with\IN\1740 alternative\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 not\RB\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 should\MD\1740 be\VB\836236 initiated\VBN\1617192 .\.\1740
D006493_D001157 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 presents\VBZ\2137132 5\CD\13741022 to\TO\1740 12\CD\13745420 days\NNS\15140892 after\IN\1740 heparin\NN\2718259 exposure\NN\5042871 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>arterial\JJ\1740 or\CC\3541091 venous\JJ\1740 thromboemboli</e2>\NN\1740 .\.\1740
D006493_D001157 CID BACKGROUND\NN\4921011 :\:\1740 Heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 presents\VBZ\2137132 5\CD\13741022 to\TO\1740 12\CD\13745420 days\NNS\15140892 after\IN\1740 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>arterial\JJ\1740 or\CC\3541091 venous\JJ\1740 thromboemboli</e2>\NN\1740 .\.\1740
D006493_D054556 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 presents\VBZ\2137132 5\CD\13741022 to\TO\1740 12\CD\13745420 days\NNS\15140892 after\IN\1740 heparin\NN\2718259 exposure\NN\5042871 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>arterial\JJ\1740 or\CC\3541091 venous\JJ\1740 thromboemboli</e2>\NN\1740 .\.\1740
D006493_D054556 CID BACKGROUND\NN\4921011 :\:\1740 Heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 presents\VBZ\2137132 5\CD\13741022 to\TO\1740 12\CD\13745420 days\NNS\15140892 after\IN\1740 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>arterial\JJ\1740 or\CC\3541091 venous\JJ\1740 thromboemboli</e2>\NN\1740 .\.\1740
D006493_D013923 NONE PATIENTS\NNS\9898892 :\:\1740 14\CD\13745420 patients\NNS\9898892 seen\VBN\2106506 over\IN\5867413 a\DT\13649268 3-year\JJ\1740 period\NN\13575869 in\IN\13603305 whom\WP\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 became\VBD\146138 apparent\JJ\1740 on\IN\1740 delayed\VBN\439958 presentation\NN\1027379 with\IN\1740 <e2>thromboembolic</e2>\JJ\1740 complications\NNS\1073995 .\.\1740
D006493_D013923 NONE MEASUREMENTS\NNS\407535 :\:\1740 Platelet\NN\5432736 counts\NNS\13582013 ,\,\1740 onset\NN\7325190 of\IN\1740 objectively\RB\1740 determined\JJ\1740 <e2>thromboembolism</e2>\NN\14100769 ,\,\1740 results\NNS\34213 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 platelet\NN\5432736 factor\NN\7326557 4\CD\13741022 antibody\NN\14728724 tests\NNS\5798043 ,\,\1740 and\CC\1740 outcomes\NNS\7291312 .\.\1740
D006493_D013923 NONE RESULTS\NNS\34213 :\:\1740 Patients\NNS\9898892 went\VBD\2367363 home\RB\1740 after\IN\1740 hospitalizations\NNS\15113229 that\WDT\1740 had\VBD\2108377 included\VBN\690614 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 --\:\1740 in\IN\13603305 most\JJS\1740 cases\NNS\7283608 ,\,\1740 with\IN\1740 no\DT\7204911 thrombocytopenia\NN\14189204 recognized\VBD\686447 --\:\1740 only\RB\1740 to\TO\1740 return\VB\1835496 to\IN\1740 the\DT\1740 hospital\NN\3739518 (\-LRB-\1740 median\JJ\1740 ,\,\1740 day\NN\15154774 14\CD\13745420 )\-RRB-\1740 with\IN\1740 <e2>thromboembolic</e2>\NN\1740 complications\NNS\1073995 .\.\1740
D006493_D013923 NONE To\TO\1740 avoid\VB\2452885 disastrous\JJ\1740 outcomes\NNS\7291312 ,\,\1740 physicians\NNS\10305802 must\MD\9367203 consider\VB\689344 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 whenever\WRB\1740 a\DT\13649268 recently\RB\1740 hospitalized\VBN\2348568 patient\NN\9898892 returns\NNS\6479665 with\IN\1740 <e2>thromboembolism</e2>\NN\14100769 ;\:\1740 therapy\NN\657604 with\IN\1740 alternative\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 not\RB\1740 heparin\NN\2718259 ,\,\1740 should\MD\1740 be\VB\836236 initiated\VBN\1617192 .\.\1740
D006493_D013923 NONE To\TO\1740 avoid\VB\2452885 disastrous\JJ\1740 outcomes\NNS\7291312 ,\,\1740 physicians\NNS\10305802 must\MD\9367203 consider\VB\689344 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 whenever\WRB\1740 a\DT\13649268 recently\RB\1740 hospitalized\VBN\2348568 patient\NN\9898892 returns\NNS\6479665 with\IN\1740 <e2>thromboembolism</e2>\NN\14100769 ;\:\1740 therapy\NN\657604 with\IN\1740 alternative\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 not\RB\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 should\MD\1740 be\VB\836236 initiated\VBN\1617192 .\.\1740
1355091
D011224_D007024 CID <e2>Orthostatic\JJ\1740 hypotension</e2>\NN\14057371 occurs\VBZ\2623529 following\VBG\1835496 alpha\NN\6828818 2-adrenoceptor\JJ\1740 blockade\NN\952963 in\IN\13603305 chronic\JJ\1740 <e1>prazosin-pretreated</e1>\JJ\1740 conscious\JJ\1740 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 .\.\1740
D011224_D007024 CID However\RB\1740 ,\,\1740 the\DT\1740 head-up\JJ\1740 tilt\NN\788973 induced\VBN\1627355 <e2>orthostatic\JJ\1740 hypotension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 SHR\NN\1740 treated\VBN\2376958 with\IN\1740 <e1>prazosin</e1>\NN\2698769 (\-LRB-\1740 -16\CD\1740 %\NN\1740 MAP\NN\4076846 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 the\DT\1740 SHR\NN\1740 treated\VBN\2376958 with\IN\1740 rauwolscine\NN\1740 (\-LRB-\1740 less\JJR\1740 than\IN\1740 +\CC\1740 2\CD\13741022 %\NN\1740 MAP\NN\4076846 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 .\.\1740
D011224_D007024 CID Head-up\NN\1740 tilts\VBZ\2035919 in\IN\13603305 these\DT\1740 rats\NNS\2329401 did\VBD\1640855 not\RB\1740 produce\VB\1617192 <e2>orthostatic\JJ\1740 hypotension</e2>\NN\14057371 when\WRB\1740 performed\VBN\2367363 either\CC\1740 prior\RB\1740 to\TO\1740 or\CC\3541091 after\IN\1740 acute\JJ\1740 dosing\NN\1740 of\IN\1740 <e1>prazosin</e1>\NN\2698769 (\-LRB-\1740 0.1\CD\1740 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D011224_D006973 NONE Orthostatic\JJ\1740 hypotension\NN\14057371 occurs\VBZ\2623529 following\VBG\1835496 alpha\NN\6828818 2-adrenoceptor\JJ\1740 blockade\NN\952963 in\IN\13603305 chronic\JJ\1740 <e1>prazosin-pretreated</e1>\JJ\1740 conscious\JJ\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D011224_D006973 NONE 1\LS\13741022 .\.\1740 Studies\NNS\635850 were\VBD\836236 performed\VBN\2367363 to\TO\1740 evaluate\VB\670261 whether\IN\1740 chronic\JJ\1740 <e1>prazosin</e1>\NN\2698769 treatment\NN\654885 alters\VBZ\126264 the\DT\1740 alpha\NN\6828818 2-adrenoceptor\JJ\1740 function\NN\13783581 for\IN\1740 orthostatic\JJ\1740 control\NN\5190804 of\IN\1740 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 in\IN\13603305 conscious\JJ\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 .\.\1740
D015016_D007024 NONE However\RB\1740 ,\,\1740 the\DT\1740 head-up\JJ\1740 tilt\NN\788973 induced\VBN\1627355 <e2>orthostatic\JJ\1740 hypotension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 SHR\NN\1740 treated\VBN\2376958 with\IN\1740 prazosin\NN\2698769 (\-LRB-\1740 -16\CD\1740 %\NN\1740 MAP\NN\4076846 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 the\DT\1740 SHR\NN\1740 treated\VBN\2376958 with\IN\1740 <e1>rauwolscine</e1>\NN\1740 (\-LRB-\1740 less\JJR\1740 than\IN\1740 +\CC\1740 2\CD\13741022 %\NN\1740 MAP\NN\4076846 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 .\.\1740
C014282_D001919 CID The\DT\1740 pressor\NN\9190918 responses\NNS\11410625 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 to\TO\1740 the\DT\1740 alpha\NN\6828818 1-agonist\JJ\1740 <e1>cirazoline</e1>\NN\1740 (\-LRB-\1740 0.6\CD\1740 and\CC\1740 2\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 alpha\NN\6828818 2-agonist\JJ\1740 Abbott-53693\NN\1740 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 noradrenaline\NN\14807929 (\-LRB-\1740 0.1\CD\1740 and\CC\1740 1.0\CD\1740 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 conscious\JJ\1740 SHR\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 chronic\JJ\1740 prazosin\NN\2698769 pretreatment\NN\1740 .\.\1740
C014282_D001919 CID Both\CC\1740 the\DT\1740 pressor\NN\9190918 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 effects\NNS\13245626 of\IN\1740 <e1>cirazoline</e1>\NN\1740 were\VBD\836236 abolished\VBN\1740 in\IN\13603305 chronic\JJ\1740 prazosin\NN\2698769 treated\VBN\2376958 SHR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 the\DT\1740 untreated\JJ\1740 SHR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 .\.\1740
C056299_D001919 CID The\DT\1740 pressor\NN\9190918 responses\NNS\11410625 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 to\TO\1740 the\DT\1740 alpha\NN\6828818 1-agonist\JJ\1740 cirazoline\NN\1740 (\-LRB-\1740 0.6\CD\1740 and\CC\1740 2\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 alpha\NN\6828818 2-agonist\JJ\1740 <e1>Abbott-53693</e1>\NN\1740 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 noradrenaline\NN\14807929 (\-LRB-\1740 0.1\CD\1740 and\CC\1740 1.0\CD\1740 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 conscious\JJ\1740 SHR\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 chronic\JJ\1740 prazosin\NN\2698769 pretreatment\NN\1740 .\.\1740
C056299_D001919 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 <e1>Abbott-53693</e1>\NN\1740 were\VBD\836236 similar\JJ\1740 in\IN\13603305 both\DT\1740 groups\NNS\2137 of\IN\1740 SHR\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 accompanying\VBG\1835496 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 greater\JJR\1740 in\IN\13603305 SHR\NN\1740 with\IN\1740 chronic\JJ\1740 prazosin\NN\2698769 treatment\NN\654885 than\IN\1740 without\IN\1740 such\JJ\1740 treatment\NN\654885 .\.\1740
D009638_D001919 CID The\DT\1740 pressor\NN\9190918 responses\NNS\11410625 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 to\TO\1740 the\DT\1740 alpha\NN\6828818 1-agonist\JJ\1740 cirazoline\NN\1740 (\-LRB-\1740 0.6\CD\1740 and\CC\1740 2\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 alpha\NN\6828818 2-agonist\JJ\1740 Abbott-53693\NN\1740 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>noradrenaline</e1>\NN\14807929 (\-LRB-\1740 0.1\CD\1740 and\CC\1740 1.0\CD\1740 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 conscious\JJ\1740 SHR\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 chronic\JJ\1740 prazosin\NN\2698769 pretreatment\NN\1740 .\.\1740
D009638_D001919 CID Furthermore\RB\1740 ,\,\1740 the\DT\1740 <e2>bradycardia</e2>\NN\14110674 that\WDT\1740 accompanied\VBD\1835496 the\DT\1740 <e1>noradrenaline-induced</e1>\JJ\1740 pressor\NN\9190918 effect\NN\34213 in\IN\13603305 SHR\NN\1740 was\VBD\836236 similar\JJ\1740 with\IN\1740 and\CC\1740 without\IN\1740 chronic\JJ\1740 prazosin\NN\2698769 treatment\NN\654885 despite\IN\7501545 a\DT\13649268 47\CD\1740 -\SYM\1740 71\CD\1740 %\NN\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 in\IN\13603305 chronic\JJ\1740 alpha\NN\6828818 1-receptor\NN\1740 blocked\VBD\1476483 SHR.(ABSTRACT\NN\1740 TRUNCATED\VBN\2257767 AT\IN\14622893 400\CD\1740 WORDS\NNS\7109196 )\-RRB-\1740
D011224_D001919 NONE The\DT\1740 pressor\NN\9190918 responses\NNS\11410625 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 to\TO\1740 the\DT\1740 alpha\NN\6828818 1-agonist\JJ\1740 cirazoline\NN\1740 (\-LRB-\1740 0.6\CD\1740 and\CC\1740 2\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 alpha\NN\6828818 2-agonist\JJ\1740 Abbott-53693\NN\1740 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 noradrenaline\NN\14807929 (\-LRB-\1740 0.1\CD\1740 and\CC\1740 1.0\CD\1740 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\NN\1740 )\-RRB-\1740 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 conscious\JJ\1740 SHR\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 chronic\JJ\1740 <e1>prazosin</e1>\NN\2698769 pretreatment\NN\1740 .\.\1740
D011224_D001919 NONE Both\CC\1740 the\DT\1740 pressor\NN\9190918 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 effects\NNS\13245626 of\IN\1740 cirazoline\NN\1740 were\VBD\836236 abolished\VBN\1740 in\IN\13603305 chronic\JJ\1740 <e1>prazosin</e1>\NN\2698769 treated\VBN\2376958 SHR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 the\DT\1740 untreated\JJ\1740 SHR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 .\.\1740
D011224_D001919 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 Abbott-53693\NN\1740 were\VBD\836236 similar\JJ\1740 in\IN\13603305 both\DT\1740 groups\NNS\2137 of\IN\1740 SHR\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 accompanying\VBG\1835496 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 greater\JJR\1740 in\IN\13603305 SHR\NN\1740 with\IN\1740 chronic\JJ\1740 <e1>prazosin</e1>\NN\2698769 treatment\NN\654885 than\IN\1740 without\IN\1740 such\JJ\1740 treatment\NN\654885 .\.\1740
D011224_D001919 NONE Furthermore\RB\1740 ,\,\1740 the\DT\1740 <e2>bradycardia</e2>\NN\14110674 that\WDT\1740 accompanied\VBD\1835496 the\DT\1740 noradrenaline-induced\JJ\1740 pressor\NN\9190918 effect\NN\34213 in\IN\13603305 SHR\NN\1740 was\VBD\836236 similar\JJ\1740 with\IN\1740 and\CC\1740 without\IN\1740 chronic\JJ\1740 <e1>prazosin</e1>\NN\2698769 treatment\NN\654885 despite\IN\7501545 a\DT\13649268 47\CD\1740 -\SYM\1740 71\CD\1740 %\NN\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 in\IN\13603305 chronic\JJ\1740 alpha\NN\6828818 1-receptor\NN\1740 blocked\VBD\1476483 SHR.(ABSTRACT\NN\1740 TRUNCATED\VBN\2257767 AT\IN\14622893 400\CD\1740 WORDS\NNS\7109196 )\-RRB-\1740
15579441
D011692_D000860 CID With\IN\1740 this\DT\1740 model\NN\5888929 ,\,\1740 we\PRP\1740 were\VBD\836236 able\JJ\1740 to\TO\1740 identify\VB\699815 diffuse\JJ\1740 cortical\JJ\1740 <e2>hypoxia</e2>\NN\14035298 in\IN\13603305 the\DT\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 nephrotic\JJ\1740 syndrome\NN\5870365 and\CC\1740 focal\JJ\1740 and\CC\1740 segmental\JJ\1740 hypoxia\NN\14035298 in\IN\13603305 the\DT\1740 remnant\JJ\1740 kidney\NN\5333259 model\NN\5888929 .\.\1740
D011692_D000860 CID With\IN\1740 this\DT\1740 model\NN\5888929 ,\,\1740 we\PRP\1740 were\VBD\836236 able\JJ\1740 to\TO\1740 identify\VB\699815 diffuse\JJ\1740 cortical\JJ\1740 hypoxia\NN\14035298 in\IN\13603305 the\DT\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 nephrotic\JJ\1740 syndrome\NN\5870365 and\CC\1740 focal\JJ\1740 and\CC\1740 segmental\JJ\1740 <e2>hypoxia</e2>\NN\14035298 in\IN\13603305 the\DT\1740 remnant\JJ\1740 kidney\NN\5333259 model\NN\5888929 .\.\1740
D011692_D000860 CID Expression\NN\4679549 of\IN\1740 the\DT\1740 <e2>hypoxia-responsive</e2>\JJ\1740 transgene\NN\5436752 increased\VBD\169651 throughout\IN\1740 the\DT\1740 observation\NN\996969 period\NN\13575869 ,\,\1740 reaching\VBG\2005948 2.2-fold\RB\1740 at\IN\14622893 2\CD\13741022 weeks\NNS\15113229 in\IN\13603305 the\DT\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 model\NN\5888929 and\CC\1740 2.6-fold\JJ\1740 at\IN\14622893 4\CD\13741022 weeks\NNS\15113229 in\IN\13603305 the\DT\1740 remnant\JJ\1740 kidney\NN\5333259 model\NN\5888929 ,\,\1740 whereas\IN\1740 that\DT\1740 of\IN\1740 vascular\JJ\1740 endothelial\JJ\1740 growth\NN\13526110 factor\NN\7326557 showed\VBD\2137132 a\DT\13649268 mild\JJ\1740 decrease\NN\7296428 ,\,\1740 reflecting\VBG\923793 distinct\JJ\1740 behaviors\NNS\407535 of\IN\1740 the\DT\1740 two\CD\13741022 genes\NNS\8459252 .\.\1740
D011692_D009404 CID With\IN\1740 this\DT\1740 model\NN\5888929 ,\,\1740 we\PRP\1740 were\VBD\836236 able\JJ\1740 to\TO\1740 identify\VB\699815 diffuse\JJ\1740 cortical\JJ\1740 hypoxia\NN\14035298 in\IN\13603305 the\DT\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 and\CC\1740 focal\JJ\1740 and\CC\1740 segmental\JJ\1740 hypoxia\NN\14035298 in\IN\13603305 the\DT\1740 remnant\JJ\1740 kidney\NN\5333259 model\NN\5888929 .\.\1740
8988571
D003042_D003693 CID Fatal\JJ\1740 excited\JJ\1740 <e2>delirium</e2>\NN\14391660 following\VBG\1835496 <e1>cocaine</e1>\NN\3492717 use\NN\407535 :\:\1740 epidemiologic\JJ\1740 findings\NNS\7951464 provide\VBP\2199590 new\JJ\1740 evidence\NN\5816287 for\IN\1740 mechanisms\NNS\13446390 of\IN\1740 cocaine\NN\3492717 toxicity\NN\13576101 .\.\1740
D003042_D003693 CID Fatal\JJ\1740 excited\JJ\1740 <e2>delirium</e2>\NN\14391660 following\VBG\1835496 cocaine\NN\3492717 use\NN\407535 :\:\1740 epidemiologic\JJ\1740 findings\NNS\7951464 provide\VBP\2199590 new\JJ\1740 evidence\NN\5816287 for\IN\1740 mechanisms\NNS\13446390 of\IN\1740 <e1>cocaine</e1>\NN\3492717 toxicity\NN\13576101 .\.\1740
D003042_D003693 CID We\PRP\1740 describe\VBP\1001294 an\DT\6697703 outbreak\NN\7283608 of\IN\1740 deaths\NNS\7296428 from\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 excited\JJ\1740 <e2>delirium</e2>\NN\14391660 (\-LRB-\1740 EDDs\NNS\6702458 )\-RRB-\1740 in\IN\13603305 Dade\NNP\1740 County\NNP\8630039 ,\,\1740 Florida\NNP\1740 between\IN\1740 1979\CD\1740 and\CC\1740 1990\CD\1740 .\.\1740
D003042_D003693 CID We\PRP\1740 describe\VBP\1001294 an\DT\6697703 outbreak\NN\7283608 of\IN\1740 deaths\NNS\7296428 from\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 excited\JJ\1740 delirium\NN\14391660 (\-LRB-\1740 <e2>EDDs</e2>\NNS\6702458 )\-RRB-\1740 in\IN\13603305 Dade\NNP\1740 County\NNP\8630039 ,\,\1740 Florida\NNP\1740 between\IN\1740 1979\CD\1740 and\CC\1740 1990\CD\1740 .\.\1740
D003042_D003693 CID From\IN\1740 a\DT\13649268 registry\NN\6502378 of\IN\1740 all\DT\1740 <e1>cocaine-related</e1>\JJ\1740 deaths\NNS\7296428 in\IN\13603305 Dade\NNP\1740 County\NNP\8630039 ,\,\1740 Florida\NNP\1740 ,\,\1740 from\IN\1740 1969\CD\1740 -\SYM\1740 1990\CD\1740 ,\,\1740 58\CD\1740 <e2>EDDs</e2>\NNS\6702458 were\VBD\836236 compared\VBN\644583 with\IN\1740 125\CD\1740 victims\NNS\9630641 of\IN\1740 accidental\JJ\1740 cocaine\NN\3492717 overdose\NN\1740 without\IN\1740 excited\JJ\1740 delirium\NN\14391660 .\.\1740
D003042_D003693 CID From\IN\1740 a\DT\13649268 registry\NN\6502378 of\IN\1740 all\DT\1740 <e1>cocaine-related</e1>\JJ\1740 deaths\NNS\7296428 in\IN\13603305 Dade\NNP\1740 County\NNP\8630039 ,\,\1740 Florida\NNP\1740 ,\,\1740 from\IN\1740 1969\CD\1740 -\SYM\1740 1990\CD\1740 ,\,\1740 58\CD\1740 EDDs\NNS\6702458 were\VBD\836236 compared\VBN\644583 with\IN\1740 125\CD\1740 victims\NNS\9630641 of\IN\1740 accidental\JJ\1740 cocaine\NN\3492717 overdose\NN\1740 without\IN\1740 excited\JJ\1740 <e2>delirium</e2>\NN\14391660 .\.\1740
D003042_D003693 CID From\IN\1740 a\DT\13649268 registry\NN\6502378 of\IN\1740 all\DT\1740 cocaine-related\JJ\1740 deaths\NNS\7296428 in\IN\13603305 Dade\NNP\1740 County\NNP\8630039 ,\,\1740 Florida\NNP\1740 ,\,\1740 from\IN\1740 1969\CD\1740 -\SYM\1740 1990\CD\1740 ,\,\1740 58\CD\1740 <e2>EDDs</e2>\NNS\6702458 were\VBD\836236 compared\VBN\644583 with\IN\1740 125\CD\1740 victims\NNS\9630641 of\IN\1740 accidental\JJ\1740 <e1>cocaine</e1>\NN\3492717 overdose\NN\1740 without\IN\1740 excited\JJ\1740 delirium\NN\14391660 .\.\1740
D003042_D003693 CID From\IN\1740 a\DT\13649268 registry\NN\6502378 of\IN\1740 all\DT\1740 cocaine-related\JJ\1740 deaths\NNS\7296428 in\IN\13603305 Dade\NNP\1740 County\NNP\8630039 ,\,\1740 Florida\NNP\1740 ,\,\1740 from\IN\1740 1969\CD\1740 -\SYM\1740 1990\CD\1740 ,\,\1740 58\CD\1740 EDDs\NNS\6702458 were\VBD\836236 compared\VBN\644583 with\IN\1740 125\CD\1740 victims\NNS\9630641 of\IN\1740 accidental\JJ\1740 <e1>cocaine</e1>\NN\3492717 overdose\NN\1740 without\IN\1740 excited\JJ\1740 <e2>delirium</e2>\NN\14391660 .\.\1740
D003042_D003693 CID <e2>EDDs</e2>\NNS\6702458 had\VBD\2108377 concentrations\NNS\4916342 of\IN\1740 <e1>cocaine</e1>\NN\3492717 and\CC\1740 benzoylecgonine\NN\1740 in\IN\13603305 autopsy\JJ\1740 blood\NN\5397468 that\WDT\1740 were\VBD\836236 similar\JJ\1740 to\TO\1740 those\DT\1740 for\IN\1740 controls\NNS\5190804 .\.\1740
D003042_D003693 CID The\DT\1740 epidemiologic\JJ\1740 findings\NNS\7951464 are\VBP\836236 most\RBS\1740 consistent\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 chronic\JJ\1740 <e1>cocaine</e1>\NN\3492717 use\VBP\1156834 disrupts\VBZ\362348 dopaminergic\JJ\1740 function\NN\13783581 and\CC\1740 ,\,\1740 when\WRB\1740 coupled\VBN\1295275 with\IN\1740 recent\JJ\1740 cocaine\NN\3492717 use\NN\407535 ,\,\1740 may\MD\15209706 precipitate\VB\1642924 agitation\NN\14373582 ,\,\1740 <e2>delirium</e2>\NN\14391660 ,\,\1740 aberrant\JJ\1740 thermoregulation\NN\1740 ,\,\1740 rhabdomyolysis\NN\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 death\NN\7296428 .\.\1740
D003042_D003693 CID The\DT\1740 epidemiologic\JJ\1740 findings\NNS\7951464 are\VBP\836236 most\RBS\1740 consistent\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 chronic\JJ\1740 cocaine\NN\3492717 use\VBP\1156834 disrupts\VBZ\362348 dopaminergic\JJ\1740 function\NN\13783581 and\CC\1740 ,\,\1740 when\WRB\1740 coupled\VBN\1295275 with\IN\1740 recent\JJ\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 ,\,\1740 may\MD\15209706 precipitate\VB\1642924 agitation\NN\14373582 ,\,\1740 <e2>delirium</e2>\NN\14391660 ,\,\1740 aberrant\JJ\1740 thermoregulation\NN\1740 ,\,\1740 rhabdomyolysis\NN\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 death\NN\7296428 .\.\1740
D003042_D064420 NONE Fatal\JJ\1740 excited\JJ\1740 delirium\NN\14391660 following\VBG\1835496 <e1>cocaine</e1>\NN\3492717 use\NN\407535 :\:\1740 epidemiologic\JJ\1740 findings\NNS\7951464 provide\VBP\2199590 new\JJ\1740 evidence\NN\5816287 for\IN\1740 mechanisms\NNS\13446390 of\IN\1740 cocaine\NN\3492717 <e2>toxicity</e2>\NN\13576101 .\.\1740
D003042_D064420 NONE Fatal\JJ\1740 excited\JJ\1740 delirium\NN\14391660 following\VBG\1835496 cocaine\NN\3492717 use\NN\407535 :\:\1740 epidemiologic\JJ\1740 findings\NNS\7951464 provide\VBP\2199590 new\JJ\1740 evidence\NN\5816287 for\IN\1740 mechanisms\NNS\13446390 of\IN\1740 <e1>cocaine</e1>\NN\3492717 <e2>toxicity</e2>\NN\13576101 .\.\1740
D003042_D062787 NONE From\IN\1740 a\DT\13649268 registry\NN\6502378 of\IN\1740 all\DT\1740 <e1>cocaine-related</e1>\JJ\1740 deaths\NNS\7296428 in\IN\13603305 Dade\NNP\1740 County\NNP\8630039 ,\,\1740 Florida\NNP\1740 ,\,\1740 from\IN\1740 1969\CD\1740 -\SYM\1740 1990\CD\1740 ,\,\1740 58\CD\1740 EDDs\NNS\6702458 were\VBD\836236 compared\VBN\644583 with\IN\1740 125\CD\1740 victims\NNS\9630641 of\IN\1740 accidental\JJ\1740 cocaine\NN\3492717 <e2>overdose</e2>\NN\1740 without\IN\1740 excited\JJ\1740 delirium\NN\14391660 .\.\1740
D003042_D062787 NONE From\IN\1740 a\DT\13649268 registry\NN\6502378 of\IN\1740 all\DT\1740 cocaine-related\JJ\1740 deaths\NNS\7296428 in\IN\13603305 Dade\NNP\1740 County\NNP\8630039 ,\,\1740 Florida\NNP\1740 ,\,\1740 from\IN\1740 1969\CD\1740 -\SYM\1740 1990\CD\1740 ,\,\1740 58\CD\1740 EDDs\NNS\6702458 were\VBD\836236 compared\VBN\644583 with\IN\1740 125\CD\1740 victims\NNS\9630641 of\IN\1740 accidental\JJ\1740 <e1>cocaine</e1>\NN\3492717 <e2>overdose</e2>\NN\1740 without\IN\1740 excited\JJ\1740 delirium\NN\14391660 .\.\1740
C005618_D003693 NONE <e2>EDDs</e2>\NNS\6702458 had\VBD\2108377 concentrations\NNS\4916342 of\IN\1740 cocaine\NN\3492717 and\CC\1740 <e1>benzoylecgonine</e1>\NN\1740 in\IN\13603305 autopsy\JJ\1740 blood\NN\5397468 that\WDT\1740 were\VBD\836236 similar\JJ\1740 to\TO\1740 those\DT\1740 for\IN\1740 controls\NNS\5190804 .\.\1740
D003042_D011595 NONE The\DT\1740 epidemiologic\JJ\1740 findings\NNS\7951464 are\VBP\836236 most\RBS\1740 consistent\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 chronic\JJ\1740 <e1>cocaine</e1>\NN\3492717 use\VBP\1156834 disrupts\VBZ\362348 dopaminergic\JJ\1740 function\NN\13783581 and\CC\1740 ,\,\1740 when\WRB\1740 coupled\VBN\1295275 with\IN\1740 recent\JJ\1740 cocaine\NN\3492717 use\NN\407535 ,\,\1740 may\MD\15209706 precipitate\VB\1642924 <e2>agitation</e2>\NN\14373582 ,\,\1740 delirium\NN\14391660 ,\,\1740 aberrant\JJ\1740 thermoregulation\NN\1740 ,\,\1740 rhabdomyolysis\NN\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 death\NN\7296428 .\.\1740
D003042_D011595 NONE The\DT\1740 epidemiologic\JJ\1740 findings\NNS\7951464 are\VBP\836236 most\RBS\1740 consistent\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 chronic\JJ\1740 cocaine\NN\3492717 use\VBP\1156834 disrupts\VBZ\362348 dopaminergic\JJ\1740 function\NN\13783581 and\CC\1740 ,\,\1740 when\WRB\1740 coupled\VBN\1295275 with\IN\1740 recent\JJ\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 ,\,\1740 may\MD\15209706 precipitate\VB\1642924 <e2>agitation</e2>\NN\14373582 ,\,\1740 delirium\NN\14391660 ,\,\1740 aberrant\JJ\1740 thermoregulation\NN\1740 ,\,\1740 rhabdomyolysis\NN\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 death\NN\7296428 .\.\1740
D003042_D012206 CID The\DT\1740 epidemiologic\JJ\1740 findings\NNS\7951464 are\VBP\836236 most\RBS\1740 consistent\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 chronic\JJ\1740 <e1>cocaine</e1>\NN\3492717 use\VBP\1156834 disrupts\VBZ\362348 dopaminergic\JJ\1740 function\NN\13783581 and\CC\1740 ,\,\1740 when\WRB\1740 coupled\VBN\1295275 with\IN\1740 recent\JJ\1740 cocaine\NN\3492717 use\NN\407535 ,\,\1740 may\MD\15209706 precipitate\VB\1642924 agitation\NN\14373582 ,\,\1740 delirium\NN\14391660 ,\,\1740 aberrant\JJ\1740 thermoregulation\NN\1740 ,\,\1740 <e2>rhabdomyolysis</e2>\NN\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 death\NN\7296428 .\.\1740
D003042_D012206 CID The\DT\1740 epidemiologic\JJ\1740 findings\NNS\7951464 are\VBP\836236 most\RBS\1740 consistent\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 chronic\JJ\1740 cocaine\NN\3492717 use\VBP\1156834 disrupts\VBZ\362348 dopaminergic\JJ\1740 function\NN\13783581 and\CC\1740 ,\,\1740 when\WRB\1740 coupled\VBN\1295275 with\IN\1740 recent\JJ\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 ,\,\1740 may\MD\15209706 precipitate\VB\1642924 agitation\NN\14373582 ,\,\1740 delirium\NN\14391660 ,\,\1740 aberrant\JJ\1740 thermoregulation\NN\1740 ,\,\1740 <e2>rhabdomyolysis</e2>\NN\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 death\NN\7296428 .\.\1740
D003042_D003645 CID The\DT\1740 epidemiologic\JJ\1740 findings\NNS\7951464 are\VBP\836236 most\RBS\1740 consistent\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 chronic\JJ\1740 <e1>cocaine</e1>\NN\3492717 use\VBP\1156834 disrupts\VBZ\362348 dopaminergic\JJ\1740 function\NN\13783581 and\CC\1740 ,\,\1740 when\WRB\1740 coupled\VBN\1295275 with\IN\1740 recent\JJ\1740 cocaine\NN\3492717 use\NN\407535 ,\,\1740 may\MD\15209706 precipitate\VB\1642924 agitation\NN\14373582 ,\,\1740 delirium\NN\14391660 ,\,\1740 aberrant\JJ\1740 thermoregulation\NN\1740 ,\,\1740 rhabdomyolysis\NN\1740 ,\,\1740 and\CC\1740 <e2>sudden\JJ\1740 death</e2>\NN\7296428 .\.\1740
D003042_D003645 CID The\DT\1740 epidemiologic\JJ\1740 findings\NNS\7951464 are\VBP\836236 most\RBS\1740 consistent\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 chronic\JJ\1740 cocaine\NN\3492717 use\VBP\1156834 disrupts\VBZ\362348 dopaminergic\JJ\1740 function\NN\13783581 and\CC\1740 ,\,\1740 when\WRB\1740 coupled\VBN\1295275 with\IN\1740 recent\JJ\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 ,\,\1740 may\MD\15209706 precipitate\VB\1642924 agitation\NN\14373582 ,\,\1740 delirium\NN\14391660 ,\,\1740 aberrant\JJ\1740 thermoregulation\NN\1740 ,\,\1740 rhabdomyolysis\NN\1740 ,\,\1740 and\CC\1740 <e2>sudden\JJ\1740 death</e2>\NN\7296428 .\.\1740
3934126
D014640_D007239 NONE <e1>Vancomycin</e1>\NN\2716866 was\VBD\836236 curative\JJ\1740 in\IN\13603305 95\CD\1740 %\NN\1740 of\IN\1740 43\CD\1740 patients\NNS\9898892 with\IN\1740 proven\JJ\1740 <e2>infection</e2>\NN\14052046 .\.\1740
D014640_D007239 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>vancomycin</e1>\NN\2716866 ,\,\1740 administered\VBN\2436349 appropriately\RB\1740 ,\,\1740 constitutes\VBZ\1647229 safe\JJ\1740 ,\,\1740 effective\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>infections</e2>\NNS\14052046 caused\VBN\1617192 by\IN\1740 susceptible\JJ\1740 bacteria\NNS\1326291 .\.\1740
D000617_D013924 NONE <e2>Thrombophlebitis</e2>\NN\14352890 occurred\VBD\2623529 only\RB\1740 with\IN\1740 infusion\NN\14589223 through\IN\1740 peripheral\JJ\1740 cannulae\NN\1740 ;\:\1740 nephrotoxicity\NN\1740 and\CC\1740 ototoxicity\NN\1740 were\VBD\836236 confined\VBN\2510337 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 an\DT\6697703 <e1>aminoglycoside</e1>\NN\1740 plus\CC\4723816 vancomycin\NN\2716866 .\.\1740
D000617_D007674 NONE Thrombophlebitis\NN\14352890 occurred\VBD\2623529 only\RB\1740 with\IN\1740 infusion\NN\14589223 through\IN\1740 peripheral\JJ\1740 cannulae\NN\1740 ;\:\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 ototoxicity\NN\1740 were\VBD\836236 confined\VBN\2510337 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 an\DT\6697703 <e1>aminoglycoside</e1>\NN\1740 plus\CC\4723816 vancomycin\NN\2716866 .\.\1740
D000617_D006311 NONE Thrombophlebitis\NN\14352890 occurred\VBD\2623529 only\RB\1740 with\IN\1740 infusion\NN\14589223 through\IN\1740 peripheral\JJ\1740 cannulae\NN\1740 ;\:\1740 nephrotoxicity\NN\1740 and\CC\1740 <e2>ototoxicity</e2>\NN\1740 were\VBD\836236 confined\VBN\2510337 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 an\DT\6697703 <e1>aminoglycoside</e1>\NN\1740 plus\CC\4723816 vancomycin\NN\2716866 .\.\1740
D014640_D013924 CID <e2>Thrombophlebitis</e2>\NN\14352890 occurred\VBD\2623529 only\RB\1740 with\IN\1740 infusion\NN\14589223 through\IN\1740 peripheral\JJ\1740 cannulae\NN\1740 ;\:\1740 nephrotoxicity\NN\1740 and\CC\1740 ototoxicity\NN\1740 were\VBD\836236 confined\VBN\2510337 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 an\DT\6697703 aminoglycoside\NN\1740 plus\CC\4723816 <e1>vancomycin</e1>\NN\2716866 .\.\1740
D014640_D007674 NONE Thrombophlebitis\NN\14352890 occurred\VBD\2623529 only\RB\1740 with\IN\1740 infusion\NN\14589223 through\IN\1740 peripheral\JJ\1740 cannulae\NN\1740 ;\:\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 ototoxicity\NN\1740 were\VBD\836236 confined\VBN\2510337 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 an\DT\6697703 aminoglycoside\NN\1740 plus\CC\4723816 <e1>vancomycin</e1>\NN\2716866 .\.\1740
D014640_D006311 CID Thrombophlebitis\NN\14352890 occurred\VBD\2623529 only\RB\1740 with\IN\1740 infusion\NN\14589223 through\IN\1740 peripheral\JJ\1740 cannulae\NN\1740 ;\:\1740 nephrotoxicity\NN\1740 and\CC\1740 <e2>ototoxicity</e2>\NN\1740 were\VBD\836236 confined\VBN\2510337 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 an\DT\6697703 aminoglycoside\NN\1740 plus\CC\4723816 <e1>vancomycin</e1>\NN\2716866 .\.\1740
16844102
D024502_D020258 NONE Effect\NN\34213 of\IN\1740 <e1>alpha-tocopherol</e1>\NN\1740 and\CC\1740 deferoxamine\VB\1740 on\IN\1740 methamphetamine-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D024502_D020258 NONE This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>alpha-tocopherol</e1>\NN\1740 (\-LRB-\1740 alpha-TC\NNS\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 scavenger\NN\14779550 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 and\CC\1740 deferoxamine\VB\1740 (\-LRB-\1740 DFO\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 iron\NN\14625458 chelator\NN\1740 ,\,\1740 on\IN\1740 the\DT\1740 MA-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D024502_D020258 NONE This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 effect\NN\34213 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 <e1>alpha-TC</e1>\NNS\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 scavenger\NN\14779550 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 and\CC\1740 deferoxamine\VB\1740 (\-LRB-\1740 DFO\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 iron\NN\14625458 chelator\NN\1740 ,\,\1740 on\IN\1740 the\DT\1740 MA-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D003676_D020258 NONE Effect\NN\34213 of\IN\1740 alpha-tocopherol\NN\1740 and\CC\1740 <e1>deferoxamine</e1>\VB\1740 on\IN\1740 methamphetamine-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D003676_D020258 NONE This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 effect\NN\34213 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-TC\NNS\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 scavenger\NN\14779550 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 and\CC\1740 <e1>deferoxamine</e1>\VB\1740 (\-LRB-\1740 DFO\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 iron\NN\14625458 chelator\NN\1740 ,\,\1740 on\IN\1740 the\DT\1740 MA-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D003676_D020258 NONE This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 effect\NN\34213 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-TC\NNS\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 scavenger\NN\14779550 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 and\CC\1740 deferoxamine\VB\1740 (\-LRB-\1740 <e1>DFO</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 iron\NN\14625458 chelator\NN\1740 ,\,\1740 on\IN\1740 the\DT\1740 MA-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008694_D020258 NONE Effect\NN\34213 of\IN\1740 alpha-tocopherol\NN\1740 and\CC\1740 deferoxamine\VB\1740 on\IN\1740 <e1>methamphetamine-induced</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008694_D020258 NONE <e1>Methamphetamine</e1>\NNP\2704153 (MA)-induced\VBN\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 believed\VBN\686447 to\TO\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 increased\VBN\169651 formation\NN\7938773 of\IN\1740 free\JJ\1740 radicals\NNS\9465459 .\.\1740
D008694_D020258 NONE Methamphetamine\NNP\2704153 <e1>(MA)-induced</e1>\VBN\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 believed\VBN\686447 to\TO\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 increased\VBN\169651 formation\NN\7938773 of\IN\1740 free\JJ\1740 radicals\NNS\9465459 .\.\1740
D008694_D020258 NONE This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 effect\NN\34213 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-TC\NNS\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 scavenger\NN\14779550 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 and\CC\1740 deferoxamine\VB\1740 (\-LRB-\1740 DFO\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 iron\NN\14625458 chelator\NN\1740 ,\,\1740 on\IN\1740 the\DT\1740 <e1>MA-induced</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D010100_D020258 NONE This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 effect\NN\34213 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-TC\NNS\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 scavenger\NN\14779550 of\IN\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 ,\,\1740 and\CC\1740 deferoxamine\VB\1740 (\-LRB-\1740 DFO\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 iron\NN\14625458 chelator\NN\1740 ,\,\1740 on\IN\1740 the\DT\1740 MA-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D007501_D020258 NONE This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 effect\NN\34213 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-TC\NNS\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 scavenger\NN\14779550 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 and\CC\1740 deferoxamine\VB\1740 (\-LRB-\1740 DFO\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 <e1>iron</e1>\NN\14625458 chelator\NN\1740 ,\,\1740 on\IN\1740 the\DT\1740 MA-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D024502_D005334 NONE <e1>alpha-TC</e1>\NN\1740 and\CC\1740 DFO\NN\1740 attenuated\VBD\224901 the\DT\1740 MA-induced\JJ\1740 <e2>hyperthermia</e2>\NN\14034177 as\RB\1740 well\RB\1740 as\IN\14622893 the\DT\1740 alterations\NNS\7283608 in\IN\13603305 the\DT\1740 locomotor\NN\1740 activity\NN\30358 .\.\1740
D003676_D005334 NONE alpha-TC\NN\1740 and\CC\1740 <e1>DFO</e1>\NN\1740 attenuated\VBD\224901 the\DT\1740 MA-induced\JJ\1740 <e2>hyperthermia</e2>\NN\14034177 as\RB\1740 well\RB\1740 as\IN\14622893 the\DT\1740 alterations\NNS\7283608 in\IN\13603305 the\DT\1740 locomotor\NN\1740 activity\NN\30358 .\.\1740
D008694_D005334 CID alpha-TC\NN\1740 and\CC\1740 DFO\NN\1740 attenuated\VBD\224901 the\DT\1740 <e1>MA-induced</e1>\JJ\1740 <e2>hyperthermia</e2>\NN\14034177 as\RB\1740 well\RB\1740 as\IN\14622893 the\DT\1740 alterations\NNS\7283608 in\IN\13603305 the\DT\1740 locomotor\NN\1740 activity\NN\30358 .\.\1740
D024502_D009422 NONE This\DT\1740 suggests\VBZ\1010118 that\IN\1740 <e1>alpha-TC</e1>\NN\1740 and\CC\1740 DFO\NN\1740 ameliorate\VBP\126264 the\DT\1740 MA-induced\JJ\1740 <e2>neuronal\JJ\1740 damage</e2>\NN\7296428 by\IN\1740 decreasing\VBG\169651 the\DT\1740 level\NN\4916342 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D003676_D009422 NONE This\DT\1740 suggests\VBZ\1010118 that\IN\1740 alpha-TC\NN\1740 and\CC\1740 <e1>DFO</e1>\NN\1740 ameliorate\VBP\126264 the\DT\1740 MA-induced\JJ\1740 <e2>neuronal\JJ\1740 damage</e2>\NN\7296428 by\IN\1740 decreasing\VBG\169651 the\DT\1740 level\NN\4916342 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D008694_D009422 CID This\DT\1740 suggests\VBZ\1010118 that\IN\1740 alpha-TC\NN\1740 and\CC\1740 DFO\NN\1740 ameliorate\VBP\126264 the\DT\1740 <e1>MA-induced</e1>\JJ\1740 <e2>neuronal\JJ\1740 damage</e2>\NN\7296428 by\IN\1740 decreasing\VBG\169651 the\DT\1740 level\NN\4916342 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
15867025
D006514_D006509 CID Assessment\NN\5732756 was\VBD\836236 done\VBN\1640855 on\IN\1740 the\DT\1740 following\NN\8180190 :\:\1740 prenatal\JJ\1740 screening\NN\6887726 for\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 and\CC\1740 rubella\NN\14123044 ,\,\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 hepatitis\NN\14127211 B\NN\1355326 vaccine\NN\3562739 birth\NN\15265518 dose\NN\3740161 to\IN\1740 all\DT\1740 infants\NNS\9918248 ,\,\1740 administration\NN\1133281 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 to\TO\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 born\VBN\2630189 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen-positive</e1>\JJ\1740 mothers\NNS\10399491 ,\,\1740 rubella\NN\14123044 immunity\NN\13920835 ,\,\1740 and\CC\1740 administration\NN\1133281 of\IN\1740 in-hospital\JJ\1740 postpartum\NN\1740 rubella\NN\14123044 vaccine\NN\3562739 to\TO\1740 rubella\NN\14123044 nonimmune\JJ\1740 women\NNS\9605289 .\.\1740
D006514_D006509 CID Assessment\NN\5732756 was\VBD\836236 done\VBN\1640855 on\IN\1740 the\DT\1740 following\NN\8180190 :\:\1740 prenatal\JJ\1740 screening\NN\6887726 for\IN\1740 hepatitis\NN\14127211 B\NN\1355326 and\CC\1740 rubella\NN\14123044 ,\,\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 vaccine\NN\3562739 birth\NN\15265518 dose\NN\3740161 to\IN\1740 all\DT\1740 infants\NNS\9918248 ,\,\1740 administration\NN\1133281 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 to\TO\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 born\VBN\2630189 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen-positive</e1>\JJ\1740 mothers\NNS\10399491 ,\,\1740 rubella\NN\14123044 immunity\NN\13920835 ,\,\1740 and\CC\1740 administration\NN\1133281 of\IN\1740 in-hospital\JJ\1740 postpartum\NN\1740 rubella\NN\14123044 vaccine\NN\3562739 to\TO\1740 rubella\NN\14123044 nonimmune\JJ\1740 women\NNS\9605289 .\.\1740
D006514_D006509 CID Assessment\NN\5732756 was\VBD\836236 done\VBN\1640855 on\IN\1740 the\DT\1740 following\NN\8180190 :\:\1740 prenatal\JJ\1740 screening\NN\6887726 for\IN\1740 hepatitis\NN\14127211 B\NN\1355326 and\CC\1740 rubella\NN\14123044 ,\,\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 hepatitis\NN\14127211 B\NN\1355326 vaccine\NN\3562739 birth\NN\15265518 dose\NN\3740161 to\IN\1740 all\DT\1740 infants\NNS\9918248 ,\,\1740 administration\NN\1133281 of\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 immune\JJ\1740 globulin\NN\14736972 to\TO\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 born\VBN\2630189 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen-positive</e1>\JJ\1740 mothers\NNS\10399491 ,\,\1740 rubella\NN\14123044 immunity\NN\13920835 ,\,\1740 and\CC\1740 administration\NN\1133281 of\IN\1740 in-hospital\JJ\1740 postpartum\NN\1740 rubella\NN\14123044 vaccine\NN\3562739 to\TO\1740 rubella\NN\14123044 nonimmune\JJ\1740 women\NNS\9605289 .\.\1740
D006514_D006509 CID All\DT\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 born\VBN\2630189 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen-positive</e1>\JJ\1740 mothers\NNS\10399491 also\RB\1740 received\VBD\2210855 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 immune\JJ\1740 globulin\NN\14736972 .\.\1740
D006514_D012409 NONE Assessment\NN\5732756 was\VBD\836236 done\VBN\1640855 on\IN\1740 the\DT\1740 following\NN\8180190 :\:\1740 prenatal\JJ\1740 screening\NN\6887726 for\IN\1740 hepatitis\NN\14127211 B\NN\1355326 and\CC\1740 <e2>rubella</e2>\NN\14123044 ,\,\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 hepatitis\NN\14127211 B\NN\1355326 vaccine\NN\3562739 birth\NN\15265518 dose\NN\3740161 to\IN\1740 all\DT\1740 infants\NNS\9918248 ,\,\1740 administration\NN\1133281 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 to\TO\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 born\VBN\2630189 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen-positive</e1>\JJ\1740 mothers\NNS\10399491 ,\,\1740 rubella\NN\14123044 immunity\NN\13920835 ,\,\1740 and\CC\1740 administration\NN\1133281 of\IN\1740 in-hospital\JJ\1740 postpartum\NN\1740 rubella\NN\14123044 vaccine\NN\3562739 to\TO\1740 rubella\NN\14123044 nonimmune\JJ\1740 women\NNS\9605289 .\.\1740
D006514_D012409 NONE Assessment\NN\5732756 was\VBD\836236 done\VBN\1640855 on\IN\1740 the\DT\1740 following\NN\8180190 :\:\1740 prenatal\JJ\1740 screening\NN\6887726 for\IN\1740 hepatitis\NN\14127211 B\NN\1355326 and\CC\1740 rubella\NN\14123044 ,\,\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 hepatitis\NN\14127211 B\NN\1355326 vaccine\NN\3562739 birth\NN\15265518 dose\NN\3740161 to\IN\1740 all\DT\1740 infants\NNS\9918248 ,\,\1740 administration\NN\1133281 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 to\TO\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 born\VBN\2630189 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen-positive</e1>\JJ\1740 mothers\NNS\10399491 ,\,\1740 <e2>rubella</e2>\NN\14123044 immunity\NN\13920835 ,\,\1740 and\CC\1740 administration\NN\1133281 of\IN\1740 in-hospital\JJ\1740 postpartum\NN\1740 rubella\NN\14123044 vaccine\NN\3562739 to\TO\1740 rubella\NN\14123044 nonimmune\JJ\1740 women\NNS\9605289 .\.\1740
D006514_D012409 NONE Assessment\NN\5732756 was\VBD\836236 done\VBN\1640855 on\IN\1740 the\DT\1740 following\NN\8180190 :\:\1740 prenatal\JJ\1740 screening\NN\6887726 for\IN\1740 hepatitis\NN\14127211 B\NN\1355326 and\CC\1740 rubella\NN\14123044 ,\,\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 hepatitis\NN\14127211 B\NN\1355326 vaccine\NN\3562739 birth\NN\15265518 dose\NN\3740161 to\IN\1740 all\DT\1740 infants\NNS\9918248 ,\,\1740 administration\NN\1133281 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 to\TO\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 born\VBN\2630189 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen-positive</e1>\JJ\1740 mothers\NNS\10399491 ,\,\1740 rubella\NN\14123044 immunity\NN\13920835 ,\,\1740 and\CC\1740 administration\NN\1133281 of\IN\1740 in-hospital\JJ\1740 postpartum\NN\1740 <e2>rubella</e2>\NN\14123044 vaccine\NN\3562739 to\TO\1740 rubella\NN\14123044 nonimmune\JJ\1740 women\NNS\9605289 .\.\1740
D006514_D012409 NONE Assessment\NN\5732756 was\VBD\836236 done\VBN\1640855 on\IN\1740 the\DT\1740 following\NN\8180190 :\:\1740 prenatal\JJ\1740 screening\NN\6887726 for\IN\1740 hepatitis\NN\14127211 B\NN\1355326 and\CC\1740 rubella\NN\14123044 ,\,\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 hepatitis\NN\14127211 B\NN\1355326 vaccine\NN\3562739 birth\NN\15265518 dose\NN\3740161 to\IN\1740 all\DT\1740 infants\NNS\9918248 ,\,\1740 administration\NN\1133281 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 to\TO\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 born\VBN\2630189 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen-positive</e1>\JJ\1740 mothers\NNS\10399491 ,\,\1740 rubella\NN\14123044 immunity\NN\13920835 ,\,\1740 and\CC\1740 administration\NN\1133281 of\IN\1740 in-hospital\JJ\1740 postpartum\NN\1740 rubella\NN\14123044 vaccine\NN\3562739 to\TO\1740 <e2>rubella</e2>\NN\14123044 nonimmune\JJ\1740 women\NNS\9605289 .\.\1740
16471092
C099041_D053201 NONE Urinary\JJ\1740 symptoms\NNS\5823932 and\CC\1740 quality\NN\24264 of\IN\1740 life\NN\13954253 changes\NNS\7283608 in\IN\13603305 Thai\JJ\1740 women\NNS\9605289 with\IN\1740 <e2>overactive\JJ\1740 bladder</e2>\NN\5515670 after\IN\1740 <e1>tolterodine</e1>\NN\1740 treatment\NN\654885 .\.\1740
C099041_D053201 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 study\VB\630380 the\DT\1740 urinary\JJ\1740 symptoms\NNS\5823932 and\CC\1740 quality\NN\24264 of\IN\1740 life\NN\13954253 changes\NNS\7283608 in\IN\13603305 Thai\JJ\1740 women\NNS\9605289 with\IN\1740 <e2>overactive\JJ\1740 bladder</e2>\NN\5515670 (\-LRB-\1740 OAB\NN\1740 )\-RRB-\1740 after\IN\1740 <e1>tolterodine</e1>\NN\1740 treatment\NN\654885 .\.\1740
C099041_D053201 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 study\VB\630380 the\DT\1740 urinary\JJ\1740 symptoms\NNS\5823932 and\CC\1740 quality\NN\24264 of\IN\1740 life\NN\13954253 changes\NNS\7283608 in\IN\13603305 Thai\JJ\1740 women\NNS\9605289 with\IN\1740 overactive\JJ\1740 bladder\NN\5515670 (\-LRB-\1740 <e2>OAB</e2>\NN\1740 )\-RRB-\1740 after\IN\1740 <e1>tolterodine</e1>\NN\1740 treatment\NN\654885 .\.\1740
C099041_D053201 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Tolterodine</e1>\NNP\1740 was\VBD\836236 well\RB\1740 tolerated\VBN\802318 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 improved\VBD\126264 the\DT\1740 quality\NN\24264 of\IN\1740 life\NN\13954253 in\IN\13603305 Thai\JJ\1740 women\NNS\9605289 with\IN\1740 <e2>OAB</e2>\NN\1740 .\.\1740
15974569
D007608_D010146 NONE Two\CD\13741022 prodrugs\NNS\1740 of\IN\1740 potent\JJ\1740 and\CC\1740 selective\JJ\1740 GluR5\NN\1740 <e1>kainate</e1>\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 actives\VBZ\1740 in\IN\13603305 three\CD\13741022 animal\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D005557_D010146 NONE Their\PRP$\1740 ester\NN\14727670 prodrugs\NNS\1740 6\CD\13741022 and\CC\1740 8\CD\13741022 were\VBD\836236 orally\RB\1740 active\JJ\1740 in\IN\13603305 three\CD\13741022 models\NNS\5888929 of\IN\1740 <e2>pain</e2>\NN\14299637 :\:\1740 reversal\NN\199130 of\IN\1740 <e1>formalin-induced</e1>\JJ\1740 paw\NN\2153445 licking\NN\7291312 ,\,\1740 carrageenan-induced\JJ\1740 thermal\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 and\CC\1740 capsaicin-induced\JJ\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 .\.\1740
D005557_D006930 NONE Their\PRP$\1740 ester\NN\14727670 prodrugs\NNS\1740 6\CD\13741022 and\CC\1740 8\CD\13741022 were\VBD\836236 orally\RB\1740 active\JJ\1740 in\IN\13603305 three\CD\13741022 models\NNS\5888929 of\IN\1740 pain\NN\14299637 :\:\1740 reversal\NN\199130 of\IN\1740 <e1>formalin-induced</e1>\JJ\1740 paw\NN\2153445 licking\NN\7291312 ,\,\1740 carrageenan-induced\JJ\1740 <e2>thermal\JJ\1740 hyperalgesia</e2>\NN\1740 ,\,\1740 and\CC\1740 capsaicin-induced\JJ\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 .\.\1740
D005557_D006930 NONE Their\PRP$\1740 ester\NN\14727670 prodrugs\NNS\1740 6\CD\13741022 and\CC\1740 8\CD\13741022 were\VBD\836236 orally\RB\1740 active\JJ\1740 in\IN\13603305 three\CD\13741022 models\NNS\5888929 of\IN\1740 pain\NN\14299637 :\:\1740 reversal\NN\199130 of\IN\1740 <e1>formalin-induced</e1>\JJ\1740 paw\NN\2153445 licking\NN\7291312 ,\,\1740 carrageenan-induced\JJ\1740 thermal\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 and\CC\1740 capsaicin-induced\JJ\1740 <e2>mechanical\JJ\1740 hyperalgesia</e2>\NN\1740 .\.\1740
D002351_D010146 NONE Their\PRP$\1740 ester\NN\14727670 prodrugs\NNS\1740 6\CD\13741022 and\CC\1740 8\CD\13741022 were\VBD\836236 orally\RB\1740 active\JJ\1740 in\IN\13603305 three\CD\13741022 models\NNS\5888929 of\IN\1740 <e2>pain</e2>\NN\14299637 :\:\1740 reversal\NN\199130 of\IN\1740 formalin-induced\JJ\1740 paw\NN\2153445 licking\NN\7291312 ,\,\1740 <e1>carrageenan-induced</e1>\JJ\1740 thermal\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 and\CC\1740 capsaicin-induced\JJ\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 .\.\1740
D002351_D006930 CID Their\PRP$\1740 ester\NN\14727670 prodrugs\NNS\1740 6\CD\13741022 and\CC\1740 8\CD\13741022 were\VBD\836236 orally\RB\1740 active\JJ\1740 in\IN\13603305 three\CD\13741022 models\NNS\5888929 of\IN\1740 pain\NN\14299637 :\:\1740 reversal\NN\199130 of\IN\1740 formalin-induced\JJ\1740 paw\NN\2153445 licking\NN\7291312 ,\,\1740 <e1>carrageenan-induced</e1>\JJ\1740 <e2>thermal\JJ\1740 hyperalgesia</e2>\NN\1740 ,\,\1740 and\CC\1740 capsaicin-induced\JJ\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 .\.\1740
D002351_D006930 CID Their\PRP$\1740 ester\NN\14727670 prodrugs\NNS\1740 6\CD\13741022 and\CC\1740 8\CD\13741022 were\VBD\836236 orally\RB\1740 active\JJ\1740 in\IN\13603305 three\CD\13741022 models\NNS\5888929 of\IN\1740 pain\NN\14299637 :\:\1740 reversal\NN\199130 of\IN\1740 formalin-induced\JJ\1740 paw\NN\2153445 licking\NN\7291312 ,\,\1740 <e1>carrageenan-induced</e1>\JJ\1740 thermal\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 and\CC\1740 capsaicin-induced\JJ\1740 <e2>mechanical\JJ\1740 hyperalgesia</e2>\NN\1740 .\.\1740
D002211_D010146 NONE Their\PRP$\1740 ester\NN\14727670 prodrugs\NNS\1740 6\CD\13741022 and\CC\1740 8\CD\13741022 were\VBD\836236 orally\RB\1740 active\JJ\1740 in\IN\13603305 three\CD\13741022 models\NNS\5888929 of\IN\1740 <e2>pain</e2>\NN\14299637 :\:\1740 reversal\NN\199130 of\IN\1740 formalin-induced\JJ\1740 paw\NN\2153445 licking\NN\7291312 ,\,\1740 carrageenan-induced\JJ\1740 thermal\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 and\CC\1740 <e1>capsaicin-induced</e1>\JJ\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 .\.\1740
D002211_D006930 CID Their\PRP$\1740 ester\NN\14727670 prodrugs\NNS\1740 6\CD\13741022 and\CC\1740 8\CD\13741022 were\VBD\836236 orally\RB\1740 active\JJ\1740 in\IN\13603305 three\CD\13741022 models\NNS\5888929 of\IN\1740 pain\NN\14299637 :\:\1740 reversal\NN\199130 of\IN\1740 formalin-induced\JJ\1740 paw\NN\2153445 licking\NN\7291312 ,\,\1740 carrageenan-induced\JJ\1740 <e2>thermal\JJ\1740 hyperalgesia</e2>\NN\1740 ,\,\1740 and\CC\1740 <e1>capsaicin-induced</e1>\JJ\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 .\.\1740
D002211_D006930 CID Their\PRP$\1740 ester\NN\14727670 prodrugs\NNS\1740 6\CD\13741022 and\CC\1740 8\CD\13741022 were\VBD\836236 orally\RB\1740 active\JJ\1740 in\IN\13603305 three\CD\13741022 models\NNS\5888929 of\IN\1740 pain\NN\14299637 :\:\1740 reversal\NN\199130 of\IN\1740 formalin-induced\JJ\1740 paw\NN\2153445 licking\NN\7291312 ,\,\1740 carrageenan-induced\JJ\1740 thermal\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 and\CC\1740 <e1>capsaicin-induced</e1>\JJ\1740 <e2>mechanical\JJ\1740 hyperalgesia</e2>\NN\1740 .\.\1740
6504332
D010634_D004409 CID <e1>Phenobarbital-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 in\IN\13603305 a\DT\13649268 neurologically-impaired\JJ\1740 child\NN\9622049 .\.\1740
D010634_D004409 CID A\DT\13649268 2-year-old\JJ\1740 child\NN\9622049 with\IN\1740 known\JJ\1740 neurologic\JJ\1740 impairment\NN\7296428 developed\VBD\1753788 a\DT\13649268 <e2>dyskinesia</e2>\NN\14084880 soon\RB\1740 after\IN\1740 starting\VBG\2009433 <e1>phenobarbital</e1>\JJ\1740 therapy\NN\657604 for\IN\1740 seizures\NNS\14081375 .\.\1740
D010634_D004409 CID On\IN\1740 repeat\NN\7296190 challenge\NN\13927383 with\IN\1740 <e1>phenobarbital</e1>\JJ\1740 ,\,\1740 the\DT\1740 <e2>dyskinesia</e2>\NN\14084880 recurred\VBD\339934 .\.\1740
D010634_D009422 NONE <e1>Phenobarbital-induced</e1>\JJ\1740 dyskinesia\NN\14084880 in\IN\13603305 a\DT\13649268 <e2>neurologically-impaired</e2>\JJ\1740 child\NN\9622049 .\.\1740
D010634_D009422 NONE A\DT\13649268 2-year-old\JJ\1740 child\NN\9622049 with\IN\1740 known\JJ\1740 <e2>neurologic\JJ\1740 impairment</e2>\NN\7296428 developed\VBD\1753788 a\DT\13649268 dyskinesia\NN\14084880 soon\RB\1740 after\IN\1740 starting\VBG\2009433 <e1>phenobarbital</e1>\JJ\1740 therapy\NN\657604 for\IN\1740 seizures\NNS\14081375 .\.\1740
D010634_D012640 NONE A\DT\13649268 2-year-old\JJ\1740 child\NN\9622049 with\IN\1740 known\JJ\1740 neurologic\JJ\1740 impairment\NN\7296428 developed\VBD\1753788 a\DT\13649268 dyskinesia\NN\14084880 soon\RB\1740 after\IN\1740 starting\VBG\2009433 <e1>phenobarbital</e1>\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010634_D009069 NONE <e1>Phenobarbital</e1>\NNP\2792049 should\MD\1740 be\VB\836236 added\VBN\156601 to\IN\1740 the\DT\1740 list\NN\6637824 of\IN\1740 anticonvulsant\JJ\1740 drugs\NNS\14778436 that\WDT\1740 can\MD\3094503 cause\VB\1617192 <e2>movement\NN\191142 disorders</e2>\NNS\14034177 .\.\1740
18356633
D000583_D007674 CID An\DT\6697703 evaluation\NN\874067 of\IN\1740 <e1>amikacin</e1>\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 hematology/oncology\JJ\1740 population\NN\7942152 .\.\1740
D000583_D007674 CID To\TO\1740 evaluate\VB\670261 <e1>amikacin-associated</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 an\DT\6697703 adult\JJ\1740 hematology/oncology\JJ\1740 population\NN\7942152 ,\,\1740 a\DT\13649268 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 ,\,\1740 open-label\JJ\1740 trial\NN\786195 was\VBD\836236 conducted\VBN\2436349 at\IN\14622893 a\DT\13649268 university-affiliated\JJ\1740 medical\JJ\1740 center\NN\8497294 .\.\1740
D000583_D007674 CID The\DT\1740 occurrence\NN\29378 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 by\IN\1740 means\NNS\44150 of\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 creatinine\NN\1740 and\CC\1740 evaluation\NN\874067 of\IN\1740 efficacy\NN\5199286 via\IN\1740 <e1>amikacin</e1>\NN\1740 serum\NN\5397468 concentrations\NNS\4916342 with\IN\1740 respective\JJ\1740 pathogens\NNS\9312843 were\VBD\836236 assessed\VBN\670261 .\.\1740
D000583_D009503 NONE <e1>Amikacin</e1>\NNP\1740 is\VBZ\836236 an\DT\6697703 aminoglycoside\NN\1740 commonly\RB\1740 used\VBN\1156834 to\TO\1740 provide\VB\2199590 empirical\JJ\1740 double\JJ\1740 gram-negative\JJ\1740 treatment\NN\654885 for\IN\1740 <e2>febrile\JJ\1740 neutropenia</e2>\NN\14196405 and\CC\1740 other\JJ\1740 suspected\VBN\916909 infections\NNS\14052046 .\.\1740
D000583_D007239 NONE <e1>Amikacin</e1>\NNP\1740 is\VBZ\836236 an\DT\6697703 aminoglycoside\NN\1740 commonly\RB\1740 used\VBN\1156834 to\TO\1740 provide\VB\2199590 empirical\JJ\1740 double\JJ\1740 gram-negative\JJ\1740 treatment\NN\654885 for\IN\1740 febrile\JJ\1740 neutropenia\NN\14196405 and\CC\1740 other\JJ\1740 suspected\VBN\916909 <e2>infections</e2>\NNS\14052046 .\.\1740
D000617_D009503 NONE Amikacin\NNP\1740 is\VBZ\836236 an\DT\6697703 <e1>aminoglycoside</e1>\NN\1740 commonly\RB\1740 used\VBN\1156834 to\TO\1740 provide\VB\2199590 empirical\JJ\1740 double\JJ\1740 gram-negative\JJ\1740 treatment\NN\654885 for\IN\1740 <e2>febrile\JJ\1740 neutropenia</e2>\NN\14196405 and\CC\1740 other\JJ\1740 suspected\VBN\916909 infections\NNS\14052046 .\.\1740
D000617_D007239 NONE Amikacin\NNP\1740 is\VBZ\836236 an\DT\6697703 <e1>aminoglycoside</e1>\NN\1740 commonly\RB\1740 used\VBN\1156834 to\TO\1740 provide\VB\2199590 empirical\JJ\1740 double\JJ\1740 gram-negative\JJ\1740 treatment\NN\654885 for\IN\1740 febrile\JJ\1740 neutropenia\NN\14196405 and\CC\1740 other\JJ\1740 suspected\VBN\916909 <e2>infections</e2>\NNS\14052046 .\.\1740
D000617_D006402 NONE Forty\CD\13745420 patients\NNS\9898892 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 consistent\JJ\1740 with\IN\1740 a\DT\13649268 <e2>hematologic/oncologic\JJ\1740 disorder</e2>\NN\14034177 that\WDT\1740 required\VBD\754942 treatment\NN\654885 with\IN\1740 an\DT\6697703 <e1>aminoglycoside</e1>\NN\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 either\CC\1740 conventional\JJ\1740 or\CC\3541091 extended-interval\JJ\1740 amikacin\NN\1740 .\.\1740
D000617_D009369 NONE Forty\CD\13745420 patients\NNS\9898892 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 consistent\JJ\1740 with\IN\1740 a\DT\13649268 <e2>hematologic/oncologic\JJ\1740 disorder</e2>\NN\14034177 that\WDT\1740 required\VBD\754942 treatment\NN\654885 with\IN\1740 an\DT\6697703 <e1>aminoglycoside</e1>\NN\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 either\CC\1740 conventional\JJ\1740 or\CC\3541091 extended-interval\JJ\1740 amikacin\NN\1740 .\.\1740
D000583_D006402 NONE Forty\CD\13745420 patients\NNS\9898892 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 consistent\JJ\1740 with\IN\1740 a\DT\13649268 <e2>hematologic/oncologic\JJ\1740 disorder</e2>\NN\14034177 that\WDT\1740 required\VBD\754942 treatment\NN\654885 with\IN\1740 an\DT\6697703 aminoglycoside\NN\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 either\CC\1740 conventional\JJ\1740 or\CC\3541091 extended-interval\JJ\1740 <e1>amikacin</e1>\NN\1740 .\.\1740
D000583_D009369 NONE Forty\CD\13745420 patients\NNS\9898892 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 consistent\JJ\1740 with\IN\1740 a\DT\13649268 <e2>hematologic/oncologic\JJ\1740 disorder</e2>\NN\14034177 that\WDT\1740 required\VBD\754942 treatment\NN\654885 with\IN\1740 an\DT\6697703 aminoglycoside\NN\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 either\CC\1740 conventional\JJ\1740 or\CC\3541091 extended-interval\JJ\1740 <e1>amikacin</e1>\NN\1740 .\.\1740
D003404_D007674 NONE The\DT\1740 occurrence\NN\29378 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 by\IN\1740 means\NNS\44150 of\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 and\CC\1740 evaluation\NN\874067 of\IN\1740 efficacy\NN\5199286 via\IN\1740 amikacin\NN\1740 serum\NN\5397468 concentrations\NNS\4916342 with\IN\1740 respective\JJ\1740 pathogens\NNS\9312843 were\VBD\836236 assessed\VBN\670261 .\.\1740
1564236
D013793_D023921 NONE Relation\NN\2137 of\IN\1740 perfusion\NN\320852 defects\NNS\14462666 observed\VBN\2163746 with\IN\1740 myocardial\JJ\1740 contrast\NN\13854649 echocardiography\NN\177127 to\TO\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 :\:\1740 correlation\NN\13841213 with\IN\1740 <e1>thallium-201</e1>\JJ\1740 single-photon\NN\1740 emission\NN\44455 tomography\NN\900375 .\.\1740
D004176_D006940 CID During\IN\1740 <e1>dipyridamole-induced</e1>\JJ\1740 <e2>hyperemia</e2>\NN\14320394 ,\,\1740 12\CD\13745420 of\IN\1740 the\DT\1740 16\CD\13745420 dogs\NNS\2083346 with\IN\1740 a\DT\13649268 partial\JJ\1740 coronary\JJ\1740 stenosis\NN\14204950 had\VBD\2108377 a\DT\13649268 visible\JJ\1740 area\NN\8630985 of\IN\1740 hypoperfusion\NN\1740 by\IN\1740 contrast\NN\13854649 echocardiography\NN\177127 .\.\1740
D004176_D006940 CID The\DT\1740 four\CD\13741022 dogs\NNS\2083346 without\IN\1740 a\DT\13649268 perfusion\NN\320852 defect\NN\14462666 had\VBD\2108377 a\DT\13649268 stenosis\NN\14204950 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mild\NN\1740 (\-LRB-\1740 0\CD\13741022 %\NN\1740 to\TO\1740 50\CD\13745420 %\NN\1740 )\-RRB-\1740 reduction\NN\351485 in\IN\13603305 <e1>dipyridamole-induced</e1>\JJ\1740 <e2>hyperemia</e2>\NN\14320394 .\.\1740
D004176_D006940 CID Thallium-201\VBG\1740 SPECT\NN\1740 demonstrated\VBD\2137132 a\DT\13649268 perfusion\NN\320852 defect\NN\14462666 in\IN\13603305 all\DT\1740 14\CD\13745420 dogs\NNS\2083346 analyzed\VBN\78760 during\IN\1740 <e1>dipyridamole-induced</e1>\JJ\1740 <e2>hyperemia</e2>\NN\14320394 ;\:\1740 the\DT\1740 size\NN\5090441 of\IN\1740 the\DT\1740 perfusion\NN\320852 defect\NN\14462666 correlated\VBD\2657219 with\IN\1740 the\DT\1740 anatomic\JJ\1740 area\NN\8630985 at\IN\14622893 risk\NN\14541044 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.58\CD\1740 ;\:\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.03\CD\1740 )\-RRB-\1740 and\CC\1740 with\IN\1740 the\DT\1740 perfusion\NN\320852 defect\NN\14462666 by\IN\1740 contrast\NN\13854649 echocardiography\NN\177127 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.58\CD\1740 ;\:\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.03\CD\1740 )\-RRB-\1740 .\.\1740
D004176_D023921 NONE During\IN\1740 <e1>dipyridamole-induced</e1>\JJ\1740 hyperemia\NN\14320394 ,\,\1740 12\CD\13745420 of\IN\1740 the\DT\1740 16\CD\13745420 dogs\NNS\2083346 with\IN\1740 a\DT\13649268 partial\JJ\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 had\VBD\2108377 a\DT\13649268 visible\JJ\1740 area\NN\8630985 of\IN\1740 hypoperfusion\NN\1740 by\IN\1740 contrast\NN\13854649 echocardiography\NN\177127 .\.\1740
D013793_D006940 NONE <e1>Thallium-201</e1>\VBG\1740 SPECT\NN\1740 demonstrated\VBD\2137132 a\DT\13649268 perfusion\NN\320852 defect\NN\14462666 in\IN\13603305 all\DT\1740 14\CD\13745420 dogs\NNS\2083346 analyzed\VBN\78760 during\IN\1740 dipyridamole-induced\JJ\1740 <e2>hyperemia</e2>\NN\14320394 ;\:\1740 the\DT\1740 size\NN\5090441 of\IN\1740 the\DT\1740 perfusion\NN\320852 defect\NN\14462666 correlated\VBD\2657219 with\IN\1740 the\DT\1740 anatomic\JJ\1740 area\NN\8630985 at\IN\14622893 risk\NN\14541044 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.58\CD\1740 ;\:\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.03\CD\1740 )\-RRB-\1740 and\CC\1740 with\IN\1740 the\DT\1740 perfusion\NN\320852 defect\NN\14462666 by\IN\1740 contrast\NN\13854649 echocardiography\NN\177127 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.58\CD\1740 ;\:\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.03\CD\1740 )\-RRB-\1740 .\.\1740
9305828
D010862_D004833 CID Neuropeptide-Y\NN\1740 immunoreactivity\NN\1740 in\IN\13603305 the\DT\1740 <e1>pilocarpine</e1>\NN\14712692 model\NN\5888929 of\IN\1740 <e2>temporal\JJ\1740 lobe\JJ\1740 epilepsy</e2>\NN\14085708 .\.\1740
D010862_D004833 CID The\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 changes\NNS\7283608 in\IN\13603305 NPY\NN\1740 expression\NN\4679549 ,\,\1740 including\VBG\690614 expression\NN\4679549 in\IN\13603305 the\DT\1740 granule\NN\9290777 cells\NNS\3080309 and\CC\1740 mossy\NN\1740 fibres\NNS\14580897 and\CC\1740 the\DT\1740 loss\NN\13252973 of\IN\1740 vulnerable\JJ\1740 NPY\NN\1740 neurons\NNS\5430628 ,\,\1740 are\VBP\836236 present\JJ\1740 in\IN\13603305 the\DT\1740 <e1>PILO</e1>\NN\1740 model\NN\5888929 of\IN\1740 <e2>TLE</e2>\NN\1740 .\.\1740
D010862_D004827 NONE The\DT\1740 <e1>pilocarpine</e1>\NN\14712692 (\-LRB-\1740 PILO\NNS\1740 )\-RRB-\1740 model\NN\5888929 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 an\DT\6697703 acute\JJ\1740 period\NN\13575869 of\IN\1740 status\NN\24720 epilepticus\NN\1740 followed\VBN\1835496 by\IN\1740 spontaneous\JJ\1740 recurrent\JJ\1740 seizures\NNS\14081375 and\CC\1740 related\JJ\1740 brain\NN\5462674 damage\NN\7296428 .\.\1740
D010862_D004827 NONE The\DT\1740 pilocarpine\NN\14712692 (\-LRB-\1740 <e1>PILO</e1>\NNS\1740 )\-RRB-\1740 model\NN\5888929 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 an\DT\6697703 acute\JJ\1740 period\NN\13575869 of\IN\1740 status\NN\24720 epilepticus\NN\1740 followed\VBN\1835496 by\IN\1740 spontaneous\JJ\1740 recurrent\JJ\1740 seizures\NNS\14081375 and\CC\1740 related\JJ\1740 brain\NN\5462674 damage\NN\7296428 .\.\1740
D010862_D013226 NONE The\DT\1740 <e1>pilocarpine</e1>\NN\14712692 (\-LRB-\1740 PILO\NNS\1740 )\-RRB-\1740 model\NN\5888929 of\IN\1740 epilepsy\NN\14085708 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 an\DT\6697703 acute\JJ\1740 period\NN\13575869 of\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 followed\VBN\1835496 by\IN\1740 spontaneous\JJ\1740 recurrent\JJ\1740 seizures\NNS\14081375 and\CC\1740 related\JJ\1740 brain\NN\5462674 damage\NN\7296428 .\.\1740
D010862_D013226 NONE The\DT\1740 pilocarpine\NN\14712692 (\-LRB-\1740 <e1>PILO</e1>\NNS\1740 )\-RRB-\1740 model\NN\5888929 of\IN\1740 epilepsy\NN\14085708 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 an\DT\6697703 acute\JJ\1740 period\NN\13575869 of\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 followed\VBN\1835496 by\IN\1740 spontaneous\JJ\1740 recurrent\JJ\1740 seizures\NNS\14081375 and\CC\1740 related\JJ\1740 brain\NN\5462674 damage\NN\7296428 .\.\1740
D010862_D012640 NONE The\DT\1740 <e1>pilocarpine</e1>\NN\14712692 (\-LRB-\1740 PILO\NNS\1740 )\-RRB-\1740 model\NN\5888929 of\IN\1740 epilepsy\NN\14085708 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 an\DT\6697703 acute\JJ\1740 period\NN\13575869 of\IN\1740 status\NN\24720 epilepticus\NN\1740 followed\VBN\1835496 by\IN\1740 spontaneous\JJ\1740 recurrent\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 related\JJ\1740 brain\NN\5462674 damage\NN\7296428 .\.\1740
D010862_D012640 NONE The\DT\1740 pilocarpine\NN\14712692 (\-LRB-\1740 <e1>PILO</e1>\NNS\1740 )\-RRB-\1740 model\NN\5888929 of\IN\1740 epilepsy\NN\14085708 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 an\DT\6697703 acute\JJ\1740 period\NN\13575869 of\IN\1740 status\NN\24720 epilepticus\NN\1740 followed\VBN\1835496 by\IN\1740 spontaneous\JJ\1740 recurrent\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 related\JJ\1740 brain\NN\5462674 damage\NN\7296428 .\.\1740
D010862_D001930 NONE The\DT\1740 <e1>pilocarpine</e1>\NN\14712692 (\-LRB-\1740 PILO\NNS\1740 )\-RRB-\1740 model\NN\5888929 of\IN\1740 epilepsy\NN\14085708 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 an\DT\6697703 acute\JJ\1740 period\NN\13575869 of\IN\1740 status\NN\24720 epilepticus\NN\1740 followed\VBN\1835496 by\IN\1740 spontaneous\JJ\1740 recurrent\JJ\1740 seizures\NNS\14081375 and\CC\1740 related\JJ\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 .\.\1740
D010862_D001930 NONE The\DT\1740 pilocarpine\NN\14712692 (\-LRB-\1740 <e1>PILO</e1>\NNS\1740 )\-RRB-\1740 model\NN\5888929 of\IN\1740 epilepsy\NN\14085708 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 an\DT\6697703 acute\JJ\1740 period\NN\13575869 of\IN\1740 status\NN\24720 epilepticus\NN\1740 followed\VBN\1835496 by\IN\1740 spontaneous\JJ\1740 recurrent\JJ\1740 seizures\NNS\14081375 and\CC\1740 related\JJ\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 .\.\1740
7791169
D016595_D007674 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>misoprostol</e1>\NN\1740 on\IN\1740 indomethacin\NN\3828465 induced\JJ\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 .\.\1740
D016595_D007674 NONE Addition\NN\3081021 of\IN\1740 <e1>misoprostol</e1>\NN\1740 can\MD\3094503 minimize\VB\441445 this\DT\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 without\IN\1740 affecting\VBG\126264 pain\NN\14299637 control\NN\5190804 .\.\1740
D007213_D007674 CID Protective\JJ\1740 effect\NN\34213 of\IN\1740 misoprostol\NN\1740 on\IN\1740 <e1>indomethacin</e1>\NN\3828465 induced\JJ\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 .\.\1740
D007213_D007674 CID CONCLUSION\NN\5837957 :\:\1740 Hospitalized\VBN\2348568 elderly\JJ\1740 patients\NNS\9898892 are\VBP\836236 at\IN\14622893 risk\NN\14541044 for\IN\1740 developing\VBG\1753788 <e1>indomethacin</e1>\NN\3828465 related\JJ\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D016595_D010146 NONE Addition\NN\3081021 of\IN\1740 <e1>misoprostol</e1>\NN\1740 can\MD\3094503 minimize\VB\441445 this\DT\1740 renal\JJ\1740 impairment\NN\7296428 without\IN\1740 affecting\VBG\126264 <e2>pain</e2>\NN\14299637 control\NN\5190804 .\.\1740
2021202
D007530_D007022 CID Renal\JJ\1740 function\NN\13783581 and\CC\1740 hemodynamics\NNS\6080522 during\IN\1740 prolonged\JJ\1740 <e1>isoflurane-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 humans\NNS\31264 .\.\1740
D007530_D007022 CID The\DT\1740 effect\NN\34213 of\IN\1740 <e1>isoflurane-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 on\IN\1740 glomerular\JJ\1740 function\NN\13783581 and\CC\1740 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 20\CD\13745420 human\JJ\1740 subjects\NNS\6598915 .\.\1740
D007530_D007022 CID <e2>Hypotension</e2>\NN\14057371 was\VBD\836236 induced\VBN\1627355 for\IN\1740 236.9\CD\1740 +/-\CC\1740 15.1\CD\1740 min\NN\15154774 by\IN\1740 increasing\VBG\169651 the\DT\1740 <e1>isoflurane</e1>\NN\3570838 inspired\JJ\1740 concentration\NN\4916342 to\TO\1740 maintain\VB\2202928 a\DT\13649268 mean\NN\6021761 arterial\JJ\1740 pressure\NN\11419404 of\IN\1740 59.8\CD\1740 +/-\CC\1740 0.4\CD\1740 mmHg\NN\1740 .\.\1740
D007530_D007022 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 renal\JJ\1740 compensatory\JJ\1740 mechanisms\NNS\13446390 are\VBP\836236 preserved\VBN\2681795 during\IN\1740 <e1>isoflurane-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 that\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 hemodynamics\VBZ\1740 quickly\RB\1740 return\VBP\1835496 to\IN\1740 normal\JJ\1740 when\WRB\1740 normotension\NN\1740 is\VBZ\836236 resumed\VBN\2679899 .\.\1740
17285209
D017311_D006973 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 on\IN\1740 a\DT\13649268 45-year\JJ\1740 old\JJ\1740 African-American\JJ\1740 female\NN\15388 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>hypertension</e2>\NN\14057371 ,\,\1740 who\WP\8299493 was\VBD\836236 started\VBN\2009433 on\IN\1740 a\DT\13649268 combination\NN\7951464 pill\NN\4424218 of\IN\1740 <e1>amlodipine/benazapril</e1>\JJ\1740 10/5\NN\1740 mg.\NN\1740 The\DT\1740 very\RB\1740 next\JJ\1740 day\NN\15154774 ,\,\1740 she\PRP\1740 presented\VBD\2137132 at\IN\14622893 the\DT\1740 emergency\NN\7417644 room\NN\2735688 (\-LRB-\1740 ER\NN\14625458 )\-RRB-\1740 with\IN\1740 abdominal\JJ\1740 pain\NN\14299637 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 .\.\1740
D017311_D015746 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 on\IN\1740 a\DT\13649268 45-year\JJ\1740 old\JJ\1740 African-American\JJ\1740 female\NN\15388 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 hypertension\NN\14057371 ,\,\1740 who\WP\8299493 was\VBD\836236 started\VBN\2009433 on\IN\1740 a\DT\13649268 combination\NN\7951464 pill\NN\4424218 of\IN\1740 <e1>amlodipine/benazapril</e1>\JJ\1740 10/5\NN\1740 mg.\NN\1740 The\DT\1740 very\RB\1740 next\JJ\1740 day\NN\15154774 ,\,\1740 she\PRP\1740 presented\VBD\2137132 at\IN\14622893 the\DT\1740 emergency\NN\7417644 room\NN\2735688 (\-LRB-\1740 ER\NN\14625458 )\-RRB-\1740 with\IN\1740 <e2>abdominal\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 .\.\1740
D017311_D009325 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 on\IN\1740 a\DT\13649268 45-year\JJ\1740 old\JJ\1740 African-American\JJ\1740 female\NN\15388 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 hypertension\NN\14057371 ,\,\1740 who\WP\8299493 was\VBD\836236 started\VBN\2009433 on\IN\1740 a\DT\13649268 combination\NN\7951464 pill\NN\4424218 of\IN\1740 <e1>amlodipine/benazapril</e1>\JJ\1740 10/5\NN\1740 mg.\NN\1740 The\DT\1740 very\RB\1740 next\JJ\1740 day\NN\15154774 ,\,\1740 she\PRP\1740 presented\VBD\2137132 at\IN\14622893 the\DT\1740 emergency\NN\7417644 room\NN\2735688 (\-LRB-\1740 ER\NN\14625458 )\-RRB-\1740 with\IN\1740 abdominal\JJ\1740 pain\NN\14299637 ,\,\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 .\.\1740
D017311_D014839 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 on\IN\1740 a\DT\13649268 45-year\JJ\1740 old\JJ\1740 African-American\JJ\1740 female\NN\15388 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 hypertension\NN\14057371 ,\,\1740 who\WP\8299493 was\VBD\836236 started\VBN\2009433 on\IN\1740 a\DT\13649268 combination\NN\7951464 pill\NN\4424218 of\IN\1740 <e1>amlodipine/benazapril</e1>\JJ\1740 10/5\NN\1740 mg.\NN\1740 The\DT\1740 very\RB\1740 next\JJ\1740 day\NN\15154774 ,\,\1740 she\PRP\1740 presented\VBD\2137132 at\IN\14622893 the\DT\1740 emergency\NN\7417644 room\NN\2735688 (\-LRB-\1740 ER\NN\14625458 )\-RRB-\1740 with\IN\1740 abdominal\JJ\1740 pain\NN\14299637 ,\,\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 .\.\1740
C044946_D006973 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 on\IN\1740 a\DT\13649268 45-year\JJ\1740 old\JJ\1740 African-American\JJ\1740 female\NN\15388 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>hypertension</e2>\NN\14057371 ,\,\1740 who\WP\8299493 was\VBD\836236 started\VBN\2009433 on\IN\1740 a\DT\13649268 combination\NN\7951464 pill\NN\4424218 of\IN\1740 <e1>amlodipine/benazapril</e1>\JJ\1740 10/5\NN\1740 mg.\NN\1740 The\DT\1740 very\RB\1740 next\JJ\1740 day\NN\15154774 ,\,\1740 she\PRP\1740 presented\VBD\2137132 at\IN\14622893 the\DT\1740 emergency\NN\7417644 room\NN\2735688 (\-LRB-\1740 ER\NN\14625458 )\-RRB-\1740 with\IN\1740 abdominal\JJ\1740 pain\NN\14299637 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 .\.\1740
C044946_D015746 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 on\IN\1740 a\DT\13649268 45-year\JJ\1740 old\JJ\1740 African-American\JJ\1740 female\NN\15388 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 hypertension\NN\14057371 ,\,\1740 who\WP\8299493 was\VBD\836236 started\VBN\2009433 on\IN\1740 a\DT\13649268 combination\NN\7951464 pill\NN\4424218 of\IN\1740 <e1>amlodipine/benazapril</e1>\JJ\1740 10/5\NN\1740 mg.\NN\1740 The\DT\1740 very\RB\1740 next\JJ\1740 day\NN\15154774 ,\,\1740 she\PRP\1740 presented\VBD\2137132 at\IN\14622893 the\DT\1740 emergency\NN\7417644 room\NN\2735688 (\-LRB-\1740 ER\NN\14625458 )\-RRB-\1740 with\IN\1740 <e2>abdominal\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 .\.\1740
C044946_D009325 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 on\IN\1740 a\DT\13649268 45-year\JJ\1740 old\JJ\1740 African-American\JJ\1740 female\NN\15388 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 hypertension\NN\14057371 ,\,\1740 who\WP\8299493 was\VBD\836236 started\VBN\2009433 on\IN\1740 a\DT\13649268 combination\NN\7951464 pill\NN\4424218 of\IN\1740 <e1>amlodipine/benazapril</e1>\JJ\1740 10/5\NN\1740 mg.\NN\1740 The\DT\1740 very\RB\1740 next\JJ\1740 day\NN\15154774 ,\,\1740 she\PRP\1740 presented\VBD\2137132 at\IN\14622893 the\DT\1740 emergency\NN\7417644 room\NN\2735688 (\-LRB-\1740 ER\NN\14625458 )\-RRB-\1740 with\IN\1740 abdominal\JJ\1740 pain\NN\14299637 ,\,\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 .\.\1740
C044946_D014839 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 on\IN\1740 a\DT\13649268 45-year\JJ\1740 old\JJ\1740 African-American\JJ\1740 female\NN\15388 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 hypertension\NN\14057371 ,\,\1740 who\WP\8299493 was\VBD\836236 started\VBN\2009433 on\IN\1740 a\DT\13649268 combination\NN\7951464 pill\NN\4424218 of\IN\1740 <e1>amlodipine/benazapril</e1>\JJ\1740 10/5\NN\1740 mg.\NN\1740 The\DT\1740 very\RB\1740 next\JJ\1740 day\NN\15154774 ,\,\1740 she\PRP\1740 presented\VBD\2137132 at\IN\14622893 the\DT\1740 emergency\NN\7417644 room\NN\2735688 (\-LRB-\1740 ER\NN\14625458 )\-RRB-\1740 with\IN\1740 abdominal\JJ\1740 pain\NN\14299637 ,\,\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 .\.\1740
D000809_D007410 NONE The\DT\1740 recognition\NN\13932421 of\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 and\CC\1740 angiotensin\NN\4522421 receptor\NN\5225602 blocker\NN\10101634 (\-LRB-\1740 ARB\NN\9882007 )\-RRB-\1740 <e2>intestinal\JJ\1740 angioedema</e2>\NN\14316714 constitutes\VBZ\1647229 a\DT\13649268 challenge\NN\13927383 to\IN\1740 primary\JJ\1740 care\NN\575741 physicians\NNS\10305802 ,\,\1740 internists\NNS\10632576 ,\,\1740 emergency\NN\7417644 room\NN\2735688 personal\JJ\1740 and\CC\1740 surgeons\NNS\10020890 .\.\1740
D000809_D007410 NONE The\DT\1740 recognition\NN\13932421 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 and\CC\1740 <e1>angiotensin</e1>\NN\4522421 receptor\NN\5225602 blocker\NN\10101634 (\-LRB-\1740 ARB\NN\9882007 )\-RRB-\1740 <e2>intestinal\JJ\1740 angioedema</e2>\NN\14316714 constitutes\VBZ\1647229 a\DT\13649268 challenge\NN\13927383 to\IN\1740 primary\JJ\1740 care\NN\575741 physicians\NNS\10305802 ,\,\1740 internists\NNS\10632576 ,\,\1740 emergency\NN\7417644 room\NN\2735688 personal\JJ\1740 and\CC\1740 surgeons\NNS\10020890 .\.\1740
D000809_D000799 NONE The\DT\1740 recognition\NN\13932421 of\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 and\CC\1740 angiotensin\NN\4522421 receptor\NN\5225602 blocker\NN\10101634 (\-LRB-\1740 ARB\NN\9882007 )\-RRB-\1740 <e2>intestinal\JJ\1740 angioedema</e2>\NN\14316714 constitutes\VBZ\1647229 a\DT\13649268 challenge\NN\13927383 to\IN\1740 primary\JJ\1740 care\NN\575741 physicians\NNS\10305802 ,\,\1740 internists\NNS\10632576 ,\,\1740 emergency\NN\7417644 room\NN\2735688 personal\JJ\1740 and\CC\1740 surgeons\NNS\10020890 .\.\1740
D000809_D000799 NONE The\DT\1740 recognition\NN\13932421 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 and\CC\1740 <e1>angiotensin</e1>\NN\4522421 receptor\NN\5225602 blocker\NN\10101634 (\-LRB-\1740 ARB\NN\9882007 )\-RRB-\1740 <e2>intestinal\JJ\1740 angioedema</e2>\NN\14316714 constitutes\VBZ\1647229 a\DT\13649268 challenge\NN\13927383 to\IN\1740 primary\JJ\1740 care\NN\575741 physicians\NNS\10305802 ,\,\1740 internists\NNS\10632576 ,\,\1740 emergency\NN\7417644 room\NN\2735688 personal\JJ\1740 and\CC\1740 surgeons\NNS\10020890 .\.\1740
7752389
D015232_D053201 CID <e1>Prostaglandin\NN\5414534 E2-induced</e1>\JJ\1740 <e2>bladder\NN\5515670 hyperactivity</e2>\NN\14052403 in\IN\13603305 normal\JJ\1740 ,\,\1740 conscious\JJ\1740 rats\NNS\2329401 :\:\1740 involvement\NN\1080366 of\IN\1740 tachykinins\NNS\1740 ?\.\1740
D015320_D053201 NONE Prostaglandin\NN\5414534 E2-induced\JJ\1740 <e2>bladder\NN\5515670 hyperactivity</e2>\NN\14052403 in\IN\13603305 normal\JJ\1740 ,\,\1740 conscious\JJ\1740 rats\NNS\2329401 :\:\1740 involvement\NN\1080366 of\IN\1740 <e1>tachykinins</e1>\NNS\1740 ?\.\1740
D015320_D053201 NONE Prostanoids\NNS\1740 may\MD\15209706 ,\,\1740 via\IN\1740 release\NN\3748886 of\IN\1740 <e1>tachykinins</e1>\NNS\1740 ,\,\1740 contribute\VBP\126264 to\TO\1740 both\CC\1740 urge\JJ\1740 and\CC\1740 <e2>bladder\NN\5515670 hyperactivity</e2>\NN\14052403 seen\VBN\2106506 in\IN\13603305 inflammatory\JJ\1740 conditions\NNS\14512817 of\IN\1740 the\DT\1740 lower\JJR\1740 urinary\JJ\1740 tract\NN\8574314 .\.\1740
D011453_D053201 NONE <e1>Prostanoids</e1>\NNS\1740 may\MD\15209706 ,\,\1740 via\IN\1740 release\NN\3748886 of\IN\1740 tachykinins\NNS\1740 ,\,\1740 contribute\VBP\126264 to\TO\1740 both\CC\1740 urge\JJ\1740 and\CC\1740 <e2>bladder\NN\5515670 hyperactivity</e2>\NN\14052403 seen\VBN\2106506 in\IN\13603305 inflammatory\JJ\1740 conditions\NNS\14512817 of\IN\1740 the\DT\1740 lower\JJR\1740 urinary\JJ\1740 tract\NN\8574314 .\.\1740
12907924
D008774_D009771 CID <e1>Methylphenidate-induced</e1>\JJ\1740 <e2>obsessive-compulsive\JJ\1740 symptoms</e2>\NNS\5823932 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 man\NN\9605289 .\.\1740
D008774_D009771 CID Significant\JJ\1740 <e2>obsessive-compulsive\JJ\1740 behavior</e2>\NN\407535 ensued\VBN\2633881 but\CC\1740 diminished\VBD\169651 over\IN\5867413 several\JJ\1740 weeks\NNS\15113229 when\WRB\1740 <e1>methylphenidate</e1>\NN\4320126 was\VBD\836236 replaced\VBN\1631072 by\IN\1740 fluvoxamine\NN\1740 .\.\1740
D008774_D061218 NONE An\DT\6697703 82-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>treatment-resistant\JJ\1740 depression</e2>\NN\14373582 and\CC\1740 early\JJ\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 was\VBD\836236 started\VBN\2009433 on\IN\1740 <e1>methylphenidate</e1>\NN\4320126 .\.\1740
D008774_D000544 NONE An\DT\6697703 82-year-old\JJ\1740 man\NN\9605289 with\IN\1740 treatment-resistant\JJ\1740 depression\NN\14373582 and\CC\1740 early\JJ\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 was\VBD\836236 started\VBN\2009433 on\IN\1740 <e1>methylphenidate</e1>\NN\4320126 .\.\1740
D016666_D009771 NONE Significant\JJ\1740 <e2>obsessive-compulsive\JJ\1740 behavior</e2>\NN\407535 ensued\VBN\2633881 but\CC\1740 diminished\VBD\169651 over\IN\5867413 several\JJ\1740 weeks\NNS\15113229 when\WRB\1740 methylphenidate\NN\4320126 was\VBD\836236 replaced\VBN\1631072 by\IN\1740 <e1>fluvoxamine</e1>\NN\1740 .\.\1740
8643973
D017239_D010051 NONE <e1>Paclitaxel</e1>\NNP\1740 combined\VBN\2630189 with\IN\1740 carboplatin\NN\1740 in\IN\13603305 the\DT\1740 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 advanced\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D017239_D010051 NONE In\IN\13603305 a\DT\13649268 phase\NN\15113229 I\PRP\14622893 study\VBP\630380 to\TO\1740 determine\VB\1645601 the\DT\1740 maximum\NN\13653902 tolerated\VBD\802318 dose\NN\3740161 of\IN\1740 <e1>paclitaxel</e1>\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 given\VBN\2327200 as\IN\14622893 a\DT\13649268 3-hour\CD\1740 infusion\NN\14589223 in\IN\13603305 combination\NN\7951464 with\IN\1740 carboplatin\NN\1740 administered\VBD\2436349 every\DT\1740 21\CD\13745420 days\NNS\15140892 to\IN\1740 women\NNS\9605289 with\IN\1740 advanced\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 ,\,\1740 paclitaxel\NN\1740 doses\NNS\3740161 were\VBD\836236 escalated\VBN\153263 as\IN\14622893 follows\NNS\1740 :\:\1740 level\NN\4916342 1\CD\13741022 ,\,\1740 135\CD\1740 mg/m2\NN\1740 ;\:\1740 level\NN\4916342 2\CD\13741022 ,\,\1740 160\CD\1740 mg/m2\NN\1740 ;\:\1740 level\NN\4916342 3\CD\13741022 ,\,\1740 185\CD\1740 mg/m2\NN\1740 ;\:\1740 and\CC\1740 level\VB\1151110 4,210\CD\1740 mg/m2\NN\1740 .\.\1740
D017239_D010051 NONE In\IN\13603305 a\DT\13649268 phase\NN\15113229 I\PRP\14622893 study\VBP\630380 to\TO\1740 determine\VB\1645601 the\DT\1740 maximum\NN\13653902 tolerated\VBD\802318 dose\NN\3740161 of\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 <e1>Taxol</e1>\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 given\VBN\2327200 as\IN\14622893 a\DT\13649268 3-hour\CD\1740 infusion\NN\14589223 in\IN\13603305 combination\NN\7951464 with\IN\1740 carboplatin\NN\1740 administered\VBD\2436349 every\DT\1740 21\CD\13745420 days\NNS\15140892 to\IN\1740 women\NNS\9605289 with\IN\1740 advanced\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 ,\,\1740 paclitaxel\NN\1740 doses\NNS\3740161 were\VBD\836236 escalated\VBN\153263 as\IN\14622893 follows\NNS\1740 :\:\1740 level\NN\4916342 1\CD\13741022 ,\,\1740 135\CD\1740 mg/m2\NN\1740 ;\:\1740 level\NN\4916342 2\CD\13741022 ,\,\1740 160\CD\1740 mg/m2\NN\1740 ;\:\1740 level\NN\4916342 3\CD\13741022 ,\,\1740 185\CD\1740 mg/m2\NN\1740 ;\:\1740 and\CC\1740 level\VB\1151110 4,210\CD\1740 mg/m2\NN\1740 .\.\1740
D017239_D010051 NONE In\IN\13603305 a\DT\13649268 phase\NN\15113229 I\PRP\14622893 study\VBP\630380 to\TO\1740 determine\VB\1645601 the\DT\1740 maximum\NN\13653902 tolerated\VBD\802318 dose\NN\3740161 of\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 given\VBN\2327200 as\IN\14622893 a\DT\13649268 3-hour\CD\1740 infusion\NN\14589223 in\IN\13603305 combination\NN\7951464 with\IN\1740 carboplatin\NN\1740 administered\VBD\2436349 every\DT\1740 21\CD\13745420 days\NNS\15140892 to\IN\1740 women\NNS\9605289 with\IN\1740 advanced\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 ,\,\1740 <e1>paclitaxel</e1>\NN\1740 doses\NNS\3740161 were\VBD\836236 escalated\VBN\153263 as\IN\14622893 follows\NNS\1740 :\:\1740 level\NN\4916342 1\CD\13741022 ,\,\1740 135\CD\1740 mg/m2\NN\1740 ;\:\1740 level\NN\4916342 2\CD\13741022 ,\,\1740 160\CD\1740 mg/m2\NN\1740 ;\:\1740 level\NN\4916342 3\CD\13741022 ,\,\1740 185\CD\1740 mg/m2\NN\1740 ;\:\1740 and\CC\1740 level\VB\1151110 4,210\CD\1740 mg/m2\NN\1740 .\.\1740
D016190_D010051 NONE Paclitaxel\NNP\1740 combined\VBN\2630189 with\IN\1740 <e1>carboplatin</e1>\NN\1740 in\IN\13603305 the\DT\1740 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 advanced\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D016190_D010051 NONE In\IN\13603305 a\DT\13649268 phase\NN\15113229 I\PRP\14622893 study\VBP\630380 to\TO\1740 determine\VB\1645601 the\DT\1740 maximum\NN\13653902 tolerated\VBD\802318 dose\NN\3740161 of\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 given\VBN\2327200 as\IN\14622893 a\DT\13649268 3-hour\CD\1740 infusion\NN\14589223 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>carboplatin</e1>\NN\1740 administered\VBD\2436349 every\DT\1740 21\CD\13745420 days\NNS\15140892 to\IN\1740 women\NNS\9605289 with\IN\1740 advanced\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 ,\,\1740 paclitaxel\NN\1740 doses\NNS\3740161 were\VBD\836236 escalated\VBN\153263 as\IN\14622893 follows\NNS\1740 :\:\1740 level\NN\4916342 1\CD\13741022 ,\,\1740 135\CD\1740 mg/m2\NN\1740 ;\:\1740 level\NN\4916342 2\CD\13741022 ,\,\1740 160\CD\1740 mg/m2\NN\1740 ;\:\1740 level\NN\4916342 3\CD\13741022 ,\,\1740 185\CD\1740 mg/m2\NN\1740 ;\:\1740 and\CC\1740 level\VB\1151110 4,210\CD\1740 mg/m2\NN\1740 .\.\1740
11912119
D007980_D004409 CID Force\NN\5194151 overflow\NN\329227 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D007980_D004409 CID We\PRP\1740 assessed\VBD\670261 force\NN\5194151 coordination\NN\5640433 of\IN\1740 the\DT\1740 hand\NN\5566919 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 and\CC\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 motor\NN\3699975 complications\NNS\1073995 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 ,\,\1740 particularly\RB\1740 to\TO\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 .\.\1740
D007980_D004409 CID We\PRP\1740 assessed\VBD\670261 force\NN\5194151 coordination\NN\5640433 of\IN\1740 the\DT\1740 hand\NN\5566919 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 and\CC\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 motor\NN\3699975 complications\NNS\1073995 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 ,\,\1740 particularly\RB\1740 to\TO\1740 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 <e2>LID</e2>\NN\5313679 )\-RRB-\1740 .\.\1740
D007980_D004409 CID We\PRP\1740 assessed\VBD\670261 force\NN\5194151 coordination\NN\5640433 of\IN\1740 the\DT\1740 hand\NN\5566919 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 and\CC\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 motor\NN\3699975 complications\NNS\1073995 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 ,\,\1740 particularly\RB\1740 to\TO\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 .\.\1740
D007980_D004409 CID We\PRP\1740 assessed\VBD\670261 force\NN\5194151 coordination\NN\5640433 of\IN\1740 the\DT\1740 hand\NN\5566919 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 and\CC\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 motor\NN\3699975 complications\NNS\1073995 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 ,\,\1740 particularly\RB\1740 to\TO\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 <e2>LID</e2>\NN\5313679 )\-RRB-\1740 .\.\1740
D007980_D004409 CID We\PRP\1740 studied\VBD\630380 two\CD\13741022 groups\NNS\2137 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 patients\NNS\9898892 with\IN\1740 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 +\CC\1740 <e2>LID</e2>\NN\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 without\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 -\HYPH\1740 LID\NNP\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 age-matched\JJ\1740 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D007980_D004409 CID We\PRP\1740 studied\VBD\630380 two\CD\13741022 groups\NNS\2137 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 patients\NNS\9898892 with\IN\1740 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 +\CC\1740 LID\NN\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 without\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 -\HYPH\1740 LID\NNP\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 age-matched\JJ\1740 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D007980_D004409 CID We\PRP\1740 studied\VBD\630380 two\CD\13741022 groups\NNS\2137 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 patients\NNS\9898892 with\IN\1740 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 +\CC\1740 LID\NN\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 without\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 -\HYPH\1740 <e2>LID</e2>\NNP\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 age-matched\JJ\1740 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D007980_D004409 CID The\DT\1740 motor\NN\3699975 score\NN\5736149 of\IN\1740 the\DT\1740 Unified\NNP\1740 Parkinson\NNP\1740 's\POS\1740 Disease\NNP\14061805 Rating\NN\5733583 Scale\NN\7260623 ,\,\1740 a\DT\13649268 <e2>dyskinesia</e2>\NN\14084880 score\NN\5736149 and\CC\1740 force\VBP\2506546 in\IN\13603305 a\DT\13649268 grip-lift\JJ\1740 paradigm\NN\13803782 were\VBD\836236 assessed\VBN\670261 ON\NN\1740 and\CC\1740 OFF\NNP\1740 <e1>levodopa</e1>\NN\14604959 .\.\1740
D007980_D004409 CID In\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 +\CC\1740 <e2>LID</e2>\NN\5313679 ,\,\1740 the\DT\1740 force\NN\5194151 involved\VBN\2676054 in\IN\13603305 pressing\VBG\1206218 down\RP\1740 the\DT\1740 object\NN\1930 before\IN\1740 lifting\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 by\IN\1740 <e1>levodopa</e1>\NN\14604959 (\-LRB-\1740 by\IN\1740 61\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D007980_D010300 NONE Force\NN\5194151 overflow\NN\329227 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D007980_D010300 NONE We\PRP\1740 assessed\VBD\670261 force\NN\5194151 coordination\NN\5640433 of\IN\1740 the\DT\1740 hand\NN\5566919 in\IN\13603305 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 and\CC\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 motor\NN\3699975 complications\NNS\1073995 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 ,\,\1740 particularly\RB\1740 to\TO\1740 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 .\.\1740
D007980_D010300 NONE We\PRP\1740 assessed\VBD\670261 force\NN\5194151 coordination\NN\5640433 of\IN\1740 the\DT\1740 hand\NN\5566919 in\IN\13603305 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 and\CC\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 motor\NN\3699975 complications\NNS\1073995 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 ,\,\1740 particularly\RB\1740 to\TO\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 .\.\1740
D007980_D010300 NONE We\PRP\1740 studied\VBD\630380 two\CD\13741022 groups\NNS\2137 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 patients\NNS\9898892 with\IN\1740 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 +\CC\1740 LID\NN\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 without\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 -\HYPH\1740 LID\NNP\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 age-matched\JJ\1740 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D007980_D010300 NONE We\PRP\1740 studied\VBD\630380 two\CD\13741022 groups\NNS\2137 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 patients\NNS\9898892 with\IN\1740 (\-LRB-\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 +\CC\1740 LID\NN\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 without\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 -\HYPH\1740 LID\NNP\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 age-matched\JJ\1740 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D007980_D010300 NONE We\PRP\1740 studied\VBD\630380 two\CD\13741022 groups\NNS\2137 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 patients\NNS\9898892 with\IN\1740 (\-LRB-\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 +\CC\1740 LID\NN\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 without\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 -\HYPH\1740 LID\NNP\5313679 ,\,\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 age-matched\JJ\1740 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D007980_D010300 NONE The\DT\1740 motor\NN\3699975 score\NN\5736149 of\IN\1740 the\DT\1740 Unified\NNP\1740 <e2>Parkinson\NNP\1740 's\POS\1740 Disease</e2>\NNP\14061805 Rating\NN\5733583 Scale\NN\7260623 ,\,\1740 a\DT\13649268 dyskinesia\NN\14084880 score\NN\5736149 and\CC\1740 force\VBP\2506546 in\IN\13603305 a\DT\13649268 grip-lift\JJ\1740 paradigm\NN\13803782 were\VBD\836236 assessed\VBN\670261 ON\NN\1740 and\CC\1740 OFF\NNP\1740 <e1>levodopa</e1>\NN\14604959 .\.\1740
D007980_D010300 NONE In\IN\13603305 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 +\CC\1740 LID\NN\5313679 ,\,\1740 the\DT\1740 force\NN\5194151 involved\VBN\2676054 in\IN\13603305 pressing\VBG\1206218 down\RP\1740 the\DT\1740 object\NN\1930 before\IN\1740 lifting\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 by\IN\1740 <e1>levodopa</e1>\NN\14604959 (\-LRB-\1740 by\IN\1740 61\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
3108839
D016685_D006463 CID <e1>Mitomycin\NN\2716866 C</e1>\NN\13714184 associated\VBD\628491 <e2>hemolytic\JJ\1740 uremic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D016685_D006463 CID <e1>Mitomycin\NN\2716866 C</e1>\NN\13714184 associated\VBD\628491 <e2>Hemolytic\NNP\1740 Uremic\JJ\1740 Syndrome</e2>\NNP\5870365 (\-LRB-\1740 HUS\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 potentially\RB\1740 fatal\JJ\1740 but\CC\1740 uncommon\JJ\1740 condition\NN\24720 that\WDT\1740 is\VBZ\836236 not\RB\1740 yet\RB\1740 widely\RB\1740 recognised\VBN\2256109 .\.\1740
D016685_D006463 CID <e1>Mitomycin\NN\2716866 C</e1>\NN\13714184 associated\VBD\628491 Hemolytic\NNP\1740 Uremic\JJ\1740 Syndrome\NNP\5870365 (\-LRB-\1740 <e2>HUS</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 potentially\RB\1740 fatal\JJ\1740 but\CC\1740 uncommon\JJ\1740 condition\NN\24720 that\WDT\1740 is\VBZ\836236 not\RB\1740 yet\RB\1740 widely\RB\1740 recognised\VBN\2256109 .\.\1740
D016685_D000743 NONE It\PRP\6125041 consists\VBZ\2603699 of\IN\1740 microangiopathic\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 ,\,\1740 thrombocytopenia\NN\14189204 and\CC\1740 progressive\JJ\1740 renal\JJ\1740 failure\NN\66216 associated\VBN\628491 with\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 treatment\NN\654885 and\CC\1740 affects\VBZ\126264 about\RB\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 this\DT\1740 agent\NN\7347 .\.\1740
D016685_D013921 NONE It\PRP\6125041 consists\VBZ\2603699 of\IN\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 <e2>thrombocytopenia</e2>\NN\14189204 and\CC\1740 progressive\JJ\1740 renal\JJ\1740 failure\NN\66216 associated\VBN\628491 with\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 treatment\NN\654885 and\CC\1740 affects\VBZ\126264 about\RB\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 this\DT\1740 agent\NN\7347 .\.\1740
D016685_D013921 NONE We\PRP\1740 describe\VBP\1001294 the\DT\1740 clinical\JJ\1740 course\NN\883297 and\CC\1740 pathological\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 65\CD\1740 yr-old\NN\1740 man\NN\9605289 with\IN\1740 gastric\JJ\1740 adenocarcinoma\NN\14242337 who\WP\8299493 developed\VBD\1753788 renal\JJ\1740 failure\NN\66216 and\CC\1740 <e2>thrombocytopenia</e2>\NN\14189204 while\IN\15122231 on\IN\1740 treatment\NN\654885 with\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 and\CC\1740 died\VBD\146138 in\IN\13603305 pulmonary\JJ\1740 edema\NN\14315192 .\.\1740
D016685_D051437 CID It\PRP\6125041 consists\VBZ\2603699 of\IN\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 thrombocytopenia\NN\14189204 and\CC\1740 progressive\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 associated\VBN\628491 with\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 treatment\NN\654885 and\CC\1740 affects\VBZ\126264 about\RB\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 this\DT\1740 agent\NN\7347 .\.\1740
D016685_D051437 CID The\DT\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 usually\RB\1740 develops\VBZ\1753788 about\RB\1740 8\CD\13741022 -\SYM\1740 10\CD\13745420 mth\NN\1740 after\IN\1740 start\NN\7290905 of\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 treatment\NN\654885 and\CC\1740 the\DT\1740 mortality\NN\5054863 is\VBZ\836236 approximately\RB\1740 60\CD\13745420 %\NN\1740 from\IN\1740 renal\JJ\1740 failure\NN\66216 or\CC\3541091 pulmonary\JJ\1740 edema\NN\14315192 .\.\1740
D016685_D051437 CID The\DT\1740 renal\JJ\1740 failure\NN\66216 usually\RB\1740 develops\VBZ\1753788 about\RB\1740 8\CD\13741022 -\SYM\1740 10\CD\13745420 mth\NN\1740 after\IN\1740 start\NN\7290905 of\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 treatment\NN\654885 and\CC\1740 the\DT\1740 mortality\NN\5054863 is\VBZ\836236 approximately\RB\1740 60\CD\13745420 %\NN\1740 from\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 or\CC\3541091 pulmonary\JJ\1740 edema\NN\14315192 .\.\1740
D016685_D051437 CID We\PRP\1740 describe\VBP\1001294 the\DT\1740 clinical\JJ\1740 course\NN\883297 and\CC\1740 pathological\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 65\CD\1740 yr-old\NN\1740 man\NN\9605289 with\IN\1740 gastric\JJ\1740 adenocarcinoma\NN\14242337 who\WP\8299493 developed\VBD\1753788 <e2>renal\JJ\1740 failure</e2>\NN\66216 and\CC\1740 thrombocytopenia\NN\14189204 while\IN\15122231 on\IN\1740 treatment\NN\654885 with\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 and\CC\1740 died\VBD\146138 in\IN\13603305 pulmonary\JJ\1740 edema\NN\14315192 .\.\1740
D016685_D011654 NONE The\DT\1740 renal\JJ\1740 failure\NN\66216 usually\RB\1740 develops\VBZ\1753788 about\RB\1740 8\CD\13741022 -\SYM\1740 10\CD\13745420 mth\NN\1740 after\IN\1740 start\NN\7290905 of\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 treatment\NN\654885 and\CC\1740 the\DT\1740 mortality\NN\5054863 is\VBZ\836236 approximately\RB\1740 60\CD\13745420 %\NN\1740 from\IN\1740 renal\JJ\1740 failure\NN\66216 or\CC\3541091 <e2>pulmonary\JJ\1740 edema</e2>\NN\14315192 .\.\1740
D016685_D011654 NONE We\PRP\1740 describe\VBP\1001294 the\DT\1740 clinical\JJ\1740 course\NN\883297 and\CC\1740 pathological\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 65\CD\1740 yr-old\NN\1740 man\NN\9605289 with\IN\1740 gastric\JJ\1740 adenocarcinoma\NN\14242337 who\WP\8299493 developed\VBD\1753788 renal\JJ\1740 failure\NN\66216 and\CC\1740 thrombocytopenia\NN\14189204 while\IN\15122231 on\IN\1740 treatment\NN\654885 with\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 and\CC\1740 died\VBD\146138 in\IN\13603305 <e2>pulmonary\JJ\1740 edema</e2>\NN\14315192 .\.\1740
D016685_D013274 NONE We\PRP\1740 describe\VBP\1001294 the\DT\1740 clinical\JJ\1740 course\NN\883297 and\CC\1740 pathological\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 65\CD\1740 yr-old\NN\1740 man\NN\9605289 with\IN\1740 <e2>gastric\JJ\1740 adenocarcinoma</e2>\NN\14242337 who\WP\8299493 developed\VBD\1753788 renal\JJ\1740 failure\NN\66216 and\CC\1740 thrombocytopenia\NN\14189204 while\IN\15122231 on\IN\1740 treatment\NN\654885 with\IN\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 and\CC\1740 died\VBD\146138 in\IN\13603305 pulmonary\JJ\1740 edema\NN\14315192 .\.\1740
17682013
D008727_D056784 CID BACKGROUND\NN\4921011 :\:\1740 A\DT\13649268 transient\JJ\1740 <e2>leukoencephalopathy</e2>\NN\1740 mimicking\VBG\1742886 cerebrovascular\NN\1740 accident\NN\7314427 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 as\IN\14622893 a\DT\13649268 complication\NN\1073995 of\IN\1740 chemotherapy\NN\661091 ,\,\1740 most\RBS\1740 commonly\RB\1740 in\IN\13603305 recipients\NNS\9764201 of\IN\1740 intrathecal\JJ\1740 <e1>methotrexate</e1>\NN\2722166 for\IN\1740 childhood\NN\15144371 leukaemia\NN\14239918 .\.\1740
D008727_D056784 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 identified\VBD\699815 27\CD\13745420 reports\NNS\6470073 of\IN\1740 toxic\JJ\1740 <e2>leukoencephalopathy</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>methotrexate</e1>\NN\2722166 (\-LRB-\1740 intrathecal\JJ\1740 ,\,\1740 systemic\JJ\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 and\CC\1740 its\PRP$\6125041 derivative\JJ\1740 carmofur\NN\1740 ,\,\1740 and\CC\1740 capecitabine\NN\1740 .\.\1740
D008727_D002544 NONE BACKGROUND\NN\4921011 :\:\1740 A\DT\13649268 transient\JJ\1740 leukoencephalopathy\NN\1740 mimicking\VBG\1742886 <e2>cerebrovascular\NN\1740 accident</e2>\NN\7314427 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 as\IN\14622893 a\DT\13649268 complication\NN\1073995 of\IN\1740 chemotherapy\NN\661091 ,\,\1740 most\RBS\1740 commonly\RB\1740 in\IN\13603305 recipients\NNS\9764201 of\IN\1740 intrathecal\JJ\1740 <e1>methotrexate</e1>\NN\2722166 for\IN\1740 childhood\NN\15144371 leukaemia\NN\14239918 .\.\1740
D008727_D007938 NONE BACKGROUND\NN\4921011 :\:\1740 A\DT\13649268 transient\JJ\1740 leukoencephalopathy\NN\1740 mimicking\VBG\1742886 cerebrovascular\NN\1740 accident\NN\7314427 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 as\IN\14622893 a\DT\13649268 complication\NN\1073995 of\IN\1740 chemotherapy\NN\661091 ,\,\1740 most\RBS\1740 commonly\RB\1740 in\IN\13603305 recipients\NNS\9764201 of\IN\1740 intrathecal\JJ\1740 <e1>methotrexate</e1>\NN\2722166 for\IN\1740 childhood\NN\15144371 <e2>leukaemia</e2>\NN\14239918 .\.\1740
D005472_D056784 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 identified\VBD\699815 27\CD\13745420 reports\NNS\6470073 of\IN\1740 toxic\JJ\1740 <e2>leukoencephalopathy</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 methotrexate\NN\2722166 (\-LRB-\1740 intrathecal\JJ\1740 ,\,\1740 systemic\JJ\1740 )\-RRB-\1740 ,\,\1740 <e1>5-fluorouracil</e1>\NN\1740 and\CC\1740 its\PRP$\6125041 derivative\JJ\1740 carmofur\NN\1740 ,\,\1740 and\CC\1740 capecitabine\NN\1740 .\.\1740
C017367_D056784 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 identified\VBD\699815 27\CD\13745420 reports\NNS\6470073 of\IN\1740 toxic\JJ\1740 <e2>leukoencephalopathy</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 methotrexate\NN\2722166 (\-LRB-\1740 intrathecal\JJ\1740 ,\,\1740 systemic\JJ\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 and\CC\1740 its\PRP$\6125041 derivative\JJ\1740 <e1>carmofur</e1>\NN\1740 ,\,\1740 and\CC\1740 capecitabine\NN\1740 .\.\1740
C110904_D056784 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 identified\VBD\699815 27\CD\13745420 reports\NNS\6470073 of\IN\1740 toxic\JJ\1740 <e2>leukoencephalopathy</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 methotrexate\NN\2722166 (\-LRB-\1740 intrathecal\JJ\1740 ,\,\1740 systemic\JJ\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 and\CC\1740 its\PRP$\6125041 derivative\JJ\1740 carmofur\NN\1740 ,\,\1740 and\CC\1740 <e1>capecitabine</e1>\NN\1740 .\.\1740
6216862
D010396_D001172 NONE Multiple\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>penicillamine</e1>\NN\3740161 therapy\NN\657604 in\IN\13603305 one\CD\13741022 patient\NN\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 .\.\1740
D010396_D001172 NONE Skin\NN\5237755 rashes\NNS\14321469 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 systemic\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 ,\,\1740 polymyositis\NN\14350292 and\CC\1740 myasthenia\NN\14187378 gravis\NN\1740 have\VBP\2108377 all\DT\1740 been\VBN\836236 recorded\VBN\2225492 as\IN\14622893 complications\NNS\1073995 of\IN\1740 <e1>penicillamine</e1>\NN\3740161 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 .\.\1740
D010396_D001172 NONE The\DT\1740 skin\NN\5237755 lesion\NN\14204950 resembled\VBD\2657219 elastosis\NN\14034177 perforans\NNS\1740 serpiginosa\NN\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 as\IN\14622893 a\DT\13649268 rare\JJ\1740 side\NN\8630039 effect\NN\34213 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Wilson\NN\1740 's\POS\1740 disease\NN\14061805 but\CC\1740 not\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 treated\VBN\2376958 with\IN\1740 <e1>penicillamine</e1>\NN\3740161 .\.\1740
D010396_D005076 CID <e2>Skin\NN\5237755 rashes</e2>\NNS\14321469 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 systemic\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 ,\,\1740 polymyositis\NN\14350292 and\CC\1740 myasthenia\NN\14187378 gravis\NN\1740 have\VBP\2108377 all\DT\1740 been\VBN\836236 recorded\VBN\2225492 as\IN\14622893 complications\NNS\1073995 of\IN\1740 <e1>penicillamine</e1>\NN\3740161 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D010396_D011507 CID Skin\NN\5237755 rashes\NNS\14321469 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 systemic\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 ,\,\1740 polymyositis\NN\14350292 and\CC\1740 myasthenia\NN\14187378 gravis\NN\1740 have\VBP\2108377 all\DT\1740 been\VBN\836236 recorded\VBN\2225492 as\IN\14622893 complications\NNS\1073995 of\IN\1740 <e1>penicillamine</e1>\NN\3740161 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D010396_D008180 CID Skin\NN\5237755 rashes\NNS\14321469 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 <e2>systemic\JJ\1740 lupus\NN\14219661 erythematosus</e2>\NN\1740 ,\,\1740 polymyositis\NN\14350292 and\CC\1740 myasthenia\NN\14187378 gravis\NN\1740 have\VBP\2108377 all\DT\1740 been\VBN\836236 recorded\VBN\2225492 as\IN\14622893 complications\NNS\1073995 of\IN\1740 <e1>penicillamine</e1>\NN\3740161 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D010396_D017285 CID Skin\NN\5237755 rashes\NNS\14321469 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 systemic\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 ,\,\1740 <e2>polymyositis</e2>\NN\14350292 and\CC\1740 myasthenia\NN\14187378 gravis\NN\1740 have\VBP\2108377 all\DT\1740 been\VBN\836236 recorded\VBN\2225492 as\IN\14622893 complications\NNS\1073995 of\IN\1740 <e1>penicillamine</e1>\NN\3740161 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D010396_D009157 CID Skin\NN\5237755 rashes\NNS\14321469 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 systemic\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 ,\,\1740 polymyositis\NN\14350292 and\CC\1740 <e2>myasthenia\NN\14187378 gravis</e2>\NN\1740 have\VBP\2108377 all\DT\1740 been\VBN\836236 recorded\VBN\2225492 as\IN\14622893 complications\NNS\1073995 of\IN\1740 <e1>penicillamine</e1>\NN\3740161 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D010396_D012871 NONE The\DT\1740 <e2>skin\NN\5237755 lesion</e2>\NN\14204950 resembled\VBD\2657219 elastosis\NN\14034177 perforans\NNS\1740 serpiginosa\NN\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 as\IN\14622893 a\DT\13649268 rare\JJ\1740 side\NN\8630039 effect\NN\34213 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Wilson\NN\1740 's\POS\1740 disease\NN\14061805 but\CC\1740 not\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 treated\VBN\2376958 with\IN\1740 <e1>penicillamine</e1>\NN\3740161 .\.\1740
D010396_C536202 NONE The\DT\1740 skin\NN\5237755 lesion\NN\14204950 resembled\VBD\2657219 <e2>elastosis\NN\14034177 perforans\NNS\1740 serpiginosa</e2>\NN\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 as\IN\14622893 a\DT\13649268 rare\JJ\1740 side\NN\8630039 effect\NN\34213 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Wilson\NN\1740 's\POS\1740 disease\NN\14061805 but\CC\1740 not\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 treated\VBN\2376958 with\IN\1740 <e1>penicillamine</e1>\NN\3740161 .\.\1740
D010396_D006527 NONE The\DT\1740 skin\NN\5237755 lesion\NN\14204950 resembled\VBD\2657219 elastosis\NN\14034177 perforans\NNS\1740 serpiginosa\NN\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 as\IN\14622893 a\DT\13649268 rare\JJ\1740 side\NN\8630039 effect\NN\34213 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Wilson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 but\CC\1740 not\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 treated\VBN\2376958 with\IN\1740 <e1>penicillamine</e1>\NN\3740161 .\.\1740
9636837
D016190_D020258 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 most\RBS\1740 striking\JJ\1740 of\IN\1740 <e1>carboplatin</e1>\NN\1740 's\POS\1740 advantages\NNS\5154517 (\-LRB-\1740 CBDCA\NN\1740 )\-RRB-\1740 over\IN\5867413 cisplatin\NN\1740 (\-LRB-\1740 CDDP\NN\1740 )\-RRB-\1740 is\VBZ\836236 its\PRP$\6125041 markedly\RB\1740 reduced\VBN\441445 rate\NN\13815152 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 effects\NNS\13245626 .\.\1740
D016190_D020258 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 most\RBS\1740 striking\JJ\1740 of\IN\1740 carboplatin\NN\1740 's\POS\1740 advantages\NNS\5154517 (\-LRB-\1740 <e1>CBDCA</e1>\NN\1740 )\-RRB-\1740 over\IN\5867413 cisplatin\NN\1740 (\-LRB-\1740 CDDP\NN\1740 )\-RRB-\1740 is\VBZ\836236 its\PRP$\6125041 markedly\RB\1740 reduced\VBN\441445 rate\NN\13815152 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 effects\NNS\13245626 .\.\1740
D016190_D020258 NONE However\RB\1740 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CBDCA</e1>\NN\1740 higher-intensity\NN\1740 schedules\NNS\5898568 and\CC\1740 the\DT\1740 association\NN\8008335 with\IN\1740 other\JJ\1740 <e2>neurotoxic</e2>\JJ\1740 drugs\NNS\14778436 in\IN\13603305 polychemotherapy\NN\1740 may\MD\15209706 cause\VB\1617192 some\DT\1740 concern\NN\5682950 about\IN\1740 its\PRP$\6125041 safety\NN\13920835 with\IN\1740 respect\NN\5817845 to\TO\1740 peripheral\JJ\1740 nervous\JJ\1740 system\NN\3575240 damage\NN\7296428 .\.\1740
D016190_D020258 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>CBDCA</e1>\NN\1740 is\VBZ\836236 <e2>neurotoxic</e2>\JJ\1740 in\IN\13603305 our\PRP$\1740 model\NN\5888929 ,\,\1740 and\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 pathological\JJ\1740 changes\NNS\7283608 it\PRP\6125041 induces\VBZ\1627355 are\VBP\836236 so\RB\1740 closely\RB\1740 similar\JJ\1740 to\TO\1740 those\DT\1740 caused\VBN\1617192 by\IN\1740 CDDP\NN\1740 that\IN\1740 it\PRP\6125041 is\VBZ\836236 probable\JJ\1740 that\IN\1740 neurotoxicity\NN\1740 is\VBZ\836236 induced\VBN\1627355 in\IN\13603305 the\DT\1740 two\CD\13741022 drugs\NNS\14778436 by\IN\1740 the\DT\1740 same\JJ\1740 mechanism\NN\13446390 .\.\1740
D016190_D020258 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>CBDCA</e1>\NN\1740 is\VBZ\836236 neurotoxic\JJ\1740 in\IN\13603305 our\PRP$\1740 model\NN\5888929 ,\,\1740 and\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 pathological\JJ\1740 changes\NNS\7283608 it\PRP\6125041 induces\VBZ\1627355 are\VBP\836236 so\RB\1740 closely\RB\1740 similar\JJ\1740 to\TO\1740 those\DT\1740 caused\VBN\1617192 by\IN\1740 CDDP\NN\1740 that\IN\1740 it\PRP\6125041 is\VBZ\836236 probable\JJ\1740 that\IN\1740 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 induced\VBN\1627355 in\IN\13603305 the\DT\1740 two\CD\13741022 drugs\NNS\14778436 by\IN\1740 the\DT\1740 same\JJ\1740 mechanism\NN\13446390 .\.\1740
D002945_D020258 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 most\RBS\1740 striking\JJ\1740 of\IN\1740 carboplatin\NN\1740 's\POS\1740 advantages\NNS\5154517 (\-LRB-\1740 CBDCA\NN\1740 )\-RRB-\1740 over\IN\5867413 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 CDDP\NN\1740 )\-RRB-\1740 is\VBZ\836236 its\PRP$\6125041 markedly\RB\1740 reduced\VBN\441445 rate\NN\13815152 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 effects\NNS\13245626 .\.\1740
D002945_D020258 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 most\RBS\1740 striking\JJ\1740 of\IN\1740 carboplatin\NN\1740 's\POS\1740 advantages\NNS\5154517 (\-LRB-\1740 CBDCA\NN\1740 )\-RRB-\1740 over\IN\5867413 cisplatin\NN\1740 (\-LRB-\1740 <e1>CDDP</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 its\PRP$\6125041 markedly\RB\1740 reduced\VBN\441445 rate\NN\13815152 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 effects\NNS\13245626 .\.\1740
D002945_D020258 NONE CONCLUSIONS\NNS\5837957 :\:\1740 CBDCA\NN\1740 is\VBZ\836236 <e2>neurotoxic</e2>\JJ\1740 in\IN\13603305 our\PRP$\1740 model\NN\5888929 ,\,\1740 and\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 pathological\JJ\1740 changes\NNS\7283608 it\PRP\6125041 induces\VBZ\1627355 are\VBP\836236 so\RB\1740 closely\RB\1740 similar\JJ\1740 to\TO\1740 those\DT\1740 caused\VBN\1617192 by\IN\1740 <e1>CDDP</e1>\NN\1740 that\IN\1740 it\PRP\6125041 is\VBZ\836236 probable\JJ\1740 that\IN\1740 neurotoxicity\NN\1740 is\VBZ\836236 induced\VBN\1627355 in\IN\13603305 the\DT\1740 two\CD\13741022 drugs\NNS\14778436 by\IN\1740 the\DT\1740 same\JJ\1740 mechanism\NN\13446390 .\.\1740
D002945_D020258 NONE CONCLUSIONS\NNS\5837957 :\:\1740 CBDCA\NN\1740 is\VBZ\836236 neurotoxic\JJ\1740 in\IN\13603305 our\PRP$\1740 model\NN\5888929 ,\,\1740 and\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 pathological\JJ\1740 changes\NNS\7283608 it\PRP\6125041 induces\VBZ\1627355 are\VBP\836236 so\RB\1740 closely\RB\1740 similar\JJ\1740 to\TO\1740 those\DT\1740 caused\VBN\1617192 by\IN\1740 <e1>CDDP</e1>\NN\1740 that\IN\1740 it\PRP\6125041 is\VBZ\836236 probable\JJ\1740 that\IN\1740 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 induced\VBN\1627355 in\IN\13603305 the\DT\1740 two\CD\13741022 drugs\NNS\14778436 by\IN\1740 the\DT\1740 same\JJ\1740 mechanism\NN\13446390 .\.\1740
D016190_D010523 CID However\RB\1740 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CBDCA</e1>\NN\1740 higher-intensity\NN\1740 schedules\NNS\5898568 and\CC\1740 the\DT\1740 association\NN\8008335 with\IN\1740 other\JJ\1740 neurotoxic\JJ\1740 drugs\NNS\14778436 in\IN\13603305 polychemotherapy\NN\1740 may\MD\15209706 cause\VB\1617192 some\DT\1740 concern\NN\5682950 about\IN\1740 its\PRP$\6125041 safety\NN\13920835 with\IN\1740 respect\NN\5817845 to\TO\1740 <e2>peripheral\JJ\1740 nervous\JJ\1740 system\NN\3575240 damage</e2>\NN\7296428 .\.\1740
D016190_D010523 CID RESULTS\NNS\34213 :\:\1740 <e1>CBDCA</e1>\NN\1740 administration\NN\1133281 induced\VBD\1627355 dose-dependent\JJ\1740 <e2>peripheral\JJ\1740 neurotoxicity</e2>\NN\1740 .\.\1740
1728915
D002220_D006331 NONE <e1>Carbamazepine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D002220_D006331 NONE From\IN\1740 the\DT\1740 analysis\NN\633864 of\IN\1740 these\DT\1740 cases\NNS\7283608 ,\,\1740 two\CD\13741022 distinct\JJ\1740 forms\NNS\6286395 of\IN\1740 <e1>carbamazepine-associated</e1>\JJ\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 emerged\VBD\422090 .\.\1740
D002220_D001919 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 sinus\NN\5248181 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 atrioventricular\JJ\1740 block\NN\21939 ,\,\1740 induced\VBN\1627355 by\IN\1740 <e1>carbamazepine</e1>\NN\1740 ,\,\1740 prompted\VBD\1645601 an\DT\6697703 extensive\JJ\1740 literature\NN\6362953 review\NN\5733583 of\IN\1740 all\DT\1740 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 .\.\1740
D002220_D001919 CID The\DT\1740 second\JJ\1740 group\NN\2137 consisted\VBD\2603699 almost\RB\1740 exclusively\RB\1740 of\IN\1740 elderly\JJ\1740 women\NNS\9605289 who\WP\8299493 developed\VBD\1753788 potentially\RB\1740 life-threatening\JJ\1740 <e2>bradyarrhythmias</e2>\NNS\1740 or\CC\3541091 atrioventricular\JJ\1740 conduction\NN\11419404 delay\NN\15271008 ,\,\1740 associated\VBN\628491 with\IN\1740 either\CC\1740 therapeutic\JJ\1740 or\CC\3541091 modestly\RB\1740 elevated\JJ\1740 <e1>carbamazepine</e1>\NN\1740 serum\NN\5397468 levels\NNS\4916342 .\.\1740
D002220_D054537 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 sinus\NN\5248181 bradycardia\NN\14110674 and\CC\1740 <e2>atrioventricular\JJ\1740 block</e2>\NN\21939 ,\,\1740 induced\VBN\1627355 by\IN\1740 <e1>carbamazepine</e1>\NN\1740 ,\,\1740 prompted\VBD\1645601 an\DT\6697703 extensive\JJ\1740 literature\NN\6362953 review\NN\5733583 of\IN\1740 all\DT\1740 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 .\.\1740
D002220_D054537 CID The\DT\1740 second\JJ\1740 group\NN\2137 consisted\VBD\2603699 almost\RB\1740 exclusively\RB\1740 of\IN\1740 elderly\JJ\1740 women\NNS\9605289 who\WP\8299493 developed\VBD\1753788 potentially\RB\1740 life-threatening\JJ\1740 bradyarrhythmias\NNS\1740 or\CC\3541091 <e2>atrioventricular\JJ\1740 conduction\NN\11419404 delay</e2>\NN\15271008 ,\,\1740 associated\VBN\628491 with\IN\1740 either\CC\1740 therapeutic\JJ\1740 or\CC\3541091 modestly\RB\1740 elevated\JJ\1740 <e1>carbamazepine</e1>\NN\1740 serum\NN\5397468 levels\NNS\4916342 .\.\1740
D002220_D013616 CID One\CD\13741022 patient\NN\9898892 group\NN\2137 developed\VBD\1753788 <e2>sinus\NN\5248181 tachycardias</e2>\NNS\14110674 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 a\DT\13649268 massive\JJ\1740 <e1>carbamazepine</e1>\NN\1740 overdose\NN\1740 .\.\1740
D002220_D062787 NONE One\CD\13741022 patient\NN\9898892 group\NN\2137 developed\VBD\1753788 sinus\NN\5248181 tachycardias\NNS\14110674 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 a\DT\13649268 massive\JJ\1740 <e1>carbamazepine</e1>\NN\1740 <e2>overdose</e2>\NN\1740 .\.\1740
D002220_D001523 NONE Because\IN\1740 <e1>carbamazepine</e1>\NN\1740 is\VBZ\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 many\JJ\1740 neurologic\JJ\1740 and\CC\1740 <e2>psychiatric</e2>\JJ\1740 conditions\NNS\14512817 ,\,\1740 the\DT\1740 recognition\NN\13932421 of\IN\1740 the\DT\1740 latter\JJ\1740 syndrome\NN\5870365 has\VBZ\2108377 important\JJ\1740 implications\NNS\5774614 for\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 this\DT\1740 drug\NN\14778436 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 .\.\1740
6323692
C018824_D001259 CID Pretreatment\NN\1740 with\IN\1740 <e1>ammonium\NN\14743582 acetate</e1>\NN\15010703 (\-LRB-\1740 NH4Ac\NN\1740 )\-RRB-\1740 (\-LRB-\1740 6\CD\13741022 mmol/kg\NNS\1740 s.c.\FW\1740 )\-RRB-\1740 approximately\RB\1740 doubled\VBD\247390 the\DT\1740 time\NN\7308889 morphine-treated\JJ\1740 mice\NNS\2329401 remained\VBD\2604760 on\IN\1740 a\DT\13649268 hot\JJ\1740 surface\NN\21939 and\CC\1740 similarly\RB\1740 increased\VBD\169651 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 by\IN\1740 diazepam\NN\2830852 ,\,\1740 but\CC\1740 NH4Ac\NN\1740 treatment\NN\654885 alone\RB\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
C018824_D001259 CID Pretreatment\NN\1740 with\IN\1740 ammonium\NN\14743582 acetate\NN\15010703 (\-LRB-\1740 <e1>NH4Ac</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 6\CD\13741022 mmol/kg\NNS\1740 s.c.\FW\1740 )\-RRB-\1740 approximately\RB\1740 doubled\VBD\247390 the\DT\1740 time\NN\7308889 morphine-treated\JJ\1740 mice\NNS\2329401 remained\VBD\2604760 on\IN\1740 a\DT\13649268 hot\JJ\1740 surface\NN\21939 and\CC\1740 similarly\RB\1740 increased\VBD\169651 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 by\IN\1740 diazepam\NN\2830852 ,\,\1740 but\CC\1740 NH4Ac\NN\1740 treatment\NN\654885 alone\RB\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
C018824_D001259 CID Pretreatment\NN\1740 with\IN\1740 ammonium\NN\14743582 acetate\NN\15010703 (\-LRB-\1740 NH4Ac\NN\1740 )\-RRB-\1740 (\-LRB-\1740 6\CD\13741022 mmol/kg\NNS\1740 s.c.\FW\1740 )\-RRB-\1740 approximately\RB\1740 doubled\VBD\247390 the\DT\1740 time\NN\7308889 morphine-treated\JJ\1740 mice\NNS\2329401 remained\VBD\2604760 on\IN\1740 a\DT\13649268 hot\JJ\1740 surface\NN\21939 and\CC\1740 similarly\RB\1740 increased\VBD\169651 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 by\IN\1740 diazepam\NN\2830852 ,\,\1740 but\CC\1740 <e1>NH4Ac</e1>\NN\1740 treatment\NN\654885 alone\RB\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
C018824_D001259 CID Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 <e1>NH4Ac</e1>\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 analgesia-\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
C018824_D001259 CID Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 analgesia-\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 <e1>NH4Ac</e1>\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D009020_D001259 NONE Pretreatment\NN\1740 with\IN\1740 ammonium\NN\14743582 acetate\NN\15010703 (\-LRB-\1740 NH4Ac\NN\1740 )\-RRB-\1740 (\-LRB-\1740 6\CD\13741022 mmol/kg\NNS\1740 s.c.\FW\1740 )\-RRB-\1740 approximately\RB\1740 doubled\VBD\247390 the\DT\1740 time\NN\7308889 <e1>morphine-treated</e1>\JJ\1740 mice\NNS\2329401 remained\VBD\2604760 on\IN\1740 a\DT\13649268 hot\JJ\1740 surface\NN\21939 and\CC\1740 similarly\RB\1740 increased\VBD\169651 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 by\IN\1740 diazepam\NN\2830852 ,\,\1740 but\CC\1740 NH4Ac\NN\1740 treatment\NN\654885 alone\RB\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
D009020_D001259 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 <e1>morphine</e1>\NN\2707683 analgesia-\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D003975_D001259 CID Pretreatment\NN\1740 with\IN\1740 ammonium\NN\14743582 acetate\NN\15010703 (\-LRB-\1740 NH4Ac\NN\1740 )\-RRB-\1740 (\-LRB-\1740 6\CD\13741022 mmol/kg\NNS\1740 s.c.\FW\1740 )\-RRB-\1740 approximately\RB\1740 doubled\VBD\247390 the\DT\1740 time\NN\7308889 morphine-treated\JJ\1740 mice\NNS\2329401 remained\VBD\2604760 on\IN\1740 a\DT\13649268 hot\JJ\1740 surface\NN\21939 and\CC\1740 similarly\RB\1740 increased\VBD\169651 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 by\IN\1740 <e1>diazepam</e1>\NN\2830852 ,\,\1740 but\CC\1740 NH4Ac\NN\1740 treatment\NN\654885 alone\RB\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
D003975_D001259 CID Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 analgesia-\JJ\1740 and\CC\1740 <e1>diazepam-induced</e1>\JJ\1740 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D002118_D003866 NONE Addition\NN\3081021 of\IN\1740 excess\JJ\1740 <e1>calcium</e1>\NN\14625458 reversed\VBD\109660 the\DT\1740 <e2>depression</e2>\NN\14373582 in\IN\13603305 both\DT\1740 tissues\NNS\5220461 ,\,\1740 but\CC\1740 calcium-independent\JJ\1740 catecholamine\NN\5407119 release\NN\3748886 by\IN\1740 acetaldehyde\NN\14584765 was\VBD\836236 not\RB\1740 blocked\VBN\1476483 by\IN\1740 NH4Ac\NN\1740 .\.\1740
D002118_D003866 NONE Addition\NN\3081021 of\IN\1740 excess\JJ\1740 calcium\NN\14625458 reversed\VBD\109660 the\DT\1740 <e2>depression</e2>\NN\14373582 in\IN\13603305 both\DT\1740 tissues\NNS\5220461 ,\,\1740 but\CC\1740 <e1>calcium-independent</e1>\JJ\1740 catecholamine\NN\5407119 release\NN\3748886 by\IN\1740 acetaldehyde\NN\14584765 was\VBD\836236 not\RB\1740 blocked\VBN\1476483 by\IN\1740 NH4Ac\NN\1740 .\.\1740
D002395_D003866 NONE Addition\NN\3081021 of\IN\1740 excess\JJ\1740 calcium\NN\14625458 reversed\VBD\109660 the\DT\1740 <e2>depression</e2>\NN\14373582 in\IN\13603305 both\DT\1740 tissues\NNS\5220461 ,\,\1740 but\CC\1740 calcium-independent\JJ\1740 <e1>catecholamine</e1>\NN\5407119 release\NN\3748886 by\IN\1740 acetaldehyde\NN\14584765 was\VBD\836236 not\RB\1740 blocked\VBN\1476483 by\IN\1740 NH4Ac\NN\1740 .\.\1740
D000079_D003866 NONE Addition\NN\3081021 of\IN\1740 excess\JJ\1740 calcium\NN\14625458 reversed\VBD\109660 the\DT\1740 <e2>depression</e2>\NN\14373582 in\IN\13603305 both\DT\1740 tissues\NNS\5220461 ,\,\1740 but\CC\1740 calcium-independent\JJ\1740 catecholamine\NN\5407119 release\NN\3748886 by\IN\1740 <e1>acetaldehyde</e1>\NN\14584765 was\VBD\836236 not\RB\1740 blocked\VBN\1476483 by\IN\1740 NH4Ac\NN\1740 .\.\1740
C018824_D003866 NONE Addition\NN\3081021 of\IN\1740 excess\JJ\1740 calcium\NN\14625458 reversed\VBD\109660 the\DT\1740 <e2>depression</e2>\NN\14373582 in\IN\13603305 both\DT\1740 tissues\NNS\5220461 ,\,\1740 but\CC\1740 calcium-independent\JJ\1740 catecholamine\NN\5407119 release\NN\3748886 by\IN\1740 acetaldehyde\NN\14584765 was\VBD\836236 not\RB\1740 blocked\VBN\1476483 by\IN\1740 <e1>NH4Ac</e1>\NN\1740 .\.\1740
D014700_D000699 NONE Both\CC\1740 <e1>verapamil</e1>\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 <e2>analgesia-</e2>\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 incoordination\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D014700_D000699 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 <e2>analgesia-</e2>\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 incoordination\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 <e1>verapamil</e1>\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D014700_D001259 NONE Both\CC\1740 <e1>verapamil</e1>\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 analgesia-\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D014700_D001259 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 analgesia-\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 <e1>verapamil</e1>\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
C018824_D000699 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 <e1>NH4Ac</e1>\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 <e2>analgesia-</e2>\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 incoordination\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
C018824_D000699 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 <e2>analgesia-</e2>\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 incoordination\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 <e1>NH4Ac</e1>\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D009020_D000699 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 <e1>morphine</e1>\NN\2707683 <e2>analgesia-</e2>\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 incoordination\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D003975_D000699 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 <e2>analgesia-</e2>\JJ\1740 and\CC\1740 <e1>diazepam-induced</e1>\JJ\1740 muscular\JJ\1740 incoordination\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D000661_D000699 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 <e2>analgesia-</e2>\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 incoordination\NN\5648247 and\CC\1740 antagonized\VBN\1787955 <e1>amphetamine-induced</e1>\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D000661_D001259 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 analgesia-\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 and\CC\1740 antagonized\VBN\1787955 <e1>amphetamine-induced</e1>\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 metrazol\NN\3740161 .\.\1740
D010433_D000699 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 <e2>analgesia-</e2>\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 incoordination\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 <e1>metrazol</e1>\NN\3740161 .\.\1740
D010433_D001259 NONE Both\CC\1740 verapamil\NN\2938514 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 NH4Ac\NN\1740 pretreatment\NN\1740 enhanced\VBD\227165 morphine\NN\2707683 analgesia-\JJ\1740 and\CC\1740 diazepam-induced\JJ\1740 muscular\JJ\1740 <e2>incoordination</e2>\NN\5648247 and\CC\1740 antagonized\VBN\1787955 amphetamine-induced\JJ\1740 motor\NN\3699975 activity\NN\30358 ,\,\1740 and\CC\1740 neither\CC\1740 verapamil\NN\2938514 nor\CC\1740 NH4Ac\NN\1740 affected\VBD\126264 the\DT\1740 convulsant\JJ\1740 action\NN\30358 of\IN\1740 <e1>metrazol</e1>\NN\3740161 .\.\1740
D002118_D022124 NONE The\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e2>hyperammonemia</e2>\NN\1740 exerts\VBZ\1158872 a\DT\13649268 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blocking\NN\562280 action\NN\30358 which\WDT\1740 enhances\VBZ\227165 the\DT\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 and\CC\1740 certain\JJ\1740 opioid\NN\1740 analgesics\NNS\3740161 .\.\1740
7072798
D002701_D000741 CID Fatal\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 following\VBG\1835496 topical\JJ\1740 administration\NN\1133281 of\IN\1740 ophthalmic\JJ\1740 <e1>chloramphenicol</e1>\NN\2716866 .\.\1740
D002701_D000741 CID A\DT\13649268 73-year-old\JJ\1740 woman\NN\9605289 died\VBD\146138 of\IN\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 less\JJR\1740 than\IN\1740 two\CD\13741022 months\NNS\15113229 after\IN\1740 undergoing\VBG\109660 cataract\JJ\1740 extraction\NN\13518963 and\CC\1740 beginning\VBG\941990 topical\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>chloramphenicol</e1>\NN\2716866 .\.\1740
D002701_D000741 CID The\DT\1740 pattern\NN\5726345 of\IN\1740 the\DT\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 idiosyncratic\JJ\1740 response\NN\11410625 to\TO\1740 <e1>chloramphenicol</e1>\NN\2716866 .\.\1740
D002701_D000741 CID This\DT\1740 was\VBD\836236 the\DT\1740 second\JJ\1740 report\NN\6470073 of\IN\1740 fatal\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 after\IN\1740 topical\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>chloramphenicol</e1>\NN\2716866 for\IN\1740 ocular\JJ\1740 conditions\NNS\14512817 ,\,\1740 although\IN\1740 two\CD\13741022 cases\NNS\7283608 of\IN\1740 reversible\JJ\1740 bone\NN\5286536 marrow\NN\5286536 hypoplasia\NN\14365950 have\VBP\2108377 also\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
D002701_D002386 NONE A\DT\13649268 73-year-old\JJ\1740 woman\NN\9605289 died\VBD\146138 of\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 less\JJR\1740 than\IN\1740 two\CD\13741022 months\NNS\15113229 after\IN\1740 undergoing\VBG\109660 <e2>cataract</e2>\JJ\1740 extraction\NN\13518963 and\CC\1740 beginning\VBG\941990 topical\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>chloramphenicol</e1>\NN\2716866 .\.\1740
D002701_D001855 NONE This\DT\1740 was\VBD\836236 the\DT\1740 second\JJ\1740 report\NN\6470073 of\IN\1740 fatal\JJ\1740 aplastic\JJ\1740 anemia\NN\14189204 after\IN\1740 topical\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>chloramphenicol</e1>\NN\2716866 for\IN\1740 ocular\JJ\1740 conditions\NNS\14512817 ,\,\1740 although\IN\1740 two\CD\13741022 cases\NNS\7283608 of\IN\1740 reversible\JJ\1740 <e2>bone\NN\5286536 marrow\NN\5286536 hypoplasia</e2>\NN\14365950 have\VBP\2108377 also\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
D002701_D005128 NONE Any\DT\1740 other\JJ\1740 suspected\VBN\916909 cases\NNS\7283608 of\IN\1740 <e2>ocular\JJ\1740 toxicity</e2>\NN\13576101 associated\VBN\628491 with\IN\1740 topically\RB\1740 applied\VBN\2676054 <e1>chloramphenicol</e1>\NN\2716866 should\MD\1740 be\VB\836236 reported\VBN\831651 to\IN\1740 the\DT\1740 National\NNP\7846 Registry\NNP\6502378 of\IN\1740 Drug-Induced\JJ\1740 Ocular\JJ\1740 Side\NN\8630039 Effects\NNS\13245626 ,\,\1740 Oregon\NNP\1740 Health\NNP\14447525 Sciences\NNPS\5996646 University\NNP\7965085 ,\,\1740 Portland\NNP\1740 ,\,\1740 OR\NNP\3541091 97201\CD\1740 .\.\1740
8441146
D006046_D000741 CID BMT\NN\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 treat\VB\2376958 severe\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 which\WDT\1740 was\VBD\836236 caused\VBN\1617192 by\IN\1740 <e1>gold</e1>\NN\13371489 in\IN\13603305 one\CD\13741022 case\NN\7283608 and\CC\1740 D-penicillamine\NN\1740 in\IN\13603305 the\DT\1740 other\JJ\1740 .\.\1740
D010396_D000741 CID BMT\NN\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 treat\VB\2376958 severe\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 which\WDT\1740 was\VBD\836236 caused\VBN\1617192 by\IN\1740 gold\NN\13371489 in\IN\13603305 one\CD\13741022 case\NN\7283608 and\CC\1740 <e1>D-penicillamine</e1>\NN\1740 in\IN\13603305 the\DT\1740 other\JJ\1740 .\.\1740
8911359
D003520_D001749 CID <e1>Cyclophosphamide</e1>\NN\1740 associated\VBD\628491 <e2>bladder\NN\5515670 cancer</e2>\NN\14239425 --\:\1740 a\DT\13649268 highly\RB\1740 aggressive\JJ\1740 disease\NN\14061805 :\:\1740 analysis\NN\633864 of\IN\1740 12\CD\13745420 cases\NNS\7283608 .\.\1740
D003520_D001749 CID MATERIALS\NNS\19613 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 The\DT\1740 medical\JJ\1740 records\NNS\6643408 of\IN\1740 6\CD\13741022 men\NNS\8208016 and\CC\1740 6\CD\13741022 women\NNS\9605289 (\-LRB-\1740 mean\NN\6021761 age\NN\4916342 55\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 associated\VBN\628491 <e2>bladder\NN\5515670 cancer</e2>\NN\14239425 were\VBD\836236 reviewed\VBN\644583 .\.\1740
D003520_D001749 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Cyclophosphamide</e1>\NN\1740 associated\VBD\628491 <e2>bladder\NN\5515670 tumor</e2>\NN\14234074 is\VBZ\836236 an\DT\6697703 aggressive\JJ\1740 disease\NN\14061805 .\.\1740
D003520_D014523 NONE PURPOSE\NNP\5980875 :\:\1740 We\PRP\1740 gained\VBD\2238085 knowledge\NN\23100 of\IN\1740 the\DT\1740 etiology\NN\7326557 ,\,\1740 treatment\NN\654885 and\CC\1740 prevention\NN\1073995 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 associated\VBN\628491 <e2>urothelial\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
10193809
D011692_D011507 CID METHODS\NNS\5616786 :\:\1740 <e1>Puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 to\IN\1740 Sprague\NNP\1740 Dawley\NNP\1740 rats\VBZ\2584097 to\TO\1740 induce\VB\1627355 <e2>proteinuria</e2>\NN\14299637 .\.\1740
D011692_D011507 CID METHODS\NNS\5616786 :\:\1740 Puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 to\IN\1740 Sprague\NNP\1740 Dawley\NNP\1740 rats\VBZ\2584097 to\TO\1740 induce\VB\1627355 <e2>proteinuria</e2>\NN\14299637 .\.\1740
3780814
D010634_D063646 NONE <e2>Anti-carcinogenic</e2>\JJ\1740 action\NN\30358 of\IN\1740 <e1>phenobarbital</e1>\JJ\1740 given\VBN\2327200 simultaneously\RB\1740 with\IN\1740 diethylnitrosamine\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D010634_D063646 NONE The\DT\1740 present\JJ\1740 work\NN\407535 has\VBZ\2108377 been\VBN\836236 planned\VBN\708538 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>phenobarbital</e1>\JJ\1740 (\-LRB-\1740 PB\NN\14625458 :\:\1740 15\CD\13745420 mg\NN\13717155 per\IN\1740 rat\NN\2329401 of\IN\1740 ingested\VBN\597915 dose\NN\3740161 )\-RRB-\1740 on\IN\1740 <e2>carcinogenesis</e2>\NN\1740 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 administered\VBN\2436349 simultaneously\RB\1740 with\IN\1740 diethylnitrosamine\NN\1740 (\-LRB-\1740 DEN\NN\8580803 :\:\1740 10\CD\13745420 mg/kg/day\NN\1740 )\-RRB-\1740 .\.\1740
D010634_D063646 NONE The\DT\1740 present\JJ\1740 work\NN\407535 has\VBZ\2108377 been\VBN\836236 planned\VBN\708538 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 effect\NN\34213 of\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 <e1>PB</e1>\NN\14625458 :\:\1740 15\CD\13745420 mg\NN\13717155 per\IN\1740 rat\NN\2329401 of\IN\1740 ingested\VBN\597915 dose\NN\3740161 )\-RRB-\1740 on\IN\1740 <e2>carcinogenesis</e2>\NN\1740 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 administered\VBN\2436349 simultaneously\RB\1740 with\IN\1740 diethylnitrosamine\NN\1740 (\-LRB-\1740 DEN\NN\8580803 :\:\1740 10\CD\13745420 mg/kg/day\NN\1740 )\-RRB-\1740 .\.\1740
D010634_D063646 NONE Wistar\DT\1740 rats\NNS\2329401 (\-LRB-\1740 180\CD\1740 g\NN\13717155 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 by\IN\1740 DEN\NN\8580803 alone\RB\1740 or\CC\3541091 by\IN\1740 DEN\NN\8580803 +\CC\1740 <e1>PB</e1>\NN\14625458 during\IN\1740 2\CD\13741022 ,\,\1740 4\CD\13741022 and\CC\1740 6\CD\13741022 weeks\NNS\15113229 according\VBG\2657219 to\IN\1740 our\PRP$\1740 schedule\NN\5898568 for\IN\1740 <e2>hepatocarcinogenesis</e2>\NN\1740 .\.\1740
D010634_D063646 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 <e1>PB</e1>\NNP\14625458 ,\,\1740 which\WDT\1740 promotes\VBZ\2556126 <e2>carcinogenesis</e2>\NN\1740 when\WRB\1740 administered\VBN\2436349 after\IN\1740 the\DT\1740 DEN\NN\8580803 treatment\NN\654885 ,\,\1740 reduces\VBZ\441445 the\DT\1740 carcinogen\NN\20090 effect\NN\34213 when\WRB\1740 given\VBN\2327200 simultaneously\RB\1740 with\IN\1740 DEN\NN\8580803 .\.\1740
D004052_D063646 NONE <e2>Anti-carcinogenic</e2>\JJ\1740 action\NN\30358 of\IN\1740 phenobarbital\JJ\1740 given\VBN\2327200 simultaneously\RB\1740 with\IN\1740 <e1>diethylnitrosamine</e1>\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D004052_D063646 NONE The\DT\1740 present\JJ\1740 work\NN\407535 has\VBZ\2108377 been\VBN\836236 planned\VBN\708538 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 effect\NN\34213 of\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 :\:\1740 15\CD\13745420 mg\NN\13717155 per\IN\1740 rat\NN\2329401 of\IN\1740 ingested\VBN\597915 dose\NN\3740161 )\-RRB-\1740 on\IN\1740 <e2>carcinogenesis</e2>\NN\1740 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 administered\VBN\2436349 simultaneously\RB\1740 with\IN\1740 <e1>diethylnitrosamine</e1>\NN\1740 (\-LRB-\1740 DEN\NN\8580803 :\:\1740 10\CD\13745420 mg/kg/day\NN\1740 )\-RRB-\1740 .\.\1740
D004052_D063646 NONE The\DT\1740 present\JJ\1740 work\NN\407535 has\VBZ\2108377 been\VBN\836236 planned\VBN\708538 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 effect\NN\34213 of\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 :\:\1740 15\CD\13745420 mg\NN\13717155 per\IN\1740 rat\NN\2329401 of\IN\1740 ingested\VBN\597915 dose\NN\3740161 )\-RRB-\1740 on\IN\1740 <e2>carcinogenesis</e2>\NN\1740 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 administered\VBN\2436349 simultaneously\RB\1740 with\IN\1740 diethylnitrosamine\NN\1740 (\-LRB-\1740 <e1>DEN</e1>\NN\8580803 :\:\1740 10\CD\13745420 mg/kg/day\NN\1740 )\-RRB-\1740 .\.\1740
D004052_D063646 NONE Wistar\DT\1740 rats\NNS\2329401 (\-LRB-\1740 180\CD\1740 g\NN\13717155 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 by\IN\1740 <e1>DEN</e1>\NN\8580803 alone\RB\1740 or\CC\3541091 by\IN\1740 DEN\NN\8580803 +\CC\1740 PB\NN\14625458 during\IN\1740 2\CD\13741022 ,\,\1740 4\CD\13741022 and\CC\1740 6\CD\13741022 weeks\NNS\15113229 according\VBG\2657219 to\IN\1740 our\PRP$\1740 schedule\NN\5898568 for\IN\1740 <e2>hepatocarcinogenesis</e2>\NN\1740 .\.\1740
D004052_D063646 NONE Wistar\DT\1740 rats\NNS\2329401 (\-LRB-\1740 180\CD\1740 g\NN\13717155 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 by\IN\1740 DEN\NN\8580803 alone\RB\1740 or\CC\3541091 by\IN\1740 <e1>DEN</e1>\NN\8580803 +\CC\1740 PB\NN\14625458 during\IN\1740 2\CD\13741022 ,\,\1740 4\CD\13741022 and\CC\1740 6\CD\13741022 weeks\NNS\15113229 according\VBG\2657219 to\IN\1740 our\PRP$\1740 schedule\NN\5898568 for\IN\1740 <e2>hepatocarcinogenesis</e2>\NN\1740 .\.\1740
D004052_D063646 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 PB\NNP\14625458 ,\,\1740 which\WDT\1740 promotes\VBZ\2556126 <e2>carcinogenesis</e2>\NN\1740 when\WRB\1740 administered\VBN\2436349 after\IN\1740 the\DT\1740 <e1>DEN</e1>\NN\8580803 treatment\NN\654885 ,\,\1740 reduces\VBZ\441445 the\DT\1740 carcinogen\NN\20090 effect\NN\34213 when\WRB\1740 given\VBN\2327200 simultaneously\RB\1740 with\IN\1740 DEN\NN\8580803 .\.\1740
D004052_D063646 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 PB\NNP\14625458 ,\,\1740 which\WDT\1740 promotes\VBZ\2556126 <e2>carcinogenesis</e2>\NN\1740 when\WRB\1740 administered\VBN\2436349 after\IN\1740 the\DT\1740 DEN\NN\8580803 treatment\NN\654885 ,\,\1740 reduces\VBZ\441445 the\DT\1740 carcinogen\NN\20090 effect\NN\34213 when\WRB\1740 given\VBN\2327200 simultaneously\RB\1740 with\IN\1740 <e1>DEN</e1>\NN\8580803 .\.\1740
D010634_D011230 NONE After\IN\1740 the\DT\1740 end\NN\8568978 of\IN\1740 the\DT\1740 treatment\NN\654885 ,\,\1740 the\DT\1740 number\NN\5107765 and\CC\1740 the\DT\1740 size\NN\5090441 of\IN\1740 induced\VBN\1627355 PAS\NN\285557 positive\JJ\1740 <e2>preneoplastic\JJ\1740 foci</e2>\NNS\5704266 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 when\WRB\1740 <e1>PB</e1>\NN\14625458 was\VBD\836236 given\VBN\2327200 simultaneously\RB\1740 with\IN\1740 DEN\NN\8580803 for\IN\1740 4\CD\13741022 and\CC\1740 6\CD\13741022 weeks\NNS\15113229 .\.\1740
D004052_D011230 CID After\IN\1740 the\DT\1740 end\NN\8568978 of\IN\1740 the\DT\1740 treatment\NN\654885 ,\,\1740 the\DT\1740 number\NN\5107765 and\CC\1740 the\DT\1740 size\NN\5090441 of\IN\1740 induced\VBN\1627355 PAS\NN\285557 positive\JJ\1740 <e2>preneoplastic\JJ\1740 foci</e2>\NNS\5704266 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 when\WRB\1740 PB\NN\14625458 was\VBD\836236 given\VBN\2327200 simultaneously\RB\1740 with\IN\1740 <e1>DEN</e1>\NN\8580803 for\IN\1740 4\CD\13741022 and\CC\1740 6\CD\13741022 weeks\NNS\15113229 .\.\1740
D004052_D009369 NONE In\IN\13603305 <e1>DEN</e1>\NN\8580803 +\CC\1740 PB\NN\14625458 treated\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 survival\NN\13961642 was\VBD\836236 prolonged\JJ\1740 and\CC\1740 the\DT\1740 <e2>tumor</e2>\NN\14234074 incidence\NN\13821570 decreased\VBD\169651 as\IN\14622893 compared\VBN\644583 with\IN\1740 the\DT\1740 results\NNS\34213 obtained\VBN\2210855 by\IN\1740 DEN\NN\8580803 alone\RB\1740 .\.\1740
D004052_D009369 NONE In\IN\13603305 DEN\NN\8580803 +\CC\1740 PB\NN\14625458 treated\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 survival\NN\13961642 was\VBD\836236 prolonged\JJ\1740 and\CC\1740 the\DT\1740 <e2>tumor</e2>\NN\14234074 incidence\NN\13821570 decreased\VBD\169651 as\IN\14622893 compared\VBN\644583 with\IN\1740 the\DT\1740 results\NNS\34213 obtained\VBN\2210855 by\IN\1740 <e1>DEN</e1>\NN\8580803 alone\RB\1740 .\.\1740
D010634_D009369 NONE In\IN\13603305 DEN\NN\8580803 +\CC\1740 <e1>PB</e1>\NN\14625458 treated\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 survival\NN\13961642 was\VBD\836236 prolonged\JJ\1740 and\CC\1740 the\DT\1740 <e2>tumor</e2>\NN\14234074 incidence\NN\13821570 decreased\VBD\169651 as\IN\14622893 compared\VBN\644583 with\IN\1740 the\DT\1740 results\NNS\34213 obtained\VBN\2210855 by\IN\1740 DEN\NN\8580803 alone\RB\1740 .\.\1740
20683499
C029036_D000544 NONE Effects\NNS\13245626 of\IN\1740 active\JJ\1740 constituents\NNS\3892891 of\IN\1740 Crocus\NN\12411461 sativus\NN\1740 L.\NNP\1740 ,\,\1740 <e1>crocin</e1>\NN\1740 on\IN\1740 streptozocin-induced\JJ\1740 model\NN\5888929 of\IN\1740 sporadic\JJ\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
C029036_D000544 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>crocins</e1>\NNS\1740 on\IN\1740 sporadic\JJ\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 induced\VBN\1627355 by\IN\1740 intracerebroventricular\JJ\1740 (\-LRB-\1740 icv\JJ\1740 )\-RRB-\1740 streptozocin\NN\1740 (\-LRB-\1740 STZ\NN\1740 )\-RRB-\1740 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 was\VBD\836236 investigated\VBN\644583 .\.\1740
C029036_D000544 NONE CONCLUSION\NN\5837957 :\:\1740 Therefore\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 <e1>crocin</e1>\NN\1740 (\-LRB-\1740 30\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 antagonizing\VBG\1787955 the\DT\1740 cognitive\JJ\1740 deficits\NNS\5113133 caused\VBN\1617192 by\IN\1740 STZ-icv\NN\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 neurodegenerative\JJ\1740 diseases\NNS\14061805 such\JJ\1740 as\IN\14622893 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D013311_D000544 CID Effects\NNS\13245626 of\IN\1740 active\JJ\1740 constituents\NNS\3892891 of\IN\1740 Crocus\NN\12411461 sativus\NN\1740 L.\NNP\1740 ,\,\1740 crocin\NN\1740 on\IN\1740 <e1>streptozocin-induced</e1>\JJ\1740 model\NN\5888929 of\IN\1740 sporadic\JJ\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
D013311_D000544 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 crocins\NNS\1740 on\IN\1740 sporadic\JJ\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 induced\VBN\1627355 by\IN\1740 intracerebroventricular\JJ\1740 (\-LRB-\1740 icv\JJ\1740 )\-RRB-\1740 <e1>streptozocin</e1>\NN\1740 (\-LRB-\1740 STZ\NN\1740 )\-RRB-\1740 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 was\VBD\836236 investigated\VBN\644583 .\.\1740
D013311_D000544 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 crocins\NNS\1740 on\IN\1740 sporadic\JJ\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 induced\VBN\1627355 by\IN\1740 intracerebroventricular\JJ\1740 (\-LRB-\1740 icv\JJ\1740 )\-RRB-\1740 streptozocin\NN\1740 (\-LRB-\1740 <e1>STZ</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 was\VBD\836236 investigated\VBN\644583 .\.\1740
D013311_D000544 CID In\IN\13603305 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 groups\NNS\2137 ,\,\1740 rats\NNS\2329401 were\VBD\836236 injected\VBN\81072 with\IN\1740 <e1>STZ-icv</e1>\NN\1740 bilaterally\RB\1740 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 first\JJ\1740 day\NN\15154774 and\CC\1740 3\CD\13741022 days\NNS\15140892 later\RB\1740 ,\,\1740 a\DT\13649268 similar\JJ\1740 STZ-icv\NN\1740 application\NN\947128 was\VBD\836236 repeated\VBN\952524 .\.\1740
D013311_D000544 CID In\IN\13603305 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 groups\NNS\2137 ,\,\1740 rats\NNS\2329401 were\VBD\836236 injected\VBN\81072 with\IN\1740 STZ-icv\NN\1740 bilaterally\RB\1740 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 first\JJ\1740 day\NN\15154774 and\CC\1740 3\CD\13741022 days\NNS\15140892 later\RB\1740 ,\,\1740 a\DT\13649268 similar\JJ\1740 <e1>STZ-icv</e1>\NN\1740 application\NN\947128 was\VBD\836236 repeated\VBN\952524 .\.\1740
D013311_D000544 CID CONCLUSION\NN\5837957 :\:\1740 Therefore\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 crocin\NN\1740 (\-LRB-\1740 30\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 antagonizing\VBG\1787955 the\DT\1740 cognitive\JJ\1740 deficits\NNS\5113133 caused\VBN\1617192 by\IN\1740 <e1>STZ-icv</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 neurodegenerative\JJ\1740 diseases\NNS\14061805 such\JJ\1740 as\IN\14622893 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
C029036_D007859 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 <e1>crocin</e1>\NN\1740 in\IN\13603305 the\DT\1740 mentioned\VBN\730052 dose\NN\3740161 could\MD\1740 significantly\RB\1740 attenuated\VBN\224901 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 treated\VBN\2376958 STZ-injected\JJ\1740 group\NN\2137 in\IN\13603305 passive\JJ\1740 avoidance\NN\203342 test\NN\5798043 .\.\1740
C029036_D008569 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 <e1>crocin</e1>\NN\1740 in\IN\13603305 the\DT\1740 mentioned\VBN\730052 dose\NN\3740161 could\MD\1740 significantly\RB\1740 attenuated\VBN\224901 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 treated\VBN\2376958 STZ-injected\JJ\1740 group\NN\2137 in\IN\13603305 passive\JJ\1740 avoidance\NN\203342 test\NN\5798043 .\.\1740
D013311_D007859 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 crocin\NN\1740 in\IN\13603305 the\DT\1740 mentioned\VBN\730052 dose\NN\3740161 could\MD\1740 significantly\RB\1740 attenuated\VBN\224901 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 treated\VBN\2376958 <e1>STZ-injected</e1>\JJ\1740 group\NN\2137 in\IN\13603305 passive\JJ\1740 avoidance\NN\203342 test\NN\5798043 .\.\1740
D013311_D008569 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 crocin\NN\1740 in\IN\13603305 the\DT\1740 mentioned\VBN\730052 dose\NN\3740161 could\MD\1740 significantly\RB\1740 attenuated\VBN\224901 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 treated\VBN\2376958 <e1>STZ-injected</e1>\JJ\1740 group\NN\2137 in\IN\13603305 passive\JJ\1740 avoidance\NN\203342 test\NN\5798043 .\.\1740
C029036_D003072 NONE CONCLUSION\NN\5837957 :\:\1740 Therefore\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 <e1>crocin</e1>\NN\1740 (\-LRB-\1740 30\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 antagonizing\VBG\1787955 the\DT\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 caused\VBN\1617192 by\IN\1740 STZ-icv\NN\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 neurodegenerative\JJ\1740 diseases\NNS\14061805 such\JJ\1740 as\IN\14622893 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
C029036_D019636 NONE CONCLUSION\NN\5837957 :\:\1740 Therefore\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 <e1>crocin</e1>\NN\1740 (\-LRB-\1740 30\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 antagonizing\VBG\1787955 the\DT\1740 cognitive\JJ\1740 deficits\NNS\5113133 caused\VBN\1617192 by\IN\1740 STZ-icv\NN\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>neurodegenerative\JJ\1740 diseases</e2>\NNS\14061805 such\JJ\1740 as\IN\14622893 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D013311_D003072 CID CONCLUSION\NN\5837957 :\:\1740 Therefore\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 crocin\NN\1740 (\-LRB-\1740 30\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 antagonizing\VBG\1787955 the\DT\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 caused\VBN\1617192 by\IN\1740 <e1>STZ-icv</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 neurodegenerative\JJ\1740 diseases\NNS\14061805 such\JJ\1740 as\IN\14622893 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D013311_D019636 NONE CONCLUSION\NN\5837957 :\:\1740 Therefore\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 crocin\NN\1740 (\-LRB-\1740 30\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 antagonizing\VBG\1787955 the\DT\1740 cognitive\JJ\1740 deficits\NNS\5113133 caused\VBN\1617192 by\IN\1740 <e1>STZ-icv</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>neurodegenerative\JJ\1740 diseases</e2>\NNS\14061805 such\JJ\1740 as\IN\14622893 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
19674115
D011718_D000857 CID Recurrent\JJ\1740 <e2>dysosmia</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 <e1>pyrazinamide</e1>\NN\1740 .\.\1740
D011718_D000857 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 reversible\JJ\1740 <e2>olfactory\JJ\1740 disorder</e2>\NN\14034177 related\JJ\1740 to\TO\1740 <e1>pyrazinamide</e1>\NN\1740 in\IN\13603305 a\DT\13649268 woman\NN\9605289 ,\,\1740 with\IN\1740 a\DT\13649268 positive\JJ\1740 rechallenge\NN\1740 .\.\1740
D011718_D000857 CID <e2>Dysosmia</e2>\NNP\14052403 disappeared\VBD\2609764 completely\RB\1740 after\IN\1740 <e1>pyrazinamide</e1>\NN\1740 withdrawal\NN\7206096 and\CC\1740 recurred\VBN\339934 after\IN\1740 its\PRP$\6125041 rechallenge\NN\1740 .\.\1740
D011718_D056486 NONE <e1>Pyrazinamide</e1>\NN\1740 can\MD\3094503 have\VB\2108377 adverse\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 <e2>hepatic\JJ\1740 toxicity</e2>\NN\13576101 ,\,\1740 hyperuricemia\NN\1740 or\CC\3541091 digestive\JJ\1740 disorders\NNS\14034177 .\.\1740
D011718_D033461 NONE <e1>Pyrazinamide</e1>\NN\1740 can\MD\3094503 have\VB\2108377 adverse\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 hepatic\JJ\1740 toxicity\NN\13576101 ,\,\1740 <e2>hyperuricemia</e2>\NN\1740 or\CC\3541091 digestive\JJ\1740 disorders\NNS\14034177 .\.\1740
19944736
D013619_D012640 CID <e1>Tacrine</e1>\NN\1740 ,\,\1740 administered\VBN\2436349 in\IN\13603305 LiCl\NN\1740 pre-treated\JJ\1740 rats\NNS\2329401 ,\,\1740 induces\VBZ\1627355 electrocorticographic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 delayed\VBD\439958 hippocampal\NN\1740 damage\NN\7296428 .\.\1740
D013619_D001930 CID <e1>Tacrine</e1>\NN\1740 ,\,\1740 administered\VBN\2436349 in\IN\13603305 LiCl\NN\1740 pre-treated\JJ\1740 rats\NNS\2329401 ,\,\1740 induces\VBZ\1627355 electrocorticographic\JJ\1740 seizures\NNS\14081375 and\CC\1740 delayed\VBD\439958 <e2>hippocampal\NN\1740 damage</e2>\NN\7296428 .\.\1740
D013619_D001930 CID In\IN\13603305 addition\NN\3081021 ,\,\1740 <e1>tacrine-loaded</e1>\JJ\1740 nanoparticles\NNS\1740 administration\NN\1133281 induced\VBD\1627355 <e2>damage\NN\7296428 of\IN\1740 neuronal\JJ\1740 cells</e2>\NNS\3080309 in\IN\13603305 CA1\NN\1740 field\NN\8673395 of\IN\1740 the\DT\1740 hippocampus\NN\5462674 in\IN\13603305 all\DT\1740 treated\VBN\2376958 animals\NNS\4475 ,\,\1740 while\IN\15122231 the\DT\1740 saline\NN\14849367 solution\NN\14586258 of\IN\1740 tacrine\NN\1740 only\RB\1740 in\IN\13603305 60\CD\13745420 %\NN\1740 of\IN\1740 animals\NNS\4475 .\.\1740
D013619_D001930 CID In\IN\13603305 addition\NN\3081021 ,\,\1740 tacrine-loaded\JJ\1740 nanoparticles\NNS\1740 administration\NN\1133281 induced\VBD\1627355 <e2>damage\NN\7296428 of\IN\1740 neuronal\JJ\1740 cells</e2>\NNS\3080309 in\IN\13603305 CA1\NN\1740 field\NN\8673395 of\IN\1740 the\DT\1740 hippocampus\NN\5462674 in\IN\13603305 all\DT\1740 treated\VBN\2376958 animals\NNS\4475 ,\,\1740 while\IN\15122231 the\DT\1740 saline\NN\14849367 solution\NN\14586258 of\IN\1740 <e1>tacrine</e1>\NN\1740 only\RB\1740 in\IN\13603305 60\CD\13745420 %\NN\1740 of\IN\1740 animals\NNS\4475 .\.\1740
D018021_D012640 CID Tacrine\NN\1740 ,\,\1740 administered\VBN\2436349 in\IN\13603305 <e1>LiCl</e1>\NN\1740 pre-treated\JJ\1740 rats\NNS\2329401 ,\,\1740 induces\VBZ\1627355 electrocorticographic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 delayed\VBD\439958 hippocampal\NN\1740 damage\NN\7296428 .\.\1740
D018021_D001930 CID Tacrine\NN\1740 ,\,\1740 administered\VBN\2436349 in\IN\13603305 <e1>LiCl</e1>\NN\1740 pre-treated\JJ\1740 rats\NNS\2329401 ,\,\1740 induces\VBZ\1627355 electrocorticographic\JJ\1740 seizures\NNS\14081375 and\CC\1740 delayed\VBD\439958 <e2>hippocampal\NN\1740 damage</e2>\NN\7296428 .\.\1740
D013619_D004827 NONE All\PDT\1740 the\DT\1740 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 <e1>tacrine-loaded</e1>\JJ\1740 nanoparticles\NNS\1740 showed\VBD\2137132 an\DT\6697703 earlier\JJR\1740 outcome\NN\7291312 of\IN\1740 CNS\NN\5237227 adverse\JJ\1740 symptoms\NNS\5823932 ,\,\1740 i.e.\FW\1740 <e2>epileptic</e2>\JJ\1740 onset\NN\7325190 ,\,\1740 with\IN\1740 respect\NN\5817845 to\IN\1740 those\DT\1740 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 the\DT\1740 free\JJ\1740 compound\NN\5869584 (\-LRB-\1740 10\CD\13745420 min\NN\15154774 vs.\CC\1740 22\CD\13745420 min\NN\15154774 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D013619_D004827 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 evaluation\NN\874067 of\IN\1740 time-to-onset\NN\1740 of\IN\1740 symptoms\NNS\5823932 and\CC\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 neurodegenerative\JJ\1740 processes\NNS\407535 induced\VBN\1627355 by\IN\1740 the\DT\1740 <e1>tacrine-lithium</e1>\NN\1740 model\NN\5888929 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 in\IN\13603305 the\DT\1740 rat\NN\2329401 ,\,\1740 could\MD\1740 be\VB\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 preliminarily\RB\1740 the\DT\1740 capability\NN\5200169 of\IN\1740 a\DT\13649268 drug\NN\14778436 delivery\NN\315986 system\NN\3575240 to\TO\1740 trespass\NN\733883 (\-LRB-\1740 or\CC\3541091 not\RB\1740 )\-RRB-\1740 the\DT\1740 BBB\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D008094_D004827 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 evaluation\NN\874067 of\IN\1740 time-to-onset\NN\1740 of\IN\1740 symptoms\NNS\5823932 and\CC\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 neurodegenerative\JJ\1740 processes\NNS\407535 induced\VBN\1627355 by\IN\1740 the\DT\1740 <e1>tacrine-lithium</e1>\NN\1740 model\NN\5888929 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 in\IN\13603305 the\DT\1740 rat\NN\2329401 ,\,\1740 could\MD\1740 be\VB\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 preliminarily\RB\1740 the\DT\1740 capability\NN\5200169 of\IN\1740 a\DT\13649268 drug\NN\14778436 delivery\NN\315986 system\NN\3575240 to\TO\1740 trespass\NN\733883 (\-LRB-\1740 or\CC\3541091 not\RB\1740 )\-RRB-\1740 the\DT\1740 BBB\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
1141447
D008094_D003919 CID The\DT\1740 renal\JJ\1740 pathology\NN\6045562 in\IN\13603305 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>diabetes\NNS\14075199 insipidus</e2>\NN\1740 .\.\1740
D008094_D003919 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>diabetes\NN\14075199 insipidus</e2>\NN\1740 is\VBZ\836236 reported\VBN\831651 .\.\1740
8686832
D008012_D001416 CID <e2>Leg\NN\5560244 and\CC\1740 back\JJ\1740 pain</e2>\NN\14299637 after\IN\1740 spinal\JJ\1740 anaesthesia\NN\14034177 involving\VBG\2676054 hyperbaric\JJ\1740 5\CD\13741022 %\NN\1740 <e1>lignocaine</e1>\NN\1740 .\.\1740
D008012_D001416 CID <e2>Leg\NNP\5560244 and/or\CC\1740 back\RB\1740 pain</e2>\NN\14299637 is\VBZ\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 intrathecal\JJ\1740 use\NN\407535 of\IN\1740 hyperbaric\NN\1740 5\CD\13741022 %\NN\1740 <e1>lignocaine</e1>\NN\1740 .\.\1740
D000431_D010146 NONE Five\CD\13741022 of\IN\1740 the\DT\1740 13\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 38\CD\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 <e2>pain</e2>\NN\14299637 and\CC\1740 seven\CD\13741022 of\IN\1740 the\DT\1740 41\CD\1740 patients\NNS\9898892 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 without\IN\1740 pain\NN\14299637 admitted\VBN\822367 to\TO\1740 a\DT\13649268 high\JJ\1740 <e1>alcohol</e1>\NN\7881800 intake\NN\13440063 ,\,\1740 which\WDT\1740 might\MD\5029706 be\VB\836236 a\DT\13649268 contributing\VBG\126264 factor\NN\7326557 .\.\1740
D000431_D010146 NONE Five\CD\13741022 of\IN\1740 the\DT\1740 13\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 38\CD\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 pain\NN\14299637 and\CC\1740 seven\CD\13741022 of\IN\1740 the\DT\1740 41\CD\1740 patients\NNS\9898892 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 without\IN\1740 <e2>pain</e2>\NN\14299637 admitted\VBN\822367 to\TO\1740 a\DT\13649268 high\JJ\1740 <e1>alcohol</e1>\NN\7881800 intake\NN\13440063 ,\,\1740 which\WDT\1740 might\MD\5029706 be\VB\836236 a\DT\13649268 contributing\VBG\126264 factor\NN\7326557 .\.\1740
11185967
D003042_D012640 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 prevalence\NN\4764412 of\IN\1740 positive\JJ\1740 plasma\NN\5398023 drug\NN\14778436 screening\NN\6887726 for\IN\1740 <e1>cocaine</e1>\NN\3492717 or\CC\3541091 amphetamine\NN\3248958 in\IN\13603305 adult\JJ\1740 emergency\NN\7417644 department\NN\8220714 <e2>seizure</e2>\NN\14081375 patients\NNS\9898892 .\.\1740
D003042_D012640 NONE CONCLUSIONS\NNS\5837957 :\:\1740 During\IN\1740 this\DT\1740 study\NN\635850 period\NN\13575869 ,\,\1740 routine\JJ\1740 plasma\NN\5398023 screening\NN\6887726 for\IN\1740 <e1>cocaine</e1>\NN\3492717 and\CC\1740 amphetamines\NNS\3248958 in\IN\13603305 adult\JJ\1740 <e2>seizure</e2>\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 low\JJ\1740 yield\NN\913705 .\.\1740
D000661_D012640 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 prevalence\NN\4764412 of\IN\1740 positive\JJ\1740 plasma\NN\5398023 drug\NN\14778436 screening\NN\6887726 for\IN\1740 cocaine\NN\3492717 or\CC\3541091 <e1>amphetamine</e1>\NN\3248958 in\IN\13603305 adult\JJ\1740 emergency\NN\7417644 department\NN\8220714 <e2>seizure</e2>\NN\14081375 patients\NNS\9898892 .\.\1740
D000431_D012640 NONE Patient\NN\9898892 demographics\NNS\6021499 ,\,\1740 history\NN\15120823 of\IN\1740 underlying\VBG\2604760 drug\NN\14778436 or\CC\3541091 <e1>alcohol-related</e1>\JJ\1740 <e2>seizure</e2>\JJ\1740 disorder\NN\14034177 ,\,\1740 estimated\VBN\637259 time\NN\7308889 from\IN\1740 seizure\NN\14081375 to\IN\1740 sample\NN\5820620 collection\NN\31264 ,\,\1740 history\NN\15120823 or\CC\3541091 suspicion\NN\5916739 of\IN\1740 cocaine\NN\3492717 or\CC\3541091 amphetamine\NN\3248958 abuse\NN\418025 ,\,\1740 results\NNS\34213 of\IN\1740 clinical\JJ\1740 urine\NN\14853947 testing\NN\639556 for\IN\1740 drugs\NNS\14778436 of\IN\1740 abuse\NN\418025 ,\,\1740 and\CC\1740 assay\NN\5733583 results\NNS\34213 were\VBD\836236 recorded\VBN\2225492 without\IN\1740 patient\NN\9898892 identifiers\NNS\6806469 .\.\1740
D000431_D012640 NONE Patient\NN\9898892 demographics\NNS\6021499 ,\,\1740 history\NN\15120823 of\IN\1740 underlying\VBG\2604760 drug\NN\14778436 or\CC\3541091 <e1>alcohol-related</e1>\JJ\1740 seizure\JJ\1740 disorder\NN\14034177 ,\,\1740 estimated\VBN\637259 time\NN\7308889 from\IN\1740 <e2>seizure</e2>\NN\14081375 to\IN\1740 sample\NN\5820620 collection\NN\31264 ,\,\1740 history\NN\15120823 or\CC\3541091 suspicion\NN\5916739 of\IN\1740 cocaine\NN\3492717 or\CC\3541091 amphetamine\NN\3248958 abuse\NN\418025 ,\,\1740 results\NNS\34213 of\IN\1740 clinical\JJ\1740 urine\NN\14853947 testing\NN\639556 for\IN\1740 drugs\NNS\14778436 of\IN\1740 abuse\NN\418025 ,\,\1740 and\CC\1740 assay\NN\5733583 results\NNS\34213 were\VBD\836236 recorded\VBN\2225492 without\IN\1740 patient\NN\9898892 identifiers\NNS\6806469 .\.\1740
D000431_D019970 NONE Patient\NN\9898892 demographics\NNS\6021499 ,\,\1740 history\NN\15120823 of\IN\1740 underlying\VBG\2604760 drug\NN\14778436 or\CC\3541091 <e1>alcohol-related</e1>\JJ\1740 seizure\JJ\1740 disorder\NN\14034177 ,\,\1740 estimated\VBN\637259 time\NN\7308889 from\IN\1740 seizure\NN\14081375 to\IN\1740 sample\NN\5820620 collection\NN\31264 ,\,\1740 history\NN\15120823 or\CC\3541091 suspicion\NN\5916739 of\IN\1740 <e2>cocaine\NN\3492717 or\CC\3541091 amphetamine\NN\3248958 abuse</e2>\NN\418025 ,\,\1740 results\NNS\34213 of\IN\1740 clinical\JJ\1740 urine\NN\14853947 testing\NN\639556 for\IN\1740 drugs\NNS\14778436 of\IN\1740 abuse\NN\418025 ,\,\1740 and\CC\1740 assay\NN\5733583 results\NNS\34213 were\VBD\836236 recorded\VBN\2225492 without\IN\1740 patient\NN\9898892 identifiers\NNS\6806469 .\.\1740
D000431_D019969 NONE Patient\NN\9898892 demographics\NNS\6021499 ,\,\1740 history\NN\15120823 of\IN\1740 underlying\VBG\2604760 drug\NN\14778436 or\CC\3541091 <e1>alcohol-related</e1>\JJ\1740 seizure\JJ\1740 disorder\NN\14034177 ,\,\1740 estimated\VBN\637259 time\NN\7308889 from\IN\1740 seizure\NN\14081375 to\IN\1740 sample\NN\5820620 collection\NN\31264 ,\,\1740 history\NN\15120823 or\CC\3541091 suspicion\NN\5916739 of\IN\1740 <e2>cocaine\NN\3492717 or\CC\3541091 amphetamine\NN\3248958 abuse</e2>\NN\418025 ,\,\1740 results\NNS\34213 of\IN\1740 clinical\JJ\1740 urine\NN\14853947 testing\NN\639556 for\IN\1740 drugs\NNS\14778436 of\IN\1740 abuse\NN\418025 ,\,\1740 and\CC\1740 assay\NN\5733583 results\NNS\34213 were\VBD\836236 recorded\VBN\2225492 without\IN\1740 patient\NN\9898892 identifiers\NNS\6806469 .\.\1740
D000662_D012640 NONE CONCLUSIONS\NNS\5837957 :\:\1740 During\IN\1740 this\DT\1740 study\NN\635850 period\NN\13575869 ,\,\1740 routine\JJ\1740 plasma\NN\5398023 screening\NN\6887726 for\IN\1740 cocaine\NN\3492717 and\CC\1740 <e1>amphetamines</e1>\NNS\3248958 in\IN\13603305 adult\JJ\1740 <e2>seizure</e2>\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 low\JJ\1740 yield\NN\913705 .\.\1740
9564988
D064704_D012852 NONE Open-label\JJ\1740 assessment\NN\5732756 of\IN\1740 <e1>levofloxacin</e1>\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 bacterial\JJ\1740 <e2>sinusitis</e2>\NN\14336539 in\IN\13603305 adults\NNS\7846 .\.\1740
D064704_D012852 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>levofloxacin</e1>\NN\1740 (\-LRB-\1740 500\CD\13745420 mg\NN\13717155 orally\RB\1740 once\RB\1740 daily\RB\1740 for\IN\1740 10\CD\13745420 to\TO\1740 14\CD\13745420 days\NNS\15140892 )\-RRB-\1740 in\IN\13603305 treating\VBG\2376958 adult\JJ\1740 outpatients\NNS\10405694 with\IN\1740 acute\JJ\1740 bacterial\JJ\1740 <e2>sinusitis</e2>\NN\14336539 .\.\1740
D064704_D012852 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 results\NNS\34213 of\IN\1740 this\DT\1740 study\NN\635850 indicate\VBP\952524 that\IN\1740 <e1>levofloxacin</e1>\NN\1740 500\CD\13745420 mg\NN\13717155 once\RB\1740 daily\RB\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 and\CC\1740 safe\JJ\1740 treatment\NN\654885 for\IN\1740 acute\JJ\1740 bacterial\JJ\1740 <e2>sinusitis</e2>\NN\14336539 .\.\1740
10565806
C076029_D001714 CID <e2>Hypomania-like</e2>\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>olanzapine</e1>\NN\1740 .\.\1740
C076029_D001714 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 female\JJ\1740 patient\NN\9898892 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 a\DT\13649268 not\RB\1740 otherwise\RB\1740 specified\JJ\1740 psychotic\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 DSM-IV\NN\1740 )\-RRB-\1740 who\WP\8299493 developed\VBD\1753788 <e2>hypomania</e2>\NN\1740 shortly\RB\1740 after\IN\1740 the\DT\1740 introduction\NN\235435 of\IN\1740 <e1>olanzapine</e1>\NN\1740 treatment\NN\654885 .\.\1740
C076029_D011618 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 female\JJ\1740 patient\NN\9898892 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 a\DT\13649268 not\RB\1740 otherwise\RB\1740 specified\JJ\1740 <e2>psychotic\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 DSM-IV\NN\1740 )\-RRB-\1740 who\WP\8299493 developed\VBD\1753788 hypomania\NN\1740 shortly\RB\1740 after\IN\1740 the\DT\1740 introduction\NN\235435 of\IN\1740 <e1>olanzapine</e1>\NN\1740 treatment\NN\654885 .\.\1740
9672273
D013629_D001943 NONE Prevention\NN\1073995 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 with\IN\1740 <e1>tamoxifen</e1>\NN\2714883 :\:\1740 preliminary\JJ\1740 findings\NNS\7951464 from\IN\1740 the\DT\1740 Italian\JJ\1740 randomised\VBN\278117 trial\NN\786195 among\IN\1740 hysterectomised\JJ\1740 women\NNS\9605289 .\.\1740
D013629_D001943 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Tamoxifen</e1>\NNP\2714883 is\VBZ\836236 a\DT\13649268 candidate\NN\10450303 chemopreventive\JJ\1740 agent\NN\7347 in\IN\13603305 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 although\IN\1740 the\DT\1740 drug\NN\14778436 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 endometrial\JJ\1740 cancer\NN\14239425 .\.\1740
D013629_D001943 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 October\NNP\15209706 ,\,\1740 1992\CD\1740 ,\,\1740 we\PRP\1740 started\VBD\2009433 a\DT\13649268 double-blind\JJ\1740 placebo-controlled\JJ\1740 ,\,\1740 randomised\VBD\278117 trial\NN\786195 of\IN\1740 <e1>tamoxifen</e1>\NN\2714883 in\IN\13603305 women\NNS\9605289 (\-LRB-\1740 mainly\RB\1740 in\IN\13603305 Italy\NNP\1740 )\-RRB-\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 have\VB\2108377 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 and\CC\1740 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 hysterectomy\NN\393369 .\.\1740
D013629_D001943 NONE There\EX\27167 is\VBZ\836236 no\DT\7204911 difference\NN\4723816 in\IN\13603305 <e2>breast-cancer</e2>\NN\1740 frequency\NN\15286249 between\IN\1740 the\DT\1740 placebo\NN\3740161 (\-LRB-\1740 22\CD\13745420 cases\NNS\7283608 )\-RRB-\1740 and\CC\1740 <e1>tamoxifen</e1>\NN\2714883 (\-LRB-\1740 19\CD\13745420 )\-RRB-\1740 arms\NNS\3575240 .\.\1740
D013629_D001943 NONE There\EX\27167 is\VBZ\836236 a\DT\13649268 statistically\RB\1740 significant\JJ\1740 reduction\NN\351485 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 among\IN\1740 women\NNS\9605289 receiving\VBG\2210855 <e1>tamoxifen</e1>\NN\2714883 who\WP\8299493 also\RB\1740 used\VBD\1156834 hormone-replacement\JJ\1740 therapy\NN\657604 during\IN\1740 the\DT\1740 trial\NN\786195 :\:\1740 among\IN\1740 390\CD\1740 women\NNS\9605289 on\IN\1740 such\JJ\1740 therapy\NN\657604 and\CC\1740 allocated\VBN\2228698 to\TO\1740 placebo\VB\1740 ,\,\1740 we\PRP\1740 found\VBD\2426171 eight\CD\13741022 cases\NNS\7283608 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 compared\VBN\644583 with\IN\1740 one\CD\13741022 case\NN\7283608 among\IN\1740 362\CD\1740 women\NNS\9605289 allocated\VBN\2228698 to\IN\1740 tamoxifen\NN\2714883 .\.\1740
D013629_D001943 NONE There\EX\27167 is\VBZ\836236 a\DT\13649268 statistically\RB\1740 significant\JJ\1740 reduction\NN\351485 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 among\IN\1740 women\NNS\9605289 receiving\VBG\2210855 <e1>tamoxifen</e1>\NN\2714883 who\WP\8299493 also\RB\1740 used\VBD\1156834 hormone-replacement\JJ\1740 therapy\NN\657604 during\IN\1740 the\DT\1740 trial\NN\786195 :\:\1740 among\IN\1740 390\CD\1740 women\NNS\9605289 on\IN\1740 such\JJ\1740 therapy\NN\657604 and\CC\1740 allocated\VBN\2228698 to\TO\1740 placebo\VB\1740 ,\,\1740 we\PRP\1740 found\VBD\2426171 eight\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 compared\VBN\644583 with\IN\1740 one\CD\13741022 case\NN\7283608 among\IN\1740 362\CD\1740 women\NNS\9605289 allocated\VBN\2228698 to\IN\1740 tamoxifen\NN\2714883 .\.\1740
D013629_D001943 NONE There\EX\27167 is\VBZ\836236 a\DT\13649268 statistically\RB\1740 significant\JJ\1740 reduction\NN\351485 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 among\IN\1740 women\NNS\9605289 receiving\VBG\2210855 tamoxifen\NN\2714883 who\WP\8299493 also\RB\1740 used\VBD\1156834 hormone-replacement\JJ\1740 therapy\NN\657604 during\IN\1740 the\DT\1740 trial\NN\786195 :\:\1740 among\IN\1740 390\CD\1740 women\NNS\9605289 on\IN\1740 such\JJ\1740 therapy\NN\657604 and\CC\1740 allocated\VBN\2228698 to\TO\1740 placebo\VB\1740 ,\,\1740 we\PRP\1740 found\VBD\2426171 eight\CD\13741022 cases\NNS\7283608 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 compared\VBN\644583 with\IN\1740 one\CD\13741022 case\NN\7283608 among\IN\1740 362\CD\1740 women\NNS\9605289 allocated\VBN\2228698 to\IN\1740 <e1>tamoxifen</e1>\NN\2714883 .\.\1740
D013629_D001943 NONE There\EX\27167 is\VBZ\836236 a\DT\13649268 statistically\RB\1740 significant\JJ\1740 reduction\NN\351485 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 among\IN\1740 women\NNS\9605289 receiving\VBG\2210855 tamoxifen\NN\2714883 who\WP\8299493 also\RB\1740 used\VBD\1156834 hormone-replacement\JJ\1740 therapy\NN\657604 during\IN\1740 the\DT\1740 trial\NN\786195 :\:\1740 among\IN\1740 390\CD\1740 women\NNS\9605289 on\IN\1740 such\JJ\1740 therapy\NN\657604 and\CC\1740 allocated\VBN\2228698 to\TO\1740 placebo\VB\1740 ,\,\1740 we\PRP\1740 found\VBD\2426171 eight\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 compared\VBN\644583 with\IN\1740 one\CD\13741022 case\NN\7283608 among\IN\1740 362\CD\1740 women\NNS\9605289 allocated\VBN\2228698 to\IN\1740 <e1>tamoxifen</e1>\NN\2714883 .\.\1740
D013629_D001943 NONE INTERPRETATION\NN\5926676 :\:\1740 Although\IN\1740 this\DT\1740 preliminary\JJ\1740 analysis\NN\633864 has\VBZ\2108377 low\JJ\1740 power\NN\4723816 ,\,\1740 in\IN\13603305 this\DT\1740 cohort\NN\8184861 of\IN\1740 women\NNS\9605289 at\IN\14622893 low-to-normal\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 the\DT\1740 postulated\VBN\756338 protective\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>tamoxifen</e1>\NN\2714883 are\VBP\836236 not\RB\1740 yet\RB\1740 apparent\JJ\1740 .\.\1740
D013629_D016889 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Tamoxifen</e1>\NNP\2714883 is\VBZ\836236 a\DT\13649268 candidate\NN\10450303 chemopreventive\JJ\1740 agent\NN\7347 in\IN\13603305 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 although\IN\1740 the\DT\1740 drug\NN\14778436 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>endometrial\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D013629_D014652 CID Compared\VBN\644583 with\IN\1740 the\DT\1740 placebo\NN\3740161 group\NN\2137 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significantly\RB\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>vascular\JJ\1740 events</e2>\NNS\23100 and\CC\1740 hypertriglyceridaemia\NN\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 <e1>tamoxifen</e1>\NN\2714883 .\.\1740
D013629_D015228 CID Compared\VBN\644583 with\IN\1740 the\DT\1740 placebo\NN\3740161 group\NN\2137 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significantly\RB\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 vascular\JJ\1740 events\NNS\23100 and\CC\1740 <e2>hypertriglyceridaemia</e2>\NN\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 <e1>tamoxifen</e1>\NN\2714883 .\.\1740
11077455
D020888_D014786 CID Electro-oculography\NN\1740 ,\,\1740 electroretinography\NN\1740 ,\,\1740 visual\JJ\1740 evoked\VBN\1617192 potentials\NNS\14481929 ,\,\1740 and\CC\1740 multifocal\JJ\1740 electroretinography\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>vigabatrin-attributed</e1>\JJ\1740 <e2>visual\JJ\1740 field\NN\8673395 constriction</e2>\NN\5071027 .\.\1740
D020888_D014786 CID PURPOSE\NNP\5980875 :\:\1740 Symptomatic\JJ\1740 <e2>visual\JJ\1740 field\NN\8673395 constriction</e2>\NN\5071027 thought\VBD\670261 to\TO\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 <e1>vigabatrin</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
D020888_D014786 CID The\DT\1740 current\JJ\1740 study\NN\635850 investigated\VBD\644583 the\DT\1740 visual\JJ\1740 fields\NNS\8673395 and\CC\1740 visual\JJ\1740 electrophysiology\NN\1740 of\IN\1740 eight\CD\13741022 patients\NNS\9898892 with\IN\1740 known\JJ\1740 <e1>vigabatrin-attributed</e1>\JJ\1740 <e2>visual\JJ\1740 field\NN\8673395 loss</e2>\NN\13252973 ,\,\1740 three\CD\13741022 of\IN\1740 whom\WP\1740 were\VBD\836236 reported\VBN\831651 previously\RB\1740 .\.\1740
D020888_D014786 CID CONCLUSION\NN\5837957 :\:\1740 Marked\JJ\1740 <e2>visual\JJ\1740 field\NN\8673395 constriction</e2>\NN\5071027 appears\VBZ\2604760 to\TO\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 <e1>vigabatrin</e1>\NN\1740 therapy\NN\657604 .\.\1740
1423339
D011433_D000647 CID <e2>Amnestic\JJ\1740 syndrome</e2>\NN\5870365 associated\VBN\628491 with\IN\1740 <e1>propranolol</e1>\NN\1740 toxicity\NN\13576101 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D011433_D064420 NONE Amnestic\JJ\1740 syndrome\NN\5870365 associated\VBN\628491 with\IN\1740 <e1>propranolol</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D011433_D064420 NONE An\DT\6697703 elderly\JJ\1740 woman\NN\9605289 developed\VBD\1753788 an\DT\6697703 Alzheimer-like\JJ\1740 subacute\NN\1740 dementia\NN\14395018 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 <e1>propranolol</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D011433_D000544 NONE An\DT\6697703 elderly\JJ\1740 woman\NN\9605289 developed\VBD\1753788 an\DT\6697703 <e2>Alzheimer-like</e2>\JJ\1740 subacute\NN\1740 dementia\NN\14395018 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 <e1>propranolol</e1>\NN\1740 toxicity\NN\13576101 .\.\1740
D011433_D003704 NONE An\DT\6697703 elderly\JJ\1740 woman\NN\9605289 developed\VBD\1753788 an\DT\6697703 Alzheimer-like\JJ\1740 subacute\NN\1740 <e2>dementia</e2>\NN\14395018 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 <e1>propranolol</e1>\NN\1740 toxicity\NN\13576101 .\.\1740
7710775
D008315_D002545 CID Time\NN\7308889 dependence\NN\24720 of\IN\1740 plasma\NN\5398023 <e1>malondialdehyde</e1>\NN\1740 ,\,\1740 oxypurines\NNS\1740 ,\,\1740 and\CC\1740 nucleosides\VBZ\1740 during\IN\1740 incomplete\JJ\1740 <e2>cerebral\JJ\1740 ischemia</e2>\NN\14195315 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
-1_D002545 NONE Time\NN\7308889 dependence\NN\24720 of\IN\1740 plasma\NN\5398023 malondialdehyde\NN\1740 ,\,\1740 <e1>oxypurines</e1>\NNS\1740 ,\,\1740 and\CC\1740 nucleosides\VBZ\1740 during\IN\1740 incomplete\JJ\1740 <e2>cerebral\JJ\1740 ischemia</e2>\NN\14195315 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D009705_D002545 NONE Time\NN\7308889 dependence\NN\24720 of\IN\1740 plasma\NN\5398023 malondialdehyde\NN\1740 ,\,\1740 oxypurines\NNS\1740 ,\,\1740 and\CC\1740 <e1>nucleosides</e1>\VBZ\1740 during\IN\1740 incomplete\JJ\1740 <e2>cerebral\JJ\1740 ischemia</e2>\NN\14195315 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
-1_D007511 NONE During\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 a\DT\13649268 time-dependent\JJ\1740 increase\NN\13576355 of\IN\1740 plasma\NN\5398023 <e1>oxypurines</e1>\NNS\1740 and\CC\1740 nucleosides\NNS\14887305 was\VBD\836236 observed\VBN\2163746 .\.\1740
-1_D007511 NONE The\DT\1740 present\JJ\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 the\DT\1740 determination\NN\43195 of\IN\1740 malondialdehyde\NN\1740 ,\,\1740 <e1>oxypurines</e1>\NNS\1740 ,\,\1740 and\CC\1740 nucleosides\VBZ\1740 in\IN\13603305 peripheral\JJ\1740 blood\NN\5397468 ,\,\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 to\TO\1740 monitor\VB\2169352 the\DT\1740 metabolic\JJ\1740 alterations\NNS\7283608 of\IN\1740 tissues\NNS\5220461 occurring\VBG\2623529 during\IN\1740 <e2>ischemic</e2>\JJ\1740 phenomena\NNS\29677 .\.\1740
D009705_D007511 NONE During\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 a\DT\13649268 time-dependent\JJ\1740 increase\NN\13576355 of\IN\1740 plasma\NN\5398023 oxypurines\NNS\1740 and\CC\1740 <e1>nucleosides</e1>\NNS\14887305 was\VBD\836236 observed\VBN\2163746 .\.\1740
D009705_D007511 NONE The\DT\1740 present\JJ\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 the\DT\1740 determination\NN\43195 of\IN\1740 malondialdehyde\NN\1740 ,\,\1740 oxypurines\NNS\1740 ,\,\1740 and\CC\1740 <e1>nucleosides</e1>\VBZ\1740 in\IN\13603305 peripheral\JJ\1740 blood\NN\5397468 ,\,\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 to\TO\1740 monitor\VB\2169352 the\DT\1740 metabolic\JJ\1740 alterations\NNS\7283608 of\IN\1740 tissues\NNS\5220461 occurring\VBG\2623529 during\IN\1740 <e2>ischemic</e2>\JJ\1740 phenomena\NNS\29677 .\.\1740
D008315_D007511 NONE Plasma\NN\5398023 <e1>malondialdehyde</e1>\NN\1740 ,\,\1740 which\WDT\1740 was\VBD\836236 present\JJ\1740 in\IN\13603305 minimal\JJ\1740 amount\NN\13329641 at\IN\14622893 zero\CD\13576982 time\NN\7308889 (\-LRB-\1740 0.058\CD\1740 mumol/liter\NN\1740 plasma\NN\5398023 ;\:\1740 SD\NN\1740 0.015\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 after\IN\1740 5\CD\13741022 min\NN\15154774 of\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 fivefold\JJ\1740 increase\NN\13576355 after\IN\1740 30\CD\13745420 min\NN\15154774 of\IN\1740 carotid\NN\1740 occlusion\NN\14081375 (\-LRB-\1740 0.298\CD\1740 mumol/liter\JJ\1740 plasma\NN\5398023 ;\:\1740 SD\NN\1740 0.078\CD\1740 )\-RRB-\1740 .\.\1740
D008315_D007511 NONE Increased\VBN\169651 plasma\NN\5398023 <e1>malondialdehyde</e1>\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 acetylsalicylate\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 hypotensive\JJ\1740 drug\NN\14778436 nitroprusside\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 ischemia\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 malondialdehyde\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D008315_D007511 NONE Increased\VBN\169651 plasma\NN\5398023 <e1>malondialdehyde</e1>\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 acetylsalicylate\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 ischemia\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 hypotensive\JJ\1740 drug\NN\14778436 nitroprusside\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 malondialdehyde\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D008315_D007511 NONE Increased\VBN\169651 plasma\NN\5398023 malondialdehyde\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 acetylsalicylate\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 hypotensive\JJ\1740 drug\NN\14778436 nitroprusside\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 ischemia\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 <e1>malondialdehyde</e1>\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D008315_D007511 NONE Increased\VBN\169651 plasma\NN\5398023 malondialdehyde\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 acetylsalicylate\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 ischemia\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 hypotensive\JJ\1740 drug\NN\14778436 nitroprusside\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 <e1>malondialdehyde</e1>\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D008315_D007511 NONE The\DT\1740 present\JJ\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 the\DT\1740 determination\NN\43195 of\IN\1740 <e1>malondialdehyde</e1>\NN\1740 ,\,\1740 oxypurines\NNS\1740 ,\,\1740 and\CC\1740 nucleosides\VBZ\1740 in\IN\13603305 peripheral\JJ\1740 blood\NN\5397468 ,\,\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 to\TO\1740 monitor\VB\2169352 the\DT\1740 metabolic\JJ\1740 alterations\NNS\7283608 of\IN\1740 tissues\NNS\5220461 occurring\VBG\2623529 during\IN\1740 <e2>ischemic</e2>\JJ\1740 phenomena\NNS\29677 .\.\1740
D008315_D007022 NONE Increased\VBN\169651 plasma\NN\5398023 <e1>malondialdehyde</e1>\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 acetylsalicylate\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 ischemia\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 drug\NN\14778436 nitroprusside\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 ischemia\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 malondialdehyde\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D008315_D007022 NONE Increased\VBN\169651 plasma\NN\5398023 malondialdehyde\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 acetylsalicylate\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 ischemia\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 drug\NN\14778436 nitroprusside\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 ischemia\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 <e1>malondialdehyde</e1>\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D001241_D007511 NONE Increased\VBN\169651 plasma\NN\5398023 malondialdehyde\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 <e1>acetylsalicylate</e1>\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 hypotensive\JJ\1740 drug\NN\14778436 nitroprusside\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 ischemia\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 malondialdehyde\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D001241_D007511 NONE Increased\VBN\169651 plasma\NN\5398023 malondialdehyde\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 <e1>acetylsalicylate</e1>\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 ischemia\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 hypotensive\JJ\1740 drug\NN\14778436 nitroprusside\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 malondialdehyde\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D001241_D007022 NONE Increased\VBN\169651 plasma\NN\5398023 malondialdehyde\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 <e1>acetylsalicylate</e1>\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 ischemia\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 drug\NN\14778436 nitroprusside\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 ischemia\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 malondialdehyde\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D009599_D007511 NONE Increased\VBN\169651 plasma\NN\5398023 malondialdehyde\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 acetylsalicylate\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 hypotensive\JJ\1740 drug\NN\14778436 <e1>nitroprusside</e1>\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 ischemia\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 malondialdehyde\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D009599_D007511 NONE Increased\VBN\169651 plasma\NN\5398023 malondialdehyde\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 acetylsalicylate\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 ischemia\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 hypotensive\JJ\1740 drug\NN\14778436 <e1>nitroprusside</e1>\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 malondialdehyde\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
D009599_D007022 NONE Increased\VBN\169651 plasma\NN\5398023 malondialdehyde\NN\1740 was\VBD\836236 also\RB\1740 recorded\VBN\2225492 in\IN\13603305 two\CD\13741022 other\JJ\1740 groups\NNS\2137 of\IN\1740 animals\NNS\4475 subjected\VBN\137313 to\IN\1740 the\DT\1740 same\JJ\1740 experimental\JJ\1740 model\NN\5888929 ,\,\1740 one\CD\13741022 receiving\VBG\2210855 20\CD\13745420 mg/kg\NN\1740 b.w\NN\1740 .\.\1740 of\IN\1740 the\DT\1740 cyclooxygenase\NN\14732946 inhibitor\NN\20090 acetylsalicylate\NN\1740 intravenously\RB\1740 immediately\RB\1740 before\IN\1740 ischemia\NN\14195315 ,\,\1740 the\DT\1740 other\JJ\1740 receiving\VBG\2210855 650\CD\1740 micrograms/kg\NNS\1740 b.w\JJ\1740 .\.\1740 of\IN\1740 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 drug\NN\14778436 <e1>nitroprusside</e1>\NN\1740 at\IN\14622893 a\DT\13649268 flow\NN\7311115 rate\NN\13815152 of\IN\1740 103\CD\1740 microliters/min\NN\1740 intravenously\RB\1740 during\IN\1740 ischemia\NN\14195315 ,\,\1740 although\IN\1740 in\IN\13603305 this\DT\1740 latter\JJ\1740 group\NN\2137 malondialdehyde\NN\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 .\.\1740
8888541
C047426_D020230 CID <e2>Serotonin\NN\14807737 syndrome</e2>\NN\5870365 from\IN\1740 <e1>venlafaxine-tranylcypromine</e1>\NN\1740 interaction\NN\37396 .\.\1740
C047426_D020230 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 <e1>venlafaxine-MAOI</e1>\JJ\1740 interaction\NN\37396 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 the\DT\1740 <e2>serotonin\NN\14807737 syndrome</e2>\NN\5870365 in\IN\13603305 a\DT\13649268 23-y-old\JJ\1740 male\NN\15388 who\WP\8299493 was\VBD\836236 taking\VBG\2367363 tranylcypromine\NN\3783017 for\IN\1740 depression\NN\14373582 .\.\1740
D014191_D020230 CID <e2>Serotonin\NN\14807737 syndrome</e2>\NN\5870365 from\IN\1740 <e1>venlafaxine-tranylcypromine</e1>\NN\1740 interaction\NN\37396 .\.\1740
D014191_D020230 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 venlafaxine-MAOI\JJ\1740 interaction\NN\37396 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 the\DT\1740 <e2>serotonin\NN\14807737 syndrome</e2>\NN\5870365 in\IN\13603305 a\DT\13649268 23-y-old\JJ\1740 male\NN\15388 who\WP\8299493 was\VBD\836236 taking\VBG\2367363 <e1>tranylcypromine</e1>\NN\3783017 for\IN\1740 depression\NN\14373582 .\.\1740
D012701_D009127 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 <e1>serotonin</e1>\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 serotonin\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 ,\,\1740 salivation\NN\13553916 ,\,\1740 confusion\NN\13972797 ,\,\1740 agitation\NN\14373582 and\CC\1740 hyperthermia\NN\14034177 .\.\1740
D012701_D009127 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 serotonin\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 <e1>serotonin</e1>\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 ,\,\1740 salivation\NN\13553916 ,\,\1740 confusion\NN\13972797 ,\,\1740 agitation\NN\14373582 and\CC\1740 hyperthermia\NN\14034177 .\.\1740
D012701_D012798 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 <e1>serotonin</e1>\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 serotonin\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 muscle\NN\5289601 rigidity\NN\5023233 ,\,\1740 <e2>salivation</e2>\NN\13553916 ,\,\1740 confusion\NN\13972797 ,\,\1740 agitation\NN\14373582 and\CC\1740 hyperthermia\NN\14034177 .\.\1740
D012701_D012798 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 serotonin\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 <e1>serotonin</e1>\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 muscle\NN\5289601 rigidity\NN\5023233 ,\,\1740 <e2>salivation</e2>\NN\13553916 ,\,\1740 confusion\NN\13972797 ,\,\1740 agitation\NN\14373582 and\CC\1740 hyperthermia\NN\14034177 .\.\1740
D012701_D003221 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 <e1>serotonin</e1>\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 serotonin\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 muscle\NN\5289601 rigidity\NN\5023233 ,\,\1740 salivation\NN\13553916 ,\,\1740 <e2>confusion</e2>\NN\13972797 ,\,\1740 agitation\NN\14373582 and\CC\1740 hyperthermia\NN\14034177 .\.\1740
D012701_D003221 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 serotonin\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 <e1>serotonin</e1>\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 muscle\NN\5289601 rigidity\NN\5023233 ,\,\1740 salivation\NN\13553916 ,\,\1740 <e2>confusion</e2>\NN\13972797 ,\,\1740 agitation\NN\14373582 and\CC\1740 hyperthermia\NN\14034177 .\.\1740
D012701_D011595 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 <e1>serotonin</e1>\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 serotonin\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 muscle\NN\5289601 rigidity\NN\5023233 ,\,\1740 salivation\NN\13553916 ,\,\1740 confusion\NN\13972797 ,\,\1740 <e2>agitation</e2>\NN\14373582 and\CC\1740 hyperthermia\NN\14034177 .\.\1740
D012701_D011595 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 serotonin\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 <e1>serotonin</e1>\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 muscle\NN\5289601 rigidity\NN\5023233 ,\,\1740 salivation\NN\13553916 ,\,\1740 confusion\NN\13972797 ,\,\1740 <e2>agitation</e2>\NN\14373582 and\CC\1740 hyperthermia\NN\14034177 .\.\1740
D012701_D005334 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 <e1>serotonin</e1>\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 serotonin\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 muscle\NN\5289601 rigidity\NN\5023233 ,\,\1740 salivation\NN\13553916 ,\,\1740 confusion\NN\13972797 ,\,\1740 agitation\NN\14373582 and\CC\1740 <e2>hyperthermia</e2>\NN\14034177 .\.\1740
D012701_D005334 NONE Excessive\JJ\1740 stimulation\NN\242808 of\IN\1740 serotonin\NN\14807737 5HT1A\NN\1740 receptors\NNS\5225602 causes\VBZ\1617192 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 <e1>serotonin</e1>\NN\14807737 excess\NN\5119367 that\WDT\1740 consists\VBZ\2603699 of\IN\1740 shivering\NN\14299637 ,\,\1740 muscle\NN\5289601 rigidity\NN\5023233 ,\,\1740 salivation\NN\13553916 ,\,\1740 confusion\NN\13972797 ,\,\1740 agitation\NN\14373582 and\CC\1740 <e2>hyperthermia</e2>\NN\14034177 .\.\1740
C047426_D003866 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 <e1>venlafaxine-MAOI</e1>\JJ\1740 interaction\NN\37396 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 the\DT\1740 serotonin\NN\14807737 syndrome\NN\5870365 in\IN\13603305 a\DT\13649268 23-y-old\JJ\1740 male\NN\15388 who\WP\8299493 was\VBD\836236 taking\VBG\2367363 tranylcypromine\NN\3783017 for\IN\1740 <e2>depression</e2>\NN\14373582 .\.\1740
D014191_D003866 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 venlafaxine-MAOI\JJ\1740 interaction\NN\37396 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 the\DT\1740 serotonin\NN\14807737 syndrome\NN\5870365 in\IN\13603305 a\DT\13649268 23-y-old\JJ\1740 male\NN\15388 who\WP\8299493 was\VBD\836236 taking\VBG\2367363 <e1>tranylcypromine</e1>\NN\3783017 for\IN\1740 <e2>depression</e2>\NN\14373582 .\.\1740
D003975_D009127 NONE Vital\JJ\1740 signs\NNS\6643763 were\VBD\836236 :\:\1740 blood\NN\5397468 pressure\NN\11419404 120/67\VB\1740 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 heart\NN\5919034 rate\NN\13815152 127/min\CD\1740 ,\,\1740 respiratory\JJ\1740 rate\NN\13815152 28/min\NN\1740 ,\,\1740 and\CC\1740 temperature\NN\13575869 97\CD\1740 F.\NN\1740 After\IN\1740 180\CD\1740 mg\NN\13717155 of\IN\1740 <e1>diazepam</e1>\NNS\2830852 i.v.\NN\1740 he\PRP\14622893 remained\VBD\2604760 tremulous\JJ\1740 with\IN\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 and\CC\1740 clenched\JJ\1740 jaws\NNS\5269901 .\.\1740
7282516
D004317_D009202 CID Dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 in\IN\13603305 <e1>doxorubicin</e1>\NN\2716866 <e2>cardiomyopathy</e2>\IN\14103288 .\.\1740
D004317_D009202 CID The\DT\1740 <e2>cardiomyopathy</e2>\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 anticancer\NN\1740 drug\NN\14778436 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DXR\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Adriamycin\NN\1740 )\-RRB-\1740 provides\VBZ\2199590 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 analyze\VB\78760 dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 during\IN\1740 development\NN\248977 of\IN\1740 myocardial\JJ\1740 disease\NN\14061805 .\.\1740
D004317_D009202 CID The\DT\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 <e2>CM</e2>\NN\13649268 )\-RRB-\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 anticancer\NN\1740 drug\NN\14778436 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DXR\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Adriamycin\NN\1740 )\-RRB-\1740 provides\VBZ\2199590 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 analyze\VB\78760 dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 during\IN\1740 development\NN\248977 of\IN\1740 myocardial\JJ\1740 disease\NN\14061805 .\.\1740
D004317_D009202 CID The\DT\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 anticancer\NN\1740 drug\NN\14778436 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DXR\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Adriamycin\NN\1740 )\-RRB-\1740 provides\VBZ\2199590 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 analyze\VB\78760 dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 during\IN\1740 development\NN\248977 of\IN\1740 <e2>myocardial\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D004317_D009202 CID The\DT\1740 <e2>cardiomyopathy</e2>\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 anticancer\NN\1740 drug\NN\14778436 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DXR</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Adriamycin\NN\1740 )\-RRB-\1740 provides\VBZ\2199590 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 analyze\VB\78760 dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 during\IN\1740 development\NN\248977 of\IN\1740 myocardial\JJ\1740 disease\NN\14061805 .\.\1740
D004317_D009202 CID The\DT\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 <e2>CM</e2>\NN\13649268 )\-RRB-\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 anticancer\NN\1740 drug\NN\14778436 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DXR</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Adriamycin\NN\1740 )\-RRB-\1740 provides\VBZ\2199590 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 analyze\VB\78760 dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 during\IN\1740 development\NN\248977 of\IN\1740 myocardial\JJ\1740 disease\NN\14061805 .\.\1740
D004317_D009202 CID The\DT\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 anticancer\NN\1740 drug\NN\14778436 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DXR</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Adriamycin\NN\1740 )\-RRB-\1740 provides\VBZ\2199590 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 analyze\VB\78760 dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 during\IN\1740 development\NN\248977 of\IN\1740 <e2>myocardial\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D004317_D009202 CID The\DT\1740 <e2>cardiomyopathy</e2>\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 anticancer\NN\1740 drug\NN\14778436 doxorubicin\NN\2716866 (\-LRB-\1740 DXR\NN\1740 )\-RRB-\1740 (\-LRB-\1740 <e1>Adriamycin</e1>\NN\1740 )\-RRB-\1740 provides\VBZ\2199590 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 analyze\VB\78760 dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 during\IN\1740 development\NN\248977 of\IN\1740 myocardial\JJ\1740 disease\NN\14061805 .\.\1740
D004317_D009202 CID The\DT\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 <e2>CM</e2>\NN\13649268 )\-RRB-\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 anticancer\NN\1740 drug\NN\14778436 doxorubicin\NN\2716866 (\-LRB-\1740 DXR\NN\1740 )\-RRB-\1740 (\-LRB-\1740 <e1>Adriamycin</e1>\NN\1740 )\-RRB-\1740 provides\VBZ\2199590 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 analyze\VB\78760 dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 during\IN\1740 development\NN\248977 of\IN\1740 myocardial\JJ\1740 disease\NN\14061805 .\.\1740
D004317_D009202 CID The\DT\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 anticancer\NN\1740 drug\NN\14778436 doxorubicin\NN\2716866 (\-LRB-\1740 DXR\NN\1740 )\-RRB-\1740 (\-LRB-\1740 <e1>Adriamycin</e1>\NN\1740 )\-RRB-\1740 provides\VBZ\2199590 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 analyze\VB\78760 dose-effect\JJ\1740 and\CC\1740 structure-function\JJ\1740 relationships\NNS\31921 during\IN\1740 development\NN\248977 of\IN\1740 <e2>myocardial\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D004317_D009202 CID In\IN\13603305 <e2><e1>DXR-CM</e1></e2>\NN\1740 myocardial\JJ\1740 damage\NN\7296428 is\VBZ\836236 proportional\JJ\1740 to\TO\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 cytotoxic\JJ\1740 insult\NN\6714976 (\-LRB-\1740 DXR\NN\1740 dose\NN\3740161 )\-RRB-\1740 while\IN\15122231 myocardial\JJ\1740 function\NN\13783581 is\VBZ\836236 preserved\VBN\2681795 until\IN\1740 a\DT\13649268 critical\JJ\1740 dose\NN\3740161 or\CC\3541091 degree\NN\4916342 of\IN\1740 damage\NN\7296428 is\VBZ\836236 reached\VBN\2005948 ,\,\1740 after\IN\1740 which\WDT\1740 myocardial\JJ\1740 performance\NN\6619065 deteriorates\NNS\1740 rapidly\RB\1740 .\.\1740
D004317_D009202 CID In\IN\13603305 <e1>DXR-CM</e1>\NN\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 is\VBZ\836236 proportional\JJ\1740 to\TO\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 cytotoxic\JJ\1740 insult\NN\6714976 (\-LRB-\1740 DXR\NN\1740 dose\NN\3740161 )\-RRB-\1740 while\IN\15122231 myocardial\JJ\1740 function\NN\13783581 is\VBZ\836236 preserved\VBN\2681795 until\IN\1740 a\DT\13649268 critical\JJ\1740 dose\NN\3740161 or\CC\3541091 degree\NN\4916342 of\IN\1740 damage\NN\7296428 is\VBZ\836236 reached\VBN\2005948 ,\,\1740 after\IN\1740 which\WDT\1740 myocardial\JJ\1740 performance\NN\6619065 deteriorates\NNS\1740 rapidly\RB\1740 .\.\1740
D004317_D009202 CID In\IN\13603305 <e2>DXR-CM</e2>\NN\1740 myocardial\JJ\1740 damage\NN\7296428 is\VBZ\836236 proportional\JJ\1740 to\TO\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 cytotoxic\JJ\1740 insult\NN\6714976 (\-LRB-\1740 <e1>DXR</e1>\NN\1740 dose\NN\3740161 )\-RRB-\1740 while\IN\15122231 myocardial\JJ\1740 function\NN\13783581 is\VBZ\836236 preserved\VBN\2681795 until\IN\1740 a\DT\13649268 critical\JJ\1740 dose\NN\3740161 or\CC\3541091 degree\NN\4916342 of\IN\1740 damage\NN\7296428 is\VBZ\836236 reached\VBN\2005948 ,\,\1740 after\IN\1740 which\WDT\1740 myocardial\JJ\1740 performance\NN\6619065 deteriorates\NNS\1740 rapidly\RB\1740 .\.\1740
D004317_D009202 CID In\IN\13603305 DXR-CM\NN\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 is\VBZ\836236 proportional\JJ\1740 to\TO\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 cytotoxic\JJ\1740 insult\NN\6714976 (\-LRB-\1740 <e1>DXR</e1>\NN\1740 dose\NN\3740161 )\-RRB-\1740 while\IN\15122231 myocardial\JJ\1740 function\NN\13783581 is\VBZ\836236 preserved\VBN\2681795 until\IN\1740 a\DT\13649268 critical\JJ\1740 dose\NN\3740161 or\CC\3541091 degree\NN\4916342 of\IN\1740 damage\NN\7296428 is\VBZ\836236 reached\VBN\2005948 ,\,\1740 after\IN\1740 which\WDT\1740 myocardial\JJ\1740 performance\NN\6619065 deteriorates\NNS\1740 rapidly\RB\1740 .\.\1740
11838826
D018967_D006966 CID Treatment\NN\654885 of\IN\1740 <e1>risperidone-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 with\IN\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 in\IN\13603305 children\NNS\9622049 .\.\1740
D018967_D006966 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Risperidone</e1>\NN\1740 ,\,\1740 a\DT\13649268 potent\JJ\1740 antagonist\NN\7846 of\IN\1740 both\CC\1740 serotonergic\NN\1740 (\-LRB-\1740 5HT2A\NN\1740 )\-RRB-\1740 and\CC\1740 dopaminergic\JJ\1740 D2\NN\1740 receptors\NNS\5225602 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 in\IN\13603305 adults\NNS\7846 and\CC\1740 children\NNS\9622049 .\.\1740
D018967_D006966 CID We\PRP\1740 report\VBP\831651 the\DT\1740 successful\JJ\1740 treatment\NN\654885 of\IN\1740 <e1>risperidone-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 with\IN\1740 cabergoline\NN\1740 in\IN\13603305 youth\NN\9622049 .\.\1740
D018967_D006966 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 undertook\VBD\1641914 a\DT\13649268 retrospective\JJ\1740 case\NN\7283608 review\NN\5733583 of\IN\1740 four\CD\13741022 children\NNS\9622049 with\IN\1740 <e1>risperidone-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 treated\VBN\2376958 with\IN\1740 cabergoline\NN\1740 .\.\1740
D018967_D006966 CID CONCLUSIONS\NNS\5837957 :\:\1740 Cabergoline\NNP\1740 may\MD\15209706 be\VB\836236 useful\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e1>risperidone-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 in\IN\13603305 youth\NN\9622049 ;\:\1740 however\RB\1740 ,\,\1740 further\JJ\1740 research\NN\633864 is\VBZ\836236 needed\VBN\2604760 .\.\1740
D004298_D006966 NONE Treatment\NN\654885 of\IN\1740 risperidone-induced\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 with\IN\1740 a\DT\13649268 <e1>dopamine</e1>\NN\14807737 agonist\NN\9613191 in\IN\13603305 children\NNS\9622049 .\.\1740
C047047_D006966 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 successful\JJ\1740 treatment\NN\654885 of\IN\1740 risperidone-induced\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 with\IN\1740 <e1>cabergoline</e1>\NN\1740 in\IN\13603305 youth\NN\9622049 .\.\1740
C047047_D006966 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 undertook\VBD\1641914 a\DT\13649268 retrospective\JJ\1740 case\NN\7283608 review\NN\5733583 of\IN\1740 four\CD\13741022 children\NNS\9622049 with\IN\1740 risperidone-induced\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 treated\VBN\2376958 with\IN\1740 <e1>cabergoline</e1>\NN\1740 .\.\1740
C047047_D006966 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Cabergoline</e1>\NNP\1740 may\MD\15209706 be\VB\836236 useful\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 risperidone-induced\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 in\IN\13603305 youth\NN\9622049 ;\:\1740 however\RB\1740 ,\,\1740 further\JJ\1740 research\NN\633864 is\VBZ\836236 needed\VBN\2604760 .\.\1740
D018967_D001523 NONE RESULTS\NNS\34213 :\:\1740 Four\CD\13741022 males\NNS\15388 (\-LRB-\1740 age\NN\4916342 6\CD\13741022 -\SYM\1740 11\CD\13745420 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 <e2>Mental\NNP\1740 Disorders</e2>\NNPS\14034177 (\-LRB-\1740 fourth\JJ\1740 edition\NN\6590210 )\-RRB-\1740 bipolar\JJ\1740 disorder\NN\14034177 or\CC\3541091 psychoses\NNS\14380140 ,\,\1740 with\IN\1740 <e1>risperidone-induced</e1>\JJ\1740 elevations\NNS\7445480 in\IN\13603305 serum\NN\5397468 prolactin\NN\5410315 levels\NNS\4916342 (\-LRB-\1740 57.5\CD\1740 -\SYM\1740 129\CD\1740 ng/mL\NN\1740 ,\,\1740 normal\JJ\1740 5\CD\13741022 -\SYM\1740 15\CD\13745420 ng/mL\NN\1740 )\-RRB-\1740 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 cabergoline\NN\1740 (\-LRB-\1740 mean\NN\6021761 dose\NN\3740161 2.13\CD\1740 +/-\CC\1740 0.09\CD\1740 mg/week\NN\1740 )\-RRB-\1740 .\.\1740
D018967_D001714 NONE RESULTS\NNS\34213 :\:\1740 Four\CD\13741022 males\NNS\15388 (\-LRB-\1740 age\NN\4916342 6\CD\13741022 -\SYM\1740 11\CD\13745420 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 (\-LRB-\1740 fourth\JJ\1740 edition\NN\6590210 )\-RRB-\1740 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 or\CC\3541091 psychoses\NNS\14380140 ,\,\1740 with\IN\1740 <e1>risperidone-induced</e1>\JJ\1740 elevations\NNS\7445480 in\IN\13603305 serum\NN\5397468 prolactin\NN\5410315 levels\NNS\4916342 (\-LRB-\1740 57.5\CD\1740 -\SYM\1740 129\CD\1740 ng/mL\NN\1740 ,\,\1740 normal\JJ\1740 5\CD\13741022 -\SYM\1740 15\CD\13745420 ng/mL\NN\1740 )\-RRB-\1740 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 cabergoline\NN\1740 (\-LRB-\1740 mean\NN\6021761 dose\NN\3740161 2.13\CD\1740 +/-\CC\1740 0.09\CD\1740 mg/week\NN\1740 )\-RRB-\1740 .\.\1740
D018967_D011605 NONE RESULTS\NNS\34213 :\:\1740 Four\CD\13741022 males\NNS\15388 (\-LRB-\1740 age\NN\4916342 6\CD\13741022 -\SYM\1740 11\CD\13745420 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 (\-LRB-\1740 fourth\JJ\1740 edition\NN\6590210 )\-RRB-\1740 bipolar\JJ\1740 disorder\NN\14034177 or\CC\3541091 <e2>psychoses</e2>\NNS\14380140 ,\,\1740 with\IN\1740 <e1>risperidone-induced</e1>\JJ\1740 elevations\NNS\7445480 in\IN\13603305 serum\NN\5397468 prolactin\NN\5410315 levels\NNS\4916342 (\-LRB-\1740 57.5\CD\1740 -\SYM\1740 129\CD\1740 ng/mL\NN\1740 ,\,\1740 normal\JJ\1740 5\CD\13741022 -\SYM\1740 15\CD\13745420 ng/mL\NN\1740 )\-RRB-\1740 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 cabergoline\NN\1740 (\-LRB-\1740 mean\NN\6021761 dose\NN\3740161 2.13\CD\1740 +/-\CC\1740 0.09\CD\1740 mg/week\NN\1740 )\-RRB-\1740 .\.\1740
C047047_D001523 NONE RESULTS\NNS\34213 :\:\1740 Four\CD\13741022 males\NNS\15388 (\-LRB-\1740 age\NN\4916342 6\CD\13741022 -\SYM\1740 11\CD\13745420 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 <e2>Mental\NNP\1740 Disorders</e2>\NNPS\14034177 (\-LRB-\1740 fourth\JJ\1740 edition\NN\6590210 )\-RRB-\1740 bipolar\JJ\1740 disorder\NN\14034177 or\CC\3541091 psychoses\NNS\14380140 ,\,\1740 with\IN\1740 risperidone-induced\JJ\1740 elevations\NNS\7445480 in\IN\13603305 serum\NN\5397468 prolactin\NN\5410315 levels\NNS\4916342 (\-LRB-\1740 57.5\CD\1740 -\SYM\1740 129\CD\1740 ng/mL\NN\1740 ,\,\1740 normal\JJ\1740 5\CD\13741022 -\SYM\1740 15\CD\13745420 ng/mL\NN\1740 )\-RRB-\1740 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>cabergoline</e1>\NN\1740 (\-LRB-\1740 mean\NN\6021761 dose\NN\3740161 2.13\CD\1740 +/-\CC\1740 0.09\CD\1740 mg/week\NN\1740 )\-RRB-\1740 .\.\1740
C047047_D001714 NONE RESULTS\NNS\34213 :\:\1740 Four\CD\13741022 males\NNS\15388 (\-LRB-\1740 age\NN\4916342 6\CD\13741022 -\SYM\1740 11\CD\13745420 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 (\-LRB-\1740 fourth\JJ\1740 edition\NN\6590210 )\-RRB-\1740 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 or\CC\3541091 psychoses\NNS\14380140 ,\,\1740 with\IN\1740 risperidone-induced\JJ\1740 elevations\NNS\7445480 in\IN\13603305 serum\NN\5397468 prolactin\NN\5410315 levels\NNS\4916342 (\-LRB-\1740 57.5\CD\1740 -\SYM\1740 129\CD\1740 ng/mL\NN\1740 ,\,\1740 normal\JJ\1740 5\CD\13741022 -\SYM\1740 15\CD\13745420 ng/mL\NN\1740 )\-RRB-\1740 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>cabergoline</e1>\NN\1740 (\-LRB-\1740 mean\NN\6021761 dose\NN\3740161 2.13\CD\1740 +/-\CC\1740 0.09\CD\1740 mg/week\NN\1740 )\-RRB-\1740 .\.\1740
C047047_D011605 NONE RESULTS\NNS\34213 :\:\1740 Four\CD\13741022 males\NNS\15388 (\-LRB-\1740 age\NN\4916342 6\CD\13741022 -\SYM\1740 11\CD\13745420 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 (\-LRB-\1740 fourth\JJ\1740 edition\NN\6590210 )\-RRB-\1740 bipolar\JJ\1740 disorder\NN\14034177 or\CC\3541091 <e2>psychoses</e2>\NNS\14380140 ,\,\1740 with\IN\1740 risperidone-induced\JJ\1740 elevations\NNS\7445480 in\IN\13603305 serum\NN\5397468 prolactin\NN\5410315 levels\NNS\4916342 (\-LRB-\1740 57.5\CD\1740 -\SYM\1740 129\CD\1740 ng/mL\NN\1740 ,\,\1740 normal\JJ\1740 5\CD\13741022 -\SYM\1740 15\CD\13745420 ng/mL\NN\1740 )\-RRB-\1740 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>cabergoline</e1>\NN\1740 (\-LRB-\1740 mean\NN\6021761 dose\NN\3740161 2.13\CD\1740 +/-\CC\1740 0.09\CD\1740 mg/week\NN\1740 )\-RRB-\1740 .\.\1740
16192988
D008694_D001523 CID <e1>Methamphetamine</e1>\NNP\2704153 causes\VBZ\1617192 alterations\NNS\7283608 in\IN\13603305 the\DT\1740 MAP\NN\4076846 kinase-related\JJ\1740 pathways\NNS\5483677 in\IN\13603305 the\DT\1740 brains\NNS\5462674 of\IN\1740 mice\NNS\2329401 that\WDT\1740 display\VBP\2137132 increased\VBN\169651 <e2>aggressiveness</e2>\NN\4835724 .\.\1740
D008694_D001523 CID <e2>Aggressive\JJ\1740 behaviors</e2>\NNS\407535 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 suffer\VBP\2110220 from\IN\1740 some\DT\1740 psychiatric\JJ\1740 disorders\NNS\14034177 ,\,\1740 and\CC\1740 are\VBP\836236 common\JJ\1740 in\IN\13603305 <e1>methamphetamine</e1>\NN\2704153 (\-LRB-\1740 METH\NN\2704153 )\-RRB-\1740 abusers\NNS\9633969 .\.\1740
D008694_D001523 CID Aggressive\JJ\1740 behaviors\NNS\407535 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 suffer\VBP\2110220 from\IN\1740 some\DT\1740 <e2>psychiatric\JJ\1740 disorders</e2>\NNS\14034177 ,\,\1740 and\CC\1740 are\VBP\836236 common\JJ\1740 in\IN\13603305 <e1>methamphetamine</e1>\NN\2704153 (\-LRB-\1740 METH\NN\2704153 )\-RRB-\1740 abusers\NNS\9633969 .\.\1740
D008694_D001523 CID <e2>Aggressive\JJ\1740 behaviors</e2>\NNS\407535 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 suffer\VBP\2110220 from\IN\1740 some\DT\1740 psychiatric\JJ\1740 disorders\NNS\14034177 ,\,\1740 and\CC\1740 are\VBP\836236 common\JJ\1740 in\IN\13603305 methamphetamine\NN\2704153 (\-LRB-\1740 <e1>METH</e1>\NN\2704153 )\-RRB-\1740 abusers\NNS\9633969 .\.\1740
D008694_D001523 CID Aggressive\JJ\1740 behaviors\NNS\407535 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 suffer\VBP\2110220 from\IN\1740 some\DT\1740 <e2>psychiatric\JJ\1740 disorders</e2>\NNS\14034177 ,\,\1740 and\CC\1740 are\VBP\836236 common\JJ\1740 in\IN\13603305 methamphetamine\NN\2704153 (\-LRB-\1740 <e1>METH</e1>\NN\2704153 )\-RRB-\1740 abusers\NNS\9633969 .\.\1740
D008694_D001523 CID Herein\RB\1740 ,\,\1740 we\PRP\1740 report\VBP\831651 that\IN\1740 multiple\JJ\1740 (\-LRB-\1740 but\CC\1740 not\RB\1740 single\JJ\1740 )\-RRB-\1740 injections\NNS\320852 of\IN\1740 <e1>METH</e1>\NN\2704153 significantly\RB\1740 increased\VBD\169651 <e2>aggressiveness</e2>\NN\4835724 in\IN\13603305 male\JJ\1740 CD-1\NN\1740 mice\NNS\2329401 .\.\1740
D008694_D001523 CID This\DT\1740 increase\NN\13576355 in\IN\13603305 <e2>aggressiveness</e2>\NN\4835724 was\VBD\836236 not\RB\1740 secondary\JJ\1740 to\TO\1740 <e1>METH-induced</e1>\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D008694_D006948 NONE This\DT\1740 increase\NN\13576355 in\IN\13603305 aggressiveness\NN\4835724 was\VBD\836236 not\RB\1740 secondary\JJ\1740 to\TO\1740 <e1>METH-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
1732442
D004317_D009202 CID Detection\NN\5708432 of\IN\1740 abnormal\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 in\IN\13603305 <e1>adriamycin-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 with\IN\1740 iodine-125-metaiodobenzylguanidine\NN\1740 .\.\1740
D004317_D009202 CID Using\VBG\1156834 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e1>adriamycin-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 ,\,\1740 we\PRP\1740 tested\VBD\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 abnormal\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 may\MD\15209706 appear\VB\2604760 and\CC\1740 be\VB\836236 exacerbated\VBN\126264 dose-dependently\RB\1740 in\IN\13603305 adriamycin\NN\1740 cardiomyopathy\JJ\1740 .\.\1740
D004317_D009202 CID Using\VBG\1156834 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e1>adriamycin-induced</e1>\JJ\1740 cardiomyopathy\NN\14103288 ,\,\1740 we\PRP\1740 tested\VBD\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 abnormal\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 may\MD\15209706 appear\VB\2604760 and\CC\1740 be\VB\836236 exacerbated\VBN\126264 dose-dependently\RB\1740 in\IN\13603305 adriamycin\NN\1740 <e2>cardiomyopathy</e2>\JJ\1740 .\.\1740
D004317_D009202 CID Using\VBG\1156834 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 adriamycin-induced\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 ,\,\1740 we\PRP\1740 tested\VBD\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 abnormal\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 may\MD\15209706 appear\VB\2604760 and\CC\1740 be\VB\836236 exacerbated\VBN\126264 dose-dependently\RB\1740 in\IN\13603305 <e1>adriamycin</e1>\NN\1740 cardiomyopathy\JJ\1740 .\.\1740
D004317_D009202 CID Using\VBG\1156834 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 adriamycin-induced\JJ\1740 cardiomyopathy\NN\14103288 ,\,\1740 we\PRP\1740 tested\VBD\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 abnormal\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 may\MD\15209706 appear\VB\2604760 and\CC\1740 be\VB\836236 exacerbated\VBN\126264 dose-dependently\RB\1740 in\IN\13603305 <e1>adriamycin</e1>\NN\1740 <e2>cardiomyopathy</e2>\JJ\1740 .\.\1740
D004317_D009202 CID The\DT\1740 appearance\NN\4723816 of\IN\1740 impaired\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 slight\JJ\1740 <e2>myocardial\JJ\1740 impairment</e2>\NN\7296428 (\-LRB-\1740 scattered\JJ\1740 or\CC\3541091 focal\JJ\1740 vacuolar\JJ\1740 degeneration\NN\29677 )\-RRB-\1740 indicates\VBZ\952524 that\IN\1740 MIBG\NNP\1740 scintigraphy\NN\1740 may\MD\15209706 be\VB\836236 a\DT\13649268 useful\JJ\1740 method\NN\5616786 for\IN\1740 detection\NN\5708432 of\IN\1740 <e1>adriamycin-induced</e1>\JJ\1740 cardiomyopathy\NN\14103288 .\.\1740
D004317_D009202 CID The\DT\1740 appearance\NN\4723816 of\IN\1740 impaired\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 slight\JJ\1740 myocardial\JJ\1740 impairment\NN\7296428 (\-LRB-\1740 scattered\JJ\1740 or\CC\3541091 focal\JJ\1740 vacuolar\JJ\1740 degeneration\NN\29677 )\-RRB-\1740 indicates\VBZ\952524 that\IN\1740 MIBG\NNP\1740 scintigraphy\NN\1740 may\MD\15209706 be\VB\836236 a\DT\13649268 useful\JJ\1740 method\NN\5616786 for\IN\1740 detection\NN\5708432 of\IN\1740 <e1>adriamycin-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 .\.\1740
D019797_D009202 NONE Detection\NN\5708432 of\IN\1740 abnormal\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 in\IN\13603305 adriamycin-induced\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 with\IN\1740 <e1>iodine-125-metaiodobenzylguanidine</e1>\NN\1740 .\.\1740
D019797_D009202 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 impaired\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 slight\JJ\1740 <e2>myocardial\JJ\1740 impairment</e2>\NN\7296428 (\-LRB-\1740 scattered\JJ\1740 or\CC\3541091 focal\JJ\1740 vacuolar\JJ\1740 degeneration\NN\29677 )\-RRB-\1740 indicates\VBZ\952524 that\IN\1740 <e1>MIBG</e1>\NNP\1740 scintigraphy\NN\1740 may\MD\15209706 be\VB\836236 a\DT\13649268 useful\JJ\1740 method\NN\5616786 for\IN\1740 detection\NN\5708432 of\IN\1740 adriamycin-induced\JJ\1740 cardiomyopathy\NN\14103288 .\.\1740
D019797_D009202 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 impaired\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 slight\JJ\1740 myocardial\JJ\1740 impairment\NN\7296428 (\-LRB-\1740 scattered\JJ\1740 or\CC\3541091 focal\JJ\1740 vacuolar\JJ\1740 degeneration\NN\29677 )\-RRB-\1740 indicates\VBZ\952524 that\IN\1740 <e1>MIBG</e1>\NNP\1740 scintigraphy\NN\1740 may\MD\15209706 be\VB\836236 a\DT\13649268 useful\JJ\1740 method\NN\5616786 for\IN\1740 detection\NN\5708432 of\IN\1740 adriamycin-induced\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 .\.\1740
D004317_C536522 NONE The\DT\1740 degree\NN\4916342 of\IN\1740 <e2>vacuolar\JJ\1740 degeneration\NN\29677 of\IN\1740 myocardial\JJ\1740 cells</e2>\NNS\3080309 was\VBD\836236 analyzed\VBN\78760 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>adriamycin</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 ,\,\1740 once\RB\1740 a\DT\13649268 week\NN\15113229 )\-RRB-\1740 .\.\1740
D004317_C536522 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 impaired\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 slight\JJ\1740 myocardial\JJ\1740 impairment\NN\7296428 (\-LRB-\1740 scattered\JJ\1740 or\CC\3541091 focal\JJ\1740 <e2>vacuolar\JJ\1740 degeneration</e2>\NN\29677 )\-RRB-\1740 indicates\VBZ\952524 that\IN\1740 MIBG\NNP\1740 scintigraphy\NN\1740 may\MD\15209706 be\VB\836236 a\DT\13649268 useful\JJ\1740 method\NN\5616786 for\IN\1740 detection\NN\5708432 of\IN\1740 <e1>adriamycin-induced</e1>\JJ\1740 cardiomyopathy\NN\14103288 .\.\1740
D019797_C536522 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 impaired\JJ\1740 cardiac\JJ\1740 adrenergic\JJ\1740 neuron\NN\5430628 activity\NN\30358 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 slight\JJ\1740 myocardial\JJ\1740 impairment\NN\7296428 (\-LRB-\1740 scattered\JJ\1740 or\CC\3541091 focal\JJ\1740 <e2>vacuolar\JJ\1740 degeneration</e2>\NN\29677 )\-RRB-\1740 indicates\VBZ\952524 that\IN\1740 <e1>MIBG</e1>\NNP\1740 scintigraphy\NN\1740 may\MD\15209706 be\VB\836236 a\DT\13649268 useful\JJ\1740 method\NN\5616786 for\IN\1740 detection\NN\5708432 of\IN\1740 adriamycin-induced\JJ\1740 cardiomyopathy\NN\14103288 .\.\1740
11890511
33969
C084820_D010302 NONE <e1>Ethopropazine</e1>\NN\1740 and\CC\1740 benztropine\NN\1740 in\IN\13603305 neuroleptic-induced\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 .\.\1740
C084820_D010302 NONE In\IN\13603305 a\DT\13649268 12-week\NN\1740 controlled\VBN\2422663 study\NN\635850 <e1>ethopropazine</e1>\NN\1740 was\VBD\836236 compared\VBN\644583 to\TO\1740 benztropine\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>parkinsonism</e2>\NN\14085708 induced\VBN\1627355 by\IN\1740 fluphenazine\NN\3713736 enanthate\NN\1740 in\IN\13603305 60\CD\13745420 schizophrenic\JJ\1740 outpatients\NNS\10405694 .\.\1740
C084820_D010302 NONE <e1>Ethopropazine</e1>\NN\1740 and\CC\1740 benztropine\NN\1740 were\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 equally\RB\1740 effective\JJ\1740 in\IN\13603305 controlling\VBG\2422663 <e2>parkinsonian\JJ\1740 symptoms</e2>\NNS\5823932 and\CC\1740 were\VBD\836236 as\RB\1740 efficacious\JJ\1740 as\IN\14622893 procyclidine\NN\3800001 ,\,\1740 their\PRP$\1740 previous\JJ\1740 antiparkinsonian\NN\1740 drug\NN\14778436 .\.\1740
D001590_D010302 NONE Ethopropazine\NN\1740 and\CC\1740 <e1>benztropine</e1>\NN\1740 in\IN\13603305 neuroleptic-induced\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 .\.\1740
D001590_D010302 NONE In\IN\13603305 a\DT\13649268 12-week\NN\1740 controlled\VBN\2422663 study\NN\635850 ethopropazine\NN\1740 was\VBD\836236 compared\VBN\644583 to\TO\1740 <e1>benztropine</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>parkinsonism</e2>\NN\14085708 induced\VBN\1627355 by\IN\1740 fluphenazine\NN\3713736 enanthate\NN\1740 in\IN\13603305 60\CD\13745420 schizophrenic\JJ\1740 outpatients\NNS\10405694 .\.\1740
D001590_D010302 NONE Ethopropazine\NN\1740 and\CC\1740 <e1>benztropine</e1>\NN\1740 were\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 equally\RB\1740 effective\JJ\1740 in\IN\13603305 controlling\VBG\2422663 <e2>parkinsonian\JJ\1740 symptoms</e2>\NNS\5823932 and\CC\1740 were\VBD\836236 as\RB\1740 efficacious\JJ\1740 as\IN\14622893 procyclidine\NN\3800001 ,\,\1740 their\PRP$\1740 previous\JJ\1740 antiparkinsonian\NN\1740 drug\NN\14778436 .\.\1740
D001590_D010302 NONE This\DT\1740 suggests\VBZ\1010118 that\IN\1740 <e1>benztropine</e1>\NN\1740 is\VBZ\836236 not\RB\1740 the\DT\1740 anticholinergic\JJ\1740 drug\NN\14778436 of\IN\1740 choice\NN\5788149 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 neuroleptic-induced\JJ\1740 <e2>parkinsonian\JJ\1740 symptoms</e2>\NNS\5823932 ,\,\1740 because\IN\1740 of\IN\1740 its\PRP$\6125041 more\JJR\1740 toxic\JJ\1740 central\JJ\1740 and\CC\1740 peripheral\JJ\1740 atropinic\JJ\1740 effect\NN\34213 .\.\1740
C084820_D012559 NONE In\IN\13603305 a\DT\13649268 12-week\NN\1740 controlled\VBN\2422663 study\NN\635850 <e1>ethopropazine</e1>\NN\1740 was\VBD\836236 compared\VBN\644583 to\TO\1740 benztropine\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 parkinsonism\NN\14085708 induced\VBN\1627355 by\IN\1740 fluphenazine\NN\3713736 enanthate\NN\1740 in\IN\13603305 60\CD\13745420 <e2>schizophrenic</e2>\JJ\1740 outpatients\NNS\10405694 .\.\1740
D001590_D012559 NONE In\IN\13603305 a\DT\13649268 12-week\NN\1740 controlled\VBN\2422663 study\NN\635850 ethopropazine\NN\1740 was\VBD\836236 compared\VBN\644583 to\TO\1740 <e1>benztropine</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 parkinsonism\NN\14085708 induced\VBN\1627355 by\IN\1740 fluphenazine\NN\3713736 enanthate\NN\1740 in\IN\13603305 60\CD\13745420 <e2>schizophrenic</e2>\JJ\1740 outpatients\NNS\10405694 .\.\1740
C017610_D010302 CID In\IN\13603305 a\DT\13649268 12-week\NN\1740 controlled\VBN\2422663 study\NN\635850 ethopropazine\NN\1740 was\VBD\836236 compared\VBN\644583 to\TO\1740 benztropine\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>parkinsonism</e2>\NN\14085708 induced\VBN\1627355 by\IN\1740 <e1>fluphenazine\NN\3713736 enanthate</e1>\NN\1740 in\IN\13603305 60\CD\13745420 schizophrenic\JJ\1740 outpatients\NNS\10405694 .\.\1740
C017610_D012559 NONE In\IN\13603305 a\DT\13649268 12-week\NN\1740 controlled\VBN\2422663 study\NN\635850 ethopropazine\NN\1740 was\VBD\836236 compared\VBN\644583 to\TO\1740 benztropine\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 parkinsonism\NN\14085708 induced\VBN\1627355 by\IN\1740 <e1>fluphenazine\NN\3713736 enanthate</e1>\NN\1740 in\IN\13603305 60\CD\13745420 <e2>schizophrenic</e2>\JJ\1740 outpatients\NNS\10405694 .\.\1740
D011352_D010302 NONE Ethopropazine\NN\1740 and\CC\1740 benztropine\NN\1740 were\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 equally\RB\1740 effective\JJ\1740 in\IN\13603305 controlling\VBG\2422663 <e2>parkinsonian\JJ\1740 symptoms</e2>\NNS\5823932 and\CC\1740 were\VBD\836236 as\RB\1740 efficacious\JJ\1740 as\IN\14622893 <e1>procyclidine</e1>\NN\3800001 ,\,\1740 their\PRP$\1740 previous\JJ\1740 antiparkinsonian\NN\1740 drug\NN\14778436 .\.\1740
D001590_D004409 CID However\RB\1740 ,\,\1740 <e1>benztropine</e1>\NN\1740 treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 <e2>tardive\JJ\1740 dyskinesia</e2>\NN\14084880 compared\VBN\644583 to\TO\1740 their\PRP$\1740 condition\NN\24720 during\IN\1740 procyclindine\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 significantly\RB\1740 more\JJR\1740 anxiety\NN\14373582 and\CC\1740 depression\NN\14373582 than\IN\1740 ethopropazine\NN\1740 treated\JJ\1740 patients\NNS\9898892 .\.\1740
D001590_D001008 CID However\RB\1740 ,\,\1740 <e1>benztropine</e1>\NN\1740 treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 tardive\JJ\1740 dyskinesia\NN\14084880 compared\VBN\644583 to\TO\1740 their\PRP$\1740 condition\NN\24720 during\IN\1740 procyclindine\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 significantly\RB\1740 more\JJR\1740 <e2>anxiety</e2>\NN\14373582 and\CC\1740 depression\NN\14373582 than\IN\1740 ethopropazine\NN\1740 treated\JJ\1740 patients\NNS\9898892 .\.\1740
D001590_D003866 CID However\RB\1740 ,\,\1740 <e1>benztropine</e1>\NN\1740 treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 tardive\JJ\1740 dyskinesia\NN\14084880 compared\VBN\644583 to\TO\1740 their\PRP$\1740 condition\NN\24720 during\IN\1740 procyclindine\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 significantly\RB\1740 more\JJR\1740 anxiety\NN\14373582 and\CC\1740 <e2>depression</e2>\NN\14373582 than\IN\1740 ethopropazine\NN\1740 treated\JJ\1740 patients\NNS\9898892 .\.\1740
D011352_D004409 NONE However\RB\1740 ,\,\1740 benztropine\NN\1740 treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 <e2>tardive\JJ\1740 dyskinesia</e2>\NN\14084880 compared\VBN\644583 to\TO\1740 their\PRP$\1740 condition\NN\24720 during\IN\1740 <e1>procyclindine</e1>\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 significantly\RB\1740 more\JJR\1740 anxiety\NN\14373582 and\CC\1740 depression\NN\14373582 than\IN\1740 ethopropazine\NN\1740 treated\JJ\1740 patients\NNS\9898892 .\.\1740
D011352_D001008 NONE However\RB\1740 ,\,\1740 benztropine\NN\1740 treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 tardive\JJ\1740 dyskinesia\NN\14084880 compared\VBN\644583 to\TO\1740 their\PRP$\1740 condition\NN\24720 during\IN\1740 <e1>procyclindine</e1>\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 significantly\RB\1740 more\JJR\1740 <e2>anxiety</e2>\NN\14373582 and\CC\1740 depression\NN\14373582 than\IN\1740 ethopropazine\NN\1740 treated\JJ\1740 patients\NNS\9898892 .\.\1740
D011352_D003866 NONE However\RB\1740 ,\,\1740 benztropine\NN\1740 treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 tardive\JJ\1740 dyskinesia\NN\14084880 compared\VBN\644583 to\TO\1740 their\PRP$\1740 condition\NN\24720 during\IN\1740 <e1>procyclindine</e1>\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 significantly\RB\1740 more\JJR\1740 anxiety\NN\14373582 and\CC\1740 <e2>depression</e2>\NN\14373582 than\IN\1740 ethopropazine\NN\1740 treated\JJ\1740 patients\NNS\9898892 .\.\1740
C084820_D004409 NONE However\RB\1740 ,\,\1740 benztropine\NN\1740 treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 <e2>tardive\JJ\1740 dyskinesia</e2>\NN\14084880 compared\VBN\644583 to\TO\1740 their\PRP$\1740 condition\NN\24720 during\IN\1740 procyclindine\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 significantly\RB\1740 more\JJR\1740 anxiety\NN\14373582 and\CC\1740 depression\NN\14373582 than\IN\1740 <e1>ethopropazine</e1>\NN\1740 treated\JJ\1740 patients\NNS\9898892 .\.\1740
C084820_D001008 NONE However\RB\1740 ,\,\1740 benztropine\NN\1740 treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 tardive\JJ\1740 dyskinesia\NN\14084880 compared\VBN\644583 to\TO\1740 their\PRP$\1740 condition\NN\24720 during\IN\1740 procyclindine\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 significantly\RB\1740 more\JJR\1740 <e2>anxiety</e2>\NN\14373582 and\CC\1740 depression\NN\14373582 than\IN\1740 <e1>ethopropazine</e1>\NN\1740 treated\JJ\1740 patients\NNS\9898892 .\.\1740
C084820_D003866 NONE However\RB\1740 ,\,\1740 benztropine\NN\1740 treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 tardive\JJ\1740 dyskinesia\NN\14084880 compared\VBN\644583 to\TO\1740 their\PRP$\1740 condition\NN\24720 during\IN\1740 procyclindine\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 significantly\RB\1740 more\JJR\1740 anxiety\NN\14373582 and\CC\1740 <e2>depression</e2>\NN\14373582 than\IN\1740 <e1>ethopropazine</e1>\NN\1740 treated\JJ\1740 patients\NNS\9898892 .\.\1740
591536
D006493_D013923 NONE Arterial\JJ\1740 <e2>thromboembolism</e2>\NN\14100769 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 systemic\JJ\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 :\:\1740 a\DT\13649268 complication\NN\1073995 associated\VBN\628491 with\IN\1740 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 .\.\1740
D006493_D013923 NONE Arterial\JJ\1740 <e2>thromboembolism</e2>\NN\14100769 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 systemic\JJ\1740 heparin\NN\2718259 therapy\NN\657604 :\:\1740 a\DT\13649268 complication\NN\1073995 associated\VBN\628491 with\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 .\.\1740
D006493_D013923 NONE Arterial\JJ\1740 <e2>thromboembolism</e2>\NN\14100769 is\VBZ\836236 a\DT\13649268 recognized\VBN\686447 complication\NN\1073995 of\IN\1740 systemic\JJ\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D013923 NONE The\DT\1740 common\JJ\1740 factor\NN\7326557 relating\NN\1740 <e2>thromboembolism</e2>\NN\14100769 and\CC\1740 thrombocytopenia\NN\14189204 is\VBZ\836236 <e1>heparin-induced</e1>\JJ\1740 platelet\NN\5432736 aggregation\NN\31264 .\.\1740
D006493_D013921 CID Arterial\JJ\1740 thromboembolism\NN\14100769 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 systemic\JJ\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 :\:\1740 a\DT\13649268 complication\NN\1073995 associated\VBN\628491 with\IN\1740 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 .\.\1740
D006493_D013921 CID Arterial\JJ\1740 thromboembolism\NN\14100769 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 systemic\JJ\1740 heparin\NN\2718259 therapy\NN\657604 :\:\1740 a\DT\13649268 complication\NN\1073995 associated\VBN\628491 with\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 .\.\1740
D006493_D013921 CID Characteristic\JJ\1740 of\IN\1740 the\DT\1740 entity\NN\1740 is\VBZ\836236 arterial\JJ\1740 occlusion\NN\14081375 by\IN\1740 platelet-fibrin\NN\1740 thrombi\NN\5402091 with\IN\1740 distal\JJ\1740 ischemia\NN\14195315 occurring\VBG\2623529 four\CD\13741022 to\TO\1740 twenty\CD\13745420 days\NNS\15140892 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 ,\,\1740 preceded\VBN\2690708 by\IN\1740 profound\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 with\IN\1740 platelet\NN\5432736 counts\NNS\13582013 in\IN\13603305 the\DT\1740 range\NN\5123416 of\IN\1740 30,000\CD\1740 to\TO\1740 40,000\CD\1740 per\IN\1740 cubic\JJ\1740 millimeter\NN\13649268 .\.\1740
D006493_D013921 CID The\DT\1740 common\JJ\1740 factor\NN\7326557 relating\NN\1740 thromboembolism\NN\14100769 and\CC\1740 <e2>thrombocytopenia</e2>\NN\14189204 is\VBZ\836236 <e1>heparin-induced</e1>\JJ\1740 platelet\NN\5432736 aggregation\NN\31264 .\.\1740
D006493_D001157 CID Characteristic\JJ\1740 of\IN\1740 the\DT\1740 entity\NN\1740 is\VBZ\836236 <e2>arterial\JJ\1740 occlusion</e2>\NN\14081375 by\IN\1740 platelet-fibrin\NN\1740 thrombi\NN\5402091 with\IN\1740 distal\JJ\1740 ischemia\NN\14195315 occurring\VBG\2623529 four\CD\13741022 to\TO\1740 twenty\CD\13745420 days\NNS\15140892 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 ,\,\1740 preceded\VBN\2690708 by\IN\1740 profound\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 platelet\NN\5432736 counts\NNS\13582013 in\IN\13603305 the\DT\1740 range\NN\5123416 of\IN\1740 30,000\CD\1740 to\TO\1740 40,000\CD\1740 per\IN\1740 cubic\JJ\1740 millimeter\NN\13649268 .\.\1740
D006493_D013927 NONE Characteristic\JJ\1740 of\IN\1740 the\DT\1740 entity\NN\1740 is\VBZ\836236 arterial\JJ\1740 occlusion\NN\14081375 by\IN\1740 platelet-fibrin\NN\1740 <e2>thrombi</e2>\NN\5402091 with\IN\1740 distal\JJ\1740 ischemia\NN\14195315 occurring\VBG\2623529 four\CD\13741022 to\TO\1740 twenty\CD\13745420 days\NNS\15140892 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 ,\,\1740 preceded\VBN\2690708 by\IN\1740 profound\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 platelet\NN\5432736 counts\NNS\13582013 in\IN\13603305 the\DT\1740 range\NN\5123416 of\IN\1740 30,000\CD\1740 to\TO\1740 40,000\CD\1740 per\IN\1740 cubic\JJ\1740 millimeter\NN\13649268 .\.\1740
D006493_D007511 NONE Characteristic\JJ\1740 of\IN\1740 the\DT\1740 entity\NN\1740 is\VBZ\836236 arterial\JJ\1740 occlusion\NN\14081375 by\IN\1740 platelet-fibrin\NN\1740 thrombi\NN\5402091 with\IN\1740 distal\JJ\1740 <e2>ischemia</e2>\NN\14195315 occurring\VBG\2623529 four\CD\13741022 to\TO\1740 twenty\CD\13745420 days\NNS\15140892 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 ,\,\1740 preceded\VBN\2690708 by\IN\1740 profound\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 platelet\NN\5432736 counts\NNS\13582013 in\IN\13603305 the\DT\1740 range\NN\5123416 of\IN\1740 30,000\CD\1740 to\TO\1740 40,000\CD\1740 per\IN\1740 cubic\JJ\1740 millimeter\NN\13649268 .\.\1740
D006493_D001791 NONE The\DT\1740 common\JJ\1740 factor\NN\7326557 relating\NN\1740 thromboembolism\NN\14100769 and\CC\1740 thrombocytopenia\NN\14189204 is\VBZ\836236 <e1>heparin-induced</e1>\JJ\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 .\.\1740
133615
D003276_D013923 NONE <e2>Thromboembolic</e2>\NN\1740 and\CC\1740 other\JJ\1740 complications\NNS\1073995 of\IN\1740 <e1>oral\JJ\1740 contraceptive</e1>\JJ\1740 therapy\NN\657604 in\IN\13603305 relationship\NN\31921 to\TO\1740 pretreatment\NN\1740 levels\NNS\4916342 of\IN\1740 blood\NN\5397468 coagulation\NN\13518963 factors\NNS\7326557 :\:\1740 summary\JJ\1740 report\NN\6470073 of\IN\1740 a\DT\13649268 ten-year\JJ\1740 study\NN\635850 .\.\1740
D003276_D001778 CID Thromboembolic\NN\1740 and\CC\1740 other\JJ\1740 complications\NNS\1073995 of\IN\1740 <e1>oral\JJ\1740 contraceptive</e1>\JJ\1740 therapy\NN\657604 in\IN\13603305 relationship\NN\31921 to\TO\1740 pretreatment\NN\1740 levels\NNS\4916342 of\IN\1740 <e2>blood\NN\5397468 coagulation</e2>\NN\13518963 factors\NNS\7326557 :\:\1740 summary\JJ\1740 report\NN\6470073 of\IN\1740 a\DT\13649268 ten-year\JJ\1740 study\NN\635850 .\.\1740
19944333
C471405_D009203 NONE <e1>Sorafenib-induced</e1>\JJ\1740 acute\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 due\JJ\1740 to\TO\1740 coronary\JJ\1740 artery\NN\5417975 spasm\NN\14299637 .\.\1740
C471405_D003329 CID <e1>Sorafenib-induced</e1>\JJ\1740 acute\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 due\JJ\1740 to\TO\1740 <e2>coronary\JJ\1740 artery\NN\5417975 spasm</e2>\NN\14299637 .\.\1740
C471405_D003329 CID We\PRP\1740 report\VBP\831651 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 <e1>sorafenib-induced</e1>\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 spasm</e2>\NN\14299637 .\.\1740
D020108_D060050 NONE Addition\NN\3081021 of\IN\1740 oral\JJ\1740 <e1>nicorandil</e1>\NN\1740 reduced\VBD\441445 his\PRP$\1740 symptoms\NNS\5823932 and\CC\1740 maintained\VBD\2202928 <e2>stable\JJ\1740 angina</e2>\JJ\1740 status\NN\24720 .\.\1740
16174948
D003042_D013345 CID Absence\NN\14449405 of\IN\1740 acute\JJ\1740 cerebral\JJ\1740 vasoconstriction\NN\1149911 after\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 .\.\1740
D003042_D013345 CID Information\NN\6598915 on\IN\1740 these\DT\1740 effects\NNS\13245626 could\MD\1740 be\VB\836236 obtained\VBN\2210855 from\IN\1740 angiograms\NNS\4100620 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 who\WP\8299493 underwent\VBD\109660 angiography\NN\904623 shortly\RB\1740 after\IN\1740 cocaine\NN\3492717 use\NN\407535 .\.\1740
D003042_D013345 CID Information\NN\6598915 on\IN\1740 these\DT\1740 effects\NNS\13245626 could\MD\1740 be\VB\836236 obtained\VBN\2210855 from\IN\1740 angiograms\NNS\4100620 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 who\WP\8299493 underwent\VBD\109660 angiography\NN\904623 shortly\RB\1740 after\IN\1740 cocaine\NN\3492717 use\NN\407535 .\.\1740
D003042_D013345 CID Information\NN\6598915 on\IN\1740 these\DT\1740 effects\NNS\13245626 could\MD\1740 be\VB\836236 obtained\VBN\2210855 from\IN\1740 angiograms\NNS\4100620 of\IN\1740 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 <e2>subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 who\WP\8299493 underwent\VBD\109660 angiography\NN\904623 shortly\RB\1740 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
D003042_D013345 CID Information\NN\6598915 on\IN\1740 these\DT\1740 effects\NNS\13245626 could\MD\1740 be\VB\836236 obtained\VBN\2210855 from\IN\1740 angiograms\NNS\4100620 of\IN\1740 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 who\WP\8299493 underwent\VBD\109660 angiography\NN\904623 shortly\RB\1740 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
D003042_D013345 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 screened\VBD\2533282 patients\NNS\9898892 with\IN\1740 <e2>SAH</e2>\NN\1740 retrospectively\RB\1740 and\CC\1740 identified\VBD\699815 those\DT\1740 with\IN\1740 positive\JJ\1740 urine\NN\14853947 toxicology\NN\6054892 for\IN\1740 <e1>cocaine</e1>\NN\3492717 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 .\.\1740
D003042_D013345 CID CONCLUSION\NN\5837957 :\:\1740 No\DT\7204911 quantitative\JJ\1740 evidence\NN\5816287 for\IN\1740 narrowing\NN\5064037 of\IN\1740 large\JJ\1740 cerebral\JJ\1740 arteries\NNS\5417975 or\CC\3541091 qualitative\JJ\1740 angiographic\JJ\1740 evidence\NN\5816287 for\IN\1740 distal\JJ\1740 narrowing\NN\5064037 or\CC\3541091 vasculitis\NN\14336539 could\MD\1740 be\VB\836236 found\VBN\2426171 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 underwent\VBD\109660 angiography\NN\904623 after\IN\1740 aneurysmal\JJ\1740 <e2>SAH</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
D003042_D013901 NONE INTRODUCTION\NNP\235435 :\:\1740 <e1>Cocaine</e1>\NN\3492717 use\NN\407535 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 <e2>neurovascular\JJ\1740 complications</e2>\NNS\1073995 ,\,\1740 including\VBG\690614 arterial\JJ\1740 vasoconstriction\NN\1149911 and\CC\1740 vasculitis\NN\14336539 .\.\1740
D003042_D014657 NONE INTRODUCTION\NNP\235435 :\:\1740 <e1>Cocaine</e1>\NN\3492717 use\NN\407535 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 neurovascular\JJ\1740 complications\NNS\1073995 ,\,\1740 including\VBG\690614 arterial\JJ\1740 vasoconstriction\NN\1149911 and\CC\1740 <e2>vasculitis</e2>\NN\14336539 .\.\1740
D003042_D014657 NONE CONCLUSION\NN\5837957 :\:\1740 No\DT\7204911 quantitative\JJ\1740 evidence\NN\5816287 for\IN\1740 narrowing\NN\5064037 of\IN\1740 large\JJ\1740 cerebral\JJ\1740 arteries\NNS\5417975 or\CC\3541091 qualitative\JJ\1740 angiographic\JJ\1740 evidence\NN\5816287 for\IN\1740 distal\JJ\1740 narrowing\NN\5064037 or\CC\3541091 <e2>vasculitis</e2>\NN\14336539 could\MD\1740 be\VB\836236 found\VBN\2426171 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 underwent\VBD\109660 angiography\NN\904623 after\IN\1740 aneurysmal\JJ\1740 SAH\NN\1740 associated\VBN\628491 with\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
D003042_D017542 CID CONCLUSION\NN\5837957 :\:\1740 No\DT\7204911 quantitative\JJ\1740 evidence\NN\5816287 for\IN\1740 narrowing\NN\5064037 of\IN\1740 large\JJ\1740 cerebral\JJ\1740 arteries\NNS\5417975 or\CC\3541091 qualitative\JJ\1740 angiographic\JJ\1740 evidence\NN\5816287 for\IN\1740 distal\JJ\1740 narrowing\NN\5064037 or\CC\3541091 vasculitis\NN\14336539 could\MD\1740 be\VB\836236 found\VBN\2426171 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 underwent\VBD\109660 angiography\NN\904623 after\IN\1740 <e2>aneurysmal</e2>\JJ\1740 SAH\NN\1740 associated\VBN\628491 with\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
8267029
D010396_D005921 CID <e1>Penicillamine-induced</e1>\JJ\1740 rapidly\RB\1740 progressive\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D010396_D005921 CID A\DT\13649268 67-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 presented\VBD\2137132 rapidly\RB\1740 progressive\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 (\-LRB-\1740 RPGN\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 months\NNS\15113229 of\IN\1740 <e1>D-penicillamine</e1>\NN\1740 (\-LRB-\1740 250\CD\1740 mg/day\NN\1740 )\-RRB-\1740 treatment\NN\654885 .\.\1740
D010396_D005921 CID A\DT\13649268 67-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 presented\VBD\2137132 rapidly\RB\1740 progressive\JJ\1740 glomerulonephritis\NN\14113798 (\-LRB-\1740 <e2>RPGN</e2>\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 months\NNS\15113229 of\IN\1740 <e1>D-penicillamine</e1>\NN\1740 (\-LRB-\1740 250\CD\1740 mg/day\NN\1740 )\-RRB-\1740 treatment\NN\654885 .\.\1740
D010396_D005921 CID This\DT\1740 new\JJ\1740 case\NN\7283608 of\IN\1740 <e2>RPGN</e2>\NN\1740 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 <e1>D-penicillamine</e1>\NN\1740 treatment\NN\654885 emphasizes\VBZ\943837 the\DT\1740 need\NN\13920835 for\IN\1740 frequent\JJ\1740 monitoring\NN\879759 of\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 evaluation\NN\874067 of\IN\1740 urinary\JJ\1740 sediment\NN\20827 and\CC\1740 proteinuria\NN\14299637 in\IN\13603305 these\DT\1740 patients\NNS\9898892 .\.\1740
D010396_D001172 NONE <e1>Penicillamine-induced</e1>\JJ\1740 rapidly\RB\1740 progressive\JJ\1740 glomerulonephritis\NN\14113798 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 .\.\1740
D010396_D001172 NONE A\DT\13649268 67-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 presented\VBD\2137132 rapidly\RB\1740 progressive\JJ\1740 glomerulonephritis\NN\14113798 (\-LRB-\1740 RPGN\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 months\NNS\15113229 of\IN\1740 <e1>D-penicillamine</e1>\NN\1740 (\-LRB-\1740 250\CD\1740 mg/day\NN\1740 )\-RRB-\1740 treatment\NN\654885 .\.\1740
D010396_D011507 NONE This\DT\1740 new\JJ\1740 case\NN\7283608 of\IN\1740 RPGN\NN\1740 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 <e1>D-penicillamine</e1>\NN\1740 treatment\NN\654885 emphasizes\VBZ\943837 the\DT\1740 need\NN\13920835 for\IN\1740 frequent\JJ\1740 monitoring\NN\879759 of\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 evaluation\NN\874067 of\IN\1740 urinary\JJ\1740 sediment\NN\20827 and\CC\1740 <e2>proteinuria</e2>\NN\14299637 in\IN\13603305 these\DT\1740 patients\NNS\9898892 .\.\1740
2435991
C032151_D001145 NONE Antiarrhythmic\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 <e1>cibenzoline</e1>\NN\1740 on\IN\1740 canine\NN\5282746 <e2>ventricular\NN\1740 arrhythmias</e2>\VBZ\1740 .\.\1740
C032151_D001145 NONE Using\VBG\1156834 two-stage\JJ\1740 coronary\JJ\1740 ligation-\NN\1740 ,\,\1740 digitalis-\NN\1740 ,\,\1740 and\CC\1740 adrenaline-induced\JJ\1740 canine\NN\5282746 <e2>ventricular\NN\1740 arrhythmias</e2>\VBZ\1740 ,\,\1740 antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>cibenzoline</e1>\NN\1740 were\VBD\836236 examined\VBN\789138 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentration\NN\4916342 for\IN\1740 each\DT\1740 arrhythmia\NN\14103288 model\NN\5888929 was\VBD\836236 determined\VBN\1645601 .\.\1740
C032151_D001145 NONE Using\VBG\1156834 two-stage\JJ\1740 coronary\JJ\1740 ligation-\NN\1740 ,\,\1740 digitalis-\NN\1740 ,\,\1740 and\CC\1740 adrenaline-induced\JJ\1740 canine\NN\5282746 ventricular\NN\1740 arrhythmias\VBZ\1740 ,\,\1740 antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>cibenzoline</e1>\NN\1740 were\VBD\836236 examined\VBN\789138 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentration\NN\4916342 for\IN\1740 each\DT\1740 <e2>arrhythmia</e2>\NN\14103288 model\NN\5888929 was\VBD\836236 determined\VBN\1645601 .\.\1740
C032151_D001145 NONE <e1>Cibenzoline</e1>\NNP\1740 suppressed\VBD\2510337 all\PDT\1740 the\DT\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 for\IN\1740 arrhythmias\NNS\14103288 induced\VBN\1627355 by\IN\1740 24-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 48-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 digitalis\NN\15059939 ,\,\1740 and\CC\1740 adrenaline\NN\14807929 were\VBD\836236 1.9\CD\1740 +/-\CC\1740 0.9\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 1.6\CD\1740 +/-\CC\1740 0.5\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 0.6\CD\1740 +/-\CC\1740 0.2\CD\1740 (\-LRB-\1740 by\IN\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 3.5\CD\1740 +/-\CC\1740 1.3\CD\1740 (\-LRB-\1740 by\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SDM\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 -\SYM\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
C032151_D001145 NONE <e1>Cibenzoline</e1>\NNP\1740 suppressed\VBD\2510337 all\PDT\1740 the\DT\1740 arrhythmias\NNS\14103288 ,\,\1740 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 for\IN\1740 <e2>arrhythmias</e2>\NNS\14103288 induced\VBN\1627355 by\IN\1740 24-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 48-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 digitalis\NN\15059939 ,\,\1740 and\CC\1740 adrenaline\NN\14807929 were\VBD\836236 1.9\CD\1740 +/-\CC\1740 0.9\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 1.6\CD\1740 +/-\CC\1740 0.5\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 0.6\CD\1740 +/-\CC\1740 0.2\CD\1740 (\-LRB-\1740 by\IN\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 3.5\CD\1740 +/-\CC\1740 1.3\CD\1740 (\-LRB-\1740 by\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SDM\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 -\SYM\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
C032151_D001145 NONE Because\IN\1740 <e1>cibenzoline</e1>\NN\1740 had\VBD\2108377 only\RB\1740 weak\JJ\1740 hypotensive\JJ\1740 and\CC\1740 sinus\NN\5248181 node\NN\13870805 depressive\JJ\1740 effects\NNS\13245626 and\CC\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 orally\RB\1740 active\JJ\1740 when\WRB\1740 given\VBN\2327200 to\TO\1740 coronary\JJ\1740 ligation\NN\149084 <e2>arrhythmia</e2>\NN\14103288 dogs\NNS\2083346 ,\,\1740 its\PRP$\6125041 clinical\JJ\1740 usefulness\NN\4723816 is\VBZ\836236 expected\VBN\670261 .\.\1740
D004071_D001145 CID Using\VBG\1156834 two-stage\JJ\1740 coronary\JJ\1740 ligation-\NN\1740 ,\,\1740 <e1>digitalis-</e1>\NN\1740 ,\,\1740 and\CC\1740 adrenaline-induced\JJ\1740 canine\NN\5282746 <e2>ventricular\NN\1740 arrhythmias</e2>\VBZ\1740 ,\,\1740 antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 cibenzoline\NN\1740 were\VBD\836236 examined\VBN\789138 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentration\NN\4916342 for\IN\1740 each\DT\1740 arrhythmia\NN\14103288 model\NN\5888929 was\VBD\836236 determined\VBN\1645601 .\.\1740
D004071_D001145 CID Using\VBG\1156834 two-stage\JJ\1740 coronary\JJ\1740 ligation-\NN\1740 ,\,\1740 <e1>digitalis-</e1>\NN\1740 ,\,\1740 and\CC\1740 adrenaline-induced\JJ\1740 canine\NN\5282746 ventricular\NN\1740 arrhythmias\VBZ\1740 ,\,\1740 antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 cibenzoline\NN\1740 were\VBD\836236 examined\VBN\789138 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentration\NN\4916342 for\IN\1740 each\DT\1740 <e2>arrhythmia</e2>\NN\14103288 model\NN\5888929 was\VBD\836236 determined\VBN\1645601 .\.\1740
D004071_D001145 CID Cibenzoline\NNP\1740 suppressed\VBD\2510337 all\PDT\1740 the\DT\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 for\IN\1740 arrhythmias\NNS\14103288 induced\VBN\1627355 by\IN\1740 24-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 48-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 <e1>digitalis</e1>\NN\15059939 ,\,\1740 and\CC\1740 adrenaline\NN\14807929 were\VBD\836236 1.9\CD\1740 +/-\CC\1740 0.9\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 1.6\CD\1740 +/-\CC\1740 0.5\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 0.6\CD\1740 +/-\CC\1740 0.2\CD\1740 (\-LRB-\1740 by\IN\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 3.5\CD\1740 +/-\CC\1740 1.3\CD\1740 (\-LRB-\1740 by\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SDM\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 -\SYM\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D004071_D001145 CID Cibenzoline\NNP\1740 suppressed\VBD\2510337 all\PDT\1740 the\DT\1740 arrhythmias\NNS\14103288 ,\,\1740 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 for\IN\1740 <e2>arrhythmias</e2>\NNS\14103288 induced\VBN\1627355 by\IN\1740 24-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 48-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 <e1>digitalis</e1>\NN\15059939 ,\,\1740 and\CC\1740 adrenaline\NN\14807929 were\VBD\836236 1.9\CD\1740 +/-\CC\1740 0.9\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 1.6\CD\1740 +/-\CC\1740 0.5\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 0.6\CD\1740 +/-\CC\1740 0.2\CD\1740 (\-LRB-\1740 by\IN\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 3.5\CD\1740 +/-\CC\1740 1.3\CD\1740 (\-LRB-\1740 by\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SDM\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 -\SYM\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D004837_D001145 CID Using\VBG\1156834 two-stage\JJ\1740 coronary\JJ\1740 ligation-\NN\1740 ,\,\1740 digitalis-\NN\1740 ,\,\1740 and\CC\1740 <e1>adrenaline-induced</e1>\JJ\1740 canine\NN\5282746 <e2>ventricular\NN\1740 arrhythmias</e2>\VBZ\1740 ,\,\1740 antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 cibenzoline\NN\1740 were\VBD\836236 examined\VBN\789138 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentration\NN\4916342 for\IN\1740 each\DT\1740 arrhythmia\NN\14103288 model\NN\5888929 was\VBD\836236 determined\VBN\1645601 .\.\1740
D004837_D001145 CID Using\VBG\1156834 two-stage\JJ\1740 coronary\JJ\1740 ligation-\NN\1740 ,\,\1740 digitalis-\NN\1740 ,\,\1740 and\CC\1740 <e1>adrenaline-induced</e1>\JJ\1740 canine\NN\5282746 ventricular\NN\1740 arrhythmias\VBZ\1740 ,\,\1740 antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 cibenzoline\NN\1740 were\VBD\836236 examined\VBN\789138 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentration\NN\4916342 for\IN\1740 each\DT\1740 <e2>arrhythmia</e2>\NN\14103288 model\NN\5888929 was\VBD\836236 determined\VBN\1645601 .\.\1740
D004837_D001145 CID Cibenzoline\NNP\1740 suppressed\VBD\2510337 all\PDT\1740 the\DT\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 for\IN\1740 arrhythmias\NNS\14103288 induced\VBN\1627355 by\IN\1740 24-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 48-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 digitalis\NN\15059939 ,\,\1740 and\CC\1740 <e1>adrenaline</e1>\NN\14807929 were\VBD\836236 1.9\CD\1740 +/-\CC\1740 0.9\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 1.6\CD\1740 +/-\CC\1740 0.5\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 0.6\CD\1740 +/-\CC\1740 0.2\CD\1740 (\-LRB-\1740 by\IN\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 3.5\CD\1740 +/-\CC\1740 1.3\CD\1740 (\-LRB-\1740 by\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SDM\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 -\SYM\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D004837_D001145 CID Cibenzoline\NNP\1740 suppressed\VBD\2510337 all\PDT\1740 the\DT\1740 arrhythmias\NNS\14103288 ,\,\1740 and\CC\1740 the\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 for\IN\1740 <e2>arrhythmias</e2>\NNS\14103288 induced\VBN\1627355 by\IN\1740 24-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 48-h\JJ\1740 coronary\JJ\1740 ligation\NN\149084 ,\,\1740 digitalis\NN\15059939 ,\,\1740 and\CC\1740 <e1>adrenaline</e1>\NN\14807929 were\VBD\836236 1.9\CD\1740 +/-\CC\1740 0.9\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 1.6\CD\1740 +/-\CC\1740 0.5\CD\1740 (\-LRB-\1740 by\IN\1740 8\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 0.6\CD\1740 +/-\CC\1740 0.2\CD\1740 (\-LRB-\1740 by\IN\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 3.5\CD\1740 +/-\CC\1740 1.3\CD\1740 (\-LRB-\1740 by\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SDM\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 -\SYM\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D004837_D001145 CID The\DT\1740 concentration\NN\4916342 for\IN\1740 <e1>adrenaline-induced</e1>\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 for\IN\1740 the\DT\1740 other\JJ\1740 types\NNS\5839024 of\IN\1740 arrhythmias\NNS\14103288 .\.\1740
D004837_D001145 CID The\DT\1740 concentration\NN\4916342 for\IN\1740 <e1>adrenaline-induced</e1>\JJ\1740 arrhythmia\NN\14103288 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 for\IN\1740 the\DT\1740 other\JJ\1740 types\NNS\5839024 of\IN\1740 <e2>arrhythmias</e2>\NNS\14103288 .\.\1740
C032151_D007022 NONE Because\IN\1740 <e1>cibenzoline</e1>\NN\1740 had\VBD\2108377 only\RB\1740 weak\JJ\1740 <e2>hypotensive</e2>\JJ\1740 and\CC\1740 sinus\NN\5248181 node\NN\13870805 depressive\JJ\1740 effects\NNS\13245626 and\CC\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 orally\RB\1740 active\JJ\1740 when\WRB\1740 given\VBN\2327200 to\TO\1740 coronary\JJ\1740 ligation\NN\149084 arrhythmia\NN\14103288 dogs\NNS\2083346 ,\,\1740 its\PRP$\6125041 clinical\JJ\1740 usefulness\NN\4723816 is\VBZ\836236 expected\VBN\670261 .\.\1740
C032151_D003866 NONE Because\IN\1740 <e1>cibenzoline</e1>\NN\1740 had\VBD\2108377 only\RB\1740 weak\JJ\1740 hypotensive\JJ\1740 and\CC\1740 sinus\NN\5248181 node\NN\13870805 <e2>depressive</e2>\JJ\1740 effects\NNS\13245626 and\CC\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 orally\RB\1740 active\JJ\1740 when\WRB\1740 given\VBN\2327200 to\TO\1740 coronary\JJ\1740 ligation\NN\149084 arrhythmia\NN\14103288 dogs\NNS\2083346 ,\,\1740 its\PRP$\6125041 clinical\JJ\1740 usefulness\NN\4723816 is\VBZ\836236 expected\VBN\670261 .\.\1740
7102237
D012601_D001049 NONE In\IN\13603305 patients\NNS\9898892 premedicated\VBN\1740 with\IN\1740 <e1>scopolamine</e1>\NN\14712692 +\CC\1740 morphine\NN\2707683 (\-LRB-\1740 +\CC\1740 5\CD\13741022 mg\NN\13717155 nitrazepam\IN\2830852 the\DT\1740 evening\NN\15164957 before\IN\1740 surgery\NN\6045562 )\-RRB-\1740 ,\,\1740 the\DT\1740 sleep-inducing\JJ\1740 effect\NN\34213 of\IN\1740 midazolam\NN\2830852 0.15\CD\1740 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 clearly\RB\1740 slower\JJR\1740 in\IN\13603305 onset\NN\7325190 than\IN\1740 that\DT\1740 of\IN\1740 thiopentone\NN\1740 4.67\CD\1740 mg/kg\NN\1740 i.v.\VBP\1740 Somewhat\RB\1740 fewer\JJR\1740 cardiovascular\JJ\1740 and\CC\1740 local\JJ\1740 sequelae\NN\14501726 were\VBD\836236 found\VBN\2426171 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 ,\,\1740 but\CC\1740 ,\,\1740 although\IN\1740 <e2>apnoea</e2>\NN\1740 occurred\VBD\2623529 less\RBR\1740 often\RB\1740 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 it\PRP\6125041 lasted\VBD\2704349 longer\RBR\1740 .\.\1740
D009020_D001049 NONE In\IN\13603305 patients\NNS\9898892 premedicated\VBN\1740 with\IN\1740 scopolamine\NN\14712692 +\CC\1740 <e1>morphine</e1>\NN\2707683 (\-LRB-\1740 +\CC\1740 5\CD\13741022 mg\NN\13717155 nitrazepam\IN\2830852 the\DT\1740 evening\NN\15164957 before\IN\1740 surgery\NN\6045562 )\-RRB-\1740 ,\,\1740 the\DT\1740 sleep-inducing\JJ\1740 effect\NN\34213 of\IN\1740 midazolam\NN\2830852 0.15\CD\1740 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 clearly\RB\1740 slower\JJR\1740 in\IN\13603305 onset\NN\7325190 than\IN\1740 that\DT\1740 of\IN\1740 thiopentone\NN\1740 4.67\CD\1740 mg/kg\NN\1740 i.v.\VBP\1740 Somewhat\RB\1740 fewer\JJR\1740 cardiovascular\JJ\1740 and\CC\1740 local\JJ\1740 sequelae\NN\14501726 were\VBD\836236 found\VBN\2426171 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 ,\,\1740 but\CC\1740 ,\,\1740 although\IN\1740 <e2>apnoea</e2>\NN\1740 occurred\VBD\2623529 less\RBR\1740 often\RB\1740 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 it\PRP\6125041 lasted\VBD\2704349 longer\RBR\1740 .\.\1740
D009567_D001049 NONE In\IN\13603305 patients\NNS\9898892 premedicated\VBN\1740 with\IN\1740 scopolamine\NN\14712692 +\CC\1740 morphine\NN\2707683 (\-LRB-\1740 +\CC\1740 5\CD\13741022 mg\NN\13717155 <e1>nitrazepam</e1>\IN\2830852 the\DT\1740 evening\NN\15164957 before\IN\1740 surgery\NN\6045562 )\-RRB-\1740 ,\,\1740 the\DT\1740 sleep-inducing\JJ\1740 effect\NN\34213 of\IN\1740 midazolam\NN\2830852 0.15\CD\1740 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 clearly\RB\1740 slower\JJR\1740 in\IN\13603305 onset\NN\7325190 than\IN\1740 that\DT\1740 of\IN\1740 thiopentone\NN\1740 4.67\CD\1740 mg/kg\NN\1740 i.v.\VBP\1740 Somewhat\RB\1740 fewer\JJR\1740 cardiovascular\JJ\1740 and\CC\1740 local\JJ\1740 sequelae\NN\14501726 were\VBD\836236 found\VBN\2426171 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 ,\,\1740 but\CC\1740 ,\,\1740 although\IN\1740 <e2>apnoea</e2>\NN\1740 occurred\VBD\2623529 less\RBR\1740 often\RB\1740 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 it\PRP\6125041 lasted\VBD\2704349 longer\RBR\1740 .\.\1740
D008874_D001049 CID In\IN\13603305 patients\NNS\9898892 premedicated\VBN\1740 with\IN\1740 scopolamine\NN\14712692 +\CC\1740 morphine\NN\2707683 (\-LRB-\1740 +\CC\1740 5\CD\13741022 mg\NN\13717155 nitrazepam\IN\2830852 the\DT\1740 evening\NN\15164957 before\IN\1740 surgery\NN\6045562 )\-RRB-\1740 ,\,\1740 the\DT\1740 sleep-inducing\JJ\1740 effect\NN\34213 of\IN\1740 <e1>midazolam</e1>\NN\2830852 0.15\CD\1740 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 clearly\RB\1740 slower\JJR\1740 in\IN\13603305 onset\NN\7325190 than\IN\1740 that\DT\1740 of\IN\1740 thiopentone\NN\1740 4.67\CD\1740 mg/kg\NN\1740 i.v.\VBP\1740 Somewhat\RB\1740 fewer\JJR\1740 cardiovascular\JJ\1740 and\CC\1740 local\JJ\1740 sequelae\NN\14501726 were\VBD\836236 found\VBN\2426171 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 ,\,\1740 but\CC\1740 ,\,\1740 although\IN\1740 <e2>apnoea</e2>\NN\1740 occurred\VBD\2623529 less\RBR\1740 often\RB\1740 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 it\PRP\6125041 lasted\VBD\2704349 longer\RBR\1740 .\.\1740
D008874_D001049 CID In\IN\13603305 patients\NNS\9898892 premedicated\VBN\1740 with\IN\1740 scopolamine\NN\14712692 +\CC\1740 morphine\NN\2707683 (\-LRB-\1740 +\CC\1740 5\CD\13741022 mg\NN\13717155 nitrazepam\IN\2830852 the\DT\1740 evening\NN\15164957 before\IN\1740 surgery\NN\6045562 )\-RRB-\1740 ,\,\1740 the\DT\1740 sleep-inducing\JJ\1740 effect\NN\34213 of\IN\1740 midazolam\NN\2830852 0.15\CD\1740 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 clearly\RB\1740 slower\JJR\1740 in\IN\13603305 onset\NN\7325190 than\IN\1740 that\DT\1740 of\IN\1740 thiopentone\NN\1740 4.67\CD\1740 mg/kg\NN\1740 i.v.\VBP\1740 Somewhat\RB\1740 fewer\JJR\1740 cardiovascular\JJ\1740 and\CC\1740 local\JJ\1740 sequelae\NN\14501726 were\VBD\836236 found\VBN\2426171 in\IN\13603305 the\DT\1740 <e1>midazolam</e1>\NN\2830852 group\NN\2137 ,\,\1740 but\CC\1740 ,\,\1740 although\IN\1740 <e2>apnoea</e2>\NN\1740 occurred\VBD\2623529 less\RBR\1740 often\RB\1740 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 it\PRP\6125041 lasted\VBD\2704349 longer\RBR\1740 .\.\1740
D008874_D001049 CID In\IN\13603305 patients\NNS\9898892 premedicated\VBN\1740 with\IN\1740 scopolamine\NN\14712692 +\CC\1740 morphine\NN\2707683 (\-LRB-\1740 +\CC\1740 5\CD\13741022 mg\NN\13717155 nitrazepam\IN\2830852 the\DT\1740 evening\NN\15164957 before\IN\1740 surgery\NN\6045562 )\-RRB-\1740 ,\,\1740 the\DT\1740 sleep-inducing\JJ\1740 effect\NN\34213 of\IN\1740 midazolam\NN\2830852 0.15\CD\1740 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 clearly\RB\1740 slower\JJR\1740 in\IN\13603305 onset\NN\7325190 than\IN\1740 that\DT\1740 of\IN\1740 thiopentone\NN\1740 4.67\CD\1740 mg/kg\NN\1740 i.v.\VBP\1740 Somewhat\RB\1740 fewer\JJR\1740 cardiovascular\JJ\1740 and\CC\1740 local\JJ\1740 sequelae\NN\14501726 were\VBD\836236 found\VBN\2426171 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 ,\,\1740 but\CC\1740 ,\,\1740 although\IN\1740 <e2>apnoea</e2>\NN\1740 occurred\VBD\2623529 less\RBR\1740 often\RB\1740 in\IN\13603305 the\DT\1740 <e1>midazolam</e1>\NN\2830852 group\NN\2137 it\PRP\6125041 lasted\VBD\2704349 longer\RBR\1740 .\.\1740
D013874_D001049 CID In\IN\13603305 patients\NNS\9898892 premedicated\VBN\1740 with\IN\1740 scopolamine\NN\14712692 +\CC\1740 morphine\NN\2707683 (\-LRB-\1740 +\CC\1740 5\CD\13741022 mg\NN\13717155 nitrazepam\IN\2830852 the\DT\1740 evening\NN\15164957 before\IN\1740 surgery\NN\6045562 )\-RRB-\1740 ,\,\1740 the\DT\1740 sleep-inducing\JJ\1740 effect\NN\34213 of\IN\1740 midazolam\NN\2830852 0.15\CD\1740 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 clearly\RB\1740 slower\JJR\1740 in\IN\13603305 onset\NN\7325190 than\IN\1740 that\DT\1740 of\IN\1740 <e1>thiopentone</e1>\NN\1740 4.67\CD\1740 mg/kg\NN\1740 i.v.\VBP\1740 Somewhat\RB\1740 fewer\JJR\1740 cardiovascular\JJ\1740 and\CC\1740 local\JJ\1740 sequelae\NN\14501726 were\VBD\836236 found\VBN\2426171 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 ,\,\1740 but\CC\1740 ,\,\1740 although\IN\1740 <e2>apnoea</e2>\NN\1740 occurred\VBD\2623529 less\RBR\1740 often\RB\1740 in\IN\13603305 the\DT\1740 midazolam\NN\2830852 group\NN\2137 it\PRP\6125041 lasted\VBD\2704349 longer\RBR\1740 .\.\1740
2051906
D001379_D002779 CID Reversible\JJ\1740 <e2>cholestasis</e2>\NN\14052403 with\IN\1740 bile\NN\5405946 duct\NN\5248181 injury\NN\14052046 following\VBG\1835496 <e1>azathioprine</e1>\NN\3740161 therapy\NN\657604 .\.\1740
D001379_D002779 CID Reversible\JJ\1740 cholestasis\NN\14052403 with\IN\1740 <e2>bile\NN\5405946 duct\NN\5248181 injury</e2>\NN\14052046 following\VBG\1835496 <e1>azathioprine</e1>\NN\3740161 therapy\NN\657604 .\.\1740
D001379_D002779 CID A\DT\13649268 67-year-old\JJ\1740 patient\NN\9898892 ,\,\1740 with\IN\1740 primary\JJ\1740 polymyositis\NN\14350292 and\CC\1740 without\IN\1740 previous\JJ\1740 evidence\NN\5816287 of\IN\1740 liver\NN\5298729 disease\NN\14061805 ,\,\1740 developed\VBD\1753788 clinical\JJ\1740 and\CC\1740 biochemical\JJ\1740 features\NNS\5849040 of\IN\1740 severe\JJ\1740 <e2>cholestasis</e2>\NN\14052403 3\CD\13741022 months\NNS\15113229 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>azathioprine</e1>\NN\3740161 therapy\NN\657604 .\.\1740
D001379_D002779 CID It\PRP\6125041 is\VBZ\836236 believed\VBN\686447 that\IN\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 reversible\JJ\1740 <e1>azathioprine-induced</e1>\JJ\1740 <e2>cholestasis</e2>\NN\14052403 associated\VBN\628491 with\IN\1740 histological\JJ\1740 evidence\NN\5816287 of\IN\1740 bile\NN\5405946 duct\NN\5248181 injury\NN\14052046 .\.\1740
D001379_D002779 CID It\PRP\6125041 is\VBZ\836236 believed\VBN\686447 that\IN\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 reversible\JJ\1740 <e1>azathioprine-induced</e1>\JJ\1740 cholestasis\NN\14052403 associated\VBN\628491 with\IN\1740 histological\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>bile\NN\5405946 duct\NN\5248181 injury</e2>\NN\14052046 .\.\1740
D001379_D017285 NONE A\DT\13649268 67-year-old\JJ\1740 patient\NN\9898892 ,\,\1740 with\IN\1740 primary\JJ\1740 <e2>polymyositis</e2>\NN\14350292 and\CC\1740 without\IN\1740 previous\JJ\1740 evidence\NN\5816287 of\IN\1740 liver\NN\5298729 disease\NN\14061805 ,\,\1740 developed\VBD\1753788 clinical\JJ\1740 and\CC\1740 biochemical\JJ\1740 features\NNS\5849040 of\IN\1740 severe\JJ\1740 cholestasis\NN\14052403 3\CD\13741022 months\NNS\15113229 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>azathioprine</e1>\NN\3740161 therapy\NN\657604 .\.\1740
D001379_D008107 NONE A\DT\13649268 67-year-old\JJ\1740 patient\NN\9898892 ,\,\1740 with\IN\1740 primary\JJ\1740 polymyositis\NN\14350292 and\CC\1740 without\IN\1740 previous\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 ,\,\1740 developed\VBD\1753788 clinical\JJ\1740 and\CC\1740 biochemical\JJ\1740 features\NNS\5849040 of\IN\1740 severe\JJ\1740 cholestasis\NN\14052403 3\CD\13741022 months\NNS\15113229 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>azathioprine</e1>\NN\3740161 therapy\NN\657604 .\.\1740
803783
D010121_D014869 CID <e2>Water\NN\14618834 intoxication</e2>\NN\14034177 associated\VBN\628491 with\IN\1740 <e1>oxytocin</e1>\NN\5407119 administration\NN\1133281 during\IN\1740 saline-induced\JJ\1740 abortion\NN\209943 .\.\1740
D010121_D014869 CID Four\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>water\NN\14618834 intoxication</e2>\NN\14034177 in\IN\13603305 connection\NN\31921 with\IN\1740 <e1>oxytocin</e1>\NN\5407119 administration\NN\1133281 during\IN\1740 saline-induced\JJ\1740 abortions\NNS\209943 are\VBP\836236 described\VBN\1001294 .\.\1740
D010121_D014869 CID <e1>Oxytocin</e1>\NN\5407119 administration\NN\1133281 during\IN\1740 midtrimester-induced\JJ\1740 abortions\NNS\209943 is\VBZ\836236 advocated\VBN\875394 only\RB\1740 if\IN\1740 it\PRP\6125041 can\MD\3094503 be\VB\836236 carried\VBN\1850315 out\RP\1740 under\IN\1740 careful\JJ\1740 observations\NNS\996969 of\IN\1740 an\DT\6697703 alert\JJ\1740 nursing\NN\654885 staff\NN\8208016 ,\,\1740 aware\JJ\1740 of\IN\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e2>water\NN\14618834 intoxication</e2>\NN\14034177 and\CC\1740 instructed\VBD\831651 to\TO\1740 watch\VB\661824 the\DT\1740 diuresis\NN\14299637 and\CC\1740 report\VB\831651 such\JJ\1740 early\JJ\1740 signs\NNS\6643763 of\IN\1740 the\DT\1740 syndrome\NN\5870365 as\IN\14622893 asthenia\NN\14547643 ,\,\1740 muscular\JJ\1740 irritability\NN\7552087 ,\,\1740 or\CC\3541091 headaches\NNS\5829480 .\.\1740
D010121_D000031 NONE Water\NN\14618834 intoxication\NN\14034177 associated\VBN\628491 with\IN\1740 <e1>oxytocin</e1>\NN\5407119 administration\NN\1133281 during\IN\1740 saline-induced\JJ\1740 <e2>abortion</e2>\NN\209943 .\.\1740
D010121_D000031 NONE Four\CD\13741022 cases\NNS\7283608 of\IN\1740 water\NN\14618834 intoxication\NN\14034177 in\IN\13603305 connection\NN\31921 with\IN\1740 <e1>oxytocin</e1>\NN\5407119 administration\NN\1133281 during\IN\1740 saline-induced\JJ\1740 <e2>abortions</e2>\NNS\209943 are\VBP\836236 described\VBN\1001294 .\.\1740
D010121_D000031 NONE <e1>Oxytocin</e1>\NN\5407119 administration\NN\1133281 during\IN\1740 midtrimester-induced\JJ\1740 <e2>abortions</e2>\NNS\209943 is\VBZ\836236 advocated\VBN\875394 only\RB\1740 if\IN\1740 it\PRP\6125041 can\MD\3094503 be\VB\836236 carried\VBN\1850315 out\RP\1740 under\IN\1740 careful\JJ\1740 observations\NNS\996969 of\IN\1740 an\DT\6697703 alert\JJ\1740 nursing\NN\654885 staff\NN\8208016 ,\,\1740 aware\JJ\1740 of\IN\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 water\NN\14618834 intoxication\NN\14034177 and\CC\1740 instructed\VBD\831651 to\TO\1740 watch\VB\661824 the\DT\1740 diuresis\NN\14299637 and\CC\1740 report\VB\831651 such\JJ\1740 early\JJ\1740 signs\NNS\6643763 of\IN\1740 the\DT\1740 syndrome\NN\5870365 as\IN\14622893 asthenia\NN\14547643 ,\,\1740 muscular\JJ\1740 irritability\NN\7552087 ,\,\1740 or\CC\3541091 headaches\NNS\5829480 .\.\1740
D010121_D001247 NONE <e1>Oxytocin</e1>\NN\5407119 administration\NN\1133281 during\IN\1740 midtrimester-induced\JJ\1740 abortions\NNS\209943 is\VBZ\836236 advocated\VBN\875394 only\RB\1740 if\IN\1740 it\PRP\6125041 can\MD\3094503 be\VB\836236 carried\VBN\1850315 out\RP\1740 under\IN\1740 careful\JJ\1740 observations\NNS\996969 of\IN\1740 an\DT\6697703 alert\JJ\1740 nursing\NN\654885 staff\NN\8208016 ,\,\1740 aware\JJ\1740 of\IN\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 water\NN\14618834 intoxication\NN\14034177 and\CC\1740 instructed\VBD\831651 to\TO\1740 watch\VB\661824 the\DT\1740 diuresis\NN\14299637 and\CC\1740 report\VB\831651 such\JJ\1740 early\JJ\1740 signs\NNS\6643763 of\IN\1740 the\DT\1740 syndrome\NN\5870365 as\IN\14622893 <e2>asthenia</e2>\NN\14547643 ,\,\1740 muscular\JJ\1740 irritability\NN\7552087 ,\,\1740 or\CC\3541091 headaches\NNS\5829480 .\.\1740
D010121_D001523 NONE <e1>Oxytocin</e1>\NN\5407119 administration\NN\1133281 during\IN\1740 midtrimester-induced\JJ\1740 abortions\NNS\209943 is\VBZ\836236 advocated\VBN\875394 only\RB\1740 if\IN\1740 it\PRP\6125041 can\MD\3094503 be\VB\836236 carried\VBN\1850315 out\RP\1740 under\IN\1740 careful\JJ\1740 observations\NNS\996969 of\IN\1740 an\DT\6697703 alert\JJ\1740 nursing\NN\654885 staff\NN\8208016 ,\,\1740 aware\JJ\1740 of\IN\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 water\NN\14618834 intoxication\NN\14034177 and\CC\1740 instructed\VBD\831651 to\TO\1740 watch\VB\661824 the\DT\1740 diuresis\NN\14299637 and\CC\1740 report\VB\831651 such\JJ\1740 early\JJ\1740 signs\NNS\6643763 of\IN\1740 the\DT\1740 syndrome\NN\5870365 as\IN\14622893 asthenia\NN\14547643 ,\,\1740 muscular\JJ\1740 <e2>irritability</e2>\NN\7552087 ,\,\1740 or\CC\3541091 headaches\NNS\5829480 .\.\1740
D010121_D006261 NONE <e1>Oxytocin</e1>\NN\5407119 administration\NN\1133281 during\IN\1740 midtrimester-induced\JJ\1740 abortions\NNS\209943 is\VBZ\836236 advocated\VBN\875394 only\RB\1740 if\IN\1740 it\PRP\6125041 can\MD\3094503 be\VB\836236 carried\VBN\1850315 out\RP\1740 under\IN\1740 careful\JJ\1740 observations\NNS\996969 of\IN\1740 an\DT\6697703 alert\JJ\1740 nursing\NN\654885 staff\NN\8208016 ,\,\1740 aware\JJ\1740 of\IN\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 water\NN\14618834 intoxication\NN\14034177 and\CC\1740 instructed\VBD\831651 to\TO\1740 watch\VB\661824 the\DT\1740 diuresis\NN\14299637 and\CC\1740 report\VB\831651 such\JJ\1740 early\JJ\1740 signs\NNS\6643763 of\IN\1740 the\DT\1740 syndrome\NN\5870365 as\IN\14622893 asthenia\NN\14547643 ,\,\1740 muscular\JJ\1740 irritability\NN\7552087 ,\,\1740 or\CC\3541091 <e2>headaches</e2>\NNS\5829480 .\.\1740
3001299
D008094_D018500 NONE It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 suggested\VBN\1010118 that\IN\1740 adenylate\NN\1740 cyclase\NN\1740 inhibition\NN\1068773 may\MD\15209706 be\VB\836236 important\JJ\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 both\CC\1740 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 and\CC\1740 hypothyroidism\NN\14059928 during\IN\1740 <e1>lithium</e1>\NN\14625458 treatment\NN\654885 .\.\1740
D008094_D007037 CID It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 suggested\VBN\1010118 that\IN\1740 adenylate\NN\1740 cyclase\NN\1740 inhibition\NN\1068773 may\MD\15209706 be\VB\836236 important\JJ\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 both\CC\1740 nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 and\CC\1740 <e2>hypothyroidism</e2>\NN\14059928 during\IN\1740 <e1>lithium</e1>\NN\14625458 treatment\NN\654885 .\.\1740
D008094_D007037 CID <e2>Hypothyroidism</e2>\NN\14059928 developed\VBD\1753788 in\IN\13603305 eight\CD\13741022 patients\NNS\9898892 while\IN\15122231 they\PRP\1740 were\VBD\836236 taking\VBG\2367363 <e1>lithium</e1>\NN\14625458 .\.\1740
1711760
D007530_D006973 NONE Under\IN\1740 <e1>isoflurane</e1>\NN\3570838 anesthesia\NN\14034177 ,\,\1740 the\DT\1740 MCA\NNP\1740 of\IN\1740 14\CD\13745420 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 was\VBD\836236 occluded\VBN\2451370 .\.\1740
C009591_D009410 NONE The\DT\1740 extent\NN\13939892 of\IN\1740 <e2>neuronal\JJ\1740 injury</e2>\NN\14052046 was\VBD\836236 determined\VBN\1645601 by\IN\1740 <e1>2,3,5-triphenyltetrazolium</e1>\NN\1740 staining\NN\275424 .\.\1740
D010656_D006973 CID The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 instituted\VBD\1641914 2\CD\13741022 h\NN\14622893 after\IN\1740 MCAO\NN\1740 does\VBZ\1640855 not\RB\1740 aggravate\NN\1740 edema\NN\14315192 in\IN\13603305 the\DT\1740 ischemic\JJ\1740 core\NN\7996689 ,\,\1740 that\IN\1740 it\PRP\6125041 improves\VBZ\126264 edema\NN\14315192 in\IN\13603305 the\DT\1740 periphery\NN\13903079 of\IN\1740 the\DT\1740 ischemic\JJ\1740 territory\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 reduces\VBZ\441445 the\DT\1740 area\NN\8630985 of\IN\1740 histochemical\JJ\1740 neuronal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D010656_D020244 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 instituted\VBD\1641914 2\CD\13741022 h\NN\14622893 after\IN\1740 <e2>MCAO</e2>\NN\1740 does\VBZ\1640855 not\RB\1740 aggravate\NN\1740 edema\NN\14315192 in\IN\13603305 the\DT\1740 ischemic\JJ\1740 core\NN\7996689 ,\,\1740 that\IN\1740 it\PRP\6125041 improves\VBZ\126264 edema\NN\14315192 in\IN\13603305 the\DT\1740 periphery\NN\13903079 of\IN\1740 the\DT\1740 ischemic\JJ\1740 territory\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 reduces\VBZ\441445 the\DT\1740 area\NN\8630985 of\IN\1740 histochemical\JJ\1740 neuronal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D010656_D004487 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 instituted\VBD\1641914 2\CD\13741022 h\NN\14622893 after\IN\1740 MCAO\NN\1740 does\VBZ\1640855 not\RB\1740 aggravate\NN\1740 <e2>edema</e2>\NN\14315192 in\IN\13603305 the\DT\1740 ischemic\JJ\1740 core\NN\7996689 ,\,\1740 that\IN\1740 it\PRP\6125041 improves\VBZ\126264 edema\NN\14315192 in\IN\13603305 the\DT\1740 periphery\NN\13903079 of\IN\1740 the\DT\1740 ischemic\JJ\1740 territory\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 reduces\VBZ\441445 the\DT\1740 area\NN\8630985 of\IN\1740 histochemical\JJ\1740 neuronal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D010656_D004487 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 instituted\VBD\1641914 2\CD\13741022 h\NN\14622893 after\IN\1740 MCAO\NN\1740 does\VBZ\1640855 not\RB\1740 aggravate\NN\1740 edema\NN\14315192 in\IN\13603305 the\DT\1740 ischemic\JJ\1740 core\NN\7996689 ,\,\1740 that\IN\1740 it\PRP\6125041 improves\VBZ\126264 <e2>edema</e2>\NN\14315192 in\IN\13603305 the\DT\1740 periphery\NN\13903079 of\IN\1740 the\DT\1740 ischemic\JJ\1740 territory\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 reduces\VBZ\441445 the\DT\1740 area\NN\8630985 of\IN\1740 histochemical\JJ\1740 neuronal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D010656_D007511 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 instituted\VBD\1641914 2\CD\13741022 h\NN\14622893 after\IN\1740 MCAO\NN\1740 does\VBZ\1640855 not\RB\1740 aggravate\NN\1740 edema\NN\14315192 in\IN\13603305 the\DT\1740 <e2>ischemic</e2>\JJ\1740 core\NN\7996689 ,\,\1740 that\IN\1740 it\PRP\6125041 improves\VBZ\126264 edema\NN\14315192 in\IN\13603305 the\DT\1740 periphery\NN\13903079 of\IN\1740 the\DT\1740 ischemic\JJ\1740 territory\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 reduces\VBZ\441445 the\DT\1740 area\NN\8630985 of\IN\1740 histochemical\JJ\1740 neuronal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D010656_D007511 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 instituted\VBD\1641914 2\CD\13741022 h\NN\14622893 after\IN\1740 MCAO\NN\1740 does\VBZ\1640855 not\RB\1740 aggravate\NN\1740 edema\NN\14315192 in\IN\13603305 the\DT\1740 ischemic\JJ\1740 core\NN\7996689 ,\,\1740 that\IN\1740 it\PRP\6125041 improves\VBZ\126264 edema\NN\14315192 in\IN\13603305 the\DT\1740 periphery\NN\13903079 of\IN\1740 the\DT\1740 <e2>ischemic</e2>\JJ\1740 territory\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 reduces\VBZ\441445 the\DT\1740 area\NN\8630985 of\IN\1740 histochemical\JJ\1740 neuronal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D010656_D009410 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 instituted\VBD\1641914 2\CD\13741022 h\NN\14622893 after\IN\1740 MCAO\NN\1740 does\VBZ\1640855 not\RB\1740 aggravate\NN\1740 edema\NN\14315192 in\IN\13603305 the\DT\1740 ischemic\JJ\1740 core\NN\7996689 ,\,\1740 that\IN\1740 it\PRP\6125041 improves\VBZ\126264 edema\NN\14315192 in\IN\13603305 the\DT\1740 periphery\NN\13903079 of\IN\1740 the\DT\1740 ischemic\JJ\1740 territory\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 reduces\VBZ\441445 the\DT\1740 area\NN\8630985 of\IN\1740 histochemical\JJ\1740 <e2>neuronal\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
20735774
D000082_D017114 CID Long-term\JJ\1740 prognosis\NN\6748969 for\IN\1740 transplant-free\JJ\1740 survivors\NNS\9630641 of\IN\1740 <e1>paracetamol-induced</e1>\JJ\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 .\.\1740
D000082_D017114 CID BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 prognosis\NN\6748969 for\IN\1740 transplant-free\JJ\1740 survivors\NNS\9630641 of\IN\1740 <e1>paracetamol-induced</e1>\JJ\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 remains\VBZ\2604760 unknown\JJ\1740 .\.\1740
D000082_D017114 CID AIM\NN\5980875 :\:\1740 To\TO\1740 examine\VB\789138 whether\IN\1740 <e1>paracetamol-induced</e1>\JJ\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 increases\VBZ\169651 long-term\JJ\1740 mortality\NN\5054863 .\.\1740
D000082_D017114 CID On\IN\1740 average\JJ\1740 ,\,\1740 age-specific\JJ\1740 mortality\NN\5054863 rates\NNS\13308999 were\VBD\836236 slightly\RB\1740 higher\JJR\1740 for\IN\1740 the\DT\1740 101\CD\1740 patients\NNS\9898892 whose\WP$\1740 <e1>paracetamol-induced</e1>\JJ\1740 liver\NN\5298729 injury\NN\14052046 had\VBD\2108377 caused\VBN\1617192 an\DT\6697703 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 (\-LRB-\1740 adjusted\VBN\126264 mortality\NN\5054863 rate\NN\13815152 ratio\NN\13815152 =\JJ\1740 1.70\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.02\CD\1740 -\SYM\1740 2.85\CD\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 the\DT\1740 association\NN\8008335 was\VBD\836236 age-dependent\JJ\1740 ,\,\1740 and\CC\1740 no\DT\7204911 survivors\NNS\9630641 of\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 died\VBD\146138 of\IN\1740 liver\NN\5298729 disease\NN\14061805 ,\,\1740 whereas\IN\1740 suicides\NNS\219012 were\VBD\836236 frequent\JJ\1740 in\IN\13603305 both\DT\1740 groups\NNS\2137 .\.\1740
D000082_D017114 CID On\IN\1740 average\JJ\1740 ,\,\1740 age-specific\JJ\1740 mortality\NN\5054863 rates\NNS\13308999 were\VBD\836236 slightly\RB\1740 higher\JJR\1740 for\IN\1740 the\DT\1740 101\CD\1740 patients\NNS\9898892 whose\WP$\1740 <e1>paracetamol-induced</e1>\JJ\1740 liver\NN\5298729 injury\NN\14052046 had\VBD\2108377 caused\VBN\1617192 an\DT\6697703 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 adjusted\VBN\126264 mortality\NN\5054863 rate\NN\13815152 ratio\NN\13815152 =\JJ\1740 1.70\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.02\CD\1740 -\SYM\1740 2.85\CD\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 the\DT\1740 association\NN\8008335 was\VBD\836236 age-dependent\JJ\1740 ,\,\1740 and\CC\1740 no\DT\7204911 survivors\NNS\9630641 of\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 died\VBD\146138 of\IN\1740 liver\NN\5298729 disease\NN\14061805 ,\,\1740 whereas\IN\1740 suicides\NNS\219012 were\VBD\836236 frequent\JJ\1740 in\IN\13603305 both\DT\1740 groups\NNS\2137 .\.\1740
D000082_D017114 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Paracetamol-induced</e1>\JJ\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 did\VBD\1640855 not\RB\1740 affect\VB\126264 long-term\JJ\1740 mortality\NN\5054863 .\.\1740
D000082_D056486 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 followed\VBD\1835496 up\RP\1740 all\DT\1740 transplant-free\JJ\1740 survivors\NNS\9630641 of\IN\1740 <e1>paracetamol-induced</e1>\JJ\1740 <e2>acute\JJ\1740 liver\NN\5298729 injury</e2>\NN\14052046 ,\,\1740 hospitalized\VBN\2348568 in\IN\13603305 a\DT\13649268 Danish\JJ\1740 national\JJ\1740 referral\NN\9898892 centre\NN\8497294 during\IN\1740 1984\CD\1740 -\SYM\1740 2004\CD\1740 .\.\1740
D000082_D056486 NONE On\IN\1740 average\JJ\1740 ,\,\1740 age-specific\JJ\1740 mortality\NN\5054863 rates\NNS\13308999 were\VBD\836236 slightly\RB\1740 higher\JJR\1740 for\IN\1740 the\DT\1740 101\CD\1740 patients\NNS\9898892 whose\WP$\1740 <e1>paracetamol-induced</e1>\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 had\VBD\2108377 caused\VBN\1617192 an\DT\6697703 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 adjusted\VBN\126264 mortality\NN\5054863 rate\NN\13815152 ratio\NN\13815152 =\JJ\1740 1.70\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.02\CD\1740 -\SYM\1740 2.85\CD\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 the\DT\1740 association\NN\8008335 was\VBD\836236 age-dependent\JJ\1740 ,\,\1740 and\CC\1740 no\DT\7204911 survivors\NNS\9630641 of\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 died\VBD\146138 of\IN\1740 liver\NN\5298729 disease\NN\14061805 ,\,\1740 whereas\IN\1740 suicides\NNS\219012 were\VBD\836236 frequent\JJ\1740 in\IN\13603305 both\DT\1740 groups\NNS\2137 .\.\1740
D000082_D008107 NONE On\IN\1740 average\JJ\1740 ,\,\1740 age-specific\JJ\1740 mortality\NN\5054863 rates\NNS\13308999 were\VBD\836236 slightly\RB\1740 higher\JJR\1740 for\IN\1740 the\DT\1740 101\CD\1740 patients\NNS\9898892 whose\WP$\1740 <e1>paracetamol-induced</e1>\JJ\1740 liver\NN\5298729 injury\NN\14052046 had\VBD\2108377 caused\VBN\1617192 an\DT\6697703 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 adjusted\VBN\126264 mortality\NN\5054863 rate\NN\13815152 ratio\NN\13815152 =\JJ\1740 1.70\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.02\CD\1740 -\SYM\1740 2.85\CD\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 the\DT\1740 association\NN\8008335 was\VBD\836236 age-dependent\JJ\1740 ,\,\1740 and\CC\1740 no\DT\7204911 survivors\NNS\9630641 of\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 died\VBD\146138 of\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 ,\,\1740 whereas\IN\1740 suicides\NNS\219012 were\VBD\836236 frequent\JJ\1740 in\IN\13603305 both\DT\1740 groups\NNS\2137 .\.\1740
20705401
D012701_D011605 NONE <e1>Serotonin</e1>\NN\14807737 6\CD\13741022 receptor\NN\5225602 gene\NN\8459252 is\VBZ\836236 associated\VBN\628491 with\IN\1740 methamphetamine-induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 in\IN\13603305 a\DT\13649268 Japanese\JJ\1740 population\NN\7942152 .\.\1740
D012701_D011605 NONE These\DT\1740 animal\NN\4475 models\NNS\5888929 were\VBD\836236 considered\VBN\689344 to\TO\1740 reflect\VB\923793 the\DT\1740 positive\JJ\1740 symptoms\NNS\5823932 of\IN\1740 schizophrenia\NN\14398067 ,\,\1740 and\CC\1740 the\DT\1740 above\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 altered\JJ\1740 <e1>5-HT6</e1>\JJ\1740 receptors\NNS\5225602 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e2>psychotic\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D012701_D011605 NONE Therefore\RB\1740 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 an\DT\6697703 analysis\NN\633864 of\IN\1740 the\DT\1740 association\NN\8008335 of\IN\1740 the\DT\1740 <e1>5-HT6</e1>\JJ\1740 gene\NN\8459252 (\-LRB-\1740 HTR6\NN\1740 )\-RRB-\1740 with\IN\1740 METH-induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 .\.\1740
D008694_D011605 CID Serotonin\NN\14807737 6\CD\13741022 receptor\NN\5225602 gene\NN\8459252 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e1>methamphetamine-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 in\IN\13603305 a\DT\13649268 Japanese\JJ\1740 population\NN\7942152 .\.\1740
D008694_D011605 CID The\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e1>methamphetamine</e1>\NN\2704153 (METH)-induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 are\VBP\836236 similar\JJ\1740 to\TO\1740 those\DT\1740 of\IN\1740 paranoid\NN\10490141 type\NN\5839024 schizophrenia\NN\14398067 .\.\1740
D008694_D011605 CID The\DT\1740 symptoms\NNS\5823932 of\IN\1740 methamphetamine\NN\2704153 <e1>(METH)-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 are\VBP\836236 similar\JJ\1740 to\TO\1740 those\DT\1740 of\IN\1740 paranoid\NN\10490141 type\NN\5839024 schizophrenia\NN\14398067 .\.\1740
D008694_D011605 CID Therefore\RB\1740 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 an\DT\6697703 analysis\NN\633864 of\IN\1740 the\DT\1740 association\NN\8008335 of\IN\1740 the\DT\1740 5-HT6\JJ\1740 gene\NN\8459252 (\-LRB-\1740 HTR6\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>METH-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 .\.\1740
D008694_D011605 CID METHOD\NNP\5616786 :\:\1740 Using\VBG\1156834 five\CD\13741022 tagging\NN\1740 SNPs\NNS\11493266 (\-LRB-\1740 rs6693503\NN\1740 ,\,\1740 rs1805054\NN\1740 ,\,\1740 rs4912138\NN\1740 ,\,\1740 rs3790757\NN\1740 and\CC\1740 rs9659997\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 genetic\JJ\1740 association\NN\8008335 analysis\NN\633864 of\IN\1740 case-control\JJ\1740 samples\NNS\5820620 (\-LRB-\1740 197\CD\1740 <e1>METH-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 patients\NNS\9898892 and\CC\1740 337\CD\1740 controls\NNS\5190804 )\-RRB-\1740 in\IN\13603305 the\DT\1740 Japanese\JJ\1740 population\NN\7942152 .\.\1740
D008694_D011605 CID RESULTS\NNS\34213 :\:\1740 rs6693503\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 <e1>METH-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 patients\NNS\9898892 in\IN\13603305 the\DT\1740 allele/genotype-wise\JJ\1740 analysis\NN\633864 .\.\1740
D008694_D011605 CID In\IN\13603305 the\DT\1740 haplotype-wise\JJ\1740 analysis\NN\633864 ,\,\1740 we\PRP\1740 detected\VBD\2163746 an\DT\6697703 association\NN\8008335 between\IN\1740 two\CD\13741022 markers\NNS\21939 (\-LRB-\1740 rs6693503\NN\1740 and\CC\1740 rs1805054\NN\1740 )\-RRB-\1740 and\CC\1740 three\CD\13741022 markers\NNS\21939 (\-LRB-\1740 rs6693503\NN\1740 ,\,\1740 rs1805054\NN\1740 and\CC\1740 rs4912138\NN\1740 )\-RRB-\1740 in\IN\13603305 HTR6\NN\1740 and\CC\1740 <e1>METH-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 patients\NNS\9898892 ,\,\1740 respectively\RB\1740 .\.\1740
D008694_D011605 CID CONCLUSION\NN\5837957 :\:\1740 HTR6\NN\1740 may\MD\15209706 play\VB\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e1>METH-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 in\IN\13603305 the\DT\1740 Japanese\JJ\1740 population\NN\7942152 .\.\1740
D012701_D006948 NONE The\DT\1740 <e1>serotonin</e1>\NN\14807737 6\CD\13741022 (\-LRB-\1740 5-HT6\JJ\1740 )\-RRB-\1740 receptor\NN\5225602 is\VBZ\836236 therapeutically\RB\1740 targeted\VBN\1151110 by\IN\1740 several\JJ\1740 second\JJ\1740 generation\NN\7942152 antipsychotics\NNS\4470232 ,\,\1740 such\JJ\1740 as\IN\14622893 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 ,\,\1740 and\CC\1740 d-amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 corrected\VBN\138508 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 a\DT\13649268 selective\JJ\1740 5-HT6\NN\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
D012701_D006948 NONE The\DT\1740 serotonin\NN\14807737 6\CD\13741022 (\-LRB-\1740 <e1>5-HT6</e1>\JJ\1740 )\-RRB-\1740 receptor\NN\5225602 is\VBZ\836236 therapeutically\RB\1740 targeted\VBN\1151110 by\IN\1740 several\JJ\1740 second\JJ\1740 generation\NN\7942152 antipsychotics\NNS\4470232 ,\,\1740 such\JJ\1740 as\IN\14622893 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 ,\,\1740 and\CC\1740 d-amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 corrected\VBN\138508 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 a\DT\13649268 selective\JJ\1740 5-HT6\NN\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
D012701_D006948 NONE The\DT\1740 serotonin\NN\14807737 6\CD\13741022 (\-LRB-\1740 5-HT6\JJ\1740 )\-RRB-\1740 receptor\NN\5225602 is\VBZ\836236 therapeutically\RB\1740 targeted\VBN\1151110 by\IN\1740 several\JJ\1740 second\JJ\1740 generation\NN\7942152 antipsychotics\NNS\4470232 ,\,\1740 such\JJ\1740 as\IN\14622893 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 ,\,\1740 and\CC\1740 d-amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 corrected\VBN\138508 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 a\DT\13649268 selective\JJ\1740 <e1>5-HT6</e1>\NN\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
D003024_D006948 NONE The\DT\1740 serotonin\NN\14807737 6\CD\13741022 (\-LRB-\1740 5-HT6\JJ\1740 )\-RRB-\1740 receptor\NN\5225602 is\VBZ\836236 therapeutically\RB\1740 targeted\VBN\1151110 by\IN\1740 several\JJ\1740 second\JJ\1740 generation\NN\7942152 antipsychotics\NNS\4470232 ,\,\1740 such\JJ\1740 as\IN\14622893 <e1>clozapine</e1>\NN\3713736 and\CC\1740 olanzapine\NN\1740 ,\,\1740 and\CC\1740 d-amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 corrected\VBN\138508 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 a\DT\13649268 selective\JJ\1740 5-HT6\NN\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
C076029_D006948 NONE The\DT\1740 serotonin\NN\14807737 6\CD\13741022 (\-LRB-\1740 5-HT6\JJ\1740 )\-RRB-\1740 receptor\NN\5225602 is\VBZ\836236 therapeutically\RB\1740 targeted\VBN\1151110 by\IN\1740 several\JJ\1740 second\JJ\1740 generation\NN\7942152 antipsychotics\NNS\4470232 ,\,\1740 such\JJ\1740 as\IN\14622893 clozapine\NN\3713736 and\CC\1740 <e1>olanzapine</e1>\NN\1740 ,\,\1740 and\CC\1740 d-amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 corrected\VBN\138508 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 a\DT\13649268 selective\JJ\1740 5-HT6\NN\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
D003913_D006948 NONE The\DT\1740 serotonin\NN\14807737 6\CD\13741022 (\-LRB-\1740 5-HT6\JJ\1740 )\-RRB-\1740 receptor\NN\5225602 is\VBZ\836236 therapeutically\RB\1740 targeted\VBN\1151110 by\IN\1740 several\JJ\1740 second\JJ\1740 generation\NN\7942152 antipsychotics\NNS\4470232 ,\,\1740 such\JJ\1740 as\IN\14622893 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 ,\,\1740 and\CC\1740 <e1>d-amphetamine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 corrected\VBN\138508 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 a\DT\13649268 selective\JJ\1740 5-HT6\NN\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
D012701_D012559 NONE These\DT\1740 animal\NN\4475 models\NNS\5888929 were\VBD\836236 considered\VBN\689344 to\TO\1740 reflect\VB\923793 the\DT\1740 positive\JJ\1740 symptoms\NNS\5823932 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 ,\,\1740 and\CC\1740 the\DT\1740 above\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 altered\JJ\1740 <e1>5-HT6</e1>\JJ\1740 receptors\NNS\5225602 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 psychotic\JJ\1740 disorders\NNS\14034177 .\.\1740
D008694_D012563 NONE The\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e1>methamphetamine</e1>\NN\2704153 (METH)-induced\JJ\1740 psychosis\NN\14380140 are\VBP\836236 similar\JJ\1740 to\TO\1740 those\DT\1740 of\IN\1740 <e2>paranoid\NN\10490141 type\NN\5839024 schizophrenia</e2>\NN\14398067 .\.\1740
D008694_D012563 NONE The\DT\1740 symptoms\NNS\5823932 of\IN\1740 methamphetamine\NN\2704153 <e1>(METH)-induced</e1>\JJ\1740 psychosis\NN\14380140 are\VBP\836236 similar\JJ\1740 to\TO\1740 those\DT\1740 of\IN\1740 <e2>paranoid\NN\10490141 type\NN\5839024 schizophrenia</e2>\NN\14398067 .\.\1740
14704468
C066440_D012640 NONE <e1>Loreclezole</e1>\NNP\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 exerted\VBD\1158872 a\DT\13649268 significant\JJ\1740 protective\JJ\1740 action\NN\30358 in\IN\13603305 amygdala-kindled\JJ\1740 rats\NNS\2329401 ,\,\1740 reducing\VBG\441445 both\CC\1740 <e2>seizure</e2>\JJ\1740 and\CC\1740 afterdischarge\JJ\1740 durations\NNS\15113229 .\.\1740
18006530
D015742_D010146 CID Reduction\NN\351485 of\IN\1740 <e2>pain</e2>\NN\14299637 during\IN\1740 induction\NN\7450842 with\IN\1740 target-controlled\JJ\1740 <e1>propofol</e1>\NN\1740 and\CC\1740 remifentanil\NN\1740 .\.\1740
D015742_D010146 CID BACKGROUND\NN\4921011 :\:\1740 <e2>Pain</e2>\NN\14299637 on\IN\1740 injection\NN\320852 of\IN\1740 <e1>propofol</e1>\NN\1740 is\VBZ\836236 unpleasant\JJ\1740 .\.\1740
D015742_D010146 CID We\PRP\1740 hypothesized\VBD\719734 that\IN\1740 <e1>propofol</e1>\NN\1740 infusion\NN\14589223 <e2>pain</e2>\NN\14299637 might\MD\5029706 be\VB\836236 prevented\VBN\1740 by\IN\1740 infusing\VBG\606335 remifentanil\NN\1740 before\IN\1740 starting\VBG\2009433 the\DT\1740 propofol\NN\1740 infusion\NN\14589223 in\IN\13603305 a\DT\13649268 clinical\JJ\1740 setting\NN\8567235 where\WRB\1740 target-controlled\JJ\1740 infusions\NNS\14589223 (\-LRB-\1740 TCI\NNP\1740 )\-RRB-\1740 of\IN\1740 both\DT\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 .\.\1740
D015742_D010146 CID We\PRP\1740 hypothesized\VBD\719734 that\IN\1740 propofol\NN\1740 infusion\NN\14589223 <e2>pain</e2>\NN\14299637 might\MD\5029706 be\VB\836236 prevented\VBN\1740 by\IN\1740 infusing\VBG\606335 remifentanil\NN\1740 before\IN\1740 starting\VBG\2009433 the\DT\1740 <e1>propofol</e1>\NN\1740 infusion\NN\14589223 in\IN\13603305 a\DT\13649268 clinical\JJ\1740 setting\NN\8567235 where\WRB\1740 target-controlled\JJ\1740 infusions\NNS\14589223 (\-LRB-\1740 TCI\NNP\1740 )\-RRB-\1740 of\IN\1740 both\DT\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 .\.\1740
D015742_D010146 CID Remifentanil-related\JJ\1740 complications\NNS\1073995 were\VBD\836236 assessed\VBN\670261 during\IN\1740 the\DT\1740 remifentanil\NN\1740 infusion\NN\14589223 ,\,\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 caused\VBN\1617192 by\IN\1740 <e1>propofol</e1>\NN\1740 was\VBD\836236 evaluated\VBN\670261 using\VBG\1156834 a\DT\13649268 four-point\JJ\1740 scale\NN\7260623 during\IN\1740 the\DT\1740 propofol\NN\1740 infusion\NN\14589223 .\.\1740
D015742_D010146 CID Remifentanil-related\JJ\1740 complications\NNS\1073995 were\VBD\836236 assessed\VBN\670261 during\IN\1740 the\DT\1740 remifentanil\NN\1740 infusion\NN\14589223 ,\,\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 caused\VBN\1617192 by\IN\1740 propofol\NN\1740 was\VBD\836236 evaluated\VBN\670261 using\VBG\1156834 a\DT\13649268 four-point\JJ\1740 scale\NN\7260623 during\IN\1740 the\DT\1740 <e1>propofol</e1>\NN\1740 infusion\NN\14589223 .\.\1740
D015742_D010146 CID CONCLUSIONS\NNS\5837957 :\:\1740 During\IN\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 with\IN\1740 TCI\NNP\1740 of\IN\1740 <e1>propofol</e1>\NN\1740 and\CC\1740 remifentanil\NN\1740 ,\,\1740 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 propofol\NN\1740 infusion\NN\14589223 <e2>pain</e2>\NN\14299637 was\VBD\836236 achieved\VBN\2524171 without\IN\1740 significant\JJ\1740 complications\NNS\1073995 by\IN\1740 prior\JJ\1740 administration\NN\1133281 of\IN\1740 remifentanil\NN\1740 at\IN\14622893 a\DT\13649268 target\NN\7258332 Ce\NN\14625458 of\IN\1740 4\CD\13741022 ng\NN\13717155 ml(-1\NN\1740 )\-RRB-\1740 .\.\1740
D015742_D010146 CID CONCLUSIONS\NNS\5837957 :\:\1740 During\IN\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 with\IN\1740 TCI\NNP\1740 of\IN\1740 propofol\NN\1740 and\CC\1740 remifentanil\NN\1740 ,\,\1740 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 <e1>propofol</e1>\NN\1740 infusion\NN\14589223 <e2>pain</e2>\NN\14299637 was\VBD\836236 achieved\VBN\2524171 without\IN\1740 significant\JJ\1740 complications\NNS\1073995 by\IN\1740 prior\JJ\1740 administration\NN\1133281 of\IN\1740 remifentanil\NN\1740 at\IN\14622893 a\DT\13649268 target\NN\7258332 Ce\NN\14625458 of\IN\1740 4\CD\13741022 ng\NN\13717155 ml(-1\NN\1740 )\-RRB-\1740 .\.\1740
C071741_D010146 NONE Reduction\NN\351485 of\IN\1740 <e2>pain</e2>\NN\14299637 during\IN\1740 induction\NN\7450842 with\IN\1740 target-controlled\JJ\1740 propofol\NN\1740 and\CC\1740 <e1>remifentanil</e1>\NN\1740 .\.\1740
C071741_D010146 NONE We\PRP\1740 hypothesized\VBD\719734 that\IN\1740 propofol\NN\1740 infusion\NN\14589223 <e2>pain</e2>\NN\14299637 might\MD\5029706 be\VB\836236 prevented\VBN\1740 by\IN\1740 infusing\VBG\606335 <e1>remifentanil</e1>\NN\1740 before\IN\1740 starting\VBG\2009433 the\DT\1740 propofol\NN\1740 infusion\NN\14589223 in\IN\13603305 a\DT\13649268 clinical\JJ\1740 setting\NN\8567235 where\WRB\1740 target-controlled\JJ\1740 infusions\NNS\14589223 (\-LRB-\1740 TCI\NNP\1740 )\-RRB-\1740 of\IN\1740 both\DT\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 .\.\1740
C071741_D010146 NONE A\DT\13649268 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 was\VBD\836236 performed\VBN\2367363 to\TO\1740 determine\VB\1645601 the\DT\1740 effect-site\JJ\1740 concentration\NN\4916342 (\-LRB-\1740 Ce\NN\14625458 )\-RRB-\1740 of\IN\1740 <e1>remifentanil</e1>\NN\1740 to\TO\1740 prevent\VB\1740 the\DT\1740 <e2>pain</e2>\NN\14299637 without\IN\1740 producing\VBG\1617192 complications\NNS\1073995 .\.\1740
C071741_D010146 NONE <e1>Remifentanil-related</e1>\JJ\1740 complications\NNS\1073995 were\VBD\836236 assessed\VBN\670261 during\IN\1740 the\DT\1740 remifentanil\NN\1740 infusion\NN\14589223 ,\,\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 caused\VBN\1617192 by\IN\1740 propofol\NN\1740 was\VBD\836236 evaluated\VBN\670261 using\VBG\1156834 a\DT\13649268 four-point\JJ\1740 scale\NN\7260623 during\IN\1740 the\DT\1740 propofol\NN\1740 infusion\NN\14589223 .\.\1740
C071741_D010146 NONE Remifentanil-related\JJ\1740 complications\NNS\1073995 were\VBD\836236 assessed\VBN\670261 during\IN\1740 the\DT\1740 <e1>remifentanil</e1>\NN\1740 infusion\NN\14589223 ,\,\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 caused\VBN\1617192 by\IN\1740 propofol\NN\1740 was\VBD\836236 evaluated\VBN\670261 using\VBG\1156834 a\DT\13649268 four-point\JJ\1740 scale\NN\7260623 during\IN\1740 the\DT\1740 propofol\NN\1740 infusion\NN\14589223 .\.\1740
C071741_D010146 NONE CONCLUSIONS\NNS\5837957 :\:\1740 During\IN\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 with\IN\1740 TCI\NNP\1740 of\IN\1740 propofol\NN\1740 and\CC\1740 <e1>remifentanil</e1>\NN\1740 ,\,\1740 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 propofol\NN\1740 infusion\NN\14589223 <e2>pain</e2>\NN\14299637 was\VBD\836236 achieved\VBN\2524171 without\IN\1740 significant\JJ\1740 complications\NNS\1073995 by\IN\1740 prior\JJ\1740 administration\NN\1133281 of\IN\1740 remifentanil\NN\1740 at\IN\14622893 a\DT\13649268 target\NN\7258332 Ce\NN\14625458 of\IN\1740 4\CD\13741022 ng\NN\13717155 ml(-1\NN\1740 )\-RRB-\1740 .\.\1740
C071741_D010146 NONE CONCLUSIONS\NNS\5837957 :\:\1740 During\IN\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 with\IN\1740 TCI\NNP\1740 of\IN\1740 propofol\NN\1740 and\CC\1740 remifentanil\NN\1740 ,\,\1740 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 propofol\NN\1740 infusion\NN\14589223 <e2>pain</e2>\NN\14299637 was\VBD\836236 achieved\VBN\2524171 without\IN\1740 significant\JJ\1740 complications\NNS\1073995 by\IN\1740 prior\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>remifentanil</e1>\NN\1740 at\IN\14622893 a\DT\13649268 target\NN\7258332 Ce\NN\14625458 of\IN\1740 4\CD\13741022 ng\NN\13717155 ml(-1\NN\1740 )\-RRB-\1740 .\.\1740
8045270
C081198_D002375 NONE Oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>KF17837</e1>\NN\1740 (\-LRB-\1740 2.5\CD\1740 ,\,\1740 10.0\CD\1740 and\CC\1740 30.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 significantly\RB\1740 ameliorated\VBD\126264 the\DT\1740 <e2>cataleptic</e2>\JJ\1740 responses\NNS\11410625 induced\VBN\1627355 by\IN\1740 intracerebroventricular\JJ\1740 administration\NN\1133281 of\IN\1740 an\DT\6697703 adenosine\NN\14964367 A2A\NN\1740 receptor\NN\5225602 agonist\NN\9613191 ,\,\1740 CGS\NN\13577934 21680\CD\1740 (\-LRB-\1740 10\CD\13745420 micrograms\NNS\13717155 )\-RRB-\1740 ,\,\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 .\.\1740
C081198_D002375 NONE <e1>KF17837</e1>\NN\1740 also\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 by\IN\1740 reserpine\NN\2721160 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D000241_D002375 NONE Oral\JJ\1740 administration\NN\1133281 of\IN\1740 KF17837\NN\1740 (\-LRB-\1740 2.5\CD\1740 ,\,\1740 10.0\CD\1740 and\CC\1740 30.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 significantly\RB\1740 ameliorated\VBD\126264 the\DT\1740 <e2>cataleptic</e2>\JJ\1740 responses\NNS\11410625 induced\VBN\1627355 by\IN\1740 intracerebroventricular\JJ\1740 administration\NN\1133281 of\IN\1740 an\DT\6697703 <e1>adenosine</e1>\NN\14964367 A2A\NN\1740 receptor\NN\5225602 agonist\NN\9613191 ,\,\1740 CGS\NN\13577934 21680\CD\1740 (\-LRB-\1740 10\CD\13745420 micrograms\NNS\13717155 )\-RRB-\1740 ,\,\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 .\.\1740
C061282_D002375 CID Oral\JJ\1740 administration\NN\1133281 of\IN\1740 KF17837\NN\1740 (\-LRB-\1740 2.5\CD\1740 ,\,\1740 10.0\CD\1740 and\CC\1740 30.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 significantly\RB\1740 ameliorated\VBD\126264 the\DT\1740 <e2>cataleptic</e2>\JJ\1740 responses\NNS\11410625 induced\VBN\1627355 by\IN\1740 intracerebroventricular\JJ\1740 administration\NN\1133281 of\IN\1740 an\DT\6697703 adenosine\NN\14964367 A2A\NN\1740 receptor\NN\5225602 agonist\NN\9613191 ,\,\1740 <e1>CGS\NN\13577934 21680</e1>\CD\1740 (\-LRB-\1740 10\CD\13745420 micrograms\NNS\13717155 )\-RRB-\1740 ,\,\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 .\.\1740
D006220_D002375 CID KF17837\NN\1740 also\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 by\IN\1740 reserpine\NN\2721160 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D012110_D002375 CID KF17837\NN\1740 also\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 by\IN\1740 <e1>reserpine</e1>\NN\2721160 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
C081198_D010302 NONE Furthermore\RB\1740 ,\,\1740 <e1>KF17837</e1>\NN\1740 may\MD\15209706 be\VB\836236 a\DT\13649268 useful\JJ\1740 drug\NN\14778436 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>parkinsonism</e2>\NN\14085708 .\.\1740
17344330
D008691_D013575 CID <e2>Syncope</e2>\NN\7478169 and\CC\1740 QT\NNP\1740 prolongation\NN\1017987 among\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>methadone</e1>\NN\3808564 for\IN\1740 heroin\JJ\1740 dependence\NN\24720 in\IN\13603305 the\DT\1740 city\NN\8626283 of\IN\1740 Copenhagen\NNP\1740 .\.\1740
D008691_D013575 CID As\IN\14622893 heroin\NN\3492717 addicts\NNS\10059582 sometimes\RB\1740 faint\VBP\23868 while\IN\15122231 using\VBG\1156834 illicit\NN\1740 drugs\NNS\14778436 ,\,\1740 doctors\NNS\10305802 might\MD\5029706 attribute\VB\670261 too\RB\1740 many\JJ\1740 episodes\NNS\7283608 of\IN\1740 <e2>syncope</e2>\NN\7478169 to\TO\1740 illicit\VB\1740 drug\NN\14778436 use\NN\407535 and\CC\1740 thereby\RB\1740 underestimate\VB\695226 the\DT\1740 incidence\NN\13821570 of\IN\1740 TdP\NN\1740 in\IN\13603305 this\DT\1740 special\JJ\1740 population\NN\7942152 ,\,\1740 and\CC\1740 the\DT\1740 high\JJ\1740 mortality\NN\5054863 in\IN\13603305 this\DT\1740 population\NN\7942152 may\MD\15209706 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 be\VB\836236 caused\VBN\1617192 by\IN\1740 the\DT\1740 proarrhythmic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>methadone</e1>\NN\3808564 .\.\1740
D008691_D013575 CID The\DT\1740 association\NN\8008335 between\IN\1740 opioid\NN\1740 dose\NN\3740161 and\CC\1740 QT\CD\1740 ,\,\1740 and\CC\1740 <e1>methadone</e1>\NN\3808564 dose\NN\3740161 and\CC\1740 reporting\NN\6681177 of\IN\1740 <e2>syncope</e2>\NN\7478169 was\VBD\836236 assessed\VBN\670261 using\VBG\1156834 multivariate\JJ\1740 linear\JJ\1740 regression\NN\14501726 and\CC\1740 logistic\JJ\1740 regression\NN\14501726 ,\,\1740 respectively\RB\1740 .\.\1740
D008691_D013575 CID A\DT\13649268 50\CD\13745420 mg\NN\13717155 higher\JJR\1740 <e1>methadone</e1>\NN\3808564 dose\NN\3740161 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 1.2\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.1\CD\1740 to\TO\1740 1.4\CD\1740 )\-RRB-\1740 times\NNS\15113229 higher\JJR\1740 odds\NNS\4756635 for\IN\1740 <e2>syncope</e2>\NN\7478169 .\.\1740
D008691_D013575 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Methadone</e1>\NN\3808564 is\VBZ\836236 associated\VBN\628491 with\IN\1740 QT\NN\1740 prolongation\NN\1017987 and\CC\1740 higher\JJR\1740 reporting\NN\6681177 of\IN\1740 <e2>syncope</e2>\NN\7478169 in\IN\13603305 a\DT\13649268 population\NN\7942152 of\IN\1740 heroin\NN\3492717 addicts\NNS\10059582 .\.\1740
D008691_D008133 CID Syncope\NN\7478169 and\CC\1740 <e2>QT\NNP\1740 prolongation</e2>\NN\1017987 among\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>methadone</e1>\NN\3808564 for\IN\1740 heroin\JJ\1740 dependence\NN\24720 in\IN\13603305 the\DT\1740 city\NN\8626283 of\IN\1740 Copenhagen\NNP\1740 .\.\1740
D008691_D008133 CID Among\IN\1740 the\DT\1740 subjects\NNS\6598915 treated\VBN\2376958 with\IN\1740 <e1>methadone</e1>\NN\3808564 ,\,\1740 28\CD\13745420 %\NN\1740 men\NNS\8208016 and\CC\1740 32\CD\1740 %\NN\1740 women\NNS\9605289 had\VBD\2108377 <e2>prolonged\VBN\317700 QTc\NN\1740 interval</e2>\NN\33615 .\.\1740
D008691_D008133 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Methadone</e1>\NN\3808564 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 and\CC\1740 higher\JJR\1740 reporting\NN\6681177 of\IN\1740 syncope\NN\7478169 in\IN\13603305 a\DT\13649268 population\NN\7942152 of\IN\1740 heroin\NN\3492717 addicts\NNS\10059582 .\.\1740
D003932_D013575 NONE <e2>Syncope</e2>\NN\7478169 and\CC\1740 QT\NNP\1740 prolongation\NN\1017987 among\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 methadone\NN\3808564 for\IN\1740 <e1>heroin</e1>\JJ\1740 dependence\NN\24720 in\IN\13603305 the\DT\1740 city\NN\8626283 of\IN\1740 Copenhagen\NNP\1740 .\.\1740
D003932_D013575 NONE As\IN\14622893 <e1>heroin</e1>\NN\3492717 addicts\NNS\10059582 sometimes\RB\1740 faint\VBP\23868 while\IN\15122231 using\VBG\1156834 illicit\NN\1740 drugs\NNS\14778436 ,\,\1740 doctors\NNS\10305802 might\MD\5029706 attribute\VB\670261 too\RB\1740 many\JJ\1740 episodes\NNS\7283608 of\IN\1740 <e2>syncope</e2>\NN\7478169 to\TO\1740 illicit\VB\1740 drug\NN\14778436 use\NN\407535 and\CC\1740 thereby\RB\1740 underestimate\VB\695226 the\DT\1740 incidence\NN\13821570 of\IN\1740 TdP\NN\1740 in\IN\13603305 this\DT\1740 special\JJ\1740 population\NN\7942152 ,\,\1740 and\CC\1740 the\DT\1740 high\JJ\1740 mortality\NN\5054863 in\IN\13603305 this\DT\1740 population\NN\7942152 may\MD\15209706 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 be\VB\836236 caused\VBN\1617192 by\IN\1740 the\DT\1740 proarrhythmic\JJ\1740 effect\NN\34213 of\IN\1740 methadone\NN\3808564 .\.\1740
D003932_D013575 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Methadone\NN\3808564 is\VBZ\836236 associated\VBN\628491 with\IN\1740 QT\NN\1740 prolongation\NN\1017987 and\CC\1740 higher\JJR\1740 reporting\NN\6681177 of\IN\1740 <e2>syncope</e2>\NN\7478169 in\IN\13603305 a\DT\13649268 population\NN\7942152 of\IN\1740 <e1>heroin</e1>\NN\3492717 addicts\NNS\10059582 .\.\1740
D003932_D008133 NONE Syncope\NN\7478169 and\CC\1740 <e2>QT\NNP\1740 prolongation</e2>\NN\1017987 among\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 methadone\NN\3808564 for\IN\1740 <e1>heroin</e1>\JJ\1740 dependence\NN\24720 in\IN\13603305 the\DT\1740 city\NN\8626283 of\IN\1740 Copenhagen\NNP\1740 .\.\1740
D003932_D008133 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Methadone\NN\3808564 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 and\CC\1740 higher\JJR\1740 reporting\NN\6681177 of\IN\1740 syncope\NN\7478169 in\IN\13603305 a\DT\13649268 population\NN\7942152 of\IN\1740 <e1>heroin</e1>\NN\3492717 addicts\NNS\10059582 .\.\1740
D008691_D016171 NONE Prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 interval\NN\33615 in\IN\13603305 the\DT\1740 ECG\NN\7000195 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>torsade\NN\1740 de\IN\1740 pointes</e2>\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 <e1>methadone</e1>\NN\3808564 users\NNS\7846 .\.\1740
D008691_D016171 NONE Prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 interval\NN\33615 in\IN\13603305 the\DT\1740 ECG\NN\7000195 of\IN\1740 patients\NNS\9898892 with\IN\1740 torsade\NN\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 <e2>TdP</e2>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 <e1>methadone</e1>\NN\3808564 users\NNS\7846 .\.\1740
D008691_D016171 NONE As\IN\14622893 heroin\NN\3492717 addicts\NNS\10059582 sometimes\RB\1740 faint\VBP\23868 while\IN\15122231 using\VBG\1156834 illicit\NN\1740 drugs\NNS\14778436 ,\,\1740 doctors\NNS\10305802 might\MD\5029706 attribute\VB\670261 too\RB\1740 many\JJ\1740 episodes\NNS\7283608 of\IN\1740 syncope\NN\7478169 to\TO\1740 illicit\VB\1740 drug\NN\14778436 use\NN\407535 and\CC\1740 thereby\RB\1740 underestimate\VB\695226 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>TdP</e2>\NN\1740 in\IN\13603305 this\DT\1740 special\JJ\1740 population\NN\7942152 ,\,\1740 and\CC\1740 the\DT\1740 high\JJ\1740 mortality\NN\5054863 in\IN\13603305 this\DT\1740 population\NN\7942152 may\MD\15209706 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 be\VB\836236 caused\VBN\1617192 by\IN\1740 the\DT\1740 proarrhythmic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>methadone</e1>\NN\3808564 .\.\1740
D003932_D016171 NONE As\IN\14622893 <e1>heroin</e1>\NN\3492717 addicts\NNS\10059582 sometimes\RB\1740 faint\VBP\23868 while\IN\15122231 using\VBG\1156834 illicit\NN\1740 drugs\NNS\14778436 ,\,\1740 doctors\NNS\10305802 might\MD\5029706 attribute\VB\670261 too\RB\1740 many\JJ\1740 episodes\NNS\7283608 of\IN\1740 syncope\NN\7478169 to\TO\1740 illicit\VB\1740 drug\NN\14778436 use\NN\407535 and\CC\1740 thereby\RB\1740 underestimate\VB\695226 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>TdP</e2>\NN\1740 in\IN\13603305 this\DT\1740 special\JJ\1740 population\NN\7942152 ,\,\1740 and\CC\1740 the\DT\1740 high\JJ\1740 mortality\NN\5054863 in\IN\13603305 this\DT\1740 population\NN\7942152 may\MD\15209706 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 be\VB\836236 caused\VBN\1617192 by\IN\1740 the\DT\1740 proarrhythmic\JJ\1740 effect\NN\34213 of\IN\1740 methadone\NN\3808564 .\.\1740
9799166
D003042_D020521 CID <e2>Stroke</e2>\NN\556313 and\CC\1740 <e1>cocaine</e1>\NN\3492717 or\CC\3541091 amphetamine\NN\3248958 use\NN\407535 .\.\1740
D003042_D020521 CID The\DT\1740 association\NN\8008335 of\IN\1740 <e1>cocaine</e1>\NN\3492717 and\CC\1740 amphetamine\NN\3248958 use\NN\407535 with\IN\1740 hemorrhagic\JJ\1740 and\CC\1740 ischemic\JJ\1740 <e2>stroke</e2>\NN\556313 is\VBZ\836236 based\VBN\2694933 almost\RB\1740 solely\RB\1740 on\IN\1740 data\NNS\7951464 from\IN\1740 case\NN\7283608 series\NN\8456993 .\.\1740
D003042_D020521 CID The\DT\1740 limited\JJ\1740 number\NN\5107765 of\IN\1740 epidemiologic\JJ\1740 studies\NNS\635850 of\IN\1740 <e2>stroke</e2>\NN\556313 and\CC\1740 use\NN\407535 of\IN\1740 <e1>cocaine</e1>\NN\3492717 and/or\CC\1740 amphetamine\NN\3248958 have\VBP\2108377 been\VBN\836236 done\VBN\1640855 in\IN\13603305 settings\NNS\8567235 that\WDT\1740 serve\VBP\2669789 mostly\RB\1740 the\DT\1740 poor\JJ\1740 and/or\CC\1740 minorities\NNS\7950920 .\.\1740
D003042_D020521 CID The\DT\1740 univariate\NN\1740 matched\VBN\2664769 odds\NNS\4756635 ratio\NN\13815152 for\IN\1740 <e2>stroke</e2>\NN\556313 in\IN\13603305 women\NNS\9605289 who\WP\8299493 admitted\VBD\822367 to\TO\1740 using\VBG\1156834 <e1>cocaine</e1>\NN\3492717 and/or\CC\1740 amphetamine\NN\3248958 was\VBD\836236 8.5\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 =\JJ\1740 3.6\CD\1740 -\SYM\1740 20.0\CD\1740 )\-RRB-\1740 .\.\1740
D003042_D020521 CID The\DT\1740 use\NN\407535 of\IN\1740 <e1>cocaine</e1>\NN\3492717 and/or\CC\1740 amphetamine\NN\3248958 is\VBZ\836236 a\DT\13649268 strong\JJ\1740 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>stroke</e2>\NN\556313 in\IN\13603305 this\DT\1740 socioeconomically\RB\1740 heterogeneous\JJ\1740 ,\,\1740 insured\VBN\664483 urban\JJ\1740 population\NN\7942152 .\.\1740
D000661_D020521 CID <e2>Stroke</e2>\NN\556313 and\CC\1740 cocaine\NN\3492717 or\CC\3541091 <e1>amphetamine</e1>\NN\3248958 use\NN\407535 .\.\1740
D000661_D020521 CID The\DT\1740 association\NN\8008335 of\IN\1740 cocaine\NN\3492717 and\CC\1740 <e1>amphetamine</e1>\NN\3248958 use\NN\407535 with\IN\1740 hemorrhagic\JJ\1740 and\CC\1740 ischemic\JJ\1740 <e2>stroke</e2>\NN\556313 is\VBZ\836236 based\VBN\2694933 almost\RB\1740 solely\RB\1740 on\IN\1740 data\NNS\7951464 from\IN\1740 case\NN\7283608 series\NN\8456993 .\.\1740
D000661_D020521 CID The\DT\1740 limited\JJ\1740 number\NN\5107765 of\IN\1740 epidemiologic\JJ\1740 studies\NNS\635850 of\IN\1740 <e2>stroke</e2>\NN\556313 and\CC\1740 use\NN\407535 of\IN\1740 cocaine\NN\3492717 and/or\CC\1740 <e1>amphetamine</e1>\NN\3248958 have\VBP\2108377 been\VBN\836236 done\VBN\1640855 in\IN\13603305 settings\NNS\8567235 that\WDT\1740 serve\VBP\2669789 mostly\RB\1740 the\DT\1740 poor\JJ\1740 and/or\CC\1740 minorities\NNS\7950920 .\.\1740
D000661_D020521 CID The\DT\1740 univariate\NN\1740 matched\VBN\2664769 odds\NNS\4756635 ratio\NN\13815152 for\IN\1740 <e2>stroke</e2>\NN\556313 in\IN\13603305 women\NNS\9605289 who\WP\8299493 admitted\VBD\822367 to\TO\1740 using\VBG\1156834 cocaine\NN\3492717 and/or\CC\1740 <e1>amphetamine</e1>\NN\3248958 was\VBD\836236 8.5\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 =\JJ\1740 3.6\CD\1740 -\SYM\1740 20.0\CD\1740 )\-RRB-\1740 .\.\1740
D000661_D020521 CID The\DT\1740 use\NN\407535 of\IN\1740 cocaine\NN\3492717 and/or\CC\1740 <e1>amphetamine</e1>\NN\3248958 is\VBZ\836236 a\DT\13649268 strong\JJ\1740 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>stroke</e2>\NN\556313 in\IN\13603305 this\DT\1740 socioeconomically\RB\1740 heterogeneous\JJ\1740 ,\,\1740 insured\VBN\664483 urban\JJ\1740 population\NN\7942152 .\.\1740
D003042_D007511 NONE The\DT\1740 association\NN\8008335 of\IN\1740 <e1>cocaine</e1>\NN\3492717 and\CC\1740 amphetamine\NN\3248958 use\NN\407535 with\IN\1740 hemorrhagic\JJ\1740 and\CC\1740 <e2>ischemic</e2>\JJ\1740 stroke\NN\556313 is\VBZ\836236 based\VBN\2694933 almost\RB\1740 solely\RB\1740 on\IN\1740 data\NNS\7951464 from\IN\1740 case\NN\7283608 series\NN\8456993 .\.\1740
D000661_D007511 NONE The\DT\1740 association\NN\8008335 of\IN\1740 cocaine\NN\3492717 and\CC\1740 <e1>amphetamine</e1>\NN\3248958 use\NN\407535 with\IN\1740 hemorrhagic\JJ\1740 and\CC\1740 <e2>ischemic</e2>\JJ\1740 stroke\NN\556313 is\VBZ\836236 based\VBN\2694933 almost\RB\1740 solely\RB\1740 on\IN\1740 data\NNS\7951464 from\IN\1740 case\NN\7283608 series\NN\8456993 .\.\1740
11226639
D008550_D053608 CID Dual\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>melatonin</e1>\NN\5407119 on\IN\1740 barbiturate-induced\JJ\1740 <e2>narcosis</e2>\NN\5678932 in\IN\13603305 rats\NNS\2329401 .\.\1740
D008550_D053608 CID <e1>Melatonin</e1>\NNP\5407119 affects\VBZ\126264 the\DT\1740 circadian\JJ\1740 sleep/wake\NN\1740 cycle\NN\15269513 ,\,\1740 but\CC\1740 it\PRP\6125041 is\VBZ\836236 not\RB\1740 clear\JJ\1740 whether\IN\1740 it\PRP\6125041 may\MD\15209706 influence\VB\137313 drug-induced\JJ\1740 <e2>narcosis</e2>\NN\5678932 .\.\1740
D008550_D053608 CID <e1>Melatonin</e1>\NN\5407119 pre-treatment\NN\1740 affected\VBD\126264 in\IN\13603305 a\DT\13649268 dual\JJ\1740 manner\NN\4916342 barbiturate\NN\4166841 <e2>narcosis</e2>\NN\5678932 ,\,\1740 however\RB\1740 ,\,\1740 no\DT\7204911 dose-effect\JJ\1740 correlation\NN\13841213 was\VBD\836236 found\VBN\2426171 .\.\1740
D008550_D053608 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 the\DT\1740 highest\JJS\1740 dose\NN\3740161 of\IN\1740 <e1>melatonin</e1>\NN\5407119 (\-LRB-\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 caused\VBD\1617192 a\DT\13649268 paradoxical\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 latency\NN\15269513 and\CC\1740 produced\VBD\1617192 a\DT\13649268 sustained\JJ\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 <e2>narcosis</e2>\NN\5678932 ,\,\1740 and\CC\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 mortality\NN\5054863 rate\NN\13815152 .\.\1740
D008550_D053608 CID <e1>Melatonin</e1>\NN\5407119 0.5\CD\1740 and\CC\1740 5\CD\13741022 mg/kg\NN\1740 influenced\VBD\137313 the\DT\1740 duration\NN\15113229 but\CC\1740 not\RB\1740 the\DT\1740 latency\NN\15269513 of\IN\1740 ketamine-\NN\1740 or\CC\3541091 diazepam-induced\JJ\1740 <e2>narcosis</e2>\NN\5678932 .\.\1740
D008550_D053608 CID Thus\RB\1740 ,\,\1740 the\DT\1740 dual\JJ\1740 action\NN\30358 of\IN\1740 <e1>melatonin</e1>\NN\5407119 on\IN\1740 pharmacological\JJ\1740 <e2>narcosis</e2>\NN\5678932 seems\VBZ\2604760 to\TO\1740 be\VB\836236 specific\JJ\1740 for\IN\1740 the\DT\1740 barbiturate\NN\4166841 mechanism\NN\13446390 of\IN\1740 action\NN\30358 .\.\1740
C032232_D053608 NONE Dual\JJ\1740 effects\NNS\13245626 of\IN\1740 melatonin\NN\5407119 on\IN\1740 <e1>barbiturate-induced</e1>\JJ\1740 <e2>narcosis</e2>\NN\5678932 in\IN\13603305 rats\NNS\2329401 .\.\1740
C032232_D053608 NONE Melatonin\NN\5407119 pre-treatment\NN\1740 affected\VBD\126264 in\IN\13603305 a\DT\13649268 dual\JJ\1740 manner\NN\4916342 <e1>barbiturate</e1>\NN\4166841 <e2>narcosis</e2>\NN\5678932 ,\,\1740 however\RB\1740 ,\,\1740 no\DT\7204911 dose-effect\JJ\1740 correlation\NN\13841213 was\VBD\836236 found\VBN\2426171 .\.\1740
C032232_D053608 NONE In\IN\13603305 particular\JJ\1740 ,\,\1740 low\JJ\1740 doses\NNS\3740161 reduced\VBD\441445 the\DT\1740 latency\NN\15269513 to\TO\1740 and\CC\1740 prolonged\VBD\317700 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>barbiturate</e1>\NN\4166841 <e2>narcosis</e2>\NN\5678932 .\.\1740
C032232_D053608 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 dual\JJ\1740 action\NN\30358 of\IN\1740 melatonin\NN\5407119 on\IN\1740 pharmacological\JJ\1740 <e2>narcosis</e2>\NN\5678932 seems\VBZ\2604760 to\TO\1740 be\VB\836236 specific\JJ\1740 for\IN\1740 the\DT\1740 <e1>barbiturate</e1>\NN\4166841 mechanism\NN\13446390 of\IN\1740 action\NN\30358 .\.\1740
D007649_D053608 CID Melatonin\NN\5407119 0.5\CD\1740 and\CC\1740 5\CD\13741022 mg/kg\NN\1740 influenced\VBD\137313 the\DT\1740 duration\NN\15113229 but\CC\1740 not\RB\1740 the\DT\1740 latency\NN\15269513 of\IN\1740 <e1>ketamine-</e1>\NN\1740 or\CC\3541091 diazepam-induced\JJ\1740 <e2>narcosis</e2>\NN\5678932 .\.\1740
D003975_D053608 CID Melatonin\NN\5407119 0.5\CD\1740 and\CC\1740 5\CD\13741022 mg/kg\NN\1740 influenced\VBD\137313 the\DT\1740 duration\NN\15113229 but\CC\1740 not\RB\1740 the\DT\1740 latency\NN\15269513 of\IN\1740 ketamine-\NN\1740 or\CC\3541091 <e1>diazepam-induced</e1>\JJ\1740 <e2>narcosis</e2>\NN\5678932 .\.\1740
2894433
D003975_D001919 CID <e1>Diazepam</e1>\NNS\2830852 facilitates\VBZ\2547586 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 in\IN\13603305 conscious\JJ\1740 rats\NNS\2329401 .\.\1740
D003975_D001919 CID Intravenous\JJ\1740 pretreatment\NN\1740 of\IN\1740 the\DT\1740 rats\NNS\2329401 with\IN\1740 <e1>diazepam</e1>\NNS\2830852 ,\,\1740 although\IN\1740 causing\VBG\1617192 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 adrenaline-induced\JJ\1740 pressor\NN\9190918 effect\NN\34213 ,\,\1740 did\VBD\1640855 enhance\VB\227165 the\DT\1740 adrenaline-induced\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
D003975_D001919 CID However\RB\1740 ,\,\1740 the\DT\1740 <e1>diazepam</e1>\NN\2830852 enhancement\NN\248977 of\IN\1740 adrenaline-induced\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 antagonized\VBN\1787955 by\IN\1740 pretreatment\NN\1740 of\IN\1740 rats\NNS\2329401 with\IN\1740 an\DT\6697703 intravenous\JJ\1740 dose\NN\3740161 of\IN\1740 picrotoxin\NN\1740 (\-LRB-\1740 an\DT\6697703 agent\NN\7347 blocks\VBZ\1476483 chloride\NN\14818238 channels\NNS\6251781 by\IN\1740 binding\VBG\1290422 to\TO\1740 sites\NNS\8673395 associated\VBN\628491 with\IN\1740 the\DT\1740 benzodiazepine-GABA-chloride\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 )\-RRB-\1740 .\.\1740
D003975_D001919 CID The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>diazepam</e1>\NN\2830852 acts\VBZ\1619354 through\IN\1740 the\DT\1740 benzodiazepine-GABA-chloride\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 within\IN\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 to\TO\1740 facilitate\VB\2547586 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 mediated\VBN\761713 through\IN\1740 baroreceptor\NN\5299178 reflexes\NNS\859001 in\IN\13603305 response\NN\11410625 to\TO\1740 an\DT\6697703 acute\JJ\1740 increase\NN\13576355 in\IN\13603305 arterial\JJ\1740 pressure\NN\11419404 .\.\1740
D004837_D001919 CID Also\RB\1740 ,\,\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 produced\VBN\1617192 in\IN\13603305 rats\NNS\2329401 by\IN\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>adrenaline</e1>\NN\14807929 (\-LRB-\1740 1.25\CD\1740 -\SYM\1740 2.5\CD\1740 micrograms\NNS\13717155 kg-1\NN\1740 )\-RRB-\1740 .\.\1740
D004837_D001919 CID Intravenous\JJ\1740 pretreatment\NN\1740 of\IN\1740 the\DT\1740 rats\NNS\2329401 with\IN\1740 diazepam\NNS\2830852 ,\,\1740 although\IN\1740 causing\VBG\1617192 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 <e1>adrenaline-induced</e1>\JJ\1740 pressor\NN\9190918 effect\NN\34213 ,\,\1740 did\VBD\1640855 enhance\VB\227165 the\DT\1740 adrenaline-induced\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
D004837_D001919 CID Intravenous\JJ\1740 pretreatment\NN\1740 of\IN\1740 the\DT\1740 rats\NNS\2329401 with\IN\1740 diazepam\NNS\2830852 ,\,\1740 although\IN\1740 causing\VBG\1617192 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 adrenaline-induced\JJ\1740 pressor\NN\9190918 effect\NN\34213 ,\,\1740 did\VBD\1640855 enhance\VB\227165 the\DT\1740 <e1>adrenaline-induced</e1>\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
D004837_D001919 CID However\RB\1740 ,\,\1740 the\DT\1740 diazepam\NN\2830852 enhancement\NN\248977 of\IN\1740 <e1>adrenaline-induced</e1>\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 antagonized\VBN\1787955 by\IN\1740 pretreatment\NN\1740 of\IN\1740 rats\NNS\2329401 with\IN\1740 an\DT\6697703 intravenous\JJ\1740 dose\NN\3740161 of\IN\1740 picrotoxin\NN\1740 (\-LRB-\1740 an\DT\6697703 agent\NN\7347 blocks\VBZ\1476483 chloride\NN\14818238 channels\NNS\6251781 by\IN\1740 binding\VBG\1290422 to\TO\1740 sites\NNS\8673395 associated\VBN\628491 with\IN\1740 the\DT\1740 benzodiazepine-GABA-chloride\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 )\-RRB-\1740 .\.\1740
D010852_D001919 NONE However\RB\1740 ,\,\1740 the\DT\1740 diazepam\NN\2830852 enhancement\NN\248977 of\IN\1740 adrenaline-induced\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 antagonized\VBN\1787955 by\IN\1740 pretreatment\NN\1740 of\IN\1740 rats\NNS\2329401 with\IN\1740 an\DT\6697703 intravenous\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>picrotoxin</e1>\NN\1740 (\-LRB-\1740 an\DT\6697703 agent\NN\7347 blocks\VBZ\1476483 chloride\NN\14818238 channels\NNS\6251781 by\IN\1740 binding\VBG\1290422 to\TO\1740 sites\NNS\8673395 associated\VBN\628491 with\IN\1740 the\DT\1740 benzodiazepine-GABA-chloride\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 )\-RRB-\1740 .\.\1740
D002712_D001919 NONE However\RB\1740 ,\,\1740 the\DT\1740 diazepam\NN\2830852 enhancement\NN\248977 of\IN\1740 adrenaline-induced\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 antagonized\VBN\1787955 by\IN\1740 pretreatment\NN\1740 of\IN\1740 rats\NNS\2329401 with\IN\1740 an\DT\6697703 intravenous\JJ\1740 dose\NN\3740161 of\IN\1740 picrotoxin\NN\1740 (\-LRB-\1740 an\DT\6697703 agent\NN\7347 blocks\VBZ\1476483 <e1>chloride</e1>\NN\14818238 channels\NNS\6251781 by\IN\1740 binding\VBG\1290422 to\TO\1740 sites\NNS\8673395 associated\VBN\628491 with\IN\1740 the\DT\1740 benzodiazepine-GABA-chloride\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 )\-RRB-\1740 .\.\1740
D002712_D001919 NONE However\RB\1740 ,\,\1740 the\DT\1740 diazepam\NN\2830852 enhancement\NN\248977 of\IN\1740 adrenaline-induced\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 antagonized\VBN\1787955 by\IN\1740 pretreatment\NN\1740 of\IN\1740 rats\NNS\2329401 with\IN\1740 an\DT\6697703 intravenous\JJ\1740 dose\NN\3740161 of\IN\1740 picrotoxin\NN\1740 (\-LRB-\1740 an\DT\6697703 agent\NN\7347 blocks\VBZ\1476483 chloride\NN\14818238 channels\NNS\6251781 by\IN\1740 binding\VBG\1290422 to\TO\1740 sites\NNS\8673395 associated\VBN\628491 with\IN\1740 the\DT\1740 <e1>benzodiazepine-GABA-chloride</e1>\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 )\-RRB-\1740 .\.\1740
D002712_D001919 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 diazepam\NN\2830852 acts\VBZ\1619354 through\IN\1740 the\DT\1740 <e1>benzodiazepine-GABA-chloride</e1>\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 within\IN\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 to\TO\1740 facilitate\VB\2547586 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 mediated\VBN\761713 through\IN\1740 baroreceptor\NN\5299178 reflexes\NNS\859001 in\IN\13603305 response\NN\11410625 to\TO\1740 an\DT\6697703 acute\JJ\1740 increase\NN\13576355 in\IN\13603305 arterial\JJ\1740 pressure\NN\11419404 .\.\1740
D001569_D001919 NONE However\RB\1740 ,\,\1740 the\DT\1740 diazepam\NN\2830852 enhancement\NN\248977 of\IN\1740 adrenaline-induced\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 antagonized\VBN\1787955 by\IN\1740 pretreatment\NN\1740 of\IN\1740 rats\NNS\2329401 with\IN\1740 an\DT\6697703 intravenous\JJ\1740 dose\NN\3740161 of\IN\1740 picrotoxin\NN\1740 (\-LRB-\1740 an\DT\6697703 agent\NN\7347 blocks\VBZ\1476483 chloride\NN\14818238 channels\NNS\6251781 by\IN\1740 binding\VBG\1290422 to\TO\1740 sites\NNS\8673395 associated\VBN\628491 with\IN\1740 the\DT\1740 <e1>benzodiazepine-GABA-chloride</e1>\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 )\-RRB-\1740 .\.\1740
D001569_D001919 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 diazepam\NN\2830852 acts\VBZ\1619354 through\IN\1740 the\DT\1740 <e1>benzodiazepine-GABA-chloride</e1>\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 within\IN\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 to\TO\1740 facilitate\VB\2547586 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 mediated\VBN\761713 through\IN\1740 baroreceptor\NN\5299178 reflexes\NNS\859001 in\IN\13603305 response\NN\11410625 to\TO\1740 an\DT\6697703 acute\JJ\1740 increase\NN\13576355 in\IN\13603305 arterial\JJ\1740 pressure\NN\11419404 .\.\1740
D005680_D001919 NONE However\RB\1740 ,\,\1740 the\DT\1740 diazepam\NN\2830852 enhancement\NN\248977 of\IN\1740 adrenaline-induced\JJ\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 antagonized\VBN\1787955 by\IN\1740 pretreatment\NN\1740 of\IN\1740 rats\NNS\2329401 with\IN\1740 an\DT\6697703 intravenous\JJ\1740 dose\NN\3740161 of\IN\1740 picrotoxin\NN\1740 (\-LRB-\1740 an\DT\6697703 agent\NN\7347 blocks\VBZ\1476483 chloride\NN\14818238 channels\NNS\6251781 by\IN\1740 binding\VBG\1290422 to\TO\1740 sites\NNS\8673395 associated\VBN\628491 with\IN\1740 the\DT\1740 <e1>benzodiazepine-GABA-chloride</e1>\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 )\-RRB-\1740 .\.\1740
D005680_D001919 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 diazepam\NN\2830852 acts\VBZ\1619354 through\IN\1740 the\DT\1740 <e1>benzodiazepine-GABA-chloride</e1>\NN\1740 channel\NN\6251781 macromolecular\JJ\1740 complex\NN\5869584 within\IN\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 to\TO\1740 facilitate\VB\2547586 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 mediated\VBN\761713 through\IN\1740 baroreceptor\NN\5299178 reflexes\NNS\859001 in\IN\13603305 response\NN\11410625 to\TO\1740 an\DT\6697703 acute\JJ\1740 increase\NN\13576355 in\IN\13603305 arterial\JJ\1740 pressure\NN\11419404 .\.\1740
7905523
C059896_D015658 NONE The\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 combination\NN\7951464 <e1>N-butyl-deoxynojirimycin</e1>\NN\1740 (\-LRB-\1740 SC-48334\NNS\1740 )\-RRB-\1740 and\CC\1740 zidovudine\NN\3834836 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>HIV-1\NN\1740 infection</e2>\NN\14052046 and\CC\1740 200\CD\1740 -\SYM\1740 500\CD\13745420 CD4\NN\14888310 cells/mm3\NNS\1740 .\.\1740
C059896_D015658 NONE The\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 combination\NN\7951464 N-butyl-deoxynojirimycin\NN\1740 (\-LRB-\1740 <e1>SC-48334</e1>\NNS\1740 )\-RRB-\1740 and\CC\1740 zidovudine\NN\3834836 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>HIV-1\NN\1740 infection</e2>\NN\14052046 and\CC\1740 200\CD\1740 -\SYM\1740 500\CD\13745420 CD4\NN\14888310 cells/mm3\NNS\1740 .\.\1740
D015215_D015658 NONE The\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 combination\NN\7951464 N-butyl-deoxynojirimycin\NN\1740 (\-LRB-\1740 SC-48334\NNS\1740 )\-RRB-\1740 and\CC\1740 <e1>zidovudine</e1>\NN\3834836 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>HIV-1\NN\1740 infection</e2>\NN\14052046 and\CC\1740 200\CD\1740 -\SYM\1740 500\CD\13745420 CD4\NN\14888310 cells/mm3\NNS\1740 .\.\1740
C059896_D007153 NONE The\DT\1740 mean\NN\6021761 <e1>SC-48334</e1>\NN\1740 steady-state\JJ\1740 trough\NN\9366017 level\NN\4916342 (\-LRB-\1740 4.04\CD\1740 +/-\CC\1740 0.99\CD\1740 micrograms/ml\NNS\1740 )\-RRB-\1740 was\VBD\836236 below\IN\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 inhibitory\JJ\1740 concentration\NN\4916342 for\IN\1740 human\JJ\1740 <e2>immunodeficiency</e2>\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 .\.\1740
19289093
D006493_D007022 NONE Recently\RB\1740 ,\,\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 commercial\JJ\1740 lots\NNS\13757724 of\IN\1740 <e1>heparin</e1>\NN\2718259 products\NNS\3076708 were\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 contaminated\VBN\1534147 with\IN\1740 an\DT\6697703 oversulfated\JJ\1740 chondroitin\NN\1740 sulfate\NN\15010703 (\-LRB-\1740 OSCS\JJ\1740 )\-RRB-\1740 derivative\NN\5802185 that\WDT\1740 could\MD\1740 elicit\VB\1617192 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 in\IN\13603305 pigs\NNS\2395003 following\VBG\1835496 a\DT\13649268 single\JJ\1740 high-dose\JJ\1740 infusion\NN\14589223 .\.\1740
D006493_D007022 NONE Using\VBG\1156834 both\DT\1740 contaminated\VBN\1534147 <e1>heparin</e1>\NN\2718259 products\NNS\3076708 and\CC\1740 the\DT\1740 synthetically\RB\1740 produced\VBN\1617192 derivative\JJ\1740 ,\,\1740 we\PRP\1740 showed\VBD\2137132 that\IN\1740 the\DT\1740 OSCS\NN\1740 produces\VBZ\1617192 dose-dependent\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 pigs\NNS\2395003 .\.\1740
D002809_D007022 CID Recently\RB\1740 ,\,\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 commercial\JJ\1740 lots\NNS\13757724 of\IN\1740 heparin\NN\2718259 products\NNS\3076708 were\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 contaminated\VBN\1534147 with\IN\1740 an\DT\6697703 oversulfated\JJ\1740 <e1>chondroitin\NN\1740 sulfate</e1>\NN\15010703 (\-LRB-\1740 OSCS\JJ\1740 )\-RRB-\1740 derivative\NN\5802185 that\WDT\1740 could\MD\1740 elicit\VB\1617192 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 in\IN\13603305 pigs\NNS\2395003 following\VBG\1835496 a\DT\13649268 single\JJ\1740 high-dose\JJ\1740 infusion\NN\14589223 .\.\1740
12231232
D006220_D010300 NONE <e1>Haloperidol</e1>\NNP\3713736 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\JJ\1740 <e2>parkinsonian-like</e2>\JJ\1740 muscle\NN\5289601 rigidity\NN\5023233 ,\,\1740 measured\VBN\697589 as\IN\14622893 an\DT\6697703 increased\VBN\169651 resistance\NN\37396 of\IN\1740 a\DT\13649268 rat\NN\2329401 's\POS\1740 hind\NN\2568959 foot\NN\5563034 to\TO\1740 passive\JJ\1740 flexion\NN\14034177 and\CC\1740 extension\NN\15272029 at\IN\14622893 the\DT\1740 ankle\NN\5578251 joint\NN\5220461 .\.\1740
D006220_D009127 CID <e1>Haloperidol</e1>\NNP\3713736 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\JJ\1740 parkinsonian-like\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 ,\,\1740 measured\VBN\697589 as\IN\14622893 an\DT\6697703 increased\VBN\169651 resistance\NN\37396 of\IN\1740 a\DT\13649268 rat\NN\2329401 's\POS\1740 hind\NN\2568959 foot\NN\5563034 to\TO\1740 passive\JJ\1740 flexion\NN\14034177 and\CC\1740 extension\NN\15272029 at\IN\14622893 the\DT\1740 ankle\NN\5578251 joint\NN\5220461 .\.\1740
D006220_D009127 CID AIDA\NN\1740 in\IN\13603305 doses\NNS\3740161 of\IN\1740 7.5\CD\1740 -\SYM\1740 15\CD\13745420 microg/0.5\CD\1740 microl\NN\1740 diminished\VBD\169651 the\DT\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 .\.\1740
C095756_D009127 NONE <e1>AIDA</e1>\NN\1740 in\IN\13603305 doses\NNS\3740161 of\IN\1740 7.5\CD\1740 -\SYM\1740 15\CD\13745420 microg/0.5\CD\1740 microl\NN\1740 diminished\VBD\169651 the\DT\1740 haloperidol-induced\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 .\.\1740
871943
D013390_D001049 CID The\DT\1740 use\NN\407535 of\IN\1740 serum\NN\5397468 cholinesterase\NN\14732946 in\IN\13603305 <e1>succinylcholine</e1>\NN\3800001 <e2>apnoea</e2>\NN\1740 .\.\1740
D013390_D001049 CID Fifteen\CD\13745420 patients\NNS\9898892 demonstrating\VBG\2137132 unexpected\JJ\1740 prolonged\JJ\1740 <e2>apnoea</e2>\NN\1740 lasting\VBG\2704349 several\JJ\1740 hours\NNS\15118228 after\IN\1740 <e1>succinylcholine</e1>\NN\3800001 have\VBP\2108377 been\VBN\836236 treated\VBN\2376958 by\IN\1740 a\DT\13649268 new\JJ\1740 preparation\NN\407535 of\IN\1740 human\JJ\1740 serum\NN\5397468 cholinesterase\NN\14732946 .\.\1740
D013390_D001049 CID The\DT\1740 use\NN\407535 of\IN\1740 serum\NN\5397468 cholinesterase\NN\14732946 in\IN\13603305 <e1>succinylcholine</e1>\NN\3800001 <e2>apnoea</e2>\NN\1740 provided\VBD\2199590 considerable\JJ\1740 relief\NN\7492516 to\IN\1740 both\CC\1740 patient\NN\9898892 and\CC\1740 anaesthetist\VBP\1740 .\.\1740
19692487
D008094_D011141 NONE Mice\NNS\2329401 lacking\VBG\1740 mPGES-1\NN\1740 are\VBP\836236 resistant\JJ\1740 to\TO\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>polyuria</e2>\NN\14113228 .\.\1740
D008094_D011141 NONE Cyclooxygenase-2\NN\14737847 activity\NN\30358 is\VBZ\836236 required\VBN\754942 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>polyuria</e2>\NN\14113228 .\.\1740
D008094_D011141 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 assess\VB\670261 <e1>lithium-induced</e1>\JJ\1740 <e2>polyuria</e2>\NN\14113228 in\IN\13603305 mice\NNS\2329401 deficient\JJ\1740 in\IN\13603305 microsomal\JJ\1740 prostaglandin\NN\5414534 E\NN\14724645 synthase-1\NN\1740 (\-LRB-\1740 mPGES-1\NN\1740 )\-RRB-\1740 .\.\1740
D008094_D011141 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 mPGES-1\NN\1740 -/-\JJ\1740 mice\NNS\2329401 were\VBD\836236 largely\RB\1740 resistant\JJ\1740 to\TO\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>polyuria</e2>\NN\14113228 and\CC\1740 a\DT\13649268 urine\NN\14853947 concentrating\NN\1740 defect\NN\14462666 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 nearly\RB\1740 complete\JJ\1740 blockade\NN\952963 of\IN\1740 high\JJ\1740 urine\NN\14853947 PGE(2\NN\1740 )\-RRB-\1740 and\CC\1740 cAMP\NN\3763727 output\NN\4007894 .\.\1740
D008094_D011141 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 mPGES-1-derived\VBD\1740 PGE(2\NN\1740 )\-RRB-\1740 mediates\VBZ\761713 <e1>lithium-induced</e1>\JJ\1740 <e2>polyuria</e2>\NN\14113228 likely\JJ\1740 via\IN\1740 inhibition\NN\1068773 of\IN\1740 AQP2\NN\1740 and\CC\1740 NKCC2\NN\1740 expression\NN\4679549 .\.\1740
D011458_D011141 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 assess\VB\670261 lithium-induced\JJ\1740 <e2>polyuria</e2>\NN\14113228 in\IN\13603305 mice\NNS\2329401 deficient\JJ\1740 in\IN\13603305 microsomal\JJ\1740 <e1>prostaglandin\NN\5414534 E</e1>\NN\14724645 synthase-1\NN\1740 (\-LRB-\1740 mPGES-1\NN\1740 )\-RRB-\1740 .\.\1740
D018021_D011141 CID A\DT\13649268 2-wk\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>LiCl</e1>\NN\1740 (\-LRB-\1740 4\CD\13741022 mmol.kg(-1).day(-1\NN\1740 )\-RRB-\1740 ip\NN\5999797 )\-RRB-\1740 in\IN\13603305 mPGES-1\NN\1740 +\CC\1740 /+\JJ\1740 mice\NNS\2329401 led\VBD\1752884 to\TO\1740 a\DT\13649268 marked\JJ\1740 <e2>polyuria</e2>\NN\14113228 with\IN\1740 hyposmotic\JJ\1740 urine\NN\14853947 .\.\1740
D015232_D011141 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 mPGES-1\NN\1740 -/-\JJ\1740 mice\NNS\2329401 were\VBD\836236 largely\RB\1740 resistant\JJ\1740 to\TO\1740 lithium-induced\JJ\1740 <e2>polyuria</e2>\NN\14113228 and\CC\1740 a\DT\13649268 urine\NN\14853947 concentrating\NN\1740 defect\NN\14462666 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 nearly\RB\1740 complete\JJ\1740 blockade\NN\952963 of\IN\1740 high\JJ\1740 urine\NN\14853947 <e1>PGE(2\NN\1740 )</e1>\-RRB-\1740 and\CC\1740 cAMP\NN\3763727 output\NN\4007894 .\.\1740
D015232_D011141 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 mPGES-1-derived\VBD\1740 <e1>PGE(2\NN\1740 )</e1>\-RRB-\1740 mediates\VBZ\761713 lithium-induced\JJ\1740 <e2>polyuria</e2>\NN\14113228 likely\JJ\1740 via\IN\1740 inhibition\NN\1068773 of\IN\1740 AQP2\NN\1740 and\CC\1740 NKCC2\NN\1740 expression\NN\4679549 .\.\1740
2907585
-1_D002375 NONE Reversal\NN\199130 of\IN\1740 neuroleptic-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 by\IN\1740 novel\JJ\1740 <e1>aryl-piperazine</e1>\JJ\1740 anxiolytic\JJ\1740 drugs\NNS\14778436 .\.\1740
-1_D002375 NONE A\DT\13649268 series\NN\8456993 of\IN\1740 <e1>aryl-piperazine</e1>\JJ\1740 analogues\NNS\4743605 of\IN\1740 buspirone\NN\3771443 and\CC\1740 other\JJ\1740 5-hydroxytryptaminergic\JJ\1740 agonists\NNS\9613191 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 reverse\VB\109660 haloperidol\NN\3713736 induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D002065_D002375 NONE The\DT\1740 novel\JJ\1740 anxiolytic\JJ\1740 drug\NN\14778436 ,\,\1740 <e1>buspirone</e1>\NN\3771443 ,\,\1740 reverses\VBZ\109660 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 .\.\1740
D002065_D002375 NONE A\DT\13649268 series\NN\8456993 of\IN\1740 aryl-piperazine\JJ\1740 analogues\NNS\4743605 of\IN\1740 <e1>buspirone</e1>\NN\3771443 and\CC\1740 other\JJ\1740 5-hydroxytryptaminergic\JJ\1740 agonists\NNS\9613191 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 reverse\VB\109660 haloperidol\NN\3713736 induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D006220_D002375 CID The\DT\1740 novel\JJ\1740 anxiolytic\JJ\1740 drug\NN\14778436 ,\,\1740 buspirone\NN\3771443 ,\,\1740 reverses\VBZ\109660 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 .\.\1740
D006220_D002375 CID A\DT\13649268 series\NN\8456993 of\IN\1740 aryl-piperazine\JJ\1740 analogues\NNS\4743605 of\IN\1740 buspirone\NN\3771443 and\CC\1740 other\JJ\1740 5-hydroxytryptaminergic\JJ\1740 agonists\NNS\9613191 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 reverse\VB\109660 <e1>haloperidol</e1>\NN\3713736 induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D058825_D002375 NONE A\DT\13649268 series\NN\8456993 of\IN\1740 aryl-piperazine\JJ\1740 analogues\NNS\4743605 of\IN\1740 buspirone\NN\3771443 and\CC\1740 other\JJ\1740 <e1>5-hydroxytryptaminergic\JJ\1740 agonists</e1>\NNS\9613191 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 reverse\VB\109660 haloperidol\NN\3713736 induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D012701_D002375 NONE Those\DT\1740 drugs\NNS\14778436 with\IN\1740 strong\JJ\1740 affinity\NN\11426530 for\IN\1740 <e1>5-hydroxytryptamine1a</e1>\NN\1740 receptors\NNS\5225602 were\VBD\836236 able\JJ\1740 to\TO\1740 reverse\VB\109660 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D012701_D002375 NONE However\RB\1740 ,\,\1740 inhibition\NN\1068773 of\IN\1740 postsynaptic\JJ\1740 <e1>5-HT</e1>\NN\1740 receptors\NNS\5225602 neither\CC\1740 inhibited\VBD\2510337 nor\CC\1740 potentiated\VBD\229605 reversal\NN\199130 of\IN\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 leaves\NNS\13087625 open\VBP\146138 the\DT\1740 question\NN\7193184 as\IN\14622893 to\IN\1740 the\DT\1740 site\NN\8673395 or\CC\3541091 mechanism\NN\13446390 for\IN\1740 this\DT\1740 effect\NN\34213 .\.\1740
9098464
D005473_D062788 CID A\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 <e2>adenomyosis</e2>\NN\14204950 :\:\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 hyperprolactinemia\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>fluoxetine\NN\4169152 hydrochloride</e1>\NN\14817592 ,\,\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 on\IN\1740 adenomyosis\NN\14204950 induction\NN\7450842 in\IN\13603305 Wistar\NNP\1740 albino\NN\9606527 rats\NNS\2329401 .\.\1740
D005473_D062788 CID A\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 adenomyosis\NN\14204950 :\:\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 hyperprolactinemia\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>fluoxetine\NN\4169152 hydrochloride</e1>\NN\14817592 ,\,\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 on\IN\1740 <e2>adenomyosis</e2>\NN\14204950 induction\NN\7450842 in\IN\13603305 Wistar\NNP\1740 albino\NN\9606527 rats\NNS\2329401 .\.\1740
D005473_D062788 CID OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 whether\IN\1740 <e1>fluoxetine</e1>\NN\4169152 given\VBN\2327200 to\TO\1740 castrated\VBN\224901 and\CC\1740 noncastrated\JJ\1740 rats\NNS\2329401 caused\VBD\1617192 hyperprolactinemia\NN\1740 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 with\IN\1740 respect\NN\5817845 to\TO\1740 <e2>adenomyosis</e2>\NN\14204950 .\.\1740
D005473_D062788 CID Histological\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 11\CD\13745420 cases\NNS\7283608 of\IN\1740 <e2>adenomyosis</e2>\NN\14204950 ,\,\1740 all\RB\1740 within\IN\1740 the\DT\1740 noncastrated\JJ\1740 group\NN\2137 receiving\VBG\2210855 <e1>fluoxetine</e1>\NN\4169152 .\.\1740
D005473_D006966 CID A\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 adenomyosis\NN\14204950 :\:\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>fluoxetine\NN\4169152 hydrochloride</e1>\NN\14817592 ,\,\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 on\IN\1740 adenomyosis\NN\14204950 induction\NN\7450842 in\IN\13603305 Wistar\NNP\1740 albino\NN\9606527 rats\NNS\2329401 .\.\1740
D005473_D006966 CID OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 whether\IN\1740 <e1>fluoxetine</e1>\NN\4169152 given\VBN\2327200 to\TO\1740 castrated\VBN\224901 and\CC\1740 noncastrated\JJ\1740 rats\NNS\2329401 caused\VBD\1617192 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 with\IN\1740 respect\NN\5817845 to\TO\1740 adenomyosis\NN\14204950 .\.\1740
D005473_D006966 CID DESIGN\NN\927261 :\:\1740 <e1>Fluoxetine</e1>\NN\4169152 ,\,\1740 a\DT\13649268 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 was\VBD\836236 given\VBN\2327200 to\IN\1740 Wistar\NNP\1740 Albino\NNPS\9606527 rats\NNS\2329401 for\IN\1740 98\CD\1740 days\NNS\15140892 to\TO\1740 produce\VB\1617192 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D012701_D062788 NONE A\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 <e2>adenomyosis</e2>\NN\14204950 :\:\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 hyperprolactinemia\NN\1740 induced\VBN\1627355 by\IN\1740 fluoxetine\NN\4169152 hydrochloride\NN\14817592 ,\,\1740 a\DT\13649268 selective\JJ\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 on\IN\1740 adenomyosis\NN\14204950 induction\NN\7450842 in\IN\13603305 Wistar\NNP\1740 albino\NN\9606527 rats\NNS\2329401 .\.\1740
D012701_D062788 NONE A\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 adenomyosis\NN\14204950 :\:\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 hyperprolactinemia\NN\1740 induced\VBN\1627355 by\IN\1740 fluoxetine\NN\4169152 hydrochloride\NN\14817592 ,\,\1740 a\DT\13649268 selective\JJ\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 on\IN\1740 <e2>adenomyosis</e2>\NN\14204950 induction\NN\7450842 in\IN\13603305 Wistar\NNP\1740 albino\NN\9606527 rats\NNS\2329401 .\.\1740
D012701_D006966 NONE A\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 adenomyosis\NN\14204950 :\:\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 fluoxetine\NN\4169152 hydrochloride\NN\14817592 ,\,\1740 a\DT\13649268 selective\JJ\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 on\IN\1740 adenomyosis\NN\14204950 induction\NN\7450842 in\IN\13603305 Wistar\NNP\1740 albino\NN\9606527 rats\NNS\2329401 .\.\1740
D012701_D006966 NONE DESIGN\NN\927261 :\:\1740 Fluoxetine\NN\4169152 ,\,\1740 a\DT\13649268 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 was\VBD\836236 given\VBN\2327200 to\IN\1740 Wistar\NNP\1740 Albino\NNPS\9606527 rats\NNS\2329401 for\IN\1740 98\CD\1740 days\NNS\15140892 to\TO\1740 produce\VB\1617192 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
28952
D011188_D007008 NONE Initial\JJ\1740 <e1>potassium</e1>\NN\14625458 loss\NN\13252973 and\CC\1740 <e2>hypokalaemia</e2>\NN\1740 during\IN\1740 chlorthalidone\NN\3214670 administration\NN\1133281 in\IN\13603305 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 hypertension\NN\14057371 :\:\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 dietary\JJ\1740 sodium\NN\14625458 restriction\NN\5846054 .\.\1740
D011188_D007008 NONE To\TO\1740 investigate\VB\644583 the\DT\1740 initial\JJ\1740 <e1>potassium</e1>\NN\14625458 loss\NN\13252973 and\CC\1740 development\NN\248977 of\IN\1740 <e2>hypokalaemia</e2>\NN\1740 during\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 an\DT\6697703 oral\JJ\1740 diuretic\NN\3247620 ,\,\1740 metabolic\JJ\1740 balance\NN\13934900 studies\NNS\635850 were\VBD\836236 performed\VBN\2367363 in\IN\13603305 ten\CD\13745420 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 hypertension\NN\14057371 who\WP\8299493 had\VBD\2108377 shown\VBN\2137132 hypokalaemia\NN\1740 under\IN\1740 prior\JJ\1740 oral\JJ\1740 diuretic\NN\3247620 treatment\NN\654885 .\.\1740
D011188_D007008 NONE To\TO\1740 investigate\VB\644583 the\DT\1740 initial\JJ\1740 <e1>potassium</e1>\NN\14625458 loss\NN\13252973 and\CC\1740 development\NN\248977 of\IN\1740 hypokalaemia\NN\1740 during\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 an\DT\6697703 oral\JJ\1740 diuretic\NN\3247620 ,\,\1740 metabolic\JJ\1740 balance\NN\13934900 studies\NNS\635850 were\VBD\836236 performed\VBN\2367363 in\IN\13603305 ten\CD\13745420 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 hypertension\NN\14057371 who\WP\8299493 had\VBD\2108377 shown\VBN\2137132 <e2>hypokalaemia</e2>\NN\1740 under\IN\1740 prior\JJ\1740 oral\JJ\1740 diuretic\NN\3247620 treatment\NN\654885 .\.\1740
D011188_D006973 NONE Initial\JJ\1740 <e1>potassium</e1>\NN\14625458 loss\NN\13252973 and\CC\1740 hypokalaemia\NN\1740 during\IN\1740 chlorthalidone\NN\3214670 administration\NN\1133281 in\IN\13603305 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 :\:\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 dietary\JJ\1740 sodium\NN\14625458 restriction\NN\5846054 .\.\1740
D011188_D006973 NONE To\TO\1740 investigate\VB\644583 the\DT\1740 initial\JJ\1740 <e1>potassium</e1>\NN\14625458 loss\NN\13252973 and\CC\1740 development\NN\248977 of\IN\1740 hypokalaemia\NN\1740 during\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 an\DT\6697703 oral\JJ\1740 diuretic\NN\3247620 ,\,\1740 metabolic\JJ\1740 balance\NN\13934900 studies\NNS\635850 were\VBD\836236 performed\VBN\2367363 in\IN\13603305 ten\CD\13745420 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 who\WP\8299493 had\VBD\2108377 shown\VBN\2137132 hypokalaemia\NN\1740 under\IN\1740 prior\JJ\1740 oral\JJ\1740 diuretic\NN\3247620 treatment\NN\654885 .\.\1740
D002752_D007008 CID Initial\JJ\1740 potassium\NN\14625458 loss\NN\13252973 and\CC\1740 <e2>hypokalaemia</e2>\NN\1740 during\IN\1740 <e1>chlorthalidone</e1>\NN\3214670 administration\NN\1133281 in\IN\13603305 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 hypertension\NN\14057371 :\:\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 dietary\JJ\1740 sodium\NN\14625458 restriction\NN\5846054 .\.\1740
D002752_D006973 NONE Initial\JJ\1740 potassium\NN\14625458 loss\NN\13252973 and\CC\1740 hypokalaemia\NN\1740 during\IN\1740 <e1>chlorthalidone</e1>\NN\3214670 administration\NN\1133281 in\IN\13603305 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 :\:\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 dietary\JJ\1740 sodium\NN\14625458 restriction\NN\5846054 .\.\1740
D012964_D007008 NONE Initial\JJ\1740 potassium\NN\14625458 loss\NN\13252973 and\CC\1740 <e2>hypokalaemia</e2>\NN\1740 during\IN\1740 chlorthalidone\NN\3214670 administration\NN\1133281 in\IN\13603305 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 hypertension\NN\14057371 :\:\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 dietary\JJ\1740 <e1>sodium</e1>\NN\14625458 restriction\NN\5846054 .\.\1740
D012964_D006973 NONE Initial\JJ\1740 potassium\NN\14625458 loss\NN\13252973 and\CC\1740 hypokalaemia\NN\1740 during\IN\1740 chlorthalidone\NN\3214670 administration\NN\1133281 in\IN\13603305 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 :\:\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 dietary\JJ\1740 <e1>sodium</e1>\NN\14625458 restriction\NN\5846054 .\.\1740
12042105
C052342_D053040 CID <e1>Topiramate-induced</e1>\JJ\1740 <e2>nephrolithiasis</e2>\NN\14115914 .\.\1740
C052342_D053040 CID We\PRP\1740 report\VBP\831651 the\DT\1740 first\JJ\1740 two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>topiramate-induced</e1>\JJ\1740 <e2>nephrolithiasis</e2>\NN\14115914 in\IN\13603305 the\DT\1740 urologic\JJ\1740 literature\NN\6362953 .\.\1740
C052342_D004827 NONE <e1>Topiramate</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 recently\RB\1740 developed\VBN\1753788 antiepileptic\JJ\1740 medication\NN\3247620 that\WDT\1740 is\VBZ\836236 becoming\VBG\146138 more\RBR\1740 widely\RB\1740 prescribed\VBN\748282 because\IN\1740 of\IN\1740 its\PRP$\6125041 efficacy\NN\5199286 in\IN\13603305 treating\VBG\2376958 <e2>refractory\JJ\1740 seizures</e2>\NNS\14081375 .\.\1740
C020243_D053040 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 a\DT\13649268 distal\JJ\1740 tubular\JJ\1740 acidification\NN\13518963 defect\NN\14462666 may\MD\15209706 result\VB\2633881 ,\,\1740 thus\RB\1740 impairing\VBG\258857 the\DT\1740 normal\JJ\1740 compensatory\JJ\1740 drop\NN\13899200 in\IN\13603305 urine\NN\14853947 pH.\NN\1740 These\DT\1740 factors\NNS\7326557 can\MD\3094503 lead\VB\1752884 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>calcium\NN\14625458 phosphate</e1>\NN\15010703 <e2>nephrolithiasis</e2>\NN\14115914 .\.\1740
15858223
D014635_D056486 CID <e1>Valproic\JJ\1740 acid</e1>\NN\14818238 I\CD\14622893 :\:\1740 time\NN\7308889 course\NN\883297 of\IN\1740 lipid\NN\14944888 peroxidation\NN\1740 biomarkers\NNS\1740 ,\,\1740 <e2>liver\NN\5298729 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 valproic\JJ\1740 acid\NN\14818238 metabolite\NN\20090 levels\NNS\4916342 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014635_D056486 CID Valproic\JJ\1740 acid\NN\14818238 I\CD\14622893 :\:\1740 time\NN\7308889 course\NN\883297 of\IN\1740 lipid\NN\14944888 peroxidation\NN\1740 biomarkers\NNS\1740 ,\,\1740 <e2>liver\NN\5298729 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 <e1>valproic\JJ\1740 acid</e1>\NN\14818238 metabolite\NN\20090 levels\NNS\4916342 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014635_D056486 CID To\TO\1740 determine\VB\1645601 whether\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>VPA-associated</e1>\JJ\1740 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 <e2>hepatotoxicity</e2>\NN\1740 ,\,\1740 adult\JJ\1740 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 were\VBD\836236 treated\VBN\2376958 ip\NN\5999797 with\IN\1740 VPA\NN\1740 (\-LRB-\1740 500\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 or\CC\3541091 0.9\CD\1740 %\NN\1740 saline\NN\14849367 (\-LRB-\1740 vehicle\NN\3100490 )\-RRB-\1740 once\RB\1740 daily\RB\1740 for\IN\1740 2\CD\13741022 ,\,\1740 4\CD\13741022 ,\,\1740 7\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 or\CC\3541091 14\CD\13745420 days\NNS\15140892 .\.\1740
D014635_D056486 CID To\TO\1740 determine\VB\1645601 whether\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 VPA-associated\JJ\1740 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 <e2>hepatotoxicity</e2>\NN\1740 ,\,\1740 adult\JJ\1740 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 were\VBD\836236 treated\VBN\2376958 ip\NN\5999797 with\IN\1740 <e1>VPA</e1>\NN\1740 (\-LRB-\1740 500\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 or\CC\3541091 0.9\CD\1740 %\NN\1740 saline\NN\14849367 (\-LRB-\1740 vehicle\NN\3100490 )\-RRB-\1740 once\RB\1740 daily\RB\1740 for\IN\1740 2\CD\13741022 ,\,\1740 4\CD\13741022 ,\,\1740 7\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 or\CC\3541091 14\CD\13745420 days\NNS\15140892 .\.\1740
D005978_D056486 NONE <e2>Liver\NN\5298729 toxicity</e2>\NN\13576101 was\VBD\836236 evaluated\VBN\670261 based\VBN\2694933 on\IN\1740 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 <e1>alpha-glutathione</e1>\JJ\1740 S-transferase\NN\1740 (\-LRB-\1740 alpha-GST\NN\1740 )\-RRB-\1740 and\CC\1740 by\IN\1740 histology\NN\6060049 .\.\1740
D014635_D009336 CID Overall\RB\1740 ,\,\1740 these\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>VPA</e1>\NN\1740 treatment\NN\654885 results\VBZ\2633881 in\IN\13603305 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 levels\NNS\4916342 of\IN\1740 15-F(2t)-IsoP\NN\1740 ,\,\1740 which\WDT\1740 precedes\VBZ\2690708 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>necrosis</e2>\NN\11444117 ,\,\1740 steatosis\NN\1740 ,\,\1740 and\CC\1740 elevated\JJ\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 alpha-GST\NN\1740 .\.\1740
D014635_D005234 CID Overall\RB\1740 ,\,\1740 these\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>VPA</e1>\NN\1740 treatment\NN\654885 results\VBZ\2633881 in\IN\13603305 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 levels\NNS\4916342 of\IN\1740 15-F(2t)-IsoP\NN\1740 ,\,\1740 which\WDT\1740 precedes\VBZ\2690708 the\DT\1740 onset\NN\7325190 of\IN\1740 necrosis\NN\11444117 ,\,\1740 <e2>steatosis</e2>\NN\1740 ,\,\1740 and\CC\1740 elevated\JJ\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 alpha-GST\NN\1740 .\.\1740
C075750_D009336 NONE Overall\RB\1740 ,\,\1740 these\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 VPA\NN\1740 treatment\NN\654885 results\VBZ\2633881 in\IN\13603305 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 levels\NNS\4916342 of\IN\1740 <e1>15-F(2t)-IsoP</e1>\NN\1740 ,\,\1740 which\WDT\1740 precedes\VBZ\2690708 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>necrosis</e2>\NN\11444117 ,\,\1740 steatosis\NN\1740 ,\,\1740 and\CC\1740 elevated\JJ\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 alpha-GST\NN\1740 .\.\1740
C075750_D005234 NONE Overall\RB\1740 ,\,\1740 these\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 VPA\NN\1740 treatment\NN\654885 results\VBZ\2633881 in\IN\13603305 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 levels\NNS\4916342 of\IN\1740 <e1>15-F(2t)-IsoP</e1>\NN\1740 ,\,\1740 which\WDT\1740 precedes\VBZ\2690708 the\DT\1740 onset\NN\7325190 of\IN\1740 necrosis\NN\11444117 ,\,\1740 <e2>steatosis</e2>\NN\1740 ,\,\1740 and\CC\1740 elevated\JJ\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 alpha-GST\NN\1740 .\.\1740
16820346
C065179_D006973 NONE <e1>Atorvastatin</e1>\NN\3676175 prevented\VBD\1740 and\CC\1740 reversed\VBN\109660 dexamethasone-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
C065179_D006973 NONE To\TO\1740 assess\VB\670261 the\DT\1740 antioxidant\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>atorvastatin</e1>\NN\3676175 (\-LRB-\1740 atorva\NN\1740 )\-RRB-\1740 on\IN\1740 dexamethasone\NN\2721538 (dex)-induced\VBD\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 60\CD\13745420 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 were\VBD\836236 treated\VBN\2376958 with\IN\1740 atorva\NN\1740 30\CD\13745420 mg/kg/day\NN\1740 or\CC\3541091 tap\NN\7371293 water\NN\14618834 for\IN\1740 15\CD\13745420 days\NNS\15140892 .\.\1740
C065179_D006973 NONE To\TO\1740 assess\VB\670261 the\DT\1740 antioxidant\JJ\1740 effects\NNS\13245626 of\IN\1740 atorvastatin\NN\3676175 (\-LRB-\1740 <e1>atorva</e1>\NN\1740 )\-RRB-\1740 on\IN\1740 dexamethasone\NN\2721538 (dex)-induced\VBD\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 60\CD\13745420 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 were\VBD\836236 treated\VBN\2376958 with\IN\1740 atorva\NN\1740 30\CD\13745420 mg/kg/day\NN\1740 or\CC\3541091 tap\NN\7371293 water\NN\14618834 for\IN\1740 15\CD\13745420 days\NNS\15140892 .\.\1740
C065179_D006973 NONE To\TO\1740 assess\VB\670261 the\DT\1740 antioxidant\JJ\1740 effects\NNS\13245626 of\IN\1740 atorvastatin\NN\3676175 (\-LRB-\1740 atorva\NN\1740 )\-RRB-\1740 on\IN\1740 dexamethasone\NN\2721538 (dex)-induced\VBD\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 60\CD\13745420 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>atorva</e1>\NN\1740 30\CD\13745420 mg/kg/day\NN\1740 or\CC\3541091 tap\NN\7371293 water\NN\14618834 for\IN\1740 15\CD\13745420 days\NNS\15140892 .\.\1740
C065179_D006973 NONE <e1>Atorva</e1>\NNP\1740 reversed\VBD\109660 dex-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 129\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 ,\,\1740 vs.\CC\1740 135\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 P\NN\14622893 '\''\1740 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 decreased\VBD\169651 plasma\NN\5398023 superoxide\NN\14971519 (\-LRB-\1740 7931\CD\1740 +/-\CC\1740 392.8\CD\1740 dex\NN\1740 ,\,\1740 1187\CD\1740 +/-\CC\1740 441.2\CD\1740 atorva\NN\1740 +\CC\1740 dex\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
C065179_D006973 NONE Atorva\NNP\1740 reversed\VBD\109660 dex-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 129\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 ,\,\1740 vs.\CC\1740 135\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 P\NN\14622893 '\''\1740 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 decreased\VBD\169651 plasma\NN\5398023 superoxide\NN\14971519 (\-LRB-\1740 7931\CD\1740 +/-\CC\1740 392.8\CD\1740 dex\NN\1740 ,\,\1740 1187\CD\1740 +/-\CC\1740 441.2\CD\1740 <e1>atorva</e1>\NN\1740 +\CC\1740 dex\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
C065179_D006973 NONE Thus\RB\1740 ,\,\1740 <e1>atorvastatin</e1>\NN\3676175 prevented\VBD\1740 and\CC\1740 reversed\VBN\109660 dexamethasone-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D003907_D006973 CID Atorvastatin\NN\3676175 prevented\VBD\1740 and\CC\1740 reversed\VBN\109660 <e1>dexamethasone-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D003907_D006973 CID To\TO\1740 assess\VB\670261 the\DT\1740 antioxidant\JJ\1740 effects\NNS\13245626 of\IN\1740 atorvastatin\NN\3676175 (\-LRB-\1740 atorva\NN\1740 )\-RRB-\1740 on\IN\1740 <e1>dexamethasone</e1>\NN\2721538 (dex)-induced\VBD\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 60\CD\13745420 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 were\VBD\836236 treated\VBN\2376958 with\IN\1740 atorva\NN\1740 30\CD\13745420 mg/kg/day\NN\1740 or\CC\3541091 tap\NN\7371293 water\NN\14618834 for\IN\1740 15\CD\13745420 days\NNS\15140892 .\.\1740
D003907_D006973 CID To\TO\1740 assess\VB\670261 the\DT\1740 antioxidant\JJ\1740 effects\NNS\13245626 of\IN\1740 atorvastatin\NN\3676175 (\-LRB-\1740 atorva\NN\1740 )\-RRB-\1740 on\IN\1740 dexamethasone\NN\2721538 <e1>(dex)-induced</e1>\VBD\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 60\CD\13745420 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 were\VBD\836236 treated\VBN\2376958 with\IN\1740 atorva\NN\1740 30\CD\13745420 mg/kg/day\NN\1740 or\CC\3541091 tap\NN\7371293 water\NN\14618834 for\IN\1740 15\CD\13745420 days\NNS\15140892 .\.\1740
D003907_D006973 CID Atorva\NNP\1740 reversed\VBD\109660 <e1>dex-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 129\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 ,\,\1740 vs.\CC\1740 135\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 P\NN\14622893 '\''\1740 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 decreased\VBD\169651 plasma\NN\5398023 superoxide\NN\14971519 (\-LRB-\1740 7931\CD\1740 +/-\CC\1740 392.8\CD\1740 dex\NN\1740 ,\,\1740 1187\CD\1740 +/-\CC\1740 441.2\CD\1740 atorva\NN\1740 +\CC\1740 dex\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
D003907_D006973 CID Atorva\NNP\1740 reversed\VBD\109660 dex-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 129\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 ,\,\1740 vs.\CC\1740 135\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 P\NN\14622893 '\''\1740 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 decreased\VBD\169651 plasma\NN\5398023 superoxide\NN\14971519 (\-LRB-\1740 7931\CD\1740 +/-\CC\1740 392.8\CD\1740 <e1>dex</e1>\NN\1740 ,\,\1740 1187\CD\1740 +/-\CC\1740 441.2\CD\1740 atorva\NN\1740 +\CC\1740 dex\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
D003907_D006973 CID Atorva\NNP\1740 reversed\VBD\109660 dex-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 129\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 ,\,\1740 vs.\CC\1740 135\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 P\NN\14622893 '\''\1740 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 decreased\VBD\169651 plasma\NN\5398023 superoxide\NN\14971519 (\-LRB-\1740 7931\CD\1740 +/-\CC\1740 392.8\CD\1740 dex\NN\1740 ,\,\1740 1187\CD\1740 +/-\CC\1740 441.2\CD\1740 atorva\NN\1740 +\CC\1740 <e1>dex</e1>\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
D003907_D006973 CID Thus\RB\1740 ,\,\1740 atorvastatin\NN\3676175 prevented\VBD\1740 and\CC\1740 reversed\VBN\109660 <e1>dexamethasone-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D013481_D006973 NONE Atorva\NNP\1740 reversed\VBD\109660 dex-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 129\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 ,\,\1740 vs.\CC\1740 135\CD\1740 +/-\CC\1740 0.6\CD\1740 mmHg\NN\1740 P\NN\14622893 '\''\1740 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 decreased\VBD\169651 plasma\NN\5398023 <e1>superoxide</e1>\NN\14971519 (\-LRB-\1740 7931\CD\1740 +/-\CC\1740 392.8\CD\1740 dex\NN\1740 ,\,\1740 1187\CD\1740 +/-\CC\1740 441.2\CD\1740 atorva\NN\1740 +\CC\1740 dex\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
18674790
D004041_D009765 CID High\JJ\1740 <e1>fat</e1>\JJ\1740 diet-fed\JJ\1740 <e2>obese</e2>\JJ\1740 rats\NNS\2329401 are\VBP\836236 highly\RB\1740 sensitive\JJ\1740 to\TO\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 .\.\1740
D004041_D009765 CID In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 whether\IN\1740 a\DT\13649268 physiological\JJ\1740 intervention\NN\1239064 by\IN\1740 feeding\VBG\1182709 40\CD\13745420 %\NN\1740 high\JJ\1740 <e1>fat</e1>\JJ\1740 diet\NN\7560652 (\-LRB-\1740 HFD\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 <e2>obesity</e2>\NN\4999401 in\IN\13603305 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 (\-LRB-\1740 250\CD\1740 -\SYM\1740 275\CD\1740 g\NN\13717155 )\-RRB-\1740 ,\,\1740 sensitizes\VBZ\126264 to\TO\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 .\.\1740
D004041_D066126 NONE High\JJ\1740 <e1>fat</e1>\JJ\1740 diet-fed\JJ\1740 obese\JJ\1740 rats\NNS\2329401 are\VBP\836236 highly\RB\1740 sensitive\JJ\1740 to\TO\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004041_D066126 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 whether\IN\1740 a\DT\13649268 physiological\JJ\1740 intervention\NN\1239064 by\IN\1740 feeding\VBG\1182709 40\CD\13745420 %\NN\1740 high\JJ\1740 <e1>fat</e1>\JJ\1740 diet\NN\7560652 (\-LRB-\1740 HFD\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 obesity\NN\4999401 in\IN\13603305 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 (\-LRB-\1740 250\CD\1740 -\SYM\1740 275\CD\1740 g\NN\13717155 )\-RRB-\1740 ,\,\1740 sensitizes\VBZ\126264 to\TO\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D009765 NONE High\JJ\1740 fat\JJ\1740 diet-fed\JJ\1740 <e2>obese</e2>\JJ\1740 rats\NNS\2329401 are\VBP\836236 highly\RB\1740 sensitive\JJ\1740 to\TO\1740 <e1>doxorubicin-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 .\.\1740
D004317_D009765 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 whether\IN\1740 a\DT\13649268 physiological\JJ\1740 intervention\NN\1239064 by\IN\1740 feeding\VBG\1182709 40\CD\13745420 %\NN\1740 high\JJ\1740 fat\JJ\1740 diet\NN\7560652 (\-LRB-\1740 HFD\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 <e2>obesity</e2>\NN\4999401 in\IN\13603305 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 (\-LRB-\1740 250\CD\1740 -\SYM\1740 275\CD\1740 g\NN\13717155 )\-RRB-\1740 ,\,\1740 sensitizes\VBZ\126264 to\TO\1740 <e1>doxorubicin-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 .\.\1740
D004317_D009765 NONE A\DT\13649268 LD(10\NN\1740 )\-RRB-\1740 dose\NN\3740161 (\-LRB-\1740 8\CD\13741022 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 ,\,\1740 ip\FW\5999797 )\-RRB-\1740 administered\VBN\2436349 on\IN\1740 day\NN\15154774 43\CD\1740 of\IN\1740 the\DT\1740 HFD\NN\1740 feeding\NN\838098 regimen\NNS\5898568 led\VBD\1752884 to\IN\1740 higher\JJR\1740 cardiotoxicity\NN\1740 ,\,\1740 cardiac\JJ\1740 dysfunction\NN\14204950 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 and\CC\1740 80\CD\13745420 %\NN\1740 mortality\NN\5054863 in\IN\13603305 the\DT\1740 <e2>obese</e2>\JJ\1740 (\-LRB-\1740 OB\NN\6043075 )\-RRB-\1740 rats\NNS\2329401 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 any\DT\1740 significant\JJ\1740 renal\JJ\1740 or\CC\3541091 hepatic\JJ\1740 toxicity\NN\13576101 .\.\1740
D004317_D009765 NONE A\DT\13649268 LD(10\NN\1740 )\-RRB-\1740 dose\NN\3740161 (\-LRB-\1740 8\CD\13741022 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 ,\,\1740 ip\FW\5999797 )\-RRB-\1740 administered\VBN\2436349 on\IN\1740 day\NN\15154774 43\CD\1740 of\IN\1740 the\DT\1740 HFD\NN\1740 feeding\NN\838098 regimen\NNS\5898568 led\VBD\1752884 to\IN\1740 higher\JJR\1740 cardiotoxicity\NN\1740 ,\,\1740 cardiac\JJ\1740 dysfunction\NN\14204950 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 and\CC\1740 80\CD\13745420 %\NN\1740 mortality\NN\5054863 in\IN\13603305 the\DT\1740 obese\JJ\1740 (\-LRB-\1740 <e2>OB</e2>\NN\6043075 )\-RRB-\1740 rats\NNS\2329401 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 any\DT\1740 significant\JJ\1740 renal\JJ\1740 or\CC\3541091 hepatic\JJ\1740 toxicity\NN\13576101 .\.\1740
D004317_D009765 NONE <e1>Doxorubicin</e1>\NN\2716866 toxicokinetics\NNS\1740 studies\NNS\635850 revealed\VBD\2137132 no\DT\7204911 change\NN\7283608 in\IN\13603305 accumulation\NN\13497135 of\IN\1740 doxorubicin\NN\2716866 and\CC\1740 doxorubicinol\NN\1740 (\-LRB-\1740 toxic\JJ\1740 metabolite\NN\20090 )\-RRB-\1740 in\IN\13603305 the\DT\1740 normal\JJ\1740 diet-fed\NN\1740 (\-LRB-\1740 ND\NN\14625458 )\-RRB-\1740 and\CC\1740 <e2>OB</e2>\NN\6043075 hearts\NNS\496167 .\.\1740
D004317_D009765 NONE Doxorubicin\NN\2716866 toxicokinetics\NNS\1740 studies\NNS\635850 revealed\VBD\2137132 no\DT\7204911 change\NN\7283608 in\IN\13603305 accumulation\NN\13497135 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 doxorubicinol\NN\1740 (\-LRB-\1740 toxic\JJ\1740 metabolite\NN\20090 )\-RRB-\1740 in\IN\13603305 the\DT\1740 normal\JJ\1740 diet-fed\NN\1740 (\-LRB-\1740 ND\NN\14625458 )\-RRB-\1740 and\CC\1740 <e2>OB</e2>\NN\6043075 hearts\NNS\496167 .\.\1740
D004317_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 <e2>OB</e2>\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 OB\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 AMP-alpha2\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 ATP\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 ATP/ADP\NN\1740 ratio\NN\13815152 after\IN\1740 <e1>doxorubicin</e1>\NN\2716866 administration\NN\1133281 .\.\1740
D004317_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 OB\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 <e2>OB</e2>\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 AMP-alpha2\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 ATP\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 ATP/ADP\NN\1740 ratio\NN\13815152 after\IN\1740 <e1>doxorubicin</e1>\NN\2716866 administration\NN\1133281 .\.\1740
D004317_D009765 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 HFD-induced\JJ\1740 <e2>obese</e2>\JJ\1740 rats\NNS\2329401 are\VBP\836236 highly\RB\1740 sensitized\VBN\126264 to\TO\1740 <e1>doxorubicin-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 substantially\RB\1740 downregulating\VBG\1740 cardiac\JJ\1740 mitochondrial\JJ\1740 ATP\NN\14964590 generation\NN\7942152 ,\,\1740 increasing\VBG\169651 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 downregulating\VBG\1740 the\DT\1740 JAK/STAT3\JJ\1740 pathway\NN\5483677 .\.\1740
D004317_D066126 NONE High\JJ\1740 fat\JJ\1740 diet-fed\JJ\1740 obese\JJ\1740 rats\NNS\2329401 are\VBP\836236 highly\RB\1740 sensitive\JJ\1740 to\TO\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 NONE Often\RB\1740 ,\,\1740 chemotherapy\NN\661091 by\IN\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 Adriamycin\NN\1740 )\-RRB-\1740 is\VBZ\836236 limited\VBN\2510337 due\IN\5174653 to\IN\1740 life\NN\13954253 threatening\VBG\2603699 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 during\IN\1740 and\CC\1740 posttherapy\NN\1740 .\.\1740
D004317_D066126 NONE Often\RB\1740 ,\,\1740 chemotherapy\NN\661091 by\IN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>Adriamycin</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 limited\VBN\2510337 due\IN\5174653 to\IN\1740 life\NN\13954253 threatening\VBG\2603699 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 during\IN\1740 and\CC\1740 posttherapy\NN\1740 .\.\1740
D004317_D066126 NONE Recently\RB\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 moderate\JJ\1740 diet\JJ\1740 restriction\NN\5846054 remarkably\RB\1740 protects\VBZ\1127795 against\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 whether\IN\1740 a\DT\13649268 physiological\JJ\1740 intervention\NN\1239064 by\IN\1740 feeding\VBG\1182709 40\CD\13745420 %\NN\1740 high\JJ\1740 fat\JJ\1740 diet\NN\7560652 (\-LRB-\1740 HFD\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 obesity\NN\4999401 in\IN\13603305 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 (\-LRB-\1740 250\CD\1740 -\SYM\1740 275\CD\1740 g\NN\13717155 )\-RRB-\1740 ,\,\1740 sensitizes\VBZ\126264 to\TO\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 NONE A\DT\13649268 LD(10\NN\1740 )\-RRB-\1740 dose\NN\3740161 (\-LRB-\1740 8\CD\13741022 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 ,\,\1740 ip\FW\5999797 )\-RRB-\1740 administered\VBN\2436349 on\IN\1740 day\NN\15154774 43\CD\1740 of\IN\1740 the\DT\1740 HFD\NN\1740 feeding\NN\838098 regimen\NNS\5898568 led\VBD\1752884 to\IN\1740 higher\JJR\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 cardiac\JJ\1740 dysfunction\NN\14204950 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 and\CC\1740 80\CD\13745420 %\NN\1740 mortality\NN\5054863 in\IN\13603305 the\DT\1740 obese\JJ\1740 (\-LRB-\1740 OB\NN\6043075 )\-RRB-\1740 rats\NNS\2329401 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 any\DT\1740 significant\JJ\1740 renal\JJ\1740 or\CC\3541091 hepatic\JJ\1740 toxicity\NN\13576101 .\.\1740
D004317_D066126 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 HFD-induced\JJ\1740 obese\JJ\1740 rats\NNS\2329401 are\VBP\836236 highly\RB\1740 sensitized\VBN\126264 to\TO\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 by\IN\1740 substantially\RB\1740 downregulating\VBG\1740 cardiac\JJ\1740 mitochondrial\JJ\1740 ATP\NN\14964590 generation\NN\7942152 ,\,\1740 increasing\VBG\169651 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 downregulating\VBG\1740 the\DT\1740 JAK/STAT3\JJ\1740 pathway\NN\5483677 .\.\1740
D004317_D006331 CID A\DT\13649268 LD(10\NN\1740 )\-RRB-\1740 dose\NN\3740161 (\-LRB-\1740 8\CD\13741022 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 ,\,\1740 ip\FW\5999797 )\-RRB-\1740 administered\VBN\2436349 on\IN\1740 day\NN\15154774 43\CD\1740 of\IN\1740 the\DT\1740 HFD\NN\1740 feeding\NN\838098 regimen\NNS\5898568 led\VBD\1752884 to\IN\1740 higher\JJR\1740 cardiotoxicity\NN\1740 ,\,\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 and\CC\1740 80\CD\13745420 %\NN\1740 mortality\NN\5054863 in\IN\13603305 the\DT\1740 obese\JJ\1740 (\-LRB-\1740 OB\NN\6043075 )\-RRB-\1740 rats\NNS\2329401 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 any\DT\1740 significant\JJ\1740 renal\JJ\1740 or\CC\3541091 hepatic\JJ\1740 toxicity\NN\13576101 .\.\1740
D004317_D007674 NONE A\DT\13649268 LD(10\NN\1740 )\-RRB-\1740 dose\NN\3740161 (\-LRB-\1740 8\CD\13741022 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 ,\,\1740 ip\FW\5999797 )\-RRB-\1740 administered\VBN\2436349 on\IN\1740 day\NN\15154774 43\CD\1740 of\IN\1740 the\DT\1740 HFD\NN\1740 feeding\NN\838098 regimen\NNS\5898568 led\VBD\1752884 to\IN\1740 higher\JJR\1740 cardiotoxicity\NN\1740 ,\,\1740 cardiac\JJ\1740 dysfunction\NN\14204950 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 and\CC\1740 80\CD\13745420 %\NN\1740 mortality\NN\5054863 in\IN\13603305 the\DT\1740 obese\JJ\1740 (\-LRB-\1740 OB\NN\6043075 )\-RRB-\1740 rats\NNS\2329401 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 any\DT\1740 significant\JJ\1740 <e2>renal\JJ\1740 or\CC\3541091 hepatic\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D004317_D056486 NONE A\DT\13649268 LD(10\NN\1740 )\-RRB-\1740 dose\NN\3740161 (\-LRB-\1740 8\CD\13741022 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 ,\,\1740 ip\FW\5999797 )\-RRB-\1740 administered\VBN\2436349 on\IN\1740 day\NN\15154774 43\CD\1740 of\IN\1740 the\DT\1740 HFD\NN\1740 feeding\NN\838098 regimen\NNS\5898568 led\VBD\1752884 to\IN\1740 higher\JJR\1740 cardiotoxicity\NN\1740 ,\,\1740 cardiac\JJ\1740 dysfunction\NN\14204950 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 and\CC\1740 80\CD\13745420 %\NN\1740 mortality\NN\5054863 in\IN\13603305 the\DT\1740 obese\JJ\1740 (\-LRB-\1740 OB\NN\6043075 )\-RRB-\1740 rats\NNS\2329401 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 any\DT\1740 significant\JJ\1740 <e2>renal\JJ\1740 or\CC\3541091 hepatic\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
C010013_D009765 NONE Doxorubicin\NN\2716866 toxicokinetics\NNS\1740 studies\NNS\635850 revealed\VBD\2137132 no\DT\7204911 change\NN\7283608 in\IN\13603305 accumulation\NN\13497135 of\IN\1740 doxorubicin\NN\2716866 and\CC\1740 <e1>doxorubicinol</e1>\NN\1740 (\-LRB-\1740 toxic\JJ\1740 metabolite\NN\20090 )\-RRB-\1740 in\IN\13603305 the\DT\1740 normal\JJ\1740 diet-fed\NN\1740 (\-LRB-\1740 ND\NN\14625458 )\-RRB-\1740 and\CC\1740 <e2>OB</e2>\NN\6043075 hearts\NNS\496167 .\.\1740
D000249_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 <e2>OB</e2>\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 OB\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 <e1>AMP-alpha2</e1>\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 ATP\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 ATP/ADP\NN\1740 ratio\NN\13815152 after\IN\1740 doxorubicin\NN\2716866 administration\NN\1133281 .\.\1740
D000249_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 OB\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 <e2>OB</e2>\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 <e1>AMP-alpha2</e1>\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 ATP\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 ATP/ADP\NN\1740 ratio\NN\13815152 after\IN\1740 doxorubicin\NN\2716866 administration\NN\1133281 .\.\1740
D000255_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 <e2>OB</e2>\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 OB\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 AMP-alpha2\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 <e1>ATP</e1>\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 ATP/ADP\NN\1740 ratio\NN\13815152 after\IN\1740 doxorubicin\NN\2716866 administration\NN\1133281 .\.\1740
D000255_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 OB\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 <e2>OB</e2>\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 AMP-alpha2\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 <e1>ATP</e1>\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 ATP/ADP\NN\1740 ratio\NN\13815152 after\IN\1740 doxorubicin\NN\2716866 administration\NN\1133281 .\.\1740
D000255_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 <e2>OB</e2>\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 OB\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 AMP-alpha2\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 ATP\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 <e1>ATP/ADP</e1>\NN\1740 ratio\NN\13815152 after\IN\1740 doxorubicin\NN\2716866 administration\NN\1133281 .\.\1740
D000255_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 OB\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 <e2>OB</e2>\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 AMP-alpha2\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 ATP\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 <e1>ATP/ADP</e1>\NN\1740 ratio\NN\13815152 after\IN\1740 doxorubicin\NN\2716866 administration\NN\1133281 .\.\1740
D000255_D009765 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 HFD-induced\JJ\1740 <e2>obese</e2>\JJ\1740 rats\NNS\2329401 are\VBP\836236 highly\RB\1740 sensitized\VBN\126264 to\TO\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 substantially\RB\1740 downregulating\VBG\1740 cardiac\JJ\1740 mitochondrial\JJ\1740 <e1>ATP</e1>\NN\14964590 generation\NN\7942152 ,\,\1740 increasing\VBG\169651 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 downregulating\VBG\1740 the\DT\1740 JAK/STAT3\JJ\1740 pathway\NN\5483677 .\.\1740
D000244_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 <e2>OB</e2>\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 OB\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 AMP-alpha2\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 ATP\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 <e1>ATP/ADP</e1>\NN\1740 ratio\NN\13815152 after\IN\1740 doxorubicin\NN\2716866 administration\NN\1133281 .\.\1740
D000244_D009765 NONE Mechanistic\JJ\1740 studies\NNS\635850 revealed\VBD\2137132 that\IN\1740 OB\NN\6043075 rats\NNS\2329401 are\VBP\836236 sensitized\VBN\126264 due\IN\5174653 to\IN\1740 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 higher\JJR\1740 oxyradical\JJ\1740 stress\NN\7083732 leading\VBG\1752884 to\TO\1740 upregulation\NN\1740 of\IN\1740 uncoupling\VBG\1356038 proteins\NNS\14944888 2\CD\13741022 and\CC\1740 3\CD\13741022 ,\,\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 downregulation\NN\1740 of\IN\1740 cardiac\JJ\1740 peroxisome\NN\1740 proliferators\NNS\1740 activated\VBD\1641914 receptor-alpha\NN\1740 ,\,\1740 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 plasma\NN\5398023 adiponectin\NN\1740 levels\NNS\4916342 ,\,\1740 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 cardiac\JJ\1740 fatty-acid\JJ\1740 oxidation\NN\13447361 (\-LRB-\1740 666.9+/-14.0\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 ND\NN\14625458 versus\CC\1740 400.2+/-11.8\CD\1740 nmol/min/g\NN\1740 heart\NN\5919034 in\IN\13603305 <e2>OB</e2>\NN\6043075 )\-RRB-\1740 ,\,\1740 (\-LRB-\1740 5\CD\13741022 )\-RRB-\1740 decreased\VBD\169651 mitochondrial\JJ\1740 AMP-alpha2\NN\1740 protein\NN\14944888 kinase\NN\14732946 ,\,\1740 and\CC\1740 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 86\CD\1740 %\NN\1740 drop\NN\13899200 in\IN\13603305 cardiac\JJ\1740 ATP\NN\14964590 levels\NNS\4916342 accompanied\VBN\1835496 by\IN\1740 decreased\VBN\169651 <e1>ATP/ADP</e1>\NN\1740 ratio\NN\13815152 after\IN\1740 doxorubicin\NN\2716866 administration\NN\1133281 .\.\1740
D000255_D066126 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 HFD-induced\JJ\1740 obese\JJ\1740 rats\NNS\2329401 are\VBP\836236 highly\RB\1740 sensitized\VBN\126264 to\TO\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 by\IN\1740 substantially\RB\1740 downregulating\VBG\1740 cardiac\JJ\1740 mitochondrial\JJ\1740 <e1>ATP</e1>\NN\14964590 generation\NN\7942152 ,\,\1740 increasing\VBG\169651 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 downregulating\VBG\1740 the\DT\1740 JAK/STAT3\JJ\1740 pathway\NN\5483677 .\.\1740
8424298
D007741_D007022 CID Effects\NNS\13245626 of\IN\1740 deliberate\JJ\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>labetalol</e1>\NNS\2721160 with\IN\1740 isoflurane\NN\3570838 on\IN\1740 neuropsychological\JJ\1740 function\NN\13783581 .\.\1740
D007741_D007022 CID Twenty-four\CD\13745420 patients\NNS\9898892 were\VBD\836236 anaesthetized\VBN\84738 for\IN\1740 middle-ear\JJ\1740 surgery\NN\6045562 with\IN\1740 deliberate\JJ\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>labetalol</e1>\NNS\2721160 with\IN\1740 isoflurane\NN\3570838 (\-LRB-\1740 hypotensive\JJ\1740 group\NN\2137 )\-RRB-\1740 .\.\1740
D007741_D007022 CID Twenty-four\CD\13745420 patients\NNS\9898892 were\VBD\836236 anaesthetized\VBN\84738 for\IN\1740 middle-ear\JJ\1740 surgery\NN\6045562 with\IN\1740 deliberate\JJ\1740 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>labetalol</e1>\NNS\2721160 with\IN\1740 isoflurane\NN\3570838 (\-LRB-\1740 <e2>hypotensive</e2>\JJ\1740 group\NN\2137 )\-RRB-\1740 .\.\1740
D007741_D007022 CID The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>labetalol</e1>\NNS\2721160 with\IN\1740 isoflurane\NN\3570838 has\VBZ\2108377 no\DT\7204911 significant\JJ\1740 harmful\JJ\1740 effects\NNS\13245626 on\IN\1740 mental\JJ\1740 functions\NNS\13783581 compared\VBN\644583 to\TO\1740 normotensive\JJ\1740 anaesthesia\NN\14034177 .\.\1740
D007530_D007022 CID Effects\NNS\13245626 of\IN\1740 deliberate\JJ\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 labetalol\NNS\2721160 with\IN\1740 <e1>isoflurane</e1>\NN\3570838 on\IN\1740 neuropsychological\JJ\1740 function\NN\13783581 .\.\1740
D007530_D007022 CID Twenty-four\CD\13745420 patients\NNS\9898892 were\VBD\836236 anaesthetized\VBN\84738 for\IN\1740 middle-ear\JJ\1740 surgery\NN\6045562 with\IN\1740 deliberate\JJ\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 labetalol\NNS\2721160 with\IN\1740 <e1>isoflurane</e1>\NN\3570838 (\-LRB-\1740 hypotensive\JJ\1740 group\NN\2137 )\-RRB-\1740 .\.\1740
D007530_D007022 CID Twenty-four\CD\13745420 patients\NNS\9898892 were\VBD\836236 anaesthetized\VBN\84738 for\IN\1740 middle-ear\JJ\1740 surgery\NN\6045562 with\IN\1740 deliberate\JJ\1740 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 labetalol\NNS\2721160 with\IN\1740 <e1>isoflurane</e1>\NN\3570838 (\-LRB-\1740 <e2>hypotensive</e2>\JJ\1740 group\NN\2137 )\-RRB-\1740 .\.\1740
D007530_D007022 CID The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 labetalol\NNS\2721160 with\IN\1740 <e1>isoflurane</e1>\NN\3570838 has\VBZ\2108377 no\DT\7204911 significant\JJ\1740 harmful\JJ\1740 effects\NNS\13245626 on\IN\1740 mental\JJ\1740 functions\NNS\13783581 compared\VBN\644583 to\TO\1740 normotensive\JJ\1740 anaesthesia\NN\14034177 .\.\1740
9758264
D005492_D008180 CID Epileptogenic\JJ\1740 activity\NN\30358 of\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 after\IN\1740 drug\NN\14778436 induces\VBZ\1627355 <e2>SLE</e2>\NN\14229912 (\-LRB-\1740 folic\JJ\1740 acid\NN\14818238 and\CC\1740 epilepsy\NN\14085708 )\-RRB-\1740
D005492_D008180 CID Epileptogenic\JJ\1740 activity\NN\30358 of\IN\1740 folic\JJ\1740 acid\NN\14818238 after\IN\1740 drug\NN\14778436 induces\VBZ\1627355 <e2>SLE</e2>\NN\14229912 (\-LRB-\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 and\CC\1740 epilepsy\NN\14085708 )\-RRB-\1740
D005492_D008180 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 epileptic\JJ\1740 pregnant\JJ\1740 patient\NN\9898892 's\POS\1740 autoimmune\JJ\1740 disease\NN\14061805 (\-LRB-\1740 probably\RB\1740 drug-induced\JJ\1740 <e2>lupus</e2>\NN\14219661 )\-RRB-\1740 could\MD\1740 damage\VB\126264 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 therefore\RB\1740 the\DT\1740 therapeutic\JJ\1740 dose\NN\3740161 (\-LRB-\1740 >\CD\1740 or\CC\3541091 =\JJ\1740 1\CD\13741022 mg\NN\13717155 )\-RRB-\1740 of\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 triggered\VBD\1641914 a\DT\13649268 cluster\NN\7959269 of\IN\1740 seizures\NNS\14081375 .\.\1740
D005492_D004827 NONE Epileptogenic\JJ\1740 activity\NN\30358 of\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 after\IN\1740 drug\NN\14778436 induces\VBZ\1627355 SLE\NN\14229912 (\-LRB-\1740 folic\JJ\1740 acid\NN\14818238 and\CC\1740 <e2>epilepsy</e2>\NN\14085708 )\-RRB-\1740
D005492_D004827 NONE Epileptogenic\JJ\1740 activity\NN\30358 of\IN\1740 folic\JJ\1740 acid\NN\14818238 after\IN\1740 drug\NN\14778436 induces\VBZ\1627355 SLE\NN\14229912 (\-LRB-\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 and\CC\1740 <e2>epilepsy</e2>\NN\14085708 )\-RRB-\1740
D005492_D004827 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 study\VB\630380 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>folic\JJ\1740 acid-containing</e1>\JJ\1740 multivitamin\NN\7938149 supplementation\NN\5108947 in\IN\13603305 <e2>epileptic</e2>\JJ\1740 women\NNS\9605289 before\IN\1740 and\CC\1740 during\IN\1740 pregnancy\NN\14034177 in\IN\13603305 order\NN\7168131 to\TO\1740 determine\VB\1645601 the\DT\1740 rate\NN\13815152 of\IN\1740 structural\JJ\1740 birth\NN\15265518 defects\NNS\14462666 and\CC\1740 epilepsy-related\JJ\1740 side\NN\8630039 effects\NNS\13245626 .\.\1740
D005492_D004827 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 study\VB\630380 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>folic\JJ\1740 acid-containing</e1>\JJ\1740 multivitamin\NN\7938149 supplementation\NN\5108947 in\IN\13603305 epileptic\JJ\1740 women\NNS\9605289 before\IN\1740 and\CC\1740 during\IN\1740 pregnancy\NN\14034177 in\IN\13603305 order\NN\7168131 to\TO\1740 determine\VB\1645601 the\DT\1740 rate\NN\13815152 of\IN\1740 structural\JJ\1740 birth\NN\15265518 defects\NNS\14462666 and\CC\1740 <e2>epilepsy-related</e2>\JJ\1740 side\NN\8630039 effects\NNS\13245626 .\.\1740
D005492_D004827 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 60\CD\13745420 <e2>epileptic</e2>\JJ\1740 women\NNS\9605289 with\IN\1740 periconceptional\JJ\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 0.8\CD\1740 mg)-containing\NN\1740 multivitamin\NN\7938149 supplementation\NN\5108947 ,\,\1740 no\DT\7204911 one\NN\13741022 developed\VBD\1753788 epilepsy-related\JJ\1740 side\NN\8630039 effects\NNS\13245626 during\IN\1740 the\DT\1740 periconception\NN\1740 period\NN\13575869 .\.\1740
D005492_D004827 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 60\CD\13745420 epileptic\JJ\1740 women\NNS\9605289 with\IN\1740 periconceptional\JJ\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 0.8\CD\1740 mg)-containing\NN\1740 multivitamin\NN\7938149 supplementation\NN\5108947 ,\,\1740 no\DT\7204911 one\NN\13741022 developed\VBD\1753788 <e2>epilepsy-related</e2>\JJ\1740 side\NN\8630039 effects\NNS\13245626 during\IN\1740 the\DT\1740 periconception\NN\1740 period\NN\13575869 .\.\1740
D005492_D004827 NONE This\DT\1740 22-year-old\JJ\1740 <e2>epileptic</e2>\JJ\1740 woman\NN\9605289 was\VBD\836236 treated\VBN\2376958 continuously\RB\1740 by\IN\1740 carbamazepine\NN\1740 and\CC\1740 a\DT\13649268 <e1>folic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 1\CD\13741022 mg)-containing\NN\1740 multivitamin\NN\7938149 from\IN\1740 the\DT\1740 20th\JJ\1740 week\NN\15113229 of\IN\1740 gestation\NN\15116532 .\.\1740
D005492_D004827 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 <e2>epileptic</e2>\JJ\1740 pregnant\JJ\1740 patient\NN\9898892 's\POS\1740 autoimmune\JJ\1740 disease\NN\14061805 (\-LRB-\1740 probably\RB\1740 drug-induced\JJ\1740 lupus\NN\14219661 )\-RRB-\1740 could\MD\1740 damage\VB\126264 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 therefore\RB\1740 the\DT\1740 therapeutic\JJ\1740 dose\NN\3740161 (\-LRB-\1740 >\CD\1740 or\CC\3541091 =\JJ\1740 1\CD\13741022 mg\NN\13717155 )\-RRB-\1740 of\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 triggered\VBD\1641914 a\DT\13649268 cluster\NN\7959269 of\IN\1740 seizures\NNS\14081375 .\.\1740
D005492_D004827 NONE Physiological\JJ\1740 dose\NN\3740161 (\-LRB-\1740 <\XX\1740 1\CD\13741022 mg\NN\13717155 )\-RRB-\1740 of\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 both\CC\1740 in\IN\13603305 healthy\JJ\1740 and\CC\1740 60\CD\13745420 <e2>epileptic</e2>\JJ\1740 women\NNS\9605289 ,\,\1740 all\DT\1740 without\IN\1740 any\DT\1740 autoimmune\JJ\1740 disease\NN\14061805 ,\,\1740 did\VBD\1640855 not\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 epileptic\JJ\1740 seizures\NNS\14081375 .\.\1740
D005492_D004827 NONE Physiological\JJ\1740 dose\NN\3740161 (\-LRB-\1740 <\XX\1740 1\CD\13741022 mg\NN\13717155 )\-RRB-\1740 of\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 both\CC\1740 in\IN\13603305 healthy\JJ\1740 and\CC\1740 60\CD\13745420 epileptic\JJ\1740 women\NNS\9605289 ,\,\1740 all\DT\1740 without\IN\1740 any\DT\1740 autoimmune\JJ\1740 disease\NN\14061805 ,\,\1740 did\VBD\1640855 not\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 <e2>epileptic\JJ\1740 seizures</e2>\NNS\14081375 .\.\1740
D005492_D000014 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 study\VB\630380 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>folic\JJ\1740 acid-containing</e1>\JJ\1740 multivitamin\NN\7938149 supplementation\NN\5108947 in\IN\13603305 epileptic\JJ\1740 women\NNS\9605289 before\IN\1740 and\CC\1740 during\IN\1740 pregnancy\NN\14034177 in\IN\13603305 order\NN\7168131 to\TO\1740 determine\VB\1645601 the\DT\1740 rate\NN\13815152 of\IN\1740 structural\JJ\1740 <e2>birth\NN\15265518 defects</e2>\NNS\14462666 and\CC\1740 epilepsy-related\JJ\1740 side\NN\8630039 effects\NNS\13245626 .\.\1740
D002220_D004827 NONE This\DT\1740 22-year-old\JJ\1740 <e2>epileptic</e2>\JJ\1740 woman\NN\9605289 was\VBD\836236 treated\VBN\2376958 continuously\RB\1740 by\IN\1740 <e1>carbamazepine</e1>\NN\1740 and\CC\1740 a\DT\13649268 folic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 1\CD\13741022 mg)-containing\NN\1740 multivitamin\NN\7938149 from\IN\1740 the\DT\1740 20th\JJ\1740 week\NN\15113229 of\IN\1740 gestation\NN\15116532 .\.\1740
D005492_D001327 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 epileptic\JJ\1740 pregnant\JJ\1740 patient\NN\9898892 's\POS\1740 <e2>autoimmune\JJ\1740 disease</e2>\NN\14061805 (\-LRB-\1740 probably\RB\1740 drug-induced\JJ\1740 lupus\NN\14219661 )\-RRB-\1740 could\MD\1740 damage\VB\126264 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 therefore\RB\1740 the\DT\1740 therapeutic\JJ\1740 dose\NN\3740161 (\-LRB-\1740 >\CD\1740 or\CC\3541091 =\JJ\1740 1\CD\13741022 mg\NN\13717155 )\-RRB-\1740 of\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 triggered\VBD\1641914 a\DT\13649268 cluster\NN\7959269 of\IN\1740 seizures\NNS\14081375 .\.\1740
D005492_D001327 NONE Physiological\JJ\1740 dose\NN\3740161 (\-LRB-\1740 <\XX\1740 1\CD\13741022 mg\NN\13717155 )\-RRB-\1740 of\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 both\CC\1740 in\IN\13603305 healthy\JJ\1740 and\CC\1740 60\CD\13745420 epileptic\JJ\1740 women\NNS\9605289 ,\,\1740 all\DT\1740 without\IN\1740 any\DT\1740 <e2>autoimmune\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 did\VBD\1640855 not\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 epileptic\JJ\1740 seizures\NNS\14081375 .\.\1740
D005492_D012640 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 epileptic\JJ\1740 pregnant\JJ\1740 patient\NN\9898892 's\POS\1740 autoimmune\JJ\1740 disease\NN\14061805 (\-LRB-\1740 probably\RB\1740 drug-induced\JJ\1740 lupus\NN\14219661 )\-RRB-\1740 could\MD\1740 damage\VB\126264 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 therefore\RB\1740 the\DT\1740 therapeutic\JJ\1740 dose\NN\3740161 (\-LRB-\1740 >\CD\1740 or\CC\3541091 =\JJ\1740 1\CD\13741022 mg\NN\13717155 )\-RRB-\1740 of\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 triggered\VBD\1641914 a\DT\13649268 cluster\NN\7959269 of\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
9875685
D014031_D064420 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 dosage\NN\13576355 regimen\NN\5898568 (\-LRB-\1740 once-daily\JJ\1740 vs.\CC\1740 twice-daily\RB\1740 )\-RRB-\1740 of\IN\1740 <e1>tobramicyn</e1>\NN\1740 on\IN\1740 steady-state\JJ\1740 serum\NN\5397468 concentrations\NNS\4916342 and\CC\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D003404_D007674 NONE Increased\VBN\169651 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 73\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 OD\NN\6702458 versus\CC\1740 57\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 TD\NN\1740 ,\,\1740 without\IN\1740 evidence\NN\5816287 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
20331935
D018967_D006966 CID OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>risperidone-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 on\IN\1740 trabecular\JJ\1740 bone\NN\5286536 mineral\JJ\1740 density\NN\4941325 (\-LRB-\1740 BMD\NN\1740 )\-RRB-\1740 in\IN\13603305 children\NNS\9622049 and\CC\1740 adolescents\NNS\9622049 .\.\1740
D018967_D006966 CID RESULTS\NNS\34213 :\:\1740 <e2>Hyperprolactinemia</e2>\NNP\1740 was\VBD\836236 present\JJ\1740 in\IN\13603305 49\CD\1740 %\NN\1740 of\IN\1740 83\CD\1740 boys\NNS\9624168 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 41\CD\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>risperidone</e1>\NN\1740 for\IN\1740 a\DT\13649268 mean\NN\6021761 of\IN\1740 2.9\CD\1740 years\NNS\15144371 .\.\1740
D018967_D006966 CID Of\IN\1740 13\CD\13745420 documented\VBN\1000214 fractures\NNS\14285662 ,\,\1740 3\CD\13741022 occurred\VBD\2623529 after\IN\1740 <e1>risperidone</e1>\NN\1740 and\CC\1740 SSRIs\NN\2718811 were\VBD\836236 started\VBN\2009433 ,\,\1740 and\CC\1740 none\NN\15228378 occurred\VBD\2623529 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D018967_D006966 CID CONCLUSIONS\NNS\5837957 :\:\1740 This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 study\NN\635850 to\TO\1740 link\VB\628491 <e1>risperidone-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 SSRI\NN\2718811 treatment\NN\654885 to\TO\1740 lower\JJR\1740 BMD\NN\1740 in\IN\13603305 children\NNS\9622049 and\CC\1740 adolescents\NNS\9622049 .\.\1740
D013739_D006966 NONE Serum\NN\5397468 <e1>testosterone</e1>\NN\14747587 concentration\NN\4916342 increased\VBN\169651 with\IN\1740 pubertal\JJ\1740 status\NN\24720 but\CC\1740 was\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D018967_D050723 NONE Of\IN\1740 13\CD\13745420 documented\VBN\1000214 <e2>fractures</e2>\NNS\14285662 ,\,\1740 3\CD\13741022 occurred\VBD\2623529 after\IN\1740 <e1>risperidone</e1>\NN\1740 and\CC\1740 SSRIs\NN\2718811 were\VBD\836236 started\VBN\2009433 ,\,\1740 and\CC\1740 none\NN\15228378 occurred\VBD\2623529 in\IN\13603305 patients\NNS\9898892 with\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
16225977
C012052_D013981 CID <e1>Amisulpride</e1>\RB\1740 related\JJ\1740 <e2>tic-like\JJ\1740 symptoms</e2>\NNS\5823932 in\IN\13603305 an\DT\6697703 adolescent\JJ\1740 schizophrenic\JJ\1740 .\.\1740
C012052_D013981 CID The\DT\1740 <e2>tic-like\JJ\1740 symptoms</e2>\NNS\5823932 resolved\VBN\352826 completely\RB\1740 after\IN\1740 we\PRP\1740 reduced\VBD\441445 the\DT\1740 dose\NN\3740161 of\IN\1740 <e1>amisulpride</e1>\NN\1740 down\IN\1896031 to\IN\1740 800\CD\1740 mg\NN\13717155 per\IN\1740 day\NN\15154774 .\.\1740
C012052_D013981 CID Together\RB\1740 with\IN\1740 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 ,\,\1740 our\PRP$\1740 patient\NN\9898892 suggests\VBZ\1010118 that\IN\1740 <e2>tic-like\JJ\1740 symptoms</e2>\NNS\5823932 might\MD\5029706 occur\VB\2623529 in\IN\13603305 certain\JJ\1740 vulnerable\JJ\1740 individuals\NNS\7347 during\IN\1740 treatment\NN\654885 with\IN\1740 atypical\JJ\1740 antipsychotics\NNS\4470232 such\JJ\1740 as\IN\14622893 quetiapine\NN\1740 ,\,\1740 clozapine\NN\3713736 ,\,\1740 or\CC\3541091 <e1>amisulpride</e1>\RB\1740 .\.\1740
C012052_D012559 NONE <e1>Amisulpride</e1>\RB\1740 related\JJ\1740 tic-like\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 an\DT\6697703 adolescent\JJ\1740 <e2>schizophrenic</e2>\JJ\1740 .\.\1740
C012052_D012559 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 15-year-old\JJ\1740 girl\NN\10787470 <e2>schizophrenic</e2>\JJ\1740 who\WP\8299493 developed\VBD\1753788 frequent\JJ\1740 involuntary\JJ\1740 eye-blinking\JJ\1740 movements\NNS\191142 after\IN\1740 5\CD\13741022 months\NNS\15113229 of\IN\1740 <e1>amisulpride</e1>\JJ\1740 treatment\NN\654885 (\-LRB-\1740 1000\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 )\-RRB-\1740 .\.\1740
D018967_D013981 NONE <e2>Tic\NN\14361664 disorders</e2>\NNS\14034177 can\MD\3094503 be\VB\836236 effectively\RB\1740 treated\VBN\2376958 by\IN\1740 atypical\JJ\1740 antipsychotics\NNS\4470232 such\JJ\1740 as\IN\14622893 <e1>risperidone</e1>\NN\1740 ,\,\1740 olanzapine\NN\1740 and\CC\1740 ziprasidone\NN\1740 .\.\1740
C076029_D013981 NONE <e2>Tic\NN\14361664 disorders</e2>\NNS\14034177 can\MD\3094503 be\VB\836236 effectively\RB\1740 treated\VBN\2376958 by\IN\1740 atypical\JJ\1740 antipsychotics\NNS\4470232 such\JJ\1740 as\IN\14622893 risperidone\NN\1740 ,\,\1740 <e1>olanzapine</e1>\NN\1740 and\CC\1740 ziprasidone\NN\1740 .\.\1740
C092292_D013981 NONE <e2>Tic\NN\14361664 disorders</e2>\NNS\14034177 can\MD\3094503 be\VB\836236 effectively\RB\1740 treated\VBN\2376958 by\IN\1740 atypical\JJ\1740 antipsychotics\NNS\4470232 such\JJ\1740 as\IN\14622893 risperidone\NN\1740 ,\,\1740 olanzapine\NN\1740 and\CC\1740 <e1>ziprasidone</e1>\NN\1740 .\.\1740
C069541_D013981 NONE However\RB\1740 ,\,\1740 there\EX\27167 are\VBP\836236 two\CD\13741022 case\NN\7283608 reports\NNS\6470073 that\WDT\1740 show\VBP\2137132 <e2>tic-like\JJ\1740 symptoms</e2>\NNS\5823932 ,\,\1740 including\VBG\690614 motor\NN\3699975 and\CC\1740 phonic\JJ\1740 variants\NNS\7366289 ,\,\1740 occurring\VBG\2623529 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>quetiapine</e1>\NN\1740 or\CC\3541091 clozapine\NN\3713736 .\.\1740
C069541_D013981 NONE Together\RB\1740 with\IN\1740 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 ,\,\1740 our\PRP$\1740 patient\NN\9898892 suggests\VBZ\1010118 that\IN\1740 <e2>tic-like\JJ\1740 symptoms</e2>\NNS\5823932 might\MD\5029706 occur\VB\2623529 in\IN\13603305 certain\JJ\1740 vulnerable\JJ\1740 individuals\NNS\7347 during\IN\1740 treatment\NN\654885 with\IN\1740 atypical\JJ\1740 antipsychotics\NNS\4470232 such\JJ\1740 as\IN\14622893 <e1>quetiapine</e1>\NN\1740 ,\,\1740 clozapine\NN\3713736 ,\,\1740 or\CC\3541091 amisulpride\RB\1740 .\.\1740
D003024_D013981 NONE However\RB\1740 ,\,\1740 there\EX\27167 are\VBP\836236 two\CD\13741022 case\NN\7283608 reports\NNS\6470073 that\WDT\1740 show\VBP\2137132 <e2>tic-like\JJ\1740 symptoms</e2>\NNS\5823932 ,\,\1740 including\VBG\690614 motor\NN\3699975 and\CC\1740 phonic\JJ\1740 variants\NNS\7366289 ,\,\1740 occurring\VBG\2623529 during\IN\1740 treatment\NN\654885 with\IN\1740 quetiapine\NN\1740 or\CC\3541091 <e1>clozapine</e1>\NN\3713736 .\.\1740
D003024_D013981 NONE Together\RB\1740 with\IN\1740 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 ,\,\1740 our\PRP$\1740 patient\NN\9898892 suggests\VBZ\1010118 that\IN\1740 <e2>tic-like\JJ\1740 symptoms</e2>\NNS\5823932 might\MD\5029706 occur\VB\2623529 in\IN\13603305 certain\JJ\1740 vulnerable\JJ\1740 individuals\NNS\7347 during\IN\1740 treatment\NN\654885 with\IN\1740 atypical\JJ\1740 antipsychotics\NNS\4470232 such\JJ\1740 as\IN\14622893 quetiapine\NN\1740 ,\,\1740 <e1>clozapine</e1>\NN\3713736 ,\,\1740 or\CC\3541091 amisulpride\RB\1740 .\.\1740
C012052_D020820 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 15-year-old\JJ\1740 girl\NN\10787470 schizophrenic\JJ\1740 who\WP\8299493 developed\VBD\1753788 frequent\JJ\1740 <e2>involuntary\JJ\1740 eye-blinking\JJ\1740 movements</e2>\NNS\191142 after\IN\1740 5\CD\13741022 months\NNS\15113229 of\IN\1740 <e1>amisulpride</e1>\JJ\1740 treatment\NN\654885 (\-LRB-\1740 1000\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 )\-RRB-\1740 .\.\1740
6540303
D000588_D002389 NONE Effects\NNS\13245626 of\IN\1740 <e1>amine</e1>\JJ\1740 pretreatment\NN\1740 on\IN\1740 ketamine\NN\3054098 <e2>catatonia</e2>\NN\14544672 in\IN\13603305 pinealectomized\JJ\1740 or\CC\3541091 hypophysectomized\VBN\173338 animals\NNS\4475 .\.\1740
D007649_D002389 CID Effects\NNS\13245626 of\IN\1740 amine\JJ\1740 pretreatment\NN\1740 on\IN\1740 <e1>ketamine</e1>\NN\3054098 <e2>catatonia</e2>\NN\14544672 in\IN\13603305 pinealectomized\JJ\1740 or\CC\3541091 hypophysectomized\VBN\173338 animals\NNS\4475 .\.\1740
D007649_D002389 CID The\DT\1740 present\JJ\1740 studies\NNS\635850 were\VBD\836236 designed\VBN\1631534 to\TO\1740 clarify\VB\939277 the\DT\1740 role\NN\719494 of\IN\1740 catecholamines\NNS\5407119 and\CC\1740 pineal\VB\1740 idolamines\NNS\1740 on\IN\1740 <e1>ketamine-induced</e1>\JJ\1740 <e2>catatonia</e2>\NN\14544672 in\IN\13603305 the\DT\1740 intact\JJ\1740 ,\,\1740 pinealectomized\JJ\1740 or\CC\3541091 hypophysectomized\JJ\1740 chick\NN\1791625 and\CC\1740 rat\NN\2329401 .\.\1740
D007649_D002389 CID In\IN\13603305 the\DT\1740 pinealectomized\JJ\1740 chick\NN\1791625 ,\,\1740 pretreatment\NN\1740 with\IN\1740 dopamine\NN\14807737 increased\VBD\169651 the\DT\1740 duration\NN\15113229 of\IN\1740 <e2>catatonia</e2>\NN\14544672 (\-LRB-\1740 DOC\NN\10305802 )\-RRB-\1740 after\IN\1740 <e1>ketamine</e1>\NN\3054098 ,\,\1740 but\CC\1740 pretreatment\NN\1740 with\IN\1740 norepinephrine\NN\14807929 did\VBD\1640855 not\RB\1740 .\.\1740
D007649_D002389 CID Furthermore\RB\1740 ,\,\1740 dopamine\NN\14807737 appeared\VBD\2604760 to\TO\1740 act\VB\1619354 on\IN\1740 systems\NNS\3575240 more\RBR\1740 closely\RB\1740 involved\VBN\2676054 with\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 <e1>ketamine</e1>\NN\3054098 <e2>catatonia</e2>\NN\14544672 rather\RB\1740 than\IN\1740 directly\RB\1740 on\IN\1740 the\DT\1740 pituitary\NN\5329735 .\.\1740
D002395_D002389 NONE The\DT\1740 present\JJ\1740 studies\NNS\635850 were\VBD\836236 designed\VBN\1631534 to\TO\1740 clarify\VB\939277 the\DT\1740 role\NN\719494 of\IN\1740 <e1>catecholamines</e1>\NNS\5407119 and\CC\1740 pineal\VB\1740 idolamines\NNS\1740 on\IN\1740 ketamine-induced\JJ\1740 <e2>catatonia</e2>\NN\14544672 in\IN\13603305 the\DT\1740 intact\JJ\1740 ,\,\1740 pinealectomized\JJ\1740 or\CC\3541091 hypophysectomized\JJ\1740 chick\NN\1791625 and\CC\1740 rat\NN\2329401 .\.\1740
D004298_D002389 CID In\IN\13603305 the\DT\1740 pinealectomized\JJ\1740 chick\NN\1791625 ,\,\1740 pretreatment\NN\1740 with\IN\1740 <e1>dopamine</e1>\NN\14807737 increased\VBD\169651 the\DT\1740 duration\NN\15113229 of\IN\1740 <e2>catatonia</e2>\NN\14544672 (\-LRB-\1740 DOC\NN\10305802 )\-RRB-\1740 after\IN\1740 ketamine\NN\3054098 ,\,\1740 but\CC\1740 pretreatment\NN\1740 with\IN\1740 norepinephrine\NN\14807929 did\VBD\1640855 not\RB\1740 .\.\1740
D004298_D002389 CID Furthermore\RB\1740 ,\,\1740 <e1>dopamine</e1>\NN\14807737 appeared\VBD\2604760 to\TO\1740 act\VB\1619354 on\IN\1740 systems\NNS\3575240 more\RBR\1740 closely\RB\1740 involved\VBN\2676054 with\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 ketamine\NN\3054098 <e2>catatonia</e2>\NN\14544672 rather\RB\1740 than\IN\1740 directly\RB\1740 on\IN\1740 the\DT\1740 pituitary\NN\5329735 .\.\1740
D009638_D002389 NONE In\IN\13603305 the\DT\1740 pinealectomized\JJ\1740 chick\NN\1791625 ,\,\1740 pretreatment\NN\1740 with\IN\1740 dopamine\NN\14807737 increased\VBD\169651 the\DT\1740 duration\NN\15113229 of\IN\1740 <e2>catatonia</e2>\NN\14544672 (\-LRB-\1740 DOC\NN\10305802 )\-RRB-\1740 after\IN\1740 ketamine\NN\3054098 ,\,\1740 but\CC\1740 pretreatment\NN\1740 with\IN\1740 <e1>norepinephrine</e1>\NN\14807929 did\VBD\1640855 not\RB\1740 .\.\1740
6292680
D004317_D009202 CID <e1>Doxorubicin</e1>\NN\2716866 <e2>cardiomyopathy</e2>\JJ\1740 in\IN\13603305 children\NNS\9622049 with\IN\1740 left-sided\JJ\1740 Wilms\NN\1740 tumor\NN\14234074 .\.\1740
D004317_D009202 CID Two\CD\13741022 children\NNS\9622049 with\IN\1740 Wilms\JJ\1740 tumor\NN\14234074 of\IN\1740 the\DT\1740 left\JJ\1740 kidney\NN\5333259 experienced\VBD\2108377 severe\JJ\1740 anthracycline\NN\1740 <e2>cardiomyopathy</e2>\NN\14103288 after\IN\1740 irradiation\NN\13920835 to\TO\1740 the\DT\1740 tumor\NN\14234074 bed\NN\2821943 and\CC\1740 conventional\JJ\1740 dosage\NN\13576355 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D009202 CID The\DT\1740 <e2>cardiomyopathy</e2>\JJ\1740 is\VBZ\836236 attributed\VBN\670261 1\CD\13741022 )\-RRB-\1740 to\TO\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 radiation\NN\11452218 fields\NNS\8673395 for\IN\1740 left\JJ\1740 Wilms\NN\1740 tumor\NN\14234074 include\VBP\690614 the\DT\1740 lower\JJR\1740 portion\NN\31921 of\IN\1740 the\DT\1740 heart\NN\5919034 and\CC\1740 2\CD\13741022 )\-RRB-\1740 to\TO\1740 the\DT\1740 interaction\NN\37396 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 irradiation\NN\13920835 on\IN\1740 cardiac\JJ\1740 muscle\NN\5289601 .\.\1740
D004317_D009396 NONE <e1>Doxorubicin</e1>\NN\2716866 cardiomyopathy\JJ\1740 in\IN\13603305 children\NNS\9622049 with\IN\1740 left-sided\JJ\1740 <e2>Wilms\NN\1740 tumor</e2>\NN\14234074 .\.\1740
D004317_D009396 NONE Two\CD\13741022 children\NNS\9622049 with\IN\1740 <e2>Wilms\JJ\1740 tumor</e2>\NN\14234074 of\IN\1740 the\DT\1740 left\JJ\1740 kidney\NN\5333259 experienced\VBD\2108377 severe\JJ\1740 anthracycline\NN\1740 cardiomyopathy\NN\14103288 after\IN\1740 irradiation\NN\13920835 to\TO\1740 the\DT\1740 tumor\NN\14234074 bed\NN\2821943 and\CC\1740 conventional\JJ\1740 dosage\NN\13576355 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D009396 NONE The\DT\1740 cardiomyopathy\JJ\1740 is\VBZ\836236 attributed\VBN\670261 1\CD\13741022 )\-RRB-\1740 to\TO\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 radiation\NN\11452218 fields\NNS\8673395 for\IN\1740 left\JJ\1740 <e2>Wilms\NN\1740 tumor</e2>\NN\14234074 include\VBP\690614 the\DT\1740 lower\JJR\1740 portion\NN\31921 of\IN\1740 the\DT\1740 heart\NN\5919034 and\CC\1740 2\CD\13741022 )\-RRB-\1740 to\TO\1740 the\DT\1740 interaction\NN\37396 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 irradiation\NN\13920835 on\IN\1740 cardiac\JJ\1740 muscle\NN\5289601 .\.\1740
D004317_D009396 NONE It\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 <e1>doxorubicin</e1>\NN\2716866 dosage\NN\13576355 be\VBP\836236 sharply\RB\1740 restricted\JJ\1740 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>Wilms\NN\1740 tumor</e2>\NN\14234074 of\IN\1740 the\DT\1740 left\JJ\1740 kidney\NN\5333259 who\WP\8299493 receive\VBP\2210855 postoperative\JJ\1740 irradiation\NN\13920835 .\.\1740
D018943_D009396 NONE Two\CD\13741022 children\NNS\9622049 with\IN\1740 <e2>Wilms\JJ\1740 tumor</e2>\NN\14234074 of\IN\1740 the\DT\1740 left\JJ\1740 kidney\NN\5333259 experienced\VBD\2108377 severe\JJ\1740 <e1>anthracycline</e1>\NN\1740 cardiomyopathy\NN\14103288 after\IN\1740 irradiation\NN\13920835 to\TO\1740 the\DT\1740 tumor\NN\14234074 bed\NN\2821943 and\CC\1740 conventional\JJ\1740 dosage\NN\13576355 of\IN\1740 doxorubicin\NN\2716866 .\.\1740
D018943_D009202 NONE Two\CD\13741022 children\NNS\9622049 with\IN\1740 Wilms\JJ\1740 tumor\NN\14234074 of\IN\1740 the\DT\1740 left\JJ\1740 kidney\NN\5333259 experienced\VBD\2108377 severe\JJ\1740 <e1>anthracycline</e1>\NN\1740 <e2>cardiomyopathy</e2>\NN\14103288 after\IN\1740 irradiation\NN\13920835 to\TO\1740 the\DT\1740 tumor\NN\14234074 bed\NN\2821943 and\CC\1740 conventional\JJ\1740 dosage\NN\13576355 of\IN\1740 doxorubicin\NN\2716866 .\.\1740
D018943_D009369 NONE Two\CD\13741022 children\NNS\9622049 with\IN\1740 Wilms\JJ\1740 tumor\NN\14234074 of\IN\1740 the\DT\1740 left\JJ\1740 kidney\NN\5333259 experienced\VBD\2108377 severe\JJ\1740 <e1>anthracycline</e1>\NN\1740 cardiomyopathy\NN\14103288 after\IN\1740 irradiation\NN\13920835 to\TO\1740 the\DT\1740 <e2>tumor</e2>\NN\14234074 bed\NN\2821943 and\CC\1740 conventional\JJ\1740 dosage\NN\13576355 of\IN\1740 doxorubicin\NN\2716866 .\.\1740
D004317_D009369 NONE Two\CD\13741022 children\NNS\9622049 with\IN\1740 Wilms\JJ\1740 tumor\NN\14234074 of\IN\1740 the\DT\1740 left\JJ\1740 kidney\NN\5333259 experienced\VBD\2108377 severe\JJ\1740 anthracycline\NN\1740 cardiomyopathy\NN\14103288 after\IN\1740 irradiation\NN\13920835 to\TO\1740 the\DT\1740 <e2>tumor</e2>\NN\14234074 bed\NN\2821943 and\CC\1740 conventional\JJ\1740 dosage\NN\13576355 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
2826064
D010096_D007008 NONE Beta-2-adrenoceptor-mediated\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 its\PRP$\6125041 abolishment\NN\209943 by\IN\1740 <e1>oxprenolol</e1>\NN\1740 .\.\1740
D010096_D007008 NONE Subsequently\RB\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>oxprenolol</e1>\NN\1740 in\IN\13603305 antagonizing\VBG\1787955 such\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 ,\,\1740 together\RB\1740 with\IN\1740 the\DT\1740 pharmacokinetic\JJ\1740 interaction\NN\37396 between\IN\1740 both\DT\1740 drugs\NNS\14778436 .\.\1740
D010096_D007008 NONE In\IN\13603305 spite\NN\7550369 of\IN\1740 higher\JJR\1740 terbutaline\NN\1740 concentrations\NNS\4916342 after\IN\1740 <e1>oxprenolol</e1>\JJ\1740 pretreatment\NN\1740 ,\,\1740 the\DT\1740 <e2>hypokalemia</e2>\NN\14299637 was\VBD\836236 almost\RB\1740 completely\RB\1740 antagonized\VBN\1787955 by\IN\1740 the\DT\1740 beta\NN\6828818 2-blocking\JJ\1740 action\NN\30358 .\.\1740
D013726_D007008 CID The\DT\1740 time\NN\7308889 course\NN\883297 and\CC\1740 concentration-effect\JJ\1740 relationship\NN\31921 of\IN\1740 <e1>terbutaline-induced</e1>\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 was\VBD\836236 studied\VBN\630380 ,\,\1740 using\VBG\1156834 computer-aided\JJ\1740 pharmacokinetic-dynamic\JJ\1740 modeling\NN\4157320 .\.\1740
D013726_D007008 CID In\IN\13603305 spite\NN\7550369 of\IN\1740 higher\JJR\1740 <e1>terbutaline</e1>\NN\1740 concentrations\NNS\4916342 after\IN\1740 oxprenolol\JJ\1740 pretreatment\NN\1740 ,\,\1740 the\DT\1740 <e2>hypokalemia</e2>\NN\14299637 was\VBD\836236 almost\RB\1740 completely\RB\1740 antagonized\VBN\1787955 by\IN\1740 the\DT\1740 beta\NN\6828818 2-blocking\JJ\1740 action\NN\30358 .\.\1740
9915601
D007538_D001919 CID Enhanced\VBN\227165 <e2>bradycardia</e2>\NN\14110674 induced\VBN\1627355 by\IN\1740 beta-adrenoceptor\JJ\1740 antagonists\NNS\7846 in\IN\13603305 rats\NNS\2329401 pretreated\VBN\1740 with\IN\1740 <e1>isoniazid</e1>\NN\2716205 .\.\1740
D007538_D001919 CID High\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>isoniazid</e1>\NNS\2716205 increase\VBP\169651 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 vasodilators\NNS\3198383 and\CC\1740 change\VBP\46534 the\DT\1740 accompanying\VBG\1835496 reflex\JJ\1740 tachycardia\NN\14110674 to\TO\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 an\DT\6697703 interaction\NN\37396 attributed\VBN\670261 to\TO\1740 decreased\VBN\169651 synthesis\NN\13446390 of\IN\1740 brain\NN\5462674 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 .\.\1740
D007538_D001919 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 possible\JJ\1740 enhancement\NN\248977 by\IN\1740 <e1>isoniazid</e1>\NN\2716205 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 induced\VBN\1627355 by\IN\1740 beta-adrenoceptor\JJ\1740 antagonists\NNS\7846 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 rats\NNS\2329401 anaesthetised\VBN\84738 with\IN\1740 chloralose-urethane\NN\1740 .\.\1740
D007538_D001919 CID <e1>Isoniazid</e1>\NNS\2716205 significantly\RB\1740 increased\VBD\169651 <e2>bradycardia</e2>\NN\14110674 after\IN\1740 propranolol\NN\1740 ,\,\1740 pindolol\NN\2832168 ,\,\1740 labetalol\NN\2721160 and\CC\1740 atenolol\NNS\2832168 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 after\IN\1740 clonidine\NN\2721160 ,\,\1740 but\CC\1740 not\RB\1740 after\IN\1740 hexamethonium\NN\1740 or\CC\3541091 carbachol\NN\1740 .\.\1740
D007538_D007022 CID High\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>isoniazid</e1>\NNS\2716205 increase\VBP\169651 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 vasodilators\NNS\3198383 and\CC\1740 change\VBP\46534 the\DT\1740 accompanying\VBG\1835496 reflex\JJ\1740 tachycardia\NN\14110674 to\TO\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 interaction\NN\37396 attributed\VBN\670261 to\TO\1740 decreased\VBN\169651 synthesis\NN\13446390 of\IN\1740 brain\NN\5462674 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 .\.\1740
D007538_D013610 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>isoniazid</e1>\NNS\2716205 increase\VBP\169651 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 vasodilators\NNS\3198383 and\CC\1740 change\VBP\46534 the\DT\1740 accompanying\VBG\1835496 reflex\JJ\1740 <e2>tachycardia</e2>\NN\14110674 to\TO\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 interaction\NN\37396 attributed\VBN\670261 to\TO\1740 decreased\VBN\169651 synthesis\NN\13446390 of\IN\1740 brain\NN\5462674 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 .\.\1740
D005680_D007022 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 isoniazid\NNS\2716205 increase\VBP\169651 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 vasodilators\NNS\3198383 and\CC\1740 change\VBP\46534 the\DT\1740 accompanying\VBG\1835496 reflex\JJ\1740 tachycardia\NN\14110674 to\TO\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 interaction\NN\37396 attributed\VBN\670261 to\TO\1740 decreased\VBN\169651 synthesis\NN\13446390 of\IN\1740 brain\NN\5462674 <e1>gamma-aminobutyric\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 .\.\1740
D005680_D007022 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 isoniazid\NNS\2716205 increase\VBP\169651 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 vasodilators\NNS\3198383 and\CC\1740 change\VBP\46534 the\DT\1740 accompanying\VBG\1835496 reflex\JJ\1740 tachycardia\NN\14110674 to\TO\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 interaction\NN\37396 attributed\VBN\670261 to\TO\1740 decreased\VBN\169651 synthesis\NN\13446390 of\IN\1740 brain\NN\5462674 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>GABA</e1>\NN\14601829 )\-RRB-\1740 .\.\1740
D005680_D013610 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 isoniazid\NNS\2716205 increase\VBP\169651 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 vasodilators\NNS\3198383 and\CC\1740 change\VBP\46534 the\DT\1740 accompanying\VBG\1835496 reflex\JJ\1740 <e2>tachycardia</e2>\NN\14110674 to\TO\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 interaction\NN\37396 attributed\VBN\670261 to\TO\1740 decreased\VBN\169651 synthesis\NN\13446390 of\IN\1740 brain\NN\5462674 <e1>gamma-aminobutyric\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 .\.\1740
D005680_D013610 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 isoniazid\NNS\2716205 increase\VBP\169651 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 vasodilators\NNS\3198383 and\CC\1740 change\VBP\46534 the\DT\1740 accompanying\VBG\1835496 reflex\JJ\1740 <e2>tachycardia</e2>\NN\14110674 to\TO\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 interaction\NN\37396 attributed\VBN\670261 to\TO\1740 decreased\VBN\169651 synthesis\NN\13446390 of\IN\1740 brain\NN\5462674 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>GABA</e1>\NN\14601829 )\-RRB-\1740 .\.\1740
D005680_D001919 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 isoniazid\NNS\2716205 increase\VBP\169651 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 vasodilators\NNS\3198383 and\CC\1740 change\VBP\46534 the\DT\1740 accompanying\VBG\1835496 reflex\JJ\1740 tachycardia\NN\14110674 to\TO\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 an\DT\6697703 interaction\NN\37396 attributed\VBN\670261 to\TO\1740 decreased\VBN\169651 synthesis\NN\13446390 of\IN\1740 brain\NN\5462674 <e1>gamma-aminobutyric\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 .\.\1740
D005680_D001919 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 isoniazid\NNS\2716205 increase\VBP\169651 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 vasodilators\NNS\3198383 and\CC\1740 change\VBP\46534 the\DT\1740 accompanying\VBG\1835496 reflex\JJ\1740 tachycardia\NN\14110674 to\TO\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 an\DT\6697703 interaction\NN\37396 attributed\VBN\670261 to\TO\1740 decreased\VBN\169651 synthesis\NN\13446390 of\IN\1740 brain\NN\5462674 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>GABA</e1>\NN\14601829 )\-RRB-\1740 .\.\1740
D002698_D001919 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 possible\JJ\1740 enhancement\NN\248977 by\IN\1740 isoniazid\NN\2716205 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 induced\VBN\1627355 by\IN\1740 beta-adrenoceptor\JJ\1740 antagonists\NNS\7846 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 rats\NNS\2329401 anaesthetised\VBN\84738 with\IN\1740 <e1>chloralose-urethane</e1>\NN\1740 .\.\1740
D014520_D001919 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 possible\JJ\1740 enhancement\NN\248977 by\IN\1740 isoniazid\NN\2716205 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 induced\VBN\1627355 by\IN\1740 beta-adrenoceptor\JJ\1740 antagonists\NNS\7846 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 rats\NNS\2329401 anaesthetised\VBN\84738 with\IN\1740 <e1>chloralose-urethane</e1>\NN\1740 .\.\1740
D011433_D001919 NONE Isoniazid\NNS\2716205 significantly\RB\1740 increased\VBD\169651 <e2>bradycardia</e2>\NN\14110674 after\IN\1740 <e1>propranolol</e1>\NN\1740 ,\,\1740 pindolol\NN\2832168 ,\,\1740 labetalol\NN\2721160 and\CC\1740 atenolol\NNS\2832168 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 after\IN\1740 clonidine\NN\2721160 ,\,\1740 but\CC\1740 not\RB\1740 after\IN\1740 hexamethonium\NN\1740 or\CC\3541091 carbachol\NN\1740 .\.\1740
D010869_D001919 NONE Isoniazid\NNS\2716205 significantly\RB\1740 increased\VBD\169651 <e2>bradycardia</e2>\NN\14110674 after\IN\1740 propranolol\NN\1740 ,\,\1740 <e1>pindolol</e1>\NN\2832168 ,\,\1740 labetalol\NN\2721160 and\CC\1740 atenolol\NNS\2832168 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 after\IN\1740 clonidine\NN\2721160 ,\,\1740 but\CC\1740 not\RB\1740 after\IN\1740 hexamethonium\NN\1740 or\CC\3541091 carbachol\NN\1740 .\.\1740
D007741_D001919 NONE Isoniazid\NNS\2716205 significantly\RB\1740 increased\VBD\169651 <e2>bradycardia</e2>\NN\14110674 after\IN\1740 propranolol\NN\1740 ,\,\1740 pindolol\NN\2832168 ,\,\1740 <e1>labetalol</e1>\NN\2721160 and\CC\1740 atenolol\NNS\2832168 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 after\IN\1740 clonidine\NN\2721160 ,\,\1740 but\CC\1740 not\RB\1740 after\IN\1740 hexamethonium\NN\1740 or\CC\3541091 carbachol\NN\1740 .\.\1740
D001262_D001919 NONE Isoniazid\NNS\2716205 significantly\RB\1740 increased\VBD\169651 <e2>bradycardia</e2>\NN\14110674 after\IN\1740 propranolol\NN\1740 ,\,\1740 pindolol\NN\2832168 ,\,\1740 labetalol\NN\2721160 and\CC\1740 <e1>atenolol</e1>\NNS\2832168 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 after\IN\1740 clonidine\NN\2721160 ,\,\1740 but\CC\1740 not\RB\1740 after\IN\1740 hexamethonium\NN\1740 or\CC\3541091 carbachol\NN\1740 .\.\1740
D003000_D001919 NONE Isoniazid\NNS\2716205 significantly\RB\1740 increased\VBD\169651 <e2>bradycardia</e2>\NN\14110674 after\IN\1740 propranolol\NN\1740 ,\,\1740 pindolol\NN\2832168 ,\,\1740 labetalol\NN\2721160 and\CC\1740 atenolol\NNS\2832168 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 after\IN\1740 <e1>clonidine</e1>\NN\2721160 ,\,\1740 but\CC\1740 not\RB\1740 after\IN\1740 hexamethonium\NN\1740 or\CC\3541091 carbachol\NN\1740 .\.\1740
D018738_D001919 NONE Isoniazid\NNS\2716205 significantly\RB\1740 increased\VBD\169651 <e2>bradycardia</e2>\NN\14110674 after\IN\1740 propranolol\NN\1740 ,\,\1740 pindolol\NN\2832168 ,\,\1740 labetalol\NN\2721160 and\CC\1740 atenolol\NNS\2832168 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 after\IN\1740 clonidine\NN\2721160 ,\,\1740 but\CC\1740 not\RB\1740 after\IN\1740 <e1>hexamethonium</e1>\NN\1740 or\CC\3541091 carbachol\NN\1740 .\.\1740
D002217_D001919 NONE Isoniazid\NNS\2716205 significantly\RB\1740 increased\VBD\169651 <e2>bradycardia</e2>\NN\14110674 after\IN\1740 propranolol\NN\1740 ,\,\1740 pindolol\NN\2832168 ,\,\1740 labetalol\NN\2721160 and\CC\1740 atenolol\NNS\2832168 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 after\IN\1740 clonidine\NN\2721160 ,\,\1740 but\CC\1740 not\RB\1740 after\IN\1740 hexamethonium\NN\1740 or\CC\3541091 <e1>carbachol</e1>\NN\1740 .\.\1740
6496797
D014196_D006327 CID Complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 following\VBG\1835496 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>trazodone</e1>\NN\3829085 .\.\1740
D014196_D006327 CID Forty\CD\13745420 minutes\NNS\6502378 after\IN\1740 receiving\VBG\2210855 a\DT\13649268 single\JJ\1740 starting\VBG\2009433 dose\NN\3740161 of\IN\1740 <e1>trazodone</e1>\NN\3829085 ,\,\1740 a\DT\13649268 patient\NN\9898892 developed\VBD\1753788 complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 .\.\1740
7604176
D017035_D009135 NONE <e1>Pravastatin-associated</e1>\JJ\1740 <e2>myopathy</e2>\NN\14204950 .\.\1740
D017035_D009135 NONE He\PRP\14622893 was\VBD\836236 admitted\VBN\822367 with\IN\1740 acute\JJ\1740 <e2>myopathy</e2>\NN\14204950 of\IN\1740 the\DT\1740 lower\JJR\1740 limbs\NNS\5559908 which\WDT\1740 resolved\VBD\352826 in\IN\13603305 a\DT\13649268 few\JJ\1740 days\NNS\15140892 after\IN\1740 <e1>pravastatin</e1>\NN\3676175 discontinuation\NN\209943 .\.\1740
D017035_D009135 NONE While\IN\15122231 lovastatin\NN\3676175 and\CC\1740 simvastatin\NN\3676175 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 toxic\JJ\1740 <e2>myopathy</e2>\NN\14204950 ,\,\1740 <e1>pravastatin-associated</e1>\JJ\1740 myopathy\NN\14204950 could\MD\1740 represent\VB\2664769 a\DT\13649268 distinct\JJ\1740 ,\,\1740 inflammatory\JJ\1740 entity\NN\1740 .\.\1740
D017035_D009135 NONE While\IN\15122231 lovastatin\NN\3676175 and\CC\1740 simvastatin\NN\3676175 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 toxic\JJ\1740 myopathy\NN\14204950 ,\,\1740 <e1>pravastatin-associated</e1>\JJ\1740 <e2>myopathy</e2>\NN\14204950 could\MD\1740 represent\VB\2664769 a\DT\13649268 distinct\JJ\1740 ,\,\1740 inflammatory\JJ\1740 entity\NN\1740 .\.\1740
D017035_D009220 CID A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>inflammatory\JJ\1740 myopathy</e2>\NN\14204950 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>pravastatin</e1>\NN\3676175 ,\,\1740 a\DT\13649268 new\JJ\1740 hydrophilic\JJ\1740 3-hydroxy-3\NN\1740 methylglutaril\NN\1740 coenzyme\NN\14682133 A\NN\13649268 reductase\NN\14732946 inhibitor\NN\20090 ,\,\1740 is\VBZ\836236 reported\VBN\831651 .\.\1740
D017035_D006937 NONE He\PRP\14622893 assumed\VBD\719734 <e1>pravastatin</e1>\NN\3676175 (\-LRB-\1740 20\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 because\IN\1740 of\IN\1740 <e2>hypercholesterolemia</e2>\NN\14299637 .\.\1740
D008148_D009135 NONE While\IN\15122231 <e1>lovastatin</e1>\NN\3676175 and\CC\1740 simvastatin\NN\3676175 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 toxic\JJ\1740 <e2>myopathy</e2>\NN\14204950 ,\,\1740 pravastatin-associated\JJ\1740 myopathy\NN\14204950 could\MD\1740 represent\VB\2664769 a\DT\13649268 distinct\JJ\1740 ,\,\1740 inflammatory\JJ\1740 entity\NN\1740 .\.\1740
D008148_D009135 NONE While\IN\15122231 <e1>lovastatin</e1>\NN\3676175 and\CC\1740 simvastatin\NN\3676175 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 toxic\JJ\1740 myopathy\NN\14204950 ,\,\1740 pravastatin-associated\JJ\1740 <e2>myopathy</e2>\NN\14204950 could\MD\1740 represent\VB\2664769 a\DT\13649268 distinct\JJ\1740 ,\,\1740 inflammatory\JJ\1740 entity\NN\1740 .\.\1740
D019821_D009135 NONE While\IN\15122231 lovastatin\NN\3676175 and\CC\1740 <e1>simvastatin</e1>\NN\3676175 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 toxic\JJ\1740 <e2>myopathy</e2>\NN\14204950 ,\,\1740 pravastatin-associated\JJ\1740 myopathy\NN\14204950 could\MD\1740 represent\VB\2664769 a\DT\13649268 distinct\JJ\1740 ,\,\1740 inflammatory\JJ\1740 entity\NN\1740 .\.\1740
D019821_D009135 NONE While\IN\15122231 lovastatin\NN\3676175 and\CC\1740 <e1>simvastatin</e1>\NN\3676175 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 toxic\JJ\1740 myopathy\NN\14204950 ,\,\1740 pravastatin-associated\JJ\1740 <e2>myopathy</e2>\NN\14204950 could\MD\1740 represent\VB\2664769 a\DT\13649268 distinct\JJ\1740 ,\,\1740 inflammatory\JJ\1740 entity\NN\1740 .\.\1740
20466178
D016559_D003872 NONE Rosaceiform\NN\1740 <e2>dermatitis</e2>\NN\14226056 associated\VBN\628491 with\IN\1740 topical\JJ\1740 <e1>tacrolimus</e1>\NN\1740 treatment\NN\654885 .\.\1740
D016559_D003872 NONE We\PRP\1740 describe\VBP\1001294 herein\RB\1740 3\CD\13741022 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 rosacea-like\JJ\1740 <e2>dermatitis</e2>\NN\14226056 eruptions\NNS\7307754 while\IN\15122231 using\VBG\1156834 0.03\CD\1740 %\NN\1740 or\CC\3541091 0.1\CD\1740 %\NN\1740 <e1>tacrolimus</e1>\NN\1740 ointment\JJ\1740 for\IN\1740 facial\JJ\1740 dermatitis\NN\14226056 .\.\1740
D016559_D003872 NONE Continuous\JJ\1740 topical\JJ\1740 use\NN\407535 of\IN\1740 immunomodulators\NNS\1740 such\JJ\1740 as\IN\14622893 <e1>tacrolimus</e1>\NN\1740 or\CC\3541091 pimecrolimus\NN\1740 should\MD\1740 be\VB\836236 regarded\VBN\689344 as\IN\14622893 a\DT\13649268 potential\JJ\1740 cause\NN\7323922 of\IN\1740 rosaceiform\NN\1740 <e2>dermatitis</e2>\NN\14226056 ,\,\1740 although\IN\1740 many\JJ\1740 cases\NNS\7283608 have\VBP\2108377 not\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
D016559_D012393 NONE We\PRP\1740 describe\VBP\1001294 herein\RB\1740 3\CD\13741022 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>rosacea-like</e2>\JJ\1740 dermatitis\NN\14226056 eruptions\NNS\7307754 while\IN\15122231 using\VBG\1156834 0.03\CD\1740 %\NN\1740 or\CC\3541091 0.1\CD\1740 %\NN\1740 <e1>tacrolimus</e1>\NN\1740 ointment\JJ\1740 for\IN\1740 facial\JJ\1740 dermatitis\NN\14226056 .\.\1740
D016559_D003875 NONE We\PRP\1740 describe\VBP\1001294 herein\RB\1740 3\CD\13741022 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 rosacea-like\JJ\1740 dermatitis\NN\14226056 <e2>eruptions</e2>\NNS\7307754 while\IN\15122231 using\VBG\1156834 0.03\CD\1740 %\NN\1740 or\CC\3541091 0.1\CD\1740 %\NN\1740 <e1>tacrolimus</e1>\NN\1740 ointment\JJ\1740 for\IN\1740 facial\JJ\1740 dermatitis\NN\14226056 .\.\1740
D016559_D005148 NONE We\PRP\1740 describe\VBP\1001294 herein\RB\1740 3\CD\13741022 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 rosacea-like\JJ\1740 dermatitis\NN\14226056 eruptions\NNS\7307754 while\IN\15122231 using\VBG\1156834 0.03\CD\1740 %\NN\1740 or\CC\3541091 0.1\CD\1740 %\NN\1740 <e1>tacrolimus</e1>\NN\1740 ointment\JJ\1740 for\IN\1740 <e2>facial\JJ\1740 dermatitis</e2>\NN\14226056 .\.\1740
C117268_D003872 CID Continuous\JJ\1740 topical\JJ\1740 use\NN\407535 of\IN\1740 immunomodulators\NNS\1740 such\JJ\1740 as\IN\14622893 tacrolimus\NN\1740 or\CC\3541091 <e1>pimecrolimus</e1>\NN\1740 should\MD\1740 be\VB\836236 regarded\VBN\689344 as\IN\14622893 a\DT\13649268 potential\JJ\1740 cause\NN\7323922 of\IN\1740 rosaceiform\NN\1740 <e2>dermatitis</e2>\NN\14226056 ,\,\1740 although\IN\1740 many\JJ\1740 cases\NNS\7283608 have\VBP\2108377 not\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
663266
D003973_D014693 NONE <e2>Ventricular\JJ\1740 fibrillation</e2>\NN\14361664 from\IN\1740 <e1>diatrizoate</e1>\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 chelating\VBG\2621395 agents\NNS\7347 .\.\1740
C027278_D064420 NONE The\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>Renografin\NNP\1740 76\CD\1740 %</e1>\NN\1740 was\VBD\836236 compared\VBN\644583 with\IN\1740 that\DT\1740 of\IN\1740 Hypaque\NN\1740 76\CD\1740 %\NN\1740 by\IN\1740 selective\JJ\1740 injection\NN\320852 of\IN\1740 each\DT\1740 into\IN\1740 the\DT\1740 right\JJ\1740 coronary\JJ\1740 artery\NN\5417975 of\IN\1740 dogs\NNS\2083346 .\.\1740
C027278_D064420 NONE The\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 Renografin\NNP\1740 76\CD\1740 %\NN\1740 was\VBD\836236 compared\VBN\644583 with\IN\1740 that\DT\1740 of\IN\1740 <e1>Hypaque\NN\1740 76\CD\1740 %</e1>\NN\1740 by\IN\1740 selective\JJ\1740 injection\NN\320852 of\IN\1740 each\DT\1740 into\IN\1740 the\DT\1740 right\JJ\1740 coronary\JJ\1740 artery\NN\5417975 of\IN\1740 dogs\NNS\2083346 .\.\1740
D003974_D014693 NONE <e2>Ventricular\JJ\1740 fibrillation</e2>\NN\14361664 occurred\VBD\2623529 significantly\RB\1740 more\RBR\1740 often\RB\1740 with\IN\1740 <e1>Renografin</e1>\NNP\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 chelating\NN\1740 agents\NNS\7347 contribute\VBP\126264 to\TO\1740 toxicity\NN\13576101 in\IN\13603305 coronary\JJ\1740 angiography\NN\904623 .\.\1740
D003974_D064420 NONE Ventricular\JJ\1740 fibrillation\NN\14361664 occurred\VBD\2623529 significantly\RB\1740 more\RBR\1740 often\RB\1740 with\IN\1740 <e1>Renografin</e1>\NNP\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 chelating\NN\1740 agents\NNS\7347 contribute\VBP\126264 to\TO\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 coronary\JJ\1740 angiography\NN\904623 .\.\1740
15638391
D006220_D006966 CID Aging\NN\13526110 process\NN\407535 of\IN\1740 epithelial\JJ\1740 cells\NNS\3080309 of\IN\1740 the\DT\1740 rat\NN\2329401 prostate\NN\5329735 lateral\NN\560529 lobe\VBD\1740 in\IN\13603305 experimental\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 .\.\1740
D006220_D006966 CID The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 examine\VB\789138 the\DT\1740 influence\NN\5190804 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 ,\,\1740 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 HAL\NN\1740 )\-RRB-\1740 on\IN\1740 age\NN\4916342 related\JJ\1740 morphology\NN\6037666 and\CC\1740 function\NN\13783581 changes\NNS\7283608 of\IN\1740 epithelial\JJ\1740 cells\NNS\3080309 in\IN\13603305 rat\NN\2329401 prostate\NN\5329735 lateral\NN\560529 lobe\VBD\1740 .\.\1740
D006220_D006966 CID The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 examine\VB\789138 the\DT\1740 influence\NN\5190804 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 ,\,\1740 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 (\-LRB-\1740 <e1>HAL</e1>\NN\1740 )\-RRB-\1740 on\IN\1740 age\NN\4916342 related\JJ\1740 morphology\NN\6037666 and\CC\1740 function\NN\13783581 changes\NNS\7283608 of\IN\1740 epithelial\JJ\1740 cells\NNS\3080309 in\IN\13603305 rat\NN\2329401 prostate\NN\5329735 lateral\NN\560529 lobe\VBD\1740 .\.\1740
15266362
D004280_D002312 NONE The\DT\1740 47-year-old\JJ\1740 female\JJ\1740 patient\NN\9898892 ,\,\1740 known\VBN\2110220 to\TO\1740 have\VB\2108377 <e2>hypertrophic\JJ\1740 cardiomyopathy</e2>\JJ\1740 ,\,\1740 was\VBD\836236 admitted\VBN\822367 with\IN\1740 biventricular\JJ\1740 failure\NN\66216 and\CC\1740 managed\VBD\2524171 aggressively\RB\1740 with\IN\1740 <e1>dobutamine</e1>\NN\1740 infusion\NN\14589223 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 while\IN\15122231 being\VBG\836236 assessed\VBN\670261 for\IN\1740 heart\NN\5919034 transplantation\NN\671351 .\.\1740
D004280_D018754 NONE The\DT\1740 47-year-old\JJ\1740 female\JJ\1740 patient\NN\9898892 ,\,\1740 known\VBN\2110220 to\TO\1740 have\VB\2108377 hypertrophic\JJ\1740 cardiomyopathy\JJ\1740 ,\,\1740 was\VBD\836236 admitted\VBN\822367 with\IN\1740 <e2>biventricular\JJ\1740 failure</e2>\NN\66216 and\CC\1740 managed\VBD\2524171 aggressively\RB\1740 with\IN\1740 <e1>dobutamine</e1>\NN\1740 infusion\NN\14589223 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 while\IN\15122231 being\VBG\836236 assessed\VBN\670261 for\IN\1740 heart\NN\5919034 transplantation\NN\671351 .\.\1740
D004280_D004342 CID It\PRP\6125041 is\VBZ\836236 likely\JJ\1740 that\IN\1740 the\DT\1740 <e2>hypersensitivity</e2>\NN\14531772 (\-LRB-\1740 eosinophilic\JJ\1740 )\-RRB-\1740 myocarditis\NN\14338942 was\VBD\836236 related\JJ\1740 to\TO\1740 <e1>dobutamine</e1>\NN\1740 infusion\NN\14589223 therapy\NN\657604 .\.\1740
D004280_D004802 CID It\PRP\6125041 is\VBZ\836236 likely\JJ\1740 that\IN\1740 the\DT\1740 hypersensitivity\NN\14531772 (\-LRB-\1740 <e2>eosinophilic</e2>\JJ\1740 )\-RRB-\1740 myocarditis\NN\14338942 was\VBD\836236 related\JJ\1740 to\TO\1740 <e1>dobutamine</e1>\NN\1740 infusion\NN\14589223 therapy\NN\657604 .\.\1740
D004280_D009205 CID It\PRP\6125041 is\VBZ\836236 likely\JJ\1740 that\IN\1740 the\DT\1740 hypersensitivity\NN\14531772 (\-LRB-\1740 eosinophilic\JJ\1740 )\-RRB-\1740 <e2>myocarditis</e2>\NN\14338942 was\VBD\836236 related\JJ\1740 to\TO\1740 <e1>dobutamine</e1>\NN\1740 infusion\NN\14589223 therapy\NN\657604 .\.\1740
2004015
D015215_C565469 NONE Sensitivity\NN\5651971 of\IN\1740 erythroid\JJ\1740 progenitor\NN\9792555 colonies\NNS\7965085 to\TO\1740 erythropoietin\NN\14888310 in\IN\13603305 <e1>azidothymidine</e1>\NN\1740 treated\JJ\1740 <e2>immunodeficient</e2>\JJ\1740 mice\NNS\2329401 .\.\1740
D015215_D000740 CID The\DT\1740 <e2>anaemia</e2>\NN\14299637 induced\VBN\1627355 by\IN\1740 <e1>3'-azido-3'dideoxythymidine</e1>\NN\1740 (\-LRB-\1740 AZT\NN\3834836 )\-RRB-\1740 is\VBZ\836236 poorly\RB\1740 understood\VBN\588888 .\.\1740
D015215_D000740 CID The\DT\1740 <e2>anaemia</e2>\NN\14299637 induced\VBN\1627355 by\IN\1740 3'-azido-3'dideoxythymidine\NN\1740 (\-LRB-\1740 <e1>AZT</e1>\NN\3834836 )\-RRB-\1740 is\VBZ\836236 poorly\RB\1740 understood\VBN\588888 .\.\1740
D015215_D000740 CID We\PRP\1740 have\VBP\2108377 used\VBN\1156834 a\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 AIDS\NN\13974317 ,\,\1740 infection\NN\14052046 of\IN\1740 female\JJ\1740 C57BL/6\NN\1740 mice\NNS\2329401 with\IN\1740 LP-BM5\NN\1740 murine\NN\2329401 leukaemia\NN\14239918 (\-LRB-\1740 MuLV\JJ\1740 )\-RRB-\1740 virus\NN\9312843 ,\,\1740 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>AZT-induced</e1>\JJ\1740 <e2>anaemia</e2>\NN\14299637 is\VBZ\836236 due\JJ\1740 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 to\TO\1740 decreased\VBN\169651 responsiveness\NN\5652926 of\IN\1740 erythropoietic\JJ\1740 precursors\NNS\14580897 (\-LRB-\1740 BFU-e\NN\1740 )\-RRB-\1740 to\TO\1740 erythropoietin\NN\14888310 (\-LRB-\1740 EPO\NN\1740 )\-RRB-\1740 .\.\1740
D015215_D000740 CID <e1>AZT</e1>\NN\3834836 produced\VBD\1617192 <e2>anaemia</e2>\NN\14299637 in\IN\13603305 both\DT\1740 groups\NNS\2137 ,\,\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 fashion\NN\4916342 .\.\1740
D015215_D000740 CID Despite\IN\7501545 the\DT\1740 <e2>anaemia</e2>\NN\14299637 ,\,\1740 the\DT\1740 number\NN\5107765 of\IN\1740 splenic\JJ\1740 and\CC\1740 bone\NN\5286536 marrow\NN\5286536 BFU-e\NN\1740 in\IN\13603305 <e1>AZT</e1>\NN\3834836 treated\JJ\1740 mice\NNS\2329401 increased\VBD\169651 up\RB\1740 to\TO\1740 five-fold\RB\1740 over\IN\5867413 levels\NNS\4916342 observed\VBN\2163746 in\IN\13603305 infected\JJ\1740 untreated\JJ\1740 animals\NNS\4475 after\IN\1740 15\CD\13745420 d\NN\15089472 of\IN\1740 treatment\NN\654885 .\.\1740
D015215_D000740 CID The\DT\1740 mean\NN\6021761 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 EPO\NN\1740 observed\VBN\2163746 in\IN\13603305 <e1>AZT</e1>\NN\3834836 treated\JJ\1740 mice\NNS\2329401 were\VBD\836236 appropriate\JJ\1740 for\IN\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 <e2>anaemia</e2>\NN\14299637 observed\VBN\2163746 when\WRB\1740 compared\VBN\644583 with\IN\1740 phenylhydrazine\NN\1740 (\-LRB-\1740 PHZ\NN\1740 )\-RRB-\1740 treated\VBN\2376958 mice\NNS\2329401 .\.\1740
D015215_D000740 CID The\DT\1740 numbers\NNS\508091 of\IN\1740 BFU-e\NN\1740 and\CC\1740 the\DT\1740 percentage\NN\13815742 of\IN\1740 bone\NN\5286536 marrow\NN\5286536 erythroblasts\NNS\5447757 observed\VBN\2163746 were\VBD\836236 comparable\JJ\1740 in\IN\13603305 <e1>AZT</e1>\NN\3834836 and\CC\1740 PHZ\NN\1740 treated\JJ\1740 mice\NNS\2329401 with\IN\1740 similar\JJ\1740 degrees\NNS\4916342 of\IN\1740 <e2>anaemia</e2>\NN\14299637 .\.\1740
D015215_D000740 CID However\RB\1740 ,\,\1740 reticulocytosis\NN\1740 was\VBD\836236 inappropriate\JJ\1740 for\IN\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 <e2>anaemia</e2>\NN\14299637 observed\VBN\2163746 in\IN\13603305 <e1>AZT</e1>\NN\3834836 treated\VBN\2376958 infected\JJ\1740 mice\NNS\2329401 .\.\1740
D015215_D000740 CID <e1>AZT-induced</e1>\JJ\1740 peripheral\JJ\1740 <e2>anaemia</e2>\NN\14299637 in\IN\13603305 the\DT\1740 face\NN\5225090 of\IN\1740 increased\VBN\169651 numbers\NNS\508091 of\IN\1740 BFU-e\NN\1740 and\CC\1740 increased\VBN\169651 levels\NNS\4916342 of\IN\1740 plasma\NN\5398023 EPO\NN\1740 suggest\VBP\1010118 a\DT\13649268 lesion\NN\14204950 in\IN\13603305 terminal\JJ\1740 differentiation\NN\5748054 .\.\1740
D015215_D000163 NONE We\PRP\1740 have\VBP\2108377 used\VBN\1156834 a\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 <e2>AIDS</e2>\NN\13974317 ,\,\1740 infection\NN\14052046 of\IN\1740 female\JJ\1740 C57BL/6\NN\1740 mice\NNS\2329401 with\IN\1740 LP-BM5\NN\1740 murine\NN\2329401 leukaemia\NN\14239918 (\-LRB-\1740 MuLV\JJ\1740 )\-RRB-\1740 virus\NN\9312843 ,\,\1740 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>AZT-induced</e1>\JJ\1740 anaemia\NN\14299637 is\VBZ\836236 due\JJ\1740 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 to\TO\1740 decreased\VBN\169651 responsiveness\NN\5652926 of\IN\1740 erythropoietic\JJ\1740 precursors\NNS\14580897 (\-LRB-\1740 BFU-e\NN\1740 )\-RRB-\1740 to\TO\1740 erythropoietin\NN\14888310 (\-LRB-\1740 EPO\NN\1740 )\-RRB-\1740 .\.\1740
D015215_D007239 NONE We\PRP\1740 have\VBP\2108377 used\VBN\1156834 a\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 AIDS\NN\13974317 ,\,\1740 <e2>infection</e2>\NN\14052046 of\IN\1740 female\JJ\1740 C57BL/6\NN\1740 mice\NNS\2329401 with\IN\1740 LP-BM5\NN\1740 murine\NN\2329401 leukaemia\NN\14239918 (\-LRB-\1740 MuLV\JJ\1740 )\-RRB-\1740 virus\NN\9312843 ,\,\1740 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>AZT-induced</e1>\JJ\1740 anaemia\NN\14299637 is\VBZ\836236 due\JJ\1740 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 to\TO\1740 decreased\VBN\169651 responsiveness\NN\5652926 of\IN\1740 erythropoietic\JJ\1740 precursors\NNS\14580897 (\-LRB-\1740 BFU-e\NN\1740 )\-RRB-\1740 to\TO\1740 erythropoietin\NN\14888310 (\-LRB-\1740 EPO\NN\1740 )\-RRB-\1740 .\.\1740
D015215_D007938 NONE We\PRP\1740 have\VBP\2108377 used\VBN\1156834 a\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 AIDS\NN\13974317 ,\,\1740 infection\NN\14052046 of\IN\1740 female\JJ\1740 C57BL/6\NN\1740 mice\NNS\2329401 with\IN\1740 LP-BM5\NN\1740 murine\NN\2329401 <e2>leukaemia</e2>\NN\14239918 (\-LRB-\1740 MuLV\JJ\1740 )\-RRB-\1740 virus\NN\9312843 ,\,\1740 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>AZT-induced</e1>\JJ\1740 anaemia\NN\14299637 is\VBZ\836236 due\JJ\1740 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 to\TO\1740 decreased\VBN\169651 responsiveness\NN\5652926 of\IN\1740 erythropoietic\JJ\1740 precursors\NNS\14580897 (\-LRB-\1740 BFU-e\NN\1740 )\-RRB-\1740 to\TO\1740 erythropoietin\NN\14888310 (\-LRB-\1740 EPO\NN\1740 )\-RRB-\1740 .\.\1740
C030299_D000740 NONE The\DT\1740 mean\NN\6021761 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 EPO\NN\1740 observed\VBN\2163746 in\IN\13603305 AZT\NN\3834836 treated\JJ\1740 mice\NNS\2329401 were\VBD\836236 appropriate\JJ\1740 for\IN\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 <e2>anaemia</e2>\NN\14299637 observed\VBN\2163746 when\WRB\1740 compared\VBN\644583 with\IN\1740 <e1>phenylhydrazine</e1>\NN\1740 (\-LRB-\1740 PHZ\NN\1740 )\-RRB-\1740 treated\VBN\2376958 mice\NNS\2329401 .\.\1740
C030299_D000740 NONE The\DT\1740 mean\NN\6021761 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 EPO\NN\1740 observed\VBN\2163746 in\IN\13603305 AZT\NN\3834836 treated\JJ\1740 mice\NNS\2329401 were\VBD\836236 appropriate\JJ\1740 for\IN\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 <e2>anaemia</e2>\NN\14299637 observed\VBN\2163746 when\WRB\1740 compared\VBN\644583 with\IN\1740 phenylhydrazine\NN\1740 (\-LRB-\1740 <e1>PHZ</e1>\NN\1740 )\-RRB-\1740 treated\VBN\2376958 mice\NNS\2329401 .\.\1740
C030299_D000740 NONE The\DT\1740 numbers\NNS\508091 of\IN\1740 BFU-e\NN\1740 and\CC\1740 the\DT\1740 percentage\NN\13815742 of\IN\1740 bone\NN\5286536 marrow\NN\5286536 erythroblasts\NNS\5447757 observed\VBN\2163746 were\VBD\836236 comparable\JJ\1740 in\IN\13603305 AZT\NN\3834836 and\CC\1740 <e1>PHZ</e1>\NN\1740 treated\JJ\1740 mice\NNS\2329401 with\IN\1740 similar\JJ\1740 degrees\NNS\4916342 of\IN\1740 <e2>anaemia</e2>\NN\14299637 .\.\1740
D015215_D045262 NONE However\RB\1740 ,\,\1740 <e2>reticulocytosis</e2>\NN\1740 was\VBD\836236 inappropriate\JJ\1740 for\IN\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 anaemia\NN\14299637 observed\VBN\2163746 in\IN\13603305 <e1>AZT</e1>\NN\3834836 treated\VBN\2376958 infected\JJ\1740 mice\NNS\2329401 .\.\1740
188339
D003276_D008113 CID Etiologic\JJ\1740 factors\NNS\7326557 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e2>liver\NN\5298729 tumors</e2>\NNS\14234074 associated\VBN\628491 with\IN\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 .\.\1740
D003276_D008113 CID Within\IN\1740 the\DT\1740 last\JJ\1740 several\JJ\1740 years\NNS\15144371 ,\,\1740 previously\RB\1740 rare\JJ\1740 <e2>liver\NN\5298729 tumors</e2>\NNS\14234074 have\VBP\2108377 been\VBN\836236 seen\VBN\2106506 in\IN\13603305 young\JJ\1740 women\NNS\9605289 using\VBG\1156834 <e1>oral\JJ\1740 contraceptive</e1>\JJ\1740 steroids\NNS\14727670 .\.\1740
D003276_D008113 CID The\DT\1740 Registry\NNP\6502378 for\IN\1740 <e2>Liver\NNP\5298729 Tumors</e2>\NNS\14234074 Associated\VBN\628491 with\IN\1740 <e1>Oral\JJ\1740 Contraceptives</e1>\NNPS\3183080 at\IN\14622893 the\DT\1740 University\NNP\7965085 of\IN\1740 California\NNP\1740 ,\,\1740 Irvine\NNP\1740 ,\,\1740 has\VBZ\2108377 clearly\RB\1740 identified\VBN\699815 27\CD\13745420 cases\NNS\7283608 .\.\1740
D013256_D008113 NONE Within\IN\1740 the\DT\1740 last\JJ\1740 several\JJ\1740 years\NNS\15144371 ,\,\1740 previously\RB\1740 rare\JJ\1740 <e2>liver\NN\5298729 tumors</e2>\NNS\14234074 have\VBP\2108377 been\VBN\836236 seen\VBN\2106506 in\IN\13603305 young\JJ\1740 women\NNS\9605289 using\VBG\1156834 oral\JJ\1740 contraceptive\JJ\1740 <e1>steroids</e1>\NNS\14727670 .\.\1740
6293644
D006220_D002375 CID Calcitonin\NN\5413241 injection\NN\320852 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 potentiation\NN\13564910 of\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 a\DT\13649268 partial\JJ\1740 prevention\NN\1073995 of\IN\1740 apomorphine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D006220_D006948 NONE Calcitonin\NN\5413241 injection\NN\320852 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 potentiation\NN\13564910 of\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 catalepsy\NN\14023236 and\CC\1740 a\DT\13649268 partial\JJ\1740 prevention\NN\1073995 of\IN\1740 apomorphine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D001058_D002375 NONE Calcitonin\NN\5413241 injection\NN\320852 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 potentiation\NN\13564910 of\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 a\DT\13649268 partial\JJ\1740 prevention\NN\1073995 of\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D001058_D006948 CID Calcitonin\NN\5413241 injection\NN\320852 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 potentiation\NN\13564910 of\IN\1740 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 and\CC\1740 a\DT\13649268 partial\JJ\1740 prevention\NN\1073995 of\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
11243580
D008012_D012640 CID The\DT\1740 role\NN\719494 of\IN\1740 nitrergic\JJ\1740 system\NN\3575240 in\IN\13603305 <e1>lidocaine-induced</e1>\JJ\1740 <e2>convulsion</e2>\NN\14081375 in\IN\13603305 the\DT\1740 mouse\NN\2329401 .\.\1740
D008012_D012640 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 N-nitro-L-arginine-methyl\NN\1740 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 a\DT\13649268 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 synthase\NN\1740 inhibitor\NN\20090 and\CC\1740 L-arginine\NN\1740 ,\,\1740 a\DT\13649268 NO\NN\7204911 precursor\NN\14580897 ,\,\1740 were\VBD\836236 investigated\VBN\644583 on\IN\1740 <e1>lidocaine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D008012_D012640 CID L-NAME\NN\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 diazepam\NN\2830852 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 significantly\RB\1740 decreased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 50\CD\13745420 mg/kg)-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D008012_D012640 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 the\DT\1740 L-arginine\NN\1740 treatment\NN\654885 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 80\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.)-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 significantly\RB\1740 .\.\1740
D008012_D012640 CID These\DT\1740 results\NNS\34213 may\MD\15209706 suggest\VB\1010118 that\IN\1740 NO\NN\7204911 is\VBZ\836236 a\DT\13649268 proconvulsant\JJ\1740 mediator\NN\10351874 in\IN\13603305 <e1>lidocaine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D019331_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>N-nitro-L-arginine-methyl\NN\1740 ester</e1>\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 a\DT\13649268 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 synthase\NN\1740 inhibitor\NN\20090 and\CC\1740 L-arginine\NN\1740 ,\,\1740 a\DT\13649268 NO\NN\7204911 precursor\NN\14580897 ,\,\1740 were\VBD\836236 investigated\VBN\644583 on\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D019331_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 N-nitro-L-arginine-methyl\NN\1740 ester\NN\14727670 (\-LRB-\1740 <e1>L-NAME</e1>\NN\1740 )\-RRB-\1740 a\DT\13649268 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 synthase\NN\1740 inhibitor\NN\20090 and\CC\1740 L-arginine\NN\1740 ,\,\1740 a\DT\13649268 NO\NN\7204911 precursor\NN\14580897 ,\,\1740 were\VBD\836236 investigated\VBN\644583 on\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D019331_D012640 NONE <e1>L-NAME</e1>\NN\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 diazepam\NN\2830852 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 significantly\RB\1740 decreased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 50\CD\13745420 mg/kg)-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D009569_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 N-nitro-L-arginine-methyl\NN\1740 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 a\DT\13649268 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 synthase\NN\1740 inhibitor\NN\20090 and\CC\1740 L-arginine\NN\1740 ,\,\1740 a\DT\13649268 NO\NN\7204911 precursor\NN\14580897 ,\,\1740 were\VBD\836236 investigated\VBN\644583 on\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D009569_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 N-nitro-L-arginine-methyl\NN\1740 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 a\DT\13649268 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 synthase\NN\1740 inhibitor\NN\20090 and\CC\1740 L-arginine\NN\1740 ,\,\1740 a\DT\13649268 NO\NN\7204911 precursor\NN\14580897 ,\,\1740 were\VBD\836236 investigated\VBN\644583 on\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D009569_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 N-nitro-L-arginine-methyl\NN\1740 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 a\DT\13649268 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 synthase\NN\1740 inhibitor\NN\20090 and\CC\1740 L-arginine\NN\1740 ,\,\1740 a\DT\13649268 <e1>NO</e1>\NN\7204911 precursor\NN\14580897 ,\,\1740 were\VBD\836236 investigated\VBN\644583 on\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D009569_D012640 NONE These\DT\1740 results\NNS\34213 may\MD\15209706 suggest\VB\1010118 that\IN\1740 <e1>NO</e1>\NN\7204911 is\VBZ\836236 a\DT\13649268 proconvulsant\JJ\1740 mediator\NN\10351874 in\IN\13603305 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D001120_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 N-nitro-L-arginine-methyl\NN\1740 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 a\DT\13649268 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 synthase\NN\1740 inhibitor\NN\20090 and\CC\1740 <e1>L-arginine</e1>\NN\1740 ,\,\1740 a\DT\13649268 NO\NN\7204911 precursor\NN\14580897 ,\,\1740 were\VBD\836236 investigated\VBN\644583 on\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D001120_D012640 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 the\DT\1740 <e1>L-arginine</e1>\NN\1740 treatment\NN\654885 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 80\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.)-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 significantly\RB\1740 .\.\1740
D003975_D012640 NONE L-NAME\NN\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 <e1>diazepam</e1>\NN\2830852 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 significantly\RB\1740 decreased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 50\CD\13745420 mg/kg)-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
326460
D001539_D007008 CID Amelioration\NN\248977 of\IN\1740 <e1>bendrofluazide-induced</e1>\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 by\IN\1740 timolol\CD\2832168 .\.\1740
D001539_D007008 CID The\DT\1740 beta\NN\6828818 adrenergic\JJ\1740 blocking\NN\562280 drug\NN\14778436 ,\,\1740 timolol\CD\2832168 ,\,\1740 tended\VBD\2604760 to\TO\1740 correct\VB\138508 the\DT\1740 <e2>hypokalemia</e2>\NN\14299637 of\IN\1740 short-term\JJ\1740 <e1>bendrofluazide</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 6\CD\13741022 healthy\JJ\1740 male\JJ\1740 subjects\NNS\6598915 and\CC\1740 although\IN\1740 the\DT\1740 effect\NN\34213 was\VBD\836236 small\JJ\1740 it\PRP\6125041 was\VBD\836236 significant\JJ\1740 .\.\1740
D013999_D007008 NONE Amelioration\NN\248977 of\IN\1740 bendrofluazide-induced\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 by\IN\1740 <e1>timolol</e1>\CD\2832168 .\.\1740
D013999_D007008 NONE The\DT\1740 beta\NN\6828818 adrenergic\JJ\1740 blocking\NN\562280 drug\NN\14778436 ,\,\1740 <e1>timolol</e1>\CD\2832168 ,\,\1740 tended\VBD\2604760 to\TO\1740 correct\VB\138508 the\DT\1740 <e2>hypokalemia</e2>\NN\14299637 of\IN\1740 short-term\JJ\1740 bendrofluazide\NN\1740 treatment\NN\654885 in\IN\13603305 6\CD\13741022 healthy\JJ\1740 male\JJ\1740 subjects\NNS\6598915 and\CC\1740 although\IN\1740 the\DT\1740 effect\NN\34213 was\VBD\836236 small\JJ\1740 it\PRP\6125041 was\VBD\836236 significant\JJ\1740 .\.\1740
17923537
D005446_D014605 NONE Intraocular\JJ\1740 pressure\NN\11419404 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>uveitis</e2>\NN\14336539 treated\VBN\2376958 with\IN\1740 <e1>fluocinolone\NN\1740 acetonide</e1>\NN\1740 implants\NNS\4013729 .\.\1740
D005446_D014605 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 the\DT\1740 incidence\NN\13821570 and\CC\1740 management\NN\1123598 of\IN\1740 elevated\JJ\1740 intraocular\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 IOP\NNS\11495041 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>uveitis</e2>\NN\14336539 treated\VBN\2376958 with\IN\1740 the\DT\1740 <e1>fluocinolone\NN\1740 acetonide</e1>\NN\1740 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 intravitreal\VBP\1740 implant\NN\4013729 .\.\1740
D005446_D014605 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 the\DT\1740 incidence\NN\13821570 and\CC\1740 management\NN\1123598 of\IN\1740 elevated\JJ\1740 intraocular\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 IOP\NNS\11495041 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>uveitis</e2>\NN\14336539 treated\VBN\2376958 with\IN\1740 the\DT\1740 fluocinolone\NN\1740 acetonide\NN\1740 (\-LRB-\1740 <e1>FA</e1>\NN\6868043 )\-RRB-\1740 intravitreal\VBP\1740 implant\NN\4013729 .\.\1740
D005446_D009798 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 the\DT\1740 incidence\NN\13821570 and\CC\1740 management\NN\1123598 of\IN\1740 <e2>elevated\JJ\1740 intraocular\JJ\1740 pressure</e2>\NN\11419404 (\-LRB-\1740 IOP\NNS\11495041 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 uveitis\NN\14336539 treated\VBN\2376958 with\IN\1740 the\DT\1740 <e1>fluocinolone\NN\1740 acetonide</e1>\NN\1740 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 intravitreal\VBP\1740 implant\NN\4013729 .\.\1740
D005446_D009798 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 the\DT\1740 incidence\NN\13821570 and\CC\1740 management\NN\1123598 of\IN\1740 <e2>elevated\JJ\1740 intraocular\JJ\1740 pressure</e2>\NN\11419404 (\-LRB-\1740 IOP\NNS\11495041 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 uveitis\NN\14336539 treated\VBN\2376958 with\IN\1740 the\DT\1740 fluocinolone\NN\1740 acetonide\NN\1740 (\-LRB-\1740 <e1>FA</e1>\NN\6868043 )\-RRB-\1740 intravitreal\VBP\1740 implant\NN\4013729 .\.\1740
14736955
D004317_D009401 CID Mitochondrial\JJ\1740 DNA\NN\14994328 and\CC\1740 its\PRP$\6125041 respiratory\JJ\1740 chain\NN\8457976 products\NNS\3076708 are\VBP\836236 defective\JJ\1740 in\IN\13603305 <e1>doxorubicin</e1>\NN\2716866 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D004317_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Doxorubicin</e1>\NN\2716866 induces\VBZ\1627355 a\DT\13649268 self-perpetuating\JJ\1740 <e2>nephropathy</e2>\JJ\1740 characterized\VBN\609683 by\IN\1740 early\JJ\1740 glomerular\JJ\1740 and\CC\1740 late-onset\JJ\1740 tubular\JJ\1740 lesions\NNS\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004317_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Doxorubicin</e1>\NN\2716866 induces\VBZ\1627355 a\DT\13649268 self-perpetuating\JJ\1740 nephropathy\JJ\1740 characterized\VBN\609683 by\IN\1740 early\JJ\1740 <e2>glomerular\JJ\1740 and\CC\1740 late-onset\JJ\1740 tubular\JJ\1740 lesions</e2>\NNS\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004317_D007674 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 suggest\VBP\1010118 an\DT\6697703 important\JJ\1740 role\NN\719494 for\IN\1740 quantitative\JJ\1740 and\CC\1740 qualitative\JJ\1740 mtDNA\NN\1740 alterations\NNS\7283608 through\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 mtDNA-encoded\JJ\1740 respiratory\JJ\1740 chain\NN\8457976 function\NN\13783581 and\CC\1740 induction\NN\7450842 of\IN\1740 superoxide\NN\14971519 in\IN\13603305 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>renal\JJ\1740 lesions</e2>\NNS\14204950 .\.\1740
C102006_D007674 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 '\``\1740 long-term\JJ\1740 '\''\1740 group\NN\2137 had\VBD\2108377 significant\JJ\1740 <e2>glomerular\JJ\1740 and\CC\1740 tubular\JJ\1740 lesions</e2>\NNS\14204950 ,\,\1740 depressed\JJ\1740 activities\NNS\30358 of\IN\1740 mtDNA-encoded\JJ\1740 NADH\NN\1740 dehydrogenase\NN\1740 and\CC\1740 cytochrome-c\NN\1740 oxidase\NN\14732946 (\-LRB-\1740 COX\NN\14732946 )\-RRB-\1740 and\CC\1740 increased\VBN\169651 <e1>citrate</e1>\NN\14850483 synthase\NN\1740 activity\NN\30358 .\.\1740
D013481_D007674 NONE Among\IN\1740 all\DT\1740 animals\NNS\4475 ,\,\1740 <e2>glomerular\JJ\1740 and\CC\1740 tubular\JJ\1740 injury</e2>\NN\14052046 were\VBD\836236 inversely\RB\1740 correlated\VBN\2657219 with\IN\1740 mtDNA\NN\1740 levels\NNS\4916342 ,\,\1740 mtDNA-encoded\JJ\1740 respiratory\JJ\1740 chain\NN\8457976 activities\NNS\30358 and\CC\1740 with\IN\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 the\DT\1740 mtDNA-encoded\JJ\1740 respiratory\JJ\1740 chain\NN\8457976 subunit\NN\13604718 COX-I.\NN\1740 Injury\NN\14052046 was\VBD\836236 positively\RB\1740 correlated\VBN\2657219 with\IN\1740 <e1>superoxide</e1>\NN\14971519 production\NN\30358 and\CC\1740 the\DT\1740 activities\NNS\30358 of\IN\1740 nucleus-encoded\JJ\1740 mitochondrial\JJ\1740 or\CC\3541091 cytoplasmic\JJ\1740 enzymes\NNS\14723628 .\.\1740
D013481_D007674 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 suggest\VBP\1010118 an\DT\6697703 important\JJ\1740 role\NN\719494 for\IN\1740 quantitative\JJ\1740 and\CC\1740 qualitative\JJ\1740 mtDNA\NN\1740 alterations\NNS\7283608 through\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 mtDNA-encoded\JJ\1740 respiratory\JJ\1740 chain\NN\8457976 function\NN\13783581 and\CC\1740 induction\NN\7450842 of\IN\1740 <e1>superoxide</e1>\NN\14971519 in\IN\13603305 doxorubicin-induced\JJ\1740 <e2>renal\JJ\1740 lesions</e2>\NNS\14204950 .\.\1740
20727411
-1_D011605 NONE Neural\NNP\1740 correlates\VBZ\2657219 of\IN\1740 <e1>S-ketamine</e1>\NN\1740 induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 during\IN\1740 overt\JJ\1740 continuous\JJ\1740 verbal\JJ\1740 fluency\NN\7066659 .\.\1740
D016202_D012559 NONE The\DT\1740 glutamatergic\JJ\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 has\VBZ\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D016202_D012559 NONE The\DT\1740 glutamatergic\JJ\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 <e1>NMDA</e1>\NN\1740 )\-RRB-\1740 receptor\NN\5225602 has\VBZ\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D016202_D012559 NONE Administered\VBN\2436349 to\TO\1740 healthy\JJ\1740 volunteers\NNS\10582746 ,\,\1740 a\DT\13649268 subanesthetic\JJ\1740 dose\NN\3740161 of\IN\1740 the\DT\1740 non-competitive\JJ\1740 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ketamine\NN\3054098 leads\VBZ\1752884 to\TO\1740 psychopathological\JJ\1740 symptoms\NNS\5823932 similar\JJ\1740 to\TO\1740 those\DT\1740 observed\VBN\2163746 in\IN\13603305 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D016202_D012559 NONE Our\PRP$\1740 results\NNS\34213 provide\VBP\2199590 further\JJ\1740 support\NN\407535 for\IN\1740 the\DT\1740 hypothesis\NN\7162194 of\IN\1740 an\DT\6697703 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 dysfunction\NN\14204950 in\IN\13603305 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D007649_D012559 NONE Administered\VBN\2436349 to\TO\1740 healthy\JJ\1740 volunteers\NNS\10582746 ,\,\1740 a\DT\13649268 subanesthetic\JJ\1740 dose\NN\3740161 of\IN\1740 the\DT\1740 non-competitive\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 <e1>ketamine</e1>\NN\3054098 leads\VBZ\1752884 to\TO\1740 psychopathological\JJ\1740 symptoms\NNS\5823932 similar\JJ\1740 to\TO\1740 those\DT\1740 observed\VBN\2163746 in\IN\13603305 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D007649_D012559 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 ,\,\1740 <e1>ketamine</e1>\NN\3054098 exacerbates\VBZ\126264 the\DT\1740 core\NN\7996689 symptoms\NNS\5823932 of\IN\1740 illness\NN\14052046 ,\,\1740 supporting\VBG\2199590 the\DT\1740 hypothesis\NN\7162194 of\IN\1740 a\DT\13649268 glutamatergic\JJ\1740 dysfunction\NN\14204950 .\.\1740
D007649_D012559 NONE <e1>Ketamine</e1>\NN\3054098 induces\VBZ\1627355 activation\NN\13561719 changes\NNS\7283608 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 similar\JJ\1740 to\TO\1740 those\DT\1740 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 ,\,\1740 particularly\RB\1740 in\IN\13603305 frontal\JJ\1740 and\CC\1740 temporal\JJ\1740 brain\NN\5462674 regions\NNS\27167 .\.\1740
D007649_D018754 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 schizophrenia\NN\14398067 ,\,\1740 <e1>ketamine</e1>\NN\3054098 exacerbates\VBZ\126264 the\DT\1740 core\NN\7996689 symptoms\NNS\5823932 of\IN\1740 illness\NN\14052046 ,\,\1740 supporting\VBG\2199590 the\DT\1740 hypothesis\NN\7162194 of\IN\1740 a\DT\13649268 <e2>glutamatergic\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D007649_D011605 CID <e1>Ketamine</e1>\NNP\3054098 elicited\VBD\1617192 <e2>psychosis</e2>\NN\14380140 like\IN\5839024 psychopathology\NN\6136258 .\.\1740
3969369
D013739_D063646 NONE Promotional\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>testosterone</e1>\NN\14747587 and\CC\1740 dietary\JJ\1740 fat\NN\14938907 on\IN\1740 prostate\NN\5329735 <e2>carcinogenesis</e2>\NN\1740 in\IN\13603305 genetically\RB\1740 susceptible\JJ\1740 rats\NNS\2329401 .\.\1740
D013739_D011471 CID Conventional\JJ\1740 LW\NNP\1740 rats\NNS\2329401 ,\,\1740 implanted\VBN\1421622 with\IN\1740 <e1>testosterone</e1>\NN\14747587 at\IN\14622893 age\NN\4916342 4\CD\13741022 months\NNS\15113229 ,\,\1740 developed\VBD\1753788 a\DT\13649268 higher\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 after\IN\1740 an\DT\6697703 average\JJ\1740 interval\NN\33615 of\IN\1740 14\CD\13745420 months\NNS\15113229 :\:\1740 24\CD\13745420 %\NN\1740 had\VBD\2108377 developed\VBN\1753788 gross\JJ\1740 tumors\NNS\14234074 ,\,\1740 and\CC\1740 40\CD\13745420 %\NN\1740 when\WRB\1740 it\PRP\6125041 included\VBD\690614 microscopic\JJ\1740 tumors\NNS\14234074 .\.\1740
D013739_D011471 CID Preliminary\JJ\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>testosterone-treated</e1>\JJ\1740 LW\NN\1740 rats\NNS\2329401 that\WDT\1740 were\VBD\836236 fed\VBN\1182709 the\DT\1740 same\JJ\1740 diet\NN\7560652 ,\,\1740 which\WDT\1740 was\VBD\836236 supplemented\VBN\182406 with\IN\1740 corn\NN\12141495 oil\NN\14938907 up\RB\1740 to\TO\1740 20\CD\13745420 %\NN\1740 fat\JJ\1740 ,\,\1740 developed\VBD\1753788 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 after\IN\1740 intervals\NNS\33615 of\IN\1740 6\CD\13741022 -\SYM\1740 12\CD\13745420 months\NNS\15113229 .\.\1740
D013739_D009369 NONE Conventional\JJ\1740 LW\NNP\1740 rats\NNS\2329401 ,\,\1740 implanted\VBN\1421622 with\IN\1740 <e1>testosterone</e1>\NN\14747587 at\IN\14622893 age\NN\4916342 4\CD\13741022 months\NNS\15113229 ,\,\1740 developed\VBD\1753788 a\DT\13649268 higher\JJR\1740 incidence\NN\13821570 of\IN\1740 prostate\NN\5329735 cancer\NN\14239425 after\IN\1740 an\DT\6697703 average\JJ\1740 interval\NN\33615 of\IN\1740 14\CD\13745420 months\NNS\15113229 :\:\1740 24\CD\13745420 %\NN\1740 had\VBD\2108377 developed\VBN\1753788 gross\JJ\1740 <e2>tumors</e2>\NNS\14234074 ,\,\1740 and\CC\1740 40\CD\13745420 %\NN\1740 when\WRB\1740 it\PRP\6125041 included\VBD\690614 microscopic\JJ\1740 tumors\NNS\14234074 .\.\1740
D013739_D009369 NONE Conventional\JJ\1740 LW\NNP\1740 rats\NNS\2329401 ,\,\1740 implanted\VBN\1421622 with\IN\1740 <e1>testosterone</e1>\NN\14747587 at\IN\14622893 age\NN\4916342 4\CD\13741022 months\NNS\15113229 ,\,\1740 developed\VBD\1753788 a\DT\13649268 higher\JJR\1740 incidence\NN\13821570 of\IN\1740 prostate\NN\5329735 cancer\NN\14239425 after\IN\1740 an\DT\6697703 average\JJ\1740 interval\NN\33615 of\IN\1740 14\CD\13745420 months\NNS\15113229 :\:\1740 24\CD\13745420 %\NN\1740 had\VBD\2108377 developed\VBN\1753788 gross\JJ\1740 tumors\NNS\14234074 ,\,\1740 and\CC\1740 40\CD\13745420 %\NN\1740 when\WRB\1740 it\PRP\6125041 included\VBD\690614 microscopic\JJ\1740 <e2>tumors</e2>\NNS\14234074 .\.\1740
D013739_D011472 CID Conventional\JJ\1740 SD\NN\1740 rats\NNS\2329401 fed\VBD\1182709 diet\JJ\1740 L-485\NN\1740 and\CC\1740 treated\VBN\2376958 with\IN\1740 <e1>testosterone</e1>\NN\14747587 developed\VBD\1753788 only\RB\1740 <e2>prostatitis</e2>\NN\14336539 .\.\1740
2339463
D015119_D020225 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 42-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 superior\JJ\1740 <e2>sagittal\JJ\1740 and\CC\1740 left\VBD\120316 transverse\JJ\1740 sinus\NN\5248181 thrombosis</e2>\NN\14100769 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 therapy\NN\657604 for\IN\1740 menorrhagia\NN\13513747 .\.\1740
D015119_D020227 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 42-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 superior\JJ\1740 <e2>sagittal\JJ\1740 and\CC\1740 left\VBD\120316 transverse\JJ\1740 sinus\NN\5248181 thrombosis</e2>\NN\14100769 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 therapy\NN\657604 for\IN\1740 menorrhagia\NN\13513747 .\.\1740
D015119_D008595 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 42-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 superior\JJ\1740 sagittal\JJ\1740 and\CC\1740 left\VBD\120316 transverse\JJ\1740 sinus\NN\5248181 thrombosis\NN\14100769 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 therapy\NN\657604 for\IN\1740 <e2>menorrhagia</e2>\NN\13513747 .\.\1740
D015119_D013923 NONE Although\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>thromboembolic\NN\1740 disease</e2>\NN\14061805 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 cerebral\JJ\1740 sinus\NN\5248181 thrombosis\NN\14100769 has\VBZ\2108377 not\RB\1740 been\VBN\836236 previously\RB\1740 described\VBN\1001294 .\.\1740
D015119_D012851 NONE Although\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 thromboembolic\NN\1740 disease\NN\14061805 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 <e2>cerebral\JJ\1740 sinus\NN\5248181 thrombosis</e2>\NN\14100769 has\VBZ\2108377 not\RB\1740 been\VBN\836236 previously\RB\1740 described\VBN\1001294 .\.\1740
8268147
D010396_D017285 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>polymyositis</e2>\NN\14350292 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 primary\JJ\1740 biliary\JJ\1740 cirrhosis\NN\14116321 treated\VBN\2376958 with\IN\1740 <e1>D-penicillamine</e1>\NN\1740 .\.\1740
D010396_D017285 CID <e2>Polymyositis/dermatomyositis</e2>\NN\1740 can\MD\3094503 develop\VB\1753788 as\IN\14622893 one\CD\13741022 of\IN\1740 the\DT\1740 autoimmune\JJ\1740 complications\NNS\1073995 of\IN\1740 <e1>D-penicillamine</e1>\NN\1740 treatment\NN\654885 ,\,\1740 but\CC\1740 its\PRP$\6125041 exact\JJ\1740 pathogenesis\NN\13533470 remains\VBZ\2604760 unclear\JJ\1740 .\.\1740
D010396_D017285 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 with\IN\1740 primary\JJ\1740 biliary\JJ\1740 cirrhosis\NN\14116321 ,\,\1740 who\WP\8299493 developed\VBD\1753788 <e2>polymyositis</e2>\NN\14350292 while\IN\15122231 receiving\VBG\2210855 <e1>D-penicillamine</e1>\NN\1740 therapy\NN\657604 .\.\1740
D010396_D017285 CID Patients\NNS\9898892 receiving\VBG\2210855 <e1>D-penicillamine</e1>\NN\1740 therapy\NN\657604 should\MD\1740 be\VB\836236 followed\VBN\1835496 carefully\RB\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 autoimmune\JJ\1740 complications\NNS\1073995 like\IN\5839024 <e2>polymyositis/dermatomyositis</e2>\NN\1740 .\.\1740
D010396_D008105 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 polymyositis\NN\14350292 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>primary\JJ\1740 biliary\JJ\1740 cirrhosis</e2>\NN\14116321 treated\VBN\2376958 with\IN\1740 <e1>D-penicillamine</e1>\NN\1740 .\.\1740
D010396_D008105 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>primary\JJ\1740 biliary\JJ\1740 cirrhosis</e2>\NN\14116321 ,\,\1740 who\WP\8299493 developed\VBD\1753788 polymyositis\NN\14350292 while\IN\15122231 receiving\VBG\2210855 <e1>D-penicillamine</e1>\NN\1740 therapy\NN\657604 .\.\1740
D010396_D012216 NONE Although\IN\1740 <e1>D-penicillamine</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 for\IN\1740 many\JJ\1740 <e2>rheumatologic\JJ\1740 diseases</e2>\NNS\14061805 ,\,\1740 toxicity\NN\13576101 limits\VBZ\2510337 its\PRP$\6125041 usefulness\NN\4723816 in\IN\13603305 many\JJ\1740 patients\NNS\9898892 .\.\1740
D010396_D064420 NONE Although\IN\1740 <e1>D-penicillamine</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 for\IN\1740 many\JJ\1740 rheumatologic\JJ\1740 diseases\NNS\14061805 ,\,\1740 <e2>toxicity</e2>\NN\13576101 limits\VBZ\2510337 its\PRP$\6125041 usefulness\NN\4723816 in\IN\13603305 many\JJ\1740 patients\NNS\9898892 .\.\1740
D010396_D003882 NONE <e2>Polymyositis/dermatomyositis</e2>\NN\1740 can\MD\3094503 develop\VB\1753788 as\IN\14622893 one\CD\13741022 of\IN\1740 the\DT\1740 autoimmune\JJ\1740 complications\NNS\1073995 of\IN\1740 <e1>D-penicillamine</e1>\NN\1740 treatment\NN\654885 ,\,\1740 but\CC\1740 its\PRP$\6125041 exact\JJ\1740 pathogenesis\NN\13533470 remains\VBZ\2604760 unclear\JJ\1740 .\.\1740
D010396_D003882 NONE Patients\NNS\9898892 receiving\VBG\2210855 <e1>D-penicillamine</e1>\NN\1740 therapy\NN\657604 should\MD\1740 be\VB\836236 followed\VBN\1835496 carefully\RB\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 autoimmune\JJ\1740 complications\NNS\1073995 like\IN\5839024 <e2>polymyositis/dermatomyositis</e2>\NN\1740 .\.\1740
9165568
D018967_D009459 CID <e2>Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 with\IN\1740 <e1>risperidone</e1>\NN\1740 .\.\1740
D018967_D009459 CID A\DT\13649268 73-year-old\JJ\1740 woman\NN\9605289 developed\VBD\1753788 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 after\IN\1740 monotherapy\NN\1740 with\IN\1740 <e1>risperidone</e1>\NN\1740 .\.\1740
D018967_D009459 CID It\PRP\6125041 appears\VBZ\2604760 that\IN\1740 the\DT\1740 protection\NN\407535 from\IN\1740 extrapyramidal\JJ\1740 side\NN\8630039 effects\NNS\13245626 observed\VBN\2163746 with\IN\1740 <e1>risperidone</e1>\NN\1740 does\VBZ\1640855 not\RB\1740 ensure\VB\664483 protection\NN\407535 from\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D004298_D009459 NONE <e2>Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 is\VBZ\836236 thought\VBN\670261 to\TO\1740 be\VB\836236 a\DT\13649268 result\NN\34213 of\IN\1740 <e1>dopamine</e1>\NN\14807737 D2\NN\1740 receptor\NN\5225602 blockade\NN\952963 in\IN\13603305 the\DT\1740 striatum\NN\5497363 of\IN\1740 the\DT\1740 basal\JJ\1740 ganglia\NN\5462674 .\.\1740
D018967_D001480 NONE The\DT\1740 high\JJ\1740 ratio\NN\13815152 is\VBZ\836236 believed\VBN\686447 to\TO\1740 impart\VB\952524 the\DT\1740 low\JJ\1740 frequency\NN\15286249 of\IN\1740 <e2>extrapyramidal\JJ\1740 symptoms</e2>\NNS\5823932 with\IN\1740 <e1>risperidone</e1>\NN\1740 at\IN\14622893 low\JJ\1740 dosages\NNS\13576355 .\.\1740
20164825
D008687_D007674 NONE <e1>Metformin</e1>\NN\2719105 prevents\VBZ\1740 experimental\JJ\1740 gentamicin-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 by\IN\1740 a\DT\13649268 mitochondria-dependent\JJ\1740 pathway\NN\5483677 .\.\1740
D008687_D007674 NONE These\DT\1740 in\FW\13603305 vivo\FW\1740 markers\NNS\21939 of\IN\1740 <e2>kidney\NN\5333259 dysfunction</e2>\NN\14204950 and\CC\1740 their\PRP$\1740 correction\NN\248977 by\IN\1740 <e1>metformin</e1>\NN\2719105 were\VBD\836236 complemented\VBN\2673134 by\IN\1740 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 of\IN\1740 mitochondrial\JJ\1740 function\NN\13783581 .\.\1740
D008687_D007674 NONE Thus\RB\1740 ,\,\1740 our\PRP$\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 pleiotropic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>metformin</e1>\NN\2719105 can\MD\3094503 lessen\NN\1740 gentamicin\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 improve\VBP\126264 mitochondrial\JJ\1740 homeostasis\NN\13934900 .\.\1740
D005839_D007674 NONE Metformin\NN\2719105 prevents\VBZ\1740 experimental\JJ\1740 <e1>gentamicin-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 by\IN\1740 a\DT\13649268 mitochondria-dependent\JJ\1740 pathway\NN\5483677 .\.\1740
D005839_D007674 NONE Thus\RB\1740 ,\,\1740 our\PRP$\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 pleiotropic\JJ\1740 effects\NNS\13245626 of\IN\1740 metformin\NN\2719105 can\MD\3094503 lessen\NN\1740 <e1>gentamicin</e1>\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 improve\VBP\126264 mitochondrial\JJ\1740 homeostasis\NN\13934900 .\.\1740
D008687_D014652 NONE The\DT\1740 antidiabetic\JJ\1740 drug\NN\14778436 <e1>metformin</e1>\NN\2719105 can\MD\3094503 diminish\VB\169651 apoptosis\NN\11486178 induced\VBN\1627355 by\IN\1740 oxidative\JJ\1740 stress\NN\7083732 in\IN\13603305 endothelial\JJ\1740 cells\NNS\3080309 and\CC\1740 prevent\VBP\1740 <e2>vascular\JJ\1740 dysfunction</e2>\NN\14204950 even\RB\1740 in\IN\13603305 nondiabetic\JJ\1740 patients\NNS\9898892 .\.\1740
D005839_D064420 NONE Here\RB\1740 we\PRP\1740 tested\VBD\670261 whether\IN\1740 it\PRP\6125041 has\VBZ\2108377 a\DT\13649268 beneficial\JJ\1740 effect\NN\34213 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e1>gentamicin</e1>\NN\2716866 <e2>toxicity</e2>\NN\13576101 .\.\1740
D008687_D058186 NONE <e1>Metformin</e1>\NN\2719105 treatment\NN\654885 fully\RB\1740 blocked\VBD\1476483 gentamicin-mediated\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D005839_D058186 CID Metformin\NN\2719105 treatment\NN\654885 fully\RB\1740 blocked\VBD\1476483 <e1>gentamicin-mediated</e1>\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
6728084
D000617_D007674 NONE <e2>Nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>aminoglycoside</e1>\NN\1740 treatment\NN\654885 on\IN\1740 renal\JJ\1740 protein\NN\14944888 reabsorption\NN\13526110 and\CC\1740 accumulation\NN\13497135 .\.\1740
D000617_D007674 NONE Thus\RB\1740 ,\,\1740 <e1>aminoglycosides</e1>\NNS\1740 may\MD\15209706 act\VB\1619354 as\IN\14622893 nephrotoxicants\NNS\1740 at\IN\14622893 glomerular\JJ\1740 and/or\CC\1740 tubular\JJ\1740 level\NN\4916342 inducing\VBG\1627355 <e2>impairment\NN\7296428 of\IN\1740 renal\JJ\1740 reabsorption</e2>\NN\13526110 and\CC\1740 accumulation\NN\13497135 of\IN\1740 proteins\NNS\14944888 .\.\1740
625456
D002119_D006934 CID One\CD\13741022 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>hypercalcaemia</e2>\NN\14299637 and\CC\1740 two\CD\13741022 of\IN\1740 recurrent\JJ\1740 nephrolithiasis\NN\14115914 are\VBP\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 regularly\RB\1740 consumed\VBN\1168468 large\JJ\1740 amounts\NNS\13329641 of\IN\1740 <e1>calcium\NN\14625458 carbon-ate-sodium</e1>\NN\1740 bicarbonate\VBP\1740 powders\NNS\15046900 for\IN\1740 more\JJR\1740 than\IN\1740 20\CD\13745420 years\NNS\15144371 .\.\1740
D002119_D053040 CID One\CD\13741022 case\NN\7283608 of\IN\1740 acute\JJ\1740 hypercalcaemia\NN\14299637 and\CC\1740 two\CD\13741022 of\IN\1740 recurrent\JJ\1740 <e2>nephrolithiasis</e2>\NN\14115914 are\VBP\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 regularly\RB\1740 consumed\VBN\1168468 large\JJ\1740 amounts\NNS\13329641 of\IN\1740 <e1>calcium\NN\14625458 carbon-ate-sodium</e1>\NN\1740 bicarbonate\VBP\1740 powders\NNS\15046900 for\IN\1740 more\JJR\1740 than\IN\1740 20\CD\13745420 years\NNS\15144371 .\.\1740
D017693_D006934 CID One\CD\13741022 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>hypercalcaemia</e2>\NN\14299637 and\CC\1740 two\CD\13741022 of\IN\1740 recurrent\JJ\1740 nephrolithiasis\NN\14115914 are\VBP\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 regularly\RB\1740 consumed\VBN\1168468 large\JJ\1740 amounts\NNS\13329641 of\IN\1740 calcium\NN\14625458 <e1>carbon-ate-sodium\NN\1740 bicarbonate</e1>\VBP\1740 powders\NNS\15046900 for\IN\1740 more\JJR\1740 than\IN\1740 20\CD\13745420 years\NNS\15144371 .\.\1740
D017693_D053040 CID One\CD\13741022 case\NN\7283608 of\IN\1740 acute\JJ\1740 hypercalcaemia\NN\14299637 and\CC\1740 two\CD\13741022 of\IN\1740 recurrent\JJ\1740 <e2>nephrolithiasis</e2>\NN\14115914 are\VBP\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 regularly\RB\1740 consumed\VBN\1168468 large\JJ\1740 amounts\NNS\13329641 of\IN\1740 calcium\NN\14625458 <e1>carbon-ate-sodium\NN\1740 bicarbonate</e1>\VBP\1740 powders\NNS\15046900 for\IN\1740 more\JJR\1740 than\IN\1740 20\CD\13745420 years\NNS\15144371 .\.\1740
18363626
D020927_D001919 CID Although\IN\1740 <e1>dexmedetomidine</e1>\NN\1740 sedation\NN\14034177 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 16\CD\13745420 %\NN\1740 incidence\NN\13821570 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 all\DT\1740 concomitant\JJ\1740 mean\VBP\928630 arterial\JJ\1740 blood\NN\5397468 pressures\NNS\11419404 were\VBD\836236 within\IN\1740 20\CD\13745420 %\NN\1740 of\IN\1740 age-adjusted\JJ\1740 normal\JJ\1740 range\NN\5123416 and\CC\1740 oxygen\NN\14622893 saturations\NNS\13534954 were\VBD\836236 95\CD\1740 %\NN\1740 or\CC\3541091 higher\JJR\1740 .\.\1740
D010100_D001919 NONE Although\IN\1740 dexmedetomidine\NN\1740 sedation\NN\14034177 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 16\CD\13745420 %\NN\1740 incidence\NN\13821570 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 all\DT\1740 concomitant\JJ\1740 mean\VBP\928630 arterial\JJ\1740 blood\NN\5397468 pressures\NNS\11419404 were\VBD\836236 within\IN\1740 20\CD\13745420 %\NN\1740 of\IN\1740 age-adjusted\JJ\1740 normal\JJ\1740 range\NN\5123416 and\CC\1740 <e1>oxygen</e1>\NN\14622893 saturations\NNS\13534954 were\VBD\836236 95\CD\1740 %\NN\1740 or\CC\3541091 higher\JJR\1740 .\.\1740
1286498
D005442_D009325 CID The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 were\VBD\836236 <e2>nausea</e2>\JJ\1740 and\CC\1740 vomiting\NN\116687 in\IN\13603305 the\DT\1740 <e1>flumazenil</e1>\NN\1740 group\NN\2137 and\CC\1740 nausea\NN\14299637 and\CC\1740 injection-site\JJ\1740 pain\NN\14299637 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
D005442_D009325 CID The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 were\VBD\836236 nausea\JJ\1740 and\CC\1740 vomiting\NN\116687 in\IN\13603305 the\DT\1740 <e1>flumazenil</e1>\NN\1740 group\NN\2137 and\CC\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 injection-site\JJ\1740 pain\NN\14299637 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
D005442_D014839 CID The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 were\VBD\836236 nausea\JJ\1740 and\CC\1740 <e2>vomiting</e2>\NN\116687 in\IN\13603305 the\DT\1740 <e1>flumazenil</e1>\NN\1740 group\NN\2137 and\CC\1740 nausea\NN\14299637 and\CC\1740 injection-site\JJ\1740 pain\NN\14299637 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
D005442_D010146 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 were\VBD\836236 nausea\JJ\1740 and\CC\1740 vomiting\NN\116687 in\IN\13603305 the\DT\1740 <e1>flumazenil</e1>\NN\1740 group\NN\2137 and\CC\1740 nausea\NN\14299637 and\CC\1740 injection-site\JJ\1740 <e2>pain</e2>\NN\14299637 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
8599504
D004329_D000799 CID <e2>Angioedema</e2>\NNP\14316714 associated\VBN\628491 with\IN\1740 <e1>droperidol</e1>\NN\1740 administration\NN\1133281 .\.\1740
D004329_D000799 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 previously\RB\1740 healthy\JJ\1740 19-year-old\JJ\1740 man\NN\9605289 with\IN\1740 no\DT\7204911 known\JJ\1740 drug\NN\14778436 allergies\NNS\14533203 in\IN\13603305 whom\WP\1740 <e2>angioedema</e2>\VBP\1740 with\IN\1740 significant\JJ\1740 tongue\NN\5301392 swelling\NN\14315071 and\CC\1740 protrusion\NN\13919685 developed\VBD\1753788 within\IN\1740 10\CD\13745420 minutes\NNS\6502378 of\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 IV\CD\13741022 dose\NN\3740161 of\IN\1740 <e1>droperidol</e1>\NN\1740 .\.\1740
D004329_D004342 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 previously\RB\1740 healthy\JJ\1740 19-year-old\JJ\1740 man\NN\9605289 with\IN\1740 no\DT\7204911 known\JJ\1740 <e2>drug\NN\14778436 allergies</e2>\NNS\14533203 in\IN\13603305 whom\WP\1740 angioedema\VBP\1740 with\IN\1740 significant\JJ\1740 tongue\NN\5301392 swelling\NN\14315071 and\CC\1740 protrusion\NN\13919685 developed\VBD\1753788 within\IN\1740 10\CD\13745420 minutes\NNS\6502378 of\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 IV\CD\13741022 dose\NN\3740161 of\IN\1740 <e1>droperidol</e1>\NN\1740 .\.\1740
D004329_D014060 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 previously\RB\1740 healthy\JJ\1740 19-year-old\JJ\1740 man\NN\9605289 with\IN\1740 no\DT\7204911 known\JJ\1740 drug\NN\14778436 allergies\NNS\14533203 in\IN\13603305 whom\WP\1740 angioedema\VBP\1740 with\IN\1740 significant\JJ\1740 <e2>tongue\NN\5301392 swelling</e2>\NN\14315071 and\CC\1740 protrusion\NN\13919685 developed\VBD\1753788 within\IN\1740 10\CD\13745420 minutes\NNS\6502378 of\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 IV\CD\13741022 dose\NN\3740161 of\IN\1740 <e1>droperidol</e1>\NN\1740 .\.\1740
D004329_D004487 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 previously\RB\1740 healthy\JJ\1740 19-year-old\JJ\1740 man\NN\9605289 with\IN\1740 no\DT\7204911 known\JJ\1740 drug\NN\14778436 allergies\NNS\14533203 in\IN\13603305 whom\WP\1740 angioedema\VBP\1740 with\IN\1740 significant\JJ\1740 <e2>tongue\NN\5301392 swelling</e2>\NN\14315071 and\CC\1740 protrusion\NN\13919685 developed\VBD\1753788 within\IN\1740 10\CD\13745420 minutes\NNS\6502378 of\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 IV\CD\13741022 dose\NN\3740161 of\IN\1740 <e1>droperidol</e1>\NN\1740 .\.\1740
9514561
D002211_D010146 CID Experimental\JJ\1740 cranial\JJ\1740 <e2>pain</e2>\NN\14299637 elicited\VBN\1617192 by\IN\1740 <e1>capsaicin</e1>\NN\15032661 :\:\1740 a\DT\13649268 PET\NN\15388 study\NN\635850 .\.\1740
D002211_D010146 CID A\DT\13649268 small\JJ\1740 amount\NN\13329641 of\IN\1740 <e1>capsaicin</e1>\NN\15032661 was\VBD\836236 administered\VBN\2436349 subcutaneously\RB\1740 in\IN\13603305 the\DT\1740 right\JJ\1740 forehead\NN\5601758 to\TO\1740 evoke\VB\1617192 a\DT\13649268 burning\VBG\1564144 <e2>painful</e2>\JJ\1740 sensation\NN\5708432 in\IN\13603305 the\DT\1740 first\JJ\1740 division\NN\8190754 of\IN\1740 the\DT\1740 trigeminal\JJ\1740 nerve\NN\5475681 .\.\1740
9848575
D018943_D009202 NONE Chronic\JJ\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 novel\JJ\1740 synthetic\JJ\1740 <e1>anthracycline</e1>\NN\1740 derivative\NN\5802185 (\-LRB-\1740 SM-5887\NN\1740 )\-RRB-\1740 on\IN\1740 normal\JJ\1740 heart\NN\5919034 and\CC\1740 doxorubicin-induced\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 .\.\1740
C055866_D009202 NONE Chronic\JJ\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 novel\JJ\1740 synthetic\JJ\1740 anthracycline\NN\1740 derivative\NN\5802185 (\-LRB-\1740 <e1>SM-5887</e1>\NN\1740 )\-RRB-\1740 on\IN\1740 normal\JJ\1740 heart\NN\5919034 and\CC\1740 doxorubicin-induced\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 .\.\1740
C055866_D009202 NONE Animals\NNS\4475 which\WDT\1740 received\VBD\2210855 over\RB\1740 six\CD\13741022 courses\NNS\883297 of\IN\1740 doxorubicin\NN\2716866 demonstrated\VBD\2137132 the\DT\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 changes\NNS\7283608 ,\,\1740 decrease\NN\7296428 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 high-grade\JJ\1740 histopathological\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 ,\,\1740 while\IN\15122231 animals\NNS\4475 which\WDT\1740 were\VBD\836236 terminally\RB\1740 sacrificed\VBN\2316304 after\IN\1740 the\DT\1740 <e1>SM-5887</e1>\JJ\1740 administration\NN\1133281 did\VBD\1640855 not\RB\1740 show\VB\2137132 any\DT\1740 changes\NNS\7283608 in\IN\13603305 ECG\NNP\7000195 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 histopathological\JJ\1740 examinations\NNS\633864 .\.\1740
C055866_D009202 NONE To\TO\1740 examine\VB\789138 a\DT\13649268 possibly\RB\1740 deteriorating\VBG\208836 cardiotoxic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>SM-5887</e1>\NN\1740 ,\,\1740 low-grade\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 was\VBD\836236 induced\VBN\1627355 in\IN\13603305 dogs\NNS\2083346 by\IN\1740 four\CD\13741022 courses\NNS\883297 of\IN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
C055866_D009202 NONE On\IN\1740 the\DT\1740 contrary\NN\13854649 ,\,\1740 the\DT\1740 <e1>SM-5887</e1>\NN\1740 treatment\NN\654885 did\VBD\1640855 not\RB\1740 progress\VB\252019 the\DT\1740 grade\NN\7975026 of\IN\1740 <e2>cardiomyopathy</e2>\JJ\1740 .\.\1740
D004317_D009202 CID Chronic\JJ\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 novel\JJ\1740 synthetic\JJ\1740 anthracycline\NN\1740 derivative\NN\5802185 (\-LRB-\1740 SM-5887\NN\1740 )\-RRB-\1740 on\IN\1740 normal\JJ\1740 heart\NN\5919034 and\CC\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 .\.\1740
D004317_D009202 CID Animals\NNS\4475 which\WDT\1740 received\VBD\2210855 over\RB\1740 six\CD\13741022 courses\NNS\883297 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 demonstrated\VBD\2137132 the\DT\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 changes\NNS\7283608 ,\,\1740 decrease\NN\7296428 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 high-grade\JJ\1740 histopathological\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 ,\,\1740 while\IN\15122231 animals\NNS\4475 which\WDT\1740 were\VBD\836236 terminally\RB\1740 sacrificed\VBN\2316304 after\IN\1740 the\DT\1740 SM-5887\JJ\1740 administration\NN\1133281 did\VBD\1640855 not\RB\1740 show\VB\2137132 any\DT\1740 changes\NNS\7283608 in\IN\13603305 ECG\NNP\7000195 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 histopathological\JJ\1740 examinations\NNS\633864 .\.\1740
D004317_D009202 CID To\TO\1740 examine\VB\789138 a\DT\13649268 possibly\RB\1740 deteriorating\VBG\208836 cardiotoxic\JJ\1740 effect\NN\34213 of\IN\1740 SM-5887\NN\1740 ,\,\1740 low-grade\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 was\VBD\836236 induced\VBN\1627355 in\IN\13603305 dogs\NNS\2083346 by\IN\1740 four\CD\13741022 courses\NNS\883297 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
C055866_D066126 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 chronic\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 potential\NN\14481929 of\IN\1740 <e1>SM-5887</e1>\NN\1740 and\CC\1740 a\DT\13649268 possible\JJ\1740 deteriorating\VBG\208836 effect\NN\34213 of\IN\1740 SM-5887\NN\1740 on\IN\1740 low-grade\JJ\1740 cardiotoxicity\NN\1740 pre-induced\VBN\1740 by\IN\1740 doxorubicin\NN\2716866 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 .\.\1740
C055866_D066126 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 chronic\JJ\1740 cardiotoxic\JJ\1740 potential\NN\14481929 of\IN\1740 <e1>SM-5887</e1>\NN\1740 and\CC\1740 a\DT\13649268 possible\JJ\1740 deteriorating\VBG\208836 effect\NN\34213 of\IN\1740 SM-5887\NN\1740 on\IN\1740 low-grade\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 pre-induced\VBN\1740 by\IN\1740 doxorubicin\NN\2716866 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 .\.\1740
C055866_D066126 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 chronic\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 potential\NN\14481929 of\IN\1740 SM-5887\NN\1740 and\CC\1740 a\DT\13649268 possible\JJ\1740 deteriorating\VBG\208836 effect\NN\34213 of\IN\1740 <e1>SM-5887</e1>\NN\1740 on\IN\1740 low-grade\JJ\1740 cardiotoxicity\NN\1740 pre-induced\VBN\1740 by\IN\1740 doxorubicin\NN\2716866 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 .\.\1740
C055866_D066126 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 chronic\JJ\1740 cardiotoxic\JJ\1740 potential\NN\14481929 of\IN\1740 SM-5887\NN\1740 and\CC\1740 a\DT\13649268 possible\JJ\1740 deteriorating\VBG\208836 effect\NN\34213 of\IN\1740 <e1>SM-5887</e1>\NN\1740 on\IN\1740 low-grade\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 pre-induced\VBN\1740 by\IN\1740 doxorubicin\NN\2716866 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 .\.\1740
C055866_D066126 NONE To\TO\1740 examine\VB\789138 a\DT\13649268 possibly\RB\1740 deteriorating\VBG\208836 <e2>cardiotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>SM-5887</e1>\NN\1740 ,\,\1740 low-grade\JJ\1740 cardiomyopathy\NN\14103288 was\VBD\836236 induced\VBN\1627355 in\IN\13603305 dogs\NNS\2083346 by\IN\1740 four\CD\13741022 courses\NNS\883297 of\IN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
C055866_D066126 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>SM-5887</e1>\NN\1740 does\VBZ\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 potential\NN\14481929 of\IN\1740 chronic\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 deteriorating\VBG\208836 effect\NN\34213 on\IN\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 dogs\NNS\2083346 .\.\1740
C055866_D066126 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>SM-5887</e1>\NN\1740 does\VBZ\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 potential\NN\14481929 of\IN\1740 chronic\JJ\1740 cardiotoxicity\NN\1740 and\CC\1740 deteriorating\VBG\208836 effect\NN\34213 on\IN\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D004317_D066126 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 chronic\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 potential\NN\14481929 of\IN\1740 SM-5887\NN\1740 and\CC\1740 a\DT\13649268 possible\JJ\1740 deteriorating\VBG\208836 effect\NN\34213 of\IN\1740 SM-5887\NN\1740 on\IN\1740 low-grade\JJ\1740 cardiotoxicity\NN\1740 pre-induced\VBN\1740 by\IN\1740 <e1>doxorubicin</e1>\NN\2716866 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 .\.\1740
D004317_D066126 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 chronic\JJ\1740 cardiotoxic\JJ\1740 potential\NN\14481929 of\IN\1740 SM-5887\NN\1740 and\CC\1740 a\DT\13649268 possible\JJ\1740 deteriorating\VBG\208836 effect\NN\34213 of\IN\1740 SM-5887\NN\1740 on\IN\1740 low-grade\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 pre-induced\VBN\1740 by\IN\1740 <e1>doxorubicin</e1>\NN\2716866 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 .\.\1740
D004317_D066126 NONE To\TO\1740 examine\VB\789138 a\DT\13649268 possibly\RB\1740 deteriorating\VBG\208836 <e2>cardiotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 SM-5887\NN\1740 ,\,\1740 low-grade\JJ\1740 cardiomyopathy\NN\14103288 was\VBD\836236 induced\VBN\1627355 in\IN\13603305 dogs\NNS\2083346 by\IN\1740 four\CD\13741022 courses\NNS\883297 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D066126 NONE The\DT\1740 low-grade\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 changes\NNS\7283608 were\VBD\836236 enhanced\VBN\227165 by\IN\1740 the\DT\1740 additional\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 treatment\NN\654885 .\.\1740
D004317_D066126 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 SM-5887\NN\1740 does\VBZ\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 potential\NN\14481929 of\IN\1740 chronic\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 deteriorating\VBG\208836 effect\NN\34213 on\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D004317_D066126 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 SM-5887\NN\1740 does\VBZ\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 potential\NN\14481929 of\IN\1740 chronic\JJ\1740 cardiotoxicity\NN\1740 and\CC\1740 deteriorating\VBG\208836 effect\NN\34213 on\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 dogs\NNS\2083346 .\.\1740
11573852
D000666_D012640 CID <e1>Amphotericin\NN\2716866 B-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 AIDS\NN\13974317 .\.\1740
D000666_D012640 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 multiple\JJ\1740 episodes\NNS\7283608 of\IN\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 in\IN\13603305 an\DT\6697703 AIDS\NN\13974317 patent\NN\6470073 following\VBG\1835496 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 infusion\NN\14589223 .\.\1740
D000666_D012640 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 46-year-old\JJ\1740 African-American\JJ\1740 man\NN\9605289 experienced\VBD\2108377 recurrent\JJ\1740 grand\JJ\1740 mal\JJ\1740 seizures\NNS\14081375 during\IN\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 ,\,\1740 then\RB\1740 petit\JJ\1740 mal\JJ\1740 <e2>seizures</e2>\NNS\14081375 as\IN\14622893 the\DT\1740 infusion\NN\14589223 was\VBD\836236 stopped\VBN\2452885 and\CC\1740 the\DT\1740 drug\NN\14778436 concentrations\NNS\4916342 decreased\VBD\169651 with\IN\1740 time\NN\7308889 .\.\1740
D000666_D012640 CID Despite\IN\7501545 administration\NN\1133281 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 lorazepam\NN\2830852 ,\,\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 persisted\VBD\118523 and\CC\1740 occurred\VBD\2623529 only\RB\1740 during\IN\1740 <e1>amphotercin\NN\1740 B</e1>\NN\1355326 administration\NN\1133281 .\.\1740
D000666_D012640 CID The\DT\1740 time\NN\7308889 course\NN\883297 of\IN\1740 events\NNS\23100 suggested\VBD\1010118 that\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 was\VBD\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 this\DT\1740 AIDS\NN\13974317 patient\NN\9898892 .\.\1740
D000666_D012640 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Amphotericin\NN\2716866 B</e1>\NN\1355326 seems\VBZ\2604760 to\TO\1740 be\VB\836236 the\DT\1740 probable\JJ\1740 cause\NN\7323922 of\IN\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D000666_D012640 CID To\IN\1740 date\NN\15155220 ,\,\1740 only\RB\1740 three\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>seizures</e2>\NNS\14081375 associated\VBN\628491 with\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 the\DT\1740 literature\NN\6362953 ,\,\1740 but\CC\1740 healthcare\NN\654885 providers\NNS\9882716 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 for\IN\1740 this\DT\1740 rare\JJ\1740 adverse\JJ\1740 effect\NN\34213 .\.\1740
D000666_D000163 NONE <e1>Amphotericin\NN\2716866 B-induced</e1>\JJ\1740 seizures\NNS\14081375 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>AIDS</e2>\NN\13974317 .\.\1740
D000666_D000163 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 multiple\JJ\1740 episodes\NNS\7283608 of\IN\1740 seizure\JJ\1740 activity\NN\30358 in\IN\13603305 an\DT\6697703 <e2>AIDS</e2>\NN\13974317 patent\NN\6470073 following\VBG\1835496 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 infusion\NN\14589223 .\.\1740
D000666_D000163 NONE The\DT\1740 time\NN\7308889 course\NN\883297 of\IN\1740 events\NNS\23100 suggested\VBD\1010118 that\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 was\VBD\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 the\DT\1740 seizures\NNS\14081375 in\IN\13603305 this\DT\1740 <e2>AIDS</e2>\NN\13974317 patient\NN\9898892 .\.\1740
D000666_D004830 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 46-year-old\JJ\1740 African-American\JJ\1740 man\NN\9605289 experienced\VBD\2108377 recurrent\JJ\1740 <e2>grand\JJ\1740 mal\JJ\1740 seizures</e2>\NNS\14081375 during\IN\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 ,\,\1740 then\RB\1740 petit\JJ\1740 mal\JJ\1740 seizures\NNS\14081375 as\IN\14622893 the\DT\1740 infusion\NN\14589223 was\VBD\836236 stopped\VBN\2452885 and\CC\1740 the\DT\1740 drug\NN\14778436 concentrations\NNS\4916342 decreased\VBD\169651 with\IN\1740 time\NN\7308889 .\.\1740
D010672_D012640 NONE Despite\IN\7501545 administration\NN\1133281 of\IN\1740 <e1>phenytoin</e1>\NN\3550533 and\CC\1740 lorazepam\NN\2830852 ,\,\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 persisted\VBD\118523 and\CC\1740 occurred\VBD\2623529 only\RB\1740 during\IN\1740 amphotercin\NN\1740 B\NN\1355326 administration\NN\1133281 .\.\1740
D008140_D012640 NONE Despite\IN\7501545 administration\NN\1133281 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 <e1>lorazepam</e1>\NN\2830852 ,\,\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 persisted\VBD\118523 and\CC\1740 occurred\VBD\2623529 only\RB\1740 during\IN\1740 amphotercin\NN\1740 B\NN\1355326 administration\NN\1133281 .\.\1740
D000431_D000437 NONE The\DT\1740 patient\NN\9898892 had\VBD\2108377 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>alcohol\NN\7881800 abuse</e2>\NN\418025 ;\:\1740 <e1>alcohol</e1>\NN\7881800 intake\VBP\1740 as\RB\1740 well\RB\1740 as\IN\14622893 withdrawal\NN\7206096 can\MD\3094503 also\RB\1740 cause\VB\1617192 seizures\NNS\14081375 .\.\1740
D000431_D012640 NONE The\DT\1740 patient\NN\9898892 had\VBD\2108377 a\DT\13649268 history\NN\15120823 of\IN\1740 alcohol\NN\7881800 abuse\NN\418025 ;\:\1740 <e1>alcohol</e1>\NN\7881800 intake\VBP\1740 as\RB\1740 well\RB\1740 as\IN\14622893 withdrawal\NN\7206096 can\MD\3094503 also\RB\1740 cause\VB\1617192 <e2>seizures</e2>\NNS\14081375 .\.\1740
D016049_D012640 NONE <e1>Didanosine</e1>\NNP\2725367 also\RB\1740 has\VBZ\2108377 a\DT\13649268 potential\NN\14481929 for\IN\1740 inducing\VBG\1627355 <e2>seizures</e2>\NNS\14081375 .\.\1740
8012887
D006493_D013927 CID Failure\NN\66216 of\IN\1740 ancrod\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 arterial\JJ\1740 <e2>thrombosis</e2>\NN\14100769 .\.\1740
D006493_D013927 CID The\DT\1740 morbidity\NN\13826959 and\CC\1740 mortality\NN\5054863 associated\VBN\628491 with\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombosis</e2>\NN\14100769 remain\VBP\2604760 high\JJ\1740 despite\IN\7501545 numerous\JJ\1740 empirical\JJ\1740 therapies\NNS\657604 .\.\1740
D006493_D013927 CID Ancrod\JJ\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 for\IN\1740 prophylaxis\NN\1077350 against\IN\1740 development\NN\248977 of\IN\1740 <e2>thrombosis</e2>\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>heparin</e1>\NN\2718259 induced\VBD\1627355 platelet\NN\5432736 aggregation\NN\31264 who\WP\8299493 require\VBP\754942 brief\JJ\1740 reexposure\NN\1740 to\TO\1740 heparin\NN\2718259 ,\,\1740 but\CC\1740 its\PRP$\6125041 success\NN\7283608 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 developed\VBN\1753788 the\DT\1740 thrombosis\NN\14100769 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 well\RB\1740 defined\VBN\2604760 .\.\1740
D006493_D013927 CID Ancrod\JJ\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 for\IN\1740 prophylaxis\NN\1077350 against\IN\1740 development\NN\248977 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>heparin</e1>\NN\2718259 induced\VBD\1627355 platelet\NN\5432736 aggregation\NN\31264 who\WP\8299493 require\VBP\754942 brief\JJ\1740 reexposure\NN\1740 to\TO\1740 heparin\NN\2718259 ,\,\1740 but\CC\1740 its\PRP$\6125041 success\NN\7283608 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 developed\VBN\1753788 the\DT\1740 <e2>thrombosis</e2>\NN\14100769 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 well\RB\1740 defined\VBN\2604760 .\.\1740
D006493_D013927 CID Ancrod\JJ\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 for\IN\1740 prophylaxis\NN\1077350 against\IN\1740 development\NN\248977 of\IN\1740 <e2>thrombosis</e2>\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 heparin\NN\2718259 induced\VBD\1627355 platelet\NN\5432736 aggregation\NN\31264 who\WP\8299493 require\VBP\754942 brief\JJ\1740 reexposure\NN\1740 to\TO\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 but\CC\1740 its\PRP$\6125041 success\NN\7283608 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 developed\VBN\1753788 the\DT\1740 thrombosis\NN\14100769 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 well\RB\1740 defined\VBN\2604760 .\.\1740
D006493_D013927 CID Ancrod\JJ\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 for\IN\1740 prophylaxis\NN\1077350 against\IN\1740 development\NN\248977 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 heparin\NN\2718259 induced\VBD\1627355 platelet\NN\5432736 aggregation\NN\31264 who\WP\8299493 require\VBP\754942 brief\JJ\1740 reexposure\NN\1740 to\TO\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 but\CC\1740 its\PRP$\6125041 success\NN\7283608 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 developed\VBN\1753788 the\DT\1740 <e2>thrombosis</e2>\NN\14100769 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 well\RB\1740 defined\VBN\2604760 .\.\1740
D006493_D013927 CID The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 failure\NN\66216 of\IN\1740 ancrod\JJ\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombosis</e2>\NN\14100769 .\.\1740
D006493_D001791 NONE Ancrod\JJ\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 for\IN\1740 prophylaxis\NN\1077350 against\IN\1740 development\NN\248977 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>heparin</e1>\NN\2718259 induced\VBD\1627355 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 who\WP\8299493 require\VBP\754942 brief\JJ\1740 reexposure\NN\1740 to\TO\1740 heparin\NN\2718259 ,\,\1740 but\CC\1740 its\PRP$\6125041 success\NN\7283608 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 developed\VBN\1753788 the\DT\1740 thrombosis\NN\14100769 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 well\RB\1740 defined\VBN\2604760 .\.\1740
D006493_D001791 NONE Ancrod\JJ\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 for\IN\1740 prophylaxis\NN\1077350 against\IN\1740 development\NN\248977 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 heparin\NN\2718259 induced\VBD\1627355 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 who\WP\8299493 require\VBP\754942 brief\JJ\1740 reexposure\NN\1740 to\TO\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 but\CC\1740 its\PRP$\6125041 success\NN\7283608 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 developed\VBN\1753788 the\DT\1740 thrombosis\NN\14100769 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 well\RB\1740 defined\VBN\2604760 .\.\1740
8766220
D014147_D006212 CID Nightmares\NNS\14411243 and\CC\1740 <e2>hallucinations</e2>\NNS\14376855 after\IN\1740 long-term\JJ\1740 intake\NN\13440063 of\IN\1740 <e1>tramadol</e1>\NN\1740 combined\VBN\2630189 with\IN\1740 antidepressants\NNS\3740161 .\.\1740
D014147_D006212 CID Fifty-six\CD\1740 days\NNS\15140892 after\IN\1740 initiation\NN\7450842 of\IN\1740 the\DT\1740 treatment\NN\654885 the\DT\1740 patient\NN\9898892 presented\VBD\2137132 <e2>hallucinations</e2>\NNS\14376855 that\WDT\1740 only\RB\1740 stopped\VBD\2452885 after\IN\1740 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 psycho-active\JJ\1740 drugs\NNS\14778436 and\CC\1740 <e1>tramadol</e1>\NN\1740 .\.\1740
D014147_D009369 NONE <e1>Tramadol</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 weak\JJ\1740 opioid\NN\1740 with\IN\1740 effects\NNS\13245626 on\IN\1740 adrenergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 neurotransmission\NN\1740 that\WDT\1740 is\VBZ\836236 used\VBN\1156834 to\TO\1740 treat\VB\2376958 <e2>cancer</e2>\NN\14239425 pain\NN\14299637 and\CC\1740 chronic\JJ\1740 non\JJ\1740 malignant\JJ\1740 pain\NN\14299637 .\.\1740
D014147_D010146 NONE <e1>Tramadol</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 weak\JJ\1740 opioid\NN\1740 with\IN\1740 effects\NNS\13245626 on\IN\1740 adrenergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 neurotransmission\NN\1740 that\WDT\1740 is\VBZ\836236 used\VBN\1156834 to\TO\1740 treat\VB\2376958 cancer\NN\14239425 <e2>pain</e2>\NN\14299637 and\CC\1740 chronic\JJ\1740 non\JJ\1740 malignant\JJ\1740 pain\NN\14299637 .\.\1740
D014147_D010146 NONE <e1>Tramadol</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 weak\JJ\1740 opioid\NN\1740 with\IN\1740 effects\NNS\13245626 on\IN\1740 adrenergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 neurotransmission\NN\1740 that\WDT\1740 is\VBZ\836236 used\VBN\1156834 to\TO\1740 treat\VB\2376958 cancer\NN\14239425 pain\NN\14299637 and\CC\1740 chronic\JJ\1740 non\JJ\1740 malignant\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D017374_-1 NONE This\DT\1740 drug\NN\14778436 was\VBD\836236 initiated\VBN\1617192 in\IN\13603305 association\NN\8008335 with\IN\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 dosulepine\NN\1740 hydrochloride\NN\14817592 in\IN\13603305 a\DT\13649268 <e2>tetraparetic</e2>\JJ\1740 patient\NN\9898892 with\IN\1740 chronic\JJ\1740 pain\NN\14299637 .\.\1740
D017374_D059350 NONE This\DT\1740 drug\NN\14778436 was\VBD\836236 initiated\VBN\1617192 in\IN\13603305 association\NN\8008335 with\IN\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 dosulepine\NN\1740 hydrochloride\NN\14817592 in\IN\13603305 a\DT\13649268 tetraparetic\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>chronic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D004308_-1 NONE This\DT\1740 drug\NN\14778436 was\VBD\836236 initiated\VBN\1617192 in\IN\13603305 association\NN\8008335 with\IN\1740 paroxetine\NN\1740 and\CC\1740 <e1>dosulepine\NN\1740 hydrochloride</e1>\NN\14817592 in\IN\13603305 a\DT\13649268 <e2>tetraparetic</e2>\JJ\1740 patient\NN\9898892 with\IN\1740 chronic\JJ\1740 pain\NN\14299637 .\.\1740
D004308_D059350 NONE This\DT\1740 drug\NN\14778436 was\VBD\836236 initiated\VBN\1617192 in\IN\13603305 association\NN\8008335 with\IN\1740 paroxetine\NN\1740 and\CC\1740 <e1>dosulepine\NN\1740 hydrochloride</e1>\NN\14817592 in\IN\13603305 a\DT\13649268 tetraparetic\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>chronic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
3088349
D000661_D009069 CID Transient\JJ\1740 <e2>contralateral\JJ\1740 rotation</e2>\NN\331950 following\VBG\1835496 unilateral\JJ\1740 substantia\RB\1740 nigra\JJ\1740 lesion\NN\14204950 reflects\VBZ\923793 susceptibility\NN\13920835 of\IN\1740 the\DT\1740 nigrostriatal\JJ\1740 system\NN\3575240 to\TO\1740 exhaustion\NN\14016361 by\IN\1740 <e1>amphetamine</e1>\NN\3248958 .\.\1740
D000661_D009069 CID In\IN\13603305 order\NN\7168131 to\TO\1740 clarify\VB\939277 the\DT\1740 nature\NN\4723816 of\IN\1740 this\DT\1740 initial\JJ\1740 <e2>contralateral\JJ\1740 rotation</e2>\NN\331950 we\PRP\1740 examined\VBD\789138 the\DT\1740 effect\NN\34213 of\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 recovery\NN\7357388 period\NN\13575869 after\IN\1740 the\DT\1740 lesion\NN\14204950 ,\,\1740 on\IN\1740 <e1>amphetamine-induced</e1>\JJ\1740 rotational\JJ\1740 behavior\NN\407535 .\.\1740
D000661_D009069 CID In\IN\13603305 order\NN\7168131 to\TO\1740 clarify\VB\939277 the\DT\1740 nature\NN\4723816 of\IN\1740 this\DT\1740 initial\JJ\1740 contralateral\JJ\1740 rotation\NN\331950 we\PRP\1740 examined\VBD\789138 the\DT\1740 effect\NN\34213 of\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 recovery\NN\7357388 period\NN\13575869 after\IN\1740 the\DT\1740 lesion\NN\14204950 ,\,\1740 on\IN\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>rotational\JJ\1740 behavior</e2>\NN\407535 .\.\1740
D000661_D009069 CID A\DT\13649268 substantial\JJ\1740 degree\NN\4916342 of\IN\1740 contralateral\JJ\1740 preference\NN\7497473 was\VBD\836236 still\RB\1740 evident\JJ\1740 when\WRB\1740 <e1>amphetamine</e1>\NN\3248958 was\VBD\836236 administered\VBN\2436349 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 24\CD\13745420 days\NNS\15140892 after\IN\1740 lesioning\NN\1740 ,\,\1740 indicating\VBG\952524 involvement\NN\1080366 of\IN\1740 spared\VBN\2725714 cells\NNS\3080309 in\IN\13603305 the\DT\1740 <e2>contralateral\JJ\1740 rotation</e2>\NN\331950 .\.\1740
D000661_D009069 CID However\RB\1740 ,\,\1740 regardless\RB\1740 of\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 recovery\NN\7357388 (\-LRB-\1740 and\CC\1740 irrespective\RB\1740 of\IN\1740 either\DT\1740 lesion\NN\14204950 volume\NN\33615 ,\,\1740 <e1>amphetamine</e1>\NN\3248958 dose\NN\3740161 ,\,\1740 or\CC\3541091 post-lesion\JJ\1740 motor\NN\3699975 exercise\NN\621627 )\-RRB-\1740 ,\,\1740 amphetamine-induced\JJ\1740 <e2>rotation</e2>\NN\331950 tended\VBD\2604760 to\TO\1740 become\VB\146138 gradually\RB\1740 more\RBR\1740 ipsilateral\JJ\1740 as\IN\14622893 the\DT\1740 observation\NN\996969 session\NN\7142566 progressed\VBD\252019 ,\,\1740 and\CC\1740 all\DT\1740 rats\NNS\2329401 circled\VBD\1835496 ipsilaterally\RB\1740 to\TO\1740 the\DT\1740 lesion\NN\14204950 in\IN\13603305 response\NN\11410625 to\TO\1740 further\JJ\1740 amphetamine\VB\1740 injections\NNS\320852 .\.\1740
D000661_D009069 CID However\RB\1740 ,\,\1740 regardless\RB\1740 of\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 recovery\NN\7357388 (\-LRB-\1740 and\CC\1740 irrespective\RB\1740 of\IN\1740 either\DT\1740 lesion\NN\14204950 volume\NN\33615 ,\,\1740 amphetamine\NN\3248958 dose\NN\3740161 ,\,\1740 or\CC\3541091 post-lesion\JJ\1740 motor\NN\3699975 exercise\NN\621627 )\-RRB-\1740 ,\,\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>rotation</e2>\NN\331950 tended\VBD\2604760 to\TO\1740 become\VB\146138 gradually\RB\1740 more\RBR\1740 ipsilateral\JJ\1740 as\IN\14622893 the\DT\1740 observation\NN\996969 session\NN\7142566 progressed\VBD\252019 ,\,\1740 and\CC\1740 all\DT\1740 rats\NNS\2329401 circled\VBD\1835496 ipsilaterally\RB\1740 to\TO\1740 the\DT\1740 lesion\NN\14204950 in\IN\13603305 response\NN\11410625 to\TO\1740 further\JJ\1740 amphetamine\VB\1740 injections\NNS\320852 .\.\1740
D000661_D009069 CID However\RB\1740 ,\,\1740 regardless\RB\1740 of\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 recovery\NN\7357388 (\-LRB-\1740 and\CC\1740 irrespective\RB\1740 of\IN\1740 either\DT\1740 lesion\NN\14204950 volume\NN\33615 ,\,\1740 amphetamine\NN\3248958 dose\NN\3740161 ,\,\1740 or\CC\3541091 post-lesion\JJ\1740 motor\NN\3699975 exercise\NN\621627 )\-RRB-\1740 ,\,\1740 amphetamine-induced\JJ\1740 <e2>rotation</e2>\NN\331950 tended\VBD\2604760 to\TO\1740 become\VB\146138 gradually\RB\1740 more\RBR\1740 ipsilateral\JJ\1740 as\IN\14622893 the\DT\1740 observation\NN\996969 session\NN\7142566 progressed\VBD\252019 ,\,\1740 and\CC\1740 all\DT\1740 rats\NNS\2329401 circled\VBD\1835496 ipsilaterally\RB\1740 to\TO\1740 the\DT\1740 lesion\NN\14204950 in\IN\13603305 response\NN\11410625 to\TO\1740 further\JJ\1740 <e1>amphetamine</e1>\VB\1740 injections\NNS\320852 .\.\1740
D000661_D009069 CID These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>amphetamine</e1>\NN\3248958 has\VBZ\2108377 an\DT\6697703 irreversible\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 post-lesion\JJ\1740 DA\NN\10484858 pool\NN\3302121 contributing\VBG\126264 to\TO\1740 <e2>contralateral\JJ\1740 rotation</e2>\NN\331950 .\.\1740
D000661_-1 NONE Transient\JJ\1740 contralateral\JJ\1740 rotation\NN\331950 following\VBG\1835496 unilateral\JJ\1740 <e2>substantia\RB\1740 nigra\JJ\1740 lesion</e2>\NN\14204950 reflects\VBZ\923793 susceptibility\NN\13920835 of\IN\1740 the\DT\1740 nigrostriatal\JJ\1740 system\NN\3575240 to\TO\1740 exhaustion\NN\14016361 by\IN\1740 <e1>amphetamine</e1>\NN\3248958 .\.\1740
D016627_-1 NONE Following\VBG\1835496 unilateral\JJ\1740 <e1>6-OHDA</e1>\NN\1740 induced\VBN\1627355 <e2>SN\NN\14625458 lesion</e2>\NN\14204950 ,\,\1740 a\DT\13649268 transient\JJ\1740 period\NN\13575869 of\IN\1740 contralateral\JJ\1740 rotation\NN\331950 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 precede\VB\2690708 the\DT\1740 predominant\JJ\1740 ipsilateral\JJ\1740 circling\NN\1740 .\.\1740
D016627_D009069 NONE Following\VBG\1835496 unilateral\JJ\1740 <e1>6-OHDA</e1>\NN\1740 induced\VBN\1627355 SN\NN\14625458 lesion\NN\14204950 ,\,\1740 a\DT\13649268 transient\JJ\1740 period\NN\13575869 of\IN\1740 <e2>contralateral\JJ\1740 rotation</e2>\NN\331950 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 precede\VB\2690708 the\DT\1740 predominant\JJ\1740 ipsilateral\JJ\1740 circling\NN\1740 .\.\1740
D016627_D009069 NONE Following\VBG\1835496 unilateral\JJ\1740 <e1>6-OHDA</e1>\NN\1740 induced\VBN\1627355 SN\NN\14625458 lesion\NN\14204950 ,\,\1740 a\DT\13649268 transient\JJ\1740 period\NN\13575869 of\IN\1740 contralateral\JJ\1740 rotation\NN\331950 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 precede\VB\2690708 the\DT\1740 predominant\JJ\1740 <e2>ipsilateral\JJ\1740 circling</e2>\NN\1740 .\.\1740
12739036
D003401_D008180 NONE Differential\JJ\1740 diagnosis\NN\152018 of\IN\1740 high\JJ\1740 serum\NN\5397468 <e1>creatine</e1>\NN\14601829 kinase\NN\14732946 levels\NNS\4916342 in\IN\13603305 <e2>systemic\JJ\1740 lupus\NN\14219661 erythematosus</e2>\NN\1740 .\.\1740
D002738_D009135 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 clinical\JJ\1740 and\CC\1740 bioptic\JJ\1740 findings\NNS\7951464 for\IN\1740 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 severe\JJ\1740 <e1>chloroquine-induced</e1>\JJ\1740 <e2>myopathy</e2>\NN\14204950 .\.\1740
D002738_D009135 NONE As\IN\14622893 it\PRP\6125041 revealed\VBD\2137132 <e1>chloroquine-induced</e1>\JJ\1740 <e2>myopathy</e2>\NN\14204950 ,\,\1740 medication\NN\3247620 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D001379_D008180 NONE Since\IN\1740 1989\CD\1740 ,\,\1740 she\PRP\1740 had\VBD\2108377 been\VBN\836236 suffering\VBG\2110220 from\IN\1740 <e2>systemic\JJ\1740 lupus\NN\14219661 erythematosus</e2>\NN\1740 (\-LRB-\1740 SLE\NN\14229912 )\-RRB-\1740 with\IN\1740 renal\JJ\1740 involvement\NN\1080366 and\CC\1740 undergone\JJ\1740 periods\NNS\13575869 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>azathioprine</e1>\NN\3740161 and\CC\1740 cyclophosphamide\NN\1740 .\.\1740
D001379_D008180 NONE Since\IN\1740 1989\CD\1740 ,\,\1740 she\PRP\1740 had\VBD\2108377 been\VBN\836236 suffering\VBG\2110220 from\IN\1740 systemic\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 (\-LRB-\1740 <e2>SLE</e2>\NN\14229912 )\-RRB-\1740 with\IN\1740 renal\JJ\1740 involvement\NN\1080366 and\CC\1740 undergone\JJ\1740 periods\NNS\13575869 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>azathioprine</e1>\NN\3740161 and\CC\1740 cyclophosphamide\NN\1740 .\.\1740
D001379_D007674 NONE Since\IN\1740 1989\CD\1740 ,\,\1740 she\PRP\1740 had\VBD\2108377 been\VBN\836236 suffering\VBG\2110220 from\IN\1740 systemic\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 (\-LRB-\1740 SLE\NN\14229912 )\-RRB-\1740 with\IN\1740 <e2>renal\JJ\1740 involvement</e2>\NN\1080366 and\CC\1740 undergone\JJ\1740 periods\NNS\13575869 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>azathioprine</e1>\NN\3740161 and\CC\1740 cyclophosphamide\NN\1740 .\.\1740
D003520_D008180 NONE Since\IN\1740 1989\CD\1740 ,\,\1740 she\PRP\1740 had\VBD\2108377 been\VBN\836236 suffering\VBG\2110220 from\IN\1740 <e2>systemic\JJ\1740 lupus\NN\14219661 erythematosus</e2>\NN\1740 (\-LRB-\1740 SLE\NN\14229912 )\-RRB-\1740 with\IN\1740 renal\JJ\1740 involvement\NN\1080366 and\CC\1740 undergone\JJ\1740 periods\NNS\13575869 of\IN\1740 treatment\NN\654885 with\IN\1740 azathioprine\NN\3740161 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 .\.\1740
D003520_D008180 NONE Since\IN\1740 1989\CD\1740 ,\,\1740 she\PRP\1740 had\VBD\2108377 been\VBN\836236 suffering\VBG\2110220 from\IN\1740 systemic\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 (\-LRB-\1740 <e2>SLE</e2>\NN\14229912 )\-RRB-\1740 with\IN\1740 renal\JJ\1740 involvement\NN\1080366 and\CC\1740 undergone\JJ\1740 periods\NNS\13575869 of\IN\1740 treatment\NN\654885 with\IN\1740 azathioprine\NN\3740161 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 .\.\1740
D003520_D007674 NONE Since\IN\1740 1989\CD\1740 ,\,\1740 she\PRP\1740 had\VBD\2108377 been\VBN\836236 suffering\VBG\2110220 from\IN\1740 systemic\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 (\-LRB-\1740 SLE\NN\14229912 )\-RRB-\1740 with\IN\1740 <e2>renal\JJ\1740 involvement</e2>\NN\1080366 and\CC\1740 undergone\JJ\1740 periods\NNS\13575869 of\IN\1740 treatment\NN\654885 with\IN\1740 azathioprine\NN\3740161 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 .\.\1740
D002738_D018771 NONE Additional\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>chloroquine</e1>\NN\2721948 (\-LRB-\1740 CQ\NN\1740 )\-RRB-\1740 was\VBD\836236 started\VBN\2009433 because\IN\1740 of\IN\1740 <e2>arthralgia</e2>\NN\14322699 .\.\1740
D002738_D018771 NONE Additional\JJ\1740 therapy\NN\657604 with\IN\1740 chloroquine\NN\2721948 (\-LRB-\1740 <e1>CQ</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 started\VBN\2009433 because\IN\1740 of\IN\1740 <e2>arthralgia</e2>\NN\14322699 .\.\1740
D013256_D009220 NONE <e2>Myositis</e2>\NNP\14336539 was\VBD\836236 suspected\VBN\916909 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>steroids</e1>\NNS\14727670 .\.\1740
3220106
D009538_D006948 CID Receptor\NN\5225602 mechanisms\NNS\13446390 of\IN\1740 <e1>nicotine-induced</e1>\JJ\1740 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 in\IN\13603305 chronic\JJ\1740 nicotine-treated\JJ\1740 rats\NNS\2329401 .\.\1740
D009538_D006948 CID Receptor\NN\5225602 mechanisms\NNS\13446390 of\IN\1740 nicotine-induced\JJ\1740 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 in\IN\13603305 chronic\JJ\1740 <e1>nicotine-treated</e1>\JJ\1740 rats\NNS\2329401 .\.\1740
D009538_D006948 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chronic\JJ\1740 <e1>nicotine-treated</e1>\JJ\1740 rats\NNS\2329401 develop\VBP\1753788 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 in\IN\13603305 response\NN\11410625 to\TO\1740 nicotine\NN\14712692 initially\RB\1740 due\JJ\1740 to\IN\1740 increases\NNS\13576355 of\IN\1740 both\CC\1740 the\DT\1740 density\NN\4941325 of\IN\1740 nicotinic\JJ\1740 receptors\NNS\5225602 and\CC\1740 DA\NN\10484858 concentration\NN\4916342 ,\,\1740 followed\VBN\1835496 by\IN\1740 inducing\VBG\1627355 DA\NN\10484858 receptor\NN\5225602 supersensitivity\NN\1740 in\IN\13603305 the\DT\1740 striatum\NN\5497363 .\.\1740
D009538_D006948 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chronic\JJ\1740 nicotine-treated\JJ\1740 rats\NNS\2329401 develop\VBP\1753788 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 in\IN\13603305 response\NN\11410625 to\TO\1740 <e1>nicotine</e1>\NN\14712692 initially\RB\1740 due\JJ\1740 to\IN\1740 increases\NNS\13576355 of\IN\1740 both\CC\1740 the\DT\1740 density\NN\4941325 of\IN\1740 nicotinic\JJ\1740 receptors\NNS\5225602 and\CC\1740 DA\NN\10484858 concentration\NN\4916342 ,\,\1740 followed\VBN\1835496 by\IN\1740 inducing\VBG\1627355 DA\NN\10484858 receptor\NN\5225602 supersensitivity\NN\1740 in\IN\13603305 the\DT\1740 striatum\NN\5497363 .\.\1740
D004298_D006948 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chronic\JJ\1740 nicotine-treated\JJ\1740 rats\NNS\2329401 develop\VBP\1753788 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 in\IN\13603305 response\NN\11410625 to\TO\1740 nicotine\NN\14712692 initially\RB\1740 due\JJ\1740 to\IN\1740 increases\NNS\13576355 of\IN\1740 both\CC\1740 the\DT\1740 density\NN\4941325 of\IN\1740 nicotinic\JJ\1740 receptors\NNS\5225602 and\CC\1740 <e1>DA</e1>\NN\10484858 concentration\NN\4916342 ,\,\1740 followed\VBN\1835496 by\IN\1740 inducing\VBG\1627355 DA\NN\10484858 receptor\NN\5225602 supersensitivity\NN\1740 in\IN\13603305 the\DT\1740 striatum\NN\5497363 .\.\1740
D004298_D006948 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chronic\JJ\1740 nicotine-treated\JJ\1740 rats\NNS\2329401 develop\VBP\1753788 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 in\IN\13603305 response\NN\11410625 to\TO\1740 nicotine\NN\14712692 initially\RB\1740 due\JJ\1740 to\IN\1740 increases\NNS\13576355 of\IN\1740 both\CC\1740 the\DT\1740 density\NN\4941325 of\IN\1740 nicotinic\JJ\1740 receptors\NNS\5225602 and\CC\1740 DA\NN\10484858 concentration\NN\4916342 ,\,\1740 followed\VBN\1835496 by\IN\1740 inducing\VBG\1627355 <e1>DA</e1>\NN\10484858 receptor\NN\5225602 supersensitivity\NN\1740 in\IN\13603305 the\DT\1740 striatum\NN\5497363 .\.\1740
2790457
D002220_D012640 NONE Chronic\JJ\1740 <e1>carbamazepine</e1>\NN\1740 inhibits\VBZ\2510337 the\DT\1740 development\NN\248977 of\IN\1740 local\JJ\1740 anesthetic\JJ\1740 <e2>seizures</e2>\NNS\14081375 kindled\VBN\2764245 by\IN\1740 cocaine\NN\3492717 and\CC\1740 lidocaine\NN\3681148 .\.\1740
D002220_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 (\-LRB-\1740 CBZ\NN\1740 )\-RRB-\1740 treatment\NN\654885 on\IN\1740 local\JJ\1740 anesthetic-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 lethality\NN\4790449 were\VBD\836236 evaluated\VBN\670261 in\IN\13603305 different\JJ\1740 stages\NNS\15113229 of\IN\1740 the\DT\1740 kindling\NN\15101361 process\NN\407535 and\CC\1740 under\IN\1740 different\JJ\1740 methods\NNS\5616786 of\IN\1740 CBZ\NN\1740 administration\NN\1133281 .\.\1740
D002220_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 carbamazepine\NN\1740 (\-LRB-\1740 <e1>CBZ</e1>\NN\1740 )\-RRB-\1740 treatment\NN\654885 on\IN\1740 local\JJ\1740 anesthetic-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 lethality\NN\4790449 were\VBD\836236 evaluated\VBN\670261 in\IN\13603305 different\JJ\1740 stages\NNS\15113229 of\IN\1740 the\DT\1740 kindling\NN\15101361 process\NN\407535 and\CC\1740 under\IN\1740 different\JJ\1740 methods\NNS\5616786 of\IN\1740 CBZ\NN\1740 administration\NN\1133281 .\.\1740
D002220_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 carbamazepine\NN\1740 (\-LRB-\1740 CBZ\NN\1740 )\-RRB-\1740 treatment\NN\654885 on\IN\1740 local\JJ\1740 anesthetic-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 lethality\NN\4790449 were\VBD\836236 evaluated\VBN\670261 in\IN\13603305 different\JJ\1740 stages\NNS\15113229 of\IN\1740 the\DT\1740 kindling\NN\15101361 process\NN\407535 and\CC\1740 under\IN\1740 different\JJ\1740 methods\NNS\5616786 of\IN\1740 <e1>CBZ</e1>\NN\1740 administration\NN\1133281 .\.\1740
D002220_D012640 NONE Chronic\JJ\1740 oral\JJ\1740 <e1>CBZ</e1>\NN\1740 inhibited\VBD\2510337 the\DT\1740 development\NN\248977 of\IN\1740 both\CC\1740 lidocaine-\NN\1740 and\CC\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 but\CC\1740 had\VBD\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 fully\RB\1740 developed\VBN\1753788 local\JJ\1740 anesthetic\JJ\1740 seizures\NNS\14081375 .\.\1740
D002220_D012640 NONE Chronic\JJ\1740 oral\JJ\1740 <e1>CBZ</e1>\NN\1740 inhibited\VBD\2510337 the\DT\1740 development\NN\248977 of\IN\1740 both\CC\1740 lidocaine-\NN\1740 and\CC\1740 cocaine-induced\JJ\1740 seizures\NNS\14081375 ,\,\1740 but\CC\1740 had\VBD\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 fully\RB\1740 developed\VBN\1753788 local\JJ\1740 anesthetic\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D002220_D012640 NONE Chronic\JJ\1740 <e1>CBZ</e1>\NN\1740 also\RB\1740 decreased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>seizure-related</e2>\JJ\1740 mortality\NN\5054863 in\IN\13603305 the\DT\1740 cocaine-injected\JJ\1740 rats\NNS\2329401 .\.\1740
D002220_D012640 NONE Acute\JJ\1740 <e1>CBZ</e1>\NN\1740 over\IN\5867413 a\DT\13649268 range\NN\5123416 of\IN\1740 doses\NNS\3740161 (\-LRB-\1740 15\CD\13745420 -\SYM\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 completed\VBN\352826 lidocaine-kindled\JJ\1740 or\CC\3541091 acute\JJ\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D002220_D012640 NONE Repeated\VBN\952524 i.p.\RB\1740 injection\NN\320852 of\IN\1740 <e1>CBZ</e1>\NN\1740 (\-LRB-\1740 15\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 also\RB\1740 was\VBD\836236 without\IN\1740 effect\NN\34213 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 lidocaine-\NN\1740 or\CC\3541091 cocaine-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D002220_D012640 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>CBZ</e1>\NN\1740 depending\VBG\2604760 upon\IN\1740 stage\NN\15113229 of\IN\1740 <e2>seizure</e2>\JJ\1740 development\NN\248977 suggest\VBP\1010118 that\IN\1740 distinct\JJ\1740 mechanisms\NNS\13446390 underlie\VBP\2604760 the\DT\1740 development\NN\248977 versus\CC\1740 maintenance\NN\266806 of\IN\1740 local\JJ\1740 anesthetic-kindled\JJ\1740 seizures\NNS\14081375 .\.\1740
D002220_D012640 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>CBZ</e1>\NN\1740 depending\VBG\2604760 upon\IN\1740 stage\NN\15113229 of\IN\1740 seizure\JJ\1740 development\NN\248977 suggest\VBP\1010118 that\IN\1740 distinct\JJ\1740 mechanisms\NNS\13446390 underlie\VBP\2604760 the\DT\1740 development\NN\248977 versus\CC\1740 maintenance\NN\266806 of\IN\1740 local\JJ\1740 anesthetic-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D003042_D012640 CID Chronic\JJ\1740 carbamazepine\NN\1740 inhibits\VBZ\2510337 the\DT\1740 development\NN\248977 of\IN\1740 local\JJ\1740 anesthetic\JJ\1740 <e2>seizures</e2>\NNS\14081375 kindled\VBN\2764245 by\IN\1740 <e1>cocaine</e1>\NN\3492717 and\CC\1740 lidocaine\NN\3681148 .\.\1740
D003042_D012640 CID Chronic\JJ\1740 oral\JJ\1740 CBZ\NN\1740 inhibited\VBD\2510337 the\DT\1740 development\NN\248977 of\IN\1740 both\CC\1740 lidocaine-\NN\1740 and\CC\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 but\CC\1740 had\VBD\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 fully\RB\1740 developed\VBN\1753788 local\JJ\1740 anesthetic\JJ\1740 seizures\NNS\14081375 .\.\1740
D003042_D012640 CID Chronic\JJ\1740 oral\JJ\1740 CBZ\NN\1740 inhibited\VBD\2510337 the\DT\1740 development\NN\248977 of\IN\1740 both\CC\1740 lidocaine-\NN\1740 and\CC\1740 <e1>cocaine-induced</e1>\JJ\1740 seizures\NNS\14081375 ,\,\1740 but\CC\1740 had\VBD\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 fully\RB\1740 developed\VBN\1753788 local\JJ\1740 anesthetic\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D003042_D012640 CID Chronic\JJ\1740 CBZ\NN\1740 also\RB\1740 decreased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>seizure-related</e2>\JJ\1740 mortality\NN\5054863 in\IN\13603305 the\DT\1740 <e1>cocaine-injected</e1>\JJ\1740 rats\NNS\2329401 .\.\1740
D003042_D012640 CID Acute\JJ\1740 CBZ\NN\1740 over\IN\5867413 a\DT\13649268 range\NN\5123416 of\IN\1740 doses\NNS\3740161 (\-LRB-\1740 15\CD\13745420 -\SYM\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 completed\VBN\352826 lidocaine-kindled\JJ\1740 or\CC\3541091 acute\JJ\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D003042_D012640 CID Repeated\VBN\952524 i.p.\RB\1740 injection\NN\320852 of\IN\1740 CBZ\NN\1740 (\-LRB-\1740 15\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 also\RB\1740 was\VBD\836236 without\IN\1740 effect\NN\34213 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 lidocaine-\NN\1740 or\CC\3541091 <e1>cocaine-kindled</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D008012_D012640 CID Chronic\JJ\1740 carbamazepine\NN\1740 inhibits\VBZ\2510337 the\DT\1740 development\NN\248977 of\IN\1740 local\JJ\1740 anesthetic\JJ\1740 <e2>seizures</e2>\NNS\14081375 kindled\VBN\2764245 by\IN\1740 cocaine\NN\3492717 and\CC\1740 <e1>lidocaine</e1>\NN\3681148 .\.\1740
D008012_D012640 CID Chronic\JJ\1740 oral\JJ\1740 CBZ\NN\1740 inhibited\VBD\2510337 the\DT\1740 development\NN\248977 of\IN\1740 both\CC\1740 <e1>lidocaine-</e1>\NN\1740 and\CC\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 but\CC\1740 had\VBD\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 fully\RB\1740 developed\VBN\1753788 local\JJ\1740 anesthetic\JJ\1740 seizures\NNS\14081375 .\.\1740
D008012_D012640 CID Chronic\JJ\1740 oral\JJ\1740 CBZ\NN\1740 inhibited\VBD\2510337 the\DT\1740 development\NN\248977 of\IN\1740 both\CC\1740 <e1>lidocaine-</e1>\NN\1740 and\CC\1740 cocaine-induced\JJ\1740 seizures\NNS\14081375 ,\,\1740 but\CC\1740 had\VBD\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 fully\RB\1740 developed\VBN\1753788 local\JJ\1740 anesthetic\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D008012_D012640 CID Acute\JJ\1740 CBZ\NN\1740 over\IN\5867413 a\DT\13649268 range\NN\5123416 of\IN\1740 doses\NNS\3740161 (\-LRB-\1740 15\CD\13745420 -\SYM\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 completed\VBN\352826 <e1>lidocaine-kindled</e1>\JJ\1740 or\CC\3541091 acute\JJ\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D008012_D012640 CID Repeated\VBN\952524 i.p.\RB\1740 injection\NN\320852 of\IN\1740 CBZ\NN\1740 (\-LRB-\1740 15\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 also\RB\1740 was\VBD\836236 without\IN\1740 effect\NN\34213 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>lidocaine-</e1>\NN\1740 or\CC\3541091 cocaine-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
16116131
D007980_D004409 CID The\DT\1740 neural\JJ\1740 mechanisms\NNS\13446390 and\CC\1740 circuitry\NN\3278248 involved\VBN\2676054 in\IN\13603305 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 are\VBP\836236 unclear\JJ\1740 .\.\1740
D001058_D010300 NONE Using\VBG\1156834 repetitive\JJ\1740 transcranial\JJ\1740 magnetic\JJ\1740 stimulation\NN\242808 (\-LRB-\1740 rTMS\NNS\1740 )\-RRB-\1740 over\IN\5867413 the\DT\1740 supplementary\NN\1740 motor\NN\3699975 area\NN\8630985 (\-LRB-\1740 SMA\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>Parkinson\NN\1740 disease</e2>\NN\14061805 ,\,\1740 the\DT\1740 authors\NNS\9610660 investigated\VBD\644583 whether\IN\1740 modulation\NN\7044917 of\IN\1740 SMA\NN\1740 excitability\NN\5653575 may\MD\15209706 result\VB\2633881 in\IN\13603305 a\DT\13649268 modification\NN\191142 of\IN\1740 a\DT\13649268 dyskinetic\JJ\1740 state\NN\8491826 induced\VBN\1627355 by\IN\1740 continuous\JJ\1740 <e1>apomorphine</e1>\NN\3786417 infusion\NN\14589223 .\.\1740
D001058_D004409 NONE Using\VBG\1156834 repetitive\JJ\1740 transcranial\JJ\1740 magnetic\JJ\1740 stimulation\NN\242808 (\-LRB-\1740 rTMS\NNS\1740 )\-RRB-\1740 over\IN\5867413 the\DT\1740 supplementary\NN\1740 motor\NN\3699975 area\NN\8630985 (\-LRB-\1740 SMA\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 Parkinson\NN\1740 disease\NN\14061805 ,\,\1740 the\DT\1740 authors\NNS\9610660 investigated\VBD\644583 whether\IN\1740 modulation\NN\7044917 of\IN\1740 SMA\NN\1740 excitability\NN\5653575 may\MD\15209706 result\VB\2633881 in\IN\13603305 a\DT\13649268 modification\NN\191142 of\IN\1740 a\DT\13649268 <e2>dyskinetic</e2>\JJ\1740 state\NN\8491826 induced\VBN\1627355 by\IN\1740 continuous\JJ\1740 <e1>apomorphine</e1>\NN\3786417 infusion\NN\14589223 .\.\1740
9867728
D005277_D006349 NONE Risk\NN\14541044 for\IN\1740 <e2>valvular\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 among\IN\1740 users\NNS\7846 of\IN\1740 <e1>fenfluramine</e1>\NN\1740 and\CC\1740 dexfenfluramine\NN\1740 who\WP\8299493 underwent\VBD\109660 echocardiography\NN\177127 before\IN\1740 use\NN\407535 of\IN\1740 medication\NN\3247620 .\.\1740
D005277_D006349 NONE BACKGROUND\NN\4921011 :\:\1740 Because\IN\1740 uncontrolled\JJ\1740 echocardiographic\JJ\1740 surveys\NNS\635850 suggested\VBD\1010118 that\IN\1740 up\IN\1740 to\TO\1740 30\CD\13745420 %\NN\1740 to\IN\1740 38\CD\1740 %\NN\1740 of\IN\1740 users\NNS\7846 of\IN\1740 <e1>fenfluramine</e1>\NN\1740 and\CC\1740 dexfenfluramine\NN\1740 had\VBD\2108377 <e2>valvular\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 these\DT\1740 drugs\NNS\14778436 were\VBD\836236 withdrawn\VBN\1835496 from\IN\1740 the\DT\1740 market\NN\407535 .\.\1740
D005277_D006349 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 risk\NN\14541044 for\IN\1740 new\JJ\1740 or\CC\3541091 worsening\VBG\146138 <e2>valvular\JJ\1740 abnormalities</e2>\NNS\14034177 among\IN\1740 users\NNS\7846 of\IN\1740 <e1>fenfluramine</e1>\NN\1740 or\CC\3541091 dexfenfluramine\NN\1740 who\WP\8299493 underwent\VBD\109660 echocardiography\NN\177127 before\IN\1740 they\PRP\1740 began\VBD\941990 to\TO\1740 take\VB\2367363 these\DT\1740 medications.\NN\1740 DESIGN\NN\927261 :\:\1740 Cohort\NN\8184861 study\NN\635850 .\.\1740
D005277_D006349 NONE RESULTS\NNS\34213 :\:\1740 Two\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 4.3\CD\1740 %\NN\1740 [\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.6\CD\1740 %\NN\1740 to\IN\1740 14.8\CD\1740 %\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 receiving\VBG\2210855 <e1>fenfluramine-phentermine</e1>\NN\1740 developed\VBD\1753788 <e2>valvular\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 .\.\1740
D020372_D006349 NONE Risk\NN\14541044 for\IN\1740 <e2>valvular\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 among\IN\1740 users\NNS\7846 of\IN\1740 fenfluramine\NN\1740 and\CC\1740 <e1>dexfenfluramine</e1>\NN\1740 who\WP\8299493 underwent\VBD\109660 echocardiography\NN\177127 before\IN\1740 use\NN\407535 of\IN\1740 medication\NN\3247620 .\.\1740
D020372_D006349 NONE BACKGROUND\NN\4921011 :\:\1740 Because\IN\1740 uncontrolled\JJ\1740 echocardiographic\JJ\1740 surveys\NNS\635850 suggested\VBD\1010118 that\IN\1740 up\IN\1740 to\TO\1740 30\CD\13745420 %\NN\1740 to\IN\1740 38\CD\1740 %\NN\1740 of\IN\1740 users\NNS\7846 of\IN\1740 fenfluramine\NN\1740 and\CC\1740 <e1>dexfenfluramine</e1>\NN\1740 had\VBD\2108377 <e2>valvular\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 these\DT\1740 drugs\NNS\14778436 were\VBD\836236 withdrawn\VBN\1835496 from\IN\1740 the\DT\1740 market\NN\407535 .\.\1740
D020372_D006349 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 risk\NN\14541044 for\IN\1740 new\JJ\1740 or\CC\3541091 worsening\VBG\146138 <e2>valvular\JJ\1740 abnormalities</e2>\NNS\14034177 among\IN\1740 users\NNS\7846 of\IN\1740 fenfluramine\NN\1740 or\CC\3541091 <e1>dexfenfluramine</e1>\NN\1740 who\WP\8299493 underwent\VBD\109660 echocardiography\NN\177127 before\IN\1740 they\PRP\1740 began\VBD\941990 to\TO\1740 take\VB\2367363 these\DT\1740 medications.\NN\1740 DESIGN\NN\927261 :\:\1740 Cohort\NN\8184861 study\NN\635850 .\.\1740
D010645_D006349 NONE RESULTS\NNS\34213 :\:\1740 Two\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 4.3\CD\1740 %\NN\1740 [\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.6\CD\1740 %\NN\1740 to\IN\1740 14.8\CD\1740 %\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 receiving\VBG\2210855 <e1>fenfluramine-phentermine</e1>\NN\1740 developed\VBD\1753788 <e2>valvular\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 .\.\1740
804391
D012293_D011507 CID Light\JJ\1740 chain\NN\8457976 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 cellular\JJ\1740 mediated\JJ\1740 immunity\NN\13920835 in\IN\13603305 <e1>rifampin</e1>\JJ\1740 treated\JJ\1740 patients\NNS\9898892 with\IN\1740 tuberculosis\NN\14127211 .\.\1740
D012293_D011507 CID Light\JJ\1740 chain\NN\8457976 <e2>proteinuria</e2>\NN\14299637 was\VBD\836236 found\VBN\2426171 in\IN\13603305 9\CD\13741022 of\IN\1740 17\CD\13745420 tuberculosis\NN\14127211 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>rifampin</e1>\NN\2716205 .\.\1740
D012293_D014376 NONE Light\JJ\1740 chain\NN\8457976 proteinuria\NN\14299637 and\CC\1740 cellular\JJ\1740 mediated\JJ\1740 immunity\NN\13920835 in\IN\13603305 <e1>rifampin</e1>\JJ\1740 treated\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>tuberculosis</e2>\NN\14127211 .\.\1740
D012293_D014376 NONE Light\JJ\1740 chain\NN\8457976 proteinuria\NN\14299637 was\VBD\836236 found\VBN\2426171 in\IN\13603305 9\CD\13741022 of\IN\1740 17\CD\13745420 <e2>tuberculosis</e2>\NN\14127211 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>rifampin</e1>\NN\2716205 .\.\1740
9523850
D008775_D018771 NONE Value\NN\5856066 of\IN\1740 <e1>methylprednisolone</e1>\NN\1740 in\IN\13603305 prevention\NN\1073995 of\IN\1740 the\DT\1740 <e2>arthralgia-myalgia</e2>\JJ\1740 syndrome\NN\5870365 associated\VBN\628491 with\IN\1740 the\DT\1740 total\JJ\1740 dose\NN\3740161 infusion\NN\14589223 of\IN\1740 iron\NN\14625458 dextran\NN\1740 :\:\1740 a\DT\13649268 double\JJ\1740 blind\JJ\1740 randomized\JJ\1740 trial\NN\786195 .\.\1740
D008775_D018771 NONE These\DT\1740 data\NNS\7951464 demonstrate\VBP\2137132 that\IN\1740 administration\NN\1133281 of\IN\1740 <e1>MP</e1>\NN\10249459 before\IN\1740 and\CC\1740 after\IN\1740 TDI\NN\1740 reduces\VBZ\441445 the\DT\1740 frequency\NN\15286249 and\CC\1740 severity\NN\5036394 of\IN\1740 the\DT\1740 <e2>arthralgia-myalgia</e2>\JJ\1740 syndrome\NN\5870365 .\.\1740
D008775_D063806 NONE Value\NN\5856066 of\IN\1740 <e1>methylprednisolone</e1>\NN\1740 in\IN\13603305 prevention\NN\1073995 of\IN\1740 the\DT\1740 <e2>arthralgia-myalgia</e2>\JJ\1740 syndrome\NN\5870365 associated\VBN\628491 with\IN\1740 the\DT\1740 total\JJ\1740 dose\NN\3740161 infusion\NN\14589223 of\IN\1740 iron\NN\14625458 dextran\NN\1740 :\:\1740 a\DT\13649268 double\JJ\1740 blind\JJ\1740 randomized\JJ\1740 trial\NN\786195 .\.\1740
D008775_D063806 NONE These\DT\1740 data\NNS\7951464 demonstrate\VBP\2137132 that\IN\1740 administration\NN\1133281 of\IN\1740 <e1>MP</e1>\NN\10249459 before\IN\1740 and\CC\1740 after\IN\1740 TDI\NN\1740 reduces\VBZ\441445 the\DT\1740 frequency\NN\15286249 and\CC\1740 severity\NN\5036394 of\IN\1740 the\DT\1740 <e2>arthralgia-myalgia</e2>\JJ\1740 syndrome\NN\5870365 .\.\1740
D007505_D018771 CID Value\NN\5856066 of\IN\1740 methylprednisolone\NN\1740 in\IN\13603305 prevention\NN\1073995 of\IN\1740 the\DT\1740 <e2>arthralgia-myalgia</e2>\JJ\1740 syndrome\NN\5870365 associated\VBN\628491 with\IN\1740 the\DT\1740 total\JJ\1740 dose\NN\3740161 infusion\NN\14589223 of\IN\1740 <e1>iron\NN\14625458 dextran</e1>\NN\1740 :\:\1740 a\DT\13649268 double\JJ\1740 blind\JJ\1740 randomized\JJ\1740 trial\NN\786195 .\.\1740
D007505_D063806 NONE Value\NN\5856066 of\IN\1740 methylprednisolone\NN\1740 in\IN\13603305 prevention\NN\1073995 of\IN\1740 the\DT\1740 <e2>arthralgia-myalgia</e2>\JJ\1740 syndrome\NN\5870365 associated\VBN\628491 with\IN\1740 the\DT\1740 total\JJ\1740 dose\NN\3740161 infusion\NN\14589223 of\IN\1740 <e1>iron\NN\14625458 dextran</e1>\NN\1740 :\:\1740 a\DT\13649268 double\JJ\1740 blind\JJ\1740 randomized\JJ\1740 trial\NN\786195 .\.\1740
2569282
D020927_D009127 NONE <e1>Dexmedetomidine</e1>\NNP\1740 ,\,\1740 acting\VBG\1619354 through\IN\1740 central\JJ\1740 alpha-2\NN\1740 adrenoceptors\NNS\1740 ,\,\1740 prevents\VBZ\1740 opiate-induced\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D020927_D009127 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 authors\NNS\9610660 determined\VBD\1645601 if\IN\1740 treatment\NN\654885 with\IN\1740 <e1>D-MED</e1>\NN\1740 prevents\VBZ\1740 the\DT\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 caused\VBN\1617192 by\IN\1740 high-dose\JJ\1740 alfentanil\JJ\1740 anesthesia\NN\14034177 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D020927_D009127 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>D-MED</e1>\NN\1740 prevented\VBD\1740 alfentanil-induced\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 fashion\NN\4916342 .\.\1740
D020927_D009123 NONE The\DT\1740 highly-selective\JJ\1740 alpha-2\NN\1740 adrenergic\JJ\1740 agonist\NN\9613191 <e1>dexmedetomidine</e1>\NN\1740 (\-LRB-\1740 D-MED\NN\1740 )\-RRB-\1740 is\VBZ\836236 capable\JJ\1740 of\IN\1740 inducing\VBG\1627355 <e2>muscle\NN\5289601 flaccidity</e2>\NN\4938228 and\CC\1740 anesthesia\NN\14034177 in\IN\13603305 rats\NNS\2329401 and\CC\1740 dogs\NNS\2083346 .\.\1740
D020927_D009123 NONE The\DT\1740 highly-selective\JJ\1740 alpha-2\NN\1740 adrenergic\JJ\1740 agonist\NN\9613191 dexmedetomidine\NN\1740 (\-LRB-\1740 <e1>D-MED</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 capable\JJ\1740 of\IN\1740 inducing\VBG\1627355 <e2>muscle\NN\5289601 flaccidity</e2>\NN\4938228 and\CC\1740 anesthesia\NN\14034177 in\IN\13603305 rats\NNS\2329401 and\CC\1740 dogs\NNS\2083346 .\.\1740
D015760_D009127 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 authors\NNS\9610660 determined\VBD\1645601 if\IN\1740 treatment\NN\654885 with\IN\1740 D-MED\NN\1740 prevents\VBZ\1740 the\DT\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 caused\VBN\1617192 by\IN\1740 high-dose\JJ\1740 <e1>alfentanil</e1>\JJ\1740 anesthesia\NN\14034177 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D015760_D009127 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 D-MED\NN\1740 prevented\VBD\1740 <e1>alfentanil-induced</e1>\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 fashion\NN\4916342 .\.\1740
D020927_D018476 NONE The\DT\1740 high-dose\JJ\1740 <e1>D-MED</e1>\NN\1740 animals\NNS\4475 were\VBD\836236 flaccid\JJ\1740 ,\,\1740 <e2>akinetic</e2>\JJ\1740 ,\,\1740 and\CC\1740 lacked\VBD\1740 a\DT\13649268 startle\JJ\1740 response\NN\11410625 during\IN\1740 the\DT\1740 entire\JJ\1740 experimental\JJ\1740 period\NN\13575869 .\.\1740
D020927_D012021 NONE The\DT\1740 high-dose\JJ\1740 <e1>D-MED</e1>\NN\1740 animals\NNS\4475 were\VBD\836236 flaccid\JJ\1740 ,\,\1740 akinetic\JJ\1740 ,\,\1740 and\CC\1740 lacked\VBD\1740 a\DT\13649268 <e2>startle</e2>\JJ\1740 response\NN\11410625 during\IN\1740 the\DT\1740 entire\JJ\1740 experimental\JJ\1740 period\NN\13575869 .\.\1740
12481039
D012964_D012640 NONE Reduced\VBN\441445 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 density\NN\4941325 ,\,\1740 altered\JJ\1740 voltage\NN\11449002 dependence\NN\24720 of\IN\1740 inactivation\NN\13518963 ,\,\1740 and\CC\1740 increased\VBD\169651 susceptibility\NN\13920835 to\TO\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 lacking\VBG\1740 sodium\NN\14625458 channel\NN\6251781 beta\NN\6828818 2-subunits\NNS\1740 .\.\1740
D012964_D012640 NONE Reduced\VBN\441445 sodium\NN\14625458 channel\NN\6251781 density\NN\4941325 ,\,\1740 altered\JJ\1740 voltage\NN\11449002 dependence\NN\24720 of\IN\1740 inactivation\NN\13518963 ,\,\1740 and\CC\1740 increased\VBD\169651 susceptibility\NN\13920835 to\TO\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 lacking\VBG\1740 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 beta\NN\6828818 2-subunits\NNS\1740 .\.\1740
D010862_D012640 CID beta2(-/-\VBN\1740 )\-RRB-\1740 mice\NNS\2329401 displayed\VBD\2137132 increased\VBN\169651 susceptibility\NN\13920835 to\IN\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 as\IN\14622893 indicated\VBN\952524 by\IN\1740 reduced\VBN\441445 latency\NN\15269513 and\CC\1740 threshold\NN\15265518 for\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 seizures\NNS\14081375 ,\,\1740 but\CC\1740 seemed\VBD\2604760 normal\JJ\1740 in\IN\13603305 other\JJ\1740 neurological\JJ\1740 tests\NNS\5798043 .\.\1740
D010862_D012640 CID beta2(-/-\VBN\1740 )\-RRB-\1740 mice\NNS\2329401 displayed\VBD\2137132 increased\VBN\169651 susceptibility\NN\13920835 to\IN\1740 seizures\NNS\14081375 ,\,\1740 as\IN\14622893 indicated\VBN\952524 by\IN\1740 reduced\VBN\441445 latency\NN\15269513 and\CC\1740 threshold\NN\15265518 for\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 but\CC\1740 seemed\VBD\2604760 normal\JJ\1740 in\IN\13603305 other\JJ\1740 neurological\JJ\1740 tests\NNS\5798043 .\.\1740
20195852
D003287_D007674 CID Risk\NN\14541044 of\IN\1740 <e2>nephropathy</e2>\NN\14573196 after\IN\1740 consumption\NN\13440063 of\IN\1740 nonionic\JJ\1740 <e1>contrast\NN\13854649 media</e1>\NNS\3575240 by\IN\1740 children\NNS\9622049 undergoing\VBG\109660 cardiac\JJ\1740 angiography\NN\904623 :\:\1740 a\DT\13649268 prospective\JJ\1740 study\NN\635850 .\.\1740
D003287_D007674 CID Despite\IN\7501545 increasing\VBG\169651 reports\NNS\6470073 on\IN\1740 nonionic\JJ\1740 <e1>contrast\NN\13854649 media-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 (\-LRB-\1740 CIN\NN\1740 )\-RRB-\1740 in\IN\13603305 hospitalized\VBN\2348568 adult\JJ\1740 patients\NNS\9898892 during\IN\1740 cardiac\JJ\1740 procedures\NNS\407535 ,\,\1740 the\DT\1740 studies\NNS\635850 in\IN\13603305 pediatrics\NNS\6043075 are\VBP\836236 limited\VBN\2510337 ,\,\1740 with\IN\1740 even\RB\1740 less\RBR\1740 focus\NN\5704266 on\IN\1740 possible\JJ\1740 predisposing\VBG\680841 factors\NNS\7326557 and\CC\1740 preventive\JJ\1740 measures\NNS\168237 for\IN\1740 patients\NNS\9898892 undergoing\VBG\109660 cardiac\JJ\1740 angiography\NN\904623 .\.\1740
D003287_D007674 CID Despite\IN\7501545 increasing\VBG\169651 reports\NNS\6470073 on\IN\1740 nonionic\JJ\1740 <e1>contrast\NN\13854649 media-induced</e1>\JJ\1740 nephropathy\NN\14573196 (\-LRB-\1740 <e2>CIN</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 hospitalized\VBN\2348568 adult\JJ\1740 patients\NNS\9898892 during\IN\1740 cardiac\JJ\1740 procedures\NNS\407535 ,\,\1740 the\DT\1740 studies\NNS\635850 in\IN\13603305 pediatrics\NNS\6043075 are\VBP\836236 limited\VBN\2510337 ,\,\1740 with\IN\1740 even\RB\1740 less\RBR\1740 focus\NN\5704266 on\IN\1740 possible\JJ\1740 predisposing\VBG\680841 factors\NNS\7326557 and\CC\1740 preventive\JJ\1740 measures\NNS\168237 for\IN\1740 patients\NNS\9898892 undergoing\VBG\109660 cardiac\JJ\1740 angiography\NN\904623 .\.\1740
D003287_D007674 CID This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>CIN</e2>\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 <e1>contrast\NN\13854649 media</e1>\NNS\3575240 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 ,\,\1740 iopromide\NN\1740 and\CC\1740 iohexol\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 cyanosis\NN\14299637 .\.\1740
D003287_D007674 CID This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>CIN</e2>\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 contrast\NN\13854649 media\NNS\3575240 (\-LRB-\1740 <e1>CM</e1>\NN\13649268 )\-RRB-\1740 ,\,\1740 iopromide\NN\1740 and\CC\1740 iohexol\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 cyanosis\NN\14299637 .\.\1740
D003287_D007674 CID This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>CIN</e2>\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 contrast\NN\13854649 media\NNS\3575240 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 ,\,\1740 iopromide\NN\1740 and\CC\1740 iohexol\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 <e1>CM</e1>\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 cyanosis\NN\14299637 .\.\1740
D003287_D007674 CID Whereas\IN\1740 33.3\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 patients\NNS\9898892 with\IN\1740 <e2>CIN</e2>\NN\1740 were\VBD\836236 among\IN\1740 those\DT\1740 who\WP\8299493 received\VBD\2210855 the\DT\1740 proper\JJ\1740 dosage\NN\13576355 of\IN\1740 <e1>CM</e1>\NN\13649268 ,\,\1740 the\DT\1740 percentage\NN\13815742 increased\VBD\169651 to\IN\1740 66.6\CD\1740 %\NN\1740 among\IN\1740 those\DT\1740 who\WP\8299493 received\VBD\2210855 larger\JJR\1740 doses\NNS\3740161 ,\,\1740 with\IN\1740 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 CIN\NN\1740 related\JJ\1740 to\TO\1740 the\DT\1740 different\JJ\1740 dosages\NNS\13576355 of\IN\1740 CM\NN\13649268 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.014\CD\1740 )\-RRB-\1740 .\.\1740
D003287_D007674 CID Whereas\IN\1740 33.3\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 patients\NNS\9898892 with\IN\1740 CIN\NN\1740 were\VBD\836236 among\IN\1740 those\DT\1740 who\WP\8299493 received\VBD\2210855 the\DT\1740 proper\JJ\1740 dosage\NN\13576355 of\IN\1740 <e1>CM</e1>\NN\13649268 ,\,\1740 the\DT\1740 percentage\NN\13815742 increased\VBD\169651 to\IN\1740 66.6\CD\1740 %\NN\1740 among\IN\1740 those\DT\1740 who\WP\8299493 received\VBD\2210855 larger\JJR\1740 doses\NNS\3740161 ,\,\1740 with\IN\1740 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>CIN</e2>\NN\1740 related\JJ\1740 to\TO\1740 the\DT\1740 different\JJ\1740 dosages\NNS\13576355 of\IN\1740 CM\NN\13649268 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.014\CD\1740 )\-RRB-\1740 .\.\1740
D003287_D007674 CID Whereas\IN\1740 33.3\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 patients\NNS\9898892 with\IN\1740 <e2>CIN</e2>\NN\1740 were\VBD\836236 among\IN\1740 those\DT\1740 who\WP\8299493 received\VBD\2210855 the\DT\1740 proper\JJ\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 ,\,\1740 the\DT\1740 percentage\NN\13815742 increased\VBD\169651 to\IN\1740 66.6\CD\1740 %\NN\1740 among\IN\1740 those\DT\1740 who\WP\8299493 received\VBD\2210855 larger\JJR\1740 doses\NNS\3740161 ,\,\1740 with\IN\1740 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 CIN\NN\1740 related\JJ\1740 to\TO\1740 the\DT\1740 different\JJ\1740 dosages\NNS\13576355 of\IN\1740 <e1>CM</e1>\NN\13649268 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.014\CD\1740 )\-RRB-\1740 .\.\1740
D003287_D007674 CID Whereas\IN\1740 33.3\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 patients\NNS\9898892 with\IN\1740 CIN\NN\1740 were\VBD\836236 among\IN\1740 those\DT\1740 who\WP\8299493 received\VBD\2210855 the\DT\1740 proper\JJ\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 ,\,\1740 the\DT\1740 percentage\NN\13815742 increased\VBD\169651 to\IN\1740 66.6\CD\1740 %\NN\1740 among\IN\1740 those\DT\1740 who\WP\8299493 received\VBD\2210855 larger\JJR\1740 doses\NNS\3740161 ,\,\1740 with\IN\1740 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>CIN</e2>\NN\1740 related\JJ\1740 to\TO\1740 the\DT\1740 different\JJ\1740 dosages\NNS\13576355 of\IN\1740 <e1>CM</e1>\NN\13649268 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.014\CD\1740 )\-RRB-\1740 .\.\1740
D003287_D007674 CID The\DT\1740 incidence\NN\13821570 depends\VBZ\2604760 on\IN\1740 dosage\NN\13576355 but\CC\1740 not\RB\1740 on\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 consumed\VBN\1168468 nonionic\JJ\1740 <e1>CM</e1>\NN\13649268 ,\,\1740 nor\CC\1740 on\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 cyanosis\NN\14299637 ,\,\1740 and\CC\1740 although\IN\1740 <e2>CIN</e2>\NN\1740 usually\RB\1740 is\VBZ\836236 reversible\JJ\1740 ,\,\1740 more\JJR\1740 concern\NN\5682950 is\VBZ\836236 needed\VBN\2604760 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 such\PDT\1740 a\DT\13649268 complication\NN\1073995 in\IN\13603305 children\NNS\9622049 .\.\1740
D003287_D003490 NONE This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 CIN\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 <e1>contrast\NN\13854649 media</e1>\NNS\3575240 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 ,\,\1740 iopromide\NN\1740 and\CC\1740 iohexol\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>cyanosis</e2>\NN\14299637 .\.\1740
D003287_D003490 NONE This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 CIN\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 contrast\NN\13854649 media\NNS\3575240 (\-LRB-\1740 <e1>CM</e1>\NN\13649268 )\-RRB-\1740 ,\,\1740 iopromide\NN\1740 and\CC\1740 iohexol\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>cyanosis</e2>\NN\14299637 .\.\1740
D003287_D003490 NONE This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 CIN\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 contrast\NN\13854649 media\NNS\3575240 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 ,\,\1740 iopromide\NN\1740 and\CC\1740 iohexol\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 <e1>CM</e1>\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>cyanosis</e2>\NN\14299637 .\.\1740
D003287_D003490 NONE The\DT\1740 incidence\NN\13821570 depends\VBZ\2604760 on\IN\1740 dosage\NN\13576355 but\CC\1740 not\RB\1740 on\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 consumed\VBN\1168468 nonionic\JJ\1740 <e1>CM</e1>\NN\13649268 ,\,\1740 nor\CC\1740 on\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>cyanosis</e2>\NN\14299637 ,\,\1740 and\CC\1740 although\IN\1740 CIN\NN\1740 usually\RB\1740 is\VBZ\836236 reversible\JJ\1740 ,\,\1740 more\JJR\1740 concern\NN\5682950 is\VBZ\836236 needed\VBN\2604760 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 such\PDT\1740 a\DT\13649268 complication\NN\1073995 in\IN\13603305 children\NNS\9622049 .\.\1740
C038192_D007674 CID This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>CIN</e2>\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 contrast\NN\13854649 media\NNS\3575240 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 ,\,\1740 <e1>iopromide</e1>\NN\1740 and\CC\1740 iohexol\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 cyanosis\NN\14299637 .\.\1740
C038192_D003490 NONE This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 CIN\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 contrast\NN\13854649 media\NNS\3575240 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 ,\,\1740 <e1>iopromide</e1>\NN\1740 and\CC\1740 iohexol\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>cyanosis</e2>\NN\14299637 .\.\1740
D007472_D007674 CID This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>CIN</e2>\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 contrast\NN\13854649 media\NNS\3575240 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 ,\,\1740 iopromide\NN\1740 and\CC\1740 <e1>iohexol</e1>\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 cyanosis\NN\14299637 .\.\1740
D007472_D003490 NONE This\DT\1740 prospective\JJ\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 CIN\NN\1740 for\IN\1740 two\CD\13741022 nonionic\JJ\1740 contrast\NN\13854649 media\NNS\3575240 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 ,\,\1740 iopromide\NN\1740 and\CC\1740 <e1>iohexol</e1>\NN\1740 ,\,\1740 among\IN\1740 80\CD\13745420 patients\NNS\9898892 younger\JJR\1740 than\IN\1740 18\CD\13745420 years\NNS\15144371 and\CC\1740 compared\VBD\644583 the\DT\1740 rates\NNS\13308999 for\IN\1740 this\DT\1740 complication\NN\1073995 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 type\NN\5839024 and\CC\1740 dosage\NN\13576355 of\IN\1740 CM\NN\13649268 and\CC\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>cyanosis</e2>\NN\14299637 .\.\1740
15673851
D016202_D020760 NONE The\DT\1740 activation\NN\13561719 of\IN\1740 spinal\JJ\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 receptors\NNS\5225602 may\MD\15209706 contribute\VB\126264 to\TO\1740 degeneration\NN\29677 of\IN\1740 spinal\JJ\1740 motor\NN\3699975 neurons\NNS\5430628 induced\VBN\1627355 by\IN\1740 neuraxial\JJ\1740 morphine\NN\2707683 after\IN\1740 a\DT\13649268 noninjurious\JJ\1740 interval\NN\33615 of\IN\1740 <e2>spinal\JJ\1740 cord\NN\3670849 ischemia</e2>\NN\14195315 .\.\1740
D016202_D020760 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 opioids\NNS\1740 may\MD\15209706 be\VB\836236 neurotoxic\JJ\1740 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e2>spinal\JJ\1740 cord\NN\3670849 ischemia</e2>\NN\14195315 via\IN\1740 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 activation\NN\13561719 .\.\1740
D009020_D020760 NONE The\DT\1740 activation\NN\13561719 of\IN\1740 spinal\JJ\1740 N-methyl-D-aspartate\NN\1740 receptors\NNS\5225602 may\MD\15209706 contribute\VB\126264 to\TO\1740 degeneration\NN\29677 of\IN\1740 spinal\JJ\1740 motor\NN\3699975 neurons\NNS\5430628 induced\VBN\1627355 by\IN\1740 neuraxial\JJ\1740 <e1>morphine</e1>\NN\2707683 after\IN\1740 a\DT\13649268 noninjurious\JJ\1740 interval\NN\33615 of\IN\1740 <e2>spinal\JJ\1740 cord\NN\3670849 ischemia</e2>\NN\14195315 .\.\1740
D016202_D001157 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 degeneration\NN\29677 of\IN\1740 spinal\JJ\1740 motor\NN\3699975 neurons\NNS\5430628 and\CC\1740 activation\NN\13561719 of\IN\1740 <e1>N-methyl-d-aspartate</e1>\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptors\NNS\5225602 after\IN\1740 neuraxial\JJ\1740 morphine\NN\2707683 following\VBG\1835496 a\DT\13649268 noninjurious\JJ\1740 interval\NN\33615 of\IN\1740 <e2>aortic\JJ\1740 occlusion</e2>\NN\14081375 in\IN\13603305 rats\NNS\2329401 .\.\1740
D016202_D001157 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 degeneration\NN\29677 of\IN\1740 spinal\JJ\1740 motor\NN\3699975 neurons\NNS\5430628 and\CC\1740 activation\NN\13561719 of\IN\1740 N-methyl-d-aspartate\NN\1740 (\-LRB-\1740 <e1>NMDA</e1>\NN\1740 )\-RRB-\1740 receptors\NNS\5225602 after\IN\1740 neuraxial\JJ\1740 morphine\NN\2707683 following\VBG\1835496 a\DT\13649268 noninjurious\JJ\1740 interval\NN\33615 of\IN\1740 <e2>aortic\JJ\1740 occlusion</e2>\NN\14081375 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009020_D001157 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 degeneration\NN\29677 of\IN\1740 spinal\JJ\1740 motor\NN\3699975 neurons\NNS\5430628 and\CC\1740 activation\NN\13561719 of\IN\1740 N-methyl-d-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptors\NNS\5225602 after\IN\1740 neuraxial\JJ\1740 <e1>morphine</e1>\NN\2707683 following\VBG\1835496 a\DT\13649268 noninjurious\JJ\1740 interval\NN\33615 of\IN\1740 <e2>aortic\JJ\1740 occlusion</e2>\NN\14081375 in\IN\13603305 rats\NNS\2329401 .\.\1740
D016291_D020336 NONE Second\RB\1740 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 effect\NN\34213 of\IN\1740 IT\NN\6125041 <e1>MK-801</e1>\NN\1740 (\-LRB-\1740 30\CD\13745420 mug\NN\13756125 )\-RRB-\1740 on\IN\1740 the\DT\1740 histopathologic\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 after\IN\1740 morphine-induced\JJ\1740 <e2>spastic\JJ\1740 paraparesis</e2>\NN\14558599 .\.\1740
D016291_D020336 NONE IT\NNP\6125041 <e1>MK-801</e1>\NN\1740 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 number\NN\5107765 of\IN\1740 dark-stained\JJ\1740 alpha-motoneurons\NNS\1740 after\IN\1740 morphine-induced\JJ\1740 <e2>spastic\JJ\1740 paraparesis</e2>\NN\14558599 compared\VBN\644583 with\IN\1740 the\DT\1740 saline\NN\14849367 group\NN\2137 .\.\1740
D009020_D020336 CID Second\RB\1740 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 effect\NN\34213 of\IN\1740 IT\NN\6125041 MK-801\NN\1740 (\-LRB-\1740 30\CD\13745420 mug\NN\13756125 )\-RRB-\1740 on\IN\1740 the\DT\1740 histopathologic\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 after\IN\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>spastic\JJ\1740 paraparesis</e2>\NN\14558599 .\.\1740
D009020_D020336 CID IT\NNP\6125041 MK-801\NN\1740 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 number\NN\5107765 of\IN\1740 dark-stained\JJ\1740 alpha-motoneurons\NNS\1740 after\IN\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>spastic\JJ\1740 paraparesis</e2>\NN\14558599 compared\VBN\644583 with\IN\1740 the\DT\1740 saline\NN\14849367 group\NN\2137 .\.\1740
D009020_D020336 CID These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 IT\NN\6125041 <e1>morphine</e1>\NN\2707683 induces\VBZ\1627355 <e2>spastic\JJ\1740 paraparesis</e2>\NN\14558599 with\IN\1740 a\DT\13649268 concomitant\JJ\1740 increase\NN\13576355 in\IN\13603305 CSF\NN\1740 glutamate\NN\15010703 ,\,\1740 which\WDT\1740 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 NMDA\NN\1740 receptor\NN\5225602 activation\NN\13561719 .\.\1740
D018698_D020336 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 IT\NN\6125041 morphine\NN\2707683 induces\VBZ\1627355 <e2>spastic\JJ\1740 paraparesis</e2>\NN\14558599 with\IN\1740 a\DT\13649268 concomitant\JJ\1740 increase\NN\13576355 in\IN\13603305 CSF\NN\1740 <e1>glutamate</e1>\NN\15010703 ,\,\1740 which\WDT\1740 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 NMDA\NN\1740 receptor\NN\5225602 activation\NN\13561719 .\.\1740
D016202_D020336 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 IT\NN\6125041 morphine\NN\2707683 induces\VBZ\1627355 <e2>spastic\JJ\1740 paraparesis</e2>\NN\14558599 with\IN\1740 a\DT\13649268 concomitant\JJ\1740 increase\NN\13576355 in\IN\13603305 CSF\NN\1740 glutamate\NN\15010703 ,\,\1740 which\WDT\1740 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 activation\NN\13561719 .\.\1740
D016202_D020258 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 opioids\NNS\1740 may\MD\15209706 be\VB\836236 <e2>neurotoxic</e2>\JJ\1740 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 spinal\JJ\1740 cord\NN\3670849 ischemia\NN\14195315 via\IN\1740 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 activation\NN\13561719 .\.\1740
7647582
D004737_D056486 CID Two\CD\13741022 halogenated\VBN\1740 anesthetics\NNS\3247620 ,\,\1740 <e1>enflurane</e1>\NN\3299929 and\CC\1740 isoflurane\NN\3570838 ,\,\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 allergic-type\JJ\1740 <e2>hepatic\JJ\1740 injury</e2>\NN\14052046 both\CC\1740 alone\RB\1740 and\CC\1740 following\VBG\1835496 previous\JJ\1740 exposure\NN\5042871 to\TO\1740 halothane\NN\3570838 .\.\1740
D004737_D056486 CID This\DT\1740 supports\NNS\407535 and\CC\1740 extends\VBZ\153263 previous\JJ\1740 evidence\NN\5816287 for\IN\1740 a\DT\13649268 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 <e1>enflurane</e1>\NN\3299929 and/or\CC\1740 isoflurane\NN\3570838 could\MD\1740 produce\VB\1617192 a\DT\13649268 hypersensitivity\NN\14531772 condition\NN\24720 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 halothane\NN\3570838 <e2>hepatitis</e2>\NN\14127211 either\CC\1740 alone\RB\1740 or\CC\3541091 subsequent\JJ\1740 to\TO\1740 halothane\NN\3570838 administration\NN\1133281 .\.\1740
D007530_D056486 CID Two\CD\13741022 halogenated\VBN\1740 anesthetics\NNS\3247620 ,\,\1740 enflurane\NN\3299929 and\CC\1740 <e1>isoflurane</e1>\NN\3570838 ,\,\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 allergic-type\JJ\1740 <e2>hepatic\JJ\1740 injury</e2>\NN\14052046 both\CC\1740 alone\RB\1740 and\CC\1740 following\VBG\1835496 previous\JJ\1740 exposure\NN\5042871 to\TO\1740 halothane\NN\3570838 .\.\1740
D007530_D056486 CID This\DT\1740 supports\NNS\407535 and\CC\1740 extends\VBZ\153263 previous\JJ\1740 evidence\NN\5816287 for\IN\1740 a\DT\13649268 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 enflurane\NN\3299929 and/or\CC\1740 <e1>isoflurane</e1>\NN\3570838 could\MD\1740 produce\VB\1617192 a\DT\13649268 hypersensitivity\NN\14531772 condition\NN\24720 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 halothane\NN\3570838 <e2>hepatitis</e2>\NN\14127211 either\CC\1740 alone\RB\1740 or\CC\3541091 subsequent\JJ\1740 to\TO\1740 halothane\NN\3570838 administration\NN\1133281 .\.\1740
D006221_D056486 CID Two\CD\13741022 halogenated\VBN\1740 anesthetics\NNS\3247620 ,\,\1740 enflurane\NN\3299929 and\CC\1740 isoflurane\NN\3570838 ,\,\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 allergic-type\JJ\1740 <e2>hepatic\JJ\1740 injury</e2>\NN\14052046 both\CC\1740 alone\RB\1740 and\CC\1740 following\VBG\1835496 previous\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>halothane</e1>\NN\3570838 .\.\1740
D006221_D056486 CID <e1>Halothane</e1>\NN\3570838 <e2>hepatitis</e2>\NN\14127211 appears\VBZ\2604760 to\TO\1740 involve\VB\2676054 an\DT\6697703 aberrant\JJ\1740 immune\JJ\1740 response\NN\11410625 .\.\1740
D006221_D056486 CID An\DT\6697703 antibody\NN\14728724 response\NN\11410625 to\TO\1740 a\DT\13649268 protein-bound\JJ\1740 biotransformation\NN\1740 product\NN\3076708 (\-LRB-\1740 trifluoroacetyl\NN\1740 adduct\NN\14818238 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 detected\VBN\2163746 on\IN\1740 <e1>halothane</e1>\NN\3570838 <e2>hepatitis</e2>\NN\14127211 patients\NNS\9898892 .\.\1740
D006221_D056486 CID This\DT\1740 supports\NNS\407535 and\CC\1740 extends\VBZ\153263 previous\JJ\1740 evidence\NN\5816287 for\IN\1740 a\DT\13649268 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 enflurane\NN\3299929 and/or\CC\1740 isoflurane\NN\3570838 could\MD\1740 produce\VB\1617192 a\DT\13649268 hypersensitivity\NN\14531772 condition\NN\24720 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 <e1>halothane</e1>\NN\3570838 <e2>hepatitis</e2>\NN\14127211 either\CC\1740 alone\RB\1740 or\CC\3541091 subsequent\JJ\1740 to\TO\1740 halothane\NN\3570838 administration\NN\1133281 .\.\1740
D006221_D056486 CID This\DT\1740 supports\NNS\407535 and\CC\1740 extends\VBZ\153263 previous\JJ\1740 evidence\NN\5816287 for\IN\1740 a\DT\13649268 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 enflurane\NN\3299929 and/or\CC\1740 isoflurane\NN\3570838 could\MD\1740 produce\VB\1617192 a\DT\13649268 hypersensitivity\NN\14531772 condition\NN\24720 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 halothane\NN\3570838 <e2>hepatitis</e2>\NN\14127211 either\CC\1740 alone\RB\1740 or\CC\3541091 subsequent\JJ\1740 to\TO\1740 <e1>halothane</e1>\NN\3570838 administration\NN\1133281 .\.\1740
D014269_D056486 NONE An\DT\6697703 antibody\NN\14728724 response\NN\11410625 to\TO\1740 a\DT\13649268 protein-bound\JJ\1740 biotransformation\NN\1740 product\NN\3076708 (\-LRB-\1740 <e1>trifluoroacetyl</e1>\NN\1740 adduct\NN\14818238 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 detected\VBN\2163746 on\IN\1740 halothane\NN\3570838 <e2>hepatitis</e2>\NN\14127211 patients\NNS\9898892 .\.\1740
D004737_D004342 NONE This\DT\1740 study\NN\635850 was\VBD\836236 performed\VBN\2367363 to\TO\1740 determine\VB\1645601 cross-reactivity\NN\1740 between\IN\1740 <e1>enflurane</e1>\NN\3299929 and\CC\1740 isoflurane\NN\3570838 with\IN\1740 the\DT\1740 <e2>hypersensitivity</e2>\NN\14531772 induced\VBN\1627355 by\IN\1740 halothane\NN\3570838 .\.\1740
D004737_D004342 NONE This\DT\1740 supports\NNS\407535 and\CC\1740 extends\VBZ\153263 previous\JJ\1740 evidence\NN\5816287 for\IN\1740 a\DT\13649268 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 <e1>enflurane</e1>\NN\3299929 and/or\CC\1740 isoflurane\NN\3570838 could\MD\1740 produce\VB\1617192 a\DT\13649268 <e2>hypersensitivity</e2>\NN\14531772 condition\NN\24720 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 halothane\NN\3570838 hepatitis\NN\14127211 either\CC\1740 alone\RB\1740 or\CC\3541091 subsequent\JJ\1740 to\TO\1740 halothane\NN\3570838 administration\NN\1133281 .\.\1740
D007530_D004342 NONE This\DT\1740 study\NN\635850 was\VBD\836236 performed\VBN\2367363 to\TO\1740 determine\VB\1645601 cross-reactivity\NN\1740 between\IN\1740 enflurane\NN\3299929 and\CC\1740 <e1>isoflurane</e1>\NN\3570838 with\IN\1740 the\DT\1740 <e2>hypersensitivity</e2>\NN\14531772 induced\VBN\1627355 by\IN\1740 halothane\NN\3570838 .\.\1740
D007530_D004342 NONE This\DT\1740 supports\NNS\407535 and\CC\1740 extends\VBZ\153263 previous\JJ\1740 evidence\NN\5816287 for\IN\1740 a\DT\13649268 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 enflurane\NN\3299929 and/or\CC\1740 <e1>isoflurane</e1>\NN\3570838 could\MD\1740 produce\VB\1617192 a\DT\13649268 <e2>hypersensitivity</e2>\NN\14531772 condition\NN\24720 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 halothane\NN\3570838 hepatitis\NN\14127211 either\CC\1740 alone\RB\1740 or\CC\3541091 subsequent\JJ\1740 to\TO\1740 halothane\NN\3570838 administration\NN\1133281 .\.\1740
D006221_D004342 NONE This\DT\1740 study\NN\635850 was\VBD\836236 performed\VBN\2367363 to\TO\1740 determine\VB\1645601 cross-reactivity\NN\1740 between\IN\1740 enflurane\NN\3299929 and\CC\1740 isoflurane\NN\3570838 with\IN\1740 the\DT\1740 <e2>hypersensitivity</e2>\NN\14531772 induced\VBN\1627355 by\IN\1740 <e1>halothane</e1>\NN\3570838 .\.\1740
D006221_D004342 NONE This\DT\1740 supports\NNS\407535 and\CC\1740 extends\VBZ\153263 previous\JJ\1740 evidence\NN\5816287 for\IN\1740 a\DT\13649268 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 enflurane\NN\3299929 and/or\CC\1740 isoflurane\NN\3570838 could\MD\1740 produce\VB\1617192 a\DT\13649268 <e2>hypersensitivity</e2>\NN\14531772 condition\NN\24720 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 <e1>halothane</e1>\NN\3570838 hepatitis\NN\14127211 either\CC\1740 alone\RB\1740 or\CC\3541091 subsequent\JJ\1740 to\TO\1740 halothane\NN\3570838 administration\NN\1133281 .\.\1740
D006221_D004342 NONE This\DT\1740 supports\NNS\407535 and\CC\1740 extends\VBZ\153263 previous\JJ\1740 evidence\NN\5816287 for\IN\1740 a\DT\13649268 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 enflurane\NN\3299929 and/or\CC\1740 isoflurane\NN\3570838 could\MD\1740 produce\VB\1617192 a\DT\13649268 <e2>hypersensitivity</e2>\NN\14531772 condition\NN\24720 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 halothane\NN\3570838 hepatitis\NN\14127211 either\CC\1740 alone\RB\1740 or\CC\3541091 subsequent\JJ\1740 to\TO\1740 <e1>halothane</e1>\NN\3570838 administration\NN\1133281 .\.\1740
7059267
D002747_D009901 CID <e1>Chlorpropamide-induced</e1>\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\JJ\1740 .\.\1740
D002747_D009901 CID A\DT\13649268 65-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 adult-onset\JJ\1740 diabetes\NNS\14075199 treated\VBN\2376958 with\IN\1740 <e1>chlorpropamide</e1>\NN\1740 (\-LRB-\1740 Diabenese\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 <e2>toxic\JJ\1740 optic\NN\5299178 neuropathy</e2>\JJ\1740 that\WDT\1740 resolved\VBD\352826 with\IN\1740 discontinuation\NN\209943 of\IN\1740 chlorpropamide\NN\1740 therapy\NN\657604 .\.\1740
D002747_D009901 CID A\DT\13649268 65-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 adult-onset\JJ\1740 diabetes\NNS\14075199 treated\VBN\2376958 with\IN\1740 chlorpropamide\NN\1740 (\-LRB-\1740 <e1>Diabenese</e1>\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 <e2>toxic\JJ\1740 optic\NN\5299178 neuropathy</e2>\JJ\1740 that\WDT\1740 resolved\VBD\352826 with\IN\1740 discontinuation\NN\209943 of\IN\1740 chlorpropamide\NN\1740 therapy\NN\657604 .\.\1740
D002747_D009901 CID A\DT\13649268 65-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 adult-onset\JJ\1740 diabetes\NNS\14075199 treated\VBN\2376958 with\IN\1740 chlorpropamide\NN\1740 (\-LRB-\1740 Diabenese\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 <e2>toxic\JJ\1740 optic\NN\5299178 neuropathy</e2>\JJ\1740 that\WDT\1740 resolved\VBD\352826 with\IN\1740 discontinuation\NN\209943 of\IN\1740 <e1>chlorpropamide</e1>\NN\1740 therapy\NN\657604 .\.\1740
D002747_D003924 NONE A\DT\13649268 65-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>adult-onset\JJ\1740 diabetes</e2>\NNS\14075199 treated\VBN\2376958 with\IN\1740 <e1>chlorpropamide</e1>\NN\1740 (\-LRB-\1740 Diabenese\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 toxic\JJ\1740 optic\NN\5299178 neuropathy\JJ\1740 that\WDT\1740 resolved\VBD\352826 with\IN\1740 discontinuation\NN\209943 of\IN\1740 chlorpropamide\NN\1740 therapy\NN\657604 .\.\1740
D002747_D003924 NONE A\DT\13649268 65-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>adult-onset\JJ\1740 diabetes</e2>\NNS\14075199 treated\VBN\2376958 with\IN\1740 chlorpropamide\NN\1740 (\-LRB-\1740 <e1>Diabenese</e1>\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 toxic\JJ\1740 optic\NN\5299178 neuropathy\JJ\1740 that\WDT\1740 resolved\VBD\352826 with\IN\1740 discontinuation\NN\209943 of\IN\1740 chlorpropamide\NN\1740 therapy\NN\657604 .\.\1740
D002747_D003924 NONE A\DT\13649268 65-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>adult-onset\JJ\1740 diabetes</e2>\NNS\14075199 treated\VBN\2376958 with\IN\1740 chlorpropamide\NN\1740 (\-LRB-\1740 Diabenese\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 toxic\JJ\1740 optic\NN\5299178 neuropathy\JJ\1740 that\WDT\1740 resolved\VBD\352826 with\IN\1740 discontinuation\NN\209943 of\IN\1740 <e1>chlorpropamide</e1>\NN\1740 therapy\NN\657604 .\.\1740
2528969
11208990
D009569_D007674 NONE Association\NN\8008335 of\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 production\NN\30358 and\CC\1740 apoptosis\NN\11486178 in\IN\13603305 a\DT\13649268 model\NN\5888929 of\IN\1740 experimental\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D009569_D009404 NONE We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 role\NN\719494 of\IN\1740 <e1>NO</e1>\NN\7204911 and\CC\1740 its\PRP$\6125041 association\NN\8008335 with\IN\1740 apoptosis\NN\11486178 in\IN\13603305 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D009404 CID We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 role\NN\719494 of\IN\1740 NO\NN\7204911 and\CC\1740 its\PRP$\6125041 association\NN\8008335 with\IN\1740 apoptosis\NN\11486178 in\IN\13603305 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 <e1>adriamycin</e1>\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D009404 CID We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 role\NN\719494 of\IN\1740 NO\NN\7204911 and\CC\1740 its\PRP$\6125041 association\NN\8008335 with\IN\1740 apoptosis\NN\11486178 in\IN\13603305 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 <e1>ADR</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D007674 NONE Rats\NNS\2329401 were\VBD\836236 stratified\VBN\650353 into\IN\1740 control\NN\5190804 groups\NNS\2137 and\CC\1740 <e1>ADR-induced</e1>\JJ\1740 <e2>nephropathy</e2>\JJ\1740 groups\NNS\2137 .\.\1740
D004317_D007674 NONE Urine\NN\14853947 nitrite\JJ\1740 levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 increased\VBN\169651 in\IN\13603305 the\DT\1740 <e2><e1>ADR-nephropathy</e1></e2>\JJ\1740 group\NN\2137 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D004317_D007674 NONE In\IN\13603305 the\DT\1740 IPRK\NN\1740 phenylephrine\NN\2682038 and\CC\1740 acetylcholine\NN\14807558 related\JJ\1740 responses\NNS\11410625 were\VBD\836236 significantly\RB\1740 impaired\JJ\1740 in\IN\13603305 the\DT\1740 <e2><e1>ADR-nephropathy</e1></e2>\JJ\1740 group\NN\2137 .\.\1740
D004317_D007674 NONE However\RB\1740 ,\,\1740 in\IN\13603305 the\DT\1740 <e2><e1>ADR-nephropathy</e1></e2>\JJ\1740 group\NN\2137 ,\,\1740 numerous\JJ\1740 apoptotic\JJ\1740 cells\NNS\3080309 were\VBD\836236 identified\VBN\699815 in\IN\13603305 the\DT\1740 tubulointerstitial\JJ\1740 areas\NNS\8630985 .\.\1740
D004317_C537346 NONE RESULTS\NNS\34213 :\:\1740 Histopathological\JJ\1740 examination\NN\633864 of\IN\1740 the\DT\1740 kidneys\NNS\5333259 of\IN\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 <e1>ADR</e1>\NN\1740 revealed\VBD\2137132 focal\JJ\1740 areas\NNS\8630985 of\IN\1740 <e2>mesangial\JJ\1740 proliferation</e2>\NN\13489037 and\CC\1740 mild\JJ\1740 tubulointerstitial\JJ\1740 inflammation\NN\14299637 .\.\1740
D004317_D009395 NONE RESULTS\NNS\34213 :\:\1740 Histopathological\JJ\1740 examination\NN\633864 of\IN\1740 the\DT\1740 kidneys\NNS\5333259 of\IN\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 <e1>ADR</e1>\NN\1740 revealed\VBD\2137132 focal\JJ\1740 areas\NNS\8630985 of\IN\1740 mesangial\JJ\1740 proliferation\NN\13489037 and\CC\1740 mild\JJ\1740 <e2>tubulointerstitial\JJ\1740 inflammation</e2>\NN\14299637 .\.\1740
D009573_D007674 NONE Urine\NN\14853947 <e1>nitrite</e1>\JJ\1740 levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 increased\VBN\169651 in\IN\13603305 the\DT\1740 <e2>ADR-nephropathy</e2>\JJ\1740 group\NN\2137 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D010656_D007674 NONE In\IN\13603305 the\DT\1740 IPRK\NN\1740 <e1>phenylephrine</e1>\NN\2682038 and\CC\1740 acetylcholine\NN\14807558 related\JJ\1740 responses\NNS\11410625 were\VBD\836236 significantly\RB\1740 impaired\JJ\1740 in\IN\13603305 the\DT\1740 <e2>ADR-nephropathy</e2>\JJ\1740 group\NN\2137 .\.\1740
D000109_D007674 NONE In\IN\13603305 the\DT\1740 IPRK\NN\1740 phenylephrine\NN\2682038 and\CC\1740 <e1>acetylcholine</e1>\NN\14807558 related\JJ\1740 responses\NNS\11410625 were\VBD\836236 significantly\RB\1740 impaired\JJ\1740 in\IN\13603305 the\DT\1740 <e2>ADR-nephropathy</e2>\JJ\1740 group\NN\2137 .\.\1740
D009569_D009401 NONE CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 suggest\VBP\1010118 that\IN\1740 interactions\NNS\37396 between\IN\1740 <e1>NO</e1>\NN\7204911 and\CC\1740 apoptosis\NN\11486178 are\VBP\836236 important\JJ\1740 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 the\DT\1740 ADR-induced\JJ\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D004317_D009401 NONE CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 suggest\VBP\1010118 that\IN\1740 interactions\NNS\37396 between\IN\1740 NO\NN\7204911 and\CC\1740 apoptosis\NN\11486178 are\VBP\836236 important\JJ\1740 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 the\DT\1740 <e1>ADR-induced</e1>\JJ\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
16634859
D000431_D006130 CID This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 utility\NN\8186047 of\IN\1740 biometry\NN\6037298 for\IN\1740 detecting\VBG\2163746 <e1>alcohol-related</e1>\JJ\1740 fetal\JJ\1740 <e2>growth\NN\13526110 impairment</e2>\NN\7296428 .\.\1740
D000431_D006130 CID Any\DT\1740 <e1>alcohol</e1>\NN\7881800 consumption\NN\13440063 postpregnancy\NN\1740 recognition\NN\13932421 among\IN\1740 the\DT\1740 heavy\JJ\1740 drinkers\NNS\9612848 resulted\VBD\2633881 in\IN\13603305 <e2>reduced\VBN\441445 cerebellar\NN\1740 growth</e2>\NN\13526110 as\RB\1740 well\RB\1740 as\IN\14622893 decreased\VBN\169651 cranial\JJ\1740 to\TO\1740 body\NN\19128 growth\NN\13526110 in\IN\13603305 comparison\NN\635850 with\IN\1740 women\NNS\9605289 who\WP\8299493 either\DT\1740 quit\VBD\2383440 drinking\NN\838098 or\CC\3541091 who\WP\8299493 were\VBD\836236 nondrinkers\NNS\7846 .\.\1740
D000431_D006130 CID Any\DT\1740 <e1>alcohol</e1>\NN\7881800 consumption\NN\13440063 postpregnancy\NN\1740 recognition\NN\13932421 among\IN\1740 the\DT\1740 heavy\JJ\1740 drinkers\NNS\9612848 resulted\VBD\2633881 in\IN\13603305 reduced\VBN\441445 cerebellar\NN\1740 growth\NN\13526110 as\RB\1740 well\RB\1740 as\IN\14622893 <e2>decreased\VBN\169651 cranial\JJ\1740 to\TO\1740 body\NN\19128 growth</e2>\NN\13526110 in\IN\13603305 comparison\NN\635850 with\IN\1740 women\NNS\9605289 who\WP\8299493 either\DT\1740 quit\VBD\2383440 drinking\NN\838098 or\CC\3541091 who\WP\8299493 were\VBD\836236 nondrinkers\NNS\7846 .\.\1740
16428827
C004742_D000647 NONE <e1>Daidzein</e1>\NN\1740 activates\VBZ\1641914 choline\NN\15090742 acetyltransferase\NN\1740 from\IN\1740 MC-IXC\NN\1740 cells\NNS\3080309 and\CC\1740 improves\VBZ\126264 drug-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
C004742_D000647 NONE Administration\NN\1133281 of\IN\1740 <e1>daidzein</e1>\NN\1740 (\-LRB-\1740 4.5\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 to\TO\1740 mice\NNS\2329401 was\VBD\836236 shown\VBN\2137132 significantly\RB\1740 to\TO\1740 reverse\VB\109660 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 results\NNS\34213 of\IN\1740 a\DT\13649268 Y-maze\JJ\1740 test\NN\5798043 .\.\1740
C004742_D000647 NONE These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>daidzein</e1>\NN\1740 might\MD\5029706 play\VB\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 acetylcholine\NN\14807558 biosynthesis\NN\13565379 as\IN\14622893 a\DT\13649268 ChAT\NN\7133701 activator\NN\19613 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 also\RB\1740 ameliorates\VBZ\126264 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D002794_D000647 NONE Daidzein\NN\1740 activates\VBZ\1641914 <e1>choline</e1>\NN\15090742 acetyltransferase\NN\1740 from\IN\1740 MC-IXC\NN\1740 cells\NNS\3080309 and\CC\1740 improves\VBZ\126264 drug-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D002794_D000544 NONE The\DT\1740 <e1>choline</e1>\NN\15090742 acetyltransferase\NN\1740 (\-LRB-\1740 ChAT\NN\7133701 )\-RRB-\1740 activator\NN\19613 ,\,\1740 which\WDT\1740 enhances\VBZ\227165 cholinergic\JJ\1740 transmission\NN\121166 via\IN\1740 an\DT\6697703 augmentation\NN\7356676 of\IN\1740 the\DT\1740 enzymatic\JJ\1740 production\NN\30358 of\IN\1740 acetylcholine\NN\14807558 (\-LRB-\1740 ACh\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 AD\NN\7247071 )\-RRB-\1740 .\.\1740
D002794_D000544 NONE The\DT\1740 <e1>choline</e1>\NN\15090742 acetyltransferase\NN\1740 (\-LRB-\1740 ChAT\NN\7133701 )\-RRB-\1740 activator\NN\19613 ,\,\1740 which\WDT\1740 enhances\VBZ\227165 cholinergic\JJ\1740 transmission\NN\121166 via\IN\1740 an\DT\6697703 augmentation\NN\7356676 of\IN\1740 the\DT\1740 enzymatic\JJ\1740 production\NN\30358 of\IN\1740 acetylcholine\NN\14807558 (\-LRB-\1740 ACh\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>AD</e2>\NN\7247071 )\-RRB-\1740 .\.\1740
D000109_D000544 NONE The\DT\1740 choline\NN\15090742 acetyltransferase\NN\1740 (\-LRB-\1740 ChAT\NN\7133701 )\-RRB-\1740 activator\NN\19613 ,\,\1740 which\WDT\1740 enhances\VBZ\227165 cholinergic\JJ\1740 transmission\NN\121166 via\IN\1740 an\DT\6697703 augmentation\NN\7356676 of\IN\1740 the\DT\1740 enzymatic\JJ\1740 production\NN\30358 of\IN\1740 <e1>acetylcholine</e1>\NN\14807558 (\-LRB-\1740 ACh\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 AD\NN\7247071 )\-RRB-\1740 .\.\1740
D000109_D000544 NONE The\DT\1740 choline\NN\15090742 acetyltransferase\NN\1740 (\-LRB-\1740 ChAT\NN\7133701 )\-RRB-\1740 activator\NN\19613 ,\,\1740 which\WDT\1740 enhances\VBZ\227165 cholinergic\JJ\1740 transmission\NN\121166 via\IN\1740 an\DT\6697703 augmentation\NN\7356676 of\IN\1740 the\DT\1740 enzymatic\JJ\1740 production\NN\30358 of\IN\1740 <e1>acetylcholine</e1>\NN\14807558 (\-LRB-\1740 ACh\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>AD</e2>\NN\7247071 )\-RRB-\1740 .\.\1740
D000109_D000544 NONE The\DT\1740 choline\NN\15090742 acetyltransferase\NN\1740 (\-LRB-\1740 ChAT\NN\7133701 )\-RRB-\1740 activator\NN\19613 ,\,\1740 which\WDT\1740 enhances\VBZ\227165 cholinergic\JJ\1740 transmission\NN\121166 via\IN\1740 an\DT\6697703 augmentation\NN\7356676 of\IN\1740 the\DT\1740 enzymatic\JJ\1740 production\NN\30358 of\IN\1740 acetylcholine\NN\14807558 (\-LRB-\1740 <e1>ACh</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 AD\NN\7247071 )\-RRB-\1740 .\.\1740
D000109_D000544 NONE The\DT\1740 choline\NN\15090742 acetyltransferase\NN\1740 (\-LRB-\1740 ChAT\NN\7133701 )\-RRB-\1740 activator\NN\19613 ,\,\1740 which\WDT\1740 enhances\VBZ\227165 cholinergic\JJ\1740 transmission\NN\121166 via\IN\1740 an\DT\6697703 augmentation\NN\7356676 of\IN\1740 the\DT\1740 enzymatic\JJ\1740 production\NN\30358 of\IN\1740 acetylcholine\NN\14807558 (\-LRB-\1740 <e1>ACh</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>AD</e2>\NN\7247071 )\-RRB-\1740 .\.\1740
C004742_D007859 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>daidzein</e1>\NN\1740 from\IN\1740 Pueraria\NNP\11585340 thunbergiana\NN\1740 on\IN\1740 scopolamine-induced\JJ\1740 <e2>impairments\NNS\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 series\NN\8456993 of\IN\1740 in\FW\13603305 vivo\FW\1740 tests\NNS\5798043 .\.\1740
C004742_D008569 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>daidzein</e1>\NN\1740 from\IN\1740 Pueraria\NNP\11585340 thunbergiana\NN\1740 on\IN\1740 scopolamine-induced\JJ\1740 <e2>impairments\NNS\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 series\NN\8456993 of\IN\1740 in\FW\13603305 vivo\FW\1740 tests\NNS\5798043 .\.\1740
D012601_D007859 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 daidzein\NN\1740 from\IN\1740 Pueraria\NNP\11585340 thunbergiana\NN\1740 on\IN\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>impairments\NNS\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 series\NN\8456993 of\IN\1740 in\FW\13603305 vivo\FW\1740 tests\NNS\5798043 .\.\1740
D012601_D008569 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 daidzein\NN\1740 from\IN\1740 Pueraria\NNP\11585340 thunbergiana\NN\1740 on\IN\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>impairments\NNS\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 series\NN\8456993 of\IN\1740 in\FW\13603305 vivo\FW\1740 tests\NNS\5798043 .\.\1740
D012601_D000647 CID Administration\NN\1133281 of\IN\1740 daidzein\NN\1740 (\-LRB-\1740 4.5\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 to\TO\1740 mice\NNS\2329401 was\VBD\836236 shown\VBN\2137132 significantly\RB\1740 to\TO\1740 reverse\VB\109660 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 results\NNS\34213 of\IN\1740 a\DT\13649268 Y-maze\JJ\1740 test\NN\5798043 .\.\1740
D012601_D000647 CID These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 daidzein\NN\1740 might\MD\5029706 play\VB\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 acetylcholine\NN\14807558 biosynthesis\NN\13565379 as\IN\14622893 a\DT\13649268 ChAT\NN\7133701 activator\NN\19613 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 also\RB\1740 ameliorates\VBZ\126264 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D000109_D000647 NONE These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 daidzein\NN\1740 might\MD\5029706 play\VB\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 <e1>acetylcholine</e1>\NN\14807558 biosynthesis\NN\13565379 as\IN\14622893 a\DT\13649268 ChAT\NN\7133701 activator\NN\19613 ,\,\1740 and\CC\1740 that\IN\1740 it\PRP\6125041 also\RB\1740 ameliorates\VBZ\126264 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
7910951
D003473_D010243 NONE Prolonged\JJ\1740 <e2>paralysis</e2>\NN\14557898 due\IN\5174653 to\IN\1740 <e1>nondepolarizing\VBG\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents</e1>\NNS\7347 and\CC\1740 corticosteroids\NNS\14745635 .\.\1740
D000305_D010243 NONE Prolonged\JJ\1740 <e2>paralysis</e2>\NN\14557898 due\IN\5174653 to\IN\1740 nondepolarizing\VBG\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 and\CC\1740 <e1>corticosteroids</e1>\NNS\14745635 .\.\1740
D003473_D018908 CID The\DT\1740 long-term\JJ\1740 use\NN\407535 of\IN\1740 <e1>nondepolarizing\VBG\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents</e1>\NNS\7347 (\-LRB-\1740 ND-NMBA\NN\1740 )\-RRB-\1740 has\VBZ\2108377 recently\RB\1740 been\VBN\836236 implicated\VBN\2677097 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 prolonged\JJ\1740 <e2>muscle\NN\5289601 weakness</e2>\NN\14462666 ,\,\1740 although\IN\1740 the\DT\1740 site\NN\8673395 of\IN\1740 the\DT\1740 lesion\NN\14204950 and\CC\1740 the\DT\1740 predisposing\VBG\680841 factors\NNS\7326557 have\VBP\2108377 been\VBN\836236 unclear\JJ\1740 .\.\1740
D003473_D018908 CID The\DT\1740 long-term\JJ\1740 use\NN\407535 of\IN\1740 nondepolarizing\VBG\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 <e1>ND-NMBA</e1>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 recently\RB\1740 been\VBN\836236 implicated\VBN\2677097 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 prolonged\JJ\1740 <e2>muscle\NN\5289601 weakness</e2>\NN\14462666 ,\,\1740 although\IN\1740 the\DT\1740 site\NN\8673395 of\IN\1740 the\DT\1740 lesion\NN\14204950 and\CC\1740 the\DT\1740 predisposing\VBG\680841 factors\NNS\7326557 have\VBP\2108377 been\VBN\836236 unclear\JJ\1740 .\.\1740
D003473_D018908 CID We\PRP\1740 report\VBP\831651 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 age\NN\4916342 37\CD\1740 -\SYM\1740 52\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 acute\JJ\1740 respiratory\JJ\1740 insufficiency\NN\14462946 who\WP\8299493 developed\VBD\1753788 prolonged\JJ\1740 <e2>weakness</e2>\NN\14462666 following\VBG\1835496 the\DT\1740 discontinuation\NN\209943 of\IN\1740 <e1>ND-NMBAs</e1>\NN\1740 .\.\1740
D003473_D018908 CID The\DT\1740 <e2>weakness</e2>\NN\14462666 in\IN\13603305 these\DT\1740 patients\NNS\9898892 is\VBZ\836236 due\JJ\1740 to\TO\1740 pathology\NN\6045562 at\IN\14622893 both\CC\1740 the\DT\1740 neuromuscular\JJ\1740 junction\NN\8664443 (\-LRB-\1740 most\RBS\1740 likely\RB\1740 due\JJ\1740 to\TO\1740 <e1>ND-NMBA</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 muscle\NN\5289601 (\-LRB-\1740 most\RBS\1740 likely\RB\1740 due\JJ\1740 to\TO\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
D003473_D012131 NONE We\PRP\1740 report\VBP\831651 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 age\NN\4916342 37\CD\1740 -\SYM\1740 52\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 acute\JJ\1740 <e2>respiratory\JJ\1740 insufficiency</e2>\NN\14462946 who\WP\8299493 developed\VBD\1753788 prolonged\JJ\1740 weakness\NN\14462666 following\VBG\1835496 the\DT\1740 discontinuation\NN\209943 of\IN\1740 <e1>ND-NMBAs</e1>\NN\1740 .\.\1740
D014673_D009135 NONE The\DT\1740 serum\NN\5397468 <e1>vecuronium</e1>\NN\1740 level\NN\4916342 measured\VBN\697589 in\IN\13603305 1\CD\13741022 patient\NN\9898892 14\CD\13745420 days\NNS\15140892 after\IN\1740 the\DT\1740 drug\NN\14778436 had\VBD\2108377 been\VBN\836236 discontinued\VBN\2609764 was\VBD\836236 172\CD\1740 ng/mL.\NN\1740 A\NN\13649268 muscle\NN\5289601 biopsy\NN\5739043 in\IN\13603305 this\DT\1740 patient\NN\9898892 showed\VBD\2137132 <e2>loss\NN\13252973 of\IN\1740 thick\JJ\1740 ,\,\1740 myosin\NN\15022171 filaments</e2>\NNS\14866889 .\.\1740
D003473_D009468 CID The\DT\1740 weakness\NN\14462666 in\IN\13603305 these\DT\1740 patients\NNS\9898892 is\VBZ\836236 due\JJ\1740 to\TO\1740 <e2>pathology\NN\6045562 at\IN\14622893 both\CC\1740 the\DT\1740 neuromuscular\JJ\1740 junction</e2>\NN\8664443 (\-LRB-\1740 most\RBS\1740 likely\RB\1740 due\JJ\1740 to\TO\1740 <e1>ND-NMBA</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 muscle\NN\5289601 (\-LRB-\1740 most\RBS\1740 likely\RB\1740 due\JJ\1740 to\TO\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
D000305_D018908 NONE The\DT\1740 <e2>weakness</e2>\NN\14462666 in\IN\13603305 these\DT\1740 patients\NNS\9898892 is\VBZ\836236 due\JJ\1740 to\TO\1740 pathology\NN\6045562 at\IN\14622893 both\CC\1740 the\DT\1740 neuromuscular\JJ\1740 junction\NN\8664443 (\-LRB-\1740 most\RBS\1740 likely\RB\1740 due\JJ\1740 to\TO\1740 ND-NMBA\NN\1740 )\-RRB-\1740 and\CC\1740 muscle\NN\5289601 (\-LRB-\1740 most\RBS\1740 likely\RB\1740 due\JJ\1740 to\TO\1740 <e1>corticosteroids</e1>\NNS\14745635 )\-RRB-\1740 .\.\1740
D000305_D009468 NONE The\DT\1740 weakness\NN\14462666 in\IN\13603305 these\DT\1740 patients\NNS\9898892 is\VBZ\836236 due\JJ\1740 to\TO\1740 <e2>pathology\NN\6045562 at\IN\14622893 both\CC\1740 the\DT\1740 neuromuscular\JJ\1740 junction</e2>\NN\8664443 (\-LRB-\1740 most\RBS\1740 likely\RB\1740 due\JJ\1740 to\TO\1740 ND-NMBA\NN\1740 )\-RRB-\1740 and\CC\1740 muscle\NN\5289601 (\-LRB-\1740 most\RBS\1740 likely\RB\1740 due\JJ\1740 to\TO\1740 <e1>corticosteroids</e1>\NNS\14745635 )\-RRB-\1740 .\.\1740
7437994
6127992
D014700_D017202 NONE Three\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>ischaemic\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 developed\VBD\1753788 profound\JJ\1740 cardiac\JJ\1740 failure\NN\66216 ,\,\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>verapamil</e1>\NN\2938514 and\CC\1740 beta-adrenergic\JJ\1740 blocking\NN\562280 drugs\NNS\14778436 .\.\1740
D014700_D006333 CID Three\CD\13741022 patients\NNS\9898892 with\IN\1740 ischaemic\JJ\1740 heart\NN\5919034 disease\NN\14061805 developed\VBD\1753788 profound\JJ\1740 <e2>cardiac\JJ\1740 failure</e2>\NN\66216 ,\,\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>verapamil</e1>\NN\2938514 and\CC\1740 beta-adrenergic\JJ\1740 blocking\NN\562280 drugs\NNS\14778436 .\.\1740
D014700_D007022 CID Three\CD\13741022 patients\NNS\9898892 with\IN\1740 ischaemic\JJ\1740 heart\NN\5919034 disease\NN\14061805 developed\VBD\1753788 profound\JJ\1740 cardiac\JJ\1740 failure\NN\66216 ,\,\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 bradycardia\NN\14110674 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>verapamil</e1>\NN\2938514 and\CC\1740 beta-adrenergic\JJ\1740 blocking\NN\562280 drugs\NNS\14778436 .\.\1740
D014700_D001919 CID Three\CD\13741022 patients\NNS\9898892 with\IN\1740 ischaemic\JJ\1740 heart\NN\5919034 disease\NN\14061805 developed\VBD\1753788 profound\JJ\1740 cardiac\JJ\1740 failure\NN\66216 ,\,\1740 hypotension\NN\14057371 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>verapamil</e1>\NN\2938514 and\CC\1740 beta-adrenergic\JJ\1740 blocking\NN\562280 drugs\NNS\14778436 .\.\1740
D000319_D017202 NONE Three\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>ischaemic\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 developed\VBD\1753788 profound\JJ\1740 cardiac\JJ\1740 failure\NN\66216 ,\,\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 verapamil\NN\2938514 and\CC\1740 <e1>beta-adrenergic\JJ\1740 blocking\NN\562280 drugs</e1>\NNS\14778436 .\.\1740
D000319_D006333 CID Three\CD\13741022 patients\NNS\9898892 with\IN\1740 ischaemic\JJ\1740 heart\NN\5919034 disease\NN\14061805 developed\VBD\1753788 profound\JJ\1740 <e2>cardiac\JJ\1740 failure</e2>\NN\66216 ,\,\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 verapamil\NN\2938514 and\CC\1740 <e1>beta-adrenergic\JJ\1740 blocking\NN\562280 drugs</e1>\NNS\14778436 .\.\1740
D000319_D007022 CID Three\CD\13741022 patients\NNS\9898892 with\IN\1740 ischaemic\JJ\1740 heart\NN\5919034 disease\NN\14061805 developed\VBD\1753788 profound\JJ\1740 cardiac\JJ\1740 failure\NN\66216 ,\,\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 bradycardia\NN\14110674 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 verapamil\NN\2938514 and\CC\1740 <e1>beta-adrenergic\JJ\1740 blocking\NN\562280 drugs</e1>\NNS\14778436 .\.\1740
D000319_D001919 CID Three\CD\13741022 patients\NNS\9898892 with\IN\1740 ischaemic\JJ\1740 heart\NN\5919034 disease\NN\14061805 developed\VBD\1753788 profound\JJ\1740 cardiac\JJ\1740 failure\NN\66216 ,\,\1740 hypotension\NN\14057371 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 verapamil\NN\2938514 and\CC\1740 <e1>beta-adrenergic\JJ\1740 blocking\NN\562280 drugs</e1>\NNS\14778436 .\.\1740
15764424
D002395_D011605 NONE Quantitative\JJ\1740 drug\NN\14778436 levels\NNS\4916342 in\IN\13603305 stimulant\JJ\1740 <e2>psychosis</e2>\NN\14380140 :\:\1740 relationship\NN\31921 to\TO\1740 symptom\NN\5823932 severity\NN\5036394 ,\,\1740 <e1>catecholamines</e1>\NNS\5407119 and\CC\1740 hyperkinesia\NN\1740 .\.\1740
D002395_D011605 NONE To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 <e1>catecholamines</e1>\NNS\5407119 ,\,\1740 and\CC\1740 <e2>psychotic\JJ\1740 symptoms</e2>\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 psychiatric\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 amphetamine-\NN\1740 or\CC\3541091 cocaine-induced\JJ\1740 psychosis\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 catecholamine\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D002395_D011605 NONE To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 <e1>catecholamines</e1>\NNS\5407119 ,\,\1740 and\CC\1740 psychotic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 psychiatric\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 amphetamine-\NN\1740 or\CC\3541091 cocaine-induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 catecholamine\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D002395_D011605 NONE To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 catecholamines\NNS\5407119 ,\,\1740 and\CC\1740 <e2>psychotic\JJ\1740 symptoms</e2>\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 psychiatric\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 amphetamine-\NN\1740 or\CC\3541091 cocaine-induced\JJ\1740 psychosis\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 <e1>catecholamine</e1>\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D002395_D011605 NONE To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 catecholamines\NNS\5407119 ,\,\1740 and\CC\1740 psychotic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 psychiatric\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 amphetamine-\NN\1740 or\CC\3541091 cocaine-induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 <e1>catecholamine</e1>\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D002395_D006948 NONE Quantitative\JJ\1740 drug\NN\14778436 levels\NNS\4916342 in\IN\13603305 stimulant\JJ\1740 psychosis\NN\14380140 :\:\1740 relationship\NN\31921 to\TO\1740 symptom\NN\5823932 severity\NN\5036394 ,\,\1740 <e1>catecholamines</e1>\NNS\5407119 and\CC\1740 <e2>hyperkinesia</e2>\NN\1740 .\.\1740
D002395_D001523 NONE To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 <e1>catecholamines</e1>\NNS\5407119 ,\,\1740 and\CC\1740 psychotic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 <e2>psychiatric</e2>\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 amphetamine-\NN\1740 or\CC\3541091 cocaine-induced\JJ\1740 psychosis\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 catecholamine\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D002395_D001523 NONE To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 catecholamines\NNS\5407119 ,\,\1740 and\CC\1740 psychotic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 <e2>psychiatric</e2>\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 amphetamine-\NN\1740 or\CC\3541091 cocaine-induced\JJ\1740 psychosis\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 <e1>catecholamine</e1>\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D000661_D011605 CID To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 catecholamines\NNS\5407119 ,\,\1740 and\CC\1740 <e2>psychotic\JJ\1740 symptoms</e2>\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 psychiatric\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 <e1>amphetamine-</e1>\NN\1740 or\CC\3541091 cocaine-induced\JJ\1740 psychosis\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 catecholamine\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D000661_D011605 CID To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 catecholamines\NNS\5407119 ,\,\1740 and\CC\1740 psychotic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 psychiatric\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 <e1>amphetamine-</e1>\NN\1740 or\CC\3541091 cocaine-induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 catecholamine\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D000661_D001523 NONE To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 catecholamines\NNS\5407119 ,\,\1740 and\CC\1740 psychotic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 <e2>psychiatric</e2>\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 <e1>amphetamine-</e1>\NN\1740 or\CC\3541091 cocaine-induced\JJ\1740 psychosis\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 catecholamine\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D003042_D011605 CID To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 catecholamines\NNS\5407119 ,\,\1740 and\CC\1740 <e2>psychotic\JJ\1740 symptoms</e2>\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 psychiatric\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 amphetamine-\NN\1740 or\CC\3541091 <e1>cocaine-induced</e1>\JJ\1740 psychosis\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 catecholamine\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D003042_D011605 CID To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 catecholamines\NNS\5407119 ,\,\1740 and\CC\1740 psychotic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 psychiatric\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 amphetamine-\NN\1740 or\CC\3541091 <e1>cocaine-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 catecholamine\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D003042_D001523 NONE To\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 quantitative\JJ\1740 stimulant\JJ\1740 drug\NN\14778436 levels\NNS\4916342 ,\,\1740 catecholamines\NNS\5407119 ,\,\1740 and\CC\1740 psychotic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 nineteen\CD\13745420 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 <e2>psychiatric</e2>\JJ\1740 emergency\NN\7417644 service\NN\575741 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 amphetamine-\NN\1740 or\CC\3541091 <e1>cocaine-induced</e1>\JJ\1740 psychosis\NN\14380140 were\VBD\836236 interviewed\VBN\964694 ,\,\1740 and\CC\1740 plasma\NN\5398023 and\CC\1740 urine\NN\14853947 were\VBD\836236 collected\VBN\2281093 for\IN\1740 quantitative\JJ\1740 assays\NNS\5733583 of\IN\1740 stimulant\JJ\1740 drug\NN\14778436 and\CC\1740 catecholamine\NN\5407119 metabolite\NN\20090 levels\NNS\4916342 .\.\1740
D008694_D006948 CID <e1>Methamphetamine</e1>\NNP\2704153 or\CC\3541091 amphetamine\NN\3248958 levels\NNS\4916342 were\VBD\836236 related\JJ\1740 to\TO\1740 several\JJ\1740 psychopathology\NN\6136258 scores\NNS\13757724 and\CC\1740 the\DT\1740 global\JJ\1740 <e2>hyperkinesia</e2>\NN\1740 rating\NN\5733583 .\.\1740
D000661_D006948 CID Methamphetamine\NNP\2704153 or\CC\3541091 <e1>amphetamine</e1>\NN\3248958 levels\NNS\4916342 were\VBD\836236 related\JJ\1740 to\TO\1740 several\JJ\1740 psychopathology\NN\6136258 scores\NNS\13757724 and\CC\1740 the\DT\1740 global\JJ\1740 <e2>hyperkinesia</e2>\NN\1740 rating\NN\5733583 .\.\1740
2343592
D015378_D012640 NONE <e2>Seizure</e2>\NN\14081375 activity\NN\30358 with\IN\1740 <e1>imipenem</e1>\NN\1740 therapy\NN\657604 :\:\1740 incidence\NN\13821570 and\CC\1740 risk\NN\14541044 factors\NNS\7326557 .\.\1740
C044650_D020521 NONE Two\CD\13741022 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 either\CC\1740 <e2>cerebral\JJ\1740 vascular\JJ\1740 accident</e2>\NN\7314427 (\-LRB-\1740 CVA\NN\14081375 )\-RRB-\1740 or\CC\3541091 head\NN\5225090 trauma\NN\14052046 and\CC\1740 no\DT\7204911 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 disease\NN\14061805 developed\VBD\1753788 seizures\NNS\14081375 while\IN\15122231 receiving\VBG\2210855 maximum\NN\13653902 doses\NNS\3740161 of\IN\1740 <e1>imipenem/cilastatin</e1>\NN\1740 .\.\1740
C044650_D020521 NONE Two\CD\13741022 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 either\CC\1740 cerebral\JJ\1740 vascular\JJ\1740 accident\NN\7314427 (\-LRB-\1740 <e2>CVA</e2>\NN\14081375 )\-RRB-\1740 or\CC\3541091 head\NN\5225090 trauma\NN\14052046 and\CC\1740 no\DT\7204911 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 disease\NN\14061805 developed\VBD\1753788 seizures\NNS\14081375 while\IN\15122231 receiving\VBG\2210855 maximum\NN\13653902 doses\NNS\3740161 of\IN\1740 <e1>imipenem/cilastatin</e1>\NN\1740 .\.\1740
C044650_D006259 NONE Two\CD\13741022 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 either\CC\1740 cerebral\JJ\1740 vascular\JJ\1740 accident\NN\7314427 (\-LRB-\1740 CVA\NN\14081375 )\-RRB-\1740 or\CC\3541091 <e2>head\NN\5225090 trauma</e2>\NN\14052046 and\CC\1740 no\DT\7204911 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 disease\NN\14061805 developed\VBD\1753788 seizures\NNS\14081375 while\IN\15122231 receiving\VBG\2210855 maximum\NN\13653902 doses\NNS\3740161 of\IN\1740 <e1>imipenem/cilastatin</e1>\NN\1740 .\.\1740
C044650_D007674 NONE Two\CD\13741022 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 either\CC\1740 cerebral\JJ\1740 vascular\JJ\1740 accident\NN\7314427 (\-LRB-\1740 CVA\NN\14081375 )\-RRB-\1740 or\CC\3541091 head\NN\5225090 trauma\NN\14052046 and\CC\1740 no\DT\7204911 evidence\NN\5816287 of\IN\1740 <e2>renal\JJ\1740 disease</e2>\NN\14061805 developed\VBD\1753788 seizures\NNS\14081375 while\IN\15122231 receiving\VBG\2210855 maximum\NN\13653902 doses\NNS\3740161 of\IN\1740 <e1>imipenem/cilastatin</e1>\NN\1740 .\.\1740
C044650_D012640 CID Two\CD\13741022 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 either\CC\1740 cerebral\JJ\1740 vascular\JJ\1740 accident\NN\7314427 (\-LRB-\1740 CVA\NN\14081375 )\-RRB-\1740 or\CC\3541091 head\NN\5225090 trauma\NN\14052046 and\CC\1740 no\DT\7204911 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 disease\NN\14061805 developed\VBD\1753788 <e2>seizures</e2>\NNS\14081375 while\IN\15122231 receiving\VBG\2210855 maximum\NN\13653902 doses\NNS\3740161 of\IN\1740 <e1>imipenem/cilastatin</e1>\NN\1740 .\.\1740
D010672_D012640 NONE All\DT\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 controlled\VBN\2422663 with\IN\1740 therapeutic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>phenytoin</e1>\NN\3550533 .\.\1740
D047090_D012640 NONE Both\DT\1740 patients\NNS\9898892 had\VBD\2108377 received\VBN\2210855 maximum\NN\13653902 doses\NNS\3740161 of\IN\1740 other\JJ\1740 <e1>beta-lactam</e1>\JJ\1740 antibiotics\NNS\2716205 without\IN\1740 evidence\NN\5816287 of\IN\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 .\.\1740
18161408
D002996_D009203 CID <e2>Myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 pregnancy\NN\14034177 associated\VBN\628491 with\IN\1740 <e1>clomiphene\NN\3329880 citrate</e1>\NN\14850483 for\IN\1740 ovulation\NN\13526110 induction\NN\7450842 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D002996_D009203 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 documenting\VBG\1000214 a\DT\13649268 possible\JJ\1740 association\NN\8008335 between\IN\1740 <e1>CC</e1>\NN\13616054 and\CC\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D002996_D013923 CID <e2>Thromboembolism</e2>\NN\14100769 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 but\CC\1740 life-threatening\JJ\1740 complication\NN\1073995 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 ovulation\NN\13526110 induction\NN\7450842 with\IN\1740 <e1>CC</e1>\NN\13616054 .\.\1740
D002996_D002637 NONE CASE\NN\7283608 :\:\1740 A\DT\13649268 33-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 a\DT\13649268 5-week\JJ\1740 gestation\NN\15116532 had\VBD\2108377 recently\RB\1740 received\VBN\2210855 <e1>CC</e1>\NN\13616054 for\IN\1740 ovulation\NN\13526110 induction\NN\7450842 and\CC\1740 presented\VBN\2137132 with\IN\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D002996_D013927 NONE <e2>Thrombosis</e2>\NN\14100769 might\MD\5029706 be\VB\836236 a\DT\13649268 rare\JJ\1740 but\CC\1740 hazardous\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>CC</e1>\NN\13616054 .\.\1740
16960342
D019259_D006509 NONE Sustained\JJ\1740 clinical\JJ\1740 improvement\NN\7359599 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 decompensated\JJ\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus-related\JJ\1740 cirrhosis\NN\14116321 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>lamivudine</e1>\NN\3834836 monotherapy\NN\1740 .\.\1740
D019259_D005355 NONE Sustained\JJ\1740 clinical\JJ\1740 improvement\NN\7359599 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 decompensated\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 virus-related\JJ\1740 <e2>cirrhosis</e2>\NN\14116321 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>lamivudine</e1>\NN\3834836 monotherapy\NN\1740 .\.\1740
D019259_D005355 NONE The\DT\1740 administration\NN\1133281 of\IN\1740 <e1>lamivudine</e1>\NN\3834836 to\TO\1740 patients\NNS\9898892 with\IN\1740 HBV-related\JJ\1740 <e2>cirrhosis</e2>\NN\14116321 ,\,\1740 like\IN\5839024 our\PRP$\1740 present\JJ\1740 case\NN\7283608 ,\,\1740 should\MD\1740 be\VB\836236 considered\VBN\689344 as\IN\14622893 an\DT\6697703 initial\JJ\1740 medical\JJ\1740 therapeutic\JJ\1740 option\NN\6480506 ,\,\1740 especially\RB\1740 in\IN\13603305 countries\NNS\8359949 where\WRB\1740 liver\NN\5298729 transplantation\NN\671351 is\VBZ\836236 not\RB\1740 reliably\RB\1740 available\JJ\1740 .\.\1740
3300918
D008784_D014652 CID A\DT\13649268 rare\JJ\1740 case\NN\7283608 of\IN\1740 morbid\JJ\1740 <e2>vasospasm</e2>\NN\1740 ,\,\1740 together\RB\1740 with\IN\1740 striking\JJ\1740 angiographic\JJ\1740 findings\NNS\7951464 ,\,\1740 is\VBZ\836236 described\VBN\1001294 secondary\JJ\1740 to\TO\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 <e1>methysergide</e1>\NN\1740 by\IN\1740 a\DT\13649268 48-year-old\JJ\1740 woman\NN\9605289 .\.\1740
D004876_D005734 NONE A\DT\13649268 discussion\NN\6252138 of\IN\1740 the\DT\1740 history\NN\15120823 of\IN\1740 <e1>ergot</e1>\NN\14276936 includes\VBZ\690614 its\PRP$\6125041 original\JJ\1740 discovery\NN\30358 ,\,\1740 the\DT\1740 epidemics\NNS\7435273 of\IN\1740 <e2>gangrene</e2>\NN\14204950 that\IN\1740 it\PRP\6125041 has\VBZ\2108377 caused\VBN\1617192 through\IN\1740 the\DT\1740 ages\NNS\4916342 and\CC\1740 its\PRP$\6125041 past\NN\28270 and\CC\1740 present\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 migraine\NN\14326607 headache\NN\5829480 .\.\1740
D004876_D008881 CID A\DT\13649268 discussion\NN\6252138 of\IN\1740 the\DT\1740 history\NN\15120823 of\IN\1740 <e1>ergot</e1>\NN\14276936 includes\VBZ\690614 its\PRP$\6125041 original\JJ\1740 discovery\NN\30358 ,\,\1740 the\DT\1740 epidemics\NNS\7435273 of\IN\1740 gangrene\NN\14204950 that\IN\1740 it\PRP\6125041 has\VBZ\2108377 caused\VBN\1617192 through\IN\1740 the\DT\1740 ages\NNS\4916342 and\CC\1740 its\PRP$\6125041 past\NN\28270 and\CC\1740 present\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 <e2>migraine\NN\14326607 headache</e2>\NN\5829480 .\.\1740
D004876_D008881 CID Despite\IN\7501545 the\DT\1740 advent\NN\48225 of\IN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 and\CC\1740 beta-adrenergic\JJ\1740 antagonists\NNS\7846 ,\,\1740 <e1>ergot</e1>\NN\14276936 preparations\NNS\407535 continue\VBP\2367363 to\TO\1740 play\VB\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 <e2>migraine</e2>\NN\14326607 therapy\NN\657604 ,\,\1740 so\IN\6868043 that\IN\1740 the\DT\1740 danger\NN\13920835 of\IN\1740 St.\NNP\1740 Anthony\NNP\1740 's\POS\1740 fire\JJ\1740 persists\NNS\1740 .\.\1740
D002118_D008881 NONE Despite\IN\7501545 the\DT\1740 advent\NN\48225 of\IN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 and\CC\1740 beta-adrenergic\JJ\1740 antagonists\NNS\7846 ,\,\1740 ergot\NN\14276936 preparations\NNS\407535 continue\VBP\2367363 to\TO\1740 play\VB\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 <e2>migraine</e2>\NN\14326607 therapy\NN\657604 ,\,\1740 so\IN\6868043 that\IN\1740 the\DT\1740 danger\NN\13920835 of\IN\1740 St.\NNP\1740 Anthony\NNP\1740 's\POS\1740 fire\JJ\1740 persists\NNS\1740 .\.\1740
D002118_D004881 NONE Despite\IN\7501545 the\DT\1740 advent\NN\48225 of\IN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 and\CC\1740 beta-adrenergic\JJ\1740 antagonists\NNS\7846 ,\,\1740 ergot\NN\14276936 preparations\NNS\407535 continue\VBP\2367363 to\TO\1740 play\VB\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 migraine\NN\14326607 therapy\NN\657604 ,\,\1740 so\IN\6868043 that\IN\1740 the\DT\1740 danger\NN\13920835 of\IN\1740 <e2>St.\NNP\1740 Anthony\NNP\1740 's\POS\1740 fire</e2>\JJ\1740 persists\NNS\1740 .\.\1740
D004876_D004881 NONE Despite\IN\7501545 the\DT\1740 advent\NN\48225 of\IN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 and\CC\1740 beta-adrenergic\JJ\1740 antagonists\NNS\7846 ,\,\1740 <e1>ergot</e1>\NN\14276936 preparations\NNS\407535 continue\VBP\2367363 to\TO\1740 play\VB\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 migraine\NN\14326607 therapy\NN\657604 ,\,\1740 so\IN\6868043 that\IN\1740 the\DT\1740 danger\NN\13920835 of\IN\1740 <e2>St.\NNP\1740 Anthony\NNP\1740 's\POS\1740 fire</e2>\JJ\1740 persists\NNS\1740 .\.\1740
19642243
C096918_D058186 NONE <e2>Acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 patients\NNS\9898892 with\IN\1740 AIDS\NN\13974317 on\IN\1740 <e1>tenofovir</e1>\NN\1740 while\IN\15122231 receiving\VBG\2210855 prolonged\JJ\1740 vancomycin\NN\2716866 course\NN\883297 for\IN\1740 osteomyelitis\NN\14351321 .\.\1740
C096918_D000163 NONE Acute\JJ\1740 renal\JJ\1740 failure\NN\66216 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>AIDS</e2>\NN\13974317 on\IN\1740 <e1>tenofovir</e1>\NN\1740 while\IN\15122231 receiving\VBG\2210855 prolonged\JJ\1740 vancomycin\NN\2716866 course\NN\883297 for\IN\1740 osteomyelitis\NN\14351321 .\.\1740
C096918_D010019 NONE Acute\JJ\1740 renal\JJ\1740 failure\NN\66216 in\IN\13603305 patients\NNS\9898892 with\IN\1740 AIDS\NN\13974317 on\IN\1740 <e1>tenofovir</e1>\NN\1740 while\IN\15122231 receiving\VBG\2210855 prolonged\JJ\1740 vancomycin\NN\2716866 course\NN\883297 for\IN\1740 <e2>osteomyelitis</e2>\NN\14351321 .\.\1740
D014640_D058186 CID <e2>Acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 patients\NNS\9898892 with\IN\1740 AIDS\NN\13974317 on\IN\1740 tenofovir\NN\1740 while\IN\15122231 receiving\VBG\2210855 prolonged\JJ\1740 <e1>vancomycin</e1>\NN\2716866 course\NN\883297 for\IN\1740 osteomyelitis\NN\14351321 .\.\1740
D014640_D000163 NONE Acute\JJ\1740 renal\JJ\1740 failure\NN\66216 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>AIDS</e2>\NN\13974317 on\IN\1740 tenofovir\NN\1740 while\IN\15122231 receiving\VBG\2210855 prolonged\JJ\1740 <e1>vancomycin</e1>\NN\2716866 course\NN\883297 for\IN\1740 osteomyelitis\NN\14351321 .\.\1740
D014640_D010019 NONE Acute\JJ\1740 renal\JJ\1740 failure\NN\66216 in\IN\13603305 patients\NNS\9898892 with\IN\1740 AIDS\NN\13974317 on\IN\1740 tenofovir\NN\1740 while\IN\15122231 receiving\VBG\2210855 prolonged\JJ\1740 <e1>vancomycin</e1>\NN\2716866 course\NN\883297 for\IN\1740 <e2>osteomyelitis</e2>\NN\14351321 .\.\1740
D014640_D051437 NONE <e2>Renal\JJ\1740 failure</e2>\NN\66216 developed\VBD\1753788 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 course\NN\883297 of\IN\1740 <e1>vancomycin</e1>\NN\2716866 therapy\NN\657604 in\IN\13603305 2\CD\13741022 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 tenofovir\NN\1740 disoproxil\NN\1740 fumarate\VBP\1740 as\IN\14622893 part\NN\31921 of\IN\1740 an\DT\6697703 antiretroviral\JJ\1740 regimen\NN\5898568 .\.\1740
D014640_D051437 NONE Clinicians\NNS\10462860 should\MD\1740 be\VB\836236 aware\JJ\1740 that\IN\1740 tenofovir\NN\1740 may\MD\15209706 raise\VB\153263 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 during\IN\1740 prolonged\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>vancomycin</e1>\NN\2716866 .\.\1740
C418563_D051437 NONE <e2>Renal\JJ\1740 failure</e2>\NN\66216 developed\VBD\1753788 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 course\NN\883297 of\IN\1740 vancomycin\NN\2716866 therapy\NN\657604 in\IN\13603305 2\CD\13741022 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 <e1>tenofovir\NN\1740 disoproxil\NN\1740 fumarate</e1>\VBP\1740 as\IN\14622893 part\NN\31921 of\IN\1740 an\DT\6697703 antiretroviral\JJ\1740 regimen\NN\5898568 .\.\1740
C096918_D005198 NONE <e1>Tenofovir</e1>\NNP\1740 has\VBZ\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>Fanconi\NN\1740 syndrome</e2>\NN\5870365 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 because\IN\1740 of\IN\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 the\DT\1740 proximal\JJ\1740 renal\JJ\1740 tubule\NN\5246511 .\.\1740
C096918_D051437 NONE <e1>Tenofovir</e1>\NNP\1740 has\VBZ\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 Fanconi\NN\1740 syndrome\NN\5870365 and\CC\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 because\IN\1740 of\IN\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 the\DT\1740 proximal\JJ\1740 renal\JJ\1740 tubule\NN\5246511 .\.\1740
C096918_D051437 NONE Clinicians\NNS\10462860 should\MD\1740 be\VB\836236 aware\JJ\1740 that\IN\1740 <e1>tenofovir</e1>\NN\1740 may\MD\15209706 raise\VB\153263 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 during\IN\1740 prolonged\JJ\1740 administration\NN\1133281 of\IN\1740 vancomycin\NN\2716866 .\.\1740
D014640_D007674 NONE <e1>Vancomycin</e1>\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 is\VBZ\836236 infrequent\JJ\1740 but\CC\1740 may\MD\15209706 result\VB\2633881 from\IN\1740 coadministration\NN\1740 with\IN\1740 a\DT\13649268 nephrotoxic\JJ\1740 agent\NN\7347 .\.\1740
D014640_D007674 NONE <e1>Vancomycin</e1>\NN\2716866 nephrotoxicity\NN\1740 is\VBZ\836236 infrequent\JJ\1740 but\CC\1740 may\MD\15209706 result\VB\2633881 from\IN\1740 coadministration\NN\1740 with\IN\1740 a\DT\13649268 <e2>nephrotoxic</e2>\JJ\1740 agent\NN\7347 .\.\1740
6454943
D002216_D011507 NONE Effect\NN\34213 of\IN\1740 <e1>captopril</e1>\NN\2673637 on\IN\1740 pre-existing\JJ\1740 and\CC\1740 aminonucleoside-induced\JJ\1740 <e2>proteinuria</e2>\NN\14299637 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 .\.\1740
D002216_D011507 NONE <e2>Proteinuria</e2>\NN\14299637 is\VBZ\836236 a\DT\13649268 side\JJ\1740 effect\NN\34213 of\IN\1740 <e1>captopril</e1>\NN\2673637 treatment\NN\654885 in\IN\13603305 hypertensive\JJ\1740 patients\NNS\9898892 .\.\1740
D002216_D011507 NONE Oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>captopril</e1>\NN\2673637 at\IN\14622893 100\CD\13745420 mg/kg\NN\1740 for\IN\1740 14\CD\13745420 days\NNS\15140892 failed\VBD\1798936 to\TO\1740 aggravate\NN\1740 <e2>proteinuria</e2>\NN\14299637 pre-existing\NN\1740 in\IN\13603305 SHR\NN\1740 .\.\1740
D002216_D011507 NONE Also\RB\1740 ,\,\1740 <e1>captopril</e1>\NN\2673637 treatment\NN\654885 failed\VBD\1798936 to\TO\1740 potentiate\VB\229605 or\CC\3541091 facilitate\VB\2547586 development\NN\248977 of\IN\1740 massive\JJ\1740 <e2>proteinuria</e2>\NN\14299637 invoked\VBN\1617192 by\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 in\IN\13603305 SHR\NN\1740 .\.\1740
D002216_D006973 NONE Effect\NN\34213 of\IN\1740 <e1>captopril</e1>\NN\2673637 on\IN\1740 pre-existing\JJ\1740 and\CC\1740 aminonucleoside-induced\JJ\1740 proteinuria\NN\14299637 in\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D002216_D006973 NONE Proteinuria\NN\14299637 is\VBZ\836236 a\DT\13649268 side\JJ\1740 effect\NN\34213 of\IN\1740 <e1>captopril</e1>\NN\2673637 treatment\NN\654885 in\IN\13603305 <e2>hypertensive</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D011692_D011507 CID Effect\NN\34213 of\IN\1740 captopril\NN\2673637 on\IN\1740 pre-existing\JJ\1740 and\CC\1740 <e1>aminonucleoside-induced</e1>\JJ\1740 <e2>proteinuria</e2>\NN\14299637 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 .\.\1740
D011692_D011507 CID Also\RB\1740 ,\,\1740 captopril\NN\2673637 treatment\NN\654885 failed\VBD\1798936 to\TO\1740 potentiate\VB\229605 or\CC\3541091 facilitate\VB\2547586 development\NN\248977 of\IN\1740 massive\JJ\1740 <e2>proteinuria</e2>\NN\14299637 invoked\VBN\1617192 by\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 in\IN\13603305 SHR\NN\1740 .\.\1740
D011692_D006973 NONE Effect\NN\34213 of\IN\1740 captopril\NN\2673637 on\IN\1740 pre-existing\JJ\1740 and\CC\1740 <e1>aminonucleoside-induced</e1>\JJ\1740 proteinuria\NN\14299637 in\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D002216_D007674 NONE The\DT\1740 possibility\NN\5944958 of\IN\1740 reproducing\VBG\1621555 the\DT\1740 same\JJ\1740 <e2>renal\JJ\1740 abnormality</e2>\NN\14034177 with\IN\1740 <e1>captopril</e1>\NN\2673637 was\VBD\836236 examined\VBN\789138 in\IN\13603305 SHR\NN\1740 .\.\1740
10328196
D020123_D064420 NONE Systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 following\VBG\1835496 administration\NN\1133281 of\IN\1740 <e1>sirolimus</e1>\NN\1740 (\-LRB-\1740 formerly\RB\1740 rapamycin\NN\1740 )\-RRB-\1740 for\IN\1740 psoriasis\NN\14219661 :\:\1740 association\NN\8008335 of\IN\1740 capillary\JJ\1740 leak\NN\9304465 syndrome\NN\5870365 with\IN\1740 apoptosis\NN\11486178 of\IN\1740 lesional\JJ\1740 lymphocytes\NNS\5449959 .\.\1740
D020123_D064420 NONE Systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 following\VBG\1835496 administration\NN\1133281 of\IN\1740 sirolimus\NN\1740 (\-LRB-\1740 formerly\RB\1740 <e1>rapamycin</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 psoriasis\NN\14219661 :\:\1740 association\NN\8008335 of\IN\1740 capillary\JJ\1740 leak\NN\9304465 syndrome\NN\5870365 with\IN\1740 apoptosis\NN\11486178 of\IN\1740 lesional\JJ\1740 lymphocytes\NNS\5449959 .\.\1740
D020123_D011565 NONE Systemic\JJ\1740 toxicity\NN\13576101 following\VBG\1835496 administration\NN\1133281 of\IN\1740 <e1>sirolimus</e1>\NN\1740 (\-LRB-\1740 formerly\RB\1740 rapamycin\NN\1740 )\-RRB-\1740 for\IN\1740 <e2>psoriasis</e2>\NN\14219661 :\:\1740 association\NN\8008335 of\IN\1740 capillary\JJ\1740 leak\NN\9304465 syndrome\NN\5870365 with\IN\1740 apoptosis\NN\11486178 of\IN\1740 lesional\JJ\1740 lymphocytes\NNS\5449959 .\.\1740
D020123_D011565 NONE Systemic\JJ\1740 toxicity\NN\13576101 following\VBG\1835496 administration\NN\1133281 of\IN\1740 sirolimus\NN\1740 (\-LRB-\1740 formerly\RB\1740 <e1>rapamycin</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 <e2>psoriasis</e2>\NN\14219661 :\:\1740 association\NN\8008335 of\IN\1740 capillary\JJ\1740 leak\NN\9304465 syndrome\NN\5870365 with\IN\1740 apoptosis\NN\11486178 of\IN\1740 lesional\JJ\1740 lymphocytes\NNS\5449959 .\.\1740
D020123_D011565 NONE After\IN\1740 2\CD\13741022 individuals\NNS\7347 with\IN\1740 <e2>psoriasis</e2>\NN\14219661 developed\VBD\1753788 a\DT\13649268 capillary\JJ\1740 leak\NN\9304465 syndrome\NN\5870365 following\VBG\1835496 treatment\NN\654885 with\IN\1740 oral\JJ\1740 <e1>sirolimus</e1>\NN\1740 lesional\JJ\1740 skin\NN\5237755 cells\NNS\3080309 and\CC\1740 activated\VBN\1641914 peripheral\JJ\1740 blood\NN\5397468 cells\NNS\3080309 were\VBD\836236 analyzed\VBN\78760 for\IN\1740 induction\NN\7450842 of\IN\1740 apoptosis\NN\11486178 .\.\1740
D020123_D011565 NONE OBSERVATIONS\NN\996969 :\:\1740 A\DT\13649268 keratome\NN\1740 skin\NN\5237755 specimen\NN\5820620 from\IN\1740 1\CD\13741022 patient\NN\9898892 with\IN\1740 <e1>sirolimus-induced</e1>\JJ\1740 capillary\JJ\1740 leak\NN\9304465 syndrome\NN\5870365 had\VBD\2108377 a\DT\13649268 2.3-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 percentage\NN\13815742 of\IN\1740 apoptotic\JJ\1740 cells\NNS\3080309 (\-LRB-\1740 to\TO\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 an\DT\6697703 unaffected\JJ\1740 sirolimus-treated\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>psoriasis</e2>\NN\14219661 (\-LRB-\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D020123_D011565 NONE OBSERVATIONS\NN\996969 :\:\1740 A\DT\13649268 keratome\NN\1740 skin\NN\5237755 specimen\NN\5820620 from\IN\1740 1\CD\13741022 patient\NN\9898892 with\IN\1740 sirolimus-induced\JJ\1740 capillary\JJ\1740 leak\NN\9304465 syndrome\NN\5870365 had\VBD\2108377 a\DT\13649268 2.3-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 percentage\NN\13815742 of\IN\1740 apoptotic\JJ\1740 cells\NNS\3080309 (\-LRB-\1740 to\TO\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 an\DT\6697703 unaffected\JJ\1740 <e1>sirolimus-treated</e1>\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>psoriasis</e2>\NN\14219661 (\-LRB-\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D020123_D011565 NONE Activated\VBN\1641914 peripheral\JJ\1740 blood\NN\5397468 T\NN\14999913 cells\NNS\3080309 from\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>psoriasis</e2>\NN\14219661 tended\VBD\2604760 to\TO\1740 exhibit\VB\2632167 greater\JJR\1740 spontaneous\JJ\1740 or\CC\3541091 dexamethasone-induced\JJ\1740 apoptosis\NN\11486178 than\IN\1740 did\VBD\1640855 normal\JJ\1740 T\NN\14999913 cells\NNS\3080309 ,\,\1740 particularly\RB\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 <e1>sirolimus</e1>\NN\1740 .\.\1740
D020123_D019559 CID Systemic\JJ\1740 toxicity\NN\13576101 following\VBG\1835496 administration\NN\1133281 of\IN\1740 <e1>sirolimus</e1>\NN\1740 (\-LRB-\1740 formerly\RB\1740 rapamycin\NN\1740 )\-RRB-\1740 for\IN\1740 psoriasis\NN\14219661 :\:\1740 association\NN\8008335 of\IN\1740 <e2>capillary\JJ\1740 leak\NN\9304465 syndrome</e2>\NN\5870365 with\IN\1740 apoptosis\NN\11486178 of\IN\1740 lesional\JJ\1740 lymphocytes\NNS\5449959 .\.\1740
D020123_D019559 CID Systemic\JJ\1740 toxicity\NN\13576101 following\VBG\1835496 administration\NN\1133281 of\IN\1740 sirolimus\NN\1740 (\-LRB-\1740 formerly\RB\1740 <e1>rapamycin</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 psoriasis\NN\14219661 :\:\1740 association\NN\8008335 of\IN\1740 <e2>capillary\JJ\1740 leak\NN\9304465 syndrome</e2>\NN\5870365 with\IN\1740 apoptosis\NN\11486178 of\IN\1740 lesional\JJ\1740 lymphocytes\NNS\5449959 .\.\1740
D020123_D019559 CID After\IN\1740 2\CD\13741022 individuals\NNS\7347 with\IN\1740 psoriasis\NN\14219661 developed\VBD\1753788 a\DT\13649268 <e2>capillary\JJ\1740 leak\NN\9304465 syndrome</e2>\NN\5870365 following\VBG\1835496 treatment\NN\654885 with\IN\1740 oral\JJ\1740 <e1>sirolimus</e1>\NN\1740 lesional\JJ\1740 skin\NN\5237755 cells\NNS\3080309 and\CC\1740 activated\VBN\1641914 peripheral\JJ\1740 blood\NN\5397468 cells\NNS\3080309 were\VBD\836236 analyzed\VBN\78760 for\IN\1740 induction\NN\7450842 of\IN\1740 apoptosis\NN\11486178 .\.\1740
D020123_D019559 CID OBSERVATIONS\NN\996969 :\:\1740 A\DT\13649268 keratome\NN\1740 skin\NN\5237755 specimen\NN\5820620 from\IN\1740 1\CD\13741022 patient\NN\9898892 with\IN\1740 <e1>sirolimus-induced</e1>\JJ\1740 <e2>capillary\JJ\1740 leak\NN\9304465 syndrome</e2>\NN\5870365 had\VBD\2108377 a\DT\13649268 2.3-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 percentage\NN\13815742 of\IN\1740 apoptotic\JJ\1740 cells\NNS\3080309 (\-LRB-\1740 to\TO\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 an\DT\6697703 unaffected\JJ\1740 sirolimus-treated\JJ\1740 patient\NN\9898892 with\IN\1740 psoriasis\NN\14219661 (\-LRB-\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D020123_D019559 CID OBSERVATIONS\NN\996969 :\:\1740 A\DT\13649268 keratome\NN\1740 skin\NN\5237755 specimen\NN\5820620 from\IN\1740 1\CD\13741022 patient\NN\9898892 with\IN\1740 sirolimus-induced\JJ\1740 <e2>capillary\JJ\1740 leak\NN\9304465 syndrome</e2>\NN\5870365 had\VBD\2108377 a\DT\13649268 2.3-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 percentage\NN\13815742 of\IN\1740 apoptotic\JJ\1740 cells\NNS\3080309 (\-LRB-\1740 to\TO\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 an\DT\6697703 unaffected\JJ\1740 <e1>sirolimus-treated</e1>\JJ\1740 patient\NN\9898892 with\IN\1740 psoriasis\NN\14219661 (\-LRB-\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D020123_D019559 CID CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>sirolimus</e1>\NN\1740 include\VBP\690614 fever\NN\14299637 ,\,\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 <e2>capillary\JJ\1740 leak\NN\9304465 syndrome</e2>\NN\5870365 .\.\1740
D003907_D011565 NONE Activated\VBN\1641914 peripheral\JJ\1740 blood\NN\5397468 T\NN\14999913 cells\NNS\3080309 from\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>psoriasis</e2>\NN\14219661 tended\VBD\2604760 to\TO\1740 exhibit\VB\2632167 greater\JJR\1740 spontaneous\JJ\1740 or\CC\3541091 <e1>dexamethasone-induced</e1>\JJ\1740 apoptosis\NN\11486178 than\IN\1740 did\VBD\1640855 normal\JJ\1740 T\NN\14999913 cells\NNS\3080309 ,\,\1740 particularly\RB\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 sirolimus\NN\1740 .\.\1740
D020123_D005334 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>sirolimus</e1>\NN\1740 include\VBP\690614 <e2>fever</e2>\NN\14299637 ,\,\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 capillary\JJ\1740 leak\NN\9304465 syndrome\NN\5870365 .\.\1740
D020123_D000740 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>sirolimus</e1>\NN\1740 include\VBP\690614 fever\NN\14299637 ,\,\1740 <e2>anemia</e2>\NN\14189204 ,\,\1740 and\CC\1740 capillary\JJ\1740 leak\NN\9304465 syndrome\NN\5870365 .\.\1740
2716967
D007649_D002375 CID <e2>Catalepsy</e2>\NNP\14023236 induced\VBN\1627355 by\IN\1740 combinations\NNS\7951464 of\IN\1740 <e1>ketamine</e1>\NN\3054098 and\CC\1740 morphine\NN\2707683 :\:\1740 potentiation\NN\13564910 ,\,\1740 antagonism\NN\24720 ,\,\1740 tolerance\NN\5032565 and\CC\1740 cross-tolerance\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D007649_D002375 CID Previous\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 both\CC\1740 <e1>ketamine</e1>\NN\3054098 and\CC\1740 morphine\NN\2707683 induced\JJ\1740 analgesia\NN\14034177 and\CC\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D007649_D002375 CID Pre-treatment\JJ\1740 with\IN\1740 <e1>ketamine</e1>\NN\3054098 produced\VBD\1617192 cross-tolerance\NN\1740 to\TO\1740 morphine\NN\2707683 ,\,\1740 whereas\IN\1740 pretreatment\NN\1740 with\IN\1740 morphine\NN\2707683 did\VBD\1640855 not\RB\1740 induce\VB\1627355 cross-tolerance\NN\1740 to\TO\1740 ketamine\VB\1740 but\CC\1740 rather\RB\1740 augmented\VBD\153263 the\DT\1740 <e2>cataleptic</e2>\JJ\1740 response\NN\11410625 ;\:\1740 this\DT\1740 augmentation\NN\7356676 was\VBD\836236 attributed\VBN\670261 to\TO\1740 residual\JJ\1740 morphine\NN\2707683 in\IN\13603305 the\DT\1740 brain\NN\5462674 .\.\1740
D007649_D002375 CID Pre-treatment\JJ\1740 with\IN\1740 ketamine\NN\3054098 produced\VBD\1617192 cross-tolerance\NN\1740 to\TO\1740 morphine\NN\2707683 ,\,\1740 whereas\IN\1740 pretreatment\NN\1740 with\IN\1740 morphine\NN\2707683 did\VBD\1640855 not\RB\1740 induce\VB\1627355 cross-tolerance\NN\1740 to\TO\1740 <e1>ketamine</e1>\VB\1740 but\CC\1740 rather\RB\1740 augmented\VBD\153263 the\DT\1740 <e2>cataleptic</e2>\JJ\1740 response\NN\11410625 ;\:\1740 this\DT\1740 augmentation\NN\7356676 was\VBD\836236 attributed\VBN\670261 to\TO\1740 residual\JJ\1740 morphine\NN\2707683 in\IN\13603305 the\DT\1740 brain\NN\5462674 .\.\1740
D009020_D002375 CID <e2>Catalepsy</e2>\NNP\14023236 induced\VBN\1627355 by\IN\1740 combinations\NNS\7951464 of\IN\1740 ketamine\NN\3054098 and\CC\1740 <e1>morphine</e1>\NN\2707683 :\:\1740 potentiation\NN\13564910 ,\,\1740 antagonism\NN\24720 ,\,\1740 tolerance\NN\5032565 and\CC\1740 cross-tolerance\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D009020_D002375 CID Previous\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 both\CC\1740 ketamine\NN\3054098 and\CC\1740 <e1>morphine</e1>\NN\2707683 induced\JJ\1740 analgesia\NN\14034177 and\CC\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D009020_D002375 CID Pre-treatment\JJ\1740 with\IN\1740 ketamine\NN\3054098 produced\VBD\1617192 cross-tolerance\NN\1740 to\TO\1740 <e1>morphine</e1>\NN\2707683 ,\,\1740 whereas\IN\1740 pretreatment\NN\1740 with\IN\1740 morphine\NN\2707683 did\VBD\1640855 not\RB\1740 induce\VB\1627355 cross-tolerance\NN\1740 to\TO\1740 ketamine\VB\1740 but\CC\1740 rather\RB\1740 augmented\VBD\153263 the\DT\1740 <e2>cataleptic</e2>\JJ\1740 response\NN\11410625 ;\:\1740 this\DT\1740 augmentation\NN\7356676 was\VBD\836236 attributed\VBN\670261 to\TO\1740 residual\JJ\1740 morphine\NN\2707683 in\IN\13603305 the\DT\1740 brain\NN\5462674 .\.\1740
D009020_D002375 CID Pre-treatment\JJ\1740 with\IN\1740 ketamine\NN\3054098 produced\VBD\1617192 cross-tolerance\NN\1740 to\TO\1740 morphine\NN\2707683 ,\,\1740 whereas\IN\1740 pretreatment\NN\1740 with\IN\1740 <e1>morphine</e1>\NN\2707683 did\VBD\1640855 not\RB\1740 induce\VB\1627355 cross-tolerance\NN\1740 to\TO\1740 ketamine\VB\1740 but\CC\1740 rather\RB\1740 augmented\VBD\153263 the\DT\1740 <e2>cataleptic</e2>\JJ\1740 response\NN\11410625 ;\:\1740 this\DT\1740 augmentation\NN\7356676 was\VBD\836236 attributed\VBN\670261 to\TO\1740 residual\JJ\1740 morphine\NN\2707683 in\IN\13603305 the\DT\1740 brain\NN\5462674 .\.\1740
D009020_D002375 CID Pre-treatment\JJ\1740 with\IN\1740 ketamine\NN\3054098 produced\VBD\1617192 cross-tolerance\NN\1740 to\TO\1740 morphine\NN\2707683 ,\,\1740 whereas\IN\1740 pretreatment\NN\1740 with\IN\1740 morphine\NN\2707683 did\VBD\1640855 not\RB\1740 induce\VB\1627355 cross-tolerance\NN\1740 to\TO\1740 ketamine\VB\1740 but\CC\1740 rather\RB\1740 augmented\VBD\153263 the\DT\1740 <e2>cataleptic</e2>\JJ\1740 response\NN\11410625 ;\:\1740 this\DT\1740 augmentation\NN\7356676 was\VBD\836236 attributed\VBN\670261 to\TO\1740 residual\JJ\1740 <e1>morphine</e1>\NN\2707683 in\IN\13603305 the\DT\1740 brain\NN\5462674 .\.\1740
D007649_D000699 NONE Previous\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 both\CC\1740 <e1>ketamine</e1>\NN\3054098 and\CC\1740 morphine\NN\2707683 induced\JJ\1740 <e2>analgesia</e2>\NN\14034177 and\CC\1740 catalepsy\NN\14023236 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D009020_D000699 NONE Previous\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 both\CC\1740 ketamine\NN\3054098 and\CC\1740 <e1>morphine</e1>\NN\2707683 induced\JJ\1740 <e2>analgesia</e2>\NN\14034177 and\CC\1740 catalepsy\NN\14023236 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D007649_D009127 NONE Latency\NN\15269513 to\TO\1740 the\DT\1740 loss\NN\13252973 of\IN\1740 righting\VBG\126264 reflex\JJ\1740 ,\,\1740 <e2>rigidity</e2>\NN\5023233 and\CC\1740 behavior\NN\407535 on\IN\1740 recovery\NN\7357388 ,\,\1740 reflected\VBD\923793 the\DT\1740 relative\JJ\1740 predominance\NN\14441825 of\IN\1740 <e1>ketamine</e1>\NN\3054098 or\CC\3541091 morphine\NN\2707683 in\IN\13603305 each\DT\1740 combination\NN\7951464 .\.\1740
D009020_D009127 NONE Latency\NN\15269513 to\TO\1740 the\DT\1740 loss\NN\13252973 of\IN\1740 righting\VBG\126264 reflex\JJ\1740 ,\,\1740 <e2>rigidity</e2>\NN\5023233 and\CC\1740 behavior\NN\407535 on\IN\1740 recovery\NN\7357388 ,\,\1740 reflected\VBD\923793 the\DT\1740 relative\JJ\1740 predominance\NN\14441825 of\IN\1740 ketamine\NN\3054098 or\CC\3541091 <e1>morphine</e1>\NN\2707683 in\IN\13603305 each\DT\1740 combination\NN\7951464 .\.\1740
D009270_D002375 NONE <e1>Naloxone</e1>\NN\3808977 inhibited\VBD\2510337 the\DT\1740 induced\VBN\1627355 <e2>cataleptic</e2>\JJ\1740 effects\NNS\13245626 .\.\1740
D009270_D002375 NONE While\IN\15122231 the\DT\1740 mutual\JJ\1740 potentiation\NN\13564910 ,\,\1740 antagonism\NN\24720 and\CC\1740 tolerance\NN\5032565 suggest\VBP\1010118 common\JJ\1740 mechanisms\NNS\13446390 for\IN\1740 the\DT\1740 induced\VBN\1627355 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 differences\NNS\4723816 in\IN\13603305 latency\NN\15269513 ,\,\1740 rigidity\NN\5023233 and\CC\1740 behavior\NN\407535 ,\,\1740 asymmetry\NN\5062748 of\IN\1740 cross-tolerance\NN\1740 and\CC\1740 a\DT\13649268 widely-different\JJ\1740 ID50\NN\1740 for\IN\1740 <e1>naloxone</e1>\NN\3808977 would\MD\1740 argue\VB\772967 against\IN\1740 an\DT\6697703 action\NN\30358 at\IN\14622893 a\DT\13649268 single\JJ\1740 opioid\JJ\1740 site\NN\8673395 .\.\1740
D009270_D009127 NONE While\IN\15122231 the\DT\1740 mutual\JJ\1740 potentiation\NN\13564910 ,\,\1740 antagonism\NN\24720 and\CC\1740 tolerance\NN\5032565 suggest\VBP\1010118 common\JJ\1740 mechanisms\NNS\13446390 for\IN\1740 the\DT\1740 induced\VBN\1627355 catalepsy\NN\14023236 ,\,\1740 differences\NNS\4723816 in\IN\13603305 latency\NN\15269513 ,\,\1740 <e2>rigidity</e2>\NN\5023233 and\CC\1740 behavior\NN\407535 ,\,\1740 asymmetry\NN\5062748 of\IN\1740 cross-tolerance\NN\1740 and\CC\1740 a\DT\13649268 widely-different\JJ\1740 ID50\NN\1740 for\IN\1740 <e1>naloxone</e1>\NN\3808977 would\MD\1740 argue\VB\772967 against\IN\1740 an\DT\6697703 action\NN\30358 at\IN\14622893 a\DT\13649268 single\JJ\1740 opioid\JJ\1740 site\NN\8673395 .\.\1740
11861791
D011064_D006333 NONE Activation\NN\13561719 of\IN\1740 <e1>poly(ADP-ribose\NN\1740 )</e1>\-RRB-\1740 polymerase\NN\14732946 contributes\VBZ\126264 to\TO\1740 development\NN\248977 of\IN\1740 doxorubicin-induced\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D004317_D006333 CID Activation\NN\13561719 of\IN\1740 poly(ADP-ribose\NN\1740 )\-RRB-\1740 polymerase\NN\14732946 contributes\VBZ\126264 to\TO\1740 development\NN\248977 of\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D004317_D066126 NONE Increased\VBN\169651 oxidative\JJ\1740 stress\NN\7083732 is\VBZ\836236 a\DT\13649268 major\JJ\1740 factor\NN\7326557 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 widely\RB\1740 used\VBN\1156834 antitumor\NN\1740 anthracycline\NN\1740 antibiotic\NN\2716205 .\.\1740
D004317_D066126 NONE Increased\VBN\169651 oxidative\JJ\1740 stress\NN\7083732 is\VBZ\836236 a\DT\13649268 major\JJ\1740 factor\NN\7326557 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DOX</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 widely\RB\1740 used\VBN\1156834 antitumor\NN\1740 anthracycline\NN\1740 antibiotic\NN\2716205 .\.\1740
D004317_D066126 NONE Thus\RB\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 PARP\NN\1740 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 <e1>DOX-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 NONE Thus\RB\1740 ,\,\1740 PARP\NN\1740 activation\NN\13561719 contributes\VBZ\126264 to\TO\1740 the\DT\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 <e1>DOX</e1>\NN\1740 .\.\1740
D018943_D066126 NONE Increased\VBN\169651 oxidative\JJ\1740 stress\NN\7083732 is\VBZ\836236 a\DT\13649268 major\JJ\1740 factor\NN\7326557 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 widely\RB\1740 used\VBN\1156834 antitumor\NN\1740 <e1>anthracycline</e1>\NN\1740 antibiotic\NN\2716205 .\.\1740
C434926_D006331 NONE Using\VBG\1156834 a\DT\13649268 dual\JJ\1740 approach\NN\940842 of\IN\1740 PARP-1\NN\1740 suppression\NN\13489037 ,\,\1740 by\IN\1740 genetic\JJ\1740 deletion\NN\13508333 or\CC\3541091 pharmacological\JJ\1740 inhibition\NN\1068773 with\IN\1740 the\DT\1740 phenanthridinone\NN\1740 PARP\NN\1740 inhibitor\NN\20090 <e1>PJ34</e1>\NN\1740 ,\,\1740 we\PRP\1740 now\RB\1740 demonstrate\VBP\2137132 the\DT\1740 role\NN\719494 of\IN\1740 PARP\NN\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 induced\VBN\1627355 by\IN\1740 DOX\NN\1740 .\.\1740
C434926_D006331 NONE Treatment\NN\654885 with\IN\1740 a\DT\13649268 <e1>PJ34</e1>\NN\1740 significantly\RB\1740 improved\VBD\126264 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 increased\VBD\169651 the\DT\1740 survival\NN\13961642 of\IN\1740 the\DT\1740 animals\NNS\4475 .\.\1740
D004317_D006331 NONE Using\VBG\1156834 a\DT\13649268 dual\JJ\1740 approach\NN\940842 of\IN\1740 PARP-1\NN\1740 suppression\NN\13489037 ,\,\1740 by\IN\1740 genetic\JJ\1740 deletion\NN\13508333 or\CC\3541091 pharmacological\JJ\1740 inhibition\NN\1068773 with\IN\1740 the\DT\1740 phenanthridinone\NN\1740 PARP\NN\1740 inhibitor\NN\20090 PJ34\NN\1740 ,\,\1740 we\PRP\1740 now\RB\1740 demonstrate\VBP\2137132 the\DT\1740 role\NN\719494 of\IN\1740 PARP\NN\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 induced\VBN\1627355 by\IN\1740 <e1>DOX</e1>\NN\1740 .\.\1740
D004317_D005117 NONE PARP\NN\1740 inhibitors\NNS\20090 may\MD\15209706 exert\VB\1158872 protective\JJ\1740 effects\NNS\13245626 against\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 severe\JJ\1740 <e2>cardiac\JJ\1740 complications</e2>\NNS\1073995 associated\VBN\628491 with\IN\1740 the\DT\1740 <e1>DOX</e1>\NN\1740 treatment\NN\654885 .\.\1740
12109865
3131282
C009166_D063646 NONE <e2>Co-carcinogenic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>retinyl\NN\1740 acetate</e1>\NN\15010703 on\IN\1740 forestomach\NN\1740 carcinogenesis\NN\1740 of\IN\1740 male\JJ\1740 F344\NN\1740 rats\NNS\2329401 induced\VBN\1627355 with\IN\1740 butylated\VBN\182406 hydroxyanisole\NN\1740 .\.\1740
C009166_D013274 NONE Co-carcinogenic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>retinyl\NN\1740 acetate</e1>\NN\15010703 on\IN\1740 <e2>forestomach\NN\1740 carcinogenesis</e2>\NN\1740 of\IN\1740 male\JJ\1740 F344\NN\1740 rats\NNS\2329401 induced\VBN\1627355 with\IN\1740 butylated\VBN\182406 hydroxyanisole\NN\1740 .\.\1740
C009166_D013274 NONE The\DT\1740 potential\JJ\1740 modifying\NN\1740 effect\NN\34213 of\IN\1740 <e1>retinyl\NN\1740 acetate</e1>\NN\15010703 (\-LRB-\1740 RA\NN\14625458 )\-RRB-\1740 on\IN\1740 butylated\VBN\182406 hydroxyanisole\NN\1740 (BHA)-induced\CD\1740 rat\NN\2329401 <e2>forestomach\NN\1740 tumorigenesis</e2>\NN\1740 was\VBD\836236 examined\VBN\789138 .\.\1740
C009166_D013274 NONE The\DT\1740 potential\JJ\1740 modifying\NN\1740 effect\NN\34213 of\IN\1740 retinyl\NN\1740 acetate\NN\15010703 (\-LRB-\1740 <e1>RA</e1>\NN\14625458 )\-RRB-\1740 on\IN\1740 butylated\VBN\182406 hydroxyanisole\NN\1740 (BHA)-induced\CD\1740 rat\NN\2329401 <e2>forestomach\NN\1740 tumorigenesis</e2>\NN\1740 was\VBD\836236 examined\VBN\789138 .\.\1740
C009166_D013274 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 <e1>RA</e1>\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>forestomach\NN\1740 tumors</e2>\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
C009166_D013274 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>forestomach\NN\1740 tumors</e2>\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 <e1>RA-free</e1>\NN\1740 water\NN\14618834 .\.\1740
C009166_D013274 NONE These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>RA</e1>\NN\14625458 acted\VBD\1619354 as\IN\14622893 a\DT\13649268 co-carcinogen\NN\1740 in\IN\13603305 the\DT\1740 BHA\NN\1740 <e2>forestomach\NN\1740 carcinogenesis</e2>\NN\1740 of\IN\1740 the\DT\1740 rat\NN\2329401 .\.\1740
D002083_D063646 NONE <e2>Co-carcinogenic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 retinyl\NN\1740 acetate\NN\15010703 on\IN\1740 forestomach\NN\1740 carcinogenesis\NN\1740 of\IN\1740 male\JJ\1740 F344\NN\1740 rats\NNS\2329401 induced\VBN\1627355 with\IN\1740 <e1>butylated\VBN\182406 hydroxyanisole</e1>\NN\1740 .\.\1740
D002083_D013274 CID Co-carcinogenic\JJ\1740 effect\NN\34213 of\IN\1740 retinyl\NN\1740 acetate\NN\15010703 on\IN\1740 <e2>forestomach\NN\1740 carcinogenesis</e2>\NN\1740 of\IN\1740 male\JJ\1740 F344\NN\1740 rats\NNS\2329401 induced\VBN\1627355 with\IN\1740 <e1>butylated\VBN\182406 hydroxyanisole</e1>\NN\1740 .\.\1740
D002083_D013274 CID The\DT\1740 potential\JJ\1740 modifying\NN\1740 effect\NN\34213 of\IN\1740 retinyl\NN\1740 acetate\NN\15010703 (\-LRB-\1740 RA\NN\14625458 )\-RRB-\1740 on\IN\1740 <e1>butylated\VBN\182406 hydroxyanisole</e1>\NN\1740 (BHA)-induced\CD\1740 rat\NN\2329401 <e2>forestomach\NN\1740 tumorigenesis</e2>\NN\1740 was\VBD\836236 examined\VBN\789138 .\.\1740
D002083_D013274 CID The\DT\1740 potential\JJ\1740 modifying\NN\1740 effect\NN\34213 of\IN\1740 retinyl\NN\1740 acetate\NN\15010703 (\-LRB-\1740 RA\NN\14625458 )\-RRB-\1740 on\IN\1740 butylated\VBN\182406 hydroxyanisole\NN\1740 <e1>(BHA)-induced</e1>\CD\1740 rat\NN\2329401 <e2>forestomach\NN\1740 tumorigenesis</e2>\NN\1740 was\VBD\836236 examined\VBN\789138 .\.\1740
D002083_D013274 CID In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 <e1>BHA</e1>\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>forestomach\NN\1740 tumors</e2>\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
D002083_D013274 CID These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 RA\NN\14625458 acted\VBD\1619354 as\IN\14622893 a\DT\13649268 co-carcinogen\NN\1740 in\IN\13603305 the\DT\1740 <e1>BHA</e1>\NN\1740 <e2>forestomach\NN\1740 carcinogenesis</e2>\NN\1740 of\IN\1740 the\DT\1740 rat\NN\2329401 .\.\1740
D002083_D010212 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 <e1>BHA</e1>\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 <e2>squamous\JJ\1740 cell\NN\3080309 papilloma</e2>\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
D002083_D002277 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 <e1>BHA</e1>\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 <e2>carcinoma</e2>\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
D002083_D002277 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 <e1>BHA</e1>\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 <e2>carcinoma</e2>\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
D002083_D002277 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 <e1>BHA</e1>\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 <e2>carcinoma</e2>\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
C009166_D010212 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 <e1>RA</e1>\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 <e2>squamous\JJ\1740 cell\NN\3080309 papilloma</e2>\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
C009166_D010212 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 <e2>squamous\JJ\1740 cell\NN\3080309 papilloma</e2>\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 <e1>RA-free</e1>\NN\1740 water\NN\14618834 .\.\1740
C009166_D010212 NONE Tumors\NNS\14234074 ,\,\1740 all\DT\1740 <e2>papillomas</e2>\NNS\14236226 ,\,\1740 were\VBD\836236 induced\VBN\1627355 in\IN\13603305 3\CD\13741022 rats\NNS\2329401 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 with\IN\1740 0.25\CD\1740 %\NN\1740 <e1>RA</e1>\NN\14625458 and\CC\1740 in\IN\13603305 one\CD\13741022 rat\NN\2329401 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 with\IN\1740 0.05\CD\1740 %\NN\1740 RA\NN\14625458 co-administration\NN\1740 .\.\1740
C009166_D010212 NONE Tumors\NNS\14234074 ,\,\1740 all\DT\1740 <e2>papillomas</e2>\NNS\14236226 ,\,\1740 were\VBD\836236 induced\VBN\1627355 in\IN\13603305 3\CD\13741022 rats\NNS\2329401 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 with\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 and\CC\1740 in\IN\13603305 one\CD\13741022 rat\NN\2329401 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 with\IN\1740 0.05\CD\1740 %\NN\1740 <e1>RA</e1>\NN\14625458 co-administration\NN\1740 .\.\1740
C009166_D002277 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 <e1>RA</e1>\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 <e2>carcinoma</e2>\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
C009166_D002277 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 <e1>RA</e1>\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 <e2>carcinoma</e2>\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
C009166_D002277 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 <e1>RA</e1>\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 <e2>carcinoma</e2>\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 RA-free\NN\1740 water\NN\14618834 .\.\1740
C009166_D002277 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 <e2>carcinoma</e2>\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 <e1>RA-free</e1>\NN\1740 water\NN\14618834 .\.\1740
C009166_D002277 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 <e2>carcinoma</e2>\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 <e1>RA-free</e1>\NN\1740 water\NN\14618834 .\.\1740
C009166_D002277 NONE In\IN\13603305 groups\NNS\2137 given\VBN\2327200 2\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 although\IN\1740 marked\JJ\1740 hyperplastic\JJ\1740 changes\NNS\7283608 of\IN\1740 the\DT\1740 forestomach\NN\1740 epithelium\NN\5267548 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 all\DT\1740 animals\NNS\4475 ,\,\1740 co-administration\NN\1740 of\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 significantly\RB\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 (\-LRB-\1740 squamous\JJ\1740 cell\NN\3080309 papilloma\NN\14236226 and\CC\1740 carcinoma\NN\14239918 )\-RRB-\1740 to\TO\1740 60\CD\13745420 %\NN\1740 (\-LRB-\1740 9/15\CD\1740 ,\,\1740 2\CD\13741022 rats\NNS\2329401 with\IN\1740 carcinoma\NN\14239918 )\-RRB-\1740 from\IN\1740 15\CD\13745420 %\NN\1740 (\-LRB-\1740 3/20\CD\1740 ,\,\1740 one\CD\13741022 rat\NN\2329401 with\IN\1740 <e2>carcinoma</e2>\NN\14239918 )\-RRB-\1740 in\IN\13603305 the\DT\1740 group\NN\2137 given\VBN\2327200 <e1>RA-free</e1>\NN\1740 water\NN\14618834 .\.\1740
D002083_D017573 NONE In\IN\13603305 rats\NNS\2329401 given\IN\5892096 1\CD\13741022 %\NN\1740 <e1>BHA</e1>\NN\1740 ,\,\1740 RA\NN\14625458 co-administered\VBN\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 0.05\CD\1740 ,\,\1740 0.1\CD\1740 ,\,\1740 0.2\CD\1740 or\CC\3541091 0.25\CD\1740 %\NN\1740 showed\VBD\2137132 a\DT\13649268 dose-dependent\JJ\1740 enhancing\NN\1740 effect\NN\34213 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 the\DT\1740 BHA-induced\JJ\1740 <e2>epithelial\JJ\1740 hyperplasia</e2>\NN\14365950 .\.\1740
D002083_D017573 NONE In\IN\13603305 rats\NNS\2329401 given\IN\5892096 1\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 RA\NN\14625458 co-administered\VBN\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 0.05\CD\1740 ,\,\1740 0.1\CD\1740 ,\,\1740 0.2\CD\1740 or\CC\3541091 0.25\CD\1740 %\NN\1740 showed\VBD\2137132 a\DT\13649268 dose-dependent\JJ\1740 enhancing\NN\1740 effect\NN\34213 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 the\DT\1740 <e1>BHA-induced</e1>\JJ\1740 <e2>epithelial\JJ\1740 hyperplasia</e2>\NN\14365950 .\.\1740
C009166_D017573 NONE In\IN\13603305 rats\NNS\2329401 given\IN\5892096 1\CD\13741022 %\NN\1740 BHA\NN\1740 ,\,\1740 <e1>RA</e1>\NN\14625458 co-administered\VBN\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 0.05\CD\1740 ,\,\1740 0.1\CD\1740 ,\,\1740 0.2\CD\1740 or\CC\3541091 0.25\CD\1740 %\NN\1740 showed\VBD\2137132 a\DT\13649268 dose-dependent\JJ\1740 enhancing\NN\1740 effect\NN\34213 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 the\DT\1740 BHA-induced\JJ\1740 <e2>epithelial\JJ\1740 hyperplasia</e2>\NN\14365950 .\.\1740
C009166_D009369 NONE <e2>Tumors</e2>\NNS\14234074 ,\,\1740 all\DT\1740 papillomas\NNS\14236226 ,\,\1740 were\VBD\836236 induced\VBN\1627355 in\IN\13603305 3\CD\13741022 rats\NNS\2329401 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 with\IN\1740 0.25\CD\1740 %\NN\1740 <e1>RA</e1>\NN\14625458 and\CC\1740 in\IN\13603305 one\CD\13741022 rat\NN\2329401 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 with\IN\1740 0.05\CD\1740 %\NN\1740 RA\NN\14625458 co-administration\NN\1740 .\.\1740
C009166_D009369 NONE <e2>Tumors</e2>\NNS\14234074 ,\,\1740 all\DT\1740 papillomas\NNS\14236226 ,\,\1740 were\VBD\836236 induced\VBN\1627355 in\IN\13603305 3\CD\13741022 rats\NNS\2329401 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 with\IN\1740 0.25\CD\1740 %\NN\1740 RA\NN\14625458 and\CC\1740 in\IN\13603305 one\CD\13741022 rat\NN\2329401 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 with\IN\1740 0.05\CD\1740 %\NN\1740 <e1>RA</e1>\NN\14625458 co-administration\NN\1740 .\.\1740
19234905
D007980_D004409 CID Ten\CD\13745420 consecutive\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 mean\NN\6021761 age\NN\4916342 ,\,\1740 58.4\CD\1740 +/-\CC\1740 6.8\CD\1740 years\NNS\15144371 ;\:\1740 7\CD\13741022 men\NNS\8208016 ,\,\1740 3\CD\13741022 women\NNS\9605289 )\-RRB-\1740 with\IN\1740 similar\JJ\1740 characteristics\NNS\5849040 at\IN\14622893 the\DT\1740 duration\NN\15113229 of\IN\1740 disease\NN\14061805 (\-LRB-\1740 mean\NN\6021761 disease\NN\14061805 time\NN\7308889 ,\,\1740 8.4\CD\1740 +/-\CC\1740 3.5\CD\1740 years\NNS\15144371 )\-RRB-\1740 ,\,\1740 disabling\VBG\126264 motor\NN\3699975 fluctuations\NNS\7345593 (\-LRB-\1740 Hoehn\NN\1740 _\NNP\1740 Yahr\NNP\1740 stage\NN\15113229 3\CD\13741022 -\SYM\1740 5\CD\13741022 in\IN\13603305 off-drug\JJ\1740 phases\NNS\15113229 )\-RRB-\1740 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 were\VBD\836236 selected\VBN\697589 .\.\1740
D014635_D006423 NONE Complications\NNS\1073995 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 two\CD\13741022 patients\NNS\9898892 :\:\1740 one\CD\13741022 had\VBD\2108377 a\DT\13649268 left\JJ\1740 <e2>homonymous\JJ\1740 hemianopsia</e2>\NN\14552802 after\IN\1740 pallidotomy\NN\1740 and\CC\1740 another\DT\1740 one\CD\13741022 developed\VBD\1753788 left\VBN\120316 hemiballistic\JJ\1740 movements\NNS\191142 3\CD\13741022 days\NNS\15140892 after\IN\1740 subthalamotomy\NN\1740 which\WDT\1740 partly\RB\1740 improved\VBD\126264 within\IN\1740 1\CD\13741022 month\NN\15113229 with\IN\1740 <e1>Valproate</e1>\NNP\1740 1000\CD\13745420 mg/day\NN\1740 .\.\1740
8600333
C053519_D001859 NONE Cardiac\JJ\1740 function\NN\13783581 was\VBD\836236 assessed\VBN\670261 in\IN\13603305 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 malignant\JJ\1740 <e2>bone\NN\5286536 tumors</e2>\NNS\14234074 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 according\VBG\2657219 to\IN\1740 <e1>Rosen\NNP\1740 's\POS\1740 T5\NN\1740 or\CC\3541091 T10\NN\1740 protocol</e1>\NN\6652242 ,\,\1740 both\DT\1740 including\VBG\690614 doxorubicin\NN\2716866 .\.\1740
D004317_D001859 NONE Cardiac\JJ\1740 function\NN\13783581 was\VBD\836236 assessed\VBN\670261 in\IN\13603305 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 malignant\JJ\1740 <e2>bone\NN\5286536 tumors</e2>\NNS\14234074 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 according\VBG\2657219 to\IN\1740 Rosen\NNP\1740 's\POS\1740 T5\NN\1740 or\CC\3541091 T10\NN\1740 protocol\NN\6652242 ,\,\1740 both\DT\1740 including\VBG\690614 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D066126 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 is\VBZ\836236 high\JJ\1740 and\CC\1740 increases\VBZ\169651 with\IN\1740 follow-up\NN\4599396 ,\,\1740 irrespective\RB\1740 of\IN\1740 cumulative\JJ\1740 dose\NN\3740161 .\.\1740
6308526
C024224_D000699 NONE Pretreatment\NN\1740 with\IN\1740 <e1>naloxazone</e1>\NN\1740 significantly\RB\1740 blocked\VBD\1476483 morphine\JJ\1740 <e2>analgesia</e2>\NN\14034177 ,\,\1740 catalepsy\NN\14023236 and\CC\1740 hypothermia\NN\14034177 at\IN\14622893 a\DT\13649268 dose\NN\3740161 which\WDT\1740 completely\RB\1740 eliminated\VBD\1619929 high-affinity\JJ\1740 binding\NN\4688246 in\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 .\.\1740
C024224_D002375 NONE Pretreatment\NN\1740 with\IN\1740 <e1>naloxazone</e1>\NN\1740 significantly\RB\1740 blocked\VBD\1476483 morphine\JJ\1740 analgesia\NN\14034177 ,\,\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 hypothermia\NN\14034177 at\IN\14622893 a\DT\13649268 dose\NN\3740161 which\WDT\1740 completely\RB\1740 eliminated\VBD\1619929 high-affinity\JJ\1740 binding\NN\4688246 in\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 .\.\1740
C024224_D007035 NONE Pretreatment\NN\1740 with\IN\1740 <e1>naloxazone</e1>\NN\1740 significantly\RB\1740 blocked\VBD\1476483 morphine\JJ\1740 analgesia\NN\14034177 ,\,\1740 catalepsy\NN\14023236 and\CC\1740 <e2>hypothermia</e2>\NN\14034177 at\IN\14622893 a\DT\13649268 dose\NN\3740161 which\WDT\1740 completely\RB\1740 eliminated\VBD\1619929 high-affinity\JJ\1740 binding\NN\4688246 in\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 .\.\1740
D009020_D000699 NONE Pretreatment\NN\1740 with\IN\1740 naloxazone\NN\1740 significantly\RB\1740 blocked\VBD\1476483 <e1>morphine</e1>\JJ\1740 <e2>analgesia</e2>\NN\14034177 ,\,\1740 catalepsy\NN\14023236 and\CC\1740 hypothermia\NN\14034177 at\IN\14622893 a\DT\13649268 dose\NN\3740161 which\WDT\1740 completely\RB\1740 eliminated\VBD\1619929 high-affinity\JJ\1740 binding\NN\4688246 in\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 .\.\1740
D009020_D002375 CID Pretreatment\NN\1740 with\IN\1740 naloxazone\NN\1740 significantly\RB\1740 blocked\VBD\1476483 <e1>morphine</e1>\JJ\1740 analgesia\NN\14034177 ,\,\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 hypothermia\NN\14034177 at\IN\14622893 a\DT\13649268 dose\NN\3740161 which\WDT\1740 completely\RB\1740 eliminated\VBD\1619929 high-affinity\JJ\1740 binding\NN\4688246 in\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 .\.\1740
D009020_D007035 CID Pretreatment\NN\1740 with\IN\1740 naloxazone\NN\1740 significantly\RB\1740 blocked\VBD\1476483 <e1>morphine</e1>\JJ\1740 analgesia\NN\14034177 ,\,\1740 catalepsy\NN\14023236 and\CC\1740 <e2>hypothermia</e2>\NN\14034177 at\IN\14622893 a\DT\13649268 dose\NN\3740161 which\WDT\1740 completely\RB\1740 eliminated\VBD\1619929 high-affinity\JJ\1740 binding\NN\4688246 in\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 .\.\1740
C024224_D007022 NONE Moreover\RB\1740 ,\,\1740 <e1>naloxazone</e1>\NN\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 morphine-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 whereas\IN\1740 morphine-induced\JJ\1740 bradycardia\NN\14110674 was\VBD\836236 less\RBR\1740 affected\VBN\126264 .\.\1740
C024224_D012131 NONE Moreover\RB\1740 ,\,\1740 <e1>naloxazone</e1>\NN\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 morphine-induced\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>respiratory\JJ\1740 depression</e2>\NN\14373582 ,\,\1740 whereas\IN\1740 morphine-induced\JJ\1740 bradycardia\NN\14110674 was\VBD\836236 less\RBR\1740 affected\VBN\126264 .\.\1740
C024224_D001919 NONE Moreover\RB\1740 ,\,\1740 <e1>naloxazone</e1>\NN\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 morphine-induced\JJ\1740 hypotension\NN\14057371 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 whereas\IN\1740 morphine-induced\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 less\RBR\1740 affected\VBN\126264 .\.\1740
D009020_D007022 CID Moreover\RB\1740 ,\,\1740 naloxazone\NN\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 whereas\IN\1740 morphine-induced\JJ\1740 bradycardia\NN\14110674 was\VBD\836236 less\RBR\1740 affected\VBN\126264 .\.\1740
D009020_D007022 CID Moreover\RB\1740 ,\,\1740 naloxazone\NN\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 morphine-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 whereas\IN\1740 <e1>morphine-induced</e1>\JJ\1740 bradycardia\NN\14110674 was\VBD\836236 less\RBR\1740 affected\VBN\126264 .\.\1740
D009020_D012131 NONE Moreover\RB\1740 ,\,\1740 naloxazone\NN\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e1>morphine-induced</e1>\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>respiratory\JJ\1740 depression</e2>\NN\14373582 ,\,\1740 whereas\IN\1740 morphine-induced\JJ\1740 bradycardia\NN\14110674 was\VBD\836236 less\RBR\1740 affected\VBN\126264 .\.\1740
D009020_D012131 NONE Moreover\RB\1740 ,\,\1740 naloxazone\NN\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 morphine-induced\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>respiratory\JJ\1740 depression</e2>\NN\14373582 ,\,\1740 whereas\IN\1740 <e1>morphine-induced</e1>\JJ\1740 bradycardia\NN\14110674 was\VBD\836236 less\RBR\1740 affected\VBN\126264 .\.\1740
D009020_D001919 CID Moreover\RB\1740 ,\,\1740 naloxazone\NN\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e1>morphine-induced</e1>\JJ\1740 hypotension\NN\14057371 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 whereas\IN\1740 morphine-induced\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 less\RBR\1740 affected\VBN\126264 .\.\1740
D009020_D001919 CID Moreover\RB\1740 ,\,\1740 naloxazone\NN\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 morphine-induced\JJ\1740 hypotension\NN\14057371 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 whereas\IN\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 less\RBR\1740 affected\VBN\126264 .\.\1740
9326871
D017291_D017180 CID <e1>Clarithromycin-induced</e1>\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 .\.\1740
D004917_D005759 CID Although\IN\1740 the\DT\1740 side-effect\JJ\1740 profile\NN\6999802 of\IN\1740 <e1>erythromycin</e1>\NN\2716866 is\VBZ\836236 established\VBN\2426171 ,\,\1740 including\VBG\690614 <e2>gastroenteritis</e2>\NN\14171682 and\CC\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 subject\JJ\1740 to\TO\1740 hepatic\JJ\1740 mixed-function\NN\1740 oxidase\NN\14732946 metabolism\NN\13526110 ,\,\1740 experience\NN\5984287 with\IN\1740 the\DT\1740 newer\JJR\1740 macrolides\NNS\1740 is\VBZ\836236 still\RB\1740 being\VBG\836236 recorded\VBN\2225492 .\.\1740
D018942_D005759 NONE Although\IN\1740 the\DT\1740 side-effect\JJ\1740 profile\NN\6999802 of\IN\1740 erythromycin\NN\2716866 is\VBZ\836236 established\VBN\2426171 ,\,\1740 including\VBG\690614 <e2>gastroenteritis</e2>\NN\14171682 and\CC\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 subject\JJ\1740 to\TO\1740 hepatic\JJ\1740 mixed-function\NN\1740 oxidase\NN\14732946 metabolism\NN\13526110 ,\,\1740 experience\NN\5984287 with\IN\1740 the\DT\1740 newer\JJR\1740 <e1>macrolides</e1>\NNS\1740 is\VBZ\836236 still\RB\1740 being\VBG\836236 recorded\VBN\2225492 .\.\1740
D004917_D066126 NONE <e2>Cardiotoxicity</e2>\NN\1740 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 after\IN\1740 both\CC\1740 intravenous\JJ\1740 and\CC\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>erythromycin</e1>\NN\2716866 but\CC\1740 has\VBZ\2108377 never\RB\1740 been\VBN\836236 reported\VBN\831651 with\IN\1740 the\DT\1740 newer\JJR\1740 macrolides\NNS\1740 .\.\1740
D018942_D066126 NONE <e2>Cardiotoxicity</e2>\NN\1740 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 after\IN\1740 both\CC\1740 intravenous\JJ\1740 and\CC\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 erythromycin\NN\2716866 but\CC\1740 has\VBZ\2108377 never\RB\1740 been\VBN\836236 reported\VBN\831651 with\IN\1740 the\DT\1740 newer\JJR\1740 <e1>macrolides</e1>\NNS\1740 .\.\1740
D017291_D001145 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>ventricular\JJ\1740 dysrhythmias</e2>\NNS\1740 that\WDT\1740 occurred\VBD\2623529 after\IN\1740 six\CD\13741022 therapeutic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>clarithromycin</e1>\NN\1740 .\.\1740
2594614
C045856_D002318 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 specific\JJ\1740 platelet-activating\JJ\1740 factor\NN\7326557 antagonist\NN\7846 ,\,\1740 <e1>BN\NN\1740 52021</e1>\CD\1740 ,\,\1740 on\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiovascular\JJ\1740 impairments</e2>\NNS\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
C045856_D002318 NONE Since\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>BN\NN\1740 52021</e1>\CD\1740 ,\,\1740 at\IN\14622893 all\DT\1740 doses\NNS\3740161 studied\VBN\630380 ,\,\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 MBP\NN\1740 and\CC\1740 HR\NN\15154774 at\IN\14622893 the\DT\1740 doses\NNS\3740161 used\VBN\1156834 ,\,\1740 the\DT\1740 bulk\NN\5121418 of\IN\1740 these\DT\1740 results\NNS\34213 clearly\RB\1740 demonstrate\VBP\2137132 a\DT\13649268 protective\JJ\1740 action\NN\30358 of\IN\1740 BN\NN\1740 52021\CD\1740 ,\,\1740 a\DT\13649268 specific\JJ\1740 antagonist\NN\7846 of\IN\1740 PAF\NN\1740 ,\,\1740 against\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiovascular\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
C045856_D002318 NONE Since\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 BN\NN\1740 52021\CD\1740 ,\,\1740 at\IN\14622893 all\DT\1740 doses\NNS\3740161 studied\VBN\630380 ,\,\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 MBP\NN\1740 and\CC\1740 HR\NN\15154774 at\IN\14622893 the\DT\1740 doses\NNS\3740161 used\VBN\1156834 ,\,\1740 the\DT\1740 bulk\NN\5121418 of\IN\1740 these\DT\1740 results\NNS\34213 clearly\RB\1740 demonstrate\VBP\2137132 a\DT\13649268 protective\JJ\1740 action\NN\30358 of\IN\1740 <e1>BN\NN\1740 52021</e1>\CD\1740 ,\,\1740 a\DT\13649268 specific\JJ\1740 antagonist\NN\7846 of\IN\1740 PAF\NN\1740 ,\,\1740 against\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiovascular\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D002045_D002318 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 specific\JJ\1740 platelet-activating\JJ\1740 factor\NN\7326557 antagonist\NN\7846 ,\,\1740 BN\NN\1740 52021\CD\1740 ,\,\1740 on\IN\1740 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>cardiovascular\JJ\1740 impairments</e2>\NNS\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002045_D002318 NONE Since\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 BN\NN\1740 52021\CD\1740 ,\,\1740 at\IN\14622893 all\DT\1740 doses\NNS\3740161 studied\VBN\630380 ,\,\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 MBP\NN\1740 and\CC\1740 HR\NN\15154774 at\IN\14622893 the\DT\1740 doses\NNS\3740161 used\VBN\1156834 ,\,\1740 the\DT\1740 bulk\NN\5121418 of\IN\1740 these\DT\1740 results\NNS\34213 clearly\RB\1740 demonstrate\VBP\2137132 a\DT\13649268 protective\JJ\1740 action\NN\30358 of\IN\1740 BN\NN\1740 52021\CD\1740 ,\,\1740 a\DT\13649268 specific\JJ\1740 antagonist\NN\7846 of\IN\1740 PAF\NN\1740 ,\,\1740 against\IN\1740 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>cardiovascular\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D002045_D007022 CID Administration\NN\1133281 of\IN\1740 the\DT\1740 local\JJ\1740 anaesthetic\JJ\1740 <e1>bupivacaine</e1>\NN\1740 (\-LRB-\1740 1.5\CD\1740 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.v.\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 elicited\VBD\1617192 a\DT\13649268 marked\JJ\1740 <e2>decrease\NN\7296428 of\IN\1740 mean\NN\6021761 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 MBP\NN\1740 )\-RRB-\1740 and\CC\1740 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 HR\NN\15154774 )</e2>\-RRB-\1740 leading\VBG\1752884 to\TO\1740 death\NN\7296428 (\-LRB-\1740 in\IN\13603305 67\CD\1740 %\NN\1740 or\CC\3541091 90\CD\13745420 %\NN\1740 of\IN\1740 animals\NNS\4475 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D002045_D007022 CID Intravenous\JJ\1740 injection\NN\320852 of\IN\1740 the\DT\1740 specific\JJ\1740 platelet-activating\JJ\1740 factor\NN\7326557 (\-LRB-\1740 PAF\NN\1740 )\-RRB-\1740 antagonist\NN\7846 BN\NN\1740 52021\CD\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 30\CD\13745420 min\NN\15154774 before\IN\1740 <e1>bupivacaine</e1>\NN\1740 administration\NN\1133281 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 suppressed\VBD\2510337 both\CC\1740 the\DT\1740 <e2>decrease\NN\7296428 of\IN\1740 MBP\NN\1740 and\CC\1740 HR</e2>\NN\15154774 .\.\1740
D002045_D007022 CID When\WRB\1740 BN\NN\1740 52021\CD\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 was\VBD\836236 injected\VBN\81072 immediately\RB\1740 after\IN\1740 <e1>bupivacaine</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 partial\JJ\1740 reversion\NN\13286801 of\IN\1740 the\DT\1740 <e2>decrease\NN\7296428 of\IN\1740 MBP\NN\1740 and\CC\1740 HR</e2>\NN\15154774 was\VBD\836236 observed\VBN\2163746 ,\,\1740 whereas\IN\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg/kg\NN\1740 was\VBD\836236 ineffective\JJ\1740 .\.\1740
D002045_D001919 CID Administration\NN\1133281 of\IN\1740 the\DT\1740 local\JJ\1740 anaesthetic\JJ\1740 <e1>bupivacaine</e1>\NN\1740 (\-LRB-\1740 1.5\CD\1740 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.v.\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 elicited\VBD\1617192 a\DT\13649268 marked\JJ\1740 <e2>decrease\NN\7296428 of\IN\1740 mean\NN\6021761 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 MBP\NN\1740 )\-RRB-\1740 and\CC\1740 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 HR\NN\15154774 )</e2>\-RRB-\1740 leading\VBG\1752884 to\TO\1740 death\NN\7296428 (\-LRB-\1740 in\IN\13603305 67\CD\1740 %\NN\1740 or\CC\3541091 90\CD\13745420 %\NN\1740 of\IN\1740 animals\NNS\4475 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D002045_D001919 CID Intravenous\JJ\1740 injection\NN\320852 of\IN\1740 the\DT\1740 specific\JJ\1740 platelet-activating\JJ\1740 factor\NN\7326557 (\-LRB-\1740 PAF\NN\1740 )\-RRB-\1740 antagonist\NN\7846 BN\NN\1740 52021\CD\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 30\CD\13745420 min\NN\15154774 before\IN\1740 <e1>bupivacaine</e1>\NN\1740 administration\NN\1133281 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 suppressed\VBD\2510337 both\CC\1740 the\DT\1740 <e2>decrease\NN\7296428 of\IN\1740 MBP\NN\1740 and\CC\1740 HR</e2>\NN\15154774 .\.\1740
D002045_D001919 CID When\WRB\1740 BN\NN\1740 52021\CD\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 was\VBD\836236 injected\VBN\81072 immediately\RB\1740 after\IN\1740 <e1>bupivacaine</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 partial\JJ\1740 reversion\NN\13286801 of\IN\1740 the\DT\1740 <e2>decrease\NN\7296428 of\IN\1740 MBP\NN\1740 and\CC\1740 HR</e2>\NN\15154774 was\VBD\836236 observed\VBN\2163746 ,\,\1740 whereas\IN\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg/kg\NN\1740 was\VBD\836236 ineffective\JJ\1740 .\.\1740
C045856_D007022 NONE Intravenous\JJ\1740 injection\NN\320852 of\IN\1740 the\DT\1740 specific\JJ\1740 platelet-activating\JJ\1740 factor\NN\7326557 (\-LRB-\1740 PAF\NN\1740 )\-RRB-\1740 antagonist\NN\7846 <e1>BN\NN\1740 52021</e1>\CD\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 30\CD\13745420 min\NN\15154774 before\IN\1740 bupivacaine\NN\1740 administration\NN\1133281 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 suppressed\VBD\2510337 both\CC\1740 the\DT\1740 <e2>decrease\NN\7296428 of\IN\1740 MBP\NN\1740 and\CC\1740 HR</e2>\NN\15154774 .\.\1740
C045856_D007022 NONE When\WRB\1740 <e1>BN\NN\1740 52021</e1>\CD\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 was\VBD\836236 injected\VBN\81072 immediately\RB\1740 after\IN\1740 bupivacaine\NN\1740 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 partial\JJ\1740 reversion\NN\13286801 of\IN\1740 the\DT\1740 <e2>decrease\NN\7296428 of\IN\1740 MBP\NN\1740 and\CC\1740 HR</e2>\NN\15154774 was\VBD\836236 observed\VBN\2163746 ,\,\1740 whereas\IN\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg/kg\NN\1740 was\VBD\836236 ineffective\JJ\1740 .\.\1740
C045856_D001919 NONE Intravenous\JJ\1740 injection\NN\320852 of\IN\1740 the\DT\1740 specific\JJ\1740 platelet-activating\JJ\1740 factor\NN\7326557 (\-LRB-\1740 PAF\NN\1740 )\-RRB-\1740 antagonist\NN\7846 <e1>BN\NN\1740 52021</e1>\CD\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 30\CD\13745420 min\NN\15154774 before\IN\1740 bupivacaine\NN\1740 administration\NN\1133281 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 suppressed\VBD\2510337 both\CC\1740 the\DT\1740 <e2>decrease\NN\7296428 of\IN\1740 MBP\NN\1740 and\CC\1740 HR</e2>\NN\15154774 .\.\1740
C045856_D001919 NONE When\WRB\1740 <e1>BN\NN\1740 52021</e1>\CD\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 was\VBD\836236 injected\VBN\81072 immediately\RB\1740 after\IN\1740 bupivacaine\NN\1740 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 partial\JJ\1740 reversion\NN\13286801 of\IN\1740 the\DT\1740 <e2>decrease\NN\7296428 of\IN\1740 MBP\NN\1740 and\CC\1740 HR</e2>\NN\15154774 was\VBD\836236 observed\VBN\2163746 ,\,\1740 whereas\IN\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg/kg\NN\1740 was\VBD\836236 ineffective\JJ\1740 .\.\1740
D002045_D018376 NONE Thus\RB\1740 ,\,\1740 consistent\JJ\1740 with\IN\1740 its\PRP$\6125041 direct\JJ\1740 effect\NN\34213 on\IN\1740 heart\NN\5919034 ,\,\1740 PAF\NN\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>cardiovascular\JJ\1740 alterations</e2>\NNS\7283608 .\.\1740
9061311
D013481_D017114 NONE Neutrophil\NN\5449959 <e1>superoxide</e1>\NN\14971519 and\CC\1740 hydrogen\NN\14622893 peroxide\NN\14780040 production\NN\30358 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 .\.\1740
D013481_D017114 NONE Defects\NNS\14462666 in\IN\13603305 <e1>superoxide</e1>\NN\14971519 and\CC\1740 hydrogen\NN\14622893 peroxide\NN\14780040 production\NN\30358 may\MD\15209706 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 high\JJ\1740 incidence\NN\13821570 of\IN\1740 bacterial\JJ\1740 infections\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 (\-LRB-\1740 ALF\NN\1740 )\-RRB-\1740 .\.\1740
D013481_D017114 NONE Defects\NNS\14462666 in\IN\13603305 <e1>superoxide</e1>\NN\14971519 and\CC\1740 hydrogen\NN\14622893 peroxide\NN\14780040 production\NN\30358 may\MD\15209706 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 high\JJ\1740 incidence\NN\13821570 of\IN\1740 bacterial\JJ\1740 infections\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 <e2>ALF</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D013481_D017114 NONE <e1>Superoxide</e1>\NN\14971519 and\CC\1740 hydrogen\NN\14622893 peroxide\NN\14780040 production\NN\30358 by\IN\1740 <e2>ALF</e2>\NN\1740 neutrophils\NNS\5449959 stimulated\VBN\137313 with\IN\1740 zymosan\NN\1740 opsonized\VBN\126264 with\IN\1740 ALF\NN\1740 serum\NN\5397468 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 compared\VBN\644583 with\IN\1740 the\DT\1740 control\JJ\1740 subjects\NNS\6598915 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D013481_D017114 NONE <e1>Superoxide</e1>\NN\14971519 and\CC\1740 hydrogen\NN\14622893 peroxide\NN\14780040 production\NN\30358 by\IN\1740 ALF\NN\1740 neutrophils\NNS\5449959 stimulated\VBN\137313 with\IN\1740 zymosan\NN\1740 opsonized\VBN\126264 with\IN\1740 <e2>ALF</e2>\NN\1740 serum\NN\5397468 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 compared\VBN\644583 with\IN\1740 the\DT\1740 control\JJ\1740 subjects\NNS\6598915 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D013481_D017114 NONE <e1>Superoxide</e1>\NN\14971519 and\CC\1740 hydrogen\NN\14622893 peroxide\NN\14780040 production\NN\30358 in\IN\13603305 neutrophils\NNS\5449959 stimulated\VBN\137313 with\IN\1740 formyl-methionyl-leucyl-phenylalanine\NN\1740 (\-LRB-\1740 fMLP\NN\1740 )\-RRB-\1740 from\IN\1740 a\DT\13649268 further\JJ\1740 18\CD\13745420 <e2>ALF</e2>\NN\1740 patients\NNS\9898892 was\VBD\836236 unaffected\JJ\1740 compared\VBN\644583 with\IN\1740 control\NN\5190804 neutrophils\NNS\5449959 .\.\1740
D006861_D017114 NONE Neutrophil\NN\5449959 superoxide\NN\14971519 and\CC\1740 <e1>hydrogen\NN\14622893 peroxide</e1>\NN\14780040 production\NN\30358 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 .\.\1740
D006861_D017114 NONE Defects\NNS\14462666 in\IN\13603305 superoxide\NN\14971519 and\CC\1740 <e1>hydrogen\NN\14622893 peroxide</e1>\NN\14780040 production\NN\30358 may\MD\15209706 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 high\JJ\1740 incidence\NN\13821570 of\IN\1740 bacterial\JJ\1740 infections\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 (\-LRB-\1740 ALF\NN\1740 )\-RRB-\1740 .\.\1740
D006861_D017114 NONE Defects\NNS\14462666 in\IN\13603305 superoxide\NN\14971519 and\CC\1740 <e1>hydrogen\NN\14622893 peroxide</e1>\NN\14780040 production\NN\30358 may\MD\15209706 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 high\JJ\1740 incidence\NN\13821570 of\IN\1740 bacterial\JJ\1740 infections\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 <e2>ALF</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D006861_D017114 NONE Superoxide\NN\14971519 and\CC\1740 <e1>hydrogen\NN\14622893 peroxide</e1>\NN\14780040 production\NN\30358 by\IN\1740 <e2>ALF</e2>\NN\1740 neutrophils\NNS\5449959 stimulated\VBN\137313 with\IN\1740 zymosan\NN\1740 opsonized\VBN\126264 with\IN\1740 ALF\NN\1740 serum\NN\5397468 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 compared\VBN\644583 with\IN\1740 the\DT\1740 control\JJ\1740 subjects\NNS\6598915 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D006861_D017114 NONE Superoxide\NN\14971519 and\CC\1740 <e1>hydrogen\NN\14622893 peroxide</e1>\NN\14780040 production\NN\30358 by\IN\1740 ALF\NN\1740 neutrophils\NNS\5449959 stimulated\VBN\137313 with\IN\1740 zymosan\NN\1740 opsonized\VBN\126264 with\IN\1740 <e2>ALF</e2>\NN\1740 serum\NN\5397468 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 compared\VBN\644583 with\IN\1740 the\DT\1740 control\JJ\1740 subjects\NNS\6598915 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D006861_D017114 NONE Superoxide\NN\14971519 and\CC\1740 <e1>hydrogen\NN\14622893 peroxide</e1>\NN\14780040 production\NN\30358 in\IN\13603305 neutrophils\NNS\5449959 stimulated\VBN\137313 with\IN\1740 formyl-methionyl-leucyl-phenylalanine\NN\1740 (\-LRB-\1740 fMLP\NN\1740 )\-RRB-\1740 from\IN\1740 a\DT\13649268 further\JJ\1740 18\CD\13745420 <e2>ALF</e2>\NN\1740 patients\NNS\9898892 was\VBD\836236 unaffected\JJ\1740 compared\VBN\644583 with\IN\1740 control\NN\5190804 neutrophils\NNS\5449959 .\.\1740
D013481_D001424 NONE Defects\NNS\14462666 in\IN\13603305 <e1>superoxide</e1>\NN\14971519 and\CC\1740 hydrogen\NN\14622893 peroxide\NN\14780040 production\NN\30358 may\MD\15209706 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 high\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>bacterial\JJ\1740 infections</e2>\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 ALF\NN\1740 )\-RRB-\1740 .\.\1740
D006861_D001424 NONE Defects\NNS\14462666 in\IN\13603305 superoxide\NN\14971519 and\CC\1740 <e1>hydrogen\NN\14622893 peroxide</e1>\NN\14780040 production\NN\30358 may\MD\15209706 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 high\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>bacterial\JJ\1740 infections</e2>\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 ALF\NN\1740 )\-RRB-\1740 .\.\1740
D010100_D017114 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 <e1>oxygen</e1>\NN\14622893 radical\JJ\1740 production\NN\30358 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>ALF</e2>\NN\1740 due\IN\5174653 to\TO\1740 paracetamol\NN\1740 overdose\NN\1740 was\VBD\836236 compared\VBN\644583 with\IN\1740 that\DT\1740 of\IN\1740 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
D010100_D062787 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 <e1>oxygen</e1>\NN\14622893 radical\JJ\1740 production\NN\30358 in\IN\13603305 patients\NNS\9898892 with\IN\1740 ALF\NN\1740 due\IN\5174653 to\TO\1740 paracetamol\NN\1740 <e2>overdose</e2>\NN\1740 was\VBD\836236 compared\VBN\644583 with\IN\1740 that\DT\1740 of\IN\1740 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
D000082_D017114 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 oxygen\NN\14622893 radical\JJ\1740 production\NN\30358 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>ALF</e2>\NN\1740 due\IN\5174653 to\TO\1740 <e1>paracetamol</e1>\NN\1740 overdose\NN\1740 was\VBD\836236 compared\VBN\644583 with\IN\1740 that\DT\1740 of\IN\1740 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
D000082_D017114 CID These\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 a\DT\13649268 neutrophil\NN\5449959 defect\NN\14462666 in\IN\13603305 <e2>ALF</e2>\NN\1740 due\IN\5174653 to\TO\1740 <e1>paracetamol</e1>\NN\1740 overdose\RB\1740 ,\,\1740 that\RB\1740 is\VBZ\836236 complement\NN\6313651 dependent\JJ\1740 but\CC\1740 independent\JJ\1740 of\IN\1740 serum\NN\5397468 complement\NN\6313651 ,\,\1740 possibly\RB\1740 connected\VBN\628491 to\TO\1740 the\DT\1740 complement\NN\6313651 receptor\NN\5225602 .\.\1740
D000082_D062787 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 oxygen\NN\14622893 radical\JJ\1740 production\NN\30358 in\IN\13603305 patients\NNS\9898892 with\IN\1740 ALF\NN\1740 due\IN\5174653 to\TO\1740 <e1>paracetamol</e1>\NN\1740 <e2>overdose</e2>\NN\1740 was\VBD\836236 compared\VBN\644583 with\IN\1740 that\DT\1740 of\IN\1740 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
D000082_D062787 NONE These\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 a\DT\13649268 neutrophil\NN\5449959 defect\NN\14462666 in\IN\13603305 ALF\NN\1740 due\IN\5174653 to\TO\1740 <e1>paracetamol</e1>\NN\1740 <e2>overdose</e2>\RB\1740 ,\,\1740 that\RB\1740 is\VBZ\836236 complement\NN\6313651 dependent\JJ\1740 but\CC\1740 independent\JJ\1740 of\IN\1740 serum\NN\5397468 complement\NN\6313651 ,\,\1740 possibly\RB\1740 connected\VBN\628491 to\TO\1740 the\DT\1740 complement\NN\6313651 receptor\NN\5225602 .\.\1740
D009240_D017114 NONE Superoxide\NN\14971519 and\CC\1740 hydrogen\NN\14622893 peroxide\NN\14780040 production\NN\30358 in\IN\13603305 neutrophils\NNS\5449959 stimulated\VBN\137313 with\IN\1740 <e1>formyl-methionyl-leucyl-phenylalanine</e1>\NN\1740 (\-LRB-\1740 fMLP\NN\1740 )\-RRB-\1740 from\IN\1740 a\DT\13649268 further\JJ\1740 18\CD\13745420 <e2>ALF</e2>\NN\1740 patients\NNS\9898892 was\VBD\836236 unaffected\JJ\1740 compared\VBN\644583 with\IN\1740 control\NN\5190804 neutrophils\NNS\5449959 .\.\1740
D009240_D017114 NONE Superoxide\NN\14971519 and\CC\1740 hydrogen\NN\14622893 peroxide\NN\14780040 production\NN\30358 in\IN\13603305 neutrophils\NNS\5449959 stimulated\VBN\137313 with\IN\1740 formyl-methionyl-leucyl-phenylalanine\NN\1740 (\-LRB-\1740 <e1>fMLP</e1>\NN\1740 )\-RRB-\1740 from\IN\1740 a\DT\13649268 further\JJ\1740 18\CD\13745420 <e2>ALF</e2>\NN\1740 patients\NNS\9898892 was\VBD\836236 unaffected\JJ\1740 compared\VBN\644583 with\IN\1740 control\NN\5190804 neutrophils\NNS\5449959 .\.\1740
18483878
D003520_D003556 CID Exaggerated\JJ\1740 expression\NN\4679549 of\IN\1740 inflammatory\JJ\1740 mediators\NNS\10351874 in\IN\13603305 vasoactive\JJ\1740 intestinal\JJ\1740 polypeptide\NN\14743046 knockout\NN\10787470 (\-LRB-\1740 VIP-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 (CYP)-induced\JJ\1740 <e2>cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID Exaggerated\JJ\1740 expression\NN\4679549 of\IN\1740 inflammatory\JJ\1740 mediators\NNS\10351874 in\IN\13603305 vasoactive\JJ\1740 intestinal\JJ\1740 polypeptide\NN\14743046 knockout\NN\10787470 (\-LRB-\1740 VIP-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 with\IN\1740 cyclophosphamide\NN\1740 <e1>(CYP)-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID VIP(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 exhibit\VBP\2632167 altered\JJ\1740 bladder\NN\5515670 function\NN\13783581 and\CC\1740 neurochemical\JJ\1740 properties\NNS\32613 in\IN\13603305 micturition\NN\13473097 pathways\NNS\5483677 after\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 (CYP)-induced\JJ\1740 <e2>cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID VIP(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 exhibit\VBP\2632167 altered\JJ\1740 bladder\NN\5515670 function\NN\13783581 and\CC\1740 neurochemical\JJ\1740 properties\NNS\32613 in\IN\13603305 micturition\NN\13473097 pathways\NNS\5483677 after\IN\1740 cyclophosphamide\NN\1740 <e1>(CYP)-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID A\DT\13649268 mouse\NN\2329401 inflammatory\JJ\1740 cytokine\NN\14728724 and\CC\1740 receptor\NN\5225602 RT2\NN\1740 profiler\NN\1740 array\NN\7938773 was\VBD\836236 used\VBN\1156834 to\TO\1740 determine\VB\1645601 regulated\JJ\1740 transcripts\NNS\6362953 in\IN\13603305 the\DT\1740 urinary\JJ\1740 bladder\NN\5515670 of\IN\1740 wild\JJ\1740 type\NN\5839024 (\-LRB-\1740 WT\NN\1740 )\-RRB-\1740 and\CC\1740 VIP(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 with\IN\1740 or\CC\3541091 without\IN\1740 <e1>CYP-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 (\-LRB-\1740 150\CD\1740 mg/kg\NN\1740 ;\:\1740 i.p.\RB\1740 ;\:\1740 48\CD\1740 h\NN\14622893 )\-RRB-\1740 .\.\1740
D003520_D001745 NONE The\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 in\IN\13603305 VIP(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 with\IN\1740 <e2>bladder\NN\5515670 inflammation</e2>\NN\14299637 ,\,\1740 inflammatory\JJ\1740 mediators\NNS\10351874 are\VBP\836236 increased\VBN\169651 above\IN\6392001 that\DT\1740 observed\VBN\2163746 in\IN\13603305 WT\NNP\1740 with\IN\1740 <e1>CYP</e1>\NNP\1740 .\.\1740
19300240
D005472_D054549 CID <e1>5\CD\13741022 flourouracil-induced</e1>\JJ\1740 <e2>apical\JJ\1740 ballooning\NN\302394 syndrome</e2>\NN\5870365 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D005472_D015179 NONE She\PRP\1740 underwent\VBD\109660 recent\JJ\1740 chemotherapy\NN\661091 with\IN\1740 <e1>fluorouracil</e1>\NN\2722166 for\IN\1740 metastatic\JJ\1740 <e2>colorectal\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D002395_D009369 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 both\CC\1740 supraphysiologic\JJ\1740 levels\NNS\4916342 of\IN\1740 plasma\NN\5398023 <e1>catecholamines</e1>\NNS\5407119 and\CC\1740 stress\NN\7083732 related\JJ\1740 neuropeptides\NNS\1740 caused\VBN\1617192 by\IN\1740 <e2>cancer</e2>\NN\14239425 diagnosis\NN\152018 as\RB\1740 well\RB\1740 as\IN\14622893 chemotherapy\NN\661091 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 the\DT\1740 development\NN\248977 of\IN\1740 ABS\NN\14592610 .\.\1740
D002395_D054549 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 both\CC\1740 supraphysiologic\JJ\1740 levels\NNS\4916342 of\IN\1740 plasma\NN\5398023 <e1>catecholamines</e1>\NNS\5407119 and\CC\1740 stress\NN\7083732 related\JJ\1740 neuropeptides\NNS\1740 caused\VBN\1617192 by\IN\1740 cancer\NN\14239425 diagnosis\NN\152018 as\RB\1740 well\RB\1740 as\IN\14622893 chemotherapy\NN\661091 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 the\DT\1740 development\NN\248977 of\IN\1740 <e2>ABS</e2>\NN\14592610 .\.\1740
11078231
D004280_D017202 NONE <e2>Myocardial\JJ\1740 ischemia</e2>\NN\14195315 due\JJ\1740 to\TO\1740 coronary\JJ\1740 artery\NN\5417975 spasm\NN\14299637 during\IN\1740 <e1>dobutamine</e1>\NN\1740 stress\NN\7083732 echocardiography\NN\177127 .\.\1740
D004280_D017202 NONE <e1>Dobutamine</e1>\JJ\1740 stress\NN\7083732 echocardiography\NN\177127 (\-LRB-\1740 DSE\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 useful\JJ\1740 and\CC\1740 safe\JJ\1740 provocation\NN\1221611 test\NN\5798043 for\IN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
D004280_D017202 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 whether\IN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 due\JJ\1740 to\TO\1740 coronary\JJ\1740 spasm\NN\14299637 is\VBZ\836236 induced\VBN\1627355 by\IN\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
D004280_D003329 CID Myocardial\JJ\1740 ischemia\NN\14195315 due\JJ\1740 to\TO\1740 <e2>coronary\JJ\1740 artery\NN\5417975 spasm</e2>\NN\14299637 during\IN\1740 <e1>dobutamine</e1>\NN\1740 stress\NN\7083732 echocardiography\NN\177127 .\.\1740
D004280_D003329 CID The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 whether\IN\1740 myocardial\JJ\1740 ischemia\NN\14195315 due\JJ\1740 to\TO\1740 <e2>coronary\JJ\1740 spasm</e2>\NN\14299637 is\VBZ\836236 induced\VBN\1627355 by\IN\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
D004280_D003329 CID These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>dobutamine</e1>\NN\1740 can\MD\3094503 provoke\VB\1617192 <e2>coronary\JJ\1740 spasm</e2>\NN\14299637 in\IN\13603305 some\DT\1740 patients\NNS\9898892 with\IN\1740 coronary\JJ\1740 spastic\JJ\1740 angina\NN\14171682 .\.\1740
D000109_D023921 NONE Coronary\JJ\1740 spasm\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 intracoronary\JJ\1740 injection\NN\320852 of\IN\1740 <e1>acetylcholine</e1>\NN\14807558 ,\,\1740 and\CC\1740 no\DT\7204911 fixed\VBN\205885 <e2>coronary\JJ\1740 artery\NN\5417975 stenosis</e2>\NN\14204950 was\VBD\836236 documented\VBN\1000214 on\IN\1740 angiograms\NNS\4100620 in\IN\13603305 all\DT\1740 patients\NNS\9898892 .\.\1740
D004280_D000788 CID These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>dobutamine</e1>\NN\1740 can\MD\3094503 provoke\VB\1617192 coronary\JJ\1740 spasm\NN\14299637 in\IN\13603305 some\DT\1740 patients\NNS\9898892 with\IN\1740 <e2>coronary\JJ\1740 spastic\JJ\1740 angina</e2>\NN\14171682 .\.\1740
9630698
D006220_D009127 CID <e2>Muscle\NN\5289601 rigidity</e2>\NN\5023233 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 2.5\CD\1740 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D006220_D009127 CID 5,7-dichlorokynurenic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5,7-DCKA\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 glycine\NN\14601829 site\NN\8673395 antagonist\NN\7846 ,\,\1740 injected\VBN\81072 in\IN\13603305 doses\NNS\3740161 of\IN\1740 2.5\CD\1740 and\CC\1740 4.5\CD\1740 microg/0.5\CD\1740 microl\NN\1740 bilaterally\RB\1740 ,\,\1740 into\IN\1740 the\DT\1740 rostral\JJ\1740 region\NN\27167 of\IN\1740 the\DT\1740 striatum\NN\5497363 ,\,\1740 decreased\VBD\169651 both\CC\1740 the\DT\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 (\-LRB-\1740 MMG\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 enhanced\VBN\227165 electromyographic\JJ\1740 activity\NN\30358 (\-LRB-\1740 EMG\NN\7005158 )\-RRB-\1740 .\.\1740
C066192_D009127 NONE <e1>5,7-dichlorokynurenic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 5,7-DCKA\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 glycine\NN\14601829 site\NN\8673395 antagonist\NN\7846 ,\,\1740 injected\VBN\81072 in\IN\13603305 doses\NNS\3740161 of\IN\1740 2.5\CD\1740 and\CC\1740 4.5\CD\1740 microg/0.5\CD\1740 microl\NN\1740 bilaterally\RB\1740 ,\,\1740 into\IN\1740 the\DT\1740 rostral\JJ\1740 region\NN\27167 of\IN\1740 the\DT\1740 striatum\NN\5497363 ,\,\1740 decreased\VBD\169651 both\CC\1740 the\DT\1740 haloperidol-induced\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 (\-LRB-\1740 MMG\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 enhanced\VBN\227165 electromyographic\JJ\1740 activity\NN\30358 (\-LRB-\1740 EMG\NN\7005158 )\-RRB-\1740 .\.\1740
C066192_D009127 NONE 5,7-dichlorokynurenic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>5,7-DCKA</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 glycine\NN\14601829 site\NN\8673395 antagonist\NN\7846 ,\,\1740 injected\VBN\81072 in\IN\13603305 doses\NNS\3740161 of\IN\1740 2.5\CD\1740 and\CC\1740 4.5\CD\1740 microg/0.5\CD\1740 microl\NN\1740 bilaterally\RB\1740 ,\,\1740 into\IN\1740 the\DT\1740 rostral\JJ\1740 region\NN\27167 of\IN\1740 the\DT\1740 striatum\NN\5497363 ,\,\1740 decreased\VBD\169651 both\CC\1740 the\DT\1740 haloperidol-induced\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 (\-LRB-\1740 MMG\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 enhanced\VBN\227165 electromyographic\JJ\1740 activity\NN\30358 (\-LRB-\1740 EMG\NN\7005158 )\-RRB-\1740 .\.\1740
D005998_D009127 NONE 5,7-dichlorokynurenic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5,7-DCKA\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 <e1>glycine</e1>\NN\14601829 site\NN\8673395 antagonist\NN\7846 ,\,\1740 injected\VBN\81072 in\IN\13603305 doses\NNS\3740161 of\IN\1740 2.5\CD\1740 and\CC\1740 4.5\CD\1740 microg/0.5\CD\1740 microl\NN\1740 bilaterally\RB\1740 ,\,\1740 into\IN\1740 the\DT\1740 rostral\JJ\1740 region\NN\27167 of\IN\1740 the\DT\1740 striatum\NN\5497363 ,\,\1740 decreased\VBD\169651 both\CC\1740 the\DT\1740 haloperidol-induced\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 (\-LRB-\1740 MMG\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 enhanced\VBN\227165 electromyographic\JJ\1740 activity\NN\30358 (\-LRB-\1740 EMG\NN\7005158 )\-RRB-\1740 .\.\1740
12139551
D008787_D006323 CID <e2>Cardiac\JJ\1740 arrest</e2>\NN\88481 after\IN\1740 intravenous\JJ\1740 <e1>metoclopramide</e1>\NN\1740 -\:\1740 a\DT\13649268 case\NN\7283608 of\IN\1740 five\CD\13741022 repeated\VBN\952524 injections\NNS\320852 of\IN\1740 metoclopramide\NN\1740 causing\VBG\1617192 five\CD\13741022 episodes\NNS\7283608 of\IN\1740 cardiac\JJ\1740 arrest\NN\88481 .\.\1740
D008787_D006323 CID Cardiac\JJ\1740 arrest\NN\88481 after\IN\1740 intravenous\JJ\1740 <e1>metoclopramide</e1>\NN\1740 -\:\1740 a\DT\13649268 case\NN\7283608 of\IN\1740 five\CD\13741022 repeated\VBN\952524 injections\NNS\320852 of\IN\1740 metoclopramide\NN\1740 causing\VBG\1617192 five\CD\13741022 episodes\NNS\7283608 of\IN\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 .\.\1740
D008787_D006323 CID <e2>Cardiac\JJ\1740 arrest</e2>\NN\88481 after\IN\1740 intravenous\JJ\1740 metoclopramide\NN\1740 -\:\1740 a\DT\13649268 case\NN\7283608 of\IN\1740 five\CD\13741022 repeated\VBN\952524 injections\NNS\320852 of\IN\1740 <e1>metoclopramide</e1>\NN\1740 causing\VBG\1617192 five\CD\13741022 episodes\NNS\7283608 of\IN\1740 cardiac\JJ\1740 arrest\NN\88481 .\.\1740
D008787_D006323 CID Cardiac\JJ\1740 arrest\NN\88481 after\IN\1740 intravenous\JJ\1740 metoclopramide\NN\1740 -\:\1740 a\DT\13649268 case\NN\7283608 of\IN\1740 five\CD\13741022 repeated\VBN\952524 injections\NNS\320852 of\IN\1740 <e1>metoclopramide</e1>\NN\1740 causing\VBG\1617192 five\CD\13741022 episodes\NNS\7283608 of\IN\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 .\.\1740
D008787_D006323 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 where\WRB\1740 intravenous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>metoclopramide</e1>\NN\1740 was\VBD\836236 immediately\RB\1740 followed\VBN\1835496 by\IN\1740 <e2>asystole</e2>\NN\14204950 repeatedly\RB\1740 .\.\1740
D008787_D006323 CID The\DT\1740 patient\NN\9898892 received\VBD\2210855 <e1>metoclopramide</e1>\NN\1740 10\CD\13745420 mg\NN\13717155 i.v.\NN\1740 five\CD\13741022 times\NNS\15113229 during\IN\1740 48\CD\1740 h.\NN\1740 After\IN\1740 interviewing\VBG\964694 the\DT\1740 attending\VBG\2655135 nurses\NNS\10165109 and\CC\1740 reviewing\VBG\644583 the\DT\1740 written\VBN\1697816 documentation\NN\6650070 ,\,\1740 it\PRP\6125041 is\VBZ\836236 clear\JJ\1740 that\IN\1740 every\DT\1740 administration\NN\1133281 of\IN\1740 metoclopramide\NN\1740 was\VBD\836236 immediately\RB\1740 (\-LRB-\1740 within\IN\1740 s\NNS\15154774 )\-RRB-\1740 followed\VBN\1835496 by\IN\1740 <e2>asystole</e2>\NN\14204950 .\.\1740
D008787_D006323 CID The\DT\1740 patient\NN\9898892 received\VBD\2210855 metoclopramide\NN\1740 10\CD\13745420 mg\NN\13717155 i.v.\NN\1740 five\CD\13741022 times\NNS\15113229 during\IN\1740 48\CD\1740 h.\NN\1740 After\IN\1740 interviewing\VBG\964694 the\DT\1740 attending\VBG\2655135 nurses\NNS\10165109 and\CC\1740 reviewing\VBG\644583 the\DT\1740 written\VBN\1697816 documentation\NN\6650070 ,\,\1740 it\PRP\6125041 is\VBZ\836236 clear\JJ\1740 that\IN\1740 every\DT\1740 administration\NN\1133281 of\IN\1740 <e1>metoclopramide</e1>\NN\1740 was\VBD\836236 immediately\RB\1740 (\-LRB-\1740 within\IN\1740 s\NNS\15154774 )\-RRB-\1740 followed\VBN\1835496 by\IN\1740 <e2>asystole</e2>\NN\14204950 .\.\1740
D008787_D006323 CID We\PRP\1740 interpret\VBP\588888 this\DT\1740 as\IN\14622893 episodes\NNS\7283608 of\IN\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 caused\VBN\1617192 by\IN\1740 <e1>metoclopramide</e1>\NN\1740 .\.\1740
11022397
D014331_D008569 NONE OUTCOME\NN\7291312 MEASURES\NN\168237 :\:\1740 Pupil\NNP\10059162 size\NN\5090441 at\IN\14622893 time\NN\7308889 points\NNS\5868954 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>tropicamide</e1>\NN\1740 and\CC\1740 pilocarpine\NN\14712692 ;\:\1740 scopolamine-induced\JJ\1740 <e2>impairment\NN\7296428 in\IN\13603305 word\NN\6284225 recall</e2>\NN\7185325 .\.\1740
D010862_D008569 NONE OUTCOME\NN\7291312 MEASURES\NN\168237 :\:\1740 Pupil\NNP\10059162 size\NN\5090441 at\IN\14622893 time\NN\7308889 points\NNS\5868954 after\IN\1740 administration\NN\1133281 of\IN\1740 tropicamide\NN\1740 and\CC\1740 <e1>pilocarpine</e1>\NN\14712692 ;\:\1740 scopolamine-induced\JJ\1740 <e2>impairment\NN\7296428 in\IN\13603305 word\NN\6284225 recall</e2>\NN\7185325 .\.\1740
D012601_D008569 CID OUTCOME\NN\7291312 MEASURES\NN\168237 :\:\1740 Pupil\NNP\10059162 size\NN\5090441 at\IN\14622893 time\NN\7308889 points\NNS\5868954 after\IN\1740 administration\NN\1133281 of\IN\1740 tropicamide\NN\1740 and\CC\1740 pilocarpine\NN\14712692 ;\:\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>impairment\NN\7296428 in\IN\13603305 word\NN\6284225 recall</e2>\NN\7185325 .\.\1740
D012601_D008569 CID Compared\VBN\644583 with\IN\1740 the\DT\1740 young\JJ\1740 group\NN\2137 ,\,\1740 the\DT\1740 elderly\JJ\1740 group\NN\2137 had\VBD\2108377 greater\JJR\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>impairment\NN\7296428 in\IN\13603305 word\NN\6284225 recall</e2>\NN\7185325 60\CD\13745420 ,\,\1740 90\CD\13745420 and\CC\1740 120\CD\13745420 minutes\NNS\6502378 after\IN\1740 administration\NN\1133281 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
16047871
D014859_C535509 NONE <e1>Warfarin-induced</e1>\JJ\1740 <e2>leukocytoclastic\JJ\1740 vasculitis</e2>\NN\14336539 .\.\1740
D014859_C535509 NONE We\PRP\1740 report\VBP\831651 4\CD\13741022 patients\NNS\9898892 with\IN\1740 late-onset\JJ\1740 <e2>LV</e2>\NN\1740 probably\RB\1740 due\IN\5174653 to\IN\1740 <e1>warfarin</e1>\NN\2718259 .\.\1740
D014859_C535509 NONE <e2>LV</e2>\NNP\1740 may\MD\15209706 be\VB\836236 a\DT\13649268 late-onset\JJ\1740 adverse\JJ\1740 reaction\NN\13446390 associated\VBN\628491 with\IN\1740 <e1>warfarin</e1>\NN\2718259 therapy\NN\657604 .\.\1740
D014859_D012871 NONE All\DT\1740 4\CD\13741022 patients\NNS\9898892 presented\VBN\2137132 with\IN\1740 <e2>skin\NN\5237755 eruptions</e2>\NNS\7307754 that\WDT\1740 developed\VBD\1753788 after\IN\1740 receiving\VBG\2210855 <e1>warfarin</e1>\NN\2718259 for\IN\1740 several\JJ\1740 years\NNS\15144371 .\.\1740
D014859_D012871 NONE The\DT\1740 results\NNS\34213 of\IN\1740 <e2>skin\NN\5237755 lesion</e2>\NN\14204950 biopsies\NNS\5739043 were\VBD\836236 available\JJ\1740 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 ,\,\1740 confirming\VBG\1011725 LV\NNP\1740 Cutaneous\JJ\1740 lesions\NNS\14204950 resolved\VBN\352826 in\IN\13603305 all\DT\1740 patients\NNS\9898892 after\IN\1740 <e1>warfarin</e1>\NN\2718259 was\VBD\836236 discontinued\VBN\2609764 .\.\1740
D014859_D018366 CID The\DT\1740 results\NNS\34213 of\IN\1740 skin\NN\5237755 lesion\NN\14204950 biopsies\NNS\5739043 were\VBD\836236 available\JJ\1740 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 ,\,\1740 confirming\VBG\1011725 <e2>LV\NNP\1740 Cutaneous\JJ\1740 lesions</e2>\NNS\14204950 resolved\VBN\352826 in\IN\13603305 all\DT\1740 patients\NNS\9898892 after\IN\1740 <e1>warfarin</e1>\NN\2718259 was\VBD\836236 discontinued\VBN\2609764 .\.\1740
16364460
D016713_D000647 NONE Microinjection\NN\1740 of\IN\1740 <e1>ritanserin</e1>\NN\1740 into\IN\1740 the\DT\1740 CA1\NN\1740 region\NN\27167 of\IN\1740 hippocampus\NN\5462674 improves\NNS\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 in\IN\13603305 adult\JJ\1740 male\JJ\1740 rats\NNS\2329401 .\.\1740
D016713_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>ritanserin</e1>\NN\1740 (\-LRB-\1740 5-HT2\NN\1740 antagonist\NN\7846 )\-RRB-\1740 on\IN\1740 scopolamine\NN\14712692 (\-LRB-\1740 muscarinic\JJ\1740 cholinergic\NN\1740 antagonist)-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 in\IN\13603305 Morris\NNP\1740 water\NN\14618834 maze\NN\4377057 (\-LRB-\1740 MWM\NN\1740 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D016713_D000647 NONE Our\PRP$\1740 findings\NNS\7951464 show\VBP\2137132 that\IN\1740 microinjection\NN\1740 of\IN\1740 <e1>ritanserin</e1>\NN\1740 into\IN\1740 the\DT\1740 CA1\NN\1740 region\NN\27167 of\IN\1740 the\DT\1740 hippocampus\NN\5462674 improves\VBZ\126264 the\DT\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D012601_D000647 CID Microinjection\NN\1740 of\IN\1740 ritanserin\NN\1740 into\IN\1740 the\DT\1740 CA1\NN\1740 region\NN\27167 of\IN\1740 hippocampus\NN\5462674 improves\NNS\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 in\IN\13603305 adult\JJ\1740 male\JJ\1740 rats\NNS\2329401 .\.\1740
D012601_D000647 CID The\DT\1740 effect\NN\34213 of\IN\1740 ritanserin\NN\1740 (\-LRB-\1740 5-HT2\NN\1740 antagonist\NN\7846 )\-RRB-\1740 on\IN\1740 <e1>scopolamine</e1>\NN\14712692 (\-LRB-\1740 muscarinic\JJ\1740 cholinergic\NN\1740 antagonist)-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 in\IN\13603305 Morris\NNP\1740 water\NN\14618834 maze\NN\4377057 (\-LRB-\1740 MWM\NN\1740 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D012601_D000647 CID Our\PRP$\1740 findings\NNS\7951464 show\VBP\2137132 that\IN\1740 microinjection\NN\1740 of\IN\1740 ritanserin\NN\1740 into\IN\1740 the\DT\1740 CA1\NN\1740 region\NN\27167 of\IN\1740 the\DT\1740 hippocampus\NN\5462674 improves\VBZ\126264 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
16418614
D011441_D014657 CID <e1>PTU-associated</e1>\JJ\1740 <e2>vasculitis</e2>\NN\14336539 in\IN\13603305 a\DT\13649268 girl\NN\10787470 with\IN\1740 Turner\NNP\10732967 Syndrome\NNP\5870365 and\CC\1740 Graves\NN\15143477 '\POS\1740 disease\NN\14061805 .\.\1740
D011441_D014657 CID The\DT\1740 diagnosis\NN\152018 of\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 (PTU)-associated\NN\1740 <e2>vasculitis</e2>\NN\14336539 was\VBD\836236 made\VBN\126264 by\IN\1740 observation\NN\996969 of\IN\1740 consistent\JJ\1740 clinical\JJ\1740 features\NNS\5849040 ,\,\1740 the\DT\1740 detection\NN\5708432 of\IN\1740 elevated\JJ\1740 ANA\NN\7951464 and\CC\1740 ANCA\NN\1740 in\IN\13603305 the\DT\1740 blood\NN\5397468 ,\,\1740 and\CC\1740 the\DT\1740 observed\VBN\2163746 clinical\JJ\1740 resolution\NN\6470073 of\IN\1740 symptoms\NNS\5823932 following\VBG\1835496 withdrawal\NN\7206096 of\IN\1740 PTU\NN\1740 .\.\1740
D011441_D014657 CID The\DT\1740 diagnosis\NN\152018 of\IN\1740 propylthiouracil\NN\14727670 <e1>(PTU)-associated</e1>\NN\1740 <e2>vasculitis</e2>\NN\14336539 was\VBD\836236 made\VBN\126264 by\IN\1740 observation\NN\996969 of\IN\1740 consistent\JJ\1740 clinical\JJ\1740 features\NNS\5849040 ,\,\1740 the\DT\1740 detection\NN\5708432 of\IN\1740 elevated\JJ\1740 ANA\NN\7951464 and\CC\1740 ANCA\NN\1740 in\IN\13603305 the\DT\1740 blood\NN\5397468 ,\,\1740 and\CC\1740 the\DT\1740 observed\VBN\2163746 clinical\JJ\1740 resolution\NN\6470073 of\IN\1740 symptoms\NNS\5823932 following\VBG\1835496 withdrawal\NN\7206096 of\IN\1740 PTU\NN\1740 .\.\1740
D011441_D014657 CID The\DT\1740 diagnosis\NN\152018 of\IN\1740 propylthiouracil\NN\14727670 (PTU)-associated\NN\1740 <e2>vasculitis</e2>\NN\14336539 was\VBD\836236 made\VBN\126264 by\IN\1740 observation\NN\996969 of\IN\1740 consistent\JJ\1740 clinical\JJ\1740 features\NNS\5849040 ,\,\1740 the\DT\1740 detection\NN\5708432 of\IN\1740 elevated\JJ\1740 ANA\NN\7951464 and\CC\1740 ANCA\NN\1740 in\IN\13603305 the\DT\1740 blood\NN\5397468 ,\,\1740 and\CC\1740 the\DT\1740 observed\VBN\2163746 clinical\JJ\1740 resolution\NN\6470073 of\IN\1740 symptoms\NNS\5823932 following\VBG\1835496 withdrawal\NN\7206096 of\IN\1740 <e1>PTU</e1>\NN\1740 .\.\1740
D011441_D014424 NONE <e1>PTU-associated</e1>\JJ\1740 vasculitis\NN\14336539 in\IN\13603305 a\DT\13649268 girl\NN\10787470 with\IN\1740 <e2>Turner\NNP\10732967 Syndrome</e2>\NNP\5870365 and\CC\1740 Graves\NN\15143477 '\POS\1740 disease\NN\14061805 .\.\1740
D011441_D006111 NONE <e1>PTU-associated</e1>\JJ\1740 vasculitis\NN\14336539 in\IN\13603305 a\DT\13649268 girl\NN\10787470 with\IN\1740 Turner\NNP\10732967 Syndrome\NNP\5870365 and\CC\1740 <e2>Graves\NN\15143477 '\POS\1740 disease</e2>\NN\14061805 .\.\1740
7263204
D007213_D000741 CID Fatal\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 due\IN\5174653 to\TO\1740 <e1>indomethacin</e1>\NN\3828465 --\:\1740 lymphocyte\NN\5449959 transformation\NN\7296428 tests\NNS\5798043 in\FW\13603305 vitro\FW\1740 .\.\1740
D007213_D000741 CID Although\IN\1740 <e1>indomethacin</e1>\NN\3828465 has\VBZ\2108377 been\VBN\836236 implicated\VBN\2677097 as\IN\14622893 a\DT\13649268 possible\JJ\1740 cause\NN\7323922 of\IN\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 a\DT\13649268 few\JJ\1740 clinical\JJ\1740 observations\NNS\996969 ,\,\1740 its\PRP$\6125041 role\NN\719494 has\VBZ\2108377 not\RB\1740 been\VBN\836236 definitely\RB\1740 established\VBN\2426171 .\.\1740
D007213_D000741 CID A\DT\13649268 case\NN\7283608 of\IN\1740 fatal\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 is\VBZ\836236 described\VBN\1001294 in\IN\13603305 which\WDT\1740 no\DT\7204911 drugs\NNS\14778436 other\JJ\1740 than\IN\1740 allopurinol\NN\3740161 and\CC\1740 <e1>indomethacin</e1>\NN\3828465 were\VBD\836236 given\VBN\2327200 .\.\1740
D007213_D000741 CID A\DT\13649268 positive\JJ\1740 lymphocyte\NN\5449959 transformation\NN\7296428 test\VBP\670261 with\IN\1740 <e1>indomethacin</e1>\NN\3828465 in\FW\13603305 vitro\FW\1740 further\RB\1740 substantiates\VBZ\2604760 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 this\DT\1740 drug\NN\14778436 in\IN\13603305 causing\VBG\1617192 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 a\DT\13649268 susceptible\JJ\1740 patient\NN\9898892 .\.\1740
D000493_D000741 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 fatal\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 is\VBZ\836236 described\VBN\1001294 in\IN\13603305 which\WDT\1740 no\DT\7204911 drugs\NNS\14778436 other\JJ\1740 than\IN\1740 <e1>allopurinol</e1>\NN\3740161 and\CC\1740 indomethacin\NN\3828465 were\VBD\836236 given\VBN\2327200 .\.\1740
9545159
D020117_D008133 CID <e2>Prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 interval</e2>\NN\33615 related\JJ\1740 to\TO\1740 <e1>cisapride-diltiazem</e1>\JJ\1740 interaction\NN\37396 .\.\1740
D004110_D008133 CID <e2>Prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 interval</e2>\NN\33615 related\JJ\1740 to\TO\1740 <e1>cisapride-diltiazem</e1>\JJ\1740 interaction\NN\37396 .\.\1740
D020117_D015835 NONE <e1>Cisapride</e1>\RB\1740 ,\,\1740 a\DT\13649268 cytochrome\NN\14888884 P450\NN\1740 3A4\NN\1740 (\-LRB-\1740 CYP3A4\NN\1740 )\-RRB-\1740 substrate\NN\19613 ,\,\1740 is\VBZ\836236 widely\RB\1740 prescribed\VBN\748282 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>gastrointestinal\JJ\1740 motility\NN\4773351 disorders</e2>\NNS\14034177 .\.\1740
D004917_D008133 CID <e2>Prolongation\NN\1017987 of\IN\1740 QT\NNP\1740 interval</e2>\NN\33615 ,\,\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 cardiac\JJ\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 <e1>erythromycin</e1>\NN\2716866 or\CC\3541091 azole\NN\1740 antifungal\NN\14778436 agents\NNS\7347 ,\,\1740 but\CC\1740 not\RB\1740 with\IN\1740 other\JJ\1740 CYP3A4\NN\1740 inhibitors\NNS\20090 .\.\1740
D004917_D016171 CID Prolongation\NN\1017987 of\IN\1740 QT\NNP\1740 interval\NN\33615 ,\,\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 cardiac\JJ\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 <e1>erythromycin</e1>\NN\2716866 or\CC\3541091 azole\NN\1740 antifungal\NN\14778436 agents\NNS\7347 ,\,\1740 but\CC\1740 not\RB\1740 with\IN\1740 other\JJ\1740 CYP3A4\NN\1740 inhibitors\NNS\20090 .\.\1740
D004917_D016757 CID Prolongation\NN\1017987 of\IN\1740 QT\NNP\1740 interval\NN\33615 ,\,\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 ,\,\1740 and\CC\1740 <e2>sudden\JJ\1740 cardiac\JJ\1740 death</e2>\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 <e1>erythromycin</e1>\NN\2716866 or\CC\3541091 azole\NN\1740 antifungal\NN\14778436 agents\NNS\7347 ,\,\1740 but\CC\1740 not\RB\1740 with\IN\1740 other\JJ\1740 CYP3A4\NN\1740 inhibitors\NNS\20090 .\.\1740
D001393_D008133 CID <e2>Prolongation\NN\1017987 of\IN\1740 QT\NNP\1740 interval</e2>\NN\33615 ,\,\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 cardiac\JJ\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 erythromycin\NN\2716866 or\CC\3541091 <e1>azole</e1>\NN\1740 antifungal\NN\14778436 agents\NNS\7347 ,\,\1740 but\CC\1740 not\RB\1740 with\IN\1740 other\JJ\1740 CYP3A4\NN\1740 inhibitors\NNS\20090 .\.\1740
D001393_D016171 CID Prolongation\NN\1017987 of\IN\1740 QT\NNP\1740 interval\NN\33615 ,\,\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 ,\,\1740 and\CC\1740 sudden\JJ\1740 cardiac\JJ\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 erythromycin\NN\2716866 or\CC\3541091 <e1>azole</e1>\NN\1740 antifungal\NN\14778436 agents\NNS\7347 ,\,\1740 but\CC\1740 not\RB\1740 with\IN\1740 other\JJ\1740 CYP3A4\NN\1740 inhibitors\NNS\20090 .\.\1740
D001393_D016757 CID Prolongation\NN\1017987 of\IN\1740 QT\NNP\1740 interval\NN\33615 ,\,\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 ,\,\1740 and\CC\1740 <e2>sudden\JJ\1740 cardiac\JJ\1740 death</e2>\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 erythromycin\NN\2716866 or\CC\3541091 <e1>azole</e1>\NN\1740 antifungal\NN\14778436 agents\NNS\7347 ,\,\1740 but\CC\1740 not\RB\1740 with\IN\1740 other\JJ\1740 CYP3A4\NN\1740 inhibitors\NNS\20090 .\.\1740
D020117_D005764 NONE A\DT\13649268 possible\JJ\1740 drug\NN\14778436 interaction\NN\37396 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 45-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 was\VBD\836236 taking\VBG\2367363 <e1>cisapride</e1>\NN\1740 for\IN\1740 <e2>gastroesophageal\JJ\1740 reflux\NN\14204950 disorder</e2>\NN\14034177 and\CC\1740 diltiazem\NN\2938514 ,\,\1740 an\DT\6697703 agent\NN\7347 that\WDT\1740 has\VBZ\2108377 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 CYP3A4\NN\1740 ,\,\1740 for\IN\1740 hypertension\NN\14057371 .\.\1740
D020117_D006973 NONE A\DT\13649268 possible\JJ\1740 drug\NN\14778436 interaction\NN\37396 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 45-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 was\VBD\836236 taking\VBG\2367363 <e1>cisapride</e1>\NN\1740 for\IN\1740 gastroesophageal\JJ\1740 reflux\NN\14204950 disorder\NN\14034177 and\CC\1740 diltiazem\NN\2938514 ,\,\1740 an\DT\6697703 agent\NN\7347 that\WDT\1740 has\VBZ\2108377 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 CYP3A4\NN\1740 ,\,\1740 for\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D004110_D005764 NONE A\DT\13649268 possible\JJ\1740 drug\NN\14778436 interaction\NN\37396 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 45-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 was\VBD\836236 taking\VBG\2367363 cisapride\NN\1740 for\IN\1740 <e2>gastroesophageal\JJ\1740 reflux\NN\14204950 disorder</e2>\NN\14034177 and\CC\1740 <e1>diltiazem</e1>\NN\2938514 ,\,\1740 an\DT\6697703 agent\NN\7347 that\WDT\1740 has\VBZ\2108377 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 CYP3A4\NN\1740 ,\,\1740 for\IN\1740 hypertension\NN\14057371 .\.\1740
D004110_D006973 NONE A\DT\13649268 possible\JJ\1740 drug\NN\14778436 interaction\NN\37396 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 45-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 was\VBD\836236 taking\VBG\2367363 cisapride\NN\1740 for\IN\1740 gastroesophageal\JJ\1740 reflux\NN\14204950 disorder\NN\14034177 and\CC\1740 <e1>diltiazem</e1>\NN\2938514 ,\,\1740 an\DT\6697703 agent\NN\7347 that\WDT\1740 has\VBZ\2108377 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 CYP3A4\NN\1740 ,\,\1740 for\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
2320800
D007069_D001002 CID Lethal\JJ\1740 <e2>anuria</e2>\NNS\14061805 complicating\VBG\126264 high\JJ\1740 dose\NN\3740161 <e1>ifosfamide</e1>\NN\1740 chemotherapy\NN\661091 in\IN\13603305 a\DT\13649268 breast\NN\5225090 cancer\NN\14239425 patient\NN\9898892 with\IN\1740 an\DT\6697703 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D007069_D001002 CID A\DT\13649268 sixty-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 advanced\JJ\1740 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 previously\RB\1740 treated\VBN\2376958 with\IN\1740 cisplatin\NN\1740 ,\,\1740 developed\VBD\1753788 an\DT\6697703 irreversible\JJ\1740 lethal\JJ\1740 renal\JJ\1740 failure\NN\66216 with\IN\1740 <e2>anuria</e2>\NN\14061805 ,\,\1740 the\DT\1740 day\NN\15154774 after\IN\1740 5\CD\13741022 g/m2\NN\1740 bolus\NN\13899404 <e1>ifosfamide</e1>\NN\1740 .\.\1740
D007069_D001002 CID We\PRP\1740 strongly\RB\1740 suspect\VBP\916909 that\IN\1740 this\DT\1740 lethal\JJ\1740 <e2>anuria</e2>\NN\14061805 was\VBD\836236 mainly\RB\1740 due\JJ\1740 to\TO\1740 <e1>ifosfamide</e1>\NN\1740 ,\,\1740 occurring\VBG\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 having\VBG\2108377 received\VBN\2210855 previous\JJ\1740 cisplatin\NN\1740 chemotherapy\NN\661091 and\CC\1740 with\IN\1740 poor\JJ\1740 kidney\NN\5333259 perfusion\NN\320852 due\JJ\1740 to\TO\1740 transient\JJ\1740 hypotension\NN\14057371 .\.\1740
D007069_D001943 NONE Lethal\JJ\1740 anuria\NNS\14061805 complicating\VBG\126264 high\JJ\1740 dose\NN\3740161 <e1>ifosfamide</e1>\NN\1740 chemotherapy\NN\661091 in\IN\13603305 a\DT\13649268 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 patient\NN\9898892 with\IN\1740 an\DT\6697703 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D007069_D001943 NONE A\DT\13649268 sixty-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 advanced\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 previously\RB\1740 treated\VBN\2376958 with\IN\1740 cisplatin\NN\1740 ,\,\1740 developed\VBD\1753788 an\DT\6697703 irreversible\JJ\1740 lethal\JJ\1740 renal\JJ\1740 failure\NN\66216 with\IN\1740 anuria\NN\14061805 ,\,\1740 the\DT\1740 day\NN\15154774 after\IN\1740 5\CD\13741022 g/m2\NN\1740 bolus\NN\13899404 <e1>ifosfamide</e1>\NN\1740 .\.\1740
D007069_D007674 CID Lethal\JJ\1740 anuria\NNS\14061805 complicating\VBG\126264 high\JJ\1740 dose\NN\3740161 <e1>ifosfamide</e1>\NN\1740 chemotherapy\NN\661091 in\IN\13603305 a\DT\13649268 breast\NN\5225090 cancer\NN\14239425 patient\NN\9898892 with\IN\1740 an\DT\6697703 <e2>impaired\JJ\1740 renal\JJ\1740 function</e2>\NN\13783581 .\.\1740
D007069_D007674 CID <e1>Ifosfamide</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 <e2>nephrotoxic</e2>\JJ\1740 drug\NN\14778436 with\IN\1740 demonstrated\VBN\2137132 tubulopathies\NNS\1740 .\.\1740
D007069_D007674 CID <e1>Ifosfamide</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 nephrotoxic\JJ\1740 drug\NN\14778436 with\IN\1740 demonstrated\VBN\2137132 <e2>tubulopathies</e2>\NNS\1740 .\.\1740
D007069_D007674 CID We\PRP\1740 recommend\VBP\875394 careful\JJ\1740 use\NN\407535 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 pretreated\VBN\1740 with\IN\1740 <e2>nephrotoxic</e2>\JJ\1740 chemotherapy\NN\661091 and\CC\1740 inadequate\JJ\1740 renal\JJ\1740 perfusion\NN\320852 .\.\1740
D002945_D001943 NONE A\DT\13649268 sixty-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 advanced\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 previously\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 developed\VBD\1753788 an\DT\6697703 irreversible\JJ\1740 lethal\JJ\1740 renal\JJ\1740 failure\NN\66216 with\IN\1740 anuria\NN\14061805 ,\,\1740 the\DT\1740 day\NN\15154774 after\IN\1740 5\CD\13741022 g/m2\NN\1740 bolus\NN\13899404 ifosfamide\NN\1740 .\.\1740
D002945_D051437 NONE A\DT\13649268 sixty-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 advanced\JJ\1740 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 previously\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 developed\VBD\1753788 an\DT\6697703 irreversible\JJ\1740 lethal\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 with\IN\1740 anuria\NN\14061805 ,\,\1740 the\DT\1740 day\NN\15154774 after\IN\1740 5\CD\13741022 g/m2\NN\1740 bolus\NN\13899404 ifosfamide\NN\1740 .\.\1740
D002945_D001002 NONE A\DT\13649268 sixty-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 advanced\JJ\1740 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 previously\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 developed\VBD\1753788 an\DT\6697703 irreversible\JJ\1740 lethal\JJ\1740 renal\JJ\1740 failure\NN\66216 with\IN\1740 <e2>anuria</e2>\NN\14061805 ,\,\1740 the\DT\1740 day\NN\15154774 after\IN\1740 5\CD\13741022 g/m2\NN\1740 bolus\NN\13899404 ifosfamide\NN\1740 .\.\1740
D002945_D001002 NONE We\PRP\1740 strongly\RB\1740 suspect\VBP\916909 that\IN\1740 this\DT\1740 lethal\JJ\1740 <e2>anuria</e2>\NN\14061805 was\VBD\836236 mainly\RB\1740 due\JJ\1740 to\TO\1740 ifosfamide\NN\1740 ,\,\1740 occurring\VBG\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 having\VBG\2108377 received\VBN\2210855 previous\JJ\1740 <e1>cisplatin</e1>\NN\1740 chemotherapy\NN\661091 and\CC\1740 with\IN\1740 poor\JJ\1740 kidney\NN\5333259 perfusion\NN\320852 due\JJ\1740 to\TO\1740 transient\JJ\1740 hypotension\NN\14057371 .\.\1740
D007069_D051437 NONE A\DT\13649268 sixty-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 advanced\JJ\1740 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 previously\RB\1740 treated\VBN\2376958 with\IN\1740 cisplatin\NN\1740 ,\,\1740 developed\VBD\1753788 an\DT\6697703 irreversible\JJ\1740 lethal\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 with\IN\1740 anuria\NN\14061805 ,\,\1740 the\DT\1740 day\NN\15154774 after\IN\1740 5\CD\13741022 g/m2\NN\1740 bolus\NN\13899404 <e1>ifosfamide</e1>\NN\1740 .\.\1740
D007069_D007022 NONE We\PRP\1740 strongly\RB\1740 suspect\VBP\916909 that\IN\1740 this\DT\1740 lethal\JJ\1740 anuria\NN\14061805 was\VBD\836236 mainly\RB\1740 due\JJ\1740 to\TO\1740 <e1>ifosfamide</e1>\NN\1740 ,\,\1740 occurring\VBG\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 having\VBG\2108377 received\VBN\2210855 previous\JJ\1740 cisplatin\NN\1740 chemotherapy\NN\661091 and\CC\1740 with\IN\1740 poor\JJ\1740 kidney\NN\5333259 perfusion\NN\320852 due\JJ\1740 to\TO\1740 transient\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D002945_D007022 NONE We\PRP\1740 strongly\RB\1740 suspect\VBP\916909 that\IN\1740 this\DT\1740 lethal\JJ\1740 anuria\NN\14061805 was\VBD\836236 mainly\RB\1740 due\JJ\1740 to\TO\1740 ifosfamide\NN\1740 ,\,\1740 occurring\VBG\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 having\VBG\2108377 received\VBN\2210855 previous\JJ\1740 <e1>cisplatin</e1>\NN\1740 chemotherapy\NN\661091 and\CC\1740 with\IN\1740 poor\JJ\1740 kidney\NN\5333259 perfusion\NN\320852 due\JJ\1740 to\TO\1740 transient\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
16586083
D016861_D009203 CID Randomised\VBN\278117 clinical\JJ\1740 trials\NNS\786195 and\CC\1740 observational\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 ,\,\1740 stroke\NN\556313 ,\,\1740 hypertension\NN\14057371 and\CC\1740 heart\NN\5919034 failure\NN\66216 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cyclooxygenase\NN\14732946 inhibitors</e1>\NNS\20090 .\.\1740
D016861_D020521 CID Randomised\VBN\278117 clinical\JJ\1740 trials\NNS\786195 and\CC\1740 observational\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 <e2>stroke</e2>\NN\556313 ,\,\1740 hypertension\NN\14057371 and\CC\1740 heart\NN\5919034 failure\NN\66216 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cyclooxygenase\NN\14732946 inhibitors</e1>\NNS\20090 .\.\1740
D016861_D006973 CID Randomised\VBN\278117 clinical\JJ\1740 trials\NNS\786195 and\CC\1740 observational\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 stroke\NN\556313 ,\,\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 heart\NN\5919034 failure\NN\66216 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cyclooxygenase\NN\14732946 inhibitors</e1>\NNS\20090 .\.\1740
D016861_D006333 CID Randomised\VBN\278117 clinical\JJ\1740 trials\NNS\786195 and\CC\1740 observational\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 stroke\NN\556313 ,\,\1740 hypertension\NN\14057371 and\CC\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cyclooxygenase\NN\14732946 inhibitors</e1>\NNS\20090 .\.\1740
C109794_D002318 NONE Diagnostic\JJ\1740 markers\NNS\21939 such\JJ\1740 as\IN\14622893 <e1>N-terminal\JJ\1740 pro\JJ\1740 brain\NN\5462674 natriuretic\JJ\1740 peptide</e1>\NN\14724264 (\-LRB-\1740 NT-proBNP\NN\1740 )\-RRB-\1740 or\CC\3541091 high-sensitive\JJ\1740 C-reactive\JJ\1740 protein\NN\14944888 might\MD\5029706 help\VB\2556126 in\IN\13603305 the\DT\1740 early\JJ\1740 identification\NN\151497 of\IN\1740 patients\NNS\9898892 at\IN\14622893 risk\NN\14541044 ,\,\1740 thus\RB\1740 avoiding\VBG\2452885 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 <e2>cardiovascular\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
C109794_D002318 NONE Diagnostic\JJ\1740 markers\NNS\21939 such\JJ\1740 as\IN\14622893 N-terminal\JJ\1740 pro\JJ\1740 brain\NN\5462674 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 <e1>NT-proBNP</e1>\NN\1740 )\-RRB-\1740 or\CC\3541091 high-sensitive\JJ\1740 C-reactive\JJ\1740 protein\NN\14944888 might\MD\5029706 help\VB\2556126 in\IN\13603305 the\DT\1740 early\JJ\1740 identification\NN\151497 of\IN\1740 patients\NNS\9898892 at\IN\14622893 risk\NN\14541044 ,\,\1740 thus\RB\1740 avoiding\VBG\2452885 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 <e2>cardiovascular\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
6615052
D006493_D013921 CID <e1>Heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 thrombosis\NN\14100769 ,\,\1740 and\CC\1740 hemorrhage\NN\14285662 .\.\1740
D006493_D013921 CID Sixty-two\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 are\VBP\836236 reported\VBN\831651 .\.\1740
D006493_D013927 NONE <e1>Heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e2>thrombosis</e2>\NN\14100769 ,\,\1740 and\CC\1740 hemorrhage\NN\14285662 .\.\1740
D006493_D006470 CID <e1>Heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 thrombosis\NN\14100769 ,\,\1740 and\CC\1740 <e2>hemorrhage</e2>\NN\14285662 .\.\1740
D006493_D006470 CID Clinical\JJ\1740 manifestations\NNS\7321772 of\IN\1740 this\DT\1740 disorder\NN\14034177 include\VBP\690614 <e2>hemorrhage</e2>\NN\14285662 or\CC\3541091 ,\,\1740 more\RBR\1740 frequently\RB\1740 ,\,\1740 thromboembolic\NN\1740 events\NNS\23100 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>heparin</e1>\NN\2718259 .\.\1740
D006493_D013923 CID Clinical\JJ\1740 manifestations\NNS\7321772 of\IN\1740 this\DT\1740 disorder\NN\14034177 include\VBP\690614 hemorrhage\NN\14285662 or\CC\3541091 ,\,\1740 more\RBR\1740 frequently\RB\1740 ,\,\1740 <e2>thromboembolic</e2>\NN\1740 events\NNS\23100 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>heparin</e1>\NN\2718259 .\.\1740
D006493_D001791 NONE Laboratory\JJ\1740 testing\NN\639556 has\VBZ\2108377 revealed\VBN\2137132 <e2>a\DT\13649268 falling\VBG\1835496 platelet\NN\5432736 count</e2>\NN\13582013 ,\,\1740 increased\VBD\169651 resistance\NN\37396 to\TO\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 and\CC\1740 aggregation\NN\31264 of\IN\1740 platelets\NNS\5432736 by\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 plasma\NN\5398023 when\WRB\1740 heparin\NN\2718259 is\VBZ\836236 added\VBN\156601 .\.\1740
D006493_D001791 NONE Laboratory\JJ\1740 testing\NN\639556 has\VBZ\2108377 revealed\VBN\2137132 <e2>a\DT\13649268 falling\VBG\1835496 platelet\NN\5432736 count</e2>\NN\13582013 ,\,\1740 increased\VBD\169651 resistance\NN\37396 to\TO\1740 heparin\NN\2718259 ,\,\1740 and\CC\1740 aggregation\NN\31264 of\IN\1740 platelets\NNS\5432736 by\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 plasma\NN\5398023 when\WRB\1740 <e1>heparin</e1>\NN\2718259 is\VBZ\836236 added\VBN\156601 .\.\1740
D006493_D001791 NONE If\IN\1740 the\DT\1740 platelet\NN\5432736 count\NN\13582013 falls\VBZ\1835496 to\IN\1740 less\JJR\1740 than\IN\1740 100,000/mm3\NN\1740 ,\,\1740 while\IN\15122231 the\DT\1740 patient\NN\9898892 is\VBZ\836236 receiving\VBG\2210855 <e1>heparin</e1>\NN\2718259 ,\,\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 testing\NN\639556 ,\,\1740 using\VBG\1156834 the\DT\1740 patient\NN\9898892 's\POS\1740 plasma\NN\5398023 ,\,\1740 is\VBZ\836236 indicated\VBN\952524 .\.\1740
14648024
D014212_D004893 CID <e1>All-\JJ\1740 trans-retinoic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>erythema\NN\14227218 nodosum</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 .\.\1740
D014212_D004893 CID <e2>Erythema\NN\14227218 nodosum</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>all-\JJ\1740 trans-retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 for\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 is\VBZ\836236 very\RB\1740 rare\JJ\1740 .\.\1740
D014212_D004893 CID <e2>Erythema\NN\14227218 nodosum</e2>\NN\1740 associated\VBN\628491 with\IN\1740 all-\JJ\1740 trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ATRA</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 is\VBZ\836236 very\RB\1740 rare\JJ\1740 .\.\1740
D014212_D004893 CID We\PRP\1740 describe\VBP\1001294 four\CD\13741022 patients\NNS\9898892 with\IN\1740 classic\JJ\1740 APL\NN\1740 who\WP\8299493 developed\VBD\1753788 <e2>erythema\NN\14227218 nodosum</e2>\NN\1740 during\IN\1740 <e1>ATRA</e1>\NN\1740 therapy\NN\657604 .\.\1740
D014212_D004893 CID Fever\NNS\14299637 and\CC\1740 subsequent\JJ\1740 multiple\JJ\1740 painful\JJ\1740 <e2>erythematous\JJ\1740 nodules</e2>\NNS\5264913 over\IN\5867413 extremities\NNS\5225090 developed\VBN\1753788 on\IN\1740 D11\NN\1740 ,\,\1740 D16\NN\1740 ,\,\1740 D17\NN\1740 ,\,\1740 and\CC\1740 D19\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 after\IN\1740 <e1>ATRA</e1>\NN\1740 therapy\NN\657604 .\.\1740
D014212_D004893 CID <e1>ATRA</e1>\NN\1740 seemed\VBD\2604760 to\TO\1740 be\VB\836236 the\DT\1740 most\RBS\1740 possible\JJ\1740 etiology\NN\7326557 of\IN\1740 <e2>erythema\NN\14227218 nodosum</e2>\NN\1740 in\IN\13603305 our\PRP$\1740 patients\NNS\9898892 .\.\1740
D014212_D004893 CID Short-term\JJ\1740 use\NN\407535 of\IN\1740 steroid\NN\14727670 is\VBZ\836236 very\RB\1740 effective\JJ\1740 in\IN\13603305 <e1>ATRA-induced</e1>\JJ\1740 <e2>erythema\NN\14227218 nodosum</e2>\NN\1740 .\.\1740
D014212_D015473 NONE <e1>All-\JJ\1740 trans-retinoic\JJ\1740 acid-induced</e1>\JJ\1740 erythema\NN\14227218 nodosum\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 .\.\1740
D014212_D015473 NONE Erythema\NN\14227218 nodosum\NN\1740 associated\VBN\628491 with\IN\1740 <e1>all-\JJ\1740 trans-retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 for\IN\1740 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 is\VBZ\836236 very\RB\1740 rare\JJ\1740 .\.\1740
D014212_D015473 NONE Erythema\NN\14227218 nodosum\NN\1740 associated\VBN\628491 with\IN\1740 <e1>all-\JJ\1740 trans-retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 for\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>APL</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 very\RB\1740 rare\JJ\1740 .\.\1740
D014212_D015473 NONE Erythema\NN\14227218 nodosum\NN\1740 associated\VBN\628491 with\IN\1740 all-\JJ\1740 trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ATRA</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 is\VBZ\836236 very\RB\1740 rare\JJ\1740 .\.\1740
D014212_D015473 NONE Erythema\NN\14227218 nodosum\NN\1740 associated\VBN\628491 with\IN\1740 all-\JJ\1740 trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ATRA</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>APL</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 very\RB\1740 rare\JJ\1740 .\.\1740
D014212_D015473 NONE We\PRP\1740 describe\VBP\1001294 four\CD\13741022 patients\NNS\9898892 with\IN\1740 classic\JJ\1740 <e2>APL</e2>\NN\1740 who\WP\8299493 developed\VBD\1753788 erythema\NN\14227218 nodosum\NN\1740 during\IN\1740 <e1>ATRA</e1>\NN\1740 therapy\NN\657604 .\.\1740
D014212_D005334 CID <e2>Fever</e2>\NNS\14299637 and\CC\1740 subsequent\JJ\1740 multiple\JJ\1740 painful\JJ\1740 erythematous\JJ\1740 nodules\NNS\5264913 over\IN\5867413 extremities\NNS\5225090 developed\VBN\1753788 on\IN\1740 D11\NN\1740 ,\,\1740 D16\NN\1740 ,\,\1740 D17\NN\1740 ,\,\1740 and\CC\1740 D19\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 after\IN\1740 <e1>ATRA</e1>\NN\1740 therapy\NN\657604 .\.\1740
D014212_D010146 NONE Fever\NNS\14299637 and\CC\1740 subsequent\JJ\1740 multiple\JJ\1740 <e2>painful</e2>\JJ\1740 erythematous\JJ\1740 nodules\NNS\5264913 over\IN\5867413 extremities\NNS\5225090 developed\VBN\1753788 on\IN\1740 D11\NN\1740 ,\,\1740 D16\NN\1740 ,\,\1740 D17\NN\1740 ,\,\1740 and\CC\1740 D19\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 after\IN\1740 <e1>ATRA</e1>\NN\1740 therapy\NN\657604 .\.\1740
D013256_D004893 NONE Short-term\JJ\1740 use\NN\407535 of\IN\1740 <e1>steroid</e1>\NN\14727670 is\VBZ\836236 very\RB\1740 effective\JJ\1740 in\IN\13603305 ATRA-induced\JJ\1740 <e2>erythema\NN\14227218 nodosum</e2>\NN\1740 .\.\1740
17490864
D000661_D006948 CID <e1>Amphetamine-induced</e1>\JJ\1740 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 was\VBD\836236 similar\JJ\1740 in\IN\13603305 all\DT\1740 groups\NNS\2137 .\.\1740
21418164
D008130_D064420 NONE <e1>CCNU</e1>\NN\1740 (\-LRB-\1740 lomustine\NN\2722458 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 dogs\NNS\2083346 :\:\1740 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 (\-LRB-\1740 2002\CD\1740 -\SYM\1740 07\CD\1740 )\-RRB-\1740 .\.\1740
D008130_D064420 NONE CCNU\NN\1740 (\-LRB-\1740 <e1>lomustine</e1>\NN\2722458 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 dogs\NNS\2083346 :\:\1740 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 (\-LRB-\1740 2002\CD\1740 -\SYM\1740 07\CD\1740 )\-RRB-\1740 .\.\1740
D008130_D064420 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 the\DT\1740 206\CD\1740 dogs\NNS\2083346 treated\VBN\2376958 with\IN\1740 <e1>CCNU</e1>\NNS\1740 ,\,\1740 185\CD\1740 met\VBD\1182709 the\DT\1740 inclusion\NN\13927383 criteria\NNS\13577171 for\IN\1740 at\IN\14622893 least\JJS\1740 one\CD\13741022 class\NN\7951464 of\IN\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D008130_D064420 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>CCNU-associated</e1>\JJ\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 dogs\NNS\2083346 is\VBZ\836236 common\JJ\1740 ,\,\1740 but\CC\1740 is\VBZ\836236 usually\RB\1740 not\RB\1740 life\NN\13954253 threatening\VBG\2603699 .\.\1740
D008130_D006402 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>haematological\JJ\1740 ,\,\1740 renal\JJ\1740 ,\,\1740 hepatic\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 toxicities</e2>\NNS\13576101 in\IN\13603305 tumour-bearing\JJ\1740 dogs\NNS\2083346 receiving\VBG\2210855 <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1>\CD\1740 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D006402 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>haematological\JJ\1740 ,\,\1740 renal\JJ\1740 ,\,\1740 hepatic\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 toxicities</e2>\NNS\13576101 in\IN\13603305 tumour-bearing\JJ\1740 dogs\NNS\2083346 receiving\VBG\2210855 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea\CD\1740 (\-LRB-\1740 <e1>CCNU</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D007674 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>haematological\JJ\1740 ,\,\1740 renal\JJ\1740 ,\,\1740 hepatic\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 toxicities</e2>\NNS\13576101 in\IN\13603305 tumour-bearing\JJ\1740 dogs\NNS\2083346 receiving\VBG\2210855 <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1>\CD\1740 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D007674 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>haematological\JJ\1740 ,\,\1740 renal\JJ\1740 ,\,\1740 hepatic\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 toxicities</e2>\NNS\13576101 in\IN\13603305 tumour-bearing\JJ\1740 dogs\NNS\2083346 receiving\VBG\2210855 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea\CD\1740 (\-LRB-\1740 <e1>CCNU</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D056486 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>haematological\JJ\1740 ,\,\1740 renal\JJ\1740 ,\,\1740 hepatic\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 toxicities</e2>\NNS\13576101 in\IN\13603305 tumour-bearing\JJ\1740 dogs\NNS\2083346 receiving\VBG\2210855 <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1>\CD\1740 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D056486 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>haematological\JJ\1740 ,\,\1740 renal\JJ\1740 ,\,\1740 hepatic\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 toxicities</e2>\NNS\13576101 in\IN\13603305 tumour-bearing\JJ\1740 dogs\NNS\2083346 receiving\VBG\2210855 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea\CD\1740 (\-LRB-\1740 <e1>CCNU</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D005767 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>haematological\JJ\1740 ,\,\1740 renal\JJ\1740 ,\,\1740 hepatic\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 toxicities</e2>\NNS\13576101 in\IN\13603305 tumour-bearing\JJ\1740 dogs\NNS\2083346 receiving\VBG\2210855 <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1>\CD\1740 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D005767 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>haematological\JJ\1740 ,\,\1740 renal\JJ\1740 ,\,\1740 hepatic\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 toxicities</e2>\NNS\13576101 in\IN\13603305 tumour-bearing\JJ\1740 dogs\NNS\2083346 receiving\VBG\2210855 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea\CD\1740 (\-LRB-\1740 <e1>CCNU</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D008223 NONE <e1>CCNU</e1>\NNS\1740 was\VBD\836236 used\VBN\1156834 most\RBS\1740 commonly\RB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>lymphoma</e2>\NN\14239918 ,\,\1740 mast\NN\4267577 cell\NN\3080309 tumour\NN\14234074 ,\,\1740 brain\NN\5462674 tumour\NN\14234074 ,\,\1740 histiocytic\JJ\1740 tumours\NNS\14234074 and\CC\1740 epitheliotropic\JJ\1740 lymphoma\NN\14239918 .\.\1740
D008130_D008223 NONE <e1>CCNU</e1>\NNS\1740 was\VBD\836236 used\VBN\1156834 most\RBS\1740 commonly\RB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 lymphoma\NN\14239918 ,\,\1740 mast\NN\4267577 cell\NN\3080309 tumour\NN\14234074 ,\,\1740 brain\NN\5462674 tumour\NN\14234074 ,\,\1740 histiocytic\JJ\1740 tumours\NNS\14234074 and\CC\1740 <e2>epitheliotropic\JJ\1740 lymphoma</e2>\NN\14239918 .\.\1740
D008130_D034801 NONE <e1>CCNU</e1>\NNS\1740 was\VBD\836236 used\VBN\1156834 most\RBS\1740 commonly\RB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 lymphoma\NN\14239918 ,\,\1740 <e2>mast\NN\4267577 cell\NN\3080309 tumour</e2>\NN\14234074 ,\,\1740 brain\NN\5462674 tumour\NN\14234074 ,\,\1740 histiocytic\JJ\1740 tumours\NNS\14234074 and\CC\1740 epitheliotropic\JJ\1740 lymphoma\NN\14239918 .\.\1740
D008130_D001932 NONE <e1>CCNU</e1>\NNS\1740 was\VBD\836236 used\VBN\1156834 most\RBS\1740 commonly\RB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 lymphoma\NN\14239918 ,\,\1740 mast\NN\4267577 cell\NN\3080309 tumour\NN\14234074 ,\,\1740 <e2>brain\NN\5462674 tumour</e2>\NN\14234074 ,\,\1740 histiocytic\JJ\1740 tumours\NNS\14234074 and\CC\1740 epitheliotropic\JJ\1740 lymphoma\NN\14239918 .\.\1740
D008130_D015620 NONE <e1>CCNU</e1>\NNS\1740 was\VBD\836236 used\VBN\1156834 most\RBS\1740 commonly\RB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 lymphoma\NN\14239918 ,\,\1740 mast\NN\4267577 cell\NN\3080309 tumour\NN\14234074 ,\,\1740 brain\NN\5462674 tumour\NN\14234074 ,\,\1740 <e2>histiocytic\JJ\1740 tumours</e2>\NNS\14234074 and\CC\1740 epitheliotropic\JJ\1740 lymphoma\NN\14239918 .\.\1740
D000409_D064420 NONE Potential\JJ\1740 renal\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 elevated\JJ\1740 <e1>alanine</e1>\NN\14601829 transaminase\NN\15077571 (\-LRB-\1740 ALT\NN\13836371 )\-RRB-\1740 concentration\NN\4916342 were\VBD\836236 reported\VBN\831651 in\IN\13603305 12.2\CD\1740 %\NN\1740 and\CC\1740 48.8\CD\1740 %\NN\1740 of\IN\1740 dogs\NNS\2083346 ,\,\1740 respectively\RB\1740 .\.\1740
9022662
D010389_D002819 CID <e1>Pemoline</e1>\NN\1740 induced\VBD\1627355 acute\JJ\1740 <e2>choreoathetosis</e2>\NN\1740 :\:\1740 case\NN\7283608 report\NN\6470073 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
D010389_D002819 CID The\DT\1740 following\VBG\1835496 case\NN\7283608 describes\VBZ\1001294 two\CD\13741022 children\NNS\9622049 acutely\RB\1740 poisoned\VBN\2579447 with\IN\1740 <e1>pemoline</e1>\NN\1740 who\WP\8299493 experienced\VBD\2108377 profound\JJ\1740 <e2>choreoathetosis</e2>\NN\1740 .\.\1740
D010389_D002819 CID The\DT\1740 possibility\NN\5944958 of\IN\1740 <e2>choreoathetoid</e2>\NN\1740 movements\NNS\191142 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 presenting\VBG\2137132 after\IN\1740 <e1>pemoline</e1>\NN\1740 overdose\NN\1740 .\.\1740
D010389_D001264 CID <e1>Pemoline</e1>\NN\1740 induced\VBD\1627355 acute\JJ\1740 <e2>choreoathetosis</e2>\NN\1740 :\:\1740 case\NN\7283608 report\NN\6470073 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
D010389_D001264 CID The\DT\1740 following\VBG\1835496 case\NN\7283608 describes\VBZ\1001294 two\CD\13741022 children\NNS\9622049 acutely\RB\1740 poisoned\VBN\2579447 with\IN\1740 <e1>pemoline</e1>\NN\1740 who\WP\8299493 experienced\VBD\2108377 profound\JJ\1740 <e2>choreoathetosis</e2>\NN\1740 .\.\1740
D010389_D001264 CID The\DT\1740 possibility\NN\5944958 of\IN\1740 <e2>choreoathetoid</e2>\NN\1740 movements\NNS\191142 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 presenting\VBG\2137132 after\IN\1740 <e1>pemoline</e1>\NN\1740 overdose\NN\1740 .\.\1740
D010389_D001289 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Pemoline</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 oxazolidine\NN\1740 derivative\NN\5802185 that\WDT\1740 is\VBZ\836236 structurally\RB\1740 different\JJ\1740 from\IN\1740 amphetamines\NNS\3248958 and\CC\1740 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>attention\NN\5701944 deficit\NN\5113133 disorder</e2>\NN\14034177 .\.\1740
C064210_D001289 NONE BACKGROUND\NN\4921011 :\:\1740 Pemoline\NN\1740 is\VBZ\836236 an\DT\6697703 <e1>oxazolidine</e1>\NN\1740 derivative\NN\5802185 that\WDT\1740 is\VBZ\836236 structurally\RB\1740 different\JJ\1740 from\IN\1740 amphetamines\NNS\3248958 and\CC\1740 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>attention\NN\5701944 deficit\NN\5113133 disorder</e2>\NN\14034177 .\.\1740
D000662_D001289 NONE BACKGROUND\NN\4921011 :\:\1740 Pemoline\NN\1740 is\VBZ\836236 an\DT\6697703 oxazolidine\NN\1740 derivative\NN\5802185 that\WDT\1740 is\VBZ\836236 structurally\RB\1740 different\JJ\1740 from\IN\1740 <e1>amphetamines</e1>\NNS\3248958 and\CC\1740 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>attention\NN\5701944 deficit\NN\5113133 disorder</e2>\NN\14034177 .\.\1740
D010389_D009069 NONE <e1>Pemoline</e1>\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 commonly\RB\1740 associated\VBN\628491 in\IN\13603305 the\DT\1740 literature\NN\6362953 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 acute\JJ\1740 <e2>movement\NN\191142 disorders</e2>\NNS\14034177 .\.\1740
D010389_D009069 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Pemoline</e1>\NN\1740 associated\VBN\628491 <e2>movement\NN\191142 disorder</e2>\NN\14034177 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 in\IN\13603305 the\DT\1740 acute\JJ\1740 toxicology\NN\6054892 literature\NN\6362953 .\.\1740
D008774_D001289 NONE The\DT\1740 children\NNS\9622049 had\VBD\2108377 a\DT\13649268 medical\JJ\1740 history\NN\15120823 significant\JJ\1740 for\IN\1740 <e2>attention\NN\5701944 deficit\NN\5113133 disorder</e2>\NN\14034177 previously\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>methylphenidate</e1>\NN\4320126 without\IN\1740 success\NN\7283608 .\.\1740
D001569_D002819 NONE The\DT\1740 children\NNS\9622049 received\VBD\2210855 gastrointestinal\JJ\1740 decontamination\NN\391599 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 intravenous\JJ\1740 <e1>benzodiazepines</e1>\NNS\3771443 in\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 control\VB\2422663 the\DT\1740 <e2>choreoathetoid</e2>\NN\1740 movements\NNS\191142 .\.\1740
D001569_D001264 NONE The\DT\1740 children\NNS\9622049 received\VBD\2210855 gastrointestinal\JJ\1740 decontamination\NN\391599 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 intravenous\JJ\1740 <e1>benzodiazepines</e1>\NNS\3771443 in\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 control\VB\2422663 the\DT\1740 <e2>choreoathetoid</e2>\NN\1740 movements\NNS\191142 .\.\1740
D010389_D062787 CID The\DT\1740 possibility\NN\5944958 of\IN\1740 choreoathetoid\NN\1740 movements\NNS\191142 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 presenting\VBG\2137132 after\IN\1740 <e1>pemoline</e1>\NN\1740 <e2>overdose</e2>\NN\1740 .\.\1740
839274
D003276_D000236 CID Hepatic\JJ\1740 <e2>adenomas</e2>\NNS\14236226 and\CC\1740 focal\JJ\1740 nodular\JJ\1740 hyperplasia\NN\14365950 of\IN\1740 the\DT\1740 liver\NN\5298729 in\IN\13603305 young\JJ\1740 women\NNS\9605289 on\IN\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 :\:\1740 case\NN\7283608 reports\NNS\6470073 .\.\1740
D003276_D000236 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 hepatic\JJ\1740 <e2>adenoma</e2>\NN\14236226 and\CC\1740 one\CD\13741022 of\IN\1740 focal\JJ\1740 nodular\JJ\1740 hyperplasia\NN\14365950 presumably\RB\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 ,\,\1740 are\VBP\836236 reported\VBN\831651 .\.\1740
D003276_D020518 CID Hepatic\JJ\1740 adenomas\NNS\14236226 and\CC\1740 <e2>focal\JJ\1740 nodular\JJ\1740 hyperplasia</e2>\NN\14365950 of\IN\1740 the\DT\1740 liver\NN\5298729 in\IN\13603305 young\JJ\1740 women\NNS\9605289 on\IN\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 :\:\1740 case\NN\7283608 reports\NNS\6470073 .\.\1740
D003276_D020518 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 hepatic\JJ\1740 adenoma\NN\14236226 and\CC\1740 one\CD\13741022 of\IN\1740 <e2>focal\JJ\1740 nodular\JJ\1740 hyperplasia</e2>\NN\14365950 presumably\RB\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 ,\,\1740 are\VBP\836236 reported\VBN\831651 .\.\1740
18177388
D000661_D054549 CID Reverse\NN\13854649 or\CC\3541091 inverted\JJ\1740 <e2>left\JJ\1740 ventricular\JJ\1740 apical\JJ\1740 ballooning\NN\302394 syndrome</e2>\NN\5870365 (\-LRB-\1740 reverse\NN\13854649 Takotsubo\NNP\1740 cardiomyopathy\NN\14103288 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 young\JJ\1740 woman\NN\9605289 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>amphetamine</e1>\NN\3248958 use\NN\407535 .\.\1740
D000661_D054549 CID Reverse\NN\13854649 or\CC\3541091 inverted\JJ\1740 left\JJ\1740 ventricular\JJ\1740 apical\JJ\1740 ballooning\NN\302394 syndrome\NN\5870365 (\-LRB-\1740 reverse\NN\13854649 <e2>Takotsubo\NNP\1740 cardiomyopathy</e2>\NN\14103288 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 young\JJ\1740 woman\NN\9605289 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>amphetamine</e1>\NN\3248958 use\NN\407535 .\.\1740
D000661_D054549 CID In\IN\13603305 this\DT\1740 article\NN\6367571 ,\,\1740 we\PRP\1740 report\VBP\831651 an\DT\6697703 interesting\JJ\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 young\JJ\1740 woman\NN\9605289 who\WP\8299493 presented\VBD\2137132 with\IN\1740 this\DT\1740 rare\JJ\1740 type\NN\5839024 of\IN\1740 reverse\JJ\1740 <e2>apical\JJ\1740 ballooning\NN\302394 syndrome</e2>\NN\5870365 occurring\VBG\2623529 after\IN\1740 <e1>amphetamine</e1>\NN\3248958 use\NN\407535 .\.\1740
12851669
D017373_D054556 NONE Absolute\JJ\1740 and\CC\1740 attributable\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 in\IN\13603305 women\NNS\9605289 on\IN\1740 combined\JJ\1740 <e1>cyproterone\NN\1740 acetate</e1>\NN\15010703 and\CC\1740 ethinylestradiol\NN\1740 .\.\1740
D017373_D054556 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 <e1>cyproterone\NN\1740 acetate</e1>\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D017373_D054556 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 <e1>cyproterone\NN\1740 acetate</e1>\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D017373_D054556 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D017373_D054556 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D017373_D054556 NONE The\DT\1740 corresponding\JJ\1740 absolute\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 3.4\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.1\CD\1740 -\SYM\1740 3.8\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 COCs\NN\1740 ,\,\1740 4.2\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.2\CD\1740 -\SYM\1740 5.2\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 women\NNS\9605289 on\IN\1740 levonorgestrel-containing\JJ\1740 COCs\NN\1740 ,\,\1740 and\CC\1740 3.1\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 1.3\CD\1740 -\SYM\1740 4.9\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D017373_D054556 NONE CONCLUSION\NN\5837957 :\:\1740 Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 the\DT\1740 absolute\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 among\IN\1740 Danish\JJ\1740 women\NNS\9605289 on\IN\1740 COCs\NN\1740 is\VBZ\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 among\IN\1740 women\NNS\9605289 taking\VBG\2367363 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D004997_D054556 NONE Absolute\JJ\1740 and\CC\1740 attributable\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 in\IN\13603305 women\NNS\9605289 on\IN\1740 combined\JJ\1740 cyproterone\NN\1740 acetate\NN\15010703 and\CC\1740 <e1>ethinylestradiol</e1>\NN\1740 .\.\1740
D004997_D054556 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 <e1>ethinylestradiol</e1>\NN\1740 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D004997_D054556 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 <e1>ethinylestradiol</e1>\NN\1740 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D004997_D054556 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D004997_D054556 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D004997_D054556 NONE The\DT\1740 corresponding\JJ\1740 absolute\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 3.4\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.1\CD\1740 -\SYM\1740 3.8\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 COCs\NN\1740 ,\,\1740 4.2\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.2\CD\1740 -\SYM\1740 5.2\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 women\NNS\9605289 on\IN\1740 levonorgestrel-containing\JJ\1740 COCs\NN\1740 ,\,\1740 and\CC\1740 3.1\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 1.3\CD\1740 -\SYM\1740 4.9\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D004997_D054556 NONE CONCLUSION\NN\5837957 :\:\1740 Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 the\DT\1740 absolute\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 among\IN\1740 Danish\JJ\1740 women\NNS\9605289 on\IN\1740 COCs\NN\1740 is\VBZ\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 among\IN\1740 women\NNS\9605289 taking\VBG\2367363 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D003277_D054556 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 <e1>combined\JJ\1740 oral\JJ\1740 contraceptives</e1>\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D003277_D054556 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 <e1>combined\JJ\1740 oral\JJ\1740 contraceptives</e1>\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D003277_D054556 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 <e1>COCs</e1>\NNS\1740 )\-RRB-\1740 .\.\1740
D003277_D054556 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 achieve\VB\2524171 absolute\JJ\1740 risk\NN\14541044 estimates\NNS\5802185 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 plus\CC\4723816 ethinylestradiol\NN\1740 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 among\IN\1740 women\NNS\9605289 on\IN\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 <e1>COCs</e1>\NNS\1740 )\-RRB-\1740 .\.\1740
D003277_D054556 CID RESULTS\NNS\34213 :\:\1740 During\IN\1740 the\DT\1740 time\NN\7308889 frame\NN\3391770 of\IN\1740 the\DT\1740 study\NN\635850 ,\,\1740 330\CD\1740 women\NNS\9605289 were\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 had\VBN\2108377 <e2>VTE</e2>\NN\1740 while\IN\15122231 on\IN\1740 <e1>COCs</e1>\NN\1740 .\.\1740
D003277_D054556 CID The\DT\1740 corresponding\JJ\1740 absolute\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 3.4\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.1\CD\1740 -\SYM\1740 3.8\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 <e1>COCs</e1>\NN\1740 ,\,\1740 4.2\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.2\CD\1740 -\SYM\1740 5.2\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 women\NNS\9605289 on\IN\1740 levonorgestrel-containing\JJ\1740 COCs\NN\1740 ,\,\1740 and\CC\1740 3.1\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 1.3\CD\1740 -\SYM\1740 4.9\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 CPA/EE\NN\1740 .\.\1740
D003277_D054556 CID The\DT\1740 corresponding\JJ\1740 absolute\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 3.4\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.1\CD\1740 -\SYM\1740 3.8\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 COCs\NN\1740 ,\,\1740 4.2\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.2\CD\1740 -\SYM\1740 5.2\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 women\NNS\9605289 on\IN\1740 levonorgestrel-containing\JJ\1740 <e1>COCs</e1>\NN\1740 ,\,\1740 and\CC\1740 3.1\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 1.3\CD\1740 -\SYM\1740 4.9\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 CPA/EE\NN\1740 .\.\1740
D003277_D054556 CID CONCLUSION\NN\5837957 :\:\1740 Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 the\DT\1740 absolute\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 among\IN\1740 Danish\JJ\1740 women\NNS\9605289 on\IN\1740 <e1>COCs</e1>\NN\1740 is\VBZ\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 among\IN\1740 women\NNS\9605289 taking\VBG\2367363 CPA/EE\NN\1740 .\.\1740
D016912_D054556 NONE The\DT\1740 corresponding\JJ\1740 absolute\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 3.4\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.1\CD\1740 -\SYM\1740 3.8\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 COCs\NN\1740 ,\,\1740 4.2\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.2\CD\1740 -\SYM\1740 5.2\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 women\NNS\9605289 on\IN\1740 <e1>levonorgestrel-containing</e1>\JJ\1740 COCs\NN\1740 ,\,\1740 and\CC\1740 3.1\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 1.3\CD\1740 -\SYM\1740 4.9\CD\1740 )\-RRB-\1740 per\IN\1740 10\CD\13745420 000\CD\1740 women\NNS\9605289 years\NNS\15144371 among\IN\1740 the\DT\1740 women\NNS\9605289 on\IN\1740 CPA/EE\NN\1740 .\.\1740
3670965
D012459_D012202 NONE <e2>Reye\NN\1740 syndrome</e2>\NN\5870365 may\MD\15209706 be\VB\836236 disappearing\VBG\2609764 from\IN\1740 Australia\NNP\1740 despite\IN\7501545 a\DT\13649268 total\JJ\1740 lack\NN\14449126 of\IN\1740 association\NN\8008335 with\IN\1740 <e1>salicylates</e1>\NNS\3828465 or\CC\3541091 aspirin\NN\2707683 ingestion\NN\13440063 ,\,\1740 since\IN\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 cases\NNS\7283608 found\VBN\2426171 at\IN\14622893 The\DT\1740 Children\NNP\9622049 's\POS\1740 Hospital\NNP\3739518 in\IN\13603305 1983\CD\1740 ,\,\1740 1984\CD\1740 ,\,\1740 or\CC\3541091 1985\CD\1740 .\.\1740
D001241_D012202 CID <e2>Reye\NN\1740 syndrome</e2>\NN\5870365 may\MD\15209706 be\VB\836236 disappearing\VBG\2609764 from\IN\1740 Australia\NNP\1740 despite\IN\7501545 a\DT\13649268 total\JJ\1740 lack\NN\14449126 of\IN\1740 association\NN\8008335 with\IN\1740 salicylates\NNS\3828465 or\CC\3541091 <e1>aspirin</e1>\NN\2707683 ingestion\NN\13440063 ,\,\1740 since\IN\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 cases\NNS\7283608 found\VBN\2426171 at\IN\14622893 The\DT\1740 Children\NNP\9622049 's\POS\1740 Hospital\NNP\3739518 in\IN\13603305 1983\CD\1740 ,\,\1740 1984\CD\1740 ,\,\1740 or\CC\3541091 1985\CD\1740 .\.\1740
10692744
D000086_D005862 CID <e1>Acetazolamide-induced</e1>\JJ\1740 <e2>Gerstmann\NN\1740 syndrome</e2>\NN\5870365 .\.\1740
D000086_D005862 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>acetazolamide-induced</e1>\JJ\1740 <e2>Gerstmann\NN\1740 syndrome</e2>\NN\5870365 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 ,\,\1740 to\TO\1740 highlight\VB\514463 predisposing\VBG\680841 factors\NNS\7326557 that\WDT\1740 are\VBP\836236 frequently\RB\1740 overlooked\VBN\2127853 .\.\1740
D000086_D003221 NONE Acute\JJ\1740 <e2>confusion</e2>\NN\13972797 induced\VBN\1627355 by\IN\1740 <e1>acetazolamide</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 well\RB\1740 known\JJ\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 in\IN\13603305 patients\NNS\9898892 with\IN\1740 renal\JJ\1740 impairment\NN\7296428 .\.\1740
D000086_D007674 NONE Acute\JJ\1740 confusion\NN\13972797 induced\VBN\1627355 by\IN\1740 <e1>acetazolamide</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 well\RB\1740 known\JJ\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 .\.\1740
19940105
D018698_D010300 NONE Metabotropic\NN\1740 <e1>glutamate</e1>\NN\15010703 7\CD\13741022 receptor\NN\5225602 subtype\NN\1740 modulates\VBZ\1724459 motor\NN\3699975 symptoms\NNS\5823932 in\IN\13603305 rodent\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D018698_D010300 NONE Metabotropic\NN\1740 <e1>glutamate</e1>\NN\15010703 (\-LRB-\1740 mGlu\NNS\1740 )\-RRB-\1740 receptors\NNS\5225602 modulate\VBP\1724459 synaptic\JJ\1740 transmission\NN\121166 in\IN\13603305 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 and\CC\1740 represent\VB\2664769 promising\VBG\1010118 therapeutic\JJ\1740 targets\NNS\7258332 for\IN\1740 symptomatic\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 .\.\1740
D018698_D010300 NONE Metabotropic\NN\1740 <e1>glutamate</e1>\NN\15010703 (\-LRB-\1740 mGlu\NNS\1740 )\-RRB-\1740 receptors\NNS\5225602 modulate\VBP\1724459 synaptic\JJ\1740 transmission\NN\121166 in\IN\13603305 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 and\CC\1740 represent\VB\2664769 promising\VBG\1010118 therapeutic\JJ\1740 targets\NNS\7258332 for\IN\1740 symptomatic\JJ\1740 treatment\NN\654885 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 .\.\1740
C507346_D010300 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>N\NN\14622893 ,\,\1740 N'-dibenzhydrylethane-1,2-diamine\NN\1740 dihydrochloride</e1>\NN\1740 (\-LRB-\1740 AMN082\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 first\JJ\1740 selective\JJ\1740 allosteric\JJ\1740 activator\NN\19613 of\IN\1740 mGlu7\NN\1740 receptors\NNS\5225602 ,\,\1740 were\VBD\836236 thus\RB\1740 tested\VBN\670261 in\IN\13603305 different\JJ\1740 rodent\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>PD</e2>\NN\14625458 .\.\1740
C507346_D010300 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 N\NN\14622893 ,\,\1740 N'-dibenzhydrylethane-1,2-diamine\NN\1740 dihydrochloride\NN\1740 (\-LRB-\1740 <e1>AMN082</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 first\JJ\1740 selective\JJ\1740 allosteric\JJ\1740 activator\NN\19613 of\IN\1740 mGlu7\NN\1740 receptors\NNS\5225602 ,\,\1740 were\VBD\836236 thus\RB\1740 tested\VBN\670261 in\IN\13603305 different\JJ\1740 rodent\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>PD</e2>\NN\14625458 .\.\1740
C507346_D010300 NONE In\IN\13603305 a\DT\13649268 more\RBR\1740 complex\JJ\1740 task\NN\575741 commonly\RB\1740 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 major\JJ\1740 akinetic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 ,\,\1740 5\CD\13741022 mg/kg\NN\1740 <e1>AMN082</e1>\NN\1740 reverses\VBZ\109660 the\DT\1740 increased\VBN\169651 reaction\NN\13446390 time\NN\7308889 to\TO\1740 respond\VB\2367363 to\TO\1740 a\DT\13649268 cue\NN\7010821 of\IN\1740 bilateral\JJ\1740 6-OHDA-lesioned\NNP\1740 rats\NNS\2329401 .\.\1740
C507346_D010300 NONE Higher\JJR\1740 doses\NNS\3740161 of\IN\1740 <e1>AMN082</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 have\VBP\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 same\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>PD</e2>\NN\14625458 .\.\1740
C507346_D002375 NONE Here\RB\1740 ,\,\1740 we\PRP\1740 show\VBP\2137132 that\IN\1740 oral\JJ\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 or\CC\3541091 intrastriatal\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.1\CD\1740 and\CC\1740 0.5\CD\1740 nmol\NNS\1740 )\-RRB-\1740 of\IN\1740 <e1>AMN082</e1>\NN\1740 reverses\VBZ\109660 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 .\.\1740
C507346_D002375 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 <e1>AMN082</e1>\NN\1740 reduces\VBZ\441445 the\DT\1740 duration\NN\15113229 of\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 a\DT\13649268 mGlu7\NN\1740 receptor-dependent\JJ\1740 manner\NN\4916342 in\IN\13603305 wild-type\JJ\1740 but\CC\1740 not\RB\1740 mGlu7\NN\1740 receptor\NN\5225602 knockout\JJ\1740 mice\NNS\2329401 .\.\1740
D006220_D002375 CID Here\RB\1740 ,\,\1740 we\PRP\1740 show\VBP\2137132 that\IN\1740 oral\JJ\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 or\CC\3541091 intrastriatal\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.1\CD\1740 and\CC\1740 0.5\CD\1740 nmol\NNS\1740 )\-RRB-\1740 of\IN\1740 AMN082\NN\1740 reverses\VBZ\109660 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006220_D002375 CID In\IN\13603305 addition\NN\3081021 ,\,\1740 AMN082\NN\1740 reduces\VBZ\441445 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 a\DT\13649268 mGlu7\NN\1740 receptor-dependent\JJ\1740 manner\NN\4916342 in\IN\13603305 wild-type\JJ\1740 but\CC\1740 not\RB\1740 mGlu7\NN\1740 receptor\NN\5225602 knockout\JJ\1740 mice\NNS\2329401 .\.\1740
C507346_D018476 NONE In\IN\13603305 a\DT\13649268 more\RBR\1740 complex\JJ\1740 task\NN\575741 commonly\RB\1740 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 major\JJ\1740 <e2>akinetic</e2>\JJ\1740 symptoms\NNS\5823932 of\IN\1740 PD\NN\14625458 patients\NNS\9898892 ,\,\1740 5\CD\13741022 mg/kg\NN\1740 <e1>AMN082</e1>\NN\1740 reverses\VBZ\109660 the\DT\1740 increased\VBN\169651 reaction\NN\13446390 time\NN\7308889 to\TO\1740 respond\VB\2367363 to\TO\1740 a\DT\13649268 cue\NN\7010821 of\IN\1740 bilateral\JJ\1740 6-OHDA-lesioned\NNP\1740 rats\NNS\2329401 .\.\1740
D016627_D018476 NONE In\IN\13603305 a\DT\13649268 more\RBR\1740 complex\JJ\1740 task\NN\575741 commonly\RB\1740 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 major\JJ\1740 <e2>akinetic</e2>\JJ\1740 symptoms\NNS\5823932 of\IN\1740 PD\NN\14625458 patients\NNS\9898892 ,\,\1740 5\CD\13741022 mg/kg\NN\1740 AMN082\NN\1740 reverses\VBZ\109660 the\DT\1740 increased\VBN\169651 reaction\NN\13446390 time\NN\7308889 to\TO\1740 respond\VB\2367363 to\TO\1740 a\DT\13649268 cue\NN\7010821 of\IN\1740 bilateral\JJ\1740 <e1>6-OHDA-lesioned</e1>\NNP\1740 rats\NNS\2329401 .\.\1740
D016627_D010300 NONE In\IN\13603305 a\DT\13649268 more\RBR\1740 complex\JJ\1740 task\NN\575741 commonly\RB\1740 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 major\JJ\1740 akinetic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 ,\,\1740 5\CD\13741022 mg/kg\NN\1740 AMN082\NN\1740 reverses\VBZ\109660 the\DT\1740 increased\VBN\169651 reaction\NN\13446390 time\NN\7308889 to\TO\1740 respond\VB\2367363 to\TO\1740 a\DT\13649268 cue\NN\7010821 of\IN\1740 bilateral\JJ\1740 <e1>6-OHDA-lesioned</e1>\NNP\1740 rats\NNS\2329401 .\.\1740
2980315
C053571_D014693 NONE Frequencies\NNS\15286249 of\IN\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 after\IN\1740 <e1>iopentol</e1>\NN\1740 (\-LRB-\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 and\CC\1740 iohexol\NN\1740 (\-LRB-\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 than\IN\1740 after\IN\1740 metrizoate\NN\1740 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D007472_D014693 NONE Frequencies\NNS\15286249 of\IN\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 after\IN\1740 iopentol\NN\1740 (\-LRB-\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>iohexol</e1>\NN\1740 (\-LRB-\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 than\IN\1740 after\IN\1740 metrizoate\NN\1740 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008794_D014693 CID Frequencies\NNS\15286249 of\IN\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 after\IN\1740 iopentol\NN\1740 (\-LRB-\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 and\CC\1740 iohexol\NN\1740 (\-LRB-\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 than\IN\1740 after\IN\1740 <e1>metrizoate</e1>\NN\1740 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
6433367
D011453_D012640 NONE Effect\NN\34213 of\IN\1740 <e1>prostaglandin</e1>\NN\5414534 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 experimentally\RB\1740 induced\VBN\1627355 <e2>convulsions</e2>\NNS\14081375 in\IN\13603305 rats\NNS\2329401 .\.\1740
D011453_D012640 NONE To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 <e1>prostaglandins</e1>\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D011453_D012640 NONE To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 <e1>prostaglandins</e1>\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 seizure\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D011453_D012640 NONE To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 <e1>PGs</e1>\NNS\1740 )\-RRB-\1740 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D011453_D012640 NONE To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 <e1>PGs</e1>\NNS\1740 )\-RRB-\1740 to\TO\1740 seizure\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D011453_D012640 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>PGs</e1>\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 fluorthyl-\NN\1740 and\CC\1740 PTZ-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 picrotoxin-\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 bicuculline-induced\JJ\1740 convulsions\NNS\14081375 .\.\1740
D011453_D012640 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>PGs</e1>\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 fluorthyl-\NN\1740 and\CC\1740 PTZ-induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 picrotoxin-\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 bicuculline-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D005481_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>flurothyl</e1>\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D005481_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 seizure\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>flurothyl</e1>\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D005481_D012640 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGs\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 <e1>fluorthyl-</e1>\NN\1740 and\CC\1740 PTZ-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 picrotoxin-\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 bicuculline-induced\JJ\1740 convulsions\NNS\14081375 .\.\1740
D005481_D012640 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGs\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 <e1>fluorthyl-</e1>\NN\1740 and\CC\1740 PTZ-induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 picrotoxin-\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 bicuculline-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D010852_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 <e1>picrotoxin</e1>\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D010852_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 seizure\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 <e1>picrotoxin</e1>\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D010852_D012640 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGs\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 fluorthyl-\NN\1740 and\CC\1740 PTZ-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 <e1>picrotoxin-</e1>\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 bicuculline-induced\JJ\1740 convulsions\NNS\14081375 .\.\1740
D010852_D012640 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGs\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 fluorthyl-\NN\1740 and\CC\1740 PTZ-induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 <e1>picrotoxin-</e1>\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 bicuculline-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D010433_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 <e1>pentetrazol</e1>\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D010433_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 seizure\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 <e1>pentetrazol</e1>\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D010433_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 <e1>PTZ</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D010433_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 seizure\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 <e1>PTZ</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 bicuculline\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D010433_D012640 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGs\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 fluorthyl-\NN\1740 and\CC\1740 <e1>PTZ-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 picrotoxin-\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 bicuculline-induced\JJ\1740 convulsions\NNS\14081375 .\.\1740
D010433_D012640 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGs\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 fluorthyl-\NN\1740 and\CC\1740 <e1>PTZ-induced</e1>\JJ\1740 convulsions\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 picrotoxin-\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 bicuculline-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D001640_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 <e1>bicuculline</e1>\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D001640_D012640 CID To\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 of\IN\1740 prostaglandins\NNS\5414534 (\-LRB-\1740 PGs\NNS\1740 )\-RRB-\1740 to\TO\1740 seizure\VB\1740 induction\NN\7450842 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 six\CD\13741022 PG\NN\1740 synthetase\NN\1740 inhibitors\NNS\20090 on\IN\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 flurothyl\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 pentetrazol\NN\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 ,\,\1740 electroshock\NN\662681 or\CC\3541091 <e1>bicuculline</e1>\NN\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D001640_D012640 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGs\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 fluorthyl-\NN\1740 and\CC\1740 PTZ-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 picrotoxin-\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 <e1>bicuculline-induced</e1>\JJ\1740 convulsions\NNS\14081375 .\.\1740
D001640_D012640 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGs\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 mechanism(s\NN\1740 )\-RRB-\1740 underlying\VBG\2604760 fluorthyl-\NN\1740 and\CC\1740 PTZ-induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 but\CC\1740 not\RB\1740 picrotoxin-\NN\1740 ,\,\1740 electroshock-\NN\1740 ,\,\1740 or\CC\3541091 <e1>bicuculline-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
16600756
D011453_D053201 NONE Nerve\NN\5475681 growth\NN\13526110 factor\NN\7326557 and\CC\1740 <e1>prostaglandins</e1>\NNS\5414534 in\IN\13603305 the\DT\1740 urine\NN\14853947 of\IN\1740 female\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>overactive\JJ\1740 bladder</e2>\NN\5515670 .\.\1740
D011453_D053201 NONE We\PRP\1740 investigated\VBD\644583 changes\NNS\7283608 in\IN\13603305 urinary\JJ\1740 NGF\NN\14734348 and\CC\1740 <e1>PGs</e1>\NNS\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 <e2>OAB</e2>\NN\1740 .\.\1740
D011453_D053201 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 correlations\NNS\13841213 between\IN\1740 urinary\JJ\1740 NGF\NN\14734348 and\CC\1740 <e1>PG</e1>\NN\1740 ,\,\1740 and\CC\1740 urodynamic\JJ\1740 parameters\NNS\5858936 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>OAB</e2>\NN\1740 were\VBD\836236 examined\VBN\789138 .\.\1740
D011453_D053201 NONE CONCLUSIONS\NNS\5837957 :\:\1740 NGF\NN\14734348 and\CC\1740 <e1>PGs</e1>\NNS\1740 have\VBP\2108377 important\JJ\1740 roles\NNS\719494 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>OAB</e2>\NN\1740 symptoms\NNS\5823932 in\IN\13603305 female\JJ\1740 patients\NNS\9898892 .\.\1740
D015232_D053201 CID RESULTS\NNS\34213 :\:\1740 Urinary\JJ\1740 NGF\NN\14734348 ,\,\1740 <e1>PGE2</e1>\NN\1740 and\CC\1740 PGF2alpha\NN\1740 were\VBD\836236 significantly\RB\1740 increased\VBN\169651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>OAB</e2>\NN\1740 compared\VBN\644583 with\IN\1740 controls\NNS\5190804 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D015232_D053201 CID In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>OAB</e2>\NN\1740 urinary\JJ\1740 <e1>PGE2</e1>\NN\1740 positively\RB\1740 correlated\VBD\2657219 with\IN\1740 volume\NN\33615 at\IN\14622893 first\JJ\1740 desire\NN\26192 to\TO\1740 void\JJ\1740 and\CC\1740 maximum\JJ\1740 cystometric\JJ\1740 capacity\NN\5202497 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D015237_D053201 CID RESULTS\NNS\34213 :\:\1740 Urinary\JJ\1740 NGF\NN\14734348 ,\,\1740 PGE2\NN\1740 and\CC\1740 <e1>PGF2alpha</e1>\NN\1740 were\VBD\836236 significantly\RB\1740 increased\VBN\169651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>OAB</e2>\NN\1740 compared\VBN\644583 with\IN\1740 controls\NNS\5190804 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D015237_D053201 CID Urinary\JJ\1740 NGF\NN\14734348 ,\,\1740 <e1>PGF2alpha</e1>\NN\1740 and\CC\1740 PGI2\NN\1740 did\VBD\1640855 not\RB\1740 correlate\VB\2657219 with\IN\1740 urodynamic\JJ\1740 parameters\NNS\5858936 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>OAB</e2>\NN\1740 .\.\1740
D011464_D053201 NONE However\RB\1740 ,\,\1740 urinary\JJ\1740 <e1>PGI2</e1>\NN\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 between\IN\1740 controls\NNS\5190804 and\CC\1740 patients\NNS\9898892 with\IN\1740 <e2>OAB</e2>\NN\1740 .\.\1740
D011464_D053201 NONE Urinary\JJ\1740 NGF\NN\14734348 ,\,\1740 PGF2alpha\NN\1740 and\CC\1740 <e1>PGI2</e1>\NN\1740 did\VBD\1640855 not\RB\1740 correlate\VB\2657219 with\IN\1740 urodynamic\JJ\1740 parameters\NNS\5858936 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>OAB</e2>\NN\1740 .\.\1740
8410199
D018698_D012640 NONE Loss\NN\13252973 of\IN\1740 <e1>glutamate</e1>\JJ\1740 decarboxylase\NN\14732946 mRNA-containing\JJ\1740 neurons\NNS\5430628 in\IN\13603305 the\DT\1740 rat\NN\2329401 dentate\NN\1740 gyrus\NN\5225602 following\VBG\1835496 pilocarpine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D018698_D012640 NONE In\FW\13603305 situ\FW\1740 hybridization\NN\847340 methods\NNS\5616786 were\VBD\836236 used\VBN\1156834 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>glutamic\JJ\1740 acid</e1>\NN\14818238 decarboxylase\NN\14732946 (\-LRB-\1740 GAD\NN\14380473 )\-RRB-\1740 mRNA-containing\JJ\1740 neurons\NNS\5430628 within\IN\1740 the\DT\1740 hilus\NN\5223370 of\IN\1740 the\DT\1740 dentate\NN\1740 gyrus\NN\5225602 are\VBP\836236 vulnerable\JJ\1740 to\TO\1740 <e2>seizure-induced</e2>\JJ\1740 damage\NN\7296428 in\IN\13603305 a\DT\13649268 model\NN\5888929 of\IN\1740 chronic\JJ\1740 seizures\NNS\14081375 .\.\1740
D018698_D012640 NONE In\FW\13603305 situ\FW\1740 hybridization\NN\847340 methods\NNS\5616786 were\VBD\836236 used\VBN\1156834 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>glutamic\JJ\1740 acid</e1>\NN\14818238 decarboxylase\NN\14732946 (\-LRB-\1740 GAD\NN\14380473 )\-RRB-\1740 mRNA-containing\JJ\1740 neurons\NNS\5430628 within\IN\1740 the\DT\1740 hilus\NN\5223370 of\IN\1740 the\DT\1740 dentate\NN\1740 gyrus\NN\5225602 are\VBP\836236 vulnerable\JJ\1740 to\TO\1740 seizure-induced\JJ\1740 damage\NN\7296428 in\IN\13603305 a\DT\13649268 model\NN\5888929 of\IN\1740 chronic\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D012640 CID Loss\NN\13252973 of\IN\1740 glutamate\JJ\1740 decarboxylase\NN\14732946 mRNA-containing\JJ\1740 neurons\NNS\5430628 in\IN\13603305 the\DT\1740 rat\NN\2329401 dentate\NN\1740 gyrus\NN\5225602 following\VBG\1835496 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D012640 CID Sprague-Dawley\JJ\1740 rats\NNS\2329401 were\VBD\836236 injected\VBN\81072 intraperitoneally\RB\1740 with\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 and\CC\1740 the\DT\1740 hippocampal\NN\1740 formation\NN\7938773 was\VBD\836236 studied\VBN\630380 histologically\RB\1740 at\IN\14622893 1\CD\13741022 ,\,\1740 2\CD\13741022 ,\,\1740 4\CD\13741022 ,\,\1740 and\CC\1740 8\CD\13741022 week\NN\15113229 intervals\NNS\33615 after\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D012640 CID Sprague-Dawley\JJ\1740 rats\NNS\2329401 were\VBD\836236 injected\VBN\81072 intraperitoneally\RB\1740 with\IN\1740 pilocarpine\NN\14712692 ,\,\1740 and\CC\1740 the\DT\1740 hippocampal\NN\1740 formation\NN\7938773 was\VBD\836236 studied\VBN\630380 histologically\RB\1740 at\IN\14622893 1\CD\13741022 ,\,\1740 2\CD\13741022 ,\,\1740 4\CD\13741022 ,\,\1740 and\CC\1740 8\CD\13741022 week\NN\15113229 intervals\NNS\33615 after\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
C028911_D009410 NONE Additional\JJ\1740 neuronanatomical\JJ\1740 studies\NNS\635850 ,\,\1740 including\VBG\690614 <e1>cresyl\NN\1740 violet</e1>\JJ\1740 staining\NN\275424 ,\,\1740 <e2>neuronal\JJ\1740 degeneration</e2>\NN\29677 methods\NNS\5616786 ,\,\1740 and\CC\1740 histochemical\JJ\1740 localization\NN\151497 of\IN\1740 glial\JJ\1740 fibrillary\JJ\1740 acidic\JJ\1740 protein\NN\14944888 ,\,\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 the\DT\1740 number\NN\5107765 of\IN\1740 GAD\NN\14380473 mRNA-containing\JJ\1740 neurons\NNS\5430628 was\VBD\836236 related\JJ\1740 to\TO\1740 neuronal\JJ\1740 loss\NN\13252973 rather\RB\1740 than\IN\1740 to\TO\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 GAD\NN\14380473 mRNA\NN\14832193 levels\NNS\4916342 .\.\1740
C028911_D009410 NONE Additional\JJ\1740 neuronanatomical\JJ\1740 studies\NNS\635850 ,\,\1740 including\VBG\690614 <e1>cresyl\NN\1740 violet</e1>\JJ\1740 staining\NN\275424 ,\,\1740 neuronal\JJ\1740 degeneration\NN\29677 methods\NNS\5616786 ,\,\1740 and\CC\1740 histochemical\JJ\1740 localization\NN\151497 of\IN\1740 glial\JJ\1740 fibrillary\JJ\1740 acidic\JJ\1740 protein\NN\14944888 ,\,\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 the\DT\1740 number\NN\5107765 of\IN\1740 GAD\NN\14380473 mRNA-containing\JJ\1740 neurons\NNS\5430628 was\VBD\836236 related\JJ\1740 to\TO\1740 <e2>neuronal\JJ\1740 loss</e2>\NN\13252973 rather\RB\1740 than\IN\1740 to\TO\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 GAD\NN\14380473 mRNA\NN\14832193 levels\NNS\4916342 .\.\1740
1636026
D013496_D058186 CID Although\IN\1740 <e1>suprofen</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 greater\JJR\1740 than\IN\1740 100\CD\13745420 subjects\NNS\6598915 ,\,\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 damage\NN\7296428 remains\VBZ\2604760 unclear\JJ\1740 .\.\1740
D013496_D058186 CID In\IN\13603305 summary\NN\6722453 ,\,\1740 <e1>suprofen</e1>\NN\1740 causes\VBZ\1617192 <e2>acute\JJ\1740 declines\NNS\13458571 in\IN\13603305 renal\JJ\1740 function</e2>\NN\13783581 ,\,\1740 most\RBS\1740 likely\RB\1740 by\IN\1740 directly\RB\1740 altering\VBG\126264 the\DT\1740 intrarenal\JJ\1740 distribution\NN\5726596 of\IN\1740 uric\JJ\1740 acid\NN\14818238 .\.\1740
D013496_D007674 NONE The\DT\1740 direct\JJ\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 15\CD\13745420 mg\NN\13717155 of\IN\1740 <e1>suprofen</e1>\NN\1740 were\VBD\836236 compared\VBN\644583 in\IN\13603305 the\DT\1740 recirculating\NN\1740 isolated\VBN\2512305 rat\NN\2329401 kidney\NN\5333259 perfused\VBN\454868 with\IN\1740 cell-free\JJ\1740 buffer\NN\14818238 with\IN\1740 or\CC\3541091 without\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 5\CD\13741022 mg/dL\NN\1740 of\IN\1740 uric\JJ\1740 acid\NN\14818238 .\.\1740
D014527_D007674 NONE The\DT\1740 direct\JJ\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 15\CD\13745420 mg\NN\13717155 of\IN\1740 suprofen\NN\1740 were\VBD\836236 compared\VBN\644583 in\IN\13603305 the\DT\1740 recirculating\NN\1740 isolated\VBN\2512305 rat\NN\2329401 kidney\NN\5333259 perfused\VBN\454868 with\IN\1740 cell-free\JJ\1740 buffer\NN\14818238 with\IN\1740 or\CC\3541091 without\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 5\CD\13741022 mg/dL\NN\1740 of\IN\1740 <e1>uric\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D014527_D058186 NONE In\IN\13603305 summary\NN\6722453 ,\,\1740 suprofen\NN\1740 causes\VBZ\1617192 <e2>acute\JJ\1740 declines\NNS\13458571 in\IN\13603305 renal\JJ\1740 function</e2>\NN\13783581 ,\,\1740 most\RBS\1740 likely\RB\1740 by\IN\1740 directly\RB\1740 altering\VBG\126264 the\DT\1740 intrarenal\JJ\1740 distribution\NN\5726596 of\IN\1740 <e1>uric\JJ\1740 acid</e1>\NN\14818238 .\.\1740
6637851
D000638_D064420 NONE Long-term\JJ\1740 efficacy\NN\5199286 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 high-dose\JJ\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 for\IN\1740 ventricular\JJ\1740 tachycardia\NN\14110674 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 .\.\1740
D000638_D064420 NONE Although\IN\1740 large-dose\JJ\1740 <e1>amiodarone</e1>\NN\2715941 is\VBZ\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 the\DT\1740 long-term\JJ\1740 treatment\NN\654885 of\IN\1740 VT\NN\1740 or\CC\3541091 VF\NN\1740 refractory\JJ\1740 to\TO\1740 conventional\JJ\1740 antiarrhythmic\JJ\1740 drugs\NNS\14778436 ,\,\1740 it\PRP\6125041 causes\VBZ\1617192 significant\JJ\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 approximately\RB\1740 50\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D000638_D017180 NONE Long-term\JJ\1740 efficacy\NN\5199286 and\CC\1740 toxicity\NN\13576101 of\IN\1740 high-dose\JJ\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 for\IN\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 .\.\1740
D000638_D017180 NONE <e1>Amiodarone</e1>\NN\2715941 was\VBD\836236 administered\VBN\2436349 to\TO\1740 154\CD\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 sustained\JJ\1740 ,\,\1740 symptomatic\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 (\-LRB-\1740 VT\NN\1740 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 118\CD\1740 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 cardiac\JJ\1740 arrest\NN\88481 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 36\CD\1740 )\-RRB-\1740 and\CC\1740 who\WP\8299493 were\VBD\836236 refractory\JJ\1740 to\TO\1740 conventional\JJ\1740 antiarrhythmic\JJ\1740 drugs\NNS\14778436 .\.\1740
D000638_D017180 NONE <e1>Amiodarone</e1>\NN\2715941 was\VBD\836236 administered\VBN\2436349 to\TO\1740 154\CD\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 sustained\JJ\1740 ,\,\1740 symptomatic\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 <e2>VT</e2>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 118\CD\1740 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 cardiac\JJ\1740 arrest\NN\88481 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 36\CD\1740 )\-RRB-\1740 and\CC\1740 who\WP\8299493 were\VBD\836236 refractory\JJ\1740 to\TO\1740 conventional\JJ\1740 antiarrhythmic\JJ\1740 drugs\NNS\14778436 .\.\1740
D000638_D017180 NONE Sixty-nine\JJ\1740 percent\NN\13815742 of\IN\1740 patients\NNS\9898892 continued\VBD\2367363 treatment\NN\654885 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 and\CC\1740 had\VBD\2108377 no\DT\7204911 recurrence\NN\7342049 of\IN\1740 symptomatic\JJ\1740 <e2>VT</e2>\NN\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 VF\NN\1740 )\-RRB-\1740 over\IN\5867413 a\DT\13649268 follow-up\NN\4599396 of\IN\1740 6\CD\13741022 to\TO\1740 52\CD\1740 months\NNS\15113229 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 standard\JJ\1740 deviation\NN\7337390 14.2\CD\1740 +/-\CC\1740 8.2\CD\1740 )\-RRB-\1740 .\.\1740
D000638_D017180 NONE Six\CD\13741022 percent\NN\13815742 of\IN\1740 the\DT\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 nonfatal\JJ\1740 recurrence\NN\7342049 of\IN\1740 <e2>VT</e2>\NN\1740 and\CC\1740 were\VBD\836236 successfully\RB\1740 managed\VBN\2524171 by\IN\1740 continuing\VBG\2367363 <e1>amiodarone</e1>\NN\2715941 at\IN\14622893 a\DT\13649268 higher\JJR\1740 dose\NN\3740161 or\CC\3541091 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 a\DT\13649268 conventional\JJ\1740 antiarrhythmic\JJ\1740 drug\NN\14778436 .\.\1740
D000638_D017180 NONE Although\IN\1740 large-dose\JJ\1740 <e1>amiodarone</e1>\NN\2715941 is\VBZ\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 the\DT\1740 long-term\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>VT</e2>\NN\1740 or\CC\3541091 VF\NN\1740 refractory\JJ\1740 to\TO\1740 conventional\JJ\1740 antiarrhythmic\JJ\1740 drugs\NNS\14778436 ,\,\1740 it\PRP\6125041 causes\VBZ\1617192 significant\JJ\1740 toxicity\NN\13576101 in\IN\13603305 approximately\RB\1740 50\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D000638_D017180 NONE However\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 dose\NN\3740161 is\VBZ\836236 adjusted\VBN\126264 based\VBN\2694933 on\IN\1740 clinical\JJ\1740 response\NN\11410625 or\CC\3541091 the\DT\1740 development\NN\248977 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 ,\,\1740 75\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>VT</e2>\NN\1740 or\CC\3541091 VF\NN\1740 can\MD\3094503 be\VB\836236 successfully\RB\1740 managed\VBN\2524171 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 .\.\1740
D000638_D014693 NONE Long-term\JJ\1740 efficacy\NN\5199286 and\CC\1740 toxicity\NN\13576101 of\IN\1740 high-dose\JJ\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 for\IN\1740 ventricular\JJ\1740 tachycardia\NN\14110674 or\CC\3541091 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 .\.\1740
D000638_D014693 NONE Sixty-nine\JJ\1740 percent\NN\13815742 of\IN\1740 patients\NNS\9898892 continued\VBD\2367363 treatment\NN\654885 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 and\CC\1740 had\VBD\2108377 no\DT\7204911 recurrence\NN\7342049 of\IN\1740 symptomatic\JJ\1740 VT\NN\1740 or\CC\3541091 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 (\-LRB-\1740 VF\NN\1740 )\-RRB-\1740 over\IN\5867413 a\DT\13649268 follow-up\NN\4599396 of\IN\1740 6\CD\13741022 to\TO\1740 52\CD\1740 months\NNS\15113229 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 standard\JJ\1740 deviation\NN\7337390 14.2\CD\1740 +/-\CC\1740 8.2\CD\1740 )\-RRB-\1740 .\.\1740
D000638_D014693 NONE Sixty-nine\JJ\1740 percent\NN\13815742 of\IN\1740 patients\NNS\9898892 continued\VBD\2367363 treatment\NN\654885 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 and\CC\1740 had\VBD\2108377 no\DT\7204911 recurrence\NN\7342049 of\IN\1740 symptomatic\JJ\1740 VT\NN\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 <e2>VF</e2>\NN\1740 )\-RRB-\1740 over\IN\5867413 a\DT\13649268 follow-up\NN\4599396 of\IN\1740 6\CD\13741022 to\TO\1740 52\CD\1740 months\NNS\15113229 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 standard\JJ\1740 deviation\NN\7337390 14.2\CD\1740 +/-\CC\1740 8.2\CD\1740 )\-RRB-\1740 .\.\1740
D000638_D014693 NONE Although\IN\1740 large-dose\JJ\1740 <e1>amiodarone</e1>\NN\2715941 is\VBZ\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 the\DT\1740 long-term\JJ\1740 treatment\NN\654885 of\IN\1740 VT\NN\1740 or\CC\3541091 <e2>VF</e2>\NN\1740 refractory\JJ\1740 to\TO\1740 conventional\JJ\1740 antiarrhythmic\JJ\1740 drugs\NNS\14778436 ,\,\1740 it\PRP\6125041 causes\VBZ\1617192 significant\JJ\1740 toxicity\NN\13576101 in\IN\13603305 approximately\RB\1740 50\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D000638_D014693 NONE However\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 dose\NN\3740161 is\VBZ\836236 adjusted\VBN\126264 based\VBN\2694933 on\IN\1740 clinical\JJ\1740 response\NN\11410625 or\CC\3541091 the\DT\1740 development\NN\248977 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 ,\,\1740 75\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 VT\NN\1740 or\CC\3541091 <e2>VF</e2>\NN\1740 can\MD\3094503 be\VB\836236 successfully\RB\1740 managed\VBN\2524171 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 .\.\1740
D000638_D006323 NONE <e1>Amiodarone</e1>\NN\2715941 was\VBD\836236 administered\VBN\2436349 to\TO\1740 154\CD\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 sustained\JJ\1740 ,\,\1740 symptomatic\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 VT\NN\1740 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 118\CD\1740 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 36\CD\1740 )\-RRB-\1740 and\CC\1740 who\WP\8299493 were\VBD\836236 refractory\JJ\1740 to\TO\1740 conventional\JJ\1740 antiarrhythmic\JJ\1740 drugs\NNS\14778436 .\.\1740
12734532
D010665_D009203 CID Case\NN\7283608 report\NN\6470073 :\:\1740 <e1>Dexatrim</e1>\NN\1740 (\-LRB-\1740 Phenylpropanolamine\NN\2682038 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D010665_D009203 CID Case\NN\7283608 report\NN\6470073 :\:\1740 Dexatrim\NN\1740 (\-LRB-\1740 <e1>Phenylpropanolamine</e1>\NN\2682038 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D010665_D009202 NONE Several\JJ\1740 reports\NNS\6470073 have\VBP\2108377 linked\VBN\628491 the\DT\1740 abuse\NN\418025 of\IN\1740 <e1>PPA</e1>\NN\1740 with\IN\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 ,\,\1740 especially\RB\1740 when\WRB\1740 overdose\NN\1740 is\VBZ\836236 involved\VBN\2676054 .\.\1740
D010665_D009202 NONE We\PRP\1740 report\VBP\831651 here\RB\1740 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 <e1>Dexatrim</e1>\NN\1740 (PPA)-induced\VBN\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 a\DT\13649268 young\JJ\1740 woman\NN\9605289 who\WP\8299493 was\VBD\836236 using\VBG\1156834 it\PRP\6125041 at\IN\14622893 recommended\VBN\875394 doses\NNS\3740161 for\IN\1740 weight\NN\5009170 control\NN\5190804 .\.\1740
D010665_D009202 NONE We\PRP\1740 report\VBP\831651 here\RB\1740 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 Dexatrim\NN\1740 <e1>(PPA)-induced</e1>\VBN\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 a\DT\13649268 young\JJ\1740 woman\NN\9605289 who\WP\8299493 was\VBD\836236 using\VBG\1156834 it\PRP\6125041 at\IN\14622893 recommended\VBN\875394 doses\NNS\3740161 for\IN\1740 weight\NN\5009170 control\NN\5190804 .\.\1740
D010665_D009202 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 we\PRP\1740 review\VBP\644583 the\DT\1740 7\CD\13741022 other\JJ\1740 cases\NNS\7283608 of\IN\1740 <e1>PPA</e1>\NN\1740 related\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 that\WDT\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 so\RB\1740 far\RB\1740 .\.\1740
D010665_D062787 NONE Several\JJ\1740 reports\NNS\6470073 have\VBP\2108377 linked\VBN\628491 the\DT\1740 abuse\NN\418025 of\IN\1740 <e1>PPA</e1>\NN\1740 with\IN\1740 myocardial\JJ\1740 injury\NN\14052046 ,\,\1740 especially\RB\1740 when\WRB\1740 <e2>overdose</e2>\NN\1740 is\VBZ\836236 involved\VBN\2676054 .\.\1740
3535719
D009428_D064420 NONE Relative\JJ\1740 efficacy\NN\5199286 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>netilmicin</e1>\NN\1740 and\CC\1740 tobramycin\NN\2716866 in\IN\13603305 oncology\NN\6043075 patients\NNS\9898892 .\.\1740
D014031_D064420 NONE Relative\JJ\1740 efficacy\NN\5199286 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 netilmicin\NN\1740 and\CC\1740 <e1>tobramycin</e1>\NN\2716866 in\IN\13603305 oncology\NN\6043075 patients\NNS\9898892 .\.\1740
D009428_D007239 NONE We\PRP\1740 prospectively\RB\1740 compared\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>netilmicin\NN\1740 sulfate</e1>\NN\15010703 or\CC\3541091 tobramycin\NN\2716866 sulfate\NN\15010703 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 piperacillin\NN\3910033 sodium\NN\14625458 in\IN\13603305 118\CD\1740 immunocompromised\VBN\1740 patients\NNS\9898892 with\IN\1740 presumed\VBN\719734 severe\JJ\1740 <e2>infections</e2>\NNS\14052046 .\.\1740
D014031_D007239 NONE We\PRP\1740 prospectively\RB\1740 compared\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 netilmicin\NN\1740 sulfate\NN\15010703 or\CC\3541091 <e1>tobramycin\NN\2716866 sulfate</e1>\NN\15010703 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 piperacillin\NN\3910033 sodium\NN\14625458 in\IN\13603305 118\CD\1740 immunocompromised\VBN\1740 patients\NNS\9898892 with\IN\1740 presumed\VBN\719734 severe\JJ\1740 <e2>infections</e2>\NNS\14052046 .\.\1740
D010878_D007239 NONE We\PRP\1740 prospectively\RB\1740 compared\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 netilmicin\NN\1740 sulfate\NN\15010703 or\CC\3541091 tobramycin\NN\2716866 sulfate\NN\15010703 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 <e1>piperacillin\NN\3910033 sodium</e1>\NN\14625458 in\IN\13603305 118\CD\1740 immunocompromised\VBN\1740 patients\NNS\9898892 with\IN\1740 presumed\VBN\719734 severe\JJ\1740 <e2>infections</e2>\NNS\14052046 .\.\1740
D009428_D007674 CID <e2>Nephrotoxicity</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 similar\JJ\1740 proportion\NN\13824815 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>netilmicin</e1>\NN\1740 and\CC\1740 tobramycin\NN\2716866 (\-LRB-\1740 17\CD\13745420 %\NN\1740 vs\CC\13634784 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D014031_D007674 CID <e2>Nephrotoxicity</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 similar\JJ\1740 proportion\NN\13824815 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 netilmicin\NN\1740 and\CC\1740 <e1>tobramycin</e1>\NN\2716866 (\-LRB-\1740 17\CD\13745420 %\NN\1740 vs\CC\13634784 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D009428_D006311 CID <e2>Ototoxicity</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 four\CD\13741022 (\-LRB-\1740 9.5\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 42\CD\1740 <e1>netilmicin</e1>\NN\1740 and\CC\1740 piperacillin\NN\3910033 and\CC\1740 in\IN\13603305 12\CD\13745420 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 54\CD\1740 tobramycin\NN\2716866 and\CC\1740 piperacillin-treated\JJ\1740 patients\NNS\9898892 .\.\1740
D009428_D006311 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 aminoglycoside-associated\JJ\1740 <e2>ototoxicity</e2>\NN\1740 was\VBD\836236 less\RBR\1740 severe\JJ\1740 and\CC\1740 more\RBR\1740 often\RB\1740 reversible\JJ\1740 with\IN\1740 <e1>netilmicin</e1>\NN\1740 than\IN\1740 with\IN\1740 tobramycin\NN\2716866 .\.\1740
D010878_D006311 CID <e2>Ototoxicity</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 four\CD\13741022 (\-LRB-\1740 9.5\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 42\CD\1740 netilmicin\NN\1740 and\CC\1740 <e1>piperacillin</e1>\NN\3910033 and\CC\1740 in\IN\13603305 12\CD\13745420 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 54\CD\1740 tobramycin\NN\2716866 and\CC\1740 piperacillin-treated\JJ\1740 patients\NNS\9898892 .\.\1740
D010878_D006311 CID <e2>Ototoxicity</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 four\CD\13741022 (\-LRB-\1740 9.5\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 42\CD\1740 netilmicin\NN\1740 and\CC\1740 piperacillin\NN\3910033 and\CC\1740 in\IN\13603305 12\CD\13745420 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 54\CD\1740 tobramycin\NN\2716866 and\CC\1740 <e1>piperacillin-treated</e1>\JJ\1740 patients\NNS\9898892 .\.\1740
D014031_D006311 CID <e2>Ototoxicity</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 four\CD\13741022 (\-LRB-\1740 9.5\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 42\CD\1740 netilmicin\NN\1740 and\CC\1740 piperacillin\NN\3910033 and\CC\1740 in\IN\13603305 12\CD\13745420 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 54\CD\1740 <e1>tobramycin</e1>\NN\2716866 and\CC\1740 piperacillin-treated\JJ\1740 patients\NNS\9898892 .\.\1740
D014031_D006311 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 aminoglycoside-associated\JJ\1740 <e2>ototoxicity</e2>\NN\1740 was\VBD\836236 less\RBR\1740 severe\JJ\1740 and\CC\1740 more\RBR\1740 often\RB\1740 reversible\JJ\1740 with\IN\1740 netilmicin\NN\1740 than\IN\1740 with\IN\1740 <e1>tobramycin</e1>\NN\2716866 .\.\1740
D000617_D006311 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>aminoglycoside-associated</e1>\JJ\1740 <e2>ototoxicity</e2>\NN\1740 was\VBD\836236 less\RBR\1740 severe\JJ\1740 and\CC\1740 more\RBR\1740 often\RB\1740 reversible\JJ\1740 with\IN\1740 netilmicin\NN\1740 than\IN\1740 with\IN\1740 tobramycin\NN\2716866 .\.\1740
6115999
D001539_D006973 NONE Adverse\JJ\1740 reactions\NNS\13446390 to\TO\1740 <e1>bendrofluazide</e1>\VB\1740 and\CC\1740 propranolol\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 mild\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D001539_D006973 NONE Participants\NNS\9816771 in\IN\13603305 the\DT\1740 Medical\NNP\635850 Research\NNP\633864 Council\NNP\8077292 treatment\NN\654885 trial\NN\786195 for\IN\1740 mild\JJ\1740 <e2>hypertension</e2>\NN\14057371 are\VBP\836236 randomly\RB\1740 allocated\VBN\2228698 to\IN\1740 one\CD\13741022 of\IN\1740 four\CD\13741022 treatment\NN\654885 groups\NNS\2137 :\:\1740 <e1>bendrofluazide</e1>\NN\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 or\CC\3541091 a\DT\13649268 placebo\NN\3740161 for\IN\1740 either\DT\1740 of\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D011433_D006973 NONE Adverse\JJ\1740 reactions\NNS\13446390 to\TO\1740 bendrofluazide\VB\1740 and\CC\1740 <e1>propranolol</e1>\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 mild\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D011433_D006973 NONE Participants\NNS\9816771 in\IN\13603305 the\DT\1740 Medical\NNP\635850 Research\NNP\633864 Council\NNP\8077292 treatment\NN\654885 trial\NN\786195 for\IN\1740 mild\JJ\1740 <e2>hypertension</e2>\NN\14057371 are\VBP\836236 randomly\RB\1740 allocated\VBN\2228698 to\IN\1740 one\CD\13741022 of\IN\1740 four\CD\13741022 treatment\NN\654885 groups\NNS\2137 :\:\1740 bendrofluazide\NN\1740 ,\,\1740 <e1>propranolol</e1>\NN\1740 ,\,\1740 or\CC\3541091 a\DT\13649268 placebo\NN\3740161 for\IN\1740 either\DT\1740 of\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D001539_D007172 CID The\DT\1740 results\NNS\34213 show\VBP\2137132 an\DT\6697703 association\NN\8008335 between\IN\1740 <e1>bendrofluazide</e1>\NN\1740 treatment\NN\654885 and\CC\1740 <e2>impotence</e2>\NN\4723816 ,\,\1740 and\CC\1740 impotence\NN\4723816 also\RB\1740 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 propranolol\NN\1740 than\IN\1740 in\IN\13603305 those\DT\1740 taking\VBG\2367363 placebos\NNS\3740161 .\.\1740
D001539_D007172 CID The\DT\1740 results\NNS\34213 show\VBP\2137132 an\DT\6697703 association\NN\8008335 between\IN\1740 <e1>bendrofluazide</e1>\NN\1740 treatment\NN\654885 and\CC\1740 impotence\NN\4723816 ,\,\1740 and\CC\1740 <e2>impotence</e2>\NN\4723816 also\RB\1740 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 propranolol\NN\1740 than\IN\1740 in\IN\13603305 those\DT\1740 taking\VBG\2367363 placebos\NNS\3740161 .\.\1740
D011433_D007172 CID The\DT\1740 results\NNS\34213 show\VBP\2137132 an\DT\6697703 association\NN\8008335 between\IN\1740 bendrofluazide\NN\1740 treatment\NN\654885 and\CC\1740 <e2>impotence</e2>\NN\4723816 ,\,\1740 and\CC\1740 impotence\NN\4723816 also\RB\1740 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 <e1>propranolol</e1>\NN\1740 than\IN\1740 in\IN\13603305 those\DT\1740 taking\VBG\2367363 placebos\NNS\3740161 .\.\1740
D011433_D007172 CID The\DT\1740 results\NNS\34213 show\VBP\2137132 an\DT\6697703 association\NN\8008335 between\IN\1740 bendrofluazide\NN\1740 treatment\NN\654885 and\CC\1740 impotence\NN\4723816 ,\,\1740 and\CC\1740 <e2>impotence</e2>\NN\4723816 also\RB\1740 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 <e1>propranolol</e1>\NN\1740 than\IN\1740 in\IN\13603305 those\DT\1740 taking\VBG\2367363 placebos\NNS\3740161 .\.\1740
D001539_D018149 CID Other\JJ\1740 adverse\JJ\1740 reactions\NNS\13446390 significantly\RB\1740 linked\VBN\628491 with\IN\1740 active\JJ\1740 drugs\NNS\14778436 include\VBP\690614 <e2>impaired\JJ\1740 glucose\NN\14710501 tolerance</e2>\NN\5032565 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 and\CC\1740 gout\NN\14186541 in\IN\13603305 men\NNS\8208016 ,\,\1740 associated\VBN\628491 with\IN\1740 <e1>bendrofluazide</e1>\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 Raynaud\NNP\1740 's\POS\1740 phenomenon\NN\29677 and\CC\1740 dyspnoea\NN\14299637 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 taking\VBG\2367363 propranolol\NN\1740 .\.\1740
D001539_D006073 CID Other\JJ\1740 adverse\JJ\1740 reactions\NNS\13446390 significantly\RB\1740 linked\VBN\628491 with\IN\1740 active\JJ\1740 drugs\NNS\14778436 include\VBP\690614 impaired\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 and\CC\1740 <e2>gout</e2>\NN\14186541 in\IN\13603305 men\NNS\8208016 ,\,\1740 associated\VBN\628491 with\IN\1740 <e1>bendrofluazide</e1>\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 Raynaud\NNP\1740 's\POS\1740 phenomenon\NN\29677 and\CC\1740 dyspnoea\NN\14299637 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 taking\VBG\2367363 propranolol\NN\1740 .\.\1740
D001539_D011928 NONE Other\JJ\1740 adverse\JJ\1740 reactions\NNS\13446390 significantly\RB\1740 linked\VBN\628491 with\IN\1740 active\JJ\1740 drugs\NNS\14778436 include\VBP\690614 impaired\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 and\CC\1740 gout\NN\14186541 in\IN\13603305 men\NNS\8208016 ,\,\1740 associated\VBN\628491 with\IN\1740 <e1>bendrofluazide</e1>\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 <e2>Raynaud\NNP\1740 's\POS\1740 phenomenon</e2>\NN\29677 and\CC\1740 dyspnoea\NN\14299637 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 taking\VBG\2367363 propranolol\NN\1740 .\.\1740
D001539_D004417 NONE Other\JJ\1740 adverse\JJ\1740 reactions\NNS\13446390 significantly\RB\1740 linked\VBN\628491 with\IN\1740 active\JJ\1740 drugs\NNS\14778436 include\VBP\690614 impaired\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 and\CC\1740 gout\NN\14186541 in\IN\13603305 men\NNS\8208016 ,\,\1740 associated\VBN\628491 with\IN\1740 <e1>bendrofluazide</e1>\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 Raynaud\NNP\1740 's\POS\1740 phenomenon\NN\29677 and\CC\1740 <e2>dyspnoea</e2>\NN\14299637 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 taking\VBG\2367363 propranolol\NN\1740 .\.\1740
D011433_D018149 NONE Other\JJ\1740 adverse\JJ\1740 reactions\NNS\13446390 significantly\RB\1740 linked\VBN\628491 with\IN\1740 active\JJ\1740 drugs\NNS\14778436 include\VBP\690614 <e2>impaired\JJ\1740 glucose\NN\14710501 tolerance</e2>\NN\5032565 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 and\CC\1740 gout\NN\14186541 in\IN\13603305 men\NNS\8208016 ,\,\1740 associated\VBN\628491 with\IN\1740 bendrofluazide\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 Raynaud\NNP\1740 's\POS\1740 phenomenon\NN\29677 and\CC\1740 dyspnoea\NN\14299637 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 taking\VBG\2367363 <e1>propranolol</e1>\NN\1740 .\.\1740
D011433_D006073 NONE Other\JJ\1740 adverse\JJ\1740 reactions\NNS\13446390 significantly\RB\1740 linked\VBN\628491 with\IN\1740 active\JJ\1740 drugs\NNS\14778436 include\VBP\690614 impaired\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 and\CC\1740 <e2>gout</e2>\NN\14186541 in\IN\13603305 men\NNS\8208016 ,\,\1740 associated\VBN\628491 with\IN\1740 bendrofluazide\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 Raynaud\NNP\1740 's\POS\1740 phenomenon\NN\29677 and\CC\1740 dyspnoea\NN\14299637 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 taking\VBG\2367363 <e1>propranolol</e1>\NN\1740 .\.\1740
D011433_D011928 CID Other\JJ\1740 adverse\JJ\1740 reactions\NNS\13446390 significantly\RB\1740 linked\VBN\628491 with\IN\1740 active\JJ\1740 drugs\NNS\14778436 include\VBP\690614 impaired\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 and\CC\1740 gout\NN\14186541 in\IN\13603305 men\NNS\8208016 ,\,\1740 associated\VBN\628491 with\IN\1740 bendrofluazide\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 <e2>Raynaud\NNP\1740 's\POS\1740 phenomenon</e2>\NN\29677 and\CC\1740 dyspnoea\NN\14299637 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 taking\VBG\2367363 <e1>propranolol</e1>\NN\1740 .\.\1740
D011433_D004417 CID Other\JJ\1740 adverse\JJ\1740 reactions\NNS\13446390 significantly\RB\1740 linked\VBN\628491 with\IN\1740 active\JJ\1740 drugs\NNS\14778436 include\VBP\690614 impaired\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 and\CC\1740 gout\NN\14186541 in\IN\13603305 men\NNS\8208016 ,\,\1740 associated\VBN\628491 with\IN\1740 bendrofluazide\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 Raynaud\NNP\1740 's\POS\1740 phenomenon\NN\29677 and\CC\1740 <e2>dyspnoea</e2>\NN\14299637 in\IN\13603305 men\NNS\8208016 and\CC\1740 women\NNS\9605289 taking\VBG\2367363 <e1>propranolol</e1>\NN\1740 .\.\1740
D011433_D003316 NONE No\DT\7204911 <e2>corneal\NN\1740 disease</e2>\NN\14061805 is\VBZ\836236 known\VBN\2110220 to\TO\1740 have\VB\2108377 occurred\VBN\2623529 in\IN\13603305 the\DT\1740 <e1>propranolol</e1>\NN\1740 group\NN\2137 .\.\1740
11847945
D007530_D002779 CID Acute\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>isoflurane</e1>\NN\3570838 .\.\1740
D007530_D002779 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 following\VBG\1835496 exposure\NN\5042871 to\TO\1740 the\DT\1740 inhalational\JJ\1740 anesthetic\JJ\1740 <e1>isoflurane</e1>\NN\3570838 .\.\1740
D007530_D002779 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Isoflurane</e1>\NNP\3570838 ,\,\1740 a\DT\13649268 common\JJ\1740 anesthetic\JJ\1740 agent\NN\7347 ,\,\1740 can\MD\3094503 cause\VB\1617192 severe\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 .\.\1740
D007530_D056486 CID Acute\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>isoflurane</e1>\NN\3570838 .\.\1740
D007530_D056486 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 following\VBG\1835496 exposure\NN\5042871 to\TO\1740 the\DT\1740 inhalational\JJ\1740 anesthetic\JJ\1740 <e1>isoflurane</e1>\NN\3570838 .\.\1740
D007530_D056486 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Isoflurane</e1>\NNP\3570838 ,\,\1740 a\DT\13649268 common\JJ\1740 anesthetic\JJ\1740 agent\NN\7347 ,\,\1740 can\MD\3094503 cause\VB\1617192 severe\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 .\.\1740
D004177_D000699 NONE No\DT\7204911 other\JJ\1740 medications\NNS\3247620 were\VBD\836236 involved\VBN\2676054 except\IN\1740 for\IN\1740 <e1>dipyrone</e1>\NN\1740 for\IN\1740 <e2>analgesia</e2>\NN\14034177 .\.\1740
12013711
D018967_D010468 CID <e1>Risperidone-associated</e1>\JJ\1740 ,\,\1740 benign\JJ\1740 transient\JJ\1740 <e2>visual\JJ\1740 disturbances</e2>\NNS\407535 in\IN\13603305 schizophrenic\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 past\JJ\1740 history\NN\15120823 of\IN\1740 LSD\NN\3097890 abuse\NN\418025 .\.\1740
D018967_D010468 CID They\PRP\1740 both\DT\1740 reported\VBD\831651 short\JJ\1740 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 <e2>visual\JJ\1740 disturbances</e2>\NNS\407535 ,\,\1740 which\WDT\1740 appeared\VBD\2604760 immediately\RB\1740 after\IN\1740 starting\VBG\2009433 treatment\NN\654885 with\IN\1740 <e1>risperidone</e1>\NN\1740 .\.\1740
D018967_D010468 CID <e1>Risperidone</e1>\NN\1740 administration\NN\1133281 was\VBD\836236 continued\VBN\2367363 and\CC\1740 the\DT\1740 <e2>visual\JJ\1740 disturbances</e2>\NNS\407535 gradually\RB\1740 wore\VBD\2630189 off\RP\1740 .\.\1740
D018967_D012559 NONE <e1>Risperidone-associated</e1>\JJ\1740 ,\,\1740 benign\JJ\1740 transient\JJ\1740 visual\JJ\1740 disturbances\NNS\407535 in\IN\13603305 <e2>schizophrenic</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 past\JJ\1740 history\NN\15120823 of\IN\1740 LSD\NN\3097890 abuse\NN\418025 .\.\1740
D018967_D012559 NONE Two\CD\13741022 <e2>schizophrenic</e2>\JJ\1740 patients\NNS\9898892 ,\,\1740 who\WP\8299493 had\VBD\2108377 a\DT\13649268 prior\JJ\1740 history\NN\15120823 of\IN\1740 LSD\NN\3097890 abuse\NN\418025 and\CC\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 developed\VBN\1753788 EPS\NN\1740 with\IN\1740 classic\JJ\1740 antipsychotics\NNS\4470232 ,\,\1740 were\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>risperidone</e1>\NN\1740 .\.\1740
D008238_D010468 NONE Risperidone-associated\JJ\1740 ,\,\1740 benign\JJ\1740 transient\JJ\1740 <e2>visual\JJ\1740 disturbances</e2>\NNS\407535 in\IN\13603305 schizophrenic\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 past\JJ\1740 history\NN\15120823 of\IN\1740 <e1>LSD</e1>\NN\3097890 abuse\NN\418025 .\.\1740
D008238_D010468 NONE This\DT\1740 imagery\NN\5765159 resembled\VBD\2657219 <e2>visual\JJ\1740 disturbances</e2>\NNS\407535 previously\RB\1740 experienced\VBN\2108377 as\IN\14622893 "\``\1740 flashbacks\NNS\6401328 "\''\1740 related\JJ\1740 to\TO\1740 prior\JJ\1740 <e1>LSD</e1>\NN\3097890 consumption\NN\13440063 .\.\1740
D008238_D012559 NONE Risperidone-associated\JJ\1740 ,\,\1740 benign\JJ\1740 transient\JJ\1740 visual\JJ\1740 disturbances\NNS\407535 in\IN\13603305 <e2>schizophrenic</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 past\JJ\1740 history\NN\15120823 of\IN\1740 <e1>LSD</e1>\NN\3097890 abuse\NN\418025 .\.\1740
D008238_D012559 NONE Two\CD\13741022 <e2>schizophrenic</e2>\JJ\1740 patients\NNS\9898892 ,\,\1740 who\WP\8299493 had\VBD\2108377 a\DT\13649268 prior\JJ\1740 history\NN\15120823 of\IN\1740 <e1>LSD</e1>\NN\3097890 abuse\NN\418025 and\CC\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 developed\VBN\1753788 EPS\NN\1740 with\IN\1740 classic\JJ\1740 antipsychotics\NNS\4470232 ,\,\1740 were\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 .\.\1740
D008238_D001480 NONE Two\CD\13741022 schizophrenic\JJ\1740 patients\NNS\9898892 ,\,\1740 who\WP\8299493 had\VBD\2108377 a\DT\13649268 prior\JJ\1740 history\NN\15120823 of\IN\1740 <e1>LSD</e1>\NN\3097890 abuse\NN\418025 and\CC\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 developed\VBN\1753788 <e2>EPS</e2>\NN\1740 with\IN\1740 classic\JJ\1740 antipsychotics\NNS\4470232 ,\,\1740 were\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 .\.\1740
D018967_D001480 NONE Two\CD\13741022 schizophrenic\JJ\1740 patients\NNS\9898892 ,\,\1740 who\WP\8299493 had\VBD\2108377 a\DT\13649268 prior\JJ\1740 history\NN\15120823 of\IN\1740 LSD\NN\3097890 abuse\NN\418025 and\CC\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 developed\VBN\1753788 <e2>EPS</e2>\NN\1740 with\IN\1740 classic\JJ\1740 antipsychotics\NNS\4470232 ,\,\1740 were\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>risperidone</e1>\NN\1740 .\.\1740
19923525
D009553_D008569 NONE <e1>Nimodipine</e1>\NN\1740 prevents\VBZ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 caused\VBN\1617192 by\IN\1740 nitroglycerin-induced\JJ\1740 hypotension\NN\14057371 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 .\.\1740
D009553_D007022 NONE <e1>Nimodipine</e1>\NN\1740 prevents\VBZ\1740 memory\NN\5926676 impairment\NN\7296428 caused\VBN\1617192 by\IN\1740 nitroglycerin-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 .\.\1740
D009553_D007022 NONE We\PRP\1740 tested\VBD\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 <e1>nimodipine</e1>\NN\1740 (\-LRB-\1740 NIMO\NN\1740 )\-RRB-\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 onset\NN\7325190 of\IN\1740 nitroglycerin\NN\15015501 (NTG)-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 would\MD\1740 preserve\VB\2681795 long-term\JJ\1740 associative\JJ\1740 memory\NN\5926676 .\.\1740
D009553_D007022 NONE We\PRP\1740 tested\VBD\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 nimodipine\NN\1740 (\-LRB-\1740 <e1>NIMO</e1>\NN\1740 )\-RRB-\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 onset\NN\7325190 of\IN\1740 nitroglycerin\NN\15015501 (NTG)-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 would\MD\1740 preserve\VB\2681795 long-term\JJ\1740 associative\JJ\1740 memory\NN\5926676 .\.\1740
D009553_D007022 NONE Mice\NNS\2329401 subjected\VBD\137313 to\TO\1740 <e2>hypotensive</e2>\JJ\1740 episodes\NNS\7283608 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 latency\NN\15269513 time\NN\7308889 (\-LRB-\1740 178\CD\1740 +/-\CC\1740 156\CD\1740 s\NNS\15154774 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 injected\VBN\81072 with\IN\1740 saline\NN\14849367 ,\,\1740 NTG\NN\1740 +\CC\1740 <e1>NIMO</e1>\NN\1740 ,\,\1740 or\CC\3541091 delayed\VBN\439958 NTG\NN\1740 (\-LRB-\1740 580\CD\1740 +/-\CC\1740 81\CD\1740 s\NNS\15154774 ,\,\1740 557\CD\1740 +/-\CC\1740 67\CD\1740 s\NNS\15154774 ,\,\1740 and\CC\1740 493\CD\1740 +/-\CC\1740 146\CD\1740 s\NNS\15154774 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D009553_D007022 NONE <e1>NIMO</e1>\NN\1740 attenuated\VBD\224901 the\DT\1740 disruption\NN\1066163 in\IN\13603305 consolidation\NN\7373803 of\IN\1740 long-term\JJ\1740 memory\NN\5926676 caused\VBN\1617192 by\IN\1740 NTG\NN\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 improve\VB\126264 latency\NN\15269513 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D009553_D007022 NONE The\DT\1740 observed\VBN\2163746 effect\NN\34213 of\IN\1740 <e1>NIMO</e1>\NN\1740 may\MD\15209706 have\VB\2108377 been\VBN\836236 attributable\JJ\1740 to\TO\1740 the\DT\1740 preservation\NN\817680 of\IN\1740 calcium\NN\14625458 homeostasis\NN\13934900 during\IN\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 because\IN\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 differences\NNS\4723816 in\IN\13603305 the\DT\1740 PbtO(2\NN\1740 )\-RRB-\1740 indices\NNS\13850304 among\IN\1740 groups\NNS\2137 .\.\1740
D005996_D008569 CID Nimodipine\NN\1740 prevents\VBZ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 caused\VBN\1617192 by\IN\1740 <e1>nitroglycerin-induced</e1>\JJ\1740 hypotension\NN\14057371 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 .\.\1740
D005996_D007022 CID Nimodipine\NN\1740 prevents\VBZ\1740 memory\NN\5926676 impairment\NN\7296428 caused\VBN\1617192 by\IN\1740 <e1>nitroglycerin-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 .\.\1740
D005996_D007022 CID We\PRP\1740 tested\VBD\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 nimodipine\NN\1740 (\-LRB-\1740 NIMO\NN\1740 )\-RRB-\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 onset\NN\7325190 of\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 (NTG)-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 would\MD\1740 preserve\VB\2681795 long-term\JJ\1740 associative\JJ\1740 memory\NN\5926676 .\.\1740
D005996_D007022 CID We\PRP\1740 tested\VBD\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 nimodipine\NN\1740 (\-LRB-\1740 NIMO\NN\1740 )\-RRB-\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 onset\NN\7325190 of\IN\1740 nitroglycerin\NN\15015501 <e1>(NTG)-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 would\MD\1740 preserve\VB\2681795 long-term\JJ\1740 associative\JJ\1740 memory\NN\5926676 .\.\1740
D005996_D007022 CID Mice\NNS\2329401 subjected\VBD\137313 to\TO\1740 <e2>hypotensive</e2>\JJ\1740 episodes\NNS\7283608 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 latency\NN\15269513 time\NN\7308889 (\-LRB-\1740 178\CD\1740 +/-\CC\1740 156\CD\1740 s\NNS\15154774 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 injected\VBN\81072 with\IN\1740 saline\NN\14849367 ,\,\1740 <e1>NTG</e1>\NN\1740 +\CC\1740 NIMO\NN\1740 ,\,\1740 or\CC\3541091 delayed\VBN\439958 NTG\NN\1740 (\-LRB-\1740 580\CD\1740 +/-\CC\1740 81\CD\1740 s\NNS\15154774 ,\,\1740 557\CD\1740 +/-\CC\1740 67\CD\1740 s\NNS\15154774 ,\,\1740 and\CC\1740 493\CD\1740 +/-\CC\1740 146\CD\1740 s\NNS\15154774 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D005996_D007022 CID Mice\NNS\2329401 subjected\VBD\137313 to\TO\1740 <e2>hypotensive</e2>\JJ\1740 episodes\NNS\7283608 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 latency\NN\15269513 time\NN\7308889 (\-LRB-\1740 178\CD\1740 +/-\CC\1740 156\CD\1740 s\NNS\15154774 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 injected\VBN\81072 with\IN\1740 saline\NN\14849367 ,\,\1740 NTG\NN\1740 +\CC\1740 NIMO\NN\1740 ,\,\1740 or\CC\3541091 delayed\VBN\439958 <e1>NTG</e1>\NN\1740 (\-LRB-\1740 580\CD\1740 +/-\CC\1740 81\CD\1740 s\NNS\15154774 ,\,\1740 557\CD\1740 +/-\CC\1740 67\CD\1740 s\NNS\15154774 ,\,\1740 and\CC\1740 493\CD\1740 +/-\CC\1740 146\CD\1740 s\NNS\15154774 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D005996_D007022 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 a\DT\13649268 PA\NN\10080869 retention\NN\809465 paradigm\NN\13803782 ,\,\1740 the\DT\1740 injection\NN\320852 of\IN\1740 <e1>NTG</e1>\NN\1740 immediately\RB\1740 after\IN\1740 learning\NN\5701944 produced\VBD\1617192 a\DT\13649268 significant\JJ\1740 impairment\NN\7296428 of\IN\1740 long-term\JJ\1740 associative\JJ\1740 memory\NN\5926676 in\IN\13603305 mice\NNS\2329401 ,\,\1740 whereas\IN\1740 delayed\VBD\439958 induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
D005996_D007022 CID NIMO\NN\1740 attenuated\VBD\224901 the\DT\1740 disruption\NN\1066163 in\IN\13603305 consolidation\NN\7373803 of\IN\1740 long-term\JJ\1740 memory\NN\5926676 caused\VBN\1617192 by\IN\1740 <e1>NTG</e1>\NN\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 improve\VB\126264 latency\NN\15269513 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D002118_D007022 NONE The\DT\1740 observed\VBN\2163746 effect\NN\34213 of\IN\1740 NIMO\NN\1740 may\MD\15209706 have\VB\2108377 been\VBN\836236 attributable\JJ\1740 to\TO\1740 the\DT\1740 preservation\NN\817680 of\IN\1740 <e1>calcium</e1>\NN\14625458 homeostasis\NN\13934900 during\IN\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 because\IN\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 differences\NNS\4723816 in\IN\13603305 the\DT\1740 PbtO(2\NN\1740 )\-RRB-\1740 indices\NNS\13850304 among\IN\1740 groups\NNS\2137 .\.\1740
6436733
D014635_D004827 NONE <e1>Valproic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 VPA\NN\1740 )\-RRB-\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 24\CD\13745420 <e2>epileptic</e2>\JJ\1740 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 already\RB\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 other\JJ\1740 antiepileptic\JJ\1740 drugs\NNS\14778436 .\.\1740
D014635_D004827 NONE Valproic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>VPA</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 24\CD\13745420 <e2>epileptic</e2>\JJ\1740 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 already\RB\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 other\JJ\1740 antiepileptic\JJ\1740 drugs\NNS\14778436 .\.\1740
D000641_D006970 CID <e1>Ammonia</e1>\NN\14940386 (\-LRB-\1740 NH3\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 ,\,\1740 during\IN\1740 continuous\JJ\1740 therapy\NN\657604 ,\,\1740 complained\VBD\843959 of\IN\1740 <e2>drowsiness</e2>\NN\14015731 (\-LRB-\1740 7\CD\13741022 patients\NNS\9898892 )\-RRB-\1740 than\IN\1740 in\IN\13603305 those\DT\1740 who\WP\8299493 were\VBD\836236 symptom-free\JJ\1740 (\-LRB-\1740 17\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 ,\,\1740 although\IN\1740 VPA\NN\1740 plasma\NN\5398023 levels\NNS\4916342 were\VBD\836236 similar\JJ\1740 in\IN\13603305 both\DT\1740 groups\NNS\2137 .\.\1740
D000641_D006970 CID Ammonia\NN\14940386 (\-LRB-\1740 <e1>NH3</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 ,\,\1740 during\IN\1740 continuous\JJ\1740 therapy\NN\657604 ,\,\1740 complained\VBD\843959 of\IN\1740 <e2>drowsiness</e2>\NN\14015731 (\-LRB-\1740 7\CD\13741022 patients\NNS\9898892 )\-RRB-\1740 than\IN\1740 in\IN\13603305 those\DT\1740 who\WP\8299493 were\VBD\836236 symptom-free\JJ\1740 (\-LRB-\1740 17\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 ,\,\1740 although\IN\1740 VPA\NN\1740 plasma\NN\5398023 levels\NNS\4916342 were\VBD\836236 similar\JJ\1740 in\IN\13603305 both\DT\1740 groups\NNS\2137 .\.\1740
D014635_D006970 CID Ammonia\NN\14940386 (\-LRB-\1740 NH3\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 ,\,\1740 during\IN\1740 continuous\JJ\1740 therapy\NN\657604 ,\,\1740 complained\VBD\843959 of\IN\1740 <e2>drowsiness</e2>\NN\14015731 (\-LRB-\1740 7\CD\13741022 patients\NNS\9898892 )\-RRB-\1740 than\IN\1740 in\IN\13603305 those\DT\1740 who\WP\8299493 were\VBD\836236 symptom-free\JJ\1740 (\-LRB-\1740 17\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 ,\,\1740 although\IN\1740 <e1>VPA</e1>\NN\1740 plasma\NN\5398023 levels\NNS\4916342 were\VBD\836236 similar\JJ\1740 in\IN\13603305 both\DT\1740 groups\NNS\2137 .\.\1740
20533999
D004298_D020258 NONE <e1>Dopamine</e1>\NNP\14807737 is\VBZ\836236 not\RB\1740 essential\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 methamphetamine-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D004298_D020258 NONE Here\RB\1740 we\PRP\1740 show\VBP\2137132 that\IN\1740 the\DT\1740 recently\RB\1740 reported\VBN\831651 ability\NN\4723816 of\IN\1740 L-dihydroxyphenylalanine\NN\1740 to\TO\1740 reverse\VB\109660 the\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 alpha-methyl-para-tyrosine\NN\1740 on\IN\1740 METH-induced\JJ\1740 <e1>DA</e1>\NN\10484858 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 also\RB\1740 confounded\VBN\2604760 by\IN\1740 drug\NN\14778436 effects\NNS\13245626 on\IN\1740 body\NN\19128 temperature\NN\13575869 .\.\1740
D004298_D020258 NONE Further\RB\1740 ,\,\1740 we\PRP\1740 show\VBP\2137132 that\IN\1740 mice\NNS\2329401 genetically\RB\1740 engineered\VBD\1639714 to\TO\1740 be\VB\836236 deficient\JJ\1740 in\IN\13603305 brain\NN\5462674 <e1>DA</e1>\NN\10484858 develop\VBP\1753788 METH\NN\2704153 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 as\RB\1740 long\RB\1740 as\IN\14622893 the\DT\1740 thermic\JJ\1740 effects\NNS\13245626 of\IN\1740 METH\NN\2704153 are\VBP\836236 preserved\VBN\2681795 .\.\1740
D004298_D020258 NONE Taken\VBN\2367363 together\RB\1740 ,\,\1740 these\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 that\IN\1740 <e1>DA</e1>\NN\10484858 is\VBZ\836236 not\RB\1740 essential\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 METH-induced\JJ\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 and\CC\1740 suggest\VBP\1010118 that\IN\1740 mechanisms\NNS\13446390 independent\JJ\1740 of\IN\1740 DA\NN\10484858 warrant\VBP\1012073 more\RBR\1740 intense\JJ\1740 investigation\NN\5797597 .\.\1740
D004298_D020258 NONE Taken\VBN\2367363 together\RB\1740 ,\,\1740 these\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 that\IN\1740 DA\NN\10484858 is\VBZ\836236 not\RB\1740 essential\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 METH-induced\JJ\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 and\CC\1740 suggest\VBP\1010118 that\IN\1740 mechanisms\NNS\13446390 independent\JJ\1740 of\IN\1740 <e1>DA</e1>\NN\10484858 warrant\VBP\1012073 more\RBR\1740 intense\JJ\1740 investigation\NN\5797597 .\.\1740
D008694_D020258 CID Dopamine\NNP\14807737 is\VBZ\836236 not\RB\1740 essential\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>methamphetamine-induced</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008694_D020258 CID Here\RB\1740 we\PRP\1740 show\VBP\2137132 that\IN\1740 the\DT\1740 recently\RB\1740 reported\VBN\831651 ability\NN\4723816 of\IN\1740 L-dihydroxyphenylalanine\NN\1740 to\TO\1740 reverse\VB\109660 the\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 alpha-methyl-para-tyrosine\NN\1740 on\IN\1740 <e1>METH-induced</e1>\JJ\1740 DA\NN\10484858 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 also\RB\1740 confounded\VBN\2604760 by\IN\1740 drug\NN\14778436 effects\NNS\13245626 on\IN\1740 body\NN\19128 temperature\NN\13575869 .\.\1740
D008694_D020258 CID Further\RB\1740 ,\,\1740 we\PRP\1740 show\VBP\2137132 that\IN\1740 mice\NNS\2329401 genetically\RB\1740 engineered\VBD\1639714 to\TO\1740 be\VB\836236 deficient\JJ\1740 in\IN\13603305 brain\NN\5462674 DA\NN\10484858 develop\VBP\1753788 <e1>METH</e1>\NN\2704153 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 as\RB\1740 long\RB\1740 as\IN\14622893 the\DT\1740 thermic\JJ\1740 effects\NNS\13245626 of\IN\1740 METH\NN\2704153 are\VBP\836236 preserved\VBN\2681795 .\.\1740
D008694_D020258 CID Further\RB\1740 ,\,\1740 we\PRP\1740 show\VBP\2137132 that\IN\1740 mice\NNS\2329401 genetically\RB\1740 engineered\VBD\1639714 to\TO\1740 be\VB\836236 deficient\JJ\1740 in\IN\13603305 brain\NN\5462674 DA\NN\10484858 develop\VBP\1753788 METH\NN\2704153 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 as\RB\1740 long\RB\1740 as\IN\14622893 the\DT\1740 thermic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>METH</e1>\NN\2704153 are\VBP\836236 preserved\VBN\2681795 .\.\1740
D008694_D020258 CID Taken\VBN\2367363 together\RB\1740 ,\,\1740 these\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 that\IN\1740 DA\NN\10484858 is\VBZ\836236 not\RB\1740 essential\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>METH-induced</e1>\JJ\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 and\CC\1740 suggest\VBP\1010118 that\IN\1740 mechanisms\NNS\13446390 independent\JJ\1740 of\IN\1740 DA\NN\10484858 warrant\VBP\1012073 more\RBR\1740 intense\JJ\1740 investigation\NN\5797597 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 <e1>dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 <e1>dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 <e2>toxicity</e2>\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 <e1>dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 <e2>toxicity</e2>\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 <e2>toxicity</e2>\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 <e2>toxicity</e2>\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 <e1>DA</e1>\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 <e1>DA</e1>\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 <e2>toxicity</e2>\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 <e1>DA</e1>\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 <e2>toxicity</e2>\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 <e1>DA</e1>\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 <e2>toxicity</e2>\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 <e1>DA</e1>\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D004298_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 <e1>DA</e1>\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 <e2>toxicity</e2>\NN\13576101 .\.\1740
D008694_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 <e1>methamphetamine</e1>\NN\2704153 (METH)-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D008694_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 <e1>methamphetamine</e1>\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 <e2>toxicity</e2>\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D008694_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 <e1>methamphetamine</e1>\NN\2704153 (METH)-induced\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 <e2>toxicity</e2>\NN\13576101 .\.\1740
D008694_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 <e1>(METH)-induced</e1>\JJ\1740 <e2>toxicity</e2>\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D008694_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 <e1>(METH)-induced</e1>\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 <e2>toxicity</e2>\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 toxicity\NN\13576101 .\.\1740
D008694_D064420 NONE It\PRP\6125041 is\VBZ\836236 widely\RB\1740 believed\VBN\686447 that\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 mediates\VBZ\761713 methamphetamine\NN\2704153 <e1>(METH)-induced</e1>\JJ\1740 toxicity\NN\13576101 to\TO\1740 brain\VB\1400044 dopaminergic\JJ\1740 neurons\NNS\5430628 ,\,\1740 because\IN\1740 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 DA\NN\10484858 neurotransmission\NN\1740 decrease\NN\7296428 toxicity\NN\13576101 ,\,\1740 whereas\IN\1740 drugs\NNS\14778436 that\WDT\1740 increase\VBP\169651 DA\NN\10484858 neurotransmission\NN\1740 enhance\VBP\227165 <e2>toxicity</e2>\NN\13576101 .\.\1740
D007980_D020258 NONE Here\RB\1740 we\PRP\1740 show\VBP\2137132 that\IN\1740 the\DT\1740 recently\RB\1740 reported\VBN\831651 ability\NN\4723816 of\IN\1740 <e1>L-dihydroxyphenylalanine</e1>\NN\1740 to\TO\1740 reverse\VB\109660 the\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 alpha-methyl-para-tyrosine\NN\1740 on\IN\1740 METH-induced\JJ\1740 DA\NN\10484858 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 also\RB\1740 confounded\VBN\2604760 by\IN\1740 drug\NN\14778436 effects\NNS\13245626 on\IN\1740 body\NN\19128 temperature\NN\13575869 .\.\1740
D019805_D020258 NONE Here\RB\1740 we\PRP\1740 show\VBP\2137132 that\IN\1740 the\DT\1740 recently\RB\1740 reported\VBN\831651 ability\NN\4723816 of\IN\1740 L-dihydroxyphenylalanine\NN\1740 to\TO\1740 reverse\VB\109660 the\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>alpha-methyl-para-tyrosine</e1>\NN\1740 on\IN\1740 METH-induced\JJ\1740 DA\NN\10484858 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 also\RB\1740 confounded\VBN\2604760 by\IN\1740 drug\NN\14778436 effects\NNS\13245626 on\IN\1740 body\NN\19128 temperature\NN\13575869 .\.\1740
D004298_D009461 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 we\PRP\1740 demonstrate\VBP\2137132 that\IN\1740 mice\NNS\2329401 genetically\RB\1740 engineered\VBD\1639714 to\TO\1740 have\VB\2108377 unilateral\JJ\1740 brain\NN\5462674 <e1>DA</e1>\NN\10484858 deficits\NNS\5113133 develop\VBP\1753788 METH-induced\JJ\1740 <e2>dopaminergic\JJ\1740 deficits</e2>\NNS\5113133 that\WDT\1740 are\VBP\836236 of\IN\1740 comparable\JJ\1740 magnitude\NN\4916342 on\IN\1740 both\DT\1740 sides\NNS\8630039 of\IN\1740 the\DT\1740 brain\NN\5462674 .\.\1740
D008694_D009461 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 we\PRP\1740 demonstrate\VBP\2137132 that\IN\1740 mice\NNS\2329401 genetically\RB\1740 engineered\VBD\1639714 to\TO\1740 have\VB\2108377 unilateral\JJ\1740 brain\NN\5462674 DA\NN\10484858 deficits\NNS\5113133 develop\VBP\1753788 <e1>METH-induced</e1>\JJ\1740 <e2>dopaminergic\JJ\1740 deficits</e2>\NNS\5113133 that\WDT\1740 are\VBP\836236 of\IN\1740 comparable\JJ\1740 magnitude\NN\4916342 on\IN\1740 both\DT\1740 sides\NNS\8630039 of\IN\1740 the\DT\1740 brain\NN\5462674 .\.\1740
15517007
D003520_D006331 CID However\RB\1740 ,\,\1740 caution\NN\4662951 is\VBZ\836236 required\VBN\754942 when\WRB\1740 <e1>cyclophosphamide</e1>\NN\1740 or\CC\3541091 anthracyclines\NNS\1740 such\JJ\1740 as\IN\14622893 mitoxantrone\NN\1740 are\VBP\836236 used\VBN\1156834 in\IN\13603305 patients\NNS\9898892 with\IN\1740 a\DT\13649268 possible\JJ\1740 underlying\VBG\2604760 <e2>heart\NN\5919034 damage</e2>\NN\7296428 ,\,\1740 for\IN\1740 example\NN\5816287 ,\,\1740 systemic\JJ\1740 sclerosis\NN\14204950 patients\NNS\9898892 .\.\1740
D003520_D012595 NONE However\RB\1740 ,\,\1740 caution\NN\4662951 is\VBZ\836236 required\VBN\754942 when\WRB\1740 <e1>cyclophosphamide</e1>\NN\1740 or\CC\3541091 anthracyclines\NNS\1740 such\JJ\1740 as\IN\14622893 mitoxantrone\NN\1740 are\VBP\836236 used\VBN\1156834 in\IN\13603305 patients\NNS\9898892 with\IN\1740 a\DT\13649268 possible\JJ\1740 underlying\VBG\2604760 heart\NN\5919034 damage\NN\7296428 ,\,\1740 for\IN\1740 example\NN\5816287 ,\,\1740 <e2>systemic\JJ\1740 sclerosis</e2>\NN\14204950 patients\NNS\9898892 .\.\1740
D018943_D006331 NONE However\RB\1740 ,\,\1740 caution\NN\4662951 is\VBZ\836236 required\VBN\754942 when\WRB\1740 cyclophosphamide\NN\1740 or\CC\3541091 <e1>anthracyclines</e1>\NNS\1740 such\JJ\1740 as\IN\14622893 mitoxantrone\NN\1740 are\VBP\836236 used\VBN\1156834 in\IN\13603305 patients\NNS\9898892 with\IN\1740 a\DT\13649268 possible\JJ\1740 underlying\VBG\2604760 <e2>heart\NN\5919034 damage</e2>\NN\7296428 ,\,\1740 for\IN\1740 example\NN\5816287 ,\,\1740 systemic\JJ\1740 sclerosis\NN\14204950 patients\NNS\9898892 .\.\1740
D018943_D012595 NONE However\RB\1740 ,\,\1740 caution\NN\4662951 is\VBZ\836236 required\VBN\754942 when\WRB\1740 cyclophosphamide\NN\1740 or\CC\3541091 <e1>anthracyclines</e1>\NNS\1740 such\JJ\1740 as\IN\14622893 mitoxantrone\NN\1740 are\VBP\836236 used\VBN\1156834 in\IN\13603305 patients\NNS\9898892 with\IN\1740 a\DT\13649268 possible\JJ\1740 underlying\VBG\2604760 heart\NN\5919034 damage\NN\7296428 ,\,\1740 for\IN\1740 example\NN\5816287 ,\,\1740 <e2>systemic\JJ\1740 sclerosis</e2>\NN\14204950 patients\NNS\9898892 .\.\1740
D008942_D006331 CID However\RB\1740 ,\,\1740 caution\NN\4662951 is\VBZ\836236 required\VBN\754942 when\WRB\1740 cyclophosphamide\NN\1740 or\CC\3541091 anthracyclines\NNS\1740 such\JJ\1740 as\IN\14622893 <e1>mitoxantrone</e1>\NN\1740 are\VBP\836236 used\VBN\1156834 in\IN\13603305 patients\NNS\9898892 with\IN\1740 a\DT\13649268 possible\JJ\1740 underlying\VBG\2604760 <e2>heart\NN\5919034 damage</e2>\NN\7296428 ,\,\1740 for\IN\1740 example\NN\5816287 ,\,\1740 systemic\JJ\1740 sclerosis\NN\14204950 patients\NNS\9898892 .\.\1740
D008942_D012595 NONE However\RB\1740 ,\,\1740 caution\NN\4662951 is\VBZ\836236 required\VBN\754942 when\WRB\1740 cyclophosphamide\NN\1740 or\CC\3541091 anthracyclines\NNS\1740 such\JJ\1740 as\IN\14622893 <e1>mitoxantrone</e1>\NN\1740 are\VBP\836236 used\VBN\1156834 in\IN\13603305 patients\NNS\9898892 with\IN\1740 a\DT\13649268 possible\JJ\1740 underlying\VBG\2604760 heart\NN\5919034 damage\NN\7296428 ,\,\1740 for\IN\1740 example\NN\5816287 ,\,\1740 <e2>systemic\JJ\1740 sclerosis</e2>\NN\14204950 patients\NNS\9898892 .\.\1740
16157917
C047781_D009207 CID <e1>Lamotrigine</e1>\NNP\1740 associated\VBD\628491 with\IN\1740 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 <e2>myoclonus</e2>\NN\14360459 in\IN\13603305 idiopathic\JJ\1740 generalized\JJ\1740 epilepsies\NNS\14085708 .\.\1740
C047781_D009207 CID Five\CD\13741022 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 generalized\JJ\1740 epilepsies\NNS\14085708 (\-LRB-\1740 IGE\NN\15030481 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>lamotrigine</e1>\NN\1740 (\-LRB-\1740 LTG\NN\1740 )\-RRB-\1740 experienced\VBD\2108377 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 appearance\NN\4723816 of\IN\1740 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 (\-LRB-\1740 MJ\NN\1740 )\-RRB-\1740 .\.\1740
C047781_D009207 CID Five\CD\13741022 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 generalized\JJ\1740 epilepsies\NNS\14085708 (\-LRB-\1740 IGE\NN\15030481 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>lamotrigine</e1>\NN\1740 (\-LRB-\1740 LTG\NN\1740 )\-RRB-\1740 experienced\VBD\2108377 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 appearance\NN\4723816 of\IN\1740 myoclonic\JJ\1740 jerks\NNS\10322238 (\-LRB-\1740 <e2>MJ</e2>\NN\1740 )\-RRB-\1740 .\.\1740
C047781_D009207 CID Five\CD\13741022 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 generalized\JJ\1740 epilepsies\NNS\14085708 (\-LRB-\1740 IGE\NN\15030481 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 lamotrigine\NN\1740 (\-LRB-\1740 <e1>LTG</e1>\NN\1740 )\-RRB-\1740 experienced\VBD\2108377 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 appearance\NN\4723816 of\IN\1740 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 (\-LRB-\1740 MJ\NN\1740 )\-RRB-\1740 .\.\1740
C047781_D009207 CID Five\CD\13741022 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 generalized\JJ\1740 epilepsies\NNS\14085708 (\-LRB-\1740 IGE\NN\15030481 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 lamotrigine\NN\1740 (\-LRB-\1740 <e1>LTG</e1>\NN\1740 )\-RRB-\1740 experienced\VBD\2108377 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 appearance\NN\4723816 of\IN\1740 myoclonic\JJ\1740 jerks\NNS\10322238 (\-LRB-\1740 <e2>MJ</e2>\NN\1740 )\-RRB-\1740 .\.\1740
C047781_D009207 CID In\IN\13603305 three\CD\13741022 patients\NNS\9898892 ,\,\1740 <e1>LTG</e1>\NN\1740 exacerbated\VBD\126264 <e2>MJ</e2>\NN\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 with\IN\1740 early\JJ\1740 aggravation\NN\7518261 during\IN\1740 titration\NN\647713 .\.\1740
C047781_D009207 CID <e2>MJ</e2>\NNP\1740 disappeared\VBD\2609764 when\WRB\1740 <e1>LTG</e1>\NN\1740 dose\NN\3740161 was\VBD\836236 decreased\VBN\169651 by\IN\1740 25\CD\13745420 to\TO\1740 50\CD\13745420 %\NN\1740 .\.\1740
C047781_D009207 CID In\IN\13603305 two\CD\13741022 patients\NNS\9898892 ,\,\1740 <e1>LTG</e1>\NN\1740 exacerbated\VBD\126264 <e2>MJ</e2>\NN\1740 in\IN\13603305 a\DT\13649268 delayed\VBN\439958 but\CC\1740 more\RBR\1740 severe\JJ\1740 manner\NN\4916342 ,\,\1740 with\IN\1740 myoclonic\JJ\1740 status\NN\24720 that\WDT\1740 only\RB\1740 ceased\VBD\1740 after\IN\1740 LTG\NNP\1740 withdrawal\NN\7206096 .\.\1740
C047781_D009207 CID In\IN\13603305 two\CD\13741022 patients\NNS\9898892 ,\,\1740 <e1>LTG</e1>\NN\1740 exacerbated\VBD\126264 MJ\NN\1740 in\IN\13603305 a\DT\13649268 delayed\VBN\439958 but\CC\1740 more\RBR\1740 severe\JJ\1740 manner\NN\4916342 ,\,\1740 with\IN\1740 <e2>myoclonic\JJ\1740 status</e2>\NN\24720 that\WDT\1740 only\RB\1740 ceased\VBD\1740 after\IN\1740 LTG\NNP\1740 withdrawal\NN\7206096 .\.\1740
C047781_D009207 CID In\IN\13603305 two\CD\13741022 patients\NNS\9898892 ,\,\1740 LTG\NN\1740 exacerbated\VBD\126264 <e2>MJ</e2>\NN\1740 in\IN\13603305 a\DT\13649268 delayed\VBN\439958 but\CC\1740 more\RBR\1740 severe\JJ\1740 manner\NN\4916342 ,\,\1740 with\IN\1740 myoclonic\JJ\1740 status\NN\24720 that\WDT\1740 only\RB\1740 ceased\VBD\1740 after\IN\1740 <e1>LTG</e1>\NNP\1740 withdrawal\NN\7206096 .\.\1740
C047781_D009207 CID In\IN\13603305 two\CD\13741022 patients\NNS\9898892 ,\,\1740 LTG\NN\1740 exacerbated\VBD\126264 MJ\NN\1740 in\IN\13603305 a\DT\13649268 delayed\VBN\439958 but\CC\1740 more\RBR\1740 severe\JJ\1740 manner\NN\4916342 ,\,\1740 with\IN\1740 <e2>myoclonic\JJ\1740 status</e2>\NN\24720 that\WDT\1740 only\RB\1740 ceased\VBD\1740 after\IN\1740 <e1>LTG</e1>\NNP\1740 withdrawal\NN\7206096 .\.\1740
C047781_C562694 NONE <e1>Lamotrigine</e1>\NNP\1740 associated\VBD\628491 with\IN\1740 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 myoclonus\NN\14360459 in\IN\13603305 <e2>idiopathic\JJ\1740 generalized\JJ\1740 epilepsies</e2>\NNS\14085708 .\.\1740
C047781_C562694 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>idiopathic\JJ\1740 generalized\JJ\1740 epilepsies</e2>\NNS\14085708 (\-LRB-\1740 IGE\NN\15030481 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>lamotrigine</e1>\NN\1740 (\-LRB-\1740 LTG\NN\1740 )\-RRB-\1740 experienced\VBD\2108377 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 appearance\NN\4723816 of\IN\1740 myoclonic\JJ\1740 jerks\NNS\10322238 (\-LRB-\1740 MJ\NN\1740 )\-RRB-\1740 .\.\1740
C047781_C562694 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 generalized\JJ\1740 epilepsies\NNS\14085708 (\-LRB-\1740 <e2>IGE</e2>\NN\15030481 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>lamotrigine</e1>\NN\1740 (\-LRB-\1740 LTG\NN\1740 )\-RRB-\1740 experienced\VBD\2108377 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 appearance\NN\4723816 of\IN\1740 myoclonic\JJ\1740 jerks\NNS\10322238 (\-LRB-\1740 MJ\NN\1740 )\-RRB-\1740 .\.\1740
C047781_C562694 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>idiopathic\JJ\1740 generalized\JJ\1740 epilepsies</e2>\NNS\14085708 (\-LRB-\1740 IGE\NN\15030481 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 lamotrigine\NN\1740 (\-LRB-\1740 <e1>LTG</e1>\NN\1740 )\-RRB-\1740 experienced\VBD\2108377 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 appearance\NN\4723816 of\IN\1740 myoclonic\JJ\1740 jerks\NNS\10322238 (\-LRB-\1740 MJ\NN\1740 )\-RRB-\1740 .\.\1740
C047781_C562694 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 generalized\JJ\1740 epilepsies\NNS\14085708 (\-LRB-\1740 <e2>IGE</e2>\NN\15030481 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 lamotrigine\NN\1740 (\-LRB-\1740 <e1>LTG</e1>\NN\1740 )\-RRB-\1740 experienced\VBD\2108377 exacerbation\NN\374224 or\CC\3541091 de\FW\1740 novo\FW\1740 appearance\NN\4723816 of\IN\1740 myoclonic\JJ\1740 jerks\NNS\10322238 (\-LRB-\1740 MJ\NN\1740 )\-RRB-\1740 .\.\1740
12911170
D002939_D009395 CID <e1>Ciprofloxacin-induced</e1>\JJ\1740 acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 and\CC\1740 autoimmune\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 .\.\1740
D002939_D009395 CID <e1>Ciprofloxacin</e1>\NN\2716866 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 several\JJ\1740 side\NN\8630039 effects\NNS\13245626 including\VBG\690614 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 and\CC\1740 hemolytic\JJ\1740 anemia\NN\14189204 .\.\1740
D002939_D009395 CID In\IN\13603305 this\DT\1740 report\NN\6470073 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>ciprofloxacin-induced</e1>\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 and\CC\1740 autoimmune\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 .\.\1740
D002939_D000744 NONE <e1>Ciprofloxacin-induced</e1>\JJ\1740 acute\JJ\1740 interstitial\JJ\1740 nephritis\NN\14113228 and\CC\1740 <e2>autoimmune\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D002939_D000744 NONE In\IN\13603305 this\DT\1740 report\NN\6470073 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>ciprofloxacin-induced</e1>\JJ\1740 interstitial\JJ\1740 nephritis\NN\14113228 and\CC\1740 <e2>autoimmune\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D002939_D000743 CID <e1>Ciprofloxacin</e1>\NN\2716866 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 several\JJ\1740 side\NN\8630039 effects\NNS\13245626 including\VBG\690614 interstitial\JJ\1740 nephritis\NN\14113228 and\CC\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D013256_D000743 NONE <e2>Hemolytic\JJ\1740 anemia</e2>\NN\14189204 improved\VBD\126264 after\IN\1740 stopping\VBG\2452885 the\DT\1740 drug\NN\14778436 and\CC\1740 initiation\NN\7450842 of\IN\1740 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 .\.\1740
2886572
D004837_D006973 CID Enhanced\VBN\227165 stimulus-induced\JJ\1740 neurotransmitter\NN\14807410 overflow\NN\329227 in\IN\13603305 <e1>epinephrine-induced</e1>\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 is\VBZ\836236 not\RB\1740 mediated\VBN\761713 by\IN\1740 prejunctional\JJ\1740 beta-adrenoceptor\NN\5608868 activation\NN\13561719 .\.\1740
2322844
D011453_D010146 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 intrathecal\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>prostaglandins</e1>\NNS\5414534 on\IN\1740 <e2>pain</e2>\NN\14299637 responses\NNS\11410625 in\IN\13603305 conscious\JJ\1740 mice\NNS\2329401 were\VBD\836236 evaluated\VBN\670261 by\IN\1740 using\VBG\1156834 hot\JJ\1740 plate\NN\2797881 and\CC\1740 acetic\JJ\1740 acid\NN\14818238 writhing\NN\1740 tests\NNS\5798043 .\.\1740
D019342_D010146 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 intrathecal\JJ\1740 administration\NN\1133281 of\IN\1740 prostaglandins\NNS\5414534 on\IN\1740 <e2>pain</e2>\NN\14299637 responses\NNS\11410625 in\IN\13603305 conscious\JJ\1740 mice\NNS\2329401 were\VBD\836236 evaluated\VBN\670261 by\IN\1740 using\VBG\1156834 hot\JJ\1740 plate\NN\2797881 and\CC\1740 <e1>acetic\JJ\1740 acid</e1>\NN\14818238 writhing\NN\1740 tests\NNS\5798043 .\.\1740
D015230_D006930 CID <e1>Prostaglandin\NN\5414534 D2</e1>\NN\1740 (\-LRB-\1740 0.5\CD\1740 -\SYM\1740 3\CD\13741022 ng/mouse\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 <e2>hyperalgesic</e2>\JJ\1740 action\NN\30358 on\IN\1740 the\DT\1740 response\NN\11410625 to\TO\1740 a\DT\13649268 hot\JJ\1740 plate\NN\2797881 during\IN\1740 a\DT\13649268 3\CD\13741022 -\SYM\1740 60\CD\13745420 min\NN\15154774 period\NN\13575869 after\IN\1740 injection\NN\320852 .\.\1740
D015230_D006930 CID Prostaglandin\NN\5414534 E2\NN\1740 showed\VBD\2137132 a\DT\13649268 <e2>hyperalgesic</e2>\JJ\1740 effect\NN\34213 at\IN\14622893 doses\NNS\3740161 of\IN\1740 1\CD\13741022 pg\NN\1740 to\TO\1740 10\CD\13745420 ng/mouse\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 effect\NN\34213 lasted\VBD\2704349 shorter\JJR\1740 (\-LRB-\1740 3\CD\13741022 -\SYM\1740 30\CD\13745420 min\NN\15154774 )\-RRB-\1740 than\IN\1740 that\DT\1740 of\IN\1740 <e1>prostaglandin\NN\5414534 D2</e1>\NN\1740 .\.\1740
D015230_D006930 CID The\DT\1740 <e2>hyperalgesic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>prostaglandin\NN\5414534 D2</e1>\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 simultaneous\JJ\1740 injection\NN\320852 of\IN\1740 a\DT\13649268 substance\NN\20827 P\NN\14622893 antagonist\NN\7846 (\-LRB-\1740 greater\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 100\CD\13745420 ng\NN\13717155 )\-RRB-\1740 but\CC\1740 not\RB\1740 by\IN\1740 AH6809\NN\1740 ,\,\1740 a\DT\13649268 prostanoid\JJ\1740 EP1-receptor\NN\1740 antagonist\NN\7846 .\.\1740
D015230_D006930 CID These\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 both\CC\1740 <e1>prostaglandin\NN\5414534 D2</e1>\NN\1740 and\CC\1740 prostaglandin\NN\5414534 E2\NN\1740 exert\VBP\1158872 <e2>hyperalgesia</e2>\NN\1740 in\IN\13603305 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 ,\,\1740 but\CC\1740 in\IN\13603305 different\JJ\1740 ways\NNS\4341686 .\.\1740
D015232_D006930 CID <e1>Prostaglandin\NN\5414534 E2</e1>\NN\1740 showed\VBD\2137132 a\DT\13649268 <e2>hyperalgesic</e2>\JJ\1740 effect\NN\34213 at\IN\14622893 doses\NNS\3740161 of\IN\1740 1\CD\13741022 pg\NN\1740 to\TO\1740 10\CD\13745420 ng/mouse\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 effect\NN\34213 lasted\VBD\2704349 shorter\JJR\1740 (\-LRB-\1740 3\CD\13741022 -\SYM\1740 30\CD\13745420 min\NN\15154774 )\-RRB-\1740 than\IN\1740 that\DT\1740 of\IN\1740 prostaglandin\NN\5414534 D2\NN\1740 .\.\1740
D015232_D006930 CID Conversely\RB\1740 ,\,\1740 <e1>prostaglandin\NN\5414534 E2-induced</e1>\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 AH6809\NN\1740 (\-LRB-\1740 greater\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 500\CD\13745420 ng\NN\13717155 )\-RRB-\1740 but\CC\1740 not\RB\1740 by\IN\1740 the\DT\1740 substance\NN\20827 P\NN\14622893 antagonist\NN\7846 .\.\1740
D015232_D006930 CID These\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 both\CC\1740 prostaglandin\NN\5414534 D2\NN\1740 and\CC\1740 <e1>prostaglandin\NN\5414534 E2</e1>\NN\1740 exert\VBP\1158872 <e2>hyperalgesia</e2>\NN\1740 in\IN\13603305 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 ,\,\1740 but\CC\1740 in\IN\13603305 different\JJ\1740 ways\NNS\4341686 .\.\1740
D011453_D006930 NONE Prostaglandin\NN\5414534 E2\NN\1740 showed\VBD\2137132 a\DT\13649268 <e2>hyperalgesic</e2>\JJ\1740 effect\NN\34213 at\IN\14622893 doses\NNS\3740161 of\IN\1740 1\CD\13741022 <e1>pg</e1>\NN\1740 to\TO\1740 10\CD\13745420 ng/mouse\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 effect\NN\34213 lasted\VBD\2704349 shorter\JJR\1740 (\-LRB-\1740 3\CD\13741022 -\SYM\1740 30\CD\13745420 min\NN\15154774 )\-RRB-\1740 than\IN\1740 that\DT\1740 of\IN\1740 prostaglandin\NN\5414534 D2\NN\1740 .\.\1740
C053876_D006930 NONE The\DT\1740 <e2>hyperalgesic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 prostaglandin\NN\5414534 D2\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 simultaneous\JJ\1740 injection\NN\320852 of\IN\1740 a\DT\13649268 substance\NN\20827 P\NN\14622893 antagonist\NN\7846 (\-LRB-\1740 greater\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 100\CD\13745420 ng\NN\13717155 )\-RRB-\1740 but\CC\1740 not\RB\1740 by\IN\1740 <e1>AH6809</e1>\NN\1740 ,\,\1740 a\DT\13649268 prostanoid\JJ\1740 EP1-receptor\NN\1740 antagonist\NN\7846 .\.\1740
C053876_D006930 NONE Conversely\RB\1740 ,\,\1740 prostaglandin\NN\5414534 E2-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 <e1>AH6809</e1>\NN\1740 (\-LRB-\1740 greater\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 500\CD\13745420 ng\NN\13717155 )\-RRB-\1740 but\CC\1740 not\RB\1740 by\IN\1740 the\DT\1740 substance\NN\20827 P\NN\14622893 antagonist\NN\7846 .\.\1740
D015237_D010146 NONE <e1>Prostaglandin\NN\5414534 F2\NNP\1740 alpha</e1>\NN\6828818 had\VBD\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 <e2>pain</e2>\NN\14299637 responses\NNS\11410625 .\.\1740
6150641
D002927_D007172 CID Sixty\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 males\NNS\15388 developed\VBD\1753788 breast\NN\5225090 changes\NNS\7283608 or\CC\3541091 <e2>impotence</e2>\NN\4723816 while\IN\15122231 taking\VBG\2367363 <e1>cimetidine</e1>\NN\14778019 and\CC\1740 in\IN\13603305 all\DT\1740 cases\NNS\7283608 these\DT\1740 changes\NNS\7283608 disappeared\VBD\2609764 when\WRB\1740 cimetidine\NN\14778019 was\VBD\836236 replaced\VBN\1631072 by\IN\1740 ranitidine\NN\14778019 .\.\1740
D002927_D007172 CID Sixty\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 males\NNS\15388 developed\VBD\1753788 breast\NN\5225090 changes\NNS\7283608 or\CC\3541091 <e2>impotence</e2>\NN\4723816 while\IN\15122231 taking\VBG\2367363 cimetidine\NN\14778019 and\CC\1740 in\IN\13603305 all\DT\1740 cases\NNS\7283608 these\DT\1740 changes\NNS\7283608 disappeared\VBD\2609764 when\WRB\1740 <e1>cimetidine</e1>\NN\14778019 was\VBD\836236 replaced\VBN\1631072 by\IN\1740 ranitidine\NN\14778019 .\.\1740
D011899_D007172 NONE Sixty\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 males\NNS\15388 developed\VBD\1753788 breast\NN\5225090 changes\NNS\7283608 or\CC\3541091 <e2>impotence</e2>\NN\4723816 while\IN\15122231 taking\VBG\2367363 cimetidine\NN\14778019 and\CC\1740 in\IN\13603305 all\DT\1740 cases\NNS\7283608 these\DT\1740 changes\NNS\7283608 disappeared\VBD\2609764 when\WRB\1740 cimetidine\NN\14778019 was\VBD\836236 replaced\VBN\1631072 by\IN\1740 <e1>ranitidine</e1>\NN\14778019 .\.\1740
D002927_D056486 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>cimetidine</e1>\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 ranitidine\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 ranitidine\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 cimetidine\NN\14778019 therapy\NN\657604 .\.\1740
D002927_D056486 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 ranitidine\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 ranitidine\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 <e1>cimetidine</e1>\NN\14778019 therapy\NN\657604 .\.\1740
D002927_D006402 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>cimetidine</e1>\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 ranitidine\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 ranitidine\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 cimetidine\NN\14778019 therapy\NN\657604 .\.\1740
D002927_D006402 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 ranitidine\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 ranitidine\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 <e1>cimetidine</e1>\NN\14778019 therapy\NN\657604 .\.\1740
D011899_D056486 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 <e1>ranitidine</e1>\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 ranitidine\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 cimetidine\NN\14778019 therapy\NN\657604 .\.\1740
D011899_D056486 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 ranitidine\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 <e1>ranitidine</e1>\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 cimetidine\NN\14778019 therapy\NN\657604 .\.\1740
D011899_D006402 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 <e1>ranitidine</e1>\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 ranitidine\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 cimetidine\NN\14778019 therapy\NN\657604 .\.\1740
D011899_D006402 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 ranitidine\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 <e1>ranitidine</e1>\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 cimetidine\NN\14778019 therapy\NN\657604 .\.\1740
D003404_D056486 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 ranitidine\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 ranitidine\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 cimetidine\NN\14778019 therapy\NN\657604 .\.\1740
D003404_D006402 NONE Treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 one\CD\13741022 to\TO\1740 60\CD\13745420 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 11\CD\13745420 months\NNS\15113229 )\-RRB-\1740 or\CC\3541091 ranitidine\NN\14778019 (\-LRB-\1740 two\CD\13741022 to\TO\1740 31\CD\1740 months\NNS\15113229 ;\:\1740 median\NN\6021761 ,\,\1740 14\CD\13745420 months\NNS\15113229 )\-RRB-\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hepatic\JJ\1740 or\CC\3541091 hematologic\JJ\1740 toxicity</e2>\NN\13576101 or\CC\3541091 alterations\NNS\7283608 of\IN\1740 serum\NN\5397468 gastrin\NN\5408684 concentrations\NNS\4916342 ,\,\1740 but\CC\1740 ranitidine\NN\14778019 therapy\NN\657604 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 level\NN\4916342 than\IN\1740 seen\VBN\2106506 with\IN\1740 cimetidine\NN\14778019 therapy\NN\657604 .\.\1740
15075188
D011692_D009404 CID Increased\VBN\169651 expression\NN\4679549 and\CC\1740 apical\JJ\1740 targeting\NN\1740 of\IN\1740 renal\JJ\1740 ENaC\NN\1740 subunits\NNS\13604718 in\IN\13603305 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 in\IN\13603305 rats\NNS\2329401 .\.\1740
D011692_D009404 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 increased\VBN\169651 or\CC\3541091 sustained\JJ\1740 expression\NN\4679549 of\IN\1740 ENaC\NN\1740 subunits\NNS\13604718 combined\VBN\2630189 with\IN\1740 increased\VBN\169651 apical\JJ\1740 targeting\NN\1740 in\IN\13603305 the\DT\1740 DCT2\NN\1740 ,\,\1740 connecting\VBG\628491 tubule\NN\5246511 ,\,\1740 and\CC\1740 collecting\VBG\2281093 duct\NN\5248181 are\VBP\836236 likely\JJ\1740 to\TO\1740 play\VB\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 the\DT\1740 sodium\NN\14625458 retention\NN\809465 associated\VBN\628491 with\IN\1740 <e1>PAN-induced</e1>\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D012964_D009404 NONE <e2>Nephrotic\JJ\1740 syndrome</e2>\NN\5870365 is\VBZ\836236 often\RB\1740 accompanied\VBN\1835496 by\IN\1740 <e1>sodium</e1>\NN\14625458 retention\NN\809465 and\CC\1740 generalized\JJ\1740 edema\NN\14315192 .\.\1740
D012964_D009404 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 increased\VBN\169651 or\CC\3541091 sustained\JJ\1740 expression\NN\4679549 of\IN\1740 ENaC\NN\1740 subunits\NNS\13604718 combined\VBN\2630189 with\IN\1740 increased\VBN\169651 apical\JJ\1740 targeting\NN\1740 in\IN\13603305 the\DT\1740 DCT2\NN\1740 ,\,\1740 connecting\VBG\628491 tubule\NN\5246511 ,\,\1740 and\CC\1740 collecting\VBG\2281093 duct\NN\5248181 are\VBP\836236 likely\JJ\1740 to\TO\1740 play\VB\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 the\DT\1740 <e1>sodium</e1>\NN\14625458 retention\NN\809465 associated\VBN\628491 with\IN\1740 PAN-induced\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D012964_D004487 NONE Nephrotic\JJ\1740 syndrome\NN\5870365 is\VBZ\836236 often\RB\1740 accompanied\VBN\1835496 by\IN\1740 <e1>sodium</e1>\NN\14625458 retention\NN\809465 and\CC\1740 generalized\JJ\1740 <e2>edema</e2>\NN\14315192 .\.\1740
D011692_D011507 CID After\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 <e1>PAN</e1>\NN\3101986 treatment\NN\654885 induced\VBD\1627355 significant\JJ\1740 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 decreased\VBD\169651 urinary\JJ\1740 sodium\NN\14625458 excretion\NN\13466586 ,\,\1740 and\CC\1740 extensive\JJ\1740 ascites\NNS\14204950 .\.\1740
D011692_D034141 CID After\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 <e1>PAN</e1>\NN\3101986 treatment\NN\654885 induced\VBD\1627355 significant\JJ\1740 proteinuria\NN\14299637 ,\,\1740 <e2>hypoalbuminemia</e2>\NN\1740 ,\,\1740 decreased\VBD\169651 urinary\JJ\1740 sodium\NN\14625458 excretion\NN\13466586 ,\,\1740 and\CC\1740 extensive\JJ\1740 ascites\NNS\14204950 .\.\1740
D011692_D001201 CID After\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 <e1>PAN</e1>\NN\3101986 treatment\NN\654885 induced\VBD\1627355 significant\JJ\1740 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 decreased\VBD\169651 urinary\JJ\1740 sodium\NN\14625458 excretion\NN\13466586 ,\,\1740 and\CC\1740 extensive\JJ\1740 <e2>ascites</e2>\NNS\14204950 .\.\1740
D012964_D011507 NONE After\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 PAN\NN\3101986 treatment\NN\654885 induced\VBD\1627355 significant\JJ\1740 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 decreased\VBD\169651 urinary\JJ\1740 <e1>sodium</e1>\NN\14625458 excretion\NN\13466586 ,\,\1740 and\CC\1740 extensive\JJ\1740 ascites\NNS\14204950 .\.\1740
D012964_D034141 NONE After\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 PAN\NN\3101986 treatment\NN\654885 induced\VBD\1627355 significant\JJ\1740 proteinuria\NN\14299637 ,\,\1740 <e2>hypoalbuminemia</e2>\NN\1740 ,\,\1740 decreased\VBD\169651 urinary\JJ\1740 <e1>sodium</e1>\NN\14625458 excretion\NN\13466586 ,\,\1740 and\CC\1740 extensive\JJ\1740 ascites\NNS\14204950 .\.\1740
D012964_D001201 NONE After\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 PAN\NN\3101986 treatment\NN\654885 induced\VBD\1627355 significant\JJ\1740 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 decreased\VBD\169651 urinary\JJ\1740 <e1>sodium</e1>\NN\14625458 excretion\NN\13466586 ,\,\1740 and\CC\1740 extensive\JJ\1740 <e2>ascites</e2>\NNS\14204950 .\.\1740
16006300
D002119_D064420 NONE <e1>Calcium\NN\14625458 carbonate</e1>\NN\15010703 <e2>toxicity</e2>\NN\13576101 :\:\1740 the\DT\1740 updated\JJ\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 ;\:\1740 report\NN\6470073 of\IN\1740 3\CD\13741022 cases\NNS\7283608 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
D002119_D006934 CID <e1>Calcium\NN\14625458 carbonate</e1>\NN\15010703 toxicity\NN\13576101 :\:\1740 the\DT\1740 updated\JJ\1740 <e2>milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 ;\:\1740 report\NN\6470073 of\IN\1740 3\CD\13741022 cases\NNS\7283608 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
D002119_D006934 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 3\CD\13741022 patients\NNS\9898892 with\IN\1740 <e1>calcium\NN\14625458 carbonate-induced</e1>\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 and\CC\1740 gain\VB\2238085 insights\NNS\5710020 into\IN\1740 the\DT\1740 cause\NN\7323922 and\CC\1740 management\NN\1123598 of\IN\1740 the\DT\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 .\.\1740
D002119_D006934 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 3\CD\13741022 patients\NNS\9898892 with\IN\1740 <e1>calcium\NN\14625458 carbonate-induced</e1>\JJ\1740 hypercalcemia\NN\14299637 and\CC\1740 gain\VB\2238085 insights\NNS\5710020 into\IN\1740 the\DT\1740 cause\NN\7323922 and\CC\1740 management\NN\1123598 of\IN\1740 the\DT\1740 <e2>milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D002119_D006934 CID CONCLUSION\NN\5837957 :\:\1740 <e2>Milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 may\MD\15209706 be\VB\836236 a\DT\13649268 common\JJ\1740 cause\NN\7323922 of\IN\1740 unexplained\JJ\1740 hypercalcemia\NN\14299637 and\CC\1740 can\MD\3094503 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 small\JJ\1740 amounts\NNS\13329641 of\IN\1740 orally\RB\1740 ingested\VBN\597915 <e1>calcium\NN\14625458 carbonate</e1>\NN\15010703 in\IN\13603305 susceptible\JJ\1740 persons\NNS\7347 .\.\1740
D002119_D006934 CID CONCLUSION\NN\5837957 :\:\1740 Milk-alkali\JJ\1740 syndrome\NN\5870365 may\MD\15209706 be\VB\836236 a\DT\13649268 common\JJ\1740 cause\NN\7323922 of\IN\1740 unexplained\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 and\CC\1740 can\MD\3094503 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 small\JJ\1740 amounts\NNS\13329641 of\IN\1740 orally\RB\1740 ingested\VBN\597915 <e1>calcium\NN\14625458 carbonate</e1>\NN\15010703 in\IN\13603305 susceptible\JJ\1740 persons\NNS\7347 .\.\1740
D002118_D006934 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 report\VBP\831651 the\DT\1740 clinical\JJ\1740 and\CC\1740 laboratory\JJ\1740 data\NNS\7951464 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 who\WP\8299493 presented\VBD\2137132 with\IN\1740 severe\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 (\-LRB-\1740 corrected\VBN\138508 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 >\NN\1740 or\CC\3541091 =\JJ\1740 14\CD\13745420 mg/dL\NN\1740 )\-RRB-\1740 and\CC\1740 review\VB\644583 the\DT\1740 pertinent\JJ\1740 literature\NN\6362953 on\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 .\.\1740
D002118_D006934 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 report\VBP\831651 the\DT\1740 clinical\JJ\1740 and\CC\1740 laboratory\JJ\1740 data\NNS\7951464 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 who\WP\8299493 presented\VBD\2137132 with\IN\1740 severe\JJ\1740 hypercalcemia\NN\14299637 (\-LRB-\1740 corrected\VBN\138508 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 >\NN\1740 or\CC\3541091 =\JJ\1740 14\CD\13745420 mg/dL\NN\1740 )\-RRB-\1740 and\CC\1740 review\VB\644583 the\DT\1740 pertinent\JJ\1740 literature\NN\6362953 on\IN\1740 <e2>milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
C097949_D058186 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 3\CD\13741022 patients\NNS\9898892 had\VBD\2108377 <e2>acute\JJ\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 ,\,\1740 relative\JJ\1740 metabolic\JJ\1740 alkalosis\NN\14204950 ,\,\1740 and\CC\1740 low\JJ\1740 parathyroid\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 PTH\NN\1740 )\-RRB-\1740 ,\,\1740 PTH-related\JJ\1740 peptide\NN\14724264 ,\,\1740 and\CC\1740 <e1>1,25-dihydroxyvitamin\NN\1740 D</e1>\NN\15089472 concentrations\NNS\4916342 .\.\1740
C097949_D000471 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 3\CD\13741022 patients\NNS\9898892 had\VBD\2108377 acute\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 relative\JJ\1740 <e2>metabolic\JJ\1740 alkalosis</e2>\NN\14204950 ,\,\1740 and\CC\1740 low\JJ\1740 parathyroid\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 PTH\NN\1740 )\-RRB-\1740 ,\,\1740 PTH-related\JJ\1740 peptide\NN\14724264 ,\,\1740 and\CC\1740 <e1>1,25-dihydroxyvitamin\NN\1740 D</e1>\NN\15089472 concentrations\NNS\4916342 .\.\1740
D002118_D006996 NONE The\DT\1740 2\CD\13741022 patients\NNS\9898892 with\IN\1740 the\DT\1740 higher\JJR\1740 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 concentrations\NNS\4916342 received\VBD\2210855 pamidronate\NN\1740 intravenously\RB\1740 (\-LRB-\1740 60\CD\13745420 and\CC\1740 30\CD\13745420 mg\NN\13717155 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 caused\VBD\1617192 severe\JJ\1740 <e2>hypocalcemia</e2>\NN\14299637 .\.\1740
C019248_D006996 CID The\DT\1740 2\CD\13741022 patients\NNS\9898892 with\IN\1740 the\DT\1740 higher\JJR\1740 serum\NN\5397468 calcium\NN\14625458 concentrations\NNS\4916342 received\VBD\2210855 <e1>pamidronate</e1>\NN\1740 intravenously\RB\1740 (\-LRB-\1740 60\CD\13745420 and\CC\1740 30\CD\13745420 mg\NN\13717155 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 caused\VBD\1617192 severe\JJ\1740 <e2>hypocalcemia</e2>\NN\14299637 .\.\1740
C019248_D006996 CID <e1>Pamidronate</e1>\NN\1740 treatment\NN\654885 is\VBZ\836236 associated\VBN\628491 with\IN\1740 considerable\JJ\1740 risk\NN\14541044 for\IN\1740 <e2>hypocalcemia</e2>\NN\14299637 ,\,\1740 even\RB\1740 in\IN\13603305 cases\NNS\7283608 of\IN\1740 initially\RB\1740 severe\JJ\1740 hypercalcemia\NN\14299637 .\.\1740
C019248_D006934 NONE <e1>Pamidronate</e1>\NN\1740 treatment\NN\654885 is\VBZ\836236 associated\VBN\628491 with\IN\1740 considerable\JJ\1740 risk\NN\14541044 for\IN\1740 hypocalcemia\NN\14299637 ,\,\1740 even\RB\1740 in\IN\13603305 cases\NNS\7283608 of\IN\1740 initially\RB\1740 severe\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 .\.\1740
3115150
D007650_D009127 NONE <e1>Ketanserin</e1>\NN\1740 pretreatment\NN\1740 reverses\VBZ\109660 alfentanil-induced\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 .\.\1740
D007650_D009127 NONE Systemic\JJ\1740 pretreatment\NN\1740 with\IN\1740 <e1>ketanserin</e1>\NN\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 type-2\JJ\1740 serotonin\NN\14807737 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 produced\VBN\1617192 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 potent\JJ\1740 short-acting\JJ\1740 opiate\JJ\1740 agonist\NN\9613191 alfentanil\NN\1740 .\.\1740
D007650_D009127 NONE Despite\IN\7501545 the\DT\1740 absence\NN\14449405 of\IN\1740 <e2>rigidity</e2>\NN\5023233 ,\,\1740 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 <e1>ketanserin</e1>\NN\1740 (\-LRB-\1740 greater\JJR\1740 than\IN\1740 0.31\CD\1740 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 followed\VBN\1835496 by\IN\1740 alfentanil\NN\1740 were\VBD\836236 motionless\JJ\1740 ,\,\1740 flaccid\NN\1740 ,\,\1740 and\CC\1740 less\RBR\1740 responsive\JJ\1740 to\TO\1740 external\JJ\1740 stimuli\NNS\5816287 than\IN\1740 were\VBD\836236 animals\NNS\4475 receiving\VBG\2210855 alfentanil\NN\1740 alone\RB\1740 .\.\1740
D015760_D009127 CID Ketanserin\NN\1740 pretreatment\NN\1740 reverses\VBZ\109660 <e1>alfentanil-induced</e1>\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 .\.\1740
D015760_D009127 CID Systemic\JJ\1740 pretreatment\NN\1740 with\IN\1740 ketanserin\NN\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 type-2\JJ\1740 serotonin\NN\14807737 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 produced\VBN\1617192 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 potent\JJ\1740 short-acting\JJ\1740 opiate\JJ\1740 agonist\NN\9613191 <e1>alfentanil</e1>\NN\1740 .\.\1740
D015760_D009127 CID Chlordiazepoxide\NN\2830852 at\IN\14622893 doses\NNS\3740161 up\IN\1740 to\TO\1740 10\CD\13745420 mg/kg\NN\1740 failed\VBD\1798936 to\TO\1740 significantly\RB\1740 influence\VB\137313 the\DT\1740 <e2>rigidity</e2>\NN\5023233 produced\VBN\1617192 by\IN\1740 <e1>alfentanil</e1>\JJ\1740 .\.\1740
D015760_D009127 CID Despite\IN\7501545 the\DT\1740 absence\NN\14449405 of\IN\1740 <e2>rigidity</e2>\NN\5023233 ,\,\1740 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 ketanserin\NN\1740 (\-LRB-\1740 greater\JJR\1740 than\IN\1740 0.31\CD\1740 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 followed\VBN\1835496 by\IN\1740 <e1>alfentanil</e1>\NN\1740 were\VBD\836236 motionless\JJ\1740 ,\,\1740 flaccid\NN\1740 ,\,\1740 and\CC\1740 less\RBR\1740 responsive\JJ\1740 to\TO\1740 external\JJ\1740 stimuli\NNS\5816287 than\IN\1740 were\VBD\836236 animals\NNS\4475 receiving\VBG\2210855 alfentanil\NN\1740 alone\RB\1740 .\.\1740
D015760_D009127 CID Despite\IN\7501545 the\DT\1740 absence\NN\14449405 of\IN\1740 <e2>rigidity</e2>\NN\5023233 ,\,\1740 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 ketanserin\NN\1740 (\-LRB-\1740 greater\JJR\1740 than\IN\1740 0.31\CD\1740 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 followed\VBN\1835496 by\IN\1740 alfentanil\NN\1740 were\VBD\836236 motionless\JJ\1740 ,\,\1740 flaccid\NN\1740 ,\,\1740 and\CC\1740 less\RBR\1740 responsive\JJ\1740 to\TO\1740 external\JJ\1740 stimuli\NNS\5816287 than\IN\1740 were\VBD\836236 animals\NNS\4475 receiving\VBG\2210855 <e1>alfentanil</e1>\NN\1740 alone\RB\1740 .\.\1740
D012701_D009127 NONE Systemic\JJ\1740 pretreatment\NN\1740 with\IN\1740 ketanserin\NN\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 type-2\JJ\1740 <e1>serotonin</e1>\NN\14807737 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 produced\VBN\1617192 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 potent\JJ\1740 short-acting\JJ\1740 opiate\JJ\1740 agonist\NN\9613191 alfentanil\NN\1740 .\.\1740
D012701_D009127 NONE Pretreatment\NN\1740 with\IN\1740 type-2\JJ\1740 <e1>serotonin</e1>\NN\14807737 antagonists\NNS\7846 may\MD\15209706 be\VB\836236 clinically\RB\1740 useful\JJ\1740 in\IN\13603305 attenuating\VBG\224901 opiate-induced\JJ\1740 <e2>rigidity</e2>\NN\5023233 ,\,\1740 although\IN\1740 further\JJ\1740 studies\NNS\635850 will\MD\5650329 be\VB\836236 necessary\JJ\1740 to\TO\1740 assess\VB\670261 the\DT\1740 interaction\NN\37396 of\IN\1740 possibly\RB\1740 enhanced\VBN\227165 CNS\NN\5237227 ,\,\1740 cardiovascular\JJ\1740 ,\,\1740 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 .\.\1740
D002707_D009127 NONE <e1>Chlordiazepoxide</e1>\NN\2830852 at\IN\14622893 doses\NNS\3740161 up\IN\1740 to\TO\1740 10\CD\13745420 mg/kg\NN\1740 failed\VBD\1798936 to\TO\1740 significantly\RB\1740 influence\VB\137313 the\DT\1740 <e2>rigidity</e2>\NN\5023233 produced\VBN\1617192 by\IN\1740 alfentanil\JJ\1740 .\.\1740
D012701_D002318 NONE Pretreatment\NN\1740 with\IN\1740 type-2\JJ\1740 <e1>serotonin</e1>\NN\14807737 antagonists\NNS\7846 may\MD\15209706 be\VB\836236 clinically\RB\1740 useful\JJ\1740 in\IN\13603305 attenuating\VBG\224901 opiate-induced\JJ\1740 rigidity\NN\5023233 ,\,\1740 although\IN\1740 further\JJ\1740 studies\NNS\635850 will\MD\5650329 be\VB\836236 necessary\JJ\1740 to\TO\1740 assess\VB\670261 the\DT\1740 interaction\NN\37396 of\IN\1740 possibly\RB\1740 enhanced\VBN\227165 CNS\NN\5237227 ,\,\1740 <e2>cardiovascular\JJ\1740 ,\,\1740 and\CC\1740 respiratory\JJ\1740 depression</e2>\NN\14373582 .\.\1740
D012701_D012131 NONE Pretreatment\NN\1740 with\IN\1740 type-2\JJ\1740 <e1>serotonin</e1>\NN\14807737 antagonists\NNS\7846 may\MD\15209706 be\VB\836236 clinically\RB\1740 useful\JJ\1740 in\IN\13603305 attenuating\VBG\224901 opiate-induced\JJ\1740 rigidity\NN\5023233 ,\,\1740 although\IN\1740 further\JJ\1740 studies\NNS\635850 will\MD\5650329 be\VB\836236 necessary\JJ\1740 to\TO\1740 assess\VB\670261 the\DT\1740 interaction\NN\37396 of\IN\1740 possibly\RB\1740 enhanced\VBN\227165 CNS\NN\5237227 ,\,\1740 <e2>cardiovascular\JJ\1740 ,\,\1740 and\CC\1740 respiratory\JJ\1740 depression</e2>\NN\14373582 .\.\1740
18513945
D010121_D007022 CID <e1>Oxytocin</e1>\NN\5407119 is\VBZ\836236 a\DT\13649268 commonly\RB\1740 used\VBN\1156834 uterotonic\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 significant\JJ\1740 and\CC\1740 even\RB\1740 fatal\JJ\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 particularly\RB\1740 when\WRB\1740 given\VBN\2327200 as\IN\14622893 a\DT\13649268 bolus\NN\13899404 .\.\1740
D010121_D007022 CID <e1>Oxytocin-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 at\IN\14622893 cesarean\NN\42541 delivery\NN\315986 may\MD\15209706 be\VB\836236 incorrectly\RB\1740 attributed\VBN\670261 to\TO\1740 blood\NN\5397468 loss\NN\13252973 .\.\1740
D010121_D007022 CID <e2>Hypotension</e2>\NN\14057371 in\IN\13603305 response\NN\11410625 to\TO\1740 <e1>oxytocin</e1>\NN\5407119 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 systemic\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 a\DT\13649268 compensatory\JJ\1740 increase\NN\13576355 in\IN\13603305 stroke\NN\556313 volume\NN\33615 ,\,\1740 heart\NN\5919034 rate\NN\13815152 and\CC\1740 cardiac\JJ\1740 output\NN\4007894 .\.\1740
D010121_D006473 NONE <e1>Oxytocin-induced</e1>\JJ\1740 hypotension\NN\14057371 at\IN\14622893 cesarean\NN\42541 delivery\NN\315986 may\MD\15209706 be\VB\836236 incorrectly\RB\1740 attributed\VBN\670261 to\TO\1740 <e2>blood\NN\5397468 loss</e2>\NN\13252973 .\.\1740
D010121_D020521 NONE Hypotension\NN\14057371 in\IN\13603305 response\NN\11410625 to\TO\1740 <e1>oxytocin</e1>\NN\5407119 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 systemic\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 a\DT\13649268 compensatory\JJ\1740 increase\NN\13576355 in\IN\13603305 <e2>stroke</e2>\NN\556313 volume\NN\33615 ,\,\1740 heart\NN\5919034 rate\NN\13815152 and\CC\1740 cardiac\JJ\1740 output\NN\4007894 .\.\1740
2722224
D006854_D006973 CID <e1>Hydrocortisone-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 humans\NNS\31264 :\:\1740 pressor\NN\9190918 responsiveness\NN\5652926 and\CC\1740 sympathetic\JJ\1740 function\NN\13783581 .\.\1740
D006854_D006973 CID The\DT\1740 <e2>rise\NN\7324673 in\IN\13603305 resting\VBG\2604760 blood\NN\5397468 pressure</e2>\NN\11419404 with\IN\1740 <e1>hydrocortisone</e1>\NN\14751417 is\VBZ\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 cardiac\JJ\1740 output\NN\4007894 (\-LRB-\1740 presumably\RB\1740 due\JJ\1740 to\TO\1740 increased\VBN\169651 blood\NN\5397468 volume\NN\33615 )\-RRB-\1740 .\.\1740
D006854_D016534 NONE The\DT\1740 rise\NN\7324673 in\IN\13603305 resting\VBG\2604760 blood\NN\5397468 pressure\NN\11419404 with\IN\1740 <e1>hydrocortisone</e1>\NN\14751417 is\VBZ\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 <e2>increased\VBN\169651 cardiac\JJ\1740 output</e2>\NN\4007894 (\-LRB-\1740 presumably\RB\1740 due\JJ\1740 to\TO\1740 increased\VBN\169651 blood\NN\5397468 volume\NN\33615 )\-RRB-\1740 .\.\1740
16720068
D017374_D009459 CID Possible\JJ\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 related\JJ\1740 to\TO\1740 concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 alprazolam\NNS\2830852 .\.\1740
D017374_D009459 CID This\DT\1740 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 symptoms\NNS\5823932 of\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 ,\,\1740 thus\RB\1740 demonstrating\VBG\2137132 that\IN\1740 NMS-like\JJ\1740 symptoms\NNS\5823932 can\MD\3094503 occur\VB\2623529 after\IN\1740 combined\JJ\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 alprazolam\NN\2830852 treatment\NN\654885 .\.\1740
D017374_D009459 CID This\DT\1740 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 symptoms\NNS\5823932 of\IN\1740 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>NMS</e2>\NN\13649268 )\-RRB-\1740 ,\,\1740 thus\RB\1740 demonstrating\VBG\2137132 that\IN\1740 NMS-like\JJ\1740 symptoms\NNS\5823932 can\MD\3094503 occur\VB\2623529 after\IN\1740 combined\JJ\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 alprazolam\NN\2830852 treatment\NN\654885 .\.\1740
D017374_D009459 CID This\DT\1740 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 symptoms\NNS\5823932 of\IN\1740 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 ,\,\1740 thus\RB\1740 demonstrating\VBG\2137132 that\IN\1740 <e2>NMS-like</e2>\JJ\1740 symptoms\NNS\5823932 can\MD\3094503 occur\VB\2623529 after\IN\1740 combined\JJ\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 alprazolam\NN\2830852 treatment\NN\654885 .\.\1740
D000525_D009459 CID Possible\JJ\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 related\JJ\1740 to\TO\1740 concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 paroxetine\NN\1740 and\CC\1740 <e1>alprazolam</e1>\NNS\2830852 .\.\1740
D000525_D009459 CID This\DT\1740 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 symptoms\NNS\5823932 of\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 ,\,\1740 thus\RB\1740 demonstrating\VBG\2137132 that\IN\1740 NMS-like\JJ\1740 symptoms\NNS\5823932 can\MD\3094503 occur\VB\2623529 after\IN\1740 combined\JJ\1740 paroxetine\NN\1740 and\CC\1740 <e1>alprazolam</e1>\NN\2830852 treatment\NN\654885 .\.\1740
D000525_D009459 CID This\DT\1740 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 symptoms\NNS\5823932 of\IN\1740 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>NMS</e2>\NN\13649268 )\-RRB-\1740 ,\,\1740 thus\RB\1740 demonstrating\VBG\2137132 that\IN\1740 NMS-like\JJ\1740 symptoms\NNS\5823932 can\MD\3094503 occur\VB\2623529 after\IN\1740 combined\JJ\1740 paroxetine\NN\1740 and\CC\1740 <e1>alprazolam</e1>\NN\2830852 treatment\NN\654885 .\.\1740
D000525_D009459 CID This\DT\1740 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 symptoms\NNS\5823932 of\IN\1740 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 ,\,\1740 thus\RB\1740 demonstrating\VBG\2137132 that\IN\1740 <e2>NMS-like</e2>\JJ\1740 symptoms\NNS\5823932 can\MD\3094503 occur\VB\2623529 after\IN\1740 combined\JJ\1740 paroxetine\NN\1740 and\CC\1740 <e1>alprazolam</e1>\NN\2830852 treatment\NN\654885 .\.\1740
D017374_D011596 NONE On\IN\1740 the\DT\1740 10th\JJ\1740 day\NN\15154774 of\IN\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 alprazolam\NN\2830852 treatment\NN\654885 ,\,\1740 the\DT\1740 patient\NN\9898892 exhibited\VBD\2632167 marked\JJ\1740 <e2>psychomotor\NN\1740 retardation</e2>\NN\7296428 ,\,\1740 disorientation\NN\5896733 ,\,\1740 and\CC\1740 severe\JJ\1740 muscle\NN\5289601 rigidity\NN\5023233 with\IN\1740 tremors\NNS\345926 .\.\1740
D017374_D009127 NONE On\IN\1740 the\DT\1740 10th\JJ\1740 day\NN\15154774 of\IN\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 alprazolam\NN\2830852 treatment\NN\654885 ,\,\1740 the\DT\1740 patient\NN\9898892 exhibited\VBD\2632167 marked\JJ\1740 psychomotor\NN\1740 retardation\NN\7296428 ,\,\1740 disorientation\NN\5896733 ,\,\1740 and\CC\1740 severe\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 with\IN\1740 tremors\NNS\345926 .\.\1740
D017374_D014202 NONE On\IN\1740 the\DT\1740 10th\JJ\1740 day\NN\15154774 of\IN\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 alprazolam\NN\2830852 treatment\NN\654885 ,\,\1740 the\DT\1740 patient\NN\9898892 exhibited\VBD\2632167 marked\JJ\1740 psychomotor\NN\1740 retardation\NN\7296428 ,\,\1740 disorientation\NN\5896733 ,\,\1740 and\CC\1740 severe\JJ\1740 muscle\NN\5289601 rigidity\NN\5023233 with\IN\1740 <e2>tremors</e2>\NNS\345926 .\.\1740
D000525_D011596 NONE On\IN\1740 the\DT\1740 10th\JJ\1740 day\NN\15154774 of\IN\1740 paroxetine\NN\1740 and\CC\1740 <e1>alprazolam</e1>\NN\2830852 treatment\NN\654885 ,\,\1740 the\DT\1740 patient\NN\9898892 exhibited\VBD\2632167 marked\JJ\1740 <e2>psychomotor\NN\1740 retardation</e2>\NN\7296428 ,\,\1740 disorientation\NN\5896733 ,\,\1740 and\CC\1740 severe\JJ\1740 muscle\NN\5289601 rigidity\NN\5023233 with\IN\1740 tremors\NNS\345926 .\.\1740
D000525_D009127 NONE On\IN\1740 the\DT\1740 10th\JJ\1740 day\NN\15154774 of\IN\1740 paroxetine\NN\1740 and\CC\1740 <e1>alprazolam</e1>\NN\2830852 treatment\NN\654885 ,\,\1740 the\DT\1740 patient\NN\9898892 exhibited\VBD\2632167 marked\JJ\1740 psychomotor\NN\1740 retardation\NN\7296428 ,\,\1740 disorientation\NN\5896733 ,\,\1740 and\CC\1740 severe\JJ\1740 <e2>muscle\NN\5289601 rigidity</e2>\NN\5023233 with\IN\1740 tremors\NNS\345926 .\.\1740
D000525_D014202 NONE On\IN\1740 the\DT\1740 10th\JJ\1740 day\NN\15154774 of\IN\1740 paroxetine\NN\1740 and\CC\1740 <e1>alprazolam</e1>\NN\2830852 treatment\NN\654885 ,\,\1740 the\DT\1740 patient\NN\9898892 exhibited\VBD\2632167 marked\JJ\1740 psychomotor\NN\1740 retardation\NN\7296428 ,\,\1740 disorientation\NN\5896733 ,\,\1740 and\CC\1740 severe\JJ\1740 muscle\NN\5289601 rigidity\NN\5023233 with\IN\1740 <e2>tremors</e2>\NNS\345926 .\.\1740
19721134
D010862_D001145 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>pilocarpine</e1>\NN\14712692 and\CC\1740 explore\VB\789138 the\DT\1740 underlying\VBG\2604760 ionic\JJ\1740 mechanism\NN\13446390 ,\,\1740 using\VBG\1156834 both\CC\1740 aconitine-induced\JJ\1740 rat\NN\2329401 and\CC\1740 ouabain-induced\JJ\1740 guinea\NN\13388245 pig\NN\2395003 <e2>arrhythmia</e2>\NN\14103288 models\NNS\5888929 .\.\1740
D010862_D001145 NONE The\DT\1740 current\JJ\1740 data\NNS\7951464 showed\VBD\2137132 that\IN\1740 <e1>pilocarpine</e1>\NN\14712692 significantly\RB\1740 delayed\VBD\439958 onset\NN\7325190 of\IN\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 decreased\VBD\169651 the\DT\1740 time\NN\7308889 course\NN\883297 of\IN\1740 ventricular\JJ\1740 tachycardia\NN\14110674 and\CC\1740 fibrillation\NN\14361664 ,\,\1740 reduced\VBN\441445 arrhythmia\NN\14103288 score\NN\5736149 ,\,\1740 and\CC\1740 increased\VBD\169651 the\DT\1740 survival\NN\13961642 time\NN\7308889 of\IN\1740 arrhythmic\JJ\1740 rats\NNS\2329401 and\CC\1740 guinea\NN\13388245 pigs\NNS\2395003 .\.\1740
D010862_D001145 NONE The\DT\1740 current\JJ\1740 data\NNS\7951464 showed\VBD\2137132 that\IN\1740 <e1>pilocarpine</e1>\NN\14712692 significantly\RB\1740 delayed\VBD\439958 onset\NN\7325190 of\IN\1740 arrhythmias\NNS\14103288 ,\,\1740 decreased\VBD\169651 the\DT\1740 time\NN\7308889 course\NN\883297 of\IN\1740 ventricular\JJ\1740 tachycardia\NN\14110674 and\CC\1740 fibrillation\NN\14361664 ,\,\1740 reduced\VBN\441445 <e2>arrhythmia</e2>\NN\14103288 score\NN\5736149 ,\,\1740 and\CC\1740 increased\VBD\169651 the\DT\1740 survival\NN\13961642 time\NN\7308889 of\IN\1740 arrhythmic\JJ\1740 rats\NNS\2329401 and\CC\1740 guinea\NN\13388245 pigs\NNS\2395003 .\.\1740
D010862_D001145 NONE The\DT\1740 current\JJ\1740 data\NNS\7951464 showed\VBD\2137132 that\IN\1740 <e1>pilocarpine</e1>\NN\14712692 significantly\RB\1740 delayed\VBD\439958 onset\NN\7325190 of\IN\1740 arrhythmias\NNS\14103288 ,\,\1740 decreased\VBD\169651 the\DT\1740 time\NN\7308889 course\NN\883297 of\IN\1740 ventricular\JJ\1740 tachycardia\NN\14110674 and\CC\1740 fibrillation\NN\14361664 ,\,\1740 reduced\VBN\441445 arrhythmia\NN\14103288 score\NN\5736149 ,\,\1740 and\CC\1740 increased\VBD\169651 the\DT\1740 survival\NN\13961642 time\NN\7308889 of\IN\1740 <e2>arrhythmic</e2>\JJ\1740 rats\NNS\2329401 and\CC\1740 guinea\NN\13388245 pigs\NNS\2395003 .\.\1740
D010862_D001145 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>pilocarpine</e1>\NN\14712692 produced\VBD\1617192 antiarrhythmic\JJ\1740 actions\NNS\30358 on\IN\1740 <e2>arrhythmic</e2>\JJ\1740 rat\NN\2329401 and\CC\1740 guinea\NN\13388245 pig\NN\2395003 models\NNS\5888929 induced\VBN\1627355 by\IN\1740 aconitine\NN\1740 or\CC\3541091 ouabain\NN\1740 via\IN\1740 stimulating\VBG\137313 the\DT\1740 cardiac\JJ\1740 M(3)-mAChR.\NN\1740 The\DT\1740 mechanism\NN\13446390 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 the\DT\1740 improvement\NN\7359599 of\IN\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 handling\NN\623162 .\.\1740
D000157_D001145 CID This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 pilocarpine\NN\14712692 and\CC\1740 explore\VB\789138 the\DT\1740 underlying\VBG\2604760 ionic\JJ\1740 mechanism\NN\13446390 ,\,\1740 using\VBG\1156834 both\CC\1740 <e1>aconitine-induced</e1>\JJ\1740 rat\NN\2329401 and\CC\1740 ouabain-induced\JJ\1740 guinea\NN\13388245 pig\NN\2395003 <e2>arrhythmia</e2>\NN\14103288 models\NNS\5888929 .\.\1740
D000157_D001145 CID These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 pilocarpine\NN\14712692 produced\VBD\1617192 antiarrhythmic\JJ\1740 actions\NNS\30358 on\IN\1740 <e2>arrhythmic</e2>\JJ\1740 rat\NN\2329401 and\CC\1740 guinea\NN\13388245 pig\NN\2395003 models\NNS\5888929 induced\VBN\1627355 by\IN\1740 <e1>aconitine</e1>\NN\1740 or\CC\3541091 ouabain\NN\1740 via\IN\1740 stimulating\VBG\137313 the\DT\1740 cardiac\JJ\1740 M(3)-mAChR.\NN\1740 The\DT\1740 mechanism\NN\13446390 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 the\DT\1740 improvement\NN\7359599 of\IN\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 handling\NN\623162 .\.\1740
D010042_D001145 CID This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 pilocarpine\NN\14712692 and\CC\1740 explore\VB\789138 the\DT\1740 underlying\VBG\2604760 ionic\JJ\1740 mechanism\NN\13446390 ,\,\1740 using\VBG\1156834 both\CC\1740 aconitine-induced\JJ\1740 rat\NN\2329401 and\CC\1740 <e1>ouabain-induced</e1>\JJ\1740 guinea\NN\13388245 pig\NN\2395003 <e2>arrhythmia</e2>\NN\14103288 models\NNS\5888929 .\.\1740
D010042_D001145 CID These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 pilocarpine\NN\14712692 produced\VBD\1617192 antiarrhythmic\JJ\1740 actions\NNS\30358 on\IN\1740 <e2>arrhythmic</e2>\JJ\1740 rat\NN\2329401 and\CC\1740 guinea\NN\13388245 pig\NN\2395003 models\NNS\5888929 induced\VBN\1627355 by\IN\1740 aconitine\NN\1740 or\CC\3541091 <e1>ouabain</e1>\NN\1740 via\IN\1740 stimulating\VBG\137313 the\DT\1740 cardiac\JJ\1740 M(3)-mAChR.\NN\1740 The\DT\1740 mechanism\NN\13446390 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 the\DT\1740 improvement\NN\7359599 of\IN\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 handling\NN\623162 .\.\1740
D010862_D017180 NONE The\DT\1740 current\JJ\1740 data\NNS\7951464 showed\VBD\2137132 that\IN\1740 <e1>pilocarpine</e1>\NN\14712692 significantly\RB\1740 delayed\VBD\439958 onset\NN\7325190 of\IN\1740 arrhythmias\NNS\14103288 ,\,\1740 decreased\VBD\169651 the\DT\1740 time\NN\7308889 course\NN\883297 of\IN\1740 <e2>ventricular\JJ\1740 tachycardia\NN\14110674 and\CC\1740 fibrillation</e2>\NN\14361664 ,\,\1740 reduced\VBN\441445 arrhythmia\NN\14103288 score\NN\5736149 ,\,\1740 and\CC\1740 increased\VBD\169651 the\DT\1740 survival\NN\13961642 time\NN\7308889 of\IN\1740 arrhythmic\JJ\1740 rats\NNS\2329401 and\CC\1740 guinea\NN\13388245 pigs\NNS\2395003 .\.\1740
D010862_D014693 NONE The\DT\1740 current\JJ\1740 data\NNS\7951464 showed\VBD\2137132 that\IN\1740 <e1>pilocarpine</e1>\NN\14712692 significantly\RB\1740 delayed\VBD\439958 onset\NN\7325190 of\IN\1740 arrhythmias\NNS\14103288 ,\,\1740 decreased\VBD\169651 the\DT\1740 time\NN\7308889 course\NN\883297 of\IN\1740 <e2>ventricular\JJ\1740 tachycardia\NN\14110674 and\CC\1740 fibrillation</e2>\NN\14361664 ,\,\1740 reduced\VBN\441445 arrhythmia\NN\14103288 score\NN\5736149 ,\,\1740 and\CC\1740 increased\VBD\169651 the\DT\1740 survival\NN\13961642 time\NN\7308889 of\IN\1740 arrhythmic\JJ\1740 rats\NNS\2329401 and\CC\1740 guinea\NN\13388245 pigs\NNS\2395003 .\.\1740
D002118_D001145 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 pilocarpine\NN\14712692 produced\VBD\1617192 antiarrhythmic\JJ\1740 actions\NNS\30358 on\IN\1740 <e2>arrhythmic</e2>\JJ\1740 rat\NN\2329401 and\CC\1740 guinea\NN\13388245 pig\NN\2395003 models\NNS\5888929 induced\VBN\1627355 by\IN\1740 aconitine\NN\1740 or\CC\3541091 ouabain\NN\1740 via\IN\1740 stimulating\VBG\137313 the\DT\1740 cardiac\JJ\1740 M(3)-mAChR.\NN\1740 The\DT\1740 mechanism\NN\13446390 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 the\DT\1740 improvement\NN\7359599 of\IN\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 handling\NN\623162 .\.\1740
21294084
D010406_D004827 NONE Effects\NNS\13245626 of\IN\1740 the\DT\1740 hippocampal\NN\1740 deep\JJ\1740 brain\NN\5462674 stimulation\NN\242808 on\IN\1740 cortical\JJ\1740 <e2>epileptic</e2>\JJ\1740 discharges\NNS\7283608 in\IN\13603305 <e1>penicillin</e1>\NN\2716866 -\HYPH\1740 induced\VBN\1627355 epilepsy\NN\14085708 model\NN\5888929 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010406_D004827 NONE Effects\NNS\13245626 of\IN\1740 the\DT\1740 hippocampal\NN\1740 deep\JJ\1740 brain\NN\5462674 stimulation\NN\242808 on\IN\1740 cortical\JJ\1740 epileptic\JJ\1740 discharges\NNS\7283608 in\IN\13603305 <e1>penicillin</e1>\NN\2716866 -\HYPH\1740 induced\VBN\1627355 <e2>epilepsy</e2>\NN\14085708 model\NN\5888929 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010406_D004827 NONE The\DT\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 high\JJ\1740 frequency\NN\15286249 hippocampal\NN\1740 stimulation\NN\242808 on\IN\1740 cortical\JJ\1740 <e2>epileptic</e2>\JJ\1740 activity\NN\30358 in\IN\13603305 <e1>penicillin-induced</e1>\JJ\1740 epilepsy\NN\14085708 model\NN\5888929 .\.\1740
D010406_D004827 NONE The\DT\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 high\JJ\1740 frequency\NN\15286249 hippocampal\NN\1740 stimulation\NN\242808 on\IN\1740 cortical\JJ\1740 epileptic\JJ\1740 activity\NN\30358 in\IN\13603305 <e1>penicillin-induced</e1>\JJ\1740 <e2>epilepsy</e2>\NN\14085708 model\NN\5888929 .\.\1740
D010406_D004827 NONE RESULTS\NNS\34213 :\:\1740 High\JJ\1740 frequency\NN\15286249 hippocampal\NN\1740 DBS\NN\14622893 suppressed\VBD\2510337 the\DT\1740 acute\JJ\1740 <e1>penicillin-induced</e1>\JJ\1740 cortical\JJ\1740 <e2>epileptic</e2>\JJ\1740 activity\NN\30358 independent\JJ\1740 from\IN\1740 stimulus\NN\5816287 intensity\NN\5090441 .\.\1740
14742097
D004809_D020018 NONE A\DT\13649268 randomized\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 ,\,\1740 crossover\NN\13526110 study\NN\635850 of\IN\1740 <e1>ephedrine</e1>\NN\14712692 for\IN\1740 SSRI-induced\JJ\1740 female\JJ\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D004809_D020018 NONE The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 <e1>ephedrine</e1>\NN\14712692 ,\,\1740 an\DT\6697703 alpha-\NN\1740 and\CC\1740 beta-adrenergic\JJ\1740 agonist\NN\9613191 previously\RB\1740 shown\VBN\2137132 to\TO\1740 enhance\VB\227165 genital\JJ\1740 blood\NN\5397468 flow\NN\7311115 in\IN\13603305 women\NNS\9605289 ,\,\1740 has\VBZ\2108377 beneficial\JJ\1740 effects\NNS\13245626 in\IN\13603305 reversing\VBG\109660 antidepressant-induced\JJ\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D004809_D020018 NONE Nineteen\CD\13745420 <e2>sexually\RB\1740 dysfunctional</e2>\JJ\1740 women\NNS\9605289 receiving\VBG\2210855 either\DT\1740 fluoxetine\NN\4169152 ,\,\1740 sertraline\NN\4169152 ,\,\1740 or\CC\3541091 paroxetine\NN\1740 participated\VBN\2367363 in\IN\13603305 an\DT\6697703 eight-week\NN\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 ,\,\1740 cross-over\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>ephedrine</e1>\NN\14712692 (\-LRB-\1740 50\CD\13745420 mg\NN\13717155 )\-RRB-\1740 on\IN\1740 self-report\JJ\1740 measures\NNS\168237 of\IN\1740 sexual\JJ\1740 desire\NN\26192 ,\,\1740 arousal\NN\199130 ,\,\1740 orgasm\NN\61598 ,\,\1740 and\CC\1740 sexual\JJ\1740 satisfaction\NN\7531105 .\.\1740
D005473_D020018 CID Nineteen\CD\13745420 <e2>sexually\RB\1740 dysfunctional</e2>\JJ\1740 women\NNS\9605289 receiving\VBG\2210855 either\DT\1740 <e1>fluoxetine</e1>\NN\4169152 ,\,\1740 sertraline\NN\4169152 ,\,\1740 or\CC\3541091 paroxetine\NN\1740 participated\VBN\2367363 in\IN\13603305 an\DT\6697703 eight-week\NN\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 ,\,\1740 cross-over\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 ephedrine\NN\14712692 (\-LRB-\1740 50\CD\13745420 mg\NN\13717155 )\-RRB-\1740 on\IN\1740 self-report\JJ\1740 measures\NNS\168237 of\IN\1740 sexual\JJ\1740 desire\NN\26192 ,\,\1740 arousal\NN\199130 ,\,\1740 orgasm\NN\61598 ,\,\1740 and\CC\1740 sexual\JJ\1740 satisfaction\NN\7531105 .\.\1740
D020280_D020018 CID Nineteen\CD\13745420 <e2>sexually\RB\1740 dysfunctional</e2>\JJ\1740 women\NNS\9605289 receiving\VBG\2210855 either\DT\1740 fluoxetine\NN\4169152 ,\,\1740 <e1>sertraline</e1>\NN\4169152 ,\,\1740 or\CC\3541091 paroxetine\NN\1740 participated\VBN\2367363 in\IN\13603305 an\DT\6697703 eight-week\NN\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 ,\,\1740 cross-over\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 ephedrine\NN\14712692 (\-LRB-\1740 50\CD\13745420 mg\NN\13717155 )\-RRB-\1740 on\IN\1740 self-report\JJ\1740 measures\NNS\168237 of\IN\1740 sexual\JJ\1740 desire\NN\26192 ,\,\1740 arousal\NN\199130 ,\,\1740 orgasm\NN\61598 ,\,\1740 and\CC\1740 sexual\JJ\1740 satisfaction\NN\7531105 .\.\1740
D017374_D020018 CID Nineteen\CD\13745420 <e2>sexually\RB\1740 dysfunctional</e2>\JJ\1740 women\NNS\9605289 receiving\VBG\2210855 either\DT\1740 fluoxetine\NN\4169152 ,\,\1740 sertraline\NN\4169152 ,\,\1740 or\CC\3541091 <e1>paroxetine</e1>\NN\1740 participated\VBN\2367363 in\IN\13603305 an\DT\6697703 eight-week\NN\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 ,\,\1740 cross-over\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 ephedrine\NN\14712692 (\-LRB-\1740 50\CD\13745420 mg\NN\13717155 )\-RRB-\1740 on\IN\1740 self-report\JJ\1740 measures\NNS\168237 of\IN\1740 sexual\JJ\1740 desire\NN\26192 ,\,\1740 arousal\NN\199130 ,\,\1740 orgasm\NN\61598 ,\,\1740 and\CC\1740 sexual\JJ\1740 satisfaction\NN\7531105 .\.\1740
11868798
D013148_D007008 NONE <e1>Spironolactone</e1>\NN\2721160 :\:\1740 is\VBZ\836236 it\PRP\6125041 a\DT\13649268 novel\JJ\1740 drug\NN\14778436 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 amphotericin\NN\2716866 B-related\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 ?\.\1740
D013148_D007008 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 <e2>hypokalemia</e2>\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D013148_D007008 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 showed\VBD\2137132 that\IN\1740 <e1>spironolactone</e1>\NN\2721160 can\MD\3094503 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 prevent\VBP\1740 <e2>hypokalemia</e2>\NN\14299637 by\IN\1740 reducing\VBG\441445 urinary\JJ\1740 potassium\NN\14625458 loss\NN\13252973 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D013148_D009369 NONE <e1>Spironolactone</e1>\NN\2721160 :\:\1740 is\VBZ\836236 it\PRP\6125041 a\DT\13649268 novel\JJ\1740 drug\NN\14778436 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 amphotericin\NN\2716866 B-related\JJ\1740 hypokalemia\NN\14299637 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 ?\.\1740
D000666_D007008 CID Spironolactone\NN\2721160 :\:\1740 is\VBZ\836236 it\PRP\6125041 a\DT\13649268 novel\JJ\1740 drug\NN\14778436 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>amphotericin\NN\2716866 B-related</e1>\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 ?\.\1740
D000666_D007008 CID Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>AmB.</e1>\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 <e2>hypokalemia</e2>\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D007008 CID Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>AmB.</e1>\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 <e2>hypokalemia</e2>\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D007008 CID Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 <e2>hypokalemia</e2>\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>AmB</e1>\NN\1740 treatment\NN\654885 .\.\1740
D000666_D007008 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 showed\VBD\2137132 that\IN\1740 spironolactone\NN\2721160 can\MD\3094503 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 prevent\VBP\1740 <e2>hypokalemia</e2>\NN\14299637 by\IN\1740 reducing\VBG\441445 urinary\JJ\1740 potassium\NN\14625458 loss\NN\13252973 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>AmB</e1>\NN\1740 treatment\NN\654885 .\.\1740
D000666_D009369 NONE Spironolactone\NN\2721160 :\:\1740 is\VBZ\836236 it\PRP\6125041 a\DT\13649268 novel\JJ\1740 drug\NN\14778436 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>amphotericin\NN\2716866 B-related</e1>\JJ\1740 hypokalemia\NN\14299637 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 ?\.\1740
D000666_D007674 NONE OBJECTIVE\NN\5980875 :\:\1740 <e2>Nephrotoxicity</e2>\NN\1740 is\VBZ\836236 the\DT\1740 major\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 (\-LRB-\1740 AmB\NN\1740 )\-RRB-\1740 ,\,\1740 often\RB\1740 limiting\VBG\2510337 administration\NN\1133281 of\IN\1740 full\JJ\1740 dosage\NN\13576355 .\.\1740
D000666_D007674 NONE OBJECTIVE\NN\5980875 :\:\1740 <e2>Nephrotoxicity</e2>\NN\1740 is\VBZ\836236 the\DT\1740 major\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 amphotericin\NN\2716866 B\NN\1355326 (\-LRB-\1740 <e1>AmB</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 often\RB\1740 limiting\VBG\2510337 administration\NN\1133281 of\IN\1740 full\JJ\1740 dosage\NN\13576355 .\.\1740
D011188_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 <e2>toxicity</e2>\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 <e1>potassium</e1>\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 <e1>potassium</e1>\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 <e2>toxicity</e2>\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 <e1>Potassium</e1>\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 <e1>Potassium</e1>\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 <e2>toxicity</e2>\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 <e1>potassium</e1>\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 <e1>potassium</e1>\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D007008 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 <e1>potassium</e1>\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 <e2>hypokalemia</e2>\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D007008 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 <e1>Potassium</e1>\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 <e2>hypokalemia</e2>\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D007008 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 <e1>potassium</e1>\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 <e2>hypokalemia</e2>\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D007008 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 showed\VBD\2137132 that\IN\1740 spironolactone\NN\2721160 can\MD\3094503 reduce\VB\441445 <e1>potassium</e1>\NN\14625458 requirements\NNS\1129920 and\CC\1740 prevent\VBP\1740 <e2>hypokalemia</e2>\NN\14299637 by\IN\1740 reducing\VBG\441445 urinary\JJ\1740 potassium\NN\14625458 loss\NN\13252973 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D007008 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 showed\VBD\2137132 that\IN\1740 spironolactone\NN\2721160 can\MD\3094503 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 prevent\VBP\1740 <e2>hypokalemia</e2>\NN\14299637 by\IN\1740 reducing\VBG\441445 urinary\JJ\1740 <e1>potassium</e1>\NN\14625458 loss\NN\13252973 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D009503 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 <e1>potassium</e1>\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D009503 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 <e1>Potassium</e1>\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D009503 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 <e1>potassium</e1>\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D009503 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 showed\VBD\2137132 that\IN\1740 spironolactone\NN\2721160 can\MD\3094503 reduce\VB\441445 <e1>potassium</e1>\NN\14625458 requirements\NNS\1129920 and\CC\1740 prevent\VBP\1740 hypokalemia\NN\14299637 by\IN\1740 reducing\VBG\441445 urinary\JJ\1740 potassium\NN\14625458 loss\NN\13252973 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D011188_D009503 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 showed\VBD\2137132 that\IN\1740 spironolactone\NN\2721160 can\MD\3094503 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 prevent\VBP\1740 hypokalemia\NN\14299637 by\IN\1740 reducing\VBG\441445 urinary\JJ\1740 <e1>potassium</e1>\NN\14625458 loss\NN\13252973 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 <e2>toxicity</e2>\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>AmB.</e1>\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>AmB.</e1>\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 <e2>toxicity</e2>\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>AmB.</e1>\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>AmB.</e1>\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 <e2>toxicity</e2>\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>AmB</e1>\NN\1740 treatment\NN\654885 .\.\1740
D000666_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>AmB</e1>\NN\1740 treatment\NN\654885 .\.\1740
D000666_D009503 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>AmB.</e1>\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D009503 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>AmB.</e1>\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D009503 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 spironolactone\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>AmB</e1>\NN\1740 treatment\NN\654885 .\.\1740
D000666_D009503 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 showed\VBD\2137132 that\IN\1740 spironolactone\NN\2721160 can\MD\3094503 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 prevent\VBP\1740 hypokalemia\NN\14299637 by\IN\1740 reducing\VBG\441445 urinary\JJ\1740 potassium\NN\14625458 loss\NN\13252973 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>AmB</e1>\NN\1740 treatment\NN\654885 .\.\1740
D013148_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 <e2>toxicity</e2>\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D013148_D064420 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 neutropenic\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D013148_D009503 NONE Selective\JJ\1740 distal\JJ\1740 tubular\JJ\1740 epithelial\JJ\1740 toxicity\NN\13576101 seems\VBZ\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 profound\JJ\1740 potassium\NN\14625458 wasting\VBG\1158572 that\WDT\1740 is\VBZ\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 AmB.\NN\1740 Potassium\NN\14625458 depletion\NN\351638 also\RB\1740 potentiates\VBZ\229605 the\DT\1740 tubular\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 assess\VB\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 to\TO\1740 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 to\TO\1740 prevent\VB\1740 hypokalemia\NN\14299637 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D013148_D009503 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 showed\VBD\2137132 that\IN\1740 <e1>spironolactone</e1>\NN\2721160 can\MD\3094503 reduce\VB\441445 potassium\NN\14625458 requirements\NNS\1129920 and\CC\1740 prevent\VBP\1740 hypokalemia\NN\14299637 by\IN\1740 reducing\VBG\441445 urinary\JJ\1740 potassium\NN\14625458 loss\NN\13252973 in\IN\13603305 <e2>neutropenic</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 AmB\NN\1740 treatment\NN\654885 .\.\1740
D000666_D006402 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 26\CD\13745420 patients\NNS\9898892 with\IN\1740 various\JJ\1740 <e2>hematological\JJ\1740 disorders</e2>\NNS\14034177 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 intravenous\JJ\1740 <e1>AmB</e1>\NN\1740 alone\RB\1740 or\CC\3541091 AmB\NN\1740 and\CC\1740 oral\JJ\1740 spironolactone\NN\2721160 100\CD\13745420 mg\NN\13717155 twice\RB\1740 daily\RB\1740 when\WRB\1740 developing\VBG\1753788 a\DT\13649268 proven\VBN\2604760 or\CC\3541091 suspected\VBN\916909 fungal\JJ\1740 infection\NN\14052046 .\.\1740
D000666_D006402 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 26\CD\13745420 patients\NNS\9898892 with\IN\1740 various\JJ\1740 <e2>hematological\JJ\1740 disorders</e2>\NNS\14034177 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 intravenous\JJ\1740 AmB\NN\1740 alone\RB\1740 or\CC\3541091 <e1>AmB</e1>\NN\1740 and\CC\1740 oral\JJ\1740 spironolactone\NN\2721160 100\CD\13745420 mg\NN\13717155 twice\RB\1740 daily\RB\1740 when\WRB\1740 developing\VBG\1753788 a\DT\13649268 proven\VBN\2604760 or\CC\3541091 suspected\VBN\916909 fungal\JJ\1740 infection\NN\14052046 .\.\1740
D000666_D009181 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 26\CD\13745420 patients\NNS\9898892 with\IN\1740 various\JJ\1740 hematological\JJ\1740 disorders\NNS\14034177 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 intravenous\JJ\1740 <e1>AmB</e1>\NN\1740 alone\RB\1740 or\CC\3541091 AmB\NN\1740 and\CC\1740 oral\JJ\1740 spironolactone\NN\2721160 100\CD\13745420 mg\NN\13717155 twice\RB\1740 daily\RB\1740 when\WRB\1740 developing\VBG\1753788 a\DT\13649268 proven\VBN\2604760 or\CC\3541091 suspected\VBN\916909 <e2>fungal\JJ\1740 infection</e2>\NN\14052046 .\.\1740
D000666_D009181 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 26\CD\13745420 patients\NNS\9898892 with\IN\1740 various\JJ\1740 hematological\JJ\1740 disorders\NNS\14034177 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 intravenous\JJ\1740 AmB\NN\1740 alone\RB\1740 or\CC\3541091 <e1>AmB</e1>\NN\1740 and\CC\1740 oral\JJ\1740 spironolactone\NN\2721160 100\CD\13745420 mg\NN\13717155 twice\RB\1740 daily\RB\1740 when\WRB\1740 developing\VBG\1753788 a\DT\13649268 proven\VBN\2604760 or\CC\3541091 suspected\VBN\916909 <e2>fungal\JJ\1740 infection</e2>\NN\14052046 .\.\1740
D013148_D006402 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 26\CD\13745420 patients\NNS\9898892 with\IN\1740 various\JJ\1740 <e2>hematological\JJ\1740 disorders</e2>\NNS\14034177 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 intravenous\JJ\1740 AmB\NN\1740 alone\RB\1740 or\CC\3541091 AmB\NN\1740 and\CC\1740 oral\JJ\1740 <e1>spironolactone</e1>\NN\2721160 100\CD\13745420 mg\NN\13717155 twice\RB\1740 daily\RB\1740 when\WRB\1740 developing\VBG\1753788 a\DT\13649268 proven\VBN\2604760 or\CC\3541091 suspected\VBN\916909 fungal\JJ\1740 infection\NN\14052046 .\.\1740
D013148_D009181 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 26\CD\13745420 patients\NNS\9898892 with\IN\1740 various\JJ\1740 hematological\JJ\1740 disorders\NNS\14034177 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 intravenous\JJ\1740 AmB\NN\1740 alone\RB\1740 or\CC\3541091 AmB\NN\1740 and\CC\1740 oral\JJ\1740 <e1>spironolactone</e1>\NN\2721160 100\CD\13745420 mg\NN\13717155 twice\RB\1740 daily\RB\1740 when\WRB\1740 developing\VBG\1753788 a\DT\13649268 proven\VBN\2604760 or\CC\3541091 suspected\VBN\916909 <e2>fungal\JJ\1740 infection</e2>\NN\14052046 .\.\1740
12549952
D016642_D017114 CID <e2>Acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 with\IN\1740 concurrent\JJ\1740 <e1>bupropion</e1>\NN\1740 and\CC\1740 carbimazole\NN\1740 therapy\NN\657604 .\.\1740
D016642_D017114 CID DISCUSSION\NN\6252138 :\:\1740 Although\IN\1740 there\EX\27167 is\VBZ\836236 increasing\VBG\169651 evidence\NN\5816287 of\IN\1740 hepatotoxicity\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>bupropion</e1>\NN\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 fatality\NN\7355491 that\WDT\1740 could\MD\1740 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 in\IN\13603305 a\DT\13649268 patient\NN\9898892 receiving\VBG\2210855 bupropion\NN\1740 while\IN\15122231 on\IN\1740 concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 carbimazole\NN\1740 .\.\1740
D016642_D017114 CID DISCUSSION\NN\6252138 :\:\1740 Although\IN\1740 there\EX\27167 is\VBZ\836236 increasing\VBG\169651 evidence\NN\5816287 of\IN\1740 hepatotoxicity\NN\1740 induced\VBN\1627355 by\IN\1740 bupropion\NN\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 fatality\NN\7355491 that\WDT\1740 could\MD\1740 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 in\IN\13603305 a\DT\13649268 patient\NN\9898892 receiving\VBG\2210855 <e1>bupropion</e1>\NN\1740 while\IN\15122231 on\IN\1740 concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 carbimazole\NN\1740 .\.\1740
D016642_D017114 CID CONCLUSIONS\NNS\5837957 :\:\1740 Clinicians\NNS\10462860 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 possibility\NN\5944958 of\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 insult</e2>\NN\6714976 induced\VBN\1627355 by\IN\1740 <e1>bupropion</e1>\NN\1740 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 other\JJ\1740 hepatotoxic\JJ\1740 drugs\NNS\14778436 .\.\1740
D002231_D017114 CID <e2>Acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 with\IN\1740 concurrent\JJ\1740 bupropion\NN\1740 and\CC\1740 <e1>carbimazole</e1>\NN\1740 therapy\NN\657604 .\.\1740
D002231_D017114 CID DISCUSSION\NN\6252138 :\:\1740 Although\IN\1740 there\EX\27167 is\VBZ\836236 increasing\VBG\169651 evidence\NN\5816287 of\IN\1740 hepatotoxicity\NN\1740 induced\VBN\1627355 by\IN\1740 bupropion\NN\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 fatality\NN\7355491 that\WDT\1740 could\MD\1740 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 in\IN\13603305 a\DT\13649268 patient\NN\9898892 receiving\VBG\2210855 bupropion\NN\1740 while\IN\15122231 on\IN\1740 concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>carbimazole</e1>\NN\1740 .\.\1740
D016642_D017093 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 fatal\JJ\1740 <e2>liver\NN\5298729 failure</e2>\NN\66216 possibly\RB\1740 associated\VBN\628491 with\IN\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 <e1>bupropion</e1>\NN\1740 and\CC\1740 carbimazole\NN\1740 .\.\1740
D002231_D017093 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 fatal\JJ\1740 <e2>liver\NN\5298729 failure</e2>\NN\66216 possibly\RB\1740 associated\VBN\628491 with\IN\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 bupropion\NN\1740 and\CC\1740 <e1>carbimazole</e1>\NN\1740 .\.\1740
D002231_D006980 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 41-year-old\JJ\1740 Chinese\JJ\1740 man\NN\9605289 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 with\IN\1740 <e1>carbimazole</e1>\NN\1740 and\CC\1740 propranolol\NN\1740 for\IN\1740 the\DT\1740 past\JJ\1740 5\CD\13741022 years\NNS\15144371 .\.\1740
D011433_D006980 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 41-year-old\JJ\1740 Chinese\JJ\1740 man\NN\9605289 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 with\IN\1740 carbimazole\NN\1740 and\CC\1740 <e1>propranolol</e1>\NN\1740 for\IN\1740 the\DT\1740 past\JJ\1740 5\CD\13741022 years\NNS\15144371 .\.\1740
D016642_D056486 CID The\DT\1740 likelihood\NN\4756172 that\IN\1740 <e1>bupropion</e1>\NN\1740 induced\VBD\1627355 <e2>hepatotoxicity</e2>\NN\1740 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 was\VBD\836236 possible\JJ\1740 ,\,\1740 based\VBN\2694933 on\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 .\.\1740
D016642_D056486 CID DISCUSSION\NN\6252138 :\:\1740 Although\IN\1740 there\EX\27167 is\VBZ\836236 increasing\VBG\169651 evidence\NN\5816287 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>bupropion</e1>\NN\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 fatality\NN\7355491 that\WDT\1740 could\MD\1740 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 in\IN\13603305 a\DT\13649268 patient\NN\9898892 receiving\VBG\2210855 bupropion\NN\1740 while\IN\15122231 on\IN\1740 concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 carbimazole\NN\1740 .\.\1740
D016642_D056486 CID DISCUSSION\NN\6252138 :\:\1740 Although\IN\1740 there\EX\27167 is\VBZ\836236 increasing\VBG\169651 evidence\NN\5816287 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 bupropion\NN\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 fatality\NN\7355491 that\WDT\1740 could\MD\1740 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 in\IN\13603305 a\DT\13649268 patient\NN\9898892 receiving\VBG\2210855 <e1>bupropion</e1>\NN\1740 while\IN\15122231 on\IN\1740 concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 carbimazole\NN\1740 .\.\1740
D016642_D056486 CID CONCLUSIONS\NNS\5837957 :\:\1740 Clinicians\NNS\10462860 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 possibility\NN\5944958 of\IN\1740 acute\JJ\1740 liver\NN\5298729 insult\NN\6714976 induced\VBN\1627355 by\IN\1740 <e1>bupropion</e1>\NN\1740 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 other\JJ\1740 <e2>hepatotoxic</e2>\JJ\1740 drugs\NNS\14778436 .\.\1740
D002231_D056486 CID DISCUSSION\NN\6252138 :\:\1740 Although\IN\1740 there\EX\27167 is\VBZ\836236 increasing\VBG\169651 evidence\NN\5816287 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 bupropion\NN\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 fatality\NN\7355491 that\WDT\1740 could\MD\1740 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 in\IN\13603305 a\DT\13649268 patient\NN\9898892 receiving\VBG\2210855 bupropion\NN\1740 while\IN\15122231 on\IN\1740 concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>carbimazole</e1>\NN\1740 .\.\1740
7197363
D001058_D012892 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 <e2>REM\NN\14024882 sleep\NN\14034177 deprivation</e2>\NN\14493145 (\-LRB-\1740 REMD\NN\1740 )\-RRB-\1740 on\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 aggressiveness\NN\4835724 and\CC\1740 quipazine-induced\JJ\1740 head\NN\5225090 twitches\VBZ\10054 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 determined\VBN\1645601 .\.\1740
D001058_D012892 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 REM\NN\14024882 sleep\NN\14034177 deprivation\NN\14493145 (\-LRB-\1740 <e2>REMD</e2>\NN\1740 )\-RRB-\1740 on\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 aggressiveness\NN\4835724 and\CC\1740 quipazine-induced\JJ\1740 head\NN\5225090 twitches\VBZ\10054 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 determined\VBN\1645601 .\.\1740
D001058_D012892 NONE Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 <e2>REMD</e2>\NN\1740 increased\VBD\169651 <e1>apomorphine-induced</e1>\JJ\1740 aggressiveness\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 quipazine-induced\JJ\1740 head\NN\5225090 twitches\VBZ\10054 .\.\1740
D001058_D012892 NONE Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 REMD\NN\1740 increased\VBD\169651 <e1>apomorphine-induced</e1>\JJ\1740 aggressiveness\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 <e2>REMD</e2>\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 quipazine-induced\JJ\1740 head\NN\5225090 twitches\VBZ\10054 .\.\1740
D001058_D012892 NONE Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 REMD\NN\1740 increased\VBD\169651 <e1>apomorphine-induced</e1>\JJ\1740 aggressiveness\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 <e2>REMD</e2>\NN\1740 )\-RRB-\1740 quipazine-induced\JJ\1740 head\NN\5225090 twitches\VBZ\10054 .\.\1740
D001058_D001523 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 REM\NN\14024882 sleep\NN\14034177 deprivation\NN\14493145 (\-LRB-\1740 REMD\NN\1740 )\-RRB-\1740 on\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 <e2>aggressiveness</e2>\NN\4835724 and\CC\1740 quipazine-induced\JJ\1740 head\NN\5225090 twitches\VBZ\10054 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 determined\VBN\1645601 .\.\1740
D001058_D001523 CID Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 REMD\NN\1740 increased\VBD\169651 <e1>apomorphine-induced</e1>\JJ\1740 <e2>aggressiveness</e2>\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 quipazine-induced\JJ\1740 head\NN\5225090 twitches\VBZ\10054 .\.\1740
D001058_D009069 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 REM\NN\14024882 sleep\NN\14034177 deprivation\NN\14493145 (\-LRB-\1740 REMD\NN\1740 )\-RRB-\1740 on\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 aggressiveness\NN\4835724 and\CC\1740 quipazine-induced\JJ\1740 <e2>head\NN\5225090 twitches</e2>\VBZ\10054 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 determined\VBN\1645601 .\.\1740
D001058_D009069 NONE Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 REMD\NN\1740 increased\VBD\169651 <e1>apomorphine-induced</e1>\JJ\1740 aggressiveness\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 quipazine-induced\JJ\1740 <e2>head\NN\5225090 twitches</e2>\VBZ\10054 .\.\1740
D011814_D012892 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 <e2>REM\NN\14024882 sleep\NN\14034177 deprivation</e2>\NN\14493145 (\-LRB-\1740 REMD\NN\1740 )\-RRB-\1740 on\IN\1740 apomorphine-induced\JJ\1740 aggressiveness\NN\4835724 and\CC\1740 <e1>quipazine-induced</e1>\JJ\1740 head\NN\5225090 twitches\VBZ\10054 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 determined\VBN\1645601 .\.\1740
D011814_D012892 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 REM\NN\14024882 sleep\NN\14034177 deprivation\NN\14493145 (\-LRB-\1740 <e2>REMD</e2>\NN\1740 )\-RRB-\1740 on\IN\1740 apomorphine-induced\JJ\1740 aggressiveness\NN\4835724 and\CC\1740 <e1>quipazine-induced</e1>\JJ\1740 head\NN\5225090 twitches\VBZ\10054 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 determined\VBN\1645601 .\.\1740
D011814_D012892 NONE Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 <e2>REMD</e2>\NN\1740 increased\VBD\169651 apomorphine-induced\JJ\1740 aggressiveness\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 <e1>quipazine-induced</e1>\JJ\1740 head\NN\5225090 twitches\VBZ\10054 .\.\1740
D011814_D012892 NONE Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 REMD\NN\1740 increased\VBD\169651 apomorphine-induced\JJ\1740 aggressiveness\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 <e2>REMD</e2>\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 <e1>quipazine-induced</e1>\JJ\1740 head\NN\5225090 twitches\VBZ\10054 .\.\1740
D011814_D012892 NONE Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 REMD\NN\1740 increased\VBD\169651 apomorphine-induced\JJ\1740 aggressiveness\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 <e2>REMD</e2>\NN\1740 )\-RRB-\1740 <e1>quipazine-induced</e1>\JJ\1740 head\NN\5225090 twitches\VBZ\10054 .\.\1740
D011814_D001523 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 REM\NN\14024882 sleep\NN\14034177 deprivation\NN\14493145 (\-LRB-\1740 REMD\NN\1740 )\-RRB-\1740 on\IN\1740 apomorphine-induced\JJ\1740 <e2>aggressiveness</e2>\NN\4835724 and\CC\1740 <e1>quipazine-induced</e1>\JJ\1740 head\NN\5225090 twitches\VBZ\10054 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 determined\VBN\1645601 .\.\1740
D011814_D001523 NONE Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 REMD\NN\1740 increased\VBD\169651 apomorphine-induced\JJ\1740 <e2>aggressiveness</e2>\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 <e1>quipazine-induced</e1>\JJ\1740 head\NN\5225090 twitches\VBZ\10054 .\.\1740
D011814_D009069 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 REM\NN\14024882 sleep\NN\14034177 deprivation\NN\14493145 (\-LRB-\1740 REMD\NN\1740 )\-RRB-\1740 on\IN\1740 apomorphine-induced\JJ\1740 aggressiveness\NN\4835724 and\CC\1740 <e1>quipazine-induced</e1>\JJ\1740 <e2>head\NN\5225090 twitches</e2>\VBZ\10054 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 determined\VBN\1645601 .\.\1740
D011814_D009069 CID Forty-eight\CD\1740 hr\NN\15154774 of\IN\1740 REMD\NN\1740 increased\VBD\169651 apomorphine-induced\JJ\1740 aggressiveness\NN\4835724 ,\,\1740 and\CC\1740 reduced\VBN\441445 (\-LRB-\1740 immediately\RB\1740 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 or\CC\3541091 increased\VBN\169651 (\-LRB-\1740 96\CD\1740 hr\NN\15154774 after\IN\1740 completing\VBG\352826 of\IN\1740 REMD\NN\1740 )\-RRB-\1740 <e1>quipazine-induced</e1>\JJ\1740 <e2>head\NN\5225090 twitches</e2>\VBZ\10054 .\.\1740
8665051
D000305_D009135 NONE Occasional\JJ\1740 case\NN\7283608 reports\NNS\6470073 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 acute\JJ\1740 <e2>myopathy</e2>\NN\14204950 may\MD\15209706 occur\VB\2623529 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>corticosteroids</e1>\NNS\14745635 .\.\1740
D008775_D000855 CID Therefore\RB\1740 ,\,\1740 60\CD\13745420 male\JJ\1740 rats\NNS\2329401 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 receive\VB\2210855 daily\JJ\1740 injection\NN\320852 of\IN\1740 saline\NN\14849367 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 <e1>methylprednisolone</e1>\NN\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 ,\,\1740 or\CC\3541091 triamcinolone\NN\14751417 (\-LRB-\1740 T\NN\14999913 )\-RRB-\1740 80\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 5\CD\13741022 d.\NN\1740 Nutritional\NNP\1740 intake\NN\13440063 ,\,\1740 measured\VBN\697589 daily\RB\1740 in\IN\13603305 15\CD\13745420 animals\NNS\4475 ,\,\1740 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 <e2>reduction\NN\351485 of\IN\1740 food\NN\20090 intake</e2>\NN\13440063 in\IN\13603305 the\DT\1740 steroid-treated\JJ\1740 groups\NNS\2137 (\-LRB-\1740 -50\CD\1740 and\CC\1740 -79\CD\1740 %\NN\1740 in\IN\13603305 M\NN\13649268 and\CC\1740 T\NN\14999913 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D008775_D000855 CID Therefore\RB\1740 ,\,\1740 60\CD\13745420 male\JJ\1740 rats\NNS\2329401 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 receive\VB\2210855 daily\JJ\1740 injection\NN\320852 of\IN\1740 saline\NN\14849367 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 methylprednisolone\NN\1740 (\-LRB-\1740 <e1>M</e1>\NN\13649268 )\-RRB-\1740 ,\,\1740 or\CC\3541091 triamcinolone\NN\14751417 (\-LRB-\1740 T\NN\14999913 )\-RRB-\1740 80\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 5\CD\13741022 d.\NN\1740 Nutritional\NNP\1740 intake\NN\13440063 ,\,\1740 measured\VBN\697589 daily\RB\1740 in\IN\13603305 15\CD\13745420 animals\NNS\4475 ,\,\1740 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 <e2>reduction\NN\351485 of\IN\1740 food\NN\20090 intake</e2>\NN\13440063 in\IN\13603305 the\DT\1740 steroid-treated\JJ\1740 groups\NNS\2137 (\-LRB-\1740 -50\CD\1740 and\CC\1740 -79\CD\1740 %\NN\1740 in\IN\13603305 M\NN\13649268 and\CC\1740 T\NN\14999913 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D008775_D000855 CID Therefore\RB\1740 ,\,\1740 60\CD\13745420 male\JJ\1740 rats\NNS\2329401 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 receive\VB\2210855 daily\JJ\1740 injection\NN\320852 of\IN\1740 saline\NN\14849367 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 methylprednisolone\NN\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 ,\,\1740 or\CC\3541091 triamcinolone\NN\14751417 (\-LRB-\1740 T\NN\14999913 )\-RRB-\1740 80\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 5\CD\13741022 d.\NN\1740 Nutritional\NNP\1740 intake\NN\13440063 ,\,\1740 measured\VBN\697589 daily\RB\1740 in\IN\13603305 15\CD\13745420 animals\NNS\4475 ,\,\1740 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 <e2>reduction\NN\351485 of\IN\1740 food\NN\20090 intake</e2>\NN\13440063 in\IN\13603305 the\DT\1740 steroid-treated\JJ\1740 groups\NNS\2137 (\-LRB-\1740 -50\CD\1740 and\CC\1740 -79\CD\1740 %\NN\1740 in\IN\13603305 <e1>M</e1>\NN\13649268 and\CC\1740 T\NN\14999913 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D014221_D000855 CID Therefore\RB\1740 ,\,\1740 60\CD\13745420 male\JJ\1740 rats\NNS\2329401 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 receive\VB\2210855 daily\JJ\1740 injection\NN\320852 of\IN\1740 saline\NN\14849367 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 methylprednisolone\NN\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 ,\,\1740 or\CC\3541091 <e1>triamcinolone</e1>\NN\14751417 (\-LRB-\1740 T\NN\14999913 )\-RRB-\1740 80\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 5\CD\13741022 d.\NN\1740 Nutritional\NNP\1740 intake\NN\13440063 ,\,\1740 measured\VBN\697589 daily\RB\1740 in\IN\13603305 15\CD\13745420 animals\NNS\4475 ,\,\1740 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 <e2>reduction\NN\351485 of\IN\1740 food\NN\20090 intake</e2>\NN\13440063 in\IN\13603305 the\DT\1740 steroid-treated\JJ\1740 groups\NNS\2137 (\-LRB-\1740 -50\CD\1740 and\CC\1740 -79\CD\1740 %\NN\1740 in\IN\13603305 M\NN\13649268 and\CC\1740 T\NN\14999913 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D014221_D000855 CID Therefore\RB\1740 ,\,\1740 60\CD\13745420 male\JJ\1740 rats\NNS\2329401 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 receive\VB\2210855 daily\JJ\1740 injection\NN\320852 of\IN\1740 saline\NN\14849367 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 methylprednisolone\NN\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 ,\,\1740 or\CC\3541091 triamcinolone\NN\14751417 (\-LRB-\1740 <e1>T</e1>\NN\14999913 )\-RRB-\1740 80\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 5\CD\13741022 d.\NN\1740 Nutritional\NNP\1740 intake\NN\13440063 ,\,\1740 measured\VBN\697589 daily\RB\1740 in\IN\13603305 15\CD\13745420 animals\NNS\4475 ,\,\1740 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 <e2>reduction\NN\351485 of\IN\1740 food\NN\20090 intake</e2>\NN\13440063 in\IN\13603305 the\DT\1740 steroid-treated\JJ\1740 groups\NNS\2137 (\-LRB-\1740 -50\CD\1740 and\CC\1740 -79\CD\1740 %\NN\1740 in\IN\13603305 M\NN\13649268 and\CC\1740 T\NN\14999913 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D014221_D000855 CID Therefore\RB\1740 ,\,\1740 60\CD\13745420 male\JJ\1740 rats\NNS\2329401 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 receive\VB\2210855 daily\JJ\1740 injection\NN\320852 of\IN\1740 saline\NN\14849367 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 methylprednisolone\NN\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 ,\,\1740 or\CC\3541091 triamcinolone\NN\14751417 (\-LRB-\1740 T\NN\14999913 )\-RRB-\1740 80\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 5\CD\13741022 d.\NN\1740 Nutritional\NNP\1740 intake\NN\13440063 ,\,\1740 measured\VBN\697589 daily\RB\1740 in\IN\13603305 15\CD\13745420 animals\NNS\4475 ,\,\1740 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 <e2>reduction\NN\351485 of\IN\1740 food\NN\20090 intake</e2>\NN\13440063 in\IN\13603305 the\DT\1740 steroid-treated\JJ\1740 groups\NNS\2137 (\-LRB-\1740 -50\CD\1740 and\CC\1740 -79\CD\1740 %\NN\1740 in\IN\13603305 M\NN\13649268 and\CC\1740 <e1>T</e1>\NN\14999913 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D013256_D000855 NONE Therefore\RB\1740 ,\,\1740 60\CD\13745420 male\JJ\1740 rats\NNS\2329401 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 receive\VB\2210855 daily\JJ\1740 injection\NN\320852 of\IN\1740 saline\NN\14849367 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 methylprednisolone\NN\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 ,\,\1740 or\CC\3541091 triamcinolone\NN\14751417 (\-LRB-\1740 T\NN\14999913 )\-RRB-\1740 80\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 5\CD\13741022 d.\NN\1740 Nutritional\NNP\1740 intake\NN\13440063 ,\,\1740 measured\VBN\697589 daily\RB\1740 in\IN\13603305 15\CD\13745420 animals\NNS\4475 ,\,\1740 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 <e2>reduction\NN\351485 of\IN\1740 food\NN\20090 intake</e2>\NN\13440063 in\IN\13603305 the\DT\1740 <e1>steroid-treated</e1>\JJ\1740 groups\NNS\2137 (\-LRB-\1740 -50\CD\1740 and\CC\1740 -79\CD\1740 %\NN\1740 in\IN\13603305 M\NN\13649268 and\CC\1740 T\NN\14999913 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D013256_D013746 NONE Half-relaxation\JJ\1740 time\NN\7308889 was\VBD\836236 prolonged\VBN\317700 in\IN\13603305 both\CC\1740 <e1>steroid</e1>\NN\14727670 groups\NNS\2137 ,\,\1740 and\CC\1740 time\NN\7308889 to\TO\1740 peak\JJ\1740 tension\NN\14375890 was\VBD\836236 longer\JJR\1740 with\IN\1740 M\NN\13649268 ,\,\1740 whereas\IN\1740 <e2>tetanic</e2>\JJ\1740 tensions\NNS\14375890 were\VBD\836236 similar\JJ\1740 .\.\1740
D008775_D013746 NONE Half-relaxation\JJ\1740 time\NN\7308889 was\VBD\836236 prolonged\VBN\317700 in\IN\13603305 both\CC\1740 steroid\NN\14727670 groups\NNS\2137 ,\,\1740 and\CC\1740 time\NN\7308889 to\TO\1740 peak\JJ\1740 tension\NN\14375890 was\VBD\836236 longer\JJR\1740 with\IN\1740 <e1>M</e1>\NN\13649268 ,\,\1740 whereas\IN\1740 <e2>tetanic</e2>\JJ\1740 tensions\NNS\14375890 were\VBD\836236 similar\JJ\1740 .\.\1740
D013256_D009133 NONE ATPase\NN\1740 staining\NN\275424 of\IN\1740 the\DT\1740 diaphragm\NN\3736970 ,\,\1740 scalenus\JJ\1740 medius\NN\1740 ,\,\1740 and\CC\1740 gastrocnemius\NN\5289861 showed\VBD\2137132 type\NN\5839024 IIb\NN\1740 fiber\NN\14580897 <e2>atrophy</e2>\NN\14299637 in\IN\13603305 the\DT\1740 <e1>steroid</e1>\NN\14727670 groups\NNS\2137 and\CC\1740 also\RB\1740 diaphragmatic\JJ\1740 type\NN\5839024 IIa\NN\1740 atrophy\NN\14299637 with\IN\1740 T\NN\14999913 ,\,\1740 whereas\IN\1740 histologic\JJ\1740 examinations\NNS\633864 revealed\VBD\2137132 a\DT\13649268 normal\JJ\1740 muscular\JJ\1740 pattern\NN\5726345 with\IN\1740 absence\NN\14449405 of\IN\1740 necrosis\NN\11444117 .\.\1740
D013256_D009133 NONE ATPase\NN\1740 staining\NN\275424 of\IN\1740 the\DT\1740 diaphragm\NN\3736970 ,\,\1740 scalenus\JJ\1740 medius\NN\1740 ,\,\1740 and\CC\1740 gastrocnemius\NN\5289861 showed\VBD\2137132 type\NN\5839024 IIb\NN\1740 fiber\NN\14580897 atrophy\NN\14299637 in\IN\13603305 the\DT\1740 <e1>steroid</e1>\NN\14727670 groups\NNS\2137 and\CC\1740 also\RB\1740 diaphragmatic\JJ\1740 type\NN\5839024 IIa\NN\1740 <e2>atrophy</e2>\NN\14299637 with\IN\1740 T\NN\14999913 ,\,\1740 whereas\IN\1740 histologic\JJ\1740 examinations\NNS\633864 revealed\VBD\2137132 a\DT\13649268 normal\JJ\1740 muscular\JJ\1740 pattern\NN\5726345 with\IN\1740 absence\NN\14449405 of\IN\1740 necrosis\NN\11444117 .\.\1740
D013256_D009133 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 short-term\JJ\1740 treatment\NN\654885 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>steroids</e1>\NNS\14727670 induced\VBD\1627355 severe\JJ\1740 respiratory\NN\1740 and\CC\1740 limb\JJ\1740 muscle\NN\5289601 wasting\VBG\1158572 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 both\DT\1740 types\NNS\5839024 of\IN\1740 steroids\NNS\14727670 induced\VBN\1627355 predominantly\RB\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 expected\VBN\670261 alterations\NNS\7283608 in\IN\13603305 diaphragm\NN\3736970 contractile\NN\1740 properties\NNS\32613 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 neither\CC\1740 steroid\NN\14727670 caused\VBD\1617192 muscle\NN\5289601 necrosis\NN\11444117 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 type\NN\5839024 IIb\NN\1740 <e2>atrophy</e2>\NN\14299637 was\VBD\836236 not\RB\1740 caused\VBN\1617192 by\IN\1740 acute\JJ\1740 nutritional\JJ\1740 deprivation\NN\14493145 alone\RB\1740 .\.\1740
D013256_D009133 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 short-term\JJ\1740 treatment\NN\654885 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 steroids\NNS\14727670 induced\VBD\1627355 severe\JJ\1740 respiratory\NN\1740 and\CC\1740 limb\JJ\1740 muscle\NN\5289601 wasting\VBG\1158572 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 both\DT\1740 types\NNS\5839024 of\IN\1740 <e1>steroids</e1>\NNS\14727670 induced\VBN\1627355 predominantly\RB\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 expected\VBN\670261 alterations\NNS\7283608 in\IN\13603305 diaphragm\NN\3736970 contractile\NN\1740 properties\NNS\32613 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 neither\CC\1740 steroid\NN\14727670 caused\VBD\1617192 muscle\NN\5289601 necrosis\NN\11444117 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 type\NN\5839024 IIb\NN\1740 <e2>atrophy</e2>\NN\14299637 was\VBD\836236 not\RB\1740 caused\VBN\1617192 by\IN\1740 acute\JJ\1740 nutritional\JJ\1740 deprivation\NN\14493145 alone\RB\1740 .\.\1740
D013256_D009133 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 short-term\JJ\1740 treatment\NN\654885 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 steroids\NNS\14727670 induced\VBD\1627355 severe\JJ\1740 respiratory\NN\1740 and\CC\1740 limb\JJ\1740 muscle\NN\5289601 wasting\VBG\1158572 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 both\DT\1740 types\NNS\5839024 of\IN\1740 steroids\NNS\14727670 induced\VBN\1627355 predominantly\RB\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 expected\VBN\670261 alterations\NNS\7283608 in\IN\13603305 diaphragm\NN\3736970 contractile\NN\1740 properties\NNS\32613 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 neither\CC\1740 <e1>steroid</e1>\NN\14727670 caused\VBD\1617192 muscle\NN\5289601 necrosis\NN\11444117 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 type\NN\5839024 IIb\NN\1740 <e2>atrophy</e2>\NN\14299637 was\VBD\836236 not\RB\1740 caused\VBN\1617192 by\IN\1740 acute\JJ\1740 nutritional\JJ\1740 deprivation\NN\14493145 alone\RB\1740 .\.\1740
D013256_D009336 NONE ATPase\NN\1740 staining\NN\275424 of\IN\1740 the\DT\1740 diaphragm\NN\3736970 ,\,\1740 scalenus\JJ\1740 medius\NN\1740 ,\,\1740 and\CC\1740 gastrocnemius\NN\5289861 showed\VBD\2137132 type\NN\5839024 IIb\NN\1740 fiber\NN\14580897 atrophy\NN\14299637 in\IN\13603305 the\DT\1740 <e1>steroid</e1>\NN\14727670 groups\NNS\2137 and\CC\1740 also\RB\1740 diaphragmatic\JJ\1740 type\NN\5839024 IIa\NN\1740 atrophy\NN\14299637 with\IN\1740 T\NN\14999913 ,\,\1740 whereas\IN\1740 histologic\JJ\1740 examinations\NNS\633864 revealed\VBD\2137132 a\DT\13649268 normal\JJ\1740 muscular\JJ\1740 pattern\NN\5726345 with\IN\1740 absence\NN\14449405 of\IN\1740 <e2>necrosis</e2>\NN\11444117 .\.\1740
D013256_D009336 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 short-term\JJ\1740 treatment\NN\654885 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>steroids</e1>\NNS\14727670 induced\VBD\1627355 severe\JJ\1740 respiratory\NN\1740 and\CC\1740 limb\JJ\1740 muscle\NN\5289601 wasting\VBG\1158572 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 both\DT\1740 types\NNS\5839024 of\IN\1740 steroids\NNS\14727670 induced\VBN\1627355 predominantly\RB\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 expected\VBN\670261 alterations\NNS\7283608 in\IN\13603305 diaphragm\NN\3736970 contractile\NN\1740 properties\NNS\32613 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 neither\CC\1740 steroid\NN\14727670 caused\VBD\1617192 muscle\NN\5289601 <e2>necrosis</e2>\NN\11444117 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 was\VBD\836236 not\RB\1740 caused\VBN\1617192 by\IN\1740 acute\JJ\1740 nutritional\JJ\1740 deprivation\NN\14493145 alone\RB\1740 .\.\1740
D013256_D009336 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 short-term\JJ\1740 treatment\NN\654885 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 steroids\NNS\14727670 induced\VBD\1627355 severe\JJ\1740 respiratory\NN\1740 and\CC\1740 limb\JJ\1740 muscle\NN\5289601 wasting\VBG\1158572 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 both\DT\1740 types\NNS\5839024 of\IN\1740 <e1>steroids</e1>\NNS\14727670 induced\VBN\1627355 predominantly\RB\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 expected\VBN\670261 alterations\NNS\7283608 in\IN\13603305 diaphragm\NN\3736970 contractile\NN\1740 properties\NNS\32613 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 neither\CC\1740 steroid\NN\14727670 caused\VBD\1617192 muscle\NN\5289601 <e2>necrosis</e2>\NN\11444117 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 was\VBD\836236 not\RB\1740 caused\VBN\1617192 by\IN\1740 acute\JJ\1740 nutritional\JJ\1740 deprivation\NN\14493145 alone\RB\1740 .\.\1740
D013256_D009336 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 short-term\JJ\1740 treatment\NN\654885 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 steroids\NNS\14727670 induced\VBD\1627355 severe\JJ\1740 respiratory\NN\1740 and\CC\1740 limb\JJ\1740 muscle\NN\5289601 wasting\VBG\1158572 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 both\DT\1740 types\NNS\5839024 of\IN\1740 steroids\NNS\14727670 induced\VBN\1627355 predominantly\RB\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 expected\VBN\670261 alterations\NNS\7283608 in\IN\13603305 diaphragm\NN\3736970 contractile\NN\1740 properties\NNS\32613 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 neither\CC\1740 <e1>steroid</e1>\NN\14727670 caused\VBD\1617192 muscle\NN\5289601 <e2>necrosis</e2>\NN\11444117 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 was\VBD\836236 not\RB\1740 caused\VBN\1617192 by\IN\1740 acute\JJ\1740 nutritional\JJ\1740 deprivation\NN\14493145 alone\RB\1740 .\.\1740
D014221_D009133 CID ATPase\NN\1740 staining\NN\275424 of\IN\1740 the\DT\1740 diaphragm\NN\3736970 ,\,\1740 scalenus\JJ\1740 medius\NN\1740 ,\,\1740 and\CC\1740 gastrocnemius\NN\5289861 showed\VBD\2137132 type\NN\5839024 IIb\NN\1740 fiber\NN\14580897 <e2>atrophy</e2>\NN\14299637 in\IN\13603305 the\DT\1740 steroid\NN\14727670 groups\NNS\2137 and\CC\1740 also\RB\1740 diaphragmatic\JJ\1740 type\NN\5839024 IIa\NN\1740 atrophy\NN\14299637 with\IN\1740 <e1>T</e1>\NN\14999913 ,\,\1740 whereas\IN\1740 histologic\JJ\1740 examinations\NNS\633864 revealed\VBD\2137132 a\DT\13649268 normal\JJ\1740 muscular\JJ\1740 pattern\NN\5726345 with\IN\1740 absence\NN\14449405 of\IN\1740 necrosis\NN\11444117 .\.\1740
D014221_D009133 CID ATPase\NN\1740 staining\NN\275424 of\IN\1740 the\DT\1740 diaphragm\NN\3736970 ,\,\1740 scalenus\JJ\1740 medius\NN\1740 ,\,\1740 and\CC\1740 gastrocnemius\NN\5289861 showed\VBD\2137132 type\NN\5839024 IIb\NN\1740 fiber\NN\14580897 atrophy\NN\14299637 in\IN\13603305 the\DT\1740 steroid\NN\14727670 groups\NNS\2137 and\CC\1740 also\RB\1740 diaphragmatic\JJ\1740 type\NN\5839024 IIa\NN\1740 <e2>atrophy</e2>\NN\14299637 with\IN\1740 <e1>T</e1>\NN\14999913 ,\,\1740 whereas\IN\1740 histologic\JJ\1740 examinations\NNS\633864 revealed\VBD\2137132 a\DT\13649268 normal\JJ\1740 muscular\JJ\1740 pattern\NN\5726345 with\IN\1740 absence\NN\14449405 of\IN\1740 necrosis\NN\11444117 .\.\1740
D014221_D009133 CID Finally\RB\1740 ,\,\1740 a\DT\13649268 pair-fed\JJ\1740 (\-LRB-\1740 PF\NN\1740 )\-RRB-\1740 study\NN\635850 ,\,\1740 performed\VBN\2367363 in\IN\13603305 18\CD\13745420 rats\NNS\2329401 (\-LRB-\1740 C\NN\13714184 ,\,\1740 <e1>T</e1>\NN\14999913 ,\,\1740 and\CC\1740 PF\NN\1740 )\-RRB-\1740 ,\,\1740 showed\VBD\2137132 that\IN\1740 <e2>muscle\NN\5289601 atrophy</e2>\NN\14299637 was\VBD\836236 considerably\RB\1740 less\RBR\1740 pronounced\JJ\1740 in\IN\13603305 PF\NN\1740 animals\NNS\4475 than\IN\1740 in\IN\13603305 T-treated\JJ\1740 animals\NNS\4475 .\.\1740
D014221_D009133 CID Finally\RB\1740 ,\,\1740 a\DT\13649268 pair-fed\JJ\1740 (\-LRB-\1740 PF\NN\1740 )\-RRB-\1740 study\NN\635850 ,\,\1740 performed\VBN\2367363 in\IN\13603305 18\CD\13745420 rats\NNS\2329401 (\-LRB-\1740 C\NN\13714184 ,\,\1740 T\NN\14999913 ,\,\1740 and\CC\1740 PF\NN\1740 )\-RRB-\1740 ,\,\1740 showed\VBD\2137132 that\IN\1740 <e2>muscle\NN\5289601 atrophy</e2>\NN\14299637 was\VBD\836236 considerably\RB\1740 less\RBR\1740 pronounced\JJ\1740 in\IN\13603305 PF\NN\1740 animals\NNS\4475 than\IN\1740 in\IN\13603305 <e1>T-treated</e1>\JJ\1740 animals\NNS\4475 .\.\1740
D014221_D009336 NONE ATPase\NN\1740 staining\NN\275424 of\IN\1740 the\DT\1740 diaphragm\NN\3736970 ,\,\1740 scalenus\JJ\1740 medius\NN\1740 ,\,\1740 and\CC\1740 gastrocnemius\NN\5289861 showed\VBD\2137132 type\NN\5839024 IIb\NN\1740 fiber\NN\14580897 atrophy\NN\14299637 in\IN\13603305 the\DT\1740 steroid\NN\14727670 groups\NNS\2137 and\CC\1740 also\RB\1740 diaphragmatic\JJ\1740 type\NN\5839024 IIa\NN\1740 atrophy\NN\14299637 with\IN\1740 <e1>T</e1>\NN\14999913 ,\,\1740 whereas\IN\1740 histologic\JJ\1740 examinations\NNS\633864 revealed\VBD\2137132 a\DT\13649268 normal\JJ\1740 muscular\JJ\1740 pattern\NN\5726345 with\IN\1740 absence\NN\14449405 of\IN\1740 <e2>necrosis</e2>\NN\11444117 .\.\1740
D013256_D001284 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 short-term\JJ\1740 treatment\NN\654885 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>steroids</e1>\NNS\14727670 induced\VBD\1627355 severe\JJ\1740 respiratory\NN\1740 and\CC\1740 limb\JJ\1740 muscle\NN\5289601 wasting\VBG\1158572 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 both\DT\1740 types\NNS\5839024 of\IN\1740 steroids\NNS\14727670 induced\VBN\1627355 predominantly\RB\1740 type\NN\5839024 IIb\NN\1740 <e2>atrophy</e2>\NN\14299637 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 expected\VBN\670261 alterations\NNS\7283608 in\IN\13603305 diaphragm\NN\3736970 contractile\NN\1740 properties\NNS\32613 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 neither\CC\1740 steroid\NN\14727670 caused\VBD\1617192 muscle\NN\5289601 necrosis\NN\11444117 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 was\VBD\836236 not\RB\1740 caused\VBN\1617192 by\IN\1740 acute\JJ\1740 nutritional\JJ\1740 deprivation\NN\14493145 alone\RB\1740 .\.\1740
D013256_D001284 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 short-term\JJ\1740 treatment\NN\654885 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 steroids\NNS\14727670 induced\VBD\1627355 severe\JJ\1740 respiratory\NN\1740 and\CC\1740 limb\JJ\1740 muscle\NN\5289601 wasting\VBG\1158572 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 both\DT\1740 types\NNS\5839024 of\IN\1740 <e1>steroids</e1>\NNS\14727670 induced\VBN\1627355 predominantly\RB\1740 type\NN\5839024 IIb\NN\1740 <e2>atrophy</e2>\NN\14299637 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 expected\VBN\670261 alterations\NNS\7283608 in\IN\13603305 diaphragm\NN\3736970 contractile\NN\1740 properties\NNS\32613 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 neither\CC\1740 steroid\NN\14727670 caused\VBD\1617192 muscle\NN\5289601 necrosis\NN\11444117 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 was\VBD\836236 not\RB\1740 caused\VBN\1617192 by\IN\1740 acute\JJ\1740 nutritional\JJ\1740 deprivation\NN\14493145 alone\RB\1740 .\.\1740
D013256_D001284 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 short-term\JJ\1740 treatment\NN\654885 with\IN\1740 massive\JJ\1740 doses\NNS\3740161 of\IN\1740 steroids\NNS\14727670 induced\VBD\1627355 severe\JJ\1740 respiratory\NN\1740 and\CC\1740 limb\JJ\1740 muscle\NN\5289601 wasting\VBG\1158572 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 both\DT\1740 types\NNS\5839024 of\IN\1740 steroids\NNS\14727670 induced\VBN\1627355 predominantly\RB\1740 type\NN\5839024 IIb\NN\1740 <e2>atrophy</e2>\NN\14299637 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 expected\VBN\670261 alterations\NNS\7283608 in\IN\13603305 diaphragm\NN\3736970 contractile\NN\1740 properties\NNS\32613 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 neither\CC\1740 <e1>steroid</e1>\NN\14727670 caused\VBD\1617192 muscle\NN\5289601 necrosis\NN\11444117 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 type\NN\5839024 IIb\NN\1740 atrophy\NN\14299637 was\VBD\836236 not\RB\1740 caused\VBN\1617192 by\IN\1740 acute\JJ\1740 nutritional\JJ\1740 deprivation\NN\14493145 alone\RB\1740 .\.\1740
2709684
D010695_D006029 NONE <e1>Phlorizin-induced</e1>\JJ\1740 <e2>glycosuria</e2>\NN\14299637 does\VBZ\1640855 not\RB\1740 prevent\VB\1740 gentamicin\NN\2716866 nephrotoxicity\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010695_D006029 NONE DM\NN\14117805 rats\NNS\2329401 with\IN\1740 mild\JJ\1740 <e2>glycosuria</e2>\NN\14299637 (\-LRB-\1740 similar\JJ\1740 in\IN\13603305 degree\NN\4916342 to\TO\1740 that\DT\1740 of\IN\1740 the\DT\1740 <e1>P</e1>\NN\14622893 treated\JJ\1740 animals\NNS\4475 )\-RRB-\1740 were\VBD\836236 also\RB\1740 studied\VBN\630380 .\.\1740
D010695_D006029 NONE In\IN\13603305 Group\NNP\2137 I\CD\14622893 ,\,\1740 <e1>P</e1>\NN\14622893 induced\VBD\1627355 a\DT\13649268 moderate\JJ\1740 and\CC\1740 stable\JJ\1740 <e2>glycosuria</e2>\NN\14299637 (\-LRB-\1740 3.9\CD\1740 +/-\CC\1740 0.1\CD\1740 g/day\NN\1740 ,\,\1740 SE\NN\14724645 )\-RRB-\1740 ,\,\1740 and\CC\1740 no\DT\7204911 functional\JJ\1740 or\CC\3541091 morphologic\JJ\1740 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 baseline\NN\7260623 CCr\NNS\1740 2.1\CD\1740 +/-\CC\1740 0.1\CD\1740 ml/min\NN\1740 ,\,\1740 undetectable\JJ\1740 lysozymuria\NNS\1740 )\-RRB-\1740 or\CC\3541091 damage\NN\7296428 (\-LRB-\1740 tubular\JJ\1740 necrosis\NN\11444117 score\NN\5736149 [\-LRB-\1740 maximum\NN\13653902 4\CD\13741022 ]\-RRB-\1740 ,\,\1740 zero\CD\13576982 )\-RRB-\1740 .\.\1740
D010695_D007674 NONE <e1>Phlorizin-induced</e1>\JJ\1740 glycosuria\NN\14299637 does\VBZ\1640855 not\RB\1740 prevent\VB\1740 gentamicin\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010695_D007674 NONE The\DT\1740 protection\NN\407535 from\IN\1740 gentamicin\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 non-diabetic\JJ\1740 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 solute\JJ\1740 diuresis\NN\14299637 induced\VBN\1627355 by\IN\1740 blockage\NN\14034177 of\IN\1740 tubular\JJ\1740 glucose\NN\14710501 reabsorption\NN\13526110 with\IN\1740 <e1>phlorizin</e1>\NN\1740 (\-LRB-\1740 P\NN\14622893 )\-RRB-\1740 .\.\1740
D010695_D007674 NONE The\DT\1740 protection\NN\407535 from\IN\1740 gentamicin\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 non-diabetic\JJ\1740 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 solute\JJ\1740 diuresis\NN\14299637 induced\VBN\1627355 by\IN\1740 blockage\NN\14034177 of\IN\1740 tubular\JJ\1740 glucose\NN\14710501 reabsorption\NN\13526110 with\IN\1740 phlorizin\NN\1740 (\-LRB-\1740 <e1>P</e1>\NN\14622893 )\-RRB-\1740 .\.\1740
D010695_D007674 NONE In\IN\13603305 Group\NNP\2137 I\CD\14622893 ,\,\1740 <e1>P</e1>\NN\14622893 induced\VBD\1627355 a\DT\13649268 moderate\JJ\1740 and\CC\1740 stable\JJ\1740 glycosuria\NN\14299637 (\-LRB-\1740 3.9\CD\1740 +/-\CC\1740 0.1\CD\1740 g/day\NN\1740 ,\,\1740 SE\NN\14724645 )\-RRB-\1740 ,\,\1740 and\CC\1740 no\DT\7204911 functional\JJ\1740 or\CC\3541091 morphologic\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 (\-LRB-\1740 baseline\NN\7260623 CCr\NNS\1740 2.1\CD\1740 +/-\CC\1740 0.1\CD\1740 ml/min\NN\1740 ,\,\1740 undetectable\JJ\1740 lysozymuria\NNS\1740 )\-RRB-\1740 or\CC\3541091 damage\NN\7296428 (\-LRB-\1740 tubular\JJ\1740 necrosis\NN\11444117 score\NN\5736149 [\-LRB-\1740 maximum\NN\13653902 4\CD\13741022 ]\-RRB-\1740 ,\,\1740 zero\CD\13576982 )\-RRB-\1740 .\.\1740
D005839_D006029 NONE Phlorizin-induced\JJ\1740 <e2>glycosuria</e2>\NN\14299637 does\VBZ\1640855 not\RB\1740 prevent\VB\1740 <e1>gentamicin</e1>\NN\2716866 nephrotoxicity\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D005839_D006029 NONE Because\IN\1740 rats\NNS\2329401 with\IN\1740 streptozotocin-induced\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 (\-LRB-\1740 DM\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 <e2>glycosuria</e2>\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 <e1>gentamicin-induced</e1>\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D005839_D007674 NONE Phlorizin-induced\JJ\1740 glycosuria\NN\14299637 does\VBZ\1640855 not\RB\1740 prevent\VB\1740 <e1>gentamicin</e1>\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D005839_D007674 NONE The\DT\1740 protection\NN\407535 from\IN\1740 <e1>gentamicin</e1>\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 non-diabetic\JJ\1740 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 solute\JJ\1740 diuresis\NN\14299637 induced\VBN\1627355 by\IN\1740 blockage\NN\14034177 of\IN\1740 tubular\JJ\1740 glucose\NN\14710501 reabsorption\NN\13526110 with\IN\1740 phlorizin\NN\1740 (\-LRB-\1740 P\NN\14622893 )\-RRB-\1740 .\.\1740
D005839_D007674 NONE <e2>Nephrotoxic</e2>\JJ\1740 doses\NNS\3740161 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 body\NN\19128 wt/day\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>gentamicin</e1>\NN\2716866 were\VBD\836236 injected\VBN\81072 during\IN\1740 the\DT\1740 last\JJ\1740 nine\CD\13741022 days\NNS\15140892 of\IN\1740 study\NN\635850 to\IN\1740 the\DT\1740 animals\NNS\4475 of\IN\1740 groups\NNS\2137 II\CD\13741022 to\TO\1740 IV\CD\13741022 .\.\1740
D013311_D003920 CID Because\IN\1740 rats\NNS\2329401 with\IN\1740 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 (\-LRB-\1740 DM\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 glycosuria\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 gentamicin-induced\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D013311_D003920 CID Because\IN\1740 rats\NNS\2329401 with\IN\1740 <e1>streptozotocin-induced</e1>\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 (\-LRB-\1740 <e2>DM</e2>\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 glycosuria\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 gentamicin-induced\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D013311_D006029 NONE Because\IN\1740 rats\NNS\2329401 with\IN\1740 <e1>streptozotocin-induced</e1>\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 (\-LRB-\1740 DM\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 <e2>glycosuria</e2>\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 gentamicin-induced\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D013311_D058186 NONE Because\IN\1740 rats\NNS\2329401 with\IN\1740 <e1>streptozotocin-induced</e1>\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 (\-LRB-\1740 DM\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 glycosuria\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 gentamicin-induced\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D013311_D058186 NONE Because\IN\1740 rats\NNS\2329401 with\IN\1740 <e1>streptozotocin-induced</e1>\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 (\-LRB-\1740 DM\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 glycosuria\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 gentamicin-induced\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 <e2>ARF</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D005839_D003920 NONE Because\IN\1740 rats\NNS\2329401 with\IN\1740 streptozotocin-induced\JJ\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 (\-LRB-\1740 DM\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 glycosuria\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 <e1>gentamicin-induced</e1>\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D005839_D003920 NONE Because\IN\1740 rats\NNS\2329401 with\IN\1740 streptozotocin-induced\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 (\-LRB-\1740 <e2>DM</e2>\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 glycosuria\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 <e1>gentamicin-induced</e1>\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D005839_D003920 NONE The\DT\1740 protection\NN\407535 from\IN\1740 <e1>gentamicin</e1>\NN\2716866 nephrotoxicity\NN\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 <e2>non-diabetic</e2>\JJ\1740 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 solute\JJ\1740 diuresis\NN\14299637 induced\VBN\1627355 by\IN\1740 blockage\NN\14034177 of\IN\1740 tubular\JJ\1740 glucose\NN\14710501 reabsorption\NN\13526110 with\IN\1740 phlorizin\NN\1740 (\-LRB-\1740 P\NN\14622893 )\-RRB-\1740 .\.\1740
D005839_D003920 NONE Group\NN\2137 1\CD\13741022 (\-LRB-\1740 P\NN\14622893 alone\RB\1740 )\-RRB-\1740 received\VBD\2210855 P\NN\14622893 ,\,\1740 360\CD\1740 mg/day\NN\1740 ,\,\1740 for\IN\1740 15\CD\13745420 days\NNS\15140892 ;\:\1740 Group\NN\2137 II\CD\13741022 (\-LRB-\1740 P\NN\14622893 +\CC\1740 <e1>gentamicin</e1>\NN\2716866 )\-RRB-\1740 ;\:\1740 Group\NN\2137 III\CD\13741022 (\-LRB-\1740 gentamicin\NN\2716866 alone\RB\1740 )\-RRB-\1740 and\CC\1740 Group\NN\2137 IV\CD\13741022 (\-LRB-\1740 mild\JJ\1740 <e2>DM</e2>\NN\14117805 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 .\.\1740
D005839_D003920 NONE Group\NN\2137 1\CD\13741022 (\-LRB-\1740 P\NN\14622893 alone\RB\1740 )\-RRB-\1740 received\VBD\2210855 P\NN\14622893 ,\,\1740 360\CD\1740 mg/day\NN\1740 ,\,\1740 for\IN\1740 15\CD\13745420 days\NNS\15140892 ;\:\1740 Group\NN\2137 II\CD\13741022 (\-LRB-\1740 P\NN\14622893 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 ;\:\1740 Group\NN\2137 III\CD\13741022 (\-LRB-\1740 <e1>gentamicin</e1>\NN\2716866 alone\RB\1740 )\-RRB-\1740 and\CC\1740 Group\NN\2137 IV\CD\13741022 (\-LRB-\1740 mild\JJ\1740 <e2>DM</e2>\NN\14117805 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 .\.\1740
D005839_D003920 NONE Group\NN\2137 1\CD\13741022 (\-LRB-\1740 P\NN\14622893 alone\RB\1740 )\-RRB-\1740 received\VBD\2210855 P\NN\14622893 ,\,\1740 360\CD\1740 mg/day\NN\1740 ,\,\1740 for\IN\1740 15\CD\13745420 days\NNS\15140892 ;\:\1740 Group\NN\2137 II\CD\13741022 (\-LRB-\1740 P\NN\14622893 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 ;\:\1740 Group\NN\2137 III\CD\13741022 (\-LRB-\1740 gentamicin\NN\2716866 alone\RB\1740 )\-RRB-\1740 and\CC\1740 Group\NN\2137 IV\CD\13741022 (\-LRB-\1740 mild\JJ\1740 <e2>DM</e2>\NN\14117805 +\CC\1740 <e1>gentamicin</e1>\NN\2716866 )\-RRB-\1740 .\.\1740
D005839_D058186 CID Because\IN\1740 rats\NNS\2329401 with\IN\1740 streptozotocin-induced\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 (\-LRB-\1740 DM\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 glycosuria\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 <e1>gentamicin-induced</e1>\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D005839_D058186 CID Because\IN\1740 rats\NNS\2329401 with\IN\1740 streptozotocin-induced\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 (\-LRB-\1740 DM\NN\14117805 )\-RRB-\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 solute\NN\20827 diuresis\NN\14299637 (\-LRB-\1740 glycosuria\NN\14299637 of\IN\1740 10\CD\13745420 to\TO\1740 12\CD\13745420 g/day\NN\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 this\DT\1740 may\MD\15209706 in\IN\13603305 part\NN\31921 be\VB\836236 responsible\JJ\1740 for\IN\1740 their\PRP$\1740 resistance\NN\37396 to\TO\1740 <e1>gentamicin-induced</e1>\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 <e2>ARF</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D005839_D058186 CID In\IN\13603305 Group\NNP\2137 II\CD\13741022 ,\,\1740 P\NN\14622893 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2><e1>gentamicin-ARF</e1></e2>\NN\1740 (\-LRB-\1740 maximal\JJ\1740 decrease\NN\7296428 in\IN\13603305 CCr\NNS\1740 at\IN\14622893 day\NN\15154774 9.89\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 ;\:\1740 peak\NN\13758296 lysozymuria\NNS\1740 ,\,\1740 1863\CD\1740 +/-\CC\1740 321\CD\1740 micrograms/day\NN\1740 ;\:\1740 and\CC\1740 tubular\JJ\1740 necrosis\NN\11444117 score\NN\5736149 ,\,\1740 3.9\CD\1740 +/-\CC\1740 0.1\CD\1740 )\-RRB-\1740 .\.\1740
D005947_D007674 NONE The\DT\1740 protection\NN\407535 from\IN\1740 gentamicin\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 non-diabetic\JJ\1740 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 solute\JJ\1740 diuresis\NN\14299637 induced\VBN\1627355 by\IN\1740 blockage\NN\14034177 of\IN\1740 tubular\JJ\1740 <e1>glucose</e1>\NN\14710501 reabsorption\NN\13526110 with\IN\1740 phlorizin\NN\1740 (\-LRB-\1740 P\NN\14622893 )\-RRB-\1740 .\.\1740
D005947_D003920 NONE The\DT\1740 protection\NN\407535 from\IN\1740 gentamicin\NN\2716866 nephrotoxicity\NN\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 <e2>non-diabetic</e2>\JJ\1740 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 solute\JJ\1740 diuresis\NN\14299637 induced\VBN\1627355 by\IN\1740 blockage\NN\14034177 of\IN\1740 tubular\JJ\1740 <e1>glucose</e1>\NN\14710501 reabsorption\NN\13526110 with\IN\1740 phlorizin\NN\1740 (\-LRB-\1740 P\NN\14622893 )\-RRB-\1740 .\.\1740
D010695_D003920 NONE The\DT\1740 protection\NN\407535 from\IN\1740 gentamicin\NN\2716866 nephrotoxicity\NN\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 <e2>non-diabetic</e2>\JJ\1740 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 solute\JJ\1740 diuresis\NN\14299637 induced\VBN\1627355 by\IN\1740 blockage\NN\14034177 of\IN\1740 tubular\JJ\1740 glucose\NN\14710501 reabsorption\NN\13526110 with\IN\1740 <e1>phlorizin</e1>\NN\1740 (\-LRB-\1740 P\NN\14622893 )\-RRB-\1740 .\.\1740
D010695_D003920 NONE The\DT\1740 protection\NN\407535 from\IN\1740 gentamicin\NN\2716866 nephrotoxicity\NN\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 <e2>non-diabetic</e2>\JJ\1740 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 solute\JJ\1740 diuresis\NN\14299637 induced\VBN\1627355 by\IN\1740 blockage\NN\14034177 of\IN\1740 tubular\JJ\1740 glucose\NN\14710501 reabsorption\NN\13526110 with\IN\1740 phlorizin\NN\1740 (\-LRB-\1740 <e1>P</e1>\NN\14622893 )\-RRB-\1740 .\.\1740
D010695_D003920 NONE <e2>DM</e2>\NN\14117805 rats\NNS\2329401 with\IN\1740 mild\JJ\1740 glycosuria\NN\14299637 (\-LRB-\1740 similar\JJ\1740 in\IN\13603305 degree\NN\4916342 to\TO\1740 that\DT\1740 of\IN\1740 the\DT\1740 <e1>P</e1>\NN\14622893 treated\JJ\1740 animals\NNS\4475 )\-RRB-\1740 were\VBD\836236 also\RB\1740 studied\VBN\630380 .\.\1740
D010695_D003920 NONE Group\NN\2137 1\CD\13741022 (\-LRB-\1740 <e1>P</e1>\NN\14622893 alone\RB\1740 )\-RRB-\1740 received\VBD\2210855 P\NN\14622893 ,\,\1740 360\CD\1740 mg/day\NN\1740 ,\,\1740 for\IN\1740 15\CD\13745420 days\NNS\15140892 ;\:\1740 Group\NN\2137 II\CD\13741022 (\-LRB-\1740 P\NN\14622893 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 ;\:\1740 Group\NN\2137 III\CD\13741022 (\-LRB-\1740 gentamicin\NN\2716866 alone\RB\1740 )\-RRB-\1740 and\CC\1740 Group\NN\2137 IV\CD\13741022 (\-LRB-\1740 mild\JJ\1740 <e2>DM</e2>\NN\14117805 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 .\.\1740
D010695_D003920 NONE Group\NN\2137 1\CD\13741022 (\-LRB-\1740 P\NN\14622893 alone\RB\1740 )\-RRB-\1740 received\VBD\2210855 <e1>P</e1>\NN\14622893 ,\,\1740 360\CD\1740 mg/day\NN\1740 ,\,\1740 for\IN\1740 15\CD\13745420 days\NNS\15140892 ;\:\1740 Group\NN\2137 II\CD\13741022 (\-LRB-\1740 P\NN\14622893 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 ;\:\1740 Group\NN\2137 III\CD\13741022 (\-LRB-\1740 gentamicin\NN\2716866 alone\RB\1740 )\-RRB-\1740 and\CC\1740 Group\NN\2137 IV\CD\13741022 (\-LRB-\1740 mild\JJ\1740 <e2>DM</e2>\NN\14117805 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 .\.\1740
D010695_D003920 NONE Group\NN\2137 1\CD\13741022 (\-LRB-\1740 P\NN\14622893 alone\RB\1740 )\-RRB-\1740 received\VBD\2210855 P\NN\14622893 ,\,\1740 360\CD\1740 mg/day\NN\1740 ,\,\1740 for\IN\1740 15\CD\13745420 days\NNS\15140892 ;\:\1740 Group\NN\2137 II\CD\13741022 (\-LRB-\1740 <e1>P</e1>\NN\14622893 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 ;\:\1740 Group\NN\2137 III\CD\13741022 (\-LRB-\1740 gentamicin\NN\2716866 alone\RB\1740 )\-RRB-\1740 and\CC\1740 Group\NN\2137 IV\CD\13741022 (\-LRB-\1740 mild\JJ\1740 <e2>DM</e2>\NN\14117805 +\CC\1740 gentamicin\NN\2716866 )\-RRB-\1740 .\.\1740
D010695_D009956 NONE In\IN\13603305 Group\NNP\2137 I\CD\14622893 ,\,\1740 <e1>P</e1>\NN\14622893 induced\VBD\1627355 a\DT\13649268 moderate\JJ\1740 and\CC\1740 stable\JJ\1740 glycosuria\NN\14299637 (\-LRB-\1740 3.9\CD\1740 +/-\CC\1740 0.1\CD\1740 g/day\NN\1740 ,\,\1740 SE\NN\14724645 )\-RRB-\1740 ,\,\1740 and\CC\1740 no\DT\7204911 functional\JJ\1740 or\CC\3541091 morphologic\JJ\1740 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 baseline\NN\7260623 CCr\NNS\1740 2.1\CD\1740 +/-\CC\1740 0.1\CD\1740 ml/min\NN\1740 ,\,\1740 undetectable\JJ\1740 lysozymuria\NNS\1740 )\-RRB-\1740 or\CC\3541091 damage\NN\7296428 (\-LRB-\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 score\NN\5736149 [\-LRB-\1740 maximum\NN\13653902 4\CD\13741022 ]\-RRB-\1740 ,\,\1740 zero\CD\13576982 )\-RRB-\1740 .\.\1740
D010695_D009956 NONE In\IN\13603305 Group\NNP\2137 II\CD\13741022 ,\,\1740 <e1>P</e1>\NN\14622893 did\VBD\1640855 not\RB\1740 prevent\VB\1740 gentamicin-ARF\NN\1740 (\-LRB-\1740 maximal\JJ\1740 decrease\NN\7296428 in\IN\13603305 CCr\NNS\1740 at\IN\14622893 day\NN\15154774 9.89\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 ;\:\1740 peak\NN\13758296 lysozymuria\NNS\1740 ,\,\1740 1863\CD\1740 +/-\CC\1740 321\CD\1740 micrograms/day\NN\1740 ;\:\1740 and\CC\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 score\NN\5736149 ,\,\1740 3.9\CD\1740 +/-\CC\1740 0.1\CD\1740 )\-RRB-\1740 .\.\1740
D010695_D009956 NONE In\IN\13603305 Group\NNP\2137 II\CD\13741022 ,\,\1740 P\NN\14622893 did\VBD\1640855 not\RB\1740 prevent\VB\1740 gentamicin-ARF\NN\1740 (\-LRB-\1740 maximal\JJ\1740 decrease\NN\7296428 in\IN\13603305 CCr\NNS\1740 at\IN\14622893 day\NN\15154774 9.89\CD\1740 %\NN\1740 ,\,\1740 <e1>P</e1>\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 ;\:\1740 peak\NN\13758296 lysozymuria\NNS\1740 ,\,\1740 1863\CD\1740 +/-\CC\1740 321\CD\1740 micrograms/day\NN\1740 ;\:\1740 and\CC\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 score\NN\5736149 ,\,\1740 3.9\CD\1740 +/-\CC\1740 0.1\CD\1740 )\-RRB-\1740 .\.\1740
D010695_D009956 NONE These\DT\1740 values\NNS\5941423 were\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 those\DT\1740 of\IN\1740 Group\NNP\2137 III\CD\13741022 :\:\1740 maximal\JJ\1740 decrease\NN\7296428 in\IN\13603305 CCr\NN\1740 73\CD\1740 %\NN\1740 (\-LRB-\1740 <e1>P</e1>\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 lysozymuria\NNS\1740 ,\,\1740 2147\CD\1740 +/-\CC\1740 701\CD\1740 micrograms/day\NN\1740 ;\:\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 score\NN\5736149 ,\,\1740 3.8\CD\1740 +/-\CC\1740 0.1\CD\1740 .\.\1740
D010695_D058186 NONE In\IN\13603305 Group\NNP\2137 II\CD\13741022 ,\,\1740 <e1>P</e1>\NN\14622893 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2>gentamicin-ARF</e2>\NN\1740 (\-LRB-\1740 maximal\JJ\1740 decrease\NN\7296428 in\IN\13603305 CCr\NNS\1740 at\IN\14622893 day\NN\15154774 9.89\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 ;\:\1740 peak\NN\13758296 lysozymuria\NNS\1740 ,\,\1740 1863\CD\1740 +/-\CC\1740 321\CD\1740 micrograms/day\NN\1740 ;\:\1740 and\CC\1740 tubular\JJ\1740 necrosis\NN\11444117 score\NN\5736149 ,\,\1740 3.9\CD\1740 +/-\CC\1740 0.1\CD\1740 )\-RRB-\1740 .\.\1740
D010695_D058186 NONE In\IN\13603305 Group\NNP\2137 II\CD\13741022 ,\,\1740 P\NN\14622893 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2>gentamicin-ARF</e2>\NN\1740 (\-LRB-\1740 maximal\JJ\1740 decrease\NN\7296428 in\IN\13603305 CCr\NNS\1740 at\IN\14622893 day\NN\15154774 9.89\CD\1740 %\NN\1740 ,\,\1740 <e1>P</e1>\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 ;\:\1740 peak\NN\13758296 lysozymuria\NNS\1740 ,\,\1740 1863\CD\1740 +/-\CC\1740 321\CD\1740 micrograms/day\NN\1740 ;\:\1740 and\CC\1740 tubular\JJ\1740 necrosis\NN\11444117 score\NN\5736149 ,\,\1740 3.9\CD\1740 +/-\CC\1740 0.1\CD\1740 )\-RRB-\1740 .\.\1740
D005839_D009956 NONE In\IN\13603305 Group\NNP\2137 II\CD\13741022 ,\,\1740 P\NN\14622893 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e1>gentamicin-ARF</e1>\NN\1740 (\-LRB-\1740 maximal\JJ\1740 decrease\NN\7296428 in\IN\13603305 CCr\NNS\1740 at\IN\14622893 day\NN\15154774 9.89\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 ;\:\1740 peak\NN\13758296 lysozymuria\NNS\1740 ,\,\1740 1863\CD\1740 +/-\CC\1740 321\CD\1740 micrograms/day\NN\1740 ;\:\1740 and\CC\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 score\NN\5736149 ,\,\1740 3.9\CD\1740 +/-\CC\1740 0.1\CD\1740 )\-RRB-\1740 .\.\1740
15531665
D001205_D002318 CID Does\VBZ\1640855 supplemental\JJ\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 increase\VBP\169651 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 risk\NN\14541044 in\IN\13603305 women\NNS\9605289 with\IN\1740 diabetes\NNS\14075199 ?\.\1740
D001205_D002318 CID OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 objective\NN\5980875 was\VBD\836236 to\TO\1740 examine\VB\789138 the\DT\1740 relation\NN\2137 between\IN\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 and\CC\1740 mortality\NN\5054863 from\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D001205_D002318 CID DESIGN\NN\927261 :\:\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 relation\NN\2137 between\IN\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 and\CC\1740 mortality\NN\5054863 from\IN\1740 total\JJ\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 281\CD\1740 )\-RRB-\1740 ,\,\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 175\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 stroke\NN\556313 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 57\CD\1740 )\-RRB-\1740 in\IN\13603305 1923\CD\1740 postmenopausal\JJ\1740 women\NNS\9605289 who\WP\8299493 reported\VBD\831651 being\VBG\836236 diabetic\JJ\1740 at\IN\14622893 baseline\NN\7260623 .\.\1740
D001205_D002318 CID Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D001205_D002318 CID Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D001205_D002318 CID <e1>Vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 was\VBD\836236 unrelated\JJ\1740 to\TO\1740 mortality\NN\5054863 from\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 in\IN\13603305 the\DT\1740 nondiabetic\JJ\1740 subjects\NNS\6598915 at\IN\14622893 baseline\NN\7260623 .\.\1740
D001205_D002318 CID CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 high\JJ\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 from\IN\1740 supplements\NNS\6365467 is\VBZ\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 mortality\NN\5054863 in\IN\13603305 postmenopausal\JJ\1740 women\NNS\9605289 with\IN\1740 diabetes\NNS\14075199 .\.\1740
D001205_D003920 NONE Does\VBZ\1640855 supplemental\JJ\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 increase\VBP\169651 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 in\IN\13603305 women\NNS\9605289 with\IN\1740 <e2>diabetes</e2>\NNS\14075199 ?\.\1740
D001205_D003920 NONE These\DT\1740 observations\NNS\996969 led\VBD\1752884 us\PRP\14964590 to\TO\1740 hypothesize\VB\719734 that\IN\1740 a\DT\13649268 high\JJ\1740 intake\NN\13440063 of\IN\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 in\IN\13603305 <e2>diabetic</e2>\JJ\1740 persons\NNS\7347 might\MD\5029706 promote\VB\2556126 atherosclerosis\NN\14108324 .\.\1740
D001205_D003920 NONE DESIGN\NN\927261 :\:\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 relation\NN\2137 between\IN\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 and\CC\1740 mortality\NN\5054863 from\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 281\CD\1740 )\-RRB-\1740 ,\,\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 175\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 stroke\NN\556313 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 57\CD\1740 )\-RRB-\1740 in\IN\13603305 1923\CD\1740 postmenopausal\JJ\1740 women\NNS\9605289 who\WP\8299493 reported\VBD\831651 being\VBG\836236 <e2>diabetic</e2>\JJ\1740 at\IN\14622893 baseline\NN\7260623 .\.\1740
D001205_D003920 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 <e2>diabetes</e2>\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D001205_D003920 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D001205_D003920 NONE CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 high\JJ\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 from\IN\1740 supplements\NNS\6365467 is\VBZ\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 in\IN\13603305 postmenopausal\JJ\1740 women\NNS\9605289 with\IN\1740 <e2>diabetes</e2>\NNS\14075199 .\.\1740
D001205_D050197 NONE These\DT\1740 observations\NNS\996969 led\VBD\1752884 us\PRP\14964590 to\TO\1740 hypothesize\VB\719734 that\IN\1740 a\DT\13649268 high\JJ\1740 intake\NN\13440063 of\IN\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 in\IN\13603305 diabetic\JJ\1740 persons\NNS\7347 might\MD\5029706 promote\VB\2556126 <e2>atherosclerosis</e2>\NN\14108324 .\.\1740
D001205_D003324 NONE DESIGN\NN\927261 :\:\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 relation\NN\2137 between\IN\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 and\CC\1740 mortality\NN\5054863 from\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 281\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 175\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 stroke\NN\556313 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 57\CD\1740 )\-RRB-\1740 in\IN\13603305 1923\CD\1740 postmenopausal\JJ\1740 women\NNS\9605289 who\WP\8299493 reported\VBD\831651 being\VBG\836236 diabetic\JJ\1740 at\IN\14622893 baseline\NN\7260623 .\.\1740
D001205_D003324 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D001205_D020521 NONE DESIGN\NN\927261 :\:\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 relation\NN\2137 between\IN\1740 <e1>vitamin\NN\7570720 C</e1>\NN\13714184 intake\NN\13440063 and\CC\1740 mortality\NN\5054863 from\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 281\CD\1740 )\-RRB-\1740 ,\,\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 175\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>stroke</e2>\NN\556313 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 57\CD\1740 )\-RRB-\1740 in\IN\13603305 1923\CD\1740 postmenopausal\JJ\1740 women\NNS\9605289 who\WP\8299493 reported\VBD\831651 being\VBG\836236 diabetic\JJ\1740 at\IN\14622893 baseline\NN\7260623 .\.\1740
D005492_D003324 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 <e1>folate</e1>\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D005492_D002318 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 <e1>folate</e1>\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D005492_D002318 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 <e1>folate</e1>\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D005492_D003920 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 <e2>diabetes</e2>\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 <e1>folate</e1>\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D005492_D003920 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 <e1>folate</e1>\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D014810_D003324 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D014810_D002318 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D014810_D002318 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D014810_D003920 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 <e2>diabetes</e2>\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D014810_D003920 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 ,\,\1740 and\CC\1740 beta-carotene\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D019207_D003324 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 <e1>beta-carotene</e1>\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D019207_D002318 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 <e1>beta-carotene</e1>\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D019207_D002318 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 <e1>beta-carotene</e1>\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D019207_D003920 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 <e2>diabetes</e2>\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 <e1>beta-carotene</e1>\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
D019207_D003920 NONE Diet\NNP\7560652 was\VBD\836236 assessed\VBN\670261 with\IN\1740 a\DT\13649268 food-frequency\JJ\1740 questionnaire\NN\6473563 at\IN\14622893 baseline\NN\7260623 ,\,\1740 and\CC\1740 subjects\NNS\6598915 initially\RB\1740 free\JJ\1740 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 were\VBD\836236 prospectively\RB\1740 followed\VBN\1835496 for\IN\1740 15\CD\13745420 y.\NN\1740 RESULTS\NNS\34213 :\:\1740 After\IN\1740 adjustment\NN\7357388 for\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 type\NN\5839024 of\IN\1740 diabetes\NN\14075199 medication\NN\3247620 used\VBN\1156834 ,\,\1740 duration\NN\15113229 of\IN\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 and\CC\1740 intakes\NNS\13440063 of\IN\1740 folate\NN\15090742 ,\,\1740 vitamin\NN\7570720 E\NN\14724645 ,\,\1740 and\CC\1740 <e1>beta-carotene</e1>\NN\14720962 ,\,\1740 the\DT\1740 adjusted\VBN\126264 relative\JJ\1740 risks\NNS\14541044 of\IN\1740 total\JJ\1740 cardiovascular\JJ\1740 disease\NN\14061805 mortality\NN\5054863 were\VBD\836236 1.0\CD\1740 ,\,\1740 0.97\CD\1740 ,\,\1740 1.11\CD\1740 ,\,\1740 1.47\CD\1740 ,\,\1740 and\CC\1740 1.84\CD\1740 (\-LRB-\1740 P\NN\14622893 for\IN\1740 trend\NN\8679972 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 across\IN\1740 quintiles\NNS\1740 of\IN\1740 total\JJ\1740 vitamin\NN\7570720 C\NN\13714184 intake\NN\13440063 from\IN\1740 food\NN\20090 and\CC\1740 supplements\NNS\6365467 .\.\1740
16563323
C071741_D009207 NONE <e1>Remifentanil</e1>\NN\1740 pretreatment\NN\1740 reduces\VBZ\441445 <e2>myoclonus</e2>\NN\14360459 after\IN\1740 etomidate\NN\1740 .\.\1740
C071741_D009207 NONE STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 <e1>remifentanil</e1>\NN\1740 1\CD\13741022 microg/kg\NN\1740 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 gender\NN\6309383 on\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>myoclonus</e2>\NN\14360459 after\IN\1740 anesthesia\NN\14034177 induction\NN\7450842 with\IN\1740 etomidate\NN\1740 .\.\1740
C071741_D009207 NONE MAIN\JJ\1740 RESULTS\NNS\34213 :\:\1740 The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>myoclonus</e2>\NN\14360459 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 the\DT\1740 <e1>remifentanil</e1>\NN\1740 group\NN\2137 (\-LRB-\1740 6.7\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 (\-LRB-\1740 70\CD\13745420 %\NN\1740 )\-RRB-\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
C071741_D009207 NONE CONCLUSION\NN\5837957 :\:\1740 Pretreatment\NN\1740 with\IN\1740 <e1>remifentanil</e1>\NN\1740 1\CD\13741022 microg/kg\NN\1740 reduced\VBD\441445 <e2>myoclonus</e2>\NN\14360459 after\IN\1740 etomidate\NN\1740 induction\NN\7450842 without\IN\1740 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedation\NN\14034177 ,\,\1740 apnea\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 or\CC\3541091 pruritus\NN\5723563 .\.\1740
D005045_D009207 CID Remifentanil\NN\1740 pretreatment\NN\1740 reduces\VBZ\441445 <e2>myoclonus</e2>\NN\14360459 after\IN\1740 <e1>etomidate</e1>\NN\1740 .\.\1740
D005045_D009207 CID STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 remifentanil\NN\1740 1\CD\13741022 microg/kg\NN\1740 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 gender\NN\6309383 on\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>myoclonus</e2>\NN\14360459 after\IN\1740 anesthesia\NN\14034177 induction\NN\7450842 with\IN\1740 <e1>etomidate</e1>\NN\1740 .\.\1740
D005045_D009207 CID In\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 ,\,\1740 male\JJ\1740 patients\NNS\9898892 were\VBD\836236 associated\VBN\628491 with\IN\1740 significantly\RB\1740 increased\VBD\169651 incidence\NN\13821570 of\IN\1740 <e2>myoclonus</e2>\NN\14360459 after\IN\1740 <e1>etomidate</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D005045_D009207 CID CONCLUSION\NN\5837957 :\:\1740 Pretreatment\NN\1740 with\IN\1740 remifentanil\NN\1740 1\CD\13741022 microg/kg\NN\1740 reduced\VBD\441445 <e2>myoclonus</e2>\NN\14360459 after\IN\1740 <e1>etomidate</e1>\NN\1740 induction\NN\7450842 without\IN\1740 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedation\NN\14034177 ,\,\1740 apnea\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 or\CC\3541091 pruritus\NN\5723563 .\.\1740
D005045_D009207 CID Men\NN\8208016 experience\NN\5984287 increased\VBD\169651 incidence\NN\13821570 of\IN\1740 <e2>myoclonus</e2>\NN\14360459 than\IN\1740 women\NNS\9605289 after\IN\1740 <e1>etomidate</e1>\JJ\1740 administration\NN\1133281 .\.\1740
C071741_D001049 NONE CONCLUSION\NN\5837957 :\:\1740 Pretreatment\NN\1740 with\IN\1740 <e1>remifentanil</e1>\NN\1740 1\CD\13741022 microg/kg\NN\1740 reduced\VBD\441445 myoclonus\NN\14360459 after\IN\1740 etomidate\NN\1740 induction\NN\7450842 without\IN\1740 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedation\NN\14034177 ,\,\1740 <e2>apnea</e2>\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 or\CC\3541091 pruritus\NN\5723563 .\.\1740
C071741_D009325 NONE CONCLUSION\NN\5837957 :\:\1740 Pretreatment\NN\1740 with\IN\1740 <e1>remifentanil</e1>\NN\1740 1\CD\13741022 microg/kg\NN\1740 reduced\VBD\441445 myoclonus\NN\14360459 after\IN\1740 etomidate\NN\1740 induction\NN\7450842 without\IN\1740 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedation\NN\14034177 ,\,\1740 apnea\NN\14299637 ,\,\1740 <e2>nausea</e2>\NN\14299637 ,\,\1740 or\CC\3541091 pruritus\NN\5723563 .\.\1740
C071741_D011537 NONE CONCLUSION\NN\5837957 :\:\1740 Pretreatment\NN\1740 with\IN\1740 <e1>remifentanil</e1>\NN\1740 1\CD\13741022 microg/kg\NN\1740 reduced\VBD\441445 myoclonus\NN\14360459 after\IN\1740 etomidate\NN\1740 induction\NN\7450842 without\IN\1740 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedation\NN\14034177 ,\,\1740 apnea\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 or\CC\3541091 <e2>pruritus</e2>\NN\5723563 .\.\1740
D005045_D001049 NONE CONCLUSION\NN\5837957 :\:\1740 Pretreatment\NN\1740 with\IN\1740 remifentanil\NN\1740 1\CD\13741022 microg/kg\NN\1740 reduced\VBD\441445 myoclonus\NN\14360459 after\IN\1740 <e1>etomidate</e1>\NN\1740 induction\NN\7450842 without\IN\1740 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedation\NN\14034177 ,\,\1740 <e2>apnea</e2>\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 or\CC\3541091 pruritus\NN\5723563 .\.\1740
D005045_D009325 NONE CONCLUSION\NN\5837957 :\:\1740 Pretreatment\NN\1740 with\IN\1740 remifentanil\NN\1740 1\CD\13741022 microg/kg\NN\1740 reduced\VBD\441445 myoclonus\NN\14360459 after\IN\1740 <e1>etomidate</e1>\NN\1740 induction\NN\7450842 without\IN\1740 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedation\NN\14034177 ,\,\1740 apnea\NN\14299637 ,\,\1740 <e2>nausea</e2>\NN\14299637 ,\,\1740 or\CC\3541091 pruritus\NN\5723563 .\.\1740
D005045_D011537 NONE CONCLUSION\NN\5837957 :\:\1740 Pretreatment\NN\1740 with\IN\1740 remifentanil\NN\1740 1\CD\13741022 microg/kg\NN\1740 reduced\VBD\441445 myoclonus\NN\14360459 after\IN\1740 <e1>etomidate</e1>\NN\1740 induction\NN\7450842 without\IN\1740 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedation\NN\14034177 ,\,\1740 apnea\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 or\CC\3541091 <e2>pruritus</e2>\NN\5723563 .\.\1740
16584858
C013592_D009203 NONE Role\NN\719494 of\IN\1740 <e1>mangiferin</e1>\NN\1740 on\IN\1740 biochemical\JJ\1740 alterations\NNS\7283608 and\CC\1740 antioxidant\JJ\1740 status\NN\24720 in\IN\13603305 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
C013592_D009203 NONE The\DT\1740 current\JJ\1740 study\NN\635850 dealt\VBD\964911 with\IN\1740 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 <e1>mangiferin</e1>\NN\1740 ,\,\1740 a\DT\13649268 polyphenol\NN\1740 from\IN\1740 Mangifera\NNP\11567411 indica\NNP\1740 Linn\NNP\1740 .\.\1740 (\-LRB-\1740 Anacardiaceae\NN\11562747 )\-RRB-\1740 ,\,\1740 on\IN\1740 isoproterenol\NN\3740161 (ISPH)-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 through\IN\1740 its\PRP$\6125041 antioxidative\JJ\1740 mechanism\NN\13446390 .\.\1740
C013592_D009203 NONE The\DT\1740 current\JJ\1740 study\NN\635850 dealt\VBD\964911 with\IN\1740 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 <e1>mangiferin</e1>\NN\1740 ,\,\1740 a\DT\13649268 polyphenol\NN\1740 from\IN\1740 Mangifera\NNP\11567411 indica\NNP\1740 Linn\NNP\1740 .\.\1740 (\-LRB-\1740 Anacardiaceae\NN\11562747 )\-RRB-\1740 ,\,\1740 on\IN\1740 isoproterenol\NN\3740161 (ISPH)-induced\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>MI</e2>\NN\14207561 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 through\IN\1740 its\PRP$\6125041 antioxidative\JJ\1740 mechanism\NN\13446390 .\.\1740
C013592_D009203 NONE Upon\IN\1740 pretreatment\NN\1740 with\IN\1740 <e1>mangiferin</e1>\NN\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 suspended\VBN\1481360 in\IN\13603305 2\CD\13741022 ml\NN\13616054 of\IN\1740 dimethyl\JJ\1740 sulphoxide\NN\1740 )\-RRB-\1740 given\VBN\2327200 intraperitoneally\RB\1740 for\IN\1740 28\CD\13745420 days\NNS\15140892 to\TO\1740 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 protected\VBD\1127795 the\DT\1740 above-mentioned\JJ\1740 parameters\NNS\5858936 to\TO\1740 fall\VB\1835496 from\IN\1740 the\DT\1740 normal\JJ\1740 levels\NNS\4916342 .\.\1740
C013592_D009203 NONE Activities\NNS\30358 of\IN\1740 heart\NN\5919034 tissue\NN\5220461 enzymic\JJ\1740 antioxidants\NNS\14724436 and\CC\1740 serum\NN\5397468 non-enzymic\JJ\1740 antioxidants\NNS\14724436 levels\NNS\4916342 rose\VBD\1835496 significantly\RB\1740 upon\IN\1740 <e1>mangiferin</e1>\NN\1740 administration\NN\1133281 as\IN\14622893 compared\VBN\644583 to\TO\1740 ISPH-induced\JJ\1740 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 .\.\1740
C013592_D009203 NONE From\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 it\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 <e1>mangiferin</e1>\NN\1740 exerts\VBZ\1158872 a\DT\13649268 beneficial\JJ\1740 effect\NN\34213 against\IN\1740 ISPH-induced\JJ\1740 <e2>MI</e2>\NN\14207561 due\JJ\1740 to\TO\1740 its\PRP$\6125041 antioxidant\JJ\1740 potential\NN\14481929 ,\,\1740 which\WDT\1740 regulated\VBD\296178 the\DT\1740 tissues\NNS\5220461 defense\NN\952963 system\NN\3575240 against\IN\1740 cardiac\JJ\1740 damage\NN\7296428 .\.\1740
D007545_D009203 CID Role\NN\719494 of\IN\1740 mangiferin\NN\1740 on\IN\1740 biochemical\JJ\1740 alterations\NNS\7283608 and\CC\1740 antioxidant\JJ\1740 status\NN\24720 in\IN\13603305 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009203 CID The\DT\1740 current\JJ\1740 study\NN\635850 dealt\VBD\964911 with\IN\1740 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 mangiferin\NN\1740 ,\,\1740 a\DT\13649268 polyphenol\NN\1740 from\IN\1740 Mangifera\NNP\11567411 indica\NNP\1740 Linn\NNP\1740 .\.\1740 (\-LRB-\1740 Anacardiaceae\NN\11562747 )\-RRB-\1740 ,\,\1740 on\IN\1740 <e1>isoproterenol</e1>\NN\3740161 (ISPH)-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 through\IN\1740 its\PRP$\6125041 antioxidative\JJ\1740 mechanism\NN\13446390 .\.\1740
D007545_D009203 CID The\DT\1740 current\JJ\1740 study\NN\635850 dealt\VBD\964911 with\IN\1740 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 mangiferin\NN\1740 ,\,\1740 a\DT\13649268 polyphenol\NN\1740 from\IN\1740 Mangifera\NNP\11567411 indica\NNP\1740 Linn\NNP\1740 .\.\1740 (\-LRB-\1740 Anacardiaceae\NN\11562747 )\-RRB-\1740 ,\,\1740 on\IN\1740 <e1>isoproterenol</e1>\NN\3740161 (ISPH)-induced\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>MI</e2>\NN\14207561 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 through\IN\1740 its\PRP$\6125041 antioxidative\JJ\1740 mechanism\NN\13446390 .\.\1740
D007545_D009203 CID The\DT\1740 current\JJ\1740 study\NN\635850 dealt\VBD\964911 with\IN\1740 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 mangiferin\NN\1740 ,\,\1740 a\DT\13649268 polyphenol\NN\1740 from\IN\1740 Mangifera\NNP\11567411 indica\NNP\1740 Linn\NNP\1740 .\.\1740 (\-LRB-\1740 Anacardiaceae\NN\11562747 )\-RRB-\1740 ,\,\1740 on\IN\1740 isoproterenol\NN\3740161 <e1>(ISPH)-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 through\IN\1740 its\PRP$\6125041 antioxidative\JJ\1740 mechanism\NN\13446390 .\.\1740
D007545_D009203 CID The\DT\1740 current\JJ\1740 study\NN\635850 dealt\VBD\964911 with\IN\1740 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 mangiferin\NN\1740 ,\,\1740 a\DT\13649268 polyphenol\NN\1740 from\IN\1740 Mangifera\NNP\11567411 indica\NNP\1740 Linn\NNP\1740 .\.\1740 (\-LRB-\1740 Anacardiaceae\NN\11562747 )\-RRB-\1740 ,\,\1740 on\IN\1740 isoproterenol\NN\3740161 <e1>(ISPH)-induced</e1>\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>MI</e2>\NN\14207561 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 through\IN\1740 its\PRP$\6125041 antioxidative\JJ\1740 mechanism\NN\13446390 .\.\1740
D007545_D009203 CID Activities\NNS\30358 of\IN\1740 heart\NN\5919034 tissue\NN\5220461 enzymic\JJ\1740 antioxidants\NNS\14724436 and\CC\1740 serum\NN\5397468 non-enzymic\JJ\1740 antioxidants\NNS\14724436 levels\NNS\4916342 rose\VBD\1835496 significantly\RB\1740 upon\IN\1740 mangiferin\NN\1740 administration\NN\1133281 as\IN\14622893 compared\VBN\644583 to\TO\1740 <e1>ISPH-induced</e1>\JJ\1740 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 .\.\1740
D007545_D009203 CID From\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 it\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 mangiferin\NN\1740 exerts\VBZ\1158872 a\DT\13649268 beneficial\JJ\1740 effect\NN\34213 against\IN\1740 <e1>ISPH-induced</e1>\JJ\1740 <e2>MI</e2>\NN\14207561 due\JJ\1740 to\TO\1740 its\PRP$\6125041 antioxidant\JJ\1740 potential\NN\14481929 ,\,\1740 which\WDT\1740 regulated\VBD\296178 the\DT\1740 tissues\NNS\5220461 defense\NN\952963 system\NN\3575240 against\IN\1740 cardiac\JJ\1740 damage\NN\7296428 .\.\1740
D059808_D009203 NONE The\DT\1740 current\JJ\1740 study\NN\635850 dealt\VBD\964911 with\IN\1740 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 mangiferin\NN\1740 ,\,\1740 a\DT\13649268 <e1>polyphenol</e1>\NN\1740 from\IN\1740 Mangifera\NNP\11567411 indica\NNP\1740 Linn\NNP\1740 .\.\1740 (\-LRB-\1740 Anacardiaceae\NN\11562747 )\-RRB-\1740 ,\,\1740 on\IN\1740 isoproterenol\NN\3740161 (ISPH)-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 through\IN\1740 its\PRP$\6125041 antioxidative\JJ\1740 mechanism\NN\13446390 .\.\1740
D059808_D009203 NONE The\DT\1740 current\JJ\1740 study\NN\635850 dealt\VBD\964911 with\IN\1740 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 mangiferin\NN\1740 ,\,\1740 a\DT\13649268 <e1>polyphenol</e1>\NN\1740 from\IN\1740 Mangifera\NNP\11567411 indica\NNP\1740 Linn\NNP\1740 .\.\1740 (\-LRB-\1740 Anacardiaceae\NN\11562747 )\-RRB-\1740 ,\,\1740 on\IN\1740 isoproterenol\NN\3740161 (ISPH)-induced\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>MI</e2>\NN\14207561 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 through\IN\1740 its\PRP$\6125041 antioxidative\JJ\1740 mechanism\NN\13446390 .\.\1740
D007545_D009202 NONE Subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>ISPH</e1>\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 in\IN\13603305 1\CD\13741022 ml\NN\13616054 saline\NN\14849367 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 2\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 caused\VBD\1617192 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rat\NN\2329401 heart\NN\5919034 ,\,\1740 which\WDT\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 the\DT\1740 increased\VBN\169651 activity\NN\30358 of\IN\1740 serum\NN\5397468 lactate\NN\14850483 dehydrogenase\NN\1740 (\-LRB-\1740 LDH\NN\1740 )\-RRB-\1740 and\CC\1740 creatine\NN\14601829 phosphokinase\NN\1740 isoenzymes\NNS\1740 (\-LRB-\1740 CK-MB\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 uric\JJ\1740 acid\NN\14818238 level\NN\4916342 and\CC\1740 reduced\VBN\441445 plasma\NN\5398023 iron\NN\14625458 binding\NN\4688246 capacity\NN\5202497 .\.\1740
D019344_D009202 NONE Subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 ISPH\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 in\IN\13603305 1\CD\13741022 ml\NN\13616054 saline\NN\14849367 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 2\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 caused\VBD\1617192 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rat\NN\2329401 heart\NN\5919034 ,\,\1740 which\WDT\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 the\DT\1740 increased\VBN\169651 activity\NN\30358 of\IN\1740 serum\NN\5397468 <e1>lactate</e1>\NN\14850483 dehydrogenase\NN\1740 (\-LRB-\1740 LDH\NN\1740 )\-RRB-\1740 and\CC\1740 creatine\NN\14601829 phosphokinase\NN\1740 isoenzymes\NNS\1740 (\-LRB-\1740 CK-MB\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 uric\JJ\1740 acid\NN\14818238 level\NN\4916342 and\CC\1740 reduced\VBN\441445 plasma\NN\5398023 iron\NN\14625458 binding\NN\4688246 capacity\NN\5202497 .\.\1740
D003401_D009202 NONE Subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 ISPH\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 in\IN\13603305 1\CD\13741022 ml\NN\13616054 saline\NN\14849367 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 2\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 caused\VBD\1617192 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rat\NN\2329401 heart\NN\5919034 ,\,\1740 which\WDT\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 the\DT\1740 increased\VBN\169651 activity\NN\30358 of\IN\1740 serum\NN\5397468 lactate\NN\14850483 dehydrogenase\NN\1740 (\-LRB-\1740 LDH\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>creatine</e1>\NN\14601829 phosphokinase\NN\1740 isoenzymes\NNS\1740 (\-LRB-\1740 CK-MB\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 uric\JJ\1740 acid\NN\14818238 level\NN\4916342 and\CC\1740 reduced\VBN\441445 plasma\NN\5398023 iron\NN\14625458 binding\NN\4688246 capacity\NN\5202497 .\.\1740
D014527_D009202 NONE Subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 ISPH\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 in\IN\13603305 1\CD\13741022 ml\NN\13616054 saline\NN\14849367 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 2\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 caused\VBD\1617192 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rat\NN\2329401 heart\NN\5919034 ,\,\1740 which\WDT\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 the\DT\1740 increased\VBN\169651 activity\NN\30358 of\IN\1740 serum\NN\5397468 lactate\NN\14850483 dehydrogenase\NN\1740 (\-LRB-\1740 LDH\NN\1740 )\-RRB-\1740 and\CC\1740 creatine\NN\14601829 phosphokinase\NN\1740 isoenzymes\NNS\1740 (\-LRB-\1740 CK-MB\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 <e1>uric\JJ\1740 acid</e1>\NN\14818238 level\NN\4916342 and\CC\1740 reduced\VBN\441445 plasma\NN\5398023 iron\NN\14625458 binding\NN\4688246 capacity\NN\5202497 .\.\1740
D007501_D009202 NONE Subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 ISPH\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 in\IN\13603305 1\CD\13741022 ml\NN\13616054 saline\NN\14849367 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 2\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 caused\VBD\1617192 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rat\NN\2329401 heart\NN\5919034 ,\,\1740 which\WDT\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 the\DT\1740 increased\VBN\169651 activity\NN\30358 of\IN\1740 serum\NN\5397468 lactate\NN\14850483 dehydrogenase\NN\1740 (\-LRB-\1740 LDH\NN\1740 )\-RRB-\1740 and\CC\1740 creatine\NN\14601829 phosphokinase\NN\1740 isoenzymes\NNS\1740 (\-LRB-\1740 CK-MB\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 uric\JJ\1740 acid\NN\14818238 level\NN\4916342 and\CC\1740 reduced\VBN\441445 plasma\NN\5398023 <e1>iron</e1>\NN\14625458 binding\NN\4688246 capacity\NN\5202497 .\.\1740
C013592_D017202 NONE The\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 <e1>mangiferin</e1>\NN\1740 was\VBD\836236 analyzed\VBN\78760 by\IN\1740 triphenyl\NN\1740 tetrazolium\NN\1740 chloride\NN\14818238 (\-LRB-\1740 TTC\NN\1740 )\-RRB-\1740 test\VBP\670261 used\VBN\1156834 for\IN\1740 macroscopic\JJ\1740 enzyme\NN\14723628 mapping\NN\13783581 assay\NN\5733583 of\IN\1740 the\DT\1740 <e2>ischemic\JJ\1740 myocardium</e2>\NN\5389939 .\.\1740
C009591_D017202 NONE The\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 mangiferin\NN\1740 was\VBD\836236 analyzed\VBN\78760 by\IN\1740 <e1>triphenyl\NN\1740 tetrazolium\NN\1740 chloride</e1>\NN\14818238 (\-LRB-\1740 TTC\NN\1740 )\-RRB-\1740 test\VBP\670261 used\VBN\1156834 for\IN\1740 macroscopic\JJ\1740 enzyme\NN\14723628 mapping\NN\13783581 assay\NN\5733583 of\IN\1740 the\DT\1740 <e2>ischemic\JJ\1740 myocardium</e2>\NN\5389939 .\.\1740
C009591_D017202 NONE The\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 mangiferin\NN\1740 was\VBD\836236 analyzed\VBN\78760 by\IN\1740 triphenyl\NN\1740 tetrazolium\NN\1740 chloride\NN\14818238 (\-LRB-\1740 <e1>TTC</e1>\NN\1740 )\-RRB-\1740 test\VBP\670261 used\VBN\1156834 for\IN\1740 macroscopic\JJ\1740 enzyme\NN\14723628 mapping\NN\13783581 assay\NN\5733583 of\IN\1740 the\DT\1740 <e2>ischemic\JJ\1740 myocardium</e2>\NN\5389939 .\.\1740
D013481_D009203 NONE The\DT\1740 heart\NN\5919034 tissue\NN\5220461 antioxidant\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 <e1>superoxide</e1>\NN\14971519 dismutase\NN\1740 ,\,\1740 catalase\NN\14732946 ,\,\1740 glutathione\NN\1740 peroxidase\NN\14971234 ,\,\1740 glutathione\NN\1740 transferase\NN\14732946 and\CC\1740 glutathione\NN\1740 reductase\NN\14732946 activities\NNS\30358 ,\,\1740 non-enzymic\JJ\1740 antioxidants\NNS\14724436 such\JJ\1740 as\IN\14622893 cerruloplasmin\NN\1740 ,\,\1740 Vitamin\NN\7570720 C\NN\13714184 ,\,\1740 Vitamin\NN\7570720 E\NN\14724645 and\CC\1740 glutathione\NN\1740 levels\NNS\4916342 were\VBD\836236 altered\VBN\126264 in\IN\13603305 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 .\.\1740
D005978_D009203 NONE The\DT\1740 heart\NN\5919034 tissue\NN\5220461 antioxidant\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 superoxide\NN\14971519 dismutase\NN\1740 ,\,\1740 catalase\NN\14732946 ,\,\1740 <e1>glutathione</e1>\NN\1740 peroxidase\NN\14971234 ,\,\1740 glutathione\NN\1740 transferase\NN\14732946 and\CC\1740 glutathione\NN\1740 reductase\NN\14732946 activities\NNS\30358 ,\,\1740 non-enzymic\JJ\1740 antioxidants\NNS\14724436 such\JJ\1740 as\IN\14622893 cerruloplasmin\NN\1740 ,\,\1740 Vitamin\NN\7570720 C\NN\13714184 ,\,\1740 Vitamin\NN\7570720 E\NN\14724645 and\CC\1740 glutathione\NN\1740 levels\NNS\4916342 were\VBD\836236 altered\VBN\126264 in\IN\13603305 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 .\.\1740
D005978_D009203 NONE The\DT\1740 heart\NN\5919034 tissue\NN\5220461 antioxidant\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 superoxide\NN\14971519 dismutase\NN\1740 ,\,\1740 catalase\NN\14732946 ,\,\1740 glutathione\NN\1740 peroxidase\NN\14971234 ,\,\1740 <e1>glutathione</e1>\NN\1740 transferase\NN\14732946 and\CC\1740 glutathione\NN\1740 reductase\NN\14732946 activities\NNS\30358 ,\,\1740 non-enzymic\JJ\1740 antioxidants\NNS\14724436 such\JJ\1740 as\IN\14622893 cerruloplasmin\NN\1740 ,\,\1740 Vitamin\NN\7570720 C\NN\13714184 ,\,\1740 Vitamin\NN\7570720 E\NN\14724645 and\CC\1740 glutathione\NN\1740 levels\NNS\4916342 were\VBD\836236 altered\VBN\126264 in\IN\13603305 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 .\.\1740
D005978_D009203 NONE The\DT\1740 heart\NN\5919034 tissue\NN\5220461 antioxidant\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 superoxide\NN\14971519 dismutase\NN\1740 ,\,\1740 catalase\NN\14732946 ,\,\1740 glutathione\NN\1740 peroxidase\NN\14971234 ,\,\1740 glutathione\NN\1740 transferase\NN\14732946 and\CC\1740 <e1>glutathione</e1>\NN\1740 reductase\NN\14732946 activities\NNS\30358 ,\,\1740 non-enzymic\JJ\1740 antioxidants\NNS\14724436 such\JJ\1740 as\IN\14622893 cerruloplasmin\NN\1740 ,\,\1740 Vitamin\NN\7570720 C\NN\13714184 ,\,\1740 Vitamin\NN\7570720 E\NN\14724645 and\CC\1740 glutathione\NN\1740 levels\NNS\4916342 were\VBD\836236 altered\VBN\126264 in\IN\13603305 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 .\.\1740
D005978_D009203 NONE The\DT\1740 heart\NN\5919034 tissue\NN\5220461 antioxidant\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 superoxide\NN\14971519 dismutase\NN\1740 ,\,\1740 catalase\NN\14732946 ,\,\1740 glutathione\NN\1740 peroxidase\NN\14971234 ,\,\1740 glutathione\NN\1740 transferase\NN\14732946 and\CC\1740 glutathione\NN\1740 reductase\NN\14732946 activities\NNS\30358 ,\,\1740 non-enzymic\JJ\1740 antioxidants\NNS\14724436 such\JJ\1740 as\IN\14622893 cerruloplasmin\NN\1740 ,\,\1740 Vitamin\NN\7570720 C\NN\13714184 ,\,\1740 Vitamin\NN\7570720 E\NN\14724645 and\CC\1740 <e1>glutathione</e1>\NN\1740 levels\NNS\4916342 were\VBD\836236 altered\VBN\126264 in\IN\13603305 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 .\.\1740
D001205_D009203 NONE The\DT\1740 heart\NN\5919034 tissue\NN\5220461 antioxidant\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 superoxide\NN\14971519 dismutase\NN\1740 ,\,\1740 catalase\NN\14732946 ,\,\1740 glutathione\NN\1740 peroxidase\NN\14971234 ,\,\1740 glutathione\NN\1740 transferase\NN\14732946 and\CC\1740 glutathione\NN\1740 reductase\NN\14732946 activities\NNS\30358 ,\,\1740 non-enzymic\JJ\1740 antioxidants\NNS\14724436 such\JJ\1740 as\IN\14622893 cerruloplasmin\NN\1740 ,\,\1740 <e1>Vitamin\NN\7570720 C</e1>\NN\13714184 ,\,\1740 Vitamin\NN\7570720 E\NN\14724645 and\CC\1740 glutathione\NN\1740 levels\NNS\4916342 were\VBD\836236 altered\VBN\126264 in\IN\13603305 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 .\.\1740
D014810_D009203 NONE The\DT\1740 heart\NN\5919034 tissue\NN\5220461 antioxidant\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 superoxide\NN\14971519 dismutase\NN\1740 ,\,\1740 catalase\NN\14732946 ,\,\1740 glutathione\NN\1740 peroxidase\NN\14971234 ,\,\1740 glutathione\NN\1740 transferase\NN\14732946 and\CC\1740 glutathione\NN\1740 reductase\NN\14732946 activities\NNS\30358 ,\,\1740 non-enzymic\JJ\1740 antioxidants\NNS\14724436 such\JJ\1740 as\IN\14622893 cerruloplasmin\NN\1740 ,\,\1740 Vitamin\NN\7570720 C\NN\13714184 ,\,\1740 <e1>Vitamin\NN\7570720 E</e1>\NN\14724645 and\CC\1740 glutathione\NN\1740 levels\NNS\4916342 were\VBD\836236 altered\VBN\126264 in\IN\13603305 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 .\.\1740
D004121_D009203 NONE Upon\IN\1740 pretreatment\NN\1740 with\IN\1740 mangiferin\NN\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 suspended\VBN\1481360 in\IN\13603305 2\CD\13741022 ml\NN\13616054 of\IN\1740 <e1>dimethyl\JJ\1740 sulphoxide</e1>\NN\1740 )\-RRB-\1740 given\VBN\2327200 intraperitoneally\RB\1740 for\IN\1740 28\CD\13745420 days\NNS\15140892 to\TO\1740 <e2>MI</e2>\NN\14207561 rats\NNS\2329401 protected\VBD\1127795 the\DT\1740 above-mentioned\JJ\1740 parameters\NNS\5858936 to\TO\1740 fall\VB\1835496 from\IN\1740 the\DT\1740 normal\JJ\1740 levels\NNS\4916342 .\.\1740
C013592_D006331 NONE From\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 it\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 <e1>mangiferin</e1>\NN\1740 exerts\VBZ\1158872 a\DT\13649268 beneficial\JJ\1740 effect\NN\34213 against\IN\1740 ISPH-induced\JJ\1740 MI\NN\14207561 due\JJ\1740 to\TO\1740 its\PRP$\6125041 antioxidant\JJ\1740 potential\NN\14481929 ,\,\1740 which\WDT\1740 regulated\VBD\296178 the\DT\1740 tissues\NNS\5220461 defense\NN\952963 system\NN\3575240 against\IN\1740 <e2>cardiac\JJ\1740 damage</e2>\NN\7296428 .\.\1740
D007545_D006331 NONE From\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 it\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 mangiferin\NN\1740 exerts\VBZ\1158872 a\DT\13649268 beneficial\JJ\1740 effect\NN\34213 against\IN\1740 <e1>ISPH-induced</e1>\JJ\1740 MI\NN\14207561 due\JJ\1740 to\TO\1740 its\PRP$\6125041 antioxidant\JJ\1740 potential\NN\14481929 ,\,\1740 which\WDT\1740 regulated\VBD\296178 the\DT\1740 tissues\NNS\5220461 defense\NN\952963 system\NN\3575240 against\IN\1740 <e2>cardiac\JJ\1740 damage</e2>\NN\7296428 .\.\1740
2004
D013881_D017180 CID Although\IN\1740 most\JJS\1740 patients\NNS\9898892 were\VBD\836236 receiving\VBG\2210855 several\JJ\1740 drugs\NNS\14778436 ,\,\1740 <e1>Mellaril</e1>\NNP\3713736 (\-LRB-\1740 thioridazine\NN\3713736 )\-RRB-\1740 appeared\VBD\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 five\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 ,\,\1740 one\CD\13741022 of\IN\1740 which\WDT\1740 was\VBD\836236 fatal\JJ\1740 in\IN\13603305 a\DT\13649268 35\CD\1740 year\NN\15113229 old\JJ\1740 woman\NN\9605289 .\.\1740
D013881_D017180 CID Although\IN\1740 most\JJS\1740 patients\NNS\9898892 were\VBD\836236 receiving\VBG\2210855 several\JJ\1740 drugs\NNS\14778436 ,\,\1740 Mellaril\NNP\3713736 (\-LRB-\1740 <e1>thioridazine</e1>\NN\3713736 )\-RRB-\1740 appeared\VBD\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 five\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 ,\,\1740 one\CD\13741022 of\IN\1740 which\WDT\1740 was\VBD\836236 fatal\JJ\1740 in\IN\13603305 a\DT\13649268 35\CD\1740 year\NN\15113229 old\JJ\1740 woman\NN\9605289 .\.\1740
D002746_D013617 NONE <e2>Supraventricular\JJ\1740 tachycardia</e2>\NN\14110674 developed\VBD\1753788 in\IN\13603305 one\CD\13741022 patient\NN\9898892 receiving\VBG\2210855 <e1>Thorazine</e1>\NN\3713736 (\-LRB-\1740 chlorpromazine\NN\3713736 )\-RRB-\1740 .\.\1740
D002746_D013617 NONE <e2>Supraventricular\JJ\1740 tachycardia</e2>\NN\14110674 developed\VBD\1753788 in\IN\13603305 one\CD\13741022 patient\NN\9898892 receiving\VBG\2210855 Thorazine\NN\3713736 (\-LRB-\1740 <e1>chlorpromazine</e1>\NN\3713736 )\-RRB-\1740 .\.\1740
D009661_D002037 CID <e1>Aventyl</e1>\NN\1740 (\-LRB-\1740 nortriptyline\NN\4482543 )\-RRB-\1740 and\CC\1740 Elavil\NN\4482543 (\-LRB-\1740 amitriptyline\NN\4482543 )\-RRB-\1740 each\DT\1740 produced\VBD\1617192 <e2>left\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block</e2>\NN\21939 in\IN\13603305 a\DT\13649268 73\CD\1740 year\NN\15113229 old\JJ\1740 woman\NN\9605289 .\.\1740
D009661_D002037 CID Aventyl\NN\1740 (\-LRB-\1740 <e1>nortriptyline</e1>\NN\4482543 )\-RRB-\1740 and\CC\1740 Elavil\NN\4482543 (\-LRB-\1740 amitriptyline\NN\4482543 )\-RRB-\1740 each\DT\1740 produced\VBD\1617192 <e2>left\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block</e2>\NN\21939 in\IN\13603305 a\DT\13649268 73\CD\1740 year\NN\15113229 old\JJ\1740 woman\NN\9605289 .\.\1740
D000639_D002037 CID Aventyl\NN\1740 (\-LRB-\1740 nortriptyline\NN\4482543 )\-RRB-\1740 and\CC\1740 <e1>Elavil</e1>\NN\4482543 (\-LRB-\1740 amitriptyline\NN\4482543 )\-RRB-\1740 each\DT\1740 produced\VBD\1617192 <e2>left\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block</e2>\NN\21939 in\IN\13603305 a\DT\13649268 73\CD\1740 year\NN\15113229 old\JJ\1740 woman\NN\9605289 .\.\1740
D000639_D002037 CID Aventyl\NN\1740 (\-LRB-\1740 nortriptyline\NN\4482543 )\-RRB-\1740 and\CC\1740 Elavil\NN\4482543 (\-LRB-\1740 <e1>amitriptyline</e1>\NN\4482543 )\-RRB-\1740 each\DT\1740 produced\VBD\1617192 <e2>left\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block</e2>\NN\21939 in\IN\13603305 a\DT\13649268 73\CD\1740 year\NN\15113229 old\JJ\1740 woman\NN\9605289 .\.\1740
D008012_D001145 NONE The\DT\1740 <e2>ventricular\NN\1740 arrhythmias</e2>\NNS\14103288 responded\VBD\2367363 to\TO\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 and\CC\1740 to\TO\1740 direct\JJ\1740 current\JJ\1740 electric\JJ\1740 shock\NN\7510495 ;\:\1740 ventricular\JJ\1740 pacing\NN\15122011 was\VBD\836236 required\VBN\754942 in\IN\13603305 some\DT\1740 instances\NNS\7283608 and\CC\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 propranolol\NN\1740 combined\VBN\2630189 with\IN\1740 ventricular\JJ\1740 pacing\NN\15122011 in\IN\13603305 one\CD\13741022 .\.\1740
D011433_D001145 NONE The\DT\1740 <e2>ventricular\NN\1740 arrhythmias</e2>\NNS\14103288 responded\VBD\2367363 to\TO\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 and\CC\1740 to\TO\1740 direct\JJ\1740 current\JJ\1740 electric\JJ\1740 shock\NN\7510495 ;\:\1740 ventricular\JJ\1740 pacing\NN\15122011 was\VBD\836236 required\VBN\754942 in\IN\13603305 some\DT\1740 instances\NNS\7283608 and\CC\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>propranolol</e1>\NN\1740 combined\VBN\2630189 with\IN\1740 ventricular\JJ\1740 pacing\NN\15122011 in\IN\13603305 one\CD\13741022 .\.\1740
D010640_D005117 NONE A\DT\13649268 prospective\JJ\1740 clinical\JJ\1740 trial\NN\786195 is\VBZ\836236 suggested\VBN\1010118 to\TO\1740 quantify\VB\947077 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>cardiac\JJ\1740 complications</e2>\NNS\1073995 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>phenothiazines</e1>\NNS\14771088 or\CC\3541091 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 .\.\1740
12745515
D016642_D012640 CID <e2>Seizure</e2>\NNP\14081375 associated\VBN\628491 with\IN\1740 sleep\NN\14034177 deprivation\NN\14493145 and\CC\1740 sustained-release\JJ\1740 <e1>bupropion</e1>\NN\1740 .\.\1740
D016642_D012640 CID This\DT\1740 case\NN\7283608 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 generalized\VBN\634472 <e2>seizure</e2>\NN\14081375 associated\VBN\628491 with\IN\1740 sustained-release\JJ\1740 <e1>bupropion</e1>\NN\1740 use\NN\407535 and\CC\1740 sleep\NN\14034177 deprivation\NN\14493145 .\.\1740
D016642_D012640 CID After\IN\1740 5\CD\13741022 weeks\NNS\15113229 of\IN\1740 <e1>bupropion</e1>\NN\1740 use\NN\407535 ,\,\1740 the\DT\1740 subject\NN\6598915 experienced\VBD\2108377 a\DT\13649268 generalized\JJ\1740 tonic\JJ\1740 clonic\NN\1740 <e2>seizure</e2>\NN\14081375 after\IN\1740 staying\VBG\2604760 up\RP\1740 nearly\RB\1740 all\DT\1740 night\NN\15113229 packing\VBG\1486312 and\CC\1740 moving\VBG\2367363 to\IN\1740 a\DT\13649268 new\JJ\1740 residence\NN\8491027 .\.\1740
D016642_D012640 CID We\PRP\1740 suggest\VBP\1010118 that\IN\1740 sleep\NN\14034177 deprivation\NN\14493145 may\MD\15209706 add\VB\156601 to\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e1>bupropion-associated</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D016642_D012892 NONE Seizure\NNP\14081375 associated\VBN\628491 with\IN\1740 <e2>sleep\NN\14034177 deprivation</e2>\NN\14493145 and\CC\1740 sustained-release\JJ\1740 <e1>bupropion</e1>\NN\1740 .\.\1740
D016642_D012892 NONE This\DT\1740 case\NN\7283608 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 generalized\VBN\634472 seizure\NN\14081375 associated\VBN\628491 with\IN\1740 sustained-release\JJ\1740 <e1>bupropion</e1>\NN\1740 use\NN\407535 and\CC\1740 <e2>sleep\NN\14034177 deprivation</e2>\NN\14493145 .\.\1740
D016642_D012892 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 <e2>sleep\NN\14034177 deprivation</e2>\NN\14493145 may\MD\15209706 add\VB\156601 to\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e1>bupropion-associated</e1>\JJ\1740 seizures\NNS\14081375 .\.\1740
3708922
D016572_D007674 CID Experimental\JJ\1740 <e1>cyclosporine</e1>\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 risk\NN\14541044 of\IN\1740 concomitant\JJ\1740 chemotherapy\NN\661091 .\.\1740
D016572_D007674 CID The\DT\1740 role\NN\719494 of\IN\1740 <e1>cyclosporine</e1>\NN\1740 (\-LRB-\1740 CSA\NN\1740 )\-RRB-\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 various\JJ\1740 chemotherapeutics\NNS\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>renal\JJ\1740 toxicity</e2>\NN\13576101 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 rats\NNS\2329401 .\.\1740
D016572_D007674 CID The\DT\1740 role\NN\719494 of\IN\1740 cyclosporine\NN\1740 (\-LRB-\1740 <e1>CSA</e1>\NN\1740 )\-RRB-\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 various\JJ\1740 chemotherapeutics\NNS\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>renal\JJ\1740 toxicity</e2>\NN\13576101 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 rats\NNS\2329401 .\.\1740
D016572_D007674 CID The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>CSA</e1>\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 <e2>nephrotoxic</e2>\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 gentamicin\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 amphothericin\NN\1740 B\NN\1355326 and\CC\1740 ketoconazole\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 CSA\NN\1740 induced\JJ\1740 toxicity\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D016572_D007674 CID The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 CSA\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 <e2>nephrotoxic</e2>\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 gentamicin\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 amphothericin\NN\1740 B\NN\1355326 and\CC\1740 ketoconazole\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 <e1>CSA</e1>\NN\1740 induced\JJ\1740 toxicity\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D016572_D007674 CID Gentamicin\NN\2716866 at\IN\14622893 toxic\JJ\1740 doses\NNS\3740161 ,\,\1740 however\RB\1740 ,\,\1740 increased\VBN\169651 <e1>CSA</e1>\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D016572_D007674 CID Thus\RB\1740 ,\,\1740 the\DT\1740 <e2>nephrotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>CSA</e1>\NN\1740 has\VBZ\2108377 a\DT\13649268 different\JJ\1740 pathogenetic\JJ\1740 mechanism\NN\13446390 .\.\1740
D016572_D064420 NONE The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>CSA</e1>\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 nephrotoxic\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 gentamicin\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 amphothericin\NN\1740 B\NN\1355326 and\CC\1740 ketoconazole\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 CSA\NN\1740 induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D016572_D064420 NONE The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 CSA\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 nephrotoxic\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 gentamicin\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 amphothericin\NN\1740 B\NN\1355326 and\CC\1740 ketoconazole\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 <e1>CSA</e1>\NN\1740 induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D005839_D007674 NONE The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 CSA\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 <e2>nephrotoxic</e2>\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 <e1>gentamicin</e1>\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 amphothericin\NN\1740 B\NN\1355326 and\CC\1740 ketoconazole\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 CSA\NN\1740 induced\JJ\1740 toxicity\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D005839_D007674 NONE <e1>Gentamicin</e1>\NN\2716866 at\IN\14622893 toxic\JJ\1740 doses\NNS\3740161 ,\,\1740 however\RB\1740 ,\,\1740 increased\VBN\169651 CSA\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D005839_D064420 NONE The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 CSA\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 nephrotoxic\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 <e1>gentamicin</e1>\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 amphothericin\NN\1740 B\NN\1355326 and\CC\1740 ketoconazole\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 CSA\NN\1740 induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D000666_D007674 NONE The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 CSA\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 <e2>nephrotoxic</e2>\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 gentamicin\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 <e1>amphothericin\NN\1740 B</e1>\NN\1355326 and\CC\1740 ketoconazole\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 CSA\NN\1740 induced\JJ\1740 toxicity\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D000666_D064420 NONE The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 CSA\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 nephrotoxic\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 gentamicin\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 <e1>amphothericin\NN\1740 B</e1>\NN\1355326 and\CC\1740 ketoconazole\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 CSA\NN\1740 induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D007654_D007674 NONE The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 CSA\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 <e2>nephrotoxic</e2>\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 gentamicin\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 amphothericin\NN\1740 B\NN\1355326 and\CC\1740 <e1>ketoconazole</e1>\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 CSA\NN\1740 induced\JJ\1740 toxicity\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D007654_D064420 NONE The\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 CSA\NN\1740 and\CC\1740 various\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 with\IN\1740 a\DT\13649268 nephrotoxic\JJ\1740 potential\NN\14481929 ,\,\1740 such\JJ\1740 as\IN\14622893 gentamicin\NN\2716866 (\-LRB-\1740 at\IN\14622893 therapeutic\JJ\1740 doses\NNS\3740161 )\-RRB-\1740 ,\,\1740 amphothericin\NN\1740 B\NN\1355326 and\CC\1740 <e1>ketoconazole</e1>\NN\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 frequently\RB\1740 used\VBN\1156834 in\IN\13603305 immunosuppressed\JJ\1740 patients\NNS\9898892 ,\,\1740 did\VBD\1640855 not\RB\1740 aggravate\VB\126264 the\DT\1740 CSA\NN\1740 induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
15266215
C406224_D013927 NONE Effects\NNS\13245626 of\IN\1740 the\DT\1740 cyclooxygenase-2\NN\14737847 specific\JJ\1740 inhibitor\NN\20090 <e1>valdecoxib</e1>\NN\3124700 versus\CC\1740 nonsteroidal\JJ\1740 antiinflammatory\JJ\1740 agents\NNS\7347 and\CC\1740 placebo\VB\1740 on\IN\1740 cardiovascular\JJ\1740 <e2>thrombotic</e2>\JJ\1740 events\NNS\23100 in\IN\13603305 patients\NNS\9898892 with\IN\1740 arthritis\NN\14171682 .\.\1740
C406224_D013927 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 <e2>thrombotic</e2>\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 <e1>valdecoxib</e1>\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
C406224_D013927 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 <e2>thrombotic</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 <e1>valdecoxib</e1>\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
C406224_D013927 NONE Crude\NN\14686352 and\CC\1740 exposure-adjusted\JJ\1740 incidences\NNS\13821570 of\IN\1740 <e2>thrombotic</e2>\JJ\1740 events\NNS\23100 were\VBD\836236 similar\JJ\1740 for\IN\1740 <e1>valdecoxib</e1>\NN\3124700 ,\,\1740 NSAIDs\NNS\2721538 ,\,\1740 and\CC\1740 placebo\NN\3740161 .\.\1740
C406224_D013927 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>thrombotic</e2>\JJ\1740 events\NNS\23100 was\VBD\836236 also\RB\1740 similar\JJ\1740 for\IN\1740 each\DT\1740 <e1>valdecoxib</e1>\NN\3124700 dose\NN\3740161 .\.\1740
C406224_D013927 NONE <e2>Thrombotic</e2>\JJ\1740 risk\NN\14541044 was\VBD\836236 consistently\RB\1740 higher\JJR\1740 for\IN\1740 users\NNS\7846 of\IN\1740 aspirin\NN\2707683 users\NNS\7846 than\IN\1740 nonusers\NNS\1740 of\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 placebo\NN\3740161 ,\,\1740 1.4\CD\1740 %\NN\1740 vs.\CC\1740 0\CD\13741022 %\NN\1740 ;\:\1740 <e1>valdecoxib</e1>\NN\3124700 ,\,\1740 1.7\CD\1740 %\NN\1740 vs.\CC\1740 0.2\CD\1740 %\NN\1740 ;\:\1740 NSAIDs\NNS\2721538 ,\,\1740 1.9\CD\1740 %\NN\1740 vs.\CC\1740 0.5\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C406224_D013927 NONE Short-\NN\1740 and\CC\1740 intermediate-term\JJ\1740 treatment\NN\654885 with\IN\1740 therapeutic\JJ\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 and\CC\1740 supratherapeutic\JJ\1740 (\-LRB-\1740 40\CD\13745420 or\CC\3541091 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 <e1>valdecoxib</e1>\NN\3124700 doses\NNS\3740161 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 <e2>thrombotic</e2>\JJ\1740 events\NNS\23100 relative\JJ\1740 to\TO\1740 nonselective\JJ\1740 NSAIDs\NNS\2721538 or\CC\3541091 placebo\NN\3740161 in\IN\13603305 osteoarthritis\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 patients\NNS\9898892 in\IN\13603305 controlled\VBN\2422663 clinical\JJ\1740 trials\NNS\786195 .\.\1740
C406224_D001168 NONE Effects\NNS\13245626 of\IN\1740 the\DT\1740 cyclooxygenase-2\NN\14737847 specific\JJ\1740 inhibitor\NN\20090 <e1>valdecoxib</e1>\NN\3124700 versus\CC\1740 nonsteroidal\JJ\1740 antiinflammatory\JJ\1740 agents\NNS\7347 and\CC\1740 placebo\VB\1740 on\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>arthritis</e2>\NN\14171682 .\.\1740
C406224_D010003 NONE We\PRP\1740 evaluated\VBD\670261 cardiovascular\JJ\1740 event\NN\23100 data\NNS\7951464 for\IN\1740 <e1>valdecoxib</e1>\NN\3124700 ,\,\1740 a\DT\13649268 new\JJ\1740 COX-2-specific\JJ\1740 inhibitor\NN\20090 in\IN\13603305 approximately\RB\1740 8000\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>osteoarthritis</e2>\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 treated\VBN\2376958 with\IN\1740 this\DT\1740 agent\NN\7347 in\IN\13603305 randomized\VBN\278117 clinical\JJ\1740 trials\NNS\786195 .\.\1740
C406224_D010003 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 <e1>valdecoxib</e1>\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 <e2>osteoarthritis</e2>\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
C406224_D010003 NONE Short-\NN\1740 and\CC\1740 intermediate-term\JJ\1740 treatment\NN\654885 with\IN\1740 therapeutic\JJ\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 and\CC\1740 supratherapeutic\JJ\1740 (\-LRB-\1740 40\CD\13745420 or\CC\3541091 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 <e1>valdecoxib</e1>\NN\3124700 doses\NNS\3740161 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 thrombotic\JJ\1740 events\NNS\23100 relative\JJ\1740 to\TO\1740 nonselective\JJ\1740 NSAIDs\NNS\2721538 or\CC\3541091 placebo\NN\3740161 in\IN\13603305 <e2>osteoarthritis</e2>\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 patients\NNS\9898892 in\IN\13603305 controlled\VBN\2422663 clinical\JJ\1740 trials\NNS\786195 .\.\1740
C406224_D001172 NONE We\PRP\1740 evaluated\VBD\670261 cardiovascular\JJ\1740 event\NN\23100 data\NNS\7951464 for\IN\1740 <e1>valdecoxib</e1>\NN\3124700 ,\,\1740 a\DT\13649268 new\JJ\1740 COX-2-specific\JJ\1740 inhibitor\NN\20090 in\IN\13603305 approximately\RB\1740 8000\CD\1740 patients\NNS\9898892 with\IN\1740 osteoarthritis\NN\14186541 and\CC\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 treated\VBN\2376958 with\IN\1740 this\DT\1740 agent\NN\7347 in\IN\13603305 randomized\VBN\278117 clinical\JJ\1740 trials\NNS\786195 .\.\1740
C406224_D001172 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 <e1>valdecoxib</e1>\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
C406224_D001172 NONE Short-\NN\1740 and\CC\1740 intermediate-term\JJ\1740 treatment\NN\654885 with\IN\1740 therapeutic\JJ\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 and\CC\1740 supratherapeutic\JJ\1740 (\-LRB-\1740 40\CD\13745420 or\CC\3541091 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 <e1>valdecoxib</e1>\NN\3124700 doses\NNS\3740161 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 thrombotic\JJ\1740 events\NNS\23100 relative\JJ\1740 to\TO\1740 nonselective\JJ\1740 NSAIDs\NNS\2721538 or\CC\3541091 placebo\NN\3740161 in\IN\13603305 osteoarthritis\NN\14186541 and\CC\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 patients\NNS\9898892 in\IN\13603305 controlled\VBN\2422663 clinical\JJ\1740 trials\NNS\786195 .\.\1740
D004008_D013927 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 <e2>thrombotic</e2>\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 <e1>diclofenac</e1>\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D004008_D013927 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 <e2>thrombotic</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 <e1>diclofenac</e1>\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D004008_D010003 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 <e1>diclofenac</e1>\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 <e2>osteoarthritis</e2>\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D004008_D001172 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 <e1>diclofenac</e1>\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D007052_D013927 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 <e2>thrombotic</e2>\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 <e1>ibuprofen</e1>\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D007052_D013927 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 <e2>thrombotic</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 <e1>ibuprofen</e1>\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D007052_D010003 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 <e1>ibuprofen</e1>\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 <e2>osteoarthritis</e2>\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D007052_D001172 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 <e1>ibuprofen</e1>\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 naproxen\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D009288_D013927 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 <e2>thrombotic</e2>\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 <e1>naproxen</e1>\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D009288_D013927 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 <e2>thrombotic</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 <e1>naproxen</e1>\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D009288_D010003 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 <e1>naproxen</e1>\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 <e2>osteoarthritis</e2>\NN\14186541 and\CC\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D009288_D001172 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 cardiovascular\JJ\1740 thrombotic\JJ\1740 events\NNS\23100 (\-LRB-\1740 cardiac\FW\1740 ,\,\1740 cerebrovascular\JJ\1740 and\CC\1740 peripheral\JJ\1740 vascular\JJ\1740 ,\,\1740 or\CC\3541091 arterial\JJ\1740 thrombotic\NN\1740 )\-RRB-\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 analyzing\VBG\78760 pooled\JJ\1740 valdecoxib\NN\3124700 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 80\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 ,\,\1740 nonselective\JJ\1740 NSAID\NN\2721538 (\-LRB-\1740 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 bid\NN\7160883 ,\,\1740 ibuprofen\NN\3828465 800\CD\1740 mg\NN\13717155 tid\NN\1740 ,\,\1740 or\CC\3541091 <e1>naproxen</e1>\NN\3828465 500\CD\13745420 mg\NN\13717155 bid\VBN\897241 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 data\NNS\7951464 from\IN\1740 10\CD\13745420 randomized\JJ\1740 osteoarthritis\NN\14186541 and\CC\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 trials\NNS\786195 that\WDT\1740 were\VBD\836236 6\CD\13741022 -\SYM\1740 52\CD\1740 weeks\NNS\15113229 in\IN\13603305 duration\NN\15113229 .\.\1740
D001241_D013927 CID <e2>Thrombotic</e2>\JJ\1740 risk\NN\14541044 was\VBD\836236 consistently\RB\1740 higher\JJR\1740 for\IN\1740 users\NNS\7846 of\IN\1740 <e1>aspirin</e1>\NN\2707683 users\NNS\7846 than\IN\1740 nonusers\NNS\1740 of\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 placebo\NN\3740161 ,\,\1740 1.4\CD\1740 %\NN\1740 vs.\CC\1740 0\CD\13741022 %\NN\1740 ;\:\1740 valdecoxib\NN\3124700 ,\,\1740 1.7\CD\1740 %\NN\1740 vs.\CC\1740 0.2\CD\1740 %\NN\1740 ;\:\1740 NSAIDs\NNS\2721538 ,\,\1740 1.9\CD\1740 %\NN\1740 vs.\CC\1740 0.5\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D001241_D013927 CID <e2>Thrombotic</e2>\JJ\1740 risk\NN\14541044 was\VBD\836236 consistently\RB\1740 higher\JJR\1740 for\IN\1740 users\NNS\7846 of\IN\1740 aspirin\NN\2707683 users\NNS\7846 than\IN\1740 nonusers\NNS\1740 of\IN\1740 <e1>aspirin</e1>\NN\2707683 (\-LRB-\1740 placebo\NN\3740161 ,\,\1740 1.4\CD\1740 %\NN\1740 vs.\CC\1740 0\CD\13741022 %\NN\1740 ;\:\1740 valdecoxib\NN\3124700 ,\,\1740 1.7\CD\1740 %\NN\1740 vs.\CC\1740 0.2\CD\1740 %\NN\1740 ;\:\1740 NSAIDs\NNS\2721538 ,\,\1740 1.9\CD\1740 %\NN\1740 vs.\CC\1740 0.5\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
3311455
D016572_D007674 CID Group\NN\2137 II\CD\13741022 also\RB\1740 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 of\IN\1740 chronic\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 secondary\JJ\1740 to\TO\1740 long-term\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>cyclosporine</e1>\NN\1740 .\.\1740
D016572_D007674 CID We\PRP\1740 think\VBP\670261 that\IN\1740 even\RB\1740 these\DT\1740 lower\JJR\1740 dosages\NNS\13576355 of\IN\1740 <e1>cyclosporine</e1>\NN\1740 can\MD\3094503 cause\VB\1617192 chronic\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 that\IN\1740 further\JJ\1740 modification\NN\191142 of\IN\1740 the\DT\1740 immunosuppressive\JJ\1740 regimen\NN\5898568 is\VBZ\836236 required\VBN\754942 to\TO\1740 completely\RB\1740 abolish\VB\1740 this\DT\1740 toxic\JJ\1740 side\NN\8630039 effect\NN\34213 .\.\1740
20635749
D000638_D006333 NONE Severe\JJ\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 patient\NN\9898892 on\IN\1740 <e1>amiodarone</e1>\JJ\1740 presenting\NN\1740 with\IN\1740 myxedemic\JJ\1740 coma\NN\5678932 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D000638_D006333 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 of\IN\1740 myxedema\JJ\1740 coma\NN\5678932 secondary\JJ\1740 to\TO\1740 <e1>amiodarone-induced</e1>\JJ\1740 hypothyroidism\NN\14059928 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 .\.\1740
D000638_D006333 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 of\IN\1740 myxedema\JJ\1740 coma\NN\5678932 secondary\JJ\1740 to\TO\1740 <e1>amiodarone-induced</e1>\JJ\1740 hypothyroidism\NN\14059928 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 <e2>CHF</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D000638_D006333 NONE Patients\NNS\9898892 with\IN\1740 <e2>CHF</e2>\NN\1740 on\IN\1740 <e1>amiodarone</e1>\NN\2715941 may\MD\15209706 suffer\VB\2110220 serious\JJ\1740 morbidity\NN\13826959 and\CC\1740 mortality\NN\5054863 from\IN\1740 hypothyroidism\NN\14059928 ,\,\1740 and\CC\1740 thus\RB\1740 may\MD\15209706 deserve\VB\2604760 closer\JJR\1740 follow\VB\1835496 up\RP\1740 for\IN\1740 thyroid\NN\5329735 stimulating\NN\1740 hormone\NN\5404728 (\-LRB-\1740 TSH\NN\5407119 )\-RRB-\1740 levels\NNS\4916342 .\.\1740
D000638_D006333 NONE This\DT\1740 case\NN\7283608 report\NN\6470073 carries\VBZ\1850315 an\DT\6697703 important\JJ\1740 clinical\JJ\1740 application\NN\947128 given\VBN\2327200 the\DT\1740 frequent\JJ\1740 usage\NN\407535 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 among\IN\1740 <e2>CHF</e2>\NN\1740 patients\NNS\9898892 .\.\1740
D000638_D009230 CID Severe\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 patient\NN\9898892 on\IN\1740 <e1>amiodarone</e1>\JJ\1740 presenting\NN\1740 with\IN\1740 <e2>myxedemic\JJ\1740 coma</e2>\NN\5678932 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D000638_D009230 CID This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 of\IN\1740 <e2>myxedema\JJ\1740 coma</e2>\NN\5678932 secondary\JJ\1740 to\TO\1740 <e1>amiodarone-induced</e1>\JJ\1740 hypothyroidism\NN\14059928 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 .\.\1740
D000638_D009230 CID To\IN\1740 our\PRP$\1740 knowledge\NN\23100 and\CC\1740 after\IN\1740 reviewing\VBG\644583 the\DT\1740 literature\NN\6362953 there\EX\27167 is\VBZ\836236 one\CD\13741022 case\NN\7283608 report\NN\6470073 of\IN\1740 <e2>myxedema\JJ\1740 coma</e2>\NN\5678932 during\IN\1740 long\JJ\1740 term\NN\6286395 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 .\.\1740
D000638_D003128 CID Severe\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 patient\NN\9898892 on\IN\1740 <e1>amiodarone</e1>\JJ\1740 presenting\NN\1740 with\IN\1740 <e2>myxedemic\JJ\1740 coma</e2>\NN\5678932 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D000638_D003128 CID This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 of\IN\1740 <e2>myxedema\JJ\1740 coma</e2>\NN\5678932 secondary\JJ\1740 to\TO\1740 <e1>amiodarone-induced</e1>\JJ\1740 hypothyroidism\NN\14059928 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 .\.\1740
D000638_D003128 CID To\IN\1740 our\PRP$\1740 knowledge\NN\23100 and\CC\1740 after\IN\1740 reviewing\VBG\644583 the\DT\1740 literature\NN\6362953 there\EX\27167 is\VBZ\836236 one\CD\13741022 case\NN\7283608 report\NN\6470073 of\IN\1740 <e2>myxedema\JJ\1740 coma</e2>\NN\5678932 during\IN\1740 long\JJ\1740 term\NN\6286395 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 .\.\1740
D000638_D007037 CID This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 of\IN\1740 myxedema\JJ\1740 coma\NN\5678932 secondary\JJ\1740 to\TO\1740 <e1>amiodarone-induced</e1>\JJ\1740 <e2>hypothyroidism</e2>\NN\14059928 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 .\.\1740
D000638_D007037 CID Patients\NNS\9898892 with\IN\1740 CHF\NN\1740 on\IN\1740 <e1>amiodarone</e1>\NN\2715941 may\MD\15209706 suffer\VB\2110220 serious\JJ\1740 morbidity\NN\13826959 and\CC\1740 mortality\NN\5054863 from\IN\1740 <e2>hypothyroidism</e2>\NN\14059928 ,\,\1740 and\CC\1740 thus\RB\1740 may\MD\15209706 deserve\VB\2604760 closer\JJR\1740 follow\VB\1835496 up\RP\1740 for\IN\1740 thyroid\NN\5329735 stimulating\NN\1740 hormone\NN\5404728 (\-LRB-\1740 TSH\NN\5407119 )\-RRB-\1740 levels\NNS\4916342 .\.\1740
17042884
C069541_D001480 NONE Placebo-level\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>extrapyramidal\JJ\1740 symptoms</e2>\NNS\5823932 (\-LRB-\1740 EPS\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 in\IN\13603305 controlled\VBN\2422663 studies\NNS\635850 of\IN\1740 patients\NNS\9898892 with\IN\1740 bipolar\JJ\1740 mania\NN\9180259 .\.\1740
C069541_D001480 NONE Placebo-level\JJ\1740 incidence\NN\13821570 of\IN\1740 extrapyramidal\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 <e2>EPS</e2>\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 in\IN\13603305 controlled\VBN\2422663 studies\NNS\635850 of\IN\1740 patients\NNS\9898892 with\IN\1740 bipolar\JJ\1740 mania\NN\9180259 .\.\1740
C069541_D001480 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 <e2>extrapyramidal\JJ\1740 symptoms</e2>\NNS\5823932 (\-LRB-\1740 EPS\NN\1740 )\-RRB-\1740 ,\,\1740 including\VBG\690614 akathisia\NN\1740 ,\,\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 bipolar\JJ\1740 mania\NN\9180259 .\.\1740
C069541_D001480 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 extrapyramidal\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 <e2>EPS</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 including\VBG\690614 akathisia\NN\1740 ,\,\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 bipolar\JJ\1740 mania\NN\9180259 .\.\1740
C069541_D001480 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>EPS-related</e2>\JJ\1740 adverse\JJ\1740 events\NNS\23100 ,\,\1740 including\VBG\690614 akathisia\NN\1740 ,\,\1740 was\VBD\836236 no\RB\1740 different\JJ\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 monotherapy\NN\1740 (\-LRB-\1740 12.9\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 with\IN\1740 placebo\NN\3740161 (\-LRB-\1740 13.1\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C069541_D001480 NONE Similarly\RB\1740 ,\,\1740 <e2>EPS-related</e2>\JJ\1740 adverse\JJ\1740 events\NNS\23100 with\IN\1740 <e1>QTP</e1>\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 21.4\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 no\RB\1740 different\JJ\1740 than\IN\1740 with\IN\1740 PBO\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 19.2\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C069541_D001480 NONE Haloperidol\NNP\3713736 induced\VBD\1627355 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 of\IN\1740 akathisia\NN\1740 (\-LRB-\1740 33.3\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 tremor\NN\345926 (\-LRB-\1740 30.3\CD\1740 %\NN\1740 versus\CC\1740 7.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>extrapyramidal\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 35.4\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 <e1>quetiapine</e1>\NN\1740 .\.\1740
C069541_D001480 NONE CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 bipolar\JJ\1740 mania\NN\9180259 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>EPS</e2>\NN\1740 ,\,\1740 including\VBG\690614 akathisia\NN\1740 ,\,\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 therapy\NN\657604 is\VBZ\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 with\IN\1740 placebo\NN\3740161 .\.\1740
C069541_D001714 NONE Placebo-level\JJ\1740 incidence\NN\13821570 of\IN\1740 extrapyramidal\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 EPS\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 in\IN\13603305 controlled\VBN\2422663 studies\NNS\635850 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>bipolar\JJ\1740 mania</e2>\NN\9180259 .\.\1740
C069541_D001714 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 extrapyramidal\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 EPS\NN\1740 )\-RRB-\1740 ,\,\1740 including\VBG\690614 akathisia\NN\1740 ,\,\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>bipolar\JJ\1740 mania</e2>\NN\9180259 .\.\1740
C069541_D001714 NONE CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 <e2>bipolar\JJ\1740 mania</e2>\NN\9180259 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 EPS\NN\1740 ,\,\1740 including\VBG\690614 akathisia\NN\1740 ,\,\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 therapy\NN\657604 is\VBZ\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 with\IN\1740 placebo\NN\3740161 .\.\1740
C069541_D017109 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 extrapyramidal\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 EPS\NN\1740 )\-RRB-\1740 ,\,\1740 including\VBG\690614 <e2>akathisia</e2>\NN\1740 ,\,\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 bipolar\JJ\1740 mania\NN\9180259 .\.\1740
C069541_D017109 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 incidence\NN\13821570 of\IN\1740 EPS-related\JJ\1740 adverse\JJ\1740 events\NNS\23100 ,\,\1740 including\VBG\690614 <e2>akathisia</e2>\NN\1740 ,\,\1740 was\VBD\836236 no\RB\1740 different\JJ\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 monotherapy\NN\1740 (\-LRB-\1740 12.9\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 with\IN\1740 placebo\NN\3740161 (\-LRB-\1740 13.1\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C069541_D017109 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>akathisia</e2>\NN\1740 was\VBD\836236 low\JJ\1740 and\CC\1740 similar\JJ\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 monotherapy\NN\1740 (\-LRB-\1740 3.3\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 (\-LRB-\1740 6.1\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 with\IN\1740 QTP\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 3.6\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 PBO\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 4.9\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C069541_D017109 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>akathisia</e2>\NN\1740 was\VBD\836236 low\JJ\1740 and\CC\1740 similar\JJ\1740 with\IN\1740 quetiapine\NN\1740 monotherapy\NN\1740 (\-LRB-\1740 3.3\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 (\-LRB-\1740 6.1\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 with\IN\1740 <e1>QTP</e1>\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 3.6\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 PBO\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 4.9\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C069541_D017109 NONE Haloperidol\NNP\3713736 induced\VBD\1627355 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 of\IN\1740 <e2>akathisia</e2>\NN\1740 (\-LRB-\1740 33.3\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 tremor\NN\345926 (\-LRB-\1740 30.3\CD\1740 %\NN\1740 versus\CC\1740 7.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 extrapyramidal\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 35.4\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 <e1>quetiapine</e1>\NN\1740 .\.\1740
C069541_D017109 NONE CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 bipolar\JJ\1740 mania\NN\9180259 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 EPS\NN\1740 ,\,\1740 including\VBG\690614 <e2>akathisia</e2>\NN\1740 ,\,\1740 with\IN\1740 <e1>quetiapine</e1>\NN\1740 therapy\NN\657604 is\VBZ\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 with\IN\1740 placebo\NN\3740161 .\.\1740
D008094_D001480 CID Similarly\RB\1740 ,\,\1740 <e2>EPS-related</e2>\JJ\1740 adverse\JJ\1740 events\NNS\23100 with\IN\1740 QTP\NN\1740 +\CC\1740 <e1>Li/DVP</e1>\NN\1740 (\-LRB-\1740 21.4\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 no\RB\1740 different\JJ\1740 than\IN\1740 with\IN\1740 PBO\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 19.2\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D008094_D001480 CID Similarly\RB\1740 ,\,\1740 <e2>EPS-related</e2>\JJ\1740 adverse\JJ\1740 events\NNS\23100 with\IN\1740 QTP\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 21.4\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 no\RB\1740 different\JJ\1740 than\IN\1740 with\IN\1740 PBO\NN\1740 +\CC\1740 <e1>Li/DVP</e1>\NN\1740 (\-LRB-\1740 19.2\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D008094_D001480 CID Adverse\JJ\1740 events\NNS\23100 related\JJ\1740 to\TO\1740 <e2>EPS</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 59.6\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 haloperidol\NN\3713736 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 99\CD\1740 )\-RRB-\1740 monotherapy\NN\1740 ,\,\1740 whereas\IN\1740 26.5\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>lithium</e1>\NN\14625458 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 98\CD\1740 )\-RRB-\1740 monotherapy\NN\1740 experienced\JJ\1740 adverse\JJ\1740 events\NNS\23100 related\JJ\1740 to\TO\1740 EPS\NN\1740 .\.\1740
D008094_D001480 CID Adverse\JJ\1740 events\NNS\23100 related\JJ\1740 to\TO\1740 EPS\NN\1740 occurred\VBD\2623529 in\IN\13603305 59.6\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 haloperidol\NN\3713736 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 99\CD\1740 )\-RRB-\1740 monotherapy\NN\1740 ,\,\1740 whereas\IN\1740 26.5\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>lithium</e1>\NN\14625458 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 98\CD\1740 )\-RRB-\1740 monotherapy\NN\1740 experienced\JJ\1740 adverse\JJ\1740 events\NNS\23100 related\JJ\1740 to\TO\1740 <e2>EPS</e2>\NN\1740 .\.\1740
D014635_D001480 NONE Similarly\RB\1740 ,\,\1740 <e2>EPS-related</e2>\JJ\1740 adverse\JJ\1740 events\NNS\23100 with\IN\1740 QTP\NN\1740 +\CC\1740 <e1>Li/DVP</e1>\NN\1740 (\-LRB-\1740 21.4\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 no\RB\1740 different\JJ\1740 than\IN\1740 with\IN\1740 PBO\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 19.2\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D014635_D001480 NONE Similarly\RB\1740 ,\,\1740 <e2>EPS-related</e2>\JJ\1740 adverse\JJ\1740 events\NNS\23100 with\IN\1740 QTP\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 21.4\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 no\RB\1740 different\JJ\1740 than\IN\1740 with\IN\1740 PBO\NN\1740 +\CC\1740 <e1>Li/DVP</e1>\NN\1740 (\-LRB-\1740 19.2\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D006220_D001480 CID Adverse\JJ\1740 events\NNS\23100 related\JJ\1740 to\TO\1740 <e2>EPS</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 59.6\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 99\CD\1740 )\-RRB-\1740 monotherapy\NN\1740 ,\,\1740 whereas\IN\1740 26.5\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 lithium\NN\14625458 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 98\CD\1740 )\-RRB-\1740 monotherapy\NN\1740 experienced\JJ\1740 adverse\JJ\1740 events\NNS\23100 related\JJ\1740 to\TO\1740 EPS\NN\1740 .\.\1740
D006220_D001480 CID Adverse\JJ\1740 events\NNS\23100 related\JJ\1740 to\TO\1740 EPS\NN\1740 occurred\VBD\2623529 in\IN\13603305 59.6\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 99\CD\1740 )\-RRB-\1740 monotherapy\NN\1740 ,\,\1740 whereas\IN\1740 26.5\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 lithium\NN\14625458 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 98\CD\1740 )\-RRB-\1740 monotherapy\NN\1740 experienced\JJ\1740 adverse\JJ\1740 events\NNS\23100 related\JJ\1740 to\TO\1740 <e2>EPS</e2>\NN\1740 .\.\1740
D006220_D001480 CID <e1>Haloperidol</e1>\NNP\3713736 induced\VBD\1627355 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 of\IN\1740 akathisia\NN\1740 (\-LRB-\1740 33.3\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 tremor\NN\345926 (\-LRB-\1740 30.3\CD\1740 %\NN\1740 versus\CC\1740 7.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>extrapyramidal\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 35.4\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 .\.\1740
D008094_D017109 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>akathisia</e2>\NN\1740 was\VBD\836236 low\JJ\1740 and\CC\1740 similar\JJ\1740 with\IN\1740 quetiapine\NN\1740 monotherapy\NN\1740 (\-LRB-\1740 3.3\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 (\-LRB-\1740 6.1\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 with\IN\1740 QTP\NN\1740 +\CC\1740 <e1>Li/DVP</e1>\NN\1740 (\-LRB-\1740 3.6\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 PBO\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 4.9\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D008094_D017109 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>akathisia</e2>\NN\1740 was\VBD\836236 low\JJ\1740 and\CC\1740 similar\JJ\1740 with\IN\1740 quetiapine\NN\1740 monotherapy\NN\1740 (\-LRB-\1740 3.3\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 (\-LRB-\1740 6.1\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 with\IN\1740 QTP\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 3.6\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 PBO\NN\1740 +\CC\1740 <e1>Li/DVP</e1>\NN\1740 (\-LRB-\1740 4.9\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D014635_D017109 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>akathisia</e2>\NN\1740 was\VBD\836236 low\JJ\1740 and\CC\1740 similar\JJ\1740 with\IN\1740 quetiapine\NN\1740 monotherapy\NN\1740 (\-LRB-\1740 3.3\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 (\-LRB-\1740 6.1\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 with\IN\1740 QTP\NN\1740 +\CC\1740 <e1>Li/DVP</e1>\NN\1740 (\-LRB-\1740 3.6\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 PBO\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 4.9\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D014635_D017109 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>akathisia</e2>\NN\1740 was\VBD\836236 low\JJ\1740 and\CC\1740 similar\JJ\1740 with\IN\1740 quetiapine\NN\1740 monotherapy\NN\1740 (\-LRB-\1740 3.3\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 placebo\NN\3740161 (\-LRB-\1740 6.1\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 with\IN\1740 QTP\NN\1740 +\CC\1740 Li/DVP\NN\1740 (\-LRB-\1740 3.6\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 PBO\NN\1740 +\CC\1740 <e1>Li/DVP</e1>\NN\1740 (\-LRB-\1740 4.9\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D008094_D014202 CID <e1>Lithium</e1>\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 <e2>tremor</e2>\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 tremor\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 lithium\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 tremor\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D014202 CID <e1>Lithium</e1>\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 tremor\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 <e2>tremor</e2>\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 lithium\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 tremor\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D014202 CID <e1>Lithium</e1>\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 tremor\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 tremor\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 lithium\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 <e2>tremor</e2>\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D014202 CID Lithium\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 <e2>tremor</e2>\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 tremor\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 tremor\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D014202 CID Lithium\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 tremor\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 <e2>tremor</e2>\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 tremor\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D014202 CID Lithium\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 tremor\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 tremor\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 <e2>tremor</e2>\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D014202 CID Lithium\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 <e2>tremor</e2>\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 tremor\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 lithium\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 tremor\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D014202 CID Lithium\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 tremor\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 <e2>tremor</e2>\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 lithium\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 tremor\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D014202 CID Lithium\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 tremor\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 tremor\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 lithium\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 <e2>tremor</e2>\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
C069541_D014202 NONE Lithium\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 <e2>tremor</e2>\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 <e1>quetiapine</e1>\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 tremor\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 lithium\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 tremor\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 therapy\NN\657604 .\.\1740
C069541_D014202 NONE Lithium\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 tremor\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 <e1>quetiapine</e1>\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 <e2>tremor</e2>\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 lithium\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 tremor\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 therapy\NN\657604 .\.\1740
C069541_D014202 NONE Lithium\NNP\14625458 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 tremor\NN\345926 (\-LRB-\1740 18.4\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 <e1>quetiapine</e1>\NN\1740 (\-LRB-\1740 5.6\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 cerebellar\JJ\1740 tremor\NN\345926 ,\,\1740 which\WDT\1740 is\VBZ\836236 a\DT\13649268 known\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 lithium\NN\14625458 ,\,\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 elevated\JJ\1740 rate\NN\13815152 of\IN\1740 <e2>tremor</e2>\NN\345926 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 therapy\NN\657604 .\.\1740
C069541_D014202 NONE Haloperidol\NNP\3713736 induced\VBD\1627355 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 of\IN\1740 akathisia\NN\1740 (\-LRB-\1740 33.3\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>tremor</e2>\NN\345926 (\-LRB-\1740 30.3\CD\1740 %\NN\1740 versus\CC\1740 7.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 extrapyramidal\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 35.4\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 <e1>quetiapine</e1>\NN\1740 .\.\1740
D006220_D017109 CID <e1>Haloperidol</e1>\NNP\3713736 induced\VBD\1627355 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 of\IN\1740 <e2>akathisia</e2>\NN\1740 (\-LRB-\1740 33.3\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 tremor\NN\345926 (\-LRB-\1740 30.3\CD\1740 %\NN\1740 versus\CC\1740 7.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 extrapyramidal\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 35.4\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 .\.\1740
D006220_D014202 CID <e1>Haloperidol</e1>\NNP\3713736 induced\VBD\1627355 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 incidence\NN\13821570 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 of\IN\1740 akathisia\NN\1740 (\-LRB-\1740 33.3\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>tremor</e2>\NN\345926 (\-LRB-\1740 30.3\CD\1740 %\NN\1740 versus\CC\1740 7.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 extrapyramidal\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 35.4\CD\1740 %\NN\1740 versus\CC\1740 5.9\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 quetiapine\NN\1740 .\.\1740
85485
D001556_D006528 CID Changes\NNS\7283608 in\IN\13603305 peroxisomes\NNS\1740 in\IN\13603305 preneoplastic\JJ\1740 liver\NN\5298729 and\CC\1740 <e2>hepatoma</e2>\NN\14242337 of\IN\1740 mice\NNS\2329401 induced\VBN\1627355 by\IN\1740 <e1>alpha-benzene\JJ\1740 hexachloride</e1>\NN\1740 .\.\1740
D001556_D006528 CID Peroxisomes\NNS\1740 in\IN\13603305 <e2>hepatomas</e2>\NNS\14242337 and\CC\1740 hyperplastic\JJ\1740 preneoplastic\JJ\1740 liver\NN\5298729 lesions\NNS\14204950 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 500\CD\13745420 ppm\NN\1740 <e1>alpha-benzene\JJ\1740 hexachloride</e1>\NN\1740 were\VBD\836236 examined\VBN\789138 histochemically\RB\1740 and\CC\1740 electron\NN\9338013 microscopically\RB\1740 .\.\1740
D001556_D017093 NONE Peroxisomes\NNS\1740 in\IN\13603305 hepatomas\NNS\14242337 and\CC\1740 hyperplastic\JJ\1740 preneoplastic\JJ\1740 <e2>liver\NN\5298729 lesions</e2>\NNS\14204950 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 500\CD\13745420 ppm\NN\1740 <e1>alpha-benzene\JJ\1740 hexachloride</e1>\NN\1740 were\VBD\836236 examined\VBN\789138 histochemically\RB\1740 and\CC\1740 electron\NN\9338013 microscopically\RB\1740 .\.\1740
C012282_D006528 NONE Although\IN\1740 most\JJS\1740 of\IN\1740 the\DT\1740 <e2>hepatomas</e2>\NNS\14242337 were\VBD\836236 well-differentiated\JJ\1740 tumors\NNS\14234074 and\CC\1740 contained\VBD\2632940 a\DT\13649268 considerable\JJ\1740 number\NN\5107765 of\IN\1740 peroxisomes\NNS\1740 ,\,\1740 the\DT\1740 tumor\NN\14234074 cells\NNS\3080309 did\VBD\1640855 not\RB\1740 respond\VB\2367363 to\IN\1740 <e1>ethyl-alpha-p-chlorophenoxyisobutyrate</e1>\CD\1740 with\IN\1740 proliferation\NN\13489037 of\IN\1740 peroxisomes\NNS\1740 .\.\1740
C012282_D009369 NONE Although\IN\1740 most\JJS\1740 of\IN\1740 the\DT\1740 hepatomas\NNS\14242337 were\VBD\836236 well-differentiated\JJ\1740 <e2>tumors</e2>\NNS\14234074 and\CC\1740 contained\VBD\2632940 a\DT\13649268 considerable\JJ\1740 number\NN\5107765 of\IN\1740 peroxisomes\NNS\1740 ,\,\1740 the\DT\1740 tumor\NN\14234074 cells\NNS\3080309 did\VBD\1640855 not\RB\1740 respond\VB\2367363 to\IN\1740 <e1>ethyl-alpha-p-chlorophenoxyisobutyrate</e1>\CD\1740 with\IN\1740 proliferation\NN\13489037 of\IN\1740 peroxisomes\NNS\1740 .\.\1740
C012282_D009369 NONE Although\IN\1740 most\JJS\1740 of\IN\1740 the\DT\1740 hepatomas\NNS\14242337 were\VBD\836236 well-differentiated\JJ\1740 tumors\NNS\14234074 and\CC\1740 contained\VBD\2632940 a\DT\13649268 considerable\JJ\1740 number\NN\5107765 of\IN\1740 peroxisomes\NNS\1740 ,\,\1740 the\DT\1740 <e2>tumor</e2>\NN\14234074 cells\NNS\3080309 did\VBD\1640855 not\RB\1740 respond\VB\2367363 to\IN\1740 <e1>ethyl-alpha-p-chlorophenoxyisobutyrate</e1>\CD\1740 with\IN\1740 proliferation\NN\13489037 of\IN\1740 peroxisomes\NNS\1740 .\.\1740
14975762
D004317_D009369 NONE <e1>Doxorubicin</e1>\NNP\2716866 is\VBZ\836236 an\DT\6697703 <e2>anti-tumor</e2>\JJ\1740 agent\NN\7347 that\WDT\1740 represses\VBZ\2424652 cardiac-specific\JJ\1740 gene\NN\8459252 expression\NN\4679549 and\CC\1740 induces\VBZ\1627355 myocardial\JJ\1740 cell\NN\3080309 apoptosis\NN\11486178 .\.\1740
D004317_D006333 CID These\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 that\IN\1740 overexpression\NN\1740 of\IN\1740 p300\NN\1740 protects\VBZ\1127795 cardiac\JJ\1740 myocytes\NNS\1740 from\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 apoptosis\NN\11486178 and\CC\1740 reduces\VBZ\441445 the\DT\1740 extent\NN\13939892 of\IN\1740 acute\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 in\FW\13603305 vivo\FW\1740 .\.\1740
15930398
D015742_D000647 CID Assessment\NN\5732756 of\IN\1740 the\DT\1740 onset\NN\7325190 and\CC\1740 persistence\NN\5053688 of\IN\1740 <e2>amnesia</e2>\NN\5669934 during\IN\1740 procedural\JJ\1740 sedation\NN\14034177 with\IN\1740 <e1>propofol</e1>\NN\1740 .\.\1740
18201582
C084178_D006973 NONE Results\NNS\34213 of\IN\1740 a\DT\13649268 comparative\JJ\1740 ,\,\1740 phase\NN\15113229 III\CD\13741022 ,\,\1740 12-week\NN\1740 ,\,\1740 multicenter\NN\1740 ,\,\1740 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 assessment\NN\5732756 of\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 a\DT\13649268 fixed-dose\JJ\1740 combination\NN\7951464 of\IN\1740 <e1>telmisartan</e1>\JJ\1740 and\CC\1740 amlodipine\NN\1740 versus\CC\1740 amlodipine\NN\1740 monotherapy\NN\1740 in\IN\13603305 Indian\JJ\1740 adults\NNS\7846 with\IN\1740 stage\NN\15113229 II\CD\13741022 <e2>hypertension</e2>\NN\14057371 .\.\1740
C084178_D006973 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 a\DT\13649268 new\JJ\1740 fixed-dose\JJ\1740 combination\NN\7951464 (\-LRB-\1740 FDC\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>telmisartan</e1>\NN\1740 40\CD\13745420 mg\NN\13717155 +\CC\1740 amlodipine\NN\1740 5\CD\13741022 mg\NN\13717155 (\-LRB-\1740 T+A\NN\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 amlodipine\JJ\1740 5-mg\JJ\1740 monotherapy\NN\1740 (\-LRB-\1740 A\NN\13649268 )\-RRB-\1740 in\IN\13603305 adult\JJ\1740 Indian\JJ\1740 patients\NNS\9898892 with\IN\1740 stage\NN\15113229 II\CD\13741022 <e2>hypertension</e2>\NN\14057371 .\.\1740
D017311_D006973 NONE Results\NNS\34213 of\IN\1740 a\DT\13649268 comparative\JJ\1740 ,\,\1740 phase\NN\15113229 III\CD\13741022 ,\,\1740 12-week\NN\1740 ,\,\1740 multicenter\NN\1740 ,\,\1740 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 assessment\NN\5732756 of\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 a\DT\13649268 fixed-dose\JJ\1740 combination\NN\7951464 of\IN\1740 telmisartan\JJ\1740 and\CC\1740 <e1>amlodipine</e1>\NN\1740 versus\CC\1740 amlodipine\NN\1740 monotherapy\NN\1740 in\IN\13603305 Indian\JJ\1740 adults\NNS\7846 with\IN\1740 stage\NN\15113229 II\CD\13741022 <e2>hypertension</e2>\NN\14057371 .\.\1740
D017311_D006973 NONE Results\NNS\34213 of\IN\1740 a\DT\13649268 comparative\JJ\1740 ,\,\1740 phase\NN\15113229 III\CD\13741022 ,\,\1740 12-week\NN\1740 ,\,\1740 multicenter\NN\1740 ,\,\1740 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 assessment\NN\5732756 of\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 a\DT\13649268 fixed-dose\JJ\1740 combination\NN\7951464 of\IN\1740 telmisartan\JJ\1740 and\CC\1740 amlodipine\NN\1740 versus\CC\1740 <e1>amlodipine</e1>\NN\1740 monotherapy\NN\1740 in\IN\13603305 Indian\JJ\1740 adults\NNS\7846 with\IN\1740 stage\NN\15113229 II\CD\13741022 <e2>hypertension</e2>\NN\14057371 .\.\1740
D017311_D006973 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 a\DT\13649268 new\JJ\1740 fixed-dose\JJ\1740 combination\NN\7951464 (\-LRB-\1740 FDC\NN\1740 )\-RRB-\1740 of\IN\1740 telmisartan\NN\1740 40\CD\13745420 mg\NN\13717155 +\CC\1740 <e1>amlodipine</e1>\NN\1740 5\CD\13741022 mg\NN\13717155 (\-LRB-\1740 T+A\NN\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 amlodipine\JJ\1740 5-mg\JJ\1740 monotherapy\NN\1740 (\-LRB-\1740 A\NN\13649268 )\-RRB-\1740 in\IN\13603305 adult\JJ\1740 Indian\JJ\1740 patients\NNS\9898892 with\IN\1740 stage\NN\15113229 II\CD\13741022 <e2>hypertension</e2>\NN\14057371 .\.\1740
D017311_D006973 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 a\DT\13649268 new\JJ\1740 fixed-dose\JJ\1740 combination\NN\7951464 (\-LRB-\1740 FDC\NN\1740 )\-RRB-\1740 of\IN\1740 telmisartan\NN\1740 40\CD\13745420 mg\NN\13717155 +\CC\1740 amlodipine\NN\1740 5\CD\13741022 mg\NN\13717155 (\-LRB-\1740 T+A\NN\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 <e1>amlodipine</e1>\JJ\1740 5-mg\JJ\1740 monotherapy\NN\1740 (\-LRB-\1740 A\NN\13649268 )\-RRB-\1740 in\IN\13603305 adult\JJ\1740 Indian\JJ\1740 patients\NNS\9898892 with\IN\1740 stage\NN\15113229 II\CD\13741022 <e2>hypertension</e2>\NN\14057371 .\.\1740
19917396
D016559_D006332 CID Reversible\JJ\1740 <e2>myocardial\JJ\1740 hypertrophy</e2>\NN\14365950 induced\VBN\1627355 by\IN\1740 <e1>tacrolimus</e1>\NN\1740 in\IN\13603305 a\DT\13649268 pediatric\JJ\1740 heart\NN\5919034 transplant\NN\5267548 recipient\NN\9764201 :\:\1740 case\NN\7283608 report\NN\6470073 .\.\1740
D016559_D006332 CID Herein\RB\1740 we\PRP\1740 describe\VBP\1001294 transient\JJ\1740 <e2>myocardial\JJ\1740 hypertrophy</e2>\NN\14365950 induced\VBN\1627355 by\IN\1740 <e1>tacrolimus</e1>\NN\1740 after\IN\1740 heart\NN\5919034 transplantation\NN\671351 .\.\1740
D016559_D006332 CID <e2>Myocardial\JJ\1740 hypertrophy</e2>\NN\14365950 completely\RB\1740 resolved\VBN\352826 upon\IN\1740 reducing\VBG\441445 the\DT\1740 target\NN\7258332 concentration\NN\4916342 of\IN\1740 <e1>tacrolimus</e1>\NN\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 recur\VB\339934 ,\,\1740 as\IN\14622893 confirmed\VBN\1011725 at\IN\14622893 echocardiography\NN\177127 and\CC\1740 myocardial\JJ\1740 biopsy\NN\5739043 .\.\1740
D016559_D006332 CID Thus\RB\1740 ,\,\1740 we\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>tacrolimus</e1>\NN\1740 induces\VBZ\1627355 reversible\JJ\1740 <e2>myocardial\JJ\1740 hypertrophy</e2>\NN\14365950 .\.\1740
10074612
D008775_D007022 CID <e2>Hypotension</e2>\NN\14057371 ,\,\1740 bradycardia\NN\14110674 ,\,\1740 and\CC\1740 asystole\NN\14204950 after\IN\1740 high-dose\JJ\1740 intravenous\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 in\IN\13603305 a\DT\13649268 monitored\VBN\2169352 patient\NN\9898892 .\.\1740
D008775_D007022 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 bradycardia\NN\14110674 ,\,\1740 and\CC\1740 asystole\NN\14204950 after\IN\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 high-dose\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 in\IN\13603305 a\DT\13649268 73-year-old\JJ\1740 patient\NN\9898892 who\WP\8299493 underwent\VBD\109660 electrocardiographic\JJ\1740 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 monitoring\VBG\2169352 throughout\IN\1740 the\DT\1740 episode\NN\7283608 .\.\1740
D008775_D001919 CID Hypotension\NN\14057371 ,\,\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 and\CC\1740 asystole\NN\14204950 after\IN\1740 high-dose\JJ\1740 intravenous\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 in\IN\13603305 a\DT\13649268 monitored\VBN\2169352 patient\NN\9898892 .\.\1740
D008775_D001919 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 hypotension\NN\14057371 ,\,\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 and\CC\1740 asystole\NN\14204950 after\IN\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 high-dose\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 in\IN\13603305 a\DT\13649268 73-year-old\JJ\1740 patient\NN\9898892 who\WP\8299493 underwent\VBD\109660 electrocardiographic\JJ\1740 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 monitoring\VBG\2169352 throughout\IN\1740 the\DT\1740 episode\NN\7283608 .\.\1740
D008775_D006323 CID Hypotension\NN\14057371 ,\,\1740 bradycardia\NN\14110674 ,\,\1740 and\CC\1740 <e2>asystole</e2>\NN\14204950 after\IN\1740 high-dose\JJ\1740 intravenous\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 in\IN\13603305 a\DT\13649268 monitored\VBN\2169352 patient\NN\9898892 .\.\1740
D008775_D006323 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 hypotension\NN\14057371 ,\,\1740 bradycardia\NN\14110674 ,\,\1740 and\CC\1740 <e2>asystole</e2>\NN\14204950 after\IN\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 high-dose\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 in\IN\13603305 a\DT\13649268 73-year-old\JJ\1740 patient\NN\9898892 who\WP\8299493 underwent\VBD\109660 electrocardiographic\JJ\1740 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 monitoring\VBG\2169352 throughout\IN\1740 the\DT\1740 episode\NN\7283608 .\.\1740
D008775_D003645 NONE This\DT\1740 study\NN\635850 reviews\VBZ\644583 the\DT\1740 current\JJ\1740 proposed\VBN\1010118 mechanisms\NNS\13446390 of\IN\1740 <e2>sudden\JJ\1740 death</e2>\NN\7296428 after\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 intravenous\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 (\-LRB-\1740 IVMP\NNP\1740 )\-RRB-\1740 .\.\1740
D008775_D003645 NONE This\DT\1740 study\NN\635850 reviews\VBZ\644583 the\DT\1740 current\JJ\1740 proposed\VBN\1010118 mechanisms\NNS\13446390 of\IN\1740 <e2>sudden\JJ\1740 death</e2>\NN\7296428 after\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 intravenous\JJ\1740 methylprednisolone\NN\1740 (\-LRB-\1740 <e1>IVMP</e1>\NNP\1740 )\-RRB-\1740 .\.\1740
11704023
D013999_D005901 NONE Comparison\NN\635850 of\IN\1740 aqueous\JJ\1740 and\CC\1740 gellan\VB\1740 ophthalmic\JJ\1740 <e1>timolol</e1>\NNS\2832168 with\IN\1740 placebo\NN\3740161 on\IN\1740 the\DT\1740 24-hour\JJ\1740 heart\NN\5919034 rate\NN\13815152 response\NN\11410625 in\IN\13603305 patients\NNS\9898892 on\IN\1740 treatment\NN\654885 for\IN\1740 <e2>glaucoma</e2>\NN\14252864 .\.\1740
D013999_D005901 NONE DESIGN\NN\927261 :\:\1740 This\DT\1740 trial\NN\786195 evaluated\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 placebo\NN\3740161 ,\,\1740 0.5\CD\1740 %\NN\1740 aqueous\JJ\1740 <e1>timolol</e1>\NNS\2832168 (\-LRB-\1740 timolol\CD\2832168 solution\NN\14586258 )\-RRB-\1740 and\CC\1740 a\DT\13649268 0.5\CD\1740 %\NN\1740 timolol\JJ\1740 suspension\NN\14586258 that\WDT\1740 forms\VBZ\1617192 a\DT\13649268 gel\NN\14588219 on\IN\1740 application\NN\947128 to\IN\1740 the\DT\1740 conjunctiva\NN\5327134 (\-LRB-\1740 timolol\CD\2832168 gellan\NN\1740 )\-RRB-\1740 on\IN\1740 the\DT\1740 24-hour\JJ\1740 heart\NN\5919034 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 currently\RB\1740 being\VBG\836236 treated\VBN\2376958 for\IN\1740 <e2>glaucoma</e2>\NN\14252864 to\TO\1740 quantify\VB\947077 the\DT\1740 reduction\NN\351485 in\IN\13603305 mean\JJ\1740 heart\NN\5919034 rate\NN\13815152 .\.\1740
D013999_D005901 NONE DESIGN\NN\927261 :\:\1740 This\DT\1740 trial\NN\786195 evaluated\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 placebo\NN\3740161 ,\,\1740 0.5\CD\1740 %\NN\1740 aqueous\JJ\1740 timolol\NNS\2832168 (\-LRB-\1740 <e1>timolol</e1>\CD\2832168 solution\NN\14586258 )\-RRB-\1740 and\CC\1740 a\DT\13649268 0.5\CD\1740 %\NN\1740 timolol\JJ\1740 suspension\NN\14586258 that\WDT\1740 forms\VBZ\1617192 a\DT\13649268 gel\NN\14588219 on\IN\1740 application\NN\947128 to\IN\1740 the\DT\1740 conjunctiva\NN\5327134 (\-LRB-\1740 timolol\CD\2832168 gellan\NN\1740 )\-RRB-\1740 on\IN\1740 the\DT\1740 24-hour\JJ\1740 heart\NN\5919034 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 currently\RB\1740 being\VBG\836236 treated\VBN\2376958 for\IN\1740 <e2>glaucoma</e2>\NN\14252864 to\TO\1740 quantify\VB\947077 the\DT\1740 reduction\NN\351485 in\IN\13603305 mean\JJ\1740 heart\NN\5919034 rate\NN\13815152 .\.\1740
D013999_D005901 NONE DESIGN\NN\927261 :\:\1740 This\DT\1740 trial\NN\786195 evaluated\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 placebo\NN\3740161 ,\,\1740 0.5\CD\1740 %\NN\1740 aqueous\JJ\1740 timolol\NNS\2832168 (\-LRB-\1740 timolol\CD\2832168 solution\NN\14586258 )\-RRB-\1740 and\CC\1740 a\DT\13649268 0.5\CD\1740 %\NN\1740 <e1>timolol</e1>\JJ\1740 suspension\NN\14586258 that\WDT\1740 forms\VBZ\1617192 a\DT\13649268 gel\NN\14588219 on\IN\1740 application\NN\947128 to\IN\1740 the\DT\1740 conjunctiva\NN\5327134 (\-LRB-\1740 timolol\CD\2832168 gellan\NN\1740 )\-RRB-\1740 on\IN\1740 the\DT\1740 24-hour\JJ\1740 heart\NN\5919034 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 currently\RB\1740 being\VBG\836236 treated\VBN\2376958 for\IN\1740 <e2>glaucoma</e2>\NN\14252864 to\TO\1740 quantify\VB\947077 the\DT\1740 reduction\NN\351485 in\IN\13603305 mean\JJ\1740 heart\NN\5919034 rate\NN\13815152 .\.\1740
D013999_D005901 NONE DESIGN\NN\927261 :\:\1740 This\DT\1740 trial\NN\786195 evaluated\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 placebo\NN\3740161 ,\,\1740 0.5\CD\1740 %\NN\1740 aqueous\JJ\1740 timolol\NNS\2832168 (\-LRB-\1740 timolol\CD\2832168 solution\NN\14586258 )\-RRB-\1740 and\CC\1740 a\DT\13649268 0.5\CD\1740 %\NN\1740 timolol\JJ\1740 suspension\NN\14586258 that\WDT\1740 forms\VBZ\1617192 a\DT\13649268 gel\NN\14588219 on\IN\1740 application\NN\947128 to\IN\1740 the\DT\1740 conjunctiva\NN\5327134 (\-LRB-\1740 <e1>timolol</e1>\CD\2832168 gellan\NN\1740 )\-RRB-\1740 on\IN\1740 the\DT\1740 24-hour\JJ\1740 heart\NN\5919034 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 currently\RB\1740 being\VBG\836236 treated\VBN\2376958 for\IN\1740 <e2>glaucoma</e2>\NN\14252864 to\TO\1740 quantify\VB\947077 the\DT\1740 reduction\NN\351485 in\IN\13603305 mean\JJ\1740 heart\NN\5919034 rate\NN\13815152 .\.\1740
D013999_D005902 NONE METHODS\NNS\5616786 :\:\1740 Forty-three\JJ\1740 Caucasian\JJ\1740 patients\NNS\9898892 with\IN\1740 primary\JJ\1740 <e2>open-angle\JJ\1740 glaucoma</e2>\NN\14252864 or\CC\3541091 ocular\JJ\1740 hypertension\NN\14057371 with\IN\1740 a\DT\13649268 mean\NN\6021761 (\-LRB-\1740 +\CC\1740 /-SD\NN\1740 )\-RRB-\1740 age\NN\4916342 of\IN\1740 63\CD\1740 (\-LRB-\1740 +\CC\1740 /-8\LS\1740 )\-RRB-\1740 years\NNS\15144371 were\VBD\836236 randomized\VBN\278117 and\CC\1740 crossed\VBN\2050132 over\RP\1740 in\IN\13603305 a\DT\13649268 double-masked\JJ\1740 manner\NN\4916342 to\TO\1740 14\CD\13745420 days\NNS\15140892 of\IN\1740 treatment\NN\654885 with\IN\1740 placebo\NN\3740161 (\-LRB-\1740 morning\NN\15113229 and\CC\1740 evening\NN\15164957 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 )\-RRB-\1740 ,\,\1740 <e1>timolol</e1>\VB\1740 solution\NN\14586258 (\-LRB-\1740 morning\NN\15113229 and\CC\1740 evening\NN\15164957 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 )\-RRB-\1740 ,\,\1740 or\CC\3541091 timolol\CD\2832168 gellan\NN\1740 (\-LRB-\1740 morning\NN\15113229 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 with\IN\1740 placebo\NN\3740161 in\IN\13603305 the\DT\1740 evening\NN\15164957 )\-RRB-\1740 .\.\1740
D013999_D005902 NONE METHODS\NNS\5616786 :\:\1740 Forty-three\JJ\1740 Caucasian\JJ\1740 patients\NNS\9898892 with\IN\1740 primary\JJ\1740 <e2>open-angle\JJ\1740 glaucoma</e2>\NN\14252864 or\CC\3541091 ocular\JJ\1740 hypertension\NN\14057371 with\IN\1740 a\DT\13649268 mean\NN\6021761 (\-LRB-\1740 +\CC\1740 /-SD\NN\1740 )\-RRB-\1740 age\NN\4916342 of\IN\1740 63\CD\1740 (\-LRB-\1740 +\CC\1740 /-8\LS\1740 )\-RRB-\1740 years\NNS\15144371 were\VBD\836236 randomized\VBN\278117 and\CC\1740 crossed\VBN\2050132 over\RP\1740 in\IN\13603305 a\DT\13649268 double-masked\JJ\1740 manner\NN\4916342 to\TO\1740 14\CD\13745420 days\NNS\15140892 of\IN\1740 treatment\NN\654885 with\IN\1740 placebo\NN\3740161 (\-LRB-\1740 morning\NN\15113229 and\CC\1740 evening\NN\15164957 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 )\-RRB-\1740 ,\,\1740 timolol\VB\1740 solution\NN\14586258 (\-LRB-\1740 morning\NN\15113229 and\CC\1740 evening\NN\15164957 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 )\-RRB-\1740 ,\,\1740 or\CC\3541091 <e1>timolol</e1>\CD\2832168 gellan\NN\1740 (\-LRB-\1740 morning\NN\15113229 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 with\IN\1740 placebo\NN\3740161 in\IN\13603305 the\DT\1740 evening\NN\15164957 )\-RRB-\1740 .\.\1740
D013999_D009798 NONE METHODS\NNS\5616786 :\:\1740 Forty-three\JJ\1740 Caucasian\JJ\1740 patients\NNS\9898892 with\IN\1740 primary\JJ\1740 open-angle\JJ\1740 glaucoma\NN\14252864 or\CC\3541091 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 with\IN\1740 a\DT\13649268 mean\NN\6021761 (\-LRB-\1740 +\CC\1740 /-SD\NN\1740 )\-RRB-\1740 age\NN\4916342 of\IN\1740 63\CD\1740 (\-LRB-\1740 +\CC\1740 /-8\LS\1740 )\-RRB-\1740 years\NNS\15144371 were\VBD\836236 randomized\VBN\278117 and\CC\1740 crossed\VBN\2050132 over\RP\1740 in\IN\13603305 a\DT\13649268 double-masked\JJ\1740 manner\NN\4916342 to\TO\1740 14\CD\13745420 days\NNS\15140892 of\IN\1740 treatment\NN\654885 with\IN\1740 placebo\NN\3740161 (\-LRB-\1740 morning\NN\15113229 and\CC\1740 evening\NN\15164957 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 )\-RRB-\1740 ,\,\1740 <e1>timolol</e1>\VB\1740 solution\NN\14586258 (\-LRB-\1740 morning\NN\15113229 and\CC\1740 evening\NN\15164957 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 )\-RRB-\1740 ,\,\1740 or\CC\3541091 timolol\CD\2832168 gellan\NN\1740 (\-LRB-\1740 morning\NN\15113229 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 with\IN\1740 placebo\NN\3740161 in\IN\13603305 the\DT\1740 evening\NN\15164957 )\-RRB-\1740 .\.\1740
D013999_D009798 NONE METHODS\NNS\5616786 :\:\1740 Forty-three\JJ\1740 Caucasian\JJ\1740 patients\NNS\9898892 with\IN\1740 primary\JJ\1740 open-angle\JJ\1740 glaucoma\NN\14252864 or\CC\3541091 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 with\IN\1740 a\DT\13649268 mean\NN\6021761 (\-LRB-\1740 +\CC\1740 /-SD\NN\1740 )\-RRB-\1740 age\NN\4916342 of\IN\1740 63\CD\1740 (\-LRB-\1740 +\CC\1740 /-8\LS\1740 )\-RRB-\1740 years\NNS\15144371 were\VBD\836236 randomized\VBN\278117 and\CC\1740 crossed\VBN\2050132 over\RP\1740 in\IN\13603305 a\DT\13649268 double-masked\JJ\1740 manner\NN\4916342 to\TO\1740 14\CD\13745420 days\NNS\15140892 of\IN\1740 treatment\NN\654885 with\IN\1740 placebo\NN\3740161 (\-LRB-\1740 morning\NN\15113229 and\CC\1740 evening\NN\15164957 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 )\-RRB-\1740 ,\,\1740 timolol\VB\1740 solution\NN\14586258 (\-LRB-\1740 morning\NN\15113229 and\CC\1740 evening\NN\15164957 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 )\-RRB-\1740 ,\,\1740 or\CC\3541091 <e1>timolol</e1>\CD\2832168 gellan\NN\1740 (\-LRB-\1740 morning\NN\15113229 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 with\IN\1740 placebo\NN\3740161 in\IN\13603305 the\DT\1740 evening\NN\15164957 )\-RRB-\1740 .\.\1740
19135948
C107135_D006086 NONE <e2>Graft-versus-host\NN\1740 disease</e2>\NN\14061805 prophylaxis\NN\1077350 with\IN\1740 <e1>everolimus</e1>\NN\1740 and\CC\1740 tacrolimus\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 sinusoidal\JJ\1740 obstruction\NN\4341686 syndrome\NN\5870365 and\CC\1740 microangiopathy\VBN\1740 :\:\1740 results\NNS\34213 of\IN\1740 the\DT\1740 EVTAC\NNP\1740 trial\NN\786195 .\.\1740
C107135_D006504 CID Graft-versus-host\NN\1740 disease\NN\14061805 prophylaxis\NN\1077350 with\IN\1740 <e1>everolimus</e1>\NN\1740 and\CC\1740 tacrolimus\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>sinusoidal\JJ\1740 obstruction\NN\4341686 syndrome</e2>\NN\5870365 and\CC\1740 microangiopathy\VBN\1740 :\:\1740 results\NNS\34213 of\IN\1740 the\DT\1740 EVTAC\NNP\1740 trial\NN\786195 .\.\1740
C107135_D014652 CID Graft-versus-host\NN\1740 disease\NN\14061805 prophylaxis\NN\1077350 with\IN\1740 <e1>everolimus</e1>\NN\1740 and\CC\1740 tacrolimus\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 sinusoidal\JJ\1740 obstruction\NN\4341686 syndrome\NN\5870365 and\CC\1740 <e2>microangiopathy</e2>\VBN\1740 :\:\1740 results\NNS\34213 of\IN\1740 the\DT\1740 EVTAC\NNP\1740 trial\NN\786195 .\.\1740
D016559_D006086 NONE <e2>Graft-versus-host\NN\1740 disease</e2>\NN\14061805 prophylaxis\NN\1077350 with\IN\1740 everolimus\NN\1740 and\CC\1740 <e1>tacrolimus</e1>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 sinusoidal\JJ\1740 obstruction\NN\4341686 syndrome\NN\5870365 and\CC\1740 microangiopathy\VBN\1740 :\:\1740 results\NNS\34213 of\IN\1740 the\DT\1740 EVTAC\NNP\1740 trial\NN\786195 .\.\1740
D016559_D006504 CID Graft-versus-host\NN\1740 disease\NN\14061805 prophylaxis\NN\1077350 with\IN\1740 everolimus\NN\1740 and\CC\1740 <e1>tacrolimus</e1>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>sinusoidal\JJ\1740 obstruction\NN\4341686 syndrome</e2>\NN\5870365 and\CC\1740 microangiopathy\VBN\1740 :\:\1740 results\NNS\34213 of\IN\1740 the\DT\1740 EVTAC\NNP\1740 trial\NN\786195 .\.\1740
D016559_D014652 CID Graft-versus-host\NN\1740 disease\NN\14061805 prophylaxis\NN\1077350 with\IN\1740 everolimus\NN\1740 and\CC\1740 <e1>tacrolimus</e1>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 sinusoidal\JJ\1740 obstruction\NN\4341686 syndrome\NN\5870365 and\CC\1740 <e2>microangiopathy</e2>\VBN\1740 :\:\1740 results\NNS\34213 of\IN\1740 the\DT\1740 EVTAC\NNP\1740 trial\NN\786195 .\.\1740
D008727_D006086 NONE A\DT\13649268 calcineurin\NN\1740 inhibitor\NN\20090 combined\VBN\2630189 with\IN\1740 <e1>methotrexate</e1>\NN\2722166 is\VBZ\836236 the\DT\1740 standard\JJ\1740 prophylaxis\NN\1077350 for\IN\1740 <e2>graft-versus-host\JJ\1740 disease</e2>\NN\14061805 (\-LRB-\1740 GVHD\NN\1740 )\-RRB-\1740 after\IN\1740 allogeneic\JJ\1740 hematopoietic\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 (\-LRB-\1740 HSCT\NNS\1740 )\-RRB-\1740 .\.\1740
D008727_D006086 NONE A\DT\13649268 calcineurin\NN\1740 inhibitor\NN\20090 combined\VBN\2630189 with\IN\1740 <e1>methotrexate</e1>\NN\2722166 is\VBZ\836236 the\DT\1740 standard\JJ\1740 prophylaxis\NN\1077350 for\IN\1740 graft-versus-host\JJ\1740 disease\NN\14061805 (\-LRB-\1740 <e2>GVHD</e2>\NN\1740 )\-RRB-\1740 after\IN\1740 allogeneic\JJ\1740 hematopoietic\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 (\-LRB-\1740 HSCT\NNS\1740 )\-RRB-\1740 .\.\1740
C107135_D009190 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>everolimus</e1>\NN\1740 and\CC\1740 tacrolimus\NN\1740 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 62\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 either\CC\1740 <e2>myelodysplastic\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 MDS\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 or\CC\3541091 acute\JJ\1740 myeloid\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 AML\NN\1740 ;\:\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 undergoing\VBG\109660 intensive\JJ\1740 conditioning\NN\5752544 followed\VBN\1835496 by\IN\1740 HSCT\NNS\1740 from\IN\1740 related\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 or\CC\3541091 unrelated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 20\CD\13745420 )\-RRB-\1740 donors\NNS\9608709 .\.\1740
C107135_D009190 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>everolimus</e1>\NN\1740 and\CC\1740 tacrolimus\NN\1740 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 62\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 either\CC\1740 myelodysplastic\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>MDS</e2>\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 or\CC\3541091 acute\JJ\1740 myeloid\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 AML\NN\1740 ;\:\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 undergoing\VBG\109660 intensive\JJ\1740 conditioning\NN\5752544 followed\VBN\1835496 by\IN\1740 HSCT\NNS\1740 from\IN\1740 related\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 or\CC\3541091 unrelated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 20\CD\13745420 )\-RRB-\1740 donors\NNS\9608709 .\.\1740
C107135_D015470 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>everolimus</e1>\NN\1740 and\CC\1740 tacrolimus\NN\1740 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 62\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 either\CC\1740 myelodysplastic\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 MDS\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 or\CC\3541091 <e2>acute\JJ\1740 myeloid\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 AML\NN\1740 ;\:\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 undergoing\VBG\109660 intensive\JJ\1740 conditioning\NN\5752544 followed\VBN\1835496 by\IN\1740 HSCT\NNS\1740 from\IN\1740 related\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 or\CC\3541091 unrelated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 20\CD\13745420 )\-RRB-\1740 donors\NNS\9608709 .\.\1740
C107135_D015470 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>everolimus</e1>\NN\1740 and\CC\1740 tacrolimus\NN\1740 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 62\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 either\CC\1740 myelodysplastic\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 MDS\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 or\CC\3541091 acute\JJ\1740 myeloid\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>AML</e2>\NN\1740 ;\:\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 undergoing\VBG\109660 intensive\JJ\1740 conditioning\NN\5752544 followed\VBN\1835496 by\IN\1740 HSCT\NNS\1740 from\IN\1740 related\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 or\CC\3541091 unrelated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 20\CD\13745420 )\-RRB-\1740 donors\NNS\9608709 .\.\1740
D016559_D009190 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 everolimus\NN\1740 and\CC\1740 <e1>tacrolimus</e1>\NN\1740 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 62\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 either\CC\1740 <e2>myelodysplastic\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 MDS\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 or\CC\3541091 acute\JJ\1740 myeloid\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 AML\NN\1740 ;\:\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 undergoing\VBG\109660 intensive\JJ\1740 conditioning\NN\5752544 followed\VBN\1835496 by\IN\1740 HSCT\NNS\1740 from\IN\1740 related\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 or\CC\3541091 unrelated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 20\CD\13745420 )\-RRB-\1740 donors\NNS\9608709 .\.\1740
D016559_D009190 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 everolimus\NN\1740 and\CC\1740 <e1>tacrolimus</e1>\NN\1740 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 62\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 either\CC\1740 myelodysplastic\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>MDS</e2>\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 or\CC\3541091 acute\JJ\1740 myeloid\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 AML\NN\1740 ;\:\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 undergoing\VBG\109660 intensive\JJ\1740 conditioning\NN\5752544 followed\VBN\1835496 by\IN\1740 HSCT\NNS\1740 from\IN\1740 related\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 or\CC\3541091 unrelated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 20\CD\13745420 )\-RRB-\1740 donors\NNS\9608709 .\.\1740
D016559_D015470 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 everolimus\NN\1740 and\CC\1740 <e1>tacrolimus</e1>\NN\1740 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 62\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 either\CC\1740 myelodysplastic\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 MDS\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 or\CC\3541091 <e2>acute\JJ\1740 myeloid\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 AML\NN\1740 ;\:\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 undergoing\VBG\109660 intensive\JJ\1740 conditioning\NN\5752544 followed\VBN\1835496 by\IN\1740 HSCT\NNS\1740 from\IN\1740 related\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 or\CC\3541091 unrelated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 20\CD\13745420 )\-RRB-\1740 donors\NNS\9608709 .\.\1740
D016559_D015470 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 everolimus\NN\1740 and\CC\1740 <e1>tacrolimus</e1>\NN\1740 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 62\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 either\CC\1740 myelodysplastic\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 MDS\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 or\CC\3541091 acute\JJ\1740 myeloid\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>AML</e2>\NN\1740 ;\:\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 undergoing\VBG\109660 intensive\JJ\1740 conditioning\NN\5752544 followed\VBN\1835496 by\IN\1740 HSCT\NNS\1740 from\IN\1740 related\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 or\CC\3541091 unrelated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 20\CD\13745420 )\-RRB-\1740 donors\NNS\9608709 .\.\1740
10091616
D007980_D004409 CID Worsening\NN\13457378 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 by\IN\1740 motor\NN\3699975 and\CC\1740 mental\JJ\1740 tasks\NNS\575741 .\.\1740
D001058_D010300 NONE Ten\CD\13745420 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 with\IN\1740 disabling\VBG\126264 dyskinesia\NN\14084880 were\VBD\836236 included\VBN\690614 in\IN\13603305 this\DT\1740 study\NN\635850 to\TO\1740 evaluate\VB\670261 the\DT\1740 role\NN\719494 of\IN\1740 mental\JJ\1740 (\-LRB-\1740 mental\JJ\1740 calculation\NN\1023820 )\-RRB-\1740 and\CC\1740 motor\NN\3699975 (\-LRB-\1740 flexion/extension\NN\1740 of\IN\1740 right\JJ\1740 fingers\NNS\5566097 ,\,\1740 flexion/extension\NN\1740 of\IN\1740 left\JJ\1740 fingers\NNS\5566097 ,\,\1740 flexion/extension\NN\1740 of\IN\1740 the\DT\1740 neck\NN\5225090 ,\,\1740 speaking\VBG\740577 aloud\RB\1740 )\-RRB-\1740 tasks\NNS\575741 on\IN\1740 the\DT\1740 worsening\NN\13457378 of\IN\1740 peak-dose\JJ\1740 dyskinesia\NN\14084880 following\VBG\1835496 administration\NN\1133281 of\IN\1740 an\DT\6697703 effective\JJ\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>apomorphine</e1>\NN\3786417 .\.\1740
D001058_D004409 CID Ten\CD\13745420 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 with\IN\1740 disabling\VBG\126264 <e2>dyskinesia</e2>\NN\14084880 were\VBD\836236 included\VBN\690614 in\IN\13603305 this\DT\1740 study\NN\635850 to\TO\1740 evaluate\VB\670261 the\DT\1740 role\NN\719494 of\IN\1740 mental\JJ\1740 (\-LRB-\1740 mental\JJ\1740 calculation\NN\1023820 )\-RRB-\1740 and\CC\1740 motor\NN\3699975 (\-LRB-\1740 flexion/extension\NN\1740 of\IN\1740 right\JJ\1740 fingers\NNS\5566097 ,\,\1740 flexion/extension\NN\1740 of\IN\1740 left\JJ\1740 fingers\NNS\5566097 ,\,\1740 flexion/extension\NN\1740 of\IN\1740 the\DT\1740 neck\NN\5225090 ,\,\1740 speaking\VBG\740577 aloud\RB\1740 )\-RRB-\1740 tasks\NNS\575741 on\IN\1740 the\DT\1740 worsening\NN\13457378 of\IN\1740 peak-dose\JJ\1740 dyskinesia\NN\14084880 following\VBG\1835496 administration\NN\1133281 of\IN\1740 an\DT\6697703 effective\JJ\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>apomorphine</e1>\NN\3786417 .\.\1740
D001058_D004409 CID Ten\CD\13745420 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 with\IN\1740 disabling\VBG\126264 dyskinesia\NN\14084880 were\VBD\836236 included\VBN\690614 in\IN\13603305 this\DT\1740 study\NN\635850 to\TO\1740 evaluate\VB\670261 the\DT\1740 role\NN\719494 of\IN\1740 mental\JJ\1740 (\-LRB-\1740 mental\JJ\1740 calculation\NN\1023820 )\-RRB-\1740 and\CC\1740 motor\NN\3699975 (\-LRB-\1740 flexion/extension\NN\1740 of\IN\1740 right\JJ\1740 fingers\NNS\5566097 ,\,\1740 flexion/extension\NN\1740 of\IN\1740 left\JJ\1740 fingers\NNS\5566097 ,\,\1740 flexion/extension\NN\1740 of\IN\1740 the\DT\1740 neck\NN\5225090 ,\,\1740 speaking\VBG\740577 aloud\RB\1740 )\-RRB-\1740 tasks\NNS\575741 on\IN\1740 the\DT\1740 worsening\NN\13457378 of\IN\1740 peak-dose\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 following\VBG\1835496 administration\NN\1133281 of\IN\1740 an\DT\6697703 effective\JJ\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>apomorphine</e1>\NN\3786417 .\.\1740
950631
D010396_D007674 CID Immunopathology\NN\6051542 of\IN\1740 <e1>penicillamine-induced</e1>\JJ\1740 <e2>glomerular\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D010396_D001172 NONE Four\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 developed\VBD\1753788 heavy\JJ\1740 proteinuria\NN\14299637 after\IN\1740 five\CD\13741022 to\TO\1740 12\CD\13745420 months\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>D-penicillamine</e1>\NN\1740 .\.\1740
D010396_D011507 CID Four\CD\13741022 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 developed\VBD\1753788 heavy\JJ\1740 <e2>proteinuria</e2>\NN\14299637 after\IN\1740 five\CD\13741022 to\TO\1740 12\CD\13745420 months\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>D-penicillamine</e1>\NN\1740 .\.\1740
7803371
D003915_D003072 CID <e2>Cognitive\JJ\1740 deterioration</e2>\NN\14560612 from\IN\1740 long-term\JJ\1740 abuse\NN\418025 of\IN\1740 <e1>dextromethorphan</e1>\NN\1740 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D003915_D003072 CID This\DT\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>cognitive\JJ\1740 deterioration</e2>\NN\14560612 resulting\VBG\2633881 from\IN\1740 prolonged\JJ\1740 use\NN\407535 of\IN\1740 <e1>DM</e1>\NN\14117805 .\.\1740
9105126
D013256_D018658 CID Postinfarction\NN\1740 <e2>ventricular\NN\1740 septal\JJ\1740 defect</e2>\NN\14462666 associated\VBN\628491 with\IN\1740 long-term\JJ\1740 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 .\.\1740
D013256_D018658 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 postinfarction\NN\1740 <e2>ventricular\NN\1740 septal\JJ\1740 rupture</e2>\NN\14285662 in\IN\13603305 patients\NNS\9898892 on\IN\1740 long-term\JJ\1740 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 are\VBP\836236 presented\VBN\2137132 and\CC\1740 the\DT\1740 favourable\JJ\1740 outcome\NN\7291312 in\IN\13603305 both\DT\1740 cases\NNS\7283608 described\VBN\1001294 .\.\1740
D013256_D018658 CID A\DT\13649268 possible\JJ\1740 association\NN\8008335 between\IN\1740 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 and\CC\1740 subsequent\JJ\1740 postinfarction\NN\1740 <e2>septal\JJ\1740 rupture</e2>\NN\14285662 is\VBZ\836236 discussed\VBN\1033527 .\.\1740
15276120
D014859_D006470 CID Time\NN\7308889 trends\NNS\8679972 in\IN\13603305 <e1>warfarin-associated</e1>\JJ\1740 <e2>hemorrhage</e2>\NN\14285662 .\.\1740
D014859_D006470 CID The\DT\1740 annual\JJ\1740 incidence\NN\13821570 of\IN\1740 <e1>warfarin-related</e1>\JJ\1740 <e2>bleeding</e2>\NN\14285662 at\IN\14622893 Brigham\NNP\1740 and\CC\1740 Women\NNP\9605289 's\POS\1740 Hospital\NNP\3739518 increased\VBD\169651 from\IN\1740 0.97/1,000\CD\1740 patient\NN\9898892 admissions\NNS\49003 in\IN\13603305 the\DT\1740 first\JJ\1740 time\NN\7308889 period\NN\13575869 (\-LRB-\1740 January\NNP\15209706 1995\CD\1740 to\IN\1740 October\NNP\15209706 1998\CD\1740 )\-RRB-\1740 to\TO\1740 1.19/1,000\NN\1740 patient\NN\9898892 admissions\NNS\49003 in\IN\13603305 the\DT\1740 second\JJ\1740 time\NN\7308889 period\NN\13575869 (\-LRB-\1740 November\NNP\15209706 1998\CD\1740 to\IN\1740 August\NNP\15209706 2002\CD\1740 )\-RRB-\1740 of\IN\1740 this\DT\1740 study\NN\635850 .\.\1740
11694026
C012655_D014581 NONE Tolerability\NN\1740 of\IN\1740 <e1>nimesulide</e1>\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
C012655_D014581 NONE In\IN\13603305 this\DT\1740 study\NN\635850 we\PRP\1740 investigated\VBD\644583 tolerability\NN\1740 and\CC\1740 reliability\NN\4669247 of\IN\1740 <e1>nimesulide</e1>\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 a\DT\13649268 very\RB\1740 large\JJ\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 an\DT\6697703 exclusive\JJ\1740 well-documented\JJ\1740 history\NN\15120823 of\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
C012655_D014581 NONE A\DT\13649268 single-placebo-controlled\JJ\1740 oral\JJ\1740 challenge\NN\13927383 procedure\NN\407535 with\IN\1740 <e1>nimesulide</e1>\NN\1740 or\CC\3541091 paracetamol\NN\1740 was\VBD\836236 applied\VBN\2676054 to\TO\1740 829\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
C012655_D014581 NONE Taken\VBN\2367363 together\RB\1740 ,\,\1740 our\PRP$\1740 results\NNS\34213 confirm\VBP\1011725 the\DT\1740 good\JJ\1740 tolerability\NN\1740 of\IN\1740 <e1>nimesulide</e1>\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 <e2>urticaria/angioedema</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 NSAIDs\NNS\2721538 .\.\1740
C012655_D000799 CID Tolerability\NN\1740 of\IN\1740 <e1>nimesulide</e1>\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
C012655_D000799 CID In\IN\13603305 this\DT\1740 study\NN\635850 we\PRP\1740 investigated\VBD\644583 tolerability\NN\1740 and\CC\1740 reliability\NN\4669247 of\IN\1740 <e1>nimesulide</e1>\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 a\DT\13649268 very\RB\1740 large\JJ\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 an\DT\6697703 exclusive\JJ\1740 well-documented\JJ\1740 history\NN\15120823 of\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
C012655_D000799 CID A\DT\13649268 single-placebo-controlled\JJ\1740 oral\JJ\1740 challenge\NN\13927383 procedure\NN\407535 with\IN\1740 <e1>nimesulide</e1>\NN\1740 or\CC\3541091 paracetamol\NN\1740 was\VBD\836236 applied\VBN\2676054 to\TO\1740 829\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
C012655_D000799 CID Taken\VBN\2367363 together\RB\1740 ,\,\1740 our\PRP$\1740 results\NNS\34213 confirm\VBP\1011725 the\DT\1740 good\JJ\1740 tolerability\NN\1740 of\IN\1740 <e1>nimesulide</e1>\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 <e2>urticaria/angioedema</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 NSAIDs\NNS\2721538 .\.\1740
D000082_D014581 NONE Tolerability\NN\1740 of\IN\1740 nimesulide\NN\1740 and\CC\1740 <e1>paracetamol</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000082_D014581 NONE In\IN\13603305 this\DT\1740 study\NN\635850 we\PRP\1740 investigated\VBD\644583 tolerability\NN\1740 and\CC\1740 reliability\NN\4669247 of\IN\1740 nimesulide\NN\1740 and\CC\1740 <e1>paracetamol</e1>\NN\1740 in\IN\13603305 a\DT\13649268 very\RB\1740 large\JJ\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 an\DT\6697703 exclusive\JJ\1740 well-documented\JJ\1740 history\NN\15120823 of\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000082_D014581 NONE A\DT\13649268 single-placebo-controlled\JJ\1740 oral\JJ\1740 challenge\NN\13927383 procedure\NN\407535 with\IN\1740 nimesulide\NN\1740 or\CC\3541091 <e1>paracetamol</e1>\NN\1740 was\VBD\836236 applied\VBN\2676054 to\TO\1740 829\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000082_D014581 NONE Taken\VBN\2367363 together\RB\1740 ,\,\1740 our\PRP$\1740 results\NNS\34213 confirm\VBP\1011725 the\DT\1740 good\JJ\1740 tolerability\NN\1740 of\IN\1740 nimesulide\NN\1740 and\CC\1740 <e1>paracetamol</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 <e2>urticaria/angioedema</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 NSAIDs\NNS\2721538 .\.\1740
D000082_D000799 CID Tolerability\NN\1740 of\IN\1740 nimesulide\NN\1740 and\CC\1740 <e1>paracetamol</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000082_D000799 CID In\IN\13603305 this\DT\1740 study\NN\635850 we\PRP\1740 investigated\VBD\644583 tolerability\NN\1740 and\CC\1740 reliability\NN\4669247 of\IN\1740 nimesulide\NN\1740 and\CC\1740 <e1>paracetamol</e1>\NN\1740 in\IN\13603305 a\DT\13649268 very\RB\1740 large\JJ\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 an\DT\6697703 exclusive\JJ\1740 well-documented\JJ\1740 history\NN\15120823 of\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000082_D000799 CID A\DT\13649268 single-placebo-controlled\JJ\1740 oral\JJ\1740 challenge\NN\13927383 procedure\NN\407535 with\IN\1740 nimesulide\NN\1740 or\CC\3541091 <e1>paracetamol</e1>\NN\1740 was\VBD\836236 applied\VBN\2676054 to\TO\1740 829\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 NSAID-induced\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000082_D000799 CID Taken\VBN\2367363 together\RB\1740 ,\,\1740 our\PRP$\1740 results\NNS\34213 confirm\VBP\1011725 the\DT\1740 good\JJ\1740 tolerability\NN\1740 of\IN\1740 nimesulide\NN\1740 and\CC\1740 <e1>paracetamol</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 <e2>urticaria/angioedema</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 NSAIDs\NNS\2721538 .\.\1740
D000894_D014581 NONE Tolerability\NN\1740 of\IN\1740 nimesulide\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000894_D014581 NONE In\IN\13603305 this\DT\1740 study\NN\635850 we\PRP\1740 investigated\VBD\644583 tolerability\NN\1740 and\CC\1740 reliability\NN\4669247 of\IN\1740 nimesulide\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 a\DT\13649268 very\RB\1740 large\JJ\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 an\DT\6697703 exclusive\JJ\1740 well-documented\JJ\1740 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000894_D014581 NONE A\DT\13649268 single-placebo-controlled\JJ\1740 oral\JJ\1740 challenge\NN\13927383 procedure\NN\407535 with\IN\1740 nimesulide\NN\1740 or\CC\3541091 paracetamol\NN\1740 was\VBD\836236 applied\VBN\2676054 to\TO\1740 829\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000894_D014581 NONE Furthermore\RB\1740 ,\,\1740 18.28\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 chronic\JJ\1740 <e2>urticaria</e2>\NNS\14533203 and\CC\1740 11.8\CD\1740 %\NN\1740 of\IN\1740 subjects\NNS\6598915 with\IN\1740 an\DT\6697703 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 urticaria/angioedema\NN\1740 or\CC\3541091 angioedema\NN\14316714 alone\RB\1740 (\-LRB-\1740 with\IN\1740 or\CC\3541091 without\IN\1740 chronic\JJ\1740 urticaria\NNS\14533203 )\-RRB-\1740 resulted\VBD\2633881 to\TO\1740 be\VB\836236 intolerant\JJ\1740 to\TO\1740 alternative\JJ\1740 drugs\NNS\14778436 .\.\1740
D000894_D014581 NONE Furthermore\RB\1740 ,\,\1740 18.28\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 chronic\JJ\1740 urticaria\NNS\14533203 and\CC\1740 11.8\CD\1740 %\NN\1740 of\IN\1740 subjects\NNS\6598915 with\IN\1740 an\DT\6697703 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 or\CC\3541091 angioedema\NN\14316714 alone\RB\1740 (\-LRB-\1740 with\IN\1740 or\CC\3541091 without\IN\1740 chronic\JJ\1740 urticaria\NNS\14533203 )\-RRB-\1740 resulted\VBD\2633881 to\TO\1740 be\VB\836236 intolerant\JJ\1740 to\TO\1740 alternative\JJ\1740 drugs\NNS\14778436 .\.\1740
D000894_D014581 NONE Furthermore\RB\1740 ,\,\1740 18.28\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 chronic\JJ\1740 urticaria\NNS\14533203 and\CC\1740 11.8\CD\1740 %\NN\1740 of\IN\1740 subjects\NNS\6598915 with\IN\1740 an\DT\6697703 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 urticaria/angioedema\NN\1740 or\CC\3541091 angioedema\NN\14316714 alone\RB\1740 (\-LRB-\1740 with\IN\1740 or\CC\3541091 without\IN\1740 chronic\JJ\1740 <e2>urticaria</e2>\NNS\14533203 )\-RRB-\1740 resulted\VBD\2633881 to\TO\1740 be\VB\836236 intolerant\JJ\1740 to\TO\1740 alternative\JJ\1740 drugs\NNS\14778436 .\.\1740
D000894_D014581 NONE Taken\VBN\2367363 together\RB\1740 ,\,\1740 our\PRP$\1740 results\NNS\34213 confirm\VBP\1011725 the\DT\1740 good\JJ\1740 tolerability\NN\1740 of\IN\1740 nimesulide\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 <e2>urticaria/angioedema</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 <e1>NSAIDs</e1>\NNS\2721538 .\.\1740
D000894_D014581 NONE However\RB\1740 ,\,\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 reaction\NN\13446390 to\TO\1740 these\DT\1740 alternative\JJ\1740 study\NN\635850 drugs\NNS\14778436 is\VBZ\836236 statistically\RB\1740 increased\VBN\169651 by\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 chronic\JJ\1740 <e2>urticaria</e2>\NNS\14533203 and\CC\1740 ,\,\1740 above\RB\1740 all\RB\1740 ,\,\1740 by\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 angioedema\NN\14316714 .\.\1740
D000894_D000799 CID Tolerability\NN\1740 of\IN\1740 nimesulide\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000894_D000799 CID In\IN\13603305 this\DT\1740 study\NN\635850 we\PRP\1740 investigated\VBD\644583 tolerability\NN\1740 and\CC\1740 reliability\NN\4669247 of\IN\1740 nimesulide\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 a\DT\13649268 very\RB\1740 large\JJ\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 an\DT\6697703 exclusive\JJ\1740 well-documented\JJ\1740 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000894_D000799 CID A\DT\13649268 single-placebo-controlled\JJ\1740 oral\JJ\1740 challenge\NN\13927383 procedure\NN\407535 with\IN\1740 nimesulide\NN\1740 or\CC\3541091 paracetamol\NN\1740 was\VBD\836236 applied\VBN\2676054 to\TO\1740 829\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 .\.\1740
D000894_D000799 CID Furthermore\RB\1740 ,\,\1740 18.28\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 chronic\JJ\1740 urticaria\NNS\14533203 and\CC\1740 11.8\CD\1740 %\NN\1740 of\IN\1740 subjects\NNS\6598915 with\IN\1740 an\DT\6697703 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 <e2>urticaria/angioedema</e2>\NN\1740 or\CC\3541091 angioedema\NN\14316714 alone\RB\1740 (\-LRB-\1740 with\IN\1740 or\CC\3541091 without\IN\1740 chronic\JJ\1740 urticaria\NNS\14533203 )\-RRB-\1740 resulted\VBD\2633881 to\TO\1740 be\VB\836236 intolerant\JJ\1740 to\TO\1740 alternative\JJ\1740 drugs\NNS\14778436 .\.\1740
D000894_D000799 CID Furthermore\RB\1740 ,\,\1740 18.28\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 chronic\JJ\1740 urticaria\NNS\14533203 and\CC\1740 11.8\CD\1740 %\NN\1740 of\IN\1740 subjects\NNS\6598915 with\IN\1740 an\DT\6697703 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 urticaria/angioedema\NN\1740 or\CC\3541091 <e2>angioedema</e2>\NN\14316714 alone\RB\1740 (\-LRB-\1740 with\IN\1740 or\CC\3541091 without\IN\1740 chronic\JJ\1740 urticaria\NNS\14533203 )\-RRB-\1740 resulted\VBD\2633881 to\TO\1740 be\VB\836236 intolerant\JJ\1740 to\TO\1740 alternative\JJ\1740 drugs\NNS\14778436 .\.\1740
D000894_D000799 CID Taken\VBN\2367363 together\RB\1740 ,\,\1740 our\PRP$\1740 results\NNS\34213 confirm\VBP\1011725 the\DT\1740 good\JJ\1740 tolerability\NN\1740 of\IN\1740 nimesulide\NN\1740 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 <e2>urticaria/angioedema</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 <e1>NSAIDs</e1>\NNS\2721538 .\.\1740
D000894_D000799 CID However\RB\1740 ,\,\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 reaction\NN\13446390 to\TO\1740 these\DT\1740 alternative\JJ\1740 study\NN\635850 drugs\NNS\14778436 is\VBZ\836236 statistically\RB\1740 increased\VBN\169651 by\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 chronic\JJ\1740 urticaria\NNS\14533203 and\CC\1740 ,\,\1740 above\RB\1740 all\RB\1740 ,\,\1740 by\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>NSAID-induced</e1>\JJ\1740 <e2>angioedema</e2>\NN\14316714 .\.\1740
19707748
D064704_D012640 CID <e2>Seizures</e2>\NNS\14081375 associated\VBN\628491 with\IN\1740 <e1>levofloxacin</e1>\NN\1740 :\:\1740 case\NN\7283608 presentation\NN\1027379 and\CC\1740 literature\NN\6362953 review\NN\5733583 .\.\1740
D064704_D012640 CID PURPOSE\NNP\5980875 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>seizures</e2>\NNS\14081375 shortly\RB\1740 after\IN\1740 initiating\VBG\1617192 treatment\NN\654885 with\IN\1740 <e1>levofloxacin</e1>\NN\1740 and\CC\1740 to\TO\1740 discuss\VB\1033527 the\DT\1740 potential\JJ\1740 drug-drug\JJ\1740 interactions\NNS\37396 related\JJ\1740 to\TO\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 cytochrome\NN\14888884 P450\NN\1740 (\-LRB-\1740 CYP\NN\1740 )\-RRB-\1740 1A2\NN\1740 in\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 in\IN\13603305 other\JJ\1740 cases\NNS\7283608 ,\,\1740 of\IN\1740 levofloxacin-induced\JJ\1740 seizures\NNS\14081375 .\.\1740
D064704_D012640 CID PURPOSE\NNP\5980875 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 seizures\NNS\14081375 shortly\RB\1740 after\IN\1740 initiating\VBG\1617192 treatment\NN\654885 with\IN\1740 <e1>levofloxacin</e1>\NN\1740 and\CC\1740 to\TO\1740 discuss\VB\1033527 the\DT\1740 potential\JJ\1740 drug-drug\JJ\1740 interactions\NNS\37396 related\JJ\1740 to\TO\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 cytochrome\NN\14888884 P450\NN\1740 (\-LRB-\1740 CYP\NN\1740 )\-RRB-\1740 1A2\NN\1740 in\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 in\IN\13603305 other\JJ\1740 cases\NNS\7283608 ,\,\1740 of\IN\1740 levofloxacin-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D064704_D012640 CID PURPOSE\NNP\5980875 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>seizures</e2>\NNS\14081375 shortly\RB\1740 after\IN\1740 initiating\VBG\1617192 treatment\NN\654885 with\IN\1740 levofloxacin\NN\1740 and\CC\1740 to\TO\1740 discuss\VB\1033527 the\DT\1740 potential\JJ\1740 drug-drug\JJ\1740 interactions\NNS\37396 related\JJ\1740 to\TO\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 cytochrome\NN\14888884 P450\NN\1740 (\-LRB-\1740 CYP\NN\1740 )\-RRB-\1740 1A2\NN\1740 in\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 in\IN\13603305 other\JJ\1740 cases\NNS\7283608 ,\,\1740 of\IN\1740 <e1>levofloxacin-induced</e1>\JJ\1740 seizures\NNS\14081375 .\.\1740
D064704_D012640 CID PURPOSE\NNP\5980875 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 seizures\NNS\14081375 shortly\RB\1740 after\IN\1740 initiating\VBG\1617192 treatment\NN\654885 with\IN\1740 levofloxacin\NN\1740 and\CC\1740 to\TO\1740 discuss\VB\1033527 the\DT\1740 potential\JJ\1740 drug-drug\JJ\1740 interactions\NNS\37396 related\JJ\1740 to\TO\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 cytochrome\NN\14888884 P450\NN\1740 (\-LRB-\1740 CYP\NN\1740 )\-RRB-\1740 1A2\NN\1740 in\IN\13603305 this\DT\1740 case\NN\7283608 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 in\IN\13603305 other\JJ\1740 cases\NNS\7283608 ,\,\1740 of\IN\1740 <e1>levofloxacin-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D064704_D012640 CID RESULTS\NNS\34213 :\:\1740 Six\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>levofloxacin-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 the\DT\1740 literature\NN\6362953 .\.\1740
15811908
C012052_D010673 NONE <e2>Pheochromocytoma</e2>\NNS\14235200 unmasked\VBN\853195 by\IN\1740 <e1>amisulpride</e1>\RB\1740 and\CC\1740 tiapride\NN\1740 .\.\1740
C012052_D010673 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 unmasking\NN\7215377 of\IN\1740 <e2>pheochromocytoma</e2>\NN\14235200 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 <e1>amisulpride</e1>\NN\1740 and\CC\1740 tiapride\NN\1740 .\.\1740
C012052_D010673 NONE CONCLUSIONS\NNS\5837957 :\:\1740 As\IN\14622893 of\IN\1740 March\NNP\15209706 24\CD\13745420 ,\,\1740 2005\CD\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 <e1>amisulpride-</e1>\NN\1740 and\CC\1740 tiapride-induced\JJ\1740 hypertensive\JJ\1740 crisis\NN\14411243 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>pheochromocytoma</e2>\NN\14235200 .\.\1740
D063325_D010673 NONE <e2>Pheochromocytoma</e2>\NNS\14235200 unmasked\VBN\853195 by\IN\1740 amisulpride\RB\1740 and\CC\1740 <e1>tiapride</e1>\NN\1740 .\.\1740
D063325_D010673 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 the\DT\1740 unmasking\NN\7215377 of\IN\1740 <e2>pheochromocytoma</e2>\NN\14235200 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 amisulpride\NN\1740 and\CC\1740 <e1>tiapride</e1>\NN\1740 .\.\1740
D063325_D010673 NONE CONCLUSIONS\NNS\5837957 :\:\1740 As\IN\14622893 of\IN\1740 March\NNP\15209706 24\CD\13745420 ,\,\1740 2005\CD\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 amisulpride-\NN\1740 and\CC\1740 <e1>tiapride-induced</e1>\JJ\1740 hypertensive\JJ\1740 crisis\NN\14411243 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>pheochromocytoma</e2>\NN\14235200 .\.\1740
C012052_D006973 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 with\IN\1740 severe\JJ\1740 headache\NN\5829480 and\CC\1740 vomiting\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>amisulpride</e1>\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 tiapride\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 nicardipine\NN\1740 and\CC\1740 verapamil\NN\2938514 treatment\NN\654885 .\.\1740
C012052_D006973 CID In\IN\13603305 our\PRP$\1740 case\NN\7283608 ,\,\1740 use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicated\VBD\952524 a\DT\13649268 possible\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 <e2>hypertensive</e2>\JJ\1740 crisis\NN\14411243 and\CC\1740 <e1>amisulpride</e1>\RB\1740 and\CC\1740 tiapride\NN\1740 therapy\NN\657604 .\.\1740
C012052_D006973 CID CONCLUSIONS\NNS\5837957 :\:\1740 As\IN\14622893 of\IN\1740 March\NNP\15209706 24\CD\13745420 ,\,\1740 2005\CD\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 <e1>amisulpride-</e1>\NN\1740 and\CC\1740 tiapride-induced\JJ\1740 <e2>hypertensive</e2>\JJ\1740 crisis\NN\14411243 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 pheochromocytoma\NN\14235200 .\.\1740
C012052_D006261 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 hypertension\NN\14057371 with\IN\1740 severe\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 vomiting\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>amisulpride</e1>\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 tiapride\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 nicardipine\NN\1740 and\CC\1740 verapamil\NN\2938514 treatment\NN\654885 .\.\1740
C012052_D014839 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 hypertension\NN\14057371 with\IN\1740 severe\JJ\1740 headache\NN\5829480 and\CC\1740 <e2>vomiting</e2>\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>amisulpride</e1>\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 tiapride\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 nicardipine\NN\1740 and\CC\1740 verapamil\NN\2938514 treatment\NN\654885 .\.\1740
D063325_D006973 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 with\IN\1740 severe\JJ\1740 headache\NN\5829480 and\CC\1740 vomiting\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 amisulpride\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 <e1>tiapride</e1>\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 nicardipine\NN\1740 and\CC\1740 verapamil\NN\2938514 treatment\NN\654885 .\.\1740
D063325_D006973 CID In\IN\13603305 our\PRP$\1740 case\NN\7283608 ,\,\1740 use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicated\VBD\952524 a\DT\13649268 possible\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 <e2>hypertensive</e2>\JJ\1740 crisis\NN\14411243 and\CC\1740 amisulpride\RB\1740 and\CC\1740 <e1>tiapride</e1>\NN\1740 therapy\NN\657604 .\.\1740
D063325_D006973 CID CONCLUSIONS\NNS\5837957 :\:\1740 As\IN\14622893 of\IN\1740 March\NNP\15209706 24\CD\13745420 ,\,\1740 2005\CD\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 amisulpride-\NN\1740 and\CC\1740 <e1>tiapride-induced</e1>\JJ\1740 <e2>hypertensive</e2>\JJ\1740 crisis\NN\14411243 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 pheochromocytoma\NN\14235200 .\.\1740
D063325_D006261 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 hypertension\NN\14057371 with\IN\1740 severe\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 vomiting\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 amisulpride\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 <e1>tiapride</e1>\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 nicardipine\NN\1740 and\CC\1740 verapamil\NN\2938514 treatment\NN\654885 .\.\1740
D063325_D014839 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 hypertension\NN\14057371 with\IN\1740 severe\JJ\1740 headache\NN\5829480 and\CC\1740 <e2>vomiting</e2>\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 amisulpride\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 <e1>tiapride</e1>\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 nicardipine\NN\1740 and\CC\1740 verapamil\NN\2938514 treatment\NN\654885 .\.\1740
D009529_D006973 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 with\IN\1740 severe\JJ\1740 headache\NN\5829480 and\CC\1740 vomiting\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 amisulpride\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 tiapride\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 <e1>nicardipine</e1>\NN\1740 and\CC\1740 verapamil\NN\2938514 treatment\NN\654885 .\.\1740
D009529_D006261 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 hypertension\NN\14057371 with\IN\1740 severe\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 vomiting\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 amisulpride\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 tiapride\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 <e1>nicardipine</e1>\NN\1740 and\CC\1740 verapamil\NN\2938514 treatment\NN\654885 .\.\1740
D009529_D014839 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 hypertension\NN\14057371 with\IN\1740 severe\JJ\1740 headache\NN\5829480 and\CC\1740 <e2>vomiting</e2>\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 amisulpride\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 tiapride\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 <e1>nicardipine</e1>\NN\1740 and\CC\1740 verapamil\NN\2938514 treatment\NN\654885 .\.\1740
D014700_D006973 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 with\IN\1740 severe\JJ\1740 headache\NN\5829480 and\CC\1740 vomiting\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 amisulpride\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 tiapride\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 nicardipine\NN\1740 and\CC\1740 <e1>verapamil</e1>\NN\2938514 treatment\NN\654885 .\.\1740
D014700_D006261 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 hypertension\NN\14057371 with\IN\1740 severe\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 vomiting\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 amisulpride\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 tiapride\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 nicardipine\NN\1740 and\CC\1740 <e1>verapamil</e1>\NN\2938514 treatment\NN\654885 .\.\1740
D014700_D014839 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 42-year-old\JJ\1740 white\JJ\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 hypertension\NN\14057371 with\IN\1740 severe\JJ\1740 headache\NN\5829480 and\CC\1740 <e2>vomiting</e2>\NN\116687 2\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 first\JJ\1740 doses\NNS\3740161 of\IN\1740 amisulpride\RB\1740 100\CD\13745420 mg\NN\13717155 and\CC\1740 tiapride\NN\1740 100\CD\13745420 mg.\NN\1740 Both\DT\1740 drugs\NNS\14778436 were\VBD\836236 immediately\RB\1740 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 recovered\VBN\2210855 after\IN\1740 subsequent\JJ\1740 nicardipine\NN\1740 and\CC\1740 <e1>verapamil</e1>\NN\2938514 treatment\NN\654885 .\.\1740
C037689_D010673 NONE DISCUSSION\NN\6252138 :\:\1740 Drug-induced\JJ\1740 symptoms\NNS\5823932 of\IN\1740 <e2>pheochromocytoma</e2>\NN\14235200 are\VBP\836236 often\RB\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 substituted\VBN\126264 <e1>benzamide</e1>\NN\1740 drugs\NNS\14778436 ,\,\1740 but\CC\1740 the\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 is\VBZ\836236 unknown\JJ\1740 .\.\1740
19719056
D019342_D010146 NONE Acute\JJ\1740 analgesic\NN\3740161 and\CC\1740 antiinflammatory\JJ\1740 activities\NNS\30358 were\VBD\836236 ascertained\VBN\664483 using\VBG\1156834 <e1>acetic\JJ\1740 acid</e1>\NN\14818238 induced\JJ\1740 <e2>writhing</e2>\NN\1740 model\NN\5888929 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 and\CC\1740 carrageenan-induced\JJ\1740 rat\NN\2329401 paw\NN\2153445 edema\NN\14315192 model\NN\5888929 ,\,\1740 respectively\RB\1740 .\.\1740
D019342_D004487 NONE Acute\JJ\1740 analgesic\NN\3740161 and\CC\1740 antiinflammatory\JJ\1740 activities\NNS\30358 were\VBD\836236 ascertained\VBN\664483 using\VBG\1156834 <e1>acetic\JJ\1740 acid</e1>\NN\14818238 induced\JJ\1740 writhing\NN\1740 model\NN\5888929 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 and\CC\1740 carrageenan-induced\JJ\1740 rat\NN\2329401 paw\NN\2153445 <e2>edema</e2>\NN\14315192 model\NN\5888929 ,\,\1740 respectively\RB\1740 .\.\1740
D002351_D010146 CID Acute\JJ\1740 analgesic\NN\3740161 and\CC\1740 antiinflammatory\JJ\1740 activities\NNS\30358 were\VBD\836236 ascertained\VBN\664483 using\VBG\1156834 acetic\JJ\1740 acid\NN\14818238 induced\JJ\1740 <e2>writhing</e2>\NN\1740 model\NN\5888929 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 and\CC\1740 <e1>carrageenan-induced</e1>\JJ\1740 rat\NN\2329401 paw\NN\2153445 edema\NN\14315192 model\NN\5888929 ,\,\1740 respectively\RB\1740 .\.\1740
D002351_D004487 CID Acute\JJ\1740 analgesic\NN\3740161 and\CC\1740 antiinflammatory\JJ\1740 activities\NNS\30358 were\VBD\836236 ascertained\VBN\664483 using\VBG\1156834 acetic\JJ\1740 acid\NN\14818238 induced\JJ\1740 writhing\NN\1740 model\NN\5888929 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 and\CC\1740 <e1>carrageenan-induced</e1>\JJ\1740 rat\NN\2329401 paw\NN\2153445 <e2>edema</e2>\NN\14315192 model\NN\5888929 ,\,\1740 respectively\RB\1740 .\.\1740
7707116
D015474_D009447 NONE Phase\NN\15113229 I\CD\14622893 trial\NN\786195 of\IN\1740 <e1>13-cis-retinoic\JJ\1740 acid</e1>\NN\14818238 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>neuroblastoma</e2>\NN\14239425 following\VBG\1835496 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 .\.\1740
D015474_D009447 NONE PURPOSE\NNP\5980875 :\:\1740 Treatment\NN\654885 of\IN\1740 <e2>neuroblastoma</e2>\NN\14239425 cell\NN\3080309 lines\NNS\8426461 with\IN\1740 <e1>13-cis-retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 cis-RA\NN\1740 )\-RRB-\1740 can\MD\3094503 cause\VB\1617192 sustained\JJ\1740 inhibition\NN\1068773 of\IN\1740 proliferation\NN\13489037 .\.\1740
D015474_D009447 NONE PURPOSE\NNP\5980875 :\:\1740 Treatment\NN\654885 of\IN\1740 <e2>neuroblastoma</e2>\NN\14239425 cell\NN\3080309 lines\NNS\8426461 with\IN\1740 13-cis-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>cis-RA</e1>\NN\1740 )\-RRB-\1740 can\MD\3094503 cause\VB\1617192 sustained\JJ\1740 inhibition\NN\1068773 of\IN\1740 proliferation\NN\13489037 .\.\1740
D015474_D009447 NONE Since\IN\1740 <e1>cis-RA</e1>\NN\1740 has\VBZ\2108377 demonstrated\VBN\2137132 clinical\JJ\1740 responses\NNS\11410625 in\IN\13603305 <e2>neuroblastoma</e2>\NN\14239425 patients\NNS\9898892 ,\,\1740 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 preventing\VBG\1740 relapse\NN\66636 after\IN\1740 cytotoxic\JJ\1740 therapy\NN\657604 .\.\1740
D015474_D009447 NONE This\DT\1740 phase\NN\15113229 I\CD\14622893 trial\NN\786195 was\VBD\836236 designed\VBN\1631534 to\TO\1740 determine\VB\1645601 the\DT\1740 maximal-tolerated\JJ\1740 dosage\NN\13576355 (\-LRB-\1740 MTD\NN\1740 )\-RRB-\1740 ,\,\1740 toxicities\NNS\13576101 ,\,\1740 and\CC\1740 pharmacokinetics\NNS\6054892 of\IN\1740 <e1>cis-RA</e1>\NN\1740 administered\VBN\2436349 on\IN\1740 an\DT\6697703 intermittent\JJ\1740 schedule\NN\5898568 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>neuroblastoma</e2>\NN\14239425 following\VBG\1835496 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 (\-LRB-\1740 BMT\NN\1740 )\-RRB-\1740 .\.\1740
D015474_D064420 NONE This\DT\1740 phase\NN\15113229 I\CD\14622893 trial\NN\786195 was\VBD\836236 designed\VBN\1631534 to\TO\1740 determine\VB\1645601 the\DT\1740 maximal-tolerated\JJ\1740 dosage\NN\13576355 (\-LRB-\1740 MTD\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>toxicities</e2>\NNS\13576101 ,\,\1740 and\CC\1740 pharmacokinetics\NNS\6054892 of\IN\1740 <e1>cis-RA</e1>\NN\1740 administered\VBN\2436349 on\IN\1740 an\DT\6697703 intermittent\JJ\1740 schedule\NN\5898568 in\IN\13603305 children\NNS\9622049 with\IN\1740 neuroblastoma\NN\14239425 following\VBG\1835496 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 (\-LRB-\1740 BMT\NN\1740 )\-RRB-\1740 .\.\1740
D015474_D064420 NONE All\DT\1740 <e2>toxicities</e2>\NNS\13576101 resolved\VBN\352826 after\IN\1740 <e1>cis-RA</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 .\.\1740
D015474_D006934 CID The\DT\1740 DLT\NN\1740 included\VBD\690614 <e2>hypercalcemia</e2>\NN\14299637 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 predicted\VBN\916909 by\IN\1740 serum\NN\5397468 <e1>cis-RA</e1>\NN\1740 levels\NNS\4916342 .\.\1740
11858397
D008787_D016171 CID <e2>Torsade\NNP\1740 de\NNP\1740 pointes</e2>\NNS\1740 induced\VBN\1627355 by\IN\1740 <e1>metoclopramide</e1>\NN\1740 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 woman\NN\9605289 with\IN\1740 preexisting\VBG\2603699 complete\JJ\1740 left\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block\NN\21939 .\.\1740
D008787_D016171 CID We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 92-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 preexisting\VBG\2603699 complete\JJ\1740 left\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block\NN\21939 who\WP\8299493 developed\VBD\1753788 <e2>torsade\NN\1740 de\IN\1740 pointes</e2>\NNS\1740 after\IN\1740 intravenous\JJ\1740 and\CC\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>metoclopramide</e1>\NN\1740 .\.\1740
D008787_D016171 CID This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 documentation\NN\6650070 that\WDT\1740 <e1>metoclopramide</e1>\NN\1740 provokes\VBZ\1617192 <e2>torsade\VB\1740 de\IN\1740 pointes</e2>\NNS\1740 clinically\RB\1740 .\.\1740
D008787_D016171 CID <e1>Metoclopramide</e1>\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 cautiously\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 a\DT\13649268 risk\NN\14541044 of\IN\1740 <e2>torsade\NN\1740 de\NNP\1740 pointes</e2>\NNS\1740 .\.\1740
D008787_D002037 NONE Torsade\NNP\1740 de\NNP\1740 pointes\NNS\1740 induced\VBN\1627355 by\IN\1740 <e1>metoclopramide</e1>\NN\1740 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 woman\NN\9605289 with\IN\1740 preexisting\VBG\2603699 complete\JJ\1740 <e2>left\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block</e2>\NN\21939 .\.\1740
D008787_D002037 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 92-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 preexisting\VBG\2603699 complete\JJ\1740 <e2>left\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block</e2>\NN\21939 who\WP\8299493 developed\VBD\1753788 torsade\NN\1740 de\IN\1740 pointes\NNS\1740 after\IN\1740 intravenous\JJ\1740 and\CC\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>metoclopramide</e1>\NN\1740 .\.\1740
D020117_D016171 CID This\DT\1740 patient\NN\9898892 also\RB\1740 developed\VBD\1753788 <e2>torsade\NN\1740 de\IN\1740 pointes</e2>\NNS\1740 when\WRB\1740 <e1>cisapride</e1>\NN\1740 and\CC\1740 erythromycin\NN\2716866 were\VBD\836236 given\VBN\2327200 simultaneously\RB\1740 .\.\1740
D004917_D016171 CID This\DT\1740 patient\NN\9898892 also\RB\1740 developed\VBD\1753788 <e2>torsade\NN\1740 de\IN\1740 pointes</e2>\NNS\1740 when\WRB\1740 cisapride\NN\1740 and\CC\1740 <e1>erythromycin</e1>\NN\2716866 were\VBD\836236 given\VBN\2327200 simultaneously\RB\1740 .\.\1740
7007443
D000082_D017114 CID Acid\NN\14818238 protease\NN\14732946 (\-LRB-\1740 cathepsin\NN\1740 D\NN\15089472 )\-RRB-\1740 activity\NN\30358 was\VBD\836236 increased\VBN\169651 about\RB\1740 tenfold\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 died\VBD\146138 and\CC\1740 nearly\RB\1740 fourfold\RB\1740 in\IN\13603305 those\DT\1740 who\WP\8299493 survived\VBD\1108148 <e2>fulminant\JJ\1740 hepatic\JJ\1740 failure</e2>\NN\66216 after\IN\1740 <e1>paracetamol</e1>\NN\1740 overdose\NN\1740 ,\,\1740 whereas\IN\1740 activities\NNS\30358 were\VBD\836236 increased\VBN\169651 equally\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fulminant\JJ\1740 hepatic\JJ\1740 failure\NN\66216 due\JJ\1740 to\TO\1740 viral\JJ\1740 hepatitis\NN\14127211 whether\IN\1740 or\CC\3541091 not\RB\1740 they\PRP\1740 survived\VBD\1108148 .\.\1740
D000082_D017114 CID Acid\NN\14818238 protease\NN\14732946 (\-LRB-\1740 cathepsin\NN\1740 D\NN\15089472 )\-RRB-\1740 activity\NN\30358 was\VBD\836236 increased\VBN\169651 about\RB\1740 tenfold\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 died\VBD\146138 and\CC\1740 nearly\RB\1740 fourfold\RB\1740 in\IN\13603305 those\DT\1740 who\WP\8299493 survived\VBD\1108148 fulminant\JJ\1740 hepatic\JJ\1740 failure\NN\66216 after\IN\1740 <e1>paracetamol</e1>\NN\1740 overdose\NN\1740 ,\,\1740 whereas\IN\1740 activities\NNS\30358 were\VBD\836236 increased\VBN\169651 equally\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>fulminant\JJ\1740 hepatic\JJ\1740 failure</e2>\NN\66216 due\JJ\1740 to\TO\1740 viral\JJ\1740 hepatitis\NN\14127211 whether\IN\1740 or\CC\3541091 not\RB\1740 they\PRP\1740 survived\VBD\1108148 .\.\1740
D000082_D062787 NONE Acid\NN\14818238 protease\NN\14732946 (\-LRB-\1740 cathepsin\NN\1740 D\NN\15089472 )\-RRB-\1740 activity\NN\30358 was\VBD\836236 increased\VBN\169651 about\RB\1740 tenfold\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 died\VBD\146138 and\CC\1740 nearly\RB\1740 fourfold\RB\1740 in\IN\13603305 those\DT\1740 who\WP\8299493 survived\VBD\1108148 fulminant\JJ\1740 hepatic\JJ\1740 failure\NN\66216 after\IN\1740 <e1>paracetamol</e1>\NN\1740 <e2>overdose</e2>\NN\1740 ,\,\1740 whereas\IN\1740 activities\NNS\30358 were\VBD\836236 increased\VBN\169651 equally\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fulminant\JJ\1740 hepatic\JJ\1740 failure\NN\66216 due\JJ\1740 to\TO\1740 viral\JJ\1740 hepatitis\NN\14127211 whether\IN\1740 or\CC\3541091 not\RB\1740 they\PRP\1740 survived\VBD\1108148 .\.\1740
D000082_D006525 NONE Acid\NN\14818238 protease\NN\14732946 (\-LRB-\1740 cathepsin\NN\1740 D\NN\15089472 )\-RRB-\1740 activity\NN\30358 was\VBD\836236 increased\VBN\169651 about\RB\1740 tenfold\NN\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 died\VBD\146138 and\CC\1740 nearly\RB\1740 fourfold\RB\1740 in\IN\13603305 those\DT\1740 who\WP\8299493 survived\VBD\1108148 fulminant\JJ\1740 hepatic\JJ\1740 failure\NN\66216 after\IN\1740 <e1>paracetamol</e1>\NN\1740 overdose\NN\1740 ,\,\1740 whereas\IN\1740 activities\NNS\30358 were\VBD\836236 increased\VBN\169651 equally\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fulminant\JJ\1740 hepatic\JJ\1740 failure\NN\66216 due\JJ\1740 to\TO\1740 <e2>viral\JJ\1740 hepatitis</e2>\NN\14127211 whether\IN\1740 or\CC\3541091 not\RB\1740 they\PRP\1740 survived\VBD\1108148 .\.\1740
3653576
C001335_D058186 CID <e2>Acute\JJ\1740 experimental\JJ\1740 models\NNS\5888929 of\IN\1740 renal\JJ\1740 damage</e2>\NN\7296428 to\TO\1740 the\DT\1740 proximal\JJ\1740 tubular\JJ\1740 ,\,\1740 glomerular\JJ\1740 ,\,\1740 and\CC\1740 papillary\JJ\1740 regions\NNS\27167 of\IN\1740 the\DT\1740 rat\NN\2329401 were\VBD\836236 produced\VBN\1617192 by\IN\1740 administration\NN\1133281 of\IN\1740 <e1>hexachloro-1:3-butadiene</e1>\NN\1740 (\-LRB-\1740 HCBD\NN\1740 )\-RRB-\1740 ,\,\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 ,\,\1740 and\CC\1740 2-bromoethylamine\NN\1740 (\-LRB-\1740 BEA\NN\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 .\.\1740
C001335_D058186 CID <e2>Acute\JJ\1740 experimental\JJ\1740 models\NNS\5888929 of\IN\1740 renal\JJ\1740 damage</e2>\NN\7296428 to\TO\1740 the\DT\1740 proximal\JJ\1740 tubular\JJ\1740 ,\,\1740 glomerular\JJ\1740 ,\,\1740 and\CC\1740 papillary\JJ\1740 regions\NNS\27167 of\IN\1740 the\DT\1740 rat\NN\2329401 were\VBD\836236 produced\VBN\1617192 by\IN\1740 administration\NN\1133281 of\IN\1740 hexachloro-1:3-butadiene\NN\1740 (\-LRB-\1740 <e1>HCBD</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 ,\,\1740 and\CC\1740 2-bromoethylamine\NN\1740 (\-LRB-\1740 BEA\NN\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 .\.\1740
D011692_D058186 CID <e2>Acute\JJ\1740 experimental\JJ\1740 models\NNS\5888929 of\IN\1740 renal\JJ\1740 damage</e2>\NN\7296428 to\TO\1740 the\DT\1740 proximal\JJ\1740 tubular\JJ\1740 ,\,\1740 glomerular\JJ\1740 ,\,\1740 and\CC\1740 papillary\JJ\1740 regions\NNS\27167 of\IN\1740 the\DT\1740 rat\NN\2329401 were\VBD\836236 produced\VBN\1617192 by\IN\1740 administration\NN\1133281 of\IN\1740 hexachloro-1:3-butadiene\NN\1740 (\-LRB-\1740 HCBD\NN\1740 )\-RRB-\1740 ,\,\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 ,\,\1740 and\CC\1740 2-bromoethylamine\NN\1740 (\-LRB-\1740 BEA\NN\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 .\.\1740
D011692_D058186 CID <e2>Acute\JJ\1740 experimental\JJ\1740 models\NNS\5888929 of\IN\1740 renal\JJ\1740 damage</e2>\NN\7296428 to\TO\1740 the\DT\1740 proximal\JJ\1740 tubular\JJ\1740 ,\,\1740 glomerular\JJ\1740 ,\,\1740 and\CC\1740 papillary\JJ\1740 regions\NNS\27167 of\IN\1740 the\DT\1740 rat\NN\2329401 were\VBD\836236 produced\VBN\1617192 by\IN\1740 administration\NN\1133281 of\IN\1740 hexachloro-1:3-butadiene\NN\1740 (\-LRB-\1740 HCBD\NN\1740 )\-RRB-\1740 ,\,\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 ,\,\1740 and\CC\1740 2-bromoethylamine\NN\1740 (\-LRB-\1740 BEA\NN\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 .\.\1740
C004504_D058186 CID <e2>Acute\JJ\1740 experimental\JJ\1740 models\NNS\5888929 of\IN\1740 renal\JJ\1740 damage</e2>\NN\7296428 to\TO\1740 the\DT\1740 proximal\JJ\1740 tubular\JJ\1740 ,\,\1740 glomerular\JJ\1740 ,\,\1740 and\CC\1740 papillary\JJ\1740 regions\NNS\27167 of\IN\1740 the\DT\1740 rat\NN\2329401 were\VBD\836236 produced\VBN\1617192 by\IN\1740 administration\NN\1133281 of\IN\1740 hexachloro-1:3-butadiene\NN\1740 (\-LRB-\1740 HCBD\NN\1740 )\-RRB-\1740 ,\,\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>2-bromoethylamine</e1>\NN\1740 (\-LRB-\1740 BEA\NN\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 .\.\1740
C004504_D058186 CID <e2>Acute\JJ\1740 experimental\JJ\1740 models\NNS\5888929 of\IN\1740 renal\JJ\1740 damage</e2>\NN\7296428 to\TO\1740 the\DT\1740 proximal\JJ\1740 tubular\JJ\1740 ,\,\1740 glomerular\JJ\1740 ,\,\1740 and\CC\1740 papillary\JJ\1740 regions\NNS\27167 of\IN\1740 the\DT\1740 rat\NN\2329401 were\VBD\836236 produced\VBN\1617192 by\IN\1740 administration\NN\1133281 of\IN\1740 hexachloro-1:3-butadiene\NN\1740 (\-LRB-\1740 HCBD\NN\1740 )\-RRB-\1740 ,\,\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 ,\,\1740 and\CC\1740 2-bromoethylamine\NN\1740 (\-LRB-\1740 <e1>BEA</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 .\.\1740
C001335_D007674 NONE Tubular\JJ\1740 damage\NN\7296428 produced\VBN\1617192 by\IN\1740 <e1>HCBD</e1>\NN\1740 or\CC\3541091 BEA\NN\1740 was\VBD\836236 discriminated\VBN\650353 both\CC\1740 quantitatively\RB\1740 and\CC\1740 qualitatively\RB\1740 from\IN\1740 <e2>glomerular\JJ\1740 damage</e2>\NN\7296428 produced\VBN\1617192 by\IN\1740 PAN\NN\3101986 .\.\1740
C004504_D007674 NONE Tubular\JJ\1740 damage\NN\7296428 produced\VBN\1617192 by\IN\1740 HCBD\NN\1740 or\CC\3541091 <e1>BEA</e1>\NN\1740 was\VBD\836236 discriminated\VBN\650353 both\CC\1740 quantitatively\RB\1740 and\CC\1740 qualitatively\RB\1740 from\IN\1740 <e2>glomerular\JJ\1740 damage</e2>\NN\7296428 produced\VBN\1617192 by\IN\1740 PAN\NN\3101986 .\.\1740
D011692_D007674 NONE Tubular\JJ\1740 damage\NN\7296428 produced\VBN\1617192 by\IN\1740 HCBD\NN\1740 or\CC\3541091 BEA\NN\1740 was\VBD\836236 discriminated\VBN\650353 both\CC\1740 quantitatively\RB\1740 and\CC\1740 qualitatively\RB\1740 from\IN\1740 <e2>glomerular\JJ\1740 damage</e2>\NN\7296428 produced\VBN\1617192 by\IN\1740 <e1>PAN</e1>\NN\3101986 .\.\1740
3084782
D008625_D009393 CID A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 <e2>nephritis</e2>\NN\14113228 and\CC\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 <e1>Tiopronin</e1>\NNP\1740 (\-LRB-\1740 a\DT\13649268 D-Penicillamine\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 gold\NN\13371489 thiosulphate\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
D008625_D009393 CID Compared\VBN\644583 to\TO\1740 healthy\JJ\1740 controls\NNS\5190804 a\DT\13649268 lower\JJR\1740 DR5\NN\1740 frequency\NN\15286249 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 RA\NN\14625458 except\IN\1740 for\IN\1740 the\DT\1740 <e1>Tiopronin</e1>\NN\1740 related\JJ\1740 <e2>nephritis</e2>\NN\14113228 group\NN\2137 .\.\1740
D008625_D003872 CID A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 nephritis\NN\14113228 and\CC\1740 <e2>dermatitis</e2>\NN\14226056 due\IN\5174653 to\TO\1740 <e1>Tiopronin</e1>\NNP\1740 (\-LRB-\1740 a\DT\13649268 D-Penicillamine\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 gold\NN\13371489 thiosulphate\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
D008625_D003872 CID A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 nephritis\NN\14113228 and\CC\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 <e1>Tiopronin</e1>\NNP\1740 (\-LRB-\1740 a\DT\13649268 D-Penicillamine\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 <e2>dermatitis</e2>\NN\14226056 due\IN\5174653 to\TO\1740 gold\NN\13371489 thiosulphate\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
D010396_D009393 NONE A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 <e2>nephritis</e2>\NN\14113228 and\CC\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 Tiopronin\NNP\1740 (\-LRB-\1740 a\DT\13649268 <e1>D-Penicillamine</e1>\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 gold\NN\13371489 thiosulphate\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
D010396_D003872 NONE A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 nephritis\NN\14113228 and\CC\1740 <e2>dermatitis</e2>\NN\14226056 due\IN\5174653 to\TO\1740 Tiopronin\NNP\1740 (\-LRB-\1740 a\DT\13649268 <e1>D-Penicillamine</e1>\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 gold\NN\13371489 thiosulphate\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
D010396_D003872 NONE A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 nephritis\NN\14113228 and\CC\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 Tiopronin\NNP\1740 (\-LRB-\1740 a\DT\13649268 <e1>D-Penicillamine</e1>\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 <e2>dermatitis</e2>\NN\14226056 due\IN\5174653 to\TO\1740 gold\NN\13371489 thiosulphate\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
D006046_D009393 NONE A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 <e2>nephritis</e2>\NN\14113228 and\CC\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 Tiopronin\NNP\1740 (\-LRB-\1740 a\DT\13649268 D-Penicillamine\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 <e1>gold</e1>\NN\13371489 thiosulphate\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
D006046_D003872 CID A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 nephritis\NN\14113228 and\CC\1740 <e2>dermatitis</e2>\NN\14226056 due\IN\5174653 to\TO\1740 Tiopronin\NNP\1740 (\-LRB-\1740 a\DT\13649268 D-Penicillamine\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 <e1>gold</e1>\NN\13371489 thiosulphate\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
D006046_D003872 CID A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 nephritis\NN\14113228 and\CC\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 Tiopronin\NNP\1740 (\-LRB-\1740 a\DT\13649268 D-Penicillamine\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 <e2>dermatitis</e2>\NN\14226056 due\IN\5174653 to\TO\1740 <e1>gold</e1>\NN\13371489 thiosulphate\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
-1_D009393 NONE A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 <e2>nephritis</e2>\NN\14113228 and\CC\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 Tiopronin\NNP\1740 (\-LRB-\1740 a\DT\13649268 D-Penicillamine\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 gold\NN\13371489 <e1>thiosulphate</e1>\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
-1_D003872 NONE A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 nephritis\NN\14113228 and\CC\1740 <e2>dermatitis</e2>\NN\14226056 due\IN\5174653 to\TO\1740 Tiopronin\NNP\1740 (\-LRB-\1740 a\DT\13649268 D-Penicillamine\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 gold\NN\13371489 <e1>thiosulphate</e1>\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
-1_D003872 NONE A\DT\13649268 strong\JJ\1740 association\NN\8008335 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 between\IN\1740 nephritis\NN\14113228 and\CC\1740 dermatitis\NN\14226056 due\IN\5174653 to\TO\1740 Tiopronin\NNP\1740 (\-LRB-\1740 a\DT\13649268 D-Penicillamine\NN\1740 like\JJ\1740 compound\NN\5869584 )\-RRB-\1740 and\CC\1740 class\NN\7951464 I\CD\14622893 antigens\NNS\20090 B35-Cw4\JJ\1740 ,\,\1740 and\CC\1740 between\IN\1740 <e2>dermatitis</e2>\NN\14226056 due\IN\5174653 to\TO\1740 gold\NN\13371489 <e1>thiosulphate</e1>\NN\1740 and\CC\1740 B35\NN\1740 .\.\1740
D008625_D001172 NONE Compared\VBN\644583 to\TO\1740 healthy\JJ\1740 controls\NNS\5190804 a\DT\13649268 lower\JJR\1740 DR5\NN\1740 frequency\NN\15286249 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>RA</e2>\NN\14625458 except\IN\1740 for\IN\1740 the\DT\1740 <e1>Tiopronin</e1>\NN\1740 related\JJ\1740 nephritis\NN\14113228 group\NN\2137 .\.\1740
3703509
D011241_D053609 NONE Following\VBG\1835496 short\JJ\1740 exposure\NN\5042871 to\TO\1740 oral\JJ\1740 <e1>prednisone</e1>\NN\2721538 ,\,\1740 both\DT\1740 boys\NNS\9624168 developed\VBD\1753788 <e2>lethargy</e2>\NN\14014621 ,\,\1740 increasing\VBG\169651 somnolence\NN\14015731 ,\,\1740 polydipsia\NNP\14040660 ,\,\1740 polyphagia\NN\1740 ,\,\1740 and\CC\1740 polyuria\VBP\1740 .\.\1740
D011241_D006970 NONE Following\VBG\1835496 short\JJ\1740 exposure\NN\5042871 to\TO\1740 oral\JJ\1740 <e1>prednisone</e1>\NN\2721538 ,\,\1740 both\DT\1740 boys\NNS\9624168 developed\VBD\1753788 lethargy\NN\14014621 ,\,\1740 increasing\VBG\169651 <e2>somnolence</e2>\NN\14015731 ,\,\1740 polydipsia\NNP\14040660 ,\,\1740 polyphagia\NN\1740 ,\,\1740 and\CC\1740 polyuria\VBP\1740 .\.\1740
D011241_D059606 NONE Following\VBG\1835496 short\JJ\1740 exposure\NN\5042871 to\TO\1740 oral\JJ\1740 <e1>prednisone</e1>\NN\2721538 ,\,\1740 both\DT\1740 boys\NNS\9624168 developed\VBD\1753788 lethargy\NN\14014621 ,\,\1740 increasing\VBG\169651 somnolence\NN\14015731 ,\,\1740 <e2>polydipsia</e2>\NNP\14040660 ,\,\1740 polyphagia\NN\1740 ,\,\1740 and\CC\1740 polyuria\VBP\1740 .\.\1740
D011241_D006963 NONE Following\VBG\1835496 short\JJ\1740 exposure\NN\5042871 to\TO\1740 oral\JJ\1740 <e1>prednisone</e1>\NN\2721538 ,\,\1740 both\DT\1740 boys\NNS\9624168 developed\VBD\1753788 lethargy\NN\14014621 ,\,\1740 increasing\VBG\169651 somnolence\NN\14015731 ,\,\1740 polydipsia\NNP\14040660 ,\,\1740 <e2>polyphagia</e2>\NN\1740 ,\,\1740 and\CC\1740 polyuria\VBP\1740 .\.\1740
D011241_D011141 NONE Following\VBG\1835496 short\JJ\1740 exposure\NN\5042871 to\TO\1740 oral\JJ\1740 <e1>prednisone</e1>\NN\2721538 ,\,\1740 both\DT\1740 boys\NNS\9624168 developed\VBD\1753788 lethargy\NN\14014621 ,\,\1740 increasing\VBG\169651 somnolence\NN\14015731 ,\,\1740 polydipsia\NNP\14040660 ,\,\1740 polyphagia\NN\1740 ,\,\1740 and\CC\1740 <e2>polyuria</e2>\VBP\1740 .\.\1740
D019344_D000140 NONE Nonketotic\JJ\1740 <e2>lactic\JJ\1740 acidosis</e2>\NN\14204950 was\VBD\836236 present\JJ\1740 in\IN\13603305 one\CD\13741022 and\CC\1740 ketosis\NN\14299637 without\IN\1740 a\DT\13649268 known\JJ\1740 serum\NN\5397468 <e1>lactate</e1>\NN\14850483 level\NN\4916342 was\VBD\836236 present\JJ\1740 in\IN\13603305 the\DT\1740 other\JJ\1740 .\.\1740
D019344_D007662 NONE Nonketotic\JJ\1740 lactic\JJ\1740 acidosis\NN\14204950 was\VBD\836236 present\JJ\1740 in\IN\13603305 one\CD\13741022 and\CC\1740 <e2>ketosis</e2>\NN\14299637 without\IN\1740 a\DT\13649268 known\JJ\1740 serum\NN\5397468 <e1>lactate</e1>\NN\14850483 level\NN\4916342 was\VBD\836236 present\JJ\1740 in\IN\13603305 the\DT\1740 other\JJ\1740 .\.\1740
1687392
D004298_D002375 NONE Blockade\NN\952963 of\IN\1740 both\CC\1740 D-1\NN\1740 and\CC\1740 D-2\JJ\1740 <e1>dopamine</e1>\NN\14807737 receptors\NNS\5225602 may\MD\15209706 induce\VB\1627355 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004298_D002375 NONE The\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>dopamine</e1>\NN\14807737 antagonists\NNS\7846 has\VBZ\2108377 been\VBN\836236 tested\VBN\670261 and\CC\1740 the\DT\1740 possible\JJ\1740 dopamine\NN\14807737 subtypes\NNS\1740 involved\VBN\2676054 in\IN\13603305 catalepsy\NN\14023236 was\VBD\836236 determined\VBN\1645601 .\.\1740
D004298_D002375 NONE The\DT\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>dopamine</e1>\NN\14807737 antagonists\NNS\7846 has\VBZ\2108377 been\VBN\836236 tested\VBN\670261 and\CC\1740 the\DT\1740 possible\JJ\1740 dopamine\NN\14807737 subtypes\NNS\1740 involved\VBN\2676054 in\IN\13603305 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 determined\VBN\1645601 .\.\1740
D004298_D002375 NONE The\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 has\VBZ\2108377 been\VBN\836236 tested\VBN\670261 and\CC\1740 the\DT\1740 possible\JJ\1740 <e1>dopamine</e1>\NN\14807737 subtypes\NNS\1740 involved\VBN\2676054 in\IN\13603305 catalepsy\NN\14023236 was\VBD\836236 determined\VBN\1645601 .\.\1740
D004298_D002375 NONE The\DT\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 has\VBZ\2108377 been\VBN\836236 tested\VBN\670261 and\CC\1740 the\DT\1740 possible\JJ\1740 <e1>dopamine</e1>\NN\14807737 subtypes\NNS\1740 involved\VBN\2676054 in\IN\13603305 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 determined\VBN\1645601 .\.\1740
D004298_D002375 NONE <e1>Dopamine</e1>\NN\14807737 antagonist\NN\7846 fluphenazine\NN\3713736 ,\,\1740 D-1\NN\1740 antagonist\NN\7846 SCH\NN\1740 23390\CD\1740 or\CC\3541091 D-2\JJ\1740 antagonist\NN\7846 sulpiride\NN\1740 induced\VBD\1627355 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D004298_D002375 NONE Combination\NN\7951464 of\IN\1740 SKF\NN\1740 38393\CD\1740 with\IN\1740 quinpirole\NN\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 potentiated\JJ\1740 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>dopamine</e1>\NN\14807737 antagonists\NNS\7846 .\.\1740
D005476_D002375 CID Dopamine\NN\14807737 antagonist\NN\7846 <e1>fluphenazine</e1>\NN\3713736 ,\,\1740 D-1\NN\1740 antagonist\NN\7846 SCH\NN\1740 23390\CD\1740 or\CC\3541091 D-2\JJ\1740 antagonist\NN\7846 sulpiride\NN\1740 induced\VBD\1627355 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D005476_D002375 CID D-1\JJ\1740 agonist\NN\9613191 SKF\NN\1740 38393\CD\1740 or\CC\3541091 D-2\JJ\1740 agonist\NN\9613191 quinpirole\NN\1740 decreased\VBD\169651 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>fluphenazine</e1>\NN\3713736 ,\,\1740 SCH\NN\1740 23390\CD\1740 or\CC\3541091 sulpiride\NN\1740 .\.\1740
C534628_D002375 CID Dopamine\NN\14807737 antagonist\NN\7846 fluphenazine\NN\3713736 ,\,\1740 D-1\NN\1740 antagonist\NN\7846 <e1>SCH\NN\1740 23390</e1>\CD\1740 or\CC\3541091 D-2\JJ\1740 antagonist\NN\7846 sulpiride\NN\1740 induced\VBD\1627355 <e2>catalepsy</e2>\NN\14023236 .\.\1740
C534628_D002375 CID Combination\NN\7951464 of\IN\1740 <e1>SCH\NN\1740 23390</e1>\CD\1740 with\IN\1740 sulpiride\NN\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 <e2>catalepsy</e2>\NN\14023236 potentiation\NN\13564910 .\.\1740
C534628_D002375 CID D-1\JJ\1740 agonist\NN\9613191 SKF\NN\1740 38393\CD\1740 or\CC\3541091 D-2\JJ\1740 agonist\NN\9613191 quinpirole\NN\1740 decreased\VBD\169651 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 fluphenazine\NN\3713736 ,\,\1740 <e1>SCH\NN\1740 23390</e1>\CD\1740 or\CC\3541091 sulpiride\NN\1740 .\.\1740
D013469_D002375 CID Dopamine\NN\14807737 antagonist\NN\7846 fluphenazine\NN\3713736 ,\,\1740 D-1\NN\1740 antagonist\NN\7846 SCH\NN\1740 23390\CD\1740 or\CC\3541091 D-2\JJ\1740 antagonist\NN\7846 <e1>sulpiride</e1>\NN\1740 induced\VBD\1627355 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D013469_D002375 CID Combination\NN\7951464 of\IN\1740 SCH\NN\1740 23390\CD\1740 with\IN\1740 <e1>sulpiride</e1>\NN\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 <e2>catalepsy</e2>\NN\14023236 potentiation\NN\13564910 .\.\1740
D013469_D002375 CID D-1\JJ\1740 agonist\NN\9613191 SKF\NN\1740 38393\CD\1740 or\CC\3541091 D-2\JJ\1740 agonist\NN\9613191 quinpirole\NN\1740 decreased\VBD\169651 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 fluphenazine\NN\3713736 ,\,\1740 SCH\NN\1740 23390\CD\1740 or\CC\3541091 <e1>sulpiride</e1>\NN\1740 .\.\1740
D015647_D002375 NONE D-1\JJ\1740 agonist\NN\9613191 <e1>SKF\NN\1740 38393</e1>\CD\1740 or\CC\3541091 D-2\JJ\1740 agonist\NN\9613191 quinpirole\NN\1740 decreased\VBD\169651 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 fluphenazine\NN\3713736 ,\,\1740 SCH\NN\1740 23390\CD\1740 or\CC\3541091 sulpiride\NN\1740 .\.\1740
D015647_D002375 NONE Combination\NN\7951464 of\IN\1740 <e1>SKF\NN\1740 38393</e1>\CD\1740 with\IN\1740 quinpirole\NN\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 potentiated\JJ\1740 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 .\.\1740
D019257_D002375 NONE D-1\JJ\1740 agonist\NN\9613191 SKF\NN\1740 38393\CD\1740 or\CC\3541091 D-2\JJ\1740 agonist\NN\9613191 <e1>quinpirole</e1>\NN\1740 decreased\VBD\169651 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 fluphenazine\NN\3713736 ,\,\1740 SCH\NN\1740 23390\CD\1740 or\CC\3541091 sulpiride\NN\1740 .\.\1740
D019257_D002375 NONE Combination\NN\7951464 of\IN\1740 SKF\NN\1740 38393\CD\1740 with\IN\1740 <e1>quinpirole</e1>\NN\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 potentiated\JJ\1740 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 .\.\1740
4090988
D000082_D001749 CID Induction\NN\7450842 by\IN\1740 <e1>paracetamol</e1>\NN\1740 of\IN\1740 <e2>bladder\NN\5515670 and\CC\1740 liver\NN\5298729 tumours</e2>\NNS\14234074 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D000082_D001749 CID Papillomas\NNS\14236226 of\IN\1740 the\DT\1740 transitional\JJ\1740 epithelium\NN\5267548 of\IN\1740 the\DT\1740 bladder\NN\5515670 developed\VBD\1753788 in\IN\13603305 all\DT\1740 <e1>paracetamol-treated</e1>\JJ\1740 groups\NNS\2137 ,\,\1740 and\CC\1740 three\CD\13741022 rats\NNS\2329401 bore\VBD\1552519 <e2>bladder\NN\5515670 carcinomas</e2>\NNS\14239918 .\.\1740
D000082_D008113 CID Induction\NN\7450842 by\IN\1740 <e1>paracetamol</e1>\NN\1740 of\IN\1740 <e2>bladder\NN\5515670 and\CC\1740 liver\NN\5298729 tumours</e2>\NNS\14234074 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D000082_D008113 CID An\DT\6697703 electron\NN\9338013 microscope\NN\3709206 study\NN\635850 of\IN\1740 the\DT\1740 livers\NNS\5298729 of\IN\1740 <e1>paracetamol-treated</e1>\JJ\1740 rats\NNS\2329401 revealed\VBD\2137132 ultrastructural\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 hepatocytes\NNS\1740 that\WDT\1740 resemble\VBP\2657219 those\DT\1740 that\WDT\1740 result\VBP\2633881 from\IN\1740 exposure\NN\5042871 to\TO\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 known\VBN\2110220 <e2>hepatocarcinogens</e2>\NNS\1740 .\.\1740
D000082_D010212 NONE <e2>Papillomas</e2>\NNS\14236226 of\IN\1740 the\DT\1740 transitional\JJ\1740 epithelium\NN\5267548 of\IN\1740 the\DT\1740 bladder\NN\5515670 developed\VBD\1753788 in\IN\13603305 all\DT\1740 <e1>paracetamol-treated</e1>\JJ\1740 groups\NNS\2137 ,\,\1740 and\CC\1740 three\CD\13741022 rats\NNS\2329401 bore\VBD\1552519 bladder\NN\5515670 carcinomas\NNS\14239918 .\.\1740
D000082_D006965 CID Additionally\RB\1740 ,\,\1740 20\CD\13745420 to\TO\1740 25\CD\13745420 %\NN\1740 of\IN\1740 <e1>paracetamol-treated</e1>\JJ\1740 rats\NNS\2329401 developed\VBD\1753788 <e2>hyperplasia</e2>\NN\14365950 of\IN\1740 the\DT\1740 bladder\NN\5515670 epithelium\NN\5267548 ,\,\1740 which\WDT\1740 was\VBD\836236 not\RB\1740 coincident\JJ\1740 with\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 bladder\NN\5515670 calculi\NNS\9416076 .\.\1740
D000082_D001744 NONE Additionally\RB\1740 ,\,\1740 20\CD\13745420 to\TO\1740 25\CD\13745420 %\NN\1740 of\IN\1740 <e1>paracetamol-treated</e1>\JJ\1740 rats\NNS\2329401 developed\VBD\1753788 hyperplasia\NN\14365950 of\IN\1740 the\DT\1740 bladder\NN\5515670 epithelium\NN\5267548 ,\,\1740 which\WDT\1740 was\VBD\836236 not\RB\1740 coincident\JJ\1740 with\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>bladder\NN\5515670 calculi</e2>\NNS\9416076 .\.\1740
D000082_D009369 NONE A\DT\13649268 low\JJ\1740 yield\NN\913705 of\IN\1740 <e2>tumours</e2>\NNS\14234074 at\IN\14622893 various\JJ\1740 other\JJ\1740 sites\NNS\8673395 also\RB\1740 arose\VBD\2623529 following\VBG\1835496 <e1>paracetamol</e1>\NN\1740 feeding\NN\838098 .\.\1740
11524350
D002045_D064420 NONE Systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 resuscitation\NN\1047338 in\IN\13603305 <e1>bupivacaine-</e1>\NN\1740 ,\,\1740 levobupivacaine-\NN\1740 ,\,\1740 or\CC\3541091 ropivacaine-infused\JJ\1740 rats\NNS\2329401 .\.\1740
D002045_D064420 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 ,\,\1740 levobupivacaine\NN\1740 ,\,\1740 and\CC\1740 ropivacaine\VB\1740 in\IN\13603305 anesthetized\JJ\1740 rats\NNS\2329401 .\.\1740
D002045_D064420 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 <e1>bupivacaine</e1>\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
D002045_D064420 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 <e1>bupivacaine</e1>\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
C476513_D064420 NONE Systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 resuscitation\NN\1047338 in\IN\13603305 bupivacaine-\NN\1740 ,\,\1740 <e1>levobupivacaine-</e1>\NN\1740 ,\,\1740 or\CC\3541091 ropivacaine-infused\JJ\1740 rats\NNS\2329401 .\.\1740
C476513_D064420 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 bupivacaine\NN\1740 ,\,\1740 <e1>levobupivacaine</e1>\NN\1740 ,\,\1740 and\CC\1740 ropivacaine\VB\1740 in\IN\13603305 anesthetized\JJ\1740 rats\NNS\2329401 .\.\1740
C476513_D064420 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
C476513_D064420 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 <e1>levobupivacaine</e1>\NN\1740 .\.\1740
C037663_D064420 NONE Systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 resuscitation\NN\1047338 in\IN\13603305 bupivacaine-\NN\1740 ,\,\1740 levobupivacaine-\NN\1740 ,\,\1740 or\CC\3541091 <e1>ropivacaine-infused</e1>\JJ\1740 rats\NNS\2329401 .\.\1740
C037663_D064420 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 bupivacaine\NN\1740 ,\,\1740 levobupivacaine\NN\1740 ,\,\1740 and\CC\1740 <e1>ropivacaine</e1>\VB\1740 in\IN\13603305 anesthetized\JJ\1740 rats\NNS\2329401 .\.\1740
C037663_D064420 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 <e1>ropivacaine</e1>\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
C037663_D064420 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 <e1>ropivacaine-induced</e1>\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
C476513_D012640 CID The\DT\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 and\CC\1740 ropivacaine\NN\1740 that\WDT\1740 produced\VBD\1617192 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 similar\JJ\1740 and\CC\1740 were\VBD\836236 larger\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 bupivacaine\NN\1740 .\.\1740
C037663_D012640 CID The\DT\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 levobupivacaine\NN\1740 and\CC\1740 <e1>ropivacaine</e1>\NN\1740 that\WDT\1740 produced\VBD\1617192 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 similar\JJ\1740 and\CC\1740 were\VBD\836236 larger\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 bupivacaine\NN\1740 .\.\1740
D002045_D012640 NONE The\DT\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 levobupivacaine\NN\1740 and\CC\1740 ropivacaine\NN\1740 that\WDT\1740 produced\VBD\1617192 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 similar\JJ\1740 and\CC\1740 were\VBD\836236 larger\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 .\.\1740
C476513_D001145 CID The\DT\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 that\WDT\1740 produced\VBD\1617192 <e2>dysrhythmias</e2>\NNS\1740 and\CC\1740 asystole\NN\14204950 were\VBD\836236 smaller\JJR\1740 than\IN\1740 the\DT\1740 corresponding\JJ\1740 doses\NNS\3740161 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 but\CC\1740 they\PRP\1740 were\VBD\836236 larger\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 bupivacaine\NN\1740 .\.\1740
C476513_D006323 CID The\DT\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 that\WDT\1740 produced\VBD\1617192 dysrhythmias\NNS\1740 and\CC\1740 <e2>asystole</e2>\NN\14204950 were\VBD\836236 smaller\JJR\1740 than\IN\1740 the\DT\1740 corresponding\JJ\1740 doses\NNS\3740161 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 but\CC\1740 they\PRP\1740 were\VBD\836236 larger\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 bupivacaine\NN\1740 .\.\1740
C476513_D006323 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
C476513_D006323 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 toxicity\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 <e1>levobupivacaine</e1>\NN\1740 .\.\1740
C037663_D001145 CID The\DT\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 levobupivacaine\NN\1740 that\WDT\1740 produced\VBD\1617192 <e2>dysrhythmias</e2>\NNS\1740 and\CC\1740 asystole\NN\14204950 were\VBD\836236 smaller\JJR\1740 than\IN\1740 the\DT\1740 corresponding\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>ropivacaine</e1>\NN\1740 ,\,\1740 but\CC\1740 they\PRP\1740 were\VBD\836236 larger\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 bupivacaine\NN\1740 .\.\1740
C037663_D006323 CID The\DT\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 levobupivacaine\NN\1740 that\WDT\1740 produced\VBD\1617192 dysrhythmias\NNS\1740 and\CC\1740 <e2>asystole</e2>\NN\14204950 were\VBD\836236 smaller\JJR\1740 than\IN\1740 the\DT\1740 corresponding\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>ropivacaine</e1>\NN\1740 ,\,\1740 but\CC\1740 they\PRP\1740 were\VBD\836236 larger\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 bupivacaine\NN\1740 .\.\1740
C037663_D006323 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 toxicity\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 <e1>ropivacaine</e1>\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
C037663_D006323 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 toxicity\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 <e1>ropivacaine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
D002045_D001145 NONE The\DT\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 levobupivacaine\NN\1740 that\WDT\1740 produced\VBD\1617192 <e2>dysrhythmias</e2>\NNS\1740 and\CC\1740 asystole\NN\14204950 were\VBD\836236 smaller\JJR\1740 than\IN\1740 the\DT\1740 corresponding\JJ\1740 doses\NNS\3740161 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 but\CC\1740 they\PRP\1740 were\VBD\836236 larger\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 .\.\1740
D002045_D006323 NONE The\DT\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 levobupivacaine\NN\1740 that\WDT\1740 produced\VBD\1617192 dysrhythmias\NNS\1740 and\CC\1740 <e2>asystole</e2>\NN\14204950 were\VBD\836236 smaller\JJR\1740 than\IN\1740 the\DT\1740 corresponding\JJ\1740 doses\NNS\3740161 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 but\CC\1740 they\PRP\1740 were\VBD\836236 larger\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 .\.\1740
D002045_D006323 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 toxicity\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 <e1>bupivacaine</e1>\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 bupivacaine\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
D002045_D006323 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 systemic\JJ\1740 toxicity\NN\13576101 of\IN\1740 levobupivacaine\NN\1740 is\VBZ\836236 intermediate\JJ\1740 between\IN\1740 that\DT\1740 of\IN\1740 ropivacaine\NN\1740 and\CC\1740 bupivacaine\NN\1740 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 rate\NN\13815152 and\CC\1740 that\IN\1740 ropivacaine-induced\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 susceptible\JJ\1740 to\TO\1740 treatment\NN\654885 than\IN\1740 that\DT\1740 induced\VBN\1627355 by\IN\1740 <e1>bupivacaine</e1>\NN\1740 or\CC\3541091 levobupivacaine\NN\1740 .\.\1740
8106150
D007980_D004409 NONE Effect\NN\34213 of\IN\1740 nondopaminergic\JJ\1740 drugs\NNS\14778436 on\IN\1740 <e1>L-dopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 MPTP-treated\JJ\1740 monkeys\NNS\2469914 .\.\1740
D007980_D004409 NONE A\DT\13649268 series\NN\8456993 of\IN\1740 agents\NNS\7347 acting\VBG\1619354 primarily\RB\1740 on\IN\1740 neurotransmitters\NNS\14807410 other\JJ\1740 than\IN\1740 dopamine\NN\14807737 were\VBD\836236 then\RB\1740 tested\VBN\670261 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>L-DOPA</e1>\NN\14604959 to\TO\1740 see\VB\2106506 if\IN\1740 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 would\MD\1740 be\VB\836236 modified\VBN\109660 .\.\1740
D015632_D004409 NONE Effect\NN\34213 of\IN\1740 nondopaminergic\JJ\1740 drugs\NNS\14778436 on\IN\1740 L-dopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 <e1>MPTP-treated</e1>\JJ\1740 monkeys\NNS\2469914 .\.\1740
D015632_D020734 CID A\DT\13649268 group\NN\2137 of\IN\1740 four\CD\13741022 monkeys\NNS\2469914 was\VBD\836236 rendered\VBN\120316 <e2>parkinsonian</e2>\JJ\1740 with\IN\1740 the\DT\1740 toxin\NN\15032376 <e1>MPTP</e1>\NNP\1740 .\.\1740
D004298_D004409 NONE A\DT\13649268 series\NN\8456993 of\IN\1740 agents\NNS\7347 acting\VBG\1619354 primarily\RB\1740 on\IN\1740 neurotransmitters\NNS\14807410 other\JJ\1740 than\IN\1740 <e1>dopamine</e1>\NN\14807737 were\VBD\836236 then\RB\1740 tested\VBN\670261 in\IN\13603305 combination\NN\7951464 with\IN\1740 L-DOPA\NN\14604959 to\TO\1740 see\VB\2106506 if\IN\1740 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 would\MD\1740 be\VB\836236 modified\VBN\109660 .\.\1740
D003000_D004409 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 <e1>clonidine</e1>\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 parkinsonian\JJ\1740 symptomatology\NN\1740 .\.\1740
D003000_D020734 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 <e1>clonidine</e1>\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 dyskinetic\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 symptomatology\NN\1740 .\.\1740
D010830_D004409 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 <e1>physostigmine</e1>\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 parkinsonian\JJ\1740 symptomatology\NN\1740 .\.\1740
D010830_D020734 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 <e1>physostigmine</e1>\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 dyskinetic\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 symptomatology\NN\1740 .\.\1740
D008784_D004409 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 <e1>methysergide</e1>\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 parkinsonian\JJ\1740 symptomatology\NN\1740 .\.\1740
D008784_D020734 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 <e1>methysergide</e1>\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 dyskinetic\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 symptomatology\NN\1740 .\.\1740
-1_D004409 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 <e1>5-MDOT</e1>\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 parkinsonian\JJ\1740 symptomatology\NN\1740 .\.\1740
-1_D020734 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 <e1>5-MDOT</e1>\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 dyskinetic\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 symptomatology\NN\1740 .\.\1740
D011433_D004409 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 <e1>propranolol</e1>\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 parkinsonian\JJ\1740 symptomatology\NN\1740 .\.\1740
D011433_D020734 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 <e1>propranolol</e1>\NN\1740 ,\,\1740 and\CC\1740 MK-801\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 dyskinetic\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 symptomatology\NN\1740 .\.\1740
D016291_D004409 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 <e1>MK-801</e1>\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 parkinsonian\JJ\1740 symptomatology\NN\1740 .\.\1740
D016291_D020734 NONE Several\JJ\1740 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 clonidine\NN\2721160 ,\,\1740 physostigmine\NN\14712692 ,\,\1740 methysergide\NN\1740 ,\,\1740 5-MDOT\FW\1740 ,\,\1740 propranolol\NN\1740 ,\,\1740 and\CC\1740 <e1>MK-801</e1>\NN\1740 ,\,\1740 markedly\RB\1740 reduced\VBD\441445 the\DT\1740 dyskinetic\JJ\1740 movements\NNS\191142 but\CC\1740 at\IN\14622893 the\DT\1740 cost\NN\13275288 of\IN\1740 a\DT\13649268 return\NN\6479665 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 symptomatology\NN\1740 .\.\1740
D015016_D004409 NONE However\RB\1740 ,\,\1740 <e1>yohimbine</e1>\NN\1740 and\CC\1740 meperidine\NN\3808564 reduced\VBD\441445 predominantly\RB\1740 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 .\.\1740
D008614_D004409 NONE However\RB\1740 ,\,\1740 yohimbine\NN\1740 and\CC\1740 <e1>meperidine</e1>\NN\3808564 reduced\VBD\441445 predominantly\RB\1740 the\DT\1740 <e2>dyskinetic</e2>\JJ\1740 movements\NNS\191142 .\.\1740
D001418_D020821 NONE <e1>Baclofen</e1>\NNP\1740 was\VBD\836236 also\RB\1740 useful\JJ\1740 in\IN\13603305 one\CD\13741022 monkey\NN\2469914 against\IN\1740 a\DT\13649268 more\RBR\1740 <e2>dystonic</e2>\JJ\1740 form\NN\6286395 of\IN\1740 dyskinesia\NN\14084880 .\.\1740
D001418_D004409 NONE <e1>Baclofen</e1>\NNP\1740 was\VBD\836236 also\RB\1740 useful\JJ\1740 in\IN\13603305 one\CD\13741022 monkey\NN\2469914 against\IN\1740 a\DT\13649268 more\RBR\1740 dystonic\JJ\1740 form\NN\6286395 of\IN\1740 <e2>dyskinesia</e2>\NN\14084880 .\.\1740
D001285_D020821 NONE <e1>Atropine</e1>\NN\14712692 converted\VBD\126264 the\DT\1740 <e2>dystonic</e2>\JJ\1740 movements\NNS\191142 into\IN\1740 chorea\NN\14253124 .\.\1740
D001285_D002819 NONE <e1>Atropine</e1>\NN\14712692 converted\VBD\126264 the\DT\1740 dystonic\JJ\1740 movements\NNS\191142 into\IN\1740 <e2>chorea</e2>\NN\14253124 .\.\1740
3431591
C031662_D064420 NONE <e1>CB\NN\1740 3717</e1>\CD\1740 ,\,\1740 N10-propargyl-5,8-dideazafolic\JJ\1740 acid\NN\14818238 ,\,\1740 is\VBZ\836236 a\DT\13649268 tight-binding\JJ\1740 inhibitor\NN\20090 of\IN\1740 thymidylate\JJ\1740 synthase\NN\1740 (\-LRB-\1740 TS\NN\14999913 )\-RRB-\1740 whose\WP$\1740 <e2>cytotoxicity</e2>\NN\13583478 is\VBZ\836236 mediated\VBN\761713 solely\RB\1740 through\IN\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 this\DT\1740 enzyme\NN\14723628 .\.\1740
C031662_D064420 NONE CB\NN\1740 3717\CD\1740 ,\,\1740 <e1>N10-propargyl-5,8-dideazafolic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 is\VBZ\836236 a\DT\13649268 tight-binding\JJ\1740 inhibitor\NN\20090 of\IN\1740 thymidylate\JJ\1740 synthase\NN\1740 (\-LRB-\1740 TS\NN\14999913 )\-RRB-\1740 whose\WP$\1740 <e2>cytotoxicity</e2>\NN\13583478 is\VBZ\836236 mediated\VBN\761713 solely\RB\1740 through\IN\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 this\DT\1740 enzyme\NN\14723628 .\.\1740
C031662_D064420 NONE As\IN\14622893 inhibitors\NNS\20090 of\IN\1740 isolated\VBN\2512305 L1210\NN\1740 TS\NN\14999913 ,\,\1740 CB\NN\1740 3717\CD\1740 di-\VBD\1740 ,\,\1740 tri-\NN\1740 ,\,\1740 tetra-\NN\1740 and\CC\1740 pentaglutamate\NN\1740 are\VBP\836236 26-\CD\1740 ,\,\1740 87-\CD\1740 ,\,\1740 119-\NN\1740 and\CC\1740 114-fold\RB\1740 more\JJR\1740 potent\JJ\1740 than\IN\1740 <e1>CB\NN\1740 3717</e1>\CD\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 and\CC\1740 their\PRP$\1740 formation\NN\7938773 may\MD\15209706 ,\,\1740 therefore\RB\1740 ,\,\1740 be\VB\836236 an\DT\6697703 important\JJ\1740 determinant\NN\5686481 of\IN\1740 CB\NN\1740 3717\CD\1740 <e2>cytotoxicity</e2>\NN\13583478 .\.\1740
C031662_D064420 NONE As\IN\14622893 inhibitors\NNS\20090 of\IN\1740 isolated\VBN\2512305 L1210\NN\1740 TS\NN\14999913 ,\,\1740 CB\NN\1740 3717\CD\1740 di-\VBD\1740 ,\,\1740 tri-\NN\1740 ,\,\1740 tetra-\NN\1740 and\CC\1740 pentaglutamate\NN\1740 are\VBP\836236 26-\CD\1740 ,\,\1740 87-\CD\1740 ,\,\1740 119-\NN\1740 and\CC\1740 114-fold\RB\1740 more\JJR\1740 potent\JJ\1740 than\IN\1740 CB\NN\1740 3717\CD\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 and\CC\1740 their\PRP$\1740 formation\NN\7938773 may\MD\15209706 ,\,\1740 therefore\RB\1740 ,\,\1740 be\VB\836236 an\DT\6697703 important\JJ\1740 determinant\NN\5686481 of\IN\1740 <e1>CB\NN\1740 3717</e1>\CD\1740 <e2>cytotoxicity</e2>\NN\13583478 .\.\1740
C031662_D001943 NONE In\IN\13603305 early\JJ\1740 clinical\JJ\1740 studies\NNS\635850 with\IN\1740 <e1>CB\NN\1740 3717</e1>\CD\1740 ,\,\1740 activity\NN\30358 has\VBZ\2108377 been\VBN\836236 seen\VBN\2106506 in\IN\13603305 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 hepatoma\NN\14242337 ,\,\1740 and\CC\1740 mesothelioma\NN\14242337 .\.\1740
C031662_D010051 NONE In\IN\13603305 early\JJ\1740 clinical\JJ\1740 studies\NNS\635850 with\IN\1740 <e1>CB\NN\1740 3717</e1>\CD\1740 ,\,\1740 activity\NN\30358 has\VBZ\2108377 been\VBN\836236 seen\VBN\2106506 in\IN\13603305 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 ,\,\1740 hepatoma\NN\14242337 ,\,\1740 and\CC\1740 mesothelioma\NN\14242337 .\.\1740
C031662_D006528 NONE In\IN\13603305 early\JJ\1740 clinical\JJ\1740 studies\NNS\635850 with\IN\1740 <e1>CB\NN\1740 3717</e1>\CD\1740 ,\,\1740 activity\NN\30358 has\VBZ\2108377 been\VBN\836236 seen\VBN\2106506 in\IN\13603305 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 <e2>hepatoma</e2>\NN\14242337 ,\,\1740 and\CC\1740 mesothelioma\NN\14242337 .\.\1740
C031662_D008654 NONE In\IN\13603305 early\JJ\1740 clinical\JJ\1740 studies\NNS\635850 with\IN\1740 <e1>CB\NN\1740 3717</e1>\CD\1740 ,\,\1740 activity\NN\30358 has\VBZ\2108377 been\VBN\836236 seen\VBN\2106506 in\IN\13603305 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 hepatoma\NN\14242337 ,\,\1740 and\CC\1740 <e2>mesothelioma</e2>\NN\14242337 .\.\1740
18589141
D006493_D013921 CID <e1>Heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D006493_D013921 CID <e1>Heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 adverse\JJ\1740 immune-mediated\JJ\1740 reaction\NN\13446390 to\TO\1740 heparin\NN\2718259 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 platelet\NN\5432736 count\NN\13582013 decreases\VBZ\169651 of\IN\1740 more\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 .\.\1740
D006493_D013921 CID <e1>Heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 <e2>HIT</e2>\NN\36762 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 adverse\JJ\1740 immune-mediated\JJ\1740 reaction\NN\13446390 to\TO\1740 heparin\NN\2718259 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 platelet\NN\5432736 count\NN\13582013 decreases\VBZ\169651 of\IN\1740 more\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 .\.\1740
D006493_D013921 CID Heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 adverse\JJ\1740 immune-mediated\JJ\1740 reaction\NN\13446390 to\TO\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 platelet\NN\5432736 count\NN\13582013 decreases\VBZ\169651 of\IN\1740 more\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 .\.\1740
D006493_D013921 CID Heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 <e2>HIT</e2>\NN\36762 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 adverse\JJ\1740 immune-mediated\JJ\1740 reaction\NN\13446390 to\TO\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 platelet\NN\5432736 count\NN\13582013 decreases\VBZ\169651 of\IN\1740 more\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 .\.\1740
D006493_D013921 CID The\DT\1740 frequencies\NNS\15286249 of\IN\1740 <e2>HIT</e2>\NN\36762 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 and\CC\1740 platelet\NN\5432736 factor\NN\7326557 <e1>4/heparin-reactive</e1>\JJ\1740 antibody\NN\14728724 (\-LRB-\1740 HIT\NN\36762 antibody\NN\14728724 )\-RRB-\1740 positivity\NN\13856574 in\IN\13603305 liver\NN\5298729 transplantation\NN\671351 patients\NNS\9898892 ,\,\1740 however\RB\1740 ,\,\1740 are\VBP\836236 unknown\JJ\1740 .\.\1740
D006493_D013921 CID The\DT\1740 frequencies\NNS\15286249 of\IN\1740 HIT\NN\36762 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 and\CC\1740 platelet\NN\5432736 factor\NN\7326557 <e1>4/heparin-reactive</e1>\JJ\1740 antibody\NN\14728724 (\-LRB-\1740 <e2>HIT</e2>\NN\36762 antibody\NN\14728724 )\-RRB-\1740 positivity\NN\13856574 in\IN\13603305 liver\NN\5298729 transplantation\NN\671351 patients\NNS\9898892 ,\,\1740 however\RB\1740 ,\,\1740 are\VBP\836236 unknown\JJ\1740 .\.\1740
D006493_D013921 CID None\NN\15228378 of\IN\1740 the\DT\1740 subjects/patients\NNS\1740 developed\VBD\1753788 <e1>UFH-related</e1>\JJ\1740 <e2>HIT</e2>\NN\36762 .\.\1740
D006493_D013927 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Unfractionated\VBN\1740 heparin\NN\2718259 sodium</e1>\NN\14625458 (\-LRB-\1740 UFH\NN\1740 )\-RRB-\1740 or\CC\3541091 low-molecular\JJ\1740 weight\NN\5009170 heparin\NN\2718259 (\-LRB-\1740 LMWH\NN\1740 )\-RRB-\1740 is\VBZ\836236 used\VBN\1156834 in\IN\13603305 anticoagulant\JJ\1740 protocols\NNS\6652242 at\IN\14622893 several\JJ\1740 institutions\NNS\8008335 to\TO\1740 prevent\VB\1740 <e2>thrombosis</e2>\NN\14100769 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D006493_D013927 NONE BACKGROUND\NN\4921011 :\:\1740 Unfractionated\VBN\1740 heparin\NN\2718259 sodium\NN\14625458 (\-LRB-\1740 <e1>UFH</e1>\NN\1740 )\-RRB-\1740 or\CC\3541091 low-molecular\JJ\1740 weight\NN\5009170 heparin\NN\2718259 (\-LRB-\1740 LMWH\NN\1740 )\-RRB-\1740 is\VBZ\836236 used\VBN\1156834 in\IN\13603305 anticoagulant\JJ\1740 protocols\NNS\6652242 at\IN\14622893 several\JJ\1740 institutions\NNS\8008335 to\TO\1740 prevent\VB\1740 <e2>thrombosis</e2>\NN\14100769 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D006495_D013927 NONE BACKGROUND\NN\4921011 :\:\1740 Unfractionated\VBN\1740 heparin\NN\2718259 sodium\NN\14625458 (\-LRB-\1740 UFH\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>low-molecular\JJ\1740 weight\NN\5009170 heparin</e1>\NN\2718259 (\-LRB-\1740 LMWH\NN\1740 )\-RRB-\1740 is\VBZ\836236 used\VBN\1156834 in\IN\13603305 anticoagulant\JJ\1740 protocols\NNS\6652242 at\IN\14622893 several\JJ\1740 institutions\NNS\8008335 to\TO\1740 prevent\VB\1740 <e2>thrombosis</e2>\NN\14100769 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D006493_D001791 NONE The\DT\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 test\NN\5798043 was\VBD\836236 negative\JJ\1740 in\IN\13603305 these\DT\1740 patients\NNS\9898892 .\.\1740
7337133
D000082_D001929 CID Massive\JJ\1740 <e2>cerebral\JJ\1740 edema</e2>\NN\14315192 associated\VBN\628491 with\IN\1740 fulminant\JJ\1740 hepatic\JJ\1740 failure\NN\66216 in\IN\13603305 <e1>acetaminophen</e1>\JJ\1740 overdose\NN\1740 :\:\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 cranial\JJ\1740 decompression\NN\617059 .\.\1740
D000082_D001929 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 patient\NN\9898892 with\IN\1740 fatal\JJ\1740 <e1>acetaminophen-induced</e1>\JJ\1740 fulminant\JJ\1740 hepatic\JJ\1740 failure\NN\66216 ,\,\1740 with\IN\1740 signs\NNS\6643763 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 <e2>cerebral\JJ\1740 edema</e2>\NN\14315192 ,\,\1740 unresponsive\JJ\1740 to\TO\1740 conventional\JJ\1740 medical\JJ\1740 therapy\NN\657604 .\.\1740
D000082_D017093 CID Massive\JJ\1740 cerebral\JJ\1740 edema\NN\14315192 associated\VBN\628491 with\IN\1740 fulminant\JJ\1740 <e2>hepatic\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 <e1>acetaminophen</e1>\JJ\1740 overdose\NN\1740 :\:\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 cranial\JJ\1740 decompression\NN\617059 .\.\1740
D000082_D017093 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 patient\NN\9898892 with\IN\1740 fatal\JJ\1740 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>fulminant\JJ\1740 hepatic\JJ\1740 failure</e2>\NN\66216 ,\,\1740 with\IN\1740 signs\NNS\6643763 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 cerebral\JJ\1740 edema\NN\14315192 ,\,\1740 unresponsive\JJ\1740 to\TO\1740 conventional\JJ\1740 medical\JJ\1740 therapy\NN\657604 .\.\1740
D000082_D062787 NONE Massive\JJ\1740 cerebral\JJ\1740 edema\NN\14315192 associated\VBN\628491 with\IN\1740 fulminant\JJ\1740 hepatic\JJ\1740 failure\NN\66216 in\IN\13603305 <e1>acetaminophen</e1>\JJ\1740 <e2>overdose</e2>\NN\1740 :\:\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 cranial\JJ\1740 decompression\NN\617059 .\.\1740
10539815
D000809_D051437 NONE Predictors\NNS\10756433 of\IN\1740 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 heart\NN\5919034 failure\NN\66216 during\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 therapy\NN\657604 :\:\1740 results\NNS\34213 from\IN\1740 the\DT\1740 studies\NNS\635850 of\IN\1740 left\JJ\1740 ventricular\NN\1740 dysfunction\NN\14204950 (\-LRB-\1740 SOLVD\NN\1740 )\-RRB-\1740
D000809_D051437 NONE BACKGROUND\NN\4921011 :\:\1740 Although\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 therapy\NN\657604 reduces\VBZ\441445 mortality\NN\5054863 rates\NNS\13308999 in\IN\13603305 patients\NNS\9898892 with\IN\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 ,\,\1740 it\PRP\6125041 may\MD\15209706 also\RB\1740 cause\VB\1617192 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 .\.\1740
D000809_D051437 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 quantify\VB\947077 specific\JJ\1740 clinical\JJ\1740 predictors\NNS\10756433 of\IN\1740 <e2>reduction\NN\351485 in\IN\13603305 renal\JJ\1740 function</e2>\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 CHF\NN\1740 who\WP\8299493 are\VBP\836236 prescribed\VBN\748282 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 therapy\NN\657604 .\.\1740
D000809_D006333 NONE Predictors\NNS\10756433 of\IN\1740 decreased\VBN\169651 renal\JJ\1740 function\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 during\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 therapy\NN\657604 :\:\1740 results\NNS\34213 from\IN\1740 the\DT\1740 studies\NNS\635850 of\IN\1740 left\JJ\1740 ventricular\NN\1740 dysfunction\NN\14204950 (\-LRB-\1740 SOLVD\NN\1740 )\-RRB-\1740
D000809_D006333 NONE BACKGROUND\NN\4921011 :\:\1740 Although\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 therapy\NN\657604 reduces\VBZ\441445 mortality\NN\5054863 rates\NNS\13308999 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 ,\,\1740 it\PRP\6125041 may\MD\15209706 also\RB\1740 cause\VB\1617192 decreased\VBN\169651 renal\JJ\1740 function\NN\13783581 .\.\1740
D000809_D006333 NONE BACKGROUND\NN\4921011 :\:\1740 Although\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 therapy\NN\657604 reduces\VBZ\441445 mortality\NN\5054863 rates\NNS\13308999 in\IN\13603305 patients\NNS\9898892 with\IN\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 <e2>CHF</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 it\PRP\6125041 may\MD\15209706 also\RB\1740 cause\VB\1617192 decreased\VBN\169651 renal\JJ\1740 function\NN\13783581 .\.\1740
D000809_D006333 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 quantify\VB\947077 specific\JJ\1740 clinical\JJ\1740 predictors\NNS\10756433 of\IN\1740 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 function\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>CHF</e2>\NN\1740 who\WP\8299493 are\VBP\836236 prescribed\VBN\748282 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 therapy\NN\657604 .\.\1740
D000809_D018487 NONE Predictors\NNS\10756433 of\IN\1740 decreased\VBN\169651 renal\JJ\1740 function\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 heart\NN\5919034 failure\NN\66216 during\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 therapy\NN\657604 :\:\1740 results\NNS\34213 from\IN\1740 the\DT\1740 studies\NNS\635850 of\IN\1740 <e2>left\JJ\1740 ventricular\NN\1740 dysfunction</e2>\NN\14204950 (\-LRB-\1740 SOLVD\NN\1740 )\-RRB-\1740
D004656_D018487 NONE METHOD\NNP\5616786 :\:\1740 We\PRP\1740 analyzed\VBD\78760 data\NNS\7951464 from\IN\1740 the\DT\1740 Studies\NNPS\635850 of\IN\1740 <e2>Left\NNP\8621598 Ventricular\NNP\1740 Dysfunction</e2>\NNP\14204950 (\-LRB-\1740 SOLVD\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 <e1>enalapril</e1>\NN\2673637 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 CHF\NN\1740 .\.\1740
D004656_D006333 NONE METHOD\NNP\5616786 :\:\1740 We\PRP\1740 analyzed\VBD\78760 data\NNS\7951464 from\IN\1740 the\DT\1740 Studies\NNPS\635850 of\IN\1740 Left\NNP\8621598 Ventricular\NNP\1740 Dysfunction\NNP\14204950 (\-LRB-\1740 SOLVD\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 <e1>enalapril</e1>\NN\2673637 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>CHF</e2>\NN\1740 .\.\1740
D004656_D006333 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Enalapril</e1>\NNP\2673637 use\NN\407535 caused\VBD\1617192 a\DT\13649268 33\CD\1740 %\NN\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 risk\NN\14541044 of\IN\1740 decreased\VBN\169651 renal\JJ\1740 function\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>CHF</e2>\NN\1740 .\.\1740
D004656_D006333 NONE Diabetes\NNS\14075199 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 renal\JJ\1740 impairment\NN\7296428 in\IN\13603305 all\DT\1740 patients\NNS\9898892 with\IN\1740 <e2>CHF</e2>\NN\1740 ,\,\1740 but\CC\1740 this\DT\1740 risk\NN\14541044 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 the\DT\1740 <e1>enalapril</e1>\NN\2673637 group\NN\2137 compared\VBN\644583 with\IN\1740 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
D003404_D051437 NONE <e2>Decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 was\VBD\836236 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 rise\NN\7324673 in\IN\13603305 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 >\NN\1740 /=0.5\:\1740 mg/dL\NN\1740 (\-LRB-\1740 44\CD\1740 micromol/L\NN\1740 )\-RRB-\1740 from\IN\1740 baseline\NN\7260623 .\.\1740
D003404_D006973 NONE We\PRP\1740 used\VBD\1156834 time-to-event\JJ\1740 analysis\NN\633864 to\TO\1740 identify\VB\699815 potential\JJ\1740 predictors\NNS\10756433 of\IN\1740 decrease\NN\7296428 in\IN\13603305 renal\JJ\1740 function\NN\13783581 including\VBG\690614 age\NN\4916342 ,\,\1740 baseline\NN\7260623 ejection\NN\45250 fraction\NN\14806838 ,\,\1740 baseline\NN\7260623 <e1>creatinine</e1>\NN\1740 ,\,\1740 low\JJ\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 <\XX\1740 100\CD\13745420 mm\NN\13649268 Hg\FW\14625458 )\-RRB-\1740 ,\,\1740 history\NN\15120823 of\IN\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 use\NN\407535 of\IN\1740 antiplatelet\NN\1740 ,\,\1740 diuretic\NN\3247620 ,\,\1740 and\CC\1740 beta-blocker\NN\1740 therapy\NN\657604 .\.\1740
D003404_D003920 NONE We\PRP\1740 used\VBD\1156834 time-to-event\JJ\1740 analysis\NN\633864 to\TO\1740 identify\VB\699815 potential\JJ\1740 predictors\NNS\10756433 of\IN\1740 decrease\NN\7296428 in\IN\13603305 renal\JJ\1740 function\NN\13783581 including\VBG\690614 age\NN\4916342 ,\,\1740 baseline\NN\7260623 ejection\NN\45250 fraction\NN\14806838 ,\,\1740 baseline\NN\7260623 <e1>creatinine</e1>\NN\1740 ,\,\1740 low\JJ\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 <\XX\1740 100\CD\13745420 mm\NN\13649268 Hg\FW\14625458 )\-RRB-\1740 ,\,\1740 history\NN\15120823 of\IN\1740 hypertension\NN\14057371 ,\,\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 and\CC\1740 use\NN\407535 of\IN\1740 antiplatelet\NN\1740 ,\,\1740 diuretic\NN\3247620 ,\,\1740 and\CC\1740 beta-blocker\NN\1740 therapy\NN\657604 .\.\1740
D004232_D006973 NONE We\PRP\1740 used\VBD\1156834 time-to-event\JJ\1740 analysis\NN\633864 to\TO\1740 identify\VB\699815 potential\JJ\1740 predictors\NNS\10756433 of\IN\1740 decrease\NN\7296428 in\IN\13603305 renal\JJ\1740 function\NN\13783581 including\VBG\690614 age\NN\4916342 ,\,\1740 baseline\NN\7260623 ejection\NN\45250 fraction\NN\14806838 ,\,\1740 baseline\NN\7260623 creatinine\NN\1740 ,\,\1740 low\JJ\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 <\XX\1740 100\CD\13745420 mm\NN\13649268 Hg\FW\14625458 )\-RRB-\1740 ,\,\1740 history\NN\15120823 of\IN\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 diabetes\NNS\14075199 ,\,\1740 and\CC\1740 use\NN\407535 of\IN\1740 antiplatelet\NN\1740 ,\,\1740 <e1>diuretic</e1>\NN\3247620 ,\,\1740 and\CC\1740 beta-blocker\NN\1740 therapy\NN\657604 .\.\1740
D004232_D003920 NONE We\PRP\1740 used\VBD\1156834 time-to-event\JJ\1740 analysis\NN\633864 to\TO\1740 identify\VB\699815 potential\JJ\1740 predictors\NNS\10756433 of\IN\1740 decrease\NN\7296428 in\IN\13603305 renal\JJ\1740 function\NN\13783581 including\VBG\690614 age\NN\4916342 ,\,\1740 baseline\NN\7260623 ejection\NN\45250 fraction\NN\14806838 ,\,\1740 baseline\NN\7260623 creatinine\NN\1740 ,\,\1740 low\JJ\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 <\XX\1740 100\CD\13745420 mm\NN\13649268 Hg\FW\14625458 )\-RRB-\1740 ,\,\1740 history\NN\15120823 of\IN\1740 hypertension\NN\14057371 ,\,\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 and\CC\1740 use\NN\407535 of\IN\1740 antiplatelet\NN\1740 ,\,\1740 <e1>diuretic</e1>\NN\3247620 ,\,\1740 and\CC\1740 beta-blocker\NN\1740 therapy\NN\657604 .\.\1740
D004232_D003920 NONE By\IN\1740 multivariate\JJ\1740 analysis\NN\633864 ,\,\1740 in\IN\13603305 both\CC\1740 the\DT\1740 placebo\NN\3740161 and\CC\1740 enalapril\JJ\1740 groups\NNS\2137 older\JJR\1740 age\NN\4916342 ,\,\1740 <e1>diuretic</e1>\NN\3247620 therapy\NN\657604 ,\,\1740 and\CC\1740 <e2>diabetes</e2>\NNS\14075199 were\VBD\836236 associated\VBN\628491 with\IN\1740 decreased\VBN\169651 renal\JJ\1740 function\NN\13783581 ,\,\1740 whereas\IN\1740 beta-blocker\NN\1740 therapy\NN\657604 and\CC\1740 higher\JJR\1740 ejection\NN\45250 fraction\NN\14806838 were\VBD\836236 renoprotective\JJ\1740 .\.\1740
D004656_D051437 CID RESULTS\NNS\34213 :\:\1740 Patients\NNS\9898892 randomly\RB\1740 assigned\VBD\2475922 to\TO\1740 <e1>enalapril</e1>\NN\2673637 had\VBD\2108377 a\DT\13649268 33\CD\1740 %\NN\1740 greater\JJR\1740 likelihood\NN\4756172 of\IN\1740 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 than\IN\1740 controls\NNS\5190804 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 .003\CD\1740 )\-RRB-\1740 .\.\1740
D004656_D051437 CID By\IN\1740 multivariate\JJ\1740 analysis\NN\633864 ,\,\1740 in\IN\13603305 both\CC\1740 the\DT\1740 placebo\NN\3740161 and\CC\1740 <e1>enalapril</e1>\JJ\1740 groups\NNS\2137 older\JJR\1740 age\NN\4916342 ,\,\1740 diuretic\NN\3247620 therapy\NN\657604 ,\,\1740 and\CC\1740 diabetes\NNS\14075199 were\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 ,\,\1740 whereas\IN\1740 beta-blocker\NN\1740 therapy\NN\657604 and\CC\1740 higher\JJR\1740 ejection\NN\45250 fraction\NN\14806838 were\VBD\836236 renoprotective\JJ\1740 .\.\1740
D004656_D051437 CID Older\JJR\1740 age\NN\4916342 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 greater\JJR\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 in\IN\13603305 both\DT\1740 groups\NNS\2137 ,\,\1740 but\CC\1740 significantly\RB\1740 more\RBR\1740 so\RB\1740 in\IN\13603305 the\DT\1740 <e1>enalapril</e1>\JJ\1740 group\NN\2137 (\-LRB-\1740 enalapril\NN\2673637 :\:\1740 risk\NN\14541044 ratio\NN\13815152 [\-LRB-\1740 RR\NN\1740 ]\-RRB-\1740 1.42\CD\1740 per\IN\1740 10\CD\13745420 years\NNS\15144371 ,\,\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 1.32\CD\1740 -\SYM\1740 1.52\CD\1740 with\IN\1740 enalapril\NN\2673637 ;\:\1740 placebo\NN\3740161 :\:\1740 RR\NN\1740 1.18\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.12\CD\1740 -\SYM\1740 1.25\CD\1740 )\-RRB-\1740 .\.\1740
D004656_D051437 CID Older\JJR\1740 age\NN\4916342 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 greater\JJR\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 in\IN\13603305 both\DT\1740 groups\NNS\2137 ,\,\1740 but\CC\1740 significantly\RB\1740 more\RBR\1740 so\RB\1740 in\IN\13603305 the\DT\1740 enalapril\JJ\1740 group\NN\2137 (\-LRB-\1740 <e1>enalapril</e1>\NN\2673637 :\:\1740 risk\NN\14541044 ratio\NN\13815152 [\-LRB-\1740 RR\NN\1740 ]\-RRB-\1740 1.42\CD\1740 per\IN\1740 10\CD\13745420 years\NNS\15144371 ,\,\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 1.32\CD\1740 -\SYM\1740 1.52\CD\1740 with\IN\1740 enalapril\NN\2673637 ;\:\1740 placebo\NN\3740161 :\:\1740 RR\NN\1740 1.18\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.12\CD\1740 -\SYM\1740 1.25\CD\1740 )\-RRB-\1740 .\.\1740
D004656_D051437 CID Older\JJR\1740 age\NN\4916342 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 greater\JJR\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 in\IN\13603305 both\DT\1740 groups\NNS\2137 ,\,\1740 but\CC\1740 significantly\RB\1740 more\RBR\1740 so\RB\1740 in\IN\13603305 the\DT\1740 enalapril\JJ\1740 group\NN\2137 (\-LRB-\1740 enalapril\NN\2673637 :\:\1740 risk\NN\14541044 ratio\NN\13815152 [\-LRB-\1740 RR\NN\1740 ]\-RRB-\1740 1.42\CD\1740 per\IN\1740 10\CD\13745420 years\NNS\15144371 ,\,\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 1.32\CD\1740 -\SYM\1740 1.52\CD\1740 with\IN\1740 <e1>enalapril</e1>\NN\2673637 ;\:\1740 placebo\NN\3740161 :\:\1740 RR\NN\1740 1.18\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.12\CD\1740 -\SYM\1740 1.25\CD\1740 )\-RRB-\1740 .\.\1740
D004656_D051437 CID Diuretic\NN\3247620 therapy\NN\657604 was\VBD\836236 likewise\RB\1740 associated\VBN\628491 with\IN\1740 a\DT\13649268 greater\JJR\1740 risk\NN\14541044 of\IN\1740 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 in\IN\13603305 the\DT\1740 <e1>enalapril</e1>\JJ\1740 group\NN\2137 (\-LRB-\1740 RR\NN\1740 1.89\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.70\CD\1740 -\SYM\1740 2.08\CD\1740 )\-RRB-\1740 than\IN\1740 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 (\-LRB-\1740 RR\NN\1740 1.35\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.09\CD\1740 -\SYM\1740 1.66\CD\1740 )\-RRB-\1740 .\.\1740
D004656_D051437 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Enalapril</e1>\NNP\2673637 use\NN\407535 caused\VBD\1617192 a\DT\13649268 33\CD\1740 %\NN\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 CHF\NN\1740 .\.\1740
D004656_D051437 CID Diabetes\NNS\14075199 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 in\IN\13603305 all\DT\1740 patients\NNS\9898892 with\IN\1740 CHF\NN\1740 ,\,\1740 but\CC\1740 this\DT\1740 risk\NN\14541044 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 the\DT\1740 <e1>enalapril</e1>\NN\2673637 group\NN\2137 compared\VBN\644583 with\IN\1740 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
D004656_D003920 NONE By\IN\1740 multivariate\JJ\1740 analysis\NN\633864 ,\,\1740 in\IN\13603305 both\CC\1740 the\DT\1740 placebo\NN\3740161 and\CC\1740 <e1>enalapril</e1>\JJ\1740 groups\NNS\2137 older\JJR\1740 age\NN\4916342 ,\,\1740 diuretic\NN\3247620 therapy\NN\657604 ,\,\1740 and\CC\1740 <e2>diabetes</e2>\NNS\14075199 were\VBD\836236 associated\VBN\628491 with\IN\1740 decreased\VBN\169651 renal\JJ\1740 function\NN\13783581 ,\,\1740 whereas\IN\1740 beta-blocker\NN\1740 therapy\NN\657604 and\CC\1740 higher\JJR\1740 ejection\NN\45250 fraction\NN\14806838 were\VBD\836236 renoprotective\JJ\1740 .\.\1740
D004656_D003920 NONE Conversely\RB\1740 ,\,\1740 <e1>enalapril</e1>\NN\2673637 had\VBD\2108377 a\DT\13649268 relative\JJ\1740 renoprotective\JJ\1740 effect\NN\34213 (\-LRB-\1740 RR\NN\1740 1.33\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.13\CD\1740 -\SYM\1740 1.53\CD\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 placebo\NN\3740161 (\-LRB-\1740 RR\NN\1740 1.96\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.57\CD\1740 -\SYM\1740 2.44\CD\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>diabetes</e2>\NNS\14075199 .\.\1740
D004656_D003920 NONE <e2>Diabetes</e2>\NNS\14075199 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 renal\JJ\1740 impairment\NN\7296428 in\IN\13603305 all\DT\1740 patients\NNS\9898892 with\IN\1740 CHF\NN\1740 ,\,\1740 but\CC\1740 this\DT\1740 risk\NN\14541044 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 the\DT\1740 <e1>enalapril</e1>\NN\2673637 group\NN\2137 compared\VBN\644583 with\IN\1740 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
D004232_D051437 CID By\IN\1740 multivariate\JJ\1740 analysis\NN\633864 ,\,\1740 in\IN\13603305 both\CC\1740 the\DT\1740 placebo\NN\3740161 and\CC\1740 enalapril\JJ\1740 groups\NNS\2137 older\JJR\1740 age\NN\4916342 ,\,\1740 <e1>diuretic</e1>\NN\3247620 therapy\NN\657604 ,\,\1740 and\CC\1740 diabetes\NNS\14075199 were\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 ,\,\1740 whereas\IN\1740 beta-blocker\NN\1740 therapy\NN\657604 and\CC\1740 higher\JJR\1740 ejection\NN\45250 fraction\NN\14806838 were\VBD\836236 renoprotective\JJ\1740 .\.\1740
D004232_D051437 CID <e1>Diuretic</e1>\NN\3247620 therapy\NN\657604 was\VBD\836236 likewise\RB\1740 associated\VBN\628491 with\IN\1740 a\DT\13649268 greater\JJR\1740 risk\NN\14541044 of\IN\1740 <e2>decreased\VBN\169651 renal\JJ\1740 function</e2>\NN\13783581 in\IN\13603305 the\DT\1740 enalapril\JJ\1740 group\NN\2137 (\-LRB-\1740 RR\NN\1740 1.89\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.70\CD\1740 -\SYM\1740 2.08\CD\1740 )\-RRB-\1740 than\IN\1740 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 (\-LRB-\1740 RR\NN\1740 1.35\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.09\CD\1740 -\SYM\1740 1.66\CD\1740 )\-RRB-\1740 .\.\1740
18441470
D008094_D054537 CID Complete\JJ\1740 <e2>atrioventricular\JJ\1740 block</e2>\NN\21939 secondary\JJ\1740 to\TO\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D054537 CID In\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 ,\,\1740 complete\VBP\352826 <e2>atrioventricular\JJ\1740 (\-LRB-\1740 AV\NN\15214068 )\-RRB-\1740 block</e2>\NN\21939 with\IN\1740 syncopal\NN\1740 attacks\NNS\955060 developed\VBD\1753788 secondary\JJ\1740 to\TO\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 ,\,\1740 necessitating\VBG\2635956 permanent\JJ\1740 pacemaker\NN\5925366 implantation\NN\13526110 .\.\1740
D008094_D012804 CID <e2>Sinus\NN\5248181 node\NN\13870805 dysfunction</e2>\NN\14204950 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 most\RBS\1740 frequently\RB\1740 among\IN\1740 the\DT\1740 adverse\JJ\1740 cardiovascular\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>lithium</e1>\NN\14625458 .\.\1740
D008094_D013575 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 ,\,\1740 complete\VBP\352826 atrioventricular\JJ\1740 (\-LRB-\1740 AV\NN\15214068 )\-RRB-\1740 block\NN\21939 with\IN\1740 <e2>syncopal\NN\1740 attacks</e2>\NNS\955060 developed\VBD\1753788 secondary\JJ\1740 to\TO\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 ,\,\1740 necessitating\VBG\2635956 permanent\JJ\1740 pacemaker\NN\5925366 implantation\NN\13526110 .\.\1740
D008094_D013575 NONE Serum\NN\5397468 <e1>lithium</e1>\NN\14625458 levels\NNS\4916342 remained\VBD\2604760 under\IN\1740 or\CC\3541091 within\IN\1740 the\DT\1740 therapeutic\JJ\1740 range\NN\5123416 during\IN\1740 the\DT\1740 <e2>syncopal\NN\1740 attacks</e2>\NNS\955060 .\.\1740
3973521
11230490
D004317_D066126 NONE Reduced\VBN\441445 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 preserved\VBD\2681795 antitumor\NN\1740 efficacy\NN\5199286 of\IN\1740 liposome-encapsulated\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 multicenter\NN\1740 trial\NN\786195 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D004317_D066126 NONE Reduced\VBN\441445 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 preserved\VBD\2681795 antitumor\NN\1740 efficacy\NN\5199286 of\IN\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 multicenter\NN\1740 trial\NN\786195 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D004317_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 <e1>Myocet</e1>\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 significantly\RB\1740 reduces\VBZ\441445 doxorubicin\NN\2716866 <e2>cardiotoxicity</e2>\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 (\-LRB-\1740 MBC\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 significantly\RB\1740 reduces\VBZ\441445 doxorubicin\NN\2716866 <e2>cardiotoxicity</e2>\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 (\-LRB-\1740 MBC\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 significantly\RB\1740 reduces\VBZ\441445 <e1>doxorubicin</e1>\NN\2716866 <e2>cardiotoxicity</e2>\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 (\-LRB-\1740 MBC\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D066126 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Myocet</e1>\NNP\1740 improves\VBZ\126264 the\DT\1740 therapeutic\JJ\1740 index\NN\13850304 of\IN\1740 doxorubicin\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 grade\NN\7975026 4\CD\13741022 neutropenia\NN\14196405 and\CC\1740 provides\VBZ\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 ,\,\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 MBC\NN\1740 .\.\1740
D004317_D066126 NONE CONCLUSION\NN\5837957 :\:\1740 Myocet\NNP\1740 improves\VBZ\126264 the\DT\1740 therapeutic\JJ\1740 index\NN\13850304 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 grade\NN\7975026 4\CD\13741022 neutropenia\NN\14196405 and\CC\1740 provides\VBZ\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 ,\,\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 MBC\NN\1740 .\.\1740
D004317_D001943 NONE Reduced\VBN\441445 cardiotoxicity\NN\1740 and\CC\1740 preserved\VBD\2681795 antitumor\NN\1740 efficacy\NN\5199286 of\IN\1740 liposome-encapsulated\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 multicenter\NN\1740 trial\NN\786195 of\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D004317_D001943 NONE Reduced\VBN\441445 cardiotoxicity\NN\1740 and\CC\1740 preserved\VBD\2681795 antitumor\NN\1740 efficacy\NN\5199286 of\IN\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 multicenter\NN\1740 trial\NN\786195 of\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D004317_D001943 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 <e1>Myocet</e1>\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 significantly\RB\1740 reduces\VBZ\441445 doxorubicin\NN\2716866 cardiotoxicity\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 (\-LRB-\1740 MBC\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D001943 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 <e1>Myocet</e1>\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 significantly\RB\1740 reduces\VBZ\441445 doxorubicin\NN\2716866 cardiotoxicity\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 (\-LRB-\1740 <e2>MBC</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D001943 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 significantly\RB\1740 reduces\VBZ\441445 doxorubicin\NN\2716866 cardiotoxicity\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 (\-LRB-\1740 MBC\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D001943 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 significantly\RB\1740 reduces\VBZ\441445 doxorubicin\NN\2716866 cardiotoxicity\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 (\-LRB-\1740 <e2>MBC</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D001943 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 significantly\RB\1740 reduces\VBZ\441445 <e1>doxorubicin</e1>\NN\2716866 cardiotoxicity\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 (\-LRB-\1740 MBC\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D001943 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 significantly\RB\1740 reduces\VBZ\441445 <e1>doxorubicin</e1>\NN\2716866 cardiotoxicity\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 (\-LRB-\1740 <e2>MBC</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D001943 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 Two\CD\13741022 hundred\CD\13745420 ninety-seven\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>MBC</e2>\NN\1740 and\CC\1740 no\DT\7204911 prior\JJ\1740 chemotherapy\NN\661091 for\IN\1740 metastatic\JJ\1740 disease\NN\14061805 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 60\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>Myocet</e1>\NNP\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 or\CC\3541091 conventional\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 A\NN\13649268 )\-RRB-\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 600\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 until\IN\1740 disease\NN\14061805 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 toxicity\NN\13576101 .\.\1740
D004317_D001943 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 Two\CD\13741022 hundred\CD\13745420 ninety-seven\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>MBC</e2>\NN\1740 and\CC\1740 no\DT\7204911 prior\JJ\1740 chemotherapy\NN\661091 for\IN\1740 metastatic\JJ\1740 disease\NN\14061805 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 60\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 or\CC\3541091 conventional\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 A\NN\13649268 )\-RRB-\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 600\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 until\IN\1740 disease\NN\14061805 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 toxicity\NN\13576101 .\.\1740
D004317_D001943 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Myocet</e1>\NNP\1740 improves\VBZ\126264 the\DT\1740 therapeutic\JJ\1740 index\NN\13850304 of\IN\1740 doxorubicin\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 cardiotoxicity\NN\1740 and\CC\1740 grade\NN\7975026 4\CD\13741022 neutropenia\NN\14196405 and\CC\1740 provides\VBZ\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 ,\,\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>MBC</e2>\NN\1740 .\.\1740
D004317_D001943 NONE CONCLUSION\NN\5837957 :\:\1740 Myocet\NNP\1740 improves\VBZ\126264 the\DT\1740 therapeutic\JJ\1740 index\NN\13850304 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 cardiotoxicity\NN\1740 and\CC\1740 grade\NN\7975026 4\CD\13741022 neutropenia\NN\14196405 and\CC\1740 provides\VBZ\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 ,\,\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>MBC</e2>\NN\1740 .\.\1740
D003520_D066126 NONE Reduced\VBN\441445 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 preserved\VBD\2681795 antitumor\NN\1740 efficacy\NN\5199286 of\IN\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 multicenter\NN\1740 trial\NN\786195 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D003520_D066126 NONE Reduced\VBN\441445 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 preserved\VBD\2681795 antitumor\NN\1740 efficacy\NN\5199286 of\IN\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 multicenter\NN\1740 trial\NN\786195 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D003520_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 significantly\RB\1740 reduces\VBZ\441445 doxorubicin\NN\2716866 <e2>cardiotoxicity</e2>\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 (\-LRB-\1740 MBC\NN\1740 )\-RRB-\1740 .\.\1740
D003520_D066126 NONE CONCLUSION\NN\5837957 :\:\1740 Myocet\NNP\1740 improves\VBZ\126264 the\DT\1740 therapeutic\JJ\1740 index\NN\13850304 of\IN\1740 doxorubicin\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 grade\NN\7975026 4\CD\13741022 neutropenia\NN\14196405 and\CC\1740 provides\VBZ\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 ,\,\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 MBC\NN\1740 .\.\1740
D003520_D001943 NONE Reduced\VBN\441445 cardiotoxicity\NN\1740 and\CC\1740 preserved\VBD\2681795 antitumor\NN\1740 efficacy\NN\5199286 of\IN\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 multicenter\NN\1740 trial\NN\786195 of\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D003520_D001943 NONE Reduced\VBN\441445 cardiotoxicity\NN\1740 and\CC\1740 preserved\VBD\2681795 antitumor\NN\1740 efficacy\NN\5199286 of\IN\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 cyclophosphamide\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 doxorubicin\NN\2716866 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 multicenter\NN\1740 trial\NN\786195 of\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D003520_D001943 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 significantly\RB\1740 reduces\VBZ\441445 doxorubicin\NN\2716866 cardiotoxicity\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 (\-LRB-\1740 MBC\NN\1740 )\-RRB-\1740 .\.\1740
D003520_D001943 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 whether\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 liposome-encapsulated\JJ\1740 doxorubicin\NN\2716866 ;\:\1740 The\DT\1740 Liposome\NNP\5517578 Company\NNP\8053576 ,\,\1740 Elan\NNP\7555184 Corporation\NNP\8059870 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 significantly\RB\1740 reduces\VBZ\441445 doxorubicin\NN\2716866 cardiotoxicity\NN\1740 while\IN\15122231 providing\VBG\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 in\IN\13603305 first-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 (\-LRB-\1740 <e2>MBC</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D003520_D001943 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 Two\CD\13741022 hundred\CD\13745420 ninety-seven\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>MBC</e2>\NN\1740 and\CC\1740 no\DT\7204911 prior\JJ\1740 chemotherapy\NN\661091 for\IN\1740 metastatic\JJ\1740 disease\NN\14061805 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 60\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 or\CC\3541091 conventional\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 A\NN\13649268 )\-RRB-\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 600\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 until\IN\1740 disease\NN\14061805 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 toxicity\NN\13576101 .\.\1740
D003520_D001943 NONE CONCLUSION\NN\5837957 :\:\1740 Myocet\NNP\1740 improves\VBZ\126264 the\DT\1740 therapeutic\JJ\1740 index\NN\13850304 of\IN\1740 doxorubicin\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 cardiotoxicity\NN\1740 and\CC\1740 grade\NN\7975026 4\CD\13741022 neutropenia\NN\14196405 and\CC\1740 provides\VBZ\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 ,\,\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>MBC</e2>\NN\1740 .\.\1740
D004317_D064420 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 Two\CD\13741022 hundred\CD\13745420 ninety-seven\JJ\1740 patients\NNS\9898892 with\IN\1740 MBC\NN\1740 and\CC\1740 no\DT\7204911 prior\JJ\1740 chemotherapy\NN\661091 for\IN\1740 metastatic\JJ\1740 disease\NN\14061805 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 60\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>Myocet</e1>\NNP\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 or\CC\3541091 conventional\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 A\NN\13649268 )\-RRB-\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 600\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 until\IN\1740 disease\NN\14061805 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D004317_D064420 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 Two\CD\13741022 hundred\CD\13745420 ninety-seven\JJ\1740 patients\NNS\9898892 with\IN\1740 MBC\NN\1740 and\CC\1740 no\DT\7204911 prior\JJ\1740 chemotherapy\NN\661091 for\IN\1740 metastatic\JJ\1740 disease\NN\14061805 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 60\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 or\CC\3541091 conventional\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 A\NN\13649268 )\-RRB-\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 600\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 until\IN\1740 disease\NN\14061805 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D003520_D064420 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 Two\CD\13741022 hundred\CD\13745420 ninety-seven\JJ\1740 patients\NNS\9898892 with\IN\1740 MBC\NN\1740 and\CC\1740 no\DT\7204911 prior\JJ\1740 chemotherapy\NN\661091 for\IN\1740 metastatic\JJ\1740 disease\NN\14061805 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 60\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 Myocet\NNP\1740 (\-LRB-\1740 M\NN\13649268 )\-RRB-\1740 or\CC\3541091 conventional\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 A\NN\13649268 )\-RRB-\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 600\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 until\IN\1740 disease\NN\14061805 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D004317_D009503 CID CONCLUSION\NN\5837957 :\:\1740 <e1>Myocet</e1>\NNP\1740 improves\VBZ\126264 the\DT\1740 therapeutic\JJ\1740 index\NN\13850304 of\IN\1740 doxorubicin\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 cardiotoxicity\NN\1740 and\CC\1740 grade\NN\7975026 4\CD\13741022 <e2>neutropenia</e2>\NN\14196405 and\CC\1740 provides\VBZ\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 ,\,\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 MBC\NN\1740 .\.\1740
D004317_D009503 CID CONCLUSION\NN\5837957 :\:\1740 Myocet\NNP\1740 improves\VBZ\126264 the\DT\1740 therapeutic\JJ\1740 index\NN\13850304 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 cardiotoxicity\NN\1740 and\CC\1740 grade\NN\7975026 4\CD\13741022 <e2>neutropenia</e2>\NN\14196405 and\CC\1740 provides\VBZ\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 ,\,\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 MBC\NN\1740 .\.\1740
D003520_D009503 CID CONCLUSION\NN\5837957 :\:\1740 Myocet\NNP\1740 improves\VBZ\126264 the\DT\1740 therapeutic\JJ\1740 index\NN\13850304 of\IN\1740 doxorubicin\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 cardiotoxicity\NN\1740 and\CC\1740 grade\NN\7975026 4\CD\13741022 <e2>neutropenia</e2>\NN\14196405 and\CC\1740 provides\VBZ\2199590 comparable\JJ\1740 antitumor\NN\1740 efficacy\NN\5199286 ,\,\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 MBC\NN\1740 .\.\1740
11467664
D008687_D041781 CID <e2>Cholestatic\JJ\1740 jaundice</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>metformin</e1>\NN\2719105 .\.\1740
D008687_D041781 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>cholestatic\NN\1740 jaundice</e2>\NN\14299637 shortly\RB\1740 after\IN\1740 initiation\NN\7450842 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>metformin\NN\2719105 hydrochloride</e1>\NN\14817592 .\.\1740
D008687_D007565 NONE <e1>Metformin\NN\2719105 hydrochloride</e1>\NN\14817592 was\VBD\836236 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>jaundice</e2>\NN\14299637 resolved\VBN\352826 slowly\RB\1740 over\IN\5867413 a\DT\13649268 period\NN\13575869 of\IN\1740 several\JJ\1740 months\NNS\15113229 .\.\1740
D008687_D007565 NONE Given\VBN\2327200 the\DT\1740 onset\NN\7325190 of\IN\1740 his\PRP$\1740 <e2>jaundice</e2>\NN\14299637 2\CD\13741022 wk\NN\1740 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>metformin</e1>\NN\2719105 ,\,\1740 we\PRP\1740 believe\VBP\686447 that\IN\1740 this\DT\1740 case\NN\7283608 represents\VBZ\2664769 an\DT\6697703 example\NN\5816287 of\IN\1740 metformin-associated\JJ\1740 hepatotoxicity\NN\1740 ,\,\1740 the\DT\1740 first\JJ\1740 such\JJ\1740 case\NN\7283608 reported\VBN\831651 .\.\1740
D008687_D007565 NONE Given\VBN\2327200 the\DT\1740 onset\NN\7325190 of\IN\1740 his\PRP$\1740 <e2>jaundice</e2>\NN\14299637 2\CD\13741022 wk\NN\1740 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 metformin\NN\2719105 ,\,\1740 we\PRP\1740 believe\VBP\686447 that\IN\1740 this\DT\1740 case\NN\7283608 represents\VBZ\2664769 an\DT\6697703 example\NN\5816287 of\IN\1740 <e1>metformin-associated</e1>\JJ\1740 hepatotoxicity\NN\1740 ,\,\1740 the\DT\1740 first\JJ\1740 such\JJ\1740 case\NN\7283608 reported\VBN\831651 .\.\1740
D008687_D056486 NONE Given\VBN\2327200 the\DT\1740 onset\NN\7325190 of\IN\1740 his\PRP$\1740 jaundice\NN\14299637 2\CD\13741022 wk\NN\1740 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>metformin</e1>\NN\2719105 ,\,\1740 we\PRP\1740 believe\VBP\686447 that\IN\1740 this\DT\1740 case\NN\7283608 represents\VBZ\2664769 an\DT\6697703 example\NN\5816287 of\IN\1740 metformin-associated\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 ,\,\1740 the\DT\1740 first\JJ\1740 such\JJ\1740 case\NN\7283608 reported\VBN\831651 .\.\1740
D008687_D056486 NONE Given\VBN\2327200 the\DT\1740 onset\NN\7325190 of\IN\1740 his\PRP$\1740 jaundice\NN\14299637 2\CD\13741022 wk\NN\1740 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 metformin\NN\2719105 ,\,\1740 we\PRP\1740 believe\VBP\686447 that\IN\1740 this\DT\1740 case\NN\7283608 represents\VBZ\2664769 an\DT\6697703 example\NN\5816287 of\IN\1740 <e1>metformin-associated</e1>\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 ,\,\1740 the\DT\1740 first\JJ\1740 such\JJ\1740 case\NN\7283608 reported\VBN\831651 .\.\1740
19319147
D014859_D006470 NONE Rapid\JJ\1740 reversal\NN\199130 of\IN\1740 anticoagulation\NN\657604 reduces\VBZ\441445 <e2>hemorrhage</e2>\NN\14285662 volume\NN\33615 in\IN\13603305 a\DT\13649268 mouse\NN\2329401 model\NN\5888929 of\IN\1740 <e1>warfarin-associated</e1>\JJ\1740 intracerebral\JJ\1740 hemorrhage\NN\14285662 .\.\1740
D014859_D002543 CID Rapid\JJ\1740 reversal\NN\199130 of\IN\1740 anticoagulation\NN\657604 reduces\VBZ\441445 hemorrhage\NN\14285662 volume\NN\33615 in\IN\13603305 a\DT\13649268 mouse\NN\2329401 model\NN\5888929 of\IN\1740 <e1>warfarin-associated</e1>\JJ\1740 <e2>intracerebral\JJ\1740 hemorrhage</e2>\NN\14285662 .\.\1740
D014859_D002543 CID <e1>Warfarin-associated</e1>\JJ\1740 <e2>intracerebral\JJ\1740 hemorrhage</e2>\NN\14285662 (\-LRB-\1740 W-ICH\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 severe\JJ\1740 type\NN\5839024 of\IN\1740 stroke\NN\556313 .\.\1740
D014859_D002543 CID <e1>Warfarin-associated</e1>\JJ\1740 intracerebral\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>W-ICH</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 severe\JJ\1740 type\NN\5839024 of\IN\1740 stroke\NN\556313 .\.\1740
D014859_D020521 NONE <e1>Warfarin-associated</e1>\JJ\1740 intracerebral\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 W-ICH\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 severe\JJ\1740 type\NN\5839024 of\IN\1740 <e2>stroke</e2>\NN\556313 .\.\1740
C025667_D002543 NONE We\PRP\1740 provide\VBP\2199590 experimental\JJ\1740 data\NNS\7951464 suggesting\VBG\1010118 <e1>PCC</e1>\NN\1740 to\TO\1740 be\VB\836236 an\DT\6697703 effective\JJ\1740 acute\JJ\1740 treatment\NN\654885 for\IN\1740 <e2>W-ICH</e2>\NN\1740 in\IN\13603305 terms\NNS\13945919 of\IN\1740 reducing\VBG\441445 hemorrhagic\JJ\1740 blood\NN\5397468 volume\NN\33615 .\.\1740
2557556
D015232_D006930 CID Intradermal\JJ\1740 injection\NN\320852 of\IN\1740 mu\NN\6828818 ,\,\1740 but\CC\1740 not\RB\1740 delta\NN\9193282 or\CC\3541091 kappa\NN\6828818 opioid-agonists\NNS\1740 ,\,\1740 however\RB\1740 ,\,\1740 produced\VBD\1617192 dose-dependent\JJ\1740 inhibition\NN\1068773 of\IN\1740 <e1>prostaglandin\NN\5414534 E2-induced</e1>\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 .\.\1740
D009020_D006930 NONE <e1>Morphine</e1>\NN\2707683 did\VBD\1640855 not\RB\1740 ,\,\1740 however\RB\1740 ,\,\1740 alter\VBP\126264 the\DT\1740 <e2>hyperalgesia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 8-bromo\JJ\1740 cyclic\JJ\1740 adenosine\NN\14964367 monophosphate\NN\1740 .\.\1740
D015124_D006930 CID Morphine\NN\2707683 did\VBD\1640855 not\RB\1740 ,\,\1740 however\RB\1740 ,\,\1740 alter\VBP\126264 the\DT\1740 <e2>hyperalgesia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>8-bromo\JJ\1740 cyclic\JJ\1740 adenosine\NN\14964367 monophosphate</e1>\NN\1740 .\.\1740
4069770
D005839_D007674 NONE <e1>Gentamicin</e1>\NN\2716866 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 a\DT\13649268 neonate\NN\9827683 .\.\1740
D005839_D058186 CID The\DT\1740 clinical\JJ\1740 and\CC\1740 autopsy\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 premature\JJ\1740 baby\NN\9918248 who\WP\8299493 died\VBD\146138 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 therapy\NN\657604 with\IN\1740 <e1>gentamicin</e1>\NN\2716866 (\-LRB-\1740 5\CD\13741022 mg/kg/day\NN\1740 )\-RRB-\1740 and\CC\1740 penicillin\NN\2716866 are\VBP\836236 presented\VBN\2137132 .\.\1740
D010406_D058186 NONE The\DT\1740 clinical\JJ\1740 and\CC\1740 autopsy\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 premature\JJ\1740 baby\NN\9918248 who\WP\8299493 died\VBD\146138 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 therapy\NN\657604 with\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 5\CD\13741022 mg/kg/day\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>penicillin</e1>\NN\2716866 are\VBP\836236 presented\VBN\2137132 .\.\1740
D005839_D001002 NONE The\DT\1740 serum\NN\5397468 <e1>gentamicin</e1>\NN\2716866 concentration\NN\4916342 had\VBD\2108377 reached\VBN\2005948 toxic\JJ\1740 levels\NNS\4916342 when\WRB\1740 <e2>anuria</e2>\NNS\14061805 developed\VBD\1753788 .\.\1740
2840807
D009074_D004421 CID A\DT\13649268 <e2>dystonia-like</e2>\JJ\1740 syndrome\NN\5870365 after\IN\1740 neuropeptide\NN\1740 (\-LRB-\1740 <e1>MSH/ACTH</e1>\JJ\1740 )\-RRB-\1740 stimulation\NN\242808 of\IN\1740 the\DT\1740 rat\NN\2329401 locus\NN\8645963 ceruleus\FW\1740 .\.\1740
D000324_D004421 CID A\DT\13649268 <e2>dystonia-like</e2>\JJ\1740 syndrome\NN\5870365 after\IN\1740 neuropeptide\NN\1740 (\-LRB-\1740 <e1>MSH/ACTH</e1>\JJ\1740 )\-RRB-\1740 stimulation\NN\242808 of\IN\1740 the\DT\1740 rat\NN\2329401 locus\NN\8645963 ceruleus\FW\1740 .\.\1740
D000324_D003866 NONE However\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 not\RB\1740 certain\JJ\1740 as\IN\14622893 to\IN\1740 the\DT\1740 following\NN\8180190 :\:\1740 (\-LRB-\1740 a\LS\13649268 )\-RRB-\1740 what\WDT\1740 receptors\NNS\5225602 were\VBD\836236 stimulated\VBN\137313 by\IN\1740 the\DT\1740 <e1>ACTH</e1>\NN\5407119 N-terminal\JJ\1740 fragments\NNS\9385911 at\IN\14622893 the\DT\1740 LC\NN\1740 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 this\DT\1740 disorder\NN\14034177 ;\:\1740 (\-LRB-\1740 b\LS\1355326 )\-RRB-\1740 whether\IN\1740 NE\NN\14622893 ,\,\1740 released\VBN\1435380 onto\IN\1740 Purkinje\NN\1740 cell\NN\3080309 synapses\NNS\13526110 located\JJ\1740 at\IN\14622893 terminals\NNS\4306080 of\IN\1740 the\DT\1740 ceruleo-cerebellar\JJ\1740 pathway\NN\5483677 ,\,\1740 did\VBD\1640855 indeed\RB\1740 cause\VB\1617192 the\DT\1740 long-term\JJ\1740 <e2>depression</e2>\NN\14373582 at\IN\14622893 Purkinje\NN\1740 cell\NN\3080309 synapses\NNS\13526110 (\-LRB-\1740 previously\RB\1740 described\VBN\1001294 by\IN\1740 others\NNS\1740 )\-RRB-\1740 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 the\DT\1740 long\JJ\1740 duration\NN\15113229 of\IN\1740 the\DT\1740 movement\NN\191142 disorder\NN\14034177 ;\:\1740 (\-LRB-\1740 c\LS\13714184 )\-RRB-\1740 whether\IN\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 inhibitory\JJ\1740 Purkinje\NN\1740 cells\NNS\3080309 resulted\VBD\2633881 in\IN\13603305 disinhibition\NN\1740 or\CC\3541091 increased\VBD\169651 excitability\NN\5653575 of\IN\1740 the\DT\1740 unilateral\JJ\1740 cerebellar\NN\1740 fastigial\JJ\1740 or\CC\3541091 interpositus\NN\1740 nuclei\NNS\5445668 ,\,\1740 the\DT\1740 output\NN\4007894 targets\NNS\7258332 of\IN\1740 the\DT\1740 Purkinje\NNP\1740 cell\NN\3080309 axons\NNS\5464104 ,\,\1740 that\WDT\1740 may\MD\15209706 have\VB\2108377 been\VBN\836236 an\DT\6697703 important\JJ\1740 contributing\VBG\126264 factor\NN\7326557 to\TO\1740 this\DT\1740 disorder\NN\14034177 .\.\1740
D000324_D009069 NONE However\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 not\RB\1740 certain\JJ\1740 as\IN\14622893 to\IN\1740 the\DT\1740 following\NN\8180190 :\:\1740 (\-LRB-\1740 a\LS\13649268 )\-RRB-\1740 what\WDT\1740 receptors\NNS\5225602 were\VBD\836236 stimulated\VBN\137313 by\IN\1740 the\DT\1740 <e1>ACTH</e1>\NN\5407119 N-terminal\JJ\1740 fragments\NNS\9385911 at\IN\14622893 the\DT\1740 LC\NN\1740 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 this\DT\1740 disorder\NN\14034177 ;\:\1740 (\-LRB-\1740 b\LS\1355326 )\-RRB-\1740 whether\IN\1740 NE\NN\14622893 ,\,\1740 released\VBN\1435380 onto\IN\1740 Purkinje\NN\1740 cell\NN\3080309 synapses\NNS\13526110 located\JJ\1740 at\IN\14622893 terminals\NNS\4306080 of\IN\1740 the\DT\1740 ceruleo-cerebellar\JJ\1740 pathway\NN\5483677 ,\,\1740 did\VBD\1640855 indeed\RB\1740 cause\VB\1617192 the\DT\1740 long-term\JJ\1740 depression\NN\14373582 at\IN\14622893 Purkinje\NN\1740 cell\NN\3080309 synapses\NNS\13526110 (\-LRB-\1740 previously\RB\1740 described\VBN\1001294 by\IN\1740 others\NNS\1740 )\-RRB-\1740 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 the\DT\1740 long\JJ\1740 duration\NN\15113229 of\IN\1740 the\DT\1740 <e2>movement\NN\191142 disorder</e2>\NN\14034177 ;\:\1740 (\-LRB-\1740 c\LS\13714184 )\-RRB-\1740 whether\IN\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 inhibitory\JJ\1740 Purkinje\NN\1740 cells\NNS\3080309 resulted\VBD\2633881 in\IN\13603305 disinhibition\NN\1740 or\CC\3541091 increased\VBD\169651 excitability\NN\5653575 of\IN\1740 the\DT\1740 unilateral\JJ\1740 cerebellar\NN\1740 fastigial\JJ\1740 or\CC\3541091 interpositus\NN\1740 nuclei\NNS\5445668 ,\,\1740 the\DT\1740 output\NN\4007894 targets\NNS\7258332 of\IN\1740 the\DT\1740 Purkinje\NNP\1740 cell\NN\3080309 axons\NNS\5464104 ,\,\1740 that\WDT\1740 may\MD\15209706 have\VB\2108377 been\VBN\836236 an\DT\6697703 important\JJ\1740 contributing\VBG\126264 factor\NN\7326557 to\TO\1740 this\DT\1740 disorder\NN\14034177 .\.\1740
2533791
D017325_D006509 NONE These\DT\1740 infants\NNS\9918248 are\VBP\836236 treated\VBN\2376958 with\IN\1740 two\CD\13741022 injections\NNS\320852 of\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 immune\JJ\1740 globulin\NN\14736972 (\-LRB-\1740 HBIG\NN\1740 )\-RRB-\1740 and\CC\1740 at\IN\14622893 least\JJS\1740 three\CD\13741022 injections\NNS\320852 of\IN\1740 plasma\NN\5398023 derived\VBN\634472 <e1>hepatitis\NN\14127211 B\NN\1355326 vaccine</e1>\NN\3562739 .\.\1740
18808529
D007545_D009202 CID <e1>Isoproterenol</e1>\NN\3740161 induces\VBZ\1627355 primary\JJ\1740 loss\NN\13252973 of\IN\1740 dystrophin\NN\1740 in\IN\13603305 rat\NN\2329401 hearts\NNS\496167 :\:\1740 correlation\NN\13841213 with\IN\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 .\.\1740
D007545_D009202 CID The\DT\1740 mechanism\NN\13446390 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 is\VBZ\836236 unknown\JJ\1740 ,\,\1740 but\CC\1740 a\DT\13649268 mismatch\NN\5695806 of\IN\1740 oxygen\NN\14622893 supply\NN\13576355 vs.\CC\1740 demand\NN\6513366 following\VBG\1835496 coronary\JJ\1740 hypotension\NN\14057371 and\CC\1740 myocardial\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 the\DT\1740 best\JJS\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 complex\JJ\1740 morphological\JJ\1740 alterations\NNS\7283608 observed\VBN\2163746 .\.\1740
D007545_D009202 CID The\DT\1740 mechanism\NN\13446390 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 myocardial\JJ\1740 damage\NN\7296428 is\VBZ\836236 unknown\JJ\1740 ,\,\1740 but\CC\1740 a\DT\13649268 mismatch\NN\5695806 of\IN\1740 oxygen\NN\14622893 supply\NN\13576355 vs.\CC\1740 demand\NN\6513366 following\VBG\1835496 coronary\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>myocardial\JJ\1740 hyperactivity</e2>\NN\14052403 is\VBZ\836236 the\DT\1740 best\JJS\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 complex\JJ\1740 morphological\JJ\1740 alterations\NNS\7283608 observed\VBN\2163746 .\.\1740
D007545_D007022 NONE The\DT\1740 mechanism\NN\13446390 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 myocardial\JJ\1740 damage\NN\7296428 is\VBZ\836236 unknown\JJ\1740 ,\,\1740 but\CC\1740 a\DT\13649268 mismatch\NN\5695806 of\IN\1740 oxygen\NN\14622893 supply\NN\13576355 vs.\CC\1740 demand\NN\6513366 following\VBG\1835496 coronary\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 myocardial\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 the\DT\1740 best\JJS\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 complex\JJ\1740 morphological\JJ\1740 alterations\NNS\7283608 observed\VBN\2163746 .\.\1740
D010100_D009202 NONE The\DT\1740 mechanism\NN\13446390 of\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 is\VBZ\836236 unknown\JJ\1740 ,\,\1740 but\CC\1740 a\DT\13649268 mismatch\NN\5695806 of\IN\1740 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 vs.\CC\1740 demand\NN\6513366 following\VBG\1835496 coronary\JJ\1740 hypotension\NN\14057371 and\CC\1740 myocardial\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 the\DT\1740 best\JJS\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 complex\JJ\1740 morphological\JJ\1740 alterations\NNS\7283608 observed\VBN\2163746 .\.\1740
D010100_D009202 NONE The\DT\1740 mechanism\NN\13446390 of\IN\1740 isoproterenol-induced\JJ\1740 myocardial\JJ\1740 damage\NN\7296428 is\VBZ\836236 unknown\JJ\1740 ,\,\1740 but\CC\1740 a\DT\13649268 mismatch\NN\5695806 of\IN\1740 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 vs.\CC\1740 demand\NN\6513366 following\VBG\1835496 coronary\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>myocardial\JJ\1740 hyperactivity</e2>\NN\14052403 is\VBZ\836236 the\DT\1740 best\JJS\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 complex\JJ\1740 morphological\JJ\1740 alterations\NNS\7283608 observed\VBN\2163746 .\.\1740
D010100_D007022 NONE The\DT\1740 mechanism\NN\13446390 of\IN\1740 isoproterenol-induced\JJ\1740 myocardial\JJ\1740 damage\NN\7296428 is\VBZ\836236 unknown\JJ\1740 ,\,\1740 but\CC\1740 a\DT\13649268 mismatch\NN\5695806 of\IN\1740 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 vs.\CC\1740 demand\NN\6513366 following\VBG\1835496 coronary\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 myocardial\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 the\DT\1740 best\JJS\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 complex\JJ\1740 morphological\JJ\1740 alterations\NNS\7283608 observed\VBN\2163746 .\.\1740
D007545_D007511 CID These\DT\1740 changes\NNS\7283608 ,\,\1740 related\JJ\1740 to\TO\1740 <e2>ischaemic\JJ\1740 injury</e2>\NN\14052046 ,\,\1740 explain\VB\831651 the\DT\1740 severe\JJ\1740 alterations\NNS\7283608 in\IN\13603305 the\DT\1740 structural\JJ\1740 integrity\NN\24720 of\IN\1740 the\DT\1740 sarcolemma\NN\5426243 of\IN\1740 cardiomyocytes\NNS\1740 and\CC\1740 hence\RB\1740 severe\JJ\1740 and\CC\1740 irreversible\JJ\1740 injury\NN\14052046 induced\VBN\1627355 by\IN\1740 <e1>isoproterenol</e1>\NN\3740161 .\.\1740
9952311
D004317_D028361 CID <e2>Structural\JJ\1740 and\CC\1740 functional\JJ\1740 impairment\NN\7296428 of\IN\1740 mitochondria</e2>\NN\5445668 in\IN\13603305 <e1>adriamycin-induced</e1>\JJ\1740 cardiomyopathy\JJ\1740 in\IN\13603305 mice\NNS\2329401 :\:\1740 suppression\NN\13489037 of\IN\1740 cytochrome\NN\14888884 c\NN\13714184 oxidase\NN\14732946 II\CD\13741022 gene\NN\8459252 expression\NN\4679549 .\.\1740
D004317_D028361 CID Knowing\VBG\2110220 that\IN\1740 heart\NN\5919034 mitochondria\NN\5445668 represent\VB\2664769 almost\RB\1740 40\CD\13745420 %\NN\1740 of\IN\1740 heart\NN\5919034 muscle\NN\5289601 by\IN\1740 weight\NN\5009170 ,\,\1740 we\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 deteriorating\VBG\208836 effects\NNS\13245626 of\IN\1740 <e1>ADR</e1>\NN\1740 on\IN\1740 cardiovascular\JJ\1740 function\NN\13783581 involve\VBP\2676054 <e2>mitochondrial\JJ\1740 structural\JJ\1740 and\CC\1740 functional\JJ\1740 impairment</e2>\NN\7296428 .\.\1740
D004317_D009202 NONE Structural\JJ\1740 and\CC\1740 functional\JJ\1740 impairment\NN\7296428 of\IN\1740 mitochondria\NN\5445668 in\IN\13603305 <e1>adriamycin-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 in\IN\13603305 mice\NNS\2329401 :\:\1740 suppression\NN\13489037 of\IN\1740 cytochrome\NN\14888884 c\NN\13714184 oxidase\NN\14732946 II\CD\13741022 gene\NN\8459252 expression\NN\4679549 .\.\1740
D004317_D009369 NONE The\DT\1740 use\NN\407535 of\IN\1740 <e1>adriamycin</e1>\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 in\IN\13603305 <e2>cancer</e2>\NN\14239425 chemotherapy\NN\661091 has\VBZ\2108377 been\VBN\836236 limited\VBN\2510337 due\IN\5174653 to\TO\1740 its\PRP$\6125041 cumulative\JJ\1740 cardiovascular\JJ\1740 toxicity\NN\13576101 .\.\1740
D004317_D009369 NONE The\DT\1740 use\NN\407535 of\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 <e1>ADR</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 <e2>cancer</e2>\NN\14239425 chemotherapy\NN\661091 has\VBZ\2108377 been\VBN\836236 limited\VBN\2510337 due\IN\5174653 to\TO\1740 its\PRP$\6125041 cumulative\JJ\1740 cardiovascular\JJ\1740 toxicity\NN\13576101 .\.\1740
D004317_D002318 NONE The\DT\1740 use\NN\407535 of\IN\1740 <e1>adriamycin</e1>\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 in\IN\13603305 cancer\NN\14239425 chemotherapy\NN\661091 has\VBZ\2108377 been\VBN\836236 limited\VBN\2510337 due\IN\5174653 to\TO\1740 its\PRP$\6125041 cumulative\JJ\1740 <e2>cardiovascular\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D004317_D002318 NONE The\DT\1740 use\NN\407535 of\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 <e1>ADR</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 cancer\NN\14239425 chemotherapy\NN\661091 has\VBZ\2108377 been\VBN\836236 limited\VBN\2510337 due\IN\5174653 to\TO\1740 its\PRP$\6125041 cumulative\JJ\1740 <e2>cardiovascular\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D004317_D001145 NONE Our\PRP$\1740 results\NNS\34213 indicated\VBD\952524 that\IN\1740 1\LS\13741022 )\-RRB-\1740 treatment\NN\654885 of\IN\1740 mice\NNS\2329401 with\IN\1740 <e1>ADR</e1>\NN\1740 caused\VBD\1617192 <e2>cardiovascular\JJ\1740 arrhythmias</e2>\NNS\14103288 characterized\VBN\609683 by\IN\1740 bradycardia\NN\14110674 ,\,\1740 extension\NN\15272029 of\IN\1740 ventricular\JJ\1740 depolarization\NN\11412727 time\NN\7308889 (\-LRB-\1740 tQRS\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 failure\NN\66216 of\IN\1740 QRS\NN\1740 at\IN\14622893 high\JJ\1740 concentrations\NNS\4916342 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 14\CD\13745420 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 cumulative\JJ\1740 dose\NN\3740161 )\-RRB-\1740 ;\:\1740 2\LS\13741022 )\-RRB-\1740 the\DT\1740 heart\NN\5919034 mitochondria\NN\5445668 underwent\VBD\109660 swelling\NN\14315071 ,\,\1740 fusion\NN\7373277 ,\,\1740 dissolution\NN\13518963 ,\,\1740 and/or\CC\1740 disruption\NN\1066163 of\IN\1740 mitochondrial\JJ\1740 cristae\NN\1740 after\IN\1740 several\JJ\1740 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D004317_D001919 CID Our\PRP$\1740 results\NNS\34213 indicated\VBD\952524 that\IN\1740 1\LS\13741022 )\-RRB-\1740 treatment\NN\654885 of\IN\1740 mice\NNS\2329401 with\IN\1740 <e1>ADR</e1>\NN\1740 caused\VBD\1617192 cardiovascular\JJ\1740 arrhythmias\NNS\14103288 characterized\VBN\609683 by\IN\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 extension\NN\15272029 of\IN\1740 ventricular\JJ\1740 depolarization\NN\11412727 time\NN\7308889 (\-LRB-\1740 tQRS\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 failure\NN\66216 of\IN\1740 QRS\NN\1740 at\IN\14622893 high\JJ\1740 concentrations\NNS\4916342 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 14\CD\13745420 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 cumulative\JJ\1740 dose\NN\3740161 )\-RRB-\1740 ;\:\1740 2\LS\13741022 )\-RRB-\1740 the\DT\1740 heart\NN\5919034 mitochondria\NN\5445668 underwent\VBD\109660 swelling\NN\14315071 ,\,\1740 fusion\NN\7373277 ,\,\1740 dissolution\NN\13518963 ,\,\1740 and/or\CC\1740 disruption\NN\1066163 of\IN\1740 mitochondrial\JJ\1740 cristae\NN\1740 after\IN\1740 several\JJ\1740 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D004317_D004487 NONE Our\PRP$\1740 results\NNS\34213 indicated\VBD\952524 that\IN\1740 1\LS\13741022 )\-RRB-\1740 treatment\NN\654885 of\IN\1740 mice\NNS\2329401 with\IN\1740 <e1>ADR</e1>\NN\1740 caused\VBD\1617192 cardiovascular\JJ\1740 arrhythmias\NNS\14103288 characterized\VBN\609683 by\IN\1740 bradycardia\NN\14110674 ,\,\1740 extension\NN\15272029 of\IN\1740 ventricular\JJ\1740 depolarization\NN\11412727 time\NN\7308889 (\-LRB-\1740 tQRS\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 failure\NN\66216 of\IN\1740 QRS\NN\1740 at\IN\14622893 high\JJ\1740 concentrations\NNS\4916342 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 14\CD\13745420 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 cumulative\JJ\1740 dose\NN\3740161 )\-RRB-\1740 ;\:\1740 2\LS\13741022 )\-RRB-\1740 the\DT\1740 heart\NN\5919034 mitochondria\NN\5445668 underwent\VBD\109660 <e2>swelling</e2>\NN\14315071 ,\,\1740 fusion\NN\7373277 ,\,\1740 dissolution\NN\13518963 ,\,\1740 and/or\CC\1740 disruption\NN\1066163 of\IN\1740 mitochondrial\JJ\1740 cristae\NN\1740 after\IN\1740 several\JJ\1740 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
10523326
D009569_D006973 NONE <e1>Nitric\JJ\1740 oxide</e1>\NN\14818238 synthase\NN\1740 expression\NN\4679549 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 lead-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D009569_D006973 NONE We\PRP\1740 recently\RB\1740 showed\VBD\2137132 elevated\JJ\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 ,\,\1740 reduced\VBD\441445 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 <e1>NO</e1>\DT\7204911 metabolites\NNS\20090 (\-LRB-\1740 NOx\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBD\169651 NO\NN\7204911 sequestration\NN\1201021 as\IN\14622893 nitrotyrosine\NN\1740 in\IN\13603305 various\JJ\1740 tissues\NNS\5220461 in\IN\13603305 rats\NNS\2329401 with\IN\1740 lead-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D009569_D006973 NONE We\PRP\1740 recently\RB\1740 showed\VBD\2137132 elevated\JJ\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 ,\,\1740 reduced\VBD\441445 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 NO\DT\7204911 metabolites\NNS\20090 (\-LRB-\1740 NOx\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBD\169651 <e1>NO</e1>\NN\7204911 sequestration\NN\1201021 as\IN\14622893 nitrotyrosine\NN\1740 in\IN\13603305 various\JJ\1740 tissues\NNS\5220461 in\IN\13603305 rats\NNS\2329401 with\IN\1740 lead-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D009569_D006973 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 discern\VB\1740 whether\IN\1740 the\DT\1740 reduction\NN\351485 in\IN\13603305 urinary\JJ\1740 NOx\NN\1740 in\IN\13603305 lead-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 due\JJ\1740 to\TO\1740 depressed\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 expression\NN\4679549 .\.\1740
D009569_D006973 NONE This\DT\1740 is\VBZ\836236 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 due\JJ\1740 to\TO\1740 ROS-mediated\JJ\1740 <e1>NO</e1>\NN\7204911 inactivation\NN\13518963 ,\,\1740 lead-associated\JJ\1740 inhibition\NN\1068773 of\IN\1740 NOS\NN\7204911 activity\NN\30358 ,\,\1740 and\CC\1740 perhaps\RB\1740 stimulatory\JJ\1740 actions\NNS\30358 of\IN\1740 increased\VBN\169651 shear\NN\7358060 stress\NN\7083732 associated\VBN\628491 with\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D007854_D006973 CID Nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 expression\NN\4679549 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 <e1>lead-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D007854_D006973 CID We\PRP\1740 recently\RB\1740 showed\VBD\2137132 elevated\JJ\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 ,\,\1740 reduced\VBD\441445 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 NO\DT\7204911 metabolites\NNS\20090 (\-LRB-\1740 NOx\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBD\169651 NO\NN\7204911 sequestration\NN\1201021 as\IN\14622893 nitrotyrosine\NN\1740 in\IN\13603305 various\JJ\1740 tissues\NNS\5220461 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e1>lead-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D007854_D006973 CID This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 discern\VB\1740 whether\IN\1740 the\DT\1740 reduction\NN\351485 in\IN\13603305 urinary\JJ\1740 NOx\NN\1740 in\IN\13603305 <e1>lead-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 due\JJ\1740 to\TO\1740 depressed\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 expression\NN\4679549 .\.\1740
D007854_D006973 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>lead-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 this\DT\1740 model\NN\5888929 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 compensatory\JJ\1740 upregulation\NN\1740 of\IN\1740 renal\JJ\1740 and\CC\1740 vascular\JJ\1740 eNOS\NN\1740 and\CC\1740 iNOS\NN\1740 expression\NN\4679549 .\.\1740
D007854_D006973 CID This\DT\1740 is\VBZ\836236 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 due\JJ\1740 to\TO\1740 ROS-mediated\JJ\1740 NO\NN\7204911 inactivation\NN\13518963 ,\,\1740 <e1>lead-associated</e1>\JJ\1740 inhibition\NN\1068773 of\IN\1740 NOS\NN\7204911 activity\NN\30358 ,\,\1740 and\CC\1740 perhaps\RB\1740 stimulatory\JJ\1740 actions\NNS\30358 of\IN\1740 increased\VBN\169651 shear\NN\7358060 stress\NN\7083732 associated\VBN\628491 with\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D010100_D006973 NONE We\PRP\1740 recently\RB\1740 showed\VBD\2137132 elevated\JJ\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 ,\,\1740 reduced\VBD\441445 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 NO\DT\7204911 metabolites\NNS\20090 (\-LRB-\1740 NOx\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBD\169651 NO\NN\7204911 sequestration\NN\1201021 as\IN\14622893 nitrotyrosine\NN\1740 in\IN\13603305 various\JJ\1740 tissues\NNS\5220461 in\IN\13603305 rats\NNS\2329401 with\IN\1740 lead-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
C002744_D006973 NONE We\PRP\1740 recently\RB\1740 showed\VBD\2137132 elevated\JJ\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 ,\,\1740 reduced\VBD\441445 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 NO\DT\7204911 metabolites\NNS\20090 (\-LRB-\1740 NOx\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBD\169651 NO\NN\7204911 sequestration\NN\1201021 as\IN\14622893 <e1>nitrotyrosine</e1>\NN\1740 in\IN\13603305 various\JJ\1740 tissues\NNS\5220461 in\IN\13603305 rats\NNS\2329401 with\IN\1740 lead-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D014810_D006973 NONE <e1>Vitamin\NN\7570720 E</e1>\NN\14724645 supplementation\NN\5108947 ameliorated\VBD\126264 <e2>hypertension</e2>\NN\14057371 ,\,\1740 lowered\JJ\1740 plasma\NN\5398023 MDA\NN\1740 concentration\NN\4916342 ,\,\1740 and\CC\1740 raised\VBD\153263 urinary\JJ\1740 NOx\NN\1740 excretion\NN\13466586 while\IN\15122231 significantly\RB\1740 lowering\VBG\1850315 vascular\JJ\1740 ,\,\1740 but\CC\1740 not\RB\1740 renal\JJ\1740 ,\,\1740 tissue\NN\5220461 eNOS\NN\1740 and\CC\1740 iNOS\NN\1740 expression\NN\4679549 .\.\1740
D008315_D006973 NONE Vitamin\NN\7570720 E\NN\14724645 supplementation\NN\5108947 ameliorated\VBD\126264 <e2>hypertension</e2>\NN\14057371 ,\,\1740 lowered\JJ\1740 plasma\NN\5398023 <e1>MDA</e1>\NN\1740 concentration\NN\4916342 ,\,\1740 and\CC\1740 raised\VBD\153263 urinary\JJ\1740 NOx\NN\1740 excretion\NN\13466586 while\IN\15122231 significantly\RB\1740 lowering\VBG\1850315 vascular\JJ\1740 ,\,\1740 but\CC\1740 not\RB\1740 renal\JJ\1740 ,\,\1740 tissue\NN\5220461 eNOS\NN\1740 and\CC\1740 iNOS\NN\1740 expression\NN\4679549 .\.\1740
1610717
D003042_D012640 CID <e1>Cocaine-induced</e1>\JJ\1740 brainstem\NN\5462674 <e2>seizures</e2>\NNS\14081375 and\CC\1740 behavior\NN\407535 .\.\1740
783197
D010042_D003324 NONE Effects\NNS\13245626 of\IN\1740 <e1>ouabain</e1>\NN\1740 on\IN\1740 myocardial\JJ\1740 oxygen\NN\14622893 supply\NN\13576355 and\CC\1740 demand\NN\6513366 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 .\.\1740
D010042_D003324 NONE We\PRP\1740 assessed\VBD\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>ouabain</e1>\NN\1740 (\-LRB-\1740 0.015\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 on\IN\1740 hemodynamic\JJ\1740 ,\,\1740 volumetric\JJ\1740 ,\,\1740 and\CC\1740 metabolic\JJ\1740 parameters\NNS\5858936 in\IN\13603305 11\CD\13745420 patients\NNS\9898892 with\IN\1740 severe\JJ\1740 chronic\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 without\IN\1740 clinical\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D010042_D003324 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 who\WP\8299493 are\VBP\836236 not\RB\1740 in\IN\13603305 clinical\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 left\VBD\120316 ventricular\JJ\1740 end-diastolic\JJ\1740 volume\NN\33615 falls\VBZ\1835496 after\IN\1740 <e1>ouabain</e1>\NN\1740 administration\NN\1133281 even\RB\1740 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 initially\RB\1740 normal\JJ\1740 .\.\1740
D010100_D003324 NONE Effects\NNS\13245626 of\IN\1740 ouabain\NN\1740 on\IN\1740 myocardial\JJ\1740 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 and\CC\1740 demand\NN\6513366 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 .\.\1740
D010100_D003324 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 digitalis\NN\15059939 glycosides\NNS\14727670 on\IN\1740 myocardial\JJ\1740 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 and\CC\1740 demand\NN\6513366 are\VBP\836236 of\IN\1740 particular\JJ\1740 interest\NN\5682570 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 obstructive\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 ,\,\1740 but\CC\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 measured\VBN\697589 previously\RB\1740 in\IN\13603305 man\NN\9605289 .\.\1740
D004071_D003324 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>digitalis\NN\15059939 glycosides</e1>\NNS\14727670 on\IN\1740 myocardial\JJ\1740 oxygen\NN\14622893 supply\NN\13576355 and\CC\1740 demand\NN\6513366 are\VBP\836236 of\IN\1740 particular\JJ\1740 interest\NN\5682570 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 obstructive\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 ,\,\1740 but\CC\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 measured\VBN\697589 previously\RB\1740 in\IN\13603305 man\NN\9605289 .\.\1740
D010042_D006333 NONE We\PRP\1740 assessed\VBD\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>ouabain</e1>\NN\1740 (\-LRB-\1740 0.015\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 on\IN\1740 hemodynamic\JJ\1740 ,\,\1740 volumetric\JJ\1740 ,\,\1740 and\CC\1740 metabolic\JJ\1740 parameters\NNS\5858936 in\IN\13603305 11\CD\13745420 patients\NNS\9898892 with\IN\1740 severe\JJ\1740 chronic\JJ\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 without\IN\1740 clinical\JJ\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D010042_D006333 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 who\WP\8299493 are\VBP\836236 not\RB\1740 in\IN\13603305 clinical\JJ\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 left\VBD\120316 ventricular\JJ\1740 end-diastolic\JJ\1740 volume\NN\33615 falls\VBZ\1835496 after\IN\1740 <e1>ouabain</e1>\NN\1740 administration\NN\1133281 even\RB\1740 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 initially\RB\1740 normal\JJ\1740 .\.\1740
D010042_D002303 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 who\WP\8299493 are\VBP\836236 not\RB\1740 in\IN\13603305 clinical\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 <e2>left\VBD\120316 ventricular\JJ\1740 end-diastolic\JJ\1740 volume\NN\33615 falls</e2>\VBZ\1835496 after\IN\1740 <e1>ouabain</e1>\NN\1740 administration\NN\1133281 even\RB\1740 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 initially\RB\1740 normal\JJ\1740 .\.\1740
2893236
D005680_D012133 NONE <e1>GABA</e1>\NN\14601829 involvement\NN\1080366 in\IN\13603305 naloxone\NN\3808977 induced\VBN\1627355 reversal\NN\199130 of\IN\1740 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 produced\VBN\1617192 by\IN\1740 thiopental\NN\2792049 .\.\1740
D005680_D012133 NONE Naloxone\NN\3808977 (\-LRB-\1740 2.5\CD\1740 mg/kg\NN\1740 ,\,\1740 i.v.\NN\1740 )\-RRB-\1740 reversed\VBN\109660 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 ,\,\1740 glutamate\NN\15010703 and\CC\1740 <e1>GABA</e1>\NN\14601829 levels\NNS\4916342 to\TO\1740 control\NN\5190804 values\NNS\5941423 in\IN\13603305 brain\NN\5462674 stem\NN\6290637 and\CC\1740 cortex\NN\5462674 with\IN\1740 no\DT\7204911 changes\NNS\7283608 in\IN\13603305 caudate\NN\5497363 or\CC\3541091 cerebellum\NN\5462674 .\.\1740
D005680_D012133 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 naloxone\NN\3808977 reverses\VBZ\109660 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 produced\VBN\1617192 by\IN\1740 thiopental\NN\2792049 and\CC\1740 involves\VBZ\2676054 <e1>GABA</e1>\NN\14601829 in\IN\13603305 its\PRP$\6125041 action\NN\30358 .\.\1740
D009270_D012133 NONE GABA\NN\14601829 involvement\NN\1080366 in\IN\13603305 <e1>naloxone</e1>\NN\3808977 induced\VBN\1627355 reversal\NN\199130 of\IN\1740 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 produced\VBN\1617192 by\IN\1740 thiopental\NN\2792049 .\.\1740
D009270_D012133 NONE In\IN\13603305 this\DT\1740 study\NN\635850 <e1>naloxone</e1>\NN\3808977 reversed\VBD\109660 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 induced\VBN\1627355 by\IN\1740 thiopental\NN\2792049 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009270_D012133 NONE <e1>Naloxone</e1>\NN\3808977 (\-LRB-\1740 2.5\CD\1740 mg/kg\NN\1740 ,\,\1740 i.v.\NN\1740 )\-RRB-\1740 reversed\VBN\109660 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 ,\,\1740 glutamate\NN\15010703 and\CC\1740 GABA\NN\14601829 levels\NNS\4916342 to\TO\1740 control\NN\5190804 values\NNS\5941423 in\IN\13603305 brain\NN\5462674 stem\NN\6290637 and\CC\1740 cortex\NN\5462674 with\IN\1740 no\DT\7204911 changes\NNS\7283608 in\IN\13603305 caudate\NN\5497363 or\CC\3541091 cerebellum\NN\5462674 .\.\1740
D009270_D012133 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 <e1>naloxone</e1>\NN\3808977 reverses\VBZ\109660 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 produced\VBN\1617192 by\IN\1740 thiopental\NN\2792049 and\CC\1740 involves\VBZ\2676054 GABA\NN\14601829 in\IN\13603305 its\PRP$\6125041 action\NN\30358 .\.\1740
D013874_D012133 CID GABA\NN\14601829 involvement\NN\1080366 in\IN\13603305 naloxone\NN\3808977 induced\VBN\1627355 reversal\NN\199130 of\IN\1740 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 produced\VBN\1617192 by\IN\1740 <e1>thiopental</e1>\NN\2792049 .\.\1740
D013874_D012133 CID In\IN\13603305 this\DT\1740 study\NN\635850 naloxone\NN\3808977 reversed\VBD\109660 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 induced\VBN\1627355 by\IN\1740 <e1>thiopental</e1>\NN\2792049 in\IN\13603305 rats\NNS\2329401 .\.\1740
D013874_D012133 CID These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 naloxone\NN\3808977 reverses\VBZ\109660 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 produced\VBN\1617192 by\IN\1740 <e1>thiopental</e1>\NN\2792049 and\CC\1740 involves\VBZ\2676054 GABA\NN\14601829 in\IN\13603305 its\PRP$\6125041 action\NN\30358 .\.\1740
D013874_D012131 NONE 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v.\NN\1740 <e1>thiopental</e1>\NN\2792049 produced\VBN\1617192 <e2>respiratory\JJ\1740 arrest</e2>\NN\88481 with\IN\1740 further\JJ\1740 increase\NN\13576355 in\IN\13603305 GABA\NN\14601829 and\CC\1740 decrease\VB\169651 in\IN\13603305 glutamate\NN\15010703 again\RB\1740 in\IN\13603305 cortex\NN\5462674 and\CC\1740 brain\NN\5462674 stem\NN\6290637 without\IN\1740 affecting\VBG\126264 any\DT\1740 of\IN\1740 the\DT\1740 amino\NN\14621446 acids\NNS\14818238 studied\VBN\630380 in\IN\13603305 four\CD\13741022 regions\NNS\27167 of\IN\1740 rat\NN\2329401 brain\NN\5462674 .\.\1740
D005680_D012131 NONE 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v.\NN\1740 thiopental\NN\2792049 produced\VBN\1617192 <e2>respiratory\JJ\1740 arrest</e2>\NN\88481 with\IN\1740 further\JJ\1740 increase\NN\13576355 in\IN\13603305 <e1>GABA</e1>\NN\14601829 and\CC\1740 decrease\VB\169651 in\IN\13603305 glutamate\NN\15010703 again\RB\1740 in\IN\13603305 cortex\NN\5462674 and\CC\1740 brain\NN\5462674 stem\NN\6290637 without\IN\1740 affecting\VBG\126264 any\DT\1740 of\IN\1740 the\DT\1740 amino\NN\14621446 acids\NNS\14818238 studied\VBN\630380 in\IN\13603305 four\CD\13741022 regions\NNS\27167 of\IN\1740 rat\NN\2329401 brain\NN\5462674 .\.\1740
D018698_D012131 NONE 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v.\NN\1740 thiopental\NN\2792049 produced\VBN\1617192 <e2>respiratory\JJ\1740 arrest</e2>\NN\88481 with\IN\1740 further\JJ\1740 increase\NN\13576355 in\IN\13603305 GABA\NN\14601829 and\CC\1740 decrease\VB\169651 in\IN\13603305 <e1>glutamate</e1>\NN\15010703 again\RB\1740 in\IN\13603305 cortex\NN\5462674 and\CC\1740 brain\NN\5462674 stem\NN\6290637 without\IN\1740 affecting\VBG\126264 any\DT\1740 of\IN\1740 the\DT\1740 amino\NN\14621446 acids\NNS\14818238 studied\VBN\630380 in\IN\13603305 four\CD\13741022 regions\NNS\27167 of\IN\1740 rat\NN\2329401 brain\NN\5462674 .\.\1740
D000596_D012131 NONE 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v.\NN\1740 thiopental\NN\2792049 produced\VBN\1617192 <e2>respiratory\JJ\1740 arrest</e2>\NN\88481 with\IN\1740 further\JJ\1740 increase\NN\13576355 in\IN\13603305 GABA\NN\14601829 and\CC\1740 decrease\VB\169651 in\IN\13603305 glutamate\NN\15010703 again\RB\1740 in\IN\13603305 cortex\NN\5462674 and\CC\1740 brain\NN\5462674 stem\NN\6290637 without\IN\1740 affecting\VBG\126264 any\DT\1740 of\IN\1740 the\DT\1740 <e1>amino\NN\14621446 acids</e1>\NNS\14818238 studied\VBN\630380 in\IN\13603305 four\CD\13741022 regions\NNS\27167 of\IN\1740 rat\NN\2329401 brain\NN\5462674 .\.\1740
D018698_D012133 NONE Naloxone\NN\3808977 (\-LRB-\1740 2.5\CD\1740 mg/kg\NN\1740 ,\,\1740 i.v.\NN\1740 )\-RRB-\1740 reversed\VBN\109660 <e2>respiratory\JJ\1740 paralysis</e2>\NN\14557898 ,\,\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 GABA\NN\14601829 levels\NNS\4916342 to\TO\1740 control\NN\5190804 values\NNS\5941423 in\IN\13603305 brain\NN\5462674 stem\NN\6290637 and\CC\1740 cortex\NN\5462674 with\IN\1740 no\DT\7204911 changes\NNS\7283608 in\IN\13603305 caudate\NN\5497363 or\CC\3541091 cerebellum\NN\5462674 .\.\1740
8677458
D015080_D006470 CID Continuous\JJ\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>mesna</e1>\NN\1740 to\TO\1740 prevent\VB\1740 ifosfamide-induced\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D015080_D006470 CID <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 is\VBZ\836236 a\DT\13649268 major\JJ\1740 potential\JJ\1740 toxicity\NN\13576101 of\IN\1740 ifosfamide\NN\1740 that\WDT\1740 can\MD\3094503 be\VB\836236 prevented\VBN\1740 by\IN\1740 administering\VBG\2436349 <e1>mesna</e1>\NN\1740 along\IN\1740 with\IN\1740 the\DT\1740 cytotoxic\JJ\1740 agent\NN\7347 .\.\1740
D015080_D003556 CID Continuous\JJ\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>mesna</e1>\NN\1740 to\TO\1740 prevent\VB\1740 ifosfamide-induced\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D015080_D003556 CID <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 is\VBZ\836236 a\DT\13649268 major\JJ\1740 potential\JJ\1740 toxicity\NN\13576101 of\IN\1740 ifosfamide\NN\1740 that\WDT\1740 can\MD\3094503 be\VB\836236 prevented\VBN\1740 by\IN\1740 administering\VBG\2436349 <e1>mesna</e1>\NN\1740 along\IN\1740 with\IN\1740 the\DT\1740 cytotoxic\JJ\1740 agent\NN\7347 .\.\1740
D007069_D006470 CID Continuous\JJ\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 mesna\NN\1740 to\TO\1740 prevent\VB\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D007069_D006470 CID <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 is\VBZ\836236 a\DT\13649268 major\JJ\1740 potential\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 that\WDT\1740 can\MD\3094503 be\VB\836236 prevented\VBN\1740 by\IN\1740 administering\VBG\2436349 mesna\NN\1740 along\IN\1740 with\IN\1740 the\DT\1740 cytotoxic\JJ\1740 agent\NN\7347 .\.\1740
D007069_D003556 CID Continuous\JJ\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 mesna\NN\1740 to\TO\1740 prevent\VB\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D007069_D003556 CID <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 is\VBZ\836236 a\DT\13649268 major\JJ\1740 potential\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 that\WDT\1740 can\MD\3094503 be\VB\836236 prevented\VBN\1740 by\IN\1740 administering\VBG\2436349 mesna\NN\1740 along\IN\1740 with\IN\1740 the\DT\1740 cytotoxic\JJ\1740 agent\NN\7347 .\.\1740
D007069_D064420 NONE Hemorrhagic\JJ\1740 cystitis\NN\14566129 is\VBZ\836236 a\DT\13649268 major\JJ\1740 potential\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 that\WDT\1740 can\MD\3094503 be\VB\836236 prevented\VBN\1740 by\IN\1740 administering\VBG\2436349 mesna\NN\1740 along\IN\1740 with\IN\1740 the\DT\1740 cytotoxic\JJ\1740 agent\NN\7347 .\.\1740
D015080_D064420 NONE Hemorrhagic\JJ\1740 cystitis\NN\14566129 is\VBZ\836236 a\DT\13649268 major\JJ\1740 potential\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 ifosfamide\NN\1740 that\WDT\1740 can\MD\3094503 be\VB\836236 prevented\VBN\1740 by\IN\1740 administering\VBG\2436349 <e1>mesna</e1>\NN\1740 along\IN\1740 with\IN\1740 the\DT\1740 cytotoxic\JJ\1740 agent\NN\7347 .\.\1740
D015080_D014839 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 subcutaneous\JJ\1740 delivery\NN\315986 of\IN\1740 the\DT\1740 neutralizing\VBG\126264 agent\NN\7347 will\MD\5650329 not\RB\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 inadequate\JJ\1740 urinary\JJ\1740 <e1>mesna</e1>\NN\1740 concentrations\NNS\4916342 ,\,\1740 such\JJ\1740 as\IN\14622893 in\IN\13603305 a\DT\13649268 patient\NN\9898892 taking\VBG\2367363 oral\JJ\1740 mesna\NN\1740 who\WP\8299493 experiences\VBZ\2108377 severe\JJ\1740 ifosfamide-induced\JJ\1740 <e2>emesis</e2>\NN\116687 and\CC\1740 is\VBZ\836236 unable\JJ\1740 to\TO\1740 absorb\VB\1540449 the\DT\1740 drug\NN\14778436 .\.\1740
D015080_D014839 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 subcutaneous\JJ\1740 delivery\NN\315986 of\IN\1740 the\DT\1740 neutralizing\VBG\126264 agent\NN\7347 will\MD\5650329 not\RB\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 inadequate\JJ\1740 urinary\JJ\1740 mesna\NN\1740 concentrations\NNS\4916342 ,\,\1740 such\JJ\1740 as\IN\14622893 in\IN\13603305 a\DT\13649268 patient\NN\9898892 taking\VBG\2367363 oral\JJ\1740 <e1>mesna</e1>\NN\1740 who\WP\8299493 experiences\VBZ\2108377 severe\JJ\1740 ifosfamide-induced\JJ\1740 <e2>emesis</e2>\NN\116687 and\CC\1740 is\VBZ\836236 unable\JJ\1740 to\TO\1740 absorb\VB\1540449 the\DT\1740 drug\NN\14778436 .\.\1740
D007069_D014839 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 subcutaneous\JJ\1740 delivery\NN\315986 of\IN\1740 the\DT\1740 neutralizing\VBG\126264 agent\NN\7347 will\MD\5650329 not\RB\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 inadequate\JJ\1740 urinary\JJ\1740 mesna\NN\1740 concentrations\NNS\4916342 ,\,\1740 such\JJ\1740 as\IN\14622893 in\IN\13603305 a\DT\13649268 patient\NN\9898892 taking\VBG\2367363 oral\JJ\1740 mesna\NN\1740 who\WP\8299493 experiences\VBZ\2108377 severe\JJ\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>emesis</e2>\NN\116687 and\CC\1740 is\VBZ\836236 unable\JJ\1740 to\TO\1740 absorb\VB\1540449 the\DT\1740 drug\NN\14778436 .\.\1740
3411101
C033457_D056486 CID <e1>Quinidine\NN\2715941 phenylethylbarbiturate-induced</e1>\JJ\1740 fulminant\JJ\1740 <e2>hepatitis</e2>\NN\14127211 in\IN\13603305 a\DT\13649268 pregnant\JJ\1740 woman\NN\9605289 .\.\1740
C033457_D056486 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 19-year-old\JJ\1740 Laotian\JJ\1740 patient\NN\9898892 affected\VBN\126264 by\IN\1740 fulminant\JJ\1740 <e2>hepatitis</e2>\NN\14127211 during\IN\1740 the\DT\1740 third\JJ\1740 trimester\NN\15113229 of\IN\1740 her\PRP$\1740 pregnancy\NN\14034177 after\IN\1740 a\DT\13649268 1-month\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>quinidine\NN\2715941 phenylethylbarbiturate</e1>\JJ\1740 .\.\1740
C033457_D056486 CID Quinidine\NN\2715941 itself\PRP\1740 or\CC\3541091 <e1>phenylethylbarbiturate</e1>\JJ\1740 may\MD\15209706 be\VB\836236 responsible\JJ\1740 for\IN\1740 fulminant\JJ\1740 <e2>hepatitis</e2>\NN\14127211 in\IN\13603305 this\DT\1740 patient\NN\9898892 .\.\1740
D011802_D056486 NONE <e1>Quinidine</e1>\NN\2715941 itself\PRP\1740 or\CC\3541091 phenylethylbarbiturate\JJ\1740 may\MD\15209706 be\VB\836236 responsible\JJ\1740 for\IN\1740 fulminant\JJ\1740 <e2>hepatitis</e2>\NN\14127211 in\IN\13603305 this\DT\1740 patient\NN\9898892 .\.\1740
17943461
D015215_D009202 CID Myocardial\JJ\1740 Fas\NN\14304060 ligand\NN\20090 expression\NN\4679549 increases\VBZ\169651 susceptibility\NN\13920835 to\TO\1740 <e1>AZT-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 .\.\1740
D015215_D002311 CID METHODS\NNS\5616786 AND\CC\1740 RESULTS\NNS\34213 :\:\1740 In\IN\13603305 order\NN\7168131 to\TO\1740 investigate\VB\644583 whether\IN\1740 the\DT\1740 HAART\NN\3740161 component\NN\5867413 <e1>zidovudine</e1>\NN\3834836 (\-LRB-\1740 3'-azido-2',3'-deoxythymidine\NN\1740 ;\:\1740 AZT\NN\3834836 )\-RRB-\1740 triggers\VBZ\1641914 the\DT\1740 Fas-dependent\JJ\1740 cell-death\NN\1740 pathway\NN\5483677 and\CC\1740 cause\VB\1617192 cytoskeletal\JJ\1740 disruption\NN\1066163 in\IN\13603305 a\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 <e2>DCM</e2>\NN\1740 ,\,\1740 8-week-old\JJ\1740 transgenic\JJ\1740 (\-LRB-\1740 expressing\VBG\928630 Fas\NN\14304060 ligand\NN\20090 in\IN\13603305 the\DT\1740 myocardium\NN\5389939 :\:\1740 FasL\NN\1740 Tg\NN\1740 )\-RRB-\1740 and\CC\1740 non-transgenic\JJ\1740 (\-LRB-\1740 NTg\NN\1740 )\-RRB-\1740 mice\NNS\2329401 received\VBD\2210855 water\NN\14618834 ad\NN\7247071 libitum\NN\1740 containing\VBG\2632940 different\JJ\1740 concentrations\NNS\4916342 of\IN\1740 AZT\NN\3834836 (\-LRB-\1740 0\CD\13741022 ,\,\1740 0.07\CD\1740 ,\,\1740 0.2\CD\1740 ,\,\1740 and\CC\1740 0.7\CD\1740 mg/ml\NN\1740 )\-RRB-\1740 .\.\1740
D015215_D002311 CID METHODS\NNS\5616786 AND\CC\1740 RESULTS\NNS\34213 :\:\1740 In\IN\13603305 order\NN\7168131 to\TO\1740 investigate\VB\644583 whether\IN\1740 the\DT\1740 HAART\NN\3740161 component\NN\5867413 zidovudine\NN\3834836 (\-LRB-\1740 <e1>3'-azido-2',3'-deoxythymidine</e1>\NN\1740 ;\:\1740 AZT\NN\3834836 )\-RRB-\1740 triggers\VBZ\1641914 the\DT\1740 Fas-dependent\JJ\1740 cell-death\NN\1740 pathway\NN\5483677 and\CC\1740 cause\VB\1617192 cytoskeletal\JJ\1740 disruption\NN\1066163 in\IN\13603305 a\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 <e2>DCM</e2>\NN\1740 ,\,\1740 8-week-old\JJ\1740 transgenic\JJ\1740 (\-LRB-\1740 expressing\VBG\928630 Fas\NN\14304060 ligand\NN\20090 in\IN\13603305 the\DT\1740 myocardium\NN\5389939 :\:\1740 FasL\NN\1740 Tg\NN\1740 )\-RRB-\1740 and\CC\1740 non-transgenic\JJ\1740 (\-LRB-\1740 NTg\NN\1740 )\-RRB-\1740 mice\NNS\2329401 received\VBD\2210855 water\NN\14618834 ad\NN\7247071 libitum\NN\1740 containing\VBG\2632940 different\JJ\1740 concentrations\NNS\4916342 of\IN\1740 AZT\NN\3834836 (\-LRB-\1740 0\CD\13741022 ,\,\1740 0.07\CD\1740 ,\,\1740 0.2\CD\1740 ,\,\1740 and\CC\1740 0.7\CD\1740 mg/ml\NN\1740 )\-RRB-\1740 .\.\1740
D015215_D002311 CID METHODS\NNS\5616786 AND\CC\1740 RESULTS\NNS\34213 :\:\1740 In\IN\13603305 order\NN\7168131 to\TO\1740 investigate\VB\644583 whether\IN\1740 the\DT\1740 HAART\NN\3740161 component\NN\5867413 zidovudine\NN\3834836 (\-LRB-\1740 3'-azido-2',3'-deoxythymidine\NN\1740 ;\:\1740 <e1>AZT</e1>\NN\3834836 )\-RRB-\1740 triggers\VBZ\1641914 the\DT\1740 Fas-dependent\JJ\1740 cell-death\NN\1740 pathway\NN\5483677 and\CC\1740 cause\VB\1617192 cytoskeletal\JJ\1740 disruption\NN\1066163 in\IN\13603305 a\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 <e2>DCM</e2>\NN\1740 ,\,\1740 8-week-old\JJ\1740 transgenic\JJ\1740 (\-LRB-\1740 expressing\VBG\928630 Fas\NN\14304060 ligand\NN\20090 in\IN\13603305 the\DT\1740 myocardium\NN\5389939 :\:\1740 FasL\NN\1740 Tg\NN\1740 )\-RRB-\1740 and\CC\1740 non-transgenic\JJ\1740 (\-LRB-\1740 NTg\NN\1740 )\-RRB-\1740 mice\NNS\2329401 received\VBD\2210855 water\NN\14618834 ad\NN\7247071 libitum\NN\1740 containing\VBG\2632940 different\JJ\1740 concentrations\NNS\4916342 of\IN\1740 AZT\NN\3834836 (\-LRB-\1740 0\CD\13741022 ,\,\1740 0.07\CD\1740 ,\,\1740 0.2\CD\1740 ,\,\1740 and\CC\1740 0.7\CD\1740 mg/ml\NN\1740 )\-RRB-\1740 .\.\1740
D015215_D002311 CID METHODS\NNS\5616786 AND\CC\1740 RESULTS\NNS\34213 :\:\1740 In\IN\13603305 order\NN\7168131 to\TO\1740 investigate\VB\644583 whether\IN\1740 the\DT\1740 HAART\NN\3740161 component\NN\5867413 zidovudine\NN\3834836 (\-LRB-\1740 3'-azido-2',3'-deoxythymidine\NN\1740 ;\:\1740 AZT\NN\3834836 )\-RRB-\1740 triggers\VBZ\1641914 the\DT\1740 Fas-dependent\JJ\1740 cell-death\NN\1740 pathway\NN\5483677 and\CC\1740 cause\VB\1617192 cytoskeletal\JJ\1740 disruption\NN\1066163 in\IN\13603305 a\DT\13649268 murine\JJ\1740 model\NN\5888929 of\IN\1740 <e2>DCM</e2>\NN\1740 ,\,\1740 8-week-old\JJ\1740 transgenic\JJ\1740 (\-LRB-\1740 expressing\VBG\928630 Fas\NN\14304060 ligand\NN\20090 in\IN\13603305 the\DT\1740 myocardium\NN\5389939 :\:\1740 FasL\NN\1740 Tg\NN\1740 )\-RRB-\1740 and\CC\1740 non-transgenic\JJ\1740 (\-LRB-\1740 NTg\NN\1740 )\-RRB-\1740 mice\NNS\2329401 received\VBD\2210855 water\NN\14618834 ad\NN\7247071 libitum\NN\1740 containing\VBG\2632940 different\JJ\1740 concentrations\NNS\4916342 of\IN\1740 <e1>AZT</e1>\NN\3834836 (\-LRB-\1740 0\CD\13741022 ,\,\1740 0.07\CD\1740 ,\,\1740 0.2\CD\1740 ,\,\1740 and\CC\1740 0.7\CD\1740 mg/ml\NN\1740 )\-RRB-\1740 .\.\1740
D015215_D002311 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>AZT-treated</e1>\JJ\1740 FasL\NN\1740 Tg\NN\1740 mice\NNS\2329401 developed\VBD\1753788 <e2>cardiac\JJ\1740 dilation</e2>\NN\7138085 and\CC\1740 depressed\JJ\1740 cardiac\JJ\1740 function\NN\13783581 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 ,\,\1740 with\IN\1740 concomitant\JJ\1740 inflammatory\JJ\1740 infiltration\NN\975452 of\IN\1740 both\DT\1740 ventricles\NNS\5303402 .\.\1740
11027904
D008691_D010146 NONE <e2>Pain</e2>\NN\14299637 responses\NNS\11410625 in\IN\13603305 <e1>methadone-maintained</e1>\JJ\1740 opioid\NN\1740 abusers\NNS\9633969 .\.\1740
D008691_D010146 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 describe\VB\1001294 <e2>pain</e2>\NN\14299637 tolerance\NN\5032565 and\CC\1740 analgesic\JJ\1740 response\NN\11410625 in\IN\13603305 a\DT\13649268 sample\NN\5820620 of\IN\1740 opioid\NN\1740 addicts\NNS\10059582 stabilized\VBD\126264 in\IN\13603305 <e1>methadone-maintenance</e1>\NN\1740 (\-LRB-\1740 MM\NN\13649268 )\-RRB-\1740 treatment\NN\654885 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 60\CD\13745420 )\-RRB-\1740 in\IN\13603305 comparison\NN\635850 to\TO\1740 matched\VBN\2664769 nondependent\JJ\1740 control\JJ\1740 subjects\NNS\6598915 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 60\CD\13745420 )\-RRB-\1740 .\.\1740
D008691_D009293 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 describe\VB\1001294 pain\NN\14299637 tolerance\NN\5032565 and\CC\1740 analgesic\JJ\1740 response\NN\11410625 in\IN\13603305 a\DT\13649268 sample\NN\5820620 of\IN\1740 <e2>opioid\NN\1740 addicts</e2>\NNS\10059582 stabilized\VBD\126264 in\IN\13603305 <e1>methadone-maintenance</e1>\NN\1740 (\-LRB-\1740 MM\NN\13649268 )\-RRB-\1740 treatment\NN\654885 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 60\CD\13745420 )\-RRB-\1740 in\IN\13603305 comparison\NN\635850 to\TO\1740 matched\VBN\2664769 nondependent\JJ\1740 control\JJ\1740 subjects\NNS\6598915 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 60\CD\13745420 )\-RRB-\1740 .\.\1740
D004091_D010146 NONE By\IN\1740 using\VBG\1156834 a\DT\13649268 placebo-controlled\JJ\1740 ,\,\1740 two-way\JJ\1740 factorial\JJ\1740 design\NN\927261 ,\,\1740 tolerance\NN\5032565 to\TO\1740 cold-pressor\NN\1740 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 <e2>pain</e2>\NN\14299637 was\VBD\836236 examined\VBN\789138 ,\,\1740 both\CC\1740 before\IN\1740 and\CC\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 therapeutic\JJ\1740 doses\NNS\3740161 of\IN\1740 common\JJ\1740 opioid\NN\1740 (\-LRB-\1740 <e1>hydromorphone</e1>\NN\2707683 2\CD\13741022 mg\NN\13717155 )\-RRB-\1740 and\CC\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 (\-LRB-\1740 ketorolac\NN\3828465 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 analgesic\NN\3740161 agents\NNS\7347 .\.\1740
D020910_D010146 NONE By\IN\1740 using\VBG\1156834 a\DT\13649268 placebo-controlled\JJ\1740 ,\,\1740 two-way\JJ\1740 factorial\JJ\1740 design\NN\927261 ,\,\1740 tolerance\NN\5032565 to\TO\1740 cold-pressor\NN\1740 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 <e2>pain</e2>\NN\14299637 was\VBD\836236 examined\VBN\789138 ,\,\1740 both\CC\1740 before\IN\1740 and\CC\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 therapeutic\JJ\1740 doses\NNS\3740161 of\IN\1740 common\JJ\1740 opioid\NN\1740 (\-LRB-\1740 hydromorphone\NN\2707683 2\CD\13741022 mg\NN\13717155 )\-RRB-\1740 and\CC\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 (\-LRB-\1740 <e1>ketorolac</e1>\NN\3828465 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 analgesic\NN\3740161 agents\NNS\7347 .\.\1740
11705128
D012254_D000743 CID Management\NN\1123598 strategies\NNS\5902545 for\IN\1740 <e1>ribavirin-induced</e1>\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 hepatitis\NN\14127211 C\NN\13714184 :\:\1740 clinical\JJ\1740 and\CC\1740 economic\JJ\1740 implications\NNS\5774614 .\.\1740
D012254_D000743 CID Combination\NN\7951464 therapy\NN\657604 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 clinically\RB\1740 important\JJ\1740 adverse\JJ\1740 effect\NN\34213 :\:\1740 <e1>ribavirin-induced</e1>\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 (\-LRB-\1740 RIHA\NN\1740 )\-RRB-\1740 .\.\1740
D012254_D000743 CID Combination\NN\7951464 therapy\NN\657604 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 clinically\RB\1740 important\JJ\1740 adverse\JJ\1740 effect\NN\34213 :\:\1740 <e1>ribavirin-induced</e1>\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 (\-LRB-\1740 <e2>RIHA</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D012254_D000743 CID The\DT\1740 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 management\NN\1123598 of\IN\1740 <e2>RIHA</e2>\NN\1740 is\VBZ\836236 reduction\NN\351485 or\CC\3541091 discontinuation\NN\209943 of\IN\1740 the\DT\1740 <e1>ribavirin</e1>\NN\2725367 dosage\NN\13576355 .\.\1740
D012254_D000743 CID Questions\NNS\7193184 remain\VBP\2604760 about\IN\1740 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 and\CC\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>RIHA</e2>\NN\1740 in\IN\13603305 a\DT\13649268 real-world\JJ\1740 population\NN\7942152 .\.\1740
D012254_D006526 NONE Management\NN\1123598 strategies\NNS\5902545 for\IN\1740 <e1>ribavirin-induced</e1>\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>hepatitis\NN\14127211 C</e2>\NN\13714184 :\:\1740 clinical\JJ\1740 and\CC\1740 economic\JJ\1740 implications\NNS\5774614 .\.\1740
D012254_D019698 NONE OBJECTIVES\NNS\5980875 :\:\1740 Recently\RB\1740 published\VBN\1621555 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 increased\VBN\169651 efficacy\NN\5199286 and\CC\1740 cost-effectiveness\NN\1740 of\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 interferon\NN\2725367 and\CC\1740 <e1>alpha-2b/ribavirin</e1>\NN\1740 compared\VBN\644583 with\IN\1740 interferon-alpha\NN\1740 monotherapy\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 (\-LRB-\1740 CHC\NN\1740 )\-RRB-\1740 .\.\1740
D012254_D019698 NONE OBJECTIVES\NNS\5980875 :\:\1740 Recently\RB\1740 published\VBN\1621555 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 increased\VBN\169651 efficacy\NN\5199286 and\CC\1740 cost-effectiveness\NN\1740 of\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 interferon\NN\2725367 and\CC\1740 <e1>alpha-2b/ribavirin</e1>\NN\1740 compared\VBN\644583 with\IN\1740 interferon-alpha\NN\1740 monotherapy\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 (\-LRB-\1740 <e2>CHC</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D016898_D019698 NONE OBJECTIVES\NNS\5980875 :\:\1740 Recently\RB\1740 published\VBN\1621555 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 increased\VBN\169651 efficacy\NN\5199286 and\CC\1740 cost-effectiveness\NN\1740 of\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 interferon\NN\2725367 and\CC\1740 alpha-2b/ribavirin\NN\1740 compared\VBN\644583 with\IN\1740 <e1>interferon-alpha</e1>\NN\1740 monotherapy\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 (\-LRB-\1740 CHC\NN\1740 )\-RRB-\1740 .\.\1740
D016898_D019698 NONE OBJECTIVES\NNS\5980875 :\:\1740 Recently\RB\1740 published\VBN\1621555 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 increased\VBN\169651 efficacy\NN\5199286 and\CC\1740 cost-effectiveness\NN\1740 of\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 interferon\NN\2725367 and\CC\1740 alpha-2b/ribavirin\NN\1740 compared\VBN\644583 with\IN\1740 <e1>interferon-alpha</e1>\NN\1740 monotherapy\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 (\-LRB-\1740 <e2>CHC</e2>\NN\1740 )\-RRB-\1740 .\.\1740
17975693
D002939_D001008 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>ciprofloxacin-</e1>\NN\1740 and\CC\1740 norfloxacin-treated\JJ\1740 rats\NNS\2329401 showed\VBD\2137132 <e2>anxious\JJ\1740 behaviour</e2>\NN\14006945 in\IN\13603305 comparison\NN\635850 to\TO\1740 control\JJ\1740 rats\NNS\2329401 in\IN\13603305 all\PDT\1740 the\DT\1740 parameters\NNS\5858936 studied\VBN\630380 .\.\1740
D009643_D001008 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 ciprofloxacin-\NN\1740 and\CC\1740 <e1>norfloxacin-treated</e1>\JJ\1740 rats\NNS\2329401 showed\VBD\2137132 <e2>anxious\JJ\1740 behaviour</e2>\NN\14006945 in\IN\13603305 comparison\NN\635850 to\TO\1740 control\JJ\1740 rats\NNS\2329401 in\IN\13603305 all\PDT\1740 the\DT\1740 parameters\NNS\5858936 studied\VBN\630380 .\.\1740
18627295
D004317_D009202 CID <e1>Doxorubicin</e1>\NN\2716866 <e2>cardiomyopathy-induced</e2>\JJ\1740 inflammation\NN\14299637 and\CC\1740 apoptosis\NN\11486178 are\VBP\836236 attenuated\VBN\224901 by\IN\1740 gene\NN\8459252 deletion\NN\13508333 of\IN\1740 the\DT\1740 kinin\NN\14744841 B1\NN\1740 receptor\NN\5225602 .\.\1740
D004317_D009202 CID To\TO\1740 elucidate\VB\939277 the\DT\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 the\DT\1740 kinin\NN\14744841 B1\NN\1740 receptor\NN\5225602 (\-LRB-\1740 B1R\NN\1740 )\-RRB-\1740 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>DOX</e1>\NN\1740 <e2>cardiomyopathy</e2>\IN\14103288 ,\,\1740 we\PRP\1740 studied\VBD\630380 B1R\NN\1740 knockout\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 B1R(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 by\IN\1740 investigating\VBG\644583 cardiac\JJ\1740 inflammation\NN\14299637 and\CC\1740 apoptosis\NN\11486178 after\IN\1740 induction\NN\7450842 of\IN\1740 DOX-induced\JJ\1740 cardiomyopathy\JJ\1740 .\.\1740
D004317_D009202 CID To\TO\1740 elucidate\VB\939277 the\DT\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 the\DT\1740 kinin\NN\14744841 B1\NN\1740 receptor\NN\5225602 (\-LRB-\1740 B1R\NN\1740 )\-RRB-\1740 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>DOX</e1>\NN\1740 cardiomyopathy\IN\14103288 ,\,\1740 we\PRP\1740 studied\VBD\630380 B1R\NN\1740 knockout\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 B1R(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 by\IN\1740 investigating\VBG\644583 cardiac\JJ\1740 inflammation\NN\14299637 and\CC\1740 apoptosis\NN\11486178 after\IN\1740 induction\NN\7450842 of\IN\1740 DOX-induced\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 .\.\1740
D004317_D009202 CID To\TO\1740 elucidate\VB\939277 the\DT\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 the\DT\1740 kinin\NN\14744841 B1\NN\1740 receptor\NN\5225602 (\-LRB-\1740 B1R\NN\1740 )\-RRB-\1740 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 DOX\NN\1740 <e2>cardiomyopathy</e2>\IN\14103288 ,\,\1740 we\PRP\1740 studied\VBD\630380 B1R\NN\1740 knockout\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 B1R(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 by\IN\1740 investigating\VBG\644583 cardiac\JJ\1740 inflammation\NN\14299637 and\CC\1740 apoptosis\NN\11486178 after\IN\1740 induction\NN\7450842 of\IN\1740 <e1>DOX-induced</e1>\JJ\1740 cardiomyopathy\JJ\1740 .\.\1740
D004317_D009202 CID To\TO\1740 elucidate\VB\939277 the\DT\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 the\DT\1740 kinin\NN\14744841 B1\NN\1740 receptor\NN\5225602 (\-LRB-\1740 B1R\NN\1740 )\-RRB-\1740 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 DOX\NN\1740 cardiomyopathy\IN\14103288 ,\,\1740 we\PRP\1740 studied\VBD\630380 B1R\NN\1740 knockout\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 B1R(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 by\IN\1740 investigating\VBG\644583 cardiac\JJ\1740 inflammation\NN\14299637 and\CC\1740 apoptosis\NN\11486178 after\IN\1740 induction\NN\7450842 of\IN\1740 <e1>DOX-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 .\.\1740
D004317_D009202 CID These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 B1R\NN\1740 is\VBZ\836236 detrimental\JJ\1740 in\IN\13603305 <e1>DOX</e1>\NN\1740 <e2>cardiomyopathy</e2>\JJ\1740 in\IN\13603305 that\IN\1740 it\PRP\6125041 mediates\VBZ\761713 the\DT\1740 inflammatory\JJ\1740 response\NN\11410625 and\CC\1740 apoptosis\NN\11486178 .\.\1740
D004317_D009202 CID These\DT\1740 insights\NNS\5710020 might\MD\5029706 have\VB\2108377 useful\JJ\1740 implications\NNS\5774614 for\IN\1740 future\JJ\1740 studies\NNS\635850 utilizing\VBG\161225 B1R\NN\1740 antagonists\NNS\7846 for\IN\1740 treatment\NN\654885 of\IN\1740 human\JJ\1740 <e1>DOX</e1>\NN\1740 <e2>cardiomyopathy</e2>\JJ\1740 .\.\1740
D004317_D007249 NONE <e1>Doxorubicin</e1>\NN\2716866 cardiomyopathy-induced\JJ\1740 <e2>inflammation</e2>\NN\14299637 and\CC\1740 apoptosis\NN\11486178 are\VBP\836236 attenuated\VBN\224901 by\IN\1740 gene\NN\8459252 deletion\NN\13508333 of\IN\1740 the\DT\1740 kinin\NN\14744841 B1\NN\1740 receptor\NN\5225602 .\.\1740
D004317_D007249 NONE To\TO\1740 elucidate\VB\939277 the\DT\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 the\DT\1740 kinin\NN\14744841 B1\NN\1740 receptor\NN\5225602 (\-LRB-\1740 B1R\NN\1740 )\-RRB-\1740 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>DOX</e1>\NN\1740 cardiomyopathy\IN\14103288 ,\,\1740 we\PRP\1740 studied\VBD\630380 B1R\NN\1740 knockout\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 B1R(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 by\IN\1740 investigating\VBG\644583 cardiac\JJ\1740 <e2>inflammation</e2>\NN\14299637 and\CC\1740 apoptosis\NN\11486178 after\IN\1740 induction\NN\7450842 of\IN\1740 DOX-induced\JJ\1740 cardiomyopathy\JJ\1740 .\.\1740
D004317_D007249 NONE To\TO\1740 elucidate\VB\939277 the\DT\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 the\DT\1740 kinin\NN\14744841 B1\NN\1740 receptor\NN\5225602 (\-LRB-\1740 B1R\NN\1740 )\-RRB-\1740 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 DOX\NN\1740 cardiomyopathy\IN\14103288 ,\,\1740 we\PRP\1740 studied\VBD\630380 B1R\NN\1740 knockout\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 B1R(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 by\IN\1740 investigating\VBG\644583 cardiac\JJ\1740 <e2>inflammation</e2>\NN\14299637 and\CC\1740 apoptosis\NN\11486178 after\IN\1740 induction\NN\7450842 of\IN\1740 <e1>DOX-induced</e1>\JJ\1740 cardiomyopathy\JJ\1740 .\.\1740
D018943_D066126 NONE Clinical\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 <e1>anthracycline</e1>\NN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 is\VBZ\836236 limited\VBN\2510337 by\IN\1740 its\PRP$\6125041 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 ,\,\1740 which\WDT\1740 are\VBP\836236 attributed\VBN\670261 to\TO\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 apoptosis\NN\11486178 .\.\1740
D004317_D066126 NONE Clinical\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 anthracycline\NN\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 is\VBZ\836236 limited\VBN\2510337 by\IN\1740 its\PRP$\6125041 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 ,\,\1740 which\WDT\1740 are\VBP\836236 attributed\VBN\670261 to\TO\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 apoptosis\NN\11486178 .\.\1740
D004317_D066126 NONE Clinical\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 anthracycline\NN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DOX</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 limited\VBN\2510337 by\IN\1740 its\PRP$\6125041 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 ,\,\1740 which\WDT\1740 are\VBP\836236 attributed\VBN\670261 to\TO\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 apoptosis\NN\11486178 .\.\1740
D004317_D006331 NONE <e1>DOX</e1>\NN\1740 control\NN\5190804 mice\NNS\2329401 showed\VBD\2137132 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 measured\VBN\697589 by\IN\1740 pressure-volume\JJ\1740 loops\NNS\3323703 in\FW\13603305 vivo\FW\1740 .\.\1740
D004317_D006331 NONE In\IN\13603305 <e1>DOX</e1>\NN\1740 B1R(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 was\VBD\836236 improved\VBN\126264 compared\VBN\644583 to\TO\1740 DOX\NN\1740 control\NN\5190804 mice\NNS\2329401 ,\,\1740 which\WDT\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 normalization\NN\1123598 of\IN\1740 the\DT\1740 bax/bcl-2\NN\1740 ratio\NN\13815152 and\CC\1740 interleukin\NN\14943950 6\CD\13741022 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 AKT\NN\1740 activation\NN\13561719 state\NN\8491826 .\.\1740
D004317_D006331 NONE In\IN\13603305 DOX\NN\1740 B1R(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 was\VBD\836236 improved\VBN\126264 compared\VBN\644583 to\TO\1740 <e1>DOX</e1>\NN\1740 control\NN\5190804 mice\NNS\2329401 ,\,\1740 which\WDT\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 normalization\NN\1123598 of\IN\1740 the\DT\1740 bax/bcl-2\NN\1740 ratio\NN\13815152 and\CC\1740 interleukin\NN\14943950 6\CD\13741022 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 AKT\NN\1740 activation\NN\13561719 state\NN\8491826 .\.\1740
2564649
D005283_D009127 CID Involvement\NN\1080366 of\IN\1740 locus\NN\8645963 coeruleus\NN\1740 and\CC\1740 noradrenergic\JJ\1740 neurotransmission\NN\1740 in\IN\13603305 <e1>fentanyl-induced</e1>\JJ\1740 <e2>muscular\JJ\1740 rigidity</e2>\NN\5023233 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D005283_D009127 CID Whereas\IN\1740 <e2>muscular\JJ\1740 rigidity</e2>\NN\5023233 is\VBZ\836236 a\DT\13649268 well-known\JJ\1740 side\NN\8630039 effect\NN\34213 that\WDT\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 high-dose\JJ\1740 <e1>fentanyl</e1>\JJ\1740 anesthesia\NN\14034177 ,\,\1740 a\DT\13649268 paucity\NN\5116953 of\IN\1740 information\NN\6598915 exists\VBZ\1740 with\IN\1740 regard\NN\5817845 to\IN\1740 its\PRP$\6125041 underlying\VBG\2604760 mechanism(s\NN\1740 )\-RRB-\1740 .\.\1740
D005283_D009127 CID It\PRP\6125041 is\VBZ\836236 speculated\VBN\719734 that\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 <e2>muscular\JJ\1740 rigidity</e2>\NN\5023233 by\IN\1740 <e1>fentanyl</e1>\NN\2707683 may\MD\15209706 involve\VB\2676054 the\DT\1740 coerulospinal\JJ\1740 noradrenergic\JJ\1740 fibers\NNS\14580897 to\IN\1740 the\DT\1740 spinal\JJ\1740 motoneurons\NNS\5465567 .\.\1740
D011224_D009127 NONE Such\JJ\1740 an\DT\6697703 induced\VBN\1627355 <e2>muscular\JJ\1740 rigidity</e2>\NN\5023233 by\IN\1740 the\DT\1740 narcotic\JJ\1740 agent\NN\7347 was\VBD\836236 significantly\RB\1740 antagonized\VBN\1787955 or\CC\3541091 even\RB\1740 reduced\VBN\441445 by\IN\1740 prior\JJ\1740 electrolytic\JJ\1740 lesions\NNS\14204950 of\IN\1740 the\DT\1740 locus\NN\8645963 coeruleus\NN\1740 or\CC\3541091 pretreatment\NN\1740 with\IN\1740 the\DT\1740 alpha-adrenoceptor\JJ\1740 blocker\NN\10101634 ,\,\1740 <e1>prazosin</e1>\NN\2698769 .\.\1740
7542793
D016572_D007674 CID <e2>Nephrotoxicity</e2>\NN\1740 of\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 and\CC\1740 FK506\NN\1740 :\:\1740 inhibition\NN\1068773 of\IN\1740 calcineurin\NN\1740 phosphatase\NN\14732946 .\.\1740
D016572_D007674 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>CsA</e1>\NN\1740 and\CC\1740 FK506\NN\1740 is\VBZ\836236 likely\RB\1740 mediated\VBN\761713 through\IN\1740 binding\NN\4688246 to\TO\1740 renal\JJ\1740 immunophilin\NN\1740 and\CC\1740 inhibiting\VBG\2510337 calcineurin\NN\1740 phosphatase\NN\14732946 .\.\1740
D016559_D007674 CID <e2>Nephrotoxicity</e2>\NN\1740 of\IN\1740 cyclosporin\NN\1740 A\NN\13649268 and\CC\1740 <e1>FK506</e1>\NN\1740 :\:\1740 inhibition\NN\1068773 of\IN\1740 calcineurin\NN\1740 phosphatase\NN\14732946 .\.\1740
D016559_D007674 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 CsA\NN\1740 and\CC\1740 <e1>FK506</e1>\NN\1740 is\VBZ\836236 likely\RB\1740 mediated\VBN\761713 through\IN\1740 binding\NN\4688246 to\TO\1740 renal\JJ\1740 immunophilin\NN\1740 and\CC\1740 inhibiting\VBG\2510337 calcineurin\NN\1740 phosphatase\NN\14732946 .\.\1740
D016572_D006984 NONE <e1>Cyclosporin\NN\1740 A</e1>\NN\13649268 (\-LRB-\1740 CsA\NN\1740 ;\:\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 Fujimycine\NN\1740 (\-LRB-\1740 FK506\NN\1740 ;\:\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 the\DT\1740 related\JJ\1740 macrolide\NN\1740 immunosuppressant\JJ\1740 rapamycin\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 caused\VBD\1617192 a\DT\13649268 reduction\NN\351485 of\IN\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 degenerative\JJ\1740 changes\NNS\7283608 of\IN\1740 proximal\JJ\1740 tubular\JJ\1740 epithelium\NN\5267548 ,\,\1740 and\CC\1740 <e2>hypertrophy</e2>\NN\14365950 of\IN\1740 the\DT\1740 juxtaglomerular\JJ\1740 apparatus\NN\3294048 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 when\WRB\1740 given\VBN\2327200 for\IN\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
D016572_D006984 NONE Cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 <e1>CsA</e1>\NN\1740 ;\:\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 Fujimycine\NN\1740 (\-LRB-\1740 FK506\NN\1740 ;\:\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 the\DT\1740 related\JJ\1740 macrolide\NN\1740 immunosuppressant\JJ\1740 rapamycin\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 caused\VBD\1617192 a\DT\13649268 reduction\NN\351485 of\IN\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 degenerative\JJ\1740 changes\NNS\7283608 of\IN\1740 proximal\JJ\1740 tubular\JJ\1740 epithelium\NN\5267548 ,\,\1740 and\CC\1740 <e2>hypertrophy</e2>\NN\14365950 of\IN\1740 the\DT\1740 juxtaglomerular\JJ\1740 apparatus\NN\3294048 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 when\WRB\1740 given\VBN\2327200 for\IN\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
D016559_D006984 NONE Cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 CsA\NN\1740 ;\:\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>Fujimycine</e1>\NN\1740 (\-LRB-\1740 FK506\NN\1740 ;\:\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 the\DT\1740 related\JJ\1740 macrolide\NN\1740 immunosuppressant\JJ\1740 rapamycin\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 caused\VBD\1617192 a\DT\13649268 reduction\NN\351485 of\IN\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 degenerative\JJ\1740 changes\NNS\7283608 of\IN\1740 proximal\JJ\1740 tubular\JJ\1740 epithelium\NN\5267548 ,\,\1740 and\CC\1740 <e2>hypertrophy</e2>\NN\14365950 of\IN\1740 the\DT\1740 juxtaglomerular\JJ\1740 apparatus\NN\3294048 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 when\WRB\1740 given\VBN\2327200 for\IN\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
D016559_D006984 NONE Cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 CsA\NN\1740 ;\:\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 Fujimycine\NN\1740 (\-LRB-\1740 <e1>FK506</e1>\NN\1740 ;\:\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 the\DT\1740 related\JJ\1740 macrolide\NN\1740 immunosuppressant\JJ\1740 rapamycin\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 caused\VBD\1617192 a\DT\13649268 reduction\NN\351485 of\IN\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 degenerative\JJ\1740 changes\NNS\7283608 of\IN\1740 proximal\JJ\1740 tubular\JJ\1740 epithelium\NN\5267548 ,\,\1740 and\CC\1740 <e2>hypertrophy</e2>\NN\14365950 of\IN\1740 the\DT\1740 juxtaglomerular\JJ\1740 apparatus\NN\3294048 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 when\WRB\1740 given\VBN\2327200 for\IN\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
D018942_D006984 NONE Cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 CsA\NN\1740 ;\:\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 Fujimycine\NN\1740 (\-LRB-\1740 FK506\NN\1740 ;\:\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 the\DT\1740 related\JJ\1740 <e1>macrolide</e1>\NN\1740 immunosuppressant\JJ\1740 rapamycin\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 caused\VBD\1617192 a\DT\13649268 reduction\NN\351485 of\IN\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 degenerative\JJ\1740 changes\NNS\7283608 of\IN\1740 proximal\JJ\1740 tubular\JJ\1740 epithelium\NN\5267548 ,\,\1740 and\CC\1740 <e2>hypertrophy</e2>\NN\14365950 of\IN\1740 the\DT\1740 juxtaglomerular\JJ\1740 apparatus\NN\3294048 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 when\WRB\1740 given\VBN\2327200 for\IN\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
D020123_D006984 NONE Cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 CsA\NN\1740 ;\:\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 Fujimycine\NN\1740 (\-LRB-\1740 FK506\NN\1740 ;\:\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 the\DT\1740 related\JJ\1740 macrolide\NN\1740 immunosuppressant\JJ\1740 <e1>rapamycin</e1>\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 caused\VBD\1617192 a\DT\13649268 reduction\NN\351485 of\IN\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 degenerative\JJ\1740 changes\NNS\7283608 of\IN\1740 proximal\JJ\1740 tubular\JJ\1740 epithelium\NN\5267548 ,\,\1740 and\CC\1740 <e2>hypertrophy</e2>\NN\14365950 of\IN\1740 the\DT\1740 juxtaglomerular\JJ\1740 apparatus\NN\3294048 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 when\WRB\1740 given\VBN\2327200 for\IN\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
D016572_D064420 NONE The\DT\1740 molecular\JJ\1740 mechanisms\NNS\13446390 of\IN\1740 <e1>CsA</e1>\NN\1740 and\CC\1740 FK506\NN\1740 <e2>toxicity</e2>\NN\13576101 were\VBD\836236 investigated\VBN\644583 .\.\1740
D016559_D064420 NONE The\DT\1740 molecular\JJ\1740 mechanisms\NNS\13446390 of\IN\1740 CsA\NN\1740 and\CC\1740 <e1>FK506</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 were\VBD\836236 investigated\VBN\644583 .\.\1740
1300436
D005665_D007674 NONE Potential\JJ\1740 deleterious\JJ\1740 effect\NN\34213 of\IN\1740 <e1>furosemide</e1>\NN\3214670 in\IN\13603305 radiocontrast\NN\1740 <e2>nephropathy</e2>\RB\1740 .\.\1740
D005665_D007674 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>furosemide</e1>\NN\3214670 in\IN\13603305 addition\NN\3081021 to\TO\1740 intravenous\JJ\1740 fluids\NNS\19613 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 radiocontrast\NN\1740 <e2>nephropathy</e2>\RB\1740 .\.\1740
D005665_D007674 NONE <e1>Furosemide</e1>\NNP\3214670 may\MD\15209706 be\VB\836236 deleterious\JJ\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 radiocontrast\NN\1740 <e2>nephropathy</e2>\RB\1740 .\.\1740
D005665_D058186 CID Radiological\JJ\1740 studies\NNS\635850 were\VBD\836236 mostly\RB\1740 angiographies\NNS\904623 performed\VBN\2367363 with\IN\1740 both\CC\1740 ionic\JJ\1740 and\CC\1740 non-ionic\JJ\1740 contrast\NN\13854649 material\NN\19613 ,\,\1740 at\IN\14622893 an\DT\6697703 average\JJ\1740 dose\NN\3740161 of\IN\1740 245\CD\1740 ml.\NN\1740 <e2>Renal\JJ\1740 function\NN\13783581 significantly\RB\1740 deteriorated</e2>\VBD\208836 in\IN\13603305 the\DT\1740 group\NN\2137 pretreated\VBN\1740 with\IN\1740 <e1>furosemide</e1>\NN\3214670 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.005\CD\1740 by\IN\1740 ANOVA\NN\6021247 )\-RRB-\1740 ,\,\1740 with\IN\1740 a\DT\13649268 rise\NN\7324673 in\IN\13603305 serum\NN\5397468 creatinine\NN\1740 from\IN\1740 145\CD\1740 +/-\CC\1740 13\CD\13745420 to\TO\1740 182\CD\1740 +/-\CC\1740 16\CD\13745420 mumol/l\NN\1740 at\IN\14622893 24\CD\13745420 h\NN\14622893 ,\,\1740 while\IN\15122231 no\DT\7204911 change\NN\7283608 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 control\NN\5190804 group\NN\2137 (\-LRB-\1740 from\IN\1740 141\CD\1740 +/-\CC\1740 6\CD\13741022 to\TO\1740 142\CD\1740 +/-\CC\1740 7\CD\13741022 mumol/l\NN\1740 )\-RRB-\1740 .\.\1740
D003404_D058186 NONE Radiological\JJ\1740 studies\NNS\635850 were\VBD\836236 mostly\RB\1740 angiographies\NNS\904623 performed\VBN\2367363 with\IN\1740 both\CC\1740 ionic\JJ\1740 and\CC\1740 non-ionic\JJ\1740 contrast\NN\13854649 material\NN\19613 ,\,\1740 at\IN\14622893 an\DT\6697703 average\JJ\1740 dose\NN\3740161 of\IN\1740 245\CD\1740 ml.\NN\1740 <e2>Renal\JJ\1740 function\NN\13783581 significantly\RB\1740 deteriorated</e2>\VBD\208836 in\IN\13603305 the\DT\1740 group\NN\2137 pretreated\VBN\1740 with\IN\1740 furosemide\NN\3214670 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.005\CD\1740 by\IN\1740 ANOVA\NN\6021247 )\-RRB-\1740 ,\,\1740 with\IN\1740 a\DT\13649268 rise\NN\7324673 in\IN\13603305 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 from\IN\1740 145\CD\1740 +/-\CC\1740 13\CD\13745420 to\TO\1740 182\CD\1740 +/-\CC\1740 16\CD\13745420 mumol/l\NN\1740 at\IN\14622893 24\CD\13745420 h\NN\14622893 ,\,\1740 while\IN\15122231 no\DT\7204911 change\NN\7283608 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 control\NN\5190804 group\NN\2137 (\-LRB-\1740 from\IN\1740 141\CD\1740 +/-\CC\1740 6\CD\13741022 to\TO\1740 142\CD\1740 +/-\CC\1740 7\CD\13741022 mumol/l\NN\1740 )\-RRB-\1740 .\.\1740
D005665_D051437 NONE <e2>Renal\JJ\1740 failure</e2>\NN\66216 was\VBD\836236 associated\VBN\628491 with\IN\1740 weight\NN\5009170 loss\NN\13252973 in\IN\13603305 the\DT\1740 <e1>furosemide-treated</e1>\JJ\1740 group\NN\2137 .\.\1740
D005665_D015431 NONE Renal\JJ\1740 failure\NN\66216 was\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 in\IN\13603305 the\DT\1740 <e1>furosemide-treated</e1>\JJ\1740 group\NN\2137 .\.\1740
12101159
D004110_D006323 CID Delayed\VBN\439958 <e2>asystolic</e2>\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 after\IN\1740 <e1>diltiazem</e1>\NN\2938514 overdose\NN\1740 ;\:\1740 resuscitation\NN\1047338 with\IN\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 calcium\NN\14625458 .\.\1740
D004110_D006323 CID Delayed\VBN\439958 asystolic\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 after\IN\1740 <e1>diltiazem</e1>\NN\2938514 overdose\NN\1740 ;\:\1740 resuscitation\NN\1047338 with\IN\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 calcium\NN\14625458 .\.\1740
D004110_D006323 CID This\DT\1740 case\NN\7283608 suggests\VBZ\1010118 there\EX\27167 is\VBZ\836236 a\DT\13649268 role\NN\719494 for\IN\1740 aggressive\JJ\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 calcium\NN\14625458 therapy\NN\657604 in\IN\13603305 severe\JJ\1740 <e1>diltiazem</e1>\NN\2938514 overdose\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>asystole</e2>\NN\14204950 .\.\1740
D004110_D006323 CID It\PRP\6125041 should\MD\1740 be\VB\836236 considered\VBN\689344 early\JJ\1740 in\IN\13603305 cases\NNS\7283608 of\IN\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 after\IN\1740 <e1>diltiazem</e1>\NN\2938514 overdose\NN\1740 .\.\1740
D004110_D062787 CID Delayed\VBN\439958 asystolic\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 after\IN\1740 <e1>diltiazem</e1>\NN\2938514 <e2>overdose</e2>\NN\1740 ;\:\1740 resuscitation\NN\1047338 with\IN\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 calcium\NN\14625458 .\.\1740
D004110_D062787 CID A\DT\13649268 51\CD\1740 year\NN\15113229 old\JJ\1740 man\NN\9605289 took\VBD\2367363 a\DT\13649268 mixed\JJ\1740 <e2>overdose</e2>\NN\1740 including\VBG\690614 1.8\CD\1740 -\SYM\1740 3.6\CD\1740 g\NN\13717155 of\IN\1740 <e1>diltiazem</e1>\NN\2938514 ,\,\1740 paracetamol\NN\1740 ,\,\1740 aspirin\NN\2707683 ,\,\1740 isosorbide\VBP\1740 nitrate\VBP\515154 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
D004110_D062787 CID This\DT\1740 case\NN\7283608 suggests\VBZ\1010118 there\EX\27167 is\VBZ\836236 a\DT\13649268 role\NN\719494 for\IN\1740 aggressive\JJ\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 calcium\NN\14625458 therapy\NN\657604 in\IN\13603305 severe\JJ\1740 <e1>diltiazem</e1>\NN\2938514 <e2>overdose</e2>\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 asystole\NN\14204950 .\.\1740
D004110_D062787 CID It\PRP\6125041 should\MD\1740 be\VB\836236 considered\VBN\689344 early\JJ\1740 in\IN\13603305 cases\NNS\7283608 of\IN\1740 cardiac\JJ\1740 arrest\NN\88481 after\IN\1740 <e1>diltiazem</e1>\NN\2938514 <e2>overdose</e2>\NN\1740 .\.\1740
D002118_D006323 NONE Delayed\VBN\439958 <e2>asystolic</e2>\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 after\IN\1740 diltiazem\NN\2938514 overdose\NN\1740 ;\:\1740 resuscitation\NN\1047338 with\IN\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 <e1>calcium</e1>\NN\14625458 .\.\1740
D002118_D006323 NONE Delayed\VBN\439958 asystolic\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 after\IN\1740 diltiazem\NN\2938514 overdose\NN\1740 ;\:\1740 resuscitation\NN\1047338 with\IN\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 <e1>calcium</e1>\NN\14625458 .\.\1740
D002118_D006323 NONE This\DT\1740 case\NN\7283608 suggests\VBZ\1010118 there\EX\27167 is\VBZ\836236 a\DT\13649268 role\NN\719494 for\IN\1740 aggressive\JJ\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 <e1>calcium</e1>\NN\14625458 therapy\NN\657604 in\IN\13603305 severe\JJ\1740 diltiazem\NN\2938514 overdose\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>asystole</e2>\NN\14204950 .\.\1740
D002118_D062787 NONE Delayed\VBN\439958 asystolic\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 after\IN\1740 diltiazem\NN\2938514 <e2>overdose</e2>\NN\1740 ;\:\1740 resuscitation\NN\1047338 with\IN\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 <e1>calcium</e1>\NN\14625458 .\.\1740
D002118_D062787 NONE This\DT\1740 case\NN\7283608 suggests\VBZ\1010118 there\EX\27167 is\VBZ\836236 a\DT\13649268 role\NN\719494 for\IN\1740 aggressive\JJ\1740 high\JJ\1740 dose\NN\3740161 intravenous\JJ\1740 <e1>calcium</e1>\NN\14625458 therapy\NN\657604 in\IN\13603305 severe\JJ\1740 diltiazem\NN\2938514 <e2>overdose</e2>\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 asystole\NN\14204950 .\.\1740
D000082_D062787 NONE A\DT\13649268 51\CD\1740 year\NN\15113229 old\JJ\1740 man\NN\9605289 took\VBD\2367363 a\DT\13649268 mixed\JJ\1740 <e2>overdose</e2>\NN\1740 including\VBG\690614 1.8\CD\1740 -\SYM\1740 3.6\CD\1740 g\NN\13717155 of\IN\1740 diltiazem\NN\2938514 ,\,\1740 <e1>paracetamol</e1>\NN\1740 ,\,\1740 aspirin\NN\2707683 ,\,\1740 isosorbide\VBP\1740 nitrate\VBP\515154 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
D001241_D062787 NONE A\DT\13649268 51\CD\1740 year\NN\15113229 old\JJ\1740 man\NN\9605289 took\VBD\2367363 a\DT\13649268 mixed\JJ\1740 <e2>overdose</e2>\NN\1740 including\VBG\690614 1.8\CD\1740 -\SYM\1740 3.6\CD\1740 g\NN\13717155 of\IN\1740 diltiazem\NN\2938514 ,\,\1740 paracetamol\NN\1740 ,\,\1740 <e1>aspirin</e1>\NN\2707683 ,\,\1740 isosorbide\VBP\1740 nitrate\VBP\515154 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
D007547_D062787 NONE A\DT\13649268 51\CD\1740 year\NN\15113229 old\JJ\1740 man\NN\9605289 took\VBD\2367363 a\DT\13649268 mixed\JJ\1740 <e2>overdose</e2>\NN\1740 including\VBG\690614 1.8\CD\1740 -\SYM\1740 3.6\CD\1740 g\NN\13717155 of\IN\1740 diltiazem\NN\2938514 ,\,\1740 paracetamol\NN\1740 ,\,\1740 aspirin\NN\2707683 ,\,\1740 <e1>isosorbide</e1>\VBP\1740 nitrate\VBP\515154 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
D009566_D062787 NONE A\DT\13649268 51\CD\1740 year\NN\15113229 old\JJ\1740 man\NN\9605289 took\VBD\2367363 a\DT\13649268 mixed\JJ\1740 <e2>overdose</e2>\NN\1740 including\VBG\690614 1.8\CD\1740 -\SYM\1740 3.6\CD\1740 g\NN\13717155 of\IN\1740 diltiazem\NN\2938514 ,\,\1740 paracetamol\NN\1740 ,\,\1740 aspirin\NN\2707683 ,\,\1740 isosorbide\VBP\1740 <e1>nitrate</e1>\VBP\515154 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
D000431_D062787 NONE A\DT\13649268 51\CD\1740 year\NN\15113229 old\JJ\1740 man\NN\9605289 took\VBD\2367363 a\DT\13649268 mixed\JJ\1740 <e2>overdose</e2>\NN\1740 including\VBG\690614 1.8\CD\1740 -\SYM\1740 3.6\CD\1740 g\NN\13717155 of\IN\1740 diltiazem\NN\2938514 ,\,\1740 paracetamol\NN\1740 ,\,\1740 aspirin\NN\2707683 ,\,\1740 isosorbide\VBP\1740 nitrate\VBP\515154 ,\,\1740 and\CC\1740 <e1>alcohol</e1>\NN\7881800 .\.\1740
11099450
D007980_D010300 NONE The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 explore\VB\789138 the\DT\1740 functional\JJ\1740 anatomy\NN\6078327 of\IN\1740 the\DT\1740 globus\NN\1740 pallidus\NN\1740 internus\NN\1740 (\-LRB-\1740 GPi\NNS\1740 )\-RRB-\1740 by\IN\1740 studying\VBG\630380 the\DT\1740 effects\NNS\13245626 of\IN\1740 unilateral\JJ\1740 pallidotomy\NN\1740 on\IN\1740 <e2>parkinsonian</e2>\JJ\1740 '\``\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 .\.\1740
D007980_D010300 NONE The\DT\1740 differential\JJ\1740 predictive\JJ\1740 value\NN\5856066 of\IN\1740 <e1>levodopa</e1>\NN\14604959 responsiveness\NN\5652926 for\IN\1740 the\DT\1740 outcome\NN\7291312 of\IN\1740 <e2>parkinsonian</e2>\NN\1740 '\``\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 LID\NN\5313679 and\CC\1740 the\DT\1740 different\JJ\1740 correlations\NNS\13841213 of\IN\1740 ventral\JJ\1740 lesion\NN\14204950 volume\NN\33615 with\IN\1740 dyskinesias\NNS\14084880 and\CC\1740 parkinsonian\JJ\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 indicate\VBP\952524 that\IN\1740 different\JJ\1740 anatomical\JJ\1740 or\CC\3541091 pathophysiological\JJ\1740 substrates\NNS\19613 may\MD\15209706 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 parkinsonian\NN\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D010300 NONE The\DT\1740 differential\JJ\1740 predictive\JJ\1740 value\NN\5856066 of\IN\1740 <e1>levodopa</e1>\NN\14604959 responsiveness\NN\5652926 for\IN\1740 the\DT\1740 outcome\NN\7291312 of\IN\1740 parkinsonian\NN\1740 '\``\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 LID\NN\5313679 and\CC\1740 the\DT\1740 different\JJ\1740 correlations\NNS\13841213 of\IN\1740 ventral\JJ\1740 lesion\NN\14204950 volume\NN\33615 with\IN\1740 dyskinesias\NNS\14084880 and\CC\1740 <e2>parkinsonian</e2>\JJ\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 indicate\VBP\952524 that\IN\1740 different\JJ\1740 anatomical\JJ\1740 or\CC\3541091 pathophysiological\JJ\1740 substrates\NNS\19613 may\MD\15209706 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 parkinsonian\NN\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D010300 NONE The\DT\1740 differential\JJ\1740 predictive\JJ\1740 value\NN\5856066 of\IN\1740 <e1>levodopa</e1>\NN\14604959 responsiveness\NN\5652926 for\IN\1740 the\DT\1740 outcome\NN\7291312 of\IN\1740 parkinsonian\NN\1740 '\``\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 LID\NN\5313679 and\CC\1740 the\DT\1740 different\JJ\1740 correlations\NNS\13841213 of\IN\1740 ventral\JJ\1740 lesion\NN\14204950 volume\NN\33615 with\IN\1740 dyskinesias\NNS\14084880 and\CC\1740 parkinsonian\JJ\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 indicate\VBP\952524 that\IN\1740 different\JJ\1740 anatomical\JJ\1740 or\CC\3541091 pathophysiological\JJ\1740 substrates\NNS\19613 may\MD\15209706 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 <e2>parkinsonian</e2>\NN\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D004409 CID The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 explore\VB\789138 the\DT\1740 functional\JJ\1740 anatomy\NN\6078327 of\IN\1740 the\DT\1740 globus\NN\1740 pallidus\NN\1740 internus\NN\1740 (\-LRB-\1740 GPi\NNS\1740 )\-RRB-\1740 by\IN\1740 studying\VBG\630380 the\DT\1740 effects\NNS\13245626 of\IN\1740 unilateral\JJ\1740 pallidotomy\NN\1740 on\IN\1740 parkinsonian\JJ\1740 '\``\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 .\.\1740
D007980_D004409 CID The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 explore\VB\789138 the\DT\1740 functional\JJ\1740 anatomy\NN\6078327 of\IN\1740 the\DT\1740 globus\NN\1740 pallidus\NN\1740 internus\NN\1740 (\-LRB-\1740 GPi\NNS\1740 )\-RRB-\1740 by\IN\1740 studying\VBG\630380 the\DT\1740 effects\NNS\13245626 of\IN\1740 unilateral\JJ\1740 pallidotomy\NN\1740 on\IN\1740 parkinsonian\JJ\1740 '\``\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 <e2>LID</e2>\NN\5313679 )\-RRB-\1740 .\.\1740
D007980_D004409 CID We\PRP\1740 found\VBD\2426171 significant\JJ\1740 positive\JJ\1740 correlations\NNS\13841213 between\IN\1740 the\DT\1740 preoperative\JJ\1740 <e1>levodopa</e1>\NN\14604959 responsiveness\NN\5652926 of\IN\1740 motor\NN\3699975 signs\NNS\6643763 and\CC\1740 the\DT\1740 levodopa\NN\14604959 responsiveness\NN\5652926 of\IN\1740 scores\NNS\13757724 in\IN\13603305 timed\VBN\489837 tests\NNS\5798043 (\-LRB-\1740 Core\NN\7996689 Assessment\NNP\5732756 Program\NNP\5833840 for\IN\1740 Intracerebral\NNP\1740 Transplantations\NNPS\671351 )\-RRB-\1740 in\IN\13603305 the\DT\1740 contralateral\JJ\1740 limbs\NNS\5559908 and\CC\1740 the\DT\1740 improvement\NN\7359599 in\IN\13603305 these\DT\1740 scores\NNS\13757724 after\IN\1740 surgery\NN\6045562 ,\,\1740 whereas\IN\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 correlation\NN\13841213 with\IN\1740 the\DT\1740 improvement\NN\7359599 in\IN\13603305 <e2>LID</e2>\NN\5313679 .\.\1740
D007980_D004409 CID We\PRP\1740 found\VBD\2426171 significant\JJ\1740 positive\JJ\1740 correlations\NNS\13841213 between\IN\1740 the\DT\1740 preoperative\JJ\1740 levodopa\NN\14604959 responsiveness\NN\5652926 of\IN\1740 motor\NN\3699975 signs\NNS\6643763 and\CC\1740 the\DT\1740 <e1>levodopa</e1>\NN\14604959 responsiveness\NN\5652926 of\IN\1740 scores\NNS\13757724 in\IN\13603305 timed\VBN\489837 tests\NNS\5798043 (\-LRB-\1740 Core\NN\7996689 Assessment\NNP\5732756 Program\NNP\5833840 for\IN\1740 Intracerebral\NNP\1740 Transplantations\NNPS\671351 )\-RRB-\1740 in\IN\13603305 the\DT\1740 contralateral\JJ\1740 limbs\NNS\5559908 and\CC\1740 the\DT\1740 improvement\NN\7359599 in\IN\13603305 these\DT\1740 scores\NNS\13757724 after\IN\1740 surgery\NN\6045562 ,\,\1740 whereas\IN\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 correlation\NN\13841213 with\IN\1740 the\DT\1740 improvement\NN\7359599 in\IN\13603305 <e2>LID</e2>\NN\5313679 .\.\1740
D007980_D004409 CID The\DT\1740 differential\JJ\1740 predictive\JJ\1740 value\NN\5856066 of\IN\1740 <e1>levodopa</e1>\NN\14604959 responsiveness\NN\5652926 for\IN\1740 the\DT\1740 outcome\NN\7291312 of\IN\1740 parkinsonian\NN\1740 '\``\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 <e2>LID</e2>\NN\5313679 and\CC\1740 the\DT\1740 different\JJ\1740 correlations\NNS\13841213 of\IN\1740 ventral\JJ\1740 lesion\NN\14204950 volume\NN\33615 with\IN\1740 dyskinesias\NNS\14084880 and\CC\1740 parkinsonian\JJ\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 indicate\VBP\952524 that\IN\1740 different\JJ\1740 anatomical\JJ\1740 or\CC\3541091 pathophysiological\JJ\1740 substrates\NNS\19613 may\MD\15209706 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 parkinsonian\NN\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D004409 CID The\DT\1740 differential\JJ\1740 predictive\JJ\1740 value\NN\5856066 of\IN\1740 <e1>levodopa</e1>\NN\14604959 responsiveness\NN\5652926 for\IN\1740 the\DT\1740 outcome\NN\7291312 of\IN\1740 parkinsonian\NN\1740 '\``\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 LID\NN\5313679 and\CC\1740 the\DT\1740 different\JJ\1740 correlations\NNS\13841213 of\IN\1740 ventral\JJ\1740 lesion\NN\14204950 volume\NN\33615 with\IN\1740 <e2>dyskinesias</e2>\NNS\14084880 and\CC\1740 parkinsonian\JJ\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 indicate\VBP\952524 that\IN\1740 different\JJ\1740 anatomical\JJ\1740 or\CC\3541091 pathophysiological\JJ\1740 substrates\NNS\19613 may\MD\15209706 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 parkinsonian\NN\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D004409 CID The\DT\1740 differential\JJ\1740 predictive\JJ\1740 value\NN\5856066 of\IN\1740 <e1>levodopa</e1>\NN\14604959 responsiveness\NN\5652926 for\IN\1740 the\DT\1740 outcome\NN\7291312 of\IN\1740 parkinsonian\NN\1740 '\``\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 LID\NN\5313679 and\CC\1740 the\DT\1740 different\JJ\1740 correlations\NNS\13841213 of\IN\1740 ventral\JJ\1740 lesion\NN\14204950 volume\NN\33615 with\IN\1740 dyskinesias\NNS\14084880 and\CC\1740 parkinsonian\JJ\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 indicate\VBP\952524 that\IN\1740 different\JJ\1740 anatomical\JJ\1740 or\CC\3541091 pathophysiological\JJ\1740 substrates\NNS\19613 may\MD\15209706 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 parkinsonian\NN\1740 '\''\1740 off\NN\1740 '\``\1740 signs\NNS\6643763 and\CC\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
1079693
D000305_D014605 NONE Even\RB\1740 after\IN\1740 early\JJ\1740 detection\NN\5708432 and\CC\1740 prompt\VB\1645601 treatment\NN\654885 ,\,\1740 41\CD\1740 %\NN\1740 of\IN\1740 cases\NNS\7283608 of\IN\1740 <e2>uveitis</e2>\NN\14336539 did\VBD\1640855 not\RB\1740 respond\VB\2367363 to\IN\1740 more\JJR\1740 than\IN\1740 six\CD\13741022 months\NNS\15113229 of\IN\1740 intensive\JJ\1740 topical\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>corticosteroids</e1>\NNS\14745635 and\CC\1740 mydriatics\NNS\3247620 .\.\1740
D002738_D012164 NONE We\PRP\1740 used\VBD\1156834 <e1>chloroquine</e1>\NN\2721948 or\CC\3541091 hydroxychloroquine\NN\2721538 in\IN\13603305 173\CD\1740 of\IN\1740 210\CD\1740 cases\NNS\7283608 and\CC\1740 found\VBD\2426171 only\RB\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 <e2>chorioretinopathy</e2>\JJ\1740 attributable\JJ\1740 to\TO\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D006886_D012164 CID We\PRP\1740 used\VBD\1156834 chloroquine\NN\2721948 or\CC\3541091 <e1>hydroxychloroquine</e1>\NN\2721538 in\IN\13603305 173\CD\1740 of\IN\1740 210\CD\1740 cases\NNS\7283608 and\CC\1740 found\VBD\2426171 only\RB\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 <e2>chorioretinopathy</e2>\JJ\1740 attributable\JJ\1740 to\TO\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D000305_D002386 NONE Systemically\RB\1740 administered\VBN\2436349 <e1>corticosteroids</e1>\NNS\14745635 were\VBD\836236 used\VBN\1156834 in\IN\13603305 75\CD\1740 of\IN\1740 210\CD\1740 cases\NNS\7283608 ;\:\1740 a\DT\13649268 significant\JJ\1740 number\NN\5107765 of\IN\1740 posterior\JJ\1740 subcapsular\JJ\1740 <e2>cataracts</e2>\NNS\14252864 was\VBD\836236 found\VBN\2426171 .\.\1740
11195262
D014635_D007177 CID Contribution\NN\786195 of\IN\1740 <e1>sodium\NN\14625458 valproate</e1>\NN\1740 to\TO\1740 the\DT\1740 <e2>syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 antidiuretic\JJ\1740 hormone</e2>\NN\5404728 .\.\1740
D014635_D007177 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 62-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 administered\VBN\2436349 <e1>sodium\NN\14625458 valproate</e1>\NN\1740 (\-LRB-\1740 VPA\NN\1740 )\-RRB-\1740 and\CC\1740 who\WP\8299493 subsequently\RB\1740 developed\VBD\1753788 the\DT\1740 <e2>syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 antidiuretic\JJ\1740 hormone</e2>\NN\5404728 (\-LRB-\1740 SIADH\NN\1740 )\-RRB-\1740 .\.\1740
D014635_D007177 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 62-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 administered\VBN\2436349 <e1>sodium\NN\14625458 valproate</e1>\NN\1740 (\-LRB-\1740 VPA\NN\1740 )\-RRB-\1740 and\CC\1740 who\WP\8299493 subsequently\RB\1740 developed\VBD\1753788 the\DT\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 antidiuretic\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 <e2>SIADH</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D014635_D007177 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 62-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 administered\VBN\2436349 sodium\NN\14625458 valproate\NN\1740 (\-LRB-\1740 <e1>VPA</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 who\WP\8299493 subsequently\RB\1740 developed\VBD\1753788 the\DT\1740 <e2>syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 antidiuretic\JJ\1740 hormone</e2>\NN\5404728 (\-LRB-\1740 SIADH\NN\1740 )\-RRB-\1740 .\.\1740
D014635_D007177 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 62-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 administered\VBN\2436349 sodium\NN\14625458 valproate\NN\1740 (\-LRB-\1740 <e1>VPA</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 who\WP\8299493 subsequently\RB\1740 developed\VBD\1753788 the\DT\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 antidiuretic\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 <e2>SIADH</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D014635_D007177 CID We\PRP\1740 consider\VBP\689344 this\DT\1740 episode\NN\7283608 of\IN\1740 <e2>SIADH</e2>\NN\1740 to\TO\1740 be\VB\836236 the\DT\1740 result\NN\34213 of\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 factors\NNS\7326557 including\VBG\690614 a\DT\13649268 weakness\NN\14462666 of\IN\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 and\CC\1740 the\DT\1740 long-term\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>VPA</e1>\NN\1740 .\.\1740
D014635_D004830 NONE He\PRP\14622893 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>VPA</e1>\NN\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 idiopathic\JJ\1740 generalized\VBN\634472 <e2>tonic-clonic\JJ\1740 convulsions</e2>\NNS\14081375 since\IN\1740 he\PRP\14622893 was\VBD\836236 56\CD\1740 years\NNS\15144371 old\JJ\1740 .\.\1740
D014635_D002493 NONE We\PRP\1740 consider\VBP\689344 this\DT\1740 episode\NN\7283608 of\IN\1740 SIADH\NN\1740 to\TO\1740 be\VB\836236 the\DT\1740 result\NN\34213 of\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 factors\NNS\7326557 including\VBG\690614 a\DT\13649268 <e2>weakness\NN\14462666 of\IN\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system</e2>\NN\3575240 and\CC\1740 the\DT\1740 long-term\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>VPA</e1>\NN\1740 .\.\1740
2334179
D010396_D012594 NONE <e1>D-penicillamine</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>localized\JJ\1740 scleroderma</e2>\NN\14187378 .\.\1740
D010396_D012594 NONE Case\NN\7283608 reports\NNS\6470073 of\IN\1740 11\CD\13745420 patients\NNS\9898892 with\IN\1740 severe\JJ\1740 ,\,\1740 extensive\JJ\1740 <e2>localized\JJ\1740 scleroderma</e2>\NN\14187378 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>D-penicillamine</e1>\NN\1740 are\VBP\836236 summarized\VBN\958334 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D010396_D012594 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>D-penicillamine</e1>\NN\1740 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 severe\JJ\1740 cases\NNS\7283608 of\IN\1740 <e2>localized\JJ\1740 scleroderma</e2>\NN\14187378 .\.\1740
D010396_D009404 CID <e1>D-Penicillamine</e1>\NN\1740 caused\VBD\1617192 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 in\IN\13603305 1\CD\13741022 patient\NN\9898892 and\CC\1740 milder\NN\1740 reversible\JJ\1740 proteinuria\NN\14299637 in\IN\13603305 3\CD\13741022 other\JJ\1740 patients\NNS\9898892 ;\:\1740 none\NN\15228378 developed\VBD\1753788 renal\JJ\1740 insufficiency\NN\14462946 .\.\1740
D010396_D011507 CID <e1>D-Penicillamine</e1>\NN\1740 caused\VBD\1617192 nephrotic\JJ\1740 syndrome\NN\5870365 in\IN\13603305 1\CD\13741022 patient\NN\9898892 and\CC\1740 milder\NN\1740 reversible\JJ\1740 <e2>proteinuria</e2>\NN\14299637 in\IN\13603305 3\CD\13741022 other\JJ\1740 patients\NNS\9898892 ;\:\1740 none\NN\15228378 developed\VBD\1753788 renal\JJ\1740 insufficiency\NN\14462946 .\.\1740
D010396_D051437 NONE <e1>D-Penicillamine</e1>\NN\1740 caused\VBD\1617192 nephrotic\JJ\1740 syndrome\NN\5870365 in\IN\13603305 1\CD\13741022 patient\NN\9898892 and\CC\1740 milder\NN\1740 reversible\JJ\1740 proteinuria\NN\14299637 in\IN\13603305 3\CD\13741022 other\JJ\1740 patients\NNS\9898892 ;\:\1740 none\NN\15228378 developed\VBD\1753788 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 .\.\1740
18657397
D010406_D004827 NONE Detailed\JJ\1740 spectral\JJ\1740 profile\NN\6999802 analysis\NN\633864 of\IN\1740 <e1>penicillin-induced</e1>\JJ\1740 <e2>epileptiform\NN\1740 activity</e2>\NN\30358 in\IN\13603305 anesthetized\JJ\1740 rats\NNS\2329401 .\.\1740
D010406_D004827 NONE <e1>Penicillin</e1>\NN\2716866 model\NN\5888929 is\VBZ\836236 a\DT\13649268 widely\RB\1740 used\VBN\1156834 experimental\JJ\1740 model\NN\5888929 for\IN\1740 <e2>epilepsy</e2>\NN\14085708 research\NN\633864 .\.\1740
D010406_D004827 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 portray\VB\988028 a\DT\13649268 detailed\VBN\955601 spectral\JJ\1740 analysis\NN\633864 of\IN\1740 <e1>penicillin-induced</e1>\JJ\1740 <e2>epileptiform\NN\1740 activity</e2>\NN\30358 in\IN\13603305 comparison\NN\635850 with\IN\1740 basal\JJ\1740 brain\NN\5462674 activity\NN\30358 in\IN\13603305 anesthetized\VBN\84738 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D010406_D004827 NONE Basal\JJ\1740 activity\NN\30358 ,\,\1740 latent\JJ\1740 period\NN\13575869 and\CC\1740 the\DT\1740 <e1>penicillin-induced</e1>\JJ\1740 <e2>epileptiform\NN\1740 activity</e2>\NN\30358 periods\NNS\13575869 were\VBD\836236 then\RB\1740 analyzed\VBN\78760 using\VBG\1156834 both\CC\1740 conventional\JJ\1740 methods\NNS\5616786 and\CC\1740 spectral\JJ\1740 analysis\NN\633864 .\.\1740
D010400_D004827 CID After\IN\1740 a\DT\13649268 short\JJ\1740 period\NN\13575869 of\IN\1740 basal\JJ\1740 activity\NN\30358 recording\NN\6791372 ,\,\1740 <e2>epileptic</e2>\JJ\1740 focus\NN\5704266 was\VBD\836236 induced\VBN\1627355 by\IN\1740 injecting\VBG\81072 400IU/2\CD\1740 microl\NN\1740 <e1>penicillin-G\NN\1740 potassium</e1>\NN\14625458 into\IN\1740 the\DT\1740 left\JJ\1740 lateral\JJ\1740 ventricle\NN\5303402 while\IN\15122231 the\DT\1740 cortical\JJ\1740 activity\NN\30358 was\VBD\836236 continuously\RB\1740 recorded\VBN\2225492 .\.\1740
9270571
D004298_D020734 NONE Potential\JJ\1740 therapeutic\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 selective\JJ\1740 <e1>dopamine</e1>\NN\14807737 D1\NN\1740 receptor\NN\5225602 agonist\NN\9613191 ,\,\1740 A-86929\NN\1740 :\:\1740 an\DT\6697703 acute\JJ\1740 study\NN\635850 in\IN\13603305 <e2>parkinsonian</e2>\JJ\1740 levodopa-primed\JJ\1740 monkeys\NNS\2469914 .\.\1740
C095427_D020734 NONE Potential\JJ\1740 therapeutic\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 selective\JJ\1740 dopamine\NN\14807737 D1\NN\1740 receptor\NN\5225602 agonist\NN\9613191 ,\,\1740 <e1>A-86929</e1>\NN\1740 :\:\1740 an\DT\6697703 acute\JJ\1740 study\NN\635850 in\IN\13603305 <e2>parkinsonian</e2>\JJ\1740 levodopa-primed\JJ\1740 monkeys\NNS\2469914 .\.\1740
C095427_D020734 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>A-86929</e1>\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
D007980_D020734 NONE Potential\JJ\1740 therapeutic\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 selective\JJ\1740 dopamine\NN\14807737 D1\NN\1740 receptor\NN\5225602 agonist\NN\9613191 ,\,\1740 A-86929\NN\1740 :\:\1740 an\DT\6697703 acute\JJ\1740 study\NN\635850 in\IN\13603305 <e2>parkinsonian</e2>\JJ\1740 <e1>levodopa-primed</e1>\JJ\1740 monkeys\NNS\2469914 .\.\1740
D007980_D020734 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 as\IN\14622893 <e1>levodopa</e1>\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
D007980_D020734 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
D007980_D020734 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 <e1>levodopa</e1>\NN\14604959 .\.\1740
D004298_D010300 NONE The\DT\1740 clinical\JJ\1740 utility\NN\8186047 of\IN\1740 <e1>dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 D1\NN\1740 receptor\NN\5225602 agonists\NNS\9613191 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 is\VBZ\836236 still\RB\1740 unclear\JJ\1740 .\.\1740
D004298_D010300 NONE The\DT\1740 clinical\JJ\1740 utility\NN\8186047 of\IN\1740 <e1>dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 D1\NN\1740 receptor\NN\5225602 agonists\NNS\9613191 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 is\VBZ\836236 still\RB\1740 unclear\JJ\1740 .\.\1740
D004298_D010300 NONE The\DT\1740 clinical\JJ\1740 utility\NN\8186047 of\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 D1\NN\1740 receptor\NN\5225602 agonists\NNS\9613191 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 is\VBZ\836236 still\RB\1740 unclear\JJ\1740 .\.\1740
D004298_D010300 NONE The\DT\1740 clinical\JJ\1740 utility\NN\8186047 of\IN\1740 dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 D1\NN\1740 receptor\NN\5225602 agonists\NNS\9613191 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 is\VBZ\836236 still\RB\1740 unclear\JJ\1740 .\.\1740
D004298_D010300 NONE Potent\JJ\1740 <e1>DA</e1>\NN\10484858 D1\NN\1740 receptor\NN\5225602 agents\NNS\7347 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 efficacy\NN\5199286 such\JJ\1740 as\IN\14622893 A-86929\NN\1740 (\-LRB-\1740 approximately\RB\1740 4\CD\13741022 hr\NN\15154774 at\IN\14622893 higher\JJR\1740 doses\NNS\3740161 tested\VBN\670261 )\-RRB-\1740 are\VBP\836236 potential\JJ\1740 therapeutic\JJ\1740 tools\NNS\3563967 in\IN\13603305 <e2>PD</e2>\NN\14625458 and\CC\1740 merit\NN\5138208 further\JJ\1740 attention\NN\5701944 .\.\1740
D015632_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 dyskinetic\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
D015632_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 <e2>dyskinetic</e2>\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
D015632_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 <e1>(MPTP)-exposed</e1>\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 dyskinetic\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
D015632_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 <e1>(MPTP)-exposed</e1>\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 <e2>dyskinetic</e2>\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
D015632_D004409 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 <e1>MPTP-induced</e1>\JJ\1740 parkinsonism\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
D007980_D004409 CID We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 dyskinetic\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
D007980_D004409 CID We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 <e2>dyskinetic</e2>\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
D007980_D004409 CID Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 parkinsonism\NN\14085708 as\IN\14622893 <e1>levodopa</e1>\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
D007980_D004409 CID Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 parkinsonism\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
D007980_D004409 CID Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 parkinsonism\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 <e1>levodopa</e1>\NN\14604959 .\.\1740
C095427_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 dyskinetic\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>A-86929</e1>\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
C095427_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 <e2>dyskinetic</e2>\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>A-86929</e1>\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
C095427_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 dyskinetic\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 <e1>[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
C095427_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 <e2>dyskinetic</e2>\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 <e1>[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 DA\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
C095427_D004409 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>A-86929</e1>\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 parkinsonism\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
D004298_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 dyskinetic\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 <e1>DA</e1>\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
D004298_D004409 NONE We\PRP\1740 therefore\RB\1740 conducted\VBD\2436349 the\DT\1740 present\JJ\1740 acute\JJ\1740 dose-response\JJ\1740 study\NN\635850 in\IN\13603305 four\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\CD\1740 (MPTP)-exposed\VBN\1740 cynomolgus\JJ\1740 monkeys\NNS\2469914 primed\VBN\406243 to\TO\1740 exhibit\VB\2632167 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 to\TO\1740 evaluate\VB\670261 the\DT\1740 locomotor\NN\1740 and\CC\1740 <e2>dyskinetic</e2>\JJ\1740 effects\NNS\13245626 on\IN\1740 challenge\NN\13927383 with\IN\1740 four\CD\13741022 doses\NNS\3740161 (\-LRB-\1740 from\IN\1740 0.03\CD\1740 to\TO\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 of\IN\1740 A-86929\NN\1740 (\-LRB-\1740 [-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+\NN\1740 +\CC\1740 +\CC\1740 azacyclopent-1-\NN\1740 ena[c]phenathrene-9\NN\1740 -\HYPH\1740 10-diol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 full\JJ\1740 <e1>DA</e1>\NN\10484858 D1-like\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 .\.\1740
D015632_D020734 CID Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 <e1>MPTP-induced</e1>\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
C416545_D020734 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 <e1>LY-171555</e1>\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
C416545_D020734 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 <e1>LY-171555</e1>\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
C416545_D004409 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 parkinsonism\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 <e1>LY-171555</e1>\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 LY-171555\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
C416545_D004409 NONE Acute\JJ\1740 administration\NN\1133281 of\IN\1740 A-86929\NN\1740 was\VBD\836236 as\IN\14622893 efficacious\JJ\1740 in\IN\13603305 alleviating\VBG\205885 MPTP-induced\JJ\1740 parkinsonism\NN\14085708 as\IN\14622893 levodopa\NN\14604959 and\CC\1740 LY-171555\NN\1740 ,\,\1740 but\CC\1740 was\VBD\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 reproduce\VB\1621555 the\DT\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 these\DT\1740 animals\NNS\4475 than\IN\1740 with\IN\1740 either\CC\1740 <e1>LY-171555</e1>\NN\1740 or\CC\3541091 subsequent\JJ\1740 challenge\NN\13927383 of\IN\1740 levodopa\NN\14604959 .\.\1740
C095427_D010300 NONE Potent\JJ\1740 DA\NN\10484858 D1\NN\1740 receptor\NN\5225602 agents\NNS\7347 with\IN\1740 an\DT\6697703 intermediate\JJ\1740 duration\NN\15113229 of\IN\1740 efficacy\NN\5199286 such\JJ\1740 as\IN\14622893 <e1>A-86929</e1>\NN\1740 (\-LRB-\1740 approximately\RB\1740 4\CD\13741022 hr\NN\15154774 at\IN\14622893 higher\JJR\1740 doses\NNS\3740161 tested\VBN\670261 )\-RRB-\1740 are\VBP\836236 potential\JJ\1740 therapeutic\JJ\1740 tools\NNS\3563967 in\IN\13603305 <e2>PD</e2>\NN\14625458 and\CC\1740 merit\NN\5138208 further\JJ\1740 attention\NN\5701944 .\.\1740
8305357
D003630_D012514 NONE Liposomal\JJ\1740 <e1>daunorubicin</e1>\NN\1740 in\IN\13603305 advanced\JJ\1740 <e2>Kaposi\NN\1740 's\POS\1740 sarcoma</e2>\NN\14239918 :\:\1740 a\DT\13649268 phase\NN\15113229 II\CD\13741022 study\NN\635850 .\.\1740
D003630_D012514 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 non-randomized\JJ\1740 Phase\NN\15113229 II\CD\13741022 clinical\JJ\1740 trial\NN\786195 to\TO\1740 assess\VB\670261 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 liposomal\JJ\1740 <e1>daunorubicin</e1>\NN\1740 (\-LRB-\1740 DaunoXome\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 AIDS\NN\13974317 related\JJ\1740 <e2>Kaposi\NN\1740 's\POS\1740 sarcoma</e2>\NN\14239918 .\.\1740
D003630_D012514 NONE In\IN\13603305 this\DT\1740 small\JJ\1740 patient\NN\9898892 sample\NN\5820620 ,\,\1740 liposomal\JJ\1740 <e1>daunorubicin</e1>\NN\1740 was\VBD\836236 an\DT\6697703 effective\JJ\1740 and\CC\1740 well\RB\1740 tolerated\VBN\802318 agent\NN\7347 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Kaposi\NN\1740 's\POS\1740 sarcoma</e2>\NN\14239918 .\.\1740
D003630_D000163 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 non-randomized\JJ\1740 Phase\NN\15113229 II\CD\13741022 clinical\JJ\1740 trial\NN\786195 to\TO\1740 assess\VB\670261 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 liposomal\JJ\1740 <e1>daunorubicin</e1>\NN\1740 (\-LRB-\1740 DaunoXome\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>AIDS</e2>\NN\13974317 related\JJ\1740 Kaposi\NN\1740 's\POS\1740 sarcoma\NN\14239918 .\.\1740
15985056
D017963_D006606 CID Possible\JJ\1740 <e1>azithromycin-associated</e1>\JJ\1740 <e2>hiccups</e2>\NNS\863513 .\.\1740
D017963_D006606 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 persistent\JJ\1740 <e2>hiccups</e2>\NNS\863513 associated\VBN\628491 by\IN\1740 <e1>azithromycin</e1>\NN\2716205 therapy\NN\657604 .\.\1740
D017963_D006606 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 presented\VBN\2137132 with\IN\1740 persistent\JJ\1740 <e2>hiccups</e2>\NNS\863513 after\IN\1740 beginning\VBG\941990 <e1>azithromycin</e1>\NN\2716205 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 pharyngitis\NN\14171682 .\.\1740
D017963_D006606 CID Discontinuation\NN\209943 of\IN\1740 <e1>azithromycin</e1>\NN\2716205 and\CC\1740 therapy\NN\657604 with\IN\1740 baclofen\NN\1740 finally\RB\1740 resolved\VBN\352826 <e2>hiccups</e2>\NNS\863513 .\.\1740
D017963_D006606 CID Our\PRP$\1740 hypothesis\NN\7162194 is\VBZ\836236 that\IN\1740 a\DT\13649268 vagal\JJ\1740 mechanism\NN\13446390 mediated\VBN\761713 by\IN\1740 <e1>azithromycin</e1>\NN\2716205 could\MD\1740 be\VB\836236 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e2>hiccups</e2>\NNS\863513 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 .\.\1740
D017963_D010612 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 presented\VBN\2137132 with\IN\1740 persistent\JJ\1740 hiccups\NNS\863513 after\IN\1740 beginning\VBG\941990 <e1>azithromycin</e1>\NN\2716205 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>pharyngitis</e2>\NN\14171682 .\.\1740
D001418_D006606 CID Discontinuation\NN\209943 of\IN\1740 azithromycin\NN\2716205 and\CC\1740 therapy\NN\657604 with\IN\1740 <e1>baclofen</e1>\NN\1740 finally\RB\1740 resolved\VBN\352826 <e2>hiccups</e2>\NNS\863513 .\.\1740
D003907_D006606 NONE Corticosteroids\NNS\14745635 (\-LRB-\1740 <e1>dexamethasone</e1>\NN\2721538 and\CC\1740 methylprednisolone\NN\1740 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 (\-LRB-\1740 midazolam\NNS\2830852 )\-RRB-\1740 and\CC\1740 general\JJ\1740 anaesthesia\NN\14034177 have\VBP\2108377 been\VBN\836236 the\DT\1740 specific\JJ\1740 agents\NNS\7347 mentioned\VBN\730052 most\RBS\1740 frequently\RB\1740 in\IN\13603305 the\DT\1740 literature\NN\6362953 as\IN\14622893 being\VBG\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hiccups</e2>\NNS\863513 .\.\1740
D008775_D006606 NONE Corticosteroids\NNS\14745635 (\-LRB-\1740 dexamethasone\NN\2721538 and\CC\1740 <e1>methylprednisolone</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 (\-LRB-\1740 midazolam\NNS\2830852 )\-RRB-\1740 and\CC\1740 general\JJ\1740 anaesthesia\NN\14034177 have\VBP\2108377 been\VBN\836236 the\DT\1740 specific\JJ\1740 agents\NNS\7347 mentioned\VBN\730052 most\RBS\1740 frequently\RB\1740 in\IN\13603305 the\DT\1740 literature\NN\6362953 as\IN\14622893 being\VBG\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hiccups</e2>\NNS\863513 .\.\1740
D001569_D006606 NONE Corticosteroids\NNS\14745635 (\-LRB-\1740 dexamethasone\NN\2721538 and\CC\1740 methylprednisolone\NN\1740 )\-RRB-\1740 ,\,\1740 <e1>benzodiazepines</e1>\NNS\3771443 (\-LRB-\1740 midazolam\NNS\2830852 )\-RRB-\1740 and\CC\1740 general\JJ\1740 anaesthesia\NN\14034177 have\VBP\2108377 been\VBN\836236 the\DT\1740 specific\JJ\1740 agents\NNS\7347 mentioned\VBN\730052 most\RBS\1740 frequently\RB\1740 in\IN\13603305 the\DT\1740 literature\NN\6362953 as\IN\14622893 being\VBG\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hiccups</e2>\NNS\863513 .\.\1740
D008874_D006606 NONE Corticosteroids\NNS\14745635 (\-LRB-\1740 dexamethasone\NN\2721538 and\CC\1740 methylprednisolone\NN\1740 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 (\-LRB-\1740 <e1>midazolam</e1>\NNS\2830852 )\-RRB-\1740 and\CC\1740 general\JJ\1740 anaesthesia\NN\14034177 have\VBP\2108377 been\VBN\836236 the\DT\1740 specific\JJ\1740 agents\NNS\7347 mentioned\VBN\730052 most\RBS\1740 frequently\RB\1740 in\IN\13603305 the\DT\1740 literature\NN\6362953 as\IN\14622893 being\VBG\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hiccups</e2>\NNS\863513 .\.\1740
D018942_D006606 NONE Few\JJ\1740 cases\NNS\7283608 of\IN\1740 drug-induced\JJ\1740 <e2>hiccups</e2>\NNS\863513 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 related\JJ\1740 to\TO\1740 <e1>macrolide</e1>\NN\1740 antimicrobials\NNS\14778436 .\.\1740
D018942_D006606 NONE Using\VBG\1156834 the\DT\1740 Naranjo\NNP\1740 adverse\JJ\1740 effect\NN\34213 reaction\NN\13446390 probability\NN\33615 scale\NN\7260623 this\DT\1740 event\NN\23100 could\MD\1740 be\VB\836236 classified\VBN\657260 as\IN\14622893 possible\JJ\1740 (\-LRB-\1740 score\NN\5736149 5\CD\13741022 points\NNS\5868954 )\-RRB-\1740 ,\,\1740 mostly\RB\1740 because\IN\1740 of\IN\1740 the\DT\1740 close\JJ\1740 temporal\JJ\1740 sequence\NN\8457976 ,\,\1740 previous\JJ\1740 reports\NNS\6470073 on\IN\1740 this\DT\1740 reaction\NN\13446390 with\IN\1740 other\JJ\1740 <e1>macrolides</e1>\NNS\1740 and\CC\1740 the\DT\1740 absence\NN\14449405 of\IN\1740 any\DT\1740 alternative\JJ\1740 explanation\NN\6722453 for\IN\1740 <e2>hiccups</e2>\NNS\863513 .\.\1740
D018942_D006606 NONE However\RB\1740 ,\,\1740 <e1>macrolide</e1>\NN\1740 antimicrobials\NNS\14778436 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 <e2>hiccups</e2>\NNS\863513 and\CC\1740 vagal\JJ\1740 mechanism\NN\13446390 could\MD\1740 explain\VB\831651 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 side-effect\NN\1740 .\.\1740
6794356
D016651_D014262 NONE <e2>Tricuspid\NN\1740 valve\VBP\1740 regurgitation</e2>\NN\7406350 and\CC\1740 <e1>lithium\NN\14625458 carbonate</e1>\NN\15010703 toxicity\NN\13576101 in\IN\13603305 a\DT\13649268 newborn\JJ\1740 infant\NN\9918248 .\.\1740
D016651_D064420 NONE Tricuspid\NN\1740 valve\VBP\1740 regurgitation\NN\7406350 and\CC\1740 <e1>lithium\NN\14625458 carbonate</e1>\NN\15010703 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 a\DT\13649268 newborn\JJ\1740 infant\NN\9918248 .\.\1740
D008094_D014262 NONE A\DT\13649268 newborn\JJ\1740 with\IN\1740 massive\JJ\1740 <e2>tricuspid\NN\1740 regurgitation</e2>\NN\7406350 ,\,\1740 atrial\JJ\1740 flutter\NN\331950 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 <e1>lithium</e1>\NN\14625458 level\NN\4916342 is\VBZ\836236 described\VBN\1001294 .\.\1740
D008094_D014262 NONE This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 patient\NN\9898892 to\TO\1740 initially\RB\1740 manifest\VB\1015244 <e2>tricuspid\NN\1740 regurgitation</e2>\NN\7406350 and\CC\1740 atrial\JJ\1740 flutter\NN\331950 ,\,\1740 and\CC\1740 the\DT\1740 11th\NN\1740 described\VBN\1001294 patient\NN\9898892 with\IN\1740 cardiac\JJ\1740 disease\NN\14061805 among\IN\1740 infants\NNS\9918248 exposed\VBN\2110927 to\TO\1740 <e1>lithium</e1>\NN\14625458 compounds\NNS\5869584 in\IN\13603305 the\DT\1740 first\JJ\1740 trimester\NN\15113229 of\IN\1740 pregnancy\NN\14034177 .\.\1740
D008094_D001282 NONE A\DT\13649268 newborn\JJ\1740 with\IN\1740 massive\JJ\1740 tricuspid\NN\1740 regurgitation\NN\7406350 ,\,\1740 <e2>atrial\JJ\1740 flutter</e2>\NN\331950 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 <e1>lithium</e1>\NN\14625458 level\NN\4916342 is\VBZ\836236 described\VBN\1001294 .\.\1740
D008094_D001282 NONE This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 patient\NN\9898892 to\TO\1740 initially\RB\1740 manifest\VB\1015244 tricuspid\NN\1740 regurgitation\NN\7406350 and\CC\1740 <e2>atrial\JJ\1740 flutter</e2>\NN\331950 ,\,\1740 and\CC\1740 the\DT\1740 11th\NN\1740 described\VBN\1001294 patient\NN\9898892 with\IN\1740 cardiac\JJ\1740 disease\NN\14061805 among\IN\1740 infants\NNS\9918248 exposed\VBN\2110927 to\TO\1740 <e1>lithium</e1>\NN\14625458 compounds\NNS\5869584 in\IN\13603305 the\DT\1740 first\JJ\1740 trimester\NN\15113229 of\IN\1740 pregnancy\NN\14034177 .\.\1740
D008094_D006333 NONE A\DT\13649268 newborn\JJ\1740 with\IN\1740 massive\JJ\1740 tricuspid\NN\1740 regurgitation\NN\7406350 ,\,\1740 atrial\JJ\1740 flutter\NN\331950 ,\,\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 ,\,\1740 and\CC\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 <e1>lithium</e1>\NN\14625458 level\NN\4916342 is\VBZ\836236 described\VBN\1001294 .\.\1740
D008094_D006331 NONE This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 patient\NN\9898892 to\TO\1740 initially\RB\1740 manifest\VB\1015244 tricuspid\NN\1740 regurgitation\NN\7406350 and\CC\1740 atrial\JJ\1740 flutter\NN\331950 ,\,\1740 and\CC\1740 the\DT\1740 11th\NN\1740 described\VBN\1001294 patient\NN\9898892 with\IN\1740 <e2>cardiac\JJ\1740 disease</e2>\NN\14061805 among\IN\1740 infants\NNS\9918248 exposed\VBN\2110927 to\TO\1740 <e1>lithium</e1>\NN\14625458 compounds\NNS\5869584 in\IN\13603305 the\DT\1740 first\JJ\1740 trimester\NN\15113229 of\IN\1740 pregnancy\NN\14034177 .\.\1740
D016651_D006331 NONE <e1>Lithium\NN\14625458 carbonate</e1>\NN\15010703 may\MD\15209706 be\VB\836236 a\DT\13649268 factor\NN\7326557 in\IN\13603305 the\DT\1740 increasing\VBG\169651 incidence\NN\13821570 of\IN\1740 <e2>congenital\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 when\WRB\1740 taken\VBN\2367363 during\IN\1740 early\JJ\1740 pregnancy\NN\14034177 .\.\1740
11999899
D012110_D009069 NONE <e1>Reserpine</e1>\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 administered\VBN\2436349 once\RB\1740 every\DT\1740 other\JJ\1740 day\NN\15154774 for\IN\1740 4\CD\13741022 days\NNS\15140892 ,\,\1740 produced\VBN\1617192 increases\NNS\13576355 in\IN\13603305 <e2>orofacial\JJ\1740 dyskinesia</e2>\NN\14084880 ,\,\1740 tongue\NN\5301392 protrusion\NN\13919685 and\CC\1740 vacuous\JJ\1740 chewing\NN\199130 in\IN\13603305 mice\NNS\2329401 ,\,\1740 which\WDT\1740 are\VBP\836236 signs\NNS\6643763 indicative\JJ\1740 of\IN\1740 tardive\JJ\1740 dyskinesia\NN\14084880 .\.\1740
D012110_D009069 NONE <e1>Reserpine</e1>\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 administered\VBN\2436349 90\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 and\CC\1740 followed\VBN\1835496 by\IN\1740 apomophine\NN\1740 injection\NN\320852 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 5\CD\13741022 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 <e2>oral\JJ\1740 dyskinesia</e2>\NN\14084880 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012110_D004409 CID <e1>Reserpine</e1>\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 administered\VBN\2436349 once\RB\1740 every\DT\1740 other\JJ\1740 day\NN\15154774 for\IN\1740 4\CD\13741022 days\NNS\15140892 ,\,\1740 produced\VBN\1617192 increases\NNS\13576355 in\IN\13603305 orofacial\JJ\1740 dyskinesia\NN\14084880 ,\,\1740 tongue\NN\5301392 protrusion\NN\13919685 and\CC\1740 vacuous\JJ\1740 chewing\NN\199130 in\IN\13603305 mice\NNS\2329401 ,\,\1740 which\WDT\1740 are\VBP\836236 signs\NNS\6643763 indicative\JJ\1740 of\IN\1740 <e2>tardive\JJ\1740 dyskinesia</e2>\NN\14084880 .\.\1740
D012110_D004409 CID These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 <e1>reserpine</e1>\NN\2721160 produces\VBZ\1617192 different\JJ\1740 and\CC\1740 <e2>abnormal\JJ\1740 movements</e2>\NNS\191142 ,\,\1740 which\WDT\1740 are\VBP\836236 related\JJ\1740 to\TO\1740 dose\NN\3740161 and\CC\1740 schedule\NN\5898568 employed\VBN\1740 and\CC\1740 can\MD\3094503 be\VB\836236 considered\VBN\689344 as\IN\14622893 parkinsonian-like\JJ\1740 and\CC\1740 tardive\JJ\1740 dsykinesia\NN\1740 signs\NNS\6643763 .\.\1740
D012110_D004409 CID These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 <e1>reserpine</e1>\NN\2721160 produces\VBZ\1617192 different\JJ\1740 and\CC\1740 abnormal\JJ\1740 movements\NNS\191142 ,\,\1740 which\WDT\1740 are\VBP\836236 related\JJ\1740 to\TO\1740 dose\NN\3740161 and\CC\1740 schedule\NN\5898568 employed\VBN\1740 and\CC\1740 can\MD\3094503 be\VB\836236 considered\VBN\689344 as\IN\14622893 parkinsonian-like\JJ\1740 and\CC\1740 <e2>tardive\JJ\1740 dsykinesia</e2>\NN\1740 signs\NNS\6643763 .\.\1740
D012110_D014202 CID <e1>Reserpine</e1>\NNP\2721160 also\RB\1740 produced\VBD\1617192 <e2>tremor</e2>\NN\345926 and\CC\1740 catalepsy\NN\14023236 ,\,\1740 which\WDT\1740 are\VBP\836236 signs\NNS\6643763 suggestive\JJ\1740 of\IN\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D012110_D014202 CID However\RB\1740 ,\,\1740 MK-801\NN\1740 injection\NN\320852 produced\VBD\1617192 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 of\IN\1740 <e2>tremor</e2>\NN\345926 in\IN\13603305 <e1>reserpine-treated</e1>\JJ\1740 mice\NNS\2329401 .\.\1740
D012110_D014202 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 <e1>reserpine</e1>\NN\2721160 induced\VBN\1627355 increases\NNS\13576355 in\IN\13603305 <e2>tremor</e2>\NN\345926 and\CC\1740 catalepsy\NN\14023236 compared\VBN\644583 to\TO\1740 control\NN\5190804 mice\NNS\2329401 .\.\1740
D012110_D014202 CID MK-801\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 administration\NN\1133281 attenuated\VBD\224901 the\DT\1740 catalepsy\NN\14023236 and\CC\1740 <e2>tremor</e2>\NN\345926 induced\VBN\1627355 by\IN\1740 <e1>reserpine</e1>\NN\2721160 .\.\1740
D012110_D014202 CID Pretreatment\NN\1740 with\IN\1740 <e1>reserpine</e1>\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 24\CD\13745420 h\NN\14622893 before\IN\1740 the\DT\1740 observation\NN\996969 test\NN\5798043 produced\VBN\1617192 increases\NNS\13576355 in\IN\13603305 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 and\CC\1740 tongue\NN\5301392 protrusion\NN\13919685 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 increases\NNS\13576355 in\IN\13603305 <e2>tremor</e2>\NN\345926 and\CC\1740 catalepsy\NN\14023236 ,\,\1740 whereas\IN\1740 MK-801\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 injection\NN\320852 90\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 reversed\VBD\109660 the\DT\1740 effects\NNS\13245626 of\IN\1740 reserpine\NN\2721160 .\.\1740
D012110_D014202 CID Pretreatment\NN\1740 with\IN\1740 reserpine\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 24\CD\13745420 h\NN\14622893 before\IN\1740 the\DT\1740 observation\NN\996969 test\NN\5798043 produced\VBN\1617192 increases\NNS\13576355 in\IN\13603305 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 and\CC\1740 tongue\NN\5301392 protrusion\NN\13919685 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 increases\NNS\13576355 in\IN\13603305 <e2>tremor</e2>\NN\345926 and\CC\1740 catalepsy\NN\14023236 ,\,\1740 whereas\IN\1740 MK-801\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 injection\NN\320852 90\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 reversed\VBD\109660 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>reserpine</e1>\NN\2721160 .\.\1740
D012110_D002375 CID <e1>Reserpine</e1>\NNP\2721160 also\RB\1740 produced\VBD\1617192 tremor\NN\345926 and\CC\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 which\WDT\1740 are\VBP\836236 signs\NNS\6643763 suggestive\JJ\1740 of\IN\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D012110_D002375 CID MK-801\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 administered\VBD\2436349 30\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 observation\NN\996969 test\NN\5798043 ,\,\1740 prevented\VBD\1740 the\DT\1740 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 ,\,\1740 tongue\NN\5301392 protrusions\NNS\13919685 and\CC\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>reserpine</e1>\NN\2721160 .\.\1740
D012110_D002375 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 <e1>reserpine</e1>\NN\2721160 induced\VBN\1627355 increases\NNS\13576355 in\IN\13603305 tremor\NN\345926 and\CC\1740 <e2>catalepsy</e2>\NN\14023236 compared\VBN\644583 to\TO\1740 control\NN\5190804 mice\NNS\2329401 .\.\1740
D012110_D002375 CID MK-801\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 administration\NN\1133281 attenuated\VBD\224901 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 tremor\NN\345926 induced\VBN\1627355 by\IN\1740 <e1>reserpine</e1>\NN\2721160 .\.\1740
D012110_D002375 CID Pretreatment\NN\1740 with\IN\1740 <e1>reserpine</e1>\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 24\CD\13745420 h\NN\14622893 before\IN\1740 the\DT\1740 observation\NN\996969 test\NN\5798043 produced\VBN\1617192 increases\NNS\13576355 in\IN\13603305 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 and\CC\1740 tongue\NN\5301392 protrusion\NN\13919685 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 increases\NNS\13576355 in\IN\13603305 tremor\NN\345926 and\CC\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 whereas\IN\1740 MK-801\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 injection\NN\320852 90\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 reversed\VBD\109660 the\DT\1740 effects\NNS\13245626 of\IN\1740 reserpine\NN\2721160 .\.\1740
D012110_D002375 CID Pretreatment\NN\1740 with\IN\1740 reserpine\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 24\CD\13745420 h\NN\14622893 before\IN\1740 the\DT\1740 observation\NN\996969 test\NN\5798043 produced\VBN\1617192 increases\NNS\13576355 in\IN\13603305 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 and\CC\1740 tongue\NN\5301392 protrusion\NN\13919685 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 increases\NNS\13576355 in\IN\13603305 tremor\NN\345926 and\CC\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 whereas\IN\1740 MK-801\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 injection\NN\320852 90\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 reversed\VBD\109660 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>reserpine</e1>\NN\2721160 .\.\1740
D012110_D010300 NONE <e1>Reserpine</e1>\NNP\2721160 also\RB\1740 produced\VBD\1617192 tremor\NN\345926 and\CC\1740 catalepsy\NN\14023236 ,\,\1740 which\WDT\1740 are\VBP\836236 signs\NNS\6643763 suggestive\JJ\1740 of\IN\1740 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D012110_D010300 NONE These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 <e1>reserpine</e1>\NN\2721160 produces\VBZ\1617192 different\JJ\1740 and\CC\1740 abnormal\JJ\1740 movements\NNS\191142 ,\,\1740 which\WDT\1740 are\VBP\836236 related\JJ\1740 to\TO\1740 dose\NN\3740161 and\CC\1740 schedule\NN\5898568 employed\VBN\1740 and\CC\1740 can\MD\3094503 be\VB\836236 considered\VBN\689344 as\IN\14622893 <e2>parkinsonian-like</e2>\JJ\1740 and\CC\1740 tardive\JJ\1740 dsykinesia\NN\1740 signs\NNS\6643763 .\.\1740
D016291_D002375 NONE <e1>MK-801</e1>\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 administered\VBD\2436349 30\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 observation\NN\996969 test\NN\5798043 ,\,\1740 prevented\VBD\1740 the\DT\1740 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 ,\,\1740 tongue\NN\5301392 protrusions\NNS\13919685 and\CC\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 reserpine\NN\2721160 .\.\1740
D016291_D002375 NONE <e1>MK-801</e1>\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 administration\NN\1133281 attenuated\VBD\224901 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 tremor\NN\345926 induced\VBN\1627355 by\IN\1740 reserpine\NN\2721160 .\.\1740
D016291_D002375 NONE Pretreatment\NN\1740 with\IN\1740 reserpine\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 24\CD\13745420 h\NN\14622893 before\IN\1740 the\DT\1740 observation\NN\996969 test\NN\5798043 produced\VBN\1617192 increases\NNS\13576355 in\IN\13603305 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 and\CC\1740 tongue\NN\5301392 protrusion\NN\13919685 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 increases\NNS\13576355 in\IN\13603305 tremor\NN\345926 and\CC\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 whereas\IN\1740 <e1>MK-801</e1>\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 injection\NN\320852 90\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 reversed\VBD\109660 the\DT\1740 effects\NNS\13245626 of\IN\1740 reserpine\NN\2721160 .\.\1740
D016291_D014202 NONE However\RB\1740 ,\,\1740 <e1>MK-801</e1>\NN\1740 injection\NN\320852 produced\VBD\1617192 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 of\IN\1740 <e2>tremor</e2>\NN\345926 in\IN\13603305 reserpine-treated\JJ\1740 mice\NNS\2329401 .\.\1740
D016291_D014202 NONE <e1>MK-801</e1>\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 administration\NN\1133281 attenuated\VBD\224901 the\DT\1740 catalepsy\NN\14023236 and\CC\1740 <e2>tremor</e2>\NN\345926 induced\VBN\1627355 by\IN\1740 reserpine\NN\2721160 .\.\1740
D016291_D014202 NONE Pretreatment\NN\1740 with\IN\1740 reserpine\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 24\CD\13745420 h\NN\14622893 before\IN\1740 the\DT\1740 observation\NN\996969 test\NN\5798043 produced\VBN\1617192 increases\NNS\13576355 in\IN\13603305 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 and\CC\1740 tongue\NN\5301392 protrusion\NN\13919685 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 increases\NNS\13576355 in\IN\13603305 <e2>tremor</e2>\NN\345926 and\CC\1740 catalepsy\NN\14023236 ,\,\1740 whereas\IN\1740 <e1>MK-801</e1>\NN\1740 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 injection\NN\320852 90\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 reversed\VBD\109660 the\DT\1740 effects\NNS\13245626 of\IN\1740 reserpine\NN\2721160 .\.\1740
D001058_D009069 NONE Reserpine\NN\2721160 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 administered\VBN\2436349 90\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 and\CC\1740 followed\VBN\1835496 by\IN\1740 <e1>apomophine</e1>\NN\1740 injection\NN\320852 (\-LRB-\1740 0.1\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 5\CD\13741022 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 <e2>oral\JJ\1740 dyskinesia</e2>\NN\14084880 in\IN\13603305 mice\NNS\2329401 .\.\1740
D016202_D002375 NONE The\DT\1740 glutamatergic\JJ\1740 blockage\NN\14034177 produced\VBN\1617192 by\IN\1740 <e1>NMDA</e1>\NN\1740 can\MD\3094503 restore\VB\1631072 these\DT\1740 signs\NNS\6643763 ,\,\1740 such\JJ\1740 as\IN\14622893 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 ,\,\1740 tongue\NN\5301392 protrusions\NNS\13919685 ,\,\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 tremor\NN\345926 according\VBG\2657219 to\IN\1740 the\DT\1740 employed\VBN\1740 model\NN\5888929 .\.\1740
D016202_D014202 NONE The\DT\1740 glutamatergic\JJ\1740 blockage\NN\14034177 produced\VBN\1617192 by\IN\1740 <e1>NMDA</e1>\NN\1740 can\MD\3094503 restore\VB\1631072 these\DT\1740 signs\NNS\6643763 ,\,\1740 such\JJ\1740 as\IN\14622893 vacuous\JJ\1740 chewing\NN\199130 movements\NNS\191142 ,\,\1740 tongue\NN\5301392 protrusions\NNS\13919685 ,\,\1740 catalepsy\NN\14023236 and\CC\1740 <e2>tremor</e2>\NN\345926 according\VBG\2657219 to\IN\1740 the\DT\1740 employed\VBN\1740 model\NN\5888929 .\.\1740
9205462
D013629_C537296 CID <e2>Granulosa\NN\1740 cell\NN\3080309 tumor\NN\14234074 of\IN\1740 the\DT\1740 ovary</e2>\NN\11675842 associated\VBN\628491 with\IN\1740 antecedent\JJ\1740 <e1>tamoxifen</e1>\NN\2714883 use\NN\407535 .\.\1740
D013629_D009369 NONE Review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 reveals\VBZ\2137132 an\DT\6697703 association\NN\8008335 between\IN\1740 <e1>tamoxifen</e1>\NN\2714883 use\NN\407535 and\CC\1740 gynecologic\JJ\1740 <e2>tumors</e2>\NNS\14234074 .\.\1740
D013629_D001943 NONE CASE\NN\7283608 :\:\1740 A\DT\13649268 52-year-old\JJ\1740 postmenopausal\JJ\1740 woman\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>tamoxifen</e1>\NN\2714883 for\IN\1740 stage\NN\15113229 II\CD\13741022 estrogen\NN\14745635 receptor-positive\JJ\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D004967_D001943 NONE CASE\NN\7283608 :\:\1740 A\DT\13649268 52-year-old\JJ\1740 postmenopausal\JJ\1740 woman\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 tamoxifen\NN\2714883 for\IN\1740 stage\NN\15113229 II\CD\13741022 <e1>estrogen</e1>\NN\14745635 receptor-positive\JJ\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D013629_D017093 CID CONCLUSION\NN\5837957 :\:\1740 Patients\NNS\9898892 with\IN\1740 <e1>tamoxifen-induced</e1>\JJ\1740 <e2>liver\NN\5298729 dysfunction</e2>\NN\14204950 may\MD\15209706 be\VB\836236 at\IN\14622893 increased\VBN\169651 risk\NN\14541044 for\IN\1740 granulosa\NN\1740 cell\NN\3080309 tumors\NNS\14234074 because\IN\1740 of\IN\1740 alterations\NNS\7283608 in\IN\13603305 tamoxifen\NN\2714883 metabolism\NN\13526110 .\.\1740
D013629_D017093 CID CONCLUSION\NN\5837957 :\:\1740 Patients\NNS\9898892 with\IN\1740 tamoxifen-induced\JJ\1740 <e2>liver\NN\5298729 dysfunction</e2>\NN\14204950 may\MD\15209706 be\VB\836236 at\IN\14622893 increased\VBN\169651 risk\NN\14541044 for\IN\1740 granulosa\NN\1740 cell\NN\3080309 tumors\NNS\14234074 because\IN\1740 of\IN\1740 alterations\NNS\7283608 in\IN\13603305 <e1>tamoxifen</e1>\NN\2714883 metabolism\NN\13526110 .\.\1740
D013629_D006106 NONE CONCLUSION\NN\5837957 :\:\1740 Patients\NNS\9898892 with\IN\1740 <e1>tamoxifen-induced</e1>\JJ\1740 liver\NN\5298729 dysfunction\NN\14204950 may\MD\15209706 be\VB\836236 at\IN\14622893 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>granulosa\NN\1740 cell\NN\3080309 tumors</e2>\NNS\14234074 because\IN\1740 of\IN\1740 alterations\NNS\7283608 in\IN\13603305 tamoxifen\NN\2714883 metabolism\NN\13526110 .\.\1740
D013629_D006106 NONE CONCLUSION\NN\5837957 :\:\1740 Patients\NNS\9898892 with\IN\1740 tamoxifen-induced\JJ\1740 liver\NN\5298729 dysfunction\NN\14204950 may\MD\15209706 be\VB\836236 at\IN\14622893 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>granulosa\NN\1740 cell\NN\3080309 tumors</e2>\NNS\14234074 because\IN\1740 of\IN\1740 alterations\NNS\7283608 in\IN\13603305 <e1>tamoxifen</e1>\NN\2714883 metabolism\NN\13526110 .\.\1740
19105845
D016642_D012640 CID Effect\NN\34213 of\IN\1740 increasing\VBG\169651 intraperitoneal\JJ\1740 infusion\NN\14589223 rates\NNS\13308999 on\IN\1740 <e1>bupropion\NN\1740 hydrochloride-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 .\.\1740
D016642_D012640 CID BACKGROUND\NN\4921011 :\:\1740 It\PRP\6125041 is\VBZ\836236 not\RB\1740 known\VBN\2110220 if\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 input\NN\6791372 rate\NN\13815152 and\CC\1740 incidence\NN\13821570 of\IN\1740 <e1>bupropion-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D016642_D012640 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 investigated\VBD\644583 the\DT\1740 effect\NN\34213 of\IN\1740 varying\VBG\2666239 the\DT\1740 intraperitoneal\JJ\1740 infusion\NN\14589223 rates\NNS\13308999 of\IN\1740 <e1>bupropion\NN\1740 HCl</e1>\NN\1740 120\CD\13745420 mg/kg\NN\1740 ,\,\1740 a\DT\13649268 known\JJ\1740 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 50\CD\13745420 (\-LRB-\1740 CD50\NN\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 bupropion-induced\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 the\DT\1740 Swiss\JJ\1740 albino\NN\9606527 mice\NNS\2329401 .\.\1740
D016642_D012640 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 investigated\VBD\644583 the\DT\1740 effect\NN\34213 of\IN\1740 varying\VBG\2666239 the\DT\1740 intraperitoneal\JJ\1740 infusion\NN\14589223 rates\NNS\13308999 of\IN\1740 <e1>bupropion\NN\1740 HCl</e1>\NN\1740 120\CD\13745420 mg/kg\NN\1740 ,\,\1740 a\DT\13649268 known\JJ\1740 convulsive\JJ\1740 dose\NN\3740161 50\CD\13745420 (\-LRB-\1740 CD50\NN\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 bupropion-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 in\IN\13603305 the\DT\1740 Swiss\JJ\1740 albino\NN\9606527 mice\NNS\2329401 .\.\1740
D016642_D012640 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 investigated\VBD\644583 the\DT\1740 effect\NN\34213 of\IN\1740 varying\VBG\2666239 the\DT\1740 intraperitoneal\JJ\1740 infusion\NN\14589223 rates\NNS\13308999 of\IN\1740 bupropion\NN\1740 HCl\NN\1740 120\CD\13745420 mg/kg\NN\1740 ,\,\1740 a\DT\13649268 known\JJ\1740 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 50\CD\13745420 (\-LRB-\1740 CD50\NN\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e1>bupropion-induced</e1>\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 the\DT\1740 Swiss\JJ\1740 albino\NN\9606527 mice\NNS\2329401 .\.\1740
D016642_D012640 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 investigated\VBD\644583 the\DT\1740 effect\NN\34213 of\IN\1740 varying\VBG\2666239 the\DT\1740 intraperitoneal\JJ\1740 infusion\NN\14589223 rates\NNS\13308999 of\IN\1740 bupropion\NN\1740 HCl\NN\1740 120\CD\13745420 mg/kg\NN\1740 ,\,\1740 a\DT\13649268 known\JJ\1740 convulsive\JJ\1740 dose\NN\3740161 50\CD\13745420 (\-LRB-\1740 CD50\NN\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e1>bupropion-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 in\IN\13603305 the\DT\1740 Swiss\JJ\1740 albino\NN\9606527 mice\NNS\2329401 .\.\1740
D016642_D012640 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 results\NNS\34213 showed\VBD\2137132 that\IN\1740 IP\NN\5999797 administration\NN\1133281 of\IN\1740 <e1>bupropion\NN\1740 HCl</e1>\NN\1740 120\CD\13745420 mg/kg\NN\1740 by\IN\1740 bolus\NN\13899404 injection\NN\320852 induced\VBD\1627355 <e2>convulsions</e2>\NNS\14081375 in\IN\13603305 6\CD\13741022 out\IN\66636 of\IN\1740 10\CD\13745420 mice\NNS\2329401 (\-LRB-\1740 60\CD\13745420 %\NN\1740 of\IN\1740 convulsing\NN\1740 mice\NNS\2329401 )\-RRB-\1740 in\IN\13603305 group\NN\2137 1\CD\13741022 .\.\1740
D016642_D012640 CID Logistic\JJ\1740 regression\NN\14501726 analysis\NN\633864 revealed\VBD\2137132 that\IN\1740 infusion\NN\14589223 time\NN\7308889 was\VBD\836236 significant\JJ\1740 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.0004\CD\1740 ;\:\1740 odds\VBZ\1740 ratio\NN\13815152 =\JJ\1740 0.974\CD\1740 )\-RRB-\1740 and\CC\1740 increasing\VBG\169651 the\DT\1740 IP\NN\5999797 infusion\NN\14589223 time\NN\7308889 of\IN\1740 <e1>bupropion\NN\1740 HCl</e1>\NN\1740 120\CD\13745420 mg/kg\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 91\CD\1740 %\NN\1740 reduced\VBN\441445 odds\NNS\4756635 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 at\IN\14622893 infusion\NN\14589223 times\NNS\15113229 of\IN\1740 15\CD\13745420 to\TO\1740 90\CD\13745420 min\NN\15154774 compared\VBN\644583 to\TO\1740 bolus\NN\13899404 injection\NN\320852 .\.\1740
D016642_D012640 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 demonstration\NN\520257 of\IN\1740 an\DT\6697703 inverse\JJ\1740 relationship\NN\31921 between\IN\1740 infusion\NN\14589223 time\NN\7308889 of\IN\1740 a\DT\13649268 fixed\VBN\205885 and\CC\1740 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>bupropion</e1>\NN\1740 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 convulsions\NNS\14081375 in\IN\13603305 a\DT\13649268 prospective\JJ\1740 study\NN\635850 is\VBZ\836236 novel\JJ\1740 .\.\1740
D016642_D012640 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 demonstration\NN\520257 of\IN\1740 an\DT\6697703 inverse\JJ\1740 relationship\NN\31921 between\IN\1740 infusion\NN\14589223 time\NN\7308889 of\IN\1740 a\DT\13649268 fixed\VBN\205885 and\CC\1740 convulsive\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>bupropion</e1>\NN\1740 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 in\IN\13603305 a\DT\13649268 prospective\JJ\1740 study\NN\635850 is\VBZ\836236 novel\JJ\1740 .\.\1740
9067481
C013440_D056486 NONE In\IN\13603305 addition\NN\3081021 to\IN\1740 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 stabilizer/rigidifier\NN\1740 of\IN\1740 membranes\NNS\4188643 ,\,\1740 <e1>cholesteryl\NN\1740 hemisuccinate</e1>\NN\1740 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CS\NN\14625458 )\-RRB-\1740 administration\NN\1133281 has\VBZ\2108377 also\RB\1740 been\VBN\836236 shown\VBN\2137132 to\TO\1740 protect\VB\1127795 rats\NNS\2329401 from\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 (\-LRB-\1740 CCl4\NN\1740 )\-RRB-\1740 .\.\1740
-1_D056486 NONE In\IN\13603305 addition\NN\3081021 to\IN\1740 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 stabilizer/rigidifier\NN\1740 of\IN\1740 membranes\NNS\4188643 ,\,\1740 cholesteryl\NN\1740 hemisuccinate\NN\1740 ,\,\1740 <e1>tris\NN\1740 salt</e1>\NN\14818238 (\-LRB-\1740 CS\NN\14625458 )\-RRB-\1740 administration\NN\1133281 has\VBZ\2108377 also\RB\1740 been\VBN\836236 shown\VBN\2137132 to\TO\1740 protect\VB\1127795 rats\NNS\2329401 from\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 (\-LRB-\1740 CCl4\NN\1740 )\-RRB-\1740 .\.\1740
-1_D056486 NONE In\IN\13603305 addition\NN\3081021 to\IN\1740 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 stabilizer/rigidifier\NN\1740 of\IN\1740 membranes\NNS\4188643 ,\,\1740 cholesteryl\NN\1740 hemisuccinate\NN\1740 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 <e1>CS</e1>\NN\14625458 )\-RRB-\1740 administration\NN\1133281 has\VBZ\2108377 also\RB\1740 been\VBN\836236 shown\VBN\2137132 to\TO\1740 protect\VB\1127795 rats\NNS\2329401 from\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 (\-LRB-\1740 CCl4\NN\1740 )\-RRB-\1740 .\.\1740
-1_D056486 NONE A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>CS</e1>\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 cardiotoxic\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
-1_D056486 NONE The\DT\1740 mechanism\NN\13446390 of\IN\1740 <e1>CS</e1>\NN\14625458 protection\NN\407535 does\VBZ\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 be\VB\836236 dependent\JJ\1740 on\IN\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 chemical\JJ\1740 bioactivation\NN\1740 to\TO\1740 a\DT\13649268 toxic\JJ\1740 reactive\JJ\1740 intermediate\NN\14806838 (\-LRB-\1740 in\IN\13603305 light\NN\11421401 of\IN\1740 the\DT\1740 protection\NN\407535 observed\VBN\2163746 against\IN\1740 galactosamine\NN\1740 <e2>hepatotoxicity</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D002251_D056486 CID In\IN\13603305 addition\NN\3081021 to\IN\1740 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 stabilizer/rigidifier\NN\1740 of\IN\1740 membranes\NNS\4188643 ,\,\1740 cholesteryl\NN\1740 hemisuccinate\NN\1740 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CS\NN\14625458 )\-RRB-\1740 administration\NN\1133281 has\VBZ\2108377 also\RB\1740 been\VBN\836236 shown\VBN\2137132 to\TO\1740 protect\VB\1127795 rats\NNS\2329401 from\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 (\-LRB-\1740 CCl4\NN\1740 )\-RRB-\1740 .\.\1740
D002251_D056486 CID In\IN\13603305 addition\NN\3081021 to\IN\1740 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 stabilizer/rigidifier\NN\1740 of\IN\1740 membranes\NNS\4188643 ,\,\1740 cholesteryl\NN\1740 hemisuccinate\NN\1740 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CS\NN\14625458 )\-RRB-\1740 administration\NN\1133281 has\VBZ\2108377 also\RB\1740 been\VBN\836236 shown\VBN\2137132 to\TO\1740 protect\VB\1127795 rats\NNS\2329401 from\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 (\-LRB-\1740 <e1>CCl4</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D002251_D056486 CID A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>CCl4</e1>\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 cardiotoxic\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
-1_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 <e1>CS</e1>\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
-1_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 <e1>CS</e1>\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
-1_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 <e1>CS</e1>\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
-1_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 <e1>tris\NN\1740 salt</e1>\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
-1_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 <e1>CSE</e1>\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
C103872_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 <e1>gamma-cholesteryloxybutyric\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D000082_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 <e1>acetaminophen-</e1>\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D004317_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 <e1>adriamycin-</e1>\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002251_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 <e1>carbon\NN\14622893 tetrachloride-</e1>\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002725_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 <e1>chloroform-</e1>\NN\1740 and\CC\1740 galactosamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D005688_D064420 NONE To\TO\1740 further\RB\1740 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 cytoprotection\NN\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\VBZ\1740 the\DT\1740 protective\JJ\1740 abilities\NNS\4723816 of\IN\1740 CS\NN\14625458 and\CC\1740 the\DT\1740 non-hydrolyzable\JJ\1740 ether\JJ\1740 form\NN\6286395 of\IN\1740 CS\NN\14625458 ,\,\1740 gamma-cholesteryloxybutyric\JJ\1740 acid\NN\14818238 ,\,\1740 tris\NN\1740 salt\NN\14818238 (\-LRB-\1740 CSE\NN\8342039 )\-RRB-\1740 against\IN\1740 acetaminophen-\NN\1740 ,\,\1740 adriamycin-\UH\1740 ,\,\1740 carbon\NN\14622893 tetrachloride-\NN\1740 ,\,\1740 chloroform-\NN\1740 and\CC\1740 <e1>galactosamine-induced</e1>\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
-1_D066126 NONE A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>CS</e1>\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 hepatotoxic\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 <e2>cardiotoxic</e2>\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
D002251_D066126 NONE A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 hepatotoxic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>CCl4</e1>\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 <e2>cardiotoxic</e2>\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
D002725_D056486 CID A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 <e1>CHCl3</e1>\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 cardiotoxic\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
D002725_D066126 NONE A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 hepatotoxic\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 <e1>CHCl3</e1>\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 <e2>cardiotoxic</e2>\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
D000082_D056486 CID A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 cardiotoxic\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
D000082_D066126 NONE A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 hepatotoxic\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 <e2>cardiotoxic</e2>\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
D005688_D056486 CID A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 <e1>galactosamine</e1>\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 cardiotoxic\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
D005688_D056486 CID The\DT\1740 mechanism\NN\13446390 of\IN\1740 CS\NN\14625458 protection\NN\407535 does\VBZ\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 be\VB\836236 dependent\JJ\1740 on\IN\1740 the\DT\1740 inhibition\NN\1068773 of\IN\1740 chemical\JJ\1740 bioactivation\NN\1740 to\TO\1740 a\DT\13649268 toxic\JJ\1740 reactive\JJ\1740 intermediate\NN\14806838 (\-LRB-\1740 in\IN\13603305 light\NN\11421401 of\IN\1740 the\DT\1740 protection\NN\407535 observed\VBN\2163746 against\IN\1740 <e1>galactosamine</e1>\NN\1740 <e2>hepatotoxicity</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D005688_D066126 NONE A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 hepatotoxic\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 <e1>galactosamine</e1>\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 <e2>cardiotoxic</e2>\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 adriamycin\NN\1740 administration\NN\1133281 .\.\1740
D004317_D056486 NONE A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 cardiotoxic\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 <e1>adriamycin</e1>\NN\1740 administration\NN\1133281 .\.\1740
D004317_D066126 CID A\DT\13649268 24-h\JJ\1740 pretreatment\NN\1740 of\IN\1740 both\DT\1740 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 CS\NN\14625458 (\-LRB-\1740 100mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 protection\NN\407535 against\IN\1740 the\DT\1740 hepatotoxic\JJ\1740 effects\NNS\13245626 of\IN\1740 CCl4\NN\1740 ,\,\1740 CHCl3\NN\1740 ,\,\1740 acetaminophen\NN\2707683 and\CC\1740 galactosamine\NN\1740 and\CC\1740 against\IN\1740 the\DT\1740 lethal\NN\1740 (\-LRB-\1740 and\CC\1740 presumably\RB\1740 <e2>cardiotoxic</e2>\JJ\1740 )\-RRB-\1740 effect\NN\34213 of\IN\1740 <e1>adriamycin</e1>\NN\1740 administration\NN\1133281 .\.\1740
2422478
D012701_D007022 NONE Midline\JJ\1740 B3\NN\1740 <e1>serotonin</e1>\NN\14807737 nerves\NNS\14373582 in\IN\13603305 rat\NN\2329401 medulla\NN\14864360 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 methyldopa\NN\2721160 .\.\1740
D012701_D007022 NONE Previous\JJ\1740 experiments\NNS\641820 in\IN\13603305 this\DT\1740 laboratory\NN\4602044 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 onto\IN\1740 the\DT\1740 ventrolateral\JJ\1740 cells\NNS\3080309 of\IN\1740 the\DT\1740 B3\NN\1740 <e1>serotonin</e1>\NN\14807737 neurons\NNS\5430628 in\IN\13603305 the\DT\1740 medulla\NN\14864360 elicits\VBZ\1617192 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 mediated\VBN\761713 by\IN\1740 a\DT\13649268 projection\NN\5775081 descending\VBG\1835496 into\IN\1740 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 .\.\1740
D012701_D007022 NONE In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 <e1>serotonin</e1>\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 <e2>hypotension</e2>\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D012701_D007022 NONE In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 <e2>hypotension</e2>\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 <e1>serotonin</e1>\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D012701_D007022 NONE However\RB\1740 ,\,\1740 intraspinal\JJ\1740 injection\NN\320852 of\IN\1740 5,7-DHT\CD\1740 to\TO\1740 produce\VB\1617192 a\DT\13649268 more\RBR\1740 selective\JJ\1740 lesion\NN\14204950 of\IN\1740 only\RB\1740 descending\VBG\1835496 <e1>serotonin</e1>\NN\14807737 projections\NNS\5775081 in\IN\13603305 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 did\VBD\1640855 not\RB\1740 affect\VB\126264 this\DT\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D012701_D007022 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 therefore\RB\1740 that\IN\1740 ,\,\1740 unlike\IN\1740 the\DT\1740 ventrolateral\JJ\1740 B3\NN\1740 cells\NNS\3080309 which\WDT\1740 mediate\VBP\761713 a\DT\13649268 methyldopa-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 via\IN\1740 descending\VBG\1835496 projections\NNS\5775081 ,\,\1740 the\DT\1740 midline\NN\13861050 <e1>serotonin</e1>\NN\14807737 B3\NN\1740 cells\NNS\3080309 in\IN\13603305 the\DT\1740 medulla\NN\14864360 contribute\VBP\126264 to\TO\1740 the\DT\1740 hypotensive\JJ\1740 action\NN\30358 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 either\CC\1740 by\IN\1740 way\NN\4916342 of\IN\1740 an\DT\6697703 ascending\NN\279835 projection\NN\5775081 which\WDT\1740 does\VBZ\1640855 not\RB\1740 pass\VB\1835496 through\IN\1740 the\DT\1740 median\JJ\1740 forebrain\NN\5462674 bundle\NN\7951464 ,\,\1740 or\CC\3541091 through\IN\1740 a\DT\13649268 projection\NN\5775081 restricted\JJ\1740 to\TO\1740 the\DT\1740 caudal\JJ\1740 brainstem\NN\5462674 .\.\1740
D012701_D007022 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 therefore\RB\1740 that\IN\1740 ,\,\1740 unlike\IN\1740 the\DT\1740 ventrolateral\JJ\1740 B3\NN\1740 cells\NNS\3080309 which\WDT\1740 mediate\VBP\761713 a\DT\13649268 methyldopa-induced\JJ\1740 hypotension\NN\14057371 via\IN\1740 descending\VBG\1835496 projections\NNS\5775081 ,\,\1740 the\DT\1740 midline\NN\13861050 <e1>serotonin</e1>\NN\14807737 B3\NN\1740 cells\NNS\3080309 in\IN\13603305 the\DT\1740 medulla\NN\14864360 contribute\VBP\126264 to\TO\1740 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 action\NN\30358 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 either\CC\1740 by\IN\1740 way\NN\4916342 of\IN\1740 an\DT\6697703 ascending\NN\279835 projection\NN\5775081 which\WDT\1740 does\VBZ\1640855 not\RB\1740 pass\VB\1835496 through\IN\1740 the\DT\1740 median\JJ\1740 forebrain\NN\5462674 bundle\NN\7951464 ,\,\1740 or\CC\3541091 through\IN\1740 a\DT\13649268 projection\NN\5775081 restricted\JJ\1740 to\TO\1740 the\DT\1740 caudal\JJ\1740 brainstem\NN\5462674 .\.\1740
D008750_D007022 CID Midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 nerves\NNS\14373582 in\IN\13603305 rat\NN\2329401 medulla\NN\14864360 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>methyldopa</e1>\NN\2721160 .\.\1740
D008750_D007022 CID Previous\JJ\1740 experiments\NNS\641820 in\IN\13603305 this\DT\1740 laboratory\NN\4602044 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 microinjection\NN\1740 of\IN\1740 <e1>methyldopa</e1>\NN\2721160 onto\IN\1740 the\DT\1740 ventrolateral\JJ\1740 cells\NNS\3080309 of\IN\1740 the\DT\1740 B3\NN\1740 serotonin\NN\14807737 neurons\NNS\5430628 in\IN\13603305 the\DT\1740 medulla\NN\14864360 elicits\VBZ\1617192 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 mediated\VBN\761713 by\IN\1740 a\DT\13649268 projection\NN\5775081 descending\VBG\1835496 into\IN\1740 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 .\.\1740
D008750_D007022 CID In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 <e1>methyldopa</e1>\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 <e2>hypotension</e2>\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D008750_D007022 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 therefore\RB\1740 that\IN\1740 ,\,\1740 unlike\IN\1740 the\DT\1740 ventrolateral\JJ\1740 B3\NN\1740 cells\NNS\3080309 which\WDT\1740 mediate\VBP\761713 a\DT\13649268 <e1>methyldopa-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 via\IN\1740 descending\VBG\1835496 projections\NNS\5775081 ,\,\1740 the\DT\1740 midline\NN\13861050 serotonin\NN\14807737 B3\NN\1740 cells\NNS\3080309 in\IN\13603305 the\DT\1740 medulla\NN\14864360 contribute\VBP\126264 to\TO\1740 the\DT\1740 hypotensive\JJ\1740 action\NN\30358 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 either\CC\1740 by\IN\1740 way\NN\4916342 of\IN\1740 an\DT\6697703 ascending\NN\279835 projection\NN\5775081 which\WDT\1740 does\VBZ\1640855 not\RB\1740 pass\VB\1835496 through\IN\1740 the\DT\1740 median\JJ\1740 forebrain\NN\5462674 bundle\NN\7951464 ,\,\1740 or\CC\3541091 through\IN\1740 a\DT\13649268 projection\NN\5775081 restricted\JJ\1740 to\TO\1740 the\DT\1740 caudal\JJ\1740 brainstem\NN\5462674 .\.\1740
D008750_D007022 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 therefore\RB\1740 that\IN\1740 ,\,\1740 unlike\IN\1740 the\DT\1740 ventrolateral\JJ\1740 B3\NN\1740 cells\NNS\3080309 which\WDT\1740 mediate\VBP\761713 a\DT\13649268 <e1>methyldopa-induced</e1>\JJ\1740 hypotension\NN\14057371 via\IN\1740 descending\VBG\1835496 projections\NNS\5775081 ,\,\1740 the\DT\1740 midline\NN\13861050 serotonin\NN\14807737 B3\NN\1740 cells\NNS\3080309 in\IN\13603305 the\DT\1740 medulla\NN\14864360 contribute\VBP\126264 to\TO\1740 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 action\NN\30358 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 either\CC\1740 by\IN\1740 way\NN\4916342 of\IN\1740 an\DT\6697703 ascending\NN\279835 projection\NN\5775081 which\WDT\1740 does\VBZ\1640855 not\RB\1740 pass\VB\1835496 through\IN\1740 the\DT\1740 median\JJ\1740 forebrain\NN\5462674 bundle\NN\7951464 ,\,\1740 or\CC\3541091 through\IN\1740 a\DT\13649268 projection\NN\5775081 restricted\JJ\1740 to\TO\1740 the\DT\1740 caudal\JJ\1740 brainstem\NN\5462674 .\.\1740
D008750_D007022 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 therefore\RB\1740 that\IN\1740 ,\,\1740 unlike\IN\1740 the\DT\1740 ventrolateral\JJ\1740 B3\NN\1740 cells\NNS\3080309 which\WDT\1740 mediate\VBP\761713 a\DT\13649268 methyldopa-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 via\IN\1740 descending\VBG\1835496 projections\NNS\5775081 ,\,\1740 the\DT\1740 midline\NN\13861050 serotonin\NN\14807737 B3\NN\1740 cells\NNS\3080309 in\IN\13603305 the\DT\1740 medulla\NN\14864360 contribute\VBP\126264 to\TO\1740 the\DT\1740 hypotensive\JJ\1740 action\NN\30358 of\IN\1740 <e1>methyldopa</e1>\NN\2721160 ,\,\1740 either\CC\1740 by\IN\1740 way\NN\4916342 of\IN\1740 an\DT\6697703 ascending\NN\279835 projection\NN\5775081 which\WDT\1740 does\VBZ\1640855 not\RB\1740 pass\VB\1835496 through\IN\1740 the\DT\1740 median\JJ\1740 forebrain\NN\5462674 bundle\NN\7951464 ,\,\1740 or\CC\3541091 through\IN\1740 a\DT\13649268 projection\NN\5775081 restricted\JJ\1740 to\TO\1740 the\DT\1740 caudal\JJ\1740 brainstem\NN\5462674 .\.\1740
D008750_D007022 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 therefore\RB\1740 that\IN\1740 ,\,\1740 unlike\IN\1740 the\DT\1740 ventrolateral\JJ\1740 B3\NN\1740 cells\NNS\3080309 which\WDT\1740 mediate\VBP\761713 a\DT\13649268 methyldopa-induced\JJ\1740 hypotension\NN\14057371 via\IN\1740 descending\VBG\1835496 projections\NNS\5775081 ,\,\1740 the\DT\1740 midline\NN\13861050 serotonin\NN\14807737 B3\NN\1740 cells\NNS\3080309 in\IN\13603305 the\DT\1740 medulla\NN\14864360 contribute\VBP\126264 to\TO\1740 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 action\NN\30358 of\IN\1740 <e1>methyldopa</e1>\NN\2721160 ,\,\1740 either\CC\1740 by\IN\1740 way\NN\4916342 of\IN\1740 an\DT\6697703 ascending\NN\279835 projection\NN\5775081 which\WDT\1740 does\VBZ\1640855 not\RB\1740 pass\VB\1835496 through\IN\1740 the\DT\1740 median\JJ\1740 forebrain\NN\5462674 bundle\NN\7951464 ,\,\1740 or\CC\3541091 through\IN\1740 a\DT\13649268 projection\NN\5775081 restricted\JJ\1740 to\TO\1740 the\DT\1740 caudal\JJ\1740 brainstem\NN\5462674 .\.\1740
D008750_D006973 NONE In\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 <e1>methyldopa</e1>\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D008750_D020521 NONE In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 <e2>stroke-prone</e2>\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 <e1>methyldopa</e1>\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D012701_D006973 NONE In\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 <e1>serotonin</e1>\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D012701_D006973 NONE In\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 <e1>serotonin</e1>\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D012701_D020521 NONE In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 <e2>stroke-prone</e2>\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 <e1>serotonin</e1>\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D012701_D020521 NONE In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 <e2>stroke-prone</e2>\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 <e1>serotonin</e1>\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D015116_D006973 NONE In\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 <e1>5,7-dihydroxytryptamine</e1>\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D015116_D006973 NONE In\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 <e1>5,7-DHT</e1>\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D015116_D020521 NONE In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 <e2>stroke-prone</e2>\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 <e1>5,7-dihydroxytryptamine</e1>\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D015116_D020521 NONE In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 <e2>stroke-prone</e2>\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 hypotension\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 <e1>5,7-DHT</e1>\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D015116_D007022 NONE In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 <e2>hypotension</e2>\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 <e1>5,7-dihydroxytryptamine</e1>\NN\1740 (\-LRB-\1740 5,7-DHT\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D015116_D007022 NONE In\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 ,\,\1740 stroke-prone\JJ\1740 rats\NNS\2329401 ,\,\1740 microinjection\NN\1740 of\IN\1740 methyldopa\NN\2721160 into\IN\1740 the\DT\1740 area\NN\8630985 of\IN\1740 the\DT\1740 midline\JJ\1740 B3\NN\1740 serotonin\NN\14807737 cell\NN\3080309 group\NN\2137 in\IN\13603305 the\DT\1740 ventral\JJ\1740 medulla\NN\14864360 caused\VBD\1617192 a\DT\13649268 potent\JJ\1740 <e2>hypotension</e2>\NN\14057371 of\IN\1740 30\CD\13745420 -\SYM\1740 40\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 which\WDT\1740 was\VBD\836236 maximal\JJ\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 the\DT\1740 serotonin\NN\14807737 neurotoxin\NN\15034074 5,7-dihydroxytryptamine\NN\1740 (\-LRB-\1740 <e1>5,7-DHT</e1>\CD\1740 )\-RRB-\1740 injected\VBN\81072 intracerebroventricularly\RB\1740 .\.\1740
D015116_D007022 NONE However\RB\1740 ,\,\1740 intraspinal\JJ\1740 injection\NN\320852 of\IN\1740 <e1>5,7-DHT</e1>\CD\1740 to\TO\1740 produce\VB\1617192 a\DT\13649268 more\RBR\1740 selective\JJ\1740 lesion\NN\14204950 of\IN\1740 only\RB\1740 descending\VBG\1835496 serotonin\NN\14807737 projections\NNS\5775081 in\IN\13603305 the\DT\1740 spinal\JJ\1740 cord\NN\3670849 did\VBD\1640855 not\RB\1740 affect\VB\126264 this\DT\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
7421734
D004967_D010049 NONE She\PRP\1740 had\VBD\2108377 <e2>ovarian\JJ\1740 failure</e2>\NN\66216 after\IN\1740 abdominal\JJ\1740 irradiation\NN\13920835 and\CC\1740 chemotherapy\NN\661091 for\IN\1740 Hodgkin\NN\1740 disease\NN\14061805 ,\,\1740 and\CC\1740 received\VBD\2210855 exogenous\JJ\1740 <e1>estrogens</e1>\NNS\14745635 ,\,\1740 a\DT\13649268 treatment\NN\654885 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 endometrial\JJ\1740 cancer\NN\14239425 in\IN\13603305 menopausal\JJ\1740 women\NNS\9605289 .\.\1740
D004967_D010049 NONE Young\JJ\1740 women\NNS\9605289 on\IN\1740 replacement\NN\196485 <e1>estrogens</e1>\NNS\14745635 for\IN\1740 <e2>ovarian\JJ\1740 failure</e2>\NN\66216 after\IN\1740 cancer\NN\14239425 therapy\NN\657604 may\MD\15209706 also\RB\1740 have\VB\2108377 increased\VBN\169651 risk\NN\14541044 of\IN\1740 endometrial\JJ\1740 carcinoma\NN\14239918 and\CC\1740 should\MD\1740 be\VB\836236 examined\VBN\789138 periodically\RB\1740 .\.\1740
D004967_D006689 NONE She\PRP\1740 had\VBD\2108377 ovarian\JJ\1740 failure\NN\66216 after\IN\1740 abdominal\JJ\1740 irradiation\NN\13920835 and\CC\1740 chemotherapy\NN\661091 for\IN\1740 <e2>Hodgkin\NN\1740 disease</e2>\NN\14061805 ,\,\1740 and\CC\1740 received\VBD\2210855 exogenous\JJ\1740 <e1>estrogens</e1>\NNS\14745635 ,\,\1740 a\DT\13649268 treatment\NN\654885 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 endometrial\JJ\1740 cancer\NN\14239425 in\IN\13603305 menopausal\JJ\1740 women\NNS\9605289 .\.\1740
D004967_D016889 CID She\PRP\1740 had\VBD\2108377 ovarian\JJ\1740 failure\NN\66216 after\IN\1740 abdominal\JJ\1740 irradiation\NN\13920835 and\CC\1740 chemotherapy\NN\661091 for\IN\1740 Hodgkin\NN\1740 disease\NN\14061805 ,\,\1740 and\CC\1740 received\VBD\2210855 exogenous\JJ\1740 <e1>estrogens</e1>\NNS\14745635 ,\,\1740 a\DT\13649268 treatment\NN\654885 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>endometrial\JJ\1740 cancer</e2>\NN\14239425 in\IN\13603305 menopausal\JJ\1740 women\NNS\9605289 .\.\1740
D004967_D016889 CID Young\JJ\1740 women\NNS\9605289 on\IN\1740 replacement\NN\196485 <e1>estrogens</e1>\NNS\14745635 for\IN\1740 ovarian\JJ\1740 failure\NN\66216 after\IN\1740 cancer\NN\14239425 therapy\NN\657604 may\MD\15209706 also\RB\1740 have\VB\2108377 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>endometrial\JJ\1740 carcinoma</e2>\NN\14239918 and\CC\1740 should\MD\1740 be\VB\836236 examined\VBN\789138 periodically\RB\1740 .\.\1740
D004967_D009369 NONE Young\JJ\1740 women\NNS\9605289 on\IN\1740 replacement\NN\196485 <e1>estrogens</e1>\NNS\14745635 for\IN\1740 ovarian\JJ\1740 failure\NN\66216 after\IN\1740 <e2>cancer</e2>\NN\14239425 therapy\NN\657604 may\MD\15209706 also\RB\1740 have\VB\2108377 increased\VBN\169651 risk\NN\14541044 of\IN\1740 endometrial\JJ\1740 carcinoma\NN\14239918 and\CC\1740 should\MD\1740 be\VB\836236 examined\VBN\789138 periodically\RB\1740 .\.\1740
7843916
D003907_D009798 CID <e1>Dexamethasone-induced</e1>\JJ\1740 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 in\IN\13603305 perfusion-cultured\JJ\1740 human\JJ\1740 eyes\NNS\5945642 .\.\1740
D003907_D009798 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 the\DT\1740 <e1>dexamethasone-treated</e1>\JJ\1740 <e2>hypertensive\JJ\1740 eyes</e2>\NNS\5945642 had\VBD\2108377 thickened\VBN\126264 trabecular\JJ\1740 beams\NNS\6791372 ,\,\1740 decreased\VBD\169651 intertrabecular\JJ\1740 spaces\NNS\24264 ,\,\1740 thickened\VBN\126264 juxtacanalicular\JJ\1740 tissue\NN\5220461 ,\,\1740 activated\VBN\1641914 trabecular\JJ\1740 meshwork\NN\3309808 cells\NNS\3080309 ,\,\1740 and\CC\1740 increased\VBD\169651 amounts\NNS\13329641 of\IN\1740 amorphogranular\JJ\1740 extracellular\JJ\1740 material\NN\19613 ,\,\1740 especially\RB\1740 in\IN\13603305 the\DT\1740 juxtacanalicular\JJ\1740 tissue\NN\5220461 and\CC\1740 beneath\IN\1740 the\DT\1740 endothelial\JJ\1740 lining\NN\4014297 of\IN\1740 the\DT\1740 canal\NN\9241247 of\IN\1740 Schlemm\NNP\1740 .\.\1740
D003907_D009798 CID CONCLUSION\NN\5837957 :\:\1740 <e1>Dexamethasone</e1>\NN\2721538 treatment\NN\654885 of\IN\1740 isolated\VBN\2512305 ,\,\1740 perfusion-cultured\JJ\1740 human\JJ\1740 eyes\NNS\5945642 led\VBD\1752884 to\TO\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 in\IN\13603305 approximately\RB\1740 30\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 dexamethasone-treated\JJ\1740 eyes\NNS\5945642 .\.\1740
D003907_D009798 CID CONCLUSION\NN\5837957 :\:\1740 Dexamethasone\NN\2721538 treatment\NN\654885 of\IN\1740 isolated\VBN\2512305 ,\,\1740 perfusion-cultured\JJ\1740 human\JJ\1740 eyes\NNS\5945642 led\VBD\1752884 to\TO\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 in\IN\13603305 approximately\RB\1740 30\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 <e1>dexamethasone-treated</e1>\JJ\1740 eyes\NNS\5945642 .\.\1740
D013256_D005901 NONE <e1>Steroid</e1>\NN\14727670 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 morphologic\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 trabecular\JJ\1740 meshwork\NN\3309808 similar\JJ\1740 to\TO\1740 those\DT\1740 reported\VBN\831651 for\IN\1740 <e2>corticosteroid\NN\14745635 glaucoma</e2>\NN\14252864 and\CC\1740 open\JJ\1740 angle\NN\13910384 glaucoma\NN\14252864 .\.\1740
D013256_D005902 NONE <e1>Steroid</e1>\NN\14727670 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 morphologic\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 trabecular\JJ\1740 meshwork\NN\3309808 similar\JJ\1740 to\TO\1740 those\DT\1740 reported\VBN\831651 for\IN\1740 corticosteroid\NN\14745635 glaucoma\NN\14252864 and\CC\1740 <e2>open\JJ\1740 angle\NN\13910384 glaucoma</e2>\NN\14252864 .\.\1740
6415512
D002220_D004831 CID <e2>Myoclonic\NNP\1740 ,\,\1740 atonic\JJ\1740 ,\,\1740 and\CC\1740 absence\NN\14449405 seizures</e2>\NNS\14081375 following\VBG\1835496 institution\NN\8008335 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 children\NNS\9622049 .\.\1740
D002220_D004831 CID Five\CD\13741022 children\NNS\9622049 ,\,\1740 aged\JJ\1740 3\CD\13741022 to\TO\1740 11\CD\13745420 years\NNS\15144371 ,\,\1740 treated\VBN\2376958 with\IN\1740 <e1>carbamazepine</e1>\NN\1740 for\IN\1740 epilepsy\NN\14085708 ,\,\1740 had\VBD\2108377 an\DT\6697703 acute\JJ\1740 aberrant\JJ\1740 reaction\NN\13446390 characterized\VBN\609683 by\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>myoclonic\NN\1740 ,\,\1740 atypical\JJ\1740 absence\NN\14449405 and/or\CC\1740 atonic\JJ\1740 (\-LRB-\1740 minor\JJ\1740 motor\NN\3699975 )\-RRB-\1740 seizures</e2>\NNS\14081375 within\IN\1740 a\DT\13649268 few\JJ\1740 days\NNS\15140892 .\.\1740
D002220_D004832 CID <e2>Myoclonic\NNP\1740 ,\,\1740 atonic\JJ\1740 ,\,\1740 and\CC\1740 absence\NN\14449405 seizures</e2>\NNS\14081375 following\VBG\1835496 institution\NN\8008335 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 children\NNS\9622049 .\.\1740
D002220_D004832 CID Five\CD\13741022 children\NNS\9622049 ,\,\1740 aged\JJ\1740 3\CD\13741022 to\TO\1740 11\CD\13745420 years\NNS\15144371 ,\,\1740 treated\VBN\2376958 with\IN\1740 <e1>carbamazepine</e1>\NN\1740 for\IN\1740 epilepsy\NN\14085708 ,\,\1740 had\VBD\2108377 an\DT\6697703 acute\JJ\1740 aberrant\JJ\1740 reaction\NN\13446390 characterized\VBN\609683 by\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>myoclonic\NN\1740 ,\,\1740 atypical\JJ\1740 absence\NN\14449405 and/or\CC\1740 atonic\JJ\1740 (\-LRB-\1740 minor\JJ\1740 motor\NN\3699975 )\-RRB-\1740 seizures</e2>\NNS\14081375 within\IN\1740 a\DT\13649268 few\JJ\1740 days\NNS\15140892 .\.\1740
D002220_D004827 NONE Five\CD\13741022 children\NNS\9622049 ,\,\1740 aged\JJ\1740 3\CD\13741022 to\TO\1740 11\CD\13745420 years\NNS\15144371 ,\,\1740 treated\VBN\2376958 with\IN\1740 <e1>carbamazepine</e1>\NN\1740 for\IN\1740 <e2>epilepsy</e2>\NN\14085708 ,\,\1740 had\VBD\2108377 an\DT\6697703 acute\JJ\1740 aberrant\JJ\1740 reaction\NN\13446390 characterized\VBN\609683 by\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 myoclonic\NN\1740 ,\,\1740 atypical\JJ\1740 absence\NN\14449405 and/or\CC\1740 atonic\JJ\1740 (\-LRB-\1740 minor\JJ\1740 motor\NN\3699975 )\-RRB-\1740 seizures\NNS\14081375 within\IN\1740 a\DT\13649268 few\JJ\1740 days\NNS\15140892 .\.\1740
D002220_D012640 NONE When\WRB\1740 the\DT\1740 <e1>carbamazepine</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ,\,\1740 two\CD\13741022 of\IN\1740 the\DT\1740 children\NNS\9622049 returned\VBD\1835496 to\IN\1740 their\PRP$\1740 former\JJ\1740 state\NN\8491826 very\RB\1740 quickly\RB\1740 ,\,\1740 two\CD\13741022 had\VBD\2108377 the\DT\1740 minor\JJ\1740 motor\NN\3699975 <e2>seizures</e2>\NNS\14081375 resolve\VBP\352826 in\IN\13603305 3\CD\13741022 and\CC\1740 6\CD\13741022 months\NNS\15113229 ,\,\1740 and\CC\1740 one\NN\13741022 had\VBD\2108377 the\DT\1740 seizures\NNS\14081375 persist\VB\118523 .\.\1740
D002220_D012640 NONE When\WRB\1740 the\DT\1740 <e1>carbamazepine</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ,\,\1740 two\CD\13741022 of\IN\1740 the\DT\1740 children\NNS\9622049 returned\VBD\1835496 to\IN\1740 their\PRP$\1740 former\JJ\1740 state\NN\8491826 very\RB\1740 quickly\RB\1740 ,\,\1740 two\CD\13741022 had\VBD\2108377 the\DT\1740 minor\JJ\1740 motor\NN\3699975 seizures\NNS\14081375 resolve\VBP\352826 in\IN\13603305 3\CD\13741022 and\CC\1740 6\CD\13741022 months\NNS\15113229 ,\,\1740 and\CC\1740 one\NN\13741022 had\VBD\2108377 the\DT\1740 <e2>seizures</e2>\NNS\14081375 persist\VB\118523 .\.\1740
1969772
D018818_D007022 CID Preservation\NN\817680 of\IN\1740 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 during\IN\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 with\IN\1740 <e1>fenoldopam</e1>\NN\1740 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D018818_D007022 CID The\DT\1740 hypothesis\NN\7162194 that\IN\1740 <e1>fenoldopam</e1>\NN\1740 could\MD\1740 be\VB\836236 used\VBN\1156834 to\TO\1740 induce\VB\1627355 <e2>hypotension</e2>\NN\14057371 and\CC\1740 preserve\VB\2681795 blood\NN\5397468 flow\NN\7311115 to\TO\1740 the\DT\1740 kidney\NN\5333259 was\VBD\836236 tested\VBN\670261 .\.\1740
D018818_D007022 CID Renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 RBF\NN\1740 )\-RRB-\1740 increased\VBD\169651 during\IN\1740 <e1>fenoldopam-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 11\CD\13745420 +/-\CC\1740 7\CD\13741022 per\NN\1740 cent\NN\13662703 and\CC\1740 decreased\VBD\169651 21\CD\13745420 +/-\CC\1740 8\CD\13741022 per\IN\1740 cent\NN\13662703 during\IN\1740 sodium\NN\14625458 nitroprusside-induced\JJ\1740 hypotension\NN\14057371 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D018818_D007022 CID Renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 RBF\NN\1740 )\-RRB-\1740 increased\VBD\169651 during\IN\1740 <e1>fenoldopam-induced</e1>\JJ\1740 hypotension\NN\14057371 11\CD\13745420 +/-\CC\1740 7\CD\13741022 per\NN\1740 cent\NN\13662703 and\CC\1740 decreased\VBD\169651 21\CD\13745420 +/-\CC\1740 8\CD\13741022 per\IN\1740 cent\NN\13662703 during\IN\1740 sodium\NN\14625458 nitroprusside-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D012964_D007022 NONE Renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 RBF\NN\1740 )\-RRB-\1740 increased\VBD\169651 during\IN\1740 fenoldopam-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 11\CD\13745420 +/-\CC\1740 7\CD\13741022 per\NN\1740 cent\NN\13662703 and\CC\1740 decreased\VBD\169651 21\CD\13745420 +/-\CC\1740 8\CD\13741022 per\IN\1740 cent\NN\13662703 during\IN\1740 <e1>sodium</e1>\NN\14625458 nitroprusside-induced\JJ\1740 hypotension\NN\14057371 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D012964_D007022 NONE Renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 RBF\NN\1740 )\-RRB-\1740 increased\VBD\169651 during\IN\1740 fenoldopam-induced\JJ\1740 hypotension\NN\14057371 11\CD\13745420 +/-\CC\1740 7\CD\13741022 per\NN\1740 cent\NN\13662703 and\CC\1740 decreased\VBD\169651 21\CD\13745420 +/-\CC\1740 8\CD\13741022 per\IN\1740 cent\NN\13662703 during\IN\1740 <e1>sodium</e1>\NN\14625458 nitroprusside-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D009599_D007022 CID Renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 RBF\NN\1740 )\-RRB-\1740 increased\VBD\169651 during\IN\1740 fenoldopam-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 11\CD\13745420 +/-\CC\1740 7\CD\13741022 per\NN\1740 cent\NN\13662703 and\CC\1740 decreased\VBD\169651 21\CD\13745420 +/-\CC\1740 8\CD\13741022 per\IN\1740 cent\NN\13662703 during\IN\1740 sodium\NN\14625458 <e1>nitroprusside-induced</e1>\JJ\1740 hypotension\NN\14057371 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D009599_D007022 CID Renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 RBF\NN\1740 )\-RRB-\1740 increased\VBD\169651 during\IN\1740 fenoldopam-induced\JJ\1740 hypotension\NN\14057371 11\CD\13745420 +/-\CC\1740 7\CD\13741022 per\NN\1740 cent\NN\13662703 and\CC\1740 decreased\VBD\169651 21\CD\13745420 +/-\CC\1740 8\CD\13741022 per\IN\1740 cent\NN\13662703 during\IN\1740 sodium\NN\14625458 <e1>nitroprusside-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D009599_D007022 CID Sodium\NN\14625458 <e1>nitroprusside</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 non-selective\JJ\1740 arteriolar\JJ\1740 and\CC\1740 venous\JJ\1740 vasodilator\NN\3198383 that\WDT\1740 can\MD\3094503 produce\VB\1617192 redistribution\NN\1083077 of\IN\1740 blood\NN\5397468 flow\NN\7311115 away\RB\1740 from\IN\1740 the\DT\1740 kidney\NN\5333259 during\IN\1740 induced\VBN\1627355 <e2>hypotension</e2>\NN\14057371 .\.\1740
D004298_D007022 NONE Fenoldopam\NN\1740 is\VBZ\836236 a\DT\13649268 selective\JJ\1740 <e1>dopamine-1</e1>\NN\1740 (\-LRB-\1740 DA1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 agonist\NN\9613191 that\WDT\1740 causes\VBZ\1617192 vasodilatation\NN\1740 to\TO\1740 the\DT\1740 kidney\NN\5333259 and\CC\1740 other\JJ\1740 organs\NNS\7649854 with\IN\1740 DA1\NN\1740 receptors\NNS\5225602 and\CC\1740 preserves\VBZ\2681795 blood\NN\5397468 flow\NN\7311115 to\TO\1740 the\DT\1740 kidney\NN\5333259 during\IN\1740 induced\VBN\1627355 <e2>hypotension</e2>\NN\14057371 .\.\1740
3686155
D001971_D011605 CID Postpartum\JJ\1740 <e2>psychosis</e2>\NN\14380140 induced\VBN\1627355 by\IN\1740 <e1>bromocriptine</e1>\NN\1740 .\.\1740
D001971_D011605 CID Two\CD\13741022 multigravida\NN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 prior\JJ\1740 psychiatric\JJ\1740 history\NN\15120823 were\VBD\836236 seen\VBN\2106506 with\IN\1740 postpartum\NN\1740 <e2>psychosis</e2>\NN\14380140 ,\,\1740 having\VBG\2108377 received\VBN\2210855 <e1>bromocriptine</e1>\NN\1740 for\IN\1740 inhibition\NN\1068773 of\IN\1740 lactation\NN\15113229 .\.\1740
D001971_D011605 CID <e1>Bromocriptine</e1>\NN\1740 given\VBN\2327200 in\IN\13603305 high\JJ\1740 doses\NNS\3740161 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 <e2>psychosis</e2>\NN\14380140 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 drug\NN\14778436 for\IN\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D001971_D011605 CID These\DT\1740 cases\NNS\7283608 demonstrate\VBP\2137132 that\IN\1740 <e1>bromocriptine</e1>\NN\1740 may\MD\15209706 cause\VB\1617192 <e2>psychosis</e2>\NN\14380140 even\RB\1740 when\WRB\1740 given\VBN\2327200 in\IN\13603305 low\JJ\1740 doses\NNS\3740161 .\.\1740
D001971_D001523 NONE Two\CD\13741022 multigravida\NN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 prior\JJ\1740 <e2>psychiatric</e2>\JJ\1740 history\NN\15120823 were\VBD\836236 seen\VBN\2106506 with\IN\1740 postpartum\NN\1740 psychosis\NN\14380140 ,\,\1740 having\VBG\2108377 received\VBN\2210855 <e1>bromocriptine</e1>\NN\1740 for\IN\1740 inhibition\NN\1068773 of\IN\1740 lactation\NN\15113229 .\.\1740
D001971_D007775 NONE Two\CD\13741022 multigravida\NN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 prior\JJ\1740 psychiatric\JJ\1740 history\NN\15120823 were\VBD\836236 seen\VBN\2106506 with\IN\1740 postpartum\NN\1740 psychosis\NN\14380140 ,\,\1740 having\VBG\2108377 received\VBN\2210855 <e1>bromocriptine</e1>\NN\1740 for\IN\1740 <e2>inhibition\NN\1068773 of\IN\1740 lactation</e2>\NN\15113229 .\.\1740
D001971_D010300 NONE <e1>Bromocriptine</e1>\NN\1740 given\VBN\2327200 in\IN\13603305 high\JJ\1740 doses\NNS\3740161 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 psychosis\NN\14380140 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 drug\NN\14778436 for\IN\1740 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
3120485
982002
D012293_D058186 CID <e2>Acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 subsequent\JJ\1740 to\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>rifampicin</e1>\NN\1740 .\.\1740
D012293_D051437 NONE The\DT\1740 patients\NNS\9898892 had\VBD\2108377 developed\VBN\1753788 transient\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 the\DT\1740 intermittent\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>rifampicin</e1>\NN\1740 .\.\1740
3950060
D000583_D007674 CID Factors\NNS\7326557 associated\VBN\628491 with\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 clinical\JJ\1740 outcome\NN\7291312 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>amikacin</e1>\NN\1740 .\.\1740
D000583_D007674 CID Data\NNS\7951464 from\IN\1740 60\CD\13745420 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>amikacin</e1>\NN\1740 were\VBD\836236 analyzed\VBN\78760 for\IN\1740 factors\NNS\7326557 associated\VBN\628491 with\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
16574713
D018817_D020258 NONE Although\IN\1740 <e1>3,4-methylenedioxymethamphetamine</e1>\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 or\CC\3541091 ecstasy\NN\13985818 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 damage\NN\7296428 brain\NN\5462674 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 neurons\NNS\5430628 in\IN\13603305 animals\NNS\4475 and\CC\1740 possibly\RB\1740 humans\NNS\31264 ,\,\1740 little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 long-term\JJ\1740 consequences\NNS\34213 of\IN\1740 MDMA-induced\JJ\1740 5-HT\NN\1740 <e2>neurotoxic\JJ\1740 lesions</e2>\NNS\14204950 on\IN\1740 functions\NNS\13783581 in\IN\13603305 which\WDT\1740 5-HT\NN\1740 is\VBZ\836236 involved\VBN\2676054 ,\,\1740 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 function\NN\13783581 .\.\1740
D018817_D020258 NONE Although\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 <e1>MDMA</e1>\NN\3054098 or\CC\3541091 ecstasy\NN\13985818 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 damage\NN\7296428 brain\NN\5462674 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 neurons\NNS\5430628 in\IN\13603305 animals\NNS\4475 and\CC\1740 possibly\RB\1740 humans\NNS\31264 ,\,\1740 little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 long-term\JJ\1740 consequences\NNS\34213 of\IN\1740 MDMA-induced\JJ\1740 5-HT\NN\1740 <e2>neurotoxic\JJ\1740 lesions</e2>\NNS\14204950 on\IN\1740 functions\NNS\13783581 in\IN\13603305 which\WDT\1740 5-HT\NN\1740 is\VBZ\836236 involved\VBN\2676054 ,\,\1740 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 function\NN\13783581 .\.\1740
D018817_D020258 NONE Although\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 or\CC\3541091 <e1>ecstasy</e1>\NN\13985818 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 damage\NN\7296428 brain\NN\5462674 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 neurons\NNS\5430628 in\IN\13603305 animals\NNS\4475 and\CC\1740 possibly\RB\1740 humans\NNS\31264 ,\,\1740 little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 long-term\JJ\1740 consequences\NNS\34213 of\IN\1740 MDMA-induced\JJ\1740 5-HT\NN\1740 <e2>neurotoxic\JJ\1740 lesions</e2>\NNS\14204950 on\IN\1740 functions\NNS\13783581 in\IN\13603305 which\WDT\1740 5-HT\NN\1740 is\VBZ\836236 involved\VBN\2676054 ,\,\1740 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 function\NN\13783581 .\.\1740
D018817_D020258 NONE Although\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 or\CC\3541091 ecstasy\NN\13985818 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 damage\NN\7296428 brain\NN\5462674 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 neurons\NNS\5430628 in\IN\13603305 animals\NNS\4475 and\CC\1740 possibly\RB\1740 humans\NNS\31264 ,\,\1740 little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 long-term\JJ\1740 consequences\NNS\34213 of\IN\1740 <e1>MDMA-induced</e1>\JJ\1740 5-HT\NN\1740 <e2>neurotoxic\JJ\1740 lesions</e2>\NNS\14204950 on\IN\1740 functions\NNS\13783581 in\IN\13603305 which\WDT\1740 5-HT\NN\1740 is\VBZ\836236 involved\VBN\2676054 ,\,\1740 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 function\NN\13783581 .\.\1740
D012701_D020258 NONE Although\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 or\CC\3541091 ecstasy\NN\13985818 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 damage\NN\7296428 brain\NN\5462674 <e1>serotonin</e1>\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 neurons\NNS\5430628 in\IN\13603305 animals\NNS\4475 and\CC\1740 possibly\RB\1740 humans\NNS\31264 ,\,\1740 little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 long-term\JJ\1740 consequences\NNS\34213 of\IN\1740 MDMA-induced\JJ\1740 5-HT\NN\1740 <e2>neurotoxic\JJ\1740 lesions</e2>\NNS\14204950 on\IN\1740 functions\NNS\13783581 in\IN\13603305 which\WDT\1740 5-HT\NN\1740 is\VBZ\836236 involved\VBN\2676054 ,\,\1740 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 function\NN\13783581 .\.\1740
D012701_D020258 NONE Although\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 or\CC\3541091 ecstasy\NN\13985818 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 damage\NN\7296428 brain\NN\5462674 serotonin\NN\14807737 (\-LRB-\1740 <e1>5-HT</e1>\NN\1740 )\-RRB-\1740 neurons\NNS\5430628 in\IN\13603305 animals\NNS\4475 and\CC\1740 possibly\RB\1740 humans\NNS\31264 ,\,\1740 little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 long-term\JJ\1740 consequences\NNS\34213 of\IN\1740 MDMA-induced\JJ\1740 5-HT\NN\1740 <e2>neurotoxic\JJ\1740 lesions</e2>\NNS\14204950 on\IN\1740 functions\NNS\13783581 in\IN\13603305 which\WDT\1740 5-HT\NN\1740 is\VBZ\836236 involved\VBN\2676054 ,\,\1740 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 function\NN\13783581 .\.\1740
D012701_D020258 NONE Although\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 or\CC\3541091 ecstasy\NN\13985818 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 damage\NN\7296428 brain\NN\5462674 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 neurons\NNS\5430628 in\IN\13603305 animals\NNS\4475 and\CC\1740 possibly\RB\1740 humans\NNS\31264 ,\,\1740 little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 long-term\JJ\1740 consequences\NNS\34213 of\IN\1740 MDMA-induced\JJ\1740 <e1>5-HT</e1>\NN\1740 <e2>neurotoxic\JJ\1740 lesions</e2>\NNS\14204950 on\IN\1740 functions\NNS\13783581 in\IN\13603305 which\WDT\1740 5-HT\NN\1740 is\VBZ\836236 involved\VBN\2676054 ,\,\1740 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 function\NN\13783581 .\.\1740
D012701_D020258 NONE Although\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 or\CC\3541091 ecstasy\NN\13985818 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 damage\NN\7296428 brain\NN\5462674 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 neurons\NNS\5430628 in\IN\13603305 animals\NNS\4475 and\CC\1740 possibly\RB\1740 humans\NNS\31264 ,\,\1740 little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 long-term\JJ\1740 consequences\NNS\34213 of\IN\1740 MDMA-induced\JJ\1740 5-HT\NN\1740 <e2>neurotoxic\JJ\1740 lesions</e2>\NNS\14204950 on\IN\1740 functions\NNS\13783581 in\IN\13603305 which\WDT\1740 <e1>5-HT</e1>\NN\1740 is\VBZ\836236 involved\VBN\2676054 ,\,\1740 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 function\NN\13783581 .\.\1740
D018817_D008569 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 no\DT\7204911 evidence\NN\5816287 of\IN\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 moderate\JJ\1740 <e1>MDMA</e1>\NN\3054098 users\NNS\7846 .\.\1740
D018817_D008569 CID While\IN\15122231 the\DT\1740 use\NN\407535 of\IN\1740 <e1>MDMA</e1>\NN\3054098 in\IN\13603305 quantities\NNS\2137 that\WDT\1740 may\MD\15209706 be\VB\836236 considered\VBN\689344 "\``\1740 moderate\JJ\1740 "\''\1740 is\VBZ\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>impaired\JJ\1740 memory\NN\5926676 functioning</e2>\VBG\2669789 ,\,\1740 heavy\JJ\1740 use\NN\407535 of\IN\1740 MDMA\NN\3054098 use\NN\407535 may\MD\15209706 lead\VB\1752884 to\TO\1740 long\RB\1740 lasting\VBG\2704349 memory\NN\5926676 impairments\NNS\7296428 .\.\1740
D018817_D008569 CID While\IN\15122231 the\DT\1740 use\NN\407535 of\IN\1740 <e1>MDMA</e1>\NN\3054098 in\IN\13603305 quantities\NNS\2137 that\WDT\1740 may\MD\15209706 be\VB\836236 considered\VBN\689344 "\``\1740 moderate\JJ\1740 "\''\1740 is\VBZ\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 impaired\JJ\1740 memory\NN\5926676 functioning\VBG\2669789 ,\,\1740 heavy\JJ\1740 use\NN\407535 of\IN\1740 MDMA\NN\3054098 use\NN\407535 may\MD\15209706 lead\VB\1752884 to\TO\1740 long\RB\1740 lasting\VBG\2704349 <e2>memory\NN\5926676 impairments</e2>\NNS\7296428 .\.\1740
D018817_D008569 CID While\IN\15122231 the\DT\1740 use\NN\407535 of\IN\1740 MDMA\NN\3054098 in\IN\13603305 quantities\NNS\2137 that\WDT\1740 may\MD\15209706 be\VB\836236 considered\VBN\689344 "\``\1740 moderate\JJ\1740 "\''\1740 is\VBZ\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>impaired\JJ\1740 memory\NN\5926676 functioning</e2>\VBG\2669789 ,\,\1740 heavy\JJ\1740 use\NN\407535 of\IN\1740 <e1>MDMA</e1>\NN\3054098 use\NN\407535 may\MD\15209706 lead\VB\1752884 to\TO\1740 long\RB\1740 lasting\VBG\2704349 memory\NN\5926676 impairments\NNS\7296428 .\.\1740
D018817_D008569 CID While\IN\15122231 the\DT\1740 use\NN\407535 of\IN\1740 MDMA\NN\3054098 in\IN\13603305 quantities\NNS\2137 that\WDT\1740 may\MD\15209706 be\VB\836236 considered\VBN\689344 "\``\1740 moderate\JJ\1740 "\''\1740 is\VBZ\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 impaired\JJ\1740 memory\NN\5926676 functioning\VBG\2669789 ,\,\1740 heavy\JJ\1740 use\NN\407535 of\IN\1740 <e1>MDMA</e1>\NN\3054098 use\NN\407535 may\MD\15209706 lead\VB\1752884 to\TO\1740 long\RB\1740 lasting\VBG\2704349 <e2>memory\NN\5926676 impairments</e2>\NNS\7296428 .\.\1740
4038130
D008619_D009135 CID In\IN\13603305 addition\NN\3081021 to\TO\1740 <e2>muscle\NN\5289601 damage</e2>\NN\7296428 ,\,\1740 severe\JJ\1740 damage\NN\7296428 was\VBD\836236 also\RB\1740 seen\VBN\2106506 in\IN\13603305 harderian\JJ\1740 glands\NNS\5297523 ,\,\1740 especially\RB\1740 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>mepivacaine</e1>\NN\1740 and\CC\1740 lidocaine\NN\3681148 plus\CC\4723816 epinephrine\NN\14807929 .\.\1740
D008012_D009135 CID In\IN\13603305 addition\NN\3081021 to\TO\1740 <e2>muscle\NN\5289601 damage</e2>\NN\7296428 ,\,\1740 severe\JJ\1740 damage\NN\7296428 was\VBD\836236 also\RB\1740 seen\VBN\2106506 in\IN\13603305 harderian\JJ\1740 glands\NNS\5297523 ,\,\1740 especially\RB\1740 after\IN\1740 exposure\NN\5042871 to\TO\1740 mepivacaine\NN\1740 and\CC\1740 <e1>lidocaine</e1>\NN\3681148 plus\CC\4723816 epinephrine\NN\14807929 .\.\1740
D004837_D009135 NONE In\IN\13603305 addition\NN\3081021 to\TO\1740 <e2>muscle\NN\5289601 damage</e2>\NN\7296428 ,\,\1740 severe\JJ\1740 damage\NN\7296428 was\VBD\836236 also\RB\1740 seen\VBN\2106506 in\IN\13603305 harderian\JJ\1740 glands\NNS\5297523 ,\,\1740 especially\RB\1740 after\IN\1740 exposure\NN\5042871 to\TO\1740 mepivacaine\NN\1740 and\CC\1740 lidocaine\NN\3681148 plus\CC\4723816 <e1>epinephrine</e1>\NN\14807929 .\.\1740
8800187
D002122_D064420 NONE Effect\NN\34213 of\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 and\CC\1740 4-aminopyridine\NN\1740 therapy\NN\657604 on\IN\1740 desipramine\NN\4482543 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 rats\NNS\2329401 .\.\1740
D015761_D064420 NONE Effect\NN\34213 of\IN\1740 calcium\NN\14625458 chloride\NN\14818238 and\CC\1740 <e1>4-aminopyridine</e1>\NN\1740 therapy\NN\657604 on\IN\1740 desipramine\NN\4482543 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003891_D064420 NONE Effect\NN\34213 of\IN\1740 calcium\NN\14625458 chloride\NN\14818238 and\CC\1740 4-aminopyridine\NN\1740 therapy\NN\657604 on\IN\1740 <e1>desipramine</e1>\NN\4482543 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002118_D007022 NONE This\DT\1740 study\NN\635850 addressed\VBD\740577 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockade\NN\952963 in\IN\13603305 tricyclic\JJ\1740 antidepressant-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D002118_D007022 NONE These\DT\1740 findings\NNS\7951464 do\VBP\1640855 not\RB\1740 support\VB\2199590 a\DT\13649268 role\NN\719494 for\IN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 inhibition\NN\1068773 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 tricyclic\JJ\1740 antidepressant-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D002118_D062787 NONE METHODS\NNS\5616786 :\:\1740 Two\CD\13741022 interventions\NNS\1239064 were\VBD\836236 studied\VBN\630380 that\WDT\1740 have\VBP\2108377 been\VBN\836236 shown\VBN\2137132 previously\RB\1740 to\TO\1740 improve\VB\126264 blood\NN\5397468 pressure\NN\11419404 with\IN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 <e2>overdose</e2>\NN\1740 .\.\1740
D003891_D007022 CID Anesthetized\JJ\1740 rats\NNS\2329401 received\VBD\2210855 the\DT\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 <e1>desipramine</e1>\NN\4482543 IP\NN\5999797 to\TO\1740 produce\VB\1617192 <e2>hypotension</e2>\NN\14057371 ,\,\1740 QRS\NN\1740 prolongation\NN\1017987 ,\,\1740 and\CC\1740 bradycardia\NN\14110674 .\.\1740
D003891_D001919 CID Anesthetized\JJ\1740 rats\NNS\2329401 received\VBD\2210855 the\DT\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 <e1>desipramine</e1>\NN\4482543 IP\NN\5999797 to\TO\1740 produce\VB\1617192 hypotension\NN\14057371 ,\,\1740 QRS\NN\1740 prolongation\NN\1017987 ,\,\1740 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
D017693_D007022 NONE RESULTS\NNS\34213 :\:\1740 <e1>NaHCO3</e1>\NN\1740 briefly\NN\1740 (\-LRB-\1740 5\CD\13741022 min\NN\15154774 )\-RRB-\1740 reversed\VBD\109660 <e2>hypotension</e2>\NN\14057371 and\CC\1740 QRS\NN\1740 prolongation\NN\1017987 .\.\1740
D002122_D001145 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>ventricular\JJ\1740 arrhythmias</e2>\NNS\14103288 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.004\CD\1740 )\-RRB-\1740 and\CC\1740 seizures\NNS\14081375 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>CaCl2</e1>\NN\1740 group\NN\2137 was\VBD\836236 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 groups\NNS\2137 .\.\1740
D002122_D012640 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 ventricular\JJ\1740 arrhythmias\NNS\14103288 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.004\CD\1740 )\-RRB-\1740 and\CC\1740 <e2>seizures</e2>\NNS\14081375 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>CaCl2</e1>\NN\1740 group\NN\2137 was\VBD\836236 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 groups\NNS\2137 .\.\1740
D002122_D007022 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 administration\NN\1133281 of\IN\1740 <e1>CaCl2</e1>\NN\1740 or\CC\3541091 4-aminopyridine\NN\1740 did\VBD\1640855 not\RB\1740 reverse\VB\109660 tricyclic\JJ\1740 antidepressant-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 .\.\1740
D015761_D007022 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 administration\NN\1133281 of\IN\1740 CaCl2\NN\1740 or\CC\3541091 <e1>4-aminopyridine</e1>\NN\1740 did\VBD\1640855 not\RB\1740 reverse\VB\109660 tricyclic\JJ\1740 antidepressant-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002122_D002318 NONE <e1>CaCl2</e1>\NN\1740 therapy\NN\657604 may\MD\15209706 possibly\RB\1740 worsen\VBN\146138 both\CC\1740 <e2>cardiovascular\JJ\1740 and\CC\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
D002122_D002493 NONE <e1>CaCl2</e1>\NN\1740 therapy\NN\657604 may\MD\15209706 possibly\RB\1740 worsen\VBN\146138 both\CC\1740 <e2>cardiovascular\JJ\1740 and\CC\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
8546130
D017291_D006212 CID <e1>Clarithromycin-associated</e1>\JJ\1740 <e2>visual\JJ\1740 hallucinations</e2>\NNS\14376855 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 on\IN\1740 continuous\JJ\1740 ambulatory\JJ\1740 peritoneal\NN\1740 dialysis\NN\646833 .\.\1740
D017291_D006212 CID Unreported\VBN\1740 in\IN\13603305 the\DT\1740 literature\NN\6362953 is\VBZ\836236 <e2>visual\JJ\1740 hallucinations</e2>\NNS\14376855 occurring\VBG\2623529 in\IN\13603305 association\NN\8008335 with\IN\1740 the\DT\1740 new\JJ\1740 macrolide\NN\1740 antibiotic\JJ\1740 ,\,\1740 <e1>clarithromycin</e1>\NN\1740 .\.\1740
D017291_D007676 NONE <e1>Clarithromycin-associated</e1>\JJ\1740 visual\JJ\1740 hallucinations\NNS\14376855 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 on\IN\1740 continuous\JJ\1740 ambulatory\JJ\1740 peritoneal\NN\1740 dialysis\NN\646833 .\.\1740
D017291_D007676 NONE The\DT\1740 combination\NN\7951464 of\IN\1740 a\DT\13649268 relatively\RB\1740 high\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>clarithromycin</e1>\NN\1740 in\IN\13603305 face\NN\5225090 of\IN\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 a\DT\13649268 functionally\RB\1740 anephric\JJ\1740 patient\NN\9898892 ,\,\1740 with\IN\1740 underlying\VBG\2604760 aluminum\NN\14625458 intoxication\NN\14034177 ,\,\1740 may\MD\15209706 have\VB\2108377 facilitated\VBN\2547586 the\DT\1740 appearance\NN\4723816 of\IN\1740 this\DT\1740 neurotoxic\JJ\1740 side\NN\8630039 effect\NN\34213 .\.\1740
D018942_D006212 NONE Unreported\VBN\1740 in\IN\13603305 the\DT\1740 literature\NN\6362953 is\VBZ\836236 <e2>visual\JJ\1740 hallucinations</e2>\NNS\14376855 occurring\VBG\2623529 in\IN\13603305 association\NN\8008335 with\IN\1740 the\DT\1740 new\JJ\1740 <e1>macrolide</e1>\NN\1740 antibiotic\JJ\1740 ,\,\1740 clarithromycin\NN\1740 .\.\1740
D017291_D020258 NONE The\DT\1740 combination\NN\7951464 of\IN\1740 a\DT\13649268 relatively\RB\1740 high\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>clarithromycin</e1>\NN\1740 in\IN\13603305 face\NN\5225090 of\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 in\IN\13603305 a\DT\13649268 functionally\RB\1740 anephric\JJ\1740 patient\NN\9898892 ,\,\1740 with\IN\1740 underlying\VBG\2604760 aluminum\NN\14625458 intoxication\NN\14034177 ,\,\1740 may\MD\15209706 have\VB\2108377 facilitated\VBN\2547586 the\DT\1740 appearance\NN\4723816 of\IN\1740 this\DT\1740 <e2>neurotoxic</e2>\JJ\1740 side\NN\8630039 effect\NN\34213 .\.\1740
D000535_D007676 NONE The\DT\1740 combination\NN\7951464 of\IN\1740 a\DT\13649268 relatively\RB\1740 high\JJ\1740 dose\NN\3740161 of\IN\1740 clarithromycin\NN\1740 in\IN\13603305 face\NN\5225090 of\IN\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 a\DT\13649268 functionally\RB\1740 anephric\JJ\1740 patient\NN\9898892 ,\,\1740 with\IN\1740 underlying\VBG\2604760 <e1>aluminum</e1>\NN\14625458 intoxication\NN\14034177 ,\,\1740 may\MD\15209706 have\VB\2108377 facilitated\VBN\2547586 the\DT\1740 appearance\NN\4723816 of\IN\1740 this\DT\1740 neurotoxic\JJ\1740 side\NN\8630039 effect\NN\34213 .\.\1740
D000535_D020258 NONE The\DT\1740 combination\NN\7951464 of\IN\1740 a\DT\13649268 relatively\RB\1740 high\JJ\1740 dose\NN\3740161 of\IN\1740 clarithromycin\NN\1740 in\IN\13603305 face\NN\5225090 of\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 in\IN\13603305 a\DT\13649268 functionally\RB\1740 anephric\JJ\1740 patient\NN\9898892 ,\,\1740 with\IN\1740 underlying\VBG\2604760 <e1>aluminum</e1>\NN\14625458 intoxication\NN\14034177 ,\,\1740 may\MD\15209706 have\VB\2108377 facilitated\VBN\2547586 the\DT\1740 appearance\NN\4723816 of\IN\1740 this\DT\1740 <e2>neurotoxic</e2>\JJ\1740 side\NN\8630039 effect\NN\34213 .\.\1740
9121607
D013256_D012640 NONE Neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 protect\VBP\1127795 against\IN\1740 pilocarpine-\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D013256_D012640 NONE <e1>Steroids</e1>\NNS\14727670 with\IN\1740 the\DT\1740 3-hydroxy\JJ\1740 group\NN\2137 in\IN\13603305 the\DT\1740 alpha-position\NN\1740 and\CC\1740 5-H\NN\1740 in\IN\13603305 the\DT\1740 alpha-\NN\1740 or\CC\3541091 beta-configurations\NNS\1740 were\VBD\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 (\-LRB-\1740 416\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.)-induced\JJ\1740 limbic\JJ\1740 motor\NN\3699975 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 (\-LRB-\1740 ED50\NN\1740 values\NNS\5941423 ,\,\1740 7.0\CD\1740 -\SYM\1740 18.7\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D013256_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 <e2>seizures</e2>\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D013256_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 <e2>seizure</e2>\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D013256_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 <e2>seizures</e2>\NNS\14081375 ,\,\1740 <e1>steroids</e1>\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D013256_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 <e1>steroids</e1>\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 <e2>seizure</e2>\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D013256_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 <e2>seizures</e2>\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D013256_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 <e2>seizure</e2>\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D013256_D012640 NONE <e1>Steroids</e1>\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-\NN\1740 or\CC\3541091 5\CD\13741022 beta,3\NN\1740 alpha-configurations\NNS\1740 also\RB\1740 produced\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 delay\NN\15271008 in\IN\13603305 the\DT\1740 onset\NN\7325190 of\IN\1740 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 kainic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 32\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 completely\RB\1740 protect\VB\1127795 against\IN\1740 the\DT\1740 seizures\NNS\14081375 .\.\1740
D013256_D012640 NONE <e1>Steroids</e1>\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-\NN\1740 or\CC\3541091 5\CD\13741022 beta,3\NN\1740 alpha-configurations\NNS\1740 also\RB\1740 produced\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 delay\NN\15271008 in\IN\13603305 the\DT\1740 onset\NN\7325190 of\IN\1740 limbic\JJ\1740 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 kainic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 32\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 completely\RB\1740 protect\VB\1127795 against\IN\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D013256_D012640 NONE However\RB\1740 ,\,\1740 when\WRB\1740 a\DT\13649268 second\JJ\1740 dose\NN\3740161 of\IN\1740 the\DT\1740 <e1>steroid</e1>\NN\14727670 was\VBD\836236 administered\VBN\2436349 1\CD\13741022 hr\NN\15154774 after\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 ,\,\1740 complete\VB\352826 protection\NN\407535 from\IN\1740 the\DT\1740 kainic\JJ\1740 acid-induced\JJ\1740 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 was\VBD\836236 obtained\VBN\2210855 .\.\1740
D013256_D012640 NONE The\DT\1740 <e1>steroids</e1>\NNS\14727670 also\RB\1740 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 delay\NN\15271008 in\IN\13603305 NMDA\NN\1740 (\-LRB-\1740 257\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.)-induced\JJ\1740 lethality\NN\4790449 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 completely\RB\1740 protect\VB\1127795 against\IN\1740 NMDA\NN\1740 <e2>seizures</e2>\NNS\14081375 or\CC\3541091 lethality\NN\4790449 .\.\1740
D013256_D012640 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 are\VBP\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\RP\1740 pilocarpine-\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 of\IN\1740 utility\NN\8186047 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 some\DT\1740 forms\NNS\6286395 of\IN\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 humans\NNS\31264 .\.\1740
D013256_D013226 NONE Neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 protect\VBP\1127795 against\IN\1740 pilocarpine-\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 limbic\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D013256_D013226 NONE <e1>Steroids</e1>\NNS\14727670 with\IN\1740 the\DT\1740 3-hydroxy\JJ\1740 group\NN\2137 in\IN\13603305 the\DT\1740 alpha-position\NN\1740 and\CC\1740 5-H\NN\1740 in\IN\13603305 the\DT\1740 alpha-\NN\1740 or\CC\3541091 beta-configurations\NNS\1740 were\VBD\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 (\-LRB-\1740 416\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.)-induced\JJ\1740 limbic\JJ\1740 motor\NN\3699975 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 (\-LRB-\1740 ED50\NN\1740 values\NNS\5941423 ,\,\1740 7.0\CD\1740 -\SYM\1740 18.7\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D013256_D013226 NONE However\RB\1740 ,\,\1740 when\WRB\1740 a\DT\13649268 second\JJ\1740 dose\NN\3740161 of\IN\1740 the\DT\1740 <e1>steroid</e1>\NN\14727670 was\VBD\836236 administered\VBN\2436349 1\CD\13741022 hr\NN\15154774 after\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 ,\,\1740 complete\VB\352826 protection\NN\407535 from\IN\1740 the\DT\1740 kainic\JJ\1740 acid-induced\JJ\1740 limbic\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 was\VBD\836236 obtained\VBN\2210855 .\.\1740
D013256_D013226 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 are\VBP\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\RP\1740 pilocarpine-\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 of\IN\1740 utility\NN\8186047 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 some\DT\1740 forms\NNS\6286395 of\IN\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 humans\NNS\31264 .\.\1740
D013256_D013226 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 are\VBP\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\RP\1740 pilocarpine-\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 of\IN\1740 utility\NN\8186047 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 some\DT\1740 forms\NNS\6286395 of\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 humans\NNS\31264 .\.\1740
D010862_D012640 CID Neuroactive\JJ\1740 steroids\NNS\14727670 protect\VBP\1127795 against\IN\1740 <e1>pilocarpine-</e1>\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010862_D012640 CID Several\JJ\1740 structurally\RB\1740 related\JJ\1740 metabolites\NNS\20090 of\IN\1740 progesterone\NN\14747338 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 deoxycorticosterone\NN\1740 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-21-diol-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 3\CD\13741022 beta-epimers\NNS\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 protective\JJ\1740 activity\NN\30358 against\IN\1740 <e1>pilocarpine-</e1>\NN\1740 ,\,\1740 kainic\JJ\1740 acid-\NN\1740 and\CC\1740 N-methyl-D-aspartate\NN\1740 (NMDA)-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010862_D012640 CID Steroids\NNS\14727670 with\IN\1740 the\DT\1740 3-hydroxy\JJ\1740 group\NN\2137 in\IN\13603305 the\DT\1740 alpha-position\NN\1740 and\CC\1740 5-H\NN\1740 in\IN\13603305 the\DT\1740 alpha-\NN\1740 or\CC\3541091 beta-configurations\NNS\1740 were\VBD\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 <e1>pilocarpine</e1>\NN\14712692 (\-LRB-\1740 416\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.)-induced\JJ\1740 limbic\JJ\1740 motor\NN\3699975 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 (\-LRB-\1740 ED50\NN\1740 values\NNS\5941423 ,\,\1740 7.0\CD\1740 -\SYM\1740 18.7\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D010862_D012640 CID Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 <e1>pilocarpine</e1>\NN\14712692 <e2>seizures</e2>\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D010862_D012640 CID Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 <e1>pilocarpine</e1>\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 <e2>seizure</e2>\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D010862_D012640 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 neuroactive\JJ\1740 steroids\NNS\14727670 are\VBP\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\RP\1740 <e1>pilocarpine-</e1>\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 of\IN\1740 utility\NN\8186047 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 some\DT\1740 forms\NNS\6286395 of\IN\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 humans\NNS\31264 .\.\1740
D010862_D013226 CID Neuroactive\JJ\1740 steroids\NNS\14727670 protect\VBP\1127795 against\IN\1740 <e1>pilocarpine-</e1>\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 limbic\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010862_D013226 CID Steroids\NNS\14727670 with\IN\1740 the\DT\1740 3-hydroxy\JJ\1740 group\NN\2137 in\IN\13603305 the\DT\1740 alpha-position\NN\1740 and\CC\1740 5-H\NN\1740 in\IN\13603305 the\DT\1740 alpha-\NN\1740 or\CC\3541091 beta-configurations\NNS\1740 were\VBD\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 <e1>pilocarpine</e1>\NN\14712692 (\-LRB-\1740 416\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.)-induced\JJ\1740 limbic\JJ\1740 motor\NN\3699975 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 (\-LRB-\1740 ED50\NN\1740 values\NNS\5941423 ,\,\1740 7.0\CD\1740 -\SYM\1740 18.7\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D010862_D013226 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 neuroactive\JJ\1740 steroids\NNS\14727670 are\VBP\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\RP\1740 <e1>pilocarpine-</e1>\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 of\IN\1740 utility\NN\8186047 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 some\DT\1740 forms\NNS\6286395 of\IN\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 humans\NNS\31264 .\.\1740
D010862_D013226 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 neuroactive\JJ\1740 steroids\NNS\14727670 are\VBP\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\RP\1740 <e1>pilocarpine-</e1>\NN\1740 and\CC\1740 kainic\JJ\1740 acid-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 of\IN\1740 utility\NN\8186047 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 some\DT\1740 forms\NNS\6286395 of\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 humans\NNS\31264 .\.\1740
D007608_D012640 CID Neuroactive\JJ\1740 steroids\NNS\14727670 protect\VBP\1127795 against\IN\1740 pilocarpine-\NN\1740 and\CC\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D007608_D012640 CID Several\JJ\1740 structurally\RB\1740 related\JJ\1740 metabolites\NNS\20090 of\IN\1740 progesterone\NN\14747338 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 deoxycorticosterone\NN\1740 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-21-diol-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 3\CD\13741022 beta-epimers\NNS\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 protective\JJ\1740 activity\NN\30358 against\IN\1740 pilocarpine-\NN\1740 ,\,\1740 <e1>kainic\JJ\1740 acid-</e1>\NN\1740 and\CC\1740 N-methyl-D-aspartate\NN\1740 (NMDA)-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 .\.\1740
D007608_D012640 CID Steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-\NN\1740 or\CC\3541091 5\CD\13741022 beta,3\NN\1740 alpha-configurations\NNS\1740 also\RB\1740 produced\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 delay\NN\15271008 in\IN\13603305 the\DT\1740 onset\NN\7325190 of\IN\1740 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>kainic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 32\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 completely\RB\1740 protect\VB\1127795 against\IN\1740 the\DT\1740 seizures\NNS\14081375 .\.\1740
D007608_D012640 CID Steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-\NN\1740 or\CC\3541091 5\CD\13741022 beta,3\NN\1740 alpha-configurations\NNS\1740 also\RB\1740 produced\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 delay\NN\15271008 in\IN\13603305 the\DT\1740 onset\NN\7325190 of\IN\1740 limbic\JJ\1740 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>kainic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 32\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 completely\RB\1740 protect\VB\1127795 against\IN\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D007608_D012640 CID However\RB\1740 ,\,\1740 when\WRB\1740 a\DT\13649268 second\JJ\1740 dose\NN\3740161 of\IN\1740 the\DT\1740 steroid\NN\14727670 was\VBD\836236 administered\VBN\2436349 1\CD\13741022 hr\NN\15154774 after\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 ,\,\1740 complete\VB\352826 protection\NN\407535 from\IN\1740 the\DT\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 was\VBD\836236 obtained\VBN\2210855 .\.\1740
D007608_D012640 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 neuroactive\JJ\1740 steroids\NNS\14727670 are\VBP\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\RP\1740 pilocarpine-\NN\1740 and\CC\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 of\IN\1740 utility\NN\8186047 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 some\DT\1740 forms\NNS\6286395 of\IN\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 humans\NNS\31264 .\.\1740
D007608_D013226 CID Neuroactive\JJ\1740 steroids\NNS\14727670 protect\VBP\1127795 against\IN\1740 pilocarpine-\NN\1740 and\CC\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 limbic\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D007608_D013226 CID However\RB\1740 ,\,\1740 when\WRB\1740 a\DT\13649268 second\JJ\1740 dose\NN\3740161 of\IN\1740 the\DT\1740 steroid\NN\14727670 was\VBD\836236 administered\VBN\2436349 1\CD\13741022 hr\NN\15154774 after\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 ,\,\1740 complete\VB\352826 protection\NN\407535 from\IN\1740 the\DT\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 limbic\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 was\VBD\836236 obtained\VBN\2210855 .\.\1740
D007608_D013226 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 neuroactive\JJ\1740 steroids\NNS\14727670 are\VBP\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\RP\1740 pilocarpine-\NN\1740 and\CC\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 of\IN\1740 utility\NN\8186047 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 some\DT\1740 forms\NNS\6286395 of\IN\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 humans\NNS\31264 .\.\1740
D007608_D013226 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 neuroactive\JJ\1740 steroids\NNS\14727670 are\VBP\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 protecting\VBG\1127795 against\RP\1740 pilocarpine-\NN\1740 and\CC\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 seizures\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 of\IN\1740 utility\NN\8186047 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 some\DT\1740 forms\NNS\6286395 of\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 humans\NNS\31264 .\.\1740
D011374_D012640 NONE Several\JJ\1740 structurally\RB\1740 related\JJ\1740 metabolites\NNS\20090 of\IN\1740 <e1>progesterone</e1>\NN\14747338 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 deoxycorticosterone\NN\1740 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-21-diol-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 3\CD\13741022 beta-epimers\NNS\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 protective\JJ\1740 activity\NN\30358 against\IN\1740 pilocarpine-\NN\1740 ,\,\1740 kainic\JJ\1740 acid-\NN\1740 and\CC\1740 N-methyl-D-aspartate\NN\1740 (NMDA)-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 .\.\1740
D011374_D012640 NONE Several\JJ\1740 structurally\RB\1740 related\JJ\1740 metabolites\NNS\20090 of\IN\1740 progesterone\NN\14747338 (\-LRB-\1740 <e1>3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-20-ones</e1>\NNS\1740 )\-RRB-\1740 and\CC\1740 deoxycorticosterone\NN\1740 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-21-diol-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 3\CD\13741022 beta-epimers\NNS\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 protective\JJ\1740 activity\NN\30358 against\IN\1740 pilocarpine-\NN\1740 ,\,\1740 kainic\JJ\1740 acid-\NN\1740 and\CC\1740 N-methyl-D-aspartate\NN\1740 (NMDA)-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003900_D012640 NONE Several\JJ\1740 structurally\RB\1740 related\JJ\1740 metabolites\NNS\20090 of\IN\1740 progesterone\NN\14747338 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 <e1>deoxycorticosterone</e1>\NN\1740 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-21-diol-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 3\CD\13741022 beta-epimers\NNS\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 protective\JJ\1740 activity\NN\30358 against\IN\1740 pilocarpine-\NN\1740 ,\,\1740 kainic\JJ\1740 acid-\NN\1740 and\CC\1740 N-methyl-D-aspartate\NN\1740 (NMDA)-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003900_D012640 NONE Several\JJ\1740 structurally\RB\1740 related\JJ\1740 metabolites\NNS\20090 of\IN\1740 progesterone\NN\14747338 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 deoxycorticosterone\NN\1740 (\-LRB-\1740 <e1>3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-21-diol-20-ones</e1>\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 3\CD\13741022 beta-epimers\NNS\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 protective\JJ\1740 activity\NN\30358 against\IN\1740 pilocarpine-\NN\1740 ,\,\1740 kainic\JJ\1740 acid-\NN\1740 and\CC\1740 N-methyl-D-aspartate\NN\1740 (NMDA)-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 .\.\1740
D016202_D012640 NONE Several\JJ\1740 structurally\RB\1740 related\JJ\1740 metabolites\NNS\20090 of\IN\1740 progesterone\NN\14747338 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 deoxycorticosterone\NN\1740 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-21-diol-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 3\CD\13741022 beta-epimers\NNS\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 protective\JJ\1740 activity\NN\30358 against\IN\1740 pilocarpine-\NN\1740 ,\,\1740 kainic\JJ\1740 acid-\NN\1740 and\CC\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 (NMDA)-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 .\.\1740
D016202_D012640 NONE Several\JJ\1740 structurally\RB\1740 related\JJ\1740 metabolites\NNS\20090 of\IN\1740 progesterone\NN\14747338 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 deoxycorticosterone\NN\1740 (\-LRB-\1740 3\CD\13741022 alpha-hydroxy\JJ\1740 pregnane-21-diol-20-ones\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 3\CD\13741022 beta-epimers\NNS\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 protective\JJ\1740 activity\NN\30358 against\IN\1740 pilocarpine-\NN\1740 ,\,\1740 kainic\JJ\1740 acid-\NN\1740 and\CC\1740 N-methyl-D-aspartate\NN\1740 <e1>(NMDA)-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mice\NNS\2329401 .\.\1740
D016202_D012640 NONE The\DT\1740 steroids\NNS\14727670 also\RB\1740 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 delay\NN\15271008 in\IN\13603305 <e1>NMDA</e1>\NN\1740 (\-LRB-\1740 257\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.)-induced\JJ\1740 lethality\NN\4790449 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 completely\RB\1740 protect\VB\1127795 against\IN\1740 NMDA\NN\1740 <e2>seizures</e2>\NNS\14081375 or\CC\3541091 lethality\NN\4790449 .\.\1740
D016202_D012640 NONE The\DT\1740 steroids\NNS\14727670 also\RB\1740 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 delay\NN\15271008 in\IN\13603305 NMDA\NN\1740 (\-LRB-\1740 257\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.)-induced\JJ\1740 lethality\NN\4790449 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 completely\RB\1740 protect\VB\1127795 against\IN\1740 <e1>NMDA</e1>\NN\1740 <e2>seizures</e2>\NNS\14081375 or\CC\3541091 lethality\NN\4790449 .\.\1740
D013256_D064420 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D013256_D064420 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 <e1>steroids</e1>\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D013256_D064420 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D001569_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 <e1>benzodiazepine</e1>\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 <e2>seizures</e2>\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D001569_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 <e1>benzodiazepine</e1>\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 <e2>seizure</e2>\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D001569_D064420 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 <e1>benzodiazepine</e1>\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002998_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 <e1>clonazepam</e1>\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 <e2>seizures</e2>\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D002998_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 <e1>clonazepam</e1>\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 <e2>seizure</e2>\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D002998_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 <e2>seizures</e2>\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 <e1>clonazepam</e1>\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D002998_D012640 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 <e2>seizure</e2>\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 <e1>clonazepam</e1>\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 toxicity\NN\13576101 .\.\1740
D002998_D064420 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 <e1>clonazepam</e1>\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002998_D064420 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 pilocarpine\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 <e1>clonazepam</e1>\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D010862_D064420 NONE Although\IN\1740 the\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 were\VBD\836236 considerably\RB\1740 less\RBR\1740 potent\JJ\1740 than\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 clonazepam\NN\1740 in\IN\13603305 protecting\VBG\1127795 against\IN\1740 <e1>pilocarpine</e1>\NN\14712692 seizures\NNS\14081375 ,\,\1740 steroids\NNS\14727670 with\IN\1740 the\DT\1740 5\CD\13741022 alpha,3\NN\1740 alpha-configuration\NN\1740 had\VBD\2108377 comparable\JJ\1740 or\CC\3541091 higher\JJR\1740 protective\JJ\1740 index\NN\13850304 values\NNS\5941423 (\-LRB-\1740 TD50\NN\1740 for\IN\1740 motor\NN\3699975 impairment\NN\7296428 divided\VBN\140123 by\IN\1740 ED50\NN\1740 for\IN\1740 seizure\JJ\1740 protection\NN\407535 )\-RRB-\1740 than\IN\1740 clonazepam\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 some\DT\1740 neuroactive\JJ\1740 steroids\NNS\14727670 may\MD\15209706 have\VB\2108377 lower\JJR\1740 relative\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
9226773
D008094_D018500 CID Persistent\JJ\1740 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 following\VBG\1835496 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D018500 CID Ten\CD\13745420 years\NNS\15144371 previously\RB\1740 he\PRP\14622893 had\VBD\2108377 been\VBN\836236 diagnosed\VBN\644583 to\TO\1740 have\VB\2108377 <e1>lithium-induced</e1>\JJ\1740 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 ,\,\1740 and\CC\1740 lithium\NN\14625458 therapy\NN\657604 had\VBD\2108377 been\VBN\836236 discontinued\VBN\2609764 .\.\1740
D008094_D018500 CID Ten\CD\13745420 years\NNS\15144371 previously\RB\1740 he\PRP\14622893 had\VBD\2108377 been\VBN\836236 diagnosed\VBN\644583 to\TO\1740 have\VB\2108377 lithium-induced\JJ\1740 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 ,\,\1740 and\CC\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 had\VBD\2108377 been\VBN\836236 discontinued\VBN\2609764 .\.\1740
D008094_D018500 CID He\PRP\14622893 remained\VBD\2604760 thirsty\JJ\1740 and\CC\1740 polyuric\JJ\1740 despite\IN\7501545 cessation\NN\7365849 of\IN\1740 <e1>lithium</e1>\NN\14625458 and\CC\1740 investigations\NNS\5797597 on\IN\1740 admission\NN\49003 showed\VBD\2137132 him\PRP\1740 to\TO\1740 have\VB\2108377 normal\JJ\1740 osmoregulated\VBN\1740 thirst\NN\14035298 and\CC\1740 vasopressin\NN\5407119 secretion\NN\13526110 ,\,\1740 with\IN\1740 clear\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 .\.\1740
D008094_D018500 CID <e1>Lithium</e1>\NN\14625458 induced\VBD\1627355 <e2>nephrogenic\JJ\1740 diabetes\NN\14075199 insipidus</e2>\NN\1740 is\VBZ\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 reversible\JJ\1740 on\IN\1740 cessation\NN\7365849 of\IN\1740 therapy\NN\657604 but\CC\1740 polyuria\NN\14113228 persisted\VBD\118523 in\IN\13603305 this\DT\1740 patient\NN\9898892 for\IN\1740 ten\CD\13745420 years\NNS\15144371 after\IN\1740 lithium\NN\14625458 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D008094_D018500 CID Lithium\NN\14625458 induced\VBD\1627355 <e2>nephrogenic\JJ\1740 diabetes\NN\14075199 insipidus</e2>\NN\1740 is\VBZ\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 reversible\JJ\1740 on\IN\1740 cessation\NN\7365849 of\IN\1740 therapy\NN\657604 but\CC\1740 polyuria\NN\14113228 persisted\VBD\118523 in\IN\13603305 this\DT\1740 patient\NN\9898892 for\IN\1740 ten\CD\13745420 years\NNS\15144371 after\IN\1740 <e1>lithium</e1>\NN\14625458 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D008094_D018500 CID We\PRP\1740 discuss\VBP\1033527 the\DT\1740 possible\JJ\1740 renal\JJ\1740 mechanisms\NNS\13446390 and\CC\1740 the\DT\1740 implications\NNS\5774614 for\IN\1740 management\NN\1123598 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 .\.\1740
D008094_D011141 CID He\PRP\14622893 remained\VBD\2604760 thirsty\JJ\1740 and\CC\1740 <e2>polyuric</e2>\JJ\1740 despite\IN\7501545 cessation\NN\7365849 of\IN\1740 <e1>lithium</e1>\NN\14625458 and\CC\1740 investigations\NNS\5797597 on\IN\1740 admission\NN\49003 showed\VBD\2137132 him\PRP\1740 to\TO\1740 have\VB\2108377 normal\JJ\1740 osmoregulated\VBN\1740 thirst\NN\14035298 and\CC\1740 vasopressin\NN\5407119 secretion\NN\13526110 ,\,\1740 with\IN\1740 clear\JJ\1740 evidence\NN\5816287 of\IN\1740 nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 .\.\1740
D008094_D011141 CID <e1>Lithium</e1>\NN\14625458 induced\VBD\1627355 nephrogenic\JJ\1740 diabetes\NN\14075199 insipidus\NN\1740 is\VBZ\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 reversible\JJ\1740 on\IN\1740 cessation\NN\7365849 of\IN\1740 therapy\NN\657604 but\CC\1740 <e2>polyuria</e2>\NN\14113228 persisted\VBD\118523 in\IN\13603305 this\DT\1740 patient\NN\9898892 for\IN\1740 ten\CD\13745420 years\NNS\15144371 after\IN\1740 lithium\NN\14625458 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D008094_D011141 CID Lithium\NN\14625458 induced\VBD\1627355 nephrogenic\JJ\1740 diabetes\NN\14075199 insipidus\NN\1740 is\VBZ\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 reversible\JJ\1740 on\IN\1740 cessation\NN\7365849 of\IN\1740 therapy\NN\657604 but\CC\1740 <e2>polyuria</e2>\NN\14113228 persisted\VBD\118523 in\IN\13603305 this\DT\1740 patient\NN\9898892 for\IN\1740 ten\CD\13745420 years\NNS\15144371 after\IN\1740 <e1>lithium</e1>\NN\14625458 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D014667_D011141 NONE He\PRP\14622893 remained\VBD\2604760 thirsty\JJ\1740 and\CC\1740 <e2>polyuric</e2>\JJ\1740 despite\IN\7501545 cessation\NN\7365849 of\IN\1740 lithium\NN\14625458 and\CC\1740 investigations\NNS\5797597 on\IN\1740 admission\NN\49003 showed\VBD\2137132 him\PRP\1740 to\TO\1740 have\VB\2108377 normal\JJ\1740 osmoregulated\VBN\1740 thirst\NN\14035298 and\CC\1740 <e1>vasopressin</e1>\NN\5407119 secretion\NN\13526110 ,\,\1740 with\IN\1740 clear\JJ\1740 evidence\NN\5816287 of\IN\1740 nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 .\.\1740
D014667_D018500 NONE He\PRP\14622893 remained\VBD\2604760 thirsty\JJ\1740 and\CC\1740 polyuric\JJ\1740 despite\IN\7501545 cessation\NN\7365849 of\IN\1740 lithium\NN\14625458 and\CC\1740 investigations\NNS\5797597 on\IN\1740 admission\NN\49003 showed\VBD\2137132 him\PRP\1740 to\TO\1740 have\VB\2108377 normal\JJ\1740 osmoregulated\VBN\1740 thirst\NN\14035298 and\CC\1740 <e1>vasopressin</e1>\NN\5407119 secretion\NN\13526110 ,\,\1740 with\IN\1740 clear\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 .\.\1740
3780697
D005283_D009127 CID Post-operative\JJ\1740 <e2>rigidity</e2>\NN\5023233 after\IN\1740 <e1>fentanyl</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D005283_D009127 CID A\DT\13649268 case\NN\7283608 of\IN\1740 thoraco-abdominal\JJ\1740 <e2>rigidity</e2>\NN\5023233 leading\VBG\1752884 to\TO\1740 respiratory\JJ\1740 failure\NN\66216 is\VBZ\836236 described\VBN\1001294 in\IN\13603305 the\DT\1740 post-operative\JJ\1740 period\NN\13575869 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 patient\NN\9898892 who\WP\8299493 received\VBD\2210855 a\DT\13649268 moderate\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 .\.\1740
D005283_D012131 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 thoraco-abdominal\JJ\1740 rigidity\NN\5023233 leading\VBG\1752884 to\TO\1740 <e2>respiratory\JJ\1740 failure</e2>\NN\66216 is\VBZ\836236 described\VBN\1001294 in\IN\13603305 the\DT\1740 post-operative\JJ\1740 period\NN\13575869 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 patient\NN\9898892 who\WP\8299493 received\VBD\2210855 a\DT\13649268 moderate\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 .\.\1740
19203554
D012460_D005921 NONE Proteinase\NN\14732946 3-antineutrophil\NN\1740 cytoplasmic\JJ\1740 antibody-(PR3-ANCA\NN\1740 )\-RRB-\1740 positive\JJ\1740 necrotizing\NN\1740 <e2>glomerulonephritis</e2>\NN\14113798 after\IN\1740 restarting\VBG\1857717 <e1>sulphasalazine</e1>\NN\1740 treatment\NN\654885 .\.\1740
D012460_D005921 NONE This\DT\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 <e1>sulphasalazine</e1>\NN\1740 can\MD\3094503 induce\VB\1627355 PR3-ANCA-positive\NN\1740 necrotizing\NN\1740 <e2>glomerulonephritis</e2>\NN\14113798 .\.\1740
D012460_D003093 NONE A\DT\13649268 59-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>ulcerative\JJ\1740 colitis</e2>\NN\14336539 developed\VBD\1753788 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 pleural\JJ\1740 effusion\NN\6880249 ,\,\1740 eosinophilia\NN\14299637 and\CC\1740 urinary\JJ\1740 abnormalities\NNS\14034177 after\IN\1740 restarting\NN\1740 of\IN\1740 <e1>sulphasalazine</e1>\NN\1740 treatment\NN\654885 .\.\1740
D012460_D005128 NONE A\DT\13649268 59-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 ulcerative\JJ\1740 colitis\NN\14336539 developed\VBD\1753788 <e2>red\JJ\1740 eyes</e2>\NNS\5945642 ,\,\1740 pleural\JJ\1740 effusion\NN\6880249 ,\,\1740 eosinophilia\NN\14299637 and\CC\1740 urinary\JJ\1740 abnormalities\NNS\14034177 after\IN\1740 restarting\NN\1740 of\IN\1740 <e1>sulphasalazine</e1>\NN\1740 treatment\NN\654885 .\.\1740
D012460_D005128 NONE Although\IN\1740 cessation\NN\7365849 of\IN\1740 <e1>sulphasalazine</e1>\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 fever\NN\14299637 ,\,\1740 <e2>red\JJ\1740 eyes</e2>\NNS\5945642 ,\,\1740 chest\VB\1740 pain\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 steroid\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 pleural\JJ\1740 effusion\NN\6880249 remained\VBD\2604760 .\.\1740
D012460_D010996 CID A\DT\13649268 59-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 ulcerative\JJ\1740 colitis\NN\14336539 developed\VBD\1753788 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 <e2>pleural\JJ\1740 effusion</e2>\NN\6880249 ,\,\1740 eosinophilia\NN\14299637 and\CC\1740 urinary\JJ\1740 abnormalities\NNS\14034177 after\IN\1740 restarting\NN\1740 of\IN\1740 <e1>sulphasalazine</e1>\NN\1740 treatment\NN\654885 .\.\1740
D012460_D010996 CID Although\IN\1740 cessation\NN\7365849 of\IN\1740 <e1>sulphasalazine</e1>\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 fever\NN\14299637 ,\,\1740 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 chest\VB\1740 pain\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 <e2>pleural\JJ\1740 effusions</e2>\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 steroid\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 pleural\JJ\1740 effusion\NN\6880249 remained\VBD\2604760 .\.\1740
D012460_D010996 CID Although\IN\1740 cessation\NN\7365849 of\IN\1740 <e1>sulphasalazine</e1>\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 fever\NN\14299637 ,\,\1740 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 chest\VB\1740 pain\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 steroid\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 <e2>pleural\JJ\1740 effusion</e2>\NN\6880249 remained\VBD\2604760 .\.\1740
D012460_D004802 NONE A\DT\13649268 59-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 ulcerative\JJ\1740 colitis\NN\14336539 developed\VBD\1753788 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 pleural\JJ\1740 effusion\NN\6880249 ,\,\1740 <e2>eosinophilia</e2>\NN\14299637 and\CC\1740 urinary\JJ\1740 abnormalities\NNS\14034177 after\IN\1740 restarting\NN\1740 of\IN\1740 <e1>sulphasalazine</e1>\NN\1740 treatment\NN\654885 .\.\1740
D012460_D001745 NONE A\DT\13649268 59-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 ulcerative\JJ\1740 colitis\NN\14336539 developed\VBD\1753788 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 pleural\JJ\1740 effusion\NN\6880249 ,\,\1740 eosinophilia\NN\14299637 and\CC\1740 <e2>urinary\JJ\1740 abnormalities</e2>\NNS\14034177 after\IN\1740 restarting\NN\1740 of\IN\1740 <e1>sulphasalazine</e1>\NN\1740 treatment\NN\654885 .\.\1740
D012460_D005334 CID Although\IN\1740 cessation\NN\7365849 of\IN\1740 <e1>sulphasalazine</e1>\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 <e2>fever</e2>\NN\14299637 ,\,\1740 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 chest\VB\1740 pain\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 steroid\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 pleural\JJ\1740 effusion\NN\6880249 remained\VBD\2604760 .\.\1740
D012460_D002637 NONE Although\IN\1740 cessation\NN\7365849 of\IN\1740 <e1>sulphasalazine</e1>\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 fever\NN\14299637 ,\,\1740 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 <e2>chest\VB\1740 pain</e2>\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 steroid\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 pleural\JJ\1740 effusion\NN\6880249 remained\VBD\2604760 .\.\1740
D013256_D005334 NONE Although\IN\1740 cessation\NN\7365849 of\IN\1740 sulphasalazine\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 <e2>fever</e2>\NN\14299637 ,\,\1740 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 chest\VB\1740 pain\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 pleural\JJ\1740 effusion\NN\6880249 remained\VBD\2604760 .\.\1740
D013256_D005128 NONE Although\IN\1740 cessation\NN\7365849 of\IN\1740 sulphasalazine\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 fever\NN\14299637 ,\,\1740 <e2>red\JJ\1740 eyes</e2>\NNS\5945642 ,\,\1740 chest\VB\1740 pain\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 pleural\JJ\1740 effusion\NN\6880249 remained\VBD\2604760 .\.\1740
D013256_D002637 NONE Although\IN\1740 cessation\NN\7365849 of\IN\1740 sulphasalazine\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 fever\NN\14299637 ,\,\1740 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 <e2>chest\VB\1740 pain</e2>\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 pleural\JJ\1740 effusion\NN\6880249 remained\VBD\2604760 .\.\1740
D013256_D010996 NONE Although\IN\1740 cessation\NN\7365849 of\IN\1740 sulphasalazine\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 fever\NN\14299637 ,\,\1740 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 chest\VB\1740 pain\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 <e2>pleural\JJ\1740 effusions</e2>\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 pleural\JJ\1740 effusion\NN\6880249 remained\VBD\2604760 .\.\1740
D013256_D010996 NONE Although\IN\1740 cessation\NN\7365849 of\IN\1740 sulphasalazine\JJ\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 improvements\NNS\7359599 in\IN\13603305 fever\NN\14299637 ,\,\1740 red\JJ\1740 eyes\NNS\5945642 ,\,\1740 chest\VB\1740 pain\NN\14299637 ,\,\1740 titer\NN\5038593 of\IN\1740 C-reactive\JJ\1740 protein\NN\14944888 and\CC\1740 volume\NN\33615 of\IN\1740 the\DT\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 we\PRP\1740 initiated\VBD\1617192 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 ,\,\1740 because\IN\1740 PR3-ANCA\NN\1740 titer\NN\5038593 rose\VBD\1835496 to\IN\1740 320\CD\1740 EU\NNP\14625458 ,\,\1740 eosinophil\NN\5449959 count\NN\13582013 increased\VBD\169651 to\TO\1740 1,100\CD\1740 cells/microl\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 <e2>pleural\JJ\1740 effusion</e2>\NN\6880249 remained\VBD\2604760 .\.\1740
D013256_D010996 NONE One\CD\13741022 month\NN\15113229 after\IN\1740 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 ,\,\1740 the\DT\1740 <e2>pleural\JJ\1740 effusion</e2>\NN\6880249 disappeared\VBD\2609764 ,\,\1740 and\CC\1740 PR3-ANCA\NN\1740 titer\NN\5038593 normalized\VBD\109660 3\CD\13741022 months\NNS\15113229 later\RB\1740 .\.\1740
12842176
D001556_D020258 NONE Effect\NN\34213 of\IN\1740 <e1>lindane</e1>\NN\14919948 on\IN\1740 hepatic\JJ\1740 and\CC\1740 brain\NN\5462674 cytochrome\NN\14888884 P450s\NN\1740 and\CC\1740 influence\NN\5190804 of\IN\1740 P450\NN\1740 modulation\NN\7044917 in\IN\13603305 lindane\NN\14919948 induced\VBN\1627355 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D001556_D020258 NONE Effect\NN\34213 of\IN\1740 lindane\NN\14919948 on\IN\1740 hepatic\JJ\1740 and\CC\1740 brain\NN\5462674 cytochrome\NN\14888884 P450s\NN\1740 and\CC\1740 influence\NN\5190804 of\IN\1740 P450\NN\1740 modulation\NN\7044917 in\IN\13603305 <e1>lindane</e1>\NN\14919948 induced\VBN\1627355 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008748_D012640 NONE Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 <e1>3-methylcholanthrene</e1>\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 convulsions\NNS\14081375 .\.\1740
D008748_D012640 NONE Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 <e1>3-methylcholanthrene</e1>\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D008748_D012640 NONE Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 <e1>MC</e1>\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 convulsions\NNS\14081375 .\.\1740
D008748_D012640 NONE Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 <e1>MC</e1>\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D001556_D012640 CID Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>lindane</e1>\NN\14919948 induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 convulsions\NNS\14081375 .\.\1740
D001556_D012640 CID Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>lindane</e1>\NN\14919948 induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D001556_D012640 CID Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>lindane</e1>\NN\14919948 induced\VBN\1627355 convulsions\NNS\14081375 .\.\1740
D001556_D012640 CID Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>lindane</e1>\NN\14919948 induced\VBN\1627355 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D001556_D012640 CID Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 <e1>lindane</e1>\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 cobalt\NN\14625458 chloride\NN\14818238 incidence\NN\13821570 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 lindane\NN\14919948 indicating\VBG\952524 that\IN\1740 lindane\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 ethanol\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 toxicity\NN\13576101 .\.\1740
D001556_D012640 CID Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 lindane\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 cobalt\NN\14625458 chloride\NN\14818238 incidence\NN\13821570 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 <e1>lindane</e1>\NN\14919948 indicating\VBG\952524 that\IN\1740 lindane\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 ethanol\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 toxicity\NN\13576101 .\.\1740
D001556_D012640 CID Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 lindane\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 cobalt\NN\14625458 chloride\NN\14818238 incidence\NN\13821570 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 lindane\NN\14919948 indicating\VBG\952524 that\IN\1740 <e1>lindane</e1>\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 ethanol\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 toxicity\NN\13576101 .\.\1740
D010634_D012640 NONE Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 <e1>phenobarbital</e1>\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 convulsions\NNS\14081375 .\.\1740
D010634_D012640 NONE Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 <e1>phenobarbital</e1>\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 ethanol\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D000431_D012640 NONE Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 <e1>ethanol</e1>\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 convulsions\NNS\14081375 .\.\1740
D000431_D012640 NONE Induction\NN\7450842 studies\NNS\635850 have\VBP\2108377 further\RB\1740 shown\VBN\2137132 that\IN\1740 while\IN\15122231 pretreatment\NN\1740 of\IN\1740 3-methylcholanthrene\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P4501A1/1A2\NN\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 any\DT\1740 significant\JJ\1740 effect\NN\34213 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\JJ\1740 convulsions\NNS\14081375 ,\,\1740 pretreatment\NN\1740 with\IN\1740 phenobarbital\JJ\1740 (\-LRB-\1740 PB\NN\14625458 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2B1/2B2\CD\1740 or\CC\3541091 <e1>ethanol</e1>\NN\14708720 ,\,\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 P450\NN\1740 2E1\NN\1740 catalysed\JJ\1740 reactions\NNS\13446390 ,\,\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 lindane\NN\14919948 induced\VBN\1627355 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D000431_D012640 NONE Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 lindane\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 cobalt\NN\14625458 chloride\NN\14818238 incidence\NN\13821570 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 lindane\NN\14919948 indicating\VBG\952524 that\IN\1740 lindane\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 <e1>ethanol</e1>\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 toxicity\NN\13576101 .\.\1740
D001556_D064420 NONE Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 <e1>lindane</e1>\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 cobalt\NN\14625458 chloride\NN\14818238 incidence\NN\13821570 of\IN\1740 convulsions\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 lindane\NN\14919948 indicating\VBG\952524 that\IN\1740 lindane\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 ethanol\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D001556_D064420 NONE Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 lindane\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 cobalt\NN\14625458 chloride\NN\14818238 incidence\NN\13821570 of\IN\1740 convulsions\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 <e1>lindane</e1>\NN\14919948 indicating\VBG\952524 that\IN\1740 lindane\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 ethanol\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D001556_D064420 NONE Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 lindane\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 cobalt\NN\14625458 chloride\NN\14818238 incidence\NN\13821570 of\IN\1740 convulsions\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 lindane\NN\14919948 indicating\VBG\952524 that\IN\1740 <e1>lindane</e1>\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 ethanol\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
C018021_D012640 NONE Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 lindane\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 <e1>cobalt\NN\14625458 chloride</e1>\NN\14818238 incidence\NN\13821570 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 lindane\NN\14919948 indicating\VBG\952524 that\IN\1740 lindane\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 ethanol\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 toxicity\NN\13576101 .\.\1740
C018021_D064420 NONE Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 lindane\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 <e1>cobalt\NN\14625458 chloride</e1>\NN\14818238 incidence\NN\13821570 of\IN\1740 convulsions\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 lindane\NN\14919948 indicating\VBG\952524 that\IN\1740 lindane\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 ethanol\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D000431_D064420 NONE Similarly\RB\1740 ,\,\1740 when\WRB\1740 the\DT\1740 P450-mediated\JJ\1740 metabolism\NN\13526110 of\IN\1740 lindane\NN\14919948 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 cobalt\NN\14625458 chloride\NN\14818238 incidence\NN\13821570 of\IN\1740 convulsions\NNS\14081375 was\VBD\836236 increased\VBN\169651 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 lindane\NN\14919948 indicating\VBG\952524 that\IN\1740 lindane\NN\14919948 per\FW\1740 se\FW\14724645 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 formed\VBN\1617192 by\IN\1740 PB\NN\14625458 or\CC\3541091 <e1>ethanol</e1>\NN\14708720 inducible\JJ\1740 P450\NN\1740 isoenzymes\NNS\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 its\PRP$\6125041 neurobehavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
6699841
D009288_D007681 CID <e2>Renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 due\IN\5174653 to\IN\1740 <e1>naproxen</e1>\NN\3828465 .\.\1740
D009288_D007681 CID A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 <e1>naproxen</e1>\NN\3828465 therapy\NN\657604 .\.\1740
D009288_D007681 CID A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 <e2>RPN</e2>\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 <e1>naproxen</e1>\NN\3828465 therapy\NN\657604 .\.\1740
D013467_D001172 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 <e1>sulindac</e1>\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D013467_D007681 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 <e1>sulindac</e1>\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D013467_D007681 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 <e1>sulindac</e1>\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 <e2>RPN</e2>\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D013467_D007681 NONE We\PRP\1740 review\VBP\644583 previous\JJ\1740 reports\NNS\6470073 linking\VBG\628491 <e2>RPN</e2>\NN\1740 to\TO\1740 antiinflammatory\JJ\1740 drug\NN\14778436 use\NN\407535 and\CC\1740 discuss\VB\1033527 possible\JJ\1740 advantages\NNS\5154517 of\IN\1740 <e1>sulindac</e1>\NN\3828465 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 experienced\VBN\2108377 renal\JJ\1740 toxicity\NN\13576101 from\IN\1740 other\JJ\1740 antiinflammatory\JJ\1740 agents\NNS\7347 .\.\1740
D005279_D001172 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 <e1>fenoprofen\JJ\1740 calcium</e1>\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D005279_D007681 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 <e1>fenoprofen\JJ\1740 calcium</e1>\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D005279_D007681 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 <e1>fenoprofen\JJ\1740 calcium</e1>\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 <e2>RPN</e2>\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D012459_D001172 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 <e1>salicylates</e1>\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D012459_D007681 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 <e1>salicylates</e1>\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D012459_D007681 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 <e1>salicylates</e1>\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 <e2>RPN</e2>\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D006046_D001172 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 <e1>gold</e1>\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D006046_D007681 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 <e1>gold</e1>\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D006046_D007681 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 <e1>gold</e1>\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 <e2>RPN</e2>\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 naproxen\NN\3828465 therapy\NN\657604 .\.\1740
D009288_D001172 NONE A\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 ,\,\1740 who\WP\8299493 had\VBD\2108377 previously\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 sulindac\NN\3828465 ,\,\1740 fenoprofen\JJ\1740 calcium\NN\14625458 ,\,\1740 high\JJ\1740 dose\NN\3740161 salicylates\NNS\3828465 and\CC\1740 gold\NN\13371489 salts\NNS\14818238 ,\,\1740 developed\VBD\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 institution\NN\8008335 of\IN\1740 <e1>naproxen</e1>\NN\3828465 therapy\NN\657604 .\.\1740
D013467_D007674 NONE We\PRP\1740 review\VBP\644583 previous\JJ\1740 reports\NNS\6470073 linking\VBG\628491 RPN\NN\1740 to\TO\1740 antiinflammatory\JJ\1740 drug\NN\14778436 use\NN\407535 and\CC\1740 discuss\VB\1033527 possible\JJ\1740 advantages\NNS\5154517 of\IN\1740 <e1>sulindac</e1>\NN\3828465 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 experienced\VBN\2108377 <e2>renal\JJ\1740 toxicity</e2>\NN\13576101 from\IN\1740 other\JJ\1740 antiinflammatory\JJ\1740 agents\NNS\7347 .\.\1740
1545575
D003520_D006470 CID <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 is\VBZ\836236 a\DT\13649268 potentially\RB\1740 serious\JJ\1740 complication\NN\1073995 of\IN\1740 high-dose\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 administered\VBN\2436349 before\IN\1740 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 .\.\1740
D003520_D006470 CID In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 obviate\VB\2452885 the\DT\1740 inconvenience\NN\14446652 of\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 feasibility\NN\5152150 trial\NN\786195 of\IN\1740 uroprophylaxis\NN\1740 with\IN\1740 mesna\NN\1740 ,\,\1740 which\WDT\1740 neutralizes\VBZ\126264 the\DT\1740 hepatic\JJ\1740 metabolite\NN\20090 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 that\WDT\1740 causes\VBZ\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 is\VBZ\836236 a\DT\13649268 potentially\RB\1740 serious\JJ\1740 complication\NN\1073995 of\IN\1740 high-dose\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 administered\VBN\2436349 before\IN\1740 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 .\.\1740
D003520_D003556 CID In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 obviate\VB\2452885 the\DT\1740 inconvenience\NN\14446652 of\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 feasibility\NN\5152150 trial\NN\786195 of\IN\1740 uroprophylaxis\NN\1740 with\IN\1740 mesna\NN\1740 ,\,\1740 which\WDT\1740 neutralizes\VBZ\126264 the\DT\1740 hepatic\JJ\1740 metabolite\NN\20090 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 that\WDT\1740 causes\VBZ\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D015080_D006470 NONE In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 obviate\VB\2452885 the\DT\1740 inconvenience\NN\14446652 of\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 feasibility\NN\5152150 trial\NN\786195 of\IN\1740 uroprophylaxis\NN\1740 with\IN\1740 <e1>mesna</e1>\NN\1740 ,\,\1740 which\WDT\1740 neutralizes\VBZ\126264 the\DT\1740 hepatic\JJ\1740 metabolite\NN\20090 of\IN\1740 cyclophosphamide\NN\1740 that\WDT\1740 causes\VBZ\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D015080_D006470 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 two\CD\13741022 of\IN\1740 four\CD\13741022 consecutive\JJ\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>mesna</e1>\NN\1740 uroprophylaxis\NN\1740 before\IN\1740 allogeneic\JJ\1740 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 had\VBD\2108377 severe\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 for\IN\1740 at\IN\14622893 least\JJS\1740 2\CD\13741022 weeks\NNS\15113229 .\.\1740
D015080_D003556 NONE In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 obviate\VB\2452885 the\DT\1740 inconvenience\NN\14446652 of\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 feasibility\NN\5152150 trial\NN\786195 of\IN\1740 uroprophylaxis\NN\1740 with\IN\1740 <e1>mesna</e1>\NN\1740 ,\,\1740 which\WDT\1740 neutralizes\VBZ\126264 the\DT\1740 hepatic\JJ\1740 metabolite\NN\20090 of\IN\1740 cyclophosphamide\NN\1740 that\WDT\1740 causes\VBZ\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D015080_D003556 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 two\CD\13741022 of\IN\1740 four\CD\13741022 consecutive\JJ\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>mesna</e1>\NN\1740 uroprophylaxis\NN\1740 before\IN\1740 allogeneic\JJ\1740 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 had\VBD\2108377 severe\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 for\IN\1740 at\IN\14622893 least\JJS\1740 2\CD\13741022 weeks\NNS\15113229 .\.\1740
12452237
D008012_D010149 NONE Can\MD\3094503 <e1>lidocaine</e1>\NN\3681148 reduce\VB\441445 succinylcholine\NN\3800001 induced\VBN\1627355 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 ?\.\1740
D008012_D010149 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 where\WRB\1740 succinylcholine\NN\3800001 is\VBZ\836236 used\VBN\1156834 ,\,\1740 <e1>lidocaine</e1>\NN\3681148 is\VBZ\836236 proven\VBN\2604760 to\TO\1740 be\VB\836236 the\DT\1740 useful\JJ\1740 pretreatment\NN\1740 agent\NN\7347 for\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 .\.\1740
D013390_D010149 CID Can\MD\3094503 lidocaine\NN\3681148 reduce\VB\441445 <e1>succinylcholine</e1>\NN\3800001 induced\VBN\1627355 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 ?\.\1740
D013390_D010149 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 where\WRB\1740 <e1>succinylcholine</e1>\NN\3800001 is\VBZ\836236 used\VBN\1156834 ,\,\1740 lidocaine\NN\3681148 is\VBZ\836236 proven\VBN\2604760 to\TO\1740 be\VB\836236 the\DT\1740 useful\JJ\1740 pretreatment\NN\1740 agent\NN\7347 for\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 <e2>postoperative\JJ\1740 myalgia</e2>\NN\14322699 .\.\1740
D008012_D063806 NONE This\DT\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 determine\VB\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 pretreatment\NN\1740 on\IN\1740 reduction\NN\351485 of\IN\1740 succinylcholine-induced\JJ\1740 <e2>myalgia</e2>\NN\14322699 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 general\JJ\1740 anesthesia\NN\14034177 for\IN\1740 gynecological\JJ\1740 surgery\NN\6045562 .\.\1740
D013390_D063806 NONE This\DT\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 determine\VB\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 lidocaine\NN\3681148 pretreatment\NN\1740 on\IN\1740 reduction\NN\351485 of\IN\1740 <e1>succinylcholine-induced</e1>\JJ\1740 <e2>myalgia</e2>\NN\14322699 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 general\JJ\1740 anesthesia\NN\14034177 for\IN\1740 gynecological\JJ\1740 surgery\NN\6045562 .\.\1740
16826348
D003561_D010523 CID <e2>Peripheral\JJ\1740 neuropathy</e2>\NN\14204950 caused\VBN\1617192 by\IN\1740 high-dose\JJ\1740 <e1>cytosine\NN\14999913 arabinoside</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 myeloid\JJ\1740 leukemia\NN\14239918 .\.\1740
D003561_D010523 CID Although\IN\1740 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 are\VBP\836236 still\RB\1740 unclear\JJ\1740 ,\,\1740 high-dose\JJ\1740 <e1>cytosine\NN\14999913 arabinoside</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 therapy\NN\657604 that\WDT\1740 is\VBZ\836236 potentially\RB\1740 toxic\JJ\1740 to\TO\1740 the\DT\1740 peripheral\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 and\CC\1740 auto/alloimmunity\NN\1740 may\MD\15209706 play\VB\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 these\DT\1740 mechanisms\NNS\13446390 .\.\1740
D003561_D015470 NONE Peripheral\JJ\1740 neuropathy\NN\14204950 caused\VBN\1617192 by\IN\1740 high-dose\JJ\1740 <e1>cytosine\NN\14999913 arabinoside</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>acute\JJ\1740 myeloid\JJ\1740 leukemia</e2>\NN\14239918 .\.\1740
D003561_D064420 NONE The\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 <e2>toxicity</e2>\NN\13576101 of\IN\1740 high-dose\JJ\1740 <e1>cytosine\NN\14999913 arabinoside</e1>\NN\1740 is\VBZ\836236 well\RB\1740 recognized\VBN\686447 ,\,\1740 but\CC\1740 the\DT\1740 toxicity\NN\13576101 of\IN\1740 cytosine\NN\14999913 arabinoside\NN\1740 in\IN\13603305 the\DT\1740 peripheral\JJ\1740 nervous\JJ\1740 system\NN\3575240 has\VBZ\2108377 been\VBN\836236 infrequently\RB\1740 reported\VBN\831651 .\.\1740
D003561_D064420 NONE The\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 of\IN\1740 high-dose\JJ\1740 <e1>cytosine\NN\14999913 arabinoside</e1>\NN\1740 is\VBZ\836236 well\RB\1740 recognized\VBN\686447 ,\,\1740 but\CC\1740 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 cytosine\NN\14999913 arabinoside\NN\1740 in\IN\13603305 the\DT\1740 peripheral\JJ\1740 nervous\JJ\1740 system\NN\3575240 has\VBZ\2108377 been\VBN\836236 infrequently\RB\1740 reported\VBN\831651 .\.\1740
D003561_D064420 NONE The\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 <e2>toxicity</e2>\NN\13576101 of\IN\1740 high-dose\JJ\1740 cytosine\NN\14999913 arabinoside\NN\1740 is\VBZ\836236 well\RB\1740 recognized\VBN\686447 ,\,\1740 but\CC\1740 the\DT\1740 toxicity\NN\13576101 of\IN\1740 <e1>cytosine\NN\14999913 arabinoside</e1>\NN\1740 in\IN\13603305 the\DT\1740 peripheral\JJ\1740 nervous\JJ\1740 system\NN\3575240 has\VBZ\2108377 been\VBN\836236 infrequently\RB\1740 reported\VBN\831651 .\.\1740
D003561_D064420 NONE The\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 of\IN\1740 high-dose\JJ\1740 cytosine\NN\14999913 arabinoside\NN\1740 is\VBZ\836236 well\RB\1740 recognized\VBN\686447 ,\,\1740 but\CC\1740 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>cytosine\NN\14999913 arabinoside</e1>\NN\1740 in\IN\13603305 the\DT\1740 peripheral\JJ\1740 nervous\JJ\1740 system\NN\3575240 has\VBZ\2108377 been\VBN\836236 infrequently\RB\1740 reported\VBN\831651 .\.\1740
D003561_D006987 NONE The\DT\1740 first\JJ\1740 course\NN\883297 of\IN\1740 high-dose\JJ\1740 <e1>cytosine\NN\14999913 arabinoside</e1>\NN\1740 resulted\VBD\2633881 in\IN\13603305 no\DT\7204911 unusual\JJ\1740 symptoms\NNS\5823932 ,\,\1740 but\CC\1740 on\IN\1740 day\NN\15154774 21\CD\13745420 of\IN\1740 the\DT\1740 second\JJ\1740 course\NN\883297 of\IN\1740 treatment\NN\654885 ,\,\1740 the\DT\1740 patient\NN\9898892 complained\VBD\843959 of\IN\1740 <e2>numbness</e2>\NN\14299637 in\IN\13603305 his\PRP$\1740 right\JJ\1740 foot\NN\5563034 .\.\1740
D008775_D009422 NONE This\DT\1740 <e2>neuropathy</e2>\NN\14204950 was\VBD\836236 gradually\RB\1740 resolving\VBG\352826 ;\:\1740 however\RB\1740 ,\,\1740 after\IN\1740 the\DT\1740 patient\NN\9898892 received\VBD\2210855 allogeneic\JJ\1740 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 ,\,\1740 the\DT\1740 symptoms\NNS\5823932 worsened\VBD\146138 ,\,\1740 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 graft-versus-host\JJ\1740 disease\NN\14061805 ,\,\1740 and\CC\1740 the\DT\1740 symptoms\NNS\5823932 subsequently\RB\1740 responded\VBD\2367363 to\IN\1740 <e1>methylprednisolone</e1>\NN\1740 .\.\1740
D008775_D006086 NONE This\DT\1740 neuropathy\NN\14204950 was\VBD\836236 gradually\RB\1740 resolving\VBG\352826 ;\:\1740 however\RB\1740 ,\,\1740 after\IN\1740 the\DT\1740 patient\NN\9898892 received\VBD\2210855 allogeneic\JJ\1740 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 ,\,\1740 the\DT\1740 symptoms\NNS\5823932 worsened\VBD\146138 ,\,\1740 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>graft-versus-host\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 and\CC\1740 the\DT\1740 symptoms\NNS\5823932 subsequently\RB\1740 responded\VBD\2367363 to\IN\1740 <e1>methylprednisolone</e1>\NN\1740 .\.\1740
3123611
D003276_D002819 CID <e2>Chorea</e2>\NNP\14253124 associated\VBN\628491 with\IN\1740 <e1>oral\JJ\1740 contraception</e1>\NN\851994 .\.\1740
D003276_D002819 CID Three\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 <e2>chorea</e2>\NN\14253124 while\IN\15122231 receiving\VBG\2210855 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 .\.\1740
D003276_D002819 CID The\DT\1740 third\JJ\1740 patient\NN\9898892 had\VBD\2108377 acute\JJ\1740 amphetamine-induced\JJ\1740 <e2>chorea</e2>\NN\14253124 after\IN\1740 prolonged\JJ\1740 <e1>oral\JJ\1740 contraception</e1>\NN\851994 .\.\1740
D000661_D002819 CID The\DT\1740 third\JJ\1740 patient\NN\9898892 had\VBD\2108377 acute\JJ\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>chorea</e2>\NN\14253124 after\IN\1740 prolonged\JJ\1740 oral\JJ\1740 contraception\NN\851994 .\.\1740
10411803
D015313_D000743 CID Severe\JJ\1740 immune\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 associated\VBN\628491 with\IN\1740 prophylactic\JJ\1740 use\NN\407535 of\IN\1740 <e1>cefotetan</e1>\NN\1740 in\IN\13603305 obstetric\JJ\1740 and\CC\1740 gynecologic\JJ\1740 procedures\NNS\407535 .\.\1740
D015313_D000743 CID Second-\NN\1740 and\CC\1740 third-generation\JJ\1740 cephalosporins\NNS\2716866 ,\,\1740 especially\RB\1740 <e1>cefotetan</e1>\JJ\1740 ,\,\1740 are\VBP\836236 increasingly\RB\1740 associated\VBN\628491 with\IN\1740 severe\JJ\1740 ,\,\1740 sometimes\RB\1740 fatal\JJ\1740 immune\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D015313_D000743 CID We\PRP\1740 noticed\VBD\2163746 that\IN\1740 10\CD\13745420 of\IN\1740 our\PRP$\1740 35\CD\1740 cases\NNS\7283608 of\IN\1740 <e1>cefotetan-induced</e1>\JJ\1740 <e2>hemolytic\JJ\1740 anemias</e2>\NNS\14189204 were\VBD\836236 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 received\VBN\2210855 cefotetan\JJ\1740 prophylactically\RB\1740 for\IN\1740 obstetric\JJ\1740 and\CC\1740 gynecologic\JJ\1740 procedures\NNS\407535 .\.\1740
D015313_D000743 CID We\PRP\1740 noticed\VBD\2163746 that\IN\1740 10\CD\13745420 of\IN\1740 our\PRP$\1740 35\CD\1740 cases\NNS\7283608 of\IN\1740 cefotetan-induced\JJ\1740 <e2>hemolytic\JJ\1740 anemias</e2>\NNS\14189204 were\VBD\836236 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 received\VBN\2210855 <e1>cefotetan</e1>\JJ\1740 prophylactically\RB\1740 for\IN\1740 obstetric\JJ\1740 and\CC\1740 gynecologic\JJ\1740 procedures\NNS\407535 .\.\1740
D002511_D000743 NONE Second-\NN\1740 and\CC\1740 third-generation\JJ\1740 <e1>cephalosporins</e1>\NNS\2716866 ,\,\1740 especially\RB\1740 cefotetan\JJ\1740 ,\,\1740 are\VBP\836236 increasingly\RB\1740 associated\VBN\628491 with\IN\1740 severe\JJ\1740 ,\,\1740 sometimes\RB\1740 fatal\JJ\1740 immune\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
16596970
D010862_D012640 NONE <e1>Pilocarpine</e1>\NN\14712692 <e2>seizures</e2>\NNS\14081375 cause\VBP\1617192 age-dependent\JJ\1740 impairment\NN\7296428 in\IN\13603305 auditory\JJ\1740 location\NN\2684 discrimination\NN\1123598 .\.\1740
D010862_D012640 NONE <e1>Pilocarpine</e1>\NN\14712692 on\IN\1740 either\DT\1740 day\NN\15154774 induced\VBN\1627355 status\NN\24720 epilepticus\NN\1740 ;\:\1740 status\NN\24720 epilepticus\NN\1740 at\IN\14622893 P45\NN\1740 resulted\VBD\2633881 in\IN\13603305 CA3\NN\1740 cell\NN\3080309 loss\NN\13252973 and\CC\1740 spontaneous\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 whereas\IN\1740 P20\NN\1740 rats\NNS\2329401 had\VBD\2108377 no\DT\7204911 cell\NN\3080309 loss\NN\13252973 or\CC\3541091 spontaneous\JJ\1740 seizures\NNS\14081375 .\.\1740
D010862_D012640 NONE <e1>Pilocarpine</e1>\NN\14712692 on\IN\1740 either\DT\1740 day\NN\15154774 induced\VBN\1627355 status\NN\24720 epilepticus\NN\1740 ;\:\1740 status\NN\24720 epilepticus\NN\1740 at\IN\14622893 P45\NN\1740 resulted\VBD\2633881 in\IN\13603305 CA3\NN\1740 cell\NN\3080309 loss\NN\13252973 and\CC\1740 spontaneous\JJ\1740 seizures\NNS\14081375 ,\,\1740 whereas\IN\1740 P20\NN\1740 rats\NNS\2329401 had\VBD\2108377 no\DT\7204911 cell\NN\3080309 loss\NN\13252973 or\CC\3541091 spontaneous\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D001308 CID <e1>Pilocarpine</e1>\NN\14712692 seizures\NNS\14081375 cause\VBP\1617192 age-dependent\JJ\1740 <e2>impairment\NN\7296428 in\IN\13603305 auditory\JJ\1740 location\NN\2684 discrimination</e2>\NN\1123598 .\.\1740
D010862_D013226 CID <e1>Pilocarpine</e1>\NN\14712692 on\IN\1740 either\DT\1740 day\NN\15154774 induced\VBN\1627355 <e2>status\NN\24720 epilepticus</e2>\NN\1740 ;\:\1740 status\NN\24720 epilepticus\NN\1740 at\IN\14622893 P45\NN\1740 resulted\VBD\2633881 in\IN\13603305 CA3\NN\1740 cell\NN\3080309 loss\NN\13252973 and\CC\1740 spontaneous\JJ\1740 seizures\NNS\14081375 ,\,\1740 whereas\IN\1740 P20\NN\1740 rats\NNS\2329401 had\VBD\2108377 no\DT\7204911 cell\NN\3080309 loss\NN\13252973 or\CC\3541091 spontaneous\JJ\1740 seizures\NNS\14081375 .\.\1740
D010862_D013226 CID <e1>Pilocarpine</e1>\NN\14712692 on\IN\1740 either\DT\1740 day\NN\15154774 induced\VBN\1627355 status\NN\24720 epilepticus\NN\1740 ;\:\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 at\IN\14622893 P45\NN\1740 resulted\VBD\2633881 in\IN\13603305 CA3\NN\1740 cell\NN\3080309 loss\NN\13252973 and\CC\1740 spontaneous\JJ\1740 seizures\NNS\14081375 ,\,\1740 whereas\IN\1740 P20\NN\1740 rats\NNS\2329401 had\VBD\2108377 no\DT\7204911 cell\NN\3080309 loss\NN\13252973 or\CC\3541091 spontaneous\JJ\1740 seizures\NNS\14081375 .\.\1740
2576810
D016666_D006948 CID A\DT\13649268 repeated\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>fluvoxamine</e1>\NN\1740 (\-LRB-\1740 twice\RB\1740 daily\RB\1740 for\IN\1740 14\CD\13745420 days\NNS\15140892 )\-RRB-\1740 potentiated\VBD\229605 in\IN\13603305 mice\NNS\2329401 and\CC\1740 in\IN\13603305 rats\NNS\2329401 (\-LRB-\1740 weaker\JJR\1740 )\-RRB-\1740 the\DT\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D016666_D006948 CID The\DT\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 nomifensine\NN\1740 in\IN\13603305 mice\NNS\2329401 remained\VBD\2604760 unaffected\JJ\1740 by\IN\1740 <e1>fluvoxamine</e1>\NN\1740 .\.\1740
D000661_D006948 CID A\DT\13649268 repeated\JJ\1740 treatment\NN\654885 with\IN\1740 fluvoxamine\NN\1740 (\-LRB-\1740 twice\RB\1740 daily\RB\1740 for\IN\1740 14\CD\13745420 days\NNS\15140892 )\-RRB-\1740 potentiated\VBD\229605 in\IN\13603305 mice\NNS\2329401 and\CC\1740 in\IN\13603305 rats\NNS\2329401 (\-LRB-\1740 weaker\JJR\1740 )\-RRB-\1740 the\DT\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D009627_D006948 CID The\DT\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 <e1>nomifensine</e1>\NN\1740 in\IN\13603305 mice\NNS\2329401 remained\VBD\2604760 unaffected\JJ\1740 by\IN\1740 fluvoxamine\NN\1740 .\.\1740
12091028
D003975_D006212 NONE <e1>Diazepam</e1>\NNP\2830852 ,\,\1740 unless\IN\1740 contraindicated\VBN\872886 or\CC\3541091 risky\JJ\1740 ,\,\1740 remains\VBZ\2604760 the\DT\1740 only\JJ\1740 necessary\JJ\1740 complementary\JJ\1740 drug\NN\14778436 to\TO\1740 ketamine\VB\1740 as\IN\14622893 it\PRP\6125041 buffers\VBZ\169806 its\PRP$\6125041 cardiovascular\JJ\1740 response\NN\11410625 and\CC\1740 decreases\VBZ\169651 the\DT\1740 duration\NN\15113229 and\CC\1740 intensity\NN\5090441 of\IN\1740 operative\JJ\1740 and\CC\1740 postoperative\JJ\1740 <e2>hallucinations</e2>\NNS\14376855 .\.\1740
D007649_D006212 CID Diazepam\NNP\2830852 ,\,\1740 unless\IN\1740 contraindicated\VBN\872886 or\CC\3541091 risky\JJ\1740 ,\,\1740 remains\VBZ\2604760 the\DT\1740 only\JJ\1740 necessary\JJ\1740 complementary\JJ\1740 drug\NN\14778436 to\TO\1740 <e1>ketamine</e1>\VB\1740 as\IN\14622893 it\PRP\6125041 buffers\VBZ\169806 its\PRP$\6125041 cardiovascular\JJ\1740 response\NN\11410625 and\CC\1740 decreases\VBZ\169651 the\DT\1740 duration\NN\15113229 and\CC\1740 intensity\NN\5090441 of\IN\1740 operative\JJ\1740 and\CC\1740 postoperative\JJ\1740 <e2>hallucinations</e2>\NNS\14376855 .\.\1740
11245434
D003520_D000740 NONE Erythropoietin\NN\14888310 restores\VBZ\1631072 the\DT\1740 <e2>anemia-induced</e2>\JJ\1740 reduction\NN\351485 in\IN\13603305 <e1>cyclophosphamide</e1>\NN\1740 cytotoxicity\NN\13583478 in\IN\13603305 rat\NN\2329401 tumors\NNS\14234074 .\.\1740
D003520_D000740 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 examine\VB\789138 the\DT\1740 impact\NN\7339329 of\IN\1740 <e2>anemia</e2>\NN\14189204 prevention\NN\1073995 by\IN\1740 recombinant\JJ\1740 human\JJ\1740 erythropoietin\NN\14888310 (\-LRB-\1740 rHuEPO\JJ\1740 )\-RRB-\1740 treatment\NN\654885 on\IN\1740 the\DT\1740 cytotoxicity\NN\13583478 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 solid\JJ\1740 experimental\JJ\1740 tumors\NNS\14234074 .\.\1740
D003520_D000740 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 reduces\VBZ\441445 cytotoxicity\NN\13583478 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 tumors\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 anemia\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 oxygen\NN\14622893 supply\NN\13576355 to\TO\1740 tumor\NN\14234074 tissue\NN\5220461 .\.\1740
D003520_D000740 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 anemia\NN\14189204 reduces\VBZ\441445 cytotoxicity\NN\13583478 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 tumors\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 <e2>anemia</e2>\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 oxygen\NN\14622893 supply\NN\13576355 to\TO\1740 tumor\NN\14234074 tissue\NN\5220461 .\.\1740
D003520_D064420 NONE Erythropoietin\NN\14888310 restores\VBZ\1631072 the\DT\1740 anemia-induced\JJ\1740 reduction\NN\351485 in\IN\13603305 <e1>cyclophosphamide</e1>\NN\1740 <e2>cytotoxicity</e2>\NN\13583478 in\IN\13603305 rat\NN\2329401 tumors\NNS\14234074 .\.\1740
D003520_D064420 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 examine\VB\789138 the\DT\1740 impact\NN\7339329 of\IN\1740 anemia\NN\14189204 prevention\NN\1073995 by\IN\1740 recombinant\JJ\1740 human\JJ\1740 erythropoietin\NN\14888310 (\-LRB-\1740 rHuEPO\JJ\1740 )\-RRB-\1740 treatment\NN\654885 on\IN\1740 the\DT\1740 <e2>cytotoxicity</e2>\NN\13583478 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 solid\JJ\1740 experimental\JJ\1740 tumors\NNS\14234074 .\.\1740
D003520_D064420 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 anemia\NN\14189204 reduces\VBZ\441445 <e2>cytotoxicity</e2>\NN\13583478 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 tumors\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 anemia\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 oxygen\NN\14622893 supply\NN\13576355 to\TO\1740 tumor\NN\14234074 tissue\NN\5220461 .\.\1740
D003520_D009369 NONE Erythropoietin\NN\14888310 restores\VBZ\1631072 the\DT\1740 anemia-induced\JJ\1740 reduction\NN\351485 in\IN\13603305 <e1>cyclophosphamide</e1>\NN\1740 cytotoxicity\NN\13583478 in\IN\13603305 rat\NN\2329401 <e2>tumors</e2>\NNS\14234074 .\.\1740
D003520_D009369 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 examine\VB\789138 the\DT\1740 impact\NN\7339329 of\IN\1740 anemia\NN\14189204 prevention\NN\1073995 by\IN\1740 recombinant\JJ\1740 human\JJ\1740 erythropoietin\NN\14888310 (\-LRB-\1740 rHuEPO\JJ\1740 )\-RRB-\1740 treatment\NN\654885 on\IN\1740 the\DT\1740 cytotoxicity\NN\13583478 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 solid\JJ\1740 experimental\JJ\1740 <e2>tumors</e2>\NNS\14234074 .\.\1740
D003520_D009369 NONE When\WRB\1740 <e2>tumors</e2>\NNS\14234074 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 60\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 5\CD\13741022 days\NNS\15140892 after\IN\1740 implantation\NN\13526110 ,\,\1740 a\DT\13649268 growth\NN\13526110 delay\NN\15271008 with\IN\1740 a\DT\13649268 subsequent\JJ\1740 regrowth\NN\1740 of\IN\1740 the\DT\1740 tumors\NNS\14234074 was\VBD\836236 observed\VBN\2163746 .\.\1740
D003520_D009369 NONE When\WRB\1740 tumors\NNS\14234074 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 60\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 5\CD\13741022 days\NNS\15140892 after\IN\1740 implantation\NN\13526110 ,\,\1740 a\DT\13649268 growth\NN\13526110 delay\NN\15271008 with\IN\1740 a\DT\13649268 subsequent\JJ\1740 regrowth\NN\1740 of\IN\1740 the\DT\1740 <e2>tumors</e2>\NNS\14234074 was\VBD\836236 observed\VBN\2163746 .\.\1740
D003520_D009369 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 anemia\NN\14189204 reduces\VBZ\441445 cytotoxicity\NN\13583478 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 <e2>tumors</e2>\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 anemia\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 oxygen\NN\14622893 supply\NN\13576355 to\TO\1740 tumor\NN\14234074 tissue\NN\5220461 .\.\1740
D003520_D009369 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 anemia\NN\14189204 reduces\VBZ\441445 cytotoxicity\NN\13583478 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 tumors\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 anemia\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 oxygen\NN\14622893 supply\NN\13576355 to\TO\1740 <e2>tumor</e2>\NN\14234074 tissue\NN\5220461 .\.\1740
D016190_D000740 CID <e2>Anemia</e2>\NN\14189204 was\VBD\836236 induced\VBN\1627355 using\VBG\1156834 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>carboplatin</e1>\NN\1740 (\-LRB-\1740 50\CD\13745420 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 long-lasting\JJ\1740 reduction\NN\351485 (\-LRB-\1740 30\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 hemoglobin\NN\14888884 concentration\NN\4916342 .\.\1740
D016190_D000740 CID In\IN\13603305 a\DT\13649268 second\JJ\1740 group\NN\2137 ,\,\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>anemia</e2>\NN\14189204 was\VBD\836236 prevented\VBN\1740 by\IN\1740 rHuEPO\NN\1740 (\-LRB-\1740 1000\CD\13745420 IU/kg\NNS\1740 )\-RRB-\1740 administered\VBD\2436349 s.c.\NN\1740 three\CD\13741022 times/week\NN\1740 starting\NN\457382 7\CD\13741022 days\NNS\15140892 before\IN\1740 <e1>carboplatin</e1>\NN\1740 application\NN\947128 .\.\1740
D016190_D009369 NONE Four\CD\13741022 days\NNS\15140892 after\IN\1740 <e1>carboplatin</e1>\NN\1740 treatment\NN\654885 ,\,\1740 <e2>tumors</e2>\NNS\14234074 (\-LRB-\1740 DS-sarcoma\NN\1740 of\IN\1740 the\DT\1740 rat\NN\2329401 )\-RRB-\1740 were\VBD\836236 implanted\VBN\1421622 s.c.\NN\1740 onto\IN\1740 the\DT\1740 hind\NN\2568959 food\NN\20090 dorsum\NN\5220461 .\.\1740
D016190_D009369 NONE Neither\CC\1740 <e1>carboplatin</e1>\NN\1740 nor\CC\1740 rHuEPO\JJ\1740 treatment\NN\654885 influenced\VBD\137313 <e2>tumor</e2>\NN\14234074 growth\NN\13526110 rate\NN\13815152 per\IN\1740 se\FW\14724645 .\.\1740
D016190_D012509 NONE Four\CD\13741022 days\NNS\15140892 after\IN\1740 <e1>carboplatin</e1>\NN\1740 treatment\NN\654885 ,\,\1740 tumors\NNS\14234074 (\-LRB-\1740 <e2>DS-sarcoma</e2>\NN\1740 of\IN\1740 the\DT\1740 rat\NN\2329401 )\-RRB-\1740 were\VBD\836236 implanted\VBN\1421622 s.c.\NN\1740 onto\IN\1740 the\DT\1740 hind\NN\2568959 food\NN\20090 dorsum\NN\5220461 .\.\1740
D010100_D000740 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 reduces\VBZ\441445 cytotoxicity\NN\13583478 of\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 tumors\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 anemia\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 to\TO\1740 tumor\NN\14234074 tissue\NN\5220461 .\.\1740
D010100_D000740 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 anemia\NN\14189204 reduces\VBZ\441445 cytotoxicity\NN\13583478 of\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 tumors\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 <e2>anemia</e2>\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 to\TO\1740 tumor\NN\14234074 tissue\NN\5220461 .\.\1740
D010100_D064420 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 anemia\NN\14189204 reduces\VBZ\441445 <e2>cytotoxicity</e2>\NN\13583478 of\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 tumors\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 anemia\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 to\TO\1740 tumor\NN\14234074 tissue\NN\5220461 .\.\1740
D010100_D009369 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 anemia\NN\14189204 reduces\VBZ\441445 cytotoxicity\NN\13583478 of\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 <e2>tumors</e2>\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 anemia\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 to\TO\1740 tumor\NN\14234074 tissue\NN\5220461 .\.\1740
D010100_D009369 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 chemotherapy-induced\JJ\1740 anemia\NN\14189204 reduces\VBZ\441445 cytotoxicity\NN\13583478 of\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 tumors\NNS\14234074 ,\,\1740 whereas\IN\1740 correction\NN\248977 of\IN\1740 anemia\NN\14189204 by\IN\1740 rHuEPO\JJ\1740 treatment\NN\654885 (\-LRB-\1740 epoetin\NN\1740 alpha\NN\6828818 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 sensitivity\NN\5651971 ,\,\1740 probably\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 an\DT\6697703 improved\VBN\126264 <e1>oxygen</e1>\NN\14622893 supply\NN\13576355 to\TO\1740 <e2>tumor</e2>\NN\14234074 tissue\NN\5220461 .\.\1740
6203632
D007545_D006332 CID Development\NN\248977 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 hypertrophy</e2>\NN\14365950 .\.\1740
D007545_D006332 CID The\DT\1740 development\NN\248977 of\IN\1740 <e2>cardiac\JJ\1740 hypertrophy</e2>\NN\14365950 was\VBD\836236 studied\VBN\630380 in\IN\13603305 adult\JJ\1740 female\NN\15388 Wistar\NNP\1740 rats\NNS\2329401 following\VBG\1835496 daily\RB\1740 subcutaneous\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>isoproterenol</e1>\NN\3740161 (\-LRB-\1740 ISO\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.3\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 .\.\1740
D007545_D006332 CID The\DT\1740 development\NN\248977 of\IN\1740 <e2>cardiac\JJ\1740 hypertrophy</e2>\NN\14365950 was\VBD\836236 studied\VBN\630380 in\IN\13603305 adult\JJ\1740 female\NN\15388 Wistar\NNP\1740 rats\NNS\2329401 following\VBG\1835496 daily\RB\1740 subcutaneous\JJ\1740 injections\NNS\320852 of\IN\1740 isoproterenol\NN\3740161 (\-LRB-\1740 <e1>ISO</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.3\CD\1740 mg/kg\NN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 .\.\1740
D007545_D006984 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 the\DT\1740 adaptive\JJ\1740 response\NN\11410625 to\TO\1740 <e1>ISO</e1>\NN\1740 shows\VBZ\2137132 an\DT\6697703 early\JJ\1740 <e2>hypertrophic</e2>\JJ\1740 phase\NN\15113229 (\-LRB-\1740 1\CD\13741022 -\SYM\1740 4\CD\13741022 days\NNS\15140892 )\-RRB-\1740 characterized\VBN\609683 by\IN\1740 a\DT\13649268 substantial\JJ\1740 increase\NN\13576355 in\IN\13603305 RNA\NN\14994328 content\NN\7951464 and\CC\1740 cardiac\JJ\1740 mass\NN\13575869 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 changes\NNS\7283608 in\IN\13603305 DNA\NN\14994328 .\.\1740
8607407
D002110_D006973 CID Acute\JJ\1740 blood\NN\5397468 pressure\NN\11419404 elevations\NNS\7445480 with\IN\1740 <e1>caffeine</e1>\NN\14712692 in\IN\13603305 men\NNS\8208016 with\IN\1740 borderline\NN\8512259 systemic\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D002110_D006973 CID Whether\IN\1740 the\DT\1740 vasoconstrictive\JJ\1740 actions\NNS\30358 of\IN\1740 <e1>caffeine</e1>\NN\14712692 are\VBP\836236 enhanced\VBN\227165 in\IN\13603305 <e2>hypertensive</e2>\JJ\1740 persons\NNS\7347 has\VBZ\2108377 not\RB\1740 been\VBN\836236 demonstrated\VBN\2137132 .\.\1740
D002110_D006973 CID Consequently\RB\1740 ,\,\1740 whereas\IN\1740 all\DT\1740 participants\NNS\9816771 exhibited\VBD\2632167 normotensive\JJ\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 resting\VBG\2604760 predrug\NN\1740 baseline\NN\7260623 ,\,\1740 33\CD\1740 %\NN\1740 of\IN\1740 borderline\NN\8512259 subjects\NNS\6598915 achieved\VBD\2524171 <e2>hypertensive</e2>\JJ\1740 BP\NN\1740 levels\NNS\4916342 after\IN\1740 <e1>caffeine</e1>\NN\14712692 ingestion\NN\13440063 .\.\1740
D002110_D006973 CID Thus\RB\1740 ,\,\1740 in\IN\13603305 borderline\NN\8512259 <e2>hypertensive</e2>\NN\10405694 men\NNS\8208016 ,\,\1740 exaggerated\JJ\1740 responses\NNS\11410625 to\TO\1740 <e1>caffeine</e1>\NN\14712692 were\VBD\836236 :\:\1740 selective\JJ\1740 for\IN\1740 diastolic\JJ\1740 BP\NN\1740 ,\,\1740 consistent\JJ\1740 with\IN\1740 greater\JJR\1740 vasoconstriction\NN\1149911 ,\,\1740 replicated\VBN\2035919 in\IN\13603305 2\CD\13741022 protocols\NNS\6652242 ,\,\1740 and\CC\1740 representative\NN\10351874 of\IN\1740 nearly\RB\1740 all\DT\1740 borderline\NN\8512259 hypertensives\NNS\10405694 .\.\1740
D002110_D006973 CID Thus\RB\1740 ,\,\1740 in\IN\13603305 borderline\NN\8512259 hypertensive\NN\10405694 men\NNS\8208016 ,\,\1740 exaggerated\JJ\1740 responses\NNS\11410625 to\TO\1740 <e1>caffeine</e1>\NN\14712692 were\VBD\836236 :\:\1740 selective\JJ\1740 for\IN\1740 diastolic\JJ\1740 BP\NN\1740 ,\,\1740 consistent\JJ\1740 with\IN\1740 greater\JJR\1740 vasoconstriction\NN\1149911 ,\,\1740 replicated\VBN\2035919 in\IN\13603305 2\CD\13741022 protocols\NNS\6652242 ,\,\1740 and\CC\1740 representative\NN\10351874 of\IN\1740 nearly\RB\1740 all\DT\1740 borderline\NN\8512259 <e2>hypertensives</e2>\NNS\10405694 .\.\1740
8473723
D008728_D012640 CID <e2>Seizures</e2>\NNP\14081375 induced\VBN\1627355 by\IN\1740 combined\JJ\1740 <e1>levomepromazine-fluvoxamine</e1>\JJ\1740 treatment\NN\654885 .\.\1740
D008728_D012640 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 combined\JJ\1740 <e1>levomepromazine-fluvoxamine</e1>\JJ\1740 treatment-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D016666_D012640 CID <e2>Seizures</e2>\NNP\14081375 induced\VBN\1627355 by\IN\1740 combined\JJ\1740 <e1>levomepromazine-fluvoxamine</e1>\JJ\1740 treatment\NN\654885 .\.\1740
D016666_D012640 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 combined\JJ\1740 <e1>levomepromazine-fluvoxamine</e1>\JJ\1740 treatment-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
17194457
-1_D001523 NONE Chronic\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>PCPA</e1>\NN\1740 alone\RB\1740 significantly\RB\1740 decreased\VBD\169651 locomotor\NN\1740 activity\NN\30358 and\CC\1740 increased\VBN\169651 <e2>irritability</e2>\NN\7552087 but\CC\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 sexual\JJ\1740 behavior\NN\407535 ,\,\1740 partner\NN\10024362 preference\NN\7497473 ,\,\1740 or\CC\3541091 aggression\NN\4657876 .\.\1740
-1_D001523 NONE Chronic\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>PCPA</e1>\NN\1740 alone\RB\1740 significantly\RB\1740 decreased\VBD\169651 locomotor\NN\1740 activity\NN\30358 and\CC\1740 increased\VBN\169651 irritability\NN\7552087 but\CC\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 sexual\JJ\1740 behavior\NN\407535 ,\,\1740 partner\NN\10024362 preference\NN\7497473 ,\,\1740 or\CC\3541091 <e2>aggression</e2>\NN\4657876 .\.\1740
D013739_D001523 CID <e1>T</e1>\NN\14999913 alone\RB\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 locomotion\NN\4773351 ,\,\1740 <e2>irritability</e2>\NN\7552087 ,\,\1740 or\CC\3541091 sexual\JJ\1740 behavior\NN\407535 but\CC\1740 increased\VBD\169651 partner\NN\10024362 preference\NN\7497473 and\CC\1740 aggression\NN\4657876 .\.\1740
D013739_D001523 CID <e1>T</e1>\NN\14999913 alone\RB\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 locomotion\NN\4773351 ,\,\1740 irritability\NN\7552087 ,\,\1740 or\CC\3541091 sexual\JJ\1740 behavior\NN\407535 but\CC\1740 increased\VBD\169651 partner\NN\10024362 preference\NN\7497473 and\CC\1740 <e2>aggression</e2>\NN\4657876 .\.\1740
D012701_D001523 NONE Based\VBN\2694933 on\IN\1740 these\DT\1740 data\NNS\7951464 ,\,\1740 it\PRP\6125041 can\MD\3094503 be\VB\836236 speculated\VBN\719734 that\IN\1740 pubertal\JJ\1740 AAS\NN\6697703 users\NNS\7846 with\IN\1740 low\JJ\1740 central\JJ\1740 <e1>5-HT</e1>\NN\1740 may\MD\15209706 be\VB\836236 especially\RB\1740 prone\JJ\1740 to\TO\1740 exhibit\VB\2632167 <e2>aggressive\JJ\1740 behavior</e2>\NN\407535 .\.\1740
20394767
D015016_D012021 CID Furthermore\RB\1740 ,\,\1740 <e1>yohimbine</e1>\NN\1740 increased\VBD\169651 baseline\NN\7260623 <e2>startle</e2>\VBP\1809064 amplitude\NN\7444668 in\IN\13603305 the\DT\1740 LES\NN\14187378 ,\,\1740 while\IN\15122231 mCPP\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 both\CC\1740 the\DT\1740 LES\NN\14187378 and\CC\1740 FPS\NN\8338847 and\CC\1740 PTZ\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 the\DT\1740 FPS\NN\8338847 .\.\1740
D015016_D012021 CID Furthermore\RB\1740 ,\,\1740 <e1>yohimbine</e1>\NN\1740 increased\VBD\169651 baseline\NN\7260623 startle\VBP\1809064 amplitude\NN\7444668 in\IN\13603305 the\DT\1740 LES\NN\14187378 ,\,\1740 while\IN\15122231 mCPP\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 <e2>startle</e2>\VBP\1809064 in\IN\13603305 both\CC\1740 the\DT\1740 LES\NN\14187378 and\CC\1740 FPS\NN\8338847 and\CC\1740 PTZ\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 the\DT\1740 FPS\NN\8338847 .\.\1740
D015016_D012021 CID Furthermore\RB\1740 ,\,\1740 <e1>yohimbine</e1>\NN\1740 increased\VBD\169651 baseline\NN\7260623 startle\VBP\1809064 amplitude\NN\7444668 in\IN\13603305 the\DT\1740 LES\NN\14187378 ,\,\1740 while\IN\15122231 mCPP\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 both\CC\1740 the\DT\1740 LES\NN\14187378 and\CC\1740 FPS\NN\8338847 and\CC\1740 PTZ\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 <e2>startle</e2>\VBP\1809064 in\IN\13603305 the\DT\1740 FPS\NN\8338847 .\.\1740
C015068_D012021 CID Furthermore\RB\1740 ,\,\1740 yohimbine\NN\1740 increased\VBD\169651 baseline\NN\7260623 <e2>startle</e2>\VBP\1809064 amplitude\NN\7444668 in\IN\13603305 the\DT\1740 LES\NN\14187378 ,\,\1740 while\IN\15122231 <e1>mCPP</e1>\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 both\CC\1740 the\DT\1740 LES\NN\14187378 and\CC\1740 FPS\NN\8338847 and\CC\1740 PTZ\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 the\DT\1740 FPS\NN\8338847 .\.\1740
C015068_D012021 CID Furthermore\RB\1740 ,\,\1740 yohimbine\NN\1740 increased\VBD\169651 baseline\NN\7260623 startle\VBP\1809064 amplitude\NN\7444668 in\IN\13603305 the\DT\1740 LES\NN\14187378 ,\,\1740 while\IN\15122231 <e1>mCPP</e1>\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 <e2>startle</e2>\VBP\1809064 in\IN\13603305 both\CC\1740 the\DT\1740 LES\NN\14187378 and\CC\1740 FPS\NN\8338847 and\CC\1740 PTZ\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 the\DT\1740 FPS\NN\8338847 .\.\1740
C015068_D012021 CID Furthermore\RB\1740 ,\,\1740 yohimbine\NN\1740 increased\VBD\169651 baseline\NN\7260623 startle\VBP\1809064 amplitude\NN\7444668 in\IN\13603305 the\DT\1740 LES\NN\14187378 ,\,\1740 while\IN\15122231 <e1>mCPP</e1>\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 both\CC\1740 the\DT\1740 LES\NN\14187378 and\CC\1740 FPS\NN\8338847 and\CC\1740 PTZ\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 <e2>startle</e2>\VBP\1809064 in\IN\13603305 the\DT\1740 FPS\NN\8338847 .\.\1740
D010433_D012021 CID Furthermore\RB\1740 ,\,\1740 yohimbine\NN\1740 increased\VBD\169651 baseline\NN\7260623 <e2>startle</e2>\VBP\1809064 amplitude\NN\7444668 in\IN\13603305 the\DT\1740 LES\NN\14187378 ,\,\1740 while\IN\15122231 mCPP\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 both\CC\1740 the\DT\1740 LES\NN\14187378 and\CC\1740 FPS\NN\8338847 and\CC\1740 <e1>PTZ</e1>\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 the\DT\1740 FPS\NN\8338847 .\.\1740
D010433_D012021 CID Furthermore\RB\1740 ,\,\1740 yohimbine\NN\1740 increased\VBD\169651 baseline\NN\7260623 startle\VBP\1809064 amplitude\NN\7444668 in\IN\13603305 the\DT\1740 LES\NN\14187378 ,\,\1740 while\IN\15122231 mCPP\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 <e2>startle</e2>\VBP\1809064 in\IN\13603305 both\CC\1740 the\DT\1740 LES\NN\14187378 and\CC\1740 FPS\NN\8338847 and\CC\1740 <e1>PTZ</e1>\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 the\DT\1740 FPS\NN\8338847 .\.\1740
D010433_D012021 CID Furthermore\RB\1740 ,\,\1740 yohimbine\NN\1740 increased\VBD\169651 baseline\NN\7260623 startle\VBP\1809064 amplitude\NN\7444668 in\IN\13603305 the\DT\1740 LES\NN\14187378 ,\,\1740 while\IN\15122231 mCPP\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 startle\VBP\1809064 in\IN\13603305 both\CC\1740 the\DT\1740 LES\NN\14187378 and\CC\1740 FPS\NN\8338847 and\CC\1740 <e1>PTZ</e1>\NN\1740 suppressed\VBD\2510337 baseline\NN\7260623 <e2>startle</e2>\VBP\1809064 in\IN\13603305 the\DT\1740 FPS\NN\8338847 .\.\1740
9228650
C049860_D000647 CID Effects\NNS\13245626 of\IN\1740 <e1>NIK-247</e1>\NN\1740 on\IN\1740 cholinesterase\NN\14732946 and\CC\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
C049860_D000647 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>NIK-247</e1>\NN\1740 on\IN\1740 cholinesterase\NN\14732946 ,\,\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 and\CC\1740 spontaneous\JJ\1740 movement\NN\191142 were\VBD\836236 examined\VBN\789138 and\CC\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 well-known\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 tacrine\VBP\1740 and\CC\1740 E-2020\NN\1740 .\.\1740
C049860_D000647 CID These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>NIK-247</e1>\NN\1740 at\IN\14622893 a\DT\13649268 low\JJ\1740 dose\NN\3740161 (\-LRB-\1740 0.1\CD\1740 -\SYM\1740 1\CD\13741022 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 improves\VBZ\126264 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 but\CC\1740 does\VBZ\1640855 not\RB\1740 affect\VB\126264 spontaneous\JJ\1740 movement\NN\191142 .\.\1740
D012601_D000647 CID Effects\NNS\13245626 of\IN\1740 NIK-247\NN\1740 on\IN\1740 cholinesterase\NN\14732946 and\CC\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D012601_D000647 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 NIK-247\NN\1740 on\IN\1740 cholinesterase\NN\14732946 ,\,\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 and\CC\1740 spontaneous\JJ\1740 movement\NN\191142 were\VBD\836236 examined\VBN\789138 and\CC\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 well-known\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 tacrine\VBP\1740 and\CC\1740 E-2020\NN\1740 .\.\1740
D012601_D000647 CID All\DT\1740 compounds\NNS\5869584 at\IN\14622893 0.1\CD\1740 -\SYM\1740 1\CD\13741022 mg/kg\NN\1740 p.o.\NN\10360747 significantly\RB\1740 improved\VBD\126264 the\DT\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 performing\VBG\2367363 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 .\.\1740
D012601_D000647 CID These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 NIK-247\NN\1740 at\IN\14622893 a\DT\13649268 low\JJ\1740 dose\NN\3740161 (\-LRB-\1740 0.1\CD\1740 -\SYM\1740 1\CD\13741022 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 improves\VBZ\126264 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 but\CC\1740 does\VBZ\1640855 not\RB\1740 affect\VB\126264 spontaneous\JJ\1740 movement\NN\191142 .\.\1740
D013619_D000647 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 NIK-247\NN\1740 on\IN\1740 cholinesterase\NN\14732946 ,\,\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 and\CC\1740 spontaneous\JJ\1740 movement\NN\191142 were\VBD\836236 examined\VBN\789138 and\CC\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 well-known\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 <e1>tacrine</e1>\VBP\1740 and\CC\1740 E-2020\NN\1740 .\.\1740
C076946_D000647 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 NIK-247\NN\1740 on\IN\1740 cholinesterase\NN\14732946 ,\,\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 and\CC\1740 spontaneous\JJ\1740 movement\NN\191142 were\VBD\836236 examined\VBN\789138 and\CC\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 well-known\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 tacrine\VBP\1740 and\CC\1740 <e1>E-2020</e1>\NN\1740 .\.\1740
C049860_D000544 NONE The\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>NIK-247</e1>\NN\1740 may\MD\15209706 be\VB\836236 a\DT\13649268 useful\JJ\1740 drug\NN\14778436 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
17702969
D005473_D005315 CID Prenatal\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>fluoxetine</e1>\NN\4169152 induces\VBZ\1627355 <e2>fetal\JJ\1740 pulmonary\JJ\1740 hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D005473_D005315 CID As\IN\14622893 compared\VBN\644583 with\IN\1740 controls\NNS\5190804 ,\,\1740 <e1>fluoxetine</e1>\NN\4169152 exposure\NN\5042871 resulted\VBD\2633881 in\IN\13603305 <e2>fetal\JJ\1740 pulmonary\JJ\1740 hypertension</e2>\NN\14057371 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 the\DT\1740 weight\NN\5009170 ratio\NN\13815152 of\IN\1740 the\DT\1740 right\JJ\1740 ventricle\NN\5303402 to\TO\1740 the\DT\1740 left\JJ\1740 ventricle\NN\5303402 plus\CC\4723816 septum\NN\5222790 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.02\CD\1740 )\-RRB-\1740 and\CC\1740 by\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 pulmonary\JJ\1740 arterial\JJ\1740 medial\JJ\1740 thickness\NN\5093581 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D005473_D006976 CID Prenatal\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>fluoxetine</e1>\NN\4169152 induces\VBZ\1627355 <e2>fetal\JJ\1740 pulmonary\JJ\1740 hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D005473_D006976 CID Epidemiological\JJ\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>fluoxetine</e1>\NN\4169152 exposure\NN\5042871 prenatally\RB\1740 increases\VBZ\169651 the\DT\1740 prevalence\NN\4764412 of\IN\1740 persistent\JJ\1740 <e2>pulmonary\JJ\1740 hypertension\NN\14057371 syndrome</e2>\NN\5870365 of\IN\1740 the\DT\1740 newborn\JJ\1740 .\.\1740
D005473_D006976 CID The\DT\1740 mechanism\NN\13446390 responsible\JJ\1740 for\IN\1740 this\DT\1740 effect\NN\34213 is\VBZ\836236 unclear\JJ\1740 and\CC\1740 paradoxical\JJ\1740 ,\,\1740 considering\VBG\689344 the\DT\1740 current\JJ\1740 evidence\NN\5816287 of\IN\1740 a\DT\13649268 <e2>pulmonary\JJ\1740 hypertension</e2>\NN\14057371 protective\JJ\1740 <e1>fluoxetine</e1>\NN\4169152 effect\NN\34213 in\IN\13603305 adult\JJ\1740 rodents\NNS\1886756 .\.\1740
D005473_D006976 CID As\IN\14622893 compared\VBN\644583 with\IN\1740 controls\NNS\5190804 ,\,\1740 <e1>fluoxetine</e1>\NN\4169152 exposure\NN\5042871 resulted\VBD\2633881 in\IN\13603305 <e2>fetal\JJ\1740 pulmonary\JJ\1740 hypertension</e2>\NN\14057371 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 the\DT\1740 weight\NN\5009170 ratio\NN\13815152 of\IN\1740 the\DT\1740 right\JJ\1740 ventricle\NN\5303402 to\TO\1740 the\DT\1740 left\JJ\1740 ventricle\NN\5303402 plus\CC\4723816 septum\NN\5222790 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.02\CD\1740 )\-RRB-\1740 and\CC\1740 by\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 pulmonary\JJ\1740 arterial\JJ\1740 medial\JJ\1740 thickness\NN\5093581 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D005473_D006976 CID CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 contrast\NN\13854649 to\TO\1740 the\DT\1740 adult\NN\7846 ,\,\1740 <e1>fluoxetine</e1>\NN\4169152 exposure\NN\5042871 in\IN\13603305 utero\NN\1740 induces\VBZ\1627355 <e2>pulmonary\JJ\1740 hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 fetal\JJ\1740 rat\NN\2329401 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 a\DT\13649268 developmentally\RB\1740 regulated\VBN\296178 increase\NN\13576355 in\IN\13603305 pulmonary\JJ\1740 vascular\JJ\1740 smooth\JJ\1740 muscle\NN\5289601 proliferation\NN\13489037 .\.\1740
17490790
D007505_D009410 CID Peripheral\JJ\1740 <e1>iron\NN\14625458 dextran</e1>\NN\1740 induced\JJ\1740 <e2>degeneration\NN\29677 of\IN\1740 dopaminergic\JJ\1740 neurons</e2>\NNS\5430628 in\IN\13603305 rat\NN\2329401 substantia\RB\1740 nigra\JJ\1740 .\.\1740
D007505_D009410 CID To\TO\1740 demonstrate\VB\2137132 the\DT\1740 relationship\NN\31921 between\IN\1740 peripheral\JJ\1740 iron\NN\14625458 overload\NN\3679986 and\CC\1740 dopaminergic\JJ\1740 neuron\NN\5430628 loss\NN\13252973 in\IN\13603305 rat\NN\2329401 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 used\VBD\1156834 fast\JJ\1740 cyclic\JJ\1740 voltammetry\NN\1740 ,\,\1740 tyrosine\NN\14601829 hydroxylase\NN\1740 (\-LRB-\1740 TH\NN\15163157 )\-RRB-\1740 immunohistochemistry\NN\791527 ,\,\1740 Perls\NNP\1740 '\POS\1740 iron\NN\14625458 staining\NN\275424 ,\,\1740 and\CC\1740 high\JJ\1740 performance\NN\6619065 liquid\NN\14939900 chromatography-electrochemical\JJ\1740 detection\NN\5708432 to\TO\1740 study\VB\630380 the\DT\1740 <e2>degeneration\NN\29677 of\IN\1740 dopaminergic\JJ\1740 neurons</e2>\NNS\5430628 and\CC\1740 increased\VBD\169651 iron\NN\14625458 content\NN\7951464 in\IN\13603305 the\DT\1740 SN\NN\14625458 of\IN\1740 <e1>iron\NN\14625458 dextran</e1>\NN\1740 overloaded\VBN\452512 animals\NNS\4475 .\.\1740
D007505_D009410 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 peripheral\JJ\1740 <e1>iron\NN\14625458 dextran</e1>\NN\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 iron\NN\14625458 level\NN\4916342 in\IN\13603305 the\DT\1740 SN\NNP\14625458 ,\,\1740 where\WRB\1740 excessive\JJ\1740 iron\NN\14625458 causes\VBZ\1617192 the\DT\1740 <e2>degeneration\NN\29677 of\IN\1740 dopaminergic\JJ\1740 neurons</e2>\NNS\5430628 .\.\1740
D007501_D010300 NONE <e1>Iron</e1>\NN\14625458 accumulation\NN\13497135 is\VBZ\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D007501_D009410 NONE To\TO\1740 demonstrate\VB\2137132 the\DT\1740 relationship\NN\31921 between\IN\1740 peripheral\JJ\1740 <e1>iron</e1>\NN\14625458 overload\NN\3679986 and\CC\1740 dopaminergic\JJ\1740 neuron\NN\5430628 loss\NN\13252973 in\IN\13603305 rat\NN\2329401 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 used\VBD\1156834 fast\JJ\1740 cyclic\JJ\1740 voltammetry\NN\1740 ,\,\1740 tyrosine\NN\14601829 hydroxylase\NN\1740 (\-LRB-\1740 TH\NN\15163157 )\-RRB-\1740 immunohistochemistry\NN\791527 ,\,\1740 Perls\NNP\1740 '\POS\1740 iron\NN\14625458 staining\NN\275424 ,\,\1740 and\CC\1740 high\JJ\1740 performance\NN\6619065 liquid\NN\14939900 chromatography-electrochemical\JJ\1740 detection\NN\5708432 to\TO\1740 study\VB\630380 the\DT\1740 <e2>degeneration\NN\29677 of\IN\1740 dopaminergic\JJ\1740 neurons</e2>\NNS\5430628 and\CC\1740 increased\VBD\169651 iron\NN\14625458 content\NN\7951464 in\IN\13603305 the\DT\1740 SN\NN\14625458 of\IN\1740 iron\NN\14625458 dextran\NN\1740 overloaded\VBN\452512 animals\NNS\4475 .\.\1740
D007501_D009410 NONE To\TO\1740 demonstrate\VB\2137132 the\DT\1740 relationship\NN\31921 between\IN\1740 peripheral\JJ\1740 iron\NN\14625458 overload\NN\3679986 and\CC\1740 dopaminergic\JJ\1740 neuron\NN\5430628 loss\NN\13252973 in\IN\13603305 rat\NN\2329401 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 used\VBD\1156834 fast\JJ\1740 cyclic\JJ\1740 voltammetry\NN\1740 ,\,\1740 tyrosine\NN\14601829 hydroxylase\NN\1740 (\-LRB-\1740 TH\NN\15163157 )\-RRB-\1740 immunohistochemistry\NN\791527 ,\,\1740 Perls\NNP\1740 '\POS\1740 <e1>iron</e1>\NN\14625458 staining\NN\275424 ,\,\1740 and\CC\1740 high\JJ\1740 performance\NN\6619065 liquid\NN\14939900 chromatography-electrochemical\JJ\1740 detection\NN\5708432 to\TO\1740 study\VB\630380 the\DT\1740 <e2>degeneration\NN\29677 of\IN\1740 dopaminergic\JJ\1740 neurons</e2>\NNS\5430628 and\CC\1740 increased\VBD\169651 iron\NN\14625458 content\NN\7951464 in\IN\13603305 the\DT\1740 SN\NN\14625458 of\IN\1740 iron\NN\14625458 dextran\NN\1740 overloaded\VBN\452512 animals\NNS\4475 .\.\1740
D007501_D009410 NONE To\TO\1740 demonstrate\VB\2137132 the\DT\1740 relationship\NN\31921 between\IN\1740 peripheral\JJ\1740 iron\NN\14625458 overload\NN\3679986 and\CC\1740 dopaminergic\JJ\1740 neuron\NN\5430628 loss\NN\13252973 in\IN\13603305 rat\NN\2329401 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 used\VBD\1156834 fast\JJ\1740 cyclic\JJ\1740 voltammetry\NN\1740 ,\,\1740 tyrosine\NN\14601829 hydroxylase\NN\1740 (\-LRB-\1740 TH\NN\15163157 )\-RRB-\1740 immunohistochemistry\NN\791527 ,\,\1740 Perls\NNP\1740 '\POS\1740 iron\NN\14625458 staining\NN\275424 ,\,\1740 and\CC\1740 high\JJ\1740 performance\NN\6619065 liquid\NN\14939900 chromatography-electrochemical\JJ\1740 detection\NN\5708432 to\TO\1740 study\VB\630380 the\DT\1740 <e2>degeneration\NN\29677 of\IN\1740 dopaminergic\JJ\1740 neurons</e2>\NNS\5430628 and\CC\1740 increased\VBD\169651 <e1>iron</e1>\NN\14625458 content\NN\7951464 in\IN\13603305 the\DT\1740 SN\NN\14625458 of\IN\1740 iron\NN\14625458 dextran\NN\1740 overloaded\VBN\452512 animals\NNS\4475 .\.\1740
D007501_D009410 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 peripheral\JJ\1740 iron\NN\14625458 dextran\NN\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 <e1>iron</e1>\NN\14625458 level\NN\4916342 in\IN\13603305 the\DT\1740 SN\NNP\14625458 ,\,\1740 where\WRB\1740 excessive\JJ\1740 iron\NN\14625458 causes\VBZ\1617192 the\DT\1740 <e2>degeneration\NN\29677 of\IN\1740 dopaminergic\JJ\1740 neurons</e2>\NNS\5430628 .\.\1740
D007501_D009410 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 peripheral\JJ\1740 iron\NN\14625458 dextran\NN\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 iron\NN\14625458 level\NN\4916342 in\IN\13603305 the\DT\1740 SN\NNP\14625458 ,\,\1740 where\WRB\1740 excessive\JJ\1740 <e1>iron</e1>\NN\14625458 causes\VBZ\1617192 the\DT\1740 <e2>degeneration\NN\29677 of\IN\1740 dopaminergic\JJ\1740 neurons</e2>\NNS\5430628 .\.\1740
D014443_D009410 NONE To\TO\1740 demonstrate\VB\2137132 the\DT\1740 relationship\NN\31921 between\IN\1740 peripheral\JJ\1740 iron\NN\14625458 overload\NN\3679986 and\CC\1740 dopaminergic\JJ\1740 neuron\NN\5430628 loss\NN\13252973 in\IN\13603305 rat\NN\2329401 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 used\VBD\1156834 fast\JJ\1740 cyclic\JJ\1740 voltammetry\NN\1740 ,\,\1740 <e1>tyrosine</e1>\NN\14601829 hydroxylase\NN\1740 (\-LRB-\1740 TH\NN\15163157 )\-RRB-\1740 immunohistochemistry\NN\791527 ,\,\1740 Perls\NNP\1740 '\POS\1740 iron\NN\14625458 staining\NN\275424 ,\,\1740 and\CC\1740 high\JJ\1740 performance\NN\6619065 liquid\NN\14939900 chromatography-electrochemical\JJ\1740 detection\NN\5708432 to\TO\1740 study\VB\630380 the\DT\1740 <e2>degeneration\NN\29677 of\IN\1740 dopaminergic\JJ\1740 neurons</e2>\NNS\5430628 and\CC\1740 increased\VBD\169651 iron\NN\14625458 content\NN\7951464 in\IN\13603305 the\DT\1740 SN\NN\14625458 of\IN\1740 iron\NN\14625458 dextran\NN\1740 overloaded\VBN\452512 animals\NNS\4475 .\.\1740
11752998
D000241_D059787 NONE BACKGROUND\NN\4921011 :\:\1740 Preclinical\JJ\1740 studies\NNS\635850 of\IN\1740 intrathecal\JJ\1740 <e1>adenosine</e1>\NN\14964367 suggest\VBP\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>acute\JJ\1740 and\CC\1740 chronic\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 humans\NNS\31264 ,\,\1740 and\CC\1740 preliminary\JJ\1740 studies\NNS\635850 in\IN\13603305 volunteers\NNS\10582746 and\CC\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 Swedish\JJ\1740 formulation\NN\14818238 of\IN\1740 adenosine\NN\14964367 suggests\VBZ\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 hypersensitivity\NN\14531772 states\NNS\8491826 but\CC\1740 not\RB\1740 with\IN\1740 acute\JJ\1740 noxious\JJ\1740 stimulation\NN\242808 .\.\1740
D000241_D059787 NONE BACKGROUND\NN\4921011 :\:\1740 Preclinical\JJ\1740 studies\NNS\635850 of\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 suggest\VBP\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>acute\JJ\1740 and\CC\1740 chronic\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 humans\NNS\31264 ,\,\1740 and\CC\1740 preliminary\JJ\1740 studies\NNS\635850 in\IN\13603305 volunteers\NNS\10582746 and\CC\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 Swedish\JJ\1740 formulation\NN\14818238 of\IN\1740 <e1>adenosine</e1>\NN\14964367 suggests\VBZ\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 hypersensitivity\NN\14531772 states\NNS\8491826 but\CC\1740 not\RB\1740 with\IN\1740 acute\JJ\1740 noxious\JJ\1740 stimulation\NN\242808 .\.\1740
D000241_D059350 NONE BACKGROUND\NN\4921011 :\:\1740 Preclinical\JJ\1740 studies\NNS\635850 of\IN\1740 intrathecal\JJ\1740 <e1>adenosine</e1>\NN\14964367 suggest\VBP\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>acute\JJ\1740 and\CC\1740 chronic\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 humans\NNS\31264 ,\,\1740 and\CC\1740 preliminary\JJ\1740 studies\NNS\635850 in\IN\13603305 volunteers\NNS\10582746 and\CC\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 Swedish\JJ\1740 formulation\NN\14818238 of\IN\1740 adenosine\NN\14964367 suggests\VBZ\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 hypersensitivity\NN\14531772 states\NNS\8491826 but\CC\1740 not\RB\1740 with\IN\1740 acute\JJ\1740 noxious\JJ\1740 stimulation\NN\242808 .\.\1740
D000241_D059350 NONE BACKGROUND\NN\4921011 :\:\1740 Preclinical\JJ\1740 studies\NNS\635850 of\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 suggest\VBP\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>acute\JJ\1740 and\CC\1740 chronic\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 humans\NNS\31264 ,\,\1740 and\CC\1740 preliminary\JJ\1740 studies\NNS\635850 in\IN\13603305 volunteers\NNS\10582746 and\CC\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 Swedish\JJ\1740 formulation\NN\14818238 of\IN\1740 <e1>adenosine</e1>\NN\14964367 suggests\VBZ\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 hypersensitivity\NN\14531772 states\NNS\8491826 but\CC\1740 not\RB\1740 with\IN\1740 acute\JJ\1740 noxious\JJ\1740 stimulation\NN\242808 .\.\1740
D000241_D004342 NONE BACKGROUND\NN\4921011 :\:\1740 Preclinical\JJ\1740 studies\NNS\635850 of\IN\1740 intrathecal\JJ\1740 <e1>adenosine</e1>\NN\14964367 suggest\VBP\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 pain\NN\14299637 in\IN\13603305 humans\NNS\31264 ,\,\1740 and\CC\1740 preliminary\JJ\1740 studies\NNS\635850 in\IN\13603305 volunteers\NNS\10582746 and\CC\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 Swedish\JJ\1740 formulation\NN\14818238 of\IN\1740 adenosine\NN\14964367 suggests\VBZ\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 <e2>hypersensitivity</e2>\NN\14531772 states\NNS\8491826 but\CC\1740 not\RB\1740 with\IN\1740 acute\JJ\1740 noxious\JJ\1740 stimulation\NN\242808 .\.\1740
D000241_D004342 NONE BACKGROUND\NN\4921011 :\:\1740 Preclinical\JJ\1740 studies\NNS\635850 of\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 suggest\VBP\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 pain\NN\14299637 in\IN\13603305 humans\NNS\31264 ,\,\1740 and\CC\1740 preliminary\JJ\1740 studies\NNS\635850 in\IN\13603305 volunteers\NNS\10582746 and\CC\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 Swedish\JJ\1740 formulation\NN\14818238 of\IN\1740 <e1>adenosine</e1>\NN\14964367 suggests\VBZ\1010118 it\PRP\6125041 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 <e2>hypersensitivity</e2>\NN\14531772 states\NNS\8491826 but\CC\1740 not\RB\1740 with\IN\1740 acute\JJ\1740 noxious\JJ\1740 stimulation\NN\242808 .\.\1740
D000241_D004342 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 screen\VB\2533282 for\IN\1740 efficacy\NN\5199286 of\IN\1740 a\DT\13649268 different\JJ\1740 formulation\NN\14818238 of\IN\1740 <e1>adenosine</e1>\NN\14964367 marketed\VBN\2260362 in\IN\13603305 the\DT\1740 US\NNP\14964590 ,\,\1740 using\VBG\1156834 both\CC\1740 acute\JJ\1740 noxious\JJ\1740 stimulation\NN\242808 and\CC\1740 capsaicin-evoked\JJ\1740 mechanical\JJ\1740 <e2>hypersensitivity</e2>\NN\14531772 .\.\1740
D000241_D004342 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 show\VBP\2137132 selective\JJ\1740 inhibition\NN\1068773 by\IN\1740 intrathecal\JJ\1740 <e1>adenosine</e1>\NN\14964367 of\IN\1740 <e2>hypersensitivity</e2>\NN\14531772 ,\,\1740 presumed\VBN\719734 to\TO\1740 reflect\VB\923793 central\JJ\1740 sensitization\NN\14531772 in\IN\13603305 humans\NNS\31264 after\IN\1740 peripheral\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 .\.\1740
D002211_D004342 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 screen\VB\2533282 for\IN\1740 efficacy\NN\5199286 of\IN\1740 a\DT\13649268 different\JJ\1740 formulation\NN\14818238 of\IN\1740 adenosine\NN\14964367 marketed\VBN\2260362 in\IN\13603305 the\DT\1740 US\NNP\14964590 ,\,\1740 using\VBG\1156834 both\CC\1740 acute\JJ\1740 noxious\JJ\1740 stimulation\NN\242808 and\CC\1740 <e1>capsaicin-evoked</e1>\JJ\1740 mechanical\JJ\1740 <e2>hypersensitivity</e2>\NN\14531772 .\.\1740
D002211_D004342 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 show\VBP\2137132 selective\JJ\1740 inhibition\NN\1068773 by\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 of\IN\1740 <e2>hypersensitivity</e2>\NN\14531772 ,\,\1740 presumed\VBN\719734 to\TO\1740 reflect\VB\923793 central\JJ\1740 sensitization\NN\14531772 in\IN\13603305 humans\NNS\31264 after\IN\1740 peripheral\JJ\1740 <e1>capsaicin</e1>\NN\15032661 injection\NN\320852 .\.\1740
D000241_D010146 NONE METHODS\NNS\5616786 :\:\1740 Following\VBG\1835496 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 and\CC\1740 institutional\JJ\1740 review\NN\5733583 board\NN\8324514 approval\NN\1212519 and\CC\1740 written\VBN\1697816 informed\JJ\1740 consent\NN\6689297 ,\,\1740 65\CD\1740 volunteers\NNS\10582746 were\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 trials\NNS\786195 :\:\1740 an\DT\6697703 open-label\JJ\1740 ,\,\1740 dose-escalating\JJ\1740 trial\NN\786195 with\IN\1740 intrathecal\JJ\1740 <e1>adenosine</e1>\NN\14964367 doses\NNS\3740161 of\IN\1740 0.25\CD\1740 -\SYM\1740 2.0\CD\1740 mg\NN\13717155 and\CC\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 adenosine\NN\14964367 ,\,\1740 2\CD\13741022 mg.\NN\1740 Cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 obtained\VBN\2210855 for\IN\1740 pharmacokinetic\JJ\1740 analysis\NN\633864 ,\,\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 ratings\NNS\5733583 in\IN\13603305 response\NN\11410625 to\TO\1740 acute\JJ\1740 heat\NN\11452218 stimuli\NNS\5816287 and\CC\1740 areas\NNS\8630985 of\IN\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\NN\1740 after\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 were\VBD\836236 determined\VBN\1645601 .\.\1740
D000241_D010146 NONE METHODS\NNS\5616786 :\:\1740 Following\VBG\1835496 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 and\CC\1740 institutional\JJ\1740 review\NN\5733583 board\NN\8324514 approval\NN\1212519 and\CC\1740 written\VBN\1697816 informed\JJ\1740 consent\NN\6689297 ,\,\1740 65\CD\1740 volunteers\NNS\10582746 were\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 trials\NNS\786195 :\:\1740 an\DT\6697703 open-label\JJ\1740 ,\,\1740 dose-escalating\JJ\1740 trial\NN\786195 with\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 doses\NNS\3740161 of\IN\1740 0.25\CD\1740 -\SYM\1740 2.0\CD\1740 mg\NN\13717155 and\CC\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 <e1>adenosine</e1>\NN\14964367 ,\,\1740 2\CD\13741022 mg.\NN\1740 Cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 obtained\VBN\2210855 for\IN\1740 pharmacokinetic\JJ\1740 analysis\NN\633864 ,\,\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 ratings\NNS\5733583 in\IN\13603305 response\NN\11410625 to\TO\1740 acute\JJ\1740 heat\NN\11452218 stimuli\NNS\5816287 and\CC\1740 areas\NNS\8630985 of\IN\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\NN\1740 after\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 were\VBD\836236 determined\VBN\1645601 .\.\1740
D000241_D010146 NONE RESULTS\NNS\34213 :\:\1740 <e1>Adenosine</e1>\NN\14964367 produced\VBD\1617192 no\DT\7204911 effect\NN\34213 on\IN\1740 <e2>pain</e2>\NN\14299637 report\NN\6470073 to\TO\1740 acute\JJ\1740 noxious\JJ\1740 thermal\JJ\1740 or\CC\3541091 chemical\JJ\1740 stimulation\NN\242808 but\CC\1740 reduced\VBD\441445 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\NN\1740 from\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 for\IN\1740 at\IN\14622893 least\JJS\1740 24\CD\13745420 h.\NN\1740 In\IN\13603305 contrast\NN\13854649 ,\,\1740 residence\NN\8491027 time\NN\7308889 of\IN\1740 adenosine\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 short\JJ\1740 (\-LRB-\1740 <\XX\1740 4\CD\13741022 h\NN\14622893 )\-RRB-\1740 .\.\1740
D000241_D010146 NONE RESULTS\NNS\34213 :\:\1740 Adenosine\NN\14964367 produced\VBD\1617192 no\DT\7204911 effect\NN\34213 on\IN\1740 <e2>pain</e2>\NN\14299637 report\NN\6470073 to\TO\1740 acute\JJ\1740 noxious\JJ\1740 thermal\JJ\1740 or\CC\3541091 chemical\JJ\1740 stimulation\NN\242808 but\CC\1740 reduced\VBD\441445 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\NN\1740 from\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 for\IN\1740 at\IN\14622893 least\JJS\1740 24\CD\13745420 h.\NN\1740 In\IN\13603305 contrast\NN\13854649 ,\,\1740 residence\NN\8491027 time\NN\7308889 of\IN\1740 <e1>adenosine</e1>\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 short\JJ\1740 (\-LRB-\1740 <\XX\1740 4\CD\13741022 h\NN\14622893 )\-RRB-\1740 .\.\1740
D000241_D006930 NONE METHODS\NNS\5616786 :\:\1740 Following\VBG\1835496 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 and\CC\1740 institutional\JJ\1740 review\NN\5733583 board\NN\8324514 approval\NN\1212519 and\CC\1740 written\VBN\1697816 informed\JJ\1740 consent\NN\6689297 ,\,\1740 65\CD\1740 volunteers\NNS\10582746 were\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 trials\NNS\786195 :\:\1740 an\DT\6697703 open-label\JJ\1740 ,\,\1740 dose-escalating\JJ\1740 trial\NN\786195 with\IN\1740 intrathecal\JJ\1740 <e1>adenosine</e1>\NN\14964367 doses\NNS\3740161 of\IN\1740 0.25\CD\1740 -\SYM\1740 2.0\CD\1740 mg\NN\13717155 and\CC\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 adenosine\NN\14964367 ,\,\1740 2\CD\13741022 mg.\NN\1740 Cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 obtained\VBN\2210855 for\IN\1740 pharmacokinetic\JJ\1740 analysis\NN\633864 ,\,\1740 and\CC\1740 pain\NN\14299637 ratings\NNS\5733583 in\IN\13603305 response\NN\11410625 to\TO\1740 acute\JJ\1740 heat\NN\11452218 stimuli\NNS\5816287 and\CC\1740 areas\NNS\8630985 of\IN\1740 <e2>mechanical\JJ\1740 hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\NN\1740 after\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 were\VBD\836236 determined\VBN\1645601 .\.\1740
D000241_D006930 NONE METHODS\NNS\5616786 :\:\1740 Following\VBG\1835496 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 and\CC\1740 institutional\JJ\1740 review\NN\5733583 board\NN\8324514 approval\NN\1212519 and\CC\1740 written\VBN\1697816 informed\JJ\1740 consent\NN\6689297 ,\,\1740 65\CD\1740 volunteers\NNS\10582746 were\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 trials\NNS\786195 :\:\1740 an\DT\6697703 open-label\JJ\1740 ,\,\1740 dose-escalating\JJ\1740 trial\NN\786195 with\IN\1740 intrathecal\JJ\1740 <e1>adenosine</e1>\NN\14964367 doses\NNS\3740161 of\IN\1740 0.25\CD\1740 -\SYM\1740 2.0\CD\1740 mg\NN\13717155 and\CC\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 adenosine\NN\14964367 ,\,\1740 2\CD\13741022 mg.\NN\1740 Cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 obtained\VBN\2210855 for\IN\1740 pharmacokinetic\JJ\1740 analysis\NN\633864 ,\,\1740 and\CC\1740 pain\NN\14299637 ratings\NNS\5733583 in\IN\13603305 response\NN\11410625 to\TO\1740 acute\JJ\1740 heat\NN\11452218 stimuli\NNS\5816287 and\CC\1740 areas\NNS\8630985 of\IN\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\NN\1740 after\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 were\VBD\836236 determined\VBN\1645601 .\.\1740
D000241_D006930 NONE METHODS\NNS\5616786 :\:\1740 Following\VBG\1835496 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 and\CC\1740 institutional\JJ\1740 review\NN\5733583 board\NN\8324514 approval\NN\1212519 and\CC\1740 written\VBN\1697816 informed\JJ\1740 consent\NN\6689297 ,\,\1740 65\CD\1740 volunteers\NNS\10582746 were\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 trials\NNS\786195 :\:\1740 an\DT\6697703 open-label\JJ\1740 ,\,\1740 dose-escalating\JJ\1740 trial\NN\786195 with\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 doses\NNS\3740161 of\IN\1740 0.25\CD\1740 -\SYM\1740 2.0\CD\1740 mg\NN\13717155 and\CC\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 <e1>adenosine</e1>\NN\14964367 ,\,\1740 2\CD\13741022 mg.\NN\1740 Cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 obtained\VBN\2210855 for\IN\1740 pharmacokinetic\JJ\1740 analysis\NN\633864 ,\,\1740 and\CC\1740 pain\NN\14299637 ratings\NNS\5733583 in\IN\13603305 response\NN\11410625 to\TO\1740 acute\JJ\1740 heat\NN\11452218 stimuli\NNS\5816287 and\CC\1740 areas\NNS\8630985 of\IN\1740 <e2>mechanical\JJ\1740 hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\NN\1740 after\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 were\VBD\836236 determined\VBN\1645601 .\.\1740
D000241_D006930 NONE METHODS\NNS\5616786 :\:\1740 Following\VBG\1835496 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 and\CC\1740 institutional\JJ\1740 review\NN\5733583 board\NN\8324514 approval\NN\1212519 and\CC\1740 written\VBN\1697816 informed\JJ\1740 consent\NN\6689297 ,\,\1740 65\CD\1740 volunteers\NNS\10582746 were\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 trials\NNS\786195 :\:\1740 an\DT\6697703 open-label\JJ\1740 ,\,\1740 dose-escalating\JJ\1740 trial\NN\786195 with\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 doses\NNS\3740161 of\IN\1740 0.25\CD\1740 -\SYM\1740 2.0\CD\1740 mg\NN\13717155 and\CC\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 <e1>adenosine</e1>\NN\14964367 ,\,\1740 2\CD\13741022 mg.\NN\1740 Cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 obtained\VBN\2210855 for\IN\1740 pharmacokinetic\JJ\1740 analysis\NN\633864 ,\,\1740 and\CC\1740 pain\NN\14299637 ratings\NNS\5733583 in\IN\13603305 response\NN\11410625 to\TO\1740 acute\JJ\1740 heat\NN\11452218 stimuli\NNS\5816287 and\CC\1740 areas\NNS\8630985 of\IN\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\NN\1740 after\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 were\VBD\836236 determined\VBN\1645601 .\.\1740
D000241_D006930 NONE RESULTS\NNS\34213 :\:\1740 <e1>Adenosine</e1>\NN\14964367 produced\VBD\1617192 no\DT\7204911 effect\NN\34213 on\IN\1740 pain\NN\14299637 report\NN\6470073 to\TO\1740 acute\JJ\1740 noxious\JJ\1740 thermal\JJ\1740 or\CC\3541091 chemical\JJ\1740 stimulation\NN\242808 but\CC\1740 reduced\VBD\441445 <e2>mechanical\JJ\1740 hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\NN\1740 from\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 for\IN\1740 at\IN\14622893 least\JJS\1740 24\CD\13745420 h.\NN\1740 In\IN\13603305 contrast\NN\13854649 ,\,\1740 residence\NN\8491027 time\NN\7308889 of\IN\1740 adenosine\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 short\JJ\1740 (\-LRB-\1740 <\XX\1740 4\CD\13741022 h\NN\14622893 )\-RRB-\1740 .\.\1740
D000241_D006930 NONE RESULTS\NNS\34213 :\:\1740 <e1>Adenosine</e1>\NN\14964367 produced\VBD\1617192 no\DT\7204911 effect\NN\34213 on\IN\1740 pain\NN\14299637 report\NN\6470073 to\TO\1740 acute\JJ\1740 noxious\JJ\1740 thermal\JJ\1740 or\CC\3541091 chemical\JJ\1740 stimulation\NN\242808 but\CC\1740 reduced\VBD\441445 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\NN\1740 from\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 for\IN\1740 at\IN\14622893 least\JJS\1740 24\CD\13745420 h.\NN\1740 In\IN\13603305 contrast\NN\13854649 ,\,\1740 residence\NN\8491027 time\NN\7308889 of\IN\1740 adenosine\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 short\JJ\1740 (\-LRB-\1740 <\XX\1740 4\CD\13741022 h\NN\14622893 )\-RRB-\1740 .\.\1740
D000241_D006930 NONE RESULTS\NNS\34213 :\:\1740 Adenosine\NN\14964367 produced\VBD\1617192 no\DT\7204911 effect\NN\34213 on\IN\1740 pain\NN\14299637 report\NN\6470073 to\TO\1740 acute\JJ\1740 noxious\JJ\1740 thermal\JJ\1740 or\CC\3541091 chemical\JJ\1740 stimulation\NN\242808 but\CC\1740 reduced\VBD\441445 <e2>mechanical\JJ\1740 hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\NN\1740 from\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 for\IN\1740 at\IN\14622893 least\JJS\1740 24\CD\13745420 h.\NN\1740 In\IN\13603305 contrast\NN\13854649 ,\,\1740 residence\NN\8491027 time\NN\7308889 of\IN\1740 <e1>adenosine</e1>\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 short\JJ\1740 (\-LRB-\1740 <\XX\1740 4\CD\13741022 h\NN\14622893 )\-RRB-\1740 .\.\1740
D000241_D006930 NONE RESULTS\NNS\34213 :\:\1740 Adenosine\NN\14964367 produced\VBD\1617192 no\DT\7204911 effect\NN\34213 on\IN\1740 pain\NN\14299637 report\NN\6470073 to\TO\1740 acute\JJ\1740 noxious\JJ\1740 thermal\JJ\1740 or\CC\3541091 chemical\JJ\1740 stimulation\NN\242808 but\CC\1740 reduced\VBD\441445 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\NN\1740 from\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 injection\NN\320852 for\IN\1740 at\IN\14622893 least\JJS\1740 24\CD\13745420 h.\NN\1740 In\IN\13603305 contrast\NN\13854649 ,\,\1740 residence\NN\8491027 time\NN\7308889 of\IN\1740 <e1>adenosine</e1>\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 short\JJ\1740 (\-LRB-\1740 <\XX\1740 4\CD\13741022 h\NN\14622893 )\-RRB-\1740 .\.\1740
D002211_D010146 NONE METHODS\NNS\5616786 :\:\1740 Following\VBG\1835496 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 and\CC\1740 institutional\JJ\1740 review\NN\5733583 board\NN\8324514 approval\NN\1212519 and\CC\1740 written\VBN\1697816 informed\JJ\1740 consent\NN\6689297 ,\,\1740 65\CD\1740 volunteers\NNS\10582746 were\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 trials\NNS\786195 :\:\1740 an\DT\6697703 open-label\JJ\1740 ,\,\1740 dose-escalating\JJ\1740 trial\NN\786195 with\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 doses\NNS\3740161 of\IN\1740 0.25\CD\1740 -\SYM\1740 2.0\CD\1740 mg\NN\13717155 and\CC\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 adenosine\NN\14964367 ,\,\1740 2\CD\13741022 mg.\NN\1740 Cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 obtained\VBN\2210855 for\IN\1740 pharmacokinetic\JJ\1740 analysis\NN\633864 ,\,\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 ratings\NNS\5733583 in\IN\13603305 response\NN\11410625 to\TO\1740 acute\JJ\1740 heat\NN\11452218 stimuli\NNS\5816287 and\CC\1740 areas\NNS\8630985 of\IN\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\NN\1740 after\IN\1740 intradermal\JJ\1740 <e1>capsaicin</e1>\NN\15032661 injection\NN\320852 were\VBD\836236 determined\VBN\1645601 .\.\1740
D002211_D010146 NONE RESULTS\NNS\34213 :\:\1740 Adenosine\NN\14964367 produced\VBD\1617192 no\DT\7204911 effect\NN\34213 on\IN\1740 <e2>pain</e2>\NN\14299637 report\NN\6470073 to\TO\1740 acute\JJ\1740 noxious\JJ\1740 thermal\JJ\1740 or\CC\3541091 chemical\JJ\1740 stimulation\NN\242808 but\CC\1740 reduced\VBD\441445 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\NN\1740 from\IN\1740 intradermal\JJ\1740 <e1>capsaicin</e1>\NN\15032661 injection\NN\320852 for\IN\1740 at\IN\14622893 least\JJS\1740 24\CD\13745420 h.\NN\1740 In\IN\13603305 contrast\NN\13854649 ,\,\1740 residence\NN\8491027 time\NN\7308889 of\IN\1740 adenosine\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 short\JJ\1740 (\-LRB-\1740 <\XX\1740 4\CD\13741022 h\NN\14622893 )\-RRB-\1740 .\.\1740
D002211_D006930 CID METHODS\NNS\5616786 :\:\1740 Following\VBG\1835496 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 and\CC\1740 institutional\JJ\1740 review\NN\5733583 board\NN\8324514 approval\NN\1212519 and\CC\1740 written\VBN\1697816 informed\JJ\1740 consent\NN\6689297 ,\,\1740 65\CD\1740 volunteers\NNS\10582746 were\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 trials\NNS\786195 :\:\1740 an\DT\6697703 open-label\JJ\1740 ,\,\1740 dose-escalating\JJ\1740 trial\NN\786195 with\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 doses\NNS\3740161 of\IN\1740 0.25\CD\1740 -\SYM\1740 2.0\CD\1740 mg\NN\13717155 and\CC\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 adenosine\NN\14964367 ,\,\1740 2\CD\13741022 mg.\NN\1740 Cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 obtained\VBN\2210855 for\IN\1740 pharmacokinetic\JJ\1740 analysis\NN\633864 ,\,\1740 and\CC\1740 pain\NN\14299637 ratings\NNS\5733583 in\IN\13603305 response\NN\11410625 to\TO\1740 acute\JJ\1740 heat\NN\11452218 stimuli\NNS\5816287 and\CC\1740 areas\NNS\8630985 of\IN\1740 <e2>mechanical\JJ\1740 hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\NN\1740 after\IN\1740 intradermal\JJ\1740 <e1>capsaicin</e1>\NN\15032661 injection\NN\320852 were\VBD\836236 determined\VBN\1645601 .\.\1740
D002211_D006930 CID METHODS\NNS\5616786 :\:\1740 Following\VBG\1835496 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 and\CC\1740 institutional\JJ\1740 review\NN\5733583 board\NN\8324514 approval\NN\1212519 and\CC\1740 written\VBN\1697816 informed\JJ\1740 consent\NN\6689297 ,\,\1740 65\CD\1740 volunteers\NNS\10582746 were\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 trials\NNS\786195 :\:\1740 an\DT\6697703 open-label\JJ\1740 ,\,\1740 dose-escalating\JJ\1740 trial\NN\786195 with\IN\1740 intrathecal\JJ\1740 adenosine\NN\14964367 doses\NNS\3740161 of\IN\1740 0.25\CD\1740 -\SYM\1740 2.0\CD\1740 mg\NN\13717155 and\CC\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 of\IN\1740 adenosine\NN\14964367 ,\,\1740 2\CD\13741022 mg.\NN\1740 Cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 obtained\VBN\2210855 for\IN\1740 pharmacokinetic\JJ\1740 analysis\NN\633864 ,\,\1740 and\CC\1740 pain\NN\14299637 ratings\NNS\5733583 in\IN\13603305 response\NN\11410625 to\TO\1740 acute\JJ\1740 heat\NN\11452218 stimuli\NNS\5816287 and\CC\1740 areas\NNS\8630985 of\IN\1740 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\NN\1740 after\IN\1740 intradermal\JJ\1740 <e1>capsaicin</e1>\NN\15032661 injection\NN\320852 were\VBD\836236 determined\VBN\1645601 .\.\1740
D002211_D006930 CID RESULTS\NNS\34213 :\:\1740 Adenosine\NN\14964367 produced\VBD\1617192 no\DT\7204911 effect\NN\34213 on\IN\1740 pain\NN\14299637 report\NN\6470073 to\TO\1740 acute\JJ\1740 noxious\JJ\1740 thermal\JJ\1740 or\CC\3541091 chemical\JJ\1740 stimulation\NN\242808 but\CC\1740 reduced\VBD\441445 <e2>mechanical\JJ\1740 hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\NN\1740 from\IN\1740 intradermal\JJ\1740 <e1>capsaicin</e1>\NN\15032661 injection\NN\320852 for\IN\1740 at\IN\14622893 least\JJS\1740 24\CD\13745420 h.\NN\1740 In\IN\13603305 contrast\NN\13854649 ,\,\1740 residence\NN\8491027 time\NN\7308889 of\IN\1740 adenosine\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 short\JJ\1740 (\-LRB-\1740 <\XX\1740 4\CD\13741022 h\NN\14622893 )\-RRB-\1740 .\.\1740
D002211_D006930 CID RESULTS\NNS\34213 :\:\1740 Adenosine\NN\14964367 produced\VBD\1617192 no\DT\7204911 effect\NN\34213 on\IN\1740 pain\NN\14299637 report\NN\6470073 to\TO\1740 acute\JJ\1740 noxious\JJ\1740 thermal\JJ\1740 or\CC\3541091 chemical\JJ\1740 stimulation\NN\242808 but\CC\1740 reduced\VBD\441445 mechanical\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\NN\1740 from\IN\1740 intradermal\JJ\1740 <e1>capsaicin</e1>\NN\15032661 injection\NN\320852 for\IN\1740 at\IN\14622893 least\JJS\1740 24\CD\13745420 h.\NN\1740 In\IN\13603305 contrast\NN\13854649 ,\,\1740 residence\NN\8491027 time\NN\7308889 of\IN\1740 adenosine\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 was\VBD\836236 short\JJ\1740 (\-LRB-\1740 <\XX\1740 4\CD\13741022 h\NN\14622893 )\-RRB-\1740 .\.\1740
D000241_D009437 NONE The\DT\1740 long-lasting\JJ\1740 effect\NN\34213 is\VBZ\836236 consistent\JJ\1740 with\IN\1740 that\DT\1740 observed\VBN\2163746 in\IN\13603305 preliminary\JJ\1740 reports\NNS\6470073 of\IN\1740 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 and\CC\1740 is\VBZ\836236 not\RB\1740 due\JJ\1740 to\TO\1740 prolonged\JJ\1740 residence\NN\8491027 of\IN\1740 <e1>adenosine</e1>\NN\14964367 in\IN\13603305 cerebrospinal\JJ\1740 fluid\NN\19613 .\.\1740
11079278
D008790_D017202 NONE Effect\NN\34213 of\IN\1740 intravenous\JJ\1740 <e1>metoprolol</e1>\NN\2832168 or\CC\3541091 intravenous\JJ\1740 metoprolol\NN\2832168 plus\CC\4723816 glucagon\VBD\1740 on\IN\1740 dobutamine-induced\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
D008790_D017202 NONE Effect\NN\34213 of\IN\1740 intravenous\JJ\1740 metoprolol\NN\2832168 or\CC\3541091 intravenous\JJ\1740 <e1>metoprolol</e1>\NN\2832168 plus\CC\4723816 glucagon\VBD\1740 on\IN\1740 dobutamine-induced\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
D008790_D017202 NONE CONCLUSION\NN\5837957 :\:\1740 During\IN\1740 dobutamine\NN\1740 stress\NN\7083732 testing\NN\639556 ,\,\1740 <e1>metoprolol</e1>\NN\2832168 attenuates\NNS\1740 or\CC\3541091 eliminates\VBZ\1619929 evidence\NN\5816287 of\IN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
D004280_D017202 CID Effect\NN\34213 of\IN\1740 intravenous\JJ\1740 metoprolol\NN\2832168 or\CC\3541091 intravenous\JJ\1740 metoprolol\NN\2832168 plus\CC\4723816 glucagon\VBD\1740 on\IN\1740 <e1>dobutamine-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
D004280_D017202 CID CONCLUSION\NN\5837957 :\:\1740 During\IN\1740 <e1>dobutamine</e1>\NN\1740 stress\NN\7083732 testing\NN\639556 ,\,\1740 metoprolol\NN\2832168 attenuates\NNS\1740 or\CC\3541091 eliminates\VBZ\1619929 evidence\NN\5816287 of\IN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
7416947
D004077_D020018 CID Subjective\JJ\1740 assessment\NN\5732756 of\IN\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 of\IN\1740 patients\NNS\9898892 on\IN\1740 long-term\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>digoxin</e1>\NN\15060131 .\.\1740
D004077_D012214 NONE The\DT\1740 patients\NNS\9898892 of\IN\1740 the\DT\1740 study\NN\635850 and\CC\1740 control\NN\5190804 group\NN\2137 (\-LRB-\1740 without\IN\1740 <e1>digoxin</e1>\NN\15060131 )\-RRB-\1740 were\VBD\836236 of\IN\1740 similar\JJ\1740 cardiac\JJ\1740 functional\JJ\1740 capacity\NN\5202497 and\CC\1740 age\NN\4916342 (\-LRB-\1740 25\CD\13745420 -\SYM\1740 40\CD\13745420 years\NNS\15144371 )\-RRB-\1740 and\CC\1740 were\VBD\836236 randomly\RB\1740 selected\VBN\697589 from\IN\1740 the\DT\1740 <e2>rheumatic\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 patients\NNS\9898892 .\.\1740
19761039
D010936_D004409 NONE Effect\NN\34213 of\IN\1740 methanolic\JJ\1740 extract\NN\14589223 of\IN\1740 <e1>Hibiscus\FW\12170585 rosa\VBD\1740 sinensis</e1>\NN\1740 (\-LRB-\1740 100\CD\13745420 -\SYM\1740 300\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 reserpine-induced\JJ\1740 orofacial\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 and\CC\1740 neurochemical\JJ\1740 alterations\NNS\7283608 .\.\1740
D010936_D004409 NONE The\DT\1740 results\NNS\34213 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 suggested\VBD\1010118 that\IN\1740 <e1>Hibiscus\NN\12170585 rosa\VBD\1740 sinensis</e1>\NN\1740 had\VBD\2108377 a\DT\13649268 protective\JJ\1740 role\NN\719494 against\IN\1740 reserpine-induced\JJ\1740 orofacial\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D012110_D004409 CID Effect\NN\34213 of\IN\1740 methanolic\JJ\1740 extract\NN\14589223 of\IN\1740 Hibiscus\FW\12170585 rosa\VBD\1740 sinensis\NN\1740 (\-LRB-\1740 100\CD\13745420 -\SYM\1740 300\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 <e1>reserpine-induced</e1>\JJ\1740 orofacial\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 and\CC\1740 neurochemical\JJ\1740 alterations\NNS\7283608 .\.\1740
D012110_D004409 CID The\DT\1740 results\NNS\34213 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 suggested\VBD\1010118 that\IN\1740 Hibiscus\NN\12170585 rosa\VBD\1740 sinensis\NN\1740 had\VBD\2108377 a\DT\13649268 protective\JJ\1740 role\NN\719494 against\IN\1740 <e1>reserpine-induced</e1>\JJ\1740 orofacial\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
12852481
D001241_D000014 CID <e1>Aspirin</e1>\NN\2707683 (\-LRB-\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 [\-LRB-\1740 ASA\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 irreversible\JJ\1740 cyclooxygenase\NN\14732946 1\CD\13741022 and\CC\1740 2\CD\13741022 inhibitor\NN\20090 ,\,\1740 induces\VBZ\1627355 <e2>developmental\JJ\1740 anomalies</e2>\NNS\14501726 when\WRB\1740 administered\VBN\2436349 to\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 on\IN\1740 gestational\JJ\1740 day\NN\15154774 (\-LRB-\1740 GD\NN\14970136 )\-RRB-\1740 9\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 or\CC\3541091 11\CD\13745420 (\-LRB-\1740 Kimmel\NNP\1740 CA\NNP\14625458 ,\,\1740 Wilson\NNP\1740 JG\NNP\1740 ,\,\1740 Schumacher\NNP\1740 HJ\NNP\1740 .\.\1740
D001241_D000014 CID Aspirin\NN\2707683 (\-LRB-\1740 <e1>acetylsalicylic\JJ\1740 acid</e1>\NN\14818238 [\-LRB-\1740 ASA\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 irreversible\JJ\1740 cyclooxygenase\NN\14732946 1\CD\13741022 and\CC\1740 2\CD\13741022 inhibitor\NN\20090 ,\,\1740 induces\VBZ\1627355 <e2>developmental\JJ\1740 anomalies</e2>\NNS\14501726 when\WRB\1740 administered\VBN\2436349 to\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 on\IN\1740 gestational\JJ\1740 day\NN\15154774 (\-LRB-\1740 GD\NN\14970136 )\-RRB-\1740 9\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 or\CC\3541091 11\CD\13745420 (\-LRB-\1740 Kimmel\NNP\1740 CA\NNP\14625458 ,\,\1740 Wilson\NNP\1740 JG\NNP\1740 ,\,\1740 Schumacher\NNP\1740 HJ\NNP\1740 .\.\1740
D001241_D000014 CID Aspirin\NN\2707683 (\-LRB-\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 [\-LRB-\1740 <e1>ASA</e1>\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 irreversible\JJ\1740 cyclooxygenase\NN\14732946 1\CD\13741022 and\CC\1740 2\CD\13741022 inhibitor\NN\20090 ,\,\1740 induces\VBZ\1627355 <e2>developmental\JJ\1740 anomalies</e2>\NNS\14501726 when\WRB\1740 administered\VBN\2436349 to\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 on\IN\1740 gestational\JJ\1740 day\NN\15154774 (\-LRB-\1740 GD\NN\14970136 )\-RRB-\1740 9\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 or\CC\3541091 11\CD\13745420 (\-LRB-\1740 Kimmel\NNP\1740 CA\NNP\14625458 ,\,\1740 Wilson\NNP\1740 JG\NNP\1740 ,\,\1740 Schumacher\NNP\1740 HJ\NNP\1740 .\.\1740
D001241_D000014 CID Objectives\NNS\5980875 of\IN\1740 the\DT\1740 current\JJ\1740 study\NN\635850 were\VBD\836236 to\TO\1740 compare\VB\644583 results\NNS\34213 between\IN\1740 Sprague-Dawley\NN\1740 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 and\CC\1740 Wistar\NNP\1740 strains\NNS\7358060 when\WRB\1740 <e1>ASA</e1>\NN\1740 is\VBZ\836236 administered\VBN\2436349 on\IN\1740 GD\NN\14970136 9\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 or\CC\3541091 11\CD\13745420 ;\:\1740 to\TO\1740 compare\VB\644583 the\DT\1740 malformation\NN\14213199 patterns\NNS\5726345 following\VBG\1835496 single\JJ\1740 and\CC\1740 multiple\JJ\1740 dosings\NNS\1740 during\IN\1740 organogenesis\NN\1740 in\IN\13603305 SD\NN\1740 rats\NNS\2329401 ;\:\1740 and\CC\1740 to\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 maternal\JJ\1740 gastrointestinal\JJ\1740 toxicity\NN\13576101 confounds\VBZ\2604760 the\DT\1740 detection\NN\5708432 of\IN\1740 low\JJ\1740 incidence\NN\13821570 <e2>malformations</e2>\NNS\14213199 with\IN\1740 ASA\NN\1740 when\WRB\1740 a\DT\13649268 multiple\JJ\1740 dosing\NN\1740 paradigm\NN\13803782 is\VBZ\836236 used\VBN\1156834 .\.\1740
D001241_D000014 CID Objectives\NNS\5980875 of\IN\1740 the\DT\1740 current\JJ\1740 study\NN\635850 were\VBD\836236 to\TO\1740 compare\VB\644583 results\NNS\34213 between\IN\1740 Sprague-Dawley\NN\1740 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 and\CC\1740 Wistar\NNP\1740 strains\NNS\7358060 when\WRB\1740 ASA\NN\1740 is\VBZ\836236 administered\VBN\2436349 on\IN\1740 GD\NN\14970136 9\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 or\CC\3541091 11\CD\13745420 ;\:\1740 to\TO\1740 compare\VB\644583 the\DT\1740 malformation\NN\14213199 patterns\NNS\5726345 following\VBG\1835496 single\JJ\1740 and\CC\1740 multiple\JJ\1740 dosings\NNS\1740 during\IN\1740 organogenesis\NN\1740 in\IN\13603305 SD\NN\1740 rats\NNS\2329401 ;\:\1740 and\CC\1740 to\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 maternal\JJ\1740 gastrointestinal\JJ\1740 toxicity\NN\13576101 confounds\VBZ\2604760 the\DT\1740 detection\NN\5708432 of\IN\1740 low\JJ\1740 incidence\NN\13821570 <e2>malformations</e2>\NNS\14213199 with\IN\1740 <e1>ASA</e1>\NN\1740 when\WRB\1740 a\DT\13649268 multiple\JJ\1740 dosing\NN\1740 paradigm\NN\13803782 is\VBZ\836236 used\VBN\1156834 .\.\1740
D001241_D000014 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 ventricular\NN\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 VSDs\NNS\1740 )\-RRB-\1740 and\CC\1740 midline\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 MDs\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 DH\NN\1740 )\-RRB-\1740 ,\,\1740 MDs\NNS\14622893 ,\,\1740 and\CC\1740 VSDs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 <e2>malformations</e2>\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 malformations\NNS\14213199 .\.\1740
D001241_D000014 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 ventricular\NN\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 VSDs\NNS\1740 )\-RRB-\1740 and\CC\1740 midline\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 MDs\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 DH\NN\1740 )\-RRB-\1740 ,\,\1740 MDs\NNS\14622893 ,\,\1740 and\CC\1740 VSDs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 malformations\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 <e2>malformations</e2>\NNS\14213199 .\.\1740
D001241_D000014 CID Variations\NNS\7296428 and\CC\1740 <e2>malformations</e2>\NNS\14213199 were\VBD\836236 similar\JJ\1740 when\WRB\1740 <e1>ASA</e1>\NN\1740 was\VBD\836236 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 during\IN\1740 the\DT\1740 period\NN\13575869 of\IN\1740 organogenesis\NN\1740 (\-LRB-\1740 GDs\NNS\14970136 6\CD\13741022 to\TO\1740 17\CD\13745420 )\-RRB-\1740 .\.\1740
D001241_D000014 CID It\PRP\6125041 was\VBD\836236 also\RB\1740 evident\JJ\1740 that\IN\1740 ,\,\1740 by\IN\1740 titrating\VBG\489837 the\DT\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 a\DT\13649268 maximum\NN\13653902 tolerated\VBN\802318 dose\NN\3740161 ,\,\1740 <e2>malformations</e2>\NNS\14213199 that\WDT\1740 normally\RB\1740 occur\VBP\2623529 at\IN\14622893 low\JJ\1740 incidence\NN\13821570 ,\,\1740 as\IN\14622893 reported\VBN\831651 from\IN\1740 previous\JJ\1740 single\JJ\1740 dose\NN\3740161 studies\NNS\635850 ,\,\1740 could\MD\1740 also\RB\1740 be\VB\836236 induced\VBN\1627355 with\IN\1740 <e1>ASA</e1>\NN\1740 given\VBN\2327200 at\IN\14622893 multiple\JJ\1740 doses\NNS\3740161 .\.\1740
D001241_D005767 NONE Objectives\NNS\5980875 of\IN\1740 the\DT\1740 current\JJ\1740 study\NN\635850 were\VBD\836236 to\TO\1740 compare\VB\644583 results\NNS\34213 between\IN\1740 Sprague-Dawley\NN\1740 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 and\CC\1740 Wistar\NNP\1740 strains\NNS\7358060 when\WRB\1740 <e1>ASA</e1>\NN\1740 is\VBZ\836236 administered\VBN\2436349 on\IN\1740 GD\NN\14970136 9\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 or\CC\3541091 11\CD\13745420 ;\:\1740 to\TO\1740 compare\VB\644583 the\DT\1740 malformation\NN\14213199 patterns\NNS\5726345 following\VBG\1835496 single\JJ\1740 and\CC\1740 multiple\JJ\1740 dosings\NNS\1740 during\IN\1740 organogenesis\NN\1740 in\IN\13603305 SD\NN\1740 rats\NNS\2329401 ;\:\1740 and\CC\1740 to\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 maternal\JJ\1740 <e2>gastrointestinal\JJ\1740 toxicity</e2>\NN\13576101 confounds\VBZ\2604760 the\DT\1740 detection\NN\5708432 of\IN\1740 low\JJ\1740 incidence\NN\13821570 malformations\NNS\14213199 with\IN\1740 ASA\NN\1740 when\WRB\1740 a\DT\13649268 multiple\JJ\1740 dosing\NN\1740 paradigm\NN\13803782 is\VBZ\836236 used\VBN\1156834 .\.\1740
D001241_D005767 NONE Objectives\NNS\5980875 of\IN\1740 the\DT\1740 current\JJ\1740 study\NN\635850 were\VBD\836236 to\TO\1740 compare\VB\644583 results\NNS\34213 between\IN\1740 Sprague-Dawley\NN\1740 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 and\CC\1740 Wistar\NNP\1740 strains\NNS\7358060 when\WRB\1740 ASA\NN\1740 is\VBZ\836236 administered\VBN\2436349 on\IN\1740 GD\NN\14970136 9\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 or\CC\3541091 11\CD\13745420 ;\:\1740 to\TO\1740 compare\VB\644583 the\DT\1740 malformation\NN\14213199 patterns\NNS\5726345 following\VBG\1835496 single\JJ\1740 and\CC\1740 multiple\JJ\1740 dosings\NNS\1740 during\IN\1740 organogenesis\NN\1740 in\IN\13603305 SD\NN\1740 rats\NNS\2329401 ;\:\1740 and\CC\1740 to\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 maternal\JJ\1740 <e2>gastrointestinal\JJ\1740 toxicity</e2>\NN\13576101 confounds\VBZ\2604760 the\DT\1740 detection\NN\5708432 of\IN\1740 low\JJ\1740 incidence\NN\13821570 malformations\NNS\14213199 with\IN\1740 <e1>ASA</e1>\NN\1740 when\WRB\1740 a\DT\13649268 multiple\JJ\1740 dosing\NN\1740 paradigm\NN\13803782 is\VBZ\836236 used\VBN\1156834 .\.\1740
D001241_D006345 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 <e2>ventricular\NN\1740 septal\JJ\1740 defects</e2>\NNS\14462666 (\-LRB-\1740 VSDs\NNS\1740 )\-RRB-\1740 and\CC\1740 midline\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 MDs\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 DH\NN\1740 )\-RRB-\1740 ,\,\1740 MDs\NNS\14622893 ,\,\1740 and\CC\1740 VSDs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 malformations\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 malformations\NNS\14213199 .\.\1740
D001241_D006345 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 ventricular\NN\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 <e2>VSDs</e2>\NNS\1740 )\-RRB-\1740 and\CC\1740 midline\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 MDs\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 DH\NN\1740 )\-RRB-\1740 ,\,\1740 MDs\NNS\14622893 ,\,\1740 and\CC\1740 VSDs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 malformations\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 malformations\NNS\14213199 .\.\1740
D001241_D006345 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 ventricular\NN\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 VSDs\NNS\1740 )\-RRB-\1740 and\CC\1740 midline\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 MDs\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 DH\NN\1740 )\-RRB-\1740 ,\,\1740 MDs\NNS\14622893 ,\,\1740 and\CC\1740 <e2>VSDs</e2>\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 malformations\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 malformations\NNS\14213199 .\.\1740
D001241_D009436 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 ventricular\NN\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 VSDs\NNS\1740 )\-RRB-\1740 and\CC\1740 <e2>midline\JJ\1740 defects</e2>\NNS\14462666 (\-LRB-\1740 MDs\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 DH\NN\1740 )\-RRB-\1740 ,\,\1740 MDs\NNS\14622893 ,\,\1740 and\CC\1740 VSDs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 malformations\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 malformations\NNS\14213199 .\.\1740
D001241_D009436 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 ventricular\NN\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 VSDs\NNS\1740 )\-RRB-\1740 and\CC\1740 midline\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 <e2>MDs</e2>\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 DH\NN\1740 )\-RRB-\1740 ,\,\1740 MDs\NNS\14622893 ,\,\1740 and\CC\1740 VSDs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 malformations\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 malformations\NNS\14213199 .\.\1740
D001241_D009436 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 ventricular\NN\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 VSDs\NNS\1740 )\-RRB-\1740 and\CC\1740 midline\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 MDs\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 DH\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>MDs</e2>\NNS\14622893 ,\,\1740 and\CC\1740 VSDs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 malformations\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 malformations\NNS\14213199 .\.\1740
D001241_D065630 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 ventricular\NN\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 VSDs\NNS\1740 )\-RRB-\1740 and\CC\1740 midline\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 MDs\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 <e2>diaphragmatic\JJ\1740 hernia</e2>\NN\14295248 (\-LRB-\1740 DH\NN\1740 )\-RRB-\1740 ,\,\1740 MDs\NNS\14622893 ,\,\1740 and\CC\1740 VSDs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 malformations\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 malformations\NNS\14213199 .\.\1740
D001241_D065630 CID RESULTS\NNS\34213 :\:\1740 The\DT\1740 literature\NN\6362953 evaluation\NN\874067 suggested\VBD\1010118 that\IN\1740 NSAIDs\NNS\2721538 induce\VBP\1627355 ventricular\NN\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 VSDs\NNS\1740 )\-RRB-\1740 and\CC\1740 midline\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 MDs\NNS\14622893 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 <e2>DH</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 MDs\NNS\14622893 ,\,\1740 and\CC\1740 VSDs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 (\-LRB-\1740 Cook\NN\10605985 JC\NN\1740 et\FW\1740 al.\FW\1740 ,\,\1740 2003\CD\1740 )\-RRB-\1740 ;\:\1740 hence\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 focused\VBD\628491 on\IN\1740 these\DT\1740 malformations\NNS\14213199 ,\,\1740 even\RB\1740 though\IN\1740 <e1>ASA</e1>\NN\1740 induces\VBZ\1627355 several\JJ\1740 other\JJ\1740 low-incidence\JJ\1740 malformations\NNS\14213199 .\.\1740
19058474
D014859_D010490 NONE Fatal\JJ\1740 <e2>haemopericardium</e2>\NN\1740 and\CC\1740 gastrointestinal\JJ\1740 haemorrhage\NN\14285662 due\JJ\1740 to\TO\1740 possible\JJ\1740 interaction\NN\37396 of\IN\1740 cranberry\NN\13112664 juice\NN\7566340 with\IN\1740 <e1>warfarin</e1>\NN\2718259 .\.\1740
D014859_D006471 CID Fatal\JJ\1740 haemopericardium\NN\1740 and\CC\1740 <e2>gastrointestinal\JJ\1740 haemorrhage</e2>\NN\14285662 due\JJ\1740 to\TO\1740 possible\JJ\1740 interaction\NN\37396 of\IN\1740 cranberry\NN\13112664 juice\NN\7566340 with\IN\1740 <e1>warfarin</e1>\NN\2718259 .\.\1740
D014859_D006470 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 fatal\JJ\1740 internal\JJ\1740 <e2>haemorrhage</e2>\NN\14285662 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 man\NN\9605289 who\WP\8299493 consumed\VBD\1168468 only\RB\1740 cranberry\VB\1740 juice\NN\7566340 for\IN\1740 two\CD\13741022 weeks\NNS\15113229 while\IN\15122231 maintaining\VBG\2202928 his\PRP$\1740 usual\JJ\1740 dosage\NN\13576355 of\IN\1740 <e1>warfarin</e1>\NN\2718259 .\.\1740
11009181
D001058_D010300 NONE <e1>Apomorphine</e1>\NN\3786417 :\:\1740 an\DT\6697703 underutilized\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D001058_D010300 NONE <e1>Apomorphine</e1>\NNP\3786417 was\VBD\836236 the\DT\1740 first\JJ\1740 dopaminergic\JJ\1740 drug\NN\14778436 ever\RB\1740 used\VBD\1156834 to\TO\1740 treat\VB\2376958 symptoms\NNS\5823932 of\IN\1740 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D001058_D010300 NONE While\IN\15122231 powerful\JJ\1740 antiparkinsonian\NN\1740 effects\NNS\13245626 had\VBD\2108377 been\VBN\836236 observed\VBN\2163746 as\RB\1740 early\RB\1740 as\IN\14622893 1951\CD\1740 ,\,\1740 the\DT\1740 potential\NN\14481929 of\IN\1740 treating\VBG\2376958 fluctuating\VBG\1850315 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 by\IN\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>apomorphine</e1>\NN\3786417 has\VBZ\2108377 only\RB\1740 recently\RB\1740 become\VBN\146138 the\DT\1740 subject\NN\6598915 of\IN\1740 systematic\JJ\1740 study\NN\635850 .\.\1740
D001058_D010300 NONE Given\VBN\2327200 the\DT\1740 marked\JJ\1740 degree\NN\4916342 of\IN\1740 efficacy\NN\5199286 of\IN\1740 subcutaneous\JJ\1740 <e1>apomorphine</e1>\NN\3786417 treatment\NN\654885 in\IN\13603305 fluctuating\VBG\1850315 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 ,\,\1740 this\DT\1740 approach\NN\940842 seems\VBZ\2604760 to\TO\1740 deserve\VB\2604760 more\RBR\1740 widespread\JJ\1740 clinical\JJ\1740 use\NN\407535 .\.\1740
D001058_D004409 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 there\EX\27167 is\VBZ\836236 convincing\VBG\766418 clinical\JJ\1740 evidence\NN\5816287 that\IN\1740 monotherapy\NN\1740 with\IN\1740 continuous\JJ\1740 subcutaneous\JJ\1740 <e1>apomorphine</e1>\NN\3786417 infusions\NNS\14589223 is\VBZ\836236 associated\VBN\628491 with\IN\1740 marked\JJ\1740 reductions\NNS\351485 of\IN\1740 preexisting\VBG\2603699 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
D007980_D004409 CID In\IN\13603305 addition\NN\3081021 ,\,\1740 there\EX\27167 is\VBZ\836236 convincing\VBG\766418 clinical\JJ\1740 evidence\NN\5816287 that\IN\1740 monotherapy\NN\1740 with\IN\1740 continuous\JJ\1740 subcutaneous\JJ\1740 apomorphine\NN\3786417 infusions\NNS\14589223 is\VBZ\836236 associated\VBN\628491 with\IN\1740 marked\JJ\1740 reductions\NNS\351485 of\IN\1740 preexisting\VBG\2603699 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
D001058_D001523 NONE The\DT\1740 main\JJ\1740 side\NN\8630039 effects\NNS\13245626 of\IN\1740 subcutaneous\JJ\1740 <e1>apomorphine</e1>\NN\3786417 treatment\NN\654885 are\VBP\836236 related\JJ\1740 to\TO\1740 cutaneous\JJ\1740 tolerability\NN\1740 problems\NNS\14408086 ,\,\1740 whereas\IN\1740 sedation\NN\14034177 and\CC\1740 <e2>psychiatric</e2>\JJ\1740 complications\NNS\1073995 play\VBP\1072262 a\DT\13649268 lesser\JJR\1740 role\NN\719494 .\.\1740
15897593
D064730_D001855 NONE <e1>Dexrazoxane</e1>\NNP\1740 protects\VBZ\1127795 against\IN\1740 <e2>myelosuppression</e2>\NN\1740 from\IN\1740 the\DT\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 etoposide\VBP\1740 and\CC\1740 daunorubicin\NN\1740 but\CC\1740 not\RB\1740 doxorubicin\NN\2716866 .\.\1740
D064730_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>dexrazoxane</e1>\NN\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D064730_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>dexrazoxane</e1>\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D064730_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 <e1>dexrazoxane</e1>\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D064730_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 <e1>dexrazoxane</e1>\NN\1740 neither\CC\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D005047_D001855 NONE Dexrazoxane\NNP\1740 protects\VBZ\1127795 against\IN\1740 <e2>myelosuppression</e2>\NN\1740 from\IN\1740 the\DT\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 <e1>etoposide</e1>\VBP\1740 and\CC\1740 daunorubicin\NN\1740 but\CC\1740 not\RB\1740 doxorubicin\NN\2716866 .\.\1740
D005047_D001855 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 anthracyclines\NNS\1740 daunorubicin\NN\1740 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 the\DT\1740 epipodophyllotoxin\NN\1740 <e1>etoposide</e1>\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 cardiac\JJ\1740 toxicity\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D005047_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 <e1>etoposide</e1>\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D005047_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 <e1>etoposide</e1>\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D003630_D001855 NONE Dexrazoxane\NNP\1740 protects\VBZ\1127795 against\IN\1740 <e2>myelosuppression</e2>\NN\1740 from\IN\1740 the\DT\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 etoposide\VBP\1740 and\CC\1740 <e1>daunorubicin</e1>\NN\1740 but\CC\1740 not\RB\1740 doxorubicin\NN\2716866 .\.\1740
D003630_D001855 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 anthracyclines\NNS\1740 <e1>daunorubicin</e1>\NN\1740 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 the\DT\1740 epipodophyllotoxin\NN\1740 etoposide\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 cardiac\JJ\1740 toxicity\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D003630_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 <e1>daunorubicin</e1>\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D003630_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 <e1>daunorubicin</e1>\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D004317_D001855 NONE Dexrazoxane\NNP\1740 protects\VBZ\1127795 against\IN\1740 <e2>myelosuppression</e2>\NN\1740 from\IN\1740 the\DT\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 etoposide\VBP\1740 and\CC\1740 daunorubicin\NN\1740 but\CC\1740 not\RB\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D001855 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 anthracyclines\NNS\1740 daunorubicin\NN\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 the\DT\1740 epipodophyllotoxin\NN\1740 etoposide\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 cardiac\JJ\1740 toxicity\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D004317_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D001855 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 <e2>myelosuppression</e2>\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D018943_D001855 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 <e1>anthracyclines</e1>\NNS\1740 daunorubicin\NN\1740 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 the\DT\1740 epipodophyllotoxin\NN\1740 etoposide\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 cardiac\JJ\1740 toxicity\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D018943_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 <e1>anthracyclines</e1>\NNS\1740 daunorubicin\NN\1740 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 the\DT\1740 epipodophyllotoxin\NN\1740 etoposide\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 myelosuppression\NN\1740 and\CC\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D018943_D066126 NONE Dexrazoxane\NNP\1740 (\-LRB-\1740 ICRF-187\NN\1740 )\-RRB-\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 protection\NN\407535 against\IN\1740 <e1>anthracycline-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D003630_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 anthracyclines\NNS\1740 <e1>daunorubicin</e1>\NN\1740 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 the\DT\1740 epipodophyllotoxin\NN\1740 etoposide\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 myelosuppression\NN\1740 and\CC\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D004317_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 anthracyclines\NNS\1740 daunorubicin\NN\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 the\DT\1740 epipodophyllotoxin\NN\1740 etoposide\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 myelosuppression\NN\1740 and\CC\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D011034_D001855 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 anthracyclines\NNS\1740 daunorubicin\NN\1740 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 the\DT\1740 <e1>epipodophyllotoxin</e1>\NN\1740 etoposide\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 <e2>myelosuppression</e2>\NN\1740 and\CC\1740 cardiac\JJ\1740 toxicity\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D011034_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 anthracyclines\NNS\1740 daunorubicin\NN\1740 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 the\DT\1740 <e1>epipodophyllotoxin</e1>\NN\1740 etoposide\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 myelosuppression\NN\1740 and\CC\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D005047_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 anthracyclines\NNS\1740 daunorubicin\NN\1740 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 the\DT\1740 epipodophyllotoxin\NN\1740 <e1>etoposide</e1>\NN\1740 are\VBP\836236 potent\JJ\1740 DNA\NN\14994328 cleavage-enhancing\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 oncology\NN\6043075 ;\:\1740 however\RB\1740 ,\,\1740 myelosuppression\NN\1740 and\CC\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 limit\NN\5123416 their\PRP$\1740 use\NN\407535 .\.\1740
D064730_D066126 NONE <e1>Dexrazoxane</e1>\NNP\1740 (\-LRB-\1740 ICRF-187\NN\1740 )\-RRB-\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 protection\NN\407535 against\IN\1740 anthracycline-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D064730_D066126 NONE Dexrazoxane\NNP\1740 (\-LRB-\1740 <e1>ICRF-187</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 protection\NN\407535 against\IN\1740 anthracycline-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D064730_D006402 NONE EXPERIMENTAL\NN\1740 DESIGN\VBD\1631534 :\:\1740 Because\IN\1740 of\IN\1740 their\PRP$\1740 widespread\JJ\1740 use\NN\407535 ,\,\1740 the\DT\1740 <e2>hematologic\JJ\1740 toxicity</e2>\NN\13576101 following\VBG\1835496 coadministration\NN\1740 of\IN\1740 <e1>dexrazoxane</e1>\NN\1740 and\CC\1740 these\DT\1740 three\CD\13741022 structurally\RB\1740 different\JJ\1740 DNA\NN\14994328 cleavage\NN\24720 enhancers\NNS\5853636 was\VBD\836236 investigated\VBN\644583 :\:\1740 Sensitivity\NN\5651971 of\IN\1740 human\JJ\1740 and\CC\1740 murine\JJ\1740 blood\NN\5397468 progenitor\NN\9792555 cells\NNS\3080309 to\TO\1740 etoposide\VB\1740 ,\,\1740 daunorubicin\NN\1740 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 +/-\CC\1740 dexrazoxane\NN\1740 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 granulocyte-macrophage\JJ\1740 colony\NN\7965085 forming\NN\1740 assays\NNS\5733583 .\.\1740
D064730_D006402 NONE EXPERIMENTAL\NN\1740 DESIGN\VBD\1631534 :\:\1740 Because\IN\1740 of\IN\1740 their\PRP$\1740 widespread\JJ\1740 use\NN\407535 ,\,\1740 the\DT\1740 <e2>hematologic\JJ\1740 toxicity</e2>\NN\13576101 following\VBG\1835496 coadministration\NN\1740 of\IN\1740 dexrazoxane\NN\1740 and\CC\1740 these\DT\1740 three\CD\13741022 structurally\RB\1740 different\JJ\1740 DNA\NN\14994328 cleavage\NN\24720 enhancers\NNS\5853636 was\VBD\836236 investigated\VBN\644583 :\:\1740 Sensitivity\NN\5651971 of\IN\1740 human\JJ\1740 and\CC\1740 murine\JJ\1740 blood\NN\5397468 progenitor\NN\9792555 cells\NNS\3080309 to\TO\1740 etoposide\VB\1740 ,\,\1740 daunorubicin\NN\1740 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 +/-\CC\1740 <e1>dexrazoxane</e1>\NN\1740 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 granulocyte-macrophage\JJ\1740 colony\NN\7965085 forming\NN\1740 assays\NNS\5733583 .\.\1740
D064730_D006402 NONE Clinical\JJ\1740 trials\NNS\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 brain\NN\5462674 metastases\NNS\13533470 combining\VBG\2630189 <e1>dexrazoxane</e1>\NN\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 etoposide\NN\1740 is\VBZ\836236 ongoing\JJ\1740 with\IN\1740 the\DT\1740 aim\NN\5980875 of\IN\1740 improving\VBG\126264 efficacy\NN\5199286 without\IN\1740 aggravating\VBG\126264 <e2>hematologic\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D005047_D006402 CID EXPERIMENTAL\NN\1740 DESIGN\VBD\1631534 :\:\1740 Because\IN\1740 of\IN\1740 their\PRP$\1740 widespread\JJ\1740 use\NN\407535 ,\,\1740 the\DT\1740 <e2>hematologic\JJ\1740 toxicity</e2>\NN\13576101 following\VBG\1835496 coadministration\NN\1740 of\IN\1740 dexrazoxane\NN\1740 and\CC\1740 these\DT\1740 three\CD\13741022 structurally\RB\1740 different\JJ\1740 DNA\NN\14994328 cleavage\NN\24720 enhancers\NNS\5853636 was\VBD\836236 investigated\VBN\644583 :\:\1740 Sensitivity\NN\5651971 of\IN\1740 human\JJ\1740 and\CC\1740 murine\JJ\1740 blood\NN\5397468 progenitor\NN\9792555 cells\NNS\3080309 to\TO\1740 <e1>etoposide</e1>\VB\1740 ,\,\1740 daunorubicin\NN\1740 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 +/-\CC\1740 dexrazoxane\NN\1740 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 granulocyte-macrophage\JJ\1740 colony\NN\7965085 forming\NN\1740 assays\NNS\5733583 .\.\1740
D005047_D006402 CID Clinical\JJ\1740 trials\NNS\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 brain\NN\5462674 metastases\NNS\13533470 combining\VBG\2630189 dexrazoxane\NN\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>etoposide</e1>\NN\1740 is\VBZ\836236 ongoing\JJ\1740 with\IN\1740 the\DT\1740 aim\NN\5980875 of\IN\1740 improving\VBG\126264 efficacy\NN\5199286 without\IN\1740 aggravating\VBG\126264 <e2>hematologic\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D003630_D006402 CID EXPERIMENTAL\NN\1740 DESIGN\VBD\1631534 :\:\1740 Because\IN\1740 of\IN\1740 their\PRP$\1740 widespread\JJ\1740 use\NN\407535 ,\,\1740 the\DT\1740 <e2>hematologic\JJ\1740 toxicity</e2>\NN\13576101 following\VBG\1835496 coadministration\NN\1740 of\IN\1740 dexrazoxane\NN\1740 and\CC\1740 these\DT\1740 three\CD\13741022 structurally\RB\1740 different\JJ\1740 DNA\NN\14994328 cleavage\NN\24720 enhancers\NNS\5853636 was\VBD\836236 investigated\VBN\644583 :\:\1740 Sensitivity\NN\5651971 of\IN\1740 human\JJ\1740 and\CC\1740 murine\JJ\1740 blood\NN\5397468 progenitor\NN\9792555 cells\NNS\3080309 to\TO\1740 etoposide\VB\1740 ,\,\1740 <e1>daunorubicin</e1>\NN\1740 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 +/-\CC\1740 dexrazoxane\NN\1740 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 granulocyte-macrophage\JJ\1740 colony\NN\7965085 forming\NN\1740 assays\NNS\5733583 .\.\1740
D004317_D006402 CID EXPERIMENTAL\NN\1740 DESIGN\VBD\1631534 :\:\1740 Because\IN\1740 of\IN\1740 their\PRP$\1740 widespread\JJ\1740 use\NN\407535 ,\,\1740 the\DT\1740 <e2>hematologic\JJ\1740 toxicity</e2>\NN\13576101 following\VBG\1835496 coadministration\NN\1740 of\IN\1740 dexrazoxane\NN\1740 and\CC\1740 these\DT\1740 three\CD\13741022 structurally\RB\1740 different\JJ\1740 DNA\NN\14994328 cleavage\NN\24720 enhancers\NNS\5853636 was\VBD\836236 investigated\VBN\644583 :\:\1740 Sensitivity\NN\5651971 of\IN\1740 human\JJ\1740 and\CC\1740 murine\JJ\1740 blood\NN\5397468 progenitor\NN\9792555 cells\NNS\3080309 to\TO\1740 etoposide\VB\1740 ,\,\1740 daunorubicin\NN\1740 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 +/-\CC\1740 dexrazoxane\NN\1740 was\VBD\836236 determined\VBN\1645601 in\IN\13603305 granulocyte-macrophage\JJ\1740 colony\NN\7965085 forming\NN\1740 assays\NNS\5733583 .\.\1740
D064730_D015431 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>dexrazoxane</e1>\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D064730_D015431 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>dexrazoxane</e1>\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D064730_D015431 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 <e1>dexrazoxane</e1>\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D064730_D015431 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 <e1>dexrazoxane</e1>\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D064730_D064420 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>dexrazoxane</e1>\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 <e2>cytotoxicity</e2>\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D064730_D064420 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 <e1>dexrazoxane</e1>\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 <e2>cytotoxicity</e2>\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D003630_D015431 CID RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 from\IN\1740 <e1>daunorubicin</e1>\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D003630_D015431 CID RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 <e1>daunorubicin</e1>\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D003630_D064420 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 <e1>daunorubicin</e1>\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 <e2>cytotoxicity</e2>\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D005047_D015431 CID RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 <e1>etoposide</e1>\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D005047_D015431 CID RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 <e1>etoposide</e1>\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D005047_D064420 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 <e1>etoposide</e1>\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 <e2>cytotoxicity</e2>\NN\13583478 from\IN\1740 doxorubicin\NN\2716866 .\.\1740
D004317_D015431 CID RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D015431 CID RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 cytotoxicity\NN\13583478 from\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D064420 NONE RESULTS\NNS\34213 :\:\1740 Nontoxic\JJ\1740 doses\NNS\3740161 of\IN\1740 dexrazoxane\NN\1740 reduced\VBD\441445 myelosuppression\NN\1740 and\CC\1740 weight\NN\5009170 loss\NN\13252973 from\IN\1740 daunorubicin\NN\1740 and\CC\1740 etoposide\NN\1740 in\IN\13603305 mice\NNS\2329401 and\CC\1740 antagonized\VBD\1787955 their\PRP$\1740 antiproliferative\JJ\1740 effects\NNS\13245626 in\IN\13603305 the\DT\1740 colony\NN\7965085 assay\NN\5733583 ;\:\1740 however\RB\1740 ,\,\1740 dexrazoxane\NN\1740 neither\CC\1740 reduced\VBD\441445 myelosuppression\NN\1740 ,\,\1740 weight\NN\5009170 loss\NN\13252973 ,\,\1740 nor\CC\1740 the\DT\1740 in\FW\13603305 vitro\FW\1740 <e2>cytotoxicity</e2>\NN\13583478 from\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D064730_D009362 NONE Clinical\JJ\1740 trials\NNS\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 brain\NN\5462674 <e2>metastases</e2>\NNS\13533470 combining\VBG\2630189 <e1>dexrazoxane</e1>\NN\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 etoposide\NN\1740 is\VBZ\836236 ongoing\JJ\1740 with\IN\1740 the\DT\1740 aim\NN\5980875 of\IN\1740 improving\VBG\126264 efficacy\NN\5199286 without\IN\1740 aggravating\VBG\126264 hematologic\JJ\1740 toxicity\NN\13576101 .\.\1740
D005047_D009362 NONE Clinical\JJ\1740 trials\NNS\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 brain\NN\5462674 <e2>metastases</e2>\NNS\13533470 combining\VBG\2630189 dexrazoxane\NN\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>etoposide</e1>\NN\1740 is\VBZ\836236 ongoing\JJ\1740 with\IN\1740 the\DT\1740 aim\NN\5980875 of\IN\1740 improving\VBG\126264 efficacy\NN\5199286 without\IN\1740 aggravating\VBG\126264 hematologic\JJ\1740 toxicity\NN\13576101 .\.\1740
1595783
D000638_D008171 NONE <e1>Amiodarone</e1>\NN\2715941 <e2>pulmonary\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D000638_D008171 NONE The\DT\1740 <e2>pulmonary\JJ\1740 toxicity</e2>\NN\13576101 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 is\VBZ\836236 thought\VBN\670261 to\TO\1740 result\VB\2633881 from\IN\1740 direct\JJ\1740 injury\NN\14052046 related\JJ\1740 to\TO\1740 the\DT\1740 intracellular\JJ\1740 accumulation\NN\13497135 of\IN\1740 phospholipid\NN\14938907 and\CC\1740 T\NN\14999913 cell-mediated\JJ\1740 hypersensitivity\NN\14531772 pneumonitis\NN\14336539 .\.\1740
D000638_D008171 NONE The\DT\1740 clinical\JJ\1740 and\CC\1740 radiographic\JJ\1740 features\NNS\5849040 of\IN\1740 <e1>amiodarone-induced</e1>\JJ\1740 <e2>pulmonary\JJ\1740 toxicity</e2>\NN\13576101 are\VBP\836236 characteristic\JJ\1740 but\CC\1740 nonspecific\JJ\1740 .\.\1740
D000638_D011014 CID <e1>Amiodarone</e1>\NN\2715941 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 antiarrhythmic\JJ\1740 agent\NN\7347 whose\WP$\1740 utility\NN\8186047 is\VBZ\836236 limited\VBN\2510337 by\IN\1740 many\JJ\1740 side-effects\NNS\1740 ,\,\1740 the\DT\1740 most\RBS\1740 problematic\JJ\1740 being\VBG\836236 <e2>pneumonitis</e2>\NN\14336539 .\.\1740
D000638_D004342 NONE The\DT\1740 pulmonary\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 is\VBZ\836236 thought\VBN\670261 to\TO\1740 result\VB\2633881 from\IN\1740 direct\JJ\1740 injury\NN\14052046 related\JJ\1740 to\TO\1740 the\DT\1740 intracellular\JJ\1740 accumulation\NN\13497135 of\IN\1740 phospholipid\NN\14938907 and\CC\1740 T\NN\14999913 cell-mediated\JJ\1740 <e2>hypersensitivity\NN\14531772 pneumonitis</e2>\NN\14336539 .\.\1740
D000638_D000542 NONE The\DT\1740 pulmonary\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 is\VBZ\836236 thought\VBN\670261 to\TO\1740 result\VB\2633881 from\IN\1740 direct\JJ\1740 injury\NN\14052046 related\JJ\1740 to\TO\1740 the\DT\1740 intracellular\JJ\1740 accumulation\NN\13497135 of\IN\1740 phospholipid\NN\14938907 and\CC\1740 T\NN\14999913 cell-mediated\JJ\1740 <e2>hypersensitivity\NN\14531772 pneumonitis</e2>\NN\14336539 .\.\1740
3952818
D005472_D066126 NONE <e2>Cardiac\JJ\1740 toxicity</e2>\NN\13576101 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 .\.\1740
D005472_D066126 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 coronary\JJ\1740 spasm\NN\14299637 may\MD\15209706 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 due\IN\5174653 to\TO\1740 <e1>5-FU</e1>\CD\1740 ,\,\1740 and\CC\1740 that\IN\1740 calcium\NN\14625458 antagonists\NNS\7846 may\MD\15209706 probably\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 prevention\NN\1073995 or\CC\3541091 treatment\NN\654885 of\IN\1740 5-FU\NN\1740 cardiotoxicity\NN\1740 .\.\1740
D005472_D066126 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 coronary\JJ\1740 spasm\NN\14299637 may\MD\15209706 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 cardiotoxicity\NN\1740 due\IN\5174653 to\TO\1740 <e1>5-FU</e1>\CD\1740 ,\,\1740 and\CC\1740 that\IN\1740 calcium\NN\14625458 antagonists\NNS\7846 may\MD\15209706 probably\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 prevention\NN\1073995 or\CC\3541091 treatment\NN\654885 of\IN\1740 5-FU\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D005472_D066126 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 coronary\JJ\1740 spasm\NN\14299637 may\MD\15209706 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 due\IN\5174653 to\TO\1740 5-FU\CD\1740 ,\,\1740 and\CC\1740 that\IN\1740 calcium\NN\14625458 antagonists\NNS\7846 may\MD\15209706 probably\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 prevention\NN\1073995 or\CC\3541091 treatment\NN\654885 of\IN\1740 <e1>5-FU</e1>\NN\1740 cardiotoxicity\NN\1740 .\.\1740
D005472_D066126 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 coronary\JJ\1740 spasm\NN\14299637 may\MD\15209706 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 cardiotoxicity\NN\1740 due\IN\5174653 to\TO\1740 5-FU\CD\1740 ,\,\1740 and\CC\1740 that\IN\1740 calcium\NN\14625458 antagonists\NNS\7846 may\MD\15209706 probably\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 prevention\NN\1073995 or\CC\3541091 treatment\NN\654885 of\IN\1740 <e1>5-FU</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D005472_D003110 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>colon\NN\5535484 carcinoma</e2>\NN\14239918 and\CC\1740 liver\NN\5298729 metastasis\NN\13533470 who\WP\8299493 presented\VBD\2137132 chest\JJ\1740 pain\NN\14299637 after\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 administration\NN\1133281 .\.\1740
D005472_D003110 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>colon\NN\5535484 carcinoma</e2>\NN\14239918 and\CC\1740 liver\NN\5298729 metastasis\NN\13533470 who\WP\8299493 presented\VBD\2137132 chest\JJ\1740 pain\NN\14299637 after\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 administration\NN\1133281 .\.\1740
D005472_D009362 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 colon\NN\5535484 carcinoma\NN\14239918 and\CC\1740 liver\NN\5298729 <e2>metastasis</e2>\NN\13533470 who\WP\8299493 presented\VBD\2137132 chest\JJ\1740 pain\NN\14299637 after\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 administration\NN\1133281 .\.\1740
D005472_D009362 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 colon\NN\5535484 carcinoma\NN\14239918 and\CC\1740 liver\NN\5298729 <e2>metastasis</e2>\NN\13533470 who\WP\8299493 presented\VBD\2137132 chest\JJ\1740 pain\NN\14299637 after\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 administration\NN\1133281 .\.\1740
D005472_D002637 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 colon\NN\5535484 carcinoma\NN\14239918 and\CC\1740 liver\NN\5298729 metastasis\NN\13533470 who\WP\8299493 presented\VBD\2137132 <e2>chest\JJ\1740 pain</e2>\NN\14299637 after\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 administration\NN\1133281 .\.\1740
D005472_D002637 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 colon\NN\5535484 carcinoma\NN\14239918 and\CC\1740 liver\NN\5298729 metastasis\NN\13533470 who\WP\8299493 presented\VBD\2137132 <e2>chest\JJ\1740 pain</e2>\NN\14299637 after\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 administration\NN\1133281 .\.\1740
D009543_D000788 NONE Clinical\JJ\1740 electrocardiographic\JJ\1740 evolution\NN\29677 was\VBD\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 observed\VBN\2163746 in\IN\13603305 <e2>Prinzmetal\NNP\1740 's\POS\1740 angina</e2>\NN\14171682 ,\,\1740 and\CC\1740 chest\JJ\1740 pain\NN\14299637 promptly\RB\1740 resolved\VBN\352826 with\IN\1740 <e1>nifedipine</e1>\NN\2938514 .\.\1740
D009543_D002637 NONE Clinical\JJ\1740 electrocardiographic\JJ\1740 evolution\NN\29677 was\VBD\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 observed\VBN\2163746 in\IN\13603305 Prinzmetal\NNP\1740 's\POS\1740 angina\NN\14171682 ,\,\1740 and\CC\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 promptly\RB\1740 resolved\VBN\352826 with\IN\1740 <e1>nifedipine</e1>\NN\2938514 .\.\1740
D005472_D003329 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e2>coronary\JJ\1740 spasm</e2>\NN\14299637 may\MD\15209706 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 cardiotoxicity\NN\1740 due\IN\5174653 to\TO\1740 <e1>5-FU</e1>\CD\1740 ,\,\1740 and\CC\1740 that\IN\1740 calcium\NN\14625458 antagonists\NNS\7846 may\MD\15209706 probably\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 prevention\NN\1073995 or\CC\3541091 treatment\NN\654885 of\IN\1740 5-FU\NN\1740 cardiotoxicity\NN\1740 .\.\1740
D005472_D003329 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e2>coronary\JJ\1740 spasm</e2>\NN\14299637 may\MD\15209706 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 cardiotoxicity\NN\1740 due\IN\5174653 to\TO\1740 5-FU\CD\1740 ,\,\1740 and\CC\1740 that\IN\1740 calcium\NN\14625458 antagonists\NNS\7846 may\MD\15209706 probably\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 prevention\NN\1073995 or\CC\3541091 treatment\NN\654885 of\IN\1740 <e1>5-FU</e1>\NN\1740 cardiotoxicity\NN\1740 .\.\1740
D002118_D003329 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e2>coronary\JJ\1740 spasm</e2>\NN\14299637 may\MD\15209706 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 cardiotoxicity\NN\1740 due\IN\5174653 to\TO\1740 5-FU\CD\1740 ,\,\1740 and\CC\1740 that\IN\1740 <e1>calcium</e1>\NN\14625458 antagonists\NNS\7846 may\MD\15209706 probably\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 prevention\NN\1073995 or\CC\3541091 treatment\NN\654885 of\IN\1740 5-FU\NN\1740 cardiotoxicity\NN\1740 .\.\1740
D002118_D066126 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 coronary\JJ\1740 spasm\NN\14299637 may\MD\15209706 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 due\IN\5174653 to\TO\1740 5-FU\CD\1740 ,\,\1740 and\CC\1740 that\IN\1740 <e1>calcium</e1>\NN\14625458 antagonists\NNS\7846 may\MD\15209706 probably\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 prevention\NN\1073995 or\CC\3541091 treatment\NN\654885 of\IN\1740 5-FU\NN\1740 cardiotoxicity\NN\1740 .\.\1740
D002118_D066126 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 coronary\JJ\1740 spasm\NN\14299637 may\MD\15209706 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 cardiotoxicity\NN\1740 due\IN\5174653 to\TO\1740 5-FU\CD\1740 ,\,\1740 and\CC\1740 that\IN\1740 <e1>calcium</e1>\NN\14625458 antagonists\NNS\7846 may\MD\15209706 probably\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 prevention\NN\1073995 or\CC\3541091 treatment\NN\654885 of\IN\1740 5-FU\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
8475949
D010419_D017180 NONE Case\NN\7283608 report\NN\6470073 :\:\1740 <e1>pentamidine</e1>\NN\1740 and\CC\1740 polymorphic\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 revisited\VBN\2004874 .\.\1740
D010419_D017180 NONE <e1>Pentamidine\NN\1740 isethionate</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 <e2>ventricular\JJ\1740 tachyarrhythmias</e2>\NNS\1740 ,\,\1740 including\VBG\690614 torsade\NN\1740 de\NNP\1740 pointes\NNS\1740 .\.\1740
D010419_D016171 CID <e1>Pentamidine\NN\1740 isethionate</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 ventricular\JJ\1740 tachyarrhythmias\NNS\1740 ,\,\1740 including\VBG\690614 <e2>torsade\NN\1740 de\NNP\1740 pointes</e2>\NNS\1740 .\.\1740
D010419_D016171 CID <e1>Pentamidine-induced</e1>\JJ\1740 <e2>torsade\NN\1740 de\IN\1740 pointes</e2>\NNS\1740 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 serum\NN\5397468 magnesium\NN\14625458 levels\NNS\4916342 and\CC\1740 hypomagnesemia\NN\1740 may\MD\15209706 synergistically\RB\1740 induce\VB\1627355 torsade\NN\1740 .\.\1740
D010419_D016171 CID <e2>Torsade\NNP\1740 de\NNP\1740 pointes</e2>\NNS\1740 occurred\VBD\2623529 after\IN\1740 an\DT\6697703 average\NN\6021499 of\IN\1740 10\CD\13745420 days\NNS\15140892 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>pentamidine</e1>\NN\1740 .\.\1740
D010419_D016171 CID <e2>Torsade\NNP\1740 de\NNP\1740 pointes</e2>\NNS\1740 can\MD\3094503 be\VB\836236 treated\VBN\2376958 when\WRB\1740 recognized\VBN\686447 early\RB\1740 ,\,\1740 possibly\RB\1740 without\IN\1740 discontinuation\NN\209943 of\IN\1740 <e1>pentamidine</e1>\NN\1740 .\.\1740
D010419_C537153 NONE <e1>Pentamidine-induced</e1>\JJ\1740 torsade\NN\1740 de\IN\1740 pointes\NNS\1740 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 serum\NN\5397468 magnesium\NN\14625458 levels\NNS\4916342 and\CC\1740 <e2>hypomagnesemia</e2>\NN\1740 may\MD\15209706 synergistically\RB\1740 induce\VB\1627355 torsade\NN\1740 .\.\1740
D008274_D016171 NONE Pentamidine-induced\JJ\1740 <e2>torsade\NN\1740 de\IN\1740 pointes</e2>\NNS\1740 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 serum\NN\5397468 <e1>magnesium</e1>\NN\14625458 levels\NNS\4916342 and\CC\1740 hypomagnesemia\NN\1740 may\MD\15209706 synergistically\RB\1740 induce\VB\1627355 torsade\NN\1740 .\.\1740
D008274_C537153 NONE Pentamidine-induced\JJ\1740 torsade\NN\1740 de\IN\1740 pointes\NNS\1740 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 serum\NN\5397468 <e1>magnesium</e1>\NN\14625458 levels\NNS\4916342 and\CC\1740 <e2>hypomagnesemia</e2>\NN\1740 may\MD\15209706 synergistically\RB\1740 induce\VB\1627355 torsade\NN\1740 .\.\1740
D008274_D008133 NONE When\WRB\1740 <e2>QTc\NN\1740 interval\NN\33615 prolongation</e2>\NN\1017987 is\VBZ\836236 observed\VBN\2163746 ,\,\1740 early\JJ\1740 <e1>magnesium</e1>\NN\14625458 supplementation\NN\5108947 is\VBZ\836236 advocated\VBN\875394 .\.\1740
11860495
D013256_D000647 NONE <e1>Steroid</e1>\NN\14727670 structure\NN\21939 and\CC\1740 pharmacological\JJ\1740 properties\NNS\32613 determine\VBP\1645601 the\DT\1740 <e2>anti-amnesic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 pregnenolone\NN\1740 sulphate\NN\15010703 in\IN\13603305 the\DT\1740 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 .\.\1740
C018370_D000647 NONE Steroid\NN\14727670 structure\NN\21939 and\CC\1740 pharmacological\JJ\1740 properties\NNS\32613 determine\VBP\1645601 the\DT\1740 <e2>anti-amnesic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>pregnenolone\NN\1740 sulphate</e1>\NN\15010703 in\IN\13603305 the\DT\1740 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 .\.\1740
C018370_D000647 NONE Moreover\RB\1740 ,\,\1740 <e1>PREGS</e1>\NNS\1740 is\VBZ\836236 able\JJ\1740 to\TO\1740 reverse\VB\109660 the\DT\1740 <e2>amnesic-like</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 NMDAR\NN\1740 and\CC\1740 GABA(A)R\NN\1740 ligands\NNS\20090 .\.\1740
C018370_D000647 NONE The\DT\1740 memory-enhancing\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>PREGS</e1>\NNS\1740 and\CC\1740 its\PRP$\6125041 analogs\NNS\4743605 were\VBD\836236 tested\VBN\670261 in\IN\13603305 the\DT\1740 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 using\VBG\1156834 the\DT\1740 model\NN\5888929 of\IN\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
C018370_D000647 NONE Moreover\RB\1740 ,\,\1740 enantioselectivity\NN\1740 was\VBD\836236 demonstrated\VBN\2137132 by\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 natural\JJ\1740 <e1>PREGS</e1>\NNS\1740 to\TO\1740 be\VB\836236 an\DT\6697703 order\NN\7168131 of\IN\1740 magnitude\NN\4916342 more\RBR\1740 effective\JJ\1740 than\IN\1740 its\PRP$\6125041 synthetic\JJ\1740 enantiomer\NN\14818238 in\IN\13603305 reversing\VBG\109660 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D005680_D000647 NONE Moreover\RB\1740 ,\,\1740 PREGS\NNS\1740 is\VBZ\836236 able\JJ\1740 to\TO\1740 reverse\VB\109660 the\DT\1740 <e2>amnesic-like</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 NMDAR\NN\1740 and\CC\1740 <e1>GABA(A)R</e1>\NN\1740 ligands\NNS\20090 .\.\1740
D012601_D000647 CID The\DT\1740 memory-enhancing\JJ\1740 effects\NNS\13245626 of\IN\1740 PREGS\NNS\1740 and\CC\1740 its\PRP$\6125041 analogs\NNS\4743605 were\VBD\836236 tested\VBN\670261 in\IN\13603305 the\DT\1740 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 using\VBG\1156834 the\DT\1740 model\NN\5888929 of\IN\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D012601_D000647 CID Moreover\RB\1740 ,\,\1740 enantioselectivity\NN\1740 was\VBD\836236 demonstrated\VBN\2137132 by\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 natural\JJ\1740 PREGS\NNS\1740 to\TO\1740 be\VB\836236 an\DT\6697703 order\NN\7168131 of\IN\1740 magnitude\NN\4916342 more\RBR\1740 effective\JJ\1740 than\IN\1740 its\PRP$\6125041 synthetic\JJ\1740 enantiomer\NN\14818238 in\IN\13603305 reversing\VBG\109660 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
2257294
C034753_D001855 NONE <e1>Benzylacyclouridine</e1>\NN\1740 reverses\VBZ\109660 azidothymidine-induced\JJ\1740 <e2>marrow\NN\5286536 suppression</e2>\NN\13489037 without\IN\1740 impairment\NN\7296428 of\IN\1740 anti-human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 activity\NN\30358 .\.\1740
C034753_D001855 NONE When\WRB\1740 coadministered\VBN\1740 with\IN\1740 AZT\NN\3834836 from\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 drug\NN\14778436 administration\NN\1133281 ,\,\1740 <e1>BAU</e1>\NN\1740 reduced\VBD\441445 AZT-induced\JJ\1740 <e2>marrow\NN\5286536 toxicity</e2>\NN\13576101 .\.\1740
C034753_D007153 NONE <e1>Benzylacyclouridine</e1>\NN\1740 reverses\VBZ\109660 azidothymidine-induced\JJ\1740 marrow\NN\5286536 suppression\NN\13489037 without\IN\1740 impairment\NN\7296428 of\IN\1740 anti-human\JJ\1740 <e2>immunodeficiency</e2>\NN\13973990 virus\NN\9312843 activity\NN\30358 .\.\1740
D015215_D001855 CID Benzylacyclouridine\NN\1740 reverses\VBZ\109660 <e1>azidothymidine-induced</e1>\JJ\1740 <e2>marrow\NN\5286536 suppression</e2>\NN\13489037 without\IN\1740 impairment\NN\7296428 of\IN\1740 anti-human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 activity\NN\30358 .\.\1740
D015215_D001855 CID When\WRB\1740 coadministered\VBN\1740 with\IN\1740 <e1>AZT</e1>\NN\3834836 from\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 drug\NN\14778436 administration\NN\1133281 ,\,\1740 BAU\NN\1740 reduced\VBD\441445 AZT-induced\JJ\1740 <e2>marrow\NN\5286536 toxicity</e2>\NN\13576101 .\.\1740
D015215_D001855 CID When\WRB\1740 coadministered\VBN\1740 with\IN\1740 AZT\NN\3834836 from\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 drug\NN\14778436 administration\NN\1133281 ,\,\1740 BAU\NN\1740 reduced\VBD\441445 <e1>AZT-induced</e1>\JJ\1740 <e2>marrow\NN\5286536 toxicity</e2>\NN\13576101 .\.\1740
D015215_D007153 NONE Benzylacyclouridine\NN\1740 reverses\VBZ\109660 <e1>azidothymidine-induced</e1>\JJ\1740 marrow\NN\5286536 suppression\NN\13489037 without\IN\1740 impairment\NN\7296428 of\IN\1740 anti-human\JJ\1740 <e2>immunodeficiency</e2>\NN\13973990 virus\NN\9312843 activity\NN\30358 .\.\1740
D015215_D007153 NONE Increased\VBN\169651 extracellular\JJ\1740 concentrations\NNS\4916342 of\IN\1740 uridine\NN\1740 (\-LRB-\1740 Urd\NN\1740 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 ,\,\1740 in\FW\13603305 vitro\FW\1740 ,\,\1740 <e1>azidothymidine</e1>\NN\1740 (AZT)-induced\JJ\1740 inhibition\NN\1068773 of\IN\1740 human\JJ\1740 granulocyte-macrophage\JJ\1740 progenitor\NN\9792555 cells\NNS\3080309 without\IN\1740 impairment\NN\7296428 of\IN\1740 its\PRP$\6125041 antihuman\NN\1740 <e2>immunodeficiency</e2>\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 activity\NN\30358 .\.\1740
D015215_D007153 NONE Increased\VBN\169651 extracellular\JJ\1740 concentrations\NNS\4916342 of\IN\1740 uridine\NN\1740 (\-LRB-\1740 Urd\NN\1740 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 ,\,\1740 in\FW\13603305 vitro\FW\1740 ,\,\1740 azidothymidine\NN\1740 <e1>(AZT)-induced</e1>\JJ\1740 inhibition\NN\1068773 of\IN\1740 human\JJ\1740 granulocyte-macrophage\JJ\1740 progenitor\NN\9792555 cells\NNS\3080309 without\IN\1740 impairment\NN\7296428 of\IN\1740 its\PRP$\6125041 antihuman\NN\1740 <e2>immunodeficiency</e2>\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 activity\NN\30358 .\.\1740
D014529_D007153 NONE Increased\VBN\169651 extracellular\JJ\1740 concentrations\NNS\4916342 of\IN\1740 <e1>uridine</e1>\NN\1740 (\-LRB-\1740 Urd\NN\1740 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 ,\,\1740 in\FW\13603305 vitro\FW\1740 ,\,\1740 azidothymidine\NN\1740 (AZT)-induced\JJ\1740 inhibition\NN\1068773 of\IN\1740 human\JJ\1740 granulocyte-macrophage\JJ\1740 progenitor\NN\9792555 cells\NNS\3080309 without\IN\1740 impairment\NN\7296428 of\IN\1740 its\PRP$\6125041 antihuman\NN\1740 <e2>immunodeficiency</e2>\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 activity\NN\30358 .\.\1740
D014529_D007153 NONE Increased\VBN\169651 extracellular\JJ\1740 concentrations\NNS\4916342 of\IN\1740 uridine\NN\1740 (\-LRB-\1740 <e1>Urd</e1>\NN\1740 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 ,\,\1740 in\FW\13603305 vitro\FW\1740 ,\,\1740 azidothymidine\NN\1740 (AZT)-induced\JJ\1740 inhibition\NN\1068773 of\IN\1740 human\JJ\1740 granulocyte-macrophage\JJ\1740 progenitor\NN\9792555 cells\NNS\3080309 without\IN\1740 impairment\NN\7296428 of\IN\1740 its\PRP$\6125041 antihuman\NN\1740 <e2>immunodeficiency</e2>\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 activity\NN\30358 .\.\1740
D014529_D064420 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 <e2>toxicities</e2>\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 <e1>Urd</e1>\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 benzylacyclouridine\NN\1740 (\-LRB-\1740 BAU\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
D014529_D064420 NONE This\DT\1740 agent\NN\7347 inhibits\VBZ\2510337 <e1>Urd</e1>\NNP\1740 catabolism\NN\13526110 and\CC\1740 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 Urd\NNP\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 ,\,\1740 without\IN\1740 Urd-related\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D014529_D064420 NONE This\DT\1740 agent\NN\7347 inhibits\VBZ\2510337 Urd\NNP\1740 catabolism\NN\13526110 and\CC\1740 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 <e1>Urd</e1>\NNP\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 ,\,\1740 without\IN\1740 Urd-related\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D014529_D064420 NONE This\DT\1740 agent\NN\7347 inhibits\VBZ\2510337 Urd\NNP\1740 catabolism\NN\13526110 and\CC\1740 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 Urd\NNP\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 ,\,\1740 without\IN\1740 <e1>Urd-related</e1>\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D014529_D000740 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 <e1>Urd</e1>\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 benzylacyclouridine\NN\1740 (\-LRB-\1740 BAU\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 AZT-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 leukopenia\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
D014529_D007970 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 <e1>Urd</e1>\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 benzylacyclouridine\NN\1740 (\-LRB-\1740 BAU\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>leukopenia</e2>\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
C034753_D064420 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 <e2>toxicities</e2>\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 Urd\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>benzylacyclouridine</e1>\NN\1740 (\-LRB-\1740 BAU\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
C034753_D064420 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 <e2>toxicities</e2>\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 Urd\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 benzylacyclouridine\NN\1740 (\-LRB-\1740 <e1>BAU</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
C034753_D000740 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 Urd\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>benzylacyclouridine</e1>\NN\1740 (\-LRB-\1740 BAU\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 AZT-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 leukopenia\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
C034753_D000740 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 Urd\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 benzylacyclouridine\NN\1740 (\-LRB-\1740 <e1>BAU</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 AZT-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 leukopenia\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
C034753_D000740 NONE In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 <e2>anemic</e2>\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 <e1>BAU</e1>\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
C034753_D000740 NONE In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 <e1>BAU</e1>\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
C034753_D007970 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 Urd\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>benzylacyclouridine</e1>\NN\1740 (\-LRB-\1740 BAU\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>leukopenia</e2>\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
C034753_D007970 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 Urd\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 benzylacyclouridine\NN\1740 (\-LRB-\1740 <e1>BAU</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>leukopenia</e2>\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
C034753_D007970 NONE In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 <e2>leukopenic</e2>\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 <e1>BAU</e1>\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
C034753_D007970 NONE In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 <e1>BAU</e1>\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>leukopenia</e2>\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D064420 NONE Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 <e2>toxicities</e2>\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 Urd\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 benzylacyclouridine\NN\1740 (\-LRB-\1740 BAU\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 <e1>AZT-induced</e1>\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
D015215_D000740 CID Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 Urd\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 benzylacyclouridine\NN\1740 (\-LRB-\1740 BAU\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 <e1>AZT-induced</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 leukopenia\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
D015215_D000740 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 <e2>anemic</e2>\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D000740 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D000740 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 <e2>anemic</e2>\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D000740 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D000740 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 <e2>anemic</e2>\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 <e1>AZT-induced</e1>\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D000740 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 <e1>AZT-induced</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D007970 CID Because\IN\1740 of\IN\1740 the\DT\1740 clinical\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 Urd\NNP\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 benzylacyclouridine\NN\1740 (\-LRB-\1740 BAU\NN\1740 )\-RRB-\1740 to\TO\1740 effect\NN\34213 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 <e1>AZT-induced</e1>\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>leukopenia</e2>\NN\14189204 was\VBD\836236 assessed\VBN\670261 .\.\1740
D015215_D007970 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 <e2>leukopenic</e2>\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D007970 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>leukopenia</e2>\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D007970 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 <e2>leukopenic</e2>\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D007970 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>leukopenia</e2>\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D007970 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 <e2>leukopenic</e2>\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 <e1>AZT-induced</e1>\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_D007970 CID In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 <e1>AZT-induced</e1>\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>leukopenia</e2>\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 megaloblastosis\NN\1740 .\.\1740
D015215_-1 NONE In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 <e2>megaloblastosis</e2>\NN\1740 .\.\1740
D015215_-1 NONE In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 <e1>AZT</e1>\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 <e2>megaloblastosis</e2>\NN\1740 .\.\1740
D015215_-1 NONE In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 BAU\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 <e1>AZT-induced</e1>\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 <e2>megaloblastosis</e2>\NN\1740 .\.\1740
C034753_-1 NONE In\IN\13603305 mice\NNS\2329401 rendered\VBN\120316 anemic\JJ\1740 and\CC\1740 leukopenic\JJ\1740 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 for\IN\1740 28\CD\13745420 days\NNS\15140892 in\IN\13603305 drinking\NN\838098 water\NN\14618834 (\-LRB-\1740 1.5\CD\1740 mg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 continued\VBN\2367363 administration\NN\1133281 of\IN\1740 AZT\NN\3834836 plus\CC\4723816 daily\JJ\1740 <e1>BAU</e1>\NN\1740 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 ,\,\1740 orally\RB\1740 )\-RRB-\1740 partially\RB\1740 reversed\VBN\109660 AZT-induced\JJ\1740 anemia\NN\14189204 and\CC\1740 leukopenia\NN\14189204 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 peripheral\JJ\1740 reticulocytes\NNS\5454070 (\-LRB-\1740 to\TO\1740 4.9\CD\1740 %\NN\1740 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 .01\CD\1740 )\-RRB-\1740 ,\,\1740 increased\VBD\169651 cellularity\NN\14034177 in\IN\13603305 the\DT\1740 marrow\NN\5286536 ,\,\1740 and\CC\1740 improved\VBD\126264 <e2>megaloblastosis</e2>\NN\1740 .\.\1740
20103708
D013311_D003928 CID The\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 Nrf2\NN\1740 in\IN\13603305 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\NN\14573196 .\.\1740
D013311_D003928 CID RESEARCH\NN\633864 DESIGN\NN\927261 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 explore\VBP\789138 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 Nrf2\NN\1740 against\IN\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\NN\14573196 using\VBG\1156834 human\JJ\1740 kidney\NN\5333259 biopsy\NN\5739043 tissues\NNS\5220461 from\IN\1740 diabetic\JJ\1740 nephropathy\JJ\1740 patients\NNS\9898892 ,\,\1740 a\DT\13649268 <e1>streptozotocin-induced</e1>\JJ\1740 diabetic\JJ\1740 nephropathy\JJ\1740 model\NN\5888929 in\IN\13603305 Nrf2(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 and\CC\1740 cultured\VBN\245457 human\JJ\1740 mesangial\JJ\1740 cells\NNS\3080309 .\.\1740
D013311_D003928 CID RESEARCH\NN\633864 DESIGN\NN\927261 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 explore\VBP\789138 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 Nrf2\NN\1740 against\IN\1740 diabetic\JJ\1740 nephropathy\NN\14573196 using\VBG\1156834 human\JJ\1740 kidney\NN\5333259 biopsy\NN\5739043 tissues\NNS\5220461 from\IN\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\JJ\1740 patients\NNS\9898892 ,\,\1740 a\DT\13649268 <e1>streptozotocin-induced</e1>\JJ\1740 diabetic\JJ\1740 nephropathy\JJ\1740 model\NN\5888929 in\IN\13603305 Nrf2(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 and\CC\1740 cultured\VBN\245457 human\JJ\1740 mesangial\JJ\1740 cells\NNS\3080309 .\.\1740
D013311_D003928 CID RESEARCH\NN\633864 DESIGN\NN\927261 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 explore\VBP\789138 the\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 Nrf2\NN\1740 against\IN\1740 diabetic\JJ\1740 nephropathy\NN\14573196 using\VBG\1156834 human\JJ\1740 kidney\NN\5333259 biopsy\NN\5739043 tissues\NNS\5220461 from\IN\1740 diabetic\JJ\1740 nephropathy\JJ\1740 patients\NNS\9898892 ,\,\1740 a\DT\13649268 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\JJ\1740 model\NN\5888929 in\IN\13603305 Nrf2(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 and\CC\1740 cultured\VBN\245457 human\JJ\1740 mesangial\JJ\1740 cells\NNS\3080309 .\.\1740
D010100_D003928 NONE OBJECTIVE\NN\5980875 :\:\1740 <e2>Diabetic\JJ\1740 nephropathy</e2>\NN\14573196 is\VBZ\836236 one\CD\13741022 of\IN\1740 the\DT\1740 major\JJ\1740 causes\NNS\7323922 of\IN\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 which\WDT\1740 is\VBZ\836236 accompanied\VBN\1835496 by\IN\1740 the\DT\1740 production\NN\30358 of\IN\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 .\.\1740
D010100_D051437 NONE OBJECTIVE\NN\5980875 :\:\1740 Diabetic\JJ\1740 nephropathy\NN\14573196 is\VBZ\836236 one\CD\13741022 of\IN\1740 the\DT\1740 major\JJ\1740 causes\NNS\7323922 of\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 which\WDT\1740 is\VBZ\836236 accompanied\VBN\1835496 by\IN\1740 the\DT\1740 production\NN\30358 of\IN\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 .\.\1740
D013311_D058186 NONE In\IN\13603305 the\DT\1740 animal\NN\4475 study\NN\635850 ,\,\1740 Nrf2\NN\1740 was\VBD\836236 demonstrated\VBN\2137132 to\TO\1740 be\VB\836236 crucial\JJ\1740 in\IN\13603305 ameliorating\VBG\126264 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 .\.\1740
18997632
D002110_D017180 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 related\JJ\1740 to\TO\1740 <e1>caffeine</e1>\NN\14712692 pretreatment\NN\1740 .\.\1740
D002110_D017180 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 no\DT\7204911 previous\JJ\1740 history\NN\15120823 of\IN\1740 cardiac\JJ\1740 disease\NN\14061805 or\CC\3541091 arrhythmia\NN\14103288 who\WP\8299493 developed\VBD\1753788 sustained\JJ\1740 bigeminy\NN\1740 and\CC\1740 2\CD\13741022 brief\JJ\1740 runs\NNS\186634 of\IN\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 after\IN\1740 <e1>caffeine</e1>\NN\14712692 administration\NN\1133281 .\.\1740
D002110_D012640 CID Intravenous\JJ\1740 <e1>caffeine</e1>\NN\14712692 is\VBZ\836236 commonly\RB\1740 used\VBN\1156834 to\TO\1740 improve\VB\126264 <e2>seizure</e2>\JJ\1740 duration\NN\15113229 and\CC\1740 quality\NN\24264 in\IN\13603305 such\JJ\1740 patients\NNS\9898892 and\CC\1740 is\VBZ\836236 generally\RB\1740 well\RB\1740 tolerated\VBN\802318 aside\RB\1740 from\IN\1740 occasional\JJ\1740 reports\NNS\6470073 of\IN\1740 relatively\RB\1740 benign\JJ\1740 ventricular\JJ\1740 ectopy\NN\1740 .\.\1740
D002110_D018879 CID Intravenous\JJ\1740 <e1>caffeine</e1>\NN\14712692 is\VBZ\836236 commonly\RB\1740 used\VBN\1156834 to\TO\1740 improve\VB\126264 seizure\JJ\1740 duration\NN\15113229 and\CC\1740 quality\NN\24264 in\IN\13603305 such\JJ\1740 patients\NNS\9898892 and\CC\1740 is\VBZ\836236 generally\RB\1740 well\RB\1740 tolerated\VBN\802318 aside\RB\1740 from\IN\1740 occasional\JJ\1740 reports\NNS\6470073 of\IN\1740 relatively\RB\1740 benign\JJ\1740 <e2>ventricular\JJ\1740 ectopy</e2>\NN\1740 .\.\1740
D002110_D006331 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 no\DT\7204911 previous\JJ\1740 history\NN\15120823 of\IN\1740 <e2>cardiac\JJ\1740 disease</e2>\NN\14061805 or\CC\3541091 arrhythmia\NN\14103288 who\WP\8299493 developed\VBD\1753788 sustained\JJ\1740 bigeminy\NN\1740 and\CC\1740 2\CD\13741022 brief\JJ\1740 runs\NNS\186634 of\IN\1740 ventricular\JJ\1740 tachycardia\NN\14110674 after\IN\1740 <e1>caffeine</e1>\NN\14712692 administration\NN\1133281 .\.\1740
D002110_D001145 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 no\DT\7204911 previous\JJ\1740 history\NN\15120823 of\IN\1740 cardiac\JJ\1740 disease\NN\14061805 or\CC\3541091 <e2>arrhythmia</e2>\NN\14103288 who\WP\8299493 developed\VBD\1753788 sustained\JJ\1740 bigeminy\NN\1740 and\CC\1740 2\CD\13741022 brief\JJ\1740 runs\NNS\186634 of\IN\1740 ventricular\JJ\1740 tachycardia\NN\14110674 after\IN\1740 <e1>caffeine</e1>\NN\14712692 administration\NN\1133281 .\.\1740
D002110_D001145 NONE Although\IN\1740 intravenous\JJ\1740 <e1>caffeine</e1>\NN\14712692 is\VBZ\836236 generally\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 the\DT\1740 clinician\NN\10462860 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 for\IN\1740 unpredictable\JJ\1740 and\CC\1740 serious\JJ\1740 <e2>ventricular\NN\1740 arrhythmias</e2>\NNS\14103288 .\.\1740
14633084
D003907_D006470 NONE Use\NN\407535 of\IN\1740 <e1>dexamethasone</e1>\NN\2721538 with\IN\1740 mesna\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 ifosfamide-induced\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D003907_D006470 NONE In\IN\13603305 the\DT\1740 study\NN\635850 presented\VBN\2137132 here\RB\1740 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 use\NN\407535 of\IN\1740 <e1>dexamethasone</e1>\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 mesna\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 IFS-induced\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D003907_D006470 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Dexamethasone</e1>\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 mesna\NN\1740 was\VBD\836236 efficient\JJ\1740 in\IN\13603305 blocking\VBG\1476483 IFS-induced\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D003907_D006470 NONE However\RB\1740 ,\,\1740 the\DT\1740 replacement\NN\196485 of\IN\1740 last\JJ\1740 two\CD\13741022 doses\NNS\3740161 of\IN\1740 mesna\NN\1740 with\IN\1740 saline\NN\14849367 or\CC\3541091 all\DT\1740 of\IN\1740 the\DT\1740 mesna\NN\1740 doses\NNS\3740161 with\IN\1740 <e1>dexamethasone</e1>\NN\2721538 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2>HC</e2>\NN\1740 .\.\1740
D003907_D003556 NONE Use\NN\407535 of\IN\1740 <e1>dexamethasone</e1>\NN\2721538 with\IN\1740 mesna\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 ifosfamide-induced\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D003907_D003556 NONE In\IN\13603305 the\DT\1740 study\NN\635850 presented\VBN\2137132 here\RB\1740 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 use\NN\407535 of\IN\1740 <e1>dexamethasone</e1>\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 mesna\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 IFS-induced\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D003907_D003556 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Dexamethasone</e1>\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 mesna\NN\1740 was\VBD\836236 efficient\JJ\1740 in\IN\13603305 blocking\VBG\1476483 IFS-induced\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D003907_D003556 NONE However\RB\1740 ,\,\1740 the\DT\1740 replacement\NN\196485 of\IN\1740 last\JJ\1740 two\CD\13741022 doses\NNS\3740161 of\IN\1740 mesna\NN\1740 with\IN\1740 saline\NN\14849367 or\CC\3541091 all\DT\1740 of\IN\1740 the\DT\1740 mesna\NN\1740 doses\NNS\3740161 with\IN\1740 <e1>dexamethasone</e1>\NN\2721538 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2>HC</e2>\NN\1740 .\.\1740
D015080_D006470 NONE Use\NN\407535 of\IN\1740 dexamethasone\NN\2721538 with\IN\1740 <e1>mesna</e1>\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 ifosfamide-induced\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D015080_D006470 NONE In\IN\13603305 the\DT\1740 study\NN\635850 presented\VBN\2137132 here\RB\1740 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 use\NN\407535 of\IN\1740 dexamethasone\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>mesna</e1>\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 IFS-induced\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D015080_D006470 NONE CONCLUSION\NN\5837957 :\:\1740 Dexamethasone\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>mesna</e1>\NN\1740 was\VBD\836236 efficient\JJ\1740 in\IN\13603305 blocking\VBG\1476483 IFS-induced\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D015080_D006470 NONE However\RB\1740 ,\,\1740 the\DT\1740 replacement\NN\196485 of\IN\1740 last\JJ\1740 two\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>mesna</e1>\NN\1740 with\IN\1740 saline\NN\14849367 or\CC\3541091 all\DT\1740 of\IN\1740 the\DT\1740 mesna\NN\1740 doses\NNS\3740161 with\IN\1740 dexamethasone\NN\2721538 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2>HC</e2>\NN\1740 .\.\1740
D015080_D006470 NONE However\RB\1740 ,\,\1740 the\DT\1740 replacement\NN\196485 of\IN\1740 last\JJ\1740 two\CD\13741022 doses\NNS\3740161 of\IN\1740 mesna\NN\1740 with\IN\1740 saline\NN\14849367 or\CC\3541091 all\DT\1740 of\IN\1740 the\DT\1740 <e1>mesna</e1>\NN\1740 doses\NNS\3740161 with\IN\1740 dexamethasone\NN\2721538 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2>HC</e2>\NN\1740 .\.\1740
D015080_D003556 NONE Use\NN\407535 of\IN\1740 dexamethasone\NN\2721538 with\IN\1740 <e1>mesna</e1>\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 ifosfamide-induced\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D015080_D003556 NONE In\IN\13603305 the\DT\1740 study\NN\635850 presented\VBN\2137132 here\RB\1740 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 use\NN\407535 of\IN\1740 dexamethasone\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>mesna</e1>\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 IFS-induced\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D015080_D003556 NONE CONCLUSION\NN\5837957 :\:\1740 Dexamethasone\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>mesna</e1>\NN\1740 was\VBD\836236 efficient\JJ\1740 in\IN\13603305 blocking\VBG\1476483 IFS-induced\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D015080_D003556 NONE However\RB\1740 ,\,\1740 the\DT\1740 replacement\NN\196485 of\IN\1740 last\JJ\1740 two\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>mesna</e1>\NN\1740 with\IN\1740 saline\NN\14849367 or\CC\3541091 all\DT\1740 of\IN\1740 the\DT\1740 mesna\NN\1740 doses\NNS\3740161 with\IN\1740 dexamethasone\NN\2721538 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2>HC</e2>\NN\1740 .\.\1740
D015080_D003556 NONE However\RB\1740 ,\,\1740 the\DT\1740 replacement\NN\196485 of\IN\1740 last\JJ\1740 two\CD\13741022 doses\NNS\3740161 of\IN\1740 mesna\NN\1740 with\IN\1740 saline\NN\14849367 or\CC\3541091 all\DT\1740 of\IN\1740 the\DT\1740 <e1>mesna</e1>\NN\1740 doses\NNS\3740161 with\IN\1740 dexamethasone\NN\2721538 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2>HC</e2>\NN\1740 .\.\1740
D007069_D006470 CID Use\NN\407535 of\IN\1740 dexamethasone\NN\2721538 with\IN\1740 mesna\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D007069_D006470 CID AIM\NN\5980875 :\:\1740 <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 (\-LRB-\1740 HC\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 limiting\VBG\2510337 side-effect\NN\1740 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 <e1>ifosfamide</e1>\NN\1740 (\-LRB-\1740 IFS\NNP\1740 )\-RRB-\1740 .\.\1740
D007069_D006470 CID AIM\NN\5980875 :\:\1740 Hemorrhagic\JJ\1740 cystitis\NN\14566129 (\-LRB-\1740 <e2>HC</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 limiting\VBG\2510337 side-effect\NN\1740 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 <e1>ifosfamide</e1>\NN\1740 (\-LRB-\1740 IFS\NNP\1740 )\-RRB-\1740 .\.\1740
D007069_D006470 CID AIM\NN\5980875 :\:\1740 <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 (\-LRB-\1740 HC\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 limiting\VBG\2510337 side-effect\NN\1740 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 <e1>IFS</e1>\NNP\1740 )\-RRB-\1740 .\.\1740
D007069_D006470 CID AIM\NN\5980875 :\:\1740 Hemorrhagic\JJ\1740 cystitis\NN\14566129 (\-LRB-\1740 <e2>HC</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 limiting\VBG\2510337 side-effect\NN\1740 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 <e1>IFS</e1>\NNP\1740 )\-RRB-\1740 .\.\1740
D007069_D006470 CID In\IN\13603305 the\DT\1740 study\NN\635850 presented\VBN\2137132 here\RB\1740 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 use\NN\407535 of\IN\1740 dexamethasone\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 mesna\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>IFS-induced</e1>\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D007069_D006470 CID CONCLUSION\NN\5837957 :\:\1740 Dexamethasone\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 mesna\NN\1740 was\VBD\836236 efficient\JJ\1740 in\IN\13603305 blocking\VBG\1476483 <e1>IFS-induced</e1>\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D007069_D003556 CID Use\NN\407535 of\IN\1740 dexamethasone\NN\2721538 with\IN\1740 mesna\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D007069_D003556 CID AIM\NN\5980875 :\:\1740 <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 (\-LRB-\1740 HC\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 limiting\VBG\2510337 side-effect\NN\1740 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 <e1>ifosfamide</e1>\NN\1740 (\-LRB-\1740 IFS\NNP\1740 )\-RRB-\1740 .\.\1740
D007069_D003556 CID AIM\NN\5980875 :\:\1740 Hemorrhagic\JJ\1740 cystitis\NN\14566129 (\-LRB-\1740 <e2>HC</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 limiting\VBG\2510337 side-effect\NN\1740 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 <e1>ifosfamide</e1>\NN\1740 (\-LRB-\1740 IFS\NNP\1740 )\-RRB-\1740 .\.\1740
D007069_D003556 CID AIM\NN\5980875 :\:\1740 <e2>Hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 (\-LRB-\1740 HC\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 limiting\VBG\2510337 side-effect\NN\1740 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 <e1>IFS</e1>\NNP\1740 )\-RRB-\1740 .\.\1740
D007069_D003556 CID AIM\NN\5980875 :\:\1740 Hemorrhagic\JJ\1740 cystitis\NN\14566129 (\-LRB-\1740 <e2>HC</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 limiting\VBG\2510337 side-effect\NN\1740 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 <e1>IFS</e1>\NNP\1740 )\-RRB-\1740 .\.\1740
D007069_D003556 CID In\IN\13603305 the\DT\1740 study\NN\635850 presented\VBN\2137132 here\RB\1740 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 use\NN\407535 of\IN\1740 dexamethasone\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 mesna\NN\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>IFS-induced</e1>\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
D007069_D003556 CID CONCLUSION\NN\5837957 :\:\1740 Dexamethasone\NN\2721538 in\IN\13603305 combination\NN\7951464 with\IN\1740 mesna\NN\1740 was\VBD\836236 efficient\JJ\1740 in\IN\13603305 blocking\VBG\1476483 <e1>IFS-induced</e1>\JJ\1740 <e2>HC</e2>\NN\1740 .\.\1740
19274460
D003520_D009101 NONE DSMM\NN\1740 XI\NN\13745420 study\NN\635850 :\:\1740 dose\NN\3740161 definition\NN\6738281 for\IN\1740 intravenous\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 bortezomib/dexamethasone\NN\1740 for\IN\1740 remission\NN\7368256 induction\NN\7450842 in\IN\13603305 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>myeloma</e2>\NN\14239425 .\.\1740
D003520_D009101 NONE A\DT\13649268 clinical\JJ\1740 trial\NN\786195 was\VBD\836236 initiated\VBN\1617192 to\TO\1740 evaluate\VB\670261 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 bortezomib\NN\1740 and\CC\1740 dexamethasone\NN\2721538 as\IN\14622893 induction\NN\7450842 treatment\NN\654885 before\IN\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 for\IN\1740 younger\JJR\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 MM\NN\13649268 )\-RRB-\1740 .\.\1740
D003520_D009101 NONE A\DT\13649268 clinical\JJ\1740 trial\NN\786195 was\VBD\836236 initiated\VBN\1617192 to\TO\1740 evaluate\VB\670261 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 bortezomib\NN\1740 and\CC\1740 dexamethasone\NN\2721538 as\IN\14622893 induction\NN\7450842 treatment\NN\654885 before\IN\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 for\IN\1740 younger\JJR\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>MM</e2>\NN\13649268 )\-RRB-\1740 .\.\1740
D003520_D009101 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 bortezomib\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 at\IN\14622893 900\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 and\CC\1740 dexamethasone\NN\2721538 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 induction\NN\7450842 treatment\NN\654885 for\IN\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>MM</e2>\NN\13649268 that\WDT\1740 warrants\VBZ\1012073 further\JJ\1740 investigation\NN\5797597 .\.\1740
C400082_D009101 NONE DSMM\NN\1740 XI\NN\13745420 study\NN\635850 :\:\1740 dose\NN\3740161 definition\NN\6738281 for\IN\1740 intravenous\JJ\1740 cyclophosphamide\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>bortezomib/dexamethasone</e1>\NN\1740 for\IN\1740 remission\NN\7368256 induction\NN\7450842 in\IN\13603305 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>myeloma</e2>\NN\14239425 .\.\1740
C400082_D009101 NONE A\DT\13649268 clinical\JJ\1740 trial\NN\786195 was\VBD\836236 initiated\VBN\1617192 to\TO\1740 evaluate\VB\670261 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>bortezomib</e1>\NN\1740 and\CC\1740 dexamethasone\NN\2721538 as\IN\14622893 induction\NN\7450842 treatment\NN\654885 before\IN\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 for\IN\1740 younger\JJR\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 MM\NN\13649268 )\-RRB-\1740 .\.\1740
C400082_D009101 NONE A\DT\13649268 clinical\JJ\1740 trial\NN\786195 was\VBD\836236 initiated\VBN\1617192 to\TO\1740 evaluate\VB\670261 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>bortezomib</e1>\NN\1740 and\CC\1740 dexamethasone\NN\2721538 as\IN\14622893 induction\NN\7450842 treatment\NN\654885 before\IN\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 for\IN\1740 younger\JJR\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>MM</e2>\NN\13649268 )\-RRB-\1740 .\.\1740
C400082_D009101 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>bortezomib</e1>\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 at\IN\14622893 900\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 and\CC\1740 dexamethasone\NN\2721538 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 induction\NN\7450842 treatment\NN\654885 for\IN\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>MM</e2>\NN\13649268 that\WDT\1740 warrants\VBZ\1012073 further\JJ\1740 investigation\NN\5797597 .\.\1740
D003907_D009101 NONE DSMM\NN\1740 XI\NN\13745420 study\NN\635850 :\:\1740 dose\NN\3740161 definition\NN\6738281 for\IN\1740 intravenous\JJ\1740 cyclophosphamide\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>bortezomib/dexamethasone</e1>\NN\1740 for\IN\1740 remission\NN\7368256 induction\NN\7450842 in\IN\13603305 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>myeloma</e2>\NN\14239425 .\.\1740
D003907_D009101 NONE A\DT\13649268 clinical\JJ\1740 trial\NN\786195 was\VBD\836236 initiated\VBN\1617192 to\TO\1740 evaluate\VB\670261 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 bortezomib\NN\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 as\IN\14622893 induction\NN\7450842 treatment\NN\654885 before\IN\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 for\IN\1740 younger\JJR\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 MM\NN\13649268 )\-RRB-\1740 .\.\1740
D003907_D009101 NONE A\DT\13649268 clinical\JJ\1740 trial\NN\786195 was\VBD\836236 initiated\VBN\1617192 to\TO\1740 evaluate\VB\670261 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 bortezomib\NN\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 as\IN\14622893 induction\NN\7450842 treatment\NN\654885 before\IN\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 for\IN\1740 younger\JJR\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>MM</e2>\NN\13649268 )\-RRB-\1740 .\.\1740
D003907_D009101 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 bortezomib\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 at\IN\14622893 900\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 induction\NN\7450842 treatment\NN\654885 for\IN\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>MM</e2>\NN\13649268 that\WDT\1740 warrants\VBZ\1012073 further\JJ\1740 investigation\NN\5797597 .\.\1740
6769133
D004317_D066126 NONE <e2>Cardiotoxic</e2>\NNP\1740 and\CC\1740 possible\JJ\1740 leukemogenic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>adriamycin</e1>\NN\1740 in\IN\13603305 nonhuman\JJ\1740 primates\NNS\1342529 .\.\1740
D004317_D006333 CID 8\CD\13741022 of\IN\1740 the\DT\1740 10\CD\13745420 monkeys\NNS\2469914 developed\VBD\1753788 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 at\IN\14622893 an\DT\6697703 average\JJ\1740 cumulative\JJ\1740 <e1>adriamycin</e1>\NN\1740 dose\NN\3740161 (\-LRB-\1740 310\CD\1740 mg/m2\NN\1740 )\-RRB-\1740 well\RB\1740 below\IN\1740 that\DT\1740 considered\VBD\689344 the\DT\1740 safe\JJ\1740 upper\JJ\1740 limit\NN\5123416 (\-LRB-\1740 550\CD\1740 mg/m2\NN\1740 )\-RRB-\1740 in\IN\13603305 man\NN\9605289 .\.\1740
D018943_D001768 NONE Histologically\RB\1740 ,\,\1740 the\DT\1740 <e2>myocardial\JJ\1740 lesions</e2>\NNS\14204950 resembled\VBD\2657219 those\DT\1740 found\VBN\2426171 in\IN\13603305 human\JJ\1740 <e1>anthracycline-induced</e1>\JJ\1740 cardiomyopathy\NN\14103288 .\.\1740
D018943_D009202 NONE Histologically\RB\1740 ,\,\1740 the\DT\1740 myocardial\JJ\1740 lesions\NNS\14204950 resembled\VBD\2657219 those\DT\1740 found\VBN\2426171 in\IN\13603305 human\JJ\1740 <e1>anthracycline-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 .\.\1740
D004317_D015470 CID 1\CD\13741022 of\IN\1740 the\DT\1740 10\CD\13745420 monkeys\NNS\2469914 developed\VBD\1753788 <e2>acute\JJ\1740 myeloblastic\JJ\1740 leukemia</e2>\NN\14239918 after\IN\1740 receiving\VBG\2210855 324\CD\1740 mg/m2\NN\1740 of\IN\1740 <e1>adriamycin</e1>\NN\1740 ;\:\1740 the\DT\1740 10th\JJ\1740 monkey\NN\2469914 is\VBZ\836236 alive\JJ\1740 and\CC\1740 well\RB\1740 26\CD\13745420 months\NNS\15113229 after\IN\1740 the\DT\1740 last\JJ\1740 dose\NN\3740161 of\IN\1740 drug\NN\14778436 .\.\1740
D004317_D007938 NONE Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>adriamycin</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 more\RBR\1740 potent\JJ\1740 cardiotoxin\NN\1740 in\IN\13603305 monkeys\NNS\2469914 than\IN\1740 in\IN\13603305 man\NN\9605289 ,\,\1740 and\CC\1740 that\IN\1740 <e2>leukemia</e2>\NN\14239918 may\MD\15209706 be\VB\836236 a\DT\13649268 consequence\NN\34213 of\IN\1740 prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 this\DT\1740 drug\NN\14778436 .\.\1740
3762968
D014042_D014899 CID Transketolase\NN\1740 abnormality\NN\14034177 in\IN\13603305 <e1>tolazamide-induced</e1>\JJ\1740 <e2>Wernicke\NNP\1740 's\POS\1740 encephalopathy</e2>\JJ\1740 .\.\1740
D014042_D014899 CID We\PRP\1740 studied\VBD\630380 a\DT\13649268 thiamine-dependent\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 diabetic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>Wernicke\NNP\1740 's\POS\1740 encephalopathy</e2>\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 <e1>tolazamide</e1>\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 thiamine\NN\15090742 pyrophosphate\NN\15010703 (\-LRB-\1740 TPP\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 Wernicke-Korsakoff\JJ\1740 syndrome\NN\5870365 .\.\1740
D014042_D014899 CID These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 a\DT\13649268 similarity\NN\4742535 between\IN\1740 postalcoholic\JJ\1740 Wernicke-Korsakoff\JJ\1740 syndrome\NN\5870365 and\CC\1740 the\DT\1740 patient\NN\9898892 with\IN\1740 <e1>tolazamide-induced</e1>\JJ\1740 <e2>Wernicke\NNP\1740 's\POS\1740 encephalopathy</e2>\JJ\1740 from\IN\1740 the\DT\1740 standpoint\NN\6196284 of\IN\1740 transketolase\NN\1740 abnormality\NN\14034177 .\.\1740
D013831_D003920 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 <e1>thiamine-dependent</e1>\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 <e2>diabetic</e2>\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 tolazamide\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 thiamine\NN\15090742 pyrophosphate\NN\15010703 (\-LRB-\1740 TPP\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 Wernicke-Korsakoff\JJ\1740 syndrome\NN\5870365 .\.\1740
D013831_D014899 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 <e1>thiamine-dependent</e1>\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 diabetic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>Wernicke\NNP\1740 's\POS\1740 encephalopathy</e2>\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 tolazamide\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 thiamine\NN\15090742 pyrophosphate\NN\15010703 (\-LRB-\1740 TPP\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 Wernicke-Korsakoff\JJ\1740 syndrome\NN\5870365 .\.\1740
D013831_D020915 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 <e1>thiamine-dependent</e1>\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 diabetic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 tolazamide\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 thiamine\NN\15090742 pyrophosphate\NN\15010703 (\-LRB-\1740 TPP\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 <e2>Wernicke-Korsakoff\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D014042_D003920 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 thiamine-dependent\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 <e2>diabetic</e2>\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 <e1>tolazamide</e1>\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 thiamine\NN\15090742 pyrophosphate\NN\15010703 (\-LRB-\1740 TPP\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 Wernicke-Korsakoff\JJ\1740 syndrome\NN\5870365 .\.\1740
D014042_D020915 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 thiamine-dependent\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 diabetic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 <e1>tolazamide</e1>\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 thiamine\NN\15090742 pyrophosphate\NN\15010703 (\-LRB-\1740 TPP\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 <e2>Wernicke-Korsakoff\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D014042_D020915 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 a\DT\13649268 similarity\NN\4742535 between\IN\1740 postalcoholic\JJ\1740 <e2>Wernicke-Korsakoff\JJ\1740 syndrome</e2>\NN\5870365 and\CC\1740 the\DT\1740 patient\NN\9898892 with\IN\1740 <e1>tolazamide-induced</e1>\JJ\1740 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 from\IN\1740 the\DT\1740 standpoint\NN\6196284 of\IN\1740 transketolase\NN\1740 abnormality\NN\14034177 .\.\1740
D013835_D003920 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 thiamine-dependent\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 <e2>diabetic</e2>\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 tolazamide\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 <e1>thiamine\NN\15090742 pyrophosphate</e1>\NN\15010703 (\-LRB-\1740 TPP\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 Wernicke-Korsakoff\JJ\1740 syndrome\NN\5870365 .\.\1740
D013835_D003920 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 thiamine-dependent\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 <e2>diabetic</e2>\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 tolazamide\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 thiamine\NN\15090742 pyrophosphate\NN\15010703 (\-LRB-\1740 <e1>TPP</e1>\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 Wernicke-Korsakoff\JJ\1740 syndrome\NN\5870365 .\.\1740
D013835_D003920 NONE We\PRP\1740 found\VBD\2426171 that\IN\1740 the\DT\1740 above-mentioned\JJ\1740 patient\NN\9898892 and\CC\1740 one\CD\13741022 of\IN\1740 the\DT\1740 <e2>diabetic</e2>\JJ\1740 kindreds\NNS\7950920 with\IN\1740 no\DT\7204911 history\NN\15120823 of\IN\1740 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 had\VBD\2108377 abnormal\JJ\1740 transketolase\NN\1740 as\IN\14622893 determined\VBN\1645601 by\IN\1740 its\PRP$\6125041 Km\NNP\13649268 for\IN\1740 <e1>TPP</e1>\NNP\1740 .\.\1740
D013835_D014899 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 thiamine-dependent\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 diabetic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>Wernicke\NNP\1740 's\POS\1740 encephalopathy</e2>\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 tolazamide\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 <e1>thiamine\NN\15090742 pyrophosphate</e1>\NN\15010703 (\-LRB-\1740 TPP\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 Wernicke-Korsakoff\JJ\1740 syndrome\NN\5870365 .\.\1740
D013835_D014899 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 thiamine-dependent\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 diabetic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>Wernicke\NNP\1740 's\POS\1740 encephalopathy</e2>\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 tolazamide\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 thiamine\NN\15090742 pyrophosphate\NN\15010703 (\-LRB-\1740 <e1>TPP</e1>\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 Wernicke-Korsakoff\JJ\1740 syndrome\NN\5870365 .\.\1740
D013835_D014899 NONE We\PRP\1740 found\VBD\2426171 that\IN\1740 the\DT\1740 above-mentioned\JJ\1740 patient\NN\9898892 and\CC\1740 one\CD\13741022 of\IN\1740 the\DT\1740 diabetic\JJ\1740 kindreds\NNS\7950920 with\IN\1740 no\DT\7204911 history\NN\15120823 of\IN\1740 <e2>Wernicke\NNP\1740 's\POS\1740 encephalopathy</e2>\JJ\1740 had\VBD\2108377 abnormal\JJ\1740 transketolase\NN\1740 as\IN\14622893 determined\VBN\1645601 by\IN\1740 its\PRP$\6125041 Km\NNP\13649268 for\IN\1740 <e1>TPP</e1>\NNP\1740 .\.\1740
D013835_D020915 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 thiamine-dependent\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 diabetic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 tolazamide\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 <e1>thiamine\NN\15090742 pyrophosphate</e1>\NN\15010703 (\-LRB-\1740 TPP\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 <e2>Wernicke-Korsakoff\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D013835_D020915 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 thiamine-dependent\JJ\1740 enzyme\NN\14723628 ,\,\1740 transketolase\NN\1740 ,\,\1740 from\IN\1740 fibroblasts\NNS\5447757 of\IN\1740 a\DT\13649268 diabetic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 Wernicke\NNP\1740 's\POS\1740 encephalopathy\JJ\1740 when\WRB\1740 treated\VBN\2376958 with\IN\1740 tolazamide\RB\1740 ,\,\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 delineate\VB\2137132 if\IN\1740 this\DT\1740 patient\NN\9898892 also\RB\1740 had\VBD\2108377 transketolase\NN\1740 abnormality\NN\14034177 [\-LRB-\1740 high\JJ\1740 Km\NN\13649268 for\IN\1740 thiamine\NN\15090742 pyrophosphate\NN\15010703 (\-LRB-\1740 <e1>TPP</e1>\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 ,\,\1740 as\IN\14622893 previously\RB\1740 reported\VBN\831651 in\IN\13603305 postalcoholic\JJ\1740 <e2>Wernicke-Korsakoff\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
3732088
D011188_D001145 NONE Diuretics\NNS\3247620 ,\,\1740 <e1>potassium</e1>\NN\14625458 and\CC\1740 <e2>arrhythmias</e2>\VBZ\1740 in\IN\13603305 hypertensive\JJ\1740 coronary\JJ\1740 disease\NN\14061805 .\.\1740
D011188_D001145 NONE It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 proposed\VBN\1010118 that\IN\1740 modest\JJ\1740 changes\NNS\7283608 in\IN\13603305 plasma\NN\5398023 <e1>potassium</e1>\NN\14625458 can\MD\3094503 alter\VB\126264 the\DT\1740 tendency\NN\6193203 towards\IN\1740 <e2>cardiac\JJ\1740 arrhythmias</e2>\NNS\14103288 .\.\1740
D011188_D006973 NONE Diuretics\NNS\3247620 ,\,\1740 <e1>potassium</e1>\NN\14625458 and\CC\1740 arrhythmias\VBZ\1740 in\IN\13603305 <e2>hypertensive</e2>\JJ\1740 coronary\JJ\1740 disease\NN\14061805 .\.\1740
D011188_D006973 NONE Thus\RB\1740 ,\,\1740 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 was\VBD\836236 measured\VBN\697589 in\IN\13603305 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 known\JJ\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 <e1>potassium-conserving</e1>\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 amiloride\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 similar\JJ\1740 period\NN\13575869 on\IN\1740 a\DT\13649268 potassium-losing\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 chlorthalidone\NN\3214670 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 study\NN\635850 .\.\1740
D011188_D006973 NONE Thus\RB\1740 ,\,\1740 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 was\VBD\836236 measured\VBN\697589 in\IN\13603305 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 known\JJ\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 potassium-conserving\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 amiloride\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 similar\JJ\1740 period\NN\13575869 on\IN\1740 a\DT\13649268 <e1>potassium-losing</e1>\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 chlorthalidone\NN\3214670 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 study\NN\635850 .\.\1740
D011188_D003327 NONE Diuretics\NNS\3247620 ,\,\1740 <e1>potassium</e1>\NN\14625458 and\CC\1740 arrhythmias\VBZ\1740 in\IN\13603305 hypertensive\JJ\1740 <e2>coronary\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D011188_D003324 NONE Thus\RB\1740 ,\,\1740 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 was\VBD\836236 measured\VBN\697589 in\IN\13603305 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 essential\JJ\1740 hypertension\NN\14057371 and\CC\1740 known\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 <e1>potassium-conserving</e1>\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 amiloride\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 similar\JJ\1740 period\NN\13575869 on\IN\1740 a\DT\13649268 potassium-losing\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 chlorthalidone\NN\3214670 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 study\NN\635850 .\.\1740
D011188_D003324 NONE Thus\RB\1740 ,\,\1740 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 was\VBD\836236 measured\VBN\697589 in\IN\13603305 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 essential\JJ\1740 hypertension\NN\14057371 and\CC\1740 known\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 potassium-conserving\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 amiloride\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 similar\JJ\1740 period\NN\13575869 on\IN\1740 a\DT\13649268 <e1>potassium-losing</e1>\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 chlorthalidone\NN\3214670 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 study\NN\635850 .\.\1740
D000584_D006973 NONE Thus\RB\1740 ,\,\1740 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 was\VBD\836236 measured\VBN\697589 in\IN\13603305 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 known\JJ\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 potassium-conserving\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 <e1>amiloride</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 similar\JJ\1740 period\NN\13575869 on\IN\1740 a\DT\13649268 potassium-losing\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 chlorthalidone\NN\3214670 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 study\NN\635850 .\.\1740
D000584_D003324 NONE Thus\RB\1740 ,\,\1740 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 was\VBD\836236 measured\VBN\697589 in\IN\13603305 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 essential\JJ\1740 hypertension\NN\14057371 and\CC\1740 known\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 potassium-conserving\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 <e1>amiloride</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 similar\JJ\1740 period\NN\13575869 on\IN\1740 a\DT\13649268 potassium-losing\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 chlorthalidone\NN\3214670 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 study\NN\635850 .\.\1740
D002752_D006973 NONE Thus\RB\1740 ,\,\1740 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 was\VBD\836236 measured\VBN\697589 in\IN\13603305 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 known\JJ\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 potassium-conserving\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 amiloride\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 similar\JJ\1740 period\NN\13575869 on\IN\1740 a\DT\13649268 potassium-losing\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 <e1>chlorthalidone</e1>\NN\3214670 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 study\NN\635850 .\.\1740
D002752_D003324 NONE Thus\RB\1740 ,\,\1740 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 was\VBD\836236 measured\VBN\697589 in\IN\13603305 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 essential\JJ\1740 hypertension\NN\14057371 and\CC\1740 known\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 potassium-conserving\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 amiloride\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 similar\JJ\1740 period\NN\13575869 on\IN\1740 a\DT\13649268 potassium-losing\JJ\1740 diuretic\NN\3247620 (\-LRB-\1740 <e1>chlorthalidone</e1>\NN\3214670 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 study\NN\635850 .\.\1740
D000584_D018879 NONE Compared\VBN\644583 to\TO\1740 <e1>amiloride</e1>\NN\1740 treatment\NN\654885 ,\,\1740 the\DT\1740 chlorthalidone\NN\3214670 phase\NN\15113229 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 frequency\NN\15286249 of\IN\1740 <e2>ventricular\JJ\1740 ectopic\JJ\1740 beats</e2>\NNS\8289449 (\-LRB-\1740 24-hour\JJ\1740 Holter\NNP\1740 monitoring\NN\879759 )\-RRB-\1740 and\CC\1740 a\DT\13649268 higher\JJR\1740 Lown\NNP\1740 grading\NN\1009871 ,\,\1740 increased\VBD\169651 upslope\NN\1740 and\CC\1740 duration\NN\15113229 of\IN\1740 the\DT\1740 monophasic\JJ\1740 action\NN\30358 potential\NN\14481929 ,\,\1740 prolonged\JJ\1740 ventricular\JJ\1740 effective\JJ\1740 refractory\JJ\1740 period\NN\13575869 ,\,\1740 and\CC\1740 increased\VBN\169651 electrical\JJ\1740 instability\NN\13972797 during\IN\1740 programmed\VBN\794981 ventricular\NN\1740 stimulation\NN\242808 .\.\1740
D002752_D018879 CID Compared\VBN\644583 to\TO\1740 amiloride\NN\1740 treatment\NN\654885 ,\,\1740 the\DT\1740 <e1>chlorthalidone</e1>\NN\3214670 phase\NN\15113229 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 frequency\NN\15286249 of\IN\1740 <e2>ventricular\JJ\1740 ectopic\JJ\1740 beats</e2>\NNS\8289449 (\-LRB-\1740 24-hour\JJ\1740 Holter\NNP\1740 monitoring\NN\879759 )\-RRB-\1740 and\CC\1740 a\DT\13649268 higher\JJR\1740 Lown\NNP\1740 grading\NN\1009871 ,\,\1740 increased\VBD\169651 upslope\NN\1740 and\CC\1740 duration\NN\15113229 of\IN\1740 the\DT\1740 monophasic\JJ\1740 action\NN\30358 potential\NN\14481929 ,\,\1740 prolonged\JJ\1740 ventricular\JJ\1740 effective\JJ\1740 refractory\JJ\1740 period\NN\13575869 ,\,\1740 and\CC\1740 increased\VBN\169651 electrical\JJ\1740 instability\NN\13972797 during\IN\1740 programmed\VBN\794981 ventricular\NN\1740 stimulation\NN\242808 .\.\1740
D011188_D017202 NONE The\DT\1740 above\JJ\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 because\IN\1740 <e1>potassium-losing</e1>\JJ\1740 diuretic\NN\3247620 therapy\NN\657604 can\MD\3094503 increase\VB\169651 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>ischaemic\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 ,\,\1740 even\RB\1740 minor\JJ\1740 falls\NNS\11692265 in\IN\13603305 plasma\NN\5398023 potassium\NN\14625458 concentrations\NNS\4916342 are\VBP\836236 probably\RB\1740 best\RBS\1740 avoided\VBN\2452885 in\IN\13603305 such\JJ\1740 patients\NNS\9898892 .\.\1740
D011188_D017202 NONE The\DT\1740 above\JJ\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 because\IN\1740 potassium-losing\JJ\1740 diuretic\NN\3247620 therapy\NN\657604 can\MD\3094503 increase\VB\169651 myocardial\JJ\1740 electrical\JJ\1740 excitability\NN\5653575 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>ischaemic\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 ,\,\1740 even\RB\1740 minor\JJ\1740 falls\NNS\11692265 in\IN\13603305 plasma\NN\5398023 <e1>potassium</e1>\NN\14625458 concentrations\NNS\4916342 are\VBP\836236 probably\RB\1740 best\RBS\1740 avoided\VBN\2452885 in\IN\13603305 such\JJ\1740 patients\NNS\9898892 .\.\1740
3137399
D016685_D066126 NONE A\DT\13649268 prospective\JJ\1740 study\NN\635850 on\IN\1740 the\DT\1740 dose\NN\3740161 dependency\NN\24720 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>mitomycin\NN\2716866 C.</e1>\NN\1740
D016685_D066126 NONE Since\IN\1740 1975\CD\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 (\-LRB-\1740 MMC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 suggested\VBN\1010118 to\TO\1740 be\VB\836236 <e2>cardiotoxic</e2>\JJ\1740 ,\,\1740 especially\RB\1740 when\WRB\1740 combined\VBN\2630189 with\IN\1740 or\CC\3541091 given\VBN\2327200 following\VBG\1835496 doxorubicin\NN\2716866 .\.\1740
D016685_D066126 NONE Since\IN\1740 1975\CD\1740 mitomycin\NN\2716866 C\NN\13714184 (\-LRB-\1740 <e1>MMC</e1>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 suggested\VBN\1010118 to\TO\1740 be\VB\836236 <e2>cardiotoxic</e2>\JJ\1740 ,\,\1740 especially\RB\1740 when\WRB\1740 combined\VBN\2630189 with\IN\1740 or\CC\3541091 given\VBN\2327200 following\VBG\1835496 doxorubicin\NN\2716866 .\.\1740
D016685_D066126 NONE Based\VBN\2694933 on\IN\1740 the\DT\1740 combined\JJ\1740 data\NNS\7951464 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 and\CC\1740 the\DT\1740 literature\NN\6362953 ,\,\1740 we\PRP\1740 suggest\VBP\1010118 that\IN\1740 <e1>MMC-related</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 is\VBZ\836236 dose\NN\3740161 dependent\JJ\1740 ,\,\1740 occurring\VBG\2623529 at\IN\14622893 cumulative\JJ\1740 dose\NN\3740161 levels\NNS\4916342 of\IN\1740 30\CD\13745420 mg\NN\13717155 m-2\NN\1740 or\CC\3541091 more\JJR\1740 ,\,\1740 mainly\RB\1740 in\IN\13603305 patients\NNS\9898892 also\RB\1740 (\-LRB-\1740 previously\RB\1740 or\CC\3541091 simultaneously\RB\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 doxorubicin\NN\2716866 .\.\1740
D004317_D066126 NONE Since\IN\1740 1975\CD\1740 mitomycin\NN\2716866 C\NN\13714184 (\-LRB-\1740 MMC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 suggested\VBN\1010118 to\TO\1740 be\VB\836236 <e2>cardiotoxic</e2>\JJ\1740 ,\,\1740 especially\RB\1740 when\WRB\1740 combined\VBN\2630189 with\IN\1740 or\CC\3541091 given\VBN\2327200 following\VBG\1835496 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D066126 NONE Based\VBN\2694933 on\IN\1740 the\DT\1740 combined\JJ\1740 data\NNS\7951464 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 and\CC\1740 the\DT\1740 literature\NN\6362953 ,\,\1740 we\PRP\1740 suggest\VBP\1010118 that\IN\1740 MMC-related\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 is\VBZ\836236 dose\NN\3740161 dependent\JJ\1740 ,\,\1740 occurring\VBG\2623529 at\IN\14622893 cumulative\JJ\1740 dose\NN\3740161 levels\NNS\4916342 of\IN\1740 30\CD\13745420 mg\NN\13717155 m-2\NN\1740 or\CC\3541091 more\JJR\1740 ,\,\1740 mainly\RB\1740 in\IN\13603305 patients\NNS\9898892 also\RB\1740 (\-LRB-\1740 previously\RB\1740 or\CC\3541091 simultaneously\RB\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D016685_D006333 CID One\CD\13741022 of\IN\1740 the\DT\1740 patients\NNS\9898892 developed\VBD\1753788 <e2>cardiac\JJ\1740 failure</e2>\NN\66216 after\IN\1740 30\CD\13745420 mg\NN\13717155 m-2\NN\1740 <e1>MMC</e1>\NN\1740 and\CC\1740 only\RB\1740 150\CD\1740 mg\NN\13717155 m-2\NN\1740 doxorubicin\NN\2716866 .\.\1740
D004317_D006333 CID One\CD\13741022 of\IN\1740 the\DT\1740 patients\NNS\9898892 developed\VBD\1753788 <e2>cardiac\JJ\1740 failure</e2>\NN\66216 after\IN\1740 30\CD\13745420 mg\NN\13717155 m-2\NN\1740 MMC\NN\1740 and\CC\1740 only\RB\1740 150\CD\1740 mg\NN\13717155 m-2\NN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
761833
D000641_D003128 NONE Reversal\NN\199130 of\IN\1740 <e1>ammonia</e1>\JJ\1740 <e2>coma</e2>\NN\5678932 in\IN\13603305 rats\NNS\2329401 by\IN\1740 L-dopa\NN\14604959 :\:\1740 a\DT\13649268 peripheral\JJ\1740 effect\NN\34213 .\.\1740
D000641_D003128 NONE <e1>Ammonia</e1>\JJ\1740 <e2>coma</e2>\NN\5678932 was\VBD\836236 produced\VBN\1617192 in\IN\13603305 rats\NNS\2329401 within\IN\1740 10\CD\13745420 to\TO\1740 15\CD\13745420 minutes\NNS\6502378 of\IN\1740 an\DT\6697703 intraperitonealinjection\NN\1740 of\IN\1740 1.7\CD\1740 mmol\NN\1740 NH4CL\NN\1740 .\.\1740
D000641_D003128 NONE Intraventricular\JJ\1740 infusion\NN\14589223 of\IN\1740 dopamine\NN\14807737 sufficient\JJ\1740 to\TO\1740 raise\VB\153263 the\DT\1740 brain\NN\5462674 dopamine\NN\14807737 to\TO\1740 the\DT\1740 same\JJ\1740 extent\NN\13939892 did\VBD\1640855 not\RB\1740 prevent\VB\1740 the\DT\1740 <e1>ammonia</e1>\JJ\1740 <e2>coma</e2>\NN\5678932 nor\CC\1740 affect\VBP\126264 the\DT\1740 blood\NN\5397468 and\CC\1740 brain\NN\5462674 ammonia\NN\14940386 concentrations\NNS\4916342 .\.\1740
D000641_D003128 NONE Intraventricular\JJ\1740 infusion\NN\14589223 of\IN\1740 dopamine\NN\14807737 sufficient\JJ\1740 to\TO\1740 raise\VB\153263 the\DT\1740 brain\NN\5462674 dopamine\NN\14807737 to\TO\1740 the\DT\1740 same\JJ\1740 extent\NN\13939892 did\VBD\1640855 not\RB\1740 prevent\VB\1740 the\DT\1740 ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 nor\CC\1740 affect\VBP\126264 the\DT\1740 blood\NN\5397468 and\CC\1740 brain\NN\5462674 <e1>ammonia</e1>\NN\14940386 concentrations\NNS\4916342 .\.\1740
D000641_D003128 NONE Bilateral\JJ\1740 nephrectomy\NN\393369 eliminated\VBD\1619929 the\DT\1740 beneficial\JJ\1740 effect\NN\34213 of\IN\1740 L-dopa\NN\14604959 on\IN\1740 blood\NN\5397468 and\CC\1740 brain\NN\5462674 <e1>ammonia</e1>\NN\14940386 and\CC\1740 the\DT\1740 ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 was\VBD\836236 not\RB\1740 prevented\VBN\1740 .\.\1740
D000641_D003128 NONE Bilateral\JJ\1740 nephrectomy\NN\393369 eliminated\VBD\1619929 the\DT\1740 beneficial\JJ\1740 effect\NN\34213 of\IN\1740 L-dopa\NN\14604959 on\IN\1740 blood\NN\5397468 and\CC\1740 brain\NN\5462674 ammonia\NN\14940386 and\CC\1740 the\DT\1740 <e1>ammonia</e1>\JJ\1740 <e2>coma</e2>\NN\5678932 was\VBD\836236 not\RB\1740 prevented\VBN\1740 .\.\1740
D000641_D003128 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 reduction\NN\351485 in\IN\13603305 blood\NN\5397468 and\CC\1740 brain\NN\5462674 <e1>ammonia</e1>\NN\14940386 and\CC\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 after\IN\1740 L-dopa\JJ\1740 ,\,\1740 can\MD\3094503 be\VB\836236 accounted\VBN\2604760 for\IN\1740 by\IN\1740 the\DT\1740 peripheral\JJ\1740 effect\NN\34213 of\IN\1740 dopamine\NN\14807737 on\IN\1740 renal\JJ\1740 function\NN\13783581 rather\RB\1740 than\IN\1740 its\PRP$\6125041 central\JJ\1740 action\NN\30358 .\.\1740
D000641_D003128 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 reduction\NN\351485 in\IN\13603305 blood\NN\5397468 and\CC\1740 brain\NN\5462674 ammonia\NN\14940386 and\CC\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>ammonia</e1>\JJ\1740 <e2>coma</e2>\NN\5678932 after\IN\1740 L-dopa\JJ\1740 ,\,\1740 can\MD\3094503 be\VB\836236 accounted\VBN\2604760 for\IN\1740 by\IN\1740 the\DT\1740 peripheral\JJ\1740 effect\NN\34213 of\IN\1740 dopamine\NN\14807737 on\IN\1740 renal\JJ\1740 function\NN\13783581 rather\RB\1740 than\IN\1740 its\PRP$\6125041 central\JJ\1740 action\NN\30358 .\.\1740
D007980_D003128 NONE Reversal\NN\199130 of\IN\1740 ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 in\IN\13603305 rats\NNS\2329401 by\IN\1740 <e1>L-dopa</e1>\NN\14604959 :\:\1740 a\DT\13649268 peripheral\JJ\1740 effect\NN\34213 .\.\1740
D007980_D003128 NONE This\DT\1740 <e2>coma</e2>\NN\5678932 was\VBD\836236 prevented\VBN\1740 with\IN\1740 1.68\CD\1740 mmol\NN\1740 <e1>L-dopa</e1>\NN\14604959 given\VBN\2327200 by\IN\1740 gastric\JJ\1740 intubation\NN\320852 15\CD\13745420 minutes\NNS\6502378 before\IN\1740 the\DT\1740 ammonium\NN\14743582 salt\NN\14818238 injection\NN\320852 .\.\1740
D007980_D003128 NONE Bilateral\JJ\1740 nephrectomy\NN\393369 eliminated\VBD\1619929 the\DT\1740 beneficial\JJ\1740 effect\NN\34213 of\IN\1740 <e1>L-dopa</e1>\NN\14604959 on\IN\1740 blood\NN\5397468 and\CC\1740 brain\NN\5462674 ammonia\NN\14940386 and\CC\1740 the\DT\1740 ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 was\VBD\836236 not\RB\1740 prevented\VBN\1740 .\.\1740
D007980_D003128 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 reduction\NN\351485 in\IN\13603305 blood\NN\5397468 and\CC\1740 brain\NN\5462674 ammonia\NN\14940386 and\CC\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 after\IN\1740 <e1>L-dopa</e1>\JJ\1740 ,\,\1740 can\MD\3094503 be\VB\836236 accounted\VBN\2604760 for\IN\1740 by\IN\1740 the\DT\1740 peripheral\JJ\1740 effect\NN\34213 of\IN\1740 dopamine\NN\14807737 on\IN\1740 renal\JJ\1740 function\NN\13783581 rather\RB\1740 than\IN\1740 its\PRP$\6125041 central\JJ\1740 action\NN\30358 .\.\1740
D000643_D003128 CID Ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 was\VBD\836236 produced\VBN\1617192 in\IN\13603305 rats\NNS\2329401 within\IN\1740 10\CD\13745420 to\TO\1740 15\CD\13745420 minutes\NNS\6502378 of\IN\1740 an\DT\6697703 intraperitonealinjection\NN\1740 of\IN\1740 1.7\CD\1740 mmol\NN\1740 <e1>NH4CL</e1>\NN\1740 .\.\1740
D064751_D003128 NONE This\DT\1740 <e2>coma</e2>\NN\5678932 was\VBD\836236 prevented\VBN\1740 with\IN\1740 1.68\CD\1740 mmol\NN\1740 L-dopa\NN\14604959 given\VBN\2327200 by\IN\1740 gastric\JJ\1740 intubation\NN\320852 15\CD\13745420 minutes\NNS\6502378 before\IN\1740 the\DT\1740 <e1>ammonium\NN\14743582 salt</e1>\NN\14818238 injection\NN\320852 .\.\1740
D004298_D003128 NONE Intraventricular\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>dopamine</e1>\NN\14807737 sufficient\JJ\1740 to\TO\1740 raise\VB\153263 the\DT\1740 brain\NN\5462674 dopamine\NN\14807737 to\TO\1740 the\DT\1740 same\JJ\1740 extent\NN\13939892 did\VBD\1640855 not\RB\1740 prevent\VB\1740 the\DT\1740 ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 nor\CC\1740 affect\VBP\126264 the\DT\1740 blood\NN\5397468 and\CC\1740 brain\NN\5462674 ammonia\NN\14940386 concentrations\NNS\4916342 .\.\1740
D004298_D003128 NONE Intraventricular\JJ\1740 infusion\NN\14589223 of\IN\1740 dopamine\NN\14807737 sufficient\JJ\1740 to\TO\1740 raise\VB\153263 the\DT\1740 brain\NN\5462674 <e1>dopamine</e1>\NN\14807737 to\TO\1740 the\DT\1740 same\JJ\1740 extent\NN\13939892 did\VBD\1640855 not\RB\1740 prevent\VB\1740 the\DT\1740 ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 nor\CC\1740 affect\VBP\126264 the\DT\1740 blood\NN\5397468 and\CC\1740 brain\NN\5462674 ammonia\NN\14940386 concentrations\NNS\4916342 .\.\1740
D004298_D003128 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 reduction\NN\351485 in\IN\13603305 blood\NN\5397468 and\CC\1740 brain\NN\5462674 ammonia\NN\14940386 and\CC\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 ammonia\JJ\1740 <e2>coma</e2>\NN\5678932 after\IN\1740 L-dopa\JJ\1740 ,\,\1740 can\MD\3094503 be\VB\836236 accounted\VBN\2604760 for\IN\1740 by\IN\1740 the\DT\1740 peripheral\JJ\1740 effect\NN\34213 of\IN\1740 <e1>dopamine</e1>\NN\14807737 on\IN\1740 renal\JJ\1740 function\NN\13783581 rather\RB\1740 than\IN\1740 its\PRP$\6125041 central\JJ\1740 action\NN\30358 .\.\1740
D007980_D001927 NONE These\DT\1740 results\NNS\34213 provide\VBP\2199590 a\DT\13649268 reasonable\JJ\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 observed\VBN\2163746 in\IN\13603305 some\DT\1740 <e2>encephalopathic</e2>\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>L-dopa</e1>\JJ\1740 .\.\1740
8278214
D009020_D006930 CID <e2>Hyperalgesia</e2>\NN\1740 and\CC\1740 myoclonus\NN\14360459 in\IN\13603305 terminal\JJ\1740 cancer\NN\14239425 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 continuous\JJ\1740 intravenous\JJ\1740 <e1>morphine</e1>\NN\2707683 .\.\1740
D009020_D006930 CID Eight\CD\13741022 cancer\NN\14239425 patients\NNS\9898892 in\IN\13603305 the\DT\1740 terminal\JJ\1740 stages\NNS\15113229 of\IN\1740 the\DT\1740 disease\NN\14061805 treated\VBN\2376958 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 intravenous\JJ\1740 <e1>morphine</e1>\NN\2707683 developed\VBD\1753788 <e2>hyperalgesia</e2>\NN\1740 .\.\1740
D009020_D006930 CID Although\IN\1740 only\RB\1740 few\JJ\1740 clinical\JJ\1740 descriptions\NNS\6722453 of\IN\1740 the\DT\1740 relationship\NN\31921 between\IN\1740 <e2>hyperalgesia/myoclonus</e2>\JJ\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>morphine</e1>\NN\2707683 are\VBP\836236 available\JJ\1740 ,\,\1740 experimental\JJ\1740 support\NN\407535 from\IN\1740 animal\JJ\1740 studies\NNS\635850 indicates\VBZ\952524 that\IN\1740 morphine\NN\2707683 ,\,\1740 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 ,\,\1740 plays\VBZ\1072262 a\DT\13649268 causative\JJ\1740 role\NN\719494 for\IN\1740 the\DT\1740 observed\VBN\2163746 behavioural\JJ\1740 syndrome\NN\5870365 .\.\1740
D009020_D006930 CID Although\IN\1740 only\RB\1740 few\JJ\1740 clinical\JJ\1740 descriptions\NNS\6722453 of\IN\1740 the\DT\1740 relationship\NN\31921 between\IN\1740 <e2>hyperalgesia/myoclonus</e2>\JJ\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 are\VBP\836236 available\JJ\1740 ,\,\1740 experimental\JJ\1740 support\NN\407535 from\IN\1740 animal\JJ\1740 studies\NNS\635850 indicates\VBZ\952524 that\IN\1740 <e1>morphine</e1>\NN\2707683 ,\,\1740 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 ,\,\1740 plays\VBZ\1072262 a\DT\13649268 causative\JJ\1740 role\NN\719494 for\IN\1740 the\DT\1740 observed\VBN\2163746 behavioural\JJ\1740 syndrome\NN\5870365 .\.\1740
D009020_D009207 CID Hyperalgesia\NN\1740 and\CC\1740 <e2>myoclonus</e2>\NN\14360459 in\IN\13603305 terminal\JJ\1740 cancer\NN\14239425 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 continuous\JJ\1740 intravenous\JJ\1740 <e1>morphine</e1>\NN\2707683 .\.\1740
D009020_D009207 CID Although\IN\1740 only\RB\1740 few\JJ\1740 clinical\JJ\1740 descriptions\NNS\6722453 of\IN\1740 the\DT\1740 relationship\NN\31921 between\IN\1740 <e2>hyperalgesia/myoclonus</e2>\JJ\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>morphine</e1>\NN\2707683 are\VBP\836236 available\JJ\1740 ,\,\1740 experimental\JJ\1740 support\NN\407535 from\IN\1740 animal\JJ\1740 studies\NNS\635850 indicates\VBZ\952524 that\IN\1740 morphine\NN\2707683 ,\,\1740 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 ,\,\1740 plays\VBZ\1072262 a\DT\13649268 causative\JJ\1740 role\NN\719494 for\IN\1740 the\DT\1740 observed\VBN\2163746 behavioural\JJ\1740 syndrome\NN\5870365 .\.\1740
D009020_D009207 CID Although\IN\1740 only\RB\1740 few\JJ\1740 clinical\JJ\1740 descriptions\NNS\6722453 of\IN\1740 the\DT\1740 relationship\NN\31921 between\IN\1740 <e2>hyperalgesia/myoclonus</e2>\JJ\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 are\VBP\836236 available\JJ\1740 ,\,\1740 experimental\JJ\1740 support\NN\407535 from\IN\1740 animal\JJ\1740 studies\NNS\635850 indicates\VBZ\952524 that\IN\1740 <e1>morphine</e1>\NN\2707683 ,\,\1740 or\CC\3541091 its\PRP$\6125041 metabolites\NNS\20090 ,\,\1740 plays\VBZ\1072262 a\DT\13649268 causative\JJ\1740 role\NN\719494 for\IN\1740 the\DT\1740 observed\VBN\2163746 behavioural\JJ\1740 syndrome\NN\5870365 .\.\1740
D009020_D009369 NONE Hyperalgesia\NN\1740 and\CC\1740 myoclonus\NN\14360459 in\IN\13603305 terminal\JJ\1740 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 continuous\JJ\1740 intravenous\JJ\1740 <e1>morphine</e1>\NN\2707683 .\.\1740
D009020_D009369 NONE Eight\CD\13741022 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 in\IN\13603305 the\DT\1740 terminal\JJ\1740 stages\NNS\15113229 of\IN\1740 the\DT\1740 disease\NN\14061805 treated\VBN\2376958 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 intravenous\JJ\1740 <e1>morphine</e1>\NN\2707683 developed\VBD\1753788 hyperalgesia\NN\1740 .\.\1740
10728962
D014667_D007022 CID <e1>Vasopressin</e1>\NN\5407119 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 milrinone-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 severe\JJ\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D014667_D007022 CID In\IN\13603305 patients\NNS\9898892 with\IN\1740 decompensated\JJ\1740 heart\NN\5919034 failure\NN\66216 with\IN\1740 <e2>hypotension</e2>\NN\14057371 after\IN\1740 treatment\NN\654885 with\IN\1740 milrinone\NN\1740 ,\,\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>vasopressin</e1>\NN\5407119 restored\VBN\1631072 blood\NN\5397468 pressure\NN\11419404 without\IN\1740 inhibiting\VBG\2510337 the\DT\1740 inotropic\JJ\1740 effect\NN\34213 of\IN\1740 milrinone\NN\1740 .\.\1740
D014667_D006333 NONE <e1>Vasopressin</e1>\NN\5407119 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 milrinone-induced\JJ\1740 hypotension\NN\14057371 in\IN\13603305 severe\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D014667_D006333 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 decompensated\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 with\IN\1740 hypotension\NN\14057371 after\IN\1740 treatment\NN\654885 with\IN\1740 milrinone\NN\1740 ,\,\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>vasopressin</e1>\NN\5407119 restored\VBN\1631072 blood\NN\5397468 pressure\NN\11419404 without\IN\1740 inhibiting\VBG\2510337 the\DT\1740 inotropic\JJ\1740 effect\NN\34213 of\IN\1740 milrinone\NN\1740 .\.\1740
D020105_D007022 CID Vasopressin\NN\5407119 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e1>milrinone-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 severe\JJ\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D020105_D007022 CID The\DT\1740 use\NN\407535 of\IN\1740 phosphodiesterase\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 <e1>milrinone</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 severe\JJ\1740 heart\NN\5919034 failure\NN\66216 is\VBZ\836236 frequently\RB\1740 restricted\JJ\1740 because\IN\1740 they\PRP\1740 cause\VBP\1617192 vasodilation\NN\365995 and\CC\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D020105_D007022 CID In\IN\13603305 patients\NNS\9898892 with\IN\1740 decompensated\JJ\1740 heart\NN\5919034 failure\NN\66216 with\IN\1740 <e2>hypotension</e2>\NN\14057371 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>milrinone</e1>\NN\1740 ,\,\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 vasopressin\NN\5407119 restored\VBN\1631072 blood\NN\5397468 pressure\NN\11419404 without\IN\1740 inhibiting\VBG\2510337 the\DT\1740 inotropic\JJ\1740 effect\NN\34213 of\IN\1740 milrinone\NN\1740 .\.\1740
D020105_D007022 CID In\IN\13603305 patients\NNS\9898892 with\IN\1740 decompensated\JJ\1740 heart\NN\5919034 failure\NN\66216 with\IN\1740 <e2>hypotension</e2>\NN\14057371 after\IN\1740 treatment\NN\654885 with\IN\1740 milrinone\NN\1740 ,\,\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 vasopressin\NN\5407119 restored\VBN\1631072 blood\NN\5397468 pressure\NN\11419404 without\IN\1740 inhibiting\VBG\2510337 the\DT\1740 inotropic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>milrinone</e1>\NN\1740 .\.\1740
D020105_D006333 NONE Vasopressin\NN\5407119 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e1>milrinone-induced</e1>\JJ\1740 hypotension\NN\14057371 in\IN\13603305 severe\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D020105_D006333 NONE The\DT\1740 use\NN\407535 of\IN\1740 phosphodiesterase\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 <e1>milrinone</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 severe\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 is\VBZ\836236 frequently\RB\1740 restricted\JJ\1740 because\IN\1740 they\PRP\1740 cause\VBP\1617192 vasodilation\NN\365995 and\CC\1740 hypotension\NN\14057371 .\.\1740
D020105_D006333 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 decompensated\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 with\IN\1740 hypotension\NN\14057371 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>milrinone</e1>\NN\1740 ,\,\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 vasopressin\NN\5407119 restored\VBN\1631072 blood\NN\5397468 pressure\NN\11419404 without\IN\1740 inhibiting\VBG\2510337 the\DT\1740 inotropic\JJ\1740 effect\NN\34213 of\IN\1740 milrinone\NN\1740 .\.\1740
D020105_D006333 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 decompensated\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 with\IN\1740 hypotension\NN\14057371 after\IN\1740 treatment\NN\654885 with\IN\1740 milrinone\NN\1740 ,\,\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 vasopressin\NN\5407119 restored\VBN\1631072 blood\NN\5397468 pressure\NN\11419404 without\IN\1740 inhibiting\VBG\2510337 the\DT\1740 inotropic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>milrinone</e1>\NN\1740 .\.\1740
343678
D006514_D006509 NONE <e2>Hepatitis\NN\14127211 B</e2>\NN\1355326 immune\JJ\1740 globulin\NN\14736972 (\-LRB-\1740 HBIG\NN\1740 )\-RRB-\1740 and\CC\1740 immune\JJ\1740 serum\NN\5397468 globulin\NN\14736972 (\-LRB-\1740 ISG\NN\1740 )\-RRB-\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 to\TO\1740 assess\VB\670261 their\PRP$\1740 relative\JJ\1740 efficacies\NNS\5199286 in\IN\13603305 preventing\VBG\1740 type\NN\5839024 B\NN\1355326 hepatitis\NN\14127211 after\IN\1740 needle-stick\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen</e1>\NN\20090 (HBsAG)-positive\JJ\1740 donors\NNS\9608709 .\.\1740
D006514_D006509 NONE Hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 (\-LRB-\1740 HBIG\NN\1740 )\-RRB-\1740 and\CC\1740 immune\JJ\1740 serum\NN\5397468 globulin\NN\14736972 (\-LRB-\1740 ISG\NN\1740 )\-RRB-\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 to\TO\1740 assess\VB\670261 their\PRP$\1740 relative\JJ\1740 efficacies\NNS\5199286 in\IN\13603305 preventing\VBG\1740 <e2>type\NN\5839024 B\NN\1355326 hepatitis</e2>\NN\14127211 after\IN\1740 needle-stick\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen</e1>\NN\20090 (HBsAG)-positive\JJ\1740 donors\NNS\9608709 .\.\1740
D006514_D006509 NONE <e2>Hepatitis\NN\14127211 B</e2>\NN\1355326 immune\JJ\1740 globulin\NN\14736972 (\-LRB-\1740 HBIG\NN\1740 )\-RRB-\1740 and\CC\1740 immune\JJ\1740 serum\NN\5397468 globulin\NN\14736972 (\-LRB-\1740 ISG\NN\1740 )\-RRB-\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 to\TO\1740 assess\VB\670261 their\PRP$\1740 relative\JJ\1740 efficacies\NNS\5199286 in\IN\13603305 preventing\VBG\1740 type\NN\5839024 B\NN\1355326 hepatitis\NN\14127211 after\IN\1740 needle-stick\JJ\1740 exposure\NN\5042871 to\TO\1740 hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen\NN\20090 <e1>(HBsAG)-positive</e1>\JJ\1740 donors\NNS\9608709 .\.\1740
D006514_D006509 NONE Hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 (\-LRB-\1740 HBIG\NN\1740 )\-RRB-\1740 and\CC\1740 immune\JJ\1740 serum\NN\5397468 globulin\NN\14736972 (\-LRB-\1740 ISG\NN\1740 )\-RRB-\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 to\TO\1740 assess\VB\670261 their\PRP$\1740 relative\JJ\1740 efficacies\NNS\5199286 in\IN\13603305 preventing\VBG\1740 <e2>type\NN\5839024 B\NN\1355326 hepatitis</e2>\NN\14127211 after\IN\1740 needle-stick\JJ\1740 exposure\NN\5042871 to\TO\1740 hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen\NN\20090 <e1>(HBsAG)-positive</e1>\JJ\1740 donors\NNS\9608709 .\.\1740
430165
D010672_D010291 CID Transient\JJ\1740 <e2>hemiparesis</e2>\NN\1740 :\:\1740 a\DT\13649268 rare\JJ\1740 manifestation\NN\7321772 of\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 toxicity\NN\13576101 .\.\1740
D010672_D010291 CID Two\CD\13741022 patients\NNS\9898892 are\VBP\836236 presented\VBN\2137132 who\WP\8299493 suffered\VBD\2110220 progressive\JJ\1740 <e2>hemiparesis</e2>\NN\1740 due\JJ\1740 to\TO\1740 <e1>DPH</e1>\NN\6702458 overdose\NN\1740 .\.\1740
D010672_D064420 NONE Transient\JJ\1740 hemiparesis\NN\1740 :\:\1740 a\DT\13649268 rare\JJ\1740 manifestation\NN\7321772 of\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 <e2>toxicity</e2>\NN\13576101 .\.\1740
D010672_D064420 NONE It\PRP\6125041 is\VBZ\836236 assumed\VBN\719734 that\IN\1740 patients\NNS\9898892 with\IN\1740 some\DT\1740 cerebral\JJ\1740 damage\NN\7296428 are\VBP\836236 liable\JJ\1740 to\TO\1740 manifest\VB\1015244 <e1>DPH</e1>\NN\6702458 <e2>toxicity</e2>\NN\13576101 as\IN\14622893 focal\JJ\1740 neurological\JJ\1740 signs\NNS\6643763 .\.\1740
D010672_D062787 CID Among\IN\1740 the\DT\1740 common\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 (\-LRB-\1740 DPH\NN\6702458 )\-RRB-\1740 <e2>overdose</e2>\RB\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequently\RB\1740 encountered\VBN\2604760 neurological\JJ\1740 signs\NNS\6643763 are\VBP\836236 those\DT\1740 of\IN\1740 cerebellar\JJ\1740 dysfunction\NN\14204950 .\.\1740
D010672_D062787 CID Among\IN\1740 the\DT\1740 common\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 diphenylhydantoin\NN\3550533 (\-LRB-\1740 <e1>DPH</e1>\NN\6702458 )\-RRB-\1740 <e2>overdose</e2>\RB\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequently\RB\1740 encountered\VBN\2604760 neurological\JJ\1740 signs\NNS\6643763 are\VBP\836236 those\DT\1740 of\IN\1740 cerebellar\JJ\1740 dysfunction\NN\14204950 .\.\1740
D010672_D062787 CID Two\CD\13741022 patients\NNS\9898892 are\VBP\836236 presented\VBN\2137132 who\WP\8299493 suffered\VBD\2110220 progressive\JJ\1740 hemiparesis\NN\1740 due\JJ\1740 to\TO\1740 <e1>DPH</e1>\NN\6702458 <e2>overdose</e2>\NN\1740 .\.\1740
D010672_D002526 CID Among\IN\1740 the\DT\1740 common\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 (\-LRB-\1740 DPH\NN\6702458 )\-RRB-\1740 overdose\RB\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequently\RB\1740 encountered\VBN\2604760 neurological\JJ\1740 signs\NNS\6643763 are\VBP\836236 those\DT\1740 of\IN\1740 <e2>cerebellar\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D010672_D002526 CID Among\IN\1740 the\DT\1740 common\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 diphenylhydantoin\NN\3550533 (\-LRB-\1740 <e1>DPH</e1>\NN\6702458 )\-RRB-\1740 overdose\RB\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequently\RB\1740 encountered\VBN\2604760 neurological\JJ\1740 signs\NNS\6643763 are\VBP\836236 those\DT\1740 of\IN\1740 <e2>cerebellar\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D010672_D001927 NONE It\PRP\6125041 is\VBZ\836236 assumed\VBN\719734 that\IN\1740 patients\NNS\9898892 with\IN\1740 some\DT\1740 <e2>cerebral\JJ\1740 damage</e2>\NN\7296428 are\VBP\836236 liable\JJ\1740 to\TO\1740 manifest\VB\1015244 <e1>DPH</e1>\NN\6702458 toxicity\NN\13576101 as\IN\14622893 focal\JJ\1740 neurological\JJ\1740 signs\NNS\6643763 .\.\1740
1628552
D002738_D006327 NONE <e1>Chloroquine</e1>\NN\2721948 related\JJ\1740 complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 with\IN\1740 blindness\NN\14552802 :\:\1740 case\NN\7283608 report\NN\6470073 .\.\1740
D002738_D006327 NONE Ophthalmological\JJ\1740 assessment\NN\5732756 revealed\VBD\2137132 features\NNS\5849040 of\IN\1740 <e1>chloroquine</e1>\NN\2721948 retinopathy\NN\14252864 ,\,\1740 cardiac\JJ\1740 assessment\NN\5732756 revealed\VBD\2137132 features\NNS\5849040 of\IN\1740 heart\NN\5919034 failure\NN\66216 and\CC\1740 a\DT\13649268 complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 with\IN\1740 right\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block\NN\21939 pattern\NN\5726345 .\.\1740
D002738_D006327 NONE The\DT\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 was\VBD\836236 treated\VBN\2376958 by\IN\1740 pacemaker\NN\5925366 insertion\NN\6598915 and\CC\1740 the\DT\1740 heart\NN\5919034 failure\NN\66216 resolved\VBD\352826 spontaneously\RB\1740 following\VBG\1835496 <e1>chloroquine</e1>\NN\2721948 discontinuation\NN\209943 .\.\1740
D002738_D001766 CID <e1>Chloroquine</e1>\NN\2721948 related\JJ\1740 complete\JJ\1740 heart\NN\5919034 block\NN\21939 with\IN\1740 <e2>blindness</e2>\NN\14552802 :\:\1740 case\NN\7283608 report\NN\6470073 .\.\1740
D002738_D015354 NONE A\DT\13649268 27-year\JJ\1740 old\JJ\1740 African\JJ\1740 woman\NN\9605289 with\IN\1740 history\NN\15120823 of\IN\1740 regular\JJ\1740 <e1>chloroquine</e1>\NN\2721948 ingestion\NN\13440063 presented\VBN\2137132 with\IN\1740 progressive\JJ\1740 <e2>deterioration\NN\14560612 of\IN\1740 vision</e2>\NN\5767733 ,\,\1740 easy\JJ\1740 fatiguability\NN\1740 ,\,\1740 dyspnoea\NN\14299637 ,\,\1740 dizziness\VBP\1740 progressing\VBG\252019 to\IN\1740 syncopal\VB\1740 attacks\NNS\955060 .\.\1740
D002738_D005221 CID A\DT\13649268 27-year\JJ\1740 old\JJ\1740 African\JJ\1740 woman\NN\9605289 with\IN\1740 history\NN\15120823 of\IN\1740 regular\JJ\1740 <e1>chloroquine</e1>\NN\2721948 ingestion\NN\13440063 presented\VBN\2137132 with\IN\1740 progressive\JJ\1740 deterioration\NN\14560612 of\IN\1740 vision\NN\5767733 ,\,\1740 easy\JJ\1740 <e2>fatiguability</e2>\NN\1740 ,\,\1740 dyspnoea\NN\14299637 ,\,\1740 dizziness\VBP\1740 progressing\VBG\252019 to\IN\1740 syncopal\VB\1740 attacks\NNS\955060 .\.\1740
D002738_D004417 CID A\DT\13649268 27-year\JJ\1740 old\JJ\1740 African\JJ\1740 woman\NN\9605289 with\IN\1740 history\NN\15120823 of\IN\1740 regular\JJ\1740 <e1>chloroquine</e1>\NN\2721948 ingestion\NN\13440063 presented\VBN\2137132 with\IN\1740 progressive\JJ\1740 deterioration\NN\14560612 of\IN\1740 vision\NN\5767733 ,\,\1740 easy\JJ\1740 fatiguability\NN\1740 ,\,\1740 <e2>dyspnoea</e2>\NN\14299637 ,\,\1740 dizziness\VBP\1740 progressing\VBG\252019 to\IN\1740 syncopal\VB\1740 attacks\NNS\955060 .\.\1740
D002738_D004244 CID A\DT\13649268 27-year\JJ\1740 old\JJ\1740 African\JJ\1740 woman\NN\9605289 with\IN\1740 history\NN\15120823 of\IN\1740 regular\JJ\1740 <e1>chloroquine</e1>\NN\2721948 ingestion\NN\13440063 presented\VBN\2137132 with\IN\1740 progressive\JJ\1740 deterioration\NN\14560612 of\IN\1740 vision\NN\5767733 ,\,\1740 easy\JJ\1740 fatiguability\NN\1740 ,\,\1740 dyspnoea\NN\14299637 ,\,\1740 <e2>dizziness</e2>\VBP\1740 progressing\VBG\252019 to\IN\1740 syncopal\VB\1740 attacks\NNS\955060 .\.\1740
D002738_D013575 CID A\DT\13649268 27-year\JJ\1740 old\JJ\1740 African\JJ\1740 woman\NN\9605289 with\IN\1740 history\NN\15120823 of\IN\1740 regular\JJ\1740 <e1>chloroquine</e1>\NN\2721948 ingestion\NN\13440063 presented\VBN\2137132 with\IN\1740 progressive\JJ\1740 deterioration\NN\14560612 of\IN\1740 vision\NN\5767733 ,\,\1740 easy\JJ\1740 fatiguability\NN\1740 ,\,\1740 dyspnoea\NN\14299637 ,\,\1740 dizziness\VBP\1740 progressing\VBG\252019 to\IN\1740 <e2>syncopal\VB\1740 attacks</e2>\NNS\955060 .\.\1740
D002738_D012164 CID Ophthalmological\JJ\1740 assessment\NN\5732756 revealed\VBD\2137132 features\NNS\5849040 of\IN\1740 <e1>chloroquine</e1>\NN\2721948 <e2>retinopathy</e2>\NN\14252864 ,\,\1740 cardiac\JJ\1740 assessment\NN\5732756 revealed\VBD\2137132 features\NNS\5849040 of\IN\1740 heart\NN\5919034 failure\NN\66216 and\CC\1740 a\DT\13649268 complete\JJ\1740 heart\NN\5919034 block\NN\21939 with\IN\1740 right\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block\NN\21939 pattern\NN\5726345 .\.\1740
D002738_D006333 CID Ophthalmological\JJ\1740 assessment\NN\5732756 revealed\VBD\2137132 features\NNS\5849040 of\IN\1740 <e1>chloroquine</e1>\NN\2721948 retinopathy\NN\14252864 ,\,\1740 cardiac\JJ\1740 assessment\NN\5732756 revealed\VBD\2137132 features\NNS\5849040 of\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 and\CC\1740 a\DT\13649268 complete\JJ\1740 heart\NN\5919034 block\NN\21939 with\IN\1740 right\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block\NN\21939 pattern\NN\5726345 .\.\1740
D002738_D006333 CID The\DT\1740 heart\NN\5919034 block\NN\21939 was\VBD\836236 treated\VBN\2376958 by\IN\1740 pacemaker\NN\5925366 insertion\NN\6598915 and\CC\1740 the\DT\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 resolved\VBD\352826 spontaneously\RB\1740 following\VBG\1835496 <e1>chloroquine</e1>\NN\2721948 discontinuation\NN\209943 .\.\1740
D002738_D002037 CID Ophthalmological\JJ\1740 assessment\NN\5732756 revealed\VBD\2137132 features\NNS\5849040 of\IN\1740 <e1>chloroquine</e1>\NN\2721948 retinopathy\NN\14252864 ,\,\1740 cardiac\JJ\1740 assessment\NN\5732756 revealed\VBD\2137132 features\NNS\5849040 of\IN\1740 heart\NN\5919034 failure\NN\66216 and\CC\1740 a\DT\13649268 complete\JJ\1740 heart\NN\5919034 block\NN\21939 with\IN\1740 <e2>right\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block</e2>\NN\21939 pattern\NN\5726345 .\.\1740
1445986
D015313_D000743 CID <e1>Cefotetan-induced</e1>\JJ\1740 immune\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D010406_D000743 NONE Immune\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 due\IN\5174653 to\TO\1740 a\DT\13649268 drug-adsorption\JJ\1740 mechanism\NN\13446390 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 primarily\RB\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>penicillins</e1>\NNS\2716866 and\CC\1740 first-generation\NN\1740 cephalosporins\NNS\2716866 .\.\1740
D002511_D000743 NONE Immune\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 due\IN\5174653 to\TO\1740 a\DT\13649268 drug-adsorption\JJ\1740 mechanism\NN\13446390 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 primarily\RB\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 penicillins\NNS\2716866 and\CC\1740 first-generation\NN\1740 <e1>cephalosporins</e1>\NNS\2716866 .\.\1740
D015313_D000740 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>anemia</e2>\NN\14189204 while\IN\15122231 receiving\VBG\2210855 intravenous\JJ\1740 <e1>cefotetan</e1>\NN\1740 .\.\1740
20042557
D015742_D003693 CID PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 performed\VBD\2367363 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 randomized\JJ\1740 controlled\VBN\2422663 trial\NN\786195 at\IN\14622893 an\DT\6697703 academic\JJ\1740 medical\JJ\1740 center\NN\8497294 of\IN\1740 elderly\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 >\NNS\1740 or=65\NNP\1740 years\NNS\15144371 )\-RRB-\1740 without\IN\1740 preoperative\JJ\1740 <e2>delirium</e2>\NN\14391660 or\CC\3541091 severe\JJ\1740 dementia\NN\14395018 who\WP\8299493 underwent\VBD\109660 hip\NN\5220461 fracture\NN\14285662 repair\NN\248977 under\IN\1740 spinal\JJ\1740 anesthesia\NN\14034177 with\IN\1740 <e1>propofol</e1>\NN\1740 sedation\NN\14034177 .\.\1740
D015742_D003693 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 use\NN\407535 of\IN\1740 light\JJ\1740 <e1>propofol</e1>\NN\1740 sedation\NN\14034177 decreased\VBD\169651 the\DT\1740 prevalence\NN\4764412 of\IN\1740 <e2>postoperative\JJ\1740 delirium</e2>\NN\14391660 by\IN\1740 50\CD\13745420 %\NN\1740 compared\VBN\644583 with\IN\1740 deep\JJ\1740 sedation\NN\14034177 .\.\1740
D015742_D003704 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 performed\VBD\2367363 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 randomized\JJ\1740 controlled\VBN\2422663 trial\NN\786195 at\IN\14622893 an\DT\6697703 academic\JJ\1740 medical\JJ\1740 center\NN\8497294 of\IN\1740 elderly\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 >\NNS\1740 or=65\NNP\1740 years\NNS\15144371 )\-RRB-\1740 without\IN\1740 preoperative\JJ\1740 delirium\NN\14391660 or\CC\3541091 severe\JJ\1740 <e2>dementia</e2>\NN\14395018 who\WP\8299493 underwent\VBD\109660 hip\NN\5220461 fracture\NN\14285662 repair\NN\248977 under\IN\1740 spinal\JJ\1740 anesthesia\NN\14034177 with\IN\1740 <e1>propofol</e1>\NN\1740 sedation\NN\14034177 .\.\1740
D015742_D006620 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 performed\VBD\2367363 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 randomized\JJ\1740 controlled\VBN\2422663 trial\NN\786195 at\IN\14622893 an\DT\6697703 academic\JJ\1740 medical\JJ\1740 center\NN\8497294 of\IN\1740 elderly\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 >\NNS\1740 or=65\NNP\1740 years\NNS\15144371 )\-RRB-\1740 without\IN\1740 preoperative\JJ\1740 delirium\NN\14391660 or\CC\3541091 severe\JJ\1740 dementia\NN\14395018 who\WP\8299493 underwent\VBD\109660 <e2>hip\NN\5220461 fracture</e2>\NN\14285662 repair\NN\248977 under\IN\1740 spinal\JJ\1740 anesthesia\NN\14034177 with\IN\1740 <e1>propofol</e1>\NN\1740 sedation\NN\14034177 .\.\1740
D015742_D011183 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 use\NN\407535 of\IN\1740 light\JJ\1740 <e1>propofol</e1>\NN\1740 sedation\NN\14034177 decreased\VBD\169651 the\DT\1740 prevalence\NN\4764412 of\IN\1740 <e2>postoperative\JJ\1740 delirium</e2>\NN\14391660 by\IN\1740 50\CD\13745420 %\NN\1740 compared\VBN\644583 with\IN\1740 deep\JJ\1740 sedation\NN\14034177 .\.\1740
10840460
D003520_D003556 CID <e1>Cyclophosphamide-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 in\IN\13603305 freely-moving\JJ\1740 conscious\JJ\1740 rats\NNS\2329401 :\:\1740 behavioral\JJ\1740 approach\NN\940842 to\IN\1740 a\DT\13649268 new\JJ\1740 model\NN\5888929 of\IN\1740 visceral\JJ\1740 pain\NN\14299637 .\.\1740
D003520_D003556 CID <e1>Cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 antitumoral\JJ\1740 agent\NN\7347 known\VBN\2110220 to\TO\1740 produce\VB\1617192 toxic\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 bladder\NN\5515670 wall\NN\3894379 through\IN\1740 its\PRP$\6125041 main\JJ\1740 toxic\JJ\1740 metabolite\NN\20090 acrolein\NN\14584765 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 induce\VB\1627355 <e2>cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID Cyclophosphamide\NN\1740 (\-LRB-\1740 <e1>CP</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 antitumoral\JJ\1740 agent\NN\7347 known\VBN\2110220 to\TO\1740 produce\VB\1617192 toxic\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 bladder\NN\5515670 wall\NN\3894379 through\IN\1740 its\PRP$\6125041 main\JJ\1740 toxic\JJ\1740 metabolite\NN\20090 acrolein\NN\14584765 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 induce\VB\1627355 <e2>cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID CONCLUSIONS\NNS\5837957 :\:\1740 Overall\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 this\DT\1740 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e1>CP-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 may\MD\15209706 be\VB\836236 an\DT\6697703 interesting\JJ\1740 new\JJ\1740 behavioral\JJ\1740 model\NN\5888929 of\IN\1740 inflammatory\JJ\1740 visceral\JJ\1740 pain\NN\14299637 ,\,\1740 allowing\VBG\797697 a\DT\13649268 better\JJR\1740 understanding\NN\5804793 of\IN\1740 these\DT\1740 painful\JJ\1740 syndromes\NNS\5870365 and\CC\1740 thus\RB\1740 a\DT\13649268 better\RBR\1740 therapeutic\JJ\1740 approach\NN\940842 to\IN\1740 them\PRP\1740 .\.\1740
D003520_D059265 NONE <e1>Cyclophosphamide-induced</e1>\JJ\1740 cystitis\NN\14566129 in\IN\13603305 freely-moving\JJ\1740 conscious\JJ\1740 rats\NNS\2329401 :\:\1740 behavioral\JJ\1740 approach\NN\940842 to\IN\1740 a\DT\13649268 new\JJ\1740 model\NN\5888929 of\IN\1740 <e2>visceral\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D003520_D059265 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Overall\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 this\DT\1740 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e1>CP-induced</e1>\JJ\1740 cystitis\NN\14566129 may\MD\15209706 be\VB\836236 an\DT\6697703 interesting\JJ\1740 new\JJ\1740 behavioral\JJ\1740 model\NN\5888929 of\IN\1740 inflammatory\JJ\1740 <e2>visceral\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 allowing\VBG\797697 a\DT\13649268 better\JJR\1740 understanding\NN\5804793 of\IN\1740 these\DT\1740 painful\JJ\1740 syndromes\NNS\5870365 and\CC\1740 thus\RB\1740 a\DT\13649268 better\RBR\1740 therapeutic\JJ\1740 approach\NN\940842 to\IN\1740 them\PRP\1740 .\.\1740
D000171_D003556 NONE Cyclophosphamide\NN\1740 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 antitumoral\JJ\1740 agent\NN\7347 known\VBN\2110220 to\TO\1740 produce\VB\1617192 toxic\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 bladder\NN\5515670 wall\NN\3894379 through\IN\1740 its\PRP$\6125041 main\JJ\1740 toxic\JJ\1740 metabolite\NN\20090 <e1>acrolein</e1>\NN\14584765 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 induce\VB\1627355 <e2>cystitis</e2>\NN\14566129 .\.\1740
D009020_D001523 NONE <e1>Morphine</e1>\NN\2707683 dose-dependently\RB\1740 reversed\VBD\109660 these\DT\1740 <e2>behavioral\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D009020_D004487 NONE At\IN\14622893 the\DT\1740 time\NN\7308889 of\IN\1740 administration\NN\1133281 of\IN\1740 <e1>morphine</e1>\NN\2707683 ,\,\1740 histological\JJ\1740 modifications\NNS\191142 of\IN\1740 the\DT\1740 bladder\NN\5515670 wall\NN\3894379 ,\,\1740 such\JJ\1740 as\IN\14622893 chorionic\JJ\1740 and\CC\1740 muscle\NN\5289601 layer\NN\21939 <e2>edema</e2>\NN\14315192 ,\,\1740 were\VBD\836236 observed\VBN\2163746 .\.\1740
D003520_D010146 CID CONCLUSIONS\NNS\5837957 :\:\1740 Overall\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 this\DT\1740 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e1>CP-induced</e1>\JJ\1740 cystitis\NN\14566129 may\MD\15209706 be\VB\836236 an\DT\6697703 interesting\JJ\1740 new\JJ\1740 behavioral\JJ\1740 model\NN\5888929 of\IN\1740 inflammatory\JJ\1740 visceral\JJ\1740 pain\NN\14299637 ,\,\1740 allowing\VBG\797697 a\DT\13649268 better\JJR\1740 understanding\NN\5804793 of\IN\1740 these\DT\1740 <e2>painful\JJ\1740 syndromes</e2>\NNS\5870365 and\CC\1740 thus\RB\1740 a\DT\13649268 better\RBR\1740 therapeutic\JJ\1740 approach\NN\940842 to\IN\1740 them\PRP\1740 .\.\1740
11860278
D004298_D004827 NONE <e1>Dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 ,\,\1740 through\IN\1740 D1/D2\NN\1740 receptor-mediated\JJ\1740 signaling\NN\33020 ,\,\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 control\NN\5190804 of\IN\1740 <e2>epileptic\JJ\1740 seizures</e2>\NNS\14081375 arising\VBG\2623529 in\IN\13603305 the\DT\1740 limbic\JJ\1740 system\NN\3575240 .\.\1740
D004298_D004827 NONE Dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 ,\,\1740 through\IN\1740 D1/D2\NN\1740 receptor-mediated\JJ\1740 signaling\NN\33020 ,\,\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 control\NN\5190804 of\IN\1740 <e2>epileptic\JJ\1740 seizures</e2>\NNS\14081375 arising\VBG\2623529 in\IN\13603305 the\DT\1740 limbic\JJ\1740 system\NN\3575240 .\.\1740
D004298_D004827 NONE In\IN\13603305 this\DT\1740 respect\NN\5817845 ,\,\1740 little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 role\NN\719494 of\IN\1740 <e1>DA</e1>\NN\10484858 receptors\NNS\5225602 in\IN\13603305 the\DT\1740 occurrence\NN\29378 of\IN\1740 <e2>epilepsy-induced</e2>\JJ\1740 neuronal\JJ\1740 cell\NN\3080309 death\NN\7296428 .\.\1740
D010862_D012640 CID Here\RB\1740 we\PRP\1740 analyze\VBP\78760 the\DT\1740 occurrence\NN\29378 of\IN\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 neurotoxicity\NN\1740 in\IN\13603305 D2R\NN\1740 -/-\JJ\1740 mice\NNS\2329401 treated\VBN\2376958 with\IN\1740 the\DT\1740 cholinergic\JJ\1740 agonist\NN\9613191 <e1>pilocarpine</e1>\NN\14712692 .\.\1740
D010862_D012640 CID However\RB\1740 ,\,\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 result\VBP\2633881 in\IN\13603305 a\DT\13649268 more\RBR\1740 widespread\JJ\1740 neuronal\JJ\1740 death\NN\7296428 in\IN\13603305 both\CC\1740 WT\NN\1740 and\CC\1740 D2R\NN\1740 -/-\NN\1740 brains\NNS\5462674 in\IN\13603305 comparison\NN\635850 to\TO\1740 KA\NN\1740 .\.\1740
D010862_D020258 NONE Here\RB\1740 we\PRP\1740 analyze\VBP\78760 the\DT\1740 occurrence\NN\29378 of\IN\1740 seizures\NNS\14081375 and\CC\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 D2R\NN\1740 -/-\JJ\1740 mice\NNS\2329401 treated\VBN\2376958 with\IN\1740 the\DT\1740 cholinergic\JJ\1740 agonist\NN\9613191 <e1>pilocarpine</e1>\NN\14712692 .\.\1740
D007608_D012640 CID However\RB\1740 ,\,\1740 pilocarpine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 result\VBP\2633881 in\IN\13603305 a\DT\13649268 more\RBR\1740 widespread\JJ\1740 neuronal\JJ\1740 death\NN\7296428 in\IN\13603305 both\CC\1740 WT\NN\1740 and\CC\1740 D2R\NN\1740 -/-\NN\1740 brains\NNS\5462674 in\IN\13603305 comparison\NN\635850 to\TO\1740 <e1>KA</e1>\NN\1740 .\.\1740
D018698_D012640 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 absence\NN\14449405 of\IN\1740 D2R\NN\1740 lowers\VBZ\1850315 the\DT\1740 threshold\NN\15265518 for\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 both\CC\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 acetylcholine\NN\14807558 .\.\1740
D000109_D012640 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 absence\NN\14449405 of\IN\1740 D2R\NN\1740 lowers\VBZ\1850315 the\DT\1740 threshold\NN\15265518 for\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 both\CC\1740 glutamate\NN\15010703 and\CC\1740 <e1>acetylcholine</e1>\NN\14807558 .\.\1740
2819587
11302406
D015725_D016171 CID <e1>Fluconazole-induced</e1>\JJ\1740 <e2>torsade\NN\1740 de\FW\1740 pointes</e2>\NNS\1740 .\.\1740
D015725_D016171 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 present\VB\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>fluconazole-associated</e1>\JJ\1740 <e2>torsade\NN\1740 de\IN\1740 pointes</e2>\NNS\1740 (\-LRB-\1740 TDP\NN\1740 )\-RRB-\1740 and\CC\1740 discuss\VB\1033527 fluconazole\NN\1740 's\POS\1740 role\NN\719494 in\IN\13603305 causing\VBG\1617192 TDP\NN\1740 .\.\1740
D015725_D016171 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 present\VB\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>fluconazole-associated</e1>\JJ\1740 torsade\NN\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 <e2>TDP</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 discuss\VB\1033527 fluconazole\NN\1740 's\POS\1740 role\NN\719494 in\IN\13603305 causing\VBG\1617192 TDP\NN\1740 .\.\1740
D015725_D016171 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 present\VB\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>fluconazole-associated</e1>\JJ\1740 torsade\NN\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 TDP\NN\1740 )\-RRB-\1740 and\CC\1740 discuss\VB\1033527 fluconazole\NN\1740 's\POS\1740 role\NN\719494 in\IN\13603305 causing\VBG\1617192 <e2>TDP</e2>\NN\1740 .\.\1740
D015725_D016171 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 present\VB\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 fluconazole-associated\JJ\1740 <e2>torsade\NN\1740 de\IN\1740 pointes</e2>\NNS\1740 (\-LRB-\1740 TDP\NN\1740 )\-RRB-\1740 and\CC\1740 discuss\VB\1033527 <e1>fluconazole</e1>\NN\1740 's\POS\1740 role\NN\719494 in\IN\13603305 causing\VBG\1617192 TDP\NN\1740 .\.\1740
D015725_D016171 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 present\VB\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 fluconazole-associated\JJ\1740 torsade\NN\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 <e2>TDP</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 discuss\VB\1033527 <e1>fluconazole</e1>\NN\1740 's\POS\1740 role\NN\719494 in\IN\13603305 causing\VBG\1617192 TDP\NN\1740 .\.\1740
D015725_D016171 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 present\VB\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 fluconazole-associated\JJ\1740 torsade\NN\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 TDP\NN\1740 )\-RRB-\1740 and\CC\1740 discuss\VB\1033527 <e1>fluconazole</e1>\NN\1740 's\POS\1740 role\NN\719494 in\IN\13603305 causing\VBG\1617192 <e2>TDP</e2>\NN\1740 .\.\1740
D015725_D016171 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 <e2>TDP</e2>\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 <e1>fluconazole</e1>\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 fluconazole\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D016171 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 <e1>fluconazole</e1>\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 <e2>TDP</e2>\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 fluconazole\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D016171 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 <e1>fluconazole</e1>\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 fluconazole\NN\1740 and\CC\1740 <e2>TDP</e2>\NN\1740 .\.\1740
D015725_D016171 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 <e2>TDP</e2>\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 fluconazole\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D016171 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 fluconazole\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 <e2>TDP</e2>\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D016171 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 fluconazole\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 <e2>TDP</e2>\NN\1740 .\.\1740
D015725_D016171 CID The\DT\1740 <e2>TDP</e2>\NN\1740 resolved\VBD\352826 when\WRB\1740 <e1>fluconazole</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 and\CC\1740 nonsustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 NSVT\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 TDP\NN\1740 .\.\1740
D015725_D016171 CID The\DT\1740 TDP\NN\1740 resolved\VBD\352826 when\WRB\1740 <e1>fluconazole</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 and\CC\1740 nonsustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 NSVT\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>TDP</e2>\NN\1740 .\.\1740
D015725_D016171 CID The\DT\1740 <e2>TDP</e2>\NN\1740 resolved\VBD\352826 when\WRB\1740 fluconazole\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 and\CC\1740 nonsustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 NSVT\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 TDP\NN\1740 .\.\1740
D015725_D016171 CID The\DT\1740 TDP\NN\1740 resolved\VBD\352826 when\WRB\1740 fluconazole\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 and\CC\1740 nonsustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 NSVT\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>TDP</e2>\NN\1740 .\.\1740
D015725_D016171 CID In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 other\JJ\1740 etiology\NN\7326557 identified\VBD\699815 that\WDT\1740 could\MD\1740 explain\VB\831651 QT\NN\1740 prolongation\NN\1017987 or\CC\3541091 <e2>TDP</e2>\NN\1740 The\DT\1740 complete\JJ\1740 disappearance\NN\42757 of\IN\1740 NSVT\NN\1740 and\CC\1740 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 followed\VBN\1835496 by\IN\1740 normalization\NN\1123598 of\IN\1740 QT\NN\1740 interval\NN\33615 after\IN\1740 the\DT\1740 drug\NN\14778436 was\VBD\836236 stopped\VBN\2452885 strongly\RB\1740 suggests\VBZ\1010118 <e1>fluconazole</e1>\NN\1740 as\IN\14622893 the\DT\1740 etiology\NN\7326557 .\.\1740
D015725_D016171 CID CONCLUSIONS\NNS\5837957 :\:\1740 Clinicians\NNS\10462860 should\MD\1740 be\VB\836236 aware\JJ\1740 that\IN\1740 <e1>fluconazole</e1>\NN\1740 ,\,\1740 even\RB\1740 at\IN\14622893 low\JJ\1740 doses\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 interval\NN\33615 ,\,\1740 leading\VBG\1752884 to\TO\1740 <e2>TDP</e2>\NN\1740 .\.\1740
D015725_D003324 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 <e1>fluconazole</e1>\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 fluconazole\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D003324 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 fluconazole\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D009202 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 <e1>fluconazole</e1>\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 <e2>cardiomyopathy</e2>\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 fluconazole\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D009202 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 fluconazole\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 <e2>cardiomyopathy</e2>\JJ\1740 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D006333 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 <e1>fluconazole</e1>\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 fluconazole\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D006333 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 68-year-old\JJ\1740 white\JJ\1740 woman\NN\9605289 with\IN\1740 Candida\NN\12992868 glabrata\NN\1740 isolated\VBN\2512305 from\IN\1740 a\DT\13649268 presacral\JJ\1740 abscess\NN\14299637 developed\VBD\1753788 TDP\NN\1740 eight\CD\13741022 days\NNS\15140892 after\IN\1740 commencing\VBG\348746 oral\JJ\1740 fluconazole\NN\1740 The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 other\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 TDP\NN\1740 ,\,\1740 including\VBG\690614 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 cardiomyopathy\JJ\1740 ,\,\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 abnormalities\NNS\14034177 There\EX\27167 was\VBD\836236 a\DT\13649268 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 TDP\NN\1740 .\.\1740
D015725_D018879 NONE The\DT\1740 TDP\NN\1740 resolved\VBD\352826 when\WRB\1740 <e1>fluconazole</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 <e2>premature\JJ\1740 ventricular\JJ\1740 contractions</e2>\NNS\358931 and\CC\1740 nonsustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 NSVT\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 TDP\NN\1740 .\.\1740
D015725_D018879 NONE The\DT\1740 TDP\NN\1740 resolved\VBD\352826 when\WRB\1740 fluconazole\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 <e2>premature\JJ\1740 ventricular\JJ\1740 contractions</e2>\NNS\358931 and\CC\1740 nonsustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 NSVT\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 TDP\NN\1740 .\.\1740
D015725_D018879 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 other\JJ\1740 etiology\NN\7326557 identified\VBD\699815 that\WDT\1740 could\MD\1740 explain\VB\831651 QT\NN\1740 prolongation\NN\1017987 or\CC\3541091 TDP\NN\1740 The\DT\1740 complete\JJ\1740 disappearance\NN\42757 of\IN\1740 NSVT\NN\1740 and\CC\1740 <e2>premature\JJ\1740 ventricular\JJ\1740 contractions</e2>\NNS\358931 followed\VBN\1835496 by\IN\1740 normalization\NN\1123598 of\IN\1740 QT\NN\1740 interval\NN\33615 after\IN\1740 the\DT\1740 drug\NN\14778436 was\VBD\836236 stopped\VBN\2452885 strongly\RB\1740 suggests\VBZ\1010118 <e1>fluconazole</e1>\NN\1740 as\IN\14622893 the\DT\1740 etiology\NN\7326557 .\.\1740
D015725_D017180 NONE The\DT\1740 TDP\NN\1740 resolved\VBD\352826 when\WRB\1740 <e1>fluconazole</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 and\CC\1740 nonsustained\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 (\-LRB-\1740 NSVT\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 TDP\NN\1740 .\.\1740
D015725_D017180 NONE The\DT\1740 TDP\NN\1740 resolved\VBD\352826 when\WRB\1740 <e1>fluconazole</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 and\CC\1740 nonsustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 <e2>NSVT</e2>\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 TDP\NN\1740 .\.\1740
D015725_D017180 NONE The\DT\1740 TDP\NN\1740 resolved\VBD\352826 when\WRB\1740 fluconazole\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 and\CC\1740 nonsustained\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 (\-LRB-\1740 NSVT\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 TDP\NN\1740 .\.\1740
D015725_D017180 NONE The\DT\1740 TDP\NN\1740 resolved\VBD\352826 when\WRB\1740 fluconazole\NN\1740 was\VBD\836236 discontinued\VBN\2609764 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 continued\VBD\2367363 to\TO\1740 have\VB\2108377 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 and\CC\1740 nonsustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 (\-LRB-\1740 <e2>NSVT</e2>\NN\1740 )\-RRB-\1740 until\IN\1740 six\CD\13741022 days\NNS\15140892 after\IN\1740 drug\NN\14778436 cessation\NN\7365849 DISCUSSION\NN\6252138 :\:\1740 Use\NN\407535 of\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 TDP\NN\1740 .\.\1740
D015725_D017180 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 other\JJ\1740 etiology\NN\7326557 identified\VBD\699815 that\WDT\1740 could\MD\1740 explain\VB\831651 QT\NN\1740 prolongation\NN\1017987 or\CC\3541091 TDP\NN\1740 The\DT\1740 complete\JJ\1740 disappearance\NN\42757 of\IN\1740 <e2>NSVT</e2>\NN\1740 and\CC\1740 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 followed\VBN\1835496 by\IN\1740 normalization\NN\1123598 of\IN\1740 QT\NN\1740 interval\NN\33615 after\IN\1740 the\DT\1740 drug\NN\14778436 was\VBD\836236 stopped\VBN\2452885 strongly\RB\1740 suggests\VBZ\1010118 <e1>fluconazole</e1>\NN\1740 as\IN\14622893 the\DT\1740 etiology\NN\7326557 .\.\1740
D011188_D003866 NONE The\DT\1740 possible\JJ\1740 mechanism\NN\13446390 is\VBZ\836236 <e2>depression</e2>\NN\14373582 of\IN\1740 rapidly\RB\1740 activating\VBG\1641914 delayed\VBN\439958 rectifier\NN\3269401 <e1>potassium</e1>\NN\14625458 currents\NNS\11449002 .\.\1740
D015725_D008133 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 other\JJ\1740 etiology\NN\7326557 identified\VBD\699815 that\WDT\1740 could\MD\1740 explain\VB\831651 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 or\CC\3541091 TDP\NN\1740 The\DT\1740 complete\JJ\1740 disappearance\NN\42757 of\IN\1740 NSVT\NN\1740 and\CC\1740 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 followed\VBN\1835496 by\IN\1740 normalization\NN\1123598 of\IN\1740 QT\NN\1740 interval\NN\33615 after\IN\1740 the\DT\1740 drug\NN\14778436 was\VBD\836236 stopped\VBN\2452885 strongly\RB\1740 suggests\VBZ\1010118 <e1>fluconazole</e1>\NN\1740 as\IN\14622893 the\DT\1740 etiology\NN\7326557 .\.\1740
D015725_D008133 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Clinicians\NNS\10462860 should\MD\1740 be\VB\836236 aware\JJ\1740 that\IN\1740 <e1>fluconazole</e1>\NN\1740 ,\,\1740 even\RB\1740 at\IN\14622893 low\JJ\1740 doses\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 <e2>prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 interval</e2>\NN\33615 ,\,\1740 leading\VBG\1752884 to\TO\1740 TDP\NN\1740 .\.\1740
D015725_D001145 NONE Serial\JJ\1740 electrocardiographic\JJ\1740 monitoring\NN\879759 may\MD\15209706 be\VB\836236 considered\VBN\689344 when\WRB\1740 <e1>fluconazole</e1>\NN\1740 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 at\IN\14622893 risk\NN\14541044 for\IN\1740 <e2>ventricular\JJ\1740 arrhythmias</e2>\NNS\14103288 .\.\1740
11271907
D003520_D006470 CID Fatal\JJ\1740 <e2>haemorrhagic\JJ\1740 myocarditis</e2>\NN\14338942 secondary\JJ\1740 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 .\.\1740
D003520_D006470 CID <e2>Haemorrhagic\JJ\1740 myocarditis</e2>\NN\14338942 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 but\CC\1740 important\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 .\.\1740
D003520_D009205 CID Fatal\JJ\1740 <e2>haemorrhagic\JJ\1740 myocarditis</e2>\NN\14338942 secondary\JJ\1740 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 .\.\1740
D003520_D009205 CID <e2>Haemorrhagic\JJ\1740 myocarditis</e2>\NN\14338942 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 but\CC\1740 important\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 .\.\1740
20304337
D003042_-1 NONE <e2>Brainstem\NN\5462674 dysgenesis</e2>\NN\14045507 in\IN\13603305 an\DT\6697703 infant\NN\9918248 prenatally\RB\1740 exposed\VBN\2110927 to\TO\1740 <e1>cocaine</e1>\NN\3492717 .\.\1740
1255900
D006493_D013924 NONE The\DT\1740 disease\NN\14061805 occurred\VBD\2623529 subsequent\JJ\1740 to\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 for\IN\1740 suspected\VBN\916909 pelvic\JJ\1740 <e2>thrombophlebitis</e2>\NN\14352890 and\CC\1740 cleared\VBD\126264 rapidly\RB\1740 subsequent\JJ\1740 to\IN\1740 its\PRP$\6125041 discontinuation\NN\209943 .\.\1740
18405372
D012460_D056486 CID <e2>Hepatotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>sulfasalazine</e1>\NN\1740 in\IN\13603305 inflammatory\JJ\1740 arthritis\NN\14171682 :\:\1740 A\DT\13649268 case\NN\7283608 series\VBZ\1740 from\IN\1740 a\DT\13649268 local\JJ\1740 surveillance\NN\635012 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 .\.\1740
D012460_D056486 CID Patients\NNS\9898892 '\''\1740 ,\,\1740 who\WP\8299493 had\VBD\2108377 <e2>hepatotoxicity</e2>\NN\1740 on\IN\1740 <e1>sulfasalazine</e1>\NN\1740 and\CC\1740 met\VBD\1182709 a\DT\13649268 definition\NN\6738281 of\IN\1740 a\DT\13649268 serious\JJ\1740 ADR\NN\1740 ,\,\1740 were\VBD\836236 identified\VBN\699815 .\.\1740
D012460_D056486 CID The\DT\1740 likely\JJ\1740 frequency\NN\15286249 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 with\IN\1740 <e1>sulfasalazine</e1>\NN\1740 was\VBD\836236 estimated\VBN\637259 by\IN\1740 making\VBG\126264 a\DT\13649268 series\NN\8456993 of\IN\1740 conservative\JJ\1740 assumptions\NNS\6753299 .\.\1740
D012460_D056486 CID The\DT\1740 likely\JJ\1740 frequency\NN\15286249 of\IN\1740 serious\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 with\IN\1740 <e1>sulfasalazine</e1>\NN\1740 was\VBD\836236 estimated\VBN\637259 at\IN\14622893 0.4\CD\1740 %\NN\1740 of\IN\1740 treated\VBN\2376958 patients\NNS\9898892 .\.\1740
D012460_D056486 CID CONCLUSION\NN\5837957 :\:\1740 Serious\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>sulfasalazine</e1>\NN\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 under-appreciated\JJ\1740 and\CC\1740 intensive\JJ\1740 monitoring\NN\879759 and\CC\1740 vigilance\NN\5650579 in\IN\13603305 the\DT\1740 first\JJ\1740 6\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 is\VBZ\836236 especially\RB\1740 important\JJ\1740 .\.\1740
D012460_D001168 NONE Hepatotoxicity\NN\1740 associated\VBN\628491 with\IN\1740 <e1>sulfasalazine</e1>\NN\1740 in\IN\13603305 inflammatory\JJ\1740 <e2>arthritis</e2>\NN\14171682 :\:\1740 A\DT\13649268 case\NN\7283608 series\VBZ\1740 from\IN\1740 a\DT\13649268 local\JJ\1740 surveillance\NN\635012 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 .\.\1740
7565311
D016190_D058186 CID <e2>Acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 high\JJ\1740 dose\NN\3740161 <e1>carboplatin</e1>\NN\1740 chemotherapy\NN\661091 .\.\1740
D016190_D058186 CID <e1>Carboplatin</e1>\NNP\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 cause\VB\1617192 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 when\WRB\1740 administered\VBN\2436349 in\IN\13603305 high\JJ\1740 doses\NNS\3740161 to\TO\1740 adult\JJ\1740 patients\NNS\9898892 .\.\1740
D016190_D018233 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 4\CD\13741022 1/2-year-old\JJ\1740 girl\NN\10787470 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 high-dose\JJ\1740 <e1>carboplatin</e1>\NN\1740 for\IN\1740 metastatic\JJ\1740 parameningeal\NN\1740 <e2>embryonal\JJ\1740 rhabdomyosarcoma</e2>\NN\14246359 .\.\1740
6695415
D010665_D002543 CID <e2>Cerebral\JJ\1740 hemorrhage</e2>\NN\14285662 associated\VBN\628491 with\IN\1740 <e1>phenylpropanolamine</e1>\NN\2682038 in\IN\13603305 combination\NN\7951464 with\IN\1740 caffeine\NN\14712692 .\.\1740
D010665_D002543 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>PPA/caffeine</e1>\NN\1740 can\MD\3094503 lead\VB\1752884 to\TO\1740 <e2>cerebral\JJ\1740 hemorrhage</e2>\NN\14285662 in\IN\13603305 previously\RB\1740 hypertensive\JJ\1740 animals\NNS\4475 when\WRB\1740 administered\VBN\2436349 in\IN\13603305 greater\JJR\1740 than\IN\1740 the\DT\1740 allowed\VBN\797697 dosage\NN\13576355 .\.\1740
D002110_D002543 CID <e2>Cerebral\JJ\1740 hemorrhage</e2>\NN\14285662 associated\VBN\628491 with\IN\1740 phenylpropanolamine\NN\2682038 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>caffeine</e1>\NN\14712692 .\.\1740
D002110_D002543 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>PPA/caffeine</e1>\NN\1740 can\MD\3094503 lead\VB\1752884 to\TO\1740 <e2>cerebral\JJ\1740 hemorrhage</e2>\NN\14285662 in\IN\13603305 previously\RB\1740 hypertensive\JJ\1740 animals\NNS\4475 when\WRB\1740 administered\VBN\2436349 in\IN\13603305 greater\JJR\1740 than\IN\1740 the\DT\1740 allowed\VBN\797697 dosage\NN\13576355 .\.\1740
D010665_D020521 CID <e1>Phenylpropanolamine</e1>\NN\2682038 (\-LRB-\1740 PPA\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 drug\NN\14778436 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 serious\JJ\1740 side\NN\8630039 effects\NNS\13245626 including\VBG\690614 <e2>stroke</e2>\NN\556313 .\.\1740
D010665_D020521 CID Phenylpropanolamine\NN\2682038 (\-LRB-\1740 <e1>PPA</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 drug\NN\14778436 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 serious\JJ\1740 side\NN\8630039 effects\NNS\13245626 including\VBG\690614 <e2>stroke</e2>\NN\556313 .\.\1740
D010665_D020521 CID In\IN\13603305 order\NN\7168131 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>PPA/caffeine</e1>\NN\1740 can\MD\3094503 lead\VB\1752884 to\TO\1740 <e2>stroke</e2>\VB\1206218 in\IN\13603305 normotensive\NN\1740 and/or\CC\1740 hypertensive\JJ\1740 rats\NNS\2329401 ,\,\1740 we\PRP\1740 administered\VBD\2436349 the\DT\1740 combination\NN\7951464 in\IN\13603305 six\CD\13741022 times\NNS\15113229 the\DT\1740 allowed\VBN\797697 human\JJ\1740 dose\NN\3740161 calculated\VBN\632627 on\IN\1740 a\DT\13649268 per\IN\1740 weight\NN\5009170 basis\NN\13790712 for\IN\1740 the\DT\1740 rats\NNS\2329401 two\CD\13741022 times\NNS\15113229 per\IN\1740 day\NN\15154774 for\IN\1740 five\CD\13741022 days\NNS\15140892 .\.\1740
D010665_D006973 CID In\IN\13603305 order\NN\7168131 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>PPA/caffeine</e1>\NN\1740 can\MD\3094503 lead\VB\1752884 to\TO\1740 stroke\VB\1206218 in\IN\13603305 normotensive\NN\1740 and/or\CC\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 ,\,\1740 we\PRP\1740 administered\VBD\2436349 the\DT\1740 combination\NN\7951464 in\IN\13603305 six\CD\13741022 times\NNS\15113229 the\DT\1740 allowed\VBN\797697 human\JJ\1740 dose\NN\3740161 calculated\VBN\632627 on\IN\1740 a\DT\13649268 per\IN\1740 weight\NN\5009170 basis\NN\13790712 for\IN\1740 the\DT\1740 rats\NNS\2329401 two\CD\13741022 times\NNS\15113229 per\IN\1740 day\NN\15154774 for\IN\1740 five\CD\13741022 days\NNS\15140892 .\.\1740
D010665_D006973 CID A\DT\13649268 single\JJ\1740 <e1>PPA/caffeine</e1>\JJ\1740 administration\NN\1133281 (\-LRB-\1740 same\JJ\1740 dose\NN\3740161 )\-RRB-\1740 lead\VBP\1752884 to\TO\1740 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 both\CC\1740 the\DT\1740 normotensive\NN\1740 and\CC\1740 hypertensive\JJ\1740 animals\NNS\4475 .\.\1740
D010665_D006973 CID A\DT\13649268 single\JJ\1740 <e1>PPA/caffeine</e1>\JJ\1740 administration\NN\1133281 (\-LRB-\1740 same\JJ\1740 dose\NN\3740161 )\-RRB-\1740 lead\VBP\1752884 to\TO\1740 acute\JJ\1740 hypertension\NN\14057371 in\IN\13603305 both\CC\1740 the\DT\1740 normotensive\NN\1740 and\CC\1740 <e2>hypertensive</e2>\JJ\1740 animals\NNS\4475 .\.\1740
D010665_D006973 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>PPA/caffeine</e1>\NN\1740 can\MD\3094503 lead\VB\1752884 to\TO\1740 cerebral\JJ\1740 hemorrhage\NN\14285662 in\IN\13603305 previously\RB\1740 <e2>hypertensive</e2>\JJ\1740 animals\NNS\4475 when\WRB\1740 administered\VBN\2436349 in\IN\13603305 greater\JJR\1740 than\IN\1740 the\DT\1740 allowed\VBN\797697 dosage\NN\13576355 .\.\1740
D002110_D020521 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>PPA/caffeine</e1>\NN\1740 can\MD\3094503 lead\VB\1752884 to\TO\1740 <e2>stroke</e2>\VB\1206218 in\IN\13603305 normotensive\NN\1740 and/or\CC\1740 hypertensive\JJ\1740 rats\NNS\2329401 ,\,\1740 we\PRP\1740 administered\VBD\2436349 the\DT\1740 combination\NN\7951464 in\IN\13603305 six\CD\13741022 times\NNS\15113229 the\DT\1740 allowed\VBN\797697 human\JJ\1740 dose\NN\3740161 calculated\VBN\632627 on\IN\1740 a\DT\13649268 per\IN\1740 weight\NN\5009170 basis\NN\13790712 for\IN\1740 the\DT\1740 rats\NNS\2329401 two\CD\13741022 times\NNS\15113229 per\IN\1740 day\NN\15154774 for\IN\1740 five\CD\13741022 days\NNS\15140892 .\.\1740
D002110_D006973 CID In\IN\13603305 order\NN\7168131 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>PPA/caffeine</e1>\NN\1740 can\MD\3094503 lead\VB\1752884 to\TO\1740 stroke\VB\1206218 in\IN\13603305 normotensive\NN\1740 and/or\CC\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 ,\,\1740 we\PRP\1740 administered\VBD\2436349 the\DT\1740 combination\NN\7951464 in\IN\13603305 six\CD\13741022 times\NNS\15113229 the\DT\1740 allowed\VBN\797697 human\JJ\1740 dose\NN\3740161 calculated\VBN\632627 on\IN\1740 a\DT\13649268 per\IN\1740 weight\NN\5009170 basis\NN\13790712 for\IN\1740 the\DT\1740 rats\NNS\2329401 two\CD\13741022 times\NNS\15113229 per\IN\1740 day\NN\15154774 for\IN\1740 five\CD\13741022 days\NNS\15140892 .\.\1740
D002110_D006973 CID A\DT\13649268 single\JJ\1740 <e1>PPA/caffeine</e1>\JJ\1740 administration\NN\1133281 (\-LRB-\1740 same\JJ\1740 dose\NN\3740161 )\-RRB-\1740 lead\VBP\1752884 to\TO\1740 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 both\CC\1740 the\DT\1740 normotensive\NN\1740 and\CC\1740 hypertensive\JJ\1740 animals\NNS\4475 .\.\1740
D002110_D006973 CID A\DT\13649268 single\JJ\1740 <e1>PPA/caffeine</e1>\JJ\1740 administration\NN\1133281 (\-LRB-\1740 same\JJ\1740 dose\NN\3740161 )\-RRB-\1740 lead\VBP\1752884 to\TO\1740 acute\JJ\1740 hypertension\NN\14057371 in\IN\13603305 both\CC\1740 the\DT\1740 normotensive\NN\1740 and\CC\1740 <e2>hypertensive</e2>\JJ\1740 animals\NNS\4475 .\.\1740
D002110_D006973 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>PPA/caffeine</e1>\NN\1740 can\MD\3094503 lead\VB\1752884 to\TO\1740 cerebral\JJ\1740 hemorrhage\NN\14285662 in\IN\13603305 previously\RB\1740 <e2>hypertensive</e2>\JJ\1740 animals\NNS\4475 when\WRB\1740 administered\VBN\2436349 in\IN\13603305 greater\JJR\1740 than\IN\1740 the\DT\1740 allowed\VBN\797697 dosage\NN\13576355 .\.\1740
7596955
D000242_D001791 NONE At\IN\14622893 various\JJ\1740 time\NN\7308889 intervals\NNS\33615 ,\,\1740 physical\JJ\1740 examination\NN\633864 and\CC\1740 blood\NN\5397468 collection\NN\31264 for\IN\1740 ex\FW\10287213 vivo\FW\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 and\CC\1740 determination\NN\43195 of\IN\1740 intraplatelet\JJ\1740 <e1>cAMP</e1>\NN\3763727 were\VBD\836236 performed\VBN\2367363 .\.\1740
C045645_D006261 CID Seven\CD\13741022 out\IN\66636 of\IN\1740 12\CD\13745420 subjects\NNS\6598915 experienced\JJ\1740 <e2>headache</e2>\NN\5829480 of\IN\1740 a\DT\13649268 short\JJ\1740 duration\NN\15113229 accompanying\VBG\1835496 facial\JJ\1740 flush\NN\15113229 in\IN\13603305 one\CD\13741022 and\CC\1740 nausea\NN\14299637 in\IN\13603305 one\CD\13741022 ,\,\1740 especially\RB\1740 after\IN\1740 ingestion\NN\13440063 of\IN\1740 <e1>CLZ</e1>\NN\1740 .\.\1740
C045645_D005483 CID Seven\CD\13741022 out\IN\66636 of\IN\1740 12\CD\13745420 subjects\NNS\6598915 experienced\JJ\1740 headache\NN\5829480 of\IN\1740 a\DT\13649268 short\JJ\1740 duration\NN\15113229 accompanying\VBG\1835496 <e2>facial\JJ\1740 flush</e2>\NN\15113229 in\IN\13603305 one\CD\13741022 and\CC\1740 nausea\NN\14299637 in\IN\13603305 one\CD\13741022 ,\,\1740 especially\RB\1740 after\IN\1740 ingestion\NN\13440063 of\IN\1740 <e1>CLZ</e1>\NN\1740 .\.\1740
C045645_D009325 CID Seven\CD\13741022 out\IN\66636 of\IN\1740 12\CD\13745420 subjects\NNS\6598915 experienced\JJ\1740 headache\NN\5829480 of\IN\1740 a\DT\13649268 short\JJ\1740 duration\NN\15113229 accompanying\VBG\1835496 facial\JJ\1740 flush\NN\15113229 in\IN\13603305 one\CD\13741022 and\CC\1740 <e2>nausea</e2>\NN\14299637 in\IN\13603305 one\CD\13741022 ,\,\1740 especially\RB\1740 after\IN\1740 ingestion\NN\13440063 of\IN\1740 <e1>CLZ</e1>\NN\1740 .\.\1740
20510337
C024989_D007674 NONE <e1>Coenzyme\NN\14682133 Q10</e1>\NN\1740 treatment\NN\654885 ameliorates\VBZ\126264 acute\JJ\1740 cisplatin\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C024989_D007674 NONE Also\RB\1740 ,\,\1740 histopathological\JJ\1740 <e2>renal\JJ\1740 tissue\NN\5220461 damage</e2>\NN\7296428 mediated\VBN\761713 by\IN\1740 cisplatin\NN\1740 was\VBD\836236 ameliorated\VBN\126264 by\IN\1740 <e1>coenzyme\NN\14682133 Q10</e1>\NN\1740 treatment\NN\654885 .\.\1740
C024989_D007674 NONE It\PRP\6125041 was\VBD\836236 concluded\VBN\628491 that\IN\1740 <e1>coenzyme\NN\14682133 Q10</e1>\NN\1740 represents\VBZ\2664769 a\DT\13649268 potential\JJ\1740 therapeutic\JJ\1740 option\NN\6480506 to\TO\1740 protect\VB\1127795 against\IN\1740 acute\JJ\1740 cisplatin\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 commonly\RB\1740 encountered\VBN\2604760 in\IN\13603305 clinical\JJ\1740 practice\NN\407535 .\.\1740
D002945_D007674 NONE Coenzyme\NN\14682133 Q10\NN\1740 treatment\NN\654885 ameliorates\VBZ\126264 acute\JJ\1740 <e1>cisplatin</e1>\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D002945_D007674 NONE Also\RB\1740 ,\,\1740 histopathological\JJ\1740 <e2>renal\JJ\1740 tissue\NN\5220461 damage</e2>\NN\7296428 mediated\VBN\761713 by\IN\1740 <e1>cisplatin</e1>\NN\1740 was\VBD\836236 ameliorated\VBN\126264 by\IN\1740 coenzyme\NN\14682133 Q10\NN\1740 treatment\NN\654885 .\.\1740
D002945_D007674 NONE It\PRP\6125041 was\VBD\836236 concluded\VBN\628491 that\IN\1740 coenzyme\NN\14682133 Q10\NN\1740 represents\VBZ\2664769 a\DT\13649268 potential\JJ\1740 therapeutic\JJ\1740 option\NN\6480506 to\TO\1740 protect\VB\1127795 against\IN\1740 acute\JJ\1740 <e1>cisplatin</e1>\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 commonly\RB\1740 encountered\VBN\2604760 in\IN\13603305 clinical\JJ\1740 practice\NN\407535 .\.\1740
C024989_D058186 NONE The\DT\1740 nephroprotective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>coenzyme\NN\14682133 Q10</e1>\NN\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 mice\NNS\2329401 with\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 injury</e2>\NN\14052046 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 i.p.\RB\1740 injection\NN\320852 of\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D002945_D058186 CID The\DT\1740 nephroprotective\JJ\1740 effect\NN\34213 of\IN\1740 coenzyme\NN\14682133 Q10\NN\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 mice\NNS\2329401 with\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 injury</e2>\NN\14052046 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 i.p.\RB\1740 injection\NN\320852 of\IN\1740 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
C024989_D009369 NONE <e1>Coenzyme\NN\14682133 Q10</e1>\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
C024989_D009336 NONE <e1>Coenzyme\NN\14682133 Q10</e1>\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D005978_D009369 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 <e1>reduced\VBN\441445 glutathione</e1>\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D005978_D009336 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 <e1>reduced\VBN\441445 glutathione</e1>\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D013481_D009369 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 <e1>superoxide</e1>\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D013481_D009336 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 <e1>superoxide</e1>\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D009569_D009369 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 ,\,\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D009569_D009336 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 ,\,\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D010984_D009369 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 <e1>platinum</e1>\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D010984_D009336 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 <e1>platinum</e1>\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D012643_D009369 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 <e1>selenium</e1>\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D012643_D009336 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 <e1>selenium</e1>\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D015032_D009369 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 <e1>zinc</e1>\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D015032_D009336 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 <e1>zinc</e1>\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 cisplatin\NN\1740 administration\NN\1133281 .\.\1740
D002945_D009369 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 <e1>cisplatin</e1>\NN\1740 administration\NN\1133281 .\.\1740
D002945_D009336 NONE Coenzyme\NN\14682133 Q10\NN\1740 significantly\RB\1740 compensated\VBD\2673134 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 antioxidant\JJ\1740 defense\NN\952963 mechanisms\NNS\13446390 (\-LRB-\1740 reduced\VBN\441445 glutathione\NN\1740 level\NN\4916342 and\CC\1740 superoxide\NN\14971519 dismutase\NN\1740 activity\NN\30358 )\-RRB-\1740 ,\,\1740 suppressed\VBD\2510337 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 decreased\VBD\169651 the\DT\1740 elevations\NNS\7445480 of\IN\1740 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 ,\,\1740 nitric\JJ\1740 oxide\NN\14818238 and\CC\1740 platinum\NN\14627081 ion\NN\9386422 concentration\NN\4916342 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 reductions\NNS\351485 of\IN\1740 selenium\NN\14724645 and\CC\1740 zinc\NN\14625458 ions\NNS\9386422 in\IN\13603305 renal\JJ\1740 tissue\NN\5220461 resulted\VBD\2633881 from\IN\1740 <e1>cisplatin</e1>\NN\1740 administration\NN\1133281 .\.\1740
17511042
C417083_D063726 CID An\DT\6697703 extremely\RB\1740 rare\JJ\1740 case\NN\7283608 of\IN\1740 <e2>delusional\JJ\1740 parasitosis</e2>\NN\1740 in\IN\13603305 a\DT\13649268 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 patient\NN\9898892 during\IN\1740 <e1>pegylated\JJ\1740 interferon\NN\2725367 alpha-2b</e1>\NN\1740 and\CC\1740 ribavirin\NN\2725367 treatment\NN\654885 .\.\1740
C417083_D063726 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 49-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 <e2>delusional\JJ\1740 parasitosis</e2>\NN\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>pegylated\JJ\1740 interferon\NN\2725367 alpha-2b</e1>\NN\1740 weekly\NN\6593803 and\CC\1740 ribavirin\NN\2725367 .\.\1740
C417083_D019698 NONE An\DT\6697703 extremely\RB\1740 rare\JJ\1740 case\NN\7283608 of\IN\1740 delusional\JJ\1740 parasitosis\NN\1740 in\IN\13603305 a\DT\13649268 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 patient\NN\9898892 during\IN\1740 <e1>pegylated\JJ\1740 interferon\NN\2725367 alpha-2b</e1>\NN\1740 and\CC\1740 ribavirin\NN\2725367 treatment\NN\654885 .\.\1740
D012254_D063726 CID An\DT\6697703 extremely\RB\1740 rare\JJ\1740 case\NN\7283608 of\IN\1740 <e2>delusional\JJ\1740 parasitosis</e2>\NN\1740 in\IN\13603305 a\DT\13649268 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 patient\NN\9898892 during\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 alpha-2b\NN\1740 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 treatment\NN\654885 .\.\1740
D012254_D063726 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 49-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 <e2>delusional\JJ\1740 parasitosis</e2>\NN\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 alpha-2b\NN\1740 weekly\NN\6593803 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 .\.\1740
D012254_D019698 NONE An\DT\6697703 extremely\RB\1740 rare\JJ\1740 case\NN\7283608 of\IN\1740 delusional\JJ\1740 parasitosis\NN\1740 in\IN\13603305 a\DT\13649268 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 patient\NN\9898892 during\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 alpha-2b\NN\1740 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 treatment\NN\654885 .\.\1740
D012254_D019698 NONE During\IN\1740 treatment\NN\654885 of\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 patients\NNS\9898892 with\IN\1740 interferon\NN\2725367 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 ,\,\1740 a\DT\13649268 lot\NN\13757724 of\IN\1740 side\NN\8630039 effects\NNS\13245626 are\VBP\836236 described\VBN\1001294 .\.\1740
1928887
D009270_D007022 NONE <e1>Naloxone</e1>\NN\3808977 reversal\NN\199130 of\IN\1740 <e2>hypotension</e2>\NN\14057371 due\JJ\1740 to\TO\1740 captopril\NN\2673637 overdose\NN\1740 .\.\1740
D009270_D007022 NONE The\DT\1740 opioid\NN\1740 antagonist\NN\7846 <e1>naloxone</e1>\NN\3808977 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 block\VB\1476483 or\CC\3541091 reverse\VB\109660 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 actions\NNS\30358 of\IN\1740 captopril\NN\2673637 .\.\1740
D009270_D007022 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 an\DT\6697703 intentional\JJ\1740 captopril\NN\2673637 overdose\NN\1740 ,\,\1740 manifested\VBN\1015244 by\IN\1740 marked\JJ\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 that\WDT\1740 resolved\VBD\352826 promptly\RB\1740 with\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>naloxone</e1>\NN\3808977 .\.\1740
D009270_D007022 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 captopril-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 treated\VBN\2376958 with\IN\1740 <e1>naloxone</e1>\NN\3808977 .\.\1740
D009270_D007022 NONE Our\PRP$\1740 experience\NN\5984287 demonstrates\VBZ\2137132 a\DT\13649268 possible\JJ\1740 role\NN\719494 of\IN\1740 <e1>naloxone</e1>\NN\3808977 in\IN\13603305 the\DT\1740 reversal\NN\199130 of\IN\1740 <e2>hypotension</e2>\NN\14057371 resulting\VBG\2633881 from\IN\1740 captopril\NN\2673637 .\.\1740
D009270_D062787 NONE <e1>Naloxone</e1>\NN\3808977 reversal\NN\199130 of\IN\1740 hypotension\NN\14057371 due\JJ\1740 to\TO\1740 captopril\NN\2673637 <e2>overdose</e2>\NN\1740 .\.\1740
D009270_D062787 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 an\DT\6697703 intentional\JJ\1740 captopril\NN\2673637 <e2>overdose</e2>\NN\1740 ,\,\1740 manifested\VBN\1015244 by\IN\1740 marked\JJ\1740 hypotension\NN\14057371 ,\,\1740 that\WDT\1740 resolved\VBD\352826 promptly\RB\1740 with\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>naloxone</e1>\NN\3808977 .\.\1740
D002216_D007022 NONE Naloxone\NN\3808977 reversal\NN\199130 of\IN\1740 <e2>hypotension</e2>\NN\14057371 due\JJ\1740 to\TO\1740 <e1>captopril</e1>\NN\2673637 overdose\NN\1740 .\.\1740
D002216_D007022 NONE The\DT\1740 opioid\NN\1740 antagonist\NN\7846 naloxone\NN\3808977 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 block\VB\1476483 or\CC\3541091 reverse\VB\109660 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 actions\NNS\30358 of\IN\1740 <e1>captopril</e1>\NN\2673637 .\.\1740
D002216_D007022 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 an\DT\6697703 intentional\JJ\1740 <e1>captopril</e1>\NN\2673637 overdose\NN\1740 ,\,\1740 manifested\VBN\1015244 by\IN\1740 marked\JJ\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 that\WDT\1740 resolved\VBD\352826 promptly\RB\1740 with\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 naloxone\NN\3808977 .\.\1740
D002216_D007022 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 <e1>captopril-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 treated\VBN\2376958 with\IN\1740 naloxone\NN\3808977 .\.\1740
D002216_D007022 NONE Our\PRP$\1740 experience\NN\5984287 demonstrates\VBZ\2137132 a\DT\13649268 possible\JJ\1740 role\NN\719494 of\IN\1740 naloxone\NN\3808977 in\IN\13603305 the\DT\1740 reversal\NN\199130 of\IN\1740 <e2>hypotension</e2>\NN\14057371 resulting\VBG\2633881 from\IN\1740 <e1>captopril</e1>\NN\2673637 .\.\1740
D002216_D062787 NONE Naloxone\NN\3808977 reversal\NN\199130 of\IN\1740 hypotension\NN\14057371 due\JJ\1740 to\TO\1740 <e1>captopril</e1>\NN\2673637 <e2>overdose</e2>\NN\1740 .\.\1740
D002216_D062787 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 an\DT\6697703 intentional\JJ\1740 <e1>captopril</e1>\NN\2673637 <e2>overdose</e2>\NN\1740 ,\,\1740 manifested\VBN\1015244 by\IN\1740 marked\JJ\1740 hypotension\NN\14057371 ,\,\1740 that\WDT\1740 resolved\VBD\352826 promptly\RB\1740 with\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 naloxone\NN\3808977 .\.\1740
10354657
D008094_D013959 NONE These\DT\1740 were\VBD\836236 evaluated\VBN\670261 with\IN\1740 respect\NN\5817845 to\TO\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 ,\,\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 and\CC\1740 family\NN\8189659 history\NN\15120823 (\-LRB-\1740 whether\IN\1740 or\CC\3541091 not\RB\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 a\DT\13649268 first-degree\JJ\1740 relative\NN\7846 with\IN\1740 <e2>thyroid\NN\5329735 disease</e2>\NN\14061805 )\-RRB-\1740 .\.\1740
D008094_D013959 NONE All\DT\1740 patients\NNS\9898892 having\VBG\2108377 first-degree\JJ\1740 relatives\NNS\7846 affected\VBN\126264 by\IN\1740 <e2>thyroid\NN\5329735 illness</e2>\NN\14052046 had\VBD\2108377 accelerated\VBN\226566 onset\NN\7325190 of\IN\1740 hypothyroidism\NN\14059928 (\-LRB-\1740 3.7\CD\1740 years\NNS\15144371 after\IN\1740 onset\NN\7325190 of\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 patients\NNS\9898892 without\IN\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 (\-LRB-\1740 8.6\CD\1740 years\NNS\15144371 after\IN\1740 onset\NN\7325190 of\IN\1740 lithium\NN\14625458 therapy\NN\657604 )\-RRB-\1740 .\.\1740
D008094_D013959 NONE All\DT\1740 patients\NNS\9898892 having\VBG\2108377 first-degree\JJ\1740 relatives\NNS\7846 affected\VBN\126264 by\IN\1740 <e2>thyroid\NN\5329735 illness</e2>\NN\14052046 had\VBD\2108377 accelerated\VBN\226566 onset\NN\7325190 of\IN\1740 hypothyroidism\NN\14059928 (\-LRB-\1740 3.7\CD\1740 years\NNS\15144371 after\IN\1740 onset\NN\7325190 of\IN\1740 lithium\NN\14625458 therapy\NN\657604 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 patients\NNS\9898892 without\IN\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 (\-LRB-\1740 8.6\CD\1740 years\NNS\15144371 after\IN\1740 onset\NN\7325190 of\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 )\-RRB-\1740 .\.\1740
D008094_D013959 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Familial\JJ\1740 <e2>thyroid\NN\5329735 illness</e2>\NN\14052046 is\VBZ\836236 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 for\IN\1740 hypothyroidism\NN\14059928 and\CC\1740 hypercalcemia\NN\14299637 during\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D001714 NONE PATIENTS\NNS\9898892 :\:\1740 One\CD\13741022 hundred\CD\13745420 and\CC\1740 one\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 28\CD\13745420 men\NNS\8208016 and\CC\1740 73\CD\1740 women\NNS\9605289 )\-RRB-\1740 with\IN\1740 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 receiving\VBG\2210855 <e1>lithium</e1>\NN\14625458 maintenance\NN\266806 therapy\NN\657604 ranging\VBG\2604760 from\IN\1740 1\CD\13741022 year\NN\15113229 's\POS\1740 to\IN\1740 32\CD\1740 years\NNS\15144371 '\POS\1740 duration\NN\15113229 .\.\1740
D008094_D007037 CID All\DT\1740 patients\NNS\9898892 having\VBG\2108377 first-degree\JJ\1740 relatives\NNS\7846 affected\VBN\126264 by\IN\1740 thyroid\NN\5329735 illness\NN\14052046 had\VBD\2108377 accelerated\VBN\226566 onset\NN\7325190 of\IN\1740 <e2>hypothyroidism</e2>\NN\14059928 (\-LRB-\1740 3.7\CD\1740 years\NNS\15144371 after\IN\1740 onset\NN\7325190 of\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 patients\NNS\9898892 without\IN\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 (\-LRB-\1740 8.6\CD\1740 years\NNS\15144371 after\IN\1740 onset\NN\7325190 of\IN\1740 lithium\NN\14625458 therapy\NN\657604 )\-RRB-\1740 .\.\1740
D008094_D007037 CID All\DT\1740 patients\NNS\9898892 having\VBG\2108377 first-degree\JJ\1740 relatives\NNS\7846 affected\VBN\126264 by\IN\1740 thyroid\NN\5329735 illness\NN\14052046 had\VBD\2108377 accelerated\VBN\226566 onset\NN\7325190 of\IN\1740 <e2>hypothyroidism</e2>\NN\14059928 (\-LRB-\1740 3.7\CD\1740 years\NNS\15144371 after\IN\1740 onset\NN\7325190 of\IN\1740 lithium\NN\14625458 therapy\NN\657604 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 patients\NNS\9898892 without\IN\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 (\-LRB-\1740 8.6\CD\1740 years\NNS\15144371 after\IN\1740 onset\NN\7325190 of\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 )\-RRB-\1740 .\.\1740
D008094_D007037 CID CONCLUSIONS\NNS\5837957 :\:\1740 Familial\JJ\1740 thyroid\NN\5329735 illness\NN\14052046 is\VBZ\836236 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>hypothyroidism</e2>\NN\14059928 and\CC\1740 hypercalcemia\NN\14299637 during\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D006934 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Familial\JJ\1740 thyroid\NN\5329735 illness\NN\14052046 is\VBZ\836236 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 for\IN\1740 hypothyroidism\NN\14059928 and\CC\1740 <e2>hypercalcemia</e2>\NN\14299637 during\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
18086064
D020927_D009203 NONE <e1>Dexmedetomidine</e1>\NNP\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 trend\NN\8679972 towards\IN\1740 improved\VBN\126264 cardiac\JJ\1740 outcomes\NNS\7291312 ;\:\1740 all-cause\JJ\1740 mortality\NN\5054863 (\-LRB-\1740 OR\NN\3541091 0.27\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.01\CD\1740 -\SYM\1740 7.13\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.44\CD\1740 )\-RRB-\1740 ,\,\1740 non-fatal\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 OR\NN\3541091 0.26\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.04\CD\1740 -\SYM\1740 1.60\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.14\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 myocardial\JJ\1740 ischaemia\NN\14195315 (\-LRB-\1740 OR\NN\3541091 0.65\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.26\CD\1740 -\SYM\1740 1.63\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.36\CD\1740 )\-RRB-\1740 .\.\1740
D020927_D017202 NONE <e1>Dexmedetomidine</e1>\NNP\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 trend\NN\8679972 towards\IN\1740 improved\VBN\126264 cardiac\JJ\1740 outcomes\NNS\7291312 ;\:\1740 all-cause\JJ\1740 mortality\NN\5054863 (\-LRB-\1740 OR\NN\3541091 0.27\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.01\CD\1740 -\SYM\1740 7.13\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.44\CD\1740 )\-RRB-\1740 ,\,\1740 non-fatal\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 OR\NN\3541091 0.26\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.04\CD\1740 -\SYM\1740 1.60\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.14\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>myocardial\JJ\1740 ischaemia</e2>\NN\14195315 (\-LRB-\1740 OR\NN\3541091 0.65\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.26\CD\1740 -\SYM\1740 1.63\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.36\CD\1740 )\-RRB-\1740 .\.\1740
1899352
D015080_D006417 NONE The\DT\1740 frequency\NN\15286249 and\CC\1740 predictability\NN\4753455 of\IN\1740 <e2>hematuria</e2>\NN\14299637 are\VBP\836236 not\RB\1740 precise\JJ\1740 ,\,\1740 and\CC\1740 at\IN\14622893 least\JJS\1740 daily\JJ\1740 monitoring\NN\879759 by\IN\1740 urine\NN\14853947 Hematest\NNP\1740 is\VBZ\836236 essential\JJ\1740 ,\,\1740 adding\VBG\156601 <e1>Mesna</e1>\NN\1740 to\IN\1740 the\DT\1740 infusate\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 persistent\JJ\1740 hematuria\NN\14299637 .\.\1740
D015080_D006417 NONE The\DT\1740 frequency\NN\15286249 and\CC\1740 predictability\NN\4753455 of\IN\1740 hematuria\NN\14299637 are\VBP\836236 not\RB\1740 precise\JJ\1740 ,\,\1740 and\CC\1740 at\IN\14622893 least\JJS\1740 daily\JJ\1740 monitoring\NN\879759 by\IN\1740 urine\NN\14853947 Hematest\NNP\1740 is\VBZ\836236 essential\JJ\1740 ,\,\1740 adding\VBG\156601 <e1>Mesna</e1>\NN\1740 to\IN\1740 the\DT\1740 infusate\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 persistent\JJ\1740 <e2>hematuria</e2>\NN\14299637 .\.\1740
16725121
D009638_D012640 NONE Down-regulation\NN\1740 of\IN\1740 <e1>norepinephrine</e1>\NN\14807929 transporter\NN\4490091 function\NN\13783581 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 linking\VBG\628491 to\TO\1740 the\DT\1740 alteration\NN\7283608 of\IN\1740 sensitivity\NN\5651971 of\IN\1740 local-anesthetics-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 the\DT\1740 counteraction\NN\231567 by\IN\1740 co-administration\NN\1740 with\IN\1740 local\JJ\1740 anesthetics\NNS\3247620 .\.\1740
D009638_D012640 NONE Alterations\NNS\7283608 of\IN\1740 <e1>norepinephrine</e1>\NN\14807929 transporter\NN\4490091 (\-LRB-\1740 NET\NN\3085333 )\-RRB-\1740 function\NN\13783581 by\IN\1740 chronic\JJ\1740 inhibition\NN\1068773 of\IN\1740 NET\NN\3085333 in\IN\13603305 relation\NN\2137 to\TO\1740 sensitization\NN\14531772 to\IN\1740 <e2>seizures</e2>\NNS\14081375 induce\NN\1740 by\IN\1740 cocaine\NN\3492717 and\CC\1740 local\JJ\1740 anesthetics\NNS\3247620 were\VBD\836236 studied\VBN\630380 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003891_D012640 NONE Down-regulation\NN\1740 of\IN\1740 norepinephrine\NN\14807929 transporter\NN\4490091 function\NN\13783581 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>desipramine</e1>\NN\4482543 linking\VBG\628491 to\TO\1740 the\DT\1740 alteration\NN\7283608 of\IN\1740 sensitivity\NN\5651971 of\IN\1740 local-anesthetics-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 the\DT\1740 counteraction\NN\231567 by\IN\1740 co-administration\NN\1740 with\IN\1740 local\JJ\1740 anesthetics\NNS\3247620 .\.\1740
D003891_D012640 NONE Daily\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>desipramine</e1>\NN\4482543 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 appearance\NN\4723816 of\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 decreased\VBD\169651 that\DT\1740 of\IN\1740 cocaine-induced\JJ\1740 convulsions\NNS\14081375 .\.\1740
D003891_D012640 NONE Daily\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>desipramine</e1>\NN\4482543 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 appearance\NN\4723816 of\IN\1740 lidocaine-induced\JJ\1740 convulsions\NNS\14081375 and\CC\1740 decreased\VBD\169651 that\DT\1740 of\IN\1740 cocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D003891_D012640 NONE Co-administration\NN\1740 of\IN\1740 lidocaine\NN\3681148 with\IN\1740 <e1>desipramine</e1>\NN\4482543 reversed\VBD\109660 the\DT\1740 changes\NNS\7283608 of\IN\1740 <e2>convulsive</e2>\JJ\1740 activity\NN\30358 of\IN\1740 lidocaine\NN\3681148 and\CC\1740 cocaine\NN\3492717 induced\VBN\1627355 by\IN\1740 repeated\VBN\952524 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 .\.\1740
D003891_D012640 NONE Co-administration\NN\1740 of\IN\1740 lidocaine\NN\3681148 with\IN\1740 desipramine\NN\4482543 reversed\VBD\109660 the\DT\1740 changes\NNS\7283608 of\IN\1740 <e2>convulsive</e2>\JJ\1740 activity\NN\30358 of\IN\1740 lidocaine\NN\3681148 and\CC\1740 cocaine\NN\3492717 induced\VBN\1627355 by\IN\1740 repeated\VBN\952524 administration\NN\1133281 of\IN\1740 <e1>desipramine</e1>\NN\4482543 .\.\1740
D003891_D012640 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 down-regulation\NN\1740 of\IN\1740 hippocampal\NN\1740 NET\NN\3085333 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>desipramine</e1>\NN\4482543 may\MD\15209706 be\VB\836236 relevant\JJ\1740 to\TO\1740 desipramine-induced\JJ\1740 sensitization\NN\14531772 of\IN\1740 lidocaine\NN\3681148 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D003891_D012640 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 down-regulation\NN\1740 of\IN\1740 hippocampal\NN\1740 NET\NN\3085333 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 may\MD\15209706 be\VB\836236 relevant\JJ\1740 to\TO\1740 <e1>desipramine-induced</e1>\JJ\1740 sensitization\NN\14531772 of\IN\1740 lidocaine\NN\3681148 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D003891_D012640 NONE <e1>Desipramine-induced</e1>\JJ\1740 sensitization\NN\14531772 of\IN\1740 lidocaine\NN\3681148 <e2>seizures</e2>\NNS\14081375 may\MD\15209706 have\VB\2108377 a\DT\13649268 mechanism\NN\13446390 distinct\JJ\1740 from\IN\1740 kindling\NN\15101361 resulting\VBG\2633881 from\IN\1740 repeated\VBN\952524 administration\NN\1133281 of\IN\1740 cocaine\NN\3492717 .\.\1740
D003042_D012640 CID Alterations\NNS\7283608 of\IN\1740 norepinephrine\NN\14807929 transporter\NN\4490091 (\-LRB-\1740 NET\NN\3085333 )\-RRB-\1740 function\NN\13783581 by\IN\1740 chronic\JJ\1740 inhibition\NN\1068773 of\IN\1740 NET\NN\3085333 in\IN\13603305 relation\NN\2137 to\TO\1740 sensitization\NN\14531772 to\IN\1740 <e2>seizures</e2>\NNS\14081375 induce\NN\1740 by\IN\1740 <e1>cocaine</e1>\NN\3492717 and\CC\1740 local\JJ\1740 anesthetics\NNS\3247620 were\VBD\836236 studied\VBN\630380 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003042_D012640 CID Daily\JJ\1740 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 appearance\NN\4723816 of\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 decreased\VBD\169651 that\DT\1740 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 convulsions\NNS\14081375 .\.\1740
D003042_D012640 CID Daily\JJ\1740 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 appearance\NN\4723816 of\IN\1740 lidocaine-induced\JJ\1740 convulsions\NNS\14081375 and\CC\1740 decreased\VBD\169651 that\DT\1740 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D003042_D012640 CID Co-administration\NN\1740 of\IN\1740 lidocaine\NN\3681148 with\IN\1740 desipramine\NN\4482543 reversed\VBD\109660 the\DT\1740 changes\NNS\7283608 of\IN\1740 <e2>convulsive</e2>\JJ\1740 activity\NN\30358 of\IN\1740 lidocaine\NN\3681148 and\CC\1740 <e1>cocaine</e1>\NN\3492717 induced\VBN\1627355 by\IN\1740 repeated\VBN\952524 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 .\.\1740
D003042_D012640 CID Desipramine-induced\JJ\1740 sensitization\NN\14531772 of\IN\1740 lidocaine\NN\3681148 <e2>seizures</e2>\NNS\14081375 may\MD\15209706 have\VB\2108377 a\DT\13649268 mechanism\NN\13446390 distinct\JJ\1740 from\IN\1740 kindling\NN\15101361 resulting\VBG\2633881 from\IN\1740 repeated\VBN\952524 administration\NN\1133281 of\IN\1740 <e1>cocaine</e1>\NN\3492717 .\.\1740
D008012_D012640 CID Daily\JJ\1740 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 appearance\NN\4723816 of\IN\1740 <e1>lidocaine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 decreased\VBD\169651 that\DT\1740 of\IN\1740 cocaine-induced\JJ\1740 convulsions\NNS\14081375 .\.\1740
D008012_D012640 CID Daily\JJ\1740 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 increased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 appearance\NN\4723816 of\IN\1740 <e1>lidocaine-induced</e1>\JJ\1740 convulsions\NNS\14081375 and\CC\1740 decreased\VBD\169651 that\DT\1740 of\IN\1740 cocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D008012_D012640 CID Co-administration\NN\1740 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 with\IN\1740 desipramine\NN\4482543 reversed\VBD\109660 the\DT\1740 changes\NNS\7283608 of\IN\1740 <e2>convulsive</e2>\JJ\1740 activity\NN\30358 of\IN\1740 lidocaine\NN\3681148 and\CC\1740 cocaine\NN\3492717 induced\VBN\1627355 by\IN\1740 repeated\VBN\952524 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 .\.\1740
D008012_D012640 CID Co-administration\NN\1740 of\IN\1740 lidocaine\NN\3681148 with\IN\1740 desipramine\NN\4482543 reversed\VBD\109660 the\DT\1740 changes\NNS\7283608 of\IN\1740 <e2>convulsive</e2>\JJ\1740 activity\NN\30358 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 and\CC\1740 cocaine\NN\3492717 induced\VBN\1627355 by\IN\1740 repeated\VBN\952524 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 .\.\1740
D008012_D012640 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 down-regulation\NN\1740 of\IN\1740 hippocampal\NN\1740 NET\NN\3085333 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 desipramine\NN\4482543 may\MD\15209706 be\VB\836236 relevant\JJ\1740 to\TO\1740 desipramine-induced\JJ\1740 sensitization\NN\14531772 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D008012_D012640 CID Desipramine-induced\JJ\1740 sensitization\NN\14531772 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 <e2>seizures</e2>\NNS\14081375 may\MD\15209706 have\VB\2108377 a\DT\13649268 mechanism\NN\13446390 distinct\JJ\1740 from\IN\1740 kindling\NN\15101361 resulting\VBG\2633881 from\IN\1740 repeated\VBN\952524 administration\NN\1133281 of\IN\1740 cocaine\NN\3492717 .\.\1740
2917114
D006024_D001919 NONE Use\NN\407535 of\IN\1740 <e1>glycopyrronium</e1>\NN\1740 5\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 provided\VBD\2199590 greater\JJR\1740 cardiovascular\JJ\1740 stability\NN\4777852 and\CC\1740 ,\,\1740 given\VBN\2327200 1\CD\13741022 min\NN\15154774 before\IN\1740 the\DT\1740 edrophonium\NN\1740 ,\,\1740 was\VBD\836236 sufficient\JJ\1740 to\TO\1740 minimize\VB\441445 early\JJ\1740 ,\,\1740 edrophonium-induced\JJ\1740 <e2>bradycardias</e2>\NNS\14110674 .\.\1740
D004491_D001919 CID Use\NN\407535 of\IN\1740 glycopyrronium\NN\1740 5\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 provided\VBD\2199590 greater\JJR\1740 cardiovascular\JJ\1740 stability\NN\4777852 and\CC\1740 ,\,\1740 given\VBN\2327200 1\CD\13741022 min\NN\15154774 before\IN\1740 the\DT\1740 <e1>edrophonium</e1>\NN\1740 ,\,\1740 was\VBD\836236 sufficient\JJ\1740 to\TO\1740 minimize\VB\441445 early\JJ\1740 ,\,\1740 edrophonium-induced\JJ\1740 <e2>bradycardias</e2>\NNS\14110674 .\.\1740
D004491_D001919 CID Use\NN\407535 of\IN\1740 glycopyrronium\NN\1740 5\CD\13741022 micrograms\NNS\13717155 kg-1\NN\1740 provided\VBD\2199590 greater\JJR\1740 cardiovascular\JJ\1740 stability\NN\4777852 and\CC\1740 ,\,\1740 given\VBN\2327200 1\CD\13741022 min\NN\15154774 before\IN\1740 the\DT\1740 edrophonium\NN\1740 ,\,\1740 was\VBD\836236 sufficient\JJ\1740 to\TO\1740 minimize\VB\441445 early\JJ\1740 ,\,\1740 <e1>edrophonium-induced</e1>\JJ\1740 <e2>bradycardias</e2>\NNS\14110674 .\.\1740
19139001
D000518_D015179 NONE Longitudinal\JJ\1740 assessment\NN\5732756 of\IN\1740 air\NN\14877585 conduction\NN\11419404 audiograms\NNS\4076846 in\IN\13603305 a\DT\13649268 phase\NN\15113229 III\CD\13741022 clinical\JJ\1740 trial\NN\786195 of\IN\1740 <e1>difluoromethylornithine</e1>\NN\1740 and\CC\1740 sulindac\NN\3828465 for\IN\1740 prevention\NN\1073995 of\IN\1740 sporadic\JJ\1740 <e2>colorectal\JJ\1740 adenomas</e2>\NNS\14236226 .\.\1740
D013467_D015179 NONE Longitudinal\JJ\1740 assessment\NN\5732756 of\IN\1740 air\NN\14877585 conduction\NN\11419404 audiograms\NNS\4076846 in\IN\13603305 a\DT\13649268 phase\NN\15113229 III\CD\13741022 clinical\JJ\1740 trial\NN\786195 of\IN\1740 difluoromethylornithine\NN\1740 and\CC\1740 <e1>sulindac</e1>\NN\3828465 for\IN\1740 prevention\NN\1073995 of\IN\1740 sporadic\JJ\1740 <e2>colorectal\JJ\1740 adenomas</e2>\NNS\14236226 .\.\1740
D000518_D018256 NONE A\DT\13649268 phase\NN\15113229 III\CD\13741022 clinical\JJ\1740 trial\NN\786195 assessed\VBD\670261 the\DT\1740 recurrence\NN\7342049 of\IN\1740 <e2>adenomatous\JJ\1740 polyps</e2>\NNS\14234074 after\IN\1740 treatment\NN\654885 for\IN\1740 36\CD\1740 months\NNS\15113229 with\IN\1740 <e1>difluoromethylornithine</e1>\NN\1740 (\-LRB-\1740 DFMO\NN\1740 )\-RRB-\1740 plus\CC\4723816 sulindac\NN\3828465 or\CC\3541091 matched\VBN\2664769 placebos\NNS\3740161 .\.\1740
D000518_D018256 NONE A\DT\13649268 phase\NN\15113229 III\CD\13741022 clinical\JJ\1740 trial\NN\786195 assessed\VBD\670261 the\DT\1740 recurrence\NN\7342049 of\IN\1740 <e2>adenomatous\JJ\1740 polyps</e2>\NNS\14234074 after\IN\1740 treatment\NN\654885 for\IN\1740 36\CD\1740 months\NNS\15113229 with\IN\1740 difluoromethylornithine\NN\1740 (\-LRB-\1740 <e1>DFMO</e1>\NN\1740 )\-RRB-\1740 plus\CC\4723816 sulindac\NN\3828465 or\CC\3541091 matched\VBN\2664769 placebos\NNS\3740161 .\.\1740
D013467_D018256 NONE A\DT\13649268 phase\NN\15113229 III\CD\13741022 clinical\JJ\1740 trial\NN\786195 assessed\VBD\670261 the\DT\1740 recurrence\NN\7342049 of\IN\1740 <e2>adenomatous\JJ\1740 polyps</e2>\NNS\14234074 after\IN\1740 treatment\NN\654885 for\IN\1740 36\CD\1740 months\NNS\15113229 with\IN\1740 difluoromethylornithine\NN\1740 (\-LRB-\1740 DFMO\NN\1740 )\-RRB-\1740 plus\CC\4723816 <e1>sulindac</e1>\NN\3828465 or\CC\3541091 matched\VBN\2664769 placebos\NNS\3740161 .\.\1740
D000518_D034381 NONE Temporary\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 is\VBZ\836236 a\DT\13649268 known\JJ\1740 toxicity\NN\13576101 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>DFMO</e1>\NN\1740 ,\,\1740 thus\RB\1740 a\DT\13649268 comprehensive\JJ\1740 approach\NN\940842 was\VBD\836236 developed\VBN\1753788 to\TO\1740 analyze\VB\78760 serial\JJ\1740 air\NN\14877585 conduction\NN\11419404 audiograms\NNS\4076846 .\.\1740
D000518_D034381 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 the\DT\1740 proportion\NN\13824815 of\IN\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 <e1>DFMO</e1>\NN\1740 plus\CC\4723816 sulindac\NN\3828465 group\NN\2137 who\WP\8299493 experienced\VBD\2108377 clinically\RB\1740 significant\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 compared\VBN\644583 with\IN\1740 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
D000518_D064420 NONE Temporary\JJ\1740 hearing\NN\1184814 loss\NN\13252973 is\VBZ\836236 a\DT\13649268 known\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>DFMO</e1>\NN\1740 ,\,\1740 thus\RB\1740 a\DT\13649268 comprehensive\JJ\1740 approach\NN\940842 was\VBD\836236 developed\VBN\1753788 to\TO\1740 analyze\VB\78760 serial\JJ\1740 air\NN\14877585 conduction\NN\11419404 audiograms\NNS\4076846 .\.\1740
D013467_D034381 CID There\EX\27167 was\VBD\836236 no\DT\7204911 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 the\DT\1740 proportion\NN\13824815 of\IN\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 DFMO\NN\1740 plus\CC\4723816 <e1>sulindac</e1>\NN\3828465 group\NN\2137 who\WP\8299493 experienced\VBD\2108377 clinically\RB\1740 significant\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 compared\VBN\644583 with\IN\1740 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
14745746
C090450_D001943 NONE Patients\NNS\9898892 participating\VBG\2367363 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 trial\NN\786195 of\IN\1740 <e1>anastrozole</e1>\NN\1740 ,\,\1740 tamoxifen\NN\2714883 alone\RB\1740 or\CC\3541091 combined\JJ\1740 (\-LRB-\1740 ATAC\NN\1740 )\-RRB-\1740 (\-LRB-\1740 n=94\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 group\NN\2137 of\IN\1740 women\NNS\9605289 without\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 completed\VBD\352826 a\DT\13649268 battery\NN\8389297 of\IN\1740 neuropsychological\JJ\1740 measures\NNS\168237 .\.\1740
D013629_D001943 NONE Patients\NNS\9898892 participating\VBG\2367363 in\IN\13603305 a\DT\13649268 randomised\VBN\278117 trial\NN\786195 of\IN\1740 anastrozole\NN\1740 ,\,\1740 <e1>tamoxifen</e1>\NN\2714883 alone\RB\1740 or\CC\3541091 combined\JJ\1740 (\-LRB-\1740 ATAC\NN\1740 )\-RRB-\1740 (\-LRB-\1740 n=94\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 group\NN\2137 of\IN\1740 women\NNS\9605289 without\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 completed\VBD\352826 a\DT\13649268 battery\NN\8389297 of\IN\1740 neuropsychological\JJ\1740 measures\NNS\168237 .\.\1740
8854309
D003042_D011681 CID A\DT\13649268 measure\NN\168237 of\IN\1740 <e2>pupillary\JJ\1740 oscillation</e2>\NN\13518963 as\IN\14622893 a\DT\13649268 marker\NN\21939 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 paranoia\NN\14398067 .\.\1740
D003042_D010259 CID A\DT\13649268 measure\NN\168237 of\IN\1740 pupillary\JJ\1740 oscillation\NN\13518963 as\IN\14622893 a\DT\13649268 marker\NN\21939 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>paranoia</e2>\NN\14398067 .\.\1740
D003042_D010259 CID <e1>Cocaine-induced</e1>\JJ\1740 <e2>paranoia</e2>\NN\14398067 (\-LRB-\1740 CIP\NN\1740 )\-RRB-\1740 remains\VBZ\2604760 an\DT\6697703 important\JJ\1740 drug-induced\JJ\1740 model\NN\5888929 of\IN\1740 idiopathic\JJ\1740 paranoia\NN\14398067 for\IN\1740 which\WDT\1740 no\DT\7204911 psychophysiologic\JJ\1740 marker\NN\21939 has\VBZ\2108377 yet\RB\1740 emerged\VBN\422090 .\.\1740
D003042_D010259 CID <e1>Cocaine-induced</e1>\JJ\1740 paranoia\NN\14398067 (\-LRB-\1740 <e2>CIP</e2>\NN\1740 )\-RRB-\1740 remains\VBZ\2604760 an\DT\6697703 important\JJ\1740 drug-induced\JJ\1740 model\NN\5888929 of\IN\1740 idiopathic\JJ\1740 paranoia\NN\14398067 for\IN\1740 which\WDT\1740 no\DT\7204911 psychophysiologic\JJ\1740 marker\NN\21939 has\VBZ\2108377 yet\RB\1740 emerged\VBN\422090 .\.\1740
D003042_D010259 CID <e1>Cocaine-induced</e1>\JJ\1740 paranoia\NN\14398067 (\-LRB-\1740 CIP\NN\1740 )\-RRB-\1740 remains\VBZ\2604760 an\DT\6697703 important\JJ\1740 drug-induced\JJ\1740 model\NN\5888929 of\IN\1740 idiopathic\JJ\1740 <e2>paranoia</e2>\NN\14398067 for\IN\1740 which\WDT\1740 no\DT\7204911 psychophysiologic\JJ\1740 marker\NN\21939 has\VBZ\2108377 yet\RB\1740 emerged\VBN\422090 .\.\1740
D016578_D011681 NONE Measures\NNS\168237 of\IN\1740 <e2>pupillary\JJ\1740 oscillation</e2>\NN\13518963 were\VBD\836236 able\JJ\1740 to\TO\1740 significantly\RB\1740 distinguish\VB\618878 a\DT\13649268 group\NN\2137 of\IN\1740 abstinent\JJ\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 abusers\NNS\9633969 endorsing\VBG\806502 past\JJ\1740 CIP\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 from\IN\1740 another\DT\1740 group\NN\2137 of\IN\1740 crack\NN\9379111 addicts\NNS\10059582 who\WP\8299493 denied\VBD\823436 past\IN\28270 CIP\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 .\.\1740
D016578_D011681 NONE Measures\NNS\168237 of\IN\1740 <e2>pupillary\JJ\1740 oscillation</e2>\NN\13518963 were\VBD\836236 able\JJ\1740 to\TO\1740 significantly\RB\1740 distinguish\VB\618878 a\DT\13649268 group\NN\2137 of\IN\1740 abstinent\JJ\1740 crack\NN\9379111 cocaine\NN\3492717 abusers\NNS\9633969 endorsing\VBG\806502 past\JJ\1740 CIP\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 from\IN\1740 another\DT\1740 group\NN\2137 of\IN\1740 <e1>crack</e1>\NN\9379111 addicts\NNS\10059582 who\WP\8299493 denied\VBD\823436 past\IN\28270 CIP\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 .\.\1740
D016578_D010259 NONE Measures\NNS\168237 of\IN\1740 pupillary\JJ\1740 oscillation\NN\13518963 were\VBD\836236 able\JJ\1740 to\TO\1740 significantly\RB\1740 distinguish\VB\618878 a\DT\13649268 group\NN\2137 of\IN\1740 abstinent\JJ\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 abusers\NNS\9633969 endorsing\VBG\806502 past\JJ\1740 <e2>CIP</e2>\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 from\IN\1740 another\DT\1740 group\NN\2137 of\IN\1740 crack\NN\9379111 addicts\NNS\10059582 who\WP\8299493 denied\VBD\823436 past\IN\28270 CIP\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 .\.\1740
D016578_D010259 NONE Measures\NNS\168237 of\IN\1740 pupillary\JJ\1740 oscillation\NN\13518963 were\VBD\836236 able\JJ\1740 to\TO\1740 significantly\RB\1740 distinguish\VB\618878 a\DT\13649268 group\NN\2137 of\IN\1740 abstinent\JJ\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 abusers\NNS\9633969 endorsing\VBG\806502 past\JJ\1740 CIP\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 from\IN\1740 another\DT\1740 group\NN\2137 of\IN\1740 crack\NN\9379111 addicts\NNS\10059582 who\WP\8299493 denied\VBD\823436 past\IN\28270 <e2>CIP</e2>\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 .\.\1740
D016578_D010259 NONE Measures\NNS\168237 of\IN\1740 pupillary\JJ\1740 oscillation\NN\13518963 were\VBD\836236 able\JJ\1740 to\TO\1740 significantly\RB\1740 distinguish\VB\618878 a\DT\13649268 group\NN\2137 of\IN\1740 abstinent\JJ\1740 crack\NN\9379111 cocaine\NN\3492717 abusers\NNS\9633969 endorsing\VBG\806502 past\JJ\1740 <e2>CIP</e2>\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 from\IN\1740 another\DT\1740 group\NN\2137 of\IN\1740 <e1>crack</e1>\NN\9379111 addicts\NNS\10059582 who\WP\8299493 denied\VBD\823436 past\IN\28270 CIP\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 .\.\1740
D016578_D010259 NONE Measures\NNS\168237 of\IN\1740 pupillary\JJ\1740 oscillation\NN\13518963 were\VBD\836236 able\JJ\1740 to\TO\1740 significantly\RB\1740 distinguish\VB\618878 a\DT\13649268 group\NN\2137 of\IN\1740 abstinent\JJ\1740 crack\NN\9379111 cocaine\NN\3492717 abusers\NNS\9633969 endorsing\VBG\806502 past\JJ\1740 CIP\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 from\IN\1740 another\DT\1740 group\NN\2137 of\IN\1740 <e1>crack</e1>\NN\9379111 addicts\NNS\10059582 who\WP\8299493 denied\VBD\823436 past\IN\28270 <e2>CIP</e2>\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 .\.\1740
9321531
D007980_D010300 NONE CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 late-stage\JJ\1740 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 ,\,\1740 pallidotomy\NN\1740 significantly\RB\1740 reduces\VBZ\441445 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 and\CC\1740 off-period\JJ\1740 disability\NN\14547369 .\.\1740
D007980_D004409 CID CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 late-stage\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 ,\,\1740 pallidotomy\NN\1740 significantly\RB\1740 reduces\VBZ\441445 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 and\CC\1740 off-period\JJ\1740 disability\NN\14547369 .\.\1740
8617710
D020280_D003072 NONE Absence\NN\14449405 of\IN\1740 effect\NN\34213 of\IN\1740 <e1>sertraline</e1>\NN\4169152 on\IN\1740 time-based\JJ\1740 sensitization\NN\14531772 of\IN\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 with\IN\1740 haloperidol\NN\3713736 .\.\1740
D020280_D003072 NONE CONCLUSION\NN\5837957 :\:\1740 Haloperidol\NNP\3713736 produced\VBD\1617192 a\DT\13649268 clear\JJ\1740 profile\NN\6999802 of\IN\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 that\WDT\1740 was\VBD\836236 not\RB\1740 worsened\VBN\146138 by\IN\1740 concomitant\JJ\1740 <e1>sertraline</e1>\NN\4169152 administration\NN\1133281 .\.\1740
D006220_D003072 CID Absence\NN\14449405 of\IN\1740 effect\NN\34213 of\IN\1740 sertraline\NN\4169152 on\IN\1740 time-based\JJ\1740 sensitization\NN\14531772 of\IN\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 with\IN\1740 <e1>haloperidol</e1>\NN\3713736 .\.\1740
D006220_D003072 CID RESULTS\NNS\34213 :\:\1740 <e2>Impairment\NN\7296428 of\IN\1740 cognitive\JJ\1740 function</e2>\NN\13783581 was\VBD\836236 observed\VBN\2163746 6\CD\13741022 to\TO\1740 8\CD\13741022 hours\NNS\15118228 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 on\IN\1740 Day\NNP\15154774 2\CD\13741022 but\CC\1740 was\VBD\836236 not\RB\1740 evident\JJ\1740 23\CD\13745420 hours\NNS\15118228 after\IN\1740 dosing\NN\1740 .\.\1740
D006220_D003072 CID CONCLUSION\NN\5837957 :\:\1740 <e1>Haloperidol</e1>\NNP\3713736 produced\VBD\1617192 a\DT\13649268 clear\JJ\1740 profile\NN\6999802 of\IN\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 that\WDT\1740 was\VBD\836236 not\RB\1740 worsened\VBN\146138 by\IN\1740 concomitant\JJ\1740 sertraline\NN\4169152 administration\NN\1133281 .\.\1740
384871
D004977_D009901 CID <e2>Bilateral\JJ\1740 optic\NN\5299178 neuropathy</e2>\NN\14204950 due\JJ\1740 to\TO\1740 combined\JJ\1740 <e1>ethambutol</e1>\NN\1740 and\CC\1740 isoniazid\NN\2716205 treatment\NN\654885 .\.\1740
D007538_D009901 CID <e2>Bilateral\JJ\1740 optic\NN\5299178 neuropathy</e2>\NN\14204950 due\JJ\1740 to\TO\1740 combined\JJ\1740 ethambutol\NN\1740 and\CC\1740 <e1>isoniazid</e1>\NN\2716205 treatment\NN\654885 .\.\1740
D004977_D064420 NONE The\DT\1740 hazards\NNS\14541044 of\IN\1740 optic\JJ\1740 nerve\NN\5475681 <e2>toxicity</e2>\NN\13576101 due\IN\5174653 to\TO\1740 <e1>ethambutol</e1>\NN\1740 are\VBP\836236 known\VBN\2110220 .\.\1740
16629641
D007372_D006526 NONE The\DT\1740 current\JJ\1740 best\JJS\1740 treatment\NN\654885 for\IN\1740 <e2>HCV\NN\1740 infection</e2>\NN\14052046 is\VBZ\836236 combination\NN\7951464 therapy\NN\657604 with\IN\1740 pegylated\JJ\1740 <e1>interferon</e1>\NN\2725367 and\CC\1740 ribavirin\NN\2725367 .\.\1740
D012254_D006526 NONE The\DT\1740 current\JJ\1740 best\JJS\1740 treatment\NN\654885 for\IN\1740 <e2>HCV\NN\1740 infection</e2>\NN\14052046 is\VBZ\836236 combination\NN\7951464 therapy\NN\657604 with\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 .\.\1740
D012254_D006526 NONE Hemoglobin\NN\14888884 concentrations\NNS\4916342 decrease\VBP\169651 mainly\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 <e1>ribavirin-induced</e1>\JJ\1740 hemolysis\NN\13509528 ,\,\1740 and\CC\1740 this\DT\1740 anemia\NN\14189204 can\MD\3094503 be\VB\836236 problematic\JJ\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>HCV\NN\1740 infection</e2>\NN\14052046 ,\,\1740 especially\RB\1740 those\DT\1740 who\WP\8299493 have\VBP\2108377 comorbid\VB\1740 renal\JJ\1740 or\CC\3541091 cardiovascular\JJ\1740 disorders\NNS\14034177 .\.\1740
D012254_D006461 NONE Hemoglobin\NN\14888884 concentrations\NNS\4916342 decrease\VBP\169651 mainly\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 <e1>ribavirin-induced</e1>\JJ\1740 <e2>hemolysis</e2>\NN\13509528 ,\,\1740 and\CC\1740 this\DT\1740 anemia\NN\14189204 can\MD\3094503 be\VB\836236 problematic\JJ\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 HCV\NN\1740 infection\NN\14052046 ,\,\1740 especially\RB\1740 those\DT\1740 who\WP\8299493 have\VBP\2108377 comorbid\VB\1740 renal\JJ\1740 or\CC\3541091 cardiovascular\JJ\1740 disorders\NNS\14034177 .\.\1740
D012254_D000740 NONE Hemoglobin\NN\14888884 concentrations\NNS\4916342 decrease\VBP\169651 mainly\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 <e1>ribavirin-induced</e1>\JJ\1740 hemolysis\NN\13509528 ,\,\1740 and\CC\1740 this\DT\1740 <e2>anemia</e2>\NN\14189204 can\MD\3094503 be\VB\836236 problematic\JJ\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 HCV\NN\1740 infection\NN\14052046 ,\,\1740 especially\RB\1740 those\DT\1740 who\WP\8299493 have\VBP\2108377 comorbid\VB\1740 renal\JJ\1740 or\CC\3541091 cardiovascular\JJ\1740 disorders\NNS\14034177 .\.\1740
D012254_D000740 NONE Although\IN\1740 <e1>ribavirin-associated</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 can\MD\3094503 be\VB\836236 reversed\VBN\109660 by\IN\1740 dose\NN\3740161 reduction\NN\351485 or\CC\3541091 discontinuation\NN\209943 ,\,\1740 this\DT\1740 approach\NN\940842 compromises\VBZ\1035530 outcomes\NNS\7291312 by\IN\1740 significantly\RB\1740 decreasing\VBG\169651 SVR\NN\8342039 rates\NNS\13308999 .\.\1740
D012254_D000740 NONE Recombinant\JJ\1740 human\JJ\1740 erythropoietin\NN\14888310 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 to\TO\1740 manage\VB\2524171 <e1>ribavirin-associated</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 but\CC\1740 has\VBZ\2108377 other\JJ\1740 potential\JJ\1740 disadvantages\NNS\5161436 .\.\1740
D012254_D007674 NONE Hemoglobin\NN\14888884 concentrations\NNS\4916342 decrease\VBP\169651 mainly\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 <e1>ribavirin-induced</e1>\JJ\1740 hemolysis\NN\13509528 ,\,\1740 and\CC\1740 this\DT\1740 anemia\NN\14189204 can\MD\3094503 be\VB\836236 problematic\JJ\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 HCV\NN\1740 infection\NN\14052046 ,\,\1740 especially\RB\1740 those\DT\1740 who\WP\8299493 have\VBP\2108377 comorbid\VB\1740 <e2>renal\JJ\1740 or\CC\3541091 cardiovascular\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D012254_D002318 NONE Hemoglobin\NN\14888884 concentrations\NNS\4916342 decrease\VBP\169651 mainly\RB\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 <e1>ribavirin-induced</e1>\JJ\1740 hemolysis\NN\13509528 ,\,\1740 and\CC\1740 this\DT\1740 anemia\NN\14189204 can\MD\3094503 be\VB\836236 problematic\JJ\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 HCV\NN\1740 infection\NN\14052046 ,\,\1740 especially\RB\1740 those\DT\1740 who\WP\8299493 have\VBP\2108377 comorbid\VB\1740 <e2>renal\JJ\1740 or\CC\3541091 cardiovascular\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
C026956_D000743 NONE <e1>Viramidine</e1>\NNP\1740 ,\,\1740 a\DT\13649268 liver-targeting\JJ\1740 prodrug\NN\1740 of\IN\1740 ribavirin\NN\2725367 ,\,\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 to\TO\1740 maintain\VB\2202928 the\DT\1740 virologic\JJ\1740 efficacy\NN\5199286 of\IN\1740 ribavirin\NN\2725367 while\IN\15122231 decreasing\VBG\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C.\NN\1740
C026956_D019698 NONE <e1>Viramidine</e1>\NNP\1740 ,\,\1740 a\DT\13649268 liver-targeting\JJ\1740 prodrug\NN\1740 of\IN\1740 ribavirin\NN\2725367 ,\,\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 to\TO\1740 maintain\VB\2202928 the\DT\1740 virologic\JJ\1740 efficacy\NN\5199286 of\IN\1740 ribavirin\NN\2725367 while\IN\15122231 decreasing\VBG\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hemolytic\JJ\1740 anemia\NN\14189204 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C.</e2>\NN\1740
D012254_D000743 CID Viramidine\NNP\1740 ,\,\1740 a\DT\13649268 liver-targeting\JJ\1740 prodrug\NN\1740 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 ,\,\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 to\TO\1740 maintain\VB\2202928 the\DT\1740 virologic\JJ\1740 efficacy\NN\5199286 of\IN\1740 ribavirin\NN\2725367 while\IN\15122231 decreasing\VBG\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C.\NN\1740
D012254_D000743 CID Viramidine\NNP\1740 ,\,\1740 a\DT\13649268 liver-targeting\JJ\1740 prodrug\NN\1740 of\IN\1740 ribavirin\NN\2725367 ,\,\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 to\TO\1740 maintain\VB\2202928 the\DT\1740 virologic\JJ\1740 efficacy\NN\5199286 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 while\IN\15122231 decreasing\VBG\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C.\NN\1740
D012254_D019698 NONE Viramidine\NNP\1740 ,\,\1740 a\DT\13649268 liver-targeting\JJ\1740 prodrug\NN\1740 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 ,\,\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 to\TO\1740 maintain\VB\2202928 the\DT\1740 virologic\JJ\1740 efficacy\NN\5199286 of\IN\1740 ribavirin\NN\2725367 while\IN\15122231 decreasing\VBG\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hemolytic\JJ\1740 anemia\NN\14189204 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C.</e2>\NN\1740
D012254_D019698 NONE Viramidine\NNP\1740 ,\,\1740 a\DT\13649268 liver-targeting\JJ\1740 prodrug\NN\1740 of\IN\1740 ribavirin\NN\2725367 ,\,\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 to\TO\1740 maintain\VB\2202928 the\DT\1740 virologic\JJ\1740 efficacy\NN\5199286 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 while\IN\15122231 decreasing\VBG\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hemolytic\JJ\1740 anemia\NN\14189204 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C.</e2>\NN\1740
16132524
D017239_D005909 NONE Intracavitary\JJ\1740 chemotherapy\NN\661091 (\-LRB-\1740 <e1>paclitaxel/carboplatin</e1>\NN\1740 liquid\NN\14939900 crystalline\NN\1740 cubic\JJ\1740 phases\NNS\15113229 )\-RRB-\1740 for\IN\1740 recurrent\JJ\1740 <e2>glioblastoma</e2>\NN\14236743 --\:\1740 clinical\JJ\1740 observations\NNS\996969 .\.\1740
D017239_D005909 NONE For\IN\1740 human\JJ\1740 <e2>glioblastoma</e2>\NN\14236743 recurrences\NNS\7342049 ,\,\1740 the\DT\1740 feasibility\NN\5152150 ,\,\1740 safety\NN\13920835 ,\,\1740 and\CC\1740 short-term\JJ\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 surgical\JJ\1740 intracavitary\JJ\1740 application\NN\947128 of\IN\1740 <e1>paclitaxel</e1>\NN\1740 and\CC\1740 carboplatin\NN\1740 encapsulated\VBN\1587062 by\IN\1740 liquid\JJ\1740 crystalline\NN\1740 cubic\JJ\1740 phases\NNS\15113229 are\VBP\836236 examined\VBN\789138 in\IN\13603305 a\DT\13649268 pilot\NN\9826204 study\NN\635850 .\.\1740
D017239_D005909 NONE A\DT\13649268 total\NN\3553 of\IN\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 a\DT\13649268 recurrence\NN\7342049 of\IN\1740 a\DT\13649268 <e2>glioblastoma</e2>\NN\14236743 multiforme\JJ\1740 underwent\VBD\109660 re-resection\NN\1740 and\CC\1740 received\VBD\2210855 an\DT\6697703 intracavitary\JJ\1740 application\NN\947128 of\IN\1740 <e1>paclitaxel</e1>\NN\1740 and\CC\1740 carboplatin\NN\1740 cubic\JJ\1740 phases\NNS\15113229 in\IN\13603305 different\JJ\1740 dosages\NNS\13576355 .\.\1740
D016190_D005909 NONE Intracavitary\JJ\1740 chemotherapy\NN\661091 (\-LRB-\1740 <e1>paclitaxel/carboplatin</e1>\NN\1740 liquid\NN\14939900 crystalline\NN\1740 cubic\JJ\1740 phases\NNS\15113229 )\-RRB-\1740 for\IN\1740 recurrent\JJ\1740 <e2>glioblastoma</e2>\NN\14236743 --\:\1740 clinical\JJ\1740 observations\NNS\996969 .\.\1740
D016190_D005909 NONE For\IN\1740 human\JJ\1740 <e2>glioblastoma</e2>\NN\14236743 recurrences\NNS\7342049 ,\,\1740 the\DT\1740 feasibility\NN\5152150 ,\,\1740 safety\NN\13920835 ,\,\1740 and\CC\1740 short-term\JJ\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 surgical\JJ\1740 intracavitary\JJ\1740 application\NN\947128 of\IN\1740 paclitaxel\NN\1740 and\CC\1740 <e1>carboplatin</e1>\NN\1740 encapsulated\VBN\1587062 by\IN\1740 liquid\JJ\1740 crystalline\NN\1740 cubic\JJ\1740 phases\NNS\15113229 are\VBP\836236 examined\VBN\789138 in\IN\13603305 a\DT\13649268 pilot\NN\9826204 study\NN\635850 .\.\1740
D016190_D005909 NONE A\DT\13649268 total\NN\3553 of\IN\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 a\DT\13649268 recurrence\NN\7342049 of\IN\1740 a\DT\13649268 <e2>glioblastoma</e2>\NN\14236743 multiforme\JJ\1740 underwent\VBD\109660 re-resection\NN\1740 and\CC\1740 received\VBD\2210855 an\DT\6697703 intracavitary\JJ\1740 application\NN\947128 of\IN\1740 paclitaxel\NN\1740 and\CC\1740 <e1>carboplatin</e1>\NN\1740 cubic\JJ\1740 phases\NNS\15113229 in\IN\13603305 different\JJ\1740 dosages\NNS\13576355 .\.\1740
D017239_D001929 CID Six\CD\13741022 of\IN\1740 the\DT\1740 patients\NNS\9898892 received\VBD\2210855 more\JJR\1740 than\IN\1740 15\CD\13745420 mg\NN\13717155 <e1>paclitaxel</e1>\NN\1740 and\CC\1740 suffered\VBN\2110220 from\IN\1740 moderate\JJ\1740 to\TO\1740 severe\JJ\1740 <e2>brain\NN\5462674 edema</e2>\NN\14315192 ,\,\1740 while\IN\15122231 the\DT\1740 remaining\VBG\2604760 patients\NNS\9898892 received\VBD\2210855 only\RB\1740 a\DT\13649268 total\NN\3553 of\IN\1740 15\CD\13745420 mg\NN\13717155 paclitaxel\NN\1740 .\.\1740
D017239_D001929 CID Six\CD\13741022 of\IN\1740 the\DT\1740 patients\NNS\9898892 received\VBD\2210855 more\JJR\1740 than\IN\1740 15\CD\13745420 mg\NN\13717155 paclitaxel\NN\1740 and\CC\1740 suffered\VBN\2110220 from\IN\1740 moderate\JJ\1740 to\TO\1740 severe\JJ\1740 <e2>brain\NN\5462674 edema</e2>\NN\14315192 ,\,\1740 while\IN\15122231 the\DT\1740 remaining\VBG\2604760 patients\NNS\9898892 received\VBD\2210855 only\RB\1740 a\DT\13649268 total\NN\3553 of\IN\1740 15\CD\13745420 mg\NN\13717155 <e1>paclitaxel</e1>\NN\1740 .\.\1740
8841157
C081489_D006973 NONE <e1>Valsartan</e1>\NNP\2712393 ,\,\1740 a\DT\13649268 new\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 antagonist\NN\7846 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 :\:\1740 a\DT\13649268 comparative\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 against\IN\1740 amlodipine\NN\1740 .\.\1740
C081489_D006973 NONE METHODS\NNS\5616786 :\:\1740 One\CD\13741022 hundred\CD\13745420 sixty-eight\JJ\1740 adult\JJ\1740 outpatients\NNS\10405694 with\IN\1740 mild\NN\1740 to\TO\1740 moderate\JJ\1740 <e2>hypertension</e2>\NN\14057371 were\VBD\836236 randomly\RB\1740 allocated\VBN\2228698 in\IN\13603305 double-blind\JJ\1740 fashion\NN\4916342 and\CC\1740 equal\JJ\1740 number\NN\5107765 to\TO\1740 receive\VB\2210855 80\CD\13745420 mg\NN\13717155 <e1>valsartan</e1>\NN\2712393 or\CC\3541091 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 for\IN\1740 12\CD\13745420 weeks\NNS\15113229 .\.\1740
C081489_D006973 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 <e1>valsartan</e1>\NN\2712393 is\VBZ\836236 at\IN\14622893 least\JJS\1740 as\IN\14622893 effective\JJ\1740 as\IN\14622893 amlodipine\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 mild\NN\1740 to\TO\1740 moderate\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D000804_D006973 NONE Valsartan\NNP\2712393 ,\,\1740 a\DT\13649268 new\JJ\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 antagonist\NN\7846 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 :\:\1740 a\DT\13649268 comparative\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 against\IN\1740 amlodipine\NN\1740 .\.\1740
D017311_D006973 NONE Valsartan\NNP\2712393 ,\,\1740 a\DT\13649268 new\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 antagonist\NN\7846 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 :\:\1740 a\DT\13649268 comparative\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 against\IN\1740 <e1>amlodipine</e1>\NN\1740 .\.\1740
D017311_D006973 NONE METHODS\NNS\5616786 :\:\1740 One\CD\13741022 hundred\CD\13745420 sixty-eight\JJ\1740 adult\JJ\1740 outpatients\NNS\10405694 with\IN\1740 mild\NN\1740 to\TO\1740 moderate\JJ\1740 <e2>hypertension</e2>\NN\14057371 were\VBD\836236 randomly\RB\1740 allocated\VBN\2228698 in\IN\13603305 double-blind\JJ\1740 fashion\NN\4916342 and\CC\1740 equal\JJ\1740 number\NN\5107765 to\TO\1740 receive\VB\2210855 80\CD\13745420 mg\NN\13717155 valsartan\NN\2712393 or\CC\3541091 5\CD\13741022 mg\NN\13717155 <e1>amlodipine</e1>\NN\1740 for\IN\1740 12\CD\13745420 weeks\NNS\15113229 .\.\1740
D017311_D006973 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 valsartan\NN\2712393 is\VBZ\836236 at\IN\14622893 least\JJS\1740 as\IN\14622893 effective\JJ\1740 as\IN\14622893 <e1>amlodipine</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 mild\NN\1740 to\TO\1740 moderate\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D017311_D004487 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 drug-related\JJ\1740 dependent\JJ\1740 <e2>edema</e2>\NN\14315192 was\VBD\836236 somewhat\RB\1740 higher\JJR\1740 in\IN\13603305 the\DT\1740 <e1>amlodipine</e1>\NN\1740 group\NN\2137 ,\,\1740 particularly\RB\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 (\-LRB-\1740 2.4\CD\1740 %\NN\1740 for\IN\1740 80\CD\13745420 mg\NN\13717155 valsartan\NN\2712393 ;\:\1740 3.6\CD\1740 %\NN\1740 for\IN\1740 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 0\CD\13741022 %\NN\1740 for\IN\1740 valsartan\NN\2712393 plus\CC\4723816 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 14.3\CD\1740 %\NN\1740 for\IN\1740 10\CD\13745420 mg\NN\13717155 amlodipine\NN\1740 )\-RRB-\1740 .\.\1740
D017311_D004487 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 drug-related\JJ\1740 dependent\JJ\1740 <e2>edema</e2>\NN\14315192 was\VBD\836236 somewhat\RB\1740 higher\JJR\1740 in\IN\13603305 the\DT\1740 amlodipine\NN\1740 group\NN\2137 ,\,\1740 particularly\RB\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 (\-LRB-\1740 2.4\CD\1740 %\NN\1740 for\IN\1740 80\CD\13745420 mg\NN\13717155 valsartan\NN\2712393 ;\:\1740 3.6\CD\1740 %\NN\1740 for\IN\1740 5\CD\13741022 mg\NN\13717155 <e1>amlodipine</e1>\NN\1740 ;\:\1740 0\CD\13741022 %\NN\1740 for\IN\1740 valsartan\NN\2712393 plus\CC\4723816 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 14.3\CD\1740 %\NN\1740 for\IN\1740 10\CD\13745420 mg\NN\13717155 amlodipine\NN\1740 )\-RRB-\1740 .\.\1740
D017311_D004487 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 drug-related\JJ\1740 dependent\JJ\1740 <e2>edema</e2>\NN\14315192 was\VBD\836236 somewhat\RB\1740 higher\JJR\1740 in\IN\13603305 the\DT\1740 amlodipine\NN\1740 group\NN\2137 ,\,\1740 particularly\RB\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 (\-LRB-\1740 2.4\CD\1740 %\NN\1740 for\IN\1740 80\CD\13745420 mg\NN\13717155 valsartan\NN\2712393 ;\:\1740 3.6\CD\1740 %\NN\1740 for\IN\1740 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 0\CD\13741022 %\NN\1740 for\IN\1740 valsartan\NN\2712393 plus\CC\4723816 5\CD\13741022 mg\NN\13717155 <e1>amlodipine</e1>\NN\1740 ;\:\1740 14.3\CD\1740 %\NN\1740 for\IN\1740 10\CD\13745420 mg\NN\13717155 amlodipine\NN\1740 )\-RRB-\1740 .\.\1740
D017311_D004487 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 drug-related\JJ\1740 dependent\JJ\1740 <e2>edema</e2>\NN\14315192 was\VBD\836236 somewhat\RB\1740 higher\JJR\1740 in\IN\13603305 the\DT\1740 amlodipine\NN\1740 group\NN\2137 ,\,\1740 particularly\RB\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 (\-LRB-\1740 2.4\CD\1740 %\NN\1740 for\IN\1740 80\CD\13745420 mg\NN\13717155 valsartan\NN\2712393 ;\:\1740 3.6\CD\1740 %\NN\1740 for\IN\1740 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 0\CD\13741022 %\NN\1740 for\IN\1740 valsartan\NN\2712393 plus\CC\4723816 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 14.3\CD\1740 %\NN\1740 for\IN\1740 10\CD\13745420 mg\NN\13717155 <e1>amlodipine</e1>\NN\1740 )\-RRB-\1740 .\.\1740
C081489_D004487 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 drug-related\JJ\1740 dependent\JJ\1740 <e2>edema</e2>\NN\14315192 was\VBD\836236 somewhat\RB\1740 higher\JJR\1740 in\IN\13603305 the\DT\1740 amlodipine\NN\1740 group\NN\2137 ,\,\1740 particularly\RB\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 (\-LRB-\1740 2.4\CD\1740 %\NN\1740 for\IN\1740 80\CD\13745420 mg\NN\13717155 <e1>valsartan</e1>\NN\2712393 ;\:\1740 3.6\CD\1740 %\NN\1740 for\IN\1740 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 0\CD\13741022 %\NN\1740 for\IN\1740 valsartan\NN\2712393 plus\CC\4723816 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 14.3\CD\1740 %\NN\1740 for\IN\1740 10\CD\13745420 mg\NN\13717155 amlodipine\NN\1740 )\-RRB-\1740 .\.\1740
C081489_D004487 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 drug-related\JJ\1740 dependent\JJ\1740 <e2>edema</e2>\NN\14315192 was\VBD\836236 somewhat\RB\1740 higher\JJR\1740 in\IN\13603305 the\DT\1740 amlodipine\NN\1740 group\NN\2137 ,\,\1740 particularly\RB\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 (\-LRB-\1740 2.4\CD\1740 %\NN\1740 for\IN\1740 80\CD\13745420 mg\NN\13717155 valsartan\NN\2712393 ;\:\1740 3.6\CD\1740 %\NN\1740 for\IN\1740 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 0\CD\13741022 %\NN\1740 for\IN\1740 <e1>valsartan</e1>\NN\2712393 plus\CC\4723816 5\CD\13741022 mg\NN\13717155 amlodipine\NN\1740 ;\:\1740 14.3\CD\1740 %\NN\1740 for\IN\1740 10\CD\13745420 mg\NN\13717155 amlodipine\NN\1740 )\-RRB-\1740 .\.\1740
12180796
D009569_D009369 NONE Immunohistochemical\JJ\1740 study\NN\635850 on\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>tumor</e2>\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 in\IN\13603305 arteritis\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 fenoldopam\NN\1740 and\CC\1740 theophylline\NN\2905612 ,\,\1740 vasodilators\NNS\3198383 .\.\1740
D009569_D009369 NONE Arteritis\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 vasodilators\NNS\3198383 ,\,\1740 fenoldopam\NN\1740 and\CC\1740 theophylline\NN\2905612 ,\,\1740 was\VBD\836236 examined\VBN\789138 immunohistochemically\RB\1740 for\IN\1740 expressions\NNS\4679549 of\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 synthase\NN\1740 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>tumor</e2>\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 .\.\1740
D009569_D001167 NONE Immunohistochemical\JJ\1740 study\NN\635850 on\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 tumor\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 in\IN\13603305 <e2>arteritis</e2>\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 fenoldopam\NN\1740 and\CC\1740 theophylline\NN\2905612 ,\,\1740 vasodilators\NNS\3198383 .\.\1740
D009569_D001167 NONE <e2>Arteritis</e2>\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 vasodilators\NNS\3198383 ,\,\1740 fenoldopam\NN\1740 and\CC\1740 theophylline\NN\2905612 ,\,\1740 was\VBD\836236 examined\VBN\789138 immunohistochemically\RB\1740 for\IN\1740 expressions\NNS\4679549 of\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 synthase\NN\1740 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 tumor\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 .\.\1740
D018818_D009369 NONE Immunohistochemical\JJ\1740 study\NN\635850 on\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>tumor</e2>\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 in\IN\13603305 arteritis\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 <e1>fenoldopam</e1>\NN\1740 and\CC\1740 theophylline\NN\2905612 ,\,\1740 vasodilators\NNS\3198383 .\.\1740
D018818_D009369 NONE Arteritis\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 vasodilators\NNS\3198383 ,\,\1740 <e1>fenoldopam</e1>\NN\1740 and\CC\1740 theophylline\NN\2905612 ,\,\1740 was\VBD\836236 examined\VBN\789138 immunohistochemically\RB\1740 for\IN\1740 expressions\NNS\4679549 of\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>tumor</e2>\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 .\.\1740
D018818_D001167 CID Immunohistochemical\JJ\1740 study\NN\635850 on\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 tumor\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 in\IN\13603305 <e2>arteritis</e2>\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 <e1>fenoldopam</e1>\NN\1740 and\CC\1740 theophylline\NN\2905612 ,\,\1740 vasodilators\NNS\3198383 .\.\1740
D018818_D001167 CID <e2>Arteritis</e2>\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 vasodilators\NNS\3198383 ,\,\1740 <e1>fenoldopam</e1>\NN\1740 and\CC\1740 theophylline\NN\2905612 ,\,\1740 was\VBD\836236 examined\VBN\789138 immunohistochemically\RB\1740 for\IN\1740 expressions\NNS\4679549 of\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 tumor\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 .\.\1740
D013806_D009369 NONE Immunohistochemical\JJ\1740 study\NN\635850 on\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>tumor</e2>\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 in\IN\13603305 arteritis\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 fenoldopam\NN\1740 and\CC\1740 <e1>theophylline</e1>\NN\2905612 ,\,\1740 vasodilators\NNS\3198383 .\.\1740
D013806_D009369 NONE Arteritis\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 vasodilators\NNS\3198383 ,\,\1740 fenoldopam\NN\1740 and\CC\1740 <e1>theophylline</e1>\NN\2905612 ,\,\1740 was\VBD\836236 examined\VBN\789138 immunohistochemically\RB\1740 for\IN\1740 expressions\NNS\4679549 of\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>tumor</e2>\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 .\.\1740
D013806_D001167 CID Immunohistochemical\JJ\1740 study\NN\635850 on\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 tumor\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 in\IN\13603305 <e2>arteritis</e2>\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 fenoldopam\NN\1740 and\CC\1740 <e1>theophylline</e1>\NN\2905612 ,\,\1740 vasodilators\NNS\3198383 .\.\1740
D013806_D001167 CID <e2>Arteritis</e2>\NN\14336539 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 vasodilators\NNS\3198383 ,\,\1740 fenoldopam\NN\1740 and\CC\1740 <e1>theophylline</e1>\NN\2905612 ,\,\1740 was\VBD\836236 examined\VBN\789138 immunohistochemically\RB\1740 for\IN\1740 expressions\NNS\4679549 of\IN\1740 inducible\JJ\1740 type\NN\5839024 of\IN\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 (\-LRB-\1740 iNOS\NN\1740 )\-RRB-\1740 ,\,\1740 basic\JJ\1740 fibroblast\NN\5447757 growth\NN\13526110 factor\NN\7326557 (\-LRB-\1740 bFGF\NN\1740 )\-RRB-\1740 and\CC\1740 tumor\NN\14234074 growth\NN\13526110 factor-beta1\NN\1740 (\-LRB-\1740 TGF-beta1\NN\1740 )\-RRB-\1740 .\.\1740
9431903
D005996_D046628 NONE Effect\NN\34213 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 on\IN\1740 the\DT\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 evoked\VBN\1617192 by\IN\1740 prostigmine-morphine\JJ\1740 administration\NN\1133281 .\.\1740
D005996_D046628 NONE OBJECTIVE\NN\5980875 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 on\IN\1740 the\DT\1740 prostigmine-morphine-induced\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 nine\CD\13741022 female\JJ\1740 patients\NNS\9898892 with\IN\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia\NN\14084880 .\.\1740
D005996_D046628 NONE OBJECTIVE\NN\5980875 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 on\IN\1740 the\DT\1740 prostigmine-morphine-induced\JJ\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm\NN\14299637 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 nine\CD\13741022 female\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia</e2>\NN\14084880 .\.\1740
D005996_D046628 NONE CONCLUSION\NN\5837957 :\:\1740 These\DT\1740 results\NNS\34213 provide\VBP\2199590 the\DT\1740 first\JJ\1740 evidence\NN\5816287 of\IN\1740 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 on\IN\1740 the\DT\1740 morphine-induced\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 in\IN\13603305 humans\NNS\31264 .\.\1740
D005996_D046628 NONE Since\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 is\VBZ\836236 able\JJ\1740 to\TO\1740 overcome\VB\1101913 even\RB\1740 the\DT\1740 drastic\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 it\PRP\6125041 might\MD\5029706 be\VB\836236 of\IN\1740 relevance\NN\13791389 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia</e2>\NN\14084880 .\.\1740
D005996_D013035 NONE Effect\NN\34213 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 on\IN\1740 the\DT\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 evoked\VBN\1617192 by\IN\1740 prostigmine-morphine\JJ\1740 administration\NN\1133281 .\.\1740
D005996_D013035 NONE OBJECTIVE\NN\5980875 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 on\IN\1740 the\DT\1740 prostigmine-morphine-induced\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 nine\CD\13741022 female\JJ\1740 patients\NNS\9898892 with\IN\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia\NN\14084880 .\.\1740
D005996_D013035 NONE CONCLUSION\NN\5837957 :\:\1740 These\DT\1740 results\NNS\34213 provide\VBP\2199590 the\DT\1740 first\JJ\1740 evidence\NN\5816287 of\IN\1740 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 on\IN\1740 the\DT\1740 morphine-induced\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 in\IN\13603305 humans\NNS\31264 .\.\1740
D009388_D046628 CID Effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 evoked\VBN\1617192 by\IN\1740 <e1>prostigmine-morphine</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D009388_D046628 CID OBJECTIVE\NN\5980875 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 the\DT\1740 effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e1>prostigmine-morphine-induced</e1>\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 nine\CD\13741022 female\JJ\1740 patients\NNS\9898892 with\IN\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia\NN\14084880 .\.\1740
D009388_D046628 CID OBJECTIVE\NN\5980875 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 the\DT\1740 effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e1>prostigmine-morphine-induced</e1>\JJ\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm\NN\14299637 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 nine\CD\13741022 female\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia</e2>\NN\14084880 .\.\1740
D009388_D046628 CID METHOD\NNP\5616786 :\:\1740 <e2>Sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>prostigmine-morphine</e1>\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 prostigmine\NN\1740 intramuscularly\RB\1740 and\CC\1740 10\CD\13745420 mg\NN\13717155 morphine\NN\2707683 subcutaneously\RB\1740 )\-RRB-\1740 and\CC\1740 visualized\VBN\1636397 by\IN\1740 quantitative\JJ\1740 hepatobiliary\JJ\1740 scintigraphy\NN\1740 .\.\1740
D009388_D046628 CID METHOD\NNP\5616786 :\:\1740 <e2>Sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 prostigmine-morphine\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 <e1>prostigmine</e1>\NN\1740 intramuscularly\RB\1740 and\CC\1740 10\CD\13745420 mg\NN\13717155 morphine\NN\2707683 subcutaneously\RB\1740 )\-RRB-\1740 and\CC\1740 visualized\VBN\1636397 by\IN\1740 quantitative\JJ\1740 hepatobiliary\JJ\1740 scintigraphy\NN\1740 .\.\1740
D009388_D013035 CID Effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 evoked\VBN\1617192 by\IN\1740 <e1>prostigmine-morphine</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D009388_D013035 CID OBJECTIVE\NN\5980875 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 the\DT\1740 effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e1>prostigmine-morphine-induced</e1>\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 nine\CD\13741022 female\JJ\1740 patients\NNS\9898892 with\IN\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia\NN\14084880 .\.\1740
D009388_D013035 CID METHOD\NNP\5616786 :\:\1740 <e2>Sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>prostigmine-morphine</e1>\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 prostigmine\NN\1740 intramuscularly\RB\1740 and\CC\1740 10\CD\13745420 mg\NN\13717155 morphine\NN\2707683 subcutaneously\RB\1740 )\-RRB-\1740 and\CC\1740 visualized\VBN\1636397 by\IN\1740 quantitative\JJ\1740 hepatobiliary\JJ\1740 scintigraphy\NN\1740 .\.\1740
D009388_D013035 CID METHOD\NNP\5616786 :\:\1740 <e2>Sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 prostigmine-morphine\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 <e1>prostigmine</e1>\NN\1740 intramuscularly\RB\1740 and\CC\1740 10\CD\13745420 mg\NN\13717155 morphine\NN\2707683 subcutaneously\RB\1740 )\-RRB-\1740 and\CC\1740 visualized\VBN\1636397 by\IN\1740 quantitative\JJ\1740 hepatobiliary\JJ\1740 scintigraphy\NN\1740 .\.\1740
D009388_D013035 CID RESULTS\NNS\34213 :\:\1740 <e1>Prostigmine-morphine</e1>\JJ\1740 provocation\NN\1221611 caused\VBD\1617192 significant\JJ\1740 increases\NNS\13576355 in\IN\13603305 the\DT\1740 time\NN\7308889 to\TO\1740 peak\VB\2020590 activity\NN\30358 (\-LRB-\1740 Tmax\NN\1740 )\-RRB-\1740 over\IN\5867413 the\DT\1740 hepatic\JJ\1740 hilum\NN\5223370 (\-LRB-\1740 HH\NN\1740 :\:\1740 34.33\CD\1740 +/-\CC\1740 5.05\CD\1740 vs.\CC\1740 22.77\CD\1740 +/-\CC\1740 3.26\CD\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 common\JJ\1740 bile\NN\5405946 duct\NN\5248181 (\-LRB-\1740 CBD\NN\1740 :\:\1740 60.44\CD\1740 +/-\CC\1740 5.99\CD\1740 vs.\CC\1740 40.0\CD\1740 +/-\CC\1740 2.88\CD\1740 )\-RRB-\1740 and\CC\1740 in\IN\13603305 the\DT\1740 half-time\NN\1740 of\IN\1740 excretion\NN\13466586 (\-LRB-\1740 T1/2\NN\1740 )\-RRB-\1740 over\IN\5867413 the\DT\1740 liver\NN\5298729 parenchyma\NN\5267548 (\-LRB-\1740 LP\NN\3924069 :\:\1740 120.04\CD\1740 +/-\CC\1740 16.01\CD\1740 vs.\CC\1740 27.37\CD\1740 +/-\CC\1740 2.19\CD\1740 )\-RRB-\1740 ,\,\1740 HH\NN\1740 (\-LRB-\1740 117.61\CD\1740 +/-\CC\1740 14.71\CD\1740 vs.\CC\1740 31.85\CD\1740 +/-\CC\1740 3.99\CD\1740 )\-RRB-\1740 and\CC\1740 CBD\NN\1740 (\-LRB-\1740 158.11\CD\1740 +/-\CC\1740 9.18\CD\1740 vs.\CC\1740 40.1\CD\1740 +/-\CC\1740 6.24\CD\1740 )\-RRB-\1740 ,\,\1740 indicating\VBG\952524 a\DT\13649268 complete\JJ\1740 <e2>spasm</e2>\NN\14299637 at\IN\14622893 the\DT\1740 level\NN\4916342 of\IN\1740 the\DT\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 .\.\1740
D009020_D046628 CID Effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 evoked\VBN\1617192 by\IN\1740 <e1>prostigmine-morphine</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D009020_D046628 CID OBJECTIVE\NN\5980875 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 the\DT\1740 effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e1>prostigmine-morphine-induced</e1>\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 nine\CD\13741022 female\JJ\1740 patients\NNS\9898892 with\IN\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia\NN\14084880 .\.\1740
D009020_D046628 CID OBJECTIVE\NN\5980875 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 the\DT\1740 effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e1>prostigmine-morphine-induced</e1>\JJ\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm\NN\14299637 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 nine\CD\13741022 female\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia</e2>\NN\14084880 .\.\1740
D009020_D046628 CID METHOD\NNP\5616786 :\:\1740 <e2>Sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>prostigmine-morphine</e1>\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 prostigmine\NN\1740 intramuscularly\RB\1740 and\CC\1740 10\CD\13745420 mg\NN\13717155 morphine\NN\2707683 subcutaneously\RB\1740 )\-RRB-\1740 and\CC\1740 visualized\VBN\1636397 by\IN\1740 quantitative\JJ\1740 hepatobiliary\JJ\1740 scintigraphy\NN\1740 .\.\1740
D009020_D046628 CID METHOD\NNP\5616786 :\:\1740 <e2>Sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 prostigmine-morphine\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 prostigmine\NN\1740 intramuscularly\RB\1740 and\CC\1740 10\CD\13745420 mg\NN\13717155 <e1>morphine</e1>\NN\2707683 subcutaneously\RB\1740 )\-RRB-\1740 and\CC\1740 visualized\VBN\1636397 by\IN\1740 quantitative\JJ\1740 hepatobiliary\JJ\1740 scintigraphy\NN\1740 .\.\1740
D009020_D046628 CID CONCLUSION\NN\5837957 :\:\1740 These\DT\1740 results\NNS\34213 provide\VBP\2199590 the\DT\1740 first\JJ\1740 evidence\NN\5816287 of\IN\1740 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 in\IN\13603305 humans\NNS\31264 .\.\1740
D009020_D046628 CID Since\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 is\VBZ\836236 able\JJ\1740 to\TO\1740 overcome\VB\1101913 even\RB\1740 the\DT\1740 drastic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>morphine</e1>\NN\2707683 ,\,\1740 it\PRP\6125041 might\MD\5029706 be\VB\836236 of\IN\1740 relevance\NN\13791389 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia</e2>\NN\14084880 .\.\1740
D009020_D013035 CID Effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 evoked\VBN\1617192 by\IN\1740 <e1>prostigmine-morphine</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D009020_D013035 CID OBJECTIVE\NN\5980875 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 the\DT\1740 effect\NN\34213 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e1>prostigmine-morphine-induced</e1>\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 nine\CD\13741022 female\JJ\1740 patients\NNS\9898892 with\IN\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 dyskinesia\NN\14084880 .\.\1740
D009020_D013035 CID METHOD\NNP\5616786 :\:\1740 <e2>Sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>prostigmine-morphine</e1>\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 prostigmine\NN\1740 intramuscularly\RB\1740 and\CC\1740 10\CD\13745420 mg\NN\13717155 morphine\NN\2707683 subcutaneously\RB\1740 )\-RRB-\1740 and\CC\1740 visualized\VBN\1636397 by\IN\1740 quantitative\JJ\1740 hepatobiliary\JJ\1740 scintigraphy\NN\1740 .\.\1740
D009020_D013035 CID METHOD\NNP\5616786 :\:\1740 <e2>Sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 prostigmine-morphine\JJ\1740 administration\NN\1133281 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 prostigmine\NN\1740 intramuscularly\RB\1740 and\CC\1740 10\CD\13745420 mg\NN\13717155 <e1>morphine</e1>\NN\2707683 subcutaneously\RB\1740 )\-RRB-\1740 and\CC\1740 visualized\VBN\1636397 by\IN\1740 quantitative\JJ\1740 hepatobiliary\JJ\1740 scintigraphy\NN\1740 .\.\1740
D009020_D013035 CID RESULTS\NNS\34213 :\:\1740 <e1>Prostigmine-morphine</e1>\JJ\1740 provocation\NN\1221611 caused\VBD\1617192 significant\JJ\1740 increases\NNS\13576355 in\IN\13603305 the\DT\1740 time\NN\7308889 to\TO\1740 peak\VB\2020590 activity\NN\30358 (\-LRB-\1740 Tmax\NN\1740 )\-RRB-\1740 over\IN\5867413 the\DT\1740 hepatic\JJ\1740 hilum\NN\5223370 (\-LRB-\1740 HH\NN\1740 :\:\1740 34.33\CD\1740 +/-\CC\1740 5.05\CD\1740 vs.\CC\1740 22.77\CD\1740 +/-\CC\1740 3.26\CD\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 common\JJ\1740 bile\NN\5405946 duct\NN\5248181 (\-LRB-\1740 CBD\NN\1740 :\:\1740 60.44\CD\1740 +/-\CC\1740 5.99\CD\1740 vs.\CC\1740 40.0\CD\1740 +/-\CC\1740 2.88\CD\1740 )\-RRB-\1740 and\CC\1740 in\IN\13603305 the\DT\1740 half-time\NN\1740 of\IN\1740 excretion\NN\13466586 (\-LRB-\1740 T1/2\NN\1740 )\-RRB-\1740 over\IN\5867413 the\DT\1740 liver\NN\5298729 parenchyma\NN\5267548 (\-LRB-\1740 LP\NN\3924069 :\:\1740 120.04\CD\1740 +/-\CC\1740 16.01\CD\1740 vs.\CC\1740 27.37\CD\1740 +/-\CC\1740 2.19\CD\1740 )\-RRB-\1740 ,\,\1740 HH\NN\1740 (\-LRB-\1740 117.61\CD\1740 +/-\CC\1740 14.71\CD\1740 vs.\CC\1740 31.85\CD\1740 +/-\CC\1740 3.99\CD\1740 )\-RRB-\1740 and\CC\1740 CBD\NN\1740 (\-LRB-\1740 158.11\CD\1740 +/-\CC\1740 9.18\CD\1740 vs.\CC\1740 40.1\CD\1740 +/-\CC\1740 6.24\CD\1740 )\-RRB-\1740 ,\,\1740 indicating\VBG\952524 a\DT\13649268 complete\JJ\1740 <e2>spasm</e2>\NN\14299637 at\IN\14622893 the\DT\1740 level\NN\4916342 of\IN\1740 the\DT\1740 sphincter\NN\5289297 of\IN\1740 Oddi\NNP\1740 .\.\1740
D009020_D013035 CID CONCLUSION\NN\5837957 :\:\1740 These\DT\1740 results\NNS\34213 provide\VBP\2199590 the\DT\1740 first\JJ\1740 evidence\NN\5816287 of\IN\1740 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 on\IN\1740 the\DT\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>sphincter\NN\5289297 of\IN\1740 Oddi\NN\1740 spasm</e2>\NN\14299637 in\IN\13603305 humans\NNS\31264 .\.\1740
3015327
D007538_D009422 CID Remodelling\NN\1740 of\IN\1740 nerve\NN\5475681 structure\NN\21939 in\IN\13603305 experimental\JJ\1740 <e1>isoniazid</e1>\NNS\2716205 <e2>neuropathy</e2>\JJ\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D007538_D009422 CID The\DT\1740 <e2>neuropathy</e2>\NN\14204950 caused\VBN\1617192 by\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>isoniazid</e1>\NNS\2716205 in\IN\13603305 rats\NNS\2329401 was\VBD\836236 studied\VBN\630380 with\IN\1740 a\DT\13649268 computer-assisted\JJ\1740 morphometric\JJ\1740 method\NN\5616786 .\.\1740
9201797
D002354_D002375 NONE The\DT\1740 attenuating\NN\1740 effect\NN\34213 of\IN\1740 <e1>carteolol\NN\1740 hydrochloride</e1>\NN\14817592 ,\,\1740 a\DT\13649268 beta-adrenoceptor\NN\5608868 antagonist\NN\7846 ,\,\1740 on\IN\1740 neuroleptic-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002354_D002375 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>carteolol</e1>\NN\1740 ,\,\1740 a\DT\13649268 beta-adrenoceptor\NN\5608868 antagonist\NN\7846 ,\,\1740 on\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 behaviorally\RB\1740 studied\VBN\630380 and\CC\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 propranolol\NN\1740 and\CC\1740 biperiden\JJ\1740 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
D002354_D002375 NONE <e1>Carteolol</e1>\NNP\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 propranolol\NN\1740 and\CC\1740 biperiden\JJ\1740 ,\,\1740 inhibited\VBD\2510337 the\DT\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D002354_D002375 NONE These\DT\1740 results\NNS\34213 strongly\RB\1740 suggest\VBP\1010118 that\IN\1740 <e1>carteolol</e1>\NN\1740 improves\VBZ\126264 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 via\IN\1740 its\PRP$\6125041 beta-adrenoceptor\NN\5608868 antagonistic\JJ\1740 activity\NN\30358 and\CC\1740 is\VBZ\836236 expected\VBN\670261 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 akathisia\NN\1740 without\IN\1740 attenuating\VBG\224901 neuroleptic-induced\JJ\1740 antipsychotic\JJ\1740 effects\NNS\13245626 due\JJ\1740 to\TO\1740 its\PRP$\6125041 postsynaptic\JJ\1740 dopamine\NN\14807737 receptor\NN\5225602 antagonistic\JJ\1740 activity\NN\30358 .\.\1740
D006220_D002375 CID Therefore\RB\1740 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 carteolol\NN\1740 ,\,\1740 a\DT\13649268 beta-adrenoceptor\NN\5608868 antagonist\NN\7846 ,\,\1740 on\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 behaviorally\RB\1740 studied\VBN\630380 and\CC\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 propranolol\NN\1740 and\CC\1740 biperiden\JJ\1740 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
D006220_D002375 CID Carteolol\NNP\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 propranolol\NN\1740 and\CC\1740 biperiden\JJ\1740 ,\,\1740 inhibited\VBD\2510337 the\DT\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D006220_D002375 CID These\DT\1740 results\NNS\34213 strongly\RB\1740 suggest\VBP\1010118 that\IN\1740 carteolol\NN\1740 improves\VBZ\126264 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 via\IN\1740 its\PRP$\6125041 beta-adrenoceptor\NN\5608868 antagonistic\JJ\1740 activity\NN\30358 and\CC\1740 is\VBZ\836236 expected\VBN\670261 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 akathisia\NN\1740 without\IN\1740 attenuating\VBG\224901 neuroleptic-induced\JJ\1740 antipsychotic\JJ\1740 effects\NNS\13245626 due\JJ\1740 to\TO\1740 its\PRP$\6125041 postsynaptic\JJ\1740 dopamine\NN\14807737 receptor\NN\5225602 antagonistic\JJ\1740 activity\NN\30358 .\.\1740
D011433_D002375 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 carteolol\NN\1740 ,\,\1740 a\DT\13649268 beta-adrenoceptor\NN\5608868 antagonist\NN\7846 ,\,\1740 on\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 behaviorally\RB\1740 studied\VBN\630380 and\CC\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 <e1>propranolol</e1>\NN\1740 and\CC\1740 biperiden\JJ\1740 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
D011433_D002375 NONE Carteolol\NNP\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 <e1>propranolol</e1>\NN\1740 and\CC\1740 biperiden\JJ\1740 ,\,\1740 inhibited\VBD\2510337 the\DT\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D001712_D002375 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 carteolol\NN\1740 ,\,\1740 a\DT\13649268 beta-adrenoceptor\NN\5608868 antagonist\NN\7846 ,\,\1740 on\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 were\VBD\836236 behaviorally\RB\1740 studied\VBN\630380 and\CC\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 propranolol\NN\1740 and\CC\1740 <e1>biperiden</e1>\JJ\1740 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 .\.\1740
D001712_D002375 NONE Carteolol\NNP\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 propranolol\NN\1740 and\CC\1740 <e1>biperiden</e1>\JJ\1740 ,\,\1740 inhibited\VBD\2510337 the\DT\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D002354_D009069 NONE <e1>Carteolol</e1>\NNP\1740 did\VBD\1640855 not\RB\1740 evoke\VB\1617192 postsynaptic\JJ\1740 dopamine\NN\14807737 receptor-stimulating\JJ\1740 behavioral\JJ\1740 signs\NNS\6643763 such\JJ\1740 as\IN\14622893 stereotypy\NN\1740 and\CC\1740 <e2>hyperlocomotion</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004298_D009069 NONE Carteolol\NNP\1740 did\VBD\1640855 not\RB\1740 evoke\VB\1617192 postsynaptic\JJ\1740 <e1>dopamine</e1>\NN\14807737 receptor-stimulating\JJ\1740 behavioral\JJ\1740 signs\NNS\6643763 such\JJ\1740 as\IN\14622893 stereotypy\NN\1740 and\CC\1740 <e2>hyperlocomotion</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002354_D017109 NONE These\DT\1740 results\NNS\34213 strongly\RB\1740 suggest\VBP\1010118 that\IN\1740 <e1>carteolol</e1>\NN\1740 improves\VBZ\126264 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 via\IN\1740 its\PRP$\6125041 beta-adrenoceptor\NN\5608868 antagonistic\JJ\1740 activity\NN\30358 and\CC\1740 is\VBZ\836236 expected\VBN\670261 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>akathisia</e2>\NN\1740 without\IN\1740 attenuating\VBG\224901 neuroleptic-induced\JJ\1740 antipsychotic\JJ\1740 effects\NNS\13245626 due\JJ\1740 to\TO\1740 its\PRP$\6125041 postsynaptic\JJ\1740 dopamine\NN\14807737 receptor\NN\5225602 antagonistic\JJ\1740 activity\NN\30358 .\.\1740
D006220_D017109 NONE These\DT\1740 results\NNS\34213 strongly\RB\1740 suggest\VBP\1010118 that\IN\1740 carteolol\NN\1740 improves\VBZ\126264 <e1>haloperidol-induced</e1>\JJ\1740 catalepsy\NN\14023236 via\IN\1740 its\PRP$\6125041 beta-adrenoceptor\NN\5608868 antagonistic\JJ\1740 activity\NN\30358 and\CC\1740 is\VBZ\836236 expected\VBN\670261 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>akathisia</e2>\NN\1740 without\IN\1740 attenuating\VBG\224901 neuroleptic-induced\JJ\1740 antipsychotic\JJ\1740 effects\NNS\13245626 due\JJ\1740 to\TO\1740 its\PRP$\6125041 postsynaptic\JJ\1740 dopamine\NN\14807737 receptor\NN\5225602 antagonistic\JJ\1740 activity\NN\30358 .\.\1740
D004298_D002375 NONE These\DT\1740 results\NNS\34213 strongly\RB\1740 suggest\VBP\1010118 that\IN\1740 carteolol\NN\1740 improves\VBZ\126264 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 via\IN\1740 its\PRP$\6125041 beta-adrenoceptor\NN\5608868 antagonistic\JJ\1740 activity\NN\30358 and\CC\1740 is\VBZ\836236 expected\VBN\670261 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 akathisia\NN\1740 without\IN\1740 attenuating\VBG\224901 neuroleptic-induced\JJ\1740 antipsychotic\JJ\1740 effects\NNS\13245626 due\JJ\1740 to\TO\1740 its\PRP$\6125041 postsynaptic\JJ\1740 <e1>dopamine</e1>\NN\14807737 receptor\NN\5225602 antagonistic\JJ\1740 activity\NN\30358 .\.\1740
D004298_D017109 NONE These\DT\1740 results\NNS\34213 strongly\RB\1740 suggest\VBP\1010118 that\IN\1740 carteolol\NN\1740 improves\VBZ\126264 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 via\IN\1740 its\PRP$\6125041 beta-adrenoceptor\NN\5608868 antagonistic\JJ\1740 activity\NN\30358 and\CC\1740 is\VBZ\836236 expected\VBN\670261 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>akathisia</e2>\NN\1740 without\IN\1740 attenuating\VBG\224901 neuroleptic-induced\JJ\1740 antipsychotic\JJ\1740 effects\NNS\13245626 due\JJ\1740 to\TO\1740 its\PRP$\6125041 postsynaptic\JJ\1740 <e1>dopamine</e1>\NN\14807737 receptor\NN\5225602 antagonistic\JJ\1740 activity\NN\30358 .\.\1740
15042318
D004317_C535648 NONE The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 unusual\JJ\1740 association\NN\8008335 between\IN\1740 diffuse\JJ\1740 B-cell\NN\1740 <e2>gastric\JJ\1740 lymphoma</e2>\NN\14239918 and\CC\1740 myotonic\JJ\1740 dystrophy\NN\14151139 ,\,\1740 the\DT\1740 most\RBS\1740 common\JJ\1740 form\NN\6286395 of\IN\1740 adult\JJ\1740 muscular\JJ\1740 dystrophy\NN\14151139 ,\,\1740 and\CC\1740 sudden\JJ\1740 atrial\JJ\1740 fibrillation\NN\14361664 following\VBG\1835496 one\CD\13741022 cycle\NN\15269513 of\IN\1740 <e1>doxorubicin-based</e1>\JJ\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 same\JJ\1740 patient\NN\9898892 .\.\1740
D004317_D009223 NONE The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 unusual\JJ\1740 association\NN\8008335 between\IN\1740 diffuse\JJ\1740 B-cell\NN\1740 gastric\JJ\1740 lymphoma\NN\14239918 and\CC\1740 <e2>myotonic\JJ\1740 dystrophy</e2>\NN\14151139 ,\,\1740 the\DT\1740 most\RBS\1740 common\JJ\1740 form\NN\6286395 of\IN\1740 adult\JJ\1740 muscular\JJ\1740 dystrophy\NN\14151139 ,\,\1740 and\CC\1740 sudden\JJ\1740 atrial\JJ\1740 fibrillation\NN\14361664 following\VBG\1835496 one\CD\13741022 cycle\NN\15269513 of\IN\1740 <e1>doxorubicin-based</e1>\JJ\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 same\JJ\1740 patient\NN\9898892 .\.\1740
D004317_D009136 NONE The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 unusual\JJ\1740 association\NN\8008335 between\IN\1740 diffuse\JJ\1740 B-cell\NN\1740 gastric\JJ\1740 lymphoma\NN\14239918 and\CC\1740 myotonic\JJ\1740 dystrophy\NN\14151139 ,\,\1740 the\DT\1740 most\RBS\1740 common\JJ\1740 form\NN\6286395 of\IN\1740 adult\JJ\1740 <e2>muscular\JJ\1740 dystrophy</e2>\NN\14151139 ,\,\1740 and\CC\1740 sudden\JJ\1740 atrial\JJ\1740 fibrillation\NN\14361664 following\VBG\1835496 one\CD\13741022 cycle\NN\15269513 of\IN\1740 <e1>doxorubicin-based</e1>\JJ\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 same\JJ\1740 patient\NN\9898892 .\.\1740
D004317_D001281 CID The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 unusual\JJ\1740 association\NN\8008335 between\IN\1740 diffuse\JJ\1740 B-cell\NN\1740 gastric\JJ\1740 lymphoma\NN\14239918 and\CC\1740 myotonic\JJ\1740 dystrophy\NN\14151139 ,\,\1740 the\DT\1740 most\RBS\1740 common\JJ\1740 form\NN\6286395 of\IN\1740 adult\JJ\1740 muscular\JJ\1740 dystrophy\NN\14151139 ,\,\1740 and\CC\1740 sudden\JJ\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 following\VBG\1835496 one\CD\13741022 cycle\NN\15269513 of\IN\1740 <e1>doxorubicin-based</e1>\JJ\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 same\JJ\1740 patient\NN\9898892 .\.\1740
8492347
D005665_D013746 CID <e2>Tetany</e2>\NN\14304060 and\CC\1740 rhabdomyolysis\NN\1740 due\IN\5174653 to\IN\1740 surreptitious\JJ\1740 <e1>furosemide</e1>\NN\3214670 --\:\1740 importance\NN\5138488 of\IN\1740 magnesium\NN\14625458 supplementation\NN\5108947 .\.\1740
D005665_D012206 CID Tetany\NN\14304060 and\CC\1740 <e2>rhabdomyolysis</e2>\NN\1740 due\IN\5174653 to\IN\1740 surreptitious\JJ\1740 <e1>furosemide</e1>\NN\3214670 --\:\1740 importance\NN\5138488 of\IN\1740 magnesium\NN\14625458 supplementation\NN\5108947 .\.\1740
D008274_D013746 NONE <e2>Tetany</e2>\NN\14304060 and\CC\1740 rhabdomyolysis\NN\1740 due\IN\5174653 to\IN\1740 surreptitious\JJ\1740 furosemide\NN\3214670 --\:\1740 importance\NN\5138488 of\IN\1740 <e1>magnesium</e1>\NN\14625458 supplementation\NN\5108947 .\.\1740
D008274_D012206 NONE Tetany\NN\14304060 and\CC\1740 <e2>rhabdomyolysis</e2>\NN\1740 due\IN\5174653 to\IN\1740 surreptitious\JJ\1740 furosemide\NN\3214670 --\:\1740 importance\NN\5138488 of\IN\1740 <e1>magnesium</e1>\NN\14625458 supplementation\NN\5108947 .\.\1740
D011188_D007008 NONE While\IN\15122231 severe\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 may\MD\15209706 cause\VB\1617192 muscle\NN\5289601 weakness\NN\14462666 ,\,\1740 severe\JJ\1740 hypomagnesemia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 muscle\NN\5289601 spasms\NNS\14299637 and\CC\1740 tetany\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 <e1>potassium</e1>\NN\14625458 and\CC\1740 calcium\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D011188_D018908 NONE While\IN\15122231 severe\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 cause\VB\1617192 <e2>muscle\NN\5289601 weakness</e2>\NN\14462666 ,\,\1740 severe\JJ\1740 hypomagnesemia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 muscle\NN\5289601 spasms\NNS\14299637 and\CC\1740 tetany\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 <e1>potassium</e1>\NN\14625458 and\CC\1740 calcium\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D011188_C537153 NONE While\IN\15122231 severe\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 cause\VB\1617192 muscle\NN\5289601 weakness\NN\14462666 ,\,\1740 severe\JJ\1740 <e2>hypomagnesemia</e2>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 muscle\NN\5289601 spasms\NNS\14299637 and\CC\1740 tetany\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 <e1>potassium</e1>\NN\14625458 and\CC\1740 calcium\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D011188_D013035 NONE While\IN\15122231 severe\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 cause\VB\1617192 muscle\NN\5289601 weakness\NN\14462666 ,\,\1740 severe\JJ\1740 hypomagnesemia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e2>muscle\NN\5289601 spasms</e2>\NNS\14299637 and\CC\1740 tetany\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 <e1>potassium</e1>\NN\14625458 and\CC\1740 calcium\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D011188_D013746 NONE While\IN\15122231 severe\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 cause\VB\1617192 muscle\NN\5289601 weakness\NN\14462666 ,\,\1740 severe\JJ\1740 hypomagnesemia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 muscle\NN\5289601 spasms\NNS\14299637 and\CC\1740 <e2>tetany</e2>\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 <e1>potassium</e1>\NN\14625458 and\CC\1740 calcium\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D002118_D007008 NONE While\IN\15122231 severe\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 may\MD\15209706 cause\VB\1617192 muscle\NN\5289601 weakness\NN\14462666 ,\,\1740 severe\JJ\1740 hypomagnesemia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 muscle\NN\5289601 spasms\NNS\14299637 and\CC\1740 tetany\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 potassium\NN\14625458 and\CC\1740 <e1>calcium</e1>\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D002118_D018908 NONE While\IN\15122231 severe\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 cause\VB\1617192 <e2>muscle\NN\5289601 weakness</e2>\NN\14462666 ,\,\1740 severe\JJ\1740 hypomagnesemia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 muscle\NN\5289601 spasms\NNS\14299637 and\CC\1740 tetany\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 potassium\NN\14625458 and\CC\1740 <e1>calcium</e1>\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D002118_C537153 NONE While\IN\15122231 severe\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 cause\VB\1617192 muscle\NN\5289601 weakness\NN\14462666 ,\,\1740 severe\JJ\1740 <e2>hypomagnesemia</e2>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 muscle\NN\5289601 spasms\NNS\14299637 and\CC\1740 tetany\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 potassium\NN\14625458 and\CC\1740 <e1>calcium</e1>\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D002118_D013035 NONE While\IN\15122231 severe\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 cause\VB\1617192 muscle\NN\5289601 weakness\NN\14462666 ,\,\1740 severe\JJ\1740 hypomagnesemia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e2>muscle\NN\5289601 spasms</e2>\NNS\14299637 and\CC\1740 tetany\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 potassium\NN\14625458 and\CC\1740 <e1>calcium</e1>\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D002118_D013746 NONE While\IN\15122231 severe\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 cause\VB\1617192 muscle\NN\5289601 weakness\NN\14462666 ,\,\1740 severe\JJ\1740 hypomagnesemia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 muscle\NN\5289601 spasms\NNS\14299637 and\CC\1740 <e2>tetany</e2>\NN\14304060 which\WDT\1740 can\MD\3094503 not\RB\1740 be\VB\836236 corrected\VBN\138508 by\IN\1740 potassium\NN\14625458 and\CC\1740 <e1>calcium</e1>\NN\14625458 supplementation\NN\5108947 alone\RB\1740 (\-LRB-\1740 1,2\CD\1740 )\-RRB-\1740 .\.\1740
D008274_D007008 NONE Symptomatic\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 such\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 3\CD\13741022 -\SYM\1740 7\CD\13741022 )\-RRB-\1740 and\CC\1740 in\IN\13603305 one\CD\13741022 case\NN\7283608 hypocalcemia\NN\14299637 was\VBD\836236 observed\VBN\2163746 (\-LRB-\1740 8)\CD\1740 ,\,\1740 but\CC\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>magnesium</e1>\NN\14625458 depletion\NN\351638 were\VBD\836236 not\RB\1740 noted\VBN\1009240 in\IN\13603305 these\DT\1740 patients\NNS\9898892 .\.\1740
D008274_D006996 NONE Symptomatic\JJ\1740 hypokalemia\NN\14299637 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 such\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 3\CD\13741022 -\SYM\1740 7\CD\13741022 )\-RRB-\1740 and\CC\1740 in\IN\13603305 one\CD\13741022 case\NN\7283608 <e2>hypocalcemia</e2>\NN\14299637 was\VBD\836236 observed\VBN\2163746 (\-LRB-\1740 8)\CD\1740 ,\,\1740 but\CC\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>magnesium</e1>\NN\14625458 depletion\NN\351638 were\VBD\836236 not\RB\1740 noted\VBN\1009240 in\IN\13603305 these\DT\1740 patients\NNS\9898892 .\.\1740
10414674
D007660_D013345 NONE Patients\NNS\9898892 with\IN\1740 <e2>aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 <e1>ketoprofen</e1>\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 SAH\NN\1740 .\.\1740
D007660_D013345 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 <e1>ketoprofen</e1>\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 SAH\NN\1740 .\.\1740
D007660_D013345 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 <e1>ketoprofen</e1>\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 <e2>SAH</e2>\NN\1740 .\.\1740
D007660_D013345 NONE Patients\NNS\9898892 with\IN\1740 <e2>aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 <e1>ketoprofen</e1>\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 SAH\NN\1740 .\.\1740
D007660_D013345 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 <e1>ketoprofen</e1>\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 SAH\NN\1740 .\.\1740
D007660_D013345 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 <e1>ketoprofen</e1>\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 <e2>SAH</e2>\NN\1740 .\.\1740
D007660_D013345 NONE <e1>Ketoprofen</e1>\NNP\3828465 but\CC\1740 not\RB\1740 acetaminophen\RB\1740 impaired\JJ\1740 platelet\NN\5432736 function\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>SAH</e2>\NN\1740 .\.\1740
D007660_D017542 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 <e1>ketoprofen</e1>\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e2>aneurysmal</e2>\JJ\1740 SAH\NN\1740 .\.\1740
D007660_D017542 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 <e1>ketoprofen</e1>\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e2>aneurysmal</e2>\JJ\1740 SAH\NN\1740 .\.\1740
D000082_D013345 NONE Patients\NNS\9898892 with\IN\1740 <e2>aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 <e1>acetaminophen</e1>\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 SAH\NN\1740 .\.\1740
D000082_D013345 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 <e1>acetaminophen</e1>\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 SAH\NN\1740 .\.\1740
D000082_D013345 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 <e1>acetaminophen</e1>\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 <e2>SAH</e2>\NN\1740 .\.\1740
D000082_D013345 NONE Patients\NNS\9898892 with\IN\1740 <e2>aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 <e1>acetaminophen</e1>\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 SAH\NN\1740 .\.\1740
D000082_D013345 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 <e1>acetaminophen</e1>\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 SAH\NN\1740 .\.\1740
D000082_D013345 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 <e1>acetaminophen</e1>\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 aneurysmal\JJ\1740 <e2>SAH</e2>\NN\1740 .\.\1740
D000082_D013345 NONE Ketoprofen\NNP\3828465 but\CC\1740 not\RB\1740 <e1>acetaminophen</e1>\RB\1740 impaired\JJ\1740 platelet\NN\5432736 function\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>SAH</e2>\NN\1740 .\.\1740
D000082_D017542 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 <e1>acetaminophen</e1>\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 acetaminophen\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e2>aneurysmal</e2>\JJ\1740 SAH\NN\1740 .\.\1740
D000082_D017542 NONE Patients\NNS\9898892 with\IN\1740 aneurysmal\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ketoprofen\NN\3828465 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 ketoprofen\NN\3828465 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 weak\JJ\1740 NSAID\NN\2721538 ,\,\1740 acetaminophen\RB\1740 ,\,\1740 1\CD\13741022 g\NN\13717155 ,\,\1740 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 (\-LRB-\1740 <e1>acetaminophen</e1>\JJ\1740 group\NN\2137 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 starting\VBG\2009433 immediately\RB\1740 after\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e2>aneurysmal</e2>\JJ\1740 SAH\NN\1740 .\.\1740
D000244_D001791 NONE Maximal\JJ\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 induced\VBN\1627355 by\IN\1740 6\CD\13741022 microM\NN\1740 of\IN\1740 <e1>adenosine\NN\14964367 diphosphate</e1>\NN\1740 decreased\VBD\169651 after\IN\1740 administration\NN\1133281 of\IN\1740 ketoprofen\NN\3828465 .\.\1740
D007660_D001791 CID Maximal\JJ\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 induced\VBN\1627355 by\IN\1740 6\CD\13741022 microM\NN\1740 of\IN\1740 adenosine\NN\14964367 diphosphate\NN\1740 decreased\VBD\169651 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>ketoprofen</e1>\NN\3828465 .\.\1740
D000082_D001791 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 maximal\JJ\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 increased\VBD\169651 in\IN\13603305 the\DT\1740 <e1>acetaminophen</e1>\NN\2707683 group\NN\2137 on\IN\1740 the\DT\1740 third\JJ\1740 postoperative\JJ\1740 day\NN\15154774 as\IN\14622893 compared\VBN\644583 with\IN\1740 the\DT\1740 pretreatment\NN\1740 platelet\NN\5432736 aggregation\NN\31264 results\NNS\34213 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .05\CD\1740 )\-RRB-\1740 .\.\1740
D000082_D001791 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 maximal\JJ\1740 platelet\NN\5432736 aggregation\NN\31264 increased\VBD\169651 in\IN\13603305 the\DT\1740 <e1>acetaminophen</e1>\NN\2707683 group\NN\2137 on\IN\1740 the\DT\1740 third\JJ\1740 postoperative\JJ\1740 day\NN\15154774 as\IN\14622893 compared\VBN\644583 with\IN\1740 the\DT\1740 pretreatment\NN\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 results\NNS\34213 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .05\CD\1740 )\-RRB-\1740 .\.\1740
D007660_D006406 CID One\CD\13741022 patient\NN\9898892 in\IN\13603305 the\DT\1740 <e1>ketoprofen</e1>\NN\3828465 group\NN\2137 developed\VBD\1753788 a\DT\13649268 postoperative\JJ\1740 intracranial\JJ\1740 <e2>hematoma</e2>\NN\14317720 .\.\1740
D007660_D002532 NONE If\IN\1740 <e1>ketoprofen</e1>\NN\3828465 is\VBZ\836236 used\VBN\1156834 before\IN\1740 surgery\NN\6045562 on\IN\1740 cerebral\JJ\1740 <e2>artery\NN\5417975 aneurysms</e2>\NNS\14057371 ,\,\1740 it\PRP\6125041 may\MD\15209706 pose\VB\2620587 an\DT\6697703 additional\JJ\1740 risk\NN\14541044 factor\NN\7326557 for\IN\1740 hemorrhage\NN\14285662 .\.\1740
D007660_D006470 NONE If\IN\1740 <e1>ketoprofen</e1>\NN\3828465 is\VBZ\836236 used\VBN\1156834 before\IN\1740 surgery\NN\6045562 on\IN\1740 cerebral\JJ\1740 artery\NN\5417975 aneurysms\NNS\14057371 ,\,\1740 it\PRP\6125041 may\MD\15209706 pose\VB\2620587 an\DT\6697703 additional\JJ\1740 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>hemorrhage</e2>\NN\14285662 .\.\1740
8643966
D017239_D002289 NONE Chemotherapy\NN\661091 of\IN\1740 advanced\JJ\1740 inoperable\JJ\1740 <e2>non-small\JJ\1740 cell\NN\3080309 lung\NN\5528060 cancer</e2>\NN\14239425 with\IN\1740 <e1>paclitaxel</e1>\NN\1740 :\:\1740 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 .\.\1740
D017239_D002289 NONE Two\CD\13741022 phase\NN\15113229 II\CD\13741022 trials\NNS\786195 of\IN\1740 24-hour\JJ\1740 <e1>paclitaxel</e1>\NN\1740 infusions\NNS\14589223 in\IN\13603305 chemotherapy-naive\JJ\1740 patients\NNS\9898892 with\IN\1740 stage\NN\15113229 IIIB\NN\1740 or\CC\3541091 IV\CD\13741022 <e2>non-small\JJ\1740 cell\NN\3080309 lung\NN\5528060 cancer</e2>\NN\14239425 (\-LRB-\1740 NSCLC\NN\1740 )\-RRB-\1740 reported\VBD\831651 response\NN\11410625 rates\NNS\13308999 of\IN\1740 21\CD\13745420 %\NN\1740 and\CC\1740 24\CD\13745420 %\NN\1740 .\.\1740
D017239_D002289 NONE Two\CD\13741022 phase\NN\15113229 II\CD\13741022 trials\NNS\786195 of\IN\1740 24-hour\JJ\1740 <e1>paclitaxel</e1>\NN\1740 infusions\NNS\14589223 in\IN\13603305 chemotherapy-naive\JJ\1740 patients\NNS\9898892 with\IN\1740 stage\NN\15113229 IIIB\NN\1740 or\CC\3541091 IV\CD\13741022 non-small\JJ\1740 cell\NN\3080309 lung\NN\5528060 cancer\NN\14239425 (\-LRB-\1740 <e2>NSCLC</e2>\NN\1740 )\-RRB-\1740 reported\VBD\831651 response\NN\11410625 rates\NNS\13308999 of\IN\1740 21\CD\13745420 %\NN\1740 and\CC\1740 24\CD\13745420 %\NN\1740 .\.\1740
D017239_D002289 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 toxicity\NN\13576101 of\IN\1740 a\DT\13649268 3-hour\CD\1740 <e1>paclitaxel</e1>\NN\1740 infusion\NN\14589223 in\IN\13603305 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 stage\NN\15113229 IIIB\NN\1740 or\CC\3541091 IV\CD\13741022 <e2>NSCLC</e2>\NN\1740 .\.\1740
D017239_D002289 NONE Further\JJ\1740 phase\NN\15113229 II\CD\13741022 studies\NNS\635850 with\IN\1740 <e1>paclitaxel</e1>\NN\1740 combined\VBN\2630189 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 active\JJ\1740 against\IN\1740 <e2>NSCLC</e2>\NN\1740 are\VBP\836236 indicated\VBN\952524 ,\,\1740 and\CC\1740 phase\NN\15113229 III\CD\13741022 studies\NNS\635850 comparing\VBG\644583 paclitaxel\NN\1740 with\IN\1740 standard\JJ\1740 chemotherapy\NN\661091 remain\VBP\2604760 to\TO\1740 be\VB\836236 completed\VBN\352826 .\.\1740
D017239_D002289 NONE Further\JJ\1740 phase\NN\15113229 II\CD\13741022 studies\NNS\635850 with\IN\1740 paclitaxel\NN\1740 combined\VBN\2630189 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 active\JJ\1740 against\IN\1740 <e2>NSCLC</e2>\NN\1740 are\VBP\836236 indicated\VBN\952524 ,\,\1740 and\CC\1740 phase\NN\15113229 III\CD\13741022 studies\NNS\635850 comparing\VBG\644583 <e1>paclitaxel</e1>\NN\1740 with\IN\1740 standard\JJ\1740 chemotherapy\NN\661091 remain\VBP\2604760 to\TO\1740 be\VB\836236 completed\VBN\352826 .\.\1740
D017239_D009369 NONE <e1>Paclitaxel</e1>\NN\1740 (\-LRB-\1740 Taxol\NNP\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 has\VBZ\2108377 demonstrated\VBN\2137132 significant\JJ\1740 antineoplastic\JJ\1740 activity\NN\30358 against\IN\1740 different\JJ\1740 <e2>tumor</e2>\NN\14234074 types\NNS\5839024 ,\,\1740 notably\RB\1740 ovarian\JJ\1740 and\CC\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D017239_D009369 NONE Paclitaxel\NN\1740 (\-LRB-\1740 <e1>Taxol</e1>\NNP\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 has\VBZ\2108377 demonstrated\VBN\2137132 significant\JJ\1740 antineoplastic\JJ\1740 activity\NN\30358 against\IN\1740 different\JJ\1740 <e2>tumor</e2>\NN\14234074 types\NNS\5839024 ,\,\1740 notably\RB\1740 ovarian\JJ\1740 and\CC\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D017239_D010051 NONE <e1>Paclitaxel</e1>\NN\1740 (\-LRB-\1740 Taxol\NNP\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 has\VBZ\2108377 demonstrated\VBN\2137132 significant\JJ\1740 antineoplastic\JJ\1740 activity\NN\30358 against\IN\1740 different\JJ\1740 tumor\NN\14234074 types\NNS\5839024 ,\,\1740 notably\RB\1740 <e2>ovarian\JJ\1740 and\CC\1740 breast\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D017239_D010051 NONE Paclitaxel\NN\1740 (\-LRB-\1740 <e1>Taxol</e1>\NNP\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 has\VBZ\2108377 demonstrated\VBN\2137132 significant\JJ\1740 antineoplastic\JJ\1740 activity\NN\30358 against\IN\1740 different\JJ\1740 tumor\NN\14234074 types\NNS\5839024 ,\,\1740 notably\RB\1740 <e2>ovarian\JJ\1740 and\CC\1740 breast\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D017239_D001943 NONE <e1>Paclitaxel</e1>\NN\1740 (\-LRB-\1740 Taxol\NNP\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 has\VBZ\2108377 demonstrated\VBN\2137132 significant\JJ\1740 antineoplastic\JJ\1740 activity\NN\30358 against\IN\1740 different\JJ\1740 tumor\NN\14234074 types\NNS\5839024 ,\,\1740 notably\RB\1740 <e2>ovarian\JJ\1740 and\CC\1740 breast\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D017239_D001943 NONE Paclitaxel\NN\1740 (\-LRB-\1740 <e1>Taxol</e1>\NNP\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 has\VBZ\2108377 demonstrated\VBN\2137132 significant\JJ\1740 antineoplastic\JJ\1740 activity\NN\30358 against\IN\1740 different\JJ\1740 tumor\NN\14234074 types\NNS\5839024 ,\,\1740 notably\RB\1740 <e2>ovarian\JJ\1740 and\CC\1740 breast\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D017239_D064420 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 a\DT\13649268 3-hour\CD\1740 <e1>paclitaxel</e1>\NN\1740 infusion\NN\14589223 in\IN\13603305 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 stage\NN\15113229 IIIB\NN\1740 or\CC\3541091 IV\CD\13741022 NSCLC\NN\1740 .\.\1740
D017239_D064420 NONE <e1>Paclitaxel</e1>\NN\1740 is\VBZ\836236 thus\RB\1740 an\DT\6697703 active\JJ\1740 single\JJ\1740 agent\NN\7347 in\IN\13603305 this\DT\1740 patient\NN\9898892 population\NN\7942152 ,\,\1740 with\IN\1740 a\DT\13649268 3-hour\NN\1740 infusion\NN\14589223 proving\VBG\2604760 comparably\RB\1740 effective\JJ\1740 to\TO\1740 a\DT\13649268 24-hour\JJ\1740 infusion\NN\14589223 and\CC\1740 superior\JJ\1740 in\IN\13603305 terms\NNS\13945919 of\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 hematologic\JJ\1740 and\CC\1740 nonhematologic\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
9041081
D013256_D009798 NONE During\IN\1740 the\DT\1740 follow-up\NN\4599396 ,\,\1740 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 12\CD\13745420 %\NN\1740 )\-RRB-\1740 developed\VBD\1753788 <e1>steroid-induced</e1>\JJ\1740 <e2>elevated\JJ\1740 intraocular\JJ\1740 pressure</e2>\NN\11419404 (\-LRB-\1740 IOP\NNS\11495041 )\-RRB-\1740 that\WDT\1740 resolved\VBN\352826 after\IN\1740 corticosteroid\NN\14745635 therapy\NN\657604 was\VBD\836236 discontinued\VBN\2609764 .\.\1740
D013256_D009798 NONE The\DT\1740 transient\JJ\1740 <e1>steroid-induced</e1>\JJ\1740 <e2>IOP\NN\11495041 rise</e2>\NN\7324673 did\VBD\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 cause\VB\1617192 functional\JJ\1740 impairment\NN\7296428 .\.\1740
D000305_D009798 CID During\IN\1740 the\DT\1740 follow-up\NN\4599396 ,\,\1740 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 12\CD\13745420 %\NN\1740 )\-RRB-\1740 developed\VBD\1753788 steroid-induced\JJ\1740 <e2>elevated\JJ\1740 intraocular\JJ\1740 pressure</e2>\NN\11419404 (\-LRB-\1740 IOP\NNS\11495041 )\-RRB-\1740 that\WDT\1740 resolved\VBN\352826 after\IN\1740 <e1>corticosteroid</e1>\NN\14745635 therapy\NN\657604 was\VBD\836236 discontinued\VBN\2609764 .\.\1740
16710500
D004977_D009901 CID <e1>Ethambutol-associated</e1>\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\JJ\1740 .\.\1740
D004977_D009901 CID CLINICAL\NN\1740 PICTURE\NN\4076846 :\:\1740 Three\CD\13741022 patients\NNS\9898892 with\IN\1740 <e1>ethambutol-associated</e1>\JJ\1740 toxic\JJ\1740 <e2>optic\JJ\1740 neuropathy</e2>\NN\14204950 are\VBP\836236 described\VBN\1001294 .\.\1740
D004977_D014376 NONE INTRODUCTION\NNP\235435 :\:\1740 <e1>Ethambutol</e1>\NNP\1740 is\VBZ\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>tuberculosis</e2>\NN\14127211 ,\,\1740 which\WDT\1740 is\VBZ\836236 still\RB\1740 prevalent\JJ\1740 in\IN\13603305 Southeast\NNP\13830305 Asia\NNP\7951464 ,\,\1740 and\CC\1740 can\MD\3094503 be\VB\836236 associated\VBN\628491 with\IN\1740 permanent\JJ\1740 visual\JJ\1740 loss\NN\13252973 .\.\1740
D004977_D014786 CID INTRODUCTION\NNP\235435 :\:\1740 <e1>Ethambutol</e1>\NNP\1740 is\VBZ\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 tuberculosis\NN\14127211 ,\,\1740 which\WDT\1740 is\VBZ\836236 still\RB\1740 prevalent\JJ\1740 in\IN\13603305 Southeast\NNP\13830305 Asia\NNP\7951464 ,\,\1740 and\CC\1740 can\MD\3094503 be\VB\836236 associated\VBN\628491 with\IN\1740 permanent\JJ\1740 <e2>visual\JJ\1740 loss</e2>\NN\13252973 .\.\1740
D004977_D014786 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Ethambutol</e1>\JJ\1740 usage\NN\407535 is\VBZ\836236 associated\VBN\628491 with\IN\1740 permanent\JJ\1740 <e2>visual\JJ\1740 loss</e2>\NN\13252973 and\CC\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 if\IN\1740 possible\JJ\1740 or\CC\3541091 used\VBN\1156834 with\IN\1740 caution\NN\4662951 and\CC\1740 proper\JJ\1740 ophthalmological\JJ\1740 follow-up\NN\4599396 .\.\1740
12093990
D012254_D000257 NONE Intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 treatment\NN\654885 for\IN\1740 severe\JJ\1740 <e2>adenovirus\NN\1335659 disease</e2>\NN\14061805 in\IN\13603305 immunocompromised\VBN\1740 children\NNS\9622049 .\.\1740
D012254_D000257 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 report\VBP\831651 our\PRP$\1740 experience\NN\5984287 with\IN\1740 intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 therapy\NN\657604 for\IN\1740 severe\JJ\1740 <e2>adenovirus\NN\1335659 disease</e2>\NN\14061805 in\IN\13603305 a\DT\13649268 series\NN\8456993 of\IN\1740 immunocompromised\VBN\1740 children\NNS\9622049 and\CC\1740 review\VB\644583 the\DT\1740 literature\NN\6362953 .\.\1740
D012254_D000257 NONE DESIGN/METHODS\PRP\1740 :\:\1740 We\PRP\1740 retrospectively\RB\1740 reviewed\VBD\644583 the\DT\1740 medical\JJ\1740 records\NNS\6643408 of\IN\1740 5\CD\13741022 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 for\IN\1740 documented\VBN\1000214 severe\JJ\1740 <e2>adenovirus\NN\1335659 disease</e2>\NN\14061805 .\.\1740
D012254_D000257 NONE Although\IN\1740 intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 was\VBD\836236 not\RB\1740 effective\JJ\1740 for\IN\1740 all\DT\1740 children\NNS\9622049 with\IN\1740 severe\JJ\1740 <e2>adenovirus\NN\1335659 disease</e2>\NN\14061805 in\IN\13603305 this\DT\1740 series\NN\8456993 or\CC\3541091 in\IN\13603305 the\DT\1740 literature\NN\6362953 ,\,\1740 therapy\NN\657604 is\VBZ\836236 unlikely\JJ\1740 to\TO\1740 be\VB\836236 of\IN\1740 benefit\NN\13278375 if\IN\1740 begun\VBN\941990 late\RB\1740 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 the\DT\1740 infection\NN\14052046 .\.\1740
D012254_D000257 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Two\CD\13741022 of\IN\1740 5\CD\13741022 children\NNS\9622049 with\IN\1740 severe\JJ\1740 <e2>adenovirus\NN\1335659 disease</e2>\NN\14061805 treated\VBN\2376958 with\IN\1740 intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 recovered\VBN\2210855 .\.\1740
D012254_D000257 NONE Given\VBN\2327200 the\DT\1740 seriousness\JJ\1740 and\CC\1740 increasing\VBG\169651 prevalence\NN\4764412 of\IN\1740 <e2>adenovirus\NN\1335659 disease</e2>\NN\14061805 in\IN\13603305 certain\JJ\1740 hosts\NNS\9605289 ,\,\1740 especially\RB\1740 children\NNS\9622049 ,\,\1740 a\DT\13649268 large\JJ\1740 ,\,\1740 multicenter\NN\1740 clinical\JJ\1740 trial\NN\786195 of\IN\1740 potentially\RB\1740 useful\JJ\1740 anti-adenoviral\JJ\1740 therapies\NNS\657604 ,\,\1740 such\JJ\1740 as\IN\14622893 intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 ,\,\1740 is\VBZ\836236 clearly\RB\1740 required\VBN\754942 to\TO\1740 demonstrate\VB\2137132 the\DT\1740 most\RBS\1740 effective\JJ\1740 and\CC\1740 least\JJS\1740 toxic\JJ\1740 therapy\NN\657604 .\.\1740
D012254_D018357 NONE <e1>Ribavirin</e1>\NN\2725367 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 aerosol\NN\11439690 form\NN\6286395 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>respiratory\JJ\1740 syncytial\JJ\1740 virus\NN\9312843 infection</e2>\NN\14052046 ,\,\1740 and\CC\1740 orally\RB\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 interferon\NN\2725367 to\TO\1740 treat\VB\2376958 hepatitis\NN\14127211 C.\NN\1740 Intravenous\JJ\1740 ribavirin\NN\2725367 is\VBZ\836236 the\DT\1740 treatment\NN\654885 of\IN\1740 choice\NN\5788149 for\IN\1740 infection\NN\14052046 with\IN\1740 hemorrhagic\JJ\1740 fever\NN\14299637 viruses\NNS\9312843 .\.\1740
D012254_D018357 NONE Ribavirin\NN\2725367 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 aerosol\NN\11439690 form\NN\6286395 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>respiratory\JJ\1740 syncytial\JJ\1740 virus\NN\9312843 infection</e2>\NN\14052046 ,\,\1740 and\CC\1740 orally\RB\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 interferon\NN\2725367 to\TO\1740 treat\VB\2376958 hepatitis\NN\14127211 C.\NN\1740 Intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 is\VBZ\836236 the\DT\1740 treatment\NN\654885 of\IN\1740 choice\NN\5788149 for\IN\1740 infection\NN\14052046 with\IN\1740 hemorrhagic\JJ\1740 fever\NN\14299637 viruses\NNS\9312843 .\.\1740
D012254_D006526 NONE <e1>Ribavirin</e1>\NN\2725367 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 aerosol\NN\11439690 form\NN\6286395 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 respiratory\JJ\1740 syncytial\JJ\1740 virus\NN\9312843 infection\NN\14052046 ,\,\1740 and\CC\1740 orally\RB\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 interferon\NN\2725367 to\TO\1740 treat\VB\2376958 <e2>hepatitis\NN\14127211 C.</e2>\NN\1740 Intravenous\JJ\1740 ribavirin\NN\2725367 is\VBZ\836236 the\DT\1740 treatment\NN\654885 of\IN\1740 choice\NN\5788149 for\IN\1740 infection\NN\14052046 with\IN\1740 hemorrhagic\JJ\1740 fever\NN\14299637 viruses\NNS\9312843 .\.\1740
D012254_D006526 NONE Ribavirin\NN\2725367 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 aerosol\NN\11439690 form\NN\6286395 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 respiratory\JJ\1740 syncytial\JJ\1740 virus\NN\9312843 infection\NN\14052046 ,\,\1740 and\CC\1740 orally\RB\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 interferon\NN\2725367 to\TO\1740 treat\VB\2376958 <e2>hepatitis\NN\14127211 C.</e2>\NN\1740 Intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 is\VBZ\836236 the\DT\1740 treatment\NN\654885 of\IN\1740 choice\NN\5788149 for\IN\1740 infection\NN\14052046 with\IN\1740 hemorrhagic\JJ\1740 fever\NN\14299637 viruses\NNS\9312843 .\.\1740
D012254_D006482 NONE <e1>Ribavirin</e1>\NN\2725367 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 aerosol\NN\11439690 form\NN\6286395 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 respiratory\JJ\1740 syncytial\JJ\1740 virus\NN\9312843 infection\NN\14052046 ,\,\1740 and\CC\1740 orally\RB\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 interferon\NN\2725367 to\TO\1740 treat\VB\2376958 hepatitis\NN\14127211 C.\NN\1740 Intravenous\JJ\1740 ribavirin\NN\2725367 is\VBZ\836236 the\DT\1740 treatment\NN\654885 of\IN\1740 choice\NN\5788149 for\IN\1740 <e2>infection\NN\14052046 with\IN\1740 hemorrhagic\JJ\1740 fever\NN\14299637 viruses</e2>\NNS\9312843 .\.\1740
D012254_D006482 NONE Ribavirin\NN\2725367 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 aerosol\NN\11439690 form\NN\6286395 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 respiratory\JJ\1740 syncytial\JJ\1740 virus\NN\9312843 infection\NN\14052046 ,\,\1740 and\CC\1740 orally\RB\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 interferon\NN\2725367 to\TO\1740 treat\VB\2376958 hepatitis\NN\14127211 C.\NN\1740 Intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 is\VBZ\836236 the\DT\1740 treatment\NN\654885 of\IN\1740 choice\NN\5788149 for\IN\1740 <e2>infection\NN\14052046 with\IN\1740 hemorrhagic\JJ\1740 fever\NN\14299637 viruses</e2>\NNS\9312843 .\.\1740
D012254_D000740 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 is\VBZ\836236 reversible\JJ\1740 mild\JJ\1740 <e2>anemia</e2>\NN\14189204 .\.\1740
C059262_D000257 NONE The\DT\1740 use\NN\407535 of\IN\1740 <e1>cidofovir</e1>\NN\1740 in\IN\13603305 severe\JJ\1740 <e2>adenovirus\NN\1335659 infection</e2>\NN\14052046 has\VBZ\2108377 been\VBN\836236 limited\VBN\2510337 by\IN\1740 adverse\JJ\1740 effects\NNS\13245626 ,\,\1740 the\DT\1740 most\RBS\1740 significant\JJ\1740 of\IN\1740 which\WDT\1740 is\VBZ\836236 nephrotoxicity\NN\1740 .\.\1740
C059262_D007674 NONE The\DT\1740 use\NN\407535 of\IN\1740 <e1>cidofovir</e1>\NN\1740 in\IN\13603305 severe\JJ\1740 adenovirus\NN\1335659 infection\NN\14052046 has\VBZ\2108377 been\VBN\836236 limited\VBN\2510337 by\IN\1740 adverse\JJ\1740 effects\NNS\13245626 ,\,\1740 the\DT\1740 most\RBS\1740 significant\JJ\1740 of\IN\1740 which\WDT\1740 is\VBZ\836236 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
C059262_D058186 CID Use\NN\407535 of\IN\1740 <e1>cidofovir</e1>\NN\1740 in\IN\13603305 1\CD\13741022 child\NN\9622049 was\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>progressive\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 and\CC\1740 neutropenia\NN\14196405 .\.\1740
C059262_D009503 CID Use\NN\407535 of\IN\1740 <e1>cidofovir</e1>\NN\1740 in\IN\13603305 1\CD\13741022 child\NN\9622049 was\VBD\836236 associated\VBN\628491 with\IN\1740 progressive\JJ\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 <e2>neutropenia</e2>\NN\14196405 .\.\1740
D012254_D007239 NONE Although\IN\1740 intravenous\JJ\1740 <e1>ribavirin</e1>\NN\2725367 was\VBD\836236 not\RB\1740 effective\JJ\1740 for\IN\1740 all\DT\1740 children\NNS\9622049 with\IN\1740 severe\JJ\1740 adenovirus\NN\1335659 disease\NN\14061805 in\IN\13603305 this\DT\1740 series\NN\8456993 or\CC\3541091 in\IN\13603305 the\DT\1740 literature\NN\6362953 ,\,\1740 therapy\NN\657604 is\VBZ\836236 unlikely\JJ\1740 to\TO\1740 be\VB\836236 of\IN\1740 benefit\NN\13278375 if\IN\1740 begun\VBN\941990 late\RB\1740 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 the\DT\1740 <e2>infection</e2>\NN\14052046 .\.\1740
17049862
D010672_D007035 NONE Is\VBZ\836236 <e1>phenytoin</e1>\NN\3550533 administration\NN\1133281 safe\JJ\1740 in\IN\13603305 a\DT\13649268 <e2>hypothermic</e2>\JJ\1740 child\NN\9622049 ?\.\1740
D010672_D007035 NONE The\DT\1740 cardiac\JJ\1740 depressant\JJ\1740 actions\NNS\30358 of\IN\1740 <e1>phenytoin</e1>\NN\3550533 and\CC\1740 <e2>hypothermia</e2>\NN\14034177 can\MD\3094503 be\VB\836236 additive\JJ\1740 .\.\1740
D010672_D007035 NONE Administration\NN\1133281 of\IN\1740 <e1>phenytoin</e1>\NN\3550533 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>hypothermia</e2>\NN\14034177 may\MD\15209706 lead\VB\1752884 to\TO\1740 an\DT\6697703 adverse\JJ\1740 cardiac\JJ\1740 event\NN\23100 in\IN\13603305 children\NNS\9622049 .\.\1740
D010672_D012640 NONE Intravenous\JJ\1740 <e1>phenytoin</e1>\NN\3550533 was\VBD\836236 administered\VBN\2436349 during\IN\1740 the\DT\1740 later\JJ\1740 part\NN\31921 of\IN\1740 the\DT\1740 surgery\NN\6045562 for\IN\1740 <e2>seizure</e2>\JJ\1740 prophylaxis\NN\1077350 .\.\1740
D010672_D001919 CID Following\VBG\1835496 <e1>phenytoin</e1>\NN\3550533 administration\NN\1133281 ,\,\1740 the\DT\1740 patient\NN\9898892 developed\VBD\1753788 acute\JJ\1740 severe\JJ\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 refractory\JJ\1740 to\TO\1740 atropine\NN\14712692 and\CC\1740 adrenaline\NN\14807929 .\.\1740
D001285_D001919 NONE Following\VBG\1835496 phenytoin\NN\3550533 administration\NN\1133281 ,\,\1740 the\DT\1740 patient\NN\9898892 developed\VBD\1753788 acute\JJ\1740 severe\JJ\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 refractory\JJ\1740 to\TO\1740 <e1>atropine</e1>\NN\14712692 and\CC\1740 adrenaline\NN\14807929 .\.\1740
D004837_D001919 NONE Following\VBG\1835496 phenytoin\NN\3550533 administration\NN\1133281 ,\,\1740 the\DT\1740 patient\NN\9898892 developed\VBD\1753788 acute\JJ\1740 severe\JJ\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 refractory\JJ\1740 to\TO\1740 atropine\NN\14712692 and\CC\1740 <e1>adrenaline</e1>\NN\14807929 .\.\1740
11063349
D020123_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>RAPA</e1>\NN\1740 conversion\NN\7359599 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 cyclosporine\NN\1740 (\-LRB-\1740 CsA\NN\1740 )\-RRB-\1740 or\CC\3541091 tacrolimus\NN\1740 (\-LRB-\1740 Tac\NN\1740 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D016572_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 RAPA\NN\1740 conversion\NN\7359599 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 <e1>cyclosporine</e1>\NN\1740 (\-LRB-\1740 CsA\NN\1740 )\-RRB-\1740 or\CC\3541091 tacrolimus\NN\1740 (\-LRB-\1740 Tac\NN\1740 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D016572_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 RAPA\NN\1740 conversion\NN\7359599 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 cyclosporine\NN\1740 (\-LRB-\1740 <e1>CsA</e1>\NN\1740 )\-RRB-\1740 or\CC\3541091 tacrolimus\NN\1740 (\-LRB-\1740 Tac\NN\1740 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D016572_D064420 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 <e2>toxicity</e2>\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_D064420 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 <e2>toxicity</e2>\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 RAPA\NN\1740 conversion\NN\7359599 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 cyclosporine\NN\1740 (\-LRB-\1740 CsA\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>tacrolimus</e1>\NN\1740 (\-LRB-\1740 Tac\NN\1740 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D016559_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 RAPA\NN\1740 conversion\NN\7359599 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 cyclosporine\NN\1740 (\-LRB-\1740 CsA\NN\1740 )\-RRB-\1740 or\CC\3541091 tacrolimus\NN\1740 (\-LRB-\1740 <e1>Tac</e1>\NN\1740 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D016559_D064420 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 <e2>toxicity</e2>\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D064420 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_D007674 CID The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_D007674 CID The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_-1 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 <e2>facial\JJ\1740 dysmorphism</e2>\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_-1 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 <e2>facial\JJ\1740 dysmorphism</e2>\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_D008232 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 <e2>posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_D008232 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 <e2>PTLD</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_D008232 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 <e2>posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_D008232 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 <e2>PTLD</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_D056486 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>hepatotoxicity</e2>\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016572_D056486 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 <e1>CsA</e1>\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>hepatotoxicity</e2>\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D007674 CID The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D007674 CID The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_-1 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 <e2>facial\JJ\1740 dysmorphism</e2>\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_-1 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 <e2>facial\JJ\1740 dysmorphism</e2>\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D008232 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 <e2>posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D008232 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 <e2>PTLD</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D008232 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 <e2>posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D008232 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 <e2>PTLD</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 hepatotoxicity\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D056486 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>hepatotoxicity</e2>\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D016559_D056486 NONE The\DT\1740 indications\NNS\33020 for\IN\1740 switch\NN\3096960 were\VBD\836236 chronic\JJ\1740 CsA\NN\1740 or\CC\3541091 Tac\NN\1740 nephrotoxicity\NN\1740 (\-LRB-\1740 12\CD\13745420 )\-RRB-\1740 ,\,\1740 acute\JJ\1740 CsA\NN\1740 or\CC\3541091 <e1>Tac</e1>\NN\1740 toxicity\NN\13576101 (\-LRB-\1740 3\CD\13741022 )\-RRB-\1740 ,\,\1740 severe\JJ\1740 facial\JJ\1740 dysmorphism\NN\1740 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 posttransplant\JJ\1740 lymphoproliferative\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PTLD\NN\1740 )\-RRB-\1740 in\IN\13603305 remission\NN\7368256 (\-LRB-\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>hepatotoxicity</e2>\NN\1740 in\IN\13603305 1\CD\13741022 .\.\1740
D003404_D007674 NONE RESULTS\NNS\34213 :\:\1740 In\IN\13603305 the\DT\1740 12\CD\13745420 patients\NNS\9898892 switched\VBD\138508 because\IN\1740 of\IN\1740 chronic\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 [\-LRB-\1740 233+/-34\CD\1740 to\TO\1740 210+/-56\CD\1740 micromol/liter\NN\1740 (\-LRB-\1740 P<0.05\NN\1740 )\-RRB-\1740 at\IN\14622893 6\CD\13741022 months\NNS\15113229 ]\-RRB-\1740 .\.\1740
D020123_D011014 NONE <e1>RAPA</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 in\IN\13603305 four\CD\13741022 patients\NNS\9898892 ,\,\1740 because\IN\1740 of\IN\1740 <e2>pneumonia</e2>\NN\14145095 in\IN\13603305 two\CD\13741022 ,\,\1740 PTLD\NN\1740 in\IN\13603305 one\CD\13741022 ,\,\1740 and\CC\1740 oral\JJ\1740 aphtous\JJ\1740 ulcers\NNS\14211294 in\IN\13603305 one\CD\13741022 .\.\1740
D020123_D008232 NONE <e1>RAPA</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 in\IN\13603305 four\CD\13741022 patients\NNS\9898892 ,\,\1740 because\IN\1740 of\IN\1740 pneumonia\NN\14145095 in\IN\13603305 two\CD\13741022 ,\,\1740 <e2>PTLD</e2>\NN\1740 in\IN\13603305 one\CD\13741022 ,\,\1740 and\CC\1740 oral\JJ\1740 aphtous\JJ\1740 ulcers\NNS\14211294 in\IN\13603305 one\CD\13741022 .\.\1740
D020123_D013281 NONE <e1>RAPA</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 in\IN\13603305 four\CD\13741022 patients\NNS\9898892 ,\,\1740 because\IN\1740 of\IN\1740 pneumonia\NN\14145095 in\IN\13603305 two\CD\13741022 ,\,\1740 PTLD\NN\1740 in\IN\13603305 one\CD\13741022 ,\,\1740 and\CC\1740 oral\JJ\1740 <e2>aphtous\JJ\1740 ulcers</e2>\NNS\14211294 in\IN\13603305 one\CD\13741022 .\.\1740
D020123_D011020 NONE However\RB\1740 ,\,\1740 when\WRB\1740 converting\VBG\126264 patients\NNS\9898892 to\TO\1740 <e1>RAPA</e1>\NN\1740 drug\NN\14778436 levels\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 to\TO\1740 avoid\VB\2452885 over-immunosuppression\NN\1740 and\CC\1740 adequate\JJ\1740 antiviral\JJ\1740 and\CC\1740 <e2>Pneumocystis\NN\1740 carinii\NN\1740 pneumonia</e2>\NN\14145095 prophylaxis\NN\1077350 should\MD\1740 be\VB\836236 given\VBN\2327200 .\.\1740
11900788
D009538_D002375 CID <e1>Nicotine</e1>\NN\14712692 potentiation\NN\13564910 of\IN\1740 morphine-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009538_D002375 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 effects\NNS\13245626 of\IN\1740 <e1>nicotine</e1>\NN\14712692 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 in\IN\13603305 mice\NNS\2329401 have\VBP\2108377 been\VBN\836236 investigated\VBN\644583 .\.\1740
D009538_D002375 CID Morphine\NN\2707683 but\CC\1740 not\RB\1740 <e1>nicotine</e1>\NN\14712692 induced\VBD\1627355 a\DT\13649268 dose-dependent\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D009538_D002375 CID Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 atropine\NN\14712692 ,\,\1740 naloxone\NN\3808977 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 and\CC\1740 hexamethonium\NN\1740 to\TO\1740 mice\NNS\2329401 reduced\VBD\441445 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 morphine\NN\2707683 with\IN\1740 <e1>nicotine</e1>\NN\14712692 .\.\1740
D009538_D002375 CID Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 atropine\NN\14712692 ,\,\1740 hexamethonium\NN\1740 ,\,\1740 and\CC\1740 naloxone\NN\3808977 also\RB\1740 decreased\VBD\169651 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 plus\CC\4723816 <e1>nicotine</e1>\NN\14712692 .\.\1740
D009538_D002375 CID It\PRP\6125041 was\VBD\836236 concluded\VBN\628491 that\IN\1740 morphine\NN\2707683 <e2>catalepsy</e2>\NN\14023236 can\MD\3094503 be\VB\836236 elicited\VBN\1617192 by\IN\1740 opioid\NN\1740 and\CC\1740 cholinergic\JJ\1740 receptors\NNS\5225602 ,\,\1740 and\CC\1740 the\DT\1740 potentiation\NN\13564910 of\IN\1740 morphine\NN\2707683 induced\VBN\1627355 by\IN\1740 <e1>nicotine</e1>\NN\14712692 may\MD\15209706 also\RB\1740 be\VB\836236 mediated\VBN\761713 through\IN\1740 cholinergic\JJ\1740 receptor\NN\5225602 mechanisms\NNS\13446390 .\.\1740
D009020_D002375 CID Nicotine\NN\14712692 potentiation\NN\13564910 of\IN\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009020_D002375 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 effects\NNS\13245626 of\IN\1740 nicotine\NN\14712692 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>morphine</e1>\NN\2707683 in\IN\13603305 mice\NNS\2329401 have\VBP\2108377 been\VBN\836236 investigated\VBN\644583 .\.\1740
D009020_D002375 CID <e1>Morphine</e1>\NN\2707683 but\CC\1740 not\RB\1740 nicotine\NN\14712692 induced\VBD\1627355 a\DT\13649268 dose-dependent\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D009020_D002375 CID Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 atropine\NN\14712692 ,\,\1740 naloxone\NN\3808977 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 and\CC\1740 hexamethonium\NN\1740 to\TO\1740 mice\NNS\2329401 reduced\VBD\441445 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>morphine</e1>\NN\2707683 with\IN\1740 nicotine\NN\14712692 .\.\1740
D009020_D002375 CID Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 atropine\NN\14712692 ,\,\1740 hexamethonium\NN\1740 ,\,\1740 and\CC\1740 naloxone\NN\3808977 also\RB\1740 decreased\VBD\169651 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>morphine</e1>\NN\2707683 plus\CC\4723816 nicotine\NN\14712692 .\.\1740
D009020_D002375 CID It\PRP\6125041 was\VBD\836236 concluded\VBN\628491 that\IN\1740 <e1>morphine</e1>\NN\2707683 <e2>catalepsy</e2>\NN\14023236 can\MD\3094503 be\VB\836236 elicited\VBN\1617192 by\IN\1740 opioid\NN\1740 and\CC\1740 cholinergic\JJ\1740 receptors\NNS\5225602 ,\,\1740 and\CC\1740 the\DT\1740 potentiation\NN\13564910 of\IN\1740 morphine\NN\2707683 induced\VBN\1627355 by\IN\1740 nicotine\NN\14712692 may\MD\15209706 also\RB\1740 be\VB\836236 mediated\VBN\761713 through\IN\1740 cholinergic\JJ\1740 receptor\NN\5225602 mechanisms\NNS\13446390 .\.\1740
D009020_D002375 CID It\PRP\6125041 was\VBD\836236 concluded\VBN\628491 that\IN\1740 morphine\NN\2707683 <e2>catalepsy</e2>\NN\14023236 can\MD\3094503 be\VB\836236 elicited\VBN\1617192 by\IN\1740 opioid\NN\1740 and\CC\1740 cholinergic\JJ\1740 receptors\NNS\5225602 ,\,\1740 and\CC\1740 the\DT\1740 potentiation\NN\13564910 of\IN\1740 <e1>morphine</e1>\NN\2707683 induced\VBN\1627355 by\IN\1740 nicotine\NN\14712692 may\MD\15209706 also\RB\1740 be\VB\836236 mediated\VBN\761713 through\IN\1740 cholinergic\JJ\1740 receptor\NN\5225602 mechanisms\NNS\13446390 .\.\1740
D001285_D002375 NONE Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>atropine</e1>\NN\14712692 ,\,\1740 naloxone\NN\3808977 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 and\CC\1740 hexamethonium\NN\1740 to\TO\1740 mice\NNS\2329401 reduced\VBD\441445 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 morphine\NN\2707683 with\IN\1740 nicotine\NN\14712692 .\.\1740
D001285_D002375 NONE Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 <e1>atropine</e1>\NN\14712692 ,\,\1740 hexamethonium\NN\1740 ,\,\1740 and\CC\1740 naloxone\NN\3808977 also\RB\1740 decreased\VBD\169651 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 plus\CC\4723816 nicotine\NN\14712692 .\.\1740
D009270_D002375 NONE Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 atropine\NN\14712692 ,\,\1740 <e1>naloxone</e1>\NN\3808977 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 and\CC\1740 hexamethonium\NN\1740 to\TO\1740 mice\NNS\2329401 reduced\VBD\441445 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 morphine\NN\2707683 with\IN\1740 nicotine\NN\14712692 .\.\1740
D009270_D002375 NONE Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 atropine\NN\14712692 ,\,\1740 hexamethonium\NN\1740 ,\,\1740 and\CC\1740 <e1>naloxone</e1>\NN\3808977 also\RB\1740 decreased\VBD\169651 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 plus\CC\4723816 nicotine\NN\14712692 .\.\1740
D008464_D002375 NONE Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 atropine\NN\14712692 ,\,\1740 naloxone\NN\3808977 ,\,\1740 <e1>mecamylamine</e1>\NN\1740 ,\,\1740 and\CC\1740 hexamethonium\NN\1740 to\TO\1740 mice\NNS\2329401 reduced\VBD\441445 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 morphine\NN\2707683 with\IN\1740 nicotine\NN\14712692 .\.\1740
D018738_D002375 NONE Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 atropine\NN\14712692 ,\,\1740 naloxone\NN\3808977 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 and\CC\1740 <e1>hexamethonium</e1>\NN\1740 to\TO\1740 mice\NNS\2329401 reduced\VBD\441445 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 morphine\NN\2707683 with\IN\1740 nicotine\NN\14712692 .\.\1740
D018738_D002375 NONE Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 atropine\NN\14712692 ,\,\1740 <e1>hexamethonium</e1>\NN\1740 ,\,\1740 and\CC\1740 naloxone\NN\3808977 also\RB\1740 decreased\VBD\169651 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 plus\CC\4723816 nicotine\NN\14712692 .\.\1740
11583940
C063008_D007674 NONE Two\CD\13741022 recently\RB\1740 available\JJ\1740 immunosuppressive\JJ\1740 agents\NNS\7347 ,\,\1740 <e1>mycophenolate\JJ\1740 mofetil</e1>\NN\1740 and\CC\1740 sirolimus\NN\1740 (\-LRB-\1740 rapamycin\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 no\DT\7204911 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D020123_D007674 NONE Two\CD\13741022 recently\RB\1740 available\JJ\1740 immunosuppressive\JJ\1740 agents\NNS\7347 ,\,\1740 mycophenolate\JJ\1740 mofetil\NN\1740 and\CC\1740 <e1>sirolimus</e1>\NN\1740 (\-LRB-\1740 rapamycin\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 no\DT\7204911 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D020123_D007674 NONE Two\CD\13741022 recently\RB\1740 available\JJ\1740 immunosuppressive\JJ\1740 agents\NNS\7347 ,\,\1740 mycophenolate\JJ\1740 mofetil\NN\1740 and\CC\1740 sirolimus\NN\1740 (\-LRB-\1740 <e1>rapamycin</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 no\DT\7204911 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
1700207
C032151_D001145 NONE Antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 optical\JJ\1740 isomers\NNS\14818238 of\IN\1740 <e1>cibenzoline</e1>\NN\1740 on\IN\1740 canine\NN\5282746 <e2>ventricular\NN\1740 arrhythmias</e2>\VBZ\1740 .\.\1740
C032151_D001145 NONE Antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>(+)-cibenzoline</e1>\NN\1740 and\CC\1740 (-)-cibenzoline\NN\1740 were\VBD\836236 examined\VBN\789138 using\VBG\1156834 two\CD\13741022 canine\NN\5282746 <e2>ventricular\NN\1740 arrhythmia</e2>\NN\14103288 models\NNS\5888929 .\.\1740
C032151_D001145 NONE Antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 (+)-cibenzoline\NN\1740 and\CC\1740 <e1>(-)-cibenzoline</e1>\NN\1740 were\VBD\836236 examined\VBN\789138 using\VBG\1156834 two\CD\13741022 canine\NN\5282746 <e2>ventricular\NN\1740 arrhythmia</e2>\NN\14103288 models\NNS\5888929 .\.\1740
C032151_D001145 NONE Ten\CD\13745420 and\CC\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 <e1>(+)-cibenzoline</e1>\NN\1740 suppressed\VBD\2510337 digitalis-\NN\1740 and\CC\1740 adrenaline-induced\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 respectively\RB\1740 .\.\1740
C032151_D001145 NONE The\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 <e1>(+)-cibenzoline</e1>\NN\1740 for\IN\1740 digitalis-\JJ\1740 and\CC\1740 adrenaline-induced\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 were\VBD\836236 1.4\CD\1740 +/-\CC\1740 0.4\CD\1740 and\CC\1740 2.0\CD\1740 +/-\CC\1740 0.6\CD\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SD\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 .\.\1740
C032151_D001145 NONE A\DT\13649268 lower\JJR\1740 dose\NN\3740161 of\IN\1740 1\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 of\IN\1740 <e1>(-)-cibenzoline</e1>\NN\1740 suppressed\VBD\2510337 the\DT\1740 digitalis-induced\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 ,\,\1740 whereas\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 needed\VBN\2604760 to\TO\1740 suppress\VB\2510337 adrenaline-induced\JJ\1740 arrhythmias\NNS\14103288 .\.\1740
C032151_D001145 NONE A\DT\13649268 lower\JJR\1740 dose\NN\3740161 of\IN\1740 1\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 of\IN\1740 <e1>(-)-cibenzoline</e1>\NN\1740 suppressed\VBD\2510337 the\DT\1740 digitalis-induced\JJ\1740 arrhythmia\NN\14103288 ,\,\1740 whereas\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 needed\VBN\2604760 to\TO\1740 suppress\VB\2510337 adrenaline-induced\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 .\.\1740
C032151_D001145 NONE The\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 <e1>(-)-cibenzoline</e1>\NN\1740 for\IN\1740 digitalis-\JJ\1740 and\CC\1740 adrenaline-induced\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 were\VBD\836236 0.06\CD\1740 +/-\CC\1740 0.04\CD\1740 and\CC\1740 0.7\CD\1740 +/-\CC\1740 0.1\CD\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SD\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 .\.\1740
D004070_D001145 NONE <e1>Digitalis</e1>\NN\15059939 <e2>arrhythmia</e2>\NN\14103288 ,\,\1740 which\WDT\1740 is\VBZ\836236 suppressed\VBN\2510337 by\IN\1740 Na\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 intermittent\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 ouabain\NN\1740 in\IN\13603305 pentobarbital-anesthetized\JJ\1740 dogs\NNS\2083346 .\.\1740
D004070_D001145 NONE Ten\CD\13745420 and\CC\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 (+)-cibenzoline\NN\1740 suppressed\VBD\2510337 <e1>digitalis-</e1>\NN\1740 and\CC\1740 adrenaline-induced\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 respectively\RB\1740 .\.\1740
D004070_D001145 NONE The\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 (+)-cibenzoline\NN\1740 for\IN\1740 <e1>digitalis-</e1>\JJ\1740 and\CC\1740 adrenaline-induced\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 were\VBD\836236 1.4\CD\1740 +/-\CC\1740 0.4\CD\1740 and\CC\1740 2.0\CD\1740 +/-\CC\1740 0.6\CD\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SD\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 .\.\1740
D004070_D001145 NONE A\DT\13649268 lower\JJR\1740 dose\NN\3740161 of\IN\1740 1\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 of\IN\1740 (-)-cibenzoline\NN\1740 suppressed\VBD\2510337 the\DT\1740 <e1>digitalis-induced</e1>\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 ,\,\1740 whereas\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 needed\VBN\2604760 to\TO\1740 suppress\VB\2510337 adrenaline-induced\JJ\1740 arrhythmias\NNS\14103288 .\.\1740
D004070_D001145 NONE A\DT\13649268 lower\JJR\1740 dose\NN\3740161 of\IN\1740 1\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 of\IN\1740 (-)-cibenzoline\NN\1740 suppressed\VBD\2510337 the\DT\1740 <e1>digitalis-induced</e1>\JJ\1740 arrhythmia\NN\14103288 ,\,\1740 whereas\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 needed\VBN\2604760 to\TO\1740 suppress\VB\2510337 adrenaline-induced\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 .\.\1740
D004070_D001145 NONE The\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 (-)-cibenzoline\NN\1740 for\IN\1740 <e1>digitalis-</e1>\JJ\1740 and\CC\1740 adrenaline-induced\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 were\VBD\836236 0.06\CD\1740 +/-\CC\1740 0.04\CD\1740 and\CC\1740 0.7\CD\1740 +/-\CC\1740 0.1\CD\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SD\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 .\.\1740
D012964_D001145 NONE Digitalis\NN\15059939 <e2>arrhythmia</e2>\NN\14103288 ,\,\1740 which\WDT\1740 is\VBZ\836236 suppressed\VBN\2510337 by\IN\1740 <e1>Na</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 intermittent\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 ouabain\NN\1740 in\IN\13603305 pentobarbital-anesthetized\JJ\1740 dogs\NNS\2083346 .\.\1740
D010042_D001145 CID Digitalis\NN\15059939 <e2>arrhythmia</e2>\NN\14103288 ,\,\1740 which\WDT\1740 is\VBZ\836236 suppressed\VBN\2510337 by\IN\1740 Na\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 intermittent\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 <e1>ouabain</e1>\NN\1740 in\IN\13603305 pentobarbital-anesthetized\JJ\1740 dogs\NNS\2083346 .\.\1740
D010424_D001145 NONE Digitalis\NN\15059939 <e2>arrhythmia</e2>\NN\14103288 ,\,\1740 which\WDT\1740 is\VBZ\836236 suppressed\VBN\2510337 by\IN\1740 Na\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 intermittent\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 ouabain\NN\1740 in\IN\13603305 <e1>pentobarbital-anesthetized</e1>\JJ\1740 dogs\NNS\2083346 .\.\1740
D002118_D001145 NONE <e2>Adrenaline\NN\14807929 arrhythmia</e2>\NN\14103288 ,\,\1740 which\WDT\1740 is\VBZ\836236 suppressed\VBN\2510337 by\IN\1740 <e1>Ca</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 adrenaline\NN\14807929 infusion\NN\14589223 in\IN\13603305 halothane-anesthetized\JJ\1740 dogs\NNS\2083346 .\.\1740
D004837_D001145 CID <e2>Adrenaline\NN\14807929 arrhythmia</e2>\NN\14103288 ,\,\1740 which\WDT\1740 is\VBZ\836236 suppressed\VBN\2510337 by\IN\1740 Ca\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>adrenaline</e1>\NN\14807929 infusion\NN\14589223 in\IN\13603305 halothane-anesthetized\JJ\1740 dogs\NNS\2083346 .\.\1740
D004837_D001145 CID Ten\CD\13745420 and\CC\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 (+)-cibenzoline\NN\1740 suppressed\VBD\2510337 digitalis-\NN\1740 and\CC\1740 <e1>adrenaline-induced</e1>\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 respectively\RB\1740 .\.\1740
D004837_D001145 CID The\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 (+)-cibenzoline\NN\1740 for\IN\1740 digitalis-\JJ\1740 and\CC\1740 <e1>adrenaline-induced</e1>\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 were\VBD\836236 1.4\CD\1740 +/-\CC\1740 0.4\CD\1740 and\CC\1740 2.0\CD\1740 +/-\CC\1740 0.6\CD\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SD\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 .\.\1740
D004837_D001145 CID A\DT\13649268 lower\JJR\1740 dose\NN\3740161 of\IN\1740 1\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 of\IN\1740 (-)-cibenzoline\NN\1740 suppressed\VBD\2510337 the\DT\1740 digitalis-induced\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 ,\,\1740 whereas\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 needed\VBN\2604760 to\TO\1740 suppress\VB\2510337 <e1>adrenaline-induced</e1>\JJ\1740 arrhythmias\NNS\14103288 .\.\1740
D004837_D001145 CID A\DT\13649268 lower\JJR\1740 dose\NN\3740161 of\IN\1740 1\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 of\IN\1740 (-)-cibenzoline\NN\1740 suppressed\VBD\2510337 the\DT\1740 digitalis-induced\JJ\1740 arrhythmia\NN\14103288 ,\,\1740 whereas\IN\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 was\VBD\836236 needed\VBN\2604760 to\TO\1740 suppress\VB\2510337 <e1>adrenaline-induced</e1>\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 .\.\1740
D004837_D001145 CID The\DT\1740 minimum\JJ\1740 effective\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 (-)-cibenzoline\NN\1740 for\IN\1740 digitalis-\JJ\1740 and\CC\1740 <e1>adrenaline-induced</e1>\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 were\VBD\836236 0.06\CD\1740 +/-\CC\1740 0.04\CD\1740 and\CC\1740 0.7\CD\1740 +/-\CC\1740 0.1\CD\1740 micrograms/ml\NNS\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SD\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 )\-RRB-\1740 .\.\1740
D006221_D001145 NONE <e2>Adrenaline\NN\14807929 arrhythmia</e2>\NN\14103288 ,\,\1740 which\WDT\1740 is\VBZ\836236 suppressed\VBN\2510337 by\IN\1740 Ca\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 adrenaline\NN\14807929 infusion\NN\14589223 in\IN\13603305 <e1>halothane-anesthetized</e1>\JJ\1740 dogs\NNS\2083346 .\.\1740
6118280
D001569_D009207 NONE Serotonergic\JJ\1740 drugs\NNS\14778436 ,\,\1740 <e1>benzodiazepines</e1>\NNS\3771443 and\CC\1740 baclofen\VB\1740 block\NN\21939 muscimol-induced\JJ\1740 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 in\IN\13603305 a\DT\13649268 strain\NN\7358060 of\IN\1740 mice\NNS\2329401 .\.\1740
D001569_D009207 NONE Of\IN\1740 the\DT\1740 <e1>benzodiazepines</e1>\NNS\3771443 ,\,\1740 clonazepam\NN\1740 (\-LRB-\1740 0.1\CD\1740 -\SYM\1740 0.3\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 several\JJ\1740 fold\NN\13864763 more\RBR\1740 potent\JJ\1740 than\IN\1740 diazepam\NN\2830852 (\-LRB-\1740 0.3\CD\1740 -\SYM\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 blocking\VBG\1476483 the\DT\1740 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 .\.\1740
D001569_D009207 NONE Considering\VBG\689344 the\DT\1740 fact\NN\5816287 that\IN\1740 5-HTP\NN\1740 and\CC\1740 the\DT\1740 <e1>benzodiazepines</e1>\NNS\3771443 have\VBP\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 beneficial\JJ\1740 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 clinical\JJ\1740 <e2>myoclonus</e2>\NN\14360459 ,\,\1740 the\DT\1740 muscimol-induced\JJ\1740 myoclonus\NN\14360459 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 satisfactory\JJ\1740 animal\NN\4475 model\NN\5888929 that\WDT\1740 may\MD\15209706 prove\VB\2604760 useful\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 new\JJ\1740 drug\NN\14778436 treatments\NNS\654885 for\IN\1740 this\DT\1740 condition\NN\24720 .\.\1740
D001569_D009207 NONE Considering\VBG\689344 the\DT\1740 fact\NN\5816287 that\IN\1740 5-HTP\NN\1740 and\CC\1740 the\DT\1740 <e1>benzodiazepines</e1>\NNS\3771443 have\VBP\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 beneficial\JJ\1740 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 clinical\JJ\1740 myoclonus\NN\14360459 ,\,\1740 the\DT\1740 muscimol-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 satisfactory\JJ\1740 animal\NN\4475 model\NN\5888929 that\WDT\1740 may\MD\15209706 prove\VB\2604760 useful\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 new\JJ\1740 drug\NN\14778436 treatments\NNS\654885 for\IN\1740 this\DT\1740 condition\NN\24720 .\.\1740
D001418_D009207 NONE Serotonergic\JJ\1740 drugs\NNS\14778436 ,\,\1740 benzodiazepines\NNS\3771443 and\CC\1740 <e1>baclofen</e1>\VB\1740 block\NN\21939 muscimol-induced\JJ\1740 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 in\IN\13603305 a\DT\13649268 strain\NN\7358060 of\IN\1740 mice\NNS\2329401 .\.\1740
D001418_D009207 NONE Our\PRP$\1740 present\JJ\1740 study\NN\635850 indicated\VBD\952524 the\DT\1740 possible\JJ\1740 value\NN\5856066 of\IN\1740 MK-212\NN\1740 and\CC\1740 <e1>(-)-baclofen</e1>\NN\1740 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 clinical\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D009118_D009207 CID Serotonergic\JJ\1740 drugs\NNS\14778436 ,\,\1740 benzodiazepines\NNS\3771443 and\CC\1740 baclofen\VB\1740 block\NN\21939 <e1>muscimol-induced</e1>\JJ\1740 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 in\IN\13603305 a\DT\13649268 strain\NN\7358060 of\IN\1740 mice\NNS\2329401 .\.\1740
D009118_D009207 CID In\IN\13603305 male\JJ\1740 Swiss\JJ\1740 mice\NNS\2329401 ,\,\1740 <e1>muscimol</e1>\NN\1740 produced\VBD\1617192 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 .\.\1740
D009118_D009207 CID Considering\VBG\689344 the\DT\1740 fact\NN\5816287 that\IN\1740 5-HTP\NN\1740 and\CC\1740 the\DT\1740 benzodiazepines\NNS\3771443 have\VBP\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 beneficial\JJ\1740 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 clinical\JJ\1740 <e2>myoclonus</e2>\NN\14360459 ,\,\1740 the\DT\1740 <e1>muscimol-induced</e1>\JJ\1740 myoclonus\NN\14360459 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 satisfactory\JJ\1740 animal\NN\4475 model\NN\5888929 that\WDT\1740 may\MD\15209706 prove\VB\2604760 useful\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 new\JJ\1740 drug\NN\14778436 treatments\NNS\654885 for\IN\1740 this\DT\1740 condition\NN\24720 .\.\1740
D009118_D009207 CID Considering\VBG\689344 the\DT\1740 fact\NN\5816287 that\IN\1740 5-HTP\NN\1740 and\CC\1740 the\DT\1740 benzodiazepines\NNS\3771443 have\VBP\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 beneficial\JJ\1740 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 clinical\JJ\1740 myoclonus\NN\14360459 ,\,\1740 the\DT\1740 <e1>muscimol-induced</e1>\JJ\1740 <e2>myoclonus</e2>\NN\14360459 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 satisfactory\JJ\1740 animal\NN\4475 model\NN\5888929 that\WDT\1740 may\MD\15209706 prove\VB\2604760 useful\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 new\JJ\1740 drug\NN\14778436 treatments\NNS\654885 for\IN\1740 this\DT\1740 condition\NN\24720 .\.\1740
D002998_D009207 NONE Of\IN\1740 the\DT\1740 benzodiazepines\NNS\3771443 ,\,\1740 <e1>clonazepam</e1>\NN\1740 (\-LRB-\1740 0.1\CD\1740 -\SYM\1740 0.3\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 several\JJ\1740 fold\NN\13864763 more\RBR\1740 potent\JJ\1740 than\IN\1740 diazepam\NN\2830852 (\-LRB-\1740 0.3\CD\1740 -\SYM\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 blocking\VBG\1476483 the\DT\1740 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 .\.\1740
D003975_D009207 NONE Of\IN\1740 the\DT\1740 benzodiazepines\NNS\3771443 ,\,\1740 clonazepam\NN\1740 (\-LRB-\1740 0.1\CD\1740 -\SYM\1740 0.3\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 several\JJ\1740 fold\NN\13864763 more\RBR\1740 potent\JJ\1740 than\IN\1740 <e1>diazepam</e1>\NN\2830852 (\-LRB-\1740 0.3\CD\1740 -\SYM\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 blocking\VBG\1476483 the\DT\1740 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 .\.\1740
D006916_D009207 NONE Considering\VBG\689344 the\DT\1740 fact\NN\5816287 that\IN\1740 <e1>5-HTP</e1>\NN\1740 and\CC\1740 the\DT\1740 benzodiazepines\NNS\3771443 have\VBP\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 beneficial\JJ\1740 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 clinical\JJ\1740 <e2>myoclonus</e2>\NN\14360459 ,\,\1740 the\DT\1740 muscimol-induced\JJ\1740 myoclonus\NN\14360459 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 satisfactory\JJ\1740 animal\NN\4475 model\NN\5888929 that\WDT\1740 may\MD\15209706 prove\VB\2604760 useful\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 new\JJ\1740 drug\NN\14778436 treatments\NNS\654885 for\IN\1740 this\DT\1740 condition\NN\24720 .\.\1740
D006916_D009207 NONE Considering\VBG\689344 the\DT\1740 fact\NN\5816287 that\IN\1740 <e1>5-HTP</e1>\NN\1740 and\CC\1740 the\DT\1740 benzodiazepines\NNS\3771443 have\VBP\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 beneficial\JJ\1740 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 clinical\JJ\1740 myoclonus\NN\14360459 ,\,\1740 the\DT\1740 muscimol-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 satisfactory\JJ\1740 animal\NN\4475 model\NN\5888929 that\WDT\1740 may\MD\15209706 prove\VB\2604760 useful\JJ\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 new\JJ\1740 drug\NN\14778436 treatments\NNS\654885 for\IN\1740 this\DT\1740 condition\NN\24720 .\.\1740
C014896_D009207 NONE Our\PRP$\1740 present\JJ\1740 study\NN\635850 indicated\VBD\952524 the\DT\1740 possible\JJ\1740 value\NN\5856066 of\IN\1740 <e1>MK-212</e1>\NN\1740 and\CC\1740 (-)-baclofen\NN\1740 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 clinical\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
20552622
D000420_D013617 CID Swallowing-induced\JJ\1740 <e2>atrial\JJ\1740 tachyarrhythmia</e2>\NN\1740 triggered\VBN\1641914 by\IN\1740 <e1>salbutamol</e1>\NN\1740 :\:\1740 case\NN\7283608 report\NN\6470073 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
D000420_D013617 CID CONCLUSION\NN\5837957 :\:\1740 <e1>Salbutamol</e1>\NNP\1740 is\VBZ\836236 presented\VBN\2137132 here\RB\1740 as\IN\14622893 a\DT\13649268 possible\JJ\1740 trigger\NN\3659292 for\IN\1740 <e2>SIAT</e2>\NN\1740 .\.\1740
D001262_D001145 NONE The\DT\1740 <e2>arrhythmia</e2>\NN\14103288 resolved\VBN\352826 after\IN\1740 therapy\NN\657604 with\IN\1740 <e1>atenolol</e1>\NNS\2832168 ,\,\1740 but\CC\1740 recurred\VBD\339934 a\DT\13649268 year\NN\15113229 later\RB\1740 .\.\1740
D001262_D001145 NONE After\IN\1740 stopping\VBG\2452885 the\DT\1740 beta-agonist\JJ\1740 ,\,\1740 and\CC\1740 after\IN\1740 a\DT\13649268 week\NN\15113229 with\IN\1740 the\DT\1740 <e1>atenolol</e1>\NNS\2832168 ,\,\1740 the\DT\1740 <e2>arrhythmia</e2>\NN\14103288 disappeared\VBD\2609764 .\.\1740
D000420_D013610 NONE Although\IN\1740 it\PRP\6125041 is\VBZ\836236 difficult\JJ\1740 to\TO\1740 define\VB\2604760 causality\NN\31921 in\IN\13603305 a\DT\13649268 case\NN\7283608 report\NN\6470073 ,\,\1740 it\PRP\6125041 is\VBZ\836236 logical\JJ\1740 to\TO\1740 think\VB\670261 that\IN\1740 a\DT\13649268 beta-agonist\JJ\1740 like\UH\5839024 <e1>salbutamol</e1>\NN\1740 (\-LRB-\1740 known\VBN\2110220 to\TO\1740 induce\VB\1627355 <e2>tachycardia</e2>\NN\14110674 )\-RRB-\1740 may\MD\15209706 be\VB\836236 the\DT\1740 trigger\NN\3659292 of\IN\1740 adrenergic\JJ\1740 reflexes\NNS\859001 originating\VBG\2623529 in\IN\13603305 the\DT\1740 esophagus\NN\5461816 while\IN\15122231 swallowing\VBG\1156834 and\CC\1740 that\IN\1740 a\DT\13649268 beta-blocker\NN\1740 such\JJ\1740 as\IN\14622893 atenolol\NNS\2832168 (\-LRB-\1740 that\WDT\1740 blocks\VBZ\1476483 the\DT\1740 adrenergic\JJ\1740 activity\NN\30358 )\-RRB-\1740 may\MD\15209706 relieve\VB\205885 it\PRP\6125041 .\.\1740
D001262_D013610 NONE Although\IN\1740 it\PRP\6125041 is\VBZ\836236 difficult\JJ\1740 to\TO\1740 define\VB\2604760 causality\NN\31921 in\IN\13603305 a\DT\13649268 case\NN\7283608 report\NN\6470073 ,\,\1740 it\PRP\6125041 is\VBZ\836236 logical\JJ\1740 to\TO\1740 think\VB\670261 that\IN\1740 a\DT\13649268 beta-agonist\JJ\1740 like\UH\5839024 salbutamol\NN\1740 (\-LRB-\1740 known\VBN\2110220 to\TO\1740 induce\VB\1627355 <e2>tachycardia</e2>\NN\14110674 )\-RRB-\1740 may\MD\15209706 be\VB\836236 the\DT\1740 trigger\NN\3659292 of\IN\1740 adrenergic\JJ\1740 reflexes\NNS\859001 originating\VBG\2623529 in\IN\13603305 the\DT\1740 esophagus\NN\5461816 while\IN\15122231 swallowing\VBG\1156834 and\CC\1740 that\IN\1740 a\DT\13649268 beta-blocker\NN\1740 such\JJ\1740 as\IN\14622893 <e1>atenolol</e1>\NNS\2832168 (\-LRB-\1740 that\WDT\1740 blocks\VBZ\1476483 the\DT\1740 adrenergic\JJ\1740 activity\NN\30358 )\-RRB-\1740 may\MD\15209706 relieve\VB\205885 it\PRP\6125041 .\.\1740
11282081
D014700_D001281 CID Effects\NNS\13245626 of\IN\1740 <e1>verapamil</e1>\NN\2938514 on\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 and\CC\1740 its\PRP$\6125041 electrophysiological\JJ\1740 determinants\NNS\5686481 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D014700_D001281 CID METHODS\NNS\5616786 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 potential\JJ\1740 mechanisms\NNS\13446390 of\IN\1740 <e2>AF</e2>\NN\1740 promotion\NN\6598915 by\IN\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 we\PRP\1740 administered\VBD\2436349 <e1>verapamil</e1>\NNS\2938514 to\TO\1740 morphine-chloralose\RB\1740 anesthetized\JJ\1740 dogs\NNS\2083346 .\.\1740
D014700_D001281 CID RESULTS\NNS\34213 :\:\1740 <e1>Verapamil</e1>\NNS\2938514 caused\VBD\1617192 <e2>AF</e2>\NN\1740 promotion\NN\6598915 in\IN\13603305 six\CD\13741022 dogs\NNS\2083346 ,\,\1740 increasing\VBG\169651 mean\NN\6021761 duration\NN\15113229 of\IN\1740 AF\NN\1740 induced\VBN\1627355 by\IN\1740 burst\NN\376063 pacing\NN\15122011 ,\,\1740 from\IN\1740 8+/-4\JJ\1740 s\NNS\15154774 (\-LRB-\1740 mean+/-S.E.\JJ\1740 )\-RRB-\1740 to\TO\1740 95+/-39\CD\1740 s\NNS\15154774 (\-LRB-\1740 P<0.01\NN\1740 vs.\NN\1740 control\NN\5190804 )\-RRB-\1740 at\IN\14622893 a\DT\13649268 loading\NN\4571088 dose\NN\3740161 of\IN\1740 0.1\CD\1740 mg/kg\NN\1740 and\CC\1740 228+/-101\CD\1740 s\NNS\15154774 (\-LRB-\1740 P<0.0005\NN\1740 vs.\IN\1740 control\NN\5190804 )\-RRB-\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 0.2\CD\1740 mg/kg\NN\1740 .\.\1740
D014700_D001281 CID RESULTS\NNS\34213 :\:\1740 <e1>Verapamil</e1>\NNS\2938514 caused\VBD\1617192 AF\NN\1740 promotion\NN\6598915 in\IN\13603305 six\CD\13741022 dogs\NNS\2083346 ,\,\1740 increasing\VBG\169651 mean\NN\6021761 duration\NN\15113229 of\IN\1740 <e2>AF</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 burst\NN\376063 pacing\NN\15122011 ,\,\1740 from\IN\1740 8+/-4\JJ\1740 s\NNS\15154774 (\-LRB-\1740 mean+/-S.E.\JJ\1740 )\-RRB-\1740 to\TO\1740 95+/-39\CD\1740 s\NNS\15154774 (\-LRB-\1740 P<0.01\NN\1740 vs.\NN\1740 control\NN\5190804 )\-RRB-\1740 at\IN\14622893 a\DT\13649268 loading\NN\4571088 dose\NN\3740161 of\IN\1740 0.1\CD\1740 mg/kg\NN\1740 and\CC\1740 228+/-101\CD\1740 s\NNS\15154774 (\-LRB-\1740 P<0.0005\NN\1740 vs.\IN\1740 control\NN\5190804 )\-RRB-\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 0.2\CD\1740 mg/kg\NN\1740 .\.\1740
D014700_D001281 CID In\IN\13603305 these\DT\1740 experiments\NNS\641820 ,\,\1740 <e1>verapamil</e1>\NN\2938514 shortened\VBD\429060 mean\NN\6021761 effective\JJ\1740 refractory\JJ\1740 period\NN\13575869 (\-LRB-\1740 ERP\NN\1740 )\-RRB-\1740 from\IN\1740 122+/-5\CD\1740 to\TO\1740 114+/-4\CD\1740 ms\NN\14187378 (\-LRB-\1740 P<0.02\NN\1740 )\-RRB-\1740 at\IN\14622893 a\DT\13649268 cycle\NN\15269513 length\NN\5093581 of\IN\1740 300\CD\1740 ms\NN\14187378 ,\,\1740 decreased\VBD\169651 ERP\NN\1740 heterogeneity\NN\4750940 (\-LRB-\1740 from\IN\1740 15+/-1\CD\1740 to\TO\1740 10+/-1\CD\1740 %\NN\1740 ,\,\1740 P<0.05\NN\1740 )\-RRB-\1740 ,\,\1740 heterogeneously\RB\1740 accelerated\VBD\226566 atrial\JJ\1740 conduction\NN\11419404 and\CC\1740 decreased\VBD\169651 the\DT\1740 cycle\NN\15269513 length\NN\5093581 of\IN\1740 <e2>AF</e2>\NN\1740 (\-LRB-\1740 94+/-4\CD\1740 to\TO\1740 84+/-3\CD\1740 ms\NN\14187378 ,\,\1740 P<0.005\JJ\1740 )\-RRB-\1740 .\.\1740
D014700_D001281 CID Diltiazem\NNP\2938514 did\VBD\1640855 not\RB\1740 affect\VB\126264 ERP\NN\1740 ,\,\1740 <e2>AF</e2>\NN\1740 cycle\NN\15269513 length\NN\5093581 or\CC\3541091 AF\NN\1740 duration\NN\15113229 ,\,\1740 but\CC\1740 produced\VBD\1617192 conduction\NN\11419404 acceleration\NN\7296428 similar\JJ\1740 to\TO\1740 that\DT\1740 caused\VBN\1617192 by\IN\1740 <e1>verapamil</e1>\NN\2938514 (\-LRB-\1740 n=5\JJ\1740 )\-RRB-\1740 .\.\1740
D014700_D001281 CID Diltiazem\NNP\2938514 did\VBD\1640855 not\RB\1740 affect\VB\126264 ERP\NN\1740 ,\,\1740 AF\NN\1740 cycle\NN\15269513 length\NN\5093581 or\CC\3541091 <e2>AF</e2>\NN\1740 duration\NN\15113229 ,\,\1740 but\CC\1740 produced\VBD\1617192 conduction\NN\11419404 acceleration\NN\7296428 similar\JJ\1740 to\TO\1740 that\DT\1740 caused\VBN\1617192 by\IN\1740 <e1>verapamil</e1>\NN\2938514 (\-LRB-\1740 n=5\JJ\1740 )\-RRB-\1740 .\.\1740
D014700_D001281 CID In\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 autonomic\JJ\1740 blockade\NN\952963 ,\,\1740 <e1>verapamil</e1>\NN\2938514 failed\VBD\1798936 to\TO\1740 promote\VB\2556126 <e2>AF</e2>\NN\1740 and\CC\1740 increased\VBD\169651 ,\,\1740 rather\RB\1740 than\IN\1740 decreasing\VBG\169651 ,\,\1740 refractoriness\VB\1740 .\.\1740
D014700_D001281 CID Epicardial\JJ\1740 mapping\NN\13783581 suggested\VBD\1010118 that\IN\1740 <e1>verapamil</e1>\NN\2938514 promoted\VBD\2556126 <e2>AF</e2>\NN\1740 by\IN\1740 increasing\VBG\169651 the\DT\1740 number\NN\5107765 of\IN\1740 simultaneous\JJ\1740 wavefronts\NNS\8660339 reflected\VBN\923793 by\IN\1740 separate\JJ\1740 zones\NNS\8664443 of\IN\1740 reactivation\NN\1740 in\IN\13603305 each\DT\1740 cycle\NN\15269513 .\.\1740
D014700_D001281 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Verapamil</e1>\NN\2938514 promotes\VBZ\2556126 <e2>AF</e2>\NN\1740 in\IN\13603305 normal\JJ\1740 dogs\NNS\2083346 by\IN\1740 promoting\VBG\2556126 multiple\JJ\1740 circuit\NN\3269401 reentry\NN\328015 ,\,\1740 an\DT\6697703 effect\NN\34213 dependent\JJ\1740 on\IN\1740 intact\JJ\1740 autonomic\JJ\1740 tone\NN\7071483 and\CC\1740 not\RB\1740 shared\VBN\2660631 by\IN\1740 diltiazem\NN\2938514 .\.\1740
D002118_D013617 NONE BACKGROUND\NN\4921011 :\:\1740 <e2>Atrial\JJ\1740 tachycardia-induced</e2>\JJ\1740 remodeling\NN\1740 promotes\VBZ\2556126 the\DT\1740 occurrence\NN\29378 and\CC\1740 maintenance\NN\266806 of\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 and\CC\1740 decreases\VBZ\169651 L-type\NN\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 current\JJ\1740 .\.\1740
D002118_D001281 NONE BACKGROUND\NN\4921011 :\:\1740 Atrial\JJ\1740 tachycardia-induced\JJ\1740 remodeling\NN\1740 promotes\VBZ\2556126 the\DT\1740 occurrence\NN\29378 and\CC\1740 maintenance\NN\266806 of\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 and\CC\1740 decreases\VBZ\169651 L-type\NN\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 current\JJ\1740 .\.\1740
D002118_D001281 NONE BACKGROUND\NN\4921011 :\:\1740 Atrial\JJ\1740 tachycardia-induced\JJ\1740 remodeling\NN\1740 promotes\VBZ\2556126 the\DT\1740 occurrence\NN\29378 and\CC\1740 maintenance\NN\266806 of\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 <e2>AF</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 decreases\VBZ\169651 L-type\NN\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 current\JJ\1740 .\.\1740
D002118_D001281 NONE There\EX\27167 is\VBZ\836236 also\RB\1740 a\DT\13649268 clinical\JJ\1740 suggestion\NN\5833840 that\IN\1740 acute\JJ\1740 L-type\NN\1740 <e1>Ca(2</e1>\NN\1740 )\-RRB-\1740 channel\NN\6251781 blockade\NN\952963 can\MD\3094503 promote\VB\2556126 <e2>AF</e2>\NN\1740 ,\,\1740 consistent\JJ\1740 with\IN\1740 an\DT\6697703 AF\NN\1740 promoting\NN\1740 effect\NN\34213 of\IN\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 channel\NN\6251781 inhibition\NN\1068773 .\.\1740
D002118_D001281 NONE There\EX\27167 is\VBZ\836236 also\RB\1740 a\DT\13649268 clinical\JJ\1740 suggestion\NN\5833840 that\IN\1740 acute\JJ\1740 L-type\NN\1740 <e1>Ca(2</e1>\NN\1740 )\-RRB-\1740 channel\NN\6251781 blockade\NN\952963 can\MD\3094503 promote\VB\2556126 AF\NN\1740 ,\,\1740 consistent\JJ\1740 with\IN\1740 an\DT\6697703 <e2>AF</e2>\NN\1740 promoting\NN\1740 effect\NN\34213 of\IN\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 channel\NN\6251781 inhibition\NN\1068773 .\.\1740
D002118_D001281 NONE There\EX\27167 is\VBZ\836236 also\RB\1740 a\DT\13649268 clinical\JJ\1740 suggestion\NN\5833840 that\IN\1740 acute\JJ\1740 L-type\NN\1740 Ca(2\NN\1740 )\-RRB-\1740 channel\NN\6251781 blockade\NN\952963 can\MD\3094503 promote\VB\2556126 <e2>AF</e2>\NN\1740 ,\,\1740 consistent\JJ\1740 with\IN\1740 an\DT\6697703 AF\NN\1740 promoting\NN\1740 effect\NN\34213 of\IN\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 channel\NN\6251781 inhibition\NN\1068773 .\.\1740
D002118_D001281 NONE There\EX\27167 is\VBZ\836236 also\RB\1740 a\DT\13649268 clinical\JJ\1740 suggestion\NN\5833840 that\IN\1740 acute\JJ\1740 L-type\NN\1740 Ca(2\NN\1740 )\-RRB-\1740 channel\NN\6251781 blockade\NN\952963 can\MD\3094503 promote\VB\2556126 AF\NN\1740 ,\,\1740 consistent\JJ\1740 with\IN\1740 an\DT\6697703 <e2>AF</e2>\NN\1740 promoting\NN\1740 effect\NN\34213 of\IN\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 channel\NN\6251781 inhibition\NN\1068773 .\.\1740
D002118_D001281 NONE METHODS\NNS\5616786 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 potential\JJ\1740 mechanisms\NNS\13446390 of\IN\1740 <e2>AF</e2>\NN\1740 promotion\NN\6598915 by\IN\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 we\PRP\1740 administered\VBD\2436349 verapamil\NNS\2938514 to\TO\1740 morphine-chloralose\RB\1740 anesthetized\JJ\1740 dogs\NNS\2083346 .\.\1740
D009020_D001281 NONE METHODS\NNS\5616786 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 potential\JJ\1740 mechanisms\NNS\13446390 of\IN\1740 <e2>AF</e2>\NN\1740 promotion\NN\6598915 by\IN\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 we\PRP\1740 administered\VBD\2436349 verapamil\NNS\2938514 to\TO\1740 <e1>morphine-chloralose</e1>\RB\1740 anesthetized\JJ\1740 dogs\NNS\2083346 .\.\1740
D002698_D001281 NONE METHODS\NNS\5616786 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 potential\JJ\1740 mechanisms\NNS\13446390 of\IN\1740 <e2>AF</e2>\NN\1740 promotion\NN\6598915 by\IN\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 we\PRP\1740 administered\VBD\2436349 verapamil\NNS\2938514 to\TO\1740 <e1>morphine-chloralose</e1>\RB\1740 anesthetized\JJ\1740 dogs\NNS\2083346 .\.\1740
D004110_D001281 NONE <e1>Diltiazem</e1>\NNP\2938514 did\VBD\1640855 not\RB\1740 affect\VB\126264 ERP\NN\1740 ,\,\1740 <e2>AF</e2>\NN\1740 cycle\NN\15269513 length\NN\5093581 or\CC\3541091 AF\NN\1740 duration\NN\15113229 ,\,\1740 but\CC\1740 produced\VBD\1617192 conduction\NN\11419404 acceleration\NN\7296428 similar\JJ\1740 to\TO\1740 that\DT\1740 caused\VBN\1617192 by\IN\1740 verapamil\NN\2938514 (\-LRB-\1740 n=5\JJ\1740 )\-RRB-\1740 .\.\1740
D004110_D001281 NONE <e1>Diltiazem</e1>\NNP\2938514 did\VBD\1640855 not\RB\1740 affect\VB\126264 ERP\NN\1740 ,\,\1740 AF\NN\1740 cycle\NN\15269513 length\NN\5093581 or\CC\3541091 <e2>AF</e2>\NN\1740 duration\NN\15113229 ,\,\1740 but\CC\1740 produced\VBD\1617192 conduction\NN\11419404 acceleration\NN\7296428 similar\JJ\1740 to\TO\1740 that\DT\1740 caused\VBN\1617192 by\IN\1740 verapamil\NN\2938514 (\-LRB-\1740 n=5\JJ\1740 )\-RRB-\1740 .\.\1740
D004110_D001281 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Verapamil\NN\2938514 promotes\VBZ\2556126 <e2>AF</e2>\NN\1740 in\IN\13603305 normal\JJ\1740 dogs\NNS\2083346 by\IN\1740 promoting\VBG\2556126 multiple\JJ\1740 circuit\NN\3269401 reentry\NN\328015 ,\,\1740 an\DT\6697703 effect\NN\34213 dependent\JJ\1740 on\IN\1740 intact\JJ\1740 autonomic\JJ\1740 tone\NN\7071483 and\CC\1740 not\RB\1740 shared\VBN\2660631 by\IN\1740 <e1>diltiazem</e1>\NN\2938514 .\.\1740
7650771
D004456_D064420 NONE Cholinergic\JJ\1740 <e2>toxicity</e2>\NN\13576101 resulting\VBG\2633881 from\IN\1740 ocular\JJ\1740 instillation\NN\320852 of\IN\1740 <e1>echothiophate\JJ\1740 iodide</e1>\NN\14904359 eye\NN\5299178 drops\NNS\13899200 .\.\1740
D004456_D018908 CID A\DT\13649268 patient\NN\9898892 developed\VBD\1753788 a\DT\13649268 severe\JJ\1740 cholinergic\JJ\1740 syndrome\NN\5870365 from\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>echothiophate\JJ\1740 iodide</e1>\NN\14904359 ophthalmic\JJ\1740 drops\NNS\13899200 ,\,\1740 presented\VBN\2137132 with\IN\1740 profound\JJ\1740 <e2>muscle\NN\5289601 weakness</e2>\NN\14462666 and\CC\1740 was\VBD\836236 initially\RB\1740 given\VBN\2327200 the\DT\1740 diagnosis\NN\152018 of\IN\1740 myasthenia\JJ\1740 gravis\NN\1740 .\.\1740
D004456_D009157 NONE A\DT\13649268 patient\NN\9898892 developed\VBD\1753788 a\DT\13649268 severe\JJ\1740 cholinergic\JJ\1740 syndrome\NN\5870365 from\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>echothiophate\JJ\1740 iodide</e1>\NN\14904359 ophthalmic\JJ\1740 drops\NNS\13899200 ,\,\1740 presented\VBN\2137132 with\IN\1740 profound\JJ\1740 muscle\NN\5289601 weakness\NN\14462666 and\CC\1740 was\VBD\836236 initially\RB\1740 given\VBN\2327200 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e2>myasthenia\JJ\1740 gravis</e2>\NN\1740 .\.\1740
19893084
D005839_D058186 CID In\IN\13603305 this\DT\1740 study\NN\635850 we\PRP\1740 postulated\VBD\756338 that\IN\1740 during\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 induced\VBN\1627355 by\IN\1740 <e1>gentamicin</e1>\NN\2716866 the\DT\1740 transient\JJ\1740 or\CC\3541091 dynamic\JJ\1740 response\NN\11410625 of\IN\1740 blood\NN\5397468 vessels\NNS\5246511 could\MD\1740 be\VB\836236 affected\VBN\126264 ,\,\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 can\MD\3094503 prevent\VB\1740 the\DT\1740 changes\NNS\7283608 in\IN\13603305 dynamic\JJ\1740 responses\NNS\11410625 of\IN\1740 blood\NN\5397468 vessels\NNS\5246511 .\.\1740
7066357
D011692_D009404 CID Plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 lipids\NNS\14944888 and\CC\1740 lipoproteins\NNS\14731135 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 in\IN\13603305 the\DT\1740 rat\NN\2329401 by\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 .\.\1740
D011692_D009404 CID This\DT\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 ascertain\VB\664483 whether\IN\1740 the\DT\1740 alterations\NNS\7283608 of\IN\1740 plasma\NN\5398023 lipoproteins\NNS\14731135 found\VBN\2426171 in\IN\13603305 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 were\VBD\836236 due\JJ\1740 to\TO\1740 nephrotic\JJ\1740 syndrome\NN\5870365 per\IN\1740 se\FW\14724645 ,\,\1740 or\CC\3541091 ,\,\1740 at\IN\14622893 least\JJS\1740 in\IN\13603305 part\NN\31921 ,\,\1740 to\TO\1740 the\DT\1740 aminonucleoside\NN\1740 .\.\1740
D011692_D009404 CID This\DT\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 ascertain\VB\664483 whether\IN\1740 the\DT\1740 alterations\NNS\7283608 of\IN\1740 plasma\NN\5398023 lipoproteins\NNS\14731135 found\VBN\2426171 in\IN\13603305 nephrotic\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 were\VBD\836236 due\JJ\1740 to\TO\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 per\IN\1740 se\FW\14724645 ,\,\1740 or\CC\3541091 ,\,\1740 at\IN\14622893 least\JJS\1740 in\IN\13603305 part\NN\31921 ,\,\1740 to\TO\1740 the\DT\1740 aminonucleoside\NN\1740 .\.\1740
D011692_D009404 CID This\DT\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 ascertain\VB\664483 whether\IN\1740 the\DT\1740 alterations\NNS\7283608 of\IN\1740 plasma\NN\5398023 lipoproteins\NNS\14731135 found\VBN\2426171 in\IN\13603305 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 were\VBD\836236 due\JJ\1740 to\TO\1740 nephrotic\JJ\1740 syndrome\NN\5870365 per\IN\1740 se\FW\14724645 ,\,\1740 or\CC\3541091 ,\,\1740 at\IN\14622893 least\JJS\1740 in\IN\13603305 part\NN\31921 ,\,\1740 to\TO\1740 the\DT\1740 <e1>aminonucleoside</e1>\NN\1740 .\.\1740
D011692_D009404 CID This\DT\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 ascertain\VB\664483 whether\IN\1740 the\DT\1740 alterations\NNS\7283608 of\IN\1740 plasma\NN\5398023 lipoproteins\NNS\14731135 found\VBN\2426171 in\IN\13603305 nephrotic\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 were\VBD\836236 due\JJ\1740 to\TO\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 per\IN\1740 se\FW\14724645 ,\,\1740 or\CC\3541091 ,\,\1740 at\IN\14622893 least\JJS\1740 in\IN\13603305 part\NN\31921 ,\,\1740 to\TO\1740 the\DT\1740 <e1>aminonucleoside</e1>\NN\1740 .\.\1740
D011692_D009404 CID The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 changes\NNS\7283608 in\IN\13603305 plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 lipoproteins\NNS\14731135 during\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 for\IN\1740 7\CD\13741022 days\NNS\15140892 )\-RRB-\1740 and\CC\1740 the\DT\1740 subsequent\JJ\1740 development\NN\248977 of\IN\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D005227_D009404 NONE In\IN\13603305 <e2>pre-nephrotic</e2>\JJ\1740 stage\NN\15113229 the\DT\1740 plasma\NN\5398023 level\NN\4916342 of\IN\1740 <e1>fatty\JJ\1740 acids</e1>\NNS\14818238 ,\,\1740 triacylglycerol\NN\1740 and\CC\1740 VLDL\NN\14939230 decreased\VBD\169651 while\IN\15122231 that\DT\1740 of\IN\1740 phospholipid\NN\14938907 ,\,\1740 cholesteryl\NN\1740 esters\NNS\14727670 and\CC\1740 HDL\NN\14939230 remained\VBD\2604760 constant\JJ\1740 .\.\1740
D014280_D009404 NONE In\IN\13603305 <e2>pre-nephrotic</e2>\JJ\1740 stage\NN\15113229 the\DT\1740 plasma\NN\5398023 level\NN\4916342 of\IN\1740 fatty\JJ\1740 acids\NNS\14818238 ,\,\1740 <e1>triacylglycerol</e1>\NN\1740 and\CC\1740 VLDL\NN\14939230 decreased\VBD\169651 while\IN\15122231 that\DT\1740 of\IN\1740 phospholipid\NN\14938907 ,\,\1740 cholesteryl\NN\1740 esters\NNS\14727670 and\CC\1740 HDL\NN\14939230 remained\VBD\2604760 constant\JJ\1740 .\.\1740
D002788_D009404 NONE In\IN\13603305 <e2>pre-nephrotic</e2>\JJ\1740 stage\NN\15113229 the\DT\1740 plasma\NN\5398023 level\NN\4916342 of\IN\1740 fatty\JJ\1740 acids\NNS\14818238 ,\,\1740 triacylglycerol\NN\1740 and\CC\1740 VLDL\NN\14939230 decreased\VBD\169651 while\IN\15122231 that\DT\1740 of\IN\1740 phospholipid\NN\14938907 ,\,\1740 <e1>cholesteryl\NN\1740 esters</e1>\NNS\14727670 and\CC\1740 HDL\NN\14939230 remained\VBD\2604760 constant\JJ\1740 .\.\1740
3962737
D000638_D056486 CID <e2>Hepatotoxicity</e2>\NN\1740 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 .\.\1740
D000638_D056486 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 due\JJ\1740 to\TO\1740 <e1>amiodarone</e1>\NN\2715941 treatment\NN\654885 is\VBZ\836236 presented\VBN\2137132 below\IN\1740 and\CC\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 hepatotoxicity\NN\1740 of\IN\1740 amiodarone\NN\2715941 is\VBZ\836236 given\VBN\2327200 .\.\1740
D000638_D056486 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 cholestatic\JJ\1740 hepatitis\NN\14127211 due\JJ\1740 to\TO\1740 <e1>amiodarone</e1>\NN\2715941 treatment\NN\654885 is\VBZ\836236 presented\VBN\2137132 below\IN\1740 and\CC\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 <e2>hepatotoxicity</e2>\NN\1740 of\IN\1740 amiodarone\NN\2715941 is\VBZ\836236 given\VBN\2327200 .\.\1740
D000638_D056486 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 due\JJ\1740 to\TO\1740 amiodarone\NN\2715941 treatment\NN\654885 is\VBZ\836236 presented\VBN\2137132 below\IN\1740 and\CC\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 hepatotoxicity\NN\1740 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 is\VBZ\836236 given\VBN\2327200 .\.\1740
D000638_D056486 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 cholestatic\JJ\1740 hepatitis\NN\14127211 due\JJ\1740 to\TO\1740 amiodarone\NN\2715941 treatment\NN\654885 is\VBZ\836236 presented\VBN\2137132 below\IN\1740 and\CC\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 <e2>hepatotoxicity</e2>\NN\1740 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 is\VBZ\836236 given\VBN\2327200 .\.\1740
D000638_D056486 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 solid\JJ\1740 evidence\NN\5816287 exists\NNS\1740 of\IN\1740 <e2>hepatic\JJ\1740 injury</e2>\NN\14052046 due\IN\5174653 to\TO\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 ,\,\1740 including\VBG\690614 steatosis\NN\1740 ,\,\1740 alterations\NNS\7283608 resembling\VBG\2657219 alcoholic\JJ\1740 hepatitis\NN\14127211 ,\,\1740 cholestatic\JJ\1740 hepatitis\NN\14127211 and\CC\1740 micronodular\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D000638_D056486 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 solid\JJ\1740 evidence\NN\5816287 exists\NNS\1740 of\IN\1740 hepatic\JJ\1740 injury\NN\14052046 due\IN\5174653 to\TO\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 ,\,\1740 including\VBG\690614 steatosis\NN\1740 ,\,\1740 alterations\NNS\7283608 resembling\VBG\2657219 alcoholic\JJ\1740 hepatitis\NN\14127211 ,\,\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 and\CC\1740 micronodular\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D000638_D013610 NONE <e1>Amiodarone</e1>\NN\2715941 has\VBZ\2108377 proved\VBN\2604760 very\RB\1740 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 otherwise\RB\1740 resistant\JJ\1740 cardiac\JJ\1740 <e2>tachyarrhythmias</e2>\NNS\1740 .\.\1740
D000638_D002779 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 due\JJ\1740 to\TO\1740 <e1>amiodarone</e1>\NN\2715941 treatment\NN\654885 is\VBZ\836236 presented\VBN\2137132 below\IN\1740 and\CC\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 hepatotoxicity\NN\1740 of\IN\1740 amiodarone\NN\2715941 is\VBZ\836236 given\VBN\2327200 .\.\1740
D000638_D002779 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 due\JJ\1740 to\TO\1740 amiodarone\NN\2715941 treatment\NN\654885 is\VBZ\836236 presented\VBN\2137132 below\IN\1740 and\CC\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 hepatotoxicity\NN\1740 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 is\VBZ\836236 given\VBN\2327200 .\.\1740
D000638_D002779 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 solid\JJ\1740 evidence\NN\5816287 exists\NNS\1740 of\IN\1740 hepatic\JJ\1740 injury\NN\14052046 due\IN\5174653 to\TO\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 ,\,\1740 including\VBG\690614 steatosis\NN\1740 ,\,\1740 alterations\NNS\7283608 resembling\VBG\2657219 alcoholic\JJ\1740 hepatitis\NN\14127211 ,\,\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 and\CC\1740 micronodular\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D000638_D005234 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 solid\JJ\1740 evidence\NN\5816287 exists\NNS\1740 of\IN\1740 hepatic\JJ\1740 injury\NN\14052046 due\IN\5174653 to\TO\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 ,\,\1740 including\VBG\690614 <e2>steatosis</e2>\NN\1740 ,\,\1740 alterations\NNS\7283608 resembling\VBG\2657219 alcoholic\JJ\1740 hepatitis\NN\14127211 ,\,\1740 cholestatic\JJ\1740 hepatitis\NN\14127211 and\CC\1740 micronodular\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D000638_D006519 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 solid\JJ\1740 evidence\NN\5816287 exists\NNS\1740 of\IN\1740 hepatic\JJ\1740 injury\NN\14052046 due\IN\5174653 to\TO\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 ,\,\1740 including\VBG\690614 steatosis\NN\1740 ,\,\1740 alterations\NNS\7283608 resembling\VBG\2657219 <e2>alcoholic\JJ\1740 hepatitis</e2>\NN\14127211 ,\,\1740 cholestatic\JJ\1740 hepatitis\NN\14127211 and\CC\1740 micronodular\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D000638_D008103 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 solid\JJ\1740 evidence\NN\5816287 exists\NNS\1740 of\IN\1740 hepatic\JJ\1740 injury\NN\14052046 due\IN\5174653 to\TO\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 ,\,\1740 including\VBG\690614 steatosis\NN\1740 ,\,\1740 alterations\NNS\7283608 resembling\VBG\2657219 alcoholic\JJ\1740 hepatitis\NN\14127211 ,\,\1740 cholestatic\JJ\1740 hepatitis\NN\14127211 and\CC\1740 micronodular\JJ\1740 <e2>cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 .\.\1740
15096016
D007980_D018476 NONE Pallidal\JJ\1740 stimulation\NN\242808 improves\VBZ\126264 <e2>bradykinesia</e2>\NN\1740 and\CC\1740 rigidity\NN\5023233 to\IN\1740 a\DT\13649268 minor\JJ\1740 extent\NN\13939892 ;\:\1740 however\RB\1740 ,\,\1740 its\PRP$\6125041 strength\NN\4916342 seems\VBZ\2604760 to\TO\1740 be\VB\836236 in\IN\13603305 improving\VBG\126264 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D009127 NONE Pallidal\JJ\1740 stimulation\NN\242808 improves\VBZ\126264 bradykinesia\NN\1740 and\CC\1740 <e2>rigidity</e2>\NN\5023233 to\IN\1740 a\DT\13649268 minor\JJ\1740 extent\NN\13939892 ;\:\1740 however\RB\1740 ,\,\1740 its\PRP$\6125041 strength\NN\4916342 seems\VBZ\2604760 to\TO\1740 be\VB\836236 in\IN\13603305 improving\VBG\126264 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D004409 CID Pallidal\JJ\1740 stimulation\NN\242808 improves\VBZ\126264 bradykinesia\NN\1740 and\CC\1740 rigidity\NN\5023233 to\IN\1740 a\DT\13649268 minor\JJ\1740 extent\NN\13939892 ;\:\1740 however\RB\1740 ,\,\1740 its\PRP$\6125041 strength\NN\4916342 seems\VBZ\2604760 to\TO\1740 be\VB\836236 in\IN\13603305 improving\VBG\126264 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
8586822
D002216_D006973 NONE Contribution\NN\786195 of\IN\1740 the\DT\1740 sympathetic\JJ\1740 nervous\JJ\1740 system\NN\3575240 to\TO\1740 salt-sensitivity\NN\1740 in\IN\13603305 lifetime\NN\15113229 <e1>captopril-treated</e1>\JJ\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D002216_D006973 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 ,\,\1740 in\IN\13603305 lifetime\NN\15113229 <e1>captopril-treated</e1>\JJ\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 sympathetic\JJ\1740 nervous\JJ\1740 system\NN\3575240 contributes\VBZ\126264 importantly\RB\1740 to\TO\1740 the\DT\1740 hypertensive\JJ\1740 effect\NN\34213 of\IN\1740 dietary\JJ\1740 sodium\NN\14625458 chloride\NN\14818238 supplementation\NN\5108947 .\.\1740
D002216_D006973 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 ,\,\1740 in\IN\13603305 lifetime\NN\15113229 <e1>captopril-treated</e1>\JJ\1740 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 sympathetic\JJ\1740 nervous\JJ\1740 system\NN\3575240 contributes\VBZ\126264 importantly\RB\1740 to\TO\1740 the\DT\1740 <e2>hypertensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 dietary\JJ\1740 sodium\NN\14625458 chloride\NN\14818238 supplementation\NN\5108947 .\.\1740
D017673_D006973 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 ,\,\1740 in\IN\13603305 lifetime\NN\15113229 captopril-treated\JJ\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 sympathetic\JJ\1740 nervous\JJ\1740 system\NN\3575240 contributes\VBZ\126264 importantly\RB\1740 to\TO\1740 the\DT\1740 hypertensive\JJ\1740 effect\NN\34213 of\IN\1740 <e1>dietary\JJ\1740 sodium\NN\14625458 chloride</e1>\NN\14818238 supplementation\NN\5108947 .\.\1740
D017673_D006973 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 ,\,\1740 in\IN\13603305 lifetime\NN\15113229 captopril-treated\JJ\1740 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 sympathetic\JJ\1740 nervous\JJ\1740 system\NN\3575240 contributes\VBZ\126264 importantly\RB\1740 to\TO\1740 the\DT\1740 <e2>hypertensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>dietary\JJ\1740 sodium\NN\14625458 chloride</e1>\NN\14818238 supplementation\NN\5108947 .\.\1740
D017673_D006973 CID Intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 the\DT\1740 ganglionic\JJ\1740 blocker\NN\10101634 hexamethonium\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 rapid\JJ\1740 decline\NN\13458571 in\IN\13603305 MAP\NN\4076846 that\WDT\1740 eliminated\VBD\1619929 the\DT\1740 <e1>dietary\JJ\1740 sodium\NN\14625458 chloride-induced</e1>\JJ\1740 <e2>increase\NN\13576355 in\IN\13603305 MAP</e2>\NN\4076846 in\IN\13603305 both\DT\1740 groups\NNS\2137 .\.\1740
D018738_D006973 NONE Intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 the\DT\1740 ganglionic\JJ\1740 blocker\NN\10101634 <e1>hexamethonium</e1>\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 rapid\JJ\1740 decline\NN\13458571 in\IN\13603305 MAP\NN\4076846 that\WDT\1740 eliminated\VBD\1619929 the\DT\1740 dietary\JJ\1740 sodium\NN\14625458 chloride-induced\JJ\1740 <e2>increase\NN\13576355 in\IN\13603305 MAP</e2>\NN\4076846 in\IN\13603305 both\DT\1740 groups\NNS\2137 .\.\1740
7651879
D005442_D012640 CID <e2>Seizure</e2>\NN\14081375 after\IN\1740 <e1>flumazenil</e1>\JJ\1740 administration\NN\1133281 in\IN\13603305 a\DT\13649268 pediatric\JJ\1740 patient\NN\9898892 .\.\1740
D005442_D012640 CID We\PRP\1740 report\VBP\831651 the\DT\1740 occurrence\NN\29378 of\IN\1740 a\DT\13649268 generalized\JJ\1740 <e2>tonic-clonic\JJ\1740 seizure</e2>\NN\14081375 in\IN\13603305 a\DT\13649268 pediatric\JJ\1740 patient\NN\9898892 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>flumazenil</e1>\NN\1740 .\.\1740
D005442_D012131 NONE <e1>Flumazenil</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 benzodiazepine\NN\3771443 receptor\NN\5225602 antagonist\NN\7846 used\VBN\1156834 to\TO\1740 reverse\VB\109660 sedation\NN\14034177 and\CC\1740 <e2>respiratory\JJ\1740 depression</e2>\NN\14373582 induced\VBN\1627355 by\IN\1740 benzodiazepines\NNS\3771443 .\.\1740
D001569_D012131 NONE Flumazenil\NN\1740 is\VBZ\836236 a\DT\13649268 <e1>benzodiazepine</e1>\NN\3771443 receptor\NN\5225602 antagonist\NN\7846 used\VBN\1156834 to\TO\1740 reverse\VB\109660 sedation\NN\14034177 and\CC\1740 <e2>respiratory\JJ\1740 depression</e2>\NN\14373582 induced\VBN\1627355 by\IN\1740 benzodiazepines\NNS\3771443 .\.\1740
D001569_D012131 NONE Flumazenil\NN\1740 is\VBZ\836236 a\DT\13649268 benzodiazepine\NN\3771443 receptor\NN\5225602 antagonist\NN\7846 used\VBN\1156834 to\TO\1740 reverse\VB\109660 sedation\NN\14034177 and\CC\1740 <e2>respiratory\JJ\1740 depression</e2>\NN\14373582 induced\VBN\1627355 by\IN\1740 <e1>benzodiazepines</e1>\NNS\3771443 .\.\1740
6402369
D007069_D001745 CID Treatment\NN\654885 of\IN\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>urothelial\JJ\1740 toxicity</e2>\NN\13576101 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 to\TO\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 lung\NN\5528060 cancer\NN\14239425 .\.\1740
D007069_D001745 CID The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 <e2>urothelial\JJ\1740 toxicity</e2>\NN\13576101 induced\VBN\1627355 by\IN\1740 <e1>ifosfamide</e1>\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 lung\NN\5528060 cancer\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D007069_D001745 CID The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 <e2>urothelial\JJ\1740 toxicity</e2>\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 <e1>IF</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 lung\NN\5528060 cancer\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D007069_D001745 CID The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 <e2>urothelial\JJ\1740 toxicity</e2>\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 lung\NN\5528060 cancer\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 <e1>IF</e1>\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D007069_D008175 NONE Treatment\NN\654885 of\IN\1740 <e1>ifosfamide-induced</e1>\JJ\1740 urothelial\JJ\1740 toxicity\NN\13576101 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 to\TO\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 .\.\1740
D007069_D008175 NONE The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 urothelial\JJ\1740 toxicity\NN\13576101 induced\VBN\1627355 by\IN\1740 <e1>ifosfamide</e1>\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D007069_D008175 NONE The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 urothelial\JJ\1740 toxicity\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 <e1>IF</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D007069_D008175 NONE The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 urothelial\JJ\1740 toxicity\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 <e1>IF</e1>\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D015080_D001745 NONE Treatment\NN\654885 of\IN\1740 ifosfamide-induced\JJ\1740 <e2>urothelial\JJ\1740 toxicity</e2>\NN\13576101 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate</e1>\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 to\TO\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 lung\NN\5528060 cancer\NN\14239425 .\.\1740
D015080_D001745 NONE Treatment\NN\654885 of\IN\1740 ifosfamide-induced\JJ\1740 <e2>urothelial\JJ\1740 toxicity</e2>\NN\13576101 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 <e1>MESNA</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 lung\NN\5528060 cancer\NN\14239425 .\.\1740
D015080_D001745 NONE The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 <e1>sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate</e1>\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 <e2>urothelial\JJ\1740 toxicity</e2>\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 lung\NN\5528060 cancer\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D015080_D001745 NONE The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 <e1>MESNA</e1>\NN\1740 )\-RRB-\1740 against\IN\1740 <e2>urothelial\JJ\1740 toxicity</e2>\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 lung\NN\5528060 cancer\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D015080_D008175 NONE Treatment\NN\654885 of\IN\1740 ifosfamide-induced\JJ\1740 urothelial\JJ\1740 toxicity\NN\13576101 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate</e1>\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 to\TO\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 .\.\1740
D015080_D008175 NONE Treatment\NN\654885 of\IN\1740 ifosfamide-induced\JJ\1740 urothelial\JJ\1740 toxicity\NN\13576101 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 <e1>MESNA</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 .\.\1740
D015080_D008175 NONE The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 <e1>sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate</e1>\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 urothelial\JJ\1740 toxicity\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D015080_D008175 NONE The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 thiol\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 <e1>MESNA</e1>\NN\1740 )\-RRB-\1740 against\IN\1740 urothelial\JJ\1740 toxicity\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D013438_D001745 NONE The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 <e1>thiol</e1>\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 <e2>urothelial\JJ\1740 toxicity</e2>\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 lung\NN\5528060 cancer\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D013438_D008175 NONE The\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 <e1>thiol</e1>\NN\1740 compound\NN\5869584 sodium\NN\14625458 2-mercaptoethane\NN\1740 sulphonate\JJ\1740 (\-LRB-\1740 MESNA\NN\1740 )\-RRB-\1740 against\IN\1740 urothelial\JJ\1740 toxicity\NN\13576101 induced\VBN\1627355 by\IN\1740 ifosfamide\NN\1740 (\-LRB-\1740 IF\NN\1740 )\-RRB-\1740 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 45\CD\1740 patients\NNS\9898892 with\IN\1740 inoperable\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 under\IN\1740 treatment\NN\654885 with\IN\1740 IF\NN\1740 (\-LRB-\1740 2250\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 polychemotherapy\NN\1740 regimen\NN\5898568 repeated\VBN\952524 in\IN\13603305 a\DT\13649268 4-week\NN\1740 cycle\NN\15269513 .\.\1740
D015080_D064420 NONE There\EX\27167 were\VBD\836236 no\DT\7204911 appreciable\JJ\1740 differences\NNS\4723816 between\IN\1740 the\DT\1740 <e1>MESNA</e1>\NN\1740 series\NN\8456993 and\CC\1740 the\DT\1740 conventional\JJ\1740 prophylaxis\NN\1077350 series\NN\8456993 with\IN\1740 respect\NN\5817845 to\TO\1740 either\CC\1740 haematological\JJ\1740 or\CC\3541091 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 cytostatic\JJ\1740 treatment\NN\654885 .\.\1740
8958188
C045894_D009369 NONE Extensive\JJ\1740 experimental\JJ\1740 and\CC\1740 limited\JJ\1740 clinical\JJ\1740 data\NNS\7951464 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 <e1>lometrexol</e1>\NN\1740 has\VBZ\2108377 activity\NN\30358 against\IN\1740 <e2>tumours</e2>\NNS\14234074 which\WDT\1740 are\VBP\836236 refractory\JJ\1740 to\TO\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 notably\RB\1740 methotrexate\VBP\1740 .\.\1740
D008727_D009369 NONE Extensive\JJ\1740 experimental\JJ\1740 and\CC\1740 limited\JJ\1740 clinical\JJ\1740 data\NNS\7951464 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 lometrexol\NN\1740 has\VBZ\2108377 activity\NN\30358 against\IN\1740 <e2>tumours</e2>\NNS\14234074 which\WDT\1740 are\VBP\836236 refractory\JJ\1740 to\TO\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 notably\RB\1740 <e1>methotrexate</e1>\VBP\1740 .\.\1740
C045894_D064420 NONE However\RB\1740 ,\,\1740 the\DT\1740 initial\JJ\1740 clinical\JJ\1740 development\NN\248977 of\IN\1740 <e1>lometrexol</e1>\NN\1740 was\VBD\836236 curtailed\VBN\235368 because\IN\1740 of\IN\1740 severe\JJ\1740 and\CC\1740 cumulative\JJ\1740 antiproliferative\JJ\1740 <e2>toxicities</e2>\NNS\13576101 .\.\1740
C045894_D064420 NONE Preclinical\JJ\1740 murine\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>lometrexol</e1>\NN\1740 can\MD\3094503 be\VB\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 dose\NN\3740161 folic\NN\1740 acid\NN\14818238 administration\NN\1133281 ,\,\1740 i.e.\FW\1740 for\IN\1740 7\CD\13741022 days\NNS\15140892 prior\RB\1740 to\IN\1740 and\CC\1740 7\CD\13741022 days\NNS\15140892 following\VBG\1835496 a\DT\13649268 single\JJ\1740 bolus\NN\13899404 dose\NN\3740161 .\.\1740
C045894_D064420 NONE This\DT\1740 observation\NN\996969 prompted\VBD\1645601 a\DT\13649268 Phase\NN\15113229 I\CD\14622893 clinical\JJ\1740 study\NN\635850 of\IN\1740 <e1>lometrexol</e1>\NN\1740 given\VBN\2327200 with\IN\1740 folic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 which\WDT\1740 has\VBZ\2108377 confirmed\VBN\1011725 that\IN\1740 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 lometrexol\NN\1740 can\MD\3094503 be\VB\836236 markedly\RB\1740 reduced\VBN\441445 by\IN\1740 folic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 .\.\1740
C045894_D064420 NONE This\DT\1740 observation\NN\996969 prompted\VBD\1645601 a\DT\13649268 Phase\NN\15113229 I\CD\14622893 clinical\JJ\1740 study\NN\635850 of\IN\1740 lometrexol\NN\1740 given\VBN\2327200 with\IN\1740 folic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 which\WDT\1740 has\VBZ\2108377 confirmed\VBN\1011725 that\IN\1740 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>lometrexol</e1>\NN\1740 can\MD\3094503 be\VB\836236 markedly\RB\1740 reduced\VBN\441445 by\IN\1740 folic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 .\.\1740
C045894_D064420 NONE Associated\VBN\628491 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 <e1>lometrexol</e1>\NN\1740 plasma\NN\5398023 pharmacokinetics\NNS\6054892 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 folic\JJ\1740 acid\NN\14818238 administration\NN\1133281 indicating\VBG\952524 that\IN\1740 supplementation\NN\5108947 is\VBZ\836236 unlikely\JJ\1740 to\TO\1740 reduce\VB\441445 <e2>toxicity</e2>\NN\13576101 by\IN\1740 enhancing\VBG\227165 lometrexol\NN\1740 plasma\NN\5398023 clearance\NN\5089947 .\.\1740
C045894_D064420 NONE Associated\VBN\628491 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 lometrexol\NN\1740 plasma\NN\5398023 pharmacokinetics\NNS\6054892 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 folic\JJ\1740 acid\NN\14818238 administration\NN\1133281 indicating\VBG\952524 that\IN\1740 supplementation\NN\5108947 is\VBZ\836236 unlikely\JJ\1740 to\TO\1740 reduce\VB\441445 <e2>toxicity</e2>\NN\13576101 by\IN\1740 enhancing\VBG\227165 <e1>lometrexol</e1>\NN\1740 plasma\NN\5398023 clearance\NN\5089947 .\.\1740
D005492_D064420 NONE Preclinical\JJ\1740 murine\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 lometrexol\NN\1740 can\MD\3094503 be\VB\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 dose\NN\3740161 <e1>folic\NN\1740 acid</e1>\NN\14818238 administration\NN\1133281 ,\,\1740 i.e.\FW\1740 for\IN\1740 7\CD\13741022 days\NNS\15140892 prior\RB\1740 to\IN\1740 and\CC\1740 7\CD\13741022 days\NNS\15140892 following\VBG\1835496 a\DT\13649268 single\JJ\1740 bolus\NN\13899404 dose\NN\3740161 .\.\1740
D005492_D064420 NONE This\DT\1740 observation\NN\996969 prompted\VBD\1645601 a\DT\13649268 Phase\NN\15113229 I\CD\14622893 clinical\JJ\1740 study\NN\635850 of\IN\1740 lometrexol\NN\1740 given\VBN\2327200 with\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 supplementation\NN\5108947 which\WDT\1740 has\VBZ\2108377 confirmed\VBN\1011725 that\IN\1740 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 lometrexol\NN\1740 can\MD\3094503 be\VB\836236 markedly\RB\1740 reduced\VBN\441445 by\IN\1740 folic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 .\.\1740
D005492_D064420 NONE This\DT\1740 observation\NN\996969 prompted\VBD\1645601 a\DT\13649268 Phase\NN\15113229 I\CD\14622893 clinical\JJ\1740 study\NN\635850 of\IN\1740 lometrexol\NN\1740 given\VBN\2327200 with\IN\1740 folic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 which\WDT\1740 has\VBZ\2108377 confirmed\VBN\1011725 that\IN\1740 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 lometrexol\NN\1740 can\MD\3094503 be\VB\836236 markedly\RB\1740 reduced\VBN\441445 by\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 supplementation\NN\5108947 .\.\1740
D005492_D064420 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 clear\JJ\1740 relationship\NN\31921 between\IN\1740 clinical\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 the\DT\1740 extent\NN\13939892 of\IN\1740 plasma\NN\5398023 <e1>folate</e1>\NN\15090742 elevation\NN\7445480 .\.\1740
D005492_D064420 NONE Associated\VBN\628491 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 lometrexol\NN\1740 plasma\NN\5398023 pharmacokinetics\NNS\6054892 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 <e1>folic\JJ\1740 acid</e1>\NN\14818238 administration\NN\1133281 indicating\VBG\952524 that\IN\1740 supplementation\NN\5108947 is\VBZ\836236 unlikely\JJ\1740 to\TO\1740 reduce\VB\441445 <e2>toxicity</e2>\NN\13576101 by\IN\1740 enhancing\VBG\227165 lometrexol\NN\1740 plasma\NN\5398023 clearance\NN\5089947 .\.\1740
10743694
1535072
D015016_D020018 NONE <e1>Yohimbine</e1>\NN\1740 treatment\NN\654885 of\IN\1740 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 induced\VBN\1627355 by\IN\1740 serotonin\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 .\.\1740
D015016_D020018 NONE A\DT\13649268 single\JJ\1740 case\NN\7283608 report\NN\6470073 suggests\VBZ\1010118 that\IN\1740 <e1>yohimbine</e1>\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 to\TO\1740 treat\VB\2376958 the\DT\1740 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 of\IN\1740 clomipramine\NN\4482543 .\.\1740
D015016_D020018 NONE This\DT\1740 study\NN\635850 evaluated\VBD\670261 <e1>yohimbine</e1>\NN\1740 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 the\DT\1740 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 caused\VBN\1617192 by\IN\1740 serotonin\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 .\.\1740
D015016_D020018 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 ,\,\1740 trichotillomania\NN\9181557 ,\,\1740 anxiety\NN\14373582 ,\,\1740 or\CC\3541091 affective\JJ\1740 disorders\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 serotonin\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 <e1>yohimbine</e1>\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
D015016_D020018 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 results\NNS\34213 of\IN\1740 this\DT\1740 study\NN\635850 indicate\VBP\952524 that\IN\1740 <e1>yohimbine</e1>\NN\1740 may\MD\15209706 be\VB\836236 an\DT\6697703 effective\JJ\1740 treatment\NN\654885 for\IN\1740 the\DT\1740 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 caused\VBN\1617192 by\IN\1740 serotonin\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 .\.\1740
D012701_D020018 NONE Yohimbine\NN\1740 treatment\NN\654885 of\IN\1740 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 induced\VBN\1627355 by\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 .\.\1740
D012701_D020018 NONE This\DT\1740 study\NN\635850 evaluated\VBD\670261 yohimbine\NN\1740 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 the\DT\1740 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 caused\VBN\1617192 by\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 .\.\1740
D012701_D020018 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 ,\,\1740 trichotillomania\NN\9181557 ,\,\1740 anxiety\NN\14373582 ,\,\1740 or\CC\3541091 affective\JJ\1740 disorders\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 yohimbine\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
D012701_D020018 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 results\NNS\34213 of\IN\1740 this\DT\1740 study\NN\635850 indicate\VBP\952524 that\IN\1740 yohimbine\NN\1740 may\MD\15209706 be\VB\836236 an\DT\6697703 effective\JJ\1740 treatment\NN\654885 for\IN\1740 the\DT\1740 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 caused\VBN\1617192 by\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 .\.\1740
D015016_D007172 NONE BACKGROUND\NN\4921011 :\:\1740 Preclinical\JJ\1740 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 suggest\VBP\1010118 that\IN\1740 <e1>yohimbine</e1>\NN\1740 facilitates\VBZ\2547586 sexual\JJ\1740 behavior\NN\407535 and\CC\1740 may\MD\15209706 be\VB\836236 helpful\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>male\JJ\1740 impotence</e2>\NN\4723816 .\.\1740
D002997_D020018 CID A\DT\13649268 single\JJ\1740 case\NN\7283608 report\NN\6470073 suggests\VBZ\1010118 that\IN\1740 yohimbine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 to\TO\1740 treat\VB\2376958 the\DT\1740 <e2>sexual\JJ\1740 side\NN\8630039 effects</e2>\NNS\13245626 of\IN\1740 <e1>clomipramine</e1>\NN\4482543 .\.\1740
D012701_D009771 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 <e2>obsessive\JJ\1740 compulsive\JJ\1740 disorder</e2>\NN\14034177 ,\,\1740 trichotillomania\NN\9181557 ,\,\1740 anxiety\NN\14373582 ,\,\1740 or\CC\3541091 affective\JJ\1740 disorders\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 sexual\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 yohimbine\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
D012701_D014256 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 ,\,\1740 <e2>trichotillomania</e2>\NN\9181557 ,\,\1740 anxiety\NN\14373582 ,\,\1740 or\CC\3541091 affective\JJ\1740 disorders\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 sexual\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 yohimbine\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
D012701_D001008 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 ,\,\1740 trichotillomania\NN\9181557 ,\,\1740 <e2>anxiety</e2>\NN\14373582 ,\,\1740 or\CC\3541091 affective\JJ\1740 disorders\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 sexual\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 yohimbine\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
D012701_D019964 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 ,\,\1740 trichotillomania\NN\9181557 ,\,\1740 anxiety\NN\14373582 ,\,\1740 or\CC\3541091 <e2>affective\JJ\1740 disorders</e2>\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 sexual\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 yohimbine\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
D015016_D009771 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 <e2>obsessive\JJ\1740 compulsive\JJ\1740 disorder</e2>\NN\14034177 ,\,\1740 trichotillomania\NN\9181557 ,\,\1740 anxiety\NN\14373582 ,\,\1740 or\CC\3541091 affective\JJ\1740 disorders\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 sexual\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 serotonin\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 <e1>yohimbine</e1>\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
D015016_D014256 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 ,\,\1740 <e2>trichotillomania</e2>\NN\9181557 ,\,\1740 anxiety\NN\14373582 ,\,\1740 or\CC\3541091 affective\JJ\1740 disorders\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 sexual\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 serotonin\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 <e1>yohimbine</e1>\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
D015016_D001008 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 ,\,\1740 trichotillomania\NN\9181557 ,\,\1740 <e2>anxiety</e2>\NN\14373582 ,\,\1740 or\CC\3541091 affective\JJ\1740 disorders\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 sexual\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 serotonin\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 <e1>yohimbine</e1>\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
D015016_D001008 NONE Side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>yohimbine</e1>\NN\1740 included\VBD\690614 excessive\JJ\1740 sweating\NN\13440063 ,\,\1740 increased\VBD\169651 <e2>anxiety</e2>\NN\14373582 ,\,\1740 and\CC\1740 a\DT\13649268 wound-up\JJ\1740 feeling\NN\24720 in\IN\13603305 some\DT\1740 patients\NNS\9898892 .\.\1740
D015016_D019964 NONE METHOD\NN\5616786 :\:\1740 Six\CD\13741022 patients\NNS\9898892 with\IN\1740 either\CC\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 ,\,\1740 trichotillomania\NN\9181557 ,\,\1740 anxiety\NN\14373582 ,\,\1740 or\CC\3541091 <e2>affective\JJ\1740 disorders</e2>\NNS\14034177 who\WP\8299493 suffered\VBD\2110220 sexual\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 treatment\NN\654885 with\IN\1740 serotonin\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 were\VBD\836236 given\VBN\2327200 <e1>yohimbine</e1>\NN\1740 on\IN\1740 a\DT\13649268 p.r.n\NN\1740 .\.\1740
7880714
7053705
D013866_D006504 CID <e2>Hepatic\JJ\1740 veno-occlusive\JJ\1740 disease</e2>\NN\14061805 caused\VBN\1617192 by\IN\1740 <e1>6-thioguanine</e1>\NN\1740 .\.\1740
D013866_D006504 CID Clinically\RB\1740 reversible\JJ\1740 <e2>veno-occlusive\JJ\1740 disease\NN\14061805 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 23-year-old\JJ\1740 man\NN\9605289 with\IN\1740 acute\JJ\1740 lymphocytic\JJ\1740 leukemia\NN\14239918 after\IN\1740 10\CD\13745420 months\NNS\15113229 of\IN\1740 maintenance\NN\266806 therapy\NN\657604 with\IN\1740 <e1>6-thioguanine</e1>\NN\1740 .\.\1740
D013866_D006504 CID This\DT\1740 case\NN\7283608 presented\VBD\2137132 a\DT\13649268 unique\JJ\1740 opportunity\NN\14481929 to\TO\1740 observe\VB\2163746 the\DT\1740 histologic\JJ\1740 features\NNS\5849040 of\IN\1740 clinically\RB\1740 reversible\JJ\1740 <e2>hepatic\JJ\1740 veno-occlusive\JJ\1740 disease</e2>\NN\14061805 over\IN\5867413 time\NN\7308889 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 veno-occlusive\JJ\1740 related\JJ\1740 solely\RB\1740 to\TO\1740 <e1>6-thioguanine</e1>\NN\1740 .\.\1740
D013866_D054198 NONE Clinically\RB\1740 reversible\JJ\1740 veno-occlusive\JJ\1740 disease\NN\14061805 of\IN\1740 the\DT\1740 liver\NN\5298729 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 23-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>acute\JJ\1740 lymphocytic\JJ\1740 leukemia</e2>\NN\14239918 after\IN\1740 10\CD\13745420 months\NNS\15113229 of\IN\1740 maintenance\NN\266806 therapy\NN\657604 with\IN\1740 <e1>6-thioguanine</e1>\NN\1740 .\.\1740
8384253
D014750_D008228 NONE Forty\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>Non-Hodgkin\NNP\1740 's\POS\1740 Lymphoma</e2>\NNP\14239918 treated\VBN\2376958 with\IN\1740 <e1>vincristine</e1>\NN\3917455 between\IN\1740 1984\CD\1740 and\CC\1740 1990\CD\1740 (\-LRB-\1740 cumulative\JJ\1740 dose\NN\3740161 12\CD\13745420 mg\NN\13717155 in\IN\13603305 18\CD\13745420 -\SYM\1740 24\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 were\VBD\836236 investigated\VBN\644583 in\IN\13603305 order\NN\7168131 to\TO\1740 evaluate\VB\670261 the\DT\1740 long\JJ\1740 term\NN\6286395 effects\NNS\13245626 of\IN\1740 vincristine\NN\3917455 on\IN\1740 the\DT\1740 peripheral\JJ\1740 nervous\JJ\1740 system\NN\3575240 .\.\1740
D014750_D008228 NONE Forty\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>Non-Hodgkin\NNP\1740 's\POS\1740 Lymphoma</e2>\NNP\14239918 treated\VBN\2376958 with\IN\1740 vincristine\NN\3917455 between\IN\1740 1984\CD\1740 and\CC\1740 1990\CD\1740 (\-LRB-\1740 cumulative\JJ\1740 dose\NN\3740161 12\CD\13745420 mg\NN\13717155 in\IN\13603305 18\CD\13745420 -\SYM\1740 24\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 were\VBD\836236 investigated\VBN\644583 in\IN\13603305 order\NN\7168131 to\TO\1740 evaluate\VB\670261 the\DT\1740 long\JJ\1740 term\NN\6286395 effects\NNS\13245626 of\IN\1740 <e1>vincristine</e1>\NN\3917455 on\IN\1740 the\DT\1740 peripheral\JJ\1740 nervous\JJ\1740 system\NN\3575240 .\.\1740
D014750_D009422 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 with\IN\1740 the\DT\1740 above\JJ\1740 mentioned\JJ\1740 <e1>vincristine</e1>\NN\3917455 dose\NN\3740161 schedule\NN\5898568 signs\NNS\6643763 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 vincristine\NN\3917455 <e2>neuropathy</e2>\NN\14204950 are\VBP\836236 reversible\JJ\1740 for\IN\1740 a\DT\13649268 great\JJ\1740 deal\NN\1106808 and\CC\1740 prognosis\NN\6748969 is\VBZ\836236 fairly\RB\1740 good\JJ\1740 .\.\1740
D014750_D009422 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 with\IN\1740 the\DT\1740 above\JJ\1740 mentioned\JJ\1740 vincristine\NN\3917455 dose\NN\3740161 schedule\NN\5898568 signs\NNS\6643763 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 <e1>vincristine</e1>\NN\3917455 <e2>neuropathy</e2>\NN\14204950 are\VBP\836236 reversible\JJ\1740 for\IN\1740 a\DT\13649268 great\JJ\1740 deal\NN\1106808 and\CC\1740 prognosis\NN\6748969 is\VBZ\836236 fairly\RB\1740 good\JJ\1740 .\.\1740
8111719
D007069_D006212 CID <e2>Hallucinations</e2>\NNS\14376855 and\CC\1740 <e1>ifosfamide-induced</e1>\JJ\1740 neurotoxicity\NN\1740 .\.\1740
D007069_D006212 CID BACKGROUND\NN\4921011 :\:\1740 <e2>Hallucinations</e2>\NNP\14376855 as\IN\14622893 a\DT\13649268 symptom\NN\5823932 of\IN\1740 central\JJ\1740 neurotoxicity\NN\1740 are\VBP\836236 a\DT\13649268 known\JJ\1740 but\CC\1740 poorly\RB\1740 described\VBN\1001294 side\NN\8630039 effect\NN\34213 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 .\.\1740
D007069_D006212 CID Most\JJS\1740 cases\NNS\7283608 of\IN\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>hallucinations</e2>\NNS\14376855 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 other\JJ\1740 mental\JJ\1740 status\NN\24720 changes\NNS\7283608 .\.\1740
D007069_D006212 CID METHODS\NNS\5616786 :\:\1740 The\DT\1740 authors\NNS\9610660 interviewed\VBD\964694 six\CD\13741022 persons\NNS\7347 with\IN\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>hallucinations</e2>\NNS\14376855 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 a\DT\13649268 clear\JJ\1740 sensorium\NN\5486920 .\.\1740
D007069_D006212 CID The\DT\1740 clinician\NN\10462860 should\MD\1740 be\VB\836236 alerted\VBN\870213 for\IN\1740 possible\JJ\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>hallucinations</e2>\NNS\14376855 ,\,\1740 which\WDT\1740 may\MD\15209706 occur\VB\2623529 without\IN\1740 other\JJ\1740 signs\NNS\6643763 of\IN\1740 neurotoxicity\NN\1740 .\.\1740
D007069_D020258 NONE Hallucinations\NNS\14376855 and\CC\1740 <e1>ifosfamide-induced</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D007069_D020258 NONE BACKGROUND\NN\4921011 :\:\1740 Hallucinations\NNP\14376855 as\IN\14622893 a\DT\13649268 symptom\NN\5823932 of\IN\1740 central\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 are\VBP\836236 a\DT\13649268 known\JJ\1740 but\CC\1740 poorly\RB\1740 described\VBN\1001294 side\NN\8630039 effect\NN\34213 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 .\.\1740
D007069_D020258 NONE The\DT\1740 clinician\NN\10462860 should\MD\1740 be\VB\836236 alerted\VBN\870213 for\IN\1740 possible\JJ\1740 <e1>ifosfamide-induced</e1>\JJ\1740 hallucinations\NNS\14376855 ,\,\1740 which\WDT\1740 may\MD\15209706 occur\VB\2623529 without\IN\1740 other\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D006220_D011595 NONE If\IN\1740 <e2>agitation</e2>\NN\14373582 becomes\VBZ\146138 marked\JJ\1740 ,\,\1740 high-potency\NN\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 <e1>haloperidol</e1>\JJ\1740 )\-RRB-\1740 may\MD\15209706 be\VB\836236 effective\JJ\1740 .\.\1740
9579567
D013629_D001943 NONE Since\IN\1740 <e1>tamoxifen</e1>\NN\2714883 is\VBZ\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 treatment\NN\654885 and\CC\1740 has\VBZ\2108377 been\VBN\836236 proposed\VBN\1010118 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 its\PRP$\6125041 endometrial\JJ\1740 iatrogenic\JJ\1740 effects\NNS\13245626 must\MD\9367203 be\VB\836236 carefully\RB\1740 examined\VBN\789138 .\.\1740
D013629_D001943 NONE Since\IN\1740 <e1>tamoxifen</e1>\NN\2714883 is\VBZ\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 breast\NN\5225090 cancer\NN\14239425 treatment\NN\654885 and\CC\1740 has\VBZ\2108377 been\VBN\836236 proposed\VBN\1010118 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 its\PRP$\6125041 endometrial\JJ\1740 iatrogenic\JJ\1740 effects\NNS\13245626 must\MD\9367203 be\VB\836236 carefully\RB\1740 examined\VBN\789138 .\.\1740
D013629_D001943 NONE We\PRP\1740 have\VBP\2108377 investigated\VBN\644583 the\DT\1740 association\NN\8008335 between\IN\1740 endometrial\JJ\1740 cancer\NN\14239425 and\CC\1740 <e1>tamoxifen</e1>\NN\2714883 use\NN\407535 or\CC\3541091 other\JJ\1740 treatments\NNS\654885 in\IN\13603305 women\NNS\9605289 treated\VBN\2376958 for\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 in\IN\13603305 a\DT\13649268 case-control\JJ\1740 study\NN\635850 .\.\1740
D013629_D001943 NONE Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 a\DT\13649268 causal\JJ\1740 role\NN\719494 of\IN\1740 <e1>tamoxifen</e1>\NN\2714883 in\IN\13603305 endometrial\JJ\1740 cancer\NN\14239425 ,\,\1740 particularly\RB\1740 when\WRB\1740 used\VBN\1156834 as\IN\14622893 currently\RB\1740 proposed\VBN\1010118 for\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 prevention\NN\1073995 .\.\1740
D013629_D001943 NONE Women\NNS\9605289 who\WP\8299493 receive\VBP\2210855 <e1>tamoxifen</e1>\NN\2714883 for\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 should\MD\1740 be\VB\836236 offered\VBN\2327200 gynaecological\JJ\1740 surveillance\NN\635012 during\IN\1740 and\CC\1740 after\IN\1740 treatment\NN\654885 .\.\1740
D013629_D001943 NONE A\DT\13649268 long-term\JJ\1740 evaluation\NN\874067 of\IN\1740 the\DT\1740 risk-benefit\JJ\1740 ratio\NN\13815152 of\IN\1740 <e1>tamoxifen</e1>\NN\2714883 as\IN\14622893 a\DT\13649268 preventive\JJ\1740 treatment\NN\654885 for\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 is\VBZ\836236 clearly\RB\1740 warranted\VBN\1012073 .\.\1740
D013629_D016889 CID We\PRP\1740 have\VBP\2108377 investigated\VBN\644583 the\DT\1740 association\NN\8008335 between\IN\1740 <e2>endometrial\JJ\1740 cancer</e2>\NN\14239425 and\CC\1740 <e1>tamoxifen</e1>\NN\2714883 use\NN\407535 or\CC\3541091 other\JJ\1740 treatments\NNS\654885 in\IN\13603305 women\NNS\9605289 treated\VBN\2376958 for\IN\1740 breast\NN\5225090 cancer\NN\14239425 in\IN\13603305 a\DT\13649268 case-control\JJ\1740 study\NN\635850 .\.\1740
D013629_D016889 CID Women\NNS\9605289 who\WP\8299493 had\VBD\2108377 received\VBN\2210855 <e1>tamoxifen</e1>\NN\2714883 were\VBD\836236 significantly\RB\1740 more\RBR\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 <e2>endometrial\JJ\1740 cancer</e2>\NN\14239425 diagnosed\VBN\644583 than\IN\1740 those\DT\1740 who\WP\8299493 had\VBD\2108377 not\RB\1740 (\-LRB-\1740 crude\JJ\1740 relative\JJ\1740 risk\NN\14541044 =\JJ\1740 4.9\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
D013629_D016889 CID Women\NNS\9605289 who\WP\8299493 had\VBD\2108377 <e2>endometrial\JJ\1740 cancer</e2>\NN\14239425 and\CC\1740 had\VBD\2108377 received\VBN\2210855 <e1>tamoxifen</e1>\NN\2714883 had\VBD\2108377 more\RBR\1740 advanced\JJ\1740 disease\NN\14061805 and\CC\1740 poorer\JJR\1740 prognosis\NN\6748969 than\IN\1740 those\DT\1740 with\IN\1740 endometrial\JJ\1740 cancer\NN\14239425 who\WP\8299493 had\VBD\2108377 not\RB\1740 received\VBN\2210855 this\DT\1740 treatment\NN\654885 .\.\1740
D013629_D016889 CID Women\NNS\9605289 who\WP\8299493 had\VBD\2108377 endometrial\JJ\1740 cancer\NN\14239425 and\CC\1740 had\VBD\2108377 received\VBN\2210855 <e1>tamoxifen</e1>\NN\2714883 had\VBD\2108377 more\RBR\1740 advanced\JJ\1740 disease\NN\14061805 and\CC\1740 poorer\JJR\1740 prognosis\NN\6748969 than\IN\1740 those\DT\1740 with\IN\1740 <e2>endometrial\JJ\1740 cancer</e2>\NN\14239425 who\WP\8299493 had\VBD\2108377 not\RB\1740 received\VBN\2210855 this\DT\1740 treatment\NN\654885 .\.\1740
D013629_D016889 CID Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 a\DT\13649268 causal\JJ\1740 role\NN\719494 of\IN\1740 <e1>tamoxifen</e1>\NN\2714883 in\IN\13603305 <e2>endometrial\JJ\1740 cancer</e2>\NN\14239425 ,\,\1740 particularly\RB\1740 when\WRB\1740 used\VBN\1156834 as\IN\14622893 currently\RB\1740 proposed\VBN\1010118 for\IN\1740 breast\NN\5225090 cancer\NN\14239425 prevention\NN\1073995 .\.\1740
D013629_D016889 CID <e2>Endometrial\JJ\1740 cancers</e2>\NNS\14239425 diagnosed\VBN\644583 in\IN\13603305 women\NNS\9605289 treated\VBN\2376958 with\IN\1740 <e1>tamoxifen</e1>\NN\2714883 have\VBP\2108377 poorer\JJR\1740 prognosis\NN\6748969 .\.\1740
D013629_D020178 NONE Women\NNS\9605289 who\WP\8299493 had\VBD\2108377 endometrial\JJ\1740 cancer\NN\14239425 and\CC\1740 had\VBD\2108377 received\VBN\2210855 <e1>tamoxifen</e1>\NN\2714883 had\VBD\2108377 more\RBR\1740 <e2>advanced\JJ\1740 disease</e2>\NN\14061805 and\CC\1740 poorer\JJR\1740 prognosis\NN\6748969 than\IN\1740 those\DT\1740 with\IN\1740 endometrial\JJ\1740 cancer\NN\14239425 who\WP\8299493 had\VBD\2108377 not\RB\1740 received\VBN\2210855 this\DT\1740 treatment\NN\654885 .\.\1740
9669632
D020117_D043183 NONE Effects\NNS\13245626 of\IN\1740 <e1>cisapride</e1>\NN\1740 on\IN\1740 symptoms\NNS\5823932 and\CC\1740 postcibal\JJ\1740 small-bowel\JJ\1740 motor\NN\3699975 function\NN\13783581 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>irritable\JJ\1740 bowel\NN\5298729 syndrome</e2>\NN\5870365 .\.\1740
D020117_D043183 NONE Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 assess\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 prokinetic\JJ\1740 agent\NN\7347 ,\,\1740 <e1>cisapride</e1>\NN\1740 ,\,\1740 on\IN\1740 postprandial\JJ\1740 jejunal\JJ\1740 motility\NN\4773351 and\CC\1740 symptoms\NNS\5823932 in\IN\13603305 the\DT\1740 <e2>irritable\JJ\1740 bowel\NN\5298729 syndrome</e2>\NN\5870365 (\-LRB-\1740 IBS\NN\1740 )\-RRB-\1740 .\.\1740
D020117_D043183 NONE Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 assess\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 a\DT\13649268 prokinetic\JJ\1740 agent\NN\7347 ,\,\1740 <e1>cisapride</e1>\NN\1740 ,\,\1740 on\IN\1740 postprandial\JJ\1740 jejunal\JJ\1740 motility\NN\4773351 and\CC\1740 symptoms\NNS\5823932 in\IN\13603305 the\DT\1740 irritable\JJ\1740 bowel\NN\5298729 syndrome\NN\5870365 (\-LRB-\1740 <e2>IBS</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D020117_D043183 NONE METHODS\NNS\5616786 :\:\1740 Thirty-eight\NN\1740 patients\NNS\9898892 with\IN\1740 <e2>IBS</e2>\NN\1740 (\-LRB-\1740 constipation-predominant\JJ\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 ;\:\1740 diarrhoea-predominant\JJ\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 21\CD\13745420 )\-RRB-\1740 underwent\VBD\109660 24-h\JJ\1740 ambulatory\JJ\1740 jejunal\JJ\1740 manometry\NN\1740 before\IN\1740 and\CC\1740 after\IN\1740 12\CD\13745420 week\NN\15113229 's\POS\1740 treatment\NN\654885 [\-LRB-\1740 <e1>cisapride</e1>\NN\1740 ,\,\1740 5\CD\13741022 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 daily\RB\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 19\CD\13745420 )\-RRB-\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 19\CD\13745420 )\-RRB-\1740 ]\-RRB-\1740 .\.\1740
D020117_D043183 NONE Symptom\NN\5823932 scores\NNS\13757724 relating\VBG\628491 to\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 constipation\NN\14299637 were\VBD\836236 lower\JJR\1740 in\IN\13603305 <e1>cisapride-treated</e1>\JJ\1740 constipation-predominant\JJ\1740 <e2>IBS</e2>\NN\1740 patients\NNS\9898892 [\-LRB-\1740 score\NN\5736149 ,\,\1740 54\CD\1740 +/-\CC\1740 5\CD\13741022 versus\CC\1740 67\CD\1740 +/-\CC\1740 14\CD\13745420 mm\NN\13649268 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 62\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D043183 NONE Symptom\NN\5823932 scores\NNS\13757724 relating\VBG\628491 to\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 constipation\NN\14299637 were\VBD\836236 lower\JJR\1740 in\IN\13603305 cisapride-treated\JJ\1740 constipation-predominant\JJ\1740 <e2>IBS</e2>\NN\1740 patients\NNS\9898892 [\-LRB-\1740 score\NN\5736149 ,\,\1740 54\CD\1740 +/-\CC\1740 5\CD\13741022 versus\CC\1740 67\CD\1740 +/-\CC\1740 14\CD\13745420 mm\NN\13649268 ,\,\1740 <e1>cisapride</e1>\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 62\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D043183 NONE Diarrhoea-predominant\JJ\1740 <e2>IBS</e2>\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 higher\JJR\1740 pain\NN\14299637 score\NN\5736149 after\IN\1740 <e1>cisapride</e1>\NN\1740 therapy\NN\657604 [\-LRB-\1740 score\NN\5736149 ,\,\1740 55\CD\1740 +/-\CC\1740 15\CD\13745420 versus\CC\1740 34\CD\1740 +/-\CC\1740 12\CD\13745420 mm\NN\13649268 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 67\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D043183 NONE Diarrhoea-predominant\JJ\1740 <e2>IBS</e2>\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 higher\JJR\1740 pain\NN\14299637 score\NN\5736149 after\IN\1740 cisapride\NN\1740 therapy\NN\657604 [\-LRB-\1740 score\NN\5736149 ,\,\1740 55\CD\1740 +/-\CC\1740 15\CD\13745420 versus\CC\1740 34\CD\1740 +/-\CC\1740 12\CD\13745420 mm\NN\13649268 ,\,\1740 <e1>cisapride</e1>\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 67\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D043183 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Cisapride</e1>\NN\1740 affects\VBZ\126264 jejunal\JJ\1740 contraction\NN\358931 characteristics\NNS\5849040 and\CC\1740 some\DT\1740 symptoms\NNS\5823932 in\IN\13603305 <e2>IBS</e2>\NNP\1740 .\.\1740
D020117_D003248 NONE METHODS\NNS\5616786 :\:\1740 Thirty-eight\NN\1740 patients\NNS\9898892 with\IN\1740 IBS\NN\1740 (\-LRB-\1740 <e2>constipation-predominant</e2>\JJ\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 ;\:\1740 diarrhoea-predominant\JJ\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 21\CD\13745420 )\-RRB-\1740 underwent\VBD\109660 24-h\JJ\1740 ambulatory\JJ\1740 jejunal\JJ\1740 manometry\NN\1740 before\IN\1740 and\CC\1740 after\IN\1740 12\CD\13745420 week\NN\15113229 's\POS\1740 treatment\NN\654885 [\-LRB-\1740 <e1>cisapride</e1>\NN\1740 ,\,\1740 5\CD\13741022 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 daily\RB\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 19\CD\13745420 )\-RRB-\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 19\CD\13745420 )\-RRB-\1740 ]\-RRB-\1740 .\.\1740
D020117_D003248 NONE Symptom\NN\5823932 scores\NNS\13757724 relating\VBG\628491 to\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>constipation</e2>\NN\14299637 were\VBD\836236 lower\JJR\1740 in\IN\13603305 <e1>cisapride-treated</e1>\JJ\1740 constipation-predominant\JJ\1740 IBS\NN\1740 patients\NNS\9898892 [\-LRB-\1740 score\NN\5736149 ,\,\1740 54\CD\1740 +/-\CC\1740 5\CD\13741022 versus\CC\1740 67\CD\1740 +/-\CC\1740 14\CD\13745420 mm\NN\13649268 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 62\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D003248 NONE Symptom\NN\5823932 scores\NNS\13757724 relating\VBG\628491 to\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 constipation\NN\14299637 were\VBD\836236 lower\JJR\1740 in\IN\13603305 <e1>cisapride-treated</e1>\JJ\1740 <e2>constipation-predominant</e2>\JJ\1740 IBS\NN\1740 patients\NNS\9898892 [\-LRB-\1740 score\NN\5736149 ,\,\1740 54\CD\1740 +/-\CC\1740 5\CD\13741022 versus\CC\1740 67\CD\1740 +/-\CC\1740 14\CD\13745420 mm\NN\13649268 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 62\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D003248 NONE Symptom\NN\5823932 scores\NNS\13757724 relating\VBG\628491 to\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>constipation</e2>\NN\14299637 were\VBD\836236 lower\JJR\1740 in\IN\13603305 cisapride-treated\JJ\1740 constipation-predominant\JJ\1740 IBS\NN\1740 patients\NNS\9898892 [\-LRB-\1740 score\NN\5736149 ,\,\1740 54\CD\1740 +/-\CC\1740 5\CD\13741022 versus\CC\1740 67\CD\1740 +/-\CC\1740 14\CD\13745420 mm\NN\13649268 ,\,\1740 <e1>cisapride</e1>\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 62\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D003248 NONE Symptom\NN\5823932 scores\NNS\13757724 relating\VBG\628491 to\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 constipation\NN\14299637 were\VBD\836236 lower\JJR\1740 in\IN\13603305 cisapride-treated\JJ\1740 <e2>constipation-predominant</e2>\JJ\1740 IBS\NN\1740 patients\NNS\9898892 [\-LRB-\1740 score\NN\5736149 ,\,\1740 54\CD\1740 +/-\CC\1740 5\CD\13741022 versus\CC\1740 67\CD\1740 +/-\CC\1740 14\CD\13745420 mm\NN\13649268 ,\,\1740 <e1>cisapride</e1>\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 62\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D003967 NONE METHODS\NNS\5616786 :\:\1740 Thirty-eight\NN\1740 patients\NNS\9898892 with\IN\1740 IBS\NN\1740 (\-LRB-\1740 constipation-predominant\JJ\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 ;\:\1740 <e2>diarrhoea-predominant</e2>\JJ\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 21\CD\13745420 )\-RRB-\1740 underwent\VBD\109660 24-h\JJ\1740 ambulatory\JJ\1740 jejunal\JJ\1740 manometry\NN\1740 before\IN\1740 and\CC\1740 after\IN\1740 12\CD\13745420 week\NN\15113229 's\POS\1740 treatment\NN\654885 [\-LRB-\1740 <e1>cisapride</e1>\NN\1740 ,\,\1740 5\CD\13741022 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 daily\RB\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 19\CD\13745420 )\-RRB-\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 19\CD\13745420 )\-RRB-\1740 ]\-RRB-\1740 .\.\1740
D020117_D003967 NONE RESULTS\NNS\34213 :\:\1740 In\IN\13603305 <e2>diarrhoea-predominant</e2>\JJ\1740 patients\NNS\9898892 significant\JJ\1740 differences\NNS\4723816 in\IN\13603305 contraction\NN\358931 characteristics\NNS\5849040 were\VBD\836236 observed\VBN\2163746 between\IN\1740 the\DT\1740 <e1>cisapride</e1>\NN\1740 and\CC\1740 placebo\NN\3740161 groups\NNS\2137 .\.\1740
D020117_D003967 NONE In\IN\13603305 <e1>cisapride-treated</e1>\JJ\1740 <e2>diarrhoea-predominant</e2>\JJ\1740 patients\NNS\9898892 the\DT\1740 mean\JJ\1740 contraction\NN\358931 amplitude\NN\7444668 was\VBD\836236 higher\JJR\1740 (\-LRB-\1740 29.3\CD\1740 +/-\CC\1740 3.2\CD\1740 versus\CC\1740 24.9\CD\1740 +/-\CC\1740 2.6\CD\1740 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 25.7\CD\1740 +/-\CC\1740 6.0\CD\1740 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 ,\,\1740 the\DT\1740 mean\JJ\1740 contraction\NN\358931 duration\NN\15113229 longer\RBR\1740 (\-LRB-\1740 3.4\CD\1740 +/-\CC\1740 0.2\CD\1740 versus\CC\1740 3.0\CD\1740 +/-\CC\1740 0.2\CD\1740 sec\NN\15154774 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 3.1\CD\1740 +/-\CC\1740 0.5\CD\1740 sec\NN\15154774 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 mean\JJ\1740 contraction\NN\358931 frequency\NN\15286249 lower\JJR\1740 (\-LRB-\1740 2.0\CD\1740 +/-\CC\1740 0.2\CD\1740 versus\CC\1740 2.5\CD\1740 +/-\CC\1740 0.4\CD\1740 cont./min\NN\1740 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 2.5\CD\1740 +/-\CC\1740 1.1\CD\1740 cont./min\NN\1740 ]\-RRB-\1740 than\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 placebo\NN\3740161 .\.\1740
D020117_D003967 NONE In\IN\13603305 cisapride-treated\JJ\1740 <e2>diarrhoea-predominant</e2>\JJ\1740 patients\NNS\9898892 the\DT\1740 mean\JJ\1740 contraction\NN\358931 amplitude\NN\7444668 was\VBD\836236 higher\JJR\1740 (\-LRB-\1740 29.3\CD\1740 +/-\CC\1740 3.2\CD\1740 versus\CC\1740 24.9\CD\1740 +/-\CC\1740 2.6\CD\1740 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 <e1>cisapride</e1>\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 25.7\CD\1740 +/-\CC\1740 6.0\CD\1740 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 ,\,\1740 the\DT\1740 mean\JJ\1740 contraction\NN\358931 duration\NN\15113229 longer\RBR\1740 (\-LRB-\1740 3.4\CD\1740 +/-\CC\1740 0.2\CD\1740 versus\CC\1740 3.0\CD\1740 +/-\CC\1740 0.2\CD\1740 sec\NN\15154774 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 3.1\CD\1740 +/-\CC\1740 0.5\CD\1740 sec\NN\15154774 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 mean\JJ\1740 contraction\NN\358931 frequency\NN\15286249 lower\JJR\1740 (\-LRB-\1740 2.0\CD\1740 +/-\CC\1740 0.2\CD\1740 versus\CC\1740 2.5\CD\1740 +/-\CC\1740 0.4\CD\1740 cont./min\NN\1740 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 2.5\CD\1740 +/-\CC\1740 1.1\CD\1740 cont./min\NN\1740 ]\-RRB-\1740 than\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 placebo\NN\3740161 .\.\1740
D020117_D003967 NONE In\IN\13603305 cisapride-treated\JJ\1740 <e2>diarrhoea-predominant</e2>\JJ\1740 patients\NNS\9898892 the\DT\1740 mean\JJ\1740 contraction\NN\358931 amplitude\NN\7444668 was\VBD\836236 higher\JJR\1740 (\-LRB-\1740 29.3\CD\1740 +/-\CC\1740 3.2\CD\1740 versus\CC\1740 24.9\CD\1740 +/-\CC\1740 2.6\CD\1740 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 25.7\CD\1740 +/-\CC\1740 6.0\CD\1740 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 ,\,\1740 the\DT\1740 mean\JJ\1740 contraction\NN\358931 duration\NN\15113229 longer\RBR\1740 (\-LRB-\1740 3.4\CD\1740 +/-\CC\1740 0.2\CD\1740 versus\CC\1740 3.0\CD\1740 +/-\CC\1740 0.2\CD\1740 sec\NN\15154774 ,\,\1740 <e1>cisapride</e1>\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 3.1\CD\1740 +/-\CC\1740 0.5\CD\1740 sec\NN\15154774 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 mean\JJ\1740 contraction\NN\358931 frequency\NN\15286249 lower\JJR\1740 (\-LRB-\1740 2.0\CD\1740 +/-\CC\1740 0.2\CD\1740 versus\CC\1740 2.5\CD\1740 +/-\CC\1740 0.4\CD\1740 cont./min\NN\1740 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 2.5\CD\1740 +/-\CC\1740 1.1\CD\1740 cont./min\NN\1740 ]\-RRB-\1740 than\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 placebo\NN\3740161 .\.\1740
D020117_D003967 NONE In\IN\13603305 cisapride-treated\JJ\1740 <e2>diarrhoea-predominant</e2>\JJ\1740 patients\NNS\9898892 the\DT\1740 mean\JJ\1740 contraction\NN\358931 amplitude\NN\7444668 was\VBD\836236 higher\JJR\1740 (\-LRB-\1740 29.3\CD\1740 +/-\CC\1740 3.2\CD\1740 versus\CC\1740 24.9\CD\1740 +/-\CC\1740 2.6\CD\1740 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 25.7\CD\1740 +/-\CC\1740 6.0\CD\1740 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 ,\,\1740 the\DT\1740 mean\JJ\1740 contraction\NN\358931 duration\NN\15113229 longer\RBR\1740 (\-LRB-\1740 3.4\CD\1740 +/-\CC\1740 0.2\CD\1740 versus\CC\1740 3.0\CD\1740 +/-\CC\1740 0.2\CD\1740 sec\NN\15154774 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 3.1\CD\1740 +/-\CC\1740 0.5\CD\1740 sec\NN\15154774 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 mean\JJ\1740 contraction\NN\358931 frequency\NN\15286249 lower\JJR\1740 (\-LRB-\1740 2.0\CD\1740 +/-\CC\1740 0.2\CD\1740 versus\CC\1740 2.5\CD\1740 +/-\CC\1740 0.4\CD\1740 cont./min\NN\1740 ,\,\1740 <e1>cisapride</e1>\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 2.5\CD\1740 +/-\CC\1740 1.1\CD\1740 cont./min\NN\1740 ]\-RRB-\1740 than\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 placebo\NN\3740161 .\.\1740
D020117_D003967 NONE <e2>Diarrhoea-predominant</e2>\JJ\1740 IBS\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 higher\JJR\1740 pain\NN\14299637 score\NN\5736149 after\IN\1740 <e1>cisapride</e1>\NN\1740 therapy\NN\657604 [\-LRB-\1740 score\NN\5736149 ,\,\1740 55\CD\1740 +/-\CC\1740 15\CD\13745420 versus\CC\1740 34\CD\1740 +/-\CC\1740 12\CD\13745420 mm\NN\13649268 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 67\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D003967 NONE <e2>Diarrhoea-predominant</e2>\JJ\1740 IBS\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 higher\JJR\1740 pain\NN\14299637 score\NN\5736149 after\IN\1740 cisapride\NN\1740 therapy\NN\657604 [\-LRB-\1740 score\NN\5736149 ,\,\1740 55\CD\1740 +/-\CC\1740 15\CD\13745420 versus\CC\1740 34\CD\1740 +/-\CC\1740 12\CD\13745420 mm\NN\13649268 ,\,\1740 <e1>cisapride</e1>\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 67\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D010146 NONE Diarrhoea-predominant\JJ\1740 IBS\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 higher\JJR\1740 <e2>pain</e2>\NN\14299637 score\NN\5736149 after\IN\1740 <e1>cisapride</e1>\NN\1740 therapy\NN\657604 [\-LRB-\1740 score\NN\5736149 ,\,\1740 55\CD\1740 +/-\CC\1740 15\CD\13745420 versus\CC\1740 34\CD\1740 +/-\CC\1740 12\CD\13745420 mm\NN\13649268 ,\,\1740 cisapride\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 67\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
D020117_D010146 NONE Diarrhoea-predominant\JJ\1740 IBS\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 higher\JJR\1740 <e2>pain</e2>\NN\14299637 score\NN\5736149 after\IN\1740 cisapride\NN\1740 therapy\NN\657604 [\-LRB-\1740 score\NN\5736149 ,\,\1740 55\CD\1740 +/-\CC\1740 15\CD\13745420 versus\CC\1740 34\CD\1740 +/-\CC\1740 12\CD\13745420 mm\NN\13649268 ,\,\1740 <e1>cisapride</e1>\NN\1740 versus\CC\1740 placebo\NN\3740161 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 pretreatment\NN\1740 ,\,\1740 67\CD\1740 +/-\CC\1740 19\CD\13745420 mm\NNS\13649268 ]\-RRB-\1740 .\.\1740
873132
D003840_D002779 NONE Increased\VBN\169651 sulfation\NN\1740 and\CC\1740 decreased\VBD\169651 7alpha-hydroxylation\NN\1740 of\IN\1740 <e1>deoxycholic\JJ\1740 acid</e1>\NN\14818238 in\IN\13603305 ethinyl\JJ\1740 estradiol-induced\JJ\1740 <e2>cholestasis</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004997_D002779 CID Increased\VBN\169651 sulfation\NN\1740 and\CC\1740 decreased\VBD\169651 7alpha-hydroxylation\NN\1740 of\IN\1740 deoxycholic\JJ\1740 acid\NN\14818238 in\IN\13603305 <e1>ethinyl\JJ\1740 estradiol-induced</e1>\JJ\1740 <e2>cholestasis</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 .\.\1740
20973483
D058915_D010300 NONE In\FW\13603305 vivo\FW\1740 characterization\NN\6724763 of\IN\1740 a\DT\13649268 dual\JJ\1740 <e1>adenosine\NN\14964367 A2A/A1\NN\1740 receptor\NN\5225602 antagonist</e1>\NN\7846 in\IN\13603305 animal\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D058915_D010300 NONE The\DT\1740 in\FW\13603305 vivo\FW\1740 characterization\NN\6724763 of\IN\1740 a\DT\13649268 dual\JJ\1740 <e1>adenosine\NN\14964367 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist</e1>\NN\7846 in\IN\13603305 several\JJ\1740 animal\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 is\VBZ\836236 described\VBN\1001294 .\.\1740
D006220_D010300 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D006220_D002375 CID Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D006220_D004409 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 <e2>akinesia</e2>\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D012110_D010300 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 <e1>reserpine-induced</e1>\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D012110_D002375 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 <e1>reserpine-induced</e1>\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D012110_D004409 CID Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 <e1>reserpine-induced</e1>\JJ\1740 <e2>akinesia</e2>\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D016627_D010300 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 <e1>6-hydroxydopamine</e1>\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D016627_D010300 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 <e1>6-OHDA</e1>\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D016627_D002375 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 <e1>6-hydroxydopamine</e1>\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D016627_D002375 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 <e1>6-OHDA</e1>\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D016627_D004409 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 <e2>akinesia</e2>\NN\14558226 ,\,\1740 rat\NN\2329401 <e1>6-hydroxydopamine</e1>\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D016627_D004409 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 <e2>akinesia</e2>\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 <e1>6-OHDA</e1>\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 MPTP-treated\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D015632_D010300 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 <e1>MPTP-treated</e1>\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D015632_D002375 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 akinesia\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 <e1>MPTP-treated</e1>\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
D015632_D004409 NONE Compound\NN\5869584 1\CD\13741022 is\VBZ\836236 a\DT\13649268 potent\JJ\1740 A(2A)/A(1\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 in\FW\13603305 vitro\FW\1740 (\-LRB-\1740 A(2A\NN\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 4.1\CD\1740 nM\NN\13649268 ;\:\1740 A(1\LS\1740 )\-RRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 17.0\CD\1740 nM\NN\13649268 )\-RRB-\1740 that\WDT\1740 has\VBZ\2108377 excellent\JJ\1740 activity\NN\30358 ,\,\1740 after\IN\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 across\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 including\VBG\690614 mouse\NN\2329401 and\CC\1740 rat\NN\2329401 models\NNS\5888929 of\IN\1740 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 mouse\NN\2329401 model\NN\5888929 of\IN\1740 reserpine-induced\JJ\1740 <e2>akinesia</e2>\NN\14558226 ,\,\1740 rat\NN\2329401 6-hydroxydopamine\NN\1740 (\-LRB-\1740 6-OHDA\NN\1740 )\-RRB-\1740 lesion\NN\14204950 model\NN\5888929 of\IN\1740 drug-induced\JJ\1740 rotation\NN\331950 ,\,\1740 and\CC\1740 <e1>MPTP-treated</e1>\JJ\1740 non-human\JJ\1740 primate\JJ\1740 model\NN\5888929 .\.\1740
3183120
C033706_D001927 CID Reversible\JJ\1740 <e2>cerebral\JJ\1740 lesions</e2>\NNS\14204950 associated\VBN\628491 with\IN\1740 <e1>tiazofurin</e1>\NN\1740 usage\NN\407535 :\:\1740 MR\NN\6339416 demonstration\NN\520257 .\.\1740
9549528
D007980_D020734 NONE Cortical\JJ\1740 motor\NN\3699975 overactivation\NN\1740 in\IN\13603305 <e2>parkinsonian</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>L-dopa-induced</e1>\JJ\1740 peak-dose\JJ\1740 dyskinesia\NN\14084880 .\.\1740
D007980_D020734 NONE We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 regional\JJ\1740 cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 rCBF\NN\1740 )\-RRB-\1740 changes\NNS\7283608 induced\VBN\1627355 by\IN\1740 the\DT\1740 execution\NN\1161161 of\IN\1740 a\DT\13649268 finger-to-thumb\JJ\1740 opposition\NN\37396 motor\NN\3699975 task\NN\575741 in\IN\13603305 the\DT\1740 supplementary\NN\1740 and\CC\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 of\IN\1740 two\CD\13741022 groups\NNS\2137 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>L-dopa</e1>\JJ\1740 medication\NN\3247620 ,\,\1740 the\DT\1740 first\JJ\1740 one\CD\13741022 without\IN\1740 L-dopa\JJ\1740 induced\VBD\1627355 dyskinesia\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 the\DT\1740 other\JJ\1740 with\IN\1740 moderate\JJ\1740 peak-dose\JJ\1740 dyskinesia\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 of\IN\1740 a\DT\13649268 group\NN\2137 of\IN\1740 14\CD\13745420 normal\JJ\1740 subjects\NNS\6598915 .\.\1740
D007980_D020734 NONE We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 regional\JJ\1740 cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 rCBF\NN\1740 )\-RRB-\1740 changes\NNS\7283608 induced\VBN\1627355 by\IN\1740 the\DT\1740 execution\NN\1161161 of\IN\1740 a\DT\13649268 finger-to-thumb\JJ\1740 opposition\NN\37396 motor\NN\3699975 task\NN\575741 in\IN\13603305 the\DT\1740 supplementary\NN\1740 and\CC\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 of\IN\1740 two\CD\13741022 groups\NNS\2137 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 patients\NNS\9898892 on\IN\1740 L-dopa\JJ\1740 medication\NN\3247620 ,\,\1740 the\DT\1740 first\JJ\1740 one\CD\13741022 without\IN\1740 <e1>L-dopa</e1>\JJ\1740 induced\VBD\1627355 dyskinesia\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 the\DT\1740 other\JJ\1740 with\IN\1740 moderate\JJ\1740 peak-dose\JJ\1740 dyskinesia\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 of\IN\1740 a\DT\13649268 group\NN\2137 of\IN\1740 14\CD\13745420 normal\JJ\1740 subjects\NNS\6598915 .\.\1740
D007980_D004409 CID Cortical\JJ\1740 motor\NN\3699975 overactivation\NN\1740 in\IN\13603305 parkinsonian\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>L-dopa-induced</e1>\JJ\1740 peak-dose\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 .\.\1740
D007980_D004409 CID We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 regional\JJ\1740 cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 rCBF\NN\1740 )\-RRB-\1740 changes\NNS\7283608 induced\VBN\1627355 by\IN\1740 the\DT\1740 execution\NN\1161161 of\IN\1740 a\DT\13649268 finger-to-thumb\JJ\1740 opposition\NN\37396 motor\NN\3699975 task\NN\575741 in\IN\13603305 the\DT\1740 supplementary\NN\1740 and\CC\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 of\IN\1740 two\CD\13741022 groups\NNS\2137 of\IN\1740 parkinsonian\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>L-dopa</e1>\JJ\1740 medication\NN\3247620 ,\,\1740 the\DT\1740 first\JJ\1740 one\CD\13741022 without\IN\1740 L-dopa\JJ\1740 induced\VBD\1627355 <e2>dyskinesia</e2>\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 the\DT\1740 other\JJ\1740 with\IN\1740 moderate\JJ\1740 peak-dose\JJ\1740 dyskinesia\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 of\IN\1740 a\DT\13649268 group\NN\2137 of\IN\1740 14\CD\13745420 normal\JJ\1740 subjects\NNS\6598915 .\.\1740
D007980_D004409 CID We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 regional\JJ\1740 cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 rCBF\NN\1740 )\-RRB-\1740 changes\NNS\7283608 induced\VBN\1627355 by\IN\1740 the\DT\1740 execution\NN\1161161 of\IN\1740 a\DT\13649268 finger-to-thumb\JJ\1740 opposition\NN\37396 motor\NN\3699975 task\NN\575741 in\IN\13603305 the\DT\1740 supplementary\NN\1740 and\CC\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 of\IN\1740 two\CD\13741022 groups\NNS\2137 of\IN\1740 parkinsonian\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>L-dopa</e1>\JJ\1740 medication\NN\3247620 ,\,\1740 the\DT\1740 first\JJ\1740 one\CD\13741022 without\IN\1740 L-dopa\JJ\1740 induced\VBD\1627355 dyskinesia\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 the\DT\1740 other\JJ\1740 with\IN\1740 moderate\JJ\1740 peak-dose\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 of\IN\1740 a\DT\13649268 group\NN\2137 of\IN\1740 14\CD\13745420 normal\JJ\1740 subjects\NNS\6598915 .\.\1740
D007980_D004409 CID We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 regional\JJ\1740 cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 rCBF\NN\1740 )\-RRB-\1740 changes\NNS\7283608 induced\VBN\1627355 by\IN\1740 the\DT\1740 execution\NN\1161161 of\IN\1740 a\DT\13649268 finger-to-thumb\JJ\1740 opposition\NN\37396 motor\NN\3699975 task\NN\575741 in\IN\13603305 the\DT\1740 supplementary\NN\1740 and\CC\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 of\IN\1740 two\CD\13741022 groups\NNS\2137 of\IN\1740 parkinsonian\JJ\1740 patients\NNS\9898892 on\IN\1740 L-dopa\JJ\1740 medication\NN\3247620 ,\,\1740 the\DT\1740 first\JJ\1740 one\CD\13741022 without\IN\1740 <e1>L-dopa</e1>\JJ\1740 induced\VBD\1627355 <e2>dyskinesia</e2>\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 the\DT\1740 other\JJ\1740 with\IN\1740 moderate\JJ\1740 peak-dose\JJ\1740 dyskinesia\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 of\IN\1740 a\DT\13649268 group\NN\2137 of\IN\1740 14\CD\13745420 normal\JJ\1740 subjects\NNS\6598915 .\.\1740
D007980_D004409 CID We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 regional\JJ\1740 cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 rCBF\NN\1740 )\-RRB-\1740 changes\NNS\7283608 induced\VBN\1627355 by\IN\1740 the\DT\1740 execution\NN\1161161 of\IN\1740 a\DT\13649268 finger-to-thumb\JJ\1740 opposition\NN\37396 motor\NN\3699975 task\NN\575741 in\IN\13603305 the\DT\1740 supplementary\NN\1740 and\CC\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 of\IN\1740 two\CD\13741022 groups\NNS\2137 of\IN\1740 parkinsonian\JJ\1740 patients\NNS\9898892 on\IN\1740 L-dopa\JJ\1740 medication\NN\3247620 ,\,\1740 the\DT\1740 first\JJ\1740 one\CD\13741022 without\IN\1740 <e1>L-dopa</e1>\JJ\1740 induced\VBD\1627355 dyskinesia\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 23\CD\13745420 )\-RRB-\1740 and\CC\1740 the\DT\1740 other\JJ\1740 with\IN\1740 moderate\JJ\1740 peak-dose\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 of\IN\1740 a\DT\13649268 group\NN\2137 of\IN\1740 14\CD\13745420 normal\JJ\1740 subjects\NNS\6598915 .\.\1740
D007980_D004409 CID These\DT\1740 results\NNS\34213 are\VBP\836236 compatible\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 an\DT\6697703 hyperkinetic\JJ\1740 <e2>abnormal\JJ\1740 involuntary\JJ\1740 movement</e2>\NN\191142 ,\,\1740 like\IN\5839024 <e1>L-dopa-induced</e1>\JJ\1740 peak\NN\13758296 dose\NN\3740161 dyskinesia\NN\14084880 ,\,\1740 is\VBZ\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 disinhibition\NN\1740 of\IN\1740 the\DT\1740 primary\JJ\1740 and\CC\1740 associated\VBN\628491 motor\NN\3699975 cortex\NN\5462674 secondary\JJ\1740 to\TO\1740 an\DT\6697703 excessive\JJ\1740 outflow\NN\7407777 of\IN\1740 the\DT\1740 pallidothalamocortical\JJ\1740 motor\NN\3699975 loop\NN\3323703 .\.\1740
D007980_D004409 CID These\DT\1740 results\NNS\34213 are\VBP\836236 compatible\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 an\DT\6697703 hyperkinetic\JJ\1740 abnormal\JJ\1740 involuntary\JJ\1740 movement\NN\191142 ,\,\1740 like\IN\5839024 <e1>L-dopa-induced</e1>\JJ\1740 peak\NN\13758296 dose\NN\3740161 <e2>dyskinesia</e2>\NN\14084880 ,\,\1740 is\VBZ\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 disinhibition\NN\1740 of\IN\1740 the\DT\1740 primary\JJ\1740 and\CC\1740 associated\VBN\628491 motor\NN\3699975 cortex\NN\5462674 secondary\JJ\1740 to\TO\1740 an\DT\6697703 excessive\JJ\1740 outflow\NN\7407777 of\IN\1740 the\DT\1740 pallidothalamocortical\JJ\1740 motor\NN\3699975 loop\NN\3323703 .\.\1740
D007980_D006948 NONE These\DT\1740 results\NNS\34213 are\VBP\836236 compatible\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 an\DT\6697703 <e2>hyperkinetic</e2>\JJ\1740 abnormal\JJ\1740 involuntary\JJ\1740 movement\NN\191142 ,\,\1740 like\IN\5839024 <e1>L-dopa-induced</e1>\JJ\1740 peak\NN\13758296 dose\NN\3740161 dyskinesia\NN\14084880 ,\,\1740 is\VBZ\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 disinhibition\NN\1740 of\IN\1740 the\DT\1740 primary\JJ\1740 and\CC\1740 associated\VBN\628491 motor\NN\3699975 cortex\NN\5462674 secondary\JJ\1740 to\TO\1740 an\DT\6697703 excessive\JJ\1740 outflow\NN\7407777 of\IN\1740 the\DT\1740 pallidothalamocortical\JJ\1740 motor\NN\3699975 loop\NN\3323703 .\.\1740
18239197
D014282_D003072 CID Increased\VBN\169651 <e2>mental\JJ\1740 slowing</e2>\NN\7296428 associated\VBN\628491 with\IN\1740 the\DT\1740 APOE\NN\1740 epsilon4\NN\1740 allele\NN\5436752 after\IN\1740 <e1>trihexyphenidyl</e1>\JJ\1740 oral\JJ\1740 anticholinergic\JJ\1740 challenge\NN\13927383 in\IN\13603305 healthy\JJ\1740 elderly\JJ\1740 .\.\1740
D014282_D003072 CID RESULTS\NNS\34213 :\:\1740 A\DT\13649268 2.0-mg\JJ\1740 oral\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>trihexyphenidyl</e1>\NN\1740 resulted\VBD\2633881 in\IN\13603305 increased\VBN\169651 subjective\JJ\1740 ratings\NNS\5733583 of\IN\1740 <e2>mental\JJ\1740 slowness</e2>\NN\5648247 in\IN\13603305 carriers\NNS\9629752 of\IN\1740 the\DT\1740 APOE\NN\1740 epsilon4\NN\1740 allele\NN\5436752 only\RB\1740 .\.\1740
D014282_D003072 CID Drug\NN\14778436 effects\NNS\13245626 as\IN\14622893 determined\VBN\1645601 by\IN\1740 difference\NN\4723816 scores\NNS\13757724 between\IN\1740 2.0\CD\1740 mg\NN\13717155 <e1>trihexyphenidyl</e1>\NN\1740 and\CC\1740 placebo\VB\1740 on\IN\1740 ratings\NNS\5733583 of\IN\1740 <e2>mental\JJ\1740 slowness</e2>\NN\5648247 significantly\RB\1740 correlated\VBN\2657219 with\IN\1740 total\JJ\1740 and\CC\1740 delayed\VBD\439958 recall\NN\7185325 on\IN\1740 the\DT\1740 Buschke\NNP\1740 Selective\NNP\1740 Reminding\NNP\1740 Test\NNP\5798043 in\IN\13603305 carriers\NNS\9629752 of\IN\1740 the\DT\1740 APOE\NN\1740 epsilon4\NN\1740 allele\NN\5436752 only\RB\1740 .\.\1740
D014282_D003072 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 epsilon4\NN\1740 allele\NN\5436752 in\IN\13603305 healthy\JJ\1740 elderly\JJ\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 subjective\JJ\1740 <e2>mental\JJ\1740 slowing</e2>\NN\7296428 after\IN\1740 <e1>trihexyphenidyl</e1>\JJ\1740 anticholinergic\JJ\1740 challenge\NN\13927383 .\.\1740
D014282_D003221 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 objectives\NNS\5980875 of\IN\1740 this\DT\1740 study\NN\635850 were\VBD\836236 to\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 APOE\NN\1740 epsilon4\NN\1740 and\CC\1740 subjective\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>trihexyphenidyl</e1>\NN\1740 on\IN\1740 measures\NNS\168237 reflecting\VBG\923793 sedation\NN\14034177 and\CC\1740 <e2>confusion</e2>\NN\13972797 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 between\IN\1740 trihexyphenidyl-induced\JJ\1740 subjective\JJ\1740 effects\NNS\13245626 and\CC\1740 objective\JJ\1740 memory\NN\5926676 performance\NN\6619065 .\.\1740
D014282_D003221 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 objectives\NNS\5980875 of\IN\1740 this\DT\1740 study\NN\635850 were\VBD\836236 to\TO\1740 examine\VB\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 APOE\NN\1740 epsilon4\NN\1740 and\CC\1740 subjective\JJ\1740 effects\NNS\13245626 of\IN\1740 trihexyphenidyl\NN\1740 on\IN\1740 measures\NNS\168237 reflecting\VBG\923793 sedation\NN\14034177 and\CC\1740 <e2>confusion</e2>\NN\13972797 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 relationship\NN\31921 between\IN\1740 <e1>trihexyphenidyl-induced</e1>\JJ\1740 subjective\JJ\1740 effects\NNS\13245626 and\CC\1740 objective\JJ\1740 memory\NN\5926676 performance\NN\6619065 .\.\1740
17241657
D003042_D012640 CID Earlier\JJR\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 that\IN\1740 antagonism\NN\24720 of\IN\1740 sigma1\NN\1740 receptors\NNS\5225602 attenuates\VBZ\224901 the\DT\1740 <e2>convulsive</e2>\JJ\1740 ,\,\1740 lethal\JJ\1740 ,\,\1740 locomotor\NN\1740 stimulatory\NN\1740 and\CC\1740 rewarding\VBG\2546467 actions\NNS\30358 of\IN\1740 <e1>cocaine</e1>\NN\3492717 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003042_D012640 CID In\IN\13603305 behavioral\JJ\1740 studies\NNS\635850 ,\,\1740 pretreatment\NN\1740 of\IN\1740 Swiss\NNP\8166552 Webster\NNP\1740 mice\NNS\2329401 with\IN\1740 UMB24\NN\1740 or\CC\3541091 (+/-)-SM\NN\1740 21\CD\13745420 significantly\RB\1740 attenuated\VBD\224901 <e1>cocaine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 locomotor\NN\1740 activity\NN\30358 ,\,\1740 but\CC\1740 not\RB\1740 lethality\NN\4790449 .\.\1740
C519696_D012640 NONE In\IN\13603305 behavioral\JJ\1740 studies\NNS\635850 ,\,\1740 pretreatment\NN\1740 of\IN\1740 Swiss\NNP\8166552 Webster\NNP\1740 mice\NNS\2329401 with\IN\1740 <e1>UMB24</e1>\NN\1740 or\CC\3541091 (+/-)-SM\NN\1740 21\CD\13745420 significantly\RB\1740 attenuated\VBD\224901 cocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 locomotor\NN\1740 activity\NN\30358 ,\,\1740 but\CC\1740 not\RB\1740 lethality\NN\4790449 .\.\1740
C107044_D012640 NONE In\IN\13603305 behavioral\JJ\1740 studies\NNS\635850 ,\,\1740 pretreatment\NN\1740 of\IN\1740 Swiss\NNP\8166552 Webster\NNP\1740 mice\NNS\2329401 with\IN\1740 UMB24\NN\1740 or\CC\3541091 <e1>(+/-)-SM\NN\1740 21</e1>\CD\13745420 significantly\RB\1740 attenuated\VBD\224901 cocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 locomotor\NN\1740 activity\NN\30358 ,\,\1740 but\CC\1740 not\RB\1740 lethality\NN\4790449 .\.\1740
20558148
D016202_D002375 NONE Glutamatergic\JJ\1740 neurotransmission\NN\1740 mediated\VBN\761713 by\IN\1740 <e1>NMDA</e1>\NN\1740 receptors\NNS\5225602 in\IN\13603305 the\DT\1740 inferior\JJ\1740 colliculus\NN\1740 can\MD\3094503 modulate\VB\1724459 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D016202_D002375 NONE Haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 challenged\VBN\869596 with\IN\1740 prior\JJ\1740 intracollicular\JJ\1740 microinjections\NNS\1740 of\IN\1740 glutamate\JJ\1740 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 ,\,\1740 MK-801\NN\1740 (\-LRB-\1740 15\CD\13745420 or\CC\3541091 30\CD\13745420 mmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 and\CC\1740 AP7\NN\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 nmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 of\IN\1740 the\DT\1740 NMDA\NN\1740 receptor\NN\5225602 agonist\NN\9613191 N-methyl-d-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 ,\,\1740 20\CD\13745420 or\CC\3541091
D016202_D002375 NONE Haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 challenged\VBN\869596 with\IN\1740 prior\JJ\1740 intracollicular\JJ\1740 microinjections\NNS\1740 of\IN\1740 glutamate\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 ,\,\1740 MK-801\NN\1740 (\-LRB-\1740 15\CD\13745420 or\CC\3541091 30\CD\13745420 mmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 and\CC\1740 AP7\NN\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 nmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 of\IN\1740 the\DT\1740 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 agonist\NN\9613191 N-methyl-d-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 ,\,\1740 20\CD\13745420 or\CC\3541091
D016202_D002375 NONE Haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 challenged\VBN\869596 with\IN\1740 prior\JJ\1740 intracollicular\JJ\1740 microinjections\NNS\1740 of\IN\1740 glutamate\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 ,\,\1740 MK-801\NN\1740 (\-LRB-\1740 15\CD\13745420 or\CC\3541091 30\CD\13745420 mmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 and\CC\1740 AP7\NN\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 nmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 of\IN\1740 the\DT\1740 NMDA\NN\1740 receptor\NN\5225602 agonist\NN\9613191 <e1>N-methyl-d-aspartate</e1>\NN\1740 (\-LRB-\1740 NMDA\NN\1740 ,\,\1740 20\CD\13745420 or\CC\3541091
D016202_D002375 NONE Haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 challenged\VBN\869596 with\IN\1740 prior\JJ\1740 intracollicular\JJ\1740 microinjections\NNS\1740 of\IN\1740 glutamate\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 ,\,\1740 MK-801\NN\1740 (\-LRB-\1740 15\CD\13745420 or\CC\3541091 30\CD\13745420 mmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 and\CC\1740 AP7\NN\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 nmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 of\IN\1740 the\DT\1740 NMDA\NN\1740 receptor\NN\5225602 agonist\NN\9613191 N-methyl-d-aspartate\NN\1740 (\-LRB-\1740 <e1>NMDA</e1>\NN\1740 ,\,\1740 20\CD\13745420 or\CC\3541091
D006220_D002375 CID Glutamatergic\JJ\1740 neurotransmission\NN\1740 mediated\VBN\761713 by\IN\1740 NMDA\NN\1740 receptors\NNS\5225602 in\IN\13603305 the\DT\1740 inferior\JJ\1740 colliculus\NN\1740 can\MD\3094503 modulate\VB\1724459 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D006220_D002375 CID The\DT\1740 present\JJ\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 influence\NN\5190804 of\IN\1740 excitatory\NN\1740 amino\NN\14621446 acid-mediated\JJ\1740 mechanisms\NNS\13446390 in\IN\13603305 the\DT\1740 IC\NN\8339454 on\IN\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 the\DT\1740 dopamine\NN\14807737 receptor\NN\5225602 blocker\NN\10101634 <e1>haloperidol</e1>\NN\3713736 administered\VBN\2436349 systemically\RB\1740 (\-LRB-\1740 1\CD\13741022 or\CC\3541091 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006220_D002375 CID <e1>Haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 challenged\VBN\869596 with\IN\1740 prior\JJ\1740 intracollicular\JJ\1740 microinjections\NNS\1740 of\IN\1740 glutamate\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 ,\,\1740 MK-801\NN\1740 (\-LRB-\1740 15\CD\13745420 or\CC\3541091 30\CD\13745420 mmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 and\CC\1740 AP7\NN\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 nmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 of\IN\1740 the\DT\1740 NMDA\NN\1740 receptor\NN\5225602 agonist\NN\9613191 N-methyl-d-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 ,\,\1740 20\CD\13745420 or\CC\3541091
D006220_D002375 CID The\DT\1740 results\NNS\34213 showed\VBD\2137132 that\IN\1740 intracollicular\JJ\1740 microinjection\NN\1740 of\IN\1740 MK-801\NN\1740 and\CC\1740 AP7\NN\1740 previous\JJ\1740 to\TO\1740 systemic\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 as\IN\14622893 indicated\VBN\952524 by\IN\1740 a\DT\13649268 reduced\VBN\441445 latency\NN\15269513 to\TO\1740 step\VB\1835496 down\RP\1740 from\IN\1740 a\DT\13649268 horizontal\JJ\1740 bar\NN\4105893 .\.\1740
D006220_D002375 CID These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 glutamate-mediated\JJ\1740 mechanisms\NNS\13446390 in\IN\13603305 the\DT\1740 neural\JJ\1740 circuits\NNS\3269401 at\IN\14622893 the\DT\1740 IC\NN\8339454 level\NN\4916342 influence\NN\5190804 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 participate\VB\2367363 in\IN\13603305 the\DT\1740 regulation\NN\6652242 of\IN\1740 motor\NN\3699975 activity\NN\30358 .\.\1740
D000596_D002375 NONE The\DT\1740 present\JJ\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 influence\NN\5190804 of\IN\1740 excitatory\NN\1740 <e1>amino\NN\14621446 acid-mediated</e1>\JJ\1740 mechanisms\NNS\13446390 in\IN\13603305 the\DT\1740 IC\NN\8339454 on\IN\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 the\DT\1740 dopamine\NN\14807737 receptor\NN\5225602 blocker\NN\10101634 haloperidol\NN\3713736 administered\VBN\2436349 systemically\RB\1740 (\-LRB-\1740 1\CD\13741022 or\CC\3541091 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004298_D002375 NONE The\DT\1740 present\JJ\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 influence\NN\5190804 of\IN\1740 excitatory\NN\1740 amino\NN\14621446 acid-mediated\JJ\1740 mechanisms\NNS\13446390 in\IN\13603305 the\DT\1740 IC\NN\8339454 on\IN\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 the\DT\1740 <e1>dopamine</e1>\NN\14807737 receptor\NN\5225602 blocker\NN\10101634 haloperidol\NN\3713736 administered\VBN\2436349 systemically\RB\1740 (\-LRB-\1740 1\CD\13741022 or\CC\3541091 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D018698_D002375 NONE Haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 challenged\VBN\869596 with\IN\1740 prior\JJ\1740 intracollicular\JJ\1740 microinjections\NNS\1740 of\IN\1740 <e1>glutamate</e1>\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 ,\,\1740 MK-801\NN\1740 (\-LRB-\1740 15\CD\13745420 or\CC\3541091 30\CD\13745420 mmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 and\CC\1740 AP7\NN\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 nmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 of\IN\1740 the\DT\1740 NMDA\NN\1740 receptor\NN\5225602 agonist\NN\9613191 N-methyl-d-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 ,\,\1740 20\CD\13745420 or\CC\3541091
D018698_D002375 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>glutamate-mediated</e1>\JJ\1740 mechanisms\NNS\13446390 in\IN\13603305 the\DT\1740 neural\JJ\1740 circuits\NNS\3269401 at\IN\14622893 the\DT\1740 IC\NN\8339454 level\NN\4916342 influence\NN\5190804 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 participate\VB\2367363 in\IN\13603305 the\DT\1740 regulation\NN\6652242 of\IN\1740 motor\NN\3699975 activity\NN\30358 .\.\1740
D016291_D002375 NONE Haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 challenged\VBN\869596 with\IN\1740 prior\JJ\1740 intracollicular\JJ\1740 microinjections\NNS\1740 of\IN\1740 glutamate\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 ,\,\1740 <e1>MK-801</e1>\NN\1740 (\-LRB-\1740 15\CD\13745420 or\CC\3541091 30\CD\13745420 mmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 and\CC\1740 AP7\NN\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 nmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 of\IN\1740 the\DT\1740 NMDA\NN\1740 receptor\NN\5225602 agonist\NN\9613191 N-methyl-d-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 ,\,\1740 20\CD\13745420 or\CC\3541091
D016291_D002375 NONE The\DT\1740 results\NNS\34213 showed\VBD\2137132 that\IN\1740 intracollicular\JJ\1740 microinjection\NN\1740 of\IN\1740 <e1>MK-801</e1>\NN\1740 and\CC\1740 AP7\NN\1740 previous\JJ\1740 to\TO\1740 systemic\JJ\1740 injections\NNS\320852 of\IN\1740 haloperidol\NN\3713736 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 as\IN\14622893 indicated\VBN\952524 by\IN\1740 a\DT\13649268 reduced\VBN\441445 latency\NN\15269513 to\TO\1740 step\VB\1835496 down\RP\1740 from\IN\1740 a\DT\13649268 horizontal\JJ\1740 bar\NN\4105893 .\.\1740
C031231_D002375 NONE Haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 challenged\VBN\869596 with\IN\1740 prior\JJ\1740 intracollicular\JJ\1740 microinjections\NNS\1740 of\IN\1740 glutamate\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 ,\,\1740 MK-801\NN\1740 (\-LRB-\1740 15\CD\13745420 or\CC\3541091 30\CD\13745420 mmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>AP7</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 or\CC\3541091 20\CD\13745420 nmol/0.5\CD\1740 microl\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 of\IN\1740 the\DT\1740 NMDA\NN\1740 receptor\NN\5225602 agonist\NN\9613191 N-methyl-d-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 ,\,\1740 20\CD\13745420 or\CC\3541091
C031231_D002375 NONE The\DT\1740 results\NNS\34213 showed\VBD\2137132 that\IN\1740 intracollicular\JJ\1740 microinjection\NN\1740 of\IN\1740 MK-801\NN\1740 and\CC\1740 <e1>AP7</e1>\NN\1740 previous\JJ\1740 to\TO\1740 systemic\JJ\1740 injections\NNS\320852 of\IN\1740 haloperidol\NN\3713736 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 as\IN\14622893 indicated\VBN\952524 by\IN\1740 a\DT\13649268 reduced\VBN\441445 latency\NN\15269513 to\TO\1740 step\VB\1835496 down\RP\1740 from\IN\1740 a\DT\13649268 horizontal\JJ\1740 bar\NN\4105893 .\.\1740
10027919
C051883_D006962 NONE <e1>22-oxacalcitriol</e1>\NN\1740 suppresses\VBZ\2510337 <e2>secondary\JJ\1740 hyperparathyroidism</e2>\NN\14059928 without\IN\1740 inducing\VBG\1627355 low\JJ\1740 bone\NN\5286536 turnover\NN\13819207 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
C051883_D006962 NONE In\IN\13603305 long-standing\JJ\1740 <e2>secondary\JJ\1740 hyperparathyroidism</e2>\NN\14059928 ,\,\1740 <e1>OCT</e1>\NN\15209706 (\-LRB-\1740 0.03\CD\1740 microg/kg\NNS\1740 )\-RRB-\1740 stabilized\VBD\126264 serum\NN\5397468 PTH\NN\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 first\JJ\1740 months\NNS\15113229 .\.\1740
C051883_D006962 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 even\RB\1740 though\IN\1740 <e1>OCT</e1>\NN\15209706 does\VBZ\1640855 not\RB\1740 completely\RB\1740 prevent\VB\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 hypercalcemia\NN\14299637 in\IN\13603305 experimental\JJ\1740 dogs\NNS\2083346 with\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 it\PRP\6125041 may\MD\15209706 be\VB\836236 of\IN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 <e2>secondary\JJ\1740 hyperparathyroidism</e2>\NN\14059928 because\IN\1740 it\PRP\6125041 does\VBZ\1640855 not\RB\1740 induce\VB\1627355 low\JJ\1740 bone\NN\5286536 turnover\NN\13819207 and\CC\1740 ,\,\1740 therefore\RB\1740 ,\,\1740 does\VBZ\1640855 not\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 adynamic\JJ\1740 bone\NN\5286536 disease\NN\14061805 .\.\1740
C051883_D001851 NONE <e1>22-oxacalcitriol</e1>\NN\1740 suppresses\VBZ\2510337 secondary\JJ\1740 hyperparathyroidism\NN\14059928 without\IN\1740 inducing\VBG\1627355 <e2>low\JJ\1740 bone\NN\5286536 turnover</e2>\NN\13819207 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
C051883_D001851 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 even\RB\1740 though\IN\1740 <e1>OCT</e1>\NN\15209706 does\VBZ\1640855 not\RB\1740 completely\RB\1740 prevent\VB\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 hypercalcemia\NN\14299637 in\IN\13603305 experimental\JJ\1740 dogs\NNS\2083346 with\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 it\PRP\6125041 may\MD\15209706 be\VB\836236 of\IN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 secondary\JJ\1740 hyperparathyroidism\NN\14059928 because\IN\1740 it\PRP\6125041 does\VBZ\1640855 not\RB\1740 induce\VB\1627355 <e2>low\JJ\1740 bone\NN\5286536 turnover</e2>\NN\13819207 and\CC\1740 ,\,\1740 therefore\RB\1740 ,\,\1740 does\VBZ\1640855 not\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 adynamic\JJ\1740 bone\NN\5286536 disease\NN\14061805 .\.\1740
C051883_D001851 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 even\RB\1740 though\IN\1740 <e1>OCT</e1>\NN\15209706 does\VBZ\1640855 not\RB\1740 completely\RB\1740 prevent\VB\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 hypercalcemia\NN\14299637 in\IN\13603305 experimental\JJ\1740 dogs\NNS\2083346 with\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 it\PRP\6125041 may\MD\15209706 be\VB\836236 of\IN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 secondary\JJ\1740 hyperparathyroidism\NN\14059928 because\IN\1740 it\PRP\6125041 does\VBZ\1640855 not\RB\1740 induce\VB\1627355 low\JJ\1740 bone\NN\5286536 turnover\NN\13819207 and\CC\1740 ,\,\1740 therefore\RB\1740 ,\,\1740 does\VBZ\1640855 not\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>adynamic\JJ\1740 bone\NN\5286536 disease</e2>\NN\14061805 .\.\1740
C051883_D051437 NONE <e1>22-oxacalcitriol</e1>\NN\1740 suppresses\VBZ\2510337 secondary\JJ\1740 hyperparathyroidism\NN\14059928 without\IN\1740 inducing\VBG\1627355 low\JJ\1740 bone\NN\5286536 turnover\NN\13819207 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
C051883_D051437 NONE RESULTS\NNS\34213 :\:\1740 In\IN\13603305 Nx\NNP\1740 dogs\NNS\2083346 ,\,\1740 <e1>OCT</e1>\NN\15209706 significantly\RB\1740 decreased\VBD\169651 serum\NN\5397468 PTH\NN\1740 levels\NNS\4916342 soon\RB\1740 after\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 .\.\1740
C051883_D051437 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 even\RB\1740 though\IN\1740 <e1>OCT</e1>\NN\15209706 does\VBZ\1640855 not\RB\1740 completely\RB\1740 prevent\VB\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 hypercalcemia\NN\14299637 in\IN\13603305 experimental\JJ\1740 dogs\NNS\2083346 with\IN\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 ,\,\1740 it\PRP\6125041 may\MD\15209706 be\VB\836236 of\IN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 secondary\JJ\1740 hyperparathyroidism\NN\14059928 because\IN\1740 it\PRP\6125041 does\VBZ\1640855 not\RB\1740 induce\VB\1627355 low\JJ\1740 bone\NN\5286536 turnover\NN\13819207 and\CC\1740 ,\,\1740 therefore\RB\1740 ,\,\1740 does\VBZ\1640855 not\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 adynamic\JJ\1740 bone\NN\5286536 disease\NN\14061805 .\.\1740
D002117_D051437 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Calcitriol</e1>\NN\1740 therapy\NN\657604 suppresses\VBZ\2510337 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 parathyroid\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 PTH\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 but\CC\1740 has\VBZ\2108377 several\JJ\1740 drawbacks\NNS\5161614 ,\,\1740 including\VBG\690614 hypercalcemia\NN\14299637 and/or\CC\1740 marked\JJ\1740 suppression\NN\13489037 of\IN\1740 bone\NN\5286536 turnover\NN\13819207 ,\,\1740 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\TO\1740 adynamic\JJ\1740 bone\NN\5286536 disease\NN\14061805 .\.\1740
D002117_D006934 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Calcitriol</e1>\NN\1740 therapy\NN\657604 suppresses\VBZ\2510337 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 parathyroid\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 PTH\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 renal\JJ\1740 failure\NN\66216 but\CC\1740 has\VBZ\2108377 several\JJ\1740 drawbacks\NNS\5161614 ,\,\1740 including\VBG\690614 <e2>hypercalcemia</e2>\NN\14299637 and/or\CC\1740 marked\JJ\1740 suppression\NN\13489037 of\IN\1740 bone\NN\5286536 turnover\NN\13819207 ,\,\1740 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\TO\1740 adynamic\JJ\1740 bone\NN\5286536 disease\NN\14061805 .\.\1740
D002117_D001851 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Calcitriol</e1>\NN\1740 therapy\NN\657604 suppresses\VBZ\2510337 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 parathyroid\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 PTH\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 renal\JJ\1740 failure\NN\66216 but\CC\1740 has\VBZ\2108377 several\JJ\1740 drawbacks\NNS\5161614 ,\,\1740 including\VBG\690614 hypercalcemia\NN\14299637 and/or\CC\1740 marked\JJ\1740 <e2>suppression\NN\13489037 of\IN\1740 bone\NN\5286536 turnover</e2>\NN\13819207 ,\,\1740 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\TO\1740 adynamic\JJ\1740 bone\NN\5286536 disease\NN\14061805 .\.\1740
D002117_D001851 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Calcitriol</e1>\NN\1740 therapy\NN\657604 suppresses\VBZ\2510337 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 parathyroid\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 PTH\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 renal\JJ\1740 failure\NN\66216 but\CC\1740 has\VBZ\2108377 several\JJ\1740 drawbacks\NNS\5161614 ,\,\1740 including\VBG\690614 hypercalcemia\NN\14299637 and/or\CC\1740 marked\JJ\1740 suppression\NN\13489037 of\IN\1740 bone\NN\5286536 turnover\NN\13819207 ,\,\1740 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\TO\1740 <e2>adynamic\JJ\1740 bone\NN\5286536 disease</e2>\NN\14061805 .\.\1740
C051883_D007674 NONE This\DT\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 determine\VB\1645601 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>OCT</e1>\NN\15209706 on\IN\1740 serum\NN\5397468 PTH\NN\1740 levels\NNS\4916342 and\CC\1740 bone\NN\5286536 turnover\NN\13819207 in\IN\13603305 states\NNS\8491826 of\IN\1740 normal\JJ\1740 or\CC\3541091 <e2>impaired\JJ\1740 renal\JJ\1740 function</e2>\NN\13783581 .\.\1740
C051883_-1 NONE In\IN\13603305 Nx\NNP\1740 dogs\NNS\2083346 ,\,\1740 <e1>OCT</e1>\NN\15209706 reversed\VBD\109660 abnormal\JJ\1740 bone\NN\5286536 formation\NN\7938773 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>woven\JJ\1740 osteoid</e2>\NN\1740 and\CC\1740 fibrosis\NN\14204950 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 alter\VB\126264 the\DT\1740 level\NN\4916342 of\IN\1740 bone\NN\5286536 turnover\NN\13819207 .\.\1740
C051883_D005355 NONE In\IN\13603305 Nx\NNP\1740 dogs\NNS\2083346 ,\,\1740 <e1>OCT</e1>\NN\15209706 reversed\VBD\109660 abnormal\JJ\1740 bone\NN\5286536 formation\NN\7938773 ,\,\1740 such\JJ\1740 as\IN\14622893 woven\JJ\1740 osteoid\NN\1740 and\CC\1740 <e2>fibrosis</e2>\NN\14204950 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 alter\VB\126264 the\DT\1740 level\NN\4916342 of\IN\1740 bone\NN\5286536 turnover\NN\13819207 .\.\1740
C051883_D006934 CID CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 even\RB\1740 though\IN\1740 <e1>OCT</e1>\NN\15209706 does\VBZ\1640855 not\RB\1740 completely\RB\1740 prevent\VB\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 <e2>hypercalcemia</e2>\NN\14299637 in\IN\13603305 experimental\JJ\1740 dogs\NNS\2083346 with\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 it\PRP\6125041 may\MD\15209706 be\VB\836236 of\IN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 secondary\JJ\1740 hyperparathyroidism\NN\14059928 because\IN\1740 it\PRP\6125041 does\VBZ\1640855 not\RB\1740 induce\VB\1627355 low\JJ\1740 bone\NN\5286536 turnover\NN\13819207 and\CC\1740 ,\,\1740 therefore\RB\1740 ,\,\1740 does\VBZ\1640855 not\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 adynamic\JJ\1740 bone\NN\5286536 disease\NN\14061805 .\.\1740
7189975
D002045_D012640 CID A\DT\13649268 CD50\NN\1740 dose\NN\3740161 of\IN\1740 local\JJ\1740 anesthetic\JJ\1740 (\-LRB-\1740 causing\VBG\1617192 <e2>convulsions</e2>\NNS\14081375 in\IN\13603305 50\CD\13745420 %\NN\1740 of\IN\1740 mice\NNS\2329401 )\-RRB-\1740 was\VBD\836236 fatal\JJ\1740 in\IN\13603305 90\CD\13745420 %\NN\1740 of\IN\1740 <e1>bupivacaine-induced</e1>\JJ\1740 seizures\NNS\14081375 ,\,\1740 in\IN\13603305 57\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 chloroprocaine\NN\1740 group\NN\2137 ,\,\1740 and\CC\1740 in\IN\13603305 6\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 lidocaine\NN\3681148 group\NN\2137 .\.\1740
D002045_D012640 CID A\DT\13649268 CD50\NN\1740 dose\NN\3740161 of\IN\1740 local\JJ\1740 anesthetic\JJ\1740 (\-LRB-\1740 causing\VBG\1617192 convulsions\NNS\14081375 in\IN\13603305 50\CD\13745420 %\NN\1740 of\IN\1740 mice\NNS\2329401 )\-RRB-\1740 was\VBD\836236 fatal\JJ\1740 in\IN\13603305 90\CD\13745420 %\NN\1740 of\IN\1740 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 in\IN\13603305 57\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 chloroprocaine\NN\1740 group\NN\2137 ,\,\1740 and\CC\1740 in\IN\13603305 6\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 lidocaine\NN\3681148 group\NN\2137 .\.\1740
C004616_D012640 CID A\DT\13649268 CD50\NN\1740 dose\NN\3740161 of\IN\1740 local\JJ\1740 anesthetic\JJ\1740 (\-LRB-\1740 causing\VBG\1617192 <e2>convulsions</e2>\NNS\14081375 in\IN\13603305 50\CD\13745420 %\NN\1740 of\IN\1740 mice\NNS\2329401 )\-RRB-\1740 was\VBD\836236 fatal\JJ\1740 in\IN\13603305 90\CD\13745420 %\NN\1740 of\IN\1740 bupivacaine-induced\JJ\1740 seizures\NNS\14081375 ,\,\1740 in\IN\13603305 57\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 <e1>chloroprocaine</e1>\NN\1740 group\NN\2137 ,\,\1740 and\CC\1740 in\IN\13603305 6\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 lidocaine\NN\3681148 group\NN\2137 .\.\1740
C004616_D012640 CID A\DT\13649268 CD50\NN\1740 dose\NN\3740161 of\IN\1740 local\JJ\1740 anesthetic\JJ\1740 (\-LRB-\1740 causing\VBG\1617192 convulsions\NNS\14081375 in\IN\13603305 50\CD\13745420 %\NN\1740 of\IN\1740 mice\NNS\2329401 )\-RRB-\1740 was\VBD\836236 fatal\JJ\1740 in\IN\13603305 90\CD\13745420 %\NN\1740 of\IN\1740 bupivacaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 in\IN\13603305 57\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 <e1>chloroprocaine</e1>\NN\1740 group\NN\2137 ,\,\1740 and\CC\1740 in\IN\13603305 6\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 lidocaine\NN\3681148 group\NN\2137 .\.\1740
D008012_D012640 CID A\DT\13649268 CD50\NN\1740 dose\NN\3740161 of\IN\1740 local\JJ\1740 anesthetic\JJ\1740 (\-LRB-\1740 causing\VBG\1617192 <e2>convulsions</e2>\NNS\14081375 in\IN\13603305 50\CD\13745420 %\NN\1740 of\IN\1740 mice\NNS\2329401 )\-RRB-\1740 was\VBD\836236 fatal\JJ\1740 in\IN\13603305 90\CD\13745420 %\NN\1740 of\IN\1740 bupivacaine-induced\JJ\1740 seizures\NNS\14081375 ,\,\1740 in\IN\13603305 57\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 chloroprocaine\NN\1740 group\NN\2137 ,\,\1740 and\CC\1740 in\IN\13603305 6\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 <e1>lidocaine</e1>\NN\3681148 group\NN\2137 .\.\1740
D008012_D012640 CID A\DT\13649268 CD50\NN\1740 dose\NN\3740161 of\IN\1740 local\JJ\1740 anesthetic\JJ\1740 (\-LRB-\1740 causing\VBG\1617192 convulsions\NNS\14081375 in\IN\13603305 50\CD\13745420 %\NN\1740 of\IN\1740 mice\NNS\2329401 )\-RRB-\1740 was\VBD\836236 fatal\JJ\1740 in\IN\13603305 90\CD\13745420 %\NN\1740 of\IN\1740 bupivacaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 in\IN\13603305 57\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 chloroprocaine\NN\1740 group\NN\2137 ,\,\1740 and\CC\1740 in\IN\13603305 6\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 <e1>lidocaine</e1>\NN\3681148 group\NN\2137 .\.\1740
7724492
D004317_D007674 NONE Acute\JJ\1740 <e2>renal\JJ\1740 toxicity</e2>\NN\13576101 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 (adriamycin)-loaded\IN\1740 cyanoacrylate\JJ\1740 nanoparticles\NNS\1740 .\.\1740
D004317_D007674 NONE Acute\JJ\1740 <e2>renal\JJ\1740 toxicity</e2>\NN\13576101 of\IN\1740 doxorubicin\NN\2716866 <e1>(adriamycin)-loaded</e1>\IN\1740 cyanoacrylate\JJ\1740 nanoparticles\NNS\1740 .\.\1740
D004317_D007674 NONE Acute\JJ\1740 <e1>doxorubicin-loaded</e1>\JJ\1740 nanoparticle\NN\1740 (\-LRB-\1740 DXNP\NNP\1740 )\-RRB-\1740 <e2>renal\JJ\1740 toxicity</e2>\NN\13576101 was\VBD\836236 explored\VBN\789138 in\IN\13603305 both\CC\1740 normal\JJ\1740 rats\NNS\2329401 and\CC\1740 rats\NNS\2329401 with\IN\1740 experimental\JJ\1740 glomerulonephritis\NN\14113798 .\.\1740
D004317_D007674 NONE These\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 ,\,\1740 in\IN\13603305 these\DT\1740 experimental\JJ\1740 conditions\NNS\14512817 ,\,\1740 DXNP\NNP\1740 killed\VBD\2473431 less\JJR\1740 animals\NNS\4475 than\IN\1740 free\JJ\1740 <e1>DX</e1>\NN\1740 ,\,\1740 despite\IN\7501545 of\IN\1740 an\DT\6697703 enhanced\VBN\227165 <e2>renal\JJ\1740 toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 former\JJ\1740 .\.\1740
D003487_D007674 NONE Acute\JJ\1740 <e2>renal\JJ\1740 toxicity</e2>\NN\13576101 of\IN\1740 doxorubicin\NN\2716866 (adriamycin)-loaded\IN\1740 <e1>cyanoacrylate</e1>\JJ\1740 nanoparticles\NNS\1740 .\.\1740
D004317_D005921 NONE Acute\JJ\1740 <e1>doxorubicin-loaded</e1>\JJ\1740 nanoparticle\NN\1740 (\-LRB-\1740 DXNP\NNP\1740 )\-RRB-\1740 renal\JJ\1740 toxicity\NN\13576101 was\VBD\836236 explored\VBN\789138 in\IN\13603305 both\CC\1740 normal\JJ\1740 rats\NNS\2329401 and\CC\1740 rats\NNS\2329401 with\IN\1740 experimental\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 .\.\1740
D004317_D005921 NONE In\IN\13603305 rats\NNS\2329401 with\IN\1740 immune\JJ\1740 experimental\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 ,\,\1740 5/6\CD\1740 rats\NNS\2329401 given\VBN\2327200 <e1>DX</e1>\NN\1740 died\VBD\146138 within\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 in\IN\13603305 contrast\NN\13854649 to\TO\1740 animals\NNS\4475 treated\VBN\2376958 by\IN\1740 DXNP\NNP\1740 ,\,\1740 NP\NNP\14625458 ,\,\1740 or\CC\3541091 untreated\JJ\1740 ,\,\1740 which\WDT\1740 all\DT\1740 survived\VBD\1108148 .\.\1740
D004317_D011507 CID A\DT\13649268 3\CD\13741022 times\NNS\15113229 higher\JJR\1740 <e2>proteinuria</e2>\NN\14299637 appeared\VBD\2604760 in\IN\13603305 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 DXNP\NNP\1740 than\IN\1740 in\IN\13603305 those\DT\1740 treated\VBN\2376958 with\IN\1740 <e1>DX</e1>\NN\1740 .\.\1740
D004317_D011507 CID <e2>Proteinuria</e2>\NNP\14299637 appeared\VBD\2604760 in\IN\13603305 all\DT\1740 series\NN\8456993 ,\,\1740 but\CC\1740 was\VBD\836236 2\CD\13741022 -\SYM\1740 5\CD\13741022 times\NNS\15113229 more\RBR\1740 intense\JJ\1740 (\-LRB-\1740 p\NN\14622893 >\NN\1740 0.001\CD\1740 )\-RRB-\1740 and\CC\1740 prolonged\VBN\317700 after\IN\1740 <e1>doxorubicin</e1>\NN\2716866 treatment\NN\654885 (\-LRB-\1740 400\CD\1740 -\SYM\1740 700\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 without\IN\1740 significant\JJ\1740 difference\NN\4723816 between\IN\1740 DXNP\NNP\1740 and\CC\1740 DX\NN\1740 .\.\1740
D004317_D011507 CID <e2>Proteinuria</e2>\NNP\14299637 appeared\VBD\2604760 in\IN\13603305 all\DT\1740 series\NN\8456993 ,\,\1740 but\CC\1740 was\VBD\836236 2\CD\13741022 -\SYM\1740 5\CD\13741022 times\NNS\15113229 more\RBR\1740 intense\JJ\1740 (\-LRB-\1740 p\NN\14622893 >\NN\1740 0.001\CD\1740 )\-RRB-\1740 and\CC\1740 prolonged\VBN\317700 after\IN\1740 doxorubicin\NN\2716866 treatment\NN\654885 (\-LRB-\1740 400\CD\1740 -\SYM\1740 700\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 without\IN\1740 significant\JJ\1740 difference\NN\4723816 between\IN\1740 DXNP\NNP\1740 and\CC\1740 <e1>DX</e1>\NN\1740 .\.\1740
15565293
D004977_D009901 CID Optical\JJ\1740 coherence\NN\14419164 tomography\NN\900375 can\MD\3094503 measure\VB\697589 axonal\JJ\1740 loss\NN\13252973 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>ethambutol-induced</e1>\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\JJ\1740 .\.\1740
D004977_D009901 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 map\VB\1686132 and\CC\1740 identify\VB\699815 the\DT\1740 pattern\NN\5726345 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 of\IN\1740 axonal\JJ\1740 degeneration\NN\29677 in\IN\13603305 <e1>ethambutol-induced</e1>\JJ\1740 <e2>optic\JJ\1740 neuropathy</e2>\JJ\1740 using\VBG\1156834 optical\JJ\1740 coherence\NN\14419164 tomography\NN\900375 (\-LRB-\1740 OCT\NN\15209706 )\-RRB-\1740 .\.\1740
D004977_D009901 CID A\DT\13649268 serious\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>ethambutol</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 <e2>optic\JJ\1740 neuropathy</e2>\JJ\1740 that\WDT\1740 impairs\VBZ\258857 visual\JJ\1740 acuity\NN\5654362 ,\,\1740 contrast\NN\13854649 sensitivity\NN\5651971 ,\,\1740 and\CC\1740 color\NN\4950126 vision\NN\5767733 .\.\1740
D004977_D009901 CID METHODS\NNS\5616786 :\:\1740 Three\CD\13741022 subjects\NNS\6598915 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>ethambutol</e1>\JJ\1740 (EMB)-induced\JJ\1740 <e2>optic\JJ\1740 neuropathy</e2>\NN\14204950 of\IN\1740 short-\NN\1740 ,\,\1740 intermediate-\NN\1740 ,\,\1740 and\CC\1740 long-term\JJ\1740 visual\JJ\1740 deficits\NNS\5113133 were\VBD\836236 administered\VBN\2436349 a\DT\13649268 full\JJ\1740 neuro-ophthalmologic\JJ\1740 examination\NN\633864 including\VBG\690614 visual\JJ\1740 acuity\NN\5654362 ,\,\1740 color\NN\4950126 vision\NN\5767733 ,\,\1740 contrast\VBP\650353 sensitivity\NN\5651971 ,\,\1740 and\CC\1740 fundus\JJ\1740 examination\NN\633864 .\.\1740
D004977_D009901 CID METHODS\NNS\5616786 :\:\1740 Three\CD\13741022 subjects\NNS\6598915 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 ethambutol\JJ\1740 <e1>(EMB)-induced</e1>\JJ\1740 <e2>optic\JJ\1740 neuropathy</e2>\NN\14204950 of\IN\1740 short-\NN\1740 ,\,\1740 intermediate-\NN\1740 ,\,\1740 and\CC\1740 long-term\JJ\1740 visual\JJ\1740 deficits\NNS\5113133 were\VBD\836236 administered\VBN\2436349 a\DT\13649268 full\JJ\1740 neuro-ophthalmologic\JJ\1740 examination\NN\633864 including\VBG\690614 visual\JJ\1740 acuity\NN\5654362 ,\,\1740 color\NN\4950126 vision\NN\5767733 ,\,\1740 contrast\VBP\650353 sensitivity\NN\5651971 ,\,\1740 and\CC\1740 fundus\JJ\1740 examination\NN\633864 .\.\1740
D004977_D009901 CID In\IN\13603305 all\DT\1740 subjects\NNS\6598915 with\IN\1740 history\NN\15120823 of\IN\1740 <e1>EMB-induced</e1>\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\JJ\1740 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 mean\JJ\1740 loss\NN\13252973 of\IN\1740 72\CD\1740 %\NN\1740 nerve\NN\5475681 fiber\NN\14580897 layer\NN\21939 thickness\NN\5093581 in\IN\13603305 the\DT\1740 temporal\JJ\1740 quadrant\NN\8593262 (\-LRB-\1740 patient\NN\9898892 A\NN\13649268 ,\,\1740 with\IN\1740 eventual\JJ\1740 recovery\NN\7357388 of\IN\1740 visual\JJ\1740 acuity\NN\5654362 and\CC\1740 fields\NNS\8673395 ,\,\1740 58\CD\1740 %\NN\1740 loss\NN\13252973 ;\:\1740 patient\NN\9898892 B\NN\1355326 ,\,\1740 with\IN\1740 intermediate\JJ\1740 visual\JJ\1740 deficits\NNS\5113133 ,\,\1740 68\CD\1740 %\NN\1740 loss\NN\13252973 ;\:\1740 patient\NN\9898892 C\NN\13714184 ,\,\1740 with\IN\1740 chronic\JJ\1740 visual\JJ\1740 deficits\NNS\5113133 ,\,\1740 90\CD\13745420 %\NN\1740 loss\NN\13252973 )\-RRB-\1740 ,\,\1740 with\IN\1740 an\DT\6697703 average\JJ\1740 mean\NN\6021761 optic\JJ\1740 nerve\NN\5475681 thickness\NN\5093581 of\IN\1740 26+/-16\CD\1740 microm\RB\1740 .\.\1740
D004977_D009901 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 OCT\NN\15209706 results\VBZ\2633881 in\IN\13603305 these\DT\1740 patients\NNS\9898892 with\IN\1740 <e1>EMB-induced</e1>\JJ\1740 <e2>optic\JJ\1740 neuropathy</e2>\JJ\1740 show\VBP\2137132 considerable\JJ\1740 loss\NN\13252973 especially\RB\1740 of\IN\1740 the\DT\1740 temporal\JJ\1740 fibers\NNS\14580897 .\.\1740
D004977_D009901 CID Additionally\RB\1740 ,\,\1740 in\IN\13603305 terms\NNS\13945919 of\IN\1740 management\NN\1123598 of\IN\1740 <e1>EMB-induced</e1>\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 properly\RB\1740 manage\VB\2524171 ethambutol\NN\1740 dosing\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 renal\JJ\1740 impairment\NN\7296428 and\CC\1740 to\TO\1740 achieve\VB\2524171 proper\JJ\1740 transition\NN\199130 to\TO\1740 a\DT\13649268 maintenance\NN\266806 dose\NN\3740161 once\IN\1740 an\DT\6697703 appropriate\JJ\1740 loading\NN\4571088 dose\NN\3740161 has\VBZ\2108377 been\VBN\836236 reached\VBN\2005948 .\.\1740
D004977_D009901 CID Additionally\RB\1740 ,\,\1740 in\IN\13603305 terms\NNS\13945919 of\IN\1740 management\NN\1123598 of\IN\1740 EMB-induced\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 properly\RB\1740 manage\VB\2524171 <e1>ethambutol</e1>\NN\1740 dosing\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 renal\JJ\1740 impairment\NN\7296428 and\CC\1740 to\TO\1740 achieve\VB\2524171 proper\JJ\1740 transition\NN\199130 to\TO\1740 a\DT\13649268 maintenance\NN\266806 dose\NN\3740161 once\IN\1740 an\DT\6697703 appropriate\JJ\1740 loading\NN\4571088 dose\NN\3740161 has\VBZ\2108377 been\VBN\836236 reached\VBN\2005948 .\.\1740
D004977_D009410 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 map\VB\1686132 and\CC\1740 identify\VB\699815 the\DT\1740 pattern\NN\5726345 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 of\IN\1740 <e2>axonal\JJ\1740 degeneration</e2>\NN\29677 in\IN\13603305 <e1>ethambutol-induced</e1>\JJ\1740 optic\JJ\1740 neuropathy\JJ\1740 using\VBG\1156834 optical\JJ\1740 coherence\NN\14419164 tomography\NN\900375 (\-LRB-\1740 OCT\NN\15209706 )\-RRB-\1740 .\.\1740
D004977_D014376 NONE <e1>Ethambutol</e1>\NNP\1740 is\VBZ\836236 an\DT\6697703 antimycobacterial\JJ\1740 agent\NN\7347 often\RB\1740 used\VBD\1156834 to\TO\1740 treat\VB\2376958 <e2>tuberculosis</e2>\NN\14127211 .\.\1740
D004977_D014786 CID METHODS\NNS\5616786 :\:\1740 Three\CD\13741022 subjects\NNS\6598915 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>ethambutol</e1>\JJ\1740 (EMB)-induced\JJ\1740 optic\JJ\1740 neuropathy\NN\14204950 of\IN\1740 short-\NN\1740 ,\,\1740 intermediate-\NN\1740 ,\,\1740 and\CC\1740 long-term\JJ\1740 <e2>visual\JJ\1740 deficits</e2>\NNS\5113133 were\VBD\836236 administered\VBN\2436349 a\DT\13649268 full\JJ\1740 neuro-ophthalmologic\JJ\1740 examination\NN\633864 including\VBG\690614 visual\JJ\1740 acuity\NN\5654362 ,\,\1740 color\NN\4950126 vision\NN\5767733 ,\,\1740 contrast\VBP\650353 sensitivity\NN\5651971 ,\,\1740 and\CC\1740 fundus\JJ\1740 examination\NN\633864 .\.\1740
D004977_D014786 CID METHODS\NNS\5616786 :\:\1740 Three\CD\13741022 subjects\NNS\6598915 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 ethambutol\JJ\1740 <e1>(EMB)-induced</e1>\JJ\1740 optic\JJ\1740 neuropathy\NN\14204950 of\IN\1740 short-\NN\1740 ,\,\1740 intermediate-\NN\1740 ,\,\1740 and\CC\1740 long-term\JJ\1740 <e2>visual\JJ\1740 deficits</e2>\NNS\5113133 were\VBD\836236 administered\VBN\2436349 a\DT\13649268 full\JJ\1740 neuro-ophthalmologic\JJ\1740 examination\NN\633864 including\VBG\690614 visual\JJ\1740 acuity\NN\5654362 ,\,\1740 color\NN\4950126 vision\NN\5767733 ,\,\1740 contrast\VBP\650353 sensitivity\NN\5651971 ,\,\1740 and\CC\1740 fundus\JJ\1740 examination\NN\633864 .\.\1740
D004977_D014786 CID In\IN\13603305 all\DT\1740 subjects\NNS\6598915 with\IN\1740 history\NN\15120823 of\IN\1740 <e1>EMB-induced</e1>\JJ\1740 optic\NN\5299178 neuropathy\JJ\1740 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 mean\JJ\1740 loss\NN\13252973 of\IN\1740 72\CD\1740 %\NN\1740 nerve\NN\5475681 fiber\NN\14580897 layer\NN\21939 thickness\NN\5093581 in\IN\13603305 the\DT\1740 temporal\JJ\1740 quadrant\NN\8593262 (\-LRB-\1740 patient\NN\9898892 A\NN\13649268 ,\,\1740 with\IN\1740 eventual\JJ\1740 recovery\NN\7357388 of\IN\1740 visual\JJ\1740 acuity\NN\5654362 and\CC\1740 fields\NNS\8673395 ,\,\1740 58\CD\1740 %\NN\1740 loss\NN\13252973 ;\:\1740 patient\NN\9898892 B\NN\1355326 ,\,\1740 with\IN\1740 intermediate\JJ\1740 <e2>visual\JJ\1740 deficits</e2>\NNS\5113133 ,\,\1740 68\CD\1740 %\NN\1740 loss\NN\13252973 ;\:\1740 patient\NN\9898892 C\NN\13714184 ,\,\1740 with\IN\1740 chronic\JJ\1740 visual\JJ\1740 deficits\NNS\5113133 ,\,\1740 90\CD\13745420 %\NN\1740 loss\NN\13252973 )\-RRB-\1740 ,\,\1740 with\IN\1740 an\DT\6697703 average\JJ\1740 mean\NN\6021761 optic\JJ\1740 nerve\NN\5475681 thickness\NN\5093581 of\IN\1740 26+/-16\CD\1740 microm\RB\1740 .\.\1740
D004977_D014786 CID In\IN\13603305 all\DT\1740 subjects\NNS\6598915 with\IN\1740 history\NN\15120823 of\IN\1740 <e1>EMB-induced</e1>\JJ\1740 optic\NN\5299178 neuropathy\JJ\1740 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 mean\JJ\1740 loss\NN\13252973 of\IN\1740 72\CD\1740 %\NN\1740 nerve\NN\5475681 fiber\NN\14580897 layer\NN\21939 thickness\NN\5093581 in\IN\13603305 the\DT\1740 temporal\JJ\1740 quadrant\NN\8593262 (\-LRB-\1740 patient\NN\9898892 A\NN\13649268 ,\,\1740 with\IN\1740 eventual\JJ\1740 recovery\NN\7357388 of\IN\1740 visual\JJ\1740 acuity\NN\5654362 and\CC\1740 fields\NNS\8673395 ,\,\1740 58\CD\1740 %\NN\1740 loss\NN\13252973 ;\:\1740 patient\NN\9898892 B\NN\1355326 ,\,\1740 with\IN\1740 intermediate\JJ\1740 visual\JJ\1740 deficits\NNS\5113133 ,\,\1740 68\CD\1740 %\NN\1740 loss\NN\13252973 ;\:\1740 patient\NN\9898892 C\NN\13714184 ,\,\1740 with\IN\1740 chronic\JJ\1740 <e2>visual\JJ\1740 deficits</e2>\NNS\5113133 ,\,\1740 90\CD\13745420 %\NN\1740 loss\NN\13252973 )\-RRB-\1740 ,\,\1740 with\IN\1740 an\DT\6697703 average\JJ\1740 mean\NN\6021761 optic\JJ\1740 nerve\NN\5475681 thickness\NN\5093581 of\IN\1740 26+/-16\CD\1740 microm\RB\1740 .\.\1740
D004977_D051437 NONE Additionally\RB\1740 ,\,\1740 in\IN\13603305 terms\NNS\13945919 of\IN\1740 management\NN\1123598 of\IN\1740 <e1>EMB-induced</e1>\JJ\1740 optic\NN\5299178 neuropathy\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 properly\RB\1740 manage\VB\2524171 ethambutol\NN\1740 dosing\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 to\TO\1740 achieve\VB\2524171 proper\JJ\1740 transition\NN\199130 to\TO\1740 a\DT\13649268 maintenance\NN\266806 dose\NN\3740161 once\IN\1740 an\DT\6697703 appropriate\JJ\1740 loading\NN\4571088 dose\NN\3740161 has\VBZ\2108377 been\VBN\836236 reached\VBN\2005948 .\.\1740
D004977_D051437 NONE Additionally\RB\1740 ,\,\1740 in\IN\13603305 terms\NNS\13945919 of\IN\1740 management\NN\1123598 of\IN\1740 EMB-induced\JJ\1740 optic\NN\5299178 neuropathy\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 properly\RB\1740 manage\VB\2524171 <e1>ethambutol</e1>\NN\1740 dosing\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 to\TO\1740 achieve\VB\2524171 proper\JJ\1740 transition\NN\199130 to\TO\1740 a\DT\13649268 maintenance\NN\266806 dose\NN\3740161 once\IN\1740 an\DT\6697703 appropriate\JJ\1740 loading\NN\4571088 dose\NN\3740161 has\VBZ\2108377 been\VBN\836236 reached\VBN\2005948 .\.\1740
17074608
D014635_D002819 CID <e1>Valproate-induced</e1>\JJ\1740 <e2>chorea</e2>\NN\14253124 and\CC\1740 encephalopathy\JJ\1740 in\IN\13603305 atypical\JJ\1740 nonketotic\JJ\1740 hyperglycinemia\NN\1740 .\.\1740
D014635_D002819 CID This\DT\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 mild\JJ\1740 language\NN\33020 delay\NN\15271008 and\CC\1740 mental\JJ\1740 retardation\NN\7296428 ,\,\1740 who\WP\8299493 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 nonketotic\JJ\1740 hyperglycinemia\NN\1740 following\VBG\1835496 her\PRP$\1740 presentation\NN\1027379 with\IN\1740 acute\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 <e2>chorea</e2>\NN\14253124 shortly\RB\1740 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>valproate</e1>\NN\1740 therapy\NN\657604 .\.\1740
D014635_D001927 CID <e1>Valproate-induced</e1>\JJ\1740 chorea\NN\14253124 and\CC\1740 <e2>encephalopathy</e2>\JJ\1740 in\IN\13603305 atypical\JJ\1740 nonketotic\JJ\1740 hyperglycinemia\NN\1740 .\.\1740
D014635_D001927 CID This\DT\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 mild\JJ\1740 language\NN\33020 delay\NN\15271008 and\CC\1740 mental\JJ\1740 retardation\NN\7296428 ,\,\1740 who\WP\8299493 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 nonketotic\JJ\1740 hyperglycinemia\NN\1740 following\VBG\1835496 her\PRP$\1740 presentation\NN\1027379 with\IN\1740 acute\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 and\CC\1740 chorea\NN\14253124 shortly\RB\1740 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>valproate</e1>\NN\1740 therapy\NN\657604 .\.\1740
D014635_D020158 NONE <e1>Valproate-induced</e1>\JJ\1740 chorea\NN\14253124 and\CC\1740 encephalopathy\JJ\1740 in\IN\13603305 atypical\JJ\1740 <e2>nonketotic\JJ\1740 hyperglycinemia</e2>\NN\1740 .\.\1740
D014635_D020158 NONE This\DT\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 mild\JJ\1740 language\NN\33020 delay\NN\15271008 and\CC\1740 mental\JJ\1740 retardation\NN\7296428 ,\,\1740 who\WP\8299493 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 <e2>nonketotic\JJ\1740 hyperglycinemia</e2>\NN\1740 following\VBG\1835496 her\PRP$\1740 presentation\NN\1027379 with\IN\1740 acute\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 chorea\NN\14253124 shortly\RB\1740 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>valproate</e1>\NN\1740 therapy\NN\657604 .\.\1740
D005998_D020158 NONE <e2>Nonketotic\JJ\1740 hyperglycinemia</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 disorder\NN\14034177 of\IN\1740 amino\NN\14621446 acid\NN\14818238 metabolism\NN\13526110 in\IN\13603305 which\WDT\1740 a\DT\13649268 defect\NN\14462666 in\IN\13603305 the\DT\1740 <e1>glycine</e1>\NN\14601829 cleavage\NN\24720 system\NN\3575240 leads\VBZ\1752884 to\TO\1740 an\DT\6697703 accumulation\NN\13497135 of\IN\1740 glycine\NN\14601829 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 other\JJ\1740 body\NN\19128 compartments\NNS\13910384 .\.\1740
D005998_D020158 NONE <e2>Nonketotic\JJ\1740 hyperglycinemia</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 disorder\NN\14034177 of\IN\1740 amino\NN\14621446 acid\NN\14818238 metabolism\NN\13526110 in\IN\13603305 which\WDT\1740 a\DT\13649268 defect\NN\14462666 in\IN\13603305 the\DT\1740 glycine\NN\14601829 cleavage\NN\24720 system\NN\3575240 leads\VBZ\1752884 to\TO\1740 an\DT\6697703 accumulation\NN\13497135 of\IN\1740 <e1>glycine</e1>\NN\14601829 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 other\JJ\1740 body\NN\19128 compartments\NNS\13910384 .\.\1740
D005998_D000592 NONE Nonketotic\JJ\1740 hyperglycinemia\NN\1740 is\VBZ\836236 a\DT\13649268 <e2>disorder\NN\14034177 of\IN\1740 amino\NN\14621446 acid\NN\14818238 metabolism</e2>\NN\13526110 in\IN\13603305 which\WDT\1740 a\DT\13649268 defect\NN\14462666 in\IN\13603305 the\DT\1740 <e1>glycine</e1>\NN\14601829 cleavage\NN\24720 system\NN\3575240 leads\VBZ\1752884 to\TO\1740 an\DT\6697703 accumulation\NN\13497135 of\IN\1740 glycine\NN\14601829 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 other\JJ\1740 body\NN\19128 compartments\NNS\13910384 .\.\1740
D005998_D000592 NONE Nonketotic\JJ\1740 hyperglycinemia\NN\1740 is\VBZ\836236 a\DT\13649268 <e2>disorder\NN\14034177 of\IN\1740 amino\NN\14621446 acid\NN\14818238 metabolism</e2>\NN\13526110 in\IN\13603305 which\WDT\1740 a\DT\13649268 defect\NN\14462666 in\IN\13603305 the\DT\1740 glycine\NN\14601829 cleavage\NN\24720 system\NN\3575240 leads\VBZ\1752884 to\TO\1740 an\DT\6697703 accumulation\NN\13497135 of\IN\1740 <e1>glycine</e1>\NN\14601829 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 other\JJ\1740 body\NN\19128 compartments\NNS\13910384 .\.\1740
D014635_D007805 NONE This\DT\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 mild\JJ\1740 <e2>language\NN\33020 delay</e2>\NN\15271008 and\CC\1740 mental\JJ\1740 retardation\NN\7296428 ,\,\1740 who\WP\8299493 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 nonketotic\JJ\1740 hyperglycinemia\NN\1740 following\VBG\1835496 her\PRP$\1740 presentation\NN\1027379 with\IN\1740 acute\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 chorea\NN\14253124 shortly\RB\1740 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>valproate</e1>\NN\1740 therapy\NN\657604 .\.\1740
D014635_D008607 NONE This\DT\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 mild\JJ\1740 language\NN\33020 delay\NN\15271008 and\CC\1740 <e2>mental\JJ\1740 retardation</e2>\NN\7296428 ,\,\1740 who\WP\8299493 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 nonketotic\JJ\1740 hyperglycinemia\NN\1740 following\VBG\1835496 her\PRP$\1740 presentation\NN\1027379 with\IN\1740 acute\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 chorea\NN\14253124 shortly\RB\1740 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>valproate</e1>\NN\1740 therapy\NN\657604 .\.\1740
15580403
D012254_D006461 NONE Adequate\JJ\1740 timing\NN\5044673 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 reduction\NN\351485 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hemolysis</e2>\NN\13509528 during\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 interferon\NN\2725367 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C.\NN\1740
D012254_D006461 NONE Adequate\JJ\1740 timing\NN\5044673 of\IN\1740 ribavirin\NN\2725367 reduction\NN\351485 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hemolysis</e2>\NN\13509528 during\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 interferon\NN\2725367 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C.\NN\1740
D012254_D006461 NONE In\IN\13603305 this\DT\1740 clinical\JJ\1740 retrospective\JJ\1740 cohort\NN\8184861 study\NN\635850 we\PRP\1740 have\VBP\2108377 examined\VBN\789138 the\DT\1740 suitable\JJ\1740 timing\NN\5044673 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 reduction\NN\351485 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hemolysis</e2>\NN\13509528 during\IN\1740 combination\NN\7951464 therapy\NN\657604 .\.\1740
D012254_D019698 NONE Adequate\JJ\1740 timing\NN\5044673 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 reduction\NN\351485 in\IN\13603305 patients\NNS\9898892 with\IN\1740 hemolysis\NN\13509528 during\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 interferon\NN\2725367 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C.</e2>\NN\1740
D012254_D019698 NONE Adequate\JJ\1740 timing\NN\5044673 of\IN\1740 ribavirin\NN\2725367 reduction\NN\351485 in\IN\13603305 patients\NNS\9898892 with\IN\1740 hemolysis\NN\13509528 during\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 interferon\NN\2725367 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 for\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C.</e2>\NN\1740
D007372_D006461 NONE Adequate\JJ\1740 timing\NN\5044673 of\IN\1740 ribavirin\NN\2725367 reduction\NN\351485 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hemolysis</e2>\NN\13509528 during\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 <e1>interferon</e1>\NN\2725367 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C.\NN\1740
D007372_D019698 NONE Adequate\JJ\1740 timing\NN\5044673 of\IN\1740 ribavirin\NN\2725367 reduction\NN\351485 in\IN\13603305 patients\NNS\9898892 with\IN\1740 hemolysis\NN\13509528 during\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 <e1>interferon</e1>\NN\2725367 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C.</e2>\NN\1740
D007372_D000743 CID BACKGROUND\NN\4921011 :\:\1740 <e2>Hemolytic\JJ\1740 anemia</e2>\NN\14189204 is\VBZ\836236 one\CD\13741022 of\IN\1740 the\DT\1740 major\JJ\1740 adverse\JJ\1740 events\NNS\23100 of\IN\1740 the\DT\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 <e1>interferon</e1>\NN\2725367 and\CC\1740 ribavirin\NN\2725367 .\.\1740
D012254_D000743 CID BACKGROUND\NN\4921011 :\:\1740 <e2>Hemolytic\JJ\1740 anemia</e2>\NN\14189204 is\VBZ\836236 one\CD\13741022 of\IN\1740 the\DT\1740 major\JJ\1740 adverse\JJ\1740 events\NNS\23100 of\IN\1740 the\DT\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 interferon\NN\2725367 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 .\.\1740
D012254_D000743 CID Because\IN\1740 of\IN\1740 <e1>ribavirin-related</e1>\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 ,\,\1740 dose\NN\3740161 reduction\NN\351485 is\VBZ\836236 a\DT\13649268 common\JJ\1740 event\NN\23100 in\IN\13603305 this\DT\1740 therapy\NN\657604 .\.\1740
D012254_D000740 NONE However\RB\1740 ,\,\1740 10\CD\13745420 of\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 reduction\NN\351485 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 could\MD\1740 not\RB\1740 continue\VB\2367363 combination\NN\7951464 therapy\NN\657604 because\IN\1740 their\PRP$\1740 <\XX\1740 8.5\CD\1740 g/dl\NN\1740 hemoglobin\NN\14888884 values\NNS\5941423 decreased\VBD\169651 to\TO\1740 or\CC\3541091 <e2>anemia-related</e2>\JJ\1740 severe\JJ\1740 side\NN\8630039 effects\NNS\13245626 occurred\VBD\2623529 (\-LRB-\1740 group\NN\2137 B\NN\1355326 )\-RRB-\1740 .\.\1740
12600698
C005435_D015837 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>edaravone</e1>\NN\1740 against\IN\1740 streptomycin-induced\JJ\1740 <e2>vestibulotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 guinea\NN\13388245 pig\NN\2395003 .\.\1740
C005435_D015837 NONE This\DT\1740 study\NN\635850 investigated\VBD\644583 alleviation\NN\7492516 of\IN\1740 streptomycin-induced\JJ\1740 <e2>vestibulotoxicity</e2>\NN\1740 by\IN\1740 <e1>edaravone</e1>\NN\1740 in\IN\13603305 guinea\NN\13388245 pigs\NNS\2395003 .\.\1740
C005435_D015837 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>edaravone</e1>\NN\1740 suppresses\VBZ\2510337 streptomycin-induced\JJ\1740 <e2>vestibulotoxicity</e2>\NN\1740 .\.\1740
D013307_D015837 CID Protective\JJ\1740 effect\NN\34213 of\IN\1740 edaravone\NN\1740 against\IN\1740 <e1>streptomycin-induced</e1>\JJ\1740 <e2>vestibulotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 guinea\NN\13388245 pig\NN\2395003 .\.\1740
D013307_D015837 CID This\DT\1740 study\NN\635850 investigated\VBD\644583 alleviation\NN\7492516 of\IN\1740 <e1>streptomycin-induced</e1>\JJ\1740 <e2>vestibulotoxicity</e2>\NN\1740 by\IN\1740 edaravone\NN\1740 in\IN\13603305 guinea\NN\13388245 pigs\NNS\2395003 .\.\1740
D013307_D015837 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 edaravone\NN\1740 suppresses\VBZ\2510337 <e1>streptomycin-induced</e1>\JJ\1740 <e2>vestibulotoxicity</e2>\NN\1740 .\.\1740
C005435_D002544 NONE <e1>Edaravone</e1>\NN\1740 ,\,\1740 a\DT\13649268 free\JJ\1740 radical\NN\9465459 scavenger\NN\14779550 ,\,\1740 has\VBZ\2108377 potent\JJ\1740 free\JJ\1740 radical\JJ\1740 quenching\NN\209943 action\NN\30358 and\CC\1740 is\VBZ\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 practice\NN\407535 to\TO\1740 treat\VB\2376958 <e2>cerebral\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
18541230
D011692_D009401 CID Protective\JJ\1740 effects\NNS\13245626 of\IN\1740 antithrombin\NN\1740 on\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 <e2>nephrosis</e2>\NN\14304060 in\IN\13603305 rats\NNS\2329401 .\.\1740
D011692_D009401 CID We\PRP\1740 investigated\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 antithrombin\NN\1740 ,\,\1740 a\DT\13649268 plasma\NN\5398023 inhibitor\NN\20090 of\IN\1740 coagulation\NN\13518963 factors\NNS\7326557 ,\,\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>nephrosis</e2>\NN\14304060 ,\,\1740 which\WDT\1740 is\VBZ\836236 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 human\JJ\1740 nephrotic\JJ\1740 syndrome\NN\5870365 .\.\1740
D011692_D009404 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 antithrombin\NN\1740 ,\,\1740 a\DT\13649268 plasma\NN\5398023 inhibitor\NN\20090 of\IN\1740 coagulation\NN\13518963 factors\NNS\7326557 ,\,\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 nephrosis\NN\14304060 ,\,\1740 which\WDT\1740 is\VBZ\836236 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 human\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D011692_D009404 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 thrombin\NN\14735953 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D011692_D006402 NONE Treatment\NN\654885 with\IN\1740 antithrombin\NN\1740 attenuated\VBD\224901 the\DT\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>hematological\JJ\1740 abnormalities</e2>\NNS\14034177 .\.\1740
D011692_D007674 NONE <e1>Puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 hyperlipidemia\NN\14299637 were\VBD\836236 also\RB\1740 suppressed\VBN\2510337 .\.\1740
D011692_D006949 NONE <e1>Puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 renal\JJ\1740 dysfunction\NN\14204950 and\CC\1740 <e2>hyperlipidemia</e2>\NN\14299637 were\VBD\836236 also\RB\1740 suppressed\VBN\2510337 .\.\1740
48362
D011802_D056486 CID <e1>Quinidine</e1>\NN\2715941 <e2>hepatitis</e2>\NN\14127211 .\.\1740
D011802_D056486 CID We\PRP\1740 concluded\VBD\628491 that\IN\1740 this\DT\1740 patient\NN\9898892 had\VBD\2108377 <e1>quinidine</e1>\NN\2715941 <e2>hepatotoxicity</e2>\NN\1740 and\CC\1740 believe\VBP\686447 that\IN\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 reported\VBN\831651 with\IN\1740 liver\NN\5298729 biopsy\NN\5739043 documentation\NN\6650070 .\.\1740
17263743
C009250_D006323 NONE <e2>Cardiac\JJ\1740 arrest</e2>\NN\88481 in\IN\13603305 a\DT\13649268 child\NN\9622049 with\IN\1740 cerebral\JJ\1740 palsy\NN\14557898 undergoing\VBG\109660 <e1>sevoflurane</e1>\NN\1740 induction\NN\7450842 of\IN\1740 anesthesia\NN\14034177 after\IN\1740 preoperative\JJ\1740 clonidine\NN\2721160 .\.\1740
C009250_D002547 NONE Cardiac\JJ\1740 arrest\NN\88481 in\IN\13603305 a\DT\13649268 child\NN\9622049 with\IN\1740 <e2>cerebral\JJ\1740 palsy</e2>\NN\14557898 undergoing\VBG\109660 <e1>sevoflurane</e1>\NN\1740 induction\NN\7450842 of\IN\1740 anesthesia\NN\14034177 after\IN\1740 preoperative\JJ\1740 clonidine\NN\2721160 .\.\1740
D003000_D006323 CID <e2>Cardiac\JJ\1740 arrest</e2>\NN\88481 in\IN\13603305 a\DT\13649268 child\NN\9622049 with\IN\1740 cerebral\JJ\1740 palsy\NN\14557898 undergoing\VBG\109660 sevoflurane\NN\1740 induction\NN\7450842 of\IN\1740 anesthesia\NN\14034177 after\IN\1740 preoperative\JJ\1740 <e1>clonidine</e1>\NN\2721160 .\.\1740
D003000_D006323 CID There\EX\27167 are\VBP\836236 no\DT\7204911 previous\JJ\1740 reports\NNS\6470073 of\IN\1740 <e1>clonidine-associated</e1>\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 in\IN\13603305 a\DT\13649268 child\NN\9622049 undergoing\VBG\109660 induction\NN\7450842 of\IN\1740 anesthesia\NN\14034177 .\.\1740
D003000_D002547 NONE Cardiac\JJ\1740 arrest\NN\88481 in\IN\13603305 a\DT\13649268 child\NN\9622049 with\IN\1740 <e2>cerebral\JJ\1740 palsy</e2>\NN\14557898 undergoing\VBG\109660 sevoflurane\NN\1740 induction\NN\7450842 of\IN\1740 anesthesia\NN\14034177 after\IN\1740 preoperative\JJ\1740 <e1>clonidine</e1>\NN\2721160 .\.\1740
D003000_D002547 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 5-year-old\JJ\1740 child\NN\9622049 with\IN\1740 <e2>cerebral\JJ\1740 palsy</e2>\NN\14557898 and\CC\1740 seizure\VB\1740 disorder\NN\14034177 ,\,\1740 receiving\VBG\2210855 <e1>clonidine</e1>\NN\2721160 for\IN\1740 restlessness\NN\4773351 ,\,\1740 who\WP\8299493 presented\VBD\2137132 for\IN\1740 placement\NN\5074774 of\IN\1740 a\DT\13649268 baclofen\NN\1740 pump\NN\3736970 .\.\1740
D003000_D004827 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 5-year-old\JJ\1740 child\NN\9622049 with\IN\1740 cerebral\JJ\1740 palsy\NN\14557898 and\CC\1740 <e2>seizure\VB\1740 disorder</e2>\NN\14034177 ,\,\1740 receiving\VBG\2210855 <e1>clonidine</e1>\NN\2721160 for\IN\1740 restlessness\NN\4773351 ,\,\1740 who\WP\8299493 presented\VBD\2137132 for\IN\1740 placement\NN\5074774 of\IN\1740 a\DT\13649268 baclofen\NN\1740 pump\NN\3736970 .\.\1740
D003000_D011595 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 5-year-old\JJ\1740 child\NN\9622049 with\IN\1740 cerebral\JJ\1740 palsy\NN\14557898 and\CC\1740 seizure\VB\1740 disorder\NN\14034177 ,\,\1740 receiving\VBG\2210855 <e1>clonidine</e1>\NN\2721160 for\IN\1740 <e2>restlessness</e2>\NN\4773351 ,\,\1740 who\WP\8299493 presented\VBD\2137132 for\IN\1740 placement\NN\5074774 of\IN\1740 a\DT\13649268 baclofen\NN\1740 pump\NN\3736970 .\.\1740
D001418_D002547 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 5-year-old\JJ\1740 child\NN\9622049 with\IN\1740 <e2>cerebral\JJ\1740 palsy</e2>\NN\14557898 and\CC\1740 seizure\VB\1740 disorder\NN\14034177 ,\,\1740 receiving\VBG\2210855 clonidine\NN\2721160 for\IN\1740 restlessness\NN\4773351 ,\,\1740 who\WP\8299493 presented\VBD\2137132 for\IN\1740 placement\NN\5074774 of\IN\1740 a\DT\13649268 <e1>baclofen</e1>\NN\1740 pump\NN\3736970 .\.\1740
D001418_D004827 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 5-year-old\JJ\1740 child\NN\9622049 with\IN\1740 cerebral\JJ\1740 palsy\NN\14557898 and\CC\1740 <e2>seizure\VB\1740 disorder</e2>\NN\14034177 ,\,\1740 receiving\VBG\2210855 clonidine\NN\2721160 for\IN\1740 restlessness\NN\4773351 ,\,\1740 who\WP\8299493 presented\VBD\2137132 for\IN\1740 placement\NN\5074774 of\IN\1740 a\DT\13649268 <e1>baclofen</e1>\NN\1740 pump\NN\3736970 .\.\1740
D001418_D011595 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 5-year-old\JJ\1740 child\NN\9622049 with\IN\1740 cerebral\JJ\1740 palsy\NN\14557898 and\CC\1740 seizure\VB\1740 disorder\NN\14034177 ,\,\1740 receiving\VBG\2210855 clonidine\NN\2721160 for\IN\1740 <e2>restlessness</e2>\NN\4773351 ,\,\1740 who\WP\8299493 presented\VBD\2137132 for\IN\1740 placement\NN\5074774 of\IN\1740 a\DT\13649268 <e1>baclofen</e1>\NN\1740 pump\NN\3736970 .\.\1740
D003000_D001008 NONE Without\IN\1740 the\DT\1740 knowledge\NN\23100 of\IN\1740 the\DT\1740 medical\JJ\1740 personnel\NNS\8008335 ,\,\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 mother\NN\10399491 administered\VBD\2436349 three\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>clonidine</e1>\NN\2721160 during\IN\1740 the\DT\1740 evening\NN\15164957 before\IN\1740 and\CC\1740 morning\NN\15113229 of\IN\1740 surgery\NN\6045562 to\TO\1740 reduce\VB\441445 <e2>anxiety</e2>\NN\14373582 .\.\1740
10910842
D011239_D018908 CID <e1>Prednisolone-induced</e1>\JJ\1740 <e2>muscle\NN\5289601 dysfunction</e2>\NN\14204950 is\VBZ\836236 caused\VBN\1617192 more\RBR\1740 by\IN\1740 atrophy\NN\14299637 than\IN\1740 by\IN\1740 altered\JJ\1740 acetylcholine\NN\14807558 receptor\NN\5225602 expression\NN\4679549 .\.\1740
D011239_D001284 NONE <e1>Prednisolone-induced</e1>\JJ\1740 muscle\NN\5289601 dysfunction\NN\14204950 is\VBZ\836236 caused\VBN\1617192 more\RBR\1740 by\IN\1740 <e2>atrophy</e2>\NN\14299637 than\IN\1740 by\IN\1740 altered\JJ\1740 acetylcholine\NN\14807558 receptor\NN\5225602 expression\NN\4679549 .\.\1740
D000109_D018908 NONE Prednisolone-induced\JJ\1740 <e2>muscle\NN\5289601 dysfunction</e2>\NN\14204950 is\VBZ\836236 caused\VBN\1617192 more\RBR\1740 by\IN\1740 atrophy\NN\14299637 than\IN\1740 by\IN\1740 altered\JJ\1740 <e1>acetylcholine</e1>\NN\14807558 receptor\NN\5225602 expression\NN\4679549 .\.\1740
D000109_D001284 NONE Prednisolone-induced\JJ\1740 muscle\NN\5289601 dysfunction\NN\14204950 is\VBZ\836236 caused\VBN\1617192 more\RBR\1740 by\IN\1740 <e2>atrophy</e2>\NN\14299637 than\IN\1740 by\IN\1740 altered\JJ\1740 <e1>acetylcholine</e1>\NN\14807558 receptor\NN\5225602 expression\NN\4679549 .\.\1740
D014403_D013746 NONE On\IN\1740 Day\NNP\15154774 8\CD\13741022 ,\,\1740 the\DT\1740 nerve-evoked\JJ\1740 peak\NN\13758296 twitch\NN\14360459 tensions\NNS\14375890 ,\,\1740 <e2>tetanic</e2>\JJ\1740 tensions\NNS\14375890 ,\,\1740 and\CC\1740 fatigability\NN\5040275 ,\,\1740 and\CC\1740 the\DT\1740 dose-response\JJ\1740 curves\NNS\13863771 of\IN\1740 <e1>d-tubocurarine</e1>\NN\1740 in\IN\13603305 the\DT\1740 tibialis\NN\5289861 cranialis\NN\1740 muscle\NN\5289601 were\VBD\836236 measured\VBN\697589 in\FW\13603305 vivo\FW\1740 and\CC\1740 related\JJ\1740 to\TO\1740 muscle\NN\5289601 mass\NN\13575869 or\CC\3541091 expression\NN\4679549 of\IN\1740 AChRs\NN\1740 .\.\1740
D011239_D009468 NONE Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 <e2>neuromuscular\JJ\1740 dysfunction</e2>\NN\14204950 after\IN\1740 <e1>prednisolone</e1>\NN\2721538 is\VBZ\836236 dose-dependent\JJ\1740 ,\,\1740 and\CC\1740 derives\VBZ\634472 primarily\RB\1740 from\IN\1740 muscle\NN\5289601 atrophy\NN\14299637 and\CC\1740 derives\VBZ\634472 less\RBR\1740 so\RB\1740 from\IN\1740 changes\NNS\7283608 in\IN\13603305 AChR\NN\1740 expression\NN\4679549 .\.\1740
D011239_D009133 CID Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 neuromuscular\JJ\1740 dysfunction\NN\14204950 after\IN\1740 <e1>prednisolone</e1>\NN\2721538 is\VBZ\836236 dose-dependent\JJ\1740 ,\,\1740 and\CC\1740 derives\VBZ\634472 primarily\RB\1740 from\IN\1740 <e2>muscle\NN\5289601 atrophy</e2>\NN\14299637 and\CC\1740 derives\VBZ\634472 less\RBR\1740 so\RB\1740 from\IN\1740 changes\NNS\7283608 in\IN\13603305 AChR\NN\1740 expression\NN\4679549 .\.\1740
D000109_D009133 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 observed\VBN\2163746 effects\NNS\13245626 are\VBP\836236 dose-dependent\JJ\1740 and\CC\1740 derive\JJ\1740 primarily\RB\1740 from\IN\1740 <e2>muscle\NN\5289601 atrophy</e2>\NN\14299637 and\CC\1740 derive\VBP\634472 less\JJR\1740 from\IN\1740 changes\NNS\7283608 in\IN\13603305 <e1>acetylcholine</e1>\NN\14807558 receptor\NN\5225602 expression\NN\4679549 .\.\1740
2750819
D008278_D020879 CID <e2>Neuromuscular\JJ\1740 blockade</e2>\NN\952963 with\IN\1740 <e1>magnesium\NN\14625458 sulfate</e1>\NN\15010703 and\CC\1740 nifedipine\NN\2938514 .\.\1740
D008278_D020879 CID A\DT\13649268 patient\NN\9898892 who\WP\8299493 received\VBD\2210855 tocolysis\NN\1740 with\IN\1740 nifedipine\NN\2938514 developed\VBD\1753788 <e2>neuromuscular\JJ\1740 blockade</e2>\NN\952963 after\IN\1740 500\CD\13745420 mg\NN\13717155 of\IN\1740 <e1>magnesium\NN\14625458 sulfate</e1>\NN\15010703 was\VBD\836236 administered\VBN\2436349 .\.\1740
D009543_D020879 CID <e2>Neuromuscular\JJ\1740 blockade</e2>\NN\952963 with\IN\1740 magnesium\NN\14625458 sulfate\NN\15010703 and\CC\1740 <e1>nifedipine</e1>\NN\2938514 .\.\1740
D009543_D020879 CID A\DT\13649268 patient\NN\9898892 who\WP\8299493 received\VBD\2210855 tocolysis\NN\1740 with\IN\1740 <e1>nifedipine</e1>\NN\2938514 developed\VBD\1753788 <e2>neuromuscular\JJ\1740 blockade</e2>\NN\952963 after\IN\1740 500\CD\13745420 mg\NN\13717155 of\IN\1740 magnesium\NN\14625458 sulfate\NN\15010703 was\VBD\836236 administered\VBN\2436349 .\.\1740
D009543_D064420 NONE This\DT\1740 reaction\NN\13446390 demonstrates\VBZ\2137132 that\IN\1740 <e1>nifedipine</e1>\NN\2938514 can\MD\3094503 seriously\RB\1740 potentiate\VB\229605 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 magnesium\NN\14625458 .\.\1740
D008274_D064420 NONE This\DT\1740 reaction\NN\13446390 demonstrates\VBZ\2137132 that\IN\1740 nifedipine\NN\2938514 can\MD\3094503 seriously\RB\1740 potentiate\VB\229605 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>magnesium</e1>\NN\14625458 .\.\1740
8494478
D002939_D007674 NONE <e1>Ciprofloxacin-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cancer\NN\14239425 .\.\1740
D002939_D007674 NONE <e2>Nephrotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>ciprofloxacin</e1>\NN\2716866 is\VBZ\836236 uncommon\JJ\1740 .\.\1740
D002939_D009369 NONE <e1>Ciprofloxacin-induced</e1>\JJ\1740 nephrotoxicity\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>cancer</e2>\NN\14239425 .\.\1740
D002939_D009369 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>cancer</e2>\NN\14239425 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 that\WDT\1740 followed\VBD\1835496 treatment\NN\654885 with\IN\1740 <e1>ciprofloxacin</e1>\NN\2716866 are\VBP\836236 described\VBN\1001294 and\CC\1740 an\DT\6697703 additional\JJ\1740 15\CD\13745420 cases\NNS\7283608 reported\VBN\831651 in\IN\13603305 the\DT\1740 literature\NN\6362953 are\VBP\836236 reviewed\VBN\644583 .\.\1740
D002939_D058186 CID Five\CD\13741022 patients\NNS\9898892 with\IN\1740 cancer\NN\14239425 who\WP\8299493 developed\VBD\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 that\WDT\1740 followed\VBD\1835496 treatment\NN\654885 with\IN\1740 <e1>ciprofloxacin</e1>\NN\2716866 are\VBP\836236 described\VBN\1001294 and\CC\1740 an\DT\6697703 additional\JJ\1740 15\CD\13745420 cases\NNS\7283608 reported\VBN\831651 in\IN\13603305 the\DT\1740 literature\NN\6362953 are\VBP\836236 reviewed\VBN\644583 .\.\1740
D002939_D058186 CID An\DT\6697703 improvement\NN\7359599 in\IN\13603305 renal\JJ\1740 function\NN\13783581 that\WDT\1740 followed\VBD\1835496 the\DT\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 offending\NN\1740 antibiotic\JJ\1740 supports\VBZ\2199590 the\DT\1740 presumptive\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e1>ciprofloxacin-induced</e1>\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
10524660
D005996_D020326 CID <e1>Glyceryl\NN\14621446 trinitrate</e1>\NN\1740 induces\VBZ\1627355 attacks\NNS\955060 of\IN\1740 <e2>migraine\NN\14326607 without\IN\1740 aura</e2>\NN\14299637 in\IN\13603305 sufferers\NNS\9630641 of\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 .\.\1740
D005996_D020325 NONE <e1>Glyceryl\NN\14621446 trinitrate</e1>\NN\1740 induces\VBZ\1627355 attacks\NNS\955060 of\IN\1740 migraine\NN\14326607 without\IN\1740 aura\NN\14299637 in\IN\13603305 sufferers\NNS\9630641 of\IN\1740 <e2>migraine\NN\14326607 with\IN\1740 aura</e2>\NN\14299637 .\.\1740
D005996_D020325 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 clarify\VB\939277 whether\IN\1740 the\DT\1740 same\JJ\1740 is\VBZ\836236 true\JJ\1740 for\IN\1740 <e2>migraine\NN\14326607 with\IN\1740 aura</e2>\NN\14299637 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 examined\VBD\789138 the\DT\1740 headache\NN\5829480 response\NN\11410625 to\TO\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.5\CD\1740 microg/kg/min\NN\1740 for\IN\1740 20\CD\13745420 min\NN\15154774 )\-RRB-\1740 in\IN\13603305 12\CD\13745420 sufferers\NNS\9630641 of\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 .\.\1740
D005996_D020325 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 clarify\VB\939277 whether\IN\1740 the\DT\1740 same\JJ\1740 is\VBZ\836236 true\JJ\1740 for\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 examined\VBD\789138 the\DT\1740 headache\NN\5829480 response\NN\11410625 to\TO\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.5\CD\1740 microg/kg/min\NN\1740 for\IN\1740 20\CD\13745420 min\NN\15154774 )\-RRB-\1740 in\IN\13603305 12\CD\13745420 sufferers\NNS\9630641 of\IN\1740 <e2>migraine\NN\14326607 with\IN\1740 aura</e2>\NN\14299637 .\.\1740
D005996_D020325 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 clarify\VB\939277 whether\IN\1740 the\DT\1740 same\JJ\1740 is\VBZ\836236 true\JJ\1740 for\IN\1740 <e2>migraine\NN\14326607 with\IN\1740 aura</e2>\NN\14299637 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 examined\VBD\789138 the\DT\1740 headache\NN\5829480 response\NN\11410625 to\TO\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 <e1>GTN</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.5\CD\1740 microg/kg/min\NN\1740 for\IN\1740 20\CD\13745420 min\NN\15154774 )\-RRB-\1740 in\IN\13603305 12\CD\13745420 sufferers\NNS\9630641 of\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 .\.\1740
D005996_D020325 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 clarify\VB\939277 whether\IN\1740 the\DT\1740 same\JJ\1740 is\VBZ\836236 true\JJ\1740 for\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 examined\VBD\789138 the\DT\1740 headache\NN\5829480 response\NN\11410625 to\TO\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 <e1>GTN</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.5\CD\1740 microg/kg/min\NN\1740 for\IN\1740 20\CD\13745420 min\NN\15154774 )\-RRB-\1740 in\IN\13603305 12\CD\13745420 sufferers\NNS\9630641 of\IN\1740 <e2>migraine\NN\14326607 with\IN\1740 aura</e2>\NN\14299637 .\.\1740
D009569_D010146 NONE In\IN\13603305 recent\JJ\1740 years\NNS\15144371 ,\,\1740 increasing\VBG\169651 evidence\NN\5816287 has\VBZ\2108377 suggested\VBN\1010118 that\IN\1740 the\DT\1740 messenger\NN\9629752 molecule\NN\9465459 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 <e2>pain</e2>\NN\14299637 mechanisms\NNS\13446390 of\IN\1740 migraine\NN\14326607 without\IN\1740 aura\NN\14299637 .\.\1740
D009569_D010146 NONE In\IN\13603305 recent\JJ\1740 years\NNS\15144371 ,\,\1740 increasing\VBG\169651 evidence\NN\5816287 has\VBZ\2108377 suggested\VBN\1010118 that\IN\1740 the\DT\1740 messenger\NN\9629752 molecule\NN\9465459 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 <e2>pain</e2>\NN\14299637 mechanisms\NNS\13446390 of\IN\1740 migraine\NN\14326607 without\IN\1740 aura\NN\14299637 .\.\1740
D009569_D010146 NONE The\DT\1740 results\NNS\34213 therefore\RB\1740 suggest\VBP\1010118 that\IN\1740 <e1>NO</e1>\NN\7204911 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 <e2>pain</e2>\NN\14299637 mechanisms\NNS\13446390 of\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 .\.\1740
D009569_D020326 CID In\IN\13603305 recent\JJ\1740 years\NNS\15144371 ,\,\1740 increasing\VBG\169651 evidence\NN\5816287 has\VBZ\2108377 suggested\VBN\1010118 that\IN\1740 the\DT\1740 messenger\NN\9629752 molecule\NN\9465459 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 pain\NN\14299637 mechanisms\NNS\13446390 of\IN\1740 <e2>migraine\NN\14326607 without\IN\1740 aura</e2>\NN\14299637 .\.\1740
D009569_D020326 CID In\IN\13603305 recent\JJ\1740 years\NNS\15144371 ,\,\1740 increasing\VBG\169651 evidence\NN\5816287 has\VBZ\2108377 suggested\VBN\1010118 that\IN\1740 the\DT\1740 messenger\NN\9629752 molecule\NN\9465459 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 pain\NN\14299637 mechanisms\NNS\13446390 of\IN\1740 <e2>migraine\NN\14326607 without\IN\1740 aura</e2>\NN\14299637 .\.\1740
D005996_D006261 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 clarify\VB\939277 whether\IN\1740 the\DT\1740 same\JJ\1740 is\VBZ\836236 true\JJ\1740 for\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 examined\VBD\789138 the\DT\1740 <e2>headache</e2>\NN\5829480 response\NN\11410625 to\TO\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.5\CD\1740 microg/kg/min\NN\1740 for\IN\1740 20\CD\13745420 min\NN\15154774 )\-RRB-\1740 in\IN\13603305 12\CD\13745420 sufferers\NNS\9630641 of\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 .\.\1740
D005996_D006261 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 clarify\VB\939277 whether\IN\1740 the\DT\1740 same\JJ\1740 is\VBZ\836236 true\JJ\1740 for\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 ,\,\1740 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 examined\VBD\789138 the\DT\1740 <e2>headache</e2>\NN\5829480 response\NN\11410625 to\TO\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 <e1>GTN</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.5\CD\1740 microg/kg/min\NN\1740 for\IN\1740 20\CD\13745420 min\NN\15154774 )\-RRB-\1740 in\IN\13603305 12\CD\13745420 sufferers\NNS\9630641 of\IN\1740 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 .\.\1740
D005996_D006261 NONE <e2>Headache</e2>\NNP\5829480 was\VBD\836236 more\RBR\1740 severe\JJ\1740 in\IN\13603305 migraineurs\NNS\1740 than\IN\1740 in\IN\13603305 the\DT\1740 controls\NNS\5190804 during\IN\1740 and\CC\1740 immediately\RB\1740 after\IN\1740 <e1>GTN</e1>\NN\1740 infusion\NN\14589223 (\-LRB-\1740 p=0.037\NN\1740 )\-RRB-\1740 as\RB\1740 well\RB\1740 as\IN\14622893 during\IN\1740 the\DT\1740 following\VBG\1835496 11\CD\13745420 h\NN\14622893 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.008\CD\1740 )\-RRB-\1740 .\.\1740
D005996_D006261 NONE In\IN\13603305 the\DT\1740 controls\NNS\5190804 ,\,\1740 the\DT\1740 <e1>GTN-induced</e1>\JJ\1740 <e2>headache</e2>\NN\5829480 gradually\RB\1740 disappeared\VBD\2609764 ,\,\1740 whereas\IN\1740 in\IN\13603305 migraineurs\NNS\1740 peak\NN\13758296 headache\NN\5829480 intensity\NN\5090441 occurred\VBD\2623529 at\IN\14622893 a\DT\13649268 mean\NN\6021761 time\NN\7308889 of\IN\1740 240\CD\1740 min\NN\15154774 post-infusion\NN\1740 .\.\1740
D005996_D006261 NONE In\IN\13603305 the\DT\1740 controls\NNS\5190804 ,\,\1740 the\DT\1740 <e1>GTN-induced</e1>\JJ\1740 headache\NN\5829480 gradually\RB\1740 disappeared\VBD\2609764 ,\,\1740 whereas\IN\1740 in\IN\13603305 migraineurs\NNS\1740 peak\NN\13758296 <e2>headache</e2>\NN\5829480 intensity\NN\5090441 occurred\VBD\2623529 at\IN\14622893 a\DT\13649268 mean\NN\6021761 time\NN\7308889 of\IN\1740 240\CD\1740 min\NN\15154774 post-infusion\NN\1740 .\.\1740
D005996_D008881 NONE Headache\NNP\5829480 was\VBD\836236 more\RBR\1740 severe\JJ\1740 in\IN\13603305 <e2>migraineurs</e2>\NNS\1740 than\IN\1740 in\IN\13603305 the\DT\1740 controls\NNS\5190804 during\IN\1740 and\CC\1740 immediately\RB\1740 after\IN\1740 <e1>GTN</e1>\NN\1740 infusion\NN\14589223 (\-LRB-\1740 p=0.037\NN\1740 )\-RRB-\1740 as\RB\1740 well\RB\1740 as\IN\14622893 during\IN\1740 the\DT\1740 following\VBG\1835496 11\CD\13745420 h\NN\14622893 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.008\CD\1740 )\-RRB-\1740 .\.\1740
D005996_D008881 NONE In\IN\13603305 the\DT\1740 controls\NNS\5190804 ,\,\1740 the\DT\1740 <e1>GTN-induced</e1>\JJ\1740 headache\NN\5829480 gradually\RB\1740 disappeared\VBD\2609764 ,\,\1740 whereas\IN\1740 in\IN\13603305 <e2>migraineurs</e2>\NNS\1740 peak\NN\13758296 headache\NN\5829480 intensity\NN\5090441 occurred\VBD\2623529 at\IN\14622893 a\DT\13649268 mean\NN\6021761 time\NN\7308889 of\IN\1740 240\CD\1740 min\NN\15154774 post-infusion\NN\1740 .\.\1740
D009569_D020325 NONE The\DT\1740 results\NNS\34213 therefore\RB\1740 suggest\VBP\1010118 that\IN\1740 <e1>NO</e1>\NN\7204911 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 pain\NN\14299637 mechanisms\NNS\13446390 of\IN\1740 <e2>migraine\NN\14326607 with\IN\1740 aura</e2>\NN\14299637 .\.\1740
D009569_D020325 NONE Since\IN\1740 cortical\JJ\1740 spreading\NN\7311115 depression\NN\14373582 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 liberate\VB\146138 <e1>NO</e1>\NN\7204911 in\IN\13603305 animals\NNS\4475 ,\,\1740 this\DT\1740 finding\NN\43195 may\MD\15209706 help\VB\2556126 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 coupling\NN\3091374 between\IN\1740 cortical\JJ\1740 spreading\NN\7311115 depression\NN\14373582 and\CC\1740 headache\NN\5829480 in\IN\13603305 <e2>migraine\NN\14326607 with\IN\1740 aura</e2>\NN\14299637 .\.\1740
D009569_D003866 NONE Since\IN\1740 cortical\JJ\1740 spreading\NN\7311115 <e2>depression</e2>\NN\14373582 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 liberate\VB\146138 <e1>NO</e1>\NN\7204911 in\IN\13603305 animals\NNS\4475 ,\,\1740 this\DT\1740 finding\NN\43195 may\MD\15209706 help\VB\2556126 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 coupling\NN\3091374 between\IN\1740 cortical\JJ\1740 spreading\NN\7311115 depression\NN\14373582 and\CC\1740 headache\NN\5829480 in\IN\13603305 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 .\.\1740
D009569_D003866 NONE Since\IN\1740 cortical\JJ\1740 spreading\NN\7311115 depression\NN\14373582 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 liberate\VB\146138 <e1>NO</e1>\NN\7204911 in\IN\13603305 animals\NNS\4475 ,\,\1740 this\DT\1740 finding\NN\43195 may\MD\15209706 help\VB\2556126 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 coupling\NN\3091374 between\IN\1740 cortical\JJ\1740 spreading\NN\7311115 <e2>depression</e2>\NN\14373582 and\CC\1740 headache\NN\5829480 in\IN\13603305 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 .\.\1740
D009569_D006261 NONE Since\IN\1740 cortical\JJ\1740 spreading\NN\7311115 depression\NN\14373582 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 liberate\VB\146138 <e1>NO</e1>\NN\7204911 in\IN\13603305 animals\NNS\4475 ,\,\1740 this\DT\1740 finding\NN\43195 may\MD\15209706 help\VB\2556126 our\PRP$\1740 understanding\NN\5804793 of\IN\1740 the\DT\1740 coupling\NN\3091374 between\IN\1740 cortical\JJ\1740 spreading\NN\7311115 depression\NN\14373582 and\CC\1740 <e2>headache</e2>\NN\5829480 in\IN\13603305 migraine\NN\14326607 with\IN\1740 aura\NN\14299637 .\.\1740
9154656
D000809_D009404 NONE Plasma\NN\5398023 concentration\NN\4916342 and\CC\1740 urine\NN\14853947 excretion\NN\13466586 of\IN\1740 the\DT\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 proteins\NNS\14944888 are\VBP\836236 altered\VBN\126264 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 NS\NN\14622893 )\-RRB-\1740 .\.\1740
D000809_D009404 NONE Plasma\NN\5398023 concentration\NN\4916342 and\CC\1740 urine\NN\14853947 excretion\NN\13466586 of\IN\1740 the\DT\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 proteins\NNS\14944888 are\VBP\836236 altered\VBN\126264 in\IN\13603305 rats\NNS\2329401 with\IN\1740 nephrotic\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>NS</e2>\NN\14622893 )\-RRB-\1740 .\.\1740
D011692_D009404 CID <e2>NS</e2>\NN\14622893 was\VBD\836236 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 <e1>puromycin\NN\1740 amino-nucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 .\.\1740
D011692_D009404 CID <e2>NS</e2>\NN\14622893 was\VBD\836236 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 amino-nucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 .\.\1740
D011692_D009404 CID Although\IN\1740 a\DT\13649268 great\JJ\1740 urinary\JJ\1740 excretion\NN\13466586 and\CC\1740 half-normal\JJ\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 Ao\NN\1740 were\VBD\836236 observed\VBN\2163746 on\IN\1740 day\NN\15154774 6\CD\13741022 after\IN\1740 <e1>PAN</e1>\NN\3101986 injection\NN\320852 ,\,\1740 when\WRB\1740 <e2>NS</e2>\NN\14622893 was\VBD\836236 clearly\RB\1740 established\VBN\2426171 ,\,\1740 hepatic\JJ\1740 Ao\NN\1740 mRNA\NN\14832193 levels\NNS\4916342 did\VBD\1640855 not\RB\1740 change\VB\46534 .\.\1740
D011692_D009404 CID These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 the\DT\1740 hepatic\JJ\1740 and\CC\1740 extrahepatic\JJ\1740 Ao\NN\1740 mRNA\NN\14832193 levels\NNS\4916342 are\VBP\836236 unaltered\JJ\1740 during\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 the\DT\1740 acute\JJ\1740 <e2>NS</e2>\NN\14622893 induced\VBN\1627355 by\IN\1740 <e1>PAN</e1>\NN\3101986 .\.\1740
7619765
D005047_D009203 CID <e1>Etoposide-related</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D005047_D009203 CID The\DT\1740 occurrence\NN\29378 of\IN\1740 a\DT\13649268 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 is\VBZ\836236 reported\VBN\831651 after\IN\1740 chemotherapy\NN\661091 containing\VBG\2632940 <e1>etoposide</e1>\NN\1740 ,\,\1740 in\IN\13603305 a\DT\13649268 man\NN\9605289 with\IN\1740 no\DT\7204911 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 coronary\JJ\1740 heart\NN\5919034 disease\NN\14061805 .\.\1740
D005047_D003327 NONE The\DT\1740 occurrence\NN\29378 of\IN\1740 a\DT\13649268 myocardial\JJ\1740 infarction\NN\14204950 is\VBZ\836236 reported\VBN\831651 after\IN\1740 chemotherapy\NN\661091 containing\VBG\2632940 <e1>etoposide</e1>\NN\1740 ,\,\1740 in\IN\13603305 a\DT\13649268 man\NN\9605289 with\IN\1740 no\DT\7204911 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 <e2>coronary\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 .\.\1740
12571256
C044834_D007674 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 prospective\JJ\1740 ,\,\1740 multicenter\NN\1740 study\NN\635850 comparing\VBG\644583 the\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 an\DT\6697703 iso-osmolar\JJ\1740 ,\,\1740 dimeric\JJ\1740 ,\,\1740 nonionic\JJ\1740 contrast\NN\13854649 medium\NN\3575240 ,\,\1740 <e1>iodixanol</e1>\NN\1740 ,\,\1740 with\IN\1740 those\DT\1740 of\IN\1740 a\DT\13649268 low-osmolar\JJ\1740 ,\,\1740 nonionic\JJ\1740 ,\,\1740 monomeric\JJ\1740 contrast\NN\13854649 medium\NN\3575240 ,\,\1740 iohexol\NN\1740 .\.\1740
C044834_D007674 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e2>Nephropathy</e2>\NNP\14573196 induced\VBN\1627355 by\IN\1740 contrast\NN\13854649 medium\NN\3575240 may\MD\15209706 be\VB\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 develop\VB\1753788 in\IN\13603305 high-risk\JJ\1740 patients\NNS\9898892 when\WRB\1740 <e1>iodixanol</e1>\NN\1740 is\VBZ\836236 used\VBN\1156834 rather\RB\1740 than\IN\1740 a\DT\13649268 low-osmolar\JJ\1740 ,\,\1740 nonionic\JJ\1740 contrast\NN\13854649 medium\NN\3575240 .\.\1740
D007472_D007674 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 prospective\JJ\1740 ,\,\1740 multicenter\NN\1740 study\NN\635850 comparing\VBG\644583 the\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 an\DT\6697703 iso-osmolar\JJ\1740 ,\,\1740 dimeric\JJ\1740 ,\,\1740 nonionic\JJ\1740 contrast\NN\13854649 medium\NN\3575240 ,\,\1740 iodixanol\NN\1740 ,\,\1740 with\IN\1740 those\DT\1740 of\IN\1740 a\DT\13649268 low-osmolar\JJ\1740 ,\,\1740 nonionic\JJ\1740 ,\,\1740 monomeric\JJ\1740 contrast\NN\13854649 medium\NN\3575240 ,\,\1740 <e1>iohexol</e1>\NN\1740 .\.\1740
D003404_D003920 NONE The\DT\1740 study\NN\635850 involved\VBD\2676054 129\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>diabetes</e2>\NNS\14075199 with\IN\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 concentrations\NNS\4916342 of\IN\1740 1.5\CD\1740 to\TO\1740 3.5\CD\1740 mg\NN\13717155 per\IN\1740 deciliter\NN\13616054 who\WP\8299493 underwent\VBD\109660 coronary\JJ\1740 or\CC\3541091 aortofemoral\JJ\1740 angiography\NN\904623 .\.\1740
1848636
D008790_D007008 NONE The\DT\1740 drug\NN\14778436 effect\NN\34213 studied\VBN\630380 was\VBD\836236 the\DT\1740 antagonism\NN\24720 by\IN\1740 <e1>metoprolol</e1>\NN\2832168 of\IN\1740 terbutaline-induced\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 .\.\1740
D013726_D007008 CID The\DT\1740 drug\NN\14778436 effect\NN\34213 studied\VBN\630380 was\VBD\836236 the\DT\1740 antagonism\NN\24720 by\IN\1740 metoprolol\NN\2832168 of\IN\1740 <e1>terbutaline-induced</e1>\JJ\1740 <e2>hypokalemia</e2>\NN\14299637 .\.\1740
10225068
D008012_D011128 CID <e2>Cauda\JJ\1740 equina\NN\1740 syndrome</e2>\NN\5870365 after\IN\1740 spinal\JJ\1740 anaesthesia\NN\14034177 with\IN\1740 hyperbaric\JJ\1740 5\CD\13741022 %\NN\1740 <e1>lignocaine</e1>\NN\1740 :\:\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 six\CD\13741022 cases\NNS\7283608 of\IN\1740 cauda\JJ\1740 equina\NN\1740 syndrome\NN\5870365 reported\VBN\831651 to\IN\1740 the\DT\1740 Swedish\NNP\6953731 Pharmaceutical\NNP\3740161 Insurance\NNP\13344071 1993\CD\1740 -\SYM\1740 1997\CD\1740 .\.\1740
D008012_D011128 CID Cauda\JJ\1740 equina\NN\1740 syndrome\NN\5870365 after\IN\1740 spinal\JJ\1740 anaesthesia\NN\14034177 with\IN\1740 hyperbaric\JJ\1740 5\CD\13741022 %\NN\1740 <e1>lignocaine</e1>\NN\1740 :\:\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 six\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>cauda\JJ\1740 equina\NN\1740 syndrome</e2>\NN\5870365 reported\VBN\831651 to\IN\1740 the\DT\1740 Swedish\NNP\6953731 Pharmaceutical\NNP\3740161 Insurance\NNP\13344071 1993\CD\1740 -\SYM\1740 1997\CD\1740 .\.\1740
D008012_D020258 NONE The\DT\1740 dose\NN\3740161 of\IN\1740 hyperbaric\NN\1740 5\CD\13741022 %\NN\1740 <e1>lignocaine</e1>\NN\1740 administered\VBN\2436349 ranged\VBD\2604760 from\IN\1740 60\CD\13745420 to\TO\1740 120\CD\13745420 mg.\NN\1740 Three\CD\13741022 of\IN\1740 the\DT\1740 cases\NNS\7283608 were\VBD\836236 most\RBS\1740 likely\RB\1740 caused\VBN\1617192 by\IN\1740 direct\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 of\IN\1740 hyperbaric\JJ\1740 5\CD\13741022 %\NN\1740 lignocaine\NN\1740 .\.\1740
D008012_D020258 NONE The\DT\1740 dose\NN\3740161 of\IN\1740 hyperbaric\NN\1740 5\CD\13741022 %\NN\1740 lignocaine\NN\1740 administered\VBN\2436349 ranged\VBD\2604760 from\IN\1740 60\CD\13745420 to\TO\1740 120\CD\13745420 mg.\NN\1740 Three\CD\13741022 of\IN\1740 the\DT\1740 cases\NNS\7283608 were\VBD\836236 most\RBS\1740 likely\RB\1740 caused\VBN\1617192 by\IN\1740 direct\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 of\IN\1740 hyperbaric\JJ\1740 5\CD\13741022 %\NN\1740 <e1>lignocaine</e1>\NN\1740 .\.\1740
11284996
D009569_D006261 CID Calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 levels\NNS\4916342 during\IN\1740 <e1>nitric\JJ\1740 oxide-induced</e1>\JJ\1740 <e2>headache</e2>\NN\5829480 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 tension-type\NN\1740 headache\NN\5829480 .\.\1740
D009569_D006261 CID It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 proposed\VBN\1010118 that\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 induced\JJ\1740 <e2>headache</e2>\NN\5829480 in\IN\13603305 primary\JJ\1740 headaches\NNS\5829480 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 release\NN\3748886 of\IN\1740 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 .\.\1740
D009569_D006261 CID It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 proposed\VBN\1010118 that\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 induced\JJ\1740 <e2>headache</e2>\NN\5829480 in\IN\13603305 primary\JJ\1740 headaches\NNS\5829480 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 release\NN\3748886 of\IN\1740 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 .\.\1740
D009569_D006261 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 investigate\VB\644583 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 CGRP\NN\1740 during\IN\1740 <e2>headache</e2>\NN\5829480 induced\VBN\1627355 by\IN\1740 the\DT\1740 <e1>NO</e1>\NN\7204911 donor\NN\9608709 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 tension-type\JJ\1740 headache\NN\5829480 and\CC\1740 16\CD\13745420 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D009569_D006261 CID The\DT\1740 present\JJ\1740 study\NN\635850 indicates\VBZ\952524 that\IN\1740 <e1>NO-induced</e1>\JJ\1740 immediate\JJ\1740 <e2>headache</e2>\NN\5829480 is\VBZ\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 release\NN\3748886 of\IN\1740 CGRP\NN\1740 .\.\1740
D009569_D018781 NONE Calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 levels\NNS\4916342 during\IN\1740 <e1>nitric\JJ\1740 oxide-induced</e1>\JJ\1740 headache\NN\5829480 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>tension-type\NN\1740 headache</e2>\NN\5829480 .\.\1740
D009569_D018781 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 investigate\VB\644583 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 CGRP\NN\1740 during\IN\1740 headache\NN\5829480 induced\VBN\1627355 by\IN\1740 the\DT\1740 <e1>NO</e1>\NN\7204911 donor\NN\9608709 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>tension-type\JJ\1740 headache</e2>\NN\5829480 and\CC\1740 16\CD\13745420 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D009569_D051270 NONE It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 proposed\VBN\1010118 that\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 induced\JJ\1740 headache\NN\5829480 in\IN\13603305 <e2>primary\JJ\1740 headaches</e2>\NNS\5829480 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 release\NN\3748886 of\IN\1740 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 .\.\1740
D009569_D051270 NONE It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 proposed\VBN\1010118 that\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 induced\JJ\1740 headache\NN\5829480 in\IN\13603305 <e2>primary\JJ\1740 headaches</e2>\NNS\5829480 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 release\NN\3748886 of\IN\1740 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 .\.\1740
D005996_D006261 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 investigate\VB\644583 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 CGRP\NN\1740 during\IN\1740 <e2>headache</e2>\NN\5829480 induced\VBN\1627355 by\IN\1740 the\DT\1740 NO\NN\7204911 donor\NN\9608709 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 tension-type\JJ\1740 headache\NN\5829480 and\CC\1740 16\CD\13745420 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D005996_D006261 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 investigate\VB\644583 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 CGRP\NN\1740 during\IN\1740 <e2>headache</e2>\NN\5829480 induced\VBN\1627355 by\IN\1740 the\DT\1740 NO\NN\7204911 donor\NN\9608709 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 <e1>GTN</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 tension-type\JJ\1740 headache\NN\5829480 and\CC\1740 16\CD\13745420 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D005996_D006261 CID The\DT\1740 subjects\NNS\6598915 were\VBD\836236 randomly\RB\1740 allocated\VBN\2228698 to\TO\1740 receive\VB\2210855 0.5\CD\1740 microg/kg/min\NN\1740 <e1>GTN</e1>\NN\1740 or\CC\3541091 placebo\VB\1740 over\IN\5867413 20\CD\13745420 min\NN\15154774 on\IN\1740 two\CD\13741022 <e2>headache-free</e2>\JJ\1740 days\NNS\15140892 .\.\1740
D005996_D006261 CID Both\DT\1740 patients\NNS\9898892 and\CC\1740 controls\NNS\5190804 developed\VBD\1753788 significantly\RB\1740 stronger\JJR\1740 immediate\JJ\1740 <e2>headache</e2>\NN\5829480 on\IN\1740 the\DT\1740 <e1>GTN</e1>\NN\1740 day\NN\15154774 than\IN\1740 on\IN\1740 the\DT\1740 placebo\NN\3740161 day\NN\15154774 and\CC\1740 the\DT\1740 headache\NN\5829480 was\VBD\836236 significantly\RB\1740 more\RBR\1740 pronounced\JJ\1740 in\IN\13603305 patients\NNS\9898892 than\IN\1740 in\IN\13603305 controls\NNS\5190804 .\.\1740
D005996_D006261 CID Both\DT\1740 patients\NNS\9898892 and\CC\1740 controls\NNS\5190804 developed\VBD\1753788 significantly\RB\1740 stronger\JJR\1740 immediate\JJ\1740 headache\NN\5829480 on\IN\1740 the\DT\1740 <e1>GTN</e1>\NN\1740 day\NN\15154774 than\IN\1740 on\IN\1740 the\DT\1740 placebo\NN\3740161 day\NN\15154774 and\CC\1740 the\DT\1740 <e2>headache</e2>\NN\5829480 was\VBD\836236 significantly\RB\1740 more\RBR\1740 pronounced\JJ\1740 in\IN\13603305 patients\NNS\9898892 than\IN\1740 in\IN\13603305 controls\NNS\5190804 .\.\1740
D005996_D018781 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 investigate\VB\644583 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 CGRP\NN\1740 during\IN\1740 headache\NN\5829480 induced\VBN\1627355 by\IN\1740 the\DT\1740 NO\NN\7204911 donor\NN\9608709 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>tension-type\JJ\1740 headache</e2>\NN\5829480 and\CC\1740 16\CD\13745420 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D005996_D018781 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 investigate\VB\644583 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 CGRP\NN\1740 during\IN\1740 headache\NN\5829480 induced\VBN\1627355 by\IN\1740 the\DT\1740 NO\NN\7204911 donor\NN\9608709 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 <e1>GTN</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 16\CD\13745420 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>tension-type\JJ\1740 headache</e2>\NN\5829480 and\CC\1740 16\CD\13745420 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
921394
D007649_D003866 NONE Injections\NNS\320852 of\IN\1740 <e1>ketamine</e1>\NN\3054098 in\IN\13603305 doses\NNS\3740161 from\IN\1740 100\CD\13745420 microgram\NN\13717155 to\IN\1740 3\CD\13741022 mg\NN\13717155 into\IN\1740 the\DT\1740 artery\NN\5417975 produced\VBD\1617192 a\DT\13649268 <e2>depression</e2>\NN\14373582 of\IN\1740 the\DT\1740 SA\NNP\8390511 nodal\NN\1740 activity\NN\30358 by\IN\1740 a\DT\13649268 direct\JJ\1740 action\NN\30358 .\.\1740
D007649_D013610 CID Bilateral\JJ\1740 vagotomy\NN\1740 and\CC\1740 sympathectomy\NN\393369 or\CC\3541091 prior\JJ\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 ganglion\NN\5462674 blocker\NN\10101634 failed\VBD\1798936 to\TO\1740 inhibit\VB\2510337 the\DT\1740 occurrence\NN\29378 of\IN\1740 the\DT\1740 <e1>ketamine-induced</e1>\JJ\1740 <e2>tachycardia</e2>\NN\14110674 ,\,\1740 while\IN\15122231 it\PRP\6125041 was\VBD\836236 completely\RB\1740 abolished\VBN\1740 in\IN\13603305 the\DT\1740 reserpinized\VBN\1740 dogs\NNS\2083346 or\CC\3541091 by\IN\1740 a\DT\13649268 prior\JJ\1740 injection\NN\320852 of\IN\1740 a\DT\13649268 beta-blocking\JJ\1740 agent\NN\7347 into\IN\1740 the\DT\1740 SA\NN\8390511 node\NN\13870805 artery\NN\5417975 .\.\1740
6817363
C036466_D007859 NONE Effects\NNS\13245626 of\IN\1740 the\DT\1740 novel\JJ\1740 compound\NN\5869584 <e1>aniracetam</e1>\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 )\-RRB-\1740 upon\IN\1740 <e2>impaired\JJ\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 in\IN\13603305 rodents\NNS\1886756 .\.\1740
C036466_D007859 NONE Effects\NNS\13245626 of\IN\1740 the\DT\1740 novel\JJ\1740 compound\NN\5869584 aniracetam\NN\1740 (\-LRB-\1740 <e1>Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057</e1>\CD\1740 )\-RRB-\1740 upon\IN\1740 <e2>impaired\JJ\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 in\IN\13603305 rodents\NNS\1886756 .\.\1740
C036466_D008569 NONE Effects\NNS\13245626 of\IN\1740 the\DT\1740 novel\JJ\1740 compound\NN\5869584 <e1>aniracetam</e1>\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 )\-RRB-\1740 upon\IN\1740 <e2>impaired\JJ\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 in\IN\13603305 rodents\NNS\1886756 .\.\1740
C036466_D008569 NONE Effects\NNS\13245626 of\IN\1740 the\DT\1740 novel\JJ\1740 compound\NN\5869584 aniracetam\NN\1740 (\-LRB-\1740 <e1>Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057</e1>\CD\1740 )\-RRB-\1740 upon\IN\1740 <e2>impaired\JJ\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 in\IN\13603305 rodents\NNS\1886756 .\.\1740
C036466_D003072 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>aniracetam</e1>\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 <e2>impaired\JJ\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D003072 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 <e1>Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057</e1>\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 <e2>impaired\JJ\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D003072 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 <e2>impaired\JJ\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D003072 NONE These\DT\1740 improvements\NNS\7359599 or\CC\3541091 normalizations\NNS\1123598 of\IN\1740 <e2>impaired\JJ\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 were\VBD\836236 seen\VBN\2106506 at\IN\14622893 oral\JJ\1740 <e1>aniracetam</e1>\NN\1740 doses\NNS\3740161 of\IN\1740 10\CD\13745420 -\SYM\1740 100\CD\13745420 mg/kg\NN\1740 .\.\1740
C036466_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>aniracetam</e1>\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 <e2>hypercapnia</e2>\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>aniracetam</e1>\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 <e2>hypercapnia</e2>\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 <e1>Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057</e1>\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 <e2>hypercapnia</e2>\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 <e1>Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057</e1>\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 <e2>hypercapnia</e2>\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 <e2>hypercapnia</e2>\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 <e2>hypercapnia</e2>\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>aniracetam</e1>\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>aniracetam</e1>\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 <e1>Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057</e1>\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 <e1>Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057</e1>\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
C036466_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D012601_D003072 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 <e2>impaired\JJ\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D012601_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 <e2>hypercapnia</e2>\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D012601_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 <e2>hypercapnia</e2>\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D012601_D000647 CID The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 short-term\JJ\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D012601_D000647 CID The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D002701_D003072 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 <e2>impaired\JJ\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 <e1>chloramphenicol</e1>\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D002701_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 <e2>hypercapnia</e2>\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 <e1>chloramphenicol</e1>\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D002701_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 <e1>chloramphenicol</e1>\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 <e2>hypercapnia</e2>\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D002701_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 <e1>chloramphenicol</e1>\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D002701_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 <e1>chloramphenicol</e1>\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D003072 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 <e2>impaired\JJ\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 <e1>cycloheximide</e1>\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D003072 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 <e2>impaired\JJ\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 <e1>cycloheximide</e1>\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 <e2>hypercapnia</e2>\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 <e1>cycloheximide</e1>\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 <e1>cycloheximide</e1>\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 <e2>hypercapnia</e2>\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 <e2>hypercapnia</e2>\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 <e1>cycloheximide</e1>\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D006935 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 <e1>cycloheximide</e1>\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 <e2>hypercapnia</e2>\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 <e1>cycloheximide</e1>\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 <e1>cycloheximide</e1>\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 cycloheximide\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 <e1>cycloheximide</e1>\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D003513_D000647 NONE The\DT\1740 effect\NN\34213 of\IN\1740 aniracetam\NN\1740 (\-LRB-\1740 Ro\NN\6894544 13\CD\13745420 -\SYM\1740 5057\CD\1740 ,\,\1740 1-anisoyl-2-pyrrolidinone\JJ\1740 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 on\IN\1740 various\JJ\1740 forms\NNS\6286395 of\IN\1740 experimentally\RB\1740 impaired\JJ\1740 cognitive\JJ\1740 functions\NNS\13783581 (\-LRB-\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 )\-RRB-\1740 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 produced\VBD\1617192 the\DT\1740 following\VBG\1835496 effects\NNS\13245626 :\:\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 almost\RB\1740 complete\VBP\352826 prevention\NN\1073995 of\IN\1740 the\DT\1740 incapacity\NN\5644922 to\TO\1740 learn\VB\607114 a\DT\13649268 discrete\JJ\1740 escape\NN\46177 response\NN\11410625 in\IN\13603305 rats\NNS\2329401 exposed\VBN\2110927 to\TO\1740 sublethal\JJ\1740 hypercapnia\NN\14034177 immediately\RB\1740 before\IN\1740 the\DT\1740 acquisition\NN\41899 session\NN\7142566 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 partial\JJ\1740 (\-LRB-\1740 rats\NNS\2329401 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 mice\NNS\2329401 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 short-term\JJ\1740 amnesia\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 complete\VBP\352826 protection\NN\407535 against\IN\1740 <e2>amnesia</e2>\NN\5669934 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 in\IN\13603305 rats\NNS\2329401 submitted\VBN\1952898 to\TO\1740 electroconvulsive\JJ\1740 shock\NN\7510495 immediately\RB\1740 after\IN\1740 avoidance\NN\203342 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 long-term\JJ\1740 retention-\NN\1740 or\CC\3541091 retrieval-deficit\NN\1740 for\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 and\CC\1740 mice\NNS\2329401 by\IN\1740 chloramphenicol\NN\2716866 or\CC\3541091 cycloheximide\NN\1740 administered\VBN\2436349 immediately\RB\1740 after\IN\1740 acquisition\NN\41899 ;\:\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 reversal\JJ\1740 ,\,\1740 when\WRB\1740 administered\VBN\2436349 as\RB\1740 late\JJ\1740 as\IN\14622893 1\CD\13741022 h\NN\14622893 before\IN\1740 the\DT\1740 retention\NN\809465 test\NN\5798043 ,\,\1740 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 retention\NN\809465 or\CC\3541091 retrieval\NN\13450862 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 by\IN\1740 <e1>cycloheximide</e1>\NN\1740 injected\VBD\81072 2\CD\13741022 days\NNS\15140892 previously\RB\1740 ;\:\1740 (\-LRB-\1740 6\LS\13741022 )\-RRB-\1740 prevention\NN\1073995 of\IN\1740 the\DT\1740 deficit\NN\5113133 in\IN\13603305 the\DT\1740 retrieval\NN\13450862 of\IN\1740 an\DT\6697703 active\JJ\1740 avoidance\NN\203342 task\NN\575741 induced\VBN\1627355 in\IN\13603305 mice\NNS\2329401 by\IN\1740 subconvulsant\JJ\1740 electroshock\NN\662681 or\CC\3541091 hypercapnia\NN\14034177 applied\VBD\2676054 immediately\RB\1740 before\IN\1740 retrieval\NN\13450862 testing\NN\639556 (\-LRB-\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
8742498
D009243_D056486 NONE Influence\NN\5190804 of\IN\1740 diet\JJ\1740 free\JJ\1740 of\IN\1740 <e1>NAD-precursors</e1>\NNS\1740 on\IN\1740 acetaminophen\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009243_D056486 NONE The\DT\1740 present\JJ\1740 study\NN\635850 investigates\VBZ\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 diet\NN\7560652 free\JJ\1740 of\IN\1740 precursors\NNS\14580897 of\IN\1740 <e1>NAD</e1>\NN\14800277 ,\,\1740 the\DT\1740 substrate\NN\19613 on\IN\1740 which\WDT\1740 PARP\NN\1740 acts\VBZ\1619354 ,\,\1740 in\IN\13603305 female\JJ\1740 NMRI\NN\1740 mice\NNS\2329401 with\IN\1740 AAP\NN\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 evaluates\VBZ\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 simultaneous\JJ\1740 ethanol\NN\14708720 consumption\NN\13440063 in\IN\13603305 these\DT\1740 animals\NNS\4475 .\.\1740
D009243_D056486 NONE Our\PRP$\1740 results\NNS\34213 provide\VBP\2199590 evidence\NN\5816287 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 its\PRP$\6125041 exacerbation\NN\374224 by\IN\1740 ethanol\NN\14708720 can\MD\3094503 either\RB\1740 be\VB\836236 reduced\VBN\441445 by\IN\1740 end-product\JJ\1740 inhibition\NN\1068773 of\IN\1740 PARP\NN\1740 by\IN\1740 NAA\NN\1740 or\CC\3541091 by\IN\1740 dietary\JJ\1740 depletion\NN\351638 of\IN\1740 the\DT\1740 enzyme\NN\14723628 's\POS\1740 substrate\JJ\1740 <e1>NAD</e1>\NN\14800277 .\.\1740
D000082_D056486 CID Influence\NN\5190804 of\IN\1740 diet\JJ\1740 free\JJ\1740 of\IN\1740 NAD-precursors\NNS\1740 on\IN\1740 <e1>acetaminophen</e1>\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000082_D056486 CID Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 nicotinic\JJ\1740 acid\NN\14818238 amide\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 poly(ADP-ribose\NN\1740 )\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 <e1>acetaminophen</e1>\JJ\1740 <e2>(AAP)-hepatitis</e2>\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 liver\NN\5298729 injury\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D000082_D056486 CID Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 nicotinic\JJ\1740 acid\NN\14818238 amide\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 poly(ADP-ribose\NN\1740 )\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 <e1>acetaminophen</e1>\JJ\1740 (AAP)-hepatitis\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D000082_D056486 CID Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 nicotinic\JJ\1740 acid\NN\14818238 amide\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 poly(ADP-ribose\NN\1740 )\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 acetaminophen\JJ\1740 <e2><e1>(AAP)-hepatitis</e1></e2>\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 liver\NN\5298729 injury\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D000082_D056486 CID Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 nicotinic\JJ\1740 acid\NN\14818238 amide\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 poly(ADP-ribose\NN\1740 )\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 acetaminophen\JJ\1740 <e1>(AAP)-hepatitis</e1>\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D000082_D056486 CID Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 nicotinic\JJ\1740 acid\NN\14818238 amide\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 poly(ADP-ribose\NN\1740 )\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 acetaminophen\JJ\1740 <e2>(AAP)-hepatitis</e2>\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 <e1>AAP-induced</e1>\JJ\1740 liver\NN\5298729 injury\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D000082_D056486 CID Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 nicotinic\JJ\1740 acid\NN\14818238 amide\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 poly(ADP-ribose\NN\1740 )\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 acetaminophen\JJ\1740 (AAP)-hepatitis\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 <e1>AAP-induced</e1>\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D000082_D056486 CID The\DT\1740 present\JJ\1740 study\NN\635850 investigates\VBZ\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 diet\NN\7560652 free\JJ\1740 of\IN\1740 precursors\NNS\14580897 of\IN\1740 NAD\NN\14800277 ,\,\1740 the\DT\1740 substrate\NN\19613 on\IN\1740 which\WDT\1740 PARP\NN\1740 acts\VBZ\1619354 ,\,\1740 in\IN\13603305 female\JJ\1740 NMRI\NN\1740 mice\NNS\2329401 with\IN\1740 <e1>AAP</e1>\NN\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 evaluates\VBZ\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 simultaneous\JJ\1740 ethanol\NN\14708720 consumption\NN\13440063 in\IN\13603305 these\DT\1740 animals\NNS\4475 .\.\1740
D000082_D056486 CID In\IN\13603305 these\DT\1740 animals\NNS\4475 ,\,\1740 only\RB\1740 minor\JJ\1740 increases\NNS\13576355 of\IN\1740 serum\NN\5397468 transaminase\NN\15077571 activities\NNS\30358 were\VBD\836236 measured\VBN\697589 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 <e1>AAP</e1>\NNS\1740 ,\,\1740 and\CC\1740 unlike\IN\1740 the\DT\1740 exacerbation\NN\374224 caused\VBN\1617192 by\IN\1740 ethanol\NN\14708720 in\IN\13603305 mice\NNS\2329401 on\IN\1740 a\DT\13649268 standard\JJ\1740 diet\NN\7560652 ,\,\1740 the\DT\1740 <e2>liver\NN\5298729 damage</e2>\NN\7296428 was\VBD\836236 inhibited\VBN\2510337 by\IN\1740 50\CD\13745420 %\NN\1740 by\IN\1740 ethanol\NN\14708720 .\.\1740
D000082_D056486 CID A\DT\13649268 further\JJ\1740 64\CD\1740 %\NN\1740 reduction\NN\351485 of\IN\1740 <e2>hepatitis</e2>\NN\14127211 was\VBD\836236 observed\VBN\2163746 ,\,\1740 when\WRB\1740 NAA\NNP\1740 was\VBD\836236 given\VBN\2327200 to\IN\1740 <e1>ethanol/AAP-mice</e1>\NN\1740 .\.\1740
D000082_D056486 CID Our\PRP$\1740 results\NNS\34213 provide\VBP\2199590 evidence\NN\5816287 that\IN\1740 the\DT\1740 <e1>AAP-induced</e1>\JJ\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 its\PRP$\6125041 exacerbation\NN\374224 by\IN\1740 ethanol\NN\14708720 can\MD\3094503 either\RB\1740 be\VB\836236 reduced\VBN\441445 by\IN\1740 end-product\JJ\1740 inhibition\NN\1068773 of\IN\1740 PARP\NN\1740 by\IN\1740 NAA\NN\1740 or\CC\3541091 by\IN\1740 dietary\JJ\1740 depletion\NN\351638 of\IN\1740 the\DT\1740 enzyme\NN\14723628 's\POS\1740 substrate\JJ\1740 NAD\NN\14800277 .\.\1740
D000082_D056486 CID We\PRP\1740 see\VBP\2106506 the\DT\1740 main\JJ\1740 application\NN\947128 of\IN\1740 NAA\NNP\1740 as\IN\14622893 for\IN\1740 the\DT\1740 combinational\JJ\1740 use\NN\407535 in\IN\13603305 pharmaceutical\JJ\1740 preparations\NNS\407535 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 in\IN\13603305 order\NN\7168131 to\TO\1740 avoid\VB\2452885 <e2>hepatic\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 this\DT\1740 widely\RB\1740 used\VBD\1156834 analgesic\NN\3740161 .\.\1740
D009536_D056486 NONE Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>nicotinic\JJ\1740 acid\NN\14818238 amide</e1>\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 poly(ADP-ribose\NN\1740 )\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 acetaminophen\JJ\1740 <e2>(AAP)-hepatitis</e2>\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 liver\NN\5298729 injury\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D009536_D056486 NONE Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>nicotinic\JJ\1740 acid\NN\14818238 amide</e1>\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 poly(ADP-ribose\NN\1740 )\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 acetaminophen\JJ\1740 (AAP)-hepatitis\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D009536_D056486 NONE A\DT\13649268 further\JJ\1740 64\CD\1740 %\NN\1740 reduction\NN\351485 of\IN\1740 <e2>hepatitis</e2>\NN\14127211 was\VBD\836236 observed\VBN\2163746 ,\,\1740 when\WRB\1740 <e1>NAA</e1>\NNP\1740 was\VBD\836236 given\VBN\2327200 to\IN\1740 ethanol/AAP-mice\NN\1740 .\.\1740
D009536_D056486 NONE Our\PRP$\1740 results\NNS\34213 provide\VBP\2199590 evidence\NN\5816287 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 its\PRP$\6125041 exacerbation\NN\374224 by\IN\1740 ethanol\NN\14708720 can\MD\3094503 either\RB\1740 be\VB\836236 reduced\VBN\441445 by\IN\1740 end-product\JJ\1740 inhibition\NN\1068773 of\IN\1740 PARP\NN\1740 by\IN\1740 <e1>NAA</e1>\NN\1740 or\CC\3541091 by\IN\1740 dietary\JJ\1740 depletion\NN\351638 of\IN\1740 the\DT\1740 enzyme\NN\14723628 's\POS\1740 substrate\JJ\1740 NAD\NN\14800277 .\.\1740
D009536_D056486 NONE We\PRP\1740 see\VBP\2106506 the\DT\1740 main\JJ\1740 application\NN\947128 of\IN\1740 <e1>NAA</e1>\NNP\1740 as\IN\14622893 for\IN\1740 the\DT\1740 combinational\JJ\1740 use\NN\407535 in\IN\13603305 pharmaceutical\JJ\1740 preparations\NNS\407535 of\IN\1740 acetaminophen\NN\2707683 in\IN\13603305 order\NN\7168131 to\TO\1740 avoid\VB\2452885 <e2>hepatic\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 this\DT\1740 widely\RB\1740 used\VBD\1156834 analgesic\NN\3740161 .\.\1740
D011064_D056486 NONE Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 nicotinic\JJ\1740 acid\NN\14818238 amide\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 <e1>poly(ADP-ribose\NN\1740 )</e1>\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 acetaminophen\JJ\1740 <e2>(AAP)-hepatitis</e2>\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 liver\NN\5298729 injury\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D011064_D056486 NONE Recently\RB\1740 ,\,\1740 we\PRP\1740 demonstrated\VBD\2137132 the\DT\1740 hepatoprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 nicotinic\JJ\1740 acid\NN\14818238 amide\NN\14727670 ,\,\1740 a\DT\13649268 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 <e1>poly(ADP-ribose\NN\1740 )</e1>\-RRB-\1740 polymerase\NN\14732946 (\-LRB-\1740 PARP\NN\1740 ;\:\1740 EC\NN\8294696 2.4.2.30\NN\1740 )\-RRB-\1740 on\IN\1740 mice\NNS\2329401 suffering\VBG\2110220 from\IN\1740 acetaminophen\JJ\1740 (AAP)-hepatitis\NN\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 involves\VBZ\2676054 a\DT\13649268 step\NN\168237 which\WDT\1740 depends\VBZ\2604760 on\IN\1740 adenoribosylation\NN\1740 .\.\1740
D000431_D056486 CID The\DT\1740 present\JJ\1740 study\NN\635850 investigates\VBZ\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 diet\NN\7560652 free\JJ\1740 of\IN\1740 precursors\NNS\14580897 of\IN\1740 NAD\NN\14800277 ,\,\1740 the\DT\1740 substrate\NN\19613 on\IN\1740 which\WDT\1740 PARP\NN\1740 acts\VBZ\1619354 ,\,\1740 in\IN\13603305 female\JJ\1740 NMRI\NN\1740 mice\NNS\2329401 with\IN\1740 AAP\NN\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 evaluates\VBZ\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 simultaneous\JJ\1740 <e1>ethanol</e1>\NN\14708720 consumption\NN\13440063 in\IN\13603305 these\DT\1740 animals\NNS\4475 .\.\1740
D000431_D056486 CID In\IN\13603305 these\DT\1740 animals\NNS\4475 ,\,\1740 only\RB\1740 minor\JJ\1740 increases\NNS\13576355 of\IN\1740 serum\NN\5397468 transaminase\NN\15077571 activities\NNS\30358 were\VBD\836236 measured\VBN\697589 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 AAP\NNS\1740 ,\,\1740 and\CC\1740 unlike\IN\1740 the\DT\1740 exacerbation\NN\374224 caused\VBN\1617192 by\IN\1740 <e1>ethanol</e1>\NN\14708720 in\IN\13603305 mice\NNS\2329401 on\IN\1740 a\DT\13649268 standard\JJ\1740 diet\NN\7560652 ,\,\1740 the\DT\1740 <e2>liver\NN\5298729 damage</e2>\NN\7296428 was\VBD\836236 inhibited\VBN\2510337 by\IN\1740 50\CD\13745420 %\NN\1740 by\IN\1740 ethanol\NN\14708720 .\.\1740
D000431_D056486 CID In\IN\13603305 these\DT\1740 animals\NNS\4475 ,\,\1740 only\RB\1740 minor\JJ\1740 increases\NNS\13576355 of\IN\1740 serum\NN\5397468 transaminase\NN\15077571 activities\NNS\30358 were\VBD\836236 measured\VBN\697589 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 AAP\NNS\1740 ,\,\1740 and\CC\1740 unlike\IN\1740 the\DT\1740 exacerbation\NN\374224 caused\VBN\1617192 by\IN\1740 ethanol\NN\14708720 in\IN\13603305 mice\NNS\2329401 on\IN\1740 a\DT\13649268 standard\JJ\1740 diet\NN\7560652 ,\,\1740 the\DT\1740 <e2>liver\NN\5298729 damage</e2>\NN\7296428 was\VBD\836236 inhibited\VBN\2510337 by\IN\1740 50\CD\13745420 %\NN\1740 by\IN\1740 <e1>ethanol</e1>\NN\14708720 .\.\1740
D000431_D056486 CID A\DT\13649268 further\JJ\1740 64\CD\1740 %\NN\1740 reduction\NN\351485 of\IN\1740 <e2>hepatitis</e2>\NN\14127211 was\VBD\836236 observed\VBN\2163746 ,\,\1740 when\WRB\1740 NAA\NNP\1740 was\VBD\836236 given\VBN\2327200 to\IN\1740 <e1>ethanol/AAP-mice</e1>\NN\1740 .\.\1740
D000431_D056486 CID Our\PRP$\1740 results\NNS\34213 provide\VBP\2199590 evidence\NN\5816287 that\IN\1740 the\DT\1740 AAP-induced\JJ\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 its\PRP$\6125041 exacerbation\NN\374224 by\IN\1740 <e1>ethanol</e1>\NN\14708720 can\MD\3094503 either\RB\1740 be\VB\836236 reduced\VBN\441445 by\IN\1740 end-product\JJ\1740 inhibition\NN\1068773 of\IN\1740 PARP\NN\1740 by\IN\1740 NAA\NN\1740 or\CC\3541091 by\IN\1740 dietary\JJ\1740 depletion\NN\351638 of\IN\1740 the\DT\1740 enzyme\NN\14723628 's\POS\1740 substrate\JJ\1740 NAD\NN\14800277 .\.\1740
D018698_D056486 NONE <e2>Liver\NN\5298729 injuries</e2>\NNS\14052046 were\VBD\836236 quantified\VBN\947077 as\IN\14622893 serum\NN\5397468 activities\NNS\30358 of\IN\1740 <e1>glutamate-oxaloacetate</e1>\JJ\1740 transaminase\NN\15077571 (\-LRB-\1740 GOT\NN\1740 )\-RRB-\1740 and\CC\1740 glutamate-pyruvate\JJ\1740 transaminase\NN\15077571 (\-LRB-\1740 GPT\NN\1740 )\-RRB-\1740 .\.\1740
D018698_D056486 NONE <e2>Liver\NN\5298729 injuries</e2>\NNS\14052046 were\VBD\836236 quantified\VBN\947077 as\IN\14622893 serum\NN\5397468 activities\NNS\30358 of\IN\1740 glutamate-oxaloacetate\JJ\1740 transaminase\NN\15077571 (\-LRB-\1740 GOT\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>glutamate-pyruvate</e1>\JJ\1740 transaminase\NN\15077571 (\-LRB-\1740 GPT\NN\1740 )\-RRB-\1740 .\.\1740
D062907_D056486 NONE <e2>Liver\NN\5298729 injuries</e2>\NNS\14052046 were\VBD\836236 quantified\VBN\947077 as\IN\14622893 serum\NN\5397468 activities\NNS\30358 of\IN\1740 <e1>glutamate-oxaloacetate</e1>\JJ\1740 transaminase\NN\15077571 (\-LRB-\1740 GOT\NN\1740 )\-RRB-\1740 and\CC\1740 glutamate-pyruvate\JJ\1740 transaminase\NN\15077571 (\-LRB-\1740 GPT\NN\1740 )\-RRB-\1740 .\.\1740
D019289_D056486 NONE <e2>Liver\NN\5298729 injuries</e2>\NNS\14052046 were\VBD\836236 quantified\VBN\947077 as\IN\14622893 serum\NN\5397468 activities\NNS\30358 of\IN\1740 glutamate-oxaloacetate\JJ\1740 transaminase\NN\15077571 (\-LRB-\1740 GOT\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>glutamate-pyruvate</e1>\JJ\1740 transaminase\NN\15077571 (\-LRB-\1740 GPT\NN\1740 )\-RRB-\1740 .\.\1740
1415380
D011803_D006463 CID <e2>Hemolytic-uremic\JJ\1740 syndrome</e2>\NN\5870365 associated\VBN\628491 with\IN\1740 ingestion\NN\13440063 of\IN\1740 <e1>quinine</e1>\NN\2721948 .\.\1740
D011803_D006463 CID <e2>Hemolytic-uremic\JJ\1740 syndrome</e2>\NN\5870365 following\VBG\1835496 <e1>quinine</e1>\NN\2721948 ingestion\NN\13440063 is\VBZ\836236 a\DT\13649268 newly\RB\1740 described\VBN\1001294 phenomenon\NN\29677 ,\,\1740 with\IN\1740 just\RB\1740 two\CD\13741022 previous\JJ\1740 descriptions\NNS\6722453 of\IN\1740 4\CD\13741022 cases\NNS\7283608 in\IN\13603305 the\DT\1740 literature\NN\6362953 .\.\1740
D011803_D006463 CID <e1>Quinine-associated</e1>\JJ\1740 <e2>hemolytic-uremic\JJ\1740 syndrome</e2>\NN\5870365 probably\RB\1740 occurs\VBZ\2623529 more\RBR\1740 often\RB\1740 than\IN\1740 is\VBZ\836236 recognized\VBN\686447 .\.\1740
8480959
D008148_D006937 NONE Efficacy\NNP\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 <e1>lovastatin</e1>\NN\3676175 in\IN\13603305 3390\CD\1740 women\NNS\9605289 with\IN\1740 moderate\JJ\1740 <e2>hypercholesterolemia</e2>\NN\14299637 .\.\1740
D008148_D006937 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>lovastatin</e1>\NN\3676175 in\IN\13603305 women\NNS\9605289 with\IN\1740 moderate\JJ\1740 <e2>hypercholesterolemia</e2>\NN\14299637 .\.\1740
D008148_D006937 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Lovastatin</e1>\NNP\3676175 is\VBZ\836236 highly\RB\1740 effective\JJ\1740 and\CC\1740 generally\RB\1740 well\RB\1740 tolerated\VBN\802318 as\IN\14622893 therapy\NN\657604 for\IN\1740 primary\JJ\1740 <e2>hypercholesterolemia</e2>\NN\14299637 in\IN\13603305 women\NNS\9605289 .\.\1740
D003401_D009135 NONE <e2>Myopathy</e2>\NNP\14204950 ,\,\1740 defined\VBN\2604760 as\IN\14622893 muscle\NN\5289601 symptoms\NNS\5823932 with\IN\1740 <e1>creatine</e1>\NN\14601829 kinase\NN\14732946 elevations\NNS\7445480 greater\JJR\1740 than\IN\1740 10\CD\13745420 times\NNS\15113229 the\DT\1740 upper\JJ\1740 limit\NN\5123416 of\IN\1740 normal\JJ\1740 ,\,\1740 was\VBD\836236 rare\JJ\1740 and\CC\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 highest\JJS\1740 recommended\VBN\875394 daily\JJ\1740 dose\NN\3740161 of\IN\1740 lovastatin\NN\3676175 (\-LRB-\1740 80\CD\13745420 mg\NN\13717155 )\-RRB-\1740 .\.\1740
D008148_D009135 CID <e2>Myopathy</e2>\NNP\14204950 ,\,\1740 defined\VBN\2604760 as\IN\14622893 muscle\NN\5289601 symptoms\NNS\5823932 with\IN\1740 creatine\NN\14601829 kinase\NN\14732946 elevations\NNS\7445480 greater\JJR\1740 than\IN\1740 10\CD\13745420 times\NNS\15113229 the\DT\1740 upper\JJ\1740 limit\NN\5123416 of\IN\1740 normal\JJ\1740 ,\,\1740 was\VBD\836236 rare\JJ\1740 and\CC\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 highest\JJS\1740 recommended\VBN\875394 daily\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>lovastatin</e1>\NN\3676175 (\-LRB-\1740 80\CD\13745420 mg\NN\13717155 )\-RRB-\1740 .\.\1740
17965424
C422649_D001172 NONE Gastrointestinal\JJ\1740 tolerability\NN\1740 of\IN\1740 <e1>etoricoxib</e1>\NN\1740 in\IN\13603305 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 patients\NNS\9898892 :\:\1740 results\NNS\34213 of\IN\1740 the\DT\1740 etoricoxib\NN\1740 vs\RB\1740 diclofenac\VB\1740 sodium\NN\14625458 gastrointestinal\NN\1740 tolerability\NN\1740 and\CC\1740 effectiveness\NN\5190804 trial\NN\786195 (\-LRB-\1740 EDGE-II\NN\1740 )\-RRB-\1740 .\.\1740
C422649_D001172 NONE Gastrointestinal\JJ\1740 tolerability\NN\1740 of\IN\1740 etoricoxib\NN\1740 in\IN\13603305 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 patients\NNS\9898892 :\:\1740 results\NNS\34213 of\IN\1740 the\DT\1740 <e1>etoricoxib</e1>\NN\1740 vs\RB\1740 diclofenac\VB\1740 sodium\NN\14625458 gastrointestinal\NN\1740 tolerability\NN\1740 and\CC\1740 effectiveness\NN\5190804 trial\NN\786195 (\-LRB-\1740 EDGE-II\NN\1740 )\-RRB-\1740 .\.\1740
C422649_D001172 NONE OBJECTIVE\NN\5980875 :\:\1740 A\DT\13649268 randomised\VBN\278117 ,\,\1740 double-blind\NN\1740 study\NN\635850 to\TO\1740 compare\VB\644583 the\DT\1740 gastrointestinal\NN\1740 (\-LRB-\1740 GI\NN\13634615 )\-RRB-\1740 tolerability\NN\1740 ,\,\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 <e1>etoricoxib</e1>\NN\1740 and\CC\1740 diclofenac\VB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 (\-LRB-\1740 RA\NN\14625458 )\-RRB-\1740 .\.\1740
C422649_D001172 NONE OBJECTIVE\NN\5980875 :\:\1740 A\DT\13649268 randomised\VBN\278117 ,\,\1740 double-blind\NN\1740 study\NN\635850 to\TO\1740 compare\VB\644583 the\DT\1740 gastrointestinal\NN\1740 (\-LRB-\1740 GI\NN\13634615 )\-RRB-\1740 tolerability\NN\1740 ,\,\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 <e1>etoricoxib</e1>\NN\1740 and\CC\1740 diclofenac\VB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 (\-LRB-\1740 <e2>RA</e2>\NN\14625458 )\-RRB-\1740 .\.\1740
C422649_D001172 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 A\DT\13649268 total\NN\3553 of\IN\1740 4086\CD\1740 patients\NNS\9898892 (\-LRB-\1740 mean\NN\6021761 age\NN\4916342 60.8\CD\1740 years\NNS\15144371 )\-RRB-\1740 diagnosed\VBN\644583 with\IN\1740 <e2>RA</e2>\NN\14625458 were\VBD\836236 enrolled\VBN\2471690 and\CC\1740 received\VBN\2210855 <e1>etoricoxib</e1>\NN\1740 90\CD\13745420 mg\NN\13717155 daily\RB\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2032\CD\1740 )\-RRB-\1740 or\CC\3541091 diclofenac\JJ\1740 75\CD\1740 mg\NN\13717155 twice\RB\1740 daily\RB\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2054\CD\1740 )\-RRB-\1740 .\.\1740
D004008_D001172 NONE Gastrointestinal\JJ\1740 tolerability\NN\1740 of\IN\1740 etoricoxib\NN\1740 in\IN\13603305 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 patients\NNS\9898892 :\:\1740 results\NNS\34213 of\IN\1740 the\DT\1740 etoricoxib\NN\1740 vs\RB\1740 <e1>diclofenac\VB\1740 sodium</e1>\NN\14625458 gastrointestinal\NN\1740 tolerability\NN\1740 and\CC\1740 effectiveness\NN\5190804 trial\NN\786195 (\-LRB-\1740 EDGE-II\NN\1740 )\-RRB-\1740 .\.\1740
D004008_D001172 NONE OBJECTIVE\NN\5980875 :\:\1740 A\DT\13649268 randomised\VBN\278117 ,\,\1740 double-blind\NN\1740 study\NN\635850 to\TO\1740 compare\VB\644583 the\DT\1740 gastrointestinal\NN\1740 (\-LRB-\1740 GI\NN\13634615 )\-RRB-\1740 tolerability\NN\1740 ,\,\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 etoricoxib\NN\1740 and\CC\1740 <e1>diclofenac</e1>\VB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 (\-LRB-\1740 RA\NN\14625458 )\-RRB-\1740 .\.\1740
D004008_D001172 NONE OBJECTIVE\NN\5980875 :\:\1740 A\DT\13649268 randomised\VBN\278117 ,\,\1740 double-blind\NN\1740 study\NN\635850 to\TO\1740 compare\VB\644583 the\DT\1740 gastrointestinal\NN\1740 (\-LRB-\1740 GI\NN\13634615 )\-RRB-\1740 tolerability\NN\1740 ,\,\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 etoricoxib\NN\1740 and\CC\1740 <e1>diclofenac</e1>\VB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 (\-LRB-\1740 <e2>RA</e2>\NN\14625458 )\-RRB-\1740 .\.\1740
D004008_D001172 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 A\DT\13649268 total\NN\3553 of\IN\1740 4086\CD\1740 patients\NNS\9898892 (\-LRB-\1740 mean\NN\6021761 age\NN\4916342 60.8\CD\1740 years\NNS\15144371 )\-RRB-\1740 diagnosed\VBN\644583 with\IN\1740 <e2>RA</e2>\NN\14625458 were\VBD\836236 enrolled\VBN\2471690 and\CC\1740 received\VBN\2210855 etoricoxib\NN\1740 90\CD\13745420 mg\NN\13717155 daily\RB\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2032\CD\1740 )\-RRB-\1740 or\CC\3541091 <e1>diclofenac</e1>\JJ\1740 75\CD\1740 mg\NN\13717155 twice\RB\1740 daily\RB\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2054\CD\1740 )\-RRB-\1740 .\.\1740
C422649_D005767 NONE The\DT\1740 cumulative\JJ\1740 discontinuation\NN\209943 rate\NN\13815152 due\IN\5174653 to\TO\1740 <e2>GI\NN\13634615 AEs</e2>\NNS\1740 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 with\IN\1740 <e1>etoricoxib</e1>\NN\1740 than\IN\1740 diclofenac\JJ\1740 (\-LRB-\1740 5.2\CD\1740 vs\CC\13634784 8.5\CD\1740 events\NNS\23100 per\IN\1740 100\CD\13745420 patient-years\NNS\1740 ,\,\1740 respectively\RB\1740 ;\:\1740 hazard\NN\14541044 ratio\NN\13815152 0.62\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 :\:\1740 0.47\CD\1740 ,\,\1740 0.81\CD\1740 ;\:\1740 p\NN\14622893 <\XX\1740 or=0.001\NN\1740 )\-RRB-\1740 )\-RRB-\1740 .\.\1740
C422649_D005767 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Etoricoxib</e1>\NN\1740 90\CD\13745420 mg\NN\13717155 demonstrated\VBD\2137132 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 risk\NN\14541044 for\IN\1740 discontinuing\VBG\2609764 treatment\NN\654885 due\JJ\1740 to\TO\1740 <e2>GI\NN\13634615 AEs</e2>\NNS\1740 compared\VBN\644583 with\IN\1740 diclofenac\JJ\1740 150\CD\1740 mg.\NN\1740 Discontinuations\NNS\209943 from\IN\1740 renovascular\JJ\1740 AEs\NNS\1740 ,\,\1740 although\IN\1740 less\RBR\1740 common\JJ\1740 than\IN\1740 discontinuations\NNS\209943 from\IN\1740 GI\NN\13634615 AEs\NNS\1740 ,\,\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 etoricoxib\NN\1740 .\.\1740
C422649_D005767 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Etoricoxib</e1>\NN\1740 90\CD\13745420 mg\NN\13717155 demonstrated\VBD\2137132 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 risk\NN\14541044 for\IN\1740 discontinuing\VBG\2609764 treatment\NN\654885 due\JJ\1740 to\TO\1740 GI\NN\13634615 AEs\NNS\1740 compared\VBN\644583 with\IN\1740 diclofenac\JJ\1740 150\CD\1740 mg.\NN\1740 Discontinuations\NNS\209943 from\IN\1740 renovascular\JJ\1740 AEs\NNS\1740 ,\,\1740 although\IN\1740 less\RBR\1740 common\JJ\1740 than\IN\1740 discontinuations\NNS\209943 from\IN\1740 <e2>GI\NN\13634615 AEs</e2>\NNS\1740 ,\,\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 etoricoxib\NN\1740 .\.\1740
C422649_D005767 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Etoricoxib\NN\1740 90\CD\13745420 mg\NN\13717155 demonstrated\VBD\2137132 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 risk\NN\14541044 for\IN\1740 discontinuing\VBG\2609764 treatment\NN\654885 due\JJ\1740 to\TO\1740 <e2>GI\NN\13634615 AEs</e2>\NNS\1740 compared\VBN\644583 with\IN\1740 diclofenac\JJ\1740 150\CD\1740 mg.\NN\1740 Discontinuations\NNS\209943 from\IN\1740 renovascular\JJ\1740 AEs\NNS\1740 ,\,\1740 although\IN\1740 less\RBR\1740 common\JJ\1740 than\IN\1740 discontinuations\NNS\209943 from\IN\1740 GI\NN\13634615 AEs\NNS\1740 ,\,\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 <e1>etoricoxib</e1>\NN\1740 .\.\1740
C422649_D005767 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Etoricoxib\NN\1740 90\CD\13745420 mg\NN\13717155 demonstrated\VBD\2137132 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 risk\NN\14541044 for\IN\1740 discontinuing\VBG\2609764 treatment\NN\654885 due\JJ\1740 to\TO\1740 GI\NN\13634615 AEs\NNS\1740 compared\VBN\644583 with\IN\1740 diclofenac\JJ\1740 150\CD\1740 mg.\NN\1740 Discontinuations\NNS\209943 from\IN\1740 renovascular\JJ\1740 AEs\NNS\1740 ,\,\1740 although\IN\1740 less\RBR\1740 common\JJ\1740 than\IN\1740 discontinuations\NNS\209943 from\IN\1740 <e2>GI\NN\13634615 AEs</e2>\NNS\1740 ,\,\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 <e1>etoricoxib</e1>\NN\1740 .\.\1740
D004008_D005767 CID The\DT\1740 cumulative\JJ\1740 discontinuation\NN\209943 rate\NN\13815152 due\IN\5174653 to\TO\1740 <e2>GI\NN\13634615 AEs</e2>\NNS\1740 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 with\IN\1740 etoricoxib\NN\1740 than\IN\1740 <e1>diclofenac</e1>\JJ\1740 (\-LRB-\1740 5.2\CD\1740 vs\CC\13634784 8.5\CD\1740 events\NNS\23100 per\IN\1740 100\CD\13745420 patient-years\NNS\1740 ,\,\1740 respectively\RB\1740 ;\:\1740 hazard\NN\14541044 ratio\NN\13815152 0.62\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 :\:\1740 0.47\CD\1740 ,\,\1740 0.81\CD\1740 ;\:\1740 p\NN\14622893 <\XX\1740 or=0.001\NN\1740 )\-RRB-\1740 )\-RRB-\1740 .\.\1740
D004008_D005767 CID CONCLUSIONS\NNS\5837957 :\:\1740 Etoricoxib\NN\1740 90\CD\13745420 mg\NN\13717155 demonstrated\VBD\2137132 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 risk\NN\14541044 for\IN\1740 discontinuing\VBG\2609764 treatment\NN\654885 due\JJ\1740 to\TO\1740 <e2>GI\NN\13634615 AEs</e2>\NNS\1740 compared\VBN\644583 with\IN\1740 <e1>diclofenac</e1>\JJ\1740 150\CD\1740 mg.\NN\1740 Discontinuations\NNS\209943 from\IN\1740 renovascular\JJ\1740 AEs\NNS\1740 ,\,\1740 although\IN\1740 less\RBR\1740 common\JJ\1740 than\IN\1740 discontinuations\NNS\209943 from\IN\1740 GI\NN\13634615 AEs\NNS\1740 ,\,\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 etoricoxib\NN\1740 .\.\1740
D004008_D005767 CID CONCLUSIONS\NNS\5837957 :\:\1740 Etoricoxib\NN\1740 90\CD\13745420 mg\NN\13717155 demonstrated\VBD\2137132 a\DT\13649268 significantly\RB\1740 lower\JJR\1740 risk\NN\14541044 for\IN\1740 discontinuing\VBG\2609764 treatment\NN\654885 due\JJ\1740 to\TO\1740 GI\NN\13634615 AEs\NNS\1740 compared\VBN\644583 with\IN\1740 <e1>diclofenac</e1>\JJ\1740 150\CD\1740 mg.\NN\1740 Discontinuations\NNS\209943 from\IN\1740 renovascular\JJ\1740 AEs\NNS\1740 ,\,\1740 although\IN\1740 less\RBR\1740 common\JJ\1740 than\IN\1740 discontinuations\NNS\209943 from\IN\1740 <e2>GI\NN\13634615 AEs</e2>\NNS\1740 ,\,\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 etoricoxib\NN\1740 .\.\1740
C422649_D006973 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 discontinuations\NNS\209943 for\IN\1740 <e2>hypertension-related</e2>\JJ\1740 and\CC\1740 oedema-related\JJ\1740 AEs\NNS\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 <e1>etoricoxib</e1>\NN\1740 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 and\CC\1740 1.1\CD\1740 %\NN\1740 respectively\RB\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 diclofenac\NN\1740 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 and\CC\1740 0.4\CD\1740 %\NN\1740 respectively\RB\1740 ;\:\1740 p<0.001\NN\1740 for\IN\1740 hypertension\NN\14057371 and\CC\1740 p<0.01\NN\1740 for\IN\1740 oedema\NN\14315192 )\-RRB-\1740 .\.\1740
C422649_D006973 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 discontinuations\NNS\209943 for\IN\1740 hypertension-related\JJ\1740 and\CC\1740 oedema-related\JJ\1740 AEs\NNS\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 <e1>etoricoxib</e1>\NN\1740 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 and\CC\1740 1.1\CD\1740 %\NN\1740 respectively\RB\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 diclofenac\NN\1740 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 and\CC\1740 0.4\CD\1740 %\NN\1740 respectively\RB\1740 ;\:\1740 p<0.001\NN\1740 for\IN\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 p<0.01\NN\1740 for\IN\1740 oedema\NN\14315192 )\-RRB-\1740 .\.\1740
C422649_D004487 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 discontinuations\NNS\209943 for\IN\1740 hypertension-related\JJ\1740 and\CC\1740 <e2>oedema-related</e2>\JJ\1740 AEs\NNS\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 <e1>etoricoxib</e1>\NN\1740 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 and\CC\1740 1.1\CD\1740 %\NN\1740 respectively\RB\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 diclofenac\NN\1740 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 and\CC\1740 0.4\CD\1740 %\NN\1740 respectively\RB\1740 ;\:\1740 p<0.001\NN\1740 for\IN\1740 hypertension\NN\14057371 and\CC\1740 p<0.01\NN\1740 for\IN\1740 oedema\NN\14315192 )\-RRB-\1740 .\.\1740
C422649_D004487 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 discontinuations\NNS\209943 for\IN\1740 hypertension-related\JJ\1740 and\CC\1740 oedema-related\JJ\1740 AEs\NNS\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 <e1>etoricoxib</e1>\NN\1740 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 and\CC\1740 1.1\CD\1740 %\NN\1740 respectively\RB\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 diclofenac\NN\1740 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 and\CC\1740 0.4\CD\1740 %\NN\1740 respectively\RB\1740 ;\:\1740 p<0.001\NN\1740 for\IN\1740 hypertension\NN\14057371 and\CC\1740 p<0.01\NN\1740 for\IN\1740 <e2>oedema</e2>\NN\14315192 )\-RRB-\1740 .\.\1740
D004008_D006973 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 discontinuations\NNS\209943 for\IN\1740 <e2>hypertension-related</e2>\JJ\1740 and\CC\1740 oedema-related\JJ\1740 AEs\NNS\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 etoricoxib\NN\1740 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 and\CC\1740 1.1\CD\1740 %\NN\1740 respectively\RB\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 <e1>diclofenac</e1>\NN\1740 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 and\CC\1740 0.4\CD\1740 %\NN\1740 respectively\RB\1740 ;\:\1740 p<0.001\NN\1740 for\IN\1740 hypertension\NN\14057371 and\CC\1740 p<0.01\NN\1740 for\IN\1740 oedema\NN\14315192 )\-RRB-\1740 .\.\1740
D004008_D006973 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 discontinuations\NNS\209943 for\IN\1740 hypertension-related\JJ\1740 and\CC\1740 oedema-related\JJ\1740 AEs\NNS\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 etoricoxib\NN\1740 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 and\CC\1740 1.1\CD\1740 %\NN\1740 respectively\RB\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 <e1>diclofenac</e1>\NN\1740 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 and\CC\1740 0.4\CD\1740 %\NN\1740 respectively\RB\1740 ;\:\1740 p<0.001\NN\1740 for\IN\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 p<0.01\NN\1740 for\IN\1740 oedema\NN\14315192 )\-RRB-\1740 .\.\1740
D004008_D004487 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 discontinuations\NNS\209943 for\IN\1740 hypertension-related\JJ\1740 and\CC\1740 <e2>oedema-related</e2>\JJ\1740 AEs\NNS\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 etoricoxib\NN\1740 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 and\CC\1740 1.1\CD\1740 %\NN\1740 respectively\RB\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 <e1>diclofenac</e1>\NN\1740 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 and\CC\1740 0.4\CD\1740 %\NN\1740 respectively\RB\1740 ;\:\1740 p<0.001\NN\1740 for\IN\1740 hypertension\NN\14057371 and\CC\1740 p<0.01\NN\1740 for\IN\1740 oedema\NN\14315192 )\-RRB-\1740 .\.\1740
D004008_D004487 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 discontinuations\NNS\209943 for\IN\1740 hypertension-related\JJ\1740 and\CC\1740 oedema-related\JJ\1740 AEs\NNS\1740 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 with\IN\1740 etoricoxib\NN\1740 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 and\CC\1740 1.1\CD\1740 %\NN\1740 respectively\RB\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 <e1>diclofenac</e1>\NN\1740 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 and\CC\1740 0.4\CD\1740 %\NN\1740 respectively\RB\1740 ;\:\1740 p<0.001\NN\1740 for\IN\1740 hypertension\NN\14057371 and\CC\1740 p<0.01\NN\1740 for\IN\1740 <e2>oedema</e2>\NN\14315192 )\-RRB-\1740 .\.\1740
6381653
D007980_D004409 CID <e1>Levodopa-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 and\CC\1740 thalamotomy\NN\1740 .\.\1740
D007980_D004409 CID <e1>Levodopa-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 of\IN\1740 the\DT\1740 limbs\NNS\5559908 in\IN\13603305 thirteen\CD\13745420 cases\NNS\7283608 of\IN\1740 Parkinsonism\NNP\14085708 ,\,\1740 which\WDT\1740 was\VBD\836236 choreic\JJ\1740 ,\,\1740 ballistic\JJ\1740 or\CC\3541091 dystonic\JJ\1740 in\IN\13603305 type\NN\5839024 ,\,\1740 was\VBD\836236 alleviated\VBN\205885 almost\RB\1740 completely\RB\1740 by\IN\1740 stereotaxic\JJ\1740 surgery\NN\6045562 using\VBG\1156834 a\DT\13649268 microelectrode\JJ\1740 technique\NN\5660268 for\IN\1740 the\DT\1740 ventralis\NN\1740 oralis\NN\1740 anterior\JJ\1740 and\CC\1740 posterior\JJ\1740 nuclei\NNS\5445668 of\IN\1740 the\DT\1740 thalamus\NN\5462674 ,\,\1740 but\CC\1740 much\RB\1740 less\JJR\1740 by\IN\1740 the\DT\1740 ventralis\NN\1740 intermedius\NN\1740 nucleus\NN\5445668 .\.\1740
D007980_D004409 CID Control\NN\5190804 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 by\IN\1740 thalamic\NN\1740 lesions\NNS\14204950 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 routine\JJ\1740 treatment\NN\654885 of\IN\1740 Parkinsonism\NN\14085708 is\VBZ\836236 discussed\VBN\1033527 .\.\1740
D007980_D010302 NONE <e1>Levodopa-induced</e1>\JJ\1740 dyskinesia\NN\14084880 of\IN\1740 the\DT\1740 limbs\NNS\5559908 in\IN\13603305 thirteen\CD\13745420 cases\NNS\7283608 of\IN\1740 <e2>Parkinsonism</e2>\NNP\14085708 ,\,\1740 which\WDT\1740 was\VBD\836236 choreic\JJ\1740 ,\,\1740 ballistic\JJ\1740 or\CC\3541091 dystonic\JJ\1740 in\IN\13603305 type\NN\5839024 ,\,\1740 was\VBD\836236 alleviated\VBN\205885 almost\RB\1740 completely\RB\1740 by\IN\1740 stereotaxic\JJ\1740 surgery\NN\6045562 using\VBG\1156834 a\DT\13649268 microelectrode\JJ\1740 technique\NN\5660268 for\IN\1740 the\DT\1740 ventralis\NN\1740 oralis\NN\1740 anterior\JJ\1740 and\CC\1740 posterior\JJ\1740 nuclei\NNS\5445668 of\IN\1740 the\DT\1740 thalamus\NN\5462674 ,\,\1740 but\CC\1740 much\RB\1740 less\JJR\1740 by\IN\1740 the\DT\1740 ventralis\NN\1740 intermedius\NN\1740 nucleus\NN\5445668 .\.\1740
D007980_D010302 NONE Control\NN\5190804 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 by\IN\1740 thalamic\NN\1740 lesions\NNS\14204950 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 routine\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>Parkinsonism</e2>\NN\14085708 is\VBZ\836236 discussed\VBN\1033527 .\.\1740
D007980_D020821 NONE <e1>Levodopa-induced</e1>\JJ\1740 dyskinesia\NN\14084880 of\IN\1740 the\DT\1740 limbs\NNS\5559908 in\IN\13603305 thirteen\CD\13745420 cases\NNS\7283608 of\IN\1740 Parkinsonism\NNP\14085708 ,\,\1740 which\WDT\1740 was\VBD\836236 choreic\JJ\1740 ,\,\1740 ballistic\JJ\1740 or\CC\3541091 <e2>dystonic</e2>\JJ\1740 in\IN\13603305 type\NN\5839024 ,\,\1740 was\VBD\836236 alleviated\VBN\205885 almost\RB\1740 completely\RB\1740 by\IN\1740 stereotaxic\JJ\1740 surgery\NN\6045562 using\VBG\1156834 a\DT\13649268 microelectrode\JJ\1740 technique\NN\5660268 for\IN\1740 the\DT\1740 ventralis\NN\1740 oralis\NN\1740 anterior\JJ\1740 and\CC\1740 posterior\JJ\1740 nuclei\NNS\5445668 of\IN\1740 the\DT\1740 thalamus\NN\5462674 ,\,\1740 but\CC\1740 much\RB\1740 less\JJR\1740 by\IN\1740 the\DT\1740 ventralis\NN\1740 intermedius\NN\1740 nucleus\NN\5445668 .\.\1740
D007980_D013786 NONE Control\NN\5190804 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 by\IN\1740 <e2>thalamic\NN\1740 lesions</e2>\NNS\14204950 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 routine\JJ\1740 treatment\NN\654885 of\IN\1740 Parkinsonism\NN\14085708 is\VBZ\836236 discussed\VBN\1033527 .\.\1740
12691807
D007980_D004421 CID <e1>Levodopa-induced</e1>\JJ\1740 oromandibular\JJ\1740 <e2>dystonia</e2>\NN\1740 in\IN\13603305 progressive\JJ\1740 supranuclear\NN\1740 palsy\NN\14557898 .\.\1740
D007980_D013494 NONE <e1>Levodopa-induced</e1>\JJ\1740 oromandibular\JJ\1740 dystonia\NN\1740 in\IN\13603305 <e2>progressive\JJ\1740 supranuclear\NN\1740 palsy</e2>\NN\14557898 .\.\1740
D007980_D013494 NONE In\IN\13603305 this\DT\1740 report\NN\6470073 we\PRP\1740 describe\VBP\1001294 an\DT\6697703 unusual\JJ\1740 case\NN\7283608 of\IN\1740 reversible\JJ\1740 <e1>levodopa-induced</e1>\JJ\1740 Oromandibular\JJ\1740 dystonia\NN\1740 (\-LRB-\1740 OMD\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 <e2>PSP</e2>\NN\1740 patient\NN\9898892 to\TO\1740 highlight\VB\514463 the\DT\1740 importance\NN\5138488 of\IN\1740 recognizing\VBG\686447 this\DT\1740 drug\NN\14778436 related\JJ\1740 complication\NN\1073995 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 PSP\NNP\1740 ,\,\1740 and\CC\1740 discuss\VBP\1033527 the\DT\1740 possible\JJ\1740 underlying\JJ\1740 pathophysiology\NN\1740 .\.\1740
D007980_D013494 NONE In\IN\13603305 this\DT\1740 report\NN\6470073 we\PRP\1740 describe\VBP\1001294 an\DT\6697703 unusual\JJ\1740 case\NN\7283608 of\IN\1740 reversible\JJ\1740 <e1>levodopa-induced</e1>\JJ\1740 Oromandibular\JJ\1740 dystonia\NN\1740 (\-LRB-\1740 OMD\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 PSP\NN\1740 patient\NN\9898892 to\TO\1740 highlight\VB\514463 the\DT\1740 importance\NN\5138488 of\IN\1740 recognizing\VBG\686447 this\DT\1740 drug\NN\14778436 related\JJ\1740 complication\NN\1073995 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 <e2>PSP</e2>\NNP\1740 ,\,\1740 and\CC\1740 discuss\VBP\1033527 the\DT\1740 possible\JJ\1740 underlying\JJ\1740 pathophysiology\NN\1740 .\.\1740
D007980_D004409 NONE <e1>Levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 and\CC\1740 multiple\JJ\1740 system\NN\3575240 atrophy\NN\14299637 .\.\1740
D007980_D010300 NONE <e1>Levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 and\CC\1740 multiple\JJ\1740 system\NN\3575240 atrophy\NN\14299637 .\.\1740
D007980_D019578 NONE <e1>Levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 and\CC\1740 <e2>multiple\JJ\1740 system\NN\3575240 atrophy</e2>\NN\14299637 .\.\1740
D007980_D008538 NONE In\IN\13603305 this\DT\1740 report\NN\6470073 we\PRP\1740 describe\VBP\1001294 an\DT\6697703 unusual\JJ\1740 case\NN\7283608 of\IN\1740 reversible\JJ\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>Oromandibular\JJ\1740 dystonia</e2>\NN\1740 (\-LRB-\1740 OMD\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 PSP\NN\1740 patient\NN\9898892 to\TO\1740 highlight\VB\514463 the\DT\1740 importance\NN\5138488 of\IN\1740 recognizing\VBG\686447 this\DT\1740 drug\NN\14778436 related\JJ\1740 complication\NN\1073995 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 PSP\NNP\1740 ,\,\1740 and\CC\1740 discuss\VBP\1033527 the\DT\1740 possible\JJ\1740 underlying\JJ\1740 pathophysiology\NN\1740 .\.\1740
D007980_D008538 NONE In\IN\13603305 this\DT\1740 report\NN\6470073 we\PRP\1740 describe\VBP\1001294 an\DT\6697703 unusual\JJ\1740 case\NN\7283608 of\IN\1740 reversible\JJ\1740 <e1>levodopa-induced</e1>\JJ\1740 Oromandibular\JJ\1740 dystonia\NN\1740 (\-LRB-\1740 <e2>OMD</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 PSP\NN\1740 patient\NN\9898892 to\TO\1740 highlight\VB\514463 the\DT\1740 importance\NN\5138488 of\IN\1740 recognizing\VBG\686447 this\DT\1740 drug\NN\14778436 related\JJ\1740 complication\NN\1073995 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 PSP\NNP\1740 ,\,\1740 and\CC\1740 discuss\VBP\1033527 the\DT\1740 possible\JJ\1740 underlying\JJ\1740 pathophysiology\NN\1740 .\.\1740
2055425
D013311_D003920 CID The\DT\1740 ability\NN\4723816 of\IN\1740 insulin\NN\5407119 treatment\NN\654885 to\TO\1740 reverse\VB\109660 or\CC\3541091 prevent\VB\1740 the\DT\1740 changes\NNS\7283608 in\IN\13603305 urinary\JJ\1740 bladder\NN\5515670 function\NN\13783581 caused\VBN\1617192 by\IN\1740 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 .\.\1740
D013311_D003920 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 insulin\NN\5407119 treatment\NN\654885 on\IN\1740 in\FW\13603305 vivo\FW\1740 and\CC\1740 in\FW\13603305 vitro\FW\1740 urinary\JJ\1740 bladder\NN\5515670 function\NN\13783581 in\IN\13603305 <e2><e1>streptozotocin-diabetic</e1></e2>\JJ\1740 rats\NNS\2329401 were\VBD\836236 investigated\VBN\644583 .\.\1740
D013311_D003920 CID The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>diabetes</e2>\NNS\14075199 on\IN\1740 urinary\JJ\1740 bladder\NN\5515670 function\NN\13783581 are\VBP\836236 both\CC\1740 prevented\VBN\1740 and\CC\1740 reversed\VBN\109660 by\IN\1740 insulin\NN\5407119 treatment\NN\654885 .\.\1740
D000255_D003920 NONE Insulin\NN\5407119 treatment\NN\654885 also\RB\1740 prevented\VBD\1740 the\DT\1740 increases\NNS\13576355 in\IN\13603305 contractile\JJ\1740 responses\NNS\11410625 of\IN\1740 bladder\NN\5515670 body\NN\19128 strips\VBZ\2205272 from\IN\1740 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 to\TO\1740 nerve\NN\5475681 stimulation\NN\242808 ,\,\1740 <e1>ATP</e1>\NN\14964590 ,\,\1740 and\CC\1740 bethanechol\NN\1740 .\.\1740
D000255_D003920 NONE Insulin\NN\5407119 treatment\NN\654885 reversed\VBD\109660 the\DT\1740 increases\NNS\13576355 in\IN\13603305 contractile\JJ\1740 responses\NNS\11410625 of\IN\1740 bladder\NN\5515670 body\NN\19128 strips\VBZ\2205272 from\IN\1740 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 to\TO\1740 nerve\NN\5475681 stimulation\NN\242808 ,\,\1740 <e1>ATP</e1>\NN\14964590 ,\,\1740 and\CC\1740 bethanechol\NN\1740 .\.\1740
D018723_D003920 NONE Insulin\NN\5407119 treatment\NN\654885 also\RB\1740 prevented\VBD\1740 the\DT\1740 increases\NNS\13576355 in\IN\13603305 contractile\JJ\1740 responses\NNS\11410625 of\IN\1740 bladder\NN\5515670 body\NN\19128 strips\VBZ\2205272 from\IN\1740 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 to\TO\1740 nerve\NN\5475681 stimulation\NN\242808 ,\,\1740 ATP\NN\14964590 ,\,\1740 and\CC\1740 <e1>bethanechol</e1>\NN\1740 .\.\1740
D018723_D003920 NONE Insulin\NN\5407119 treatment\NN\654885 reversed\VBD\109660 the\DT\1740 increases\NNS\13576355 in\IN\13603305 contractile\JJ\1740 responses\NNS\11410625 of\IN\1740 bladder\NN\5515670 body\NN\19128 strips\VBZ\2205272 from\IN\1740 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 to\TO\1740 nerve\NN\5475681 stimulation\NN\242808 ,\,\1740 ATP\NN\14964590 ,\,\1740 and\CC\1740 <e1>bethanechol</e1>\NN\1740 .\.\1740
3769769
D014282_D001919 CID <e2>Bradycardia</e2>\NNP\14110674 due\IN\5174653 to\TO\1740 <e1>trihexyphenidyl\VB\1740 hydrochloride</e1>\NN\14817592 .\.\1740
D014282_D012559 NONE A\DT\13649268 chronic\JJ\1740 <e2>schizophrenic</e2>\JJ\1740 patient\NN\9898892 was\VBD\836236 treated\VBN\2376958 with\IN\1740 an\DT\6697703 anticholinergic\JJ\1740 drug\NN\14778436 ,\,\1740 <e1>trihexyphenidyl\NN\1740 hydrochloride</e1>\NN\14817592 .\.\1740
6674249
D015119_D009135 CID Why\WRB\9178999 may\MD\15209706 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 EACA\NN\1740 )\-RRB-\1740 induce\VBP\1627355 <e2>myopathy</e2>\NN\14204950 in\IN\13603305 man\NN\9605289 ?\.\1740
D015119_D009135 CID Why\WRB\9178999 may\MD\15209706 epsilon-aminocaproic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>EACA</e1>\NN\1740 )\-RRB-\1740 induce\VBP\1627355 <e2>myopathy</e2>\NN\14204950 in\IN\13603305 man\NN\9605289 ?\.\1740
D015119_D009135 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>necrotizing\VBG\1740 myopathy</e2>\NN\14204950 due\JJ\1740 to\TO\1740 a\DT\13649268 short\JJ\1740 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 EACA\NN\1740 )\-RRB-\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 72\CD\1740 year-old\NN\1740 patient\NN\9898892 with\IN\1740 subarachnoid\JJ\1740 haemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 is\VBZ\836236 described\VBN\1001294 .\.\1740
D015119_D009135 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>necrotizing\VBG\1740 myopathy</e2>\NN\14204950 due\JJ\1740 to\TO\1740 a\DT\13649268 short\JJ\1740 epsilon-aminocaproic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>EACA</e1>\NN\1740 )\-RRB-\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 72\CD\1740 year-old\NN\1740 patient\NN\9898892 with\IN\1740 subarachnoid\JJ\1740 haemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 is\VBZ\836236 described\VBN\1001294 .\.\1740
D015119_D009336 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>necrotizing\VBG\1740 myopathy</e2>\NN\14204950 due\JJ\1740 to\TO\1740 a\DT\13649268 short\JJ\1740 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 EACA\NN\1740 )\-RRB-\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 72\CD\1740 year-old\NN\1740 patient\NN\9898892 with\IN\1740 subarachnoid\JJ\1740 haemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 is\VBZ\836236 described\VBN\1001294 .\.\1740
D015119_D009336 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>necrotizing\VBG\1740 myopathy</e2>\NN\14204950 due\JJ\1740 to\TO\1740 a\DT\13649268 short\JJ\1740 epsilon-aminocaproic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>EACA</e1>\NN\1740 )\-RRB-\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 72\CD\1740 year-old\NN\1740 patient\NN\9898892 with\IN\1740 subarachnoid\JJ\1740 haemorrhage\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 is\VBZ\836236 described\VBN\1001294 .\.\1740
D015119_D013345 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 necrotizing\VBG\1740 myopathy\NN\14204950 due\JJ\1740 to\TO\1740 a\DT\13649268 short\JJ\1740 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 EACA\NN\1740 )\-RRB-\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 72\CD\1740 year-old\NN\1740 patient\NN\9898892 with\IN\1740 <e2>subarachnoid\JJ\1740 haemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 is\VBZ\836236 described\VBN\1001294 .\.\1740
D015119_D013345 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 necrotizing\VBG\1740 myopathy\NN\14204950 due\JJ\1740 to\TO\1740 a\DT\13649268 short\JJ\1740 <e1>epsilon-aminocaproic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 EACA\NN\1740 )\-RRB-\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 72\CD\1740 year-old\NN\1740 patient\NN\9898892 with\IN\1740 subarachnoid\JJ\1740 haemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 described\VBN\1001294 .\.\1740
D015119_D013345 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 necrotizing\VBG\1740 myopathy\NN\14204950 due\JJ\1740 to\TO\1740 a\DT\13649268 short\JJ\1740 epsilon-aminocaproic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>EACA</e1>\NN\1740 )\-RRB-\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 72\CD\1740 year-old\NN\1740 patient\NN\9898892 with\IN\1740 <e2>subarachnoid\JJ\1740 haemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 is\VBZ\836236 described\VBN\1001294 .\.\1740
D015119_D013345 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 necrotizing\VBG\1740 myopathy\NN\14204950 due\JJ\1740 to\TO\1740 a\DT\13649268 short\JJ\1740 epsilon-aminocaproic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>EACA</e1>\NN\1740 )\-RRB-\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 72\CD\1740 year-old\NN\1740 patient\NN\9898892 with\IN\1740 subarachnoid\JJ\1740 haemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 described\VBN\1001294 .\.\1740
15686794
D000638_D017116 CID Acute\JJ\1740 <e2>low\JJ\1740 back\JJ\1740 pain</e2>\NN\14299637 during\IN\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 :\:\1740 a\DT\13649268 report\NN\6470073 of\IN\1740 two\CD\13741022 cases\NNS\7283608 .\.\1740
D000638_D017116 CID We\PRP\1740 briefly\RB\1740 describe\VBP\1001294 two\CD\13741022 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 recent-onset\JJ\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 who\WP\8299493 experienced\VBD\2108377 an\DT\6697703 acute\JJ\1740 devastating\VBG\1564144 <e2>low\JJ\1740 back\RB\1740 pain</e2>\NN\14299637 a\DT\13649268 few\JJ\1740 minutes\NNS\6502378 after\IN\1740 initiation\NN\7450842 of\IN\1740 intravenous\JJ\1740 <e1>amiodarone</e1>\NN\2715941 loading\NN\4571088 .\.\1740
D000638_D001281 NONE <e1>Amiodarone</e1>\NN\2715941 represents\VBZ\2664769 an\DT\6697703 effective\JJ\1740 antiarrhythmic\JJ\1740 drug\NN\14778436 for\IN\1740 cardioversion\NN\1740 of\IN\1740 recent-onset\JJ\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 and\CC\1740 maintenance\NN\266806 of\IN\1740 sinus\NN\5248181 rhythm\NN\15122011 .\.\1740
D000638_D001281 NONE <e1>Amiodarone</e1>\NN\2715941 represents\VBZ\2664769 an\DT\6697703 effective\JJ\1740 antiarrhythmic\JJ\1740 drug\NN\14778436 for\IN\1740 cardioversion\NN\1740 of\IN\1740 recent-onset\JJ\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 <e2>AF</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 maintenance\NN\266806 of\IN\1740 sinus\NN\5248181 rhythm\NN\15122011 .\.\1740
D000638_D001281 NONE We\PRP\1740 briefly\RB\1740 describe\VBP\1001294 two\CD\13741022 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 recent-onset\JJ\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 ,\,\1740 who\WP\8299493 experienced\VBD\2108377 an\DT\6697703 acute\JJ\1740 devastating\VBG\1564144 low\JJ\1740 back\RB\1740 pain\NN\14299637 a\DT\13649268 few\JJ\1740 minutes\NNS\6502378 after\IN\1740 initiation\NN\7450842 of\IN\1740 intravenous\JJ\1740 <e1>amiodarone</e1>\NN\2715941 loading\NN\4571088 .\.\1740
3413271
D004837_D017202 CID Mechanisms\NNS\13446390 of\IN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 induced\VBN\1627355 by\IN\1740 <e1>epinephrine</e1>\NN\14807929 :\:\1740 comparison\NN\635850 with\IN\1740 exercise-induced\JJ\1740 ischemia\NN\14195315 .\.\1740
D004837_D017202 CID The\DT\1740 role\NN\719494 of\IN\1740 <e1>epinephrine</e1>\NN\14807929 in\IN\13603305 eliciting\VBG\1617192 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 was\VBD\836236 examined\VBN\789138 in\IN\13603305 patients\NNS\9898892 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 .\.\1740
D004837_D017202 CID Both\CC\1740 <e1>epinephrine</e1>\NN\14807929 and\CC\1740 exercise\NN\621627 produced\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 ST\JJ\1740 segment\NN\3892891 depression\NN\14373582 and\CC\1740 angina\NN\14171682 .\.\1740
D004837_D017202 CID However\RB\1740 ,\,\1740 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 induced\VBN\1627355 by\IN\1740 <e1>epinephrine</e1>\NN\14807929 were\VBD\836236 significantly\RB\1740 different\JJ\1740 from\IN\1740 those\DT\1740 of\IN\1740 exercise\NN\621627 .\.\1740
D004837_D017202 CID Exercise-induced\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 was\VBD\836236 marked\VBN\1296462 predominantly\RB\1740 by\IN\1740 increased\VBN\169651 heart\NN\5919034 rate\NN\13815152 and\CC\1740 rate-pressure\JJ\1740 product\NN\3076708 with\IN\1740 a\DT\13649268 minor\JJ\1740 contribution\NN\786195 of\IN\1740 end-diastolic\JJ\1740 volume\NN\33615 ,\,\1740 while\IN\15122231 <e1>epinephrine-induced</e1>\JJ\1740 ischemia\NN\14195315 was\VBD\836236 characterized\VBN\609683 by\IN\1740 a\DT\13649268 marked\JJ\1740 increase\NN\13576355 in\IN\13603305 contractility\NN\5200169 and\CC\1740 a\DT\13649268 less\RBR\1740 pronounced\JJ\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 rate-pressure\JJ\1740 product\NN\3076708 .\.\1740
D004837_D007511 NONE Mechanisms\NNS\13446390 of\IN\1740 myocardial\JJ\1740 ischemia\NN\14195315 induced\VBN\1627355 by\IN\1740 <e1>epinephrine</e1>\NN\14807929 :\:\1740 comparison\NN\635850 with\IN\1740 exercise-induced\JJ\1740 <e2>ischemia</e2>\NN\14195315 .\.\1740
D004837_D007511 NONE Objective\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>ischemia</e2>\NN\14195315 and\CC\1740 factors\NNS\7326557 increasing\VBG\169651 myocardial\JJ\1740 oxygen\NN\14622893 consumption\NN\13440063 were\VBD\836236 compared\VBN\644583 during\IN\1740 <e1>epinephrine</e1>\NN\14807929 infusion\NN\14589223 and\CC\1740 supine\JJ\1740 bicycle\NN\4576211 exercise\NN\621627 .\.\1740
D004837_D007511 NONE Exercise-induced\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 was\VBD\836236 marked\VBN\1296462 predominantly\RB\1740 by\IN\1740 increased\VBN\169651 heart\NN\5919034 rate\NN\13815152 and\CC\1740 rate-pressure\JJ\1740 product\NN\3076708 with\IN\1740 a\DT\13649268 minor\JJ\1740 contribution\NN\786195 of\IN\1740 end-diastolic\JJ\1740 volume\NN\33615 ,\,\1740 while\IN\15122231 <e1>epinephrine-induced</e1>\JJ\1740 <e2>ischemia</e2>\NN\14195315 was\VBD\836236 characterized\VBN\609683 by\IN\1740 a\DT\13649268 marked\JJ\1740 increase\NN\13576355 in\IN\13603305 contractility\NN\5200169 and\CC\1740 a\DT\13649268 less\RBR\1740 pronounced\JJ\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 rate-pressure\JJ\1740 product\NN\3076708 .\.\1740
D004837_D007511 NONE These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e2>ischemia</e2>\NN\14195315 produced\VBN\1617192 by\IN\1740 <e1>epinephrine</e1>\NN\14807929 ,\,\1740 as\IN\14622893 may\MD\15209706 occur\VB\2623529 during\IN\1740 states\NNS\8491826 of\IN\1740 emotional\JJ\1740 distress\NN\7494363 ,\,\1740 has\VBZ\2108377 a\DT\13649268 mechanism\NN\13446390 distinct\JJ\1740 from\IN\1740 that\DT\1740 due\IN\5174653 to\IN\1740 physical\JJ\1740 exertion\NN\620752 .\.\1740
D004837_D003324 NONE The\DT\1740 role\NN\719494 of\IN\1740 <e1>epinephrine</e1>\NN\14807929 in\IN\13603305 eliciting\VBG\1617192 myocardial\JJ\1740 ischemia\NN\14195315 was\VBD\836236 examined\VBN\789138 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 .\.\1740
D010100_D007511 NONE Objective\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>ischemia</e2>\NN\14195315 and\CC\1740 factors\NNS\7326557 increasing\VBG\169651 myocardial\JJ\1740 <e1>oxygen</e1>\NN\14622893 consumption\NN\13440063 were\VBD\836236 compared\VBN\644583 during\IN\1740 epinephrine\NN\14807929 infusion\NN\14589223 and\CC\1740 supine\JJ\1740 bicycle\NN\4576211 exercise\NN\621627 .\.\1740
D004837_D003866 NONE Both\CC\1740 <e1>epinephrine</e1>\NN\14807929 and\CC\1740 exercise\NN\621627 produced\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 ST\JJ\1740 segment\NN\3892891 <e2>depression</e2>\NN\14373582 and\CC\1740 angina\NN\14171682 .\.\1740
D004837_D000787 NONE Both\CC\1740 <e1>epinephrine</e1>\NN\14807929 and\CC\1740 exercise\NN\621627 produced\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 ST\JJ\1740 segment\NN\3892891 depression\NN\14373582 and\CC\1740 <e2>angina</e2>\NN\14171682 .\.\1740
7161250
D006220_D010302 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>parkinsonism</e2>\NN\14085708 was\VBD\836236 higher\JJR\1740 at\IN\14622893 higher\JJR\1740 doses\NNS\3740161 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 and\CC\1740 in\IN\13603305 younger\JJR\1740 patients\NNS\9898892 .\.\1740
D001569_D017109 NONE <e2>Akathisia</e2>\NNP\1740 was\VBD\836236 controlled\VBN\2422663 by\IN\1740 the\DT\1740 <e1>benzodiazepine</e1>\NN\3771443 lorazepam\NN\2830852 in\IN\13603305 14\CD\13745420 out\IN\66636 of\IN\1740 16\CD\13745420 patients\NNS\9898892 ,\,\1740 while\IN\15122231 prophylactic\JJ\1740 antiparkinsonians\NNS\1740 were\VBD\836236 ineffective\JJ\1740 .\.\1740
D008140_D017109 NONE <e2>Akathisia</e2>\NNP\1740 was\VBD\836236 controlled\VBN\2422663 by\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 <e1>lorazepam</e1>\NN\2830852 in\IN\13603305 14\CD\13745420 out\IN\66636 of\IN\1740 16\CD\13745420 patients\NNS\9898892 ,\,\1740 while\IN\15122231 prophylactic\JJ\1740 antiparkinsonians\NNS\1740 were\VBD\836236 ineffective\JJ\1740 .\.\1740
19996135
D014148_D012640 CID High-dose\JJ\1740 <e1>tranexamic\NN\1740 Acid</e1>\NNP\14818238 is\VBZ\836236 associated\VBN\628491 with\IN\1740 nonischemic\JJ\1740 clinical\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 cardiac\JJ\1740 surgical\JJ\1740 patients\NNS\9898892 .\.\1740
D014148_D012640 CID The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 review\NN\5733583 was\VBD\836236 to\TO\1740 perform\VB\2367363 a\DT\13649268 retrospective\JJ\1740 analysis\NN\633864 to\TO\1740 examine\VB\789138 whether\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relation\NN\2137 between\IN\1740 <e1>TXA</e1>\NN\1740 usage\NN\407535 and\CC\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 cardiac\JJ\1740 surgery\NN\6045562 .\.\1740
D014148_D012640 CID All\DT\1740 24\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>seizures</e2>\NNS\14081375 received\VBD\2210855 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>TXA</e1>\NN\1740 intraoperatively\RB\1740 ranging\VBG\2604760 from\IN\1740 61\CD\1740 to\TO\1740 259\CD\1740 mg/kg\NN\1740 ,\,\1740 had\VBD\2108377 a\DT\13649268 mean\NN\6021761 age\NN\4916342 of\IN\1740 69.9\CD\1740 years\NNS\15144371 ,\,\1740 and\CC\1740 21\CD\13745420 of\IN\1740 24\CD\13745420 had\VBD\2108377 undergone\VBN\109660 open\JJ\1740 chamber\NN\3285912 rather\RB\1740 than\IN\1740 coronary\JJ\1740 bypass\NN\3519981 procedures\NNS\407535 .\.\1740
D014148_D012640 CID CONCLUSION\NN\5837957 :\:\1740 Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 use\NN\407535 of\IN\1740 high-dose\JJ\1740 <e1>TXA</e1>\NN\1740 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 cardiopulmonary\JJ\1740 bypass\NN\3519981 and\CC\1740 open-chamber\NN\1740 cardiac\JJ\1740 surgery\NN\6045562 is\VBZ\836236 associated\VBN\628491 with\IN\1740 clinical\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 susceptible\JJ\1740 patients\NNS\9898892 .\.\1740
